cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
KIRC	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-31.43	4.91e-120	4.29e-114	-1.08	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	31.04	3.28e-118	2.69e-112	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	30.99	5.01e-118	4.03e-112	1.07	0.81	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	30.91	1.22e-117	9.61e-112	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	30.86	2.05e-117	1.59e-111	0.91	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	30.83	2.9e-117	2.21e-111	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	30.74	7.27e-117	5.42e-111	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	30.72	9.1e-117	6.55e-111	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	30.58	3.84e-116	2.62e-110	1.06	0.81	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	30.55	5.27e-116	3.54e-110	0.9	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	30.54	6.16e-116	4.08e-110	1.08	0.81	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	30.43	2.06e-115	1.32e-109	1.28	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	30.41	2.49e-115	1.57e-109	1.29	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	30.24	1.54e-114	9.43e-109	1.28	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
KIRC	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	30.14	4.36e-114	2.63e-108	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	30.01	1.67e-113	9.93e-108	1.07	0.8	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	30	1.83e-113	1.07e-107	0.89	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	29.88	7.2e-113	3.99e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	29.88	7.2e-113	3.99e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	29.88	7.2e-113	3.99e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	29.87	7.57e-113	4.14e-107	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	29.84	1.04e-112	5.47e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	29.84	1.04e-112	5.47e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	29.84	1.04e-112	5.47e-107	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	29.81	1.47e-112	7.65e-107	1.29	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
KIRC	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	29.8	1.56e-112	7.99e-107	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	29.8	1.58e-112	8.01e-107	1.06	0.8	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	29.75	2.84e-112	1.41e-106	1.06	0.8	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	29.73	3.29e-112	1.59e-106	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	29.73	3.29e-112	1.59e-106	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	29.72	3.98e-112	1.9e-106	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
KIRC	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	29.66	7.12e-112	3.32e-106	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-29.58	1.73e-111	7.88e-106	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	29.55	2.32e-111	1.04e-105	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	29.54	2.49e-111	1.11e-105	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	29.51	3.75e-111	1.65e-105	1.04	0.8	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	29.47	5.58e-111	2.44e-105	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	29.45	6.49e-111	2.8e-105	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	29.45	6.62e-111	2.83e-105	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	29.44	7.38e-111	3.12e-105	0.9	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	29.37	1.69e-110	7.02e-105	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	29.36	1.73e-110	7.06e-105	1.07	0.8	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-29.36	1.77e-110	7.06e-105	-1.09	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-29.36	1.77e-110	7.06e-105	-1.09	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-29.36	1.77e-110	7.06e-105	-1.09	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-29.35	1.9e-110	7.49e-105	-1.09	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	29.34	2.26e-110	8.66e-105	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	29.34	2.26e-110	8.66e-105	1.26	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-29.33	2.38e-110	9.05e-105	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	29.29	3.95e-110	1.46e-104	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	29.29	3.95e-110	1.46e-104	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	29.29	3.95e-110	1.46e-104	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	29.28	4.33e-110	1.57e-104	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	29.28	4.33e-110	1.57e-104	1.05	0.8	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-29.24	6.28e-110	2.2e-104	-1.05	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	29.24	6.29e-110	2.2e-104	1.07	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	29.24	6.75e-110	2.35e-104	1.08	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	29.21	8.57e-110	2.95e-104	1.07	0.8	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-29.2	9.59e-110	3.28e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-29.2	1.03e-109	3.44e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-29.2	1.03e-109	3.44e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-29.2	1.03e-109	3.44e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-29.19	1.07e-109	3.55e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-29.18	1.24e-109	3.79e-104	-1.08	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	29.17	1.42e-109	4.26e-104	1.06	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	29.17	1.42e-109	4.26e-104	1.06	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	29.15	1.72e-109	5.01e-104	1.05	0.79	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	29.15	1.72e-109	5.01e-104	1.05	0.79	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	29.13	2.09e-109	6.04e-104	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	29.12	2.28e-109	6.49e-104	1.05	0.79	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	29.12	2.31e-109	6.54e-104	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-29.12	2.4e-109	6.6e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-29.12	2.4e-109	6.6e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	29.1	2.98e-109	8.14e-104	1.25	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	29.09	3.28e-109	8.25e-104	1.25	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	29.09	3.34e-109	8.25e-104	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	29.09	3.34e-109	8.25e-104	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-29.09	3.34e-109	8.25e-104	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	29.09	3.39e-109	8.32e-104	1.07	0.79	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	29.07	4e-109	9.75e-104	1.08	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-29.06	4.29e-109	1.03e-103	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-29.03	6.1e-109	1.43e-103	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	28.99	9.08e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	28.99	9.23e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-28.99	9.51e-109	1.99e-103	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-28.99	9.51e-109	1.99e-103	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-28.99	9.74e-109	1.99e-103	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	28.99	9.74e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	28.99	9.74e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	28.99	9.74e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	28.99	9.74e-109	1.99e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	28.97	1.23e-108	2.22e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-28.87	3.53e-108	6.06e-103	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-28.87	3.53e-108	6.06e-103	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-28.87	3.53e-108	6.06e-103	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-28.85	4.44e-108	7.17e-103	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	28.82	6.03e-108	9.2e-103	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-28.79	8.31e-108	1.26e-102	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-28.79	8.31e-108	1.26e-102	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-28.77	9.89e-108	1.47e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-28.77	9.89e-108	1.47e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-28.76	1.1e-107	1.63e-102	-1.08	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	28.74	1.36e-107	2.01e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	28.74	1.36e-107	2.01e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-28.72	1.84e-107	2.68e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-28.7	2.25e-107	3.27e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	28.68	2.57e-107	3.72e-102	1.05	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	28.68	2.81e-107	4.06e-102	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	28.67	2.97e-107	4.27e-102	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-28.66	3.32e-107	4.75e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	28.66	3.47e-107	4.94e-102	1.05	0.79	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	28.65	3.84e-107	5.45e-102	1.07	0.79	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	28.63	4.5e-107	6.32e-102	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-28.63	4.72e-107	6.61e-102	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	28.62	5.16e-107	7.18e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	28.62	5.31e-107	7.29e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	28.62	5.31e-107	7.29e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	28.62	5.31e-107	7.29e-102	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	28.6	6.11e-107	8.33e-102	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	28.6	6.59e-107	8.89e-102	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	28.58	8.06e-107	1.08e-101	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	28.57	8.68e-107	1.16e-101	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-28.57	8.95e-107	1.19e-101	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.56	9.65e-107	1.28e-101	1.23	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	28.53	1.36e-106	1.8e-101	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-28.52	1.51e-106	2e-101	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	28.52	1.58e-106	2.08e-101	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-28.47	2.52e-106	3.27e-101	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	28.45	3.31e-106	4.28e-101	1.04	0.79	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	28.41	4.93e-106	6.3e-101	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	28.39	5.99e-106	7.63e-101	1.22	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	28.39	6.06e-106	7.7e-101	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	28.37	7.5e-106	9.47e-101	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	28.37	7.5e-106	9.47e-101	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	28.37	7.58e-106	9.54e-101	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	28.36	8.32e-106	1.04e-100	0.87	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-28.35	9e-106	1.1e-100	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-28.35	9e-106	1.1e-100	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-28.35	9e-106	1.1e-100	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	28.34	1.01e-105	1.21e-100	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	28.34	1.01e-105	1.21e-100	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	28.34	1.01e-105	1.21e-100	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-28.34	1.07e-105	1.28e-100	-1.05	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-28.31	1.44e-105	1.71e-100	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-28.31	1.44e-105	1.71e-100	-1.06	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	28.31	1.45e-105	1.72e-100	1.05	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	28.31	1.47e-105	1.73e-100	1.07	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	28.28	1.96e-105	2.29e-100	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	28.28	1.96e-105	2.29e-100	1.06	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-28.26	2.65e-105	3.08e-100	-1.07	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-28.23	3.4e-105	3.87e-100	-1.05	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-28.23	3.4e-105	3.87e-100	-1.05	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-28.23	3.4e-105	3.87e-100	-1.05	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-28.23	3.4e-105	3.87e-100	-1.05	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	28.19	5.46e-105	6.1e-100	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	28.18	5.7e-105	6.35e-100	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-28.18	5.85e-105	6.49e-100	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-28.16	7.51e-105	8.29e-100	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	28.16	7.72e-105	8.49e-100	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	28.15	8.06e-105	8.76e-100	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	28.15	8.06e-105	8.76e-100	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	28.15	8.06e-105	8.76e-100	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-28.15	8.26e-105	8.94e-100	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	28.15	8.32e-105	8.98e-100	0.88	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	28.13	9.96e-105	1.07e-99	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	28.12	1.11e-104	1.19e-99	1.03	0.78	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-28.12	1.15e-104	1.22e-99	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-28.12	1.15e-104	1.23e-99	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	28.1	1.4e-104	1.48e-99	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	28.1	1.42e-104	1.5e-99	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	28.09	1.59e-104	1.67e-99	0.88	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	28.08	1.78e-104	1.87e-99	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	28.05	2.54e-104	2.66e-99	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-28.04	2.63e-104	2.75e-99	-1.04	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-28.03	2.93e-104	3.05e-99	-1.06	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	28.02	3.5e-104	3.63e-99	0.88	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	28.01	3.62e-104	3.74e-99	1.03	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-28.01	3.98e-104	4.09e-99	-1.04	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	27.99	4.78e-104	4.9e-99	1.09	0.78	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	27.95	7.23e-104	7.38e-99	1.01	0.78	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	27.86	1.87e-103	1.88e-98	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	27.82	2.84e-103	2.83e-98	1.08	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	27.82	3.07e-103	3.05e-98	1.09	0.78	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	27.81	3.19e-103	3.16e-98	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	27.81	3.49e-103	3.45e-98	0.86	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	27.8	3.66e-103	3.61e-98	0.87	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	27.79	4.19e-103	4.12e-98	1.08	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	27.68	1.32e-102	1.29e-97	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	27.67	1.5e-102	1.46e-97	1.05	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	27.63	2.35e-102	2.28e-97	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	27.6	3.13e-102	2.99e-97	1.24	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	27.58	4.05e-102	3.87e-97	0.86	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	27.54	6.32e-102	5.98e-97	1.04	0.78	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	27.54	6.35e-102	5.99e-97	0.98	0.78	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	27.54	6.35e-102	5.99e-97	0.98	0.78	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	27.53	7.03e-102	6.61e-97	1.07	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	27.53	7.36e-102	6.91e-97	1.05	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	27.5	9.31e-102	8.72e-97	0.98	0.78	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	27.5	9.37e-102	8.76e-97	1.05	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	27.45	1.6e-101	1.49e-96	1.22	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	27.45	1.74e-101	1.61e-96	0.87	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	27.45	1.74e-101	1.61e-96	0.87	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	27.44	1.86e-101	1.71e-96	1.03	0.78	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	27.44	1.86e-101	1.71e-96	1.03	0.78	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	27.44	1.86e-101	1.71e-96	1.03	0.78	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	27.44	1.93e-101	1.77e-96	1.04	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	27.41	2.54e-101	2.31e-96	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	27.41	2.54e-101	2.31e-96	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	27.41	2.59e-101	2.35e-96	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	27.41	2.59e-101	2.35e-96	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	27.37	4.11e-101	3.72e-96	1.06	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-27.34	5.62e-101	5.03e-96	-1.04	-0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	27.3	8.22e-101	7.32e-96	1.04	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	27.3	8.39e-101	7.45e-96	1.03	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	27.3	8.73e-101	7.74e-96	0.99	0.78	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	27.28	1.01e-100	8.93e-96	0.87	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	27.28	1.12e-100	9.86e-96	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-27.27	1.24e-100	1.09e-95	-1.03	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-27.26	1.38e-100	1.21e-95	-1.07	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	27.24	1.64e-100	1.43e-95	1	0.77	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	27.24	1.64e-100	1.43e-95	0.99	0.77	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	27.24	1.71e-100	1.49e-95	1.03	0.77	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-27.22	1.96e-100	1.71e-95	-1.04	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.22	2.06e-100	1.77e-95	1.29	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
KIRC	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	27.22	2.13e-100	1.83e-95	0.99	0.77	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.21	2.18e-100	1.87e-95	1.29	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
KIRC	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	27.21	2.33e-100	2e-95	1	0.77	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	27.18	3.15e-100	2.69e-95	0.99	0.77	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	27.18	3.3e-100	2.81e-95	1.03	0.77	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	27.15	4.23e-100	3.6e-95	1.04	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	27.14	4.73e-100	4.01e-95	1.04	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	27.14	5.04e-100	4.26e-95	1.07	0.77	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	27.13	5.26e-100	4.42e-95	0.99	0.77	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	27.13	5.26e-100	4.42e-95	0.99	0.77	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	27.13	5.41e-100	4.53e-95	0.98	0.77	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	27.12	5.93e-100	4.94e-95	0.99	0.77	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	27.12	5.93e-100	4.94e-95	0.99	0.77	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	27.11	6.72e-100	5.58e-95	0.99	0.77	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	27.11	6.84e-100	5.64e-95	0.99	0.77	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	27.11	6.84e-100	5.64e-95	0.99	0.77	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	27.11	6.84e-100	5.64e-95	0.99	0.77	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	27.1	7.63e-100	6.14e-95	1.07	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	27.1	7.67e-100	6.14e-95	0.99	0.77	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	27.08	9.54e-100	7.62e-95	0.97	0.77	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	27.07	1.05e-99	8.38e-95	1.04	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	27.07	1.11e-99	8.85e-95	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	27.02	1.85e-99	1.43e-94	0.99	0.77	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	27.01	2.09e-99	1.61e-94	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-26.98	2.7e-99	2.07e-94	-1.06	-0.77	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	26.97	3.01e-99	2.29e-94	0.98	0.77	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	26.97	3.01e-99	2.29e-94	0.98	0.77	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	26.97	3.14e-99	2.38e-94	0.99	0.77	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
KIRC	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	26.94	4.59e-99	3.47e-94	1.07	0.77	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	26.93	4.91e-99	3.7e-94	0.97	0.77	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	26.93	4.91e-99	3.7e-94	0.97	0.77	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	26.92	5.5e-99	4.13e-94	1.03	0.77	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	26.87	9.3e-99	6.81e-94	0.98	0.77	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	26.87	9.3e-99	6.81e-94	0.98	0.77	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	26.87	9.3e-99	6.81e-94	0.98	0.77	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	26.87	9.3e-99	6.81e-94	0.98	0.77	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	26.87	9.3e-99	6.81e-94	0.98	0.77	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	26.86	1.02e-98	7.43e-94	1.04	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-26.85	1.14e-98	8.34e-94	-1.05	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
KIRC	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	26.81	1.87e-98	1.32e-93	0.98	0.77	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	26.8	2.03e-98	1.43e-93	0.99	0.77	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
KIRC	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-26.78	2.57e-98	1.8e-93	-1.05	-0.77	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	26.78	2.66e-98	1.85e-93	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
KIRC	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-26.74	3.79e-98	2.64e-93	-1.06	-0.77	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-26.74	4e-98	2.78e-93	-1.03	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	26.74	4.02e-98	2.78e-93	1.01	0.77	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	26.72	5e-98	3.43e-93	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	26.72	5e-98	3.43e-93	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	26.72	5e-98	3.43e-93	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
KIRC	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	26.72	5e-98	3.43e-93	1.02	0.77	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	26.72	5e-98	3.43e-93	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
KIRC	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-26.7	5.94e-98	4.05e-93	-1.06	-0.77	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
KIRC	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-26.7	5.97e-98	4.07e-93	-1.06	-0.77	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
KIRC	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	26.65	1.04e-97	7.02e-93	1.27	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	26.63	1.28e-97	8.64e-93	1.01	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	26.61	1.66e-97	1.12e-92	0.97	0.77	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	26.59	2.06e-97	1.37e-92	0.97	0.77	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	26.59	2.06e-97	1.37e-92	0.97	0.77	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	26.58	2.15e-97	1.43e-92	1.04	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	26.58	2.22e-97	1.46e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	26.57	2.51e-97	1.64e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	26.57	2.51e-97	1.64e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-26.55	3.3e-97	2.15e-92	-1.05	-0.77	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
KIRC	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	26.54	3.41e-97	2.22e-92	1.27	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	26.53	3.77e-97	2.45e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	26.53	3.77e-97	2.45e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	26.53	4.03e-97	2.61e-92	0.98	0.77	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	26.52	4.19e-97	2.71e-92	1.29	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	26.5	5.25e-97	3.38e-92	1.27	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	26.5	5.25e-97	3.38e-92	1.27	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	26.5	5.7e-97	3.62e-92	1.02	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	26.47	7.84e-97	4.94e-92	0.97	0.77	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	26.47	7.84e-97	4.94e-92	0.97	0.77	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	26.4	1.68e-96	1.04e-91	1.27	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	26.35	2.96e-96	1.82e-91	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	26.28	6.17e-96	3.73e-91	0.86	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	26.27	6.82e-96	4.1e-91	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	26.27	6.82e-96	4.1e-91	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	26.27	6.82e-96	4.1e-91	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	26.25	8.17e-96	4.9e-91	1.02	0.76	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	26.23	1.11e-95	6.6e-91	0.97	0.76	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
KIRC	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-26.18	1.8e-95	1.06e-90	-1.04	-0.76	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	26.17	1.95e-95	1.15e-90	0.86	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-26.17	2.03e-95	1.19e-90	-1	-0.76	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-26.17	2.03e-95	1.19e-90	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	26.16	2.15e-95	1.26e-90	0.97	0.76	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
KIRC	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	26.12	3.38e-95	1.98e-90	0.96	0.76	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	26.12	3.55e-95	2.05e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-26.09	4.71e-95	2.71e-90	-1.04	-0.76	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	26.08	5.67e-95	3.17e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	26.08	5.67e-95	3.17e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	26.07	6e-95	3.35e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
KIRC	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-26.07	6.03e-95	3.36e-90	-1.04	-0.76	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	26.07	6.09e-95	3.38e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	26.07	6.09e-95	3.38e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	26.06	7.01e-95	3.88e-90	0.85	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
KIRC	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-26.04	8.28e-95	4.55e-90	-0.95	-0.76	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	26.01	1.14e-94	6.23e-90	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-26	1.33e-94	7.22e-90	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-26	1.33e-94	7.22e-90	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-26	1.33e-94	7.22e-90	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	25.99	1.4e-94	7.57e-90	0.98	0.76	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	25.99	1.4e-94	7.57e-90	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	25.97	1.74e-94	9.34e-90	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
KIRC	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-25.97	1.81e-94	9.62e-90	-1.04	-0.76	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-25.96	2.05e-94	1.08e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-25.96	2.05e-94	1.08e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-25.96	2.05e-94	1.08e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	25.96	2.05e-94	1.08e-89	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	25.96	2.05e-94	1.08e-89	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	25.96	2.05e-94	1.08e-89	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	25.96	2.16e-94	1.14e-89	1.24	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
KIRC	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	25.95	2.39e-94	1.26e-89	0.97	0.76	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-25.94	2.67e-94	1.39e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-25.94	2.67e-94	1.39e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-25.94	2.67e-94	1.39e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-25.94	2.67e-94	1.39e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-25.94	2.67e-94	1.39e-89	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-25.92	3.04e-94	1.58e-89	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	25.92	3.08e-94	1.59e-89	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	25.92	3.08e-94	1.59e-89	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	25.92	3.11e-94	1.61e-89	0.96	0.76	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	25.92	3.36e-94	1.72e-89	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-25.88	4.91e-94	2.49e-89	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	25.88	5.04e-94	2.55e-89	0.85	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	25.88	5.04e-94	2.55e-89	0.85	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
KIRC	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	25.87	5.6e-94	2.83e-89	0.98	0.76	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	25.86	6.08e-94	3.05e-89	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	25.83	8.96e-94	4.47e-89	0.98	0.76	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-25.81	1.09e-93	5.4e-89	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	25.81	1.11e-93	5.49e-89	0.97	0.76	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	25.81	1.12e-93	5.54e-89	1.25	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-25.8	1.14e-93	5.66e-89	-0.85	-0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
KIRC	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	25.79	1.27e-93	6.27e-89	0.97	0.76	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	25.79	1.3e-93	6.38e-89	0.95	0.76	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	25.79	1.32e-93	6.5e-89	0.97	0.76	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-25.78	1.44e-93	7.07e-89	-0.85	-0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
KIRC	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-25.74	2.35e-93	1.14e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-25.74	2.35e-93	1.14e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-25.74	2.35e-93	1.14e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
KIRC	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-25.73	2.65e-93	1.29e-88	-1.04	-0.76	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-25.73	2.72e-93	1.32e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-25.73	2.72e-93	1.32e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-25.73	2.72e-93	1.32e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	25.69	3.8e-93	1.83e-88	0.94	0.76	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	25.69	3.8e-93	1.83e-88	0.94	0.76	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	25.69	3.8e-93	1.83e-88	0.94	0.76	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	25.69	3.8e-93	1.83e-88	0.94	0.76	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	25.69	3.8e-93	1.83e-88	0.94	0.76	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	25.69	3.93e-93	1.88e-88	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	25.69	3.93e-93	1.88e-88	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	25.69	3.93e-93	1.88e-88	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
KIRC	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	25.68	4.49e-93	2.14e-88	1.05	0.76	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	25.64	7.32e-93	3.43e-88	1.03	0.76	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-25.62	8.42e-93	3.93e-88	-1.04	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	25.62	8.51e-93	3.97e-88	1.04	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	25.62	8.79e-93	4.09e-88	1.03	0.76	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	25.62	8.79e-93	4.09e-88	1.03	0.76	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	25.62	9.08e-93	4.2e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	25.62	9.08e-93	4.2e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	25.62	9.08e-93	4.2e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	25.62	9.08e-93	4.2e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	25.62	9.08e-93	4.2e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	25.57	1.57e-92	7.22e-88	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
KIRC	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-25.53	2.27e-92	1.04e-87	-0.87	-0.75	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
KIRC	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	25.51	2.77e-92	1.27e-87	0.99	0.75	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	25.51	2.8e-92	1.28e-87	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-25.51	2.91e-92	1.31e-87	-0.95	-0.75	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	25.49	3.52e-92	1.57e-87	0.99	0.75	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	25.44	6.33e-92	2.81e-87	1.25	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	25.42	7.75e-92	3.42e-87	0.99	0.75	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-25.41	8.35e-92	3.67e-87	-0.97	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
KIRC	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	25.41	8.69e-92	3.81e-87	0.97	0.75	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	25.41	9.09e-92	3.98e-87	0.94	0.75	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	25.41	9.09e-92	3.98e-87	0.94	0.75	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	25.41	9.16e-92	4.01e-87	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	25.39	1.16e-91	5.05e-87	0.85	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
KIRC	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	25.37	1.37e-91	5.96e-87	1.18	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
KIRC	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-25.37	1.42e-91	6.04e-87	-0.87	-0.75	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
KIRC	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	25.33	2.08e-91	8.75e-87	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-25.32	2.44e-91	1.03e-86	-1.02	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-25.29	3.35e-91	1.36e-86	-1	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	25.23	6.66e-91	2.66e-86	1.04	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
KIRC	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	25.22	7.31e-91	2.92e-86	1.02	0.75	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	25.21	7.74e-91	3.08e-86	0.96	0.75	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	25.21	8.18e-91	3.25e-86	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	25.19	9.93e-91	3.93e-86	1	0.75	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-25.18	1.08e-90	4.24e-86	-1.03	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	25.16	1.4e-90	5.48e-86	1.23	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	25.15	1.59e-90	6.17e-86	1.01	0.75	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	25.15	1.63e-90	6.34e-86	1.06	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	25.12	2.07e-90	8e-86	1	0.75	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	25.12	2.17e-90	8.38e-86	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	25.12	2.23e-90	8.58e-86	1.01	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	25.11	2.32e-90	8.93e-86	1.04	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-25.11	2.38e-90	9.17e-86	-1.03	-0.75	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	25.1	2.6e-90	9.95e-86	1.04	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-25.08	3.26e-90	1.25e-85	-1.04	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	25.08	3.45e-90	1.32e-85	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-25.06	4.18e-90	1.59e-85	-1.05	-0.75	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
KIRC	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-25.05	4.76e-90	1.8e-85	-0.87	-0.75	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
KIRC	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-25	8.17e-90	3.04e-85	-0.99	-0.75	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	24.97	1.09e-89	4.05e-85	0.95	0.75	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	24.92	2.06e-89	7.53e-85	1.06	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-24.9	2.42e-89	8.58e-85	-1.15	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-24.9	2.42e-89	8.58e-85	-1.15	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	24.9	2.53e-89	8.97e-85	1.23	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
KIRC	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	24.87	3.62e-89	1.27e-84	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-24.85	4.15e-89	1.46e-84	-0.99	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-24.84	4.78e-89	1.67e-84	-1.04	-0.74	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	24.83	5.43e-89	1.9e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	24.81	6.66e-89	2.31e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	24.81	7e-89	2.42e-84	0.93	0.74	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	24.76	1.2e-88	4.11e-84	1.01	0.74	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	24.75	1.3e-88	4.45e-84	0.97	0.74	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	24.74	1.52e-88	5.21e-84	0.95	0.74	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	24.73	1.6e-88	5.49e-84	1.23	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	24.72	1.78e-88	6.07e-84	1	0.74	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	24.71	2.1e-88	7.09e-84	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	24.66	3.44e-88	1.15e-83	0.99	0.74	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	24.62	5.64e-88	1.87e-83	1.23	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
KIRC	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	24.6	6.99e-88	2.3e-83	0.99	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	24.59	7.78e-88	2.56e-83	1.03	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
KIRC	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-24.57	9.59e-88	3.11e-83	-0.86	-0.74	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
KIRC	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	24.54	1.38e-87	4.41e-83	1.21	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
KIRC	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	24.52	1.59e-87	5.04e-83	1.09	0.74	Shingles;	chr7:38346957	chr7:38343894~38350022:-
KIRC	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	24.51	1.77e-87	5.58e-83	0.94	0.74	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	24.49	2.23e-87	7.02e-83	1.21	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-24.49	2.44e-87	7.67e-83	-1.2	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-24.48	2.52e-87	7.91e-83	-0.84	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
KIRC	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-24.47	2.92e-87	9.13e-83	-1.14	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-24.45	3.66e-87	1.14e-82	-1.14	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
KIRC	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	24.43	4.37e-87	1.36e-82	1.01	0.74	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	24.43	4.44e-87	1.38e-82	0.93	0.74	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	24.33	1.39e-86	4.26e-82	1.02	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
KIRC	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-24.25	3.36e-86	1.03e-81	-0.71	-0.74	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-24.24	3.64e-86	1.11e-81	-1.18	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-24.24	3.64e-86	1.11e-81	-1.18	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
KIRC	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	24.24	3.68e-86	1.12e-81	1.01	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	24.24	3.89e-86	1.19e-81	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	24.21	5.45e-86	1.66e-81	0.95	0.74	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	24.19	6.49e-86	1.97e-81	0.71	0.74	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
KIRC	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	24.11	1.64e-85	4.96e-81	0.86	0.73	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
KIRC	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	24.08	2.22e-85	6.68e-81	0.91	0.73	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
KIRC	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-23.98	6.55e-85	1.96e-80	-0.85	-0.73	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
KIRC	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-23.98	6.65e-85	1.99e-80	-0.71	-0.73	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-23.97	7.21e-85	2.15e-80	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-23.97	7.66e-85	2.28e-80	-1.18	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-23.97	7.66e-85	2.28e-80	-1.18	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-23.97	7.9e-85	2.35e-80	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
KIRC	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	23.96	8.61e-85	2.56e-80	0.93	0.73	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
KIRC	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-23.95	9.09e-85	2.7e-80	-1.18	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-23.94	1.08e-84	3.2e-80	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-23.94	1.08e-84	3.2e-80	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-23.94	1.08e-84	3.2e-80	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-23.94	1.08e-84	3.2e-80	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
KIRC	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-23.86	2.5e-84	7.37e-80	-0.71	-0.73	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	23.85	2.79e-84	8.22e-80	1.1	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-23.83	3.63e-84	1.06e-79	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-23.83	3.63e-84	1.06e-79	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-23.83	3.63e-84	1.06e-79	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-23.83	3.63e-84	1.06e-79	-1.11	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-23.81	4.28e-84	1.25e-79	-1.15	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
KIRC	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	23.81	4.59e-84	1.34e-79	0.92	0.73	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-23.78	6.03e-84	1.76e-79	-1.01	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
KIRC	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-23.75	8.69e-84	2.53e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-23.75	9e-84	2.61e-79	-0.72	-0.73	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-23.74	9.19e-84	2.67e-79	-0.72	-0.73	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-23.74	9.74e-84	2.82e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-23.74	9.74e-84	2.82e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-23.72	1.23e-83	3.56e-79	-0.72	-0.73	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-23.72	1.23e-83	3.56e-79	-0.72	-0.73	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	23.72	1.27e-83	3.65e-79	0.99	0.73	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	23.71	1.31e-83	3.78e-79	1.03	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
KIRC	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-23.71	1.4e-83	4.04e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-23.71	1.4e-83	4.04e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-23.71	1.4e-83	4.04e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-23.7	1.58e-83	4.53e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-23.7	1.58e-83	4.53e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-23.7	1.58e-83	4.53e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-23.7	1.58e-83	4.53e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-23.69	1.75e-83	5.01e-79	-1.12	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-23.69	1.75e-83	5.01e-79	-1.12	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
KIRC	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-23.67	2e-83	5.73e-79	-0.72	-0.73	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-23.67	2.18e-83	6.23e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	23.66	2.36e-83	6.7e-79	0.98	0.73	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-23.65	2.78e-83	7.86e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-23.65	2.78e-83	7.86e-79	-0.71	-0.73	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	23.63	3.19e-83	9.03e-79	0.8	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
KIRC	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-23.61	4.07e-83	1.15e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-23.61	4.07e-83	1.15e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-23.6	4.54e-83	1.28e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-23.6	4.54e-83	1.28e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-23.6	4.84e-83	1.36e-78	-0.72	-0.73	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-23.58	5.46e-83	1.53e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-23.58	5.46e-83	1.53e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-23.58	5.46e-83	1.53e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-23.58	5.46e-83	1.53e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-23.58	5.46e-83	1.53e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	23.57	6.62e-83	1.84e-78	0.91	0.73	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	23.57	6.65e-83	1.85e-78	0.7	0.73	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-23.56	7.02e-83	1.95e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-23.55	8.14e-83	2.26e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-23.54	9.16e-83	2.54e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	23.54	9.2e-83	2.55e-78	0.79	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
KIRC	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-23.53	1.02e-82	2.81e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-23.53	1.04e-82	2.84e-78	-0.72	-0.73	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-23.52	1.06e-82	2.9e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-23.52	1.06e-82	2.9e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-23.52	1.06e-82	2.9e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-23.51	1.28e-82	3.49e-78	-0.72	-0.73	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-23.5	1.45e-82	3.95e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-23.49	1.58e-82	4.28e-78	-1.09	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
KIRC	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-23.48	1.83e-82	4.98e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-23.47	2.04e-82	5.54e-78	-0.71	-0.73	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-23.39	4.88e-82	1.32e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-23.36	6.89e-82	1.86e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-23.36	6.89e-82	1.86e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-23.36	6.89e-82	1.86e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	23.35	7.16e-82	1.93e-77	0.9	0.72	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	23.34	8.26e-82	2.22e-77	0.91	0.72	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-23.24	2.48e-81	6.64e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-23.23	2.81e-81	7.5e-77	-0.71	-0.72	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	23.23	2.91e-81	7.74e-77	0.83	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
KIRC	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	23.18	4.8e-81	1.27e-76	0.92	0.72	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-23.17	5.49e-81	1.45e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-23.17	5.49e-81	1.45e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-23.16	5.83e-81	1.53e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-23.16	5.83e-81	1.53e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-23.16	5.83e-81	1.53e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-23.14	7.32e-81	1.92e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-23.11	1.07e-80	2.8e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
KIRC	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-23.11	1.08e-80	2.84e-76	-0.89	-0.72	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-23.07	1.66e-80	4.33e-76	-0.71	-0.72	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-22.99	3.93e-80	1.02e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-22.99	3.93e-80	1.02e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-22.99	3.93e-80	1.02e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-22.99	3.93e-80	1.02e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	22.97	5.32e-80	1.37e-75	0.79	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
KIRC	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-22.94	6.87e-80	1.76e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
KIRC	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	22.93	7.62e-80	1.96e-75	1.01	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
KIRC	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-22.93	7.74e-80	1.98e-75	-0.71	-0.72	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	22.91	9.82e-80	2.51e-75	0.98	0.72	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	22.88	1.35e-79	3.43e-75	0.8	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	22.87	1.54e-79	3.93e-75	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	22.87	1.56e-79	3.98e-75	0.96	0.72	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	22.87	1.58e-79	4.02e-75	1.18	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
KIRC	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	22.8	3.31e-79	8.35e-75	0.98	0.72	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-22.8	3.38e-79	8.5e-75	-0.7	-0.72	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-22.8	3.38e-79	8.5e-75	-0.7	-0.72	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-22.8	3.38e-79	8.5e-75	-0.7	-0.72	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-22.8	3.38e-79	8.5e-75	-0.7	-0.72	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-22.77	4.88e-79	1.22e-74	-0.7	-0.72	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	22.76	5.56e-79	1.39e-74	0.96	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
KIRC	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	22.74	6.89e-79	1.72e-74	0.89	0.71	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	22.71	9.63e-79	2.4e-74	0.89	0.71	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	22.71	9.63e-79	2.4e-74	0.89	0.71	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	22.71	9.63e-79	2.4e-74	0.89	0.71	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	22.71	9.63e-79	2.4e-74	0.89	0.71	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	22.7	1.03e-78	2.57e-74	0.88	0.71	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
KIRC	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	22.69	1.19e-78	2.95e-74	0.99	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-22.67	1.41e-78	3.49e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-22.67	1.41e-78	3.49e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-22.67	1.41e-78	3.49e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-22.63	2.19e-78	5.41e-74	-0.82	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
KIRC	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	22.63	2.28e-78	5.63e-74	0.88	0.71	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	22.63	2.28e-78	5.63e-74	0.88	0.71	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	22.63	2.28e-78	5.63e-74	0.88	0.71	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	22.63	2.28e-78	5.63e-74	0.88	0.71	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
KIRC	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-22.61	2.79e-78	6.84e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-22.61	2.79e-78	6.84e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-22.61	2.79e-78	6.84e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-22.61	2.79e-78	6.84e-74	-0.7	-0.71	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	22.55	5.4e-78	1.32e-73	0.78	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	22.54	6.16e-78	1.48e-73	0.99	0.71	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	22.54	6.38e-78	1.54e-73	0.98	0.71	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-22.53	6.62e-78	1.59e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-22.53	6.62e-78	1.59e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-22.53	6.62e-78	1.59e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-22.51	8.82e-78	2.1e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-22.51	8.96e-78	2.14e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	22.49	1.11e-77	2.64e-73	0.98	0.71	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	22.49	1.11e-77	2.64e-73	0.98	0.71	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
KIRC	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	22.47	1.3e-77	3.05e-73	0.89	0.71	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
KIRC	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	22.45	1.73e-77	4.05e-73	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
KIRC	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	22.44	1.84e-77	4.29e-73	0.89	0.71	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	22.44	1.84e-77	4.29e-73	0.89	0.71	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
KIRC	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	22.44	1.88e-77	4.4e-73	1.04	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
KIRC	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-22.42	2.42e-77	5.64e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	22.41	2.51e-77	5.84e-73	0.98	0.71	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	22.39	3.3e-77	7.66e-73	0.78	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
KIRC	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-22.37	3.88e-77	8.98e-73	-0.7	-0.71	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
KIRC	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	22.36	4.55e-77	1.05e-72	0.87	0.71	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	22.36	4.55e-77	1.05e-72	0.87	0.71	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
KIRC	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	22.36	4.6e-77	1.06e-72	1.04	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
KIRC	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	22.35	4.92e-77	1.13e-72	0.88	0.71	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	22.34	5.43e-77	1.25e-72	0.88	0.71	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	22.28	1.1e-76	2.52e-72	0.89	0.71	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	22.25	1.56e-76	3.55e-72	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
KIRC	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-22.25	1.64e-76	3.74e-72	-0.88	-0.71	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	22.24	1.72e-76	3.9e-72	0.88	0.71	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	22.24	1.72e-76	3.9e-72	0.88	0.71	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-22.22	2.14e-76	4.84e-72	-0.94	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-22.2	2.83e-76	6.37e-72	-0.69	-0.71	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-22.2	2.83e-76	6.37e-72	-0.69	-0.71	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-22.19	3.17e-76	7.13e-72	-0.7	-0.71	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-22.19	3.17e-76	7.13e-72	-0.7	-0.71	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-22.15	4.91e-76	1.1e-71	-1.06	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
KIRC	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	22.14	5.28e-76	1.18e-71	0.88	0.71	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	22.14	5.28e-76	1.18e-71	0.88	0.71	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
KIRC	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	22.13	6.21e-76	1.39e-71	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-22.13	6.22e-76	1.39e-71	-0.69	-0.71	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-22.13	6.22e-76	1.39e-71	-0.69	-0.71	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	22.09	8.94e-76	1.97e-71	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	22.09	9.06e-76	2e-71	0.88	0.7	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	22.08	1.01e-75	2.22e-71	0.87	0.7	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	22.08	1.07e-75	2.35e-71	0.88	0.7	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	22.07	1.12e-75	2.45e-71	0.88	0.7	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	22.06	1.36e-75	2.96e-71	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
KIRC	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-22.04	1.59e-75	3.45e-71	-0.69	-0.7	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	22.04	1.67e-75	3.63e-71	0.88	0.7	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	22.04	1.7e-75	3.69e-71	0.98	0.7	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
KIRC	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	22.03	1.72e-75	3.72e-71	0.87	0.7	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
KIRC	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-22.02	2.11e-75	4.56e-71	-0.69	-0.7	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
KIRC	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	22.01	2.35e-75	5.07e-71	0.86	0.7	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	22	2.5e-75	5.38e-71	0.87	0.7	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	21.99	2.76e-75	5.93e-71	0.78	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
KIRC	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-21.97	3.59e-75	7.67e-71	-0.68	-0.7	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-21.97	3.59e-75	7.67e-71	-0.68	-0.7	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-21.95	4.6e-75	9.78e-71	-0.7	-0.7	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-21.95	4.6e-75	9.78e-71	-0.7	-0.7	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	21.93	5.79e-75	1.23e-70	0.88	0.7	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	21.92	6e-75	1.27e-70	0.87	0.7	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	21.91	7.05e-75	1.49e-70	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
KIRC	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-21.89	8.63e-75	1.82e-70	-0.69	-0.7	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	21.89	8.74e-75	1.84e-70	0.87	0.7	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	21.89	8.74e-75	1.84e-70	0.87	0.7	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	21.89	8.74e-75	1.84e-70	0.87	0.7	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	21.88	9.29e-75	1.95e-70	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	21.87	1.03e-74	2.16e-70	0.78	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
KIRC	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-21.86	1.16e-74	2.43e-70	-0.68	-0.7	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-21.84	1.52e-74	3.16e-70	-0.68	-0.7	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-21.84	1.52e-74	3.16e-70	-0.68	-0.7	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	21.84	1.53e-74	3.19e-70	0.87	0.7	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	21.81	2.08e-74	4.32e-70	0.87	0.7	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	21.81	2.08e-74	4.32e-70	0.87	0.7	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	21.81	2.08e-74	4.32e-70	0.87	0.7	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	21.81	2.08e-74	4.32e-70	0.87	0.7	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	21.81	2.08e-74	4.32e-70	0.87	0.7	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	21.79	2.61e-74	5.4e-70	0.87	0.7	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	21.77	3.24e-74	6.69e-70	0.87	0.7	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-21.77	3.31e-74	6.82e-70	-0.93	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
KIRC	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	21.77	3.38e-74	6.96e-70	0.79	0.7	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
KIRC	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	21.77	3.39e-74	6.98e-70	0.87	0.7	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-21.77	3.39e-74	6.98e-70	-0.69	-0.7	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	21.77	3.4e-74	6.98e-70	0.89	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
KIRC	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-21.77	3.41e-74	7e-70	-0.69	-0.7	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-21.77	3.41e-74	7e-70	-0.69	-0.7	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-21.77	3.41e-74	7e-70	-0.69	-0.7	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
KIRC	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-21.74	4.55e-74	9.28e-70	-1	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
KIRC	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	21.74	4.75e-74	9.69e-70	0.88	0.7	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	21.71	6.19e-74	1.26e-69	0.87	0.7	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	21.71	6.19e-74	1.26e-69	0.87	0.7	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-21.71	6.49e-74	1.31e-69	-0.87	-0.7	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	21.71	6.74e-74	1.36e-69	0.87	0.7	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	21.71	6.74e-74	1.36e-69	0.87	0.7	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	21.69	7.81e-74	1.57e-69	0.87	0.7	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	21.69	7.81e-74	1.57e-69	0.87	0.7	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-21.69	8.2e-74	1.65e-69	-0.79	-0.7	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
KIRC	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-21.66	1.12e-73	2.24e-69	-0.69	-0.7	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
KIRC	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-21.66	1.17e-73	2.34e-69	-0.87	-0.7	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-21.61	2.03e-73	4.04e-69	-0.87	-0.7	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-21.6	2.12e-73	4.22e-69	-0.87	-0.7	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	21.6	2.21e-73	4.39e-69	0.77	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
KIRC	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-21.6	2.28e-73	4.52e-69	-0.87	-0.7	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-21.6	2.28e-73	4.52e-69	-0.87	-0.7	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-21.6	2.28e-73	4.52e-69	-0.87	-0.7	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-21.6	2.28e-73	4.52e-69	-0.87	-0.7	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-21.6	2.28e-73	4.52e-69	-0.87	-0.7	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-21.59	2.34e-73	4.64e-69	-0.87	-0.7	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-21.59	2.34e-73	4.64e-69	-0.87	-0.7	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	21.59	2.35e-73	4.65e-69	0.88	0.7	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-21.59	2.5e-73	4.95e-69	-0.79	-0.7	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
KIRC	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	21.58	2.74e-73	5.42e-69	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
KIRC	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-21.57	2.99e-73	5.91e-69	-0.87	-0.7	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	21.56	3.28e-73	6.47e-69	0.77	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
KIRC	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-21.56	3.34e-73	6.59e-69	-0.87	-0.7	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
KIRC	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	21.55	3.68e-73	7.26e-69	0.68	0.7	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
KIRC	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-21.55	3.77e-73	7.4e-69	-0.87	-0.7	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-21.55	3.77e-73	7.4e-69	-0.87	-0.7	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-21.55	3.77e-73	7.4e-69	-0.87	-0.7	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-21.55	3.77e-73	7.4e-69	-0.87	-0.7	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
KIRC	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	21.54	4.31e-73	8.46e-69	1.1	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	21.53	4.61e-73	9.04e-69	0.78	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
KIRC	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	21.51	5.68e-73	1.11e-68	0.94	0.7	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	21.49	7.07e-73	1.38e-68	0.87	0.69	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	21.49	7.29e-73	1.42e-68	0.87	0.69	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-21.48	8.29e-73	1.61e-68	-0.95	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	21.48	8.45e-73	1.64e-68	0.88	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
KIRC	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-21.47	9.29e-73	1.8e-68	-0.87	-0.69	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	21.45	1.11e-72	2.16e-68	0.87	0.69	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-21.44	1.31e-72	2.52e-68	-0.86	-0.69	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-21.44	1.31e-72	2.52e-68	-0.86	-0.69	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-21.44	1.31e-72	2.52e-68	-0.86	-0.69	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-21.44	1.31e-72	2.52e-68	-0.86	-0.69	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-21.44	1.31e-72	2.52e-68	-0.86	-0.69	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-21.44	1.37e-72	2.64e-68	-0.77	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
KIRC	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	21.43	1.48e-72	2.86e-68	0.88	0.69	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	21.42	1.54e-72	2.96e-68	0.88	0.69	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	21.42	1.61e-72	3.1e-68	0.88	0.69	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	21.42	1.7e-72	3.26e-68	0.88	0.69	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	21.41	1.79e-72	3.43e-68	0.77	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	21.41	1.8e-72	3.46e-68	0.77	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
KIRC	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	21.4	1.94e-72	3.72e-68	0.87	0.69	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-21.39	2.19e-72	4.18e-68	-0.87	-0.69	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-21.39	2.19e-72	4.18e-68	-0.87	-0.69	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-21.39	2.21e-72	4.22e-68	-0.86	-0.69	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-21.39	2.24e-72	4.27e-68	-0.86	-0.69	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-21.39	2.24e-72	4.27e-68	-0.86	-0.69	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	21.39	2.35e-72	4.49e-68	0.87	0.69	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	21.32	5.06e-72	9.55e-68	0.87	0.69	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-21.3	5.87e-72	1.1e-67	-0.68	-0.69	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-21.3	5.87e-72	1.1e-67	-0.68	-0.69	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-21.3	5.87e-72	1.1e-67	-0.68	-0.69	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	21.3	6.28e-72	1.18e-67	0.93	0.69	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	21.29	6.54e-72	1.23e-67	0.87	0.69	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	21.28	7.88e-72	1.47e-67	0.68	0.69	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-21.28	8.08e-72	1.51e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-21.28	8.08e-72	1.51e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-21.28	8.08e-72	1.51e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-21.27	8.3e-72	1.55e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	21.27	8.68e-72	1.62e-67	0.86	0.69	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	21.27	8.68e-72	1.62e-67	0.86	0.69	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-21.26	9.74e-72	1.82e-67	-0.78	-0.69	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	21.25	1.09e-71	2.02e-67	0.78	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
KIRC	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	21.25	1.1e-71	2.05e-67	0.86	0.69	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	21.24	1.2e-71	2.22e-67	0.86	0.69	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	21.24	1.2e-71	2.22e-67	0.86	0.69	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	21.24	1.2e-71	2.22e-67	0.86	0.69	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	21.24	1.25e-71	2.3e-67	0.86	0.69	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	21.24	1.25e-71	2.3e-67	0.86	0.69	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	21.22	1.45e-71	2.68e-67	0.86	0.69	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	21.22	1.51e-71	2.79e-67	0.87	0.69	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	21.22	1.52e-71	2.81e-67	0.86	0.69	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
KIRC	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	21.21	1.77e-71	3.24e-67	0.86	0.69	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	21.2	1.87e-71	3.42e-67	0.87	0.69	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	21.2	1.87e-71	3.42e-67	0.87	0.69	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	21.19	2.13e-71	3.88e-67	0.86	0.69	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-21.19	2.13e-71	3.88e-67	-0.86	-0.69	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	21.19	2.15e-71	3.93e-67	0.86	0.69	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
KIRC	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-21.18	2.33e-71	4.24e-67	-0.68	-0.69	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
KIRC	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	21.17	2.52e-71	4.58e-67	1.02	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	21.17	2.52e-71	4.58e-67	1.02	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
KIRC	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-21.16	2.81e-71	5.1e-67	-0.68	-0.69	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
KIRC	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	21.15	3.15e-71	5.71e-67	0.86	0.69	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
KIRC	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-21.14	3.62e-71	6.56e-67	-0.86	-0.69	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	21.14	3.69e-71	6.68e-67	0.88	0.69	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	21.13	4.04e-71	7.32e-67	0.88	0.69	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	21.11	4.91e-71	8.88e-67	0.87	0.69	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.887	rs4870139	ENSG00000231760.4	RP11-350J20.5	21.11	5e-71	9.03e-67	0.89	0.69	Lung cancer;	chr6:149575182	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	21.11	5.11e-71	9.23e-67	0.88	0.69	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-21.11	5.37e-71	9.68e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-21.11	5.37e-71	9.68e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-21.11	5.37e-71	9.68e-67	-0.7	-0.69	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	21.1	5.6e-71	1.01e-66	0.85	0.69	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	21.09	6.41e-71	1.15e-66	0.88	0.69	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	21.08	6.96e-71	1.25e-66	0.88	0.69	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	21.08	7.08e-71	1.27e-66	0.88	0.69	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	21.08	7.08e-71	1.27e-66	0.88	0.69	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	21.07	7.76e-71	1.39e-66	0.88	0.69	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-21.07	7.85e-71	1.4e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	21.06	9.39e-71	1.67e-66	0.87	0.69	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	21.05	9.69e-71	1.72e-66	0.88	0.69	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
KIRC	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-21.05	9.77e-71	1.73e-66	-0.86	-0.69	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-21.05	9.77e-71	1.73e-66	-0.86	-0.69	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-21.05	1.01e-70	1.79e-66	-0.68	-0.69	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	21.04	1.12e-70	1.99e-66	0.87	0.69	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	21.04	1.12e-70	1.99e-66	0.87	0.69	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	21.03	1.22e-70	2.16e-66	0.87	0.69	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	21.03	1.3e-70	2.29e-66	0.87	0.69	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	21.01	1.6e-70	2.81e-66	0.87	0.69	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
KIRC	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-21.01	1.63e-70	2.85e-66	-0.69	-0.69	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-21.01	1.63e-70	2.85e-66	-0.69	-0.69	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-21.01	1.63e-70	2.85e-66	-0.69	-0.69	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-21.01	1.63e-70	2.85e-66	-0.69	-0.69	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	21	1.75e-70	3.05e-66	0.86	0.69	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-21	1.83e-70	3.2e-66	-0.7	-0.69	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	20.99	2.01e-70	3.5e-66	0.88	0.69	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
KIRC	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	20.99	2.04e-70	3.55e-66	0.89	0.69	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
KIRC	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	20.98	2.14e-70	3.72e-66	0.86	0.69	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	20.98	2.29e-70	3.97e-66	0.88	0.69	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	20.98	2.29e-70	3.97e-66	0.88	0.69	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	20.97	2.34e-70	4.05e-66	0.87	0.69	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	20.97	2.53e-70	4.37e-66	0.89	0.69	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
KIRC	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-20.97	2.57e-70	4.43e-66	-0.86	-0.69	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
KIRC	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	20.96	2.58e-70	4.44e-66	0.86	0.69	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	20.96	2.78e-70	4.78e-66	0.87	0.69	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
KIRC	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-20.95	2.94e-70	5.07e-66	-0.98	-0.69	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	20.95	3e-70	5.16e-66	0.76	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
KIRC	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	20.95	3.02e-70	5.2e-66	0.88	0.69	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	20.95	3.13e-70	5.38e-66	0.77	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
KIRC	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	20.95	3.18e-70	5.45e-66	0.88	0.69	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	20.94	3.35e-70	5.75e-66	0.88	0.69	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	20.93	3.64e-70	6.24e-66	0.88	0.69	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	20.93	3.8e-70	6.49e-66	0.86	0.69	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	20.93	3.8e-70	6.49e-66	0.86	0.69	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	20.93	3.8e-70	6.49e-66	0.86	0.69	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	20.92	4.12e-70	7.05e-66	0.88	0.69	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	20.91	4.55e-70	7.77e-66	0.87	0.68	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	20.91	4.55e-70	7.77e-66	0.87	0.68	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	20.91	4.79e-70	8.18e-66	0.86	0.68	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
KIRC	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	20.91	4.98e-70	8.49e-66	0.68	0.68	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	20.89	5.61e-70	9.54e-66	0.88	0.68	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	20.89	5.64e-70	9.57e-66	0.88	0.68	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	20.89	5.64e-70	9.57e-66	0.88	0.68	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	20.89	5.64e-70	9.57e-66	0.88	0.68	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	20.89	5.78e-70	9.81e-66	0.87	0.68	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
KIRC	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-20.89	6e-70	1.02e-65	-0.68	-0.68	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	20.88	6.85e-70	1.16e-65	0.87	0.68	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-20.87	7.24e-70	1.23e-65	-0.68	-0.68	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	20.87	7.72e-70	1.3e-65	0.87	0.68	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	20.86	7.9e-70	1.33e-65	0.88	0.68	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	20.86	7.93e-70	1.34e-65	0.87	0.68	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	20.83	1.16e-69	1.94e-65	0.87	0.68	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
KIRC	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	20.83	1.18e-69	1.97e-65	0.84	0.68	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	20.83	1.18e-69	1.97e-65	0.88	0.68	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	20.82	1.23e-69	2.05e-65	0.93	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	20.82	1.23e-69	2.05e-65	0.88	0.68	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	20.82	1.27e-69	2.11e-65	0.87	0.68	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	20.82	1.28e-69	2.14e-65	0.85	0.68	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	20.8	1.53e-69	2.55e-65	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
KIRC	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	20.8	1.54e-69	2.55e-65	0.88	0.68	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-20.8	1.67e-69	2.77e-65	-0.84	-0.68	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	20.8	1.7e-69	2.81e-65	0.87	0.68	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	20.79	1.9e-69	3.15e-65	0.88	0.68	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	20.78	2.11e-69	3.5e-65	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
KIRC	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-20.78	2.13e-69	3.51e-65	-0.69	-0.68	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-20.78	2.13e-69	3.51e-65	-0.69	-0.68	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-20.78	2.13e-69	3.51e-65	-0.69	-0.68	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-20.78	2.13e-69	3.51e-65	-0.69	-0.68	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-20.78	2.13e-69	3.51e-65	-0.69	-0.68	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-20.77	2.17e-69	3.58e-65	-0.68	-0.68	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	20.77	2.17e-69	3.58e-65	0.88	0.68	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	20.77	2.21e-69	3.64e-65	0.87	0.68	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	20.77	2.21e-69	3.64e-65	0.87	0.68	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	20.76	2.5e-69	4.12e-65	0.87	0.68	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	20.76	2.56e-69	4.22e-65	0.88	0.68	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	20.75	2.66e-69	4.38e-65	0.87	0.68	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	20.75	2.68e-69	4.4e-65	0.85	0.68	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	20.75	2.8e-69	4.6e-65	0.88	0.68	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-20.73	3.45e-69	5.64e-65	-0.85	-0.68	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	20.73	3.64e-69	5.94e-65	0.88	0.68	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	20.72	3.8e-69	6.2e-65	0.88	0.68	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-20.72	3.96e-69	6.46e-65	-0.85	-0.68	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-20.71	4.54e-69	7.4e-65	-0.68	-0.68	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	20.69	5.25e-69	8.55e-65	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
KIRC	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	20.67	6.86e-69	1.11e-64	0.85	0.68	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	20.67	7.15e-69	1.16e-64	0.87	0.68	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
KIRC	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-20.66	7.33e-69	1.19e-64	-0.68	-0.68	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-20.66	7.33e-69	1.19e-64	-0.68	-0.68	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-20.66	7.33e-69	1.19e-64	-0.68	-0.68	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	20.65	8.21e-69	1.33e-64	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	20.65	8.34e-69	1.35e-64	0.87	0.68	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	20.64	9.39e-69	1.52e-64	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
KIRC	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	20.64	9.46e-69	1.53e-64	0.86	0.68	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
KIRC	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-20.63	1.06e-68	1.71e-64	-0.69	-0.68	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
KIRC	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	20.62	1.15e-68	1.85e-64	0.85	0.68	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-20.62	1.2e-68	1.93e-64	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	20.61	1.33e-68	2.13e-64	0.88	0.68	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-20.6	1.5e-68	2.4e-64	-0.69	-0.68	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
KIRC	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	20.58	1.84e-68	2.94e-64	0.85	0.68	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	20.57	2.08e-68	3.32e-64	0.85	0.68	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	20.57	2.08e-68	3.32e-64	0.85	0.68	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	20.57	2.08e-68	3.32e-64	0.85	0.68	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
KIRC	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	20.57	2.08e-68	3.32e-64	0.85	0.68	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-20.56	2.27e-68	3.62e-64	-0.68	-0.68	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	20.55	2.47e-68	3.93e-64	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
KIRC	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-20.54	2.76e-68	4.39e-64	-0.85	-0.68	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-20.53	3.21e-68	5.11e-64	-0.69	-0.68	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	20.51	3.87e-68	6.15e-64	0.84	0.68	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	20.5	4.49e-68	7.1e-64	0.86	0.68	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	20.46	7.1e-68	1.12e-63	0.85	0.68	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
KIRC	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-20.46	7.18e-68	1.13e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-20.46	7.18e-68	1.13e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-20.46	7.2e-68	1.13e-63	-0.86	-0.68	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-20.46	7.34e-68	1.16e-63	-0.69	-0.68	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
KIRC	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-20.46	7.37e-68	1.16e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	20.45	7.74e-68	1.21e-63	0.87	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
KIRC	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	20.45	8.06e-68	1.26e-63	0.85	0.68	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
KIRC	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-20.44	9.06e-68	1.42e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-20.43	9.57e-68	1.5e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-20.43	9.57e-68	1.5e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	20.43	9.66e-68	1.51e-63	0.88	0.68	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
KIRC	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-20.42	1.05e-67	1.64e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-20.42	1.05e-67	1.64e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-20.42	1.05e-67	1.64e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-20.42	1.05e-67	1.64e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-20.42	1.14e-67	1.78e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	20.4	1.36e-67	2.11e-63	0.76	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-20.4	1.42e-67	2.2e-63	-0.68	-0.68	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-20.39	1.45e-67	2.25e-63	-0.69	-0.68	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
KIRC	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-20.37	1.87e-67	2.88e-63	-0.68	-0.68	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	20.37	1.88e-67	2.9e-63	0.88	0.68	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	20.36	2.06e-67	3.17e-63	0.89	0.68	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	20.36	2.11e-67	3.24e-63	0.67	0.68	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	20.36	2.12e-67	3.26e-63	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	20.36	2.18e-67	3.34e-63	0.86	0.68	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	20.35	2.27e-67	3.48e-63	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
KIRC	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-20.35	2.29e-67	3.51e-63	-0.67	-0.67	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	20.34	2.63e-67	4.02e-63	0.91	0.67	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	20.33	2.94e-67	4.47e-63	0.89	0.67	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	20.33	2.97e-67	4.52e-63	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
KIRC	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	20.33	3.06e-67	4.65e-63	0.87	0.67	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
KIRC	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	20.3	4.33e-67	6.56e-63	0.86	0.67	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	20.29	4.55e-67	6.89e-63	0.88	0.67	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
KIRC	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-20.29	4.81e-67	7.28e-63	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
KIRC	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-20.26	6.18e-67	9.34e-63	-0.87	-0.67	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	20.24	7.8e-67	1.18e-62	0.68	0.67	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	20.23	8.94e-67	1.35e-62	0.87	0.67	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-20.21	1.13e-66	1.7e-62	-0.89	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
KIRC	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	20.21	1.17e-66	1.76e-62	0.89	0.67	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
KIRC	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	20.2	1.21e-66	1.81e-62	0.68	0.67	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
KIRC	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-20.2	1.24e-66	1.87e-62	-0.68	-0.67	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
KIRC	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	20.19	1.49e-66	2.22e-62	0.86	0.67	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
KIRC	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-20.18	1.63e-66	2.43e-62	-0.67	-0.67	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	20.18	1.64e-66	2.46e-62	0.86	0.67	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	20.17	1.7e-66	2.54e-62	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	20.16	1.89e-66	2.82e-62	0.87	0.67	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	20.16	1.91e-66	2.86e-62	0.67	0.67	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-20.15	2.25e-66	3.35e-62	-0.88	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	20.14	2.44e-66	3.64e-62	0.87	0.67	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	20.14	2.46e-66	3.66e-62	0.84	0.67	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
KIRC	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-20.11	3.54e-66	5.26e-62	-0.83	-0.67	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
KIRC	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-20.1	3.71e-66	5.51e-62	-0.96	-0.67	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	20.1	3.74e-66	5.55e-62	0.86	0.67	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
KIRC	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	20.09	4.21e-66	6.23e-62	0.82	0.67	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	20.09	4.21e-66	6.23e-62	0.82	0.67	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	20.09	4.21e-66	6.23e-62	0.82	0.67	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	20.09	4.21e-66	6.23e-62	0.82	0.67	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
KIRC	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-20.09	4.33e-66	6.41e-62	-0.85	-0.67	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	20.09	4.49e-66	6.64e-62	0.86	0.67	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	20.07	5.3e-66	7.81e-62	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
KIRC	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-20.06	6.12e-66	9e-62	-0.69	-0.67	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
KIRC	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	20.05	6.37e-66	9.36e-62	0.92	0.67	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
KIRC	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	20.05	6.78e-66	9.95e-62	0.68	0.67	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-20.04	7.7e-66	1.13e-61	-0.85	-0.67	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
KIRC	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-20.03	8.59e-66	1.26e-61	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	20.02	9.09e-66	1.33e-61	0.86	0.67	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	20.01	1.07e-65	1.56e-61	0.85	0.67	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	19.99	1.27e-65	1.85e-61	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	19.99	1.27e-65	1.85e-61	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-19.98	1.44e-65	2.1e-61	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
KIRC	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	19.98	1.46e-65	2.13e-61	0.67	0.67	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
KIRC	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	19.98	1.51e-65	2.2e-61	0.82	0.67	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	19.96	1.77e-65	2.57e-61	0.85	0.67	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
KIRC	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	19.95	1.93e-65	2.8e-61	0.84	0.67	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	19.95	1.93e-65	2.8e-61	0.84	0.67	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	19.95	2.02e-65	2.93e-61	0.85	0.67	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-19.93	2.61e-65	3.79e-61	-0.66	-0.67	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-19.92	2.83e-65	4.1e-61	-0.66	-0.67	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
KIRC	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-19.91	3.27e-65	4.74e-61	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
KIRC	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	19.9	3.55e-65	5.14e-61	0.84	0.67	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-19.89	4.16e-65	6.01e-61	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	19.88	4.19e-65	6.04e-61	0.83	0.67	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	19.88	4.35e-65	6.28e-61	0.84	0.67	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	19.88	4.5e-65	6.49e-61	0.82	0.67	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-19.87	4.77e-65	6.87e-61	-0.69	-0.67	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	19.87	4.97e-65	7.16e-61	0.85	0.67	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	19.86	5.27e-65	7.59e-61	0.84	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
KIRC	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-19.86	5.31e-65	7.64e-61	-0.89	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
KIRC	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	19.86	5.35e-65	7.69e-61	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
KIRC	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-19.85	5.83e-65	8.37e-61	-0.75	-0.67	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
KIRC	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	19.85	6.46e-65	9.27e-61	0.84	0.67	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	19.85	6.46e-65	9.27e-61	0.84	0.67	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	19.85	6.46e-65	9.27e-61	0.84	0.67	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-19.85	6.47e-65	9.28e-61	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
KIRC	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-19.84	6.7e-65	9.6e-61	-0.68	-0.67	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
KIRC	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	19.84	6.87e-65	9.82e-61	0.84	0.67	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	19.84	6.87e-65	9.82e-61	0.84	0.67	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	19.84	6.87e-65	9.82e-61	0.84	0.67	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	19.84	6.87e-65	9.82e-61	0.84	0.67	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	19.84	6.87e-65	9.82e-61	0.84	0.67	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	19.84	7.09e-65	1.01e-60	0.84	0.67	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	19.84	7.09e-65	1.01e-60	0.84	0.67	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	19.83	7.38e-65	1.05e-60	0.84	0.67	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	19.83	7.38e-65	1.05e-60	0.84	0.67	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	19.83	7.38e-65	1.05e-60	0.84	0.67	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	19.83	7.66e-65	1.09e-60	0.84	0.67	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	19.83	7.77e-65	1.11e-60	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-19.82	8.12e-65	1.15e-60	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-19.82	8.12e-65	1.15e-60	-0.68	-0.67	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
KIRC	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	19.81	9.54e-65	1.36e-60	0.84	0.66	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	19.8	1.01e-64	1.44e-60	0.82	0.66	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
KIRC	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-19.8	1.12e-64	1.59e-60	-0.68	-0.66	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
KIRC	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	19.79	1.24e-64	1.75e-60	0.84	0.66	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
KIRC	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-19.78	1.29e-64	1.83e-60	-0.68	-0.66	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	19.78	1.37e-64	1.93e-60	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	19.78	1.37e-64	1.94e-60	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
KIRC	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	19.77	1.42e-64	2e-60	0.84	0.66	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	19.77	1.42e-64	2e-60	0.84	0.66	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	19.76	1.58e-64	2.22e-60	0.85	0.66	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	19.76	1.69e-64	2.37e-60	0.88	0.66	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-19.74	2.09e-64	2.93e-60	-0.84	-0.66	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-19.74	2.09e-64	2.93e-60	-0.84	-0.66	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	19.73	2.31e-64	3.24e-60	0.89	0.66	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	19.73	2.31e-64	3.24e-60	0.89	0.66	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	19.73	2.36e-64	3.31e-60	0.89	0.66	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
KIRC	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-19.73	2.38e-64	3.33e-60	-0.83	-0.66	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-19.73	2.38e-64	3.33e-60	-0.83	-0.66	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
KIRC	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	19.7	3.24e-64	4.52e-60	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	19.69	3.44e-64	4.8e-60	0.9	0.66	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
KIRC	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	19.68	4.09e-64	5.7e-60	0.81	0.66	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	19.68	4.14e-64	5.77e-60	0.81	0.66	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
KIRC	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	19.67	4.29e-64	5.98e-60	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
KIRC	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	19.66	4.93e-64	6.86e-60	0.84	0.66	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	19.66	5.27e-64	7.34e-60	0.83	0.66	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	19.65	5.44e-64	7.56e-60	0.84	0.66	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	19.65	5.8e-64	8.06e-60	0.9	0.66	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
KIRC	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	19.64	6.18e-64	8.59e-60	0.83	0.66	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-19.64	6.31e-64	8.76e-60	-0.83	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	19.64	6.43e-64	8.92e-60	0.84	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
KIRC	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	19.63	6.81e-64	9.45e-60	0.85	0.66	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	19.63	7.06e-64	9.79e-60	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	19.62	8.25e-64	1.14e-59	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
KIRC	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	19.59	1.07e-63	1.49e-59	0.83	0.66	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	19.59	1.07e-63	1.49e-59	0.83	0.66	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	19.59	1.08e-63	1.49e-59	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
KIRC	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	19.59	1.09e-63	1.51e-59	0.87	0.66	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	19.59	1.14e-63	1.58e-59	0.87	0.66	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-19.59	1.15e-63	1.59e-59	-0.75	-0.66	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
KIRC	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-19.56	1.48e-63	2.04e-59	-0.66	-0.66	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
KIRC	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	19.56	1.5e-63	2.06e-59	0.82	0.66	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	19.56	1.54e-63	2.12e-59	0.83	0.66	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	19.56	1.54e-63	2.12e-59	0.83	0.66	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-19.55	1.7e-63	2.34e-59	-0.67	-0.66	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
KIRC	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	19.55	1.75e-63	2.4e-59	0.81	0.66	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	19.55	1.75e-63	2.4e-59	0.81	0.66	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	19.55	1.76e-63	2.42e-59	0.81	0.66	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
KIRC	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-19.54	1.94e-63	2.67e-59	-0.83	-0.66	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	19.51	2.76e-63	3.78e-59	0.87	0.66	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
KIRC	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	19.5	3.03e-63	4.15e-59	0.81	0.66	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	19.5	3.1e-63	4.25e-59	0.87	0.66	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-19.49	3.26e-63	4.46e-59	-0.84	-0.66	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-19.49	3.42e-63	4.68e-59	-0.83	-0.66	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-19.48	3.64e-63	4.97e-59	-0.86	-0.66	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
KIRC	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-19.47	4.13e-63	5.64e-59	-0.8	-0.66	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	19.47	4.31e-63	5.87e-59	0.83	0.66	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-19.46	4.48e-63	6.1e-59	-0.83	-0.66	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	19.46	4.74e-63	6.45e-59	0.83	0.66	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	19.45	4.92e-63	6.69e-59	0.86	0.66	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-19.45	4.99e-63	6.78e-59	-0.7	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
KIRC	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	19.45	5.18e-63	7.03e-59	1.03	0.66	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
KIRC	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-19.43	6.17e-63	8.36e-59	-0.66	-0.66	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
KIRC	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	19.43	6.31e-63	8.55e-59	1.04	0.66	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
KIRC	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	19.42	7.29e-63	9.86e-59	0.81	0.66	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
KIRC	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-19.41	7.96e-63	1.08e-58	-1.05	-0.66	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	19.41	8.24e-63	1.11e-58	0.9	0.66	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-19.4	8.98e-63	1.21e-58	-1.06	-0.66	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
KIRC	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	19.4	9.32e-63	1.26e-58	0.81	0.66	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
KIRC	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-19.4	9.43e-63	1.27e-58	-0.87	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
KIRC	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	19.39	9.73e-63	1.31e-58	1.03	0.66	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
KIRC	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	19.39	1.01e-62	1.35e-58	1.04	0.66	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	19.39	1.01e-62	1.35e-58	1.04	0.66	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
KIRC	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	19.38	1.1e-62	1.48e-58	1.03	0.66	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
KIRC	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-19.37	1.18e-62	1.58e-58	-0.65	-0.66	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
KIRC	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-19.37	1.24e-62	1.66e-58	-0.66	-0.66	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
KIRC	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	19.36	1.37e-62	1.83e-58	0.85	0.66	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
KIRC	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	19.35	1.6e-62	2.13e-58	1.04	0.66	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
KIRC	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	19.33	1.94e-62	2.58e-58	1.04	0.66	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
KIRC	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	19.32	2.18e-62	2.9e-58	0.86	0.66	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
KIRC	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-19.32	2.27e-62	3.02e-58	-0.86	-0.66	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-19.32	2.27e-62	3.02e-58	-0.86	-0.66	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
KIRC	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-19.31	2.52e-62	3.35e-58	-0.64	-0.66	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
KIRC	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-19.3	2.62e-62	3.48e-58	-0.67	-0.66	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
KIRC	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	19.27	3.63e-62	4.82e-58	0.85	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-19.26	4.38e-62	5.79e-58	-1.05	-0.65	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
KIRC	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	19.25	4.49e-62	5.94e-58	0.86	0.65	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
KIRC	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-19.25	4.55e-62	6.01e-58	-0.66	-0.65	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	19.25	4.58e-62	6.06e-58	0.86	0.65	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
KIRC	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-19.23	5.78e-62	7.62e-58	-0.65	-0.65	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	19.23	5.79e-62	7.63e-58	0.9	0.65	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	19.23	6.04e-62	7.96e-58	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
KIRC	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-19.22	6.79e-62	8.94e-58	-0.74	-0.65	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
KIRC	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	19.19	9.3e-62	1.22e-57	0.9	0.65	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
KIRC	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-19.19	9.46e-62	1.24e-57	-0.83	-0.65	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	19.18	9.63e-62	1.26e-57	0.85	0.65	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
KIRC	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	19.18	1.01e-61	1.33e-57	0.86	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	19.16	1.22e-61	1.59e-57	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	19.16	1.22e-61	1.59e-57	0.84	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	19.16	1.26e-61	1.65e-57	0.84	0.65	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	19.15	1.37e-61	1.8e-57	0.66	0.65	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
KIRC	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-19.15	1.45e-61	1.89e-57	-0.83	-0.65	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-19.15	1.46e-61	1.91e-57	-0.64	-0.65	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	19.14	1.66e-61	2.16e-57	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
KIRC	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	19.13	1.69e-61	2.2e-57	0.64	0.65	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
KIRC	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	19.12	1.87e-61	2.44e-57	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	19.12	1.96e-61	2.55e-57	0.9	0.65	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-19.1	2.33e-61	3.04e-57	-1.05	-0.65	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
KIRC	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-19.1	2.57e-61	3.34e-57	-0.66	-0.65	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
KIRC	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.09	2.75e-61	3.58e-57	0.9	0.65	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	19.08	3.02e-61	3.91e-57	0.85	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	19.07	3.34e-61	4.33e-57	0.84	0.65	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	19.07	3.37e-61	4.36e-57	0.82	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
KIRC	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	19.04	4.64e-61	6e-57	1	0.65	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
KIRC	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	19.04	4.64e-61	6e-57	1	0.65	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
KIRC	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-19.04	4.66e-61	6.02e-57	-1.05	-0.65	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-19.04	4.66e-61	6.02e-57	-1.05	-0.65	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
KIRC	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-19.02	5.9e-61	7.59e-57	-0.65	-0.65	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	19.02	5.94e-61	7.63e-57	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	19.02	5.94e-61	7.63e-57	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
KIRC	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	19.01	6.81e-61	8.72e-57	0.97	0.65	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	19.01	6.82e-61	8.73e-57	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
KIRC	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	19.01	6.85e-61	8.77e-57	1.02	0.65	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
KIRC	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	19.01	6.93e-61	8.87e-57	0.97	0.65	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-19	7.57e-61	9.67e-57	-0.86	-0.65	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
KIRC	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	19	7.7e-61	9.83e-57	1.02	0.65	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
KIRC	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	18.99	7.89e-61	1.01e-56	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
KIRC	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	18.99	8.15e-61	1.04e-56	0.66	0.65	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
KIRC	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	18.93	1.54e-60	1.95e-56	0.97	0.65	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
KIRC	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	18.92	1.7e-60	2.14e-56	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-18.91	1.94e-60	2.45e-56	-1.06	-0.65	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	18.89	2.42e-60	3.05e-56	0.83	0.65	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	18.89	2.43e-60	3.07e-56	0.83	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	18.89	2.51e-60	3.15e-56	0.85	0.65	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
KIRC	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-18.88	2.7e-60	3.4e-56	-0.66	-0.65	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
KIRC	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	18.87	2.96e-60	3.71e-56	0.85	0.65	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
KIRC	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	18.87	3.14e-60	3.94e-56	0.97	0.65	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
KIRC	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	18.86	3.57e-60	4.47e-56	1.02	0.65	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
KIRC	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	18.85	3.77e-60	4.71e-56	0.83	0.65	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-18.84	4.24e-60	5.28e-56	-0.81	-0.65	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-18.83	4.66e-60	5.79e-56	-0.64	-0.65	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
KIRC	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	18.81	5.76e-60	7.13e-56	0.78	0.65	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	18.81	5.76e-60	7.13e-56	0.78	0.65	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	18.81	5.76e-60	7.13e-56	0.78	0.65	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
KIRC	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-18.81	6.29e-60	7.77e-56	-0.82	-0.65	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	18.8	6.48e-60	8e-56	0.72	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	18.8	6.48e-60	8e-56	0.72	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
KIRC	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-18.79	7.11e-60	8.76e-56	-0.81	-0.65	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	18.78	8.13e-60	1e-55	0.73	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
KIRC	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	18.76	1.03e-59	1.27e-55	0.87	0.64	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
KIRC	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	18.75	1.13e-59	1.39e-55	1.02	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
KIRC	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	18.75	1.13e-59	1.39e-55	1.02	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
KIRC	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-18.75	1.19e-59	1.46e-55	-0.83	-0.64	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-18.74	1.23e-59	1.51e-55	-0.65	-0.64	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
KIRC	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-18.74	1.23e-59	1.51e-55	-0.65	-0.64	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
KIRC	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-18.74	1.27e-59	1.55e-55	-0.81	-0.64	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-18.74	1.33e-59	1.62e-55	-0.81	-0.64	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	18.73	1.47e-59	1.79e-55	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
KIRC	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-18.71	1.7e-59	2.07e-55	-0.81	-0.64	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-18.71	1.78e-59	2.17e-55	-0.81	-0.64	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-18.7	2e-59	2.43e-55	-0.72	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	18.66	2.99e-59	3.61e-55	0.7	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	18.66	3.09e-59	3.72e-55	0.65	0.64	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
KIRC	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	18.65	3.37e-59	4.05e-55	0.78	0.64	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-18.65	3.49e-59	4.19e-55	-0.81	-0.64	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-18.65	3.64e-59	4.35e-55	-0.83	-0.64	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	18.64	3.95e-59	4.72e-55	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
KIRC	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	18.64	4.09e-59	4.88e-55	0.65	0.64	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	18.63	4.28e-59	5.11e-55	0.65	0.64	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	18.63	4.46e-59	5.32e-55	0.7	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
KIRC	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	18.62	4.6e-59	5.49e-55	0.96	0.64	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	18.61	5.23e-59	6.21e-55	0.73	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
KIRC	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	18.61	5.44e-59	6.46e-55	0.96	0.64	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
KIRC	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	18.61	5.47e-59	6.49e-55	0.65	0.64	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
KIRC	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-18.6	6.19e-59	7.31e-55	-0.65	-0.64	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
KIRC	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	18.59	6.41e-59	7.56e-55	0.77	0.64	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
KIRC	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-18.59	6.82e-59	8.04e-55	-1.04	-0.64	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
KIRC	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-18.57	8.4e-59	9.89e-55	-0.65	-0.64	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
KIRC	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	18.55	1.02e-58	1.2e-54	0.82	0.64	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-18.54	1.11e-58	1.3e-54	-0.72	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
KIRC	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	18.54	1.2e-58	1.41e-54	0.95	0.64	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
KIRC	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	18.53	1.25e-58	1.47e-54	0.79	0.64	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	18.53	1.28e-58	1.5e-54	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-18.53	1.28e-58	1.5e-54	-1.04	-0.64	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-18.52	1.42e-58	1.65e-54	-1.04	-0.64	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-18.52	1.48e-58	1.73e-54	-0.78	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
KIRC	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-18.51	1.67e-58	1.94e-54	-0.64	-0.64	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
KIRC	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-18.5	1.75e-58	2.04e-54	-0.64	-0.64	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
KIRC	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	18.5	1.84e-58	2.14e-54	0.82	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-18.49	2e-58	2.32e-54	-1.04	-0.64	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
KIRC	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	18.47	2.47e-58	2.86e-54	1.02	0.64	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
KIRC	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-18.47	2.5e-58	2.89e-54	-0.81	-0.64	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-18.47	2.51e-58	2.91e-54	-0.85	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
KIRC	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-18.46	2.64e-58	3.06e-54	-0.65	-0.64	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
KIRC	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-18.45	3.16e-58	3.65e-54	-0.68	-0.64	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-18.44	3.39e-58	3.9e-54	-0.82	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	18.43	4.02e-58	4.61e-54	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	18.43	4.02e-58	4.61e-54	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
KIRC	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-18.42	4.56e-58	5.23e-54	-0.82	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.41	4.81e-58	5.52e-54	0.82	0.64	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
KIRC	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-18.4	5.46e-58	6.25e-54	-0.68	-0.64	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
KIRC	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	18.37	7.22e-58	8.22e-54	0.86	0.64	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
KIRC	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-18.37	7.44e-58	8.47e-54	-0.81	-0.64	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-18.37	7.82e-58	8.88e-54	-0.66	-0.64	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
KIRC	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-18.37	7.89e-58	8.96e-54	-0.79	-0.64	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.36	8.74e-58	9.9e-54	0.82	0.64	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	18.35	9.42e-58	1.06e-53	0.8	0.64	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-18.33	1.11e-57	1.25e-53	-0.64	-0.64	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
KIRC	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	18.33	1.11e-57	1.25e-53	0.81	0.64	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-18.33	1.16e-57	1.31e-53	-0.8	-0.64	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
KIRC	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	18.32	1.23e-57	1.38e-53	0.76	0.64	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	18.32	1.27e-57	1.43e-53	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
KIRC	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-18.31	1.48e-57	1.66e-53	-0.65	-0.64	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
KIRC	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-18.31	1.52e-57	1.7e-53	-0.81	-0.64	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	18.29	1.87e-57	2.09e-53	0.8	0.63	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
KIRC	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-18.28	2.07e-57	2.31e-53	-0.81	-0.63	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-18.28	2.1e-57	2.35e-53	-0.82	-0.63	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
KIRC	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-18.26	2.59e-57	2.89e-53	-0.81	-0.63	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-18.25	2.68e-57	2.99e-53	-0.8	-0.63	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	18.24	3.09e-57	3.44e-53	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
KIRC	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-18.24	3.12e-57	3.48e-53	-1.03	-0.63	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-18.24	3.12e-57	3.48e-53	-1.03	-0.63	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	18.23	3.42e-57	3.8e-53	0.8	0.63	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-18.22	3.68e-57	4.09e-53	-0.81	-0.63	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	18.22	3.73e-57	4.14e-53	0.69	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
KIRC	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-18.21	4.52e-57	5e-53	-0.81	-0.63	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	18.2	4.83e-57	5.34e-53	0.8	0.63	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	18.2	4.83e-57	5.34e-53	0.8	0.63	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
KIRC	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	18.2	4.92e-57	5.44e-53	0.77	0.63	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
KIRC	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	18.2	5.06e-57	5.6e-53	0.68	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
KIRC	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-18.19	5.12e-57	5.66e-53	-0.8	-0.63	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	18.19	5.35e-57	5.9e-53	0.7	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	18.19	5.43e-57	6e-53	0.64	0.63	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	18.19	5.48e-57	6.04e-53	0.64	0.63	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
KIRC	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	18.19	5.48e-57	6.04e-53	0.64	0.63	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
KIRC	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	18.18	6.25e-57	6.88e-53	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
KIRC	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	18.17	6.33e-57	6.97e-53	0.8	0.63	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	18.17	6.33e-57	6.97e-53	0.8	0.63	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	18.17	6.58e-57	7.24e-53	0.64	0.63	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	18.17	6.87e-57	7.54e-53	0.81	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
KIRC	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-18.16	7.11e-57	7.8e-53	-0.82	-0.63	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-18.16	7.11e-57	7.8e-53	-0.82	-0.63	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-18.16	7.37e-57	8.08e-53	-0.8	-0.63	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
KIRC	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-18.16	7.48e-57	8.2e-53	-0.93	-0.63	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-18.15	7.92e-57	8.68e-53	-0.79	-0.63	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
KIRC	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-18.15	8.17e-57	8.95e-53	-0.81	-0.63	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
KIRC	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	18.15	8.77e-57	9.59e-53	0.98	0.63	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
KIRC	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	18.14	9.04e-57	9.88e-53	0.96	0.63	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-18.14	9.64e-57	1.05e-52	-0.8	-0.63	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	18.13	1.02e-56	1.12e-52	0.77	0.63	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-18.13	1.04e-56	1.14e-52	-0.79	-0.63	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
KIRC	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	18.12	1.13e-56	1.23e-52	0.97	0.63	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
KIRC	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	18.12	1.21e-56	1.32e-52	0.97	0.63	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
KIRC	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	18.11	1.25e-56	1.36e-52	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	18.11	1.26e-56	1.37e-52	0.79	0.63	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-18.09	1.55e-56	1.68e-52	-0.71	-0.63	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
KIRC	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-18.09	1.66e-56	1.79e-52	-0.8	-0.63	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
KIRC	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	18.09	1.67e-56	1.8e-52	0.77	0.63	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	18.09	1.67e-56	1.8e-52	0.77	0.63	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	18.08	1.87e-56	2.02e-52	0.8	0.63	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	18.08	1.88e-56	2.03e-52	0.64	0.63	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	18.07	2.04e-56	2.19e-52	0.81	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
KIRC	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	18.06	2.18e-56	2.34e-52	0.77	0.63	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
KIRC	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	18.06	2.22e-56	2.39e-52	0.64	0.63	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
KIRC	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-18.06	2.31e-56	2.49e-52	-0.8	-0.63	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
KIRC	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	18.05	2.47e-56	2.66e-52	0.58	0.63	Breast cancer;	chr11:750849	chr11:779617~780755:+
KIRC	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	18.04	2.7e-56	2.88e-52	0.77	0.63	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	18.04	2.7e-56	2.88e-52	0.77	0.63	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	18.04	2.75e-56	2.94e-52	0.77	0.63	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	18.04	2.81e-56	3e-52	0.77	0.63	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	18.04	2.81e-56	3e-52	0.77	0.63	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	18.04	2.9e-56	3.09e-52	0.79	0.63	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
KIRC	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	18.03	2.99e-56	3.18e-52	0.77	0.63	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	18.03	3.01e-56	3.21e-52	0.8	0.63	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	18.03	3.01e-56	3.21e-52	0.77	0.63	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	18.03	3.05e-56	3.24e-52	0.82	0.63	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	18.03	3.15e-56	3.35e-52	0.79	0.63	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
KIRC	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-18.02	3.42e-56	3.63e-52	-1.02	-0.63	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
KIRC	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	18	4.18e-56	4.43e-52	0.96	0.63	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
KIRC	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	18	4.35e-56	4.61e-52	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
KIRC	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-18	4.41e-56	4.67e-52	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	18	4.45e-56	4.71e-52	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
KIRC	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-17.99	4.7e-56	4.97e-52	-1.02	-0.63	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
KIRC	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	17.99	4.99e-56	5.27e-52	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
KIRC	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	17.97	5.72e-56	6.03e-52	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
KIRC	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	17.95	7.66e-56	8.05e-52	0.77	0.63	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	17.94	8.32e-56	8.74e-52	0.76	0.63	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
KIRC	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	17.94	8.36e-56	8.77e-52	0.76	0.63	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	17.94	8.51e-56	8.93e-52	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	17.94	8.61e-56	9.03e-52	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
KIRC	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-17.93	9.12e-56	9.56e-52	-0.76	-0.63	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
KIRC	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-17.93	9.19e-56	9.63e-52	-0.77	-0.63	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	17.91	1.13e-55	1.18e-51	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
KIRC	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	17.91	1.13e-55	1.18e-51	0.79	0.63	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	17.91	1.13e-55	1.18e-51	0.79	0.63	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	17.91	1.18e-55	1.23e-51	0.81	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	17.9	1.22e-55	1.27e-51	0.69	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	17.9	1.23e-55	1.29e-51	0.77	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
KIRC	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	17.9	1.34e-55	1.39e-51	0.79	0.63	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
KIRC	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	17.89	1.39e-55	1.45e-51	0.91	0.63	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
KIRC	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	17.89	1.43e-55	1.49e-51	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
KIRC	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	17.89	1.44e-55	1.5e-51	0.79	0.63	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-17.88	1.61e-55	1.67e-51	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
KIRC	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-17.87	1.71e-55	1.77e-51	-0.92	-0.63	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	17.87	1.79e-55	1.86e-51	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
KIRC	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-17.85	2.13e-55	2.2e-51	-0.82	-0.63	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-17.85	2.13e-55	2.2e-51	-0.82	-0.63	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-17.85	2.14e-55	2.21e-51	-0.72	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
KIRC	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	17.84	2.46e-55	2.55e-51	0.75	0.63	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
KIRC	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-17.84	2.48e-55	2.57e-51	-0.77	-0.63	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
KIRC	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	17.84	2.53e-55	2.62e-51	0.95	0.63	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
KIRC	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	17.84	2.53e-55	2.62e-51	0.95	0.63	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
KIRC	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	17.84	2.53e-55	2.62e-51	0.95	0.63	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
KIRC	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-17.83	2.62e-55	2.71e-51	-0.67	-0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
KIRC	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	17.81	3.3e-55	3.4e-51	0.76	0.62	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	17.81	3.3e-55	3.4e-51	0.76	0.62	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
KIRC	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-17.81	3.35e-55	3.45e-51	-0.94	-0.62	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
KIRC	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-17.81	3.47e-55	3.57e-51	-0.68	-0.62	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
KIRC	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	17.79	4.01e-55	4.12e-51	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	17.79	4.22e-55	4.34e-51	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
KIRC	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	17.78	4.63e-55	4.76e-51	0.84	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
KIRC	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	17.77	5.06e-55	5.19e-51	0.79	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
KIRC	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	17.76	5.91e-55	6.06e-51	0.97	0.62	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
KIRC	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	17.76	5.93e-55	6.08e-51	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
KIRC	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	17.76	6.11e-55	6.26e-51	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-17.75	6.21e-55	6.35e-51	-0.8	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
KIRC	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-17.74	6.97e-55	7.12e-51	-0.81	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
KIRC	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-17.72	8.81e-55	8.99e-51	-0.82	-0.62	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
KIRC	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	17.72	9.04e-55	9.22e-51	0.67	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
KIRC	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	17.72	9.49e-55	9.67e-51	0.65	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
KIRC	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	17.72	9.5e-55	9.69e-51	0.96	0.62	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-17.71	9.6e-55	9.78e-51	-0.82	-0.62	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
KIRC	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	17.71	9.62e-55	9.8e-51	0.76	0.62	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
KIRC	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	17.71	9.71e-55	9.89e-51	0.65	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
KIRC	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	17.71	1.03e-54	1.05e-50	0.97	0.62	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
KIRC	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-17.7	1.09e-54	1.11e-50	-0.67	-0.62	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
KIRC	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	17.7	1.09e-54	1.11e-50	0.94	0.62	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
KIRC	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	17.7	1.1e-54	1.12e-50	1.07	0.62	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
KIRC	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	17.7	1.13e-54	1.15e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	17.69	1.19e-54	1.21e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
KIRC	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-17.69	1.2e-54	1.22e-50	-0.82	-0.62	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-17.69	1.2e-54	1.22e-50	-0.82	-0.62	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
KIRC	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	17.69	1.22e-54	1.24e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	17.69	1.22e-54	1.24e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	17.69	1.22e-54	1.24e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	17.69	1.22e-54	1.24e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
KIRC	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-17.69	1.31e-54	1.32e-50	-0.68	-0.62	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
KIRC	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	17.68	1.46e-54	1.47e-50	0.67	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
KIRC	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-17.67	1.5e-54	1.52e-50	-0.76	-0.62	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
KIRC	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	17.67	1.53e-54	1.55e-50	0.94	0.62	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	17.67	1.59e-54	1.6e-50	0.79	0.62	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
KIRC	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	17.66	1.68e-54	1.7e-50	0.99	0.62	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
KIRC	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-17.66	1.72e-54	1.74e-50	-0.78	-0.62	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-17.65	1.91e-54	1.92e-50	-0.82	-0.62	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-17.65	1.91e-54	1.92e-50	-0.82	-0.62	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
KIRC	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	17.64	2.28e-54	2.29e-50	0.67	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
KIRC	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	17.63	2.39e-54	2.4e-50	0.83	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
KIRC	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	17.63	2.42e-54	2.43e-50	0.75	0.62	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
KIRC	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	17.62	2.67e-54	2.68e-50	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	17.62	2.67e-54	2.68e-50	0.77	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
KIRC	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	17.62	2.72e-54	2.73e-50	0.66	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
KIRC	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-17.61	3.14e-54	3.15e-50	-0.67	-0.62	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
KIRC	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	17.6	3.48e-54	3.48e-50	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-17.59	3.6e-54	3.61e-50	-0.81	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
KIRC	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	17.59	3.65e-54	3.65e-50	0.93	0.62	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	17.59	3.76e-54	3.77e-50	0.81	0.62	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
KIRC	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	17.59	3.91e-54	3.9e-50	0.71	0.62	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
KIRC	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	17.58	3.92e-54	3.92e-50	0.75	0.62	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
KIRC	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-17.57	4.47e-54	4.46e-50	-0.8	-0.62	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
KIRC	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-17.57	4.8e-54	4.79e-50	-0.7	-0.62	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
KIRC	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	17.55	5.82e-54	5.8e-50	0.77	0.62	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
KIRC	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	17.55	5.82e-54	5.8e-50	0.77	0.62	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	17.54	6.33e-54	6.29e-50	0.82	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
KIRC	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	17.54	6.67e-54	6.63e-50	0.81	0.62	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	17.54	6.67e-54	6.63e-50	0.81	0.62	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
KIRC	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	17.53	6.95e-54	6.9e-50	1.05	0.62	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
KIRC	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	17.53	7.3e-54	7.25e-50	0.71	0.62	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	17.51	8.72e-54	8.65e-50	0.68	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
KIRC	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	17.5	1e-53	9.94e-50	0.82	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
KIRC	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	17.5	1.02e-53	1.01e-49	0.75	0.62	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
KIRC	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-17.49	1.08e-53	1.06e-49	-0.67	-0.62	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
KIRC	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	17.49	1.11e-53	1.09e-49	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
KIRC	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-17.49	1.11e-53	1.1e-49	-0.8	-0.62	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
KIRC	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	17.47	1.39e-53	1.38e-49	0.65	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
KIRC	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-17.46	1.49e-53	1.47e-49	-0.82	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
KIRC	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	17.44	1.97e-53	1.93e-49	0.81	0.62	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
KIRC	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	17.41	2.67e-53	2.62e-49	0.91	0.62	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-17.4	2.95e-53	2.88e-49	-0.67	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
KIRC	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	17.4	3.01e-53	2.95e-49	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	17.39	3.16e-53	3.08e-49	0.81	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	17.37	4.23e-53	4.12e-49	0.8	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
KIRC	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	17.36	4.35e-53	4.23e-49	0.66	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
KIRC	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	17.35	5.03e-53	4.89e-49	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
KIRC	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	17.35	5.12e-53	4.98e-49	0.94	0.61	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
KIRC	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	17.35	5.21e-53	5.06e-49	0.82	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-17.35	5.22e-53	5.07e-49	-0.79	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-17.34	5.54e-53	5.38e-49	-0.77	-0.61	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	17.34	5.66e-53	5.49e-49	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	17.34	5.66e-53	5.49e-49	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
KIRC	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	17.34	5.75e-53	5.57e-49	0.95	0.61	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
KIRC	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	17.34	5.75e-53	5.57e-49	0.95	0.61	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
KIRC	cis	rs10256972	0.552	rs6953538	ENSG00000229043.2	AC091729.9	-17.33	6.14e-53	5.92e-49	-0.69	-0.61	Endometriosis;Longevity;	chr7:1157338	chr7:1160374~1165267:+
KIRC	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-17.33	6.18e-53	5.96e-49	-0.76	-0.61	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
KIRC	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	17.32	6.73e-53	6.47e-49	0.82	0.61	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
KIRC	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	17.31	7.49e-53	7.2e-49	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
KIRC	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	17.31	7.76e-53	7.44e-49	0.76	0.61	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
KIRC	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	17.31	7.98e-53	7.65e-49	0.82	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	17.31	7.98e-53	7.65e-49	0.82	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
KIRC	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	17.3	8.52e-53	8.17e-49	0.64	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
KIRC	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	17.3	8.79e-53	8.42e-49	0.98	0.61	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	17.3	8.85e-53	8.47e-49	0.8	0.61	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	17.3	8.85e-53	8.47e-49	0.8	0.61	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	17.3	8.85e-53	8.47e-49	0.8	0.61	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	17.3	9.01e-53	8.62e-49	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	17.28	1.12e-52	1.06e-48	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
KIRC	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	17.27	1.16e-52	1.1e-48	0.81	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	17.27	1.21e-52	1.15e-48	0.81	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
KIRC	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	17.26	1.3e-52	1.23e-48	0.66	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	17.26	1.31e-52	1.25e-48	0.68	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	17.25	1.46e-52	1.39e-48	0.67	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
KIRC	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	17.25	1.52e-52	1.44e-48	0.7	0.61	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
KIRC	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	17.24	1.58e-52	1.5e-48	0.91	0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
KIRC	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	17.24	1.72e-52	1.63e-48	0.7	0.61	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
KIRC	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	17.24	1.73e-52	1.64e-48	0.75	0.61	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
KIRC	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	17.23	1.75e-52	1.66e-48	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
KIRC	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	17.23	1.85e-52	1.75e-48	0.71	0.61	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
KIRC	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-17.23	1.91e-52	1.8e-48	-0.79	-0.61	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
KIRC	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	17.22	2.03e-52	1.91e-48	0.9	0.61	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
KIRC	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	17.19	2.73e-52	2.57e-48	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
KIRC	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	17.19	2.94e-52	2.76e-48	1	0.61	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
KIRC	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-17.18	3.09e-52	2.91e-48	-0.68	-0.61	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
KIRC	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-17.18	3.21e-52	3.01e-48	-0.78	-0.61	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-17.18	3.24e-52	3.05e-48	-0.8	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
KIRC	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	17.18	3.29e-52	3.09e-48	1	0.61	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
KIRC	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	17.17	3.56e-52	3.34e-48	0.73	0.61	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
KIRC	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-17.16	3.78e-52	3.55e-48	-0.8	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
KIRC	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	17.16	3.82e-52	3.58e-48	1.11	0.61	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
KIRC	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-17.16	4.08e-52	3.82e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-17.15	4.27e-52	4e-48	-0.51	-0.61	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
KIRC	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	17.15	4.39e-52	4.11e-48	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
KIRC	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	17.15	4.47e-52	4.18e-48	0.79	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-17.12	6.08e-52	5.68e-48	-0.8	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
KIRC	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	17.11	6.8e-52	6.35e-48	0.62	0.61	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
KIRC	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	17.1	7.33e-52	6.83e-48	0.79	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.1	7.66e-52	7.14e-48	0.76	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
KIRC	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	17.09	8.28e-52	7.71e-48	0.51	0.61	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
KIRC	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	17.09	8.54e-52	7.95e-48	1.12	0.61	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
KIRC	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	17.08	8.85e-52	8.22e-48	0.69	0.61	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
KIRC	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
KIRC	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-17.08	9.56e-52	8.86e-48	-0.51	-0.61	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
KIRC	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	17.07	9.96e-52	9.22e-48	0.63	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
KIRC	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-17.07	1.05e-51	9.73e-48	-0.5	-0.61	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
KIRC	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	17.05	1.28e-51	1.19e-47	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
KIRC	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	17.05	1.29e-51	1.19e-47	0.9	0.61	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
KIRC	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-17.05	1.32e-51	1.22e-47	-0.53	-0.61	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
KIRC	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-17.05	1.34e-51	1.24e-47	-0.67	-0.61	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
KIRC	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-17.04	1.46e-51	1.35e-47	-0.67	-0.61	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
KIRC	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	17.03	1.55e-51	1.43e-47	0.74	0.61	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
KIRC	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	17.03	1.63e-51	1.5e-47	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
KIRC	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-17.02	1.68e-51	1.54e-47	-0.67	-0.61	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	17.02	1.72e-51	1.58e-47	0.67	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
KIRC	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	17.02	1.78e-51	1.64e-47	0.8	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
KIRC	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-17.02	1.85e-51	1.7e-47	-0.51	-0.61	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-17.02	1.85e-51	1.7e-47	-0.51	-0.61	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-17.02	1.85e-51	1.7e-47	-0.51	-0.61	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
KIRC	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	17.02	1.86e-51	1.7e-47	0.69	0.61	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	17.01	1.99e-51	1.82e-47	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
KIRC	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-17.01	2.04e-51	1.86e-47	-0.74	-0.61	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	17.01	2.04e-51	1.86e-47	0.74	0.61	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
KIRC	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	17.01	2.08e-51	1.89e-47	1.01	0.61	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
KIRC	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	17	2.08e-51	1.9e-47	0.69	0.61	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
KIRC	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	16.97	3.14e-51	2.83e-47	0.75	0.61	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	16.96	3.5e-51	3.16e-47	0.77	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
KIRC	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-16.95	3.9e-51	3.51e-47	-0.76	-0.61	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
KIRC	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-16.94	4.19e-51	3.77e-47	-0.51	-0.61	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
KIRC	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-16.94	4.23e-51	3.8e-47	-0.63	-0.61	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
KIRC	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	16.94	4.29e-51	3.85e-47	0.74	0.61	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
KIRC	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	16.94	4.32e-51	3.88e-47	0.78	0.61	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
KIRC	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	16.93	4.49e-51	4.03e-47	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
KIRC	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	16.93	4.49e-51	4.03e-47	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
KIRC	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-16.93	4.76e-51	4.27e-47	-0.81	-0.61	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
KIRC	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	16.92	5.21e-51	4.66e-47	0.77	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
KIRC	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	16.87	8.88e-51	7.85e-47	0.74	0.6	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
KIRC	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	16.86	9.92e-51	8.75e-47	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-16.84	1.24e-50	1.08e-46	-0.67	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
KIRC	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.84	1.26e-50	1.1e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-16.84	1.26e-50	1.1e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	16.83	1.36e-50	1.19e-46	0.76	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
KIRC	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	16.83	1.41e-50	1.23e-46	0.77	0.6	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
KIRC	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	16.82	1.49e-50	1.3e-46	0.69	0.6	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
KIRC	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-16.82	1.54e-50	1.34e-46	-0.75	-0.6	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
KIRC	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-16.81	1.64e-50	1.43e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
KIRC	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	16.81	1.69e-50	1.47e-46	0.69	0.6	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	16.81	1.69e-50	1.47e-46	0.69	0.6	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
KIRC	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-16.81	1.73e-50	1.5e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
KIRC	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	16.81	1.75e-50	1.52e-46	1.13	0.6	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
KIRC	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.81	1.77e-50	1.53e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.81	1.77e-50	1.53e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
KIRC	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	16.81	1.78e-50	1.54e-46	0.69	0.6	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
KIRC	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	16.8	1.92e-50	1.66e-46	1	0.6	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
KIRC	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	16.79	2.01e-50	1.74e-46	0.7	0.6	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
KIRC	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-16.79	2.04e-50	1.77e-46	-0.73	-0.6	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
KIRC	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-16.79	2.17e-50	1.88e-46	-0.91	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
KIRC	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-16.78	2.29e-50	1.98e-46	-0.66	-0.6	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
KIRC	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	16.78	2.36e-50	2.04e-46	0.74	0.6	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
KIRC	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-16.78	2.37e-50	2.05e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.78	2.39e-50	2.06e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.78	2.39e-50	2.06e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.78	2.39e-50	2.06e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-16.78	2.39e-50	2.06e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.78	2.45e-50	2.11e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
KIRC	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-16.77	2.61e-50	2.25e-46	-0.51	-0.6	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
KIRC	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-16.76	2.76e-50	2.37e-46	-1.1	-0.6	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
KIRC	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.75	3.38e-50	2.9e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
KIRC	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	16.74	3.53e-50	3.02e-46	0.73	0.6	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
KIRC	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	16.74	3.55e-50	3.05e-46	0.75	0.6	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
KIRC	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-16.74	3.67e-50	3.15e-46	-0.51	-0.6	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-16.74	3.67e-50	3.15e-46	-0.51	-0.6	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
KIRC	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-16.74	3.67e-50	3.15e-46	-0.51	-0.6	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
KIRC	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	16.73	4.21e-50	3.59e-46	0.61	0.6	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
KIRC	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-16.71	4.85e-50	4.12e-46	-0.51	-0.6	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
KIRC	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-16.71	4.85e-50	4.12e-46	-0.51	-0.6	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-16.71	4.85e-50	4.12e-46	-0.51	-0.6	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
KIRC	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-16.71	4.9e-50	4.15e-46	-0.8	-0.6	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
KIRC	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-16.71	4.91e-50	4.16e-46	-0.76	-0.6	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	16.71	5.05e-50	4.28e-46	0.79	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-16.71	5.09e-50	4.31e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
KIRC	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	16.7	5.41e-50	4.58e-46	0.9	0.6	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
KIRC	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-16.69	6.01e-50	5.08e-46	-0.6	-0.6	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
KIRC	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	16.69	6.24e-50	5.26e-46	0.73	0.6	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	16.69	6.35e-50	5.36e-46	0.73	0.6	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
KIRC	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	16.69	6.36e-50	5.36e-46	0.79	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
KIRC	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	16.68	6.96e-50	5.86e-46	0.76	0.6	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
KIRC	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	16.68	7.04e-50	5.92e-46	0.62	0.6	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
KIRC	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	16.67	7.29e-50	6.13e-46	0.68	0.6	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	16.67	7.51e-50	6.31e-46	0.68	0.6	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
KIRC	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-16.67	7.65e-50	6.43e-46	-0.61	-0.6	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
KIRC	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	16.66	8.09e-50	6.79e-46	0.71	0.6	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
KIRC	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-16.66	8.71e-50	7.3e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-16.66	8.71e-50	7.3e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-16.65	9.51e-50	7.96e-46	-0.62	-0.6	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
KIRC	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-16.64	9.99e-50	8.36e-46	-0.85	-0.6	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
KIRC	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-16.64	1.01e-49	8.49e-46	-0.78	-0.6	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
KIRC	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-16.63	1.14e-49	9.53e-46	-0.69	-0.6	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
KIRC	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	16.61	1.42e-49	1.18e-45	0.92	0.6	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	16.61	1.47e-49	1.23e-45	0.66	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
KIRC	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	16.6	1.59e-49	1.32e-45	0.78	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	16.59	1.71e-49	1.42e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
KIRC	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-16.59	1.84e-49	1.53e-45	-0.51	-0.6	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
KIRC	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	16.59	1.89e-49	1.57e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
KIRC	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-16.58	2e-49	1.66e-45	-0.77	-0.6	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
KIRC	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.57	2.15e-49	1.78e-45	-0.61	-0.6	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
KIRC	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	16.57	2.33e-49	1.93e-45	0.8	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
KIRC	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-16.56	2.47e-49	2.04e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-16.56	2.47e-49	2.04e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
KIRC	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	16.56	2.57e-49	2.12e-45	0.95	0.6	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
KIRC	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-16.55	2.65e-49	2.18e-45	-0.61	-0.6	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
KIRC	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	16.55	2.68e-49	2.2e-45	0.68	0.6	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
KIRC	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	16.54	3.07e-49	2.52e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
KIRC	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	16.54	3.09e-49	2.54e-45	0.7	0.6	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	16.54	3.09e-49	2.54e-45	0.7	0.6	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	16.54	3.09e-49	2.54e-45	0.7	0.6	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
KIRC	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	16.53	3.48e-49	2.86e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	16.53	3.48e-49	2.86e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
KIRC	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	16.53	3.49e-49	2.86e-45	0.7	0.6	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-16.52	3.64e-49	2.98e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
KIRC	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	16.52	3.75e-49	3.07e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
KIRC	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	16.51	4.11e-49	3.36e-45	0.7	0.6	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
KIRC	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-16.5	4.5e-49	3.67e-45	-0.61	-0.6	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
KIRC	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	16.49	5.38e-49	4.37e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16.49	5.44e-49	4.42e-45	-0.61	-0.6	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
KIRC	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	16.48	5.81e-49	4.71e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
KIRC	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-16.48	6.08e-49	4.92e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-16.48	6.08e-49	4.92e-45	-0.74	-0.6	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
KIRC	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-16.47	6.4e-49	5.18e-45	-0.63	-0.6	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
KIRC	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-16.47	6.4e-49	5.18e-45	-0.63	-0.6	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
KIRC	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	16.47	6.51e-49	5.26e-45	0.65	0.59	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
KIRC	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	16.46	7e-49	5.66e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	16.46	7e-49	5.66e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
KIRC	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-16.46	7e-49	5.66e-45	-0.68	-0.59	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
KIRC	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.46	7.04e-49	5.68e-45	-0.61	-0.59	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
KIRC	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	16.46	7.37e-49	5.95e-45	0.83	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
KIRC	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	16.45	7.79e-49	6.27e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	16.45	7.79e-49	6.27e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	16.45	7.79e-49	6.27e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	16.45	8.07e-49	6.48e-45	0.66	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
KIRC	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	16.44	8.55e-49	6.86e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	16.44	8.69e-49	6.97e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
KIRC	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	16.43	9.5e-49	7.62e-45	0.74	0.59	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	16.43	9.73e-49	7.79e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	16.43	9.77e-49	7.81e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
KIRC	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-16.43	9.77e-49	7.82e-45	-0.83	-0.59	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-16.43	1.01e-48	8.04e-45	-0.79	-0.59	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
KIRC	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	16.43	1.04e-48	8.27e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.42	1.07e-48	8.58e-45	-0.61	-0.59	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-16.42	1.12e-48	8.96e-45	-0.6	-0.59	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
KIRC	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	16.42	1.13e-48	9.03e-45	1.11	0.59	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
KIRC	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	16.42	1.15e-48	9.14e-45	0.9	0.59	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	16.41	1.17e-48	9.27e-45	0.75	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
KIRC	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	16.41	1.2e-48	9.55e-45	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.41	1.26e-48	1e-44	-0.61	-0.59	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.4	1.3e-48	1.03e-44	-0.61	-0.59	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
KIRC	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-16.4	1.31e-48	1.04e-44	-0.74	-0.59	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
KIRC	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	16.4	1.34e-48	1.06e-44	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
KIRC	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	16.38	1.74e-48	1.37e-44	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	16.38	1.74e-48	1.37e-44	0.74	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
KIRC	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-16.37	1.83e-48	1.44e-44	-1.07	-0.59	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
KIRC	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	16.37	1.84e-48	1.45e-44	0.61	0.59	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
KIRC	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-16.37	1.9e-48	1.49e-44	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
KIRC	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-16.37	1.9e-48	1.49e-44	-0.8	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
KIRC	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	16.37	1.96e-48	1.54e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
KIRC	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	16.36	1.99e-48	1.56e-44	0.68	0.59	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
KIRC	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-16.36	2.06e-48	1.61e-44	-0.78	-0.59	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-16.36	2.06e-48	1.61e-44	-0.78	-0.59	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
KIRC	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-16.36	2.06e-48	1.61e-44	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
KIRC	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	16.35	2.28e-48	1.79e-44	0.67	0.59	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
KIRC	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	16.35	2.29e-48	1.79e-44	0.69	0.59	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
KIRC	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	16.34	2.47e-48	1.93e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
KIRC	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-16.33	2.95e-48	2.29e-44	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
KIRC	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-16.32	3.17e-48	2.46e-44	-0.5	-0.59	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
KIRC	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-16.32	3.18e-48	2.47e-44	-0.71	-0.59	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
KIRC	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	16.32	3.32e-48	2.57e-44	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	16.32	3.32e-48	2.57e-44	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
KIRC	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-16.31	3.51e-48	2.72e-44	-0.5	-0.59	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
KIRC	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	16.31	3.51e-48	2.72e-44	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
KIRC	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	16.31	3.63e-48	2.8e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
KIRC	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	16.3	3.76e-48	2.9e-44	0.71	0.59	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
KIRC	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-16.3	3.96e-48	3.06e-44	-0.77	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
KIRC	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	16.3	3.98e-48	3.07e-44	0.89	0.59	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	16.3	3.98e-48	3.07e-44	0.89	0.59	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
KIRC	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-16.3	4.04e-48	3.12e-44	-0.96	-0.59	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
KIRC	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	16.3	4.12e-48	3.18e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
KIRC	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-16.3	4.14e-48	3.19e-44	-0.67	-0.59	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
KIRC	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	16.29	4.18e-48	3.22e-44	0.73	0.59	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
KIRC	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	16.29	4.33e-48	3.33e-44	0.69	0.59	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-16.29	4.52e-48	3.48e-44	-0.75	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
KIRC	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	16.28	4.81e-48	3.7e-44	0.68	0.59	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
KIRC	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	16.28	5.05e-48	3.88e-44	0.77	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
KIRC	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	16.27	5.2e-48	3.99e-44	0.68	0.59	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
KIRC	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	16.27	5.21e-48	4e-44	0.69	0.59	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
KIRC	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	16.27	5.25e-48	4.03e-44	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-16.27	5.7e-48	4.37e-44	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
KIRC	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	16.26	5.85e-48	4.48e-44	0.82	0.59	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
KIRC	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	16.26	5.93e-48	4.54e-44	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	16.26	6e-48	4.59e-44	0.78	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
KIRC	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-16.26	6.12e-48	4.68e-44	-0.83	-0.59	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
KIRC	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-16.26	6.23e-48	4.76e-44	-0.5	-0.59	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
KIRC	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	16.25	6.42e-48	4.9e-44	0.73	0.59	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	16.25	6.42e-48	4.9e-44	0.73	0.59	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
KIRC	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-16.25	6.89e-48	5.25e-44	-0.5	-0.59	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
KIRC	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-16.25	7.1e-48	5.41e-44	-0.82	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
KIRC	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	16.24	7.26e-48	5.53e-44	0.69	0.59	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
KIRC	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	16.23	8.53e-48	6.48e-44	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
KIRC	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-16.22	9.2e-48	6.97e-44	-0.5	-0.59	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
KIRC	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	16.21	9.8e-48	7.42e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	16.21	9.94e-48	7.53e-44	0.69	0.59	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
KIRC	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-16.21	1.08e-47	8.17e-44	-0.67	-0.59	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
KIRC	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	16.2	1.1e-47	8.3e-44	0.72	0.59	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
KIRC	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-16.2	1.18e-47	8.87e-44	-0.83	-0.59	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-16.2	1.18e-47	8.87e-44	-0.83	-0.59	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
KIRC	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	16.2	1.18e-47	8.91e-44	0.7	0.59	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-16.19	1.3e-47	9.82e-44	-0.73	-0.59	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
KIRC	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	16.19	1.32e-47	9.89e-44	0.73	0.59	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	16.19	1.34e-47	1.01e-43	0.66	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
KIRC	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	16.18	1.35e-47	1.02e-43	0.73	0.59	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
KIRC	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	16.18	1.37e-47	1.03e-43	0.67	0.59	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
KIRC	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	16.18	1.41e-47	1.06e-43	0.67	0.59	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
KIRC	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	16.18	1.43e-47	1.07e-43	0.73	0.59	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
KIRC	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	16.18	1.45e-47	1.09e-43	0.88	0.59	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
KIRC	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	16.17	1.56e-47	1.17e-43	0.73	0.59	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	16.17	1.56e-47	1.17e-43	0.73	0.59	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	16.17	1.56e-47	1.17e-43	0.73	0.59	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
KIRC	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	16.17	1.57e-47	1.18e-43	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
KIRC	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	16.17	1.59e-47	1.19e-43	0.73	0.59	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
KIRC	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-16.16	1.71e-47	1.27e-43	-0.83	-0.59	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
KIRC	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-16.16	1.77e-47	1.32e-43	-0.72	-0.59	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-16.16	1.77e-47	1.32e-43	-0.72	-0.59	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-16.16	1.77e-47	1.32e-43	-0.72	-0.59	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
KIRC	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-16.16	1.79e-47	1.33e-43	-0.67	-0.59	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
KIRC	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-16.15	1.95e-47	1.45e-43	-0.74	-0.59	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
KIRC	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-16.15	1.96e-47	1.45e-43	-0.92	-0.59	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
KIRC	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-16.15	1.99e-47	1.47e-43	-0.74	-0.59	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
KIRC	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-16.14	2.08e-47	1.54e-43	-0.73	-0.59	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
KIRC	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	16.14	2.1e-47	1.55e-43	0.73	0.59	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
KIRC	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-16.14	2.18e-47	1.62e-43	-0.64	-0.59	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
KIRC	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	16.14	2.23e-47	1.65e-43	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	16.14	2.26e-47	1.67e-43	0.75	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
KIRC	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	16.13	2.3e-47	1.7e-43	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
KIRC	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-16.13	2.31e-47	1.71e-43	-0.54	-0.59	Breast cancer;	chr11:743813	chr11:779617~780755:+
KIRC	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-16.13	2.38e-47	1.76e-43	-0.59	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
KIRC	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	16.13	2.42e-47	1.78e-43	0.75	0.59	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
KIRC	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-16.12	2.8e-47	2.07e-43	-0.59	-0.59	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
KIRC	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	16.11	2.96e-47	2.18e-43	0.72	0.59	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-16.11	3.02e-47	2.23e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-16.11	3.02e-47	2.23e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-16.11	3.13e-47	2.3e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
KIRC	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	16.1	3.17e-47	2.33e-43	0.71	0.59	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
KIRC	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-16.1	3.36e-47	2.47e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-16.1	3.36e-47	2.47e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-16.1	3.36e-47	2.47e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
KIRC	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	16.1	3.49e-47	2.56e-43	1.08	0.59	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
KIRC	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-16.09	3.5e-47	2.56e-43	-0.83	-0.59	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
KIRC	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-16.09	3.56e-47	2.61e-43	-0.78	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
KIRC	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-16.09	3.68e-47	2.7e-43	-0.82	-0.59	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
KIRC	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	16.09	3.82e-47	2.79e-43	0.83	0.59	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-16.08	3.95e-47	2.88e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-16.08	3.95e-47	2.88e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
KIRC	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	16.08	4.03e-47	2.95e-43	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
KIRC	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	16.08	4.09e-47	2.98e-43	0.72	0.59	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
KIRC	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	16.08	4.2e-47	3.07e-43	0.73	0.59	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-16.07	4.47e-47	3.26e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-16.07	4.47e-47	3.26e-43	-0.75	-0.59	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
KIRC	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	16.07	4.59e-47	3.35e-43	1.08	0.59	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
KIRC	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-16.07	4.6e-47	3.35e-43	-0.82	-0.59	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
KIRC	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	16.06	5.01e-47	3.64e-43	0.88	0.59	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	16.06	5.05e-47	3.67e-43	0.75	0.59	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
KIRC	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-16.06	5.09e-47	3.7e-43	-0.68	-0.59	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	16.06	5.15e-47	3.74e-43	0.75	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
KIRC	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	16.06	5.29e-47	3.84e-43	0.76	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	16.05	5.58e-47	4.04e-43	0.6	0.59	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.05	5.69e-47	4.12e-43	-0.61	-0.59	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
KIRC	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	16.05	5.72e-47	4.14e-43	0.87	0.59	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	16.05	5.73e-47	4.14e-43	0.88	0.59	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-16.04	6.21e-47	4.49e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-16.04	6.21e-47	4.49e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
KIRC	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-16.04	6.34e-47	4.58e-43	-0.61	-0.58	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
KIRC	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-16.04	6.35e-47	4.58e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-16.04	6.35e-47	4.58e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-16.04	6.6e-47	4.75e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-16.04	6.6e-47	4.75e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
KIRC	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-16.03	6.6e-47	4.76e-43	-0.61	-0.58	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
KIRC	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-16.03	6.75e-47	4.86e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-16.03	6.75e-47	4.86e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
KIRC	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-16.03	6.97e-47	5.02e-43	-0.73	-0.58	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	16.02	7.35e-47	5.28e-43	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
KIRC	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	16.02	7.82e-47	5.61e-43	0.88	0.58	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	16.02	7.82e-47	5.61e-43	0.88	0.58	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	16.02	7.82e-47	5.61e-43	0.88	0.58	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
KIRC	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	16.01	8.24e-47	5.9e-43	0.67	0.58	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
KIRC	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-16.01	8.25e-47	5.91e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
KIRC	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	16.01	8.28e-47	5.93e-43	0.67	0.58	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
KIRC	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	16.01	8.43e-47	6.04e-43	0.88	0.58	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
KIRC	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	16.01	8.85e-47	6.33e-43	0.82	0.58	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
KIRC	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	16.01	8.86e-47	6.34e-43	0.87	0.58	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	16.01	8.86e-47	6.34e-43	0.87	0.58	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	16	9.11e-47	6.52e-43	0.74	0.58	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-16	9.16e-47	6.55e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
KIRC	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	16	9.18e-47	6.56e-43	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
KIRC	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	16	9.77e-47	6.97e-43	0.75	0.58	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
KIRC	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-16	9.89e-47	7.06e-43	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-16	9.89e-47	7.06e-43	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-15.99	1.03e-46	7.37e-43	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
KIRC	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-15.99	1.05e-46	7.48e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-15.99	1.08e-46	7.67e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-15.99	1.09e-46	7.79e-43	-0.75	-0.58	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
KIRC	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	15.98	1.14e-46	8.14e-43	0.83	0.58	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
KIRC	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-15.98	1.22e-46	8.68e-43	-0.9	-0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
KIRC	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	15.98	1.23e-46	8.71e-43	0.67	0.58	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
KIRC	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-15.98	1.24e-46	8.81e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
KIRC	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	15.97	1.34e-46	9.52e-43	0.68	0.58	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
KIRC	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-15.97	1.36e-46	9.64e-43	-0.74	-0.58	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
KIRC	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	15.96	1.43e-46	1.01e-42	0.76	0.58	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
KIRC	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	15.96	1.45e-46	1.03e-42	0.72	0.58	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
KIRC	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	15.95	1.57e-46	1.11e-42	0.6	0.58	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
KIRC	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	15.95	1.57e-46	1.11e-42	0.66	0.58	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
KIRC	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	15.95	1.57e-46	1.11e-42	0.72	0.58	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-15.95	1.58e-46	1.11e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
KIRC	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	15.95	1.6e-46	1.13e-42	0.87	0.58	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	15.95	1.6e-46	1.13e-42	0.87	0.58	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	15.95	1.6e-46	1.13e-42	0.87	0.58	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
KIRC	cis	rs6085948	0.861	rs6085955	ENSG00000238102.1	RP11-19D2.1	-15.95	1.68e-46	1.18e-42	-0.65	-0.58	Interleukin-10 levels;	chr20:7258347	chr20:7256580~7258214:-
KIRC	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-15.95	1.69e-46	1.19e-42	-0.82	-0.58	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
KIRC	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	15.95	1.69e-46	1.19e-42	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
KIRC	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	15.94	1.74e-46	1.22e-42	0.76	0.58	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
KIRC	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	15.93	1.92e-46	1.35e-42	0.67	0.58	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
KIRC	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-15.92	2.11e-46	1.48e-42	-0.84	-0.58	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
KIRC	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	15.92	2.16e-46	1.51e-42	0.87	0.58	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-15.92	2.34e-46	1.64e-42	-0.78	-0.58	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-15.91	2.4e-46	1.68e-42	-0.78	-0.58	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-15.91	2.41e-46	1.68e-42	-0.82	-0.58	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
KIRC	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	15.91	2.5e-46	1.74e-42	0.71	0.58	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
KIRC	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	15.91	2.5e-46	1.75e-42	0.72	0.58	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
KIRC	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	15.9	2.63e-46	1.83e-42	0.83	0.58	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-15.9	2.69e-46	1.87e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-15.9	2.69e-46	1.87e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
KIRC	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-15.9	2.69e-46	1.87e-42	-0.67	-0.58	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
KIRC	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	15.9	2.73e-46	1.9e-42	0.84	0.58	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
KIRC	cis	rs6085948	0.861	rs8121934	ENSG00000238102.1	RP11-19D2.1	-15.89	2.91e-46	2.02e-42	-0.65	-0.58	Interleukin-10 levels;	chr20:7263706	chr20:7256580~7258214:-
KIRC	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	15.89	3e-46	2.09e-42	0.72	0.58	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
KIRC	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-15.89	3.07e-46	2.13e-42	-0.51	-0.58	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
KIRC	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-15.89	3.21e-46	2.23e-42	-0.67	-0.58	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
KIRC	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-15.88	3.33e-46	2.31e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-15.88	3.33e-46	2.31e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-15.88	3.33e-46	2.31e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-15.88	3.33e-46	2.31e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-15.88	3.49e-46	2.42e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
KIRC	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-15.88	3.5e-46	2.42e-42	-0.76	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
KIRC	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-15.88	3.53e-46	2.44e-42	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-15.88	3.53e-46	2.44e-42	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-15.88	3.53e-46	2.44e-42	-0.68	-0.58	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
KIRC	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	15.88	3.54e-46	2.44e-42	0.66	0.58	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
KIRC	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-15.87	3.76e-46	2.59e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-15.87	3.85e-46	2.65e-42	-0.76	-0.58	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
KIRC	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	15.87	3.93e-46	2.7e-42	0.87	0.58	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	15.86	4.02e-46	2.76e-42	0.88	0.58	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	15.86	4.03e-46	2.77e-42	0.84	0.58	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
KIRC	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-15.86	4.1e-46	2.82e-42	-0.76	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
KIRC	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	15.86	4.37e-46	3e-42	0.84	0.58	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
KIRC	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	15.85	4.43e-46	3.04e-42	0.67	0.58	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
KIRC	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	15.85	4.75e-46	3.26e-42	0.72	0.58	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
KIRC	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-15.84	5.4e-46	3.69e-42	-0.73	-0.58	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
KIRC	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	15.84	5.44e-46	3.72e-42	0.69	0.58	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
KIRC	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	15.83	5.51e-46	3.74e-42	0.76	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.83	5.53e-46	3.76e-42	-0.59	-0.58	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
KIRC	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	15.83	5.92e-46	4.01e-42	0.84	0.58	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
KIRC	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	15.82	6.35e-46	4.26e-42	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	15.81	6.94e-46	4.64e-42	0.59	0.58	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	15.81	7.05e-46	4.71e-42	0.59	0.58	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
KIRC	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-15.79	8.59e-46	5.72e-42	-0.77	-0.58	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-15.79	8.93e-46	5.94e-42	-0.75	-0.58	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
KIRC	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	15.78	1.01e-45	6.68e-42	0.7	0.58	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
KIRC	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	15.78	1.01e-45	6.72e-42	0.72	0.58	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	15.78	1.01e-45	6.72e-42	0.72	0.58	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
KIRC	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	15.78	1.01e-45	6.72e-42	0.72	0.58	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
KIRC	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	15.77	1.04e-45	6.93e-42	0.87	0.58	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-15.77	1.1e-45	7.28e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-15.76	1.2e-45	7.92e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-15.76	1.2e-45	7.92e-42	-0.74	-0.58	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
KIRC	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	15.76	1.25e-45	8.22e-42	0.66	0.58	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
KIRC	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-15.75	1.35e-45	8.89e-42	-0.91	-0.58	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
KIRC	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-15.75	1.38e-45	9.1e-42	-0.74	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	15.75	1.41e-45	9.29e-42	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
KIRC	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-15.74	1.43e-45	9.43e-42	-0.83	-0.58	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-15.74	1.45e-45	9.53e-42	-0.83	-0.58	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-15.74	1.45e-45	9.53e-42	-0.83	-0.58	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-15.74	1.48e-45	9.71e-42	-0.82	-0.58	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
KIRC	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	15.74	1.56e-45	1.02e-41	0.7	0.58	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
KIRC	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	15.73	1.62e-45	1.06e-41	0.94	0.58	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
KIRC	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-15.72	1.79e-45	1.17e-41	-0.49	-0.58	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-15.72	1.79e-45	1.17e-41	-0.49	-0.58	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-15.72	1.79e-45	1.17e-41	-0.49	-0.58	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
KIRC	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-15.72	1.79e-45	1.17e-41	-0.75	-0.58	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
KIRC	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	15.72	1.8e-45	1.18e-41	0.59	0.58	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
KIRC	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	15.72	1.86e-45	1.22e-41	0.84	0.58	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
KIRC	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-15.72	1.91e-45	1.24e-41	-0.6	-0.58	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
KIRC	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-15.71	1.95e-45	1.27e-41	-0.5	-0.58	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
KIRC	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-15.71	2.06e-45	1.34e-41	-0.74	-0.58	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
KIRC	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	15.71	2.07e-45	1.34e-41	0.59	0.58	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
KIRC	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.71	2.07e-45	1.35e-41	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
KIRC	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-15.71	2.09e-45	1.36e-41	-0.74	-0.58	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-15.71	2.09e-45	1.36e-41	-0.74	-0.58	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-15.71	2.09e-45	1.36e-41	-0.74	-0.58	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
KIRC	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	15.71	2.14e-45	1.39e-41	0.71	0.58	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
KIRC	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	15.7	2.16e-45	1.4e-41	0.81	0.58	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
KIRC	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	15.7	2.26e-45	1.46e-41	0.84	0.58	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
KIRC	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	15.7	2.31e-45	1.5e-41	0.77	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
KIRC	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-15.7	2.35e-45	1.52e-41	-0.67	-0.58	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
KIRC	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	15.7	2.36e-45	1.53e-41	1.04	0.58	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
KIRC	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	15.69	2.42e-45	1.57e-41	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
KIRC	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-15.69	2.45e-45	1.59e-41	-0.51	-0.58	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
KIRC	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-15.69	2.45e-45	1.59e-41	-0.79	-0.58	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-15.69	2.45e-45	1.59e-41	-0.79	-0.58	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
KIRC	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	15.69	2.47e-45	1.6e-41	0.67	0.58	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
KIRC	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-15.68	2.86e-45	1.85e-41	-0.65	-0.58	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
KIRC	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-15.68	2.89e-45	1.86e-41	-0.84	-0.58	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
KIRC	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-15.68	2.91e-45	1.88e-41	-0.82	-0.58	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-15.68	2.91e-45	1.88e-41	-0.82	-0.58	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-15.68	2.91e-45	1.88e-41	-0.82	-0.58	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-15.68	2.91e-45	1.88e-41	-0.82	-0.58	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
KIRC	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	15.68	2.92e-45	1.88e-41	0.81	0.58	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-15.68	2.94e-45	1.89e-41	-0.74	-0.58	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
KIRC	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-15.67	3.07e-45	1.98e-41	-0.81	-0.58	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-15.67	3.09e-45	1.99e-41	-0.73	-0.58	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
KIRC	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-15.67	3.09e-45	1.99e-41	-0.71	-0.58	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
KIRC	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	15.67	3.24e-45	2.08e-41	0.5	0.58	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
KIRC	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-15.66	3.31e-45	2.13e-41	-0.73	-0.58	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-15.66	3.31e-45	2.13e-41	-0.73	-0.58	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
KIRC	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-15.66	3.54e-45	2.27e-41	-0.74	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
KIRC	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	15.66	3.58e-45	2.29e-41	0.83	0.58	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	15.65	3.65e-45	2.34e-41	0.84	0.58	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
KIRC	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	15.65	3.78e-45	2.42e-41	0.75	0.58	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	15.65	3.83e-45	2.45e-41	0.71	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
KIRC	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	15.65	3.89e-45	2.48e-41	0.81	0.58	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
KIRC	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	15.64	4.11e-45	2.63e-41	0.84	0.58	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
KIRC	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	15.64	4.21e-45	2.69e-41	0.71	0.58	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
KIRC	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	15.64	4.25e-45	2.71e-41	0.57	0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
KIRC	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-15.64	4.26e-45	2.72e-41	-0.82	-0.58	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
KIRC	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	15.64	4.45e-45	2.84e-41	0.59	0.57	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
KIRC	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	15.63	4.61e-45	2.94e-41	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	15.63	4.61e-45	2.94e-41	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
KIRC	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	15.63	4.89e-45	3.11e-41	0.75	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
KIRC	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	15.62	5.04e-45	3.2e-41	1.06	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
KIRC	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-15.62	5.1e-45	3.24e-41	-0.74	-0.57	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-15.62	5.12e-45	3.25e-41	-0.82	-0.57	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
KIRC	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	15.62	5.47e-45	3.48e-41	0.59	0.57	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
KIRC	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	15.61	5.63e-45	3.57e-41	0.74	0.57	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
KIRC	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-15.61	5.65e-45	3.58e-41	-0.82	-0.57	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-15.61	5.65e-45	3.58e-41	-0.82	-0.57	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
KIRC	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	15.61	5.66e-45	3.59e-41	0.69	0.57	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
KIRC	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	15.61	5.69e-45	3.61e-41	0.59	0.57	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
KIRC	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	15.61	5.69e-45	3.61e-41	0.59	0.57	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
KIRC	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	15.61	6.03e-45	3.82e-41	0.74	0.57	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
KIRC	cis	rs9457247	0.905	rs444210	ENSG00000265828.1	MIR3939	-15.61	6.06e-45	3.84e-41	-0.65	-0.57	Crohn's disease;	chr6:166976754	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-15.6	6.17e-45	3.91e-41	-0.82	-0.57	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
KIRC	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	15.6	6.4e-45	4.05e-41	0.67	0.57	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
KIRC	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-15.6	6.68e-45	4.23e-41	-0.76	-0.57	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-15.59	6.87e-45	4.35e-41	-0.82	-0.57	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
KIRC	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	15.59	7.3e-45	4.61e-41	0.65	0.57	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
KIRC	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-15.58	7.82e-45	4.94e-41	-0.82	-0.57	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
KIRC	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	15.58	8.03e-45	5.07e-41	0.65	0.57	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
KIRC	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	15.58	8.19e-45	5.17e-41	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	15.58	8.28e-45	5.23e-41	0.74	0.57	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
KIRC	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-15.58	8.33e-45	5.26e-41	-0.82	-0.57	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-15.58	8.38e-45	5.28e-41	-0.8	-0.57	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
KIRC	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	15.57	8.58e-45	5.41e-41	0.94	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
KIRC	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	15.57	8.66e-45	5.45e-41	1.08	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
KIRC	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	15.57	8.8e-45	5.54e-41	0.83	0.57	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	15.57	8.8e-45	5.54e-41	0.83	0.57	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	15.57	8.8e-45	5.54e-41	0.83	0.57	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	15.57	8.8e-45	5.54e-41	0.83	0.57	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
KIRC	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-15.57	8.92e-45	5.61e-41	-0.59	-0.57	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
KIRC	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-15.57	9.1e-45	5.72e-41	-0.82	-0.57	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
KIRC	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-15.57	9.24e-45	5.81e-41	-0.61	-0.57	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
KIRC	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-15.57	9.31e-45	5.85e-41	-0.8	-0.57	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
KIRC	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-15.56	9.46e-45	5.95e-41	-0.64	-0.57	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
KIRC	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	15.56	9.52e-45	5.98e-41	0.71	0.57	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
KIRC	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	15.56	9.91e-45	6.21e-41	0.73	0.57	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
KIRC	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	15.56	9.92e-45	6.22e-41	0.65	0.57	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
KIRC	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	15.56	1e-44	6.26e-41	0.67	0.57	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	15.55	1.05e-44	6.55e-41	0.76	0.57	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
KIRC	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-15.55	1.05e-44	6.58e-41	-0.68	-0.57	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
KIRC	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	15.55	1.08e-44	6.72e-41	0.74	0.57	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	15.55	1.1e-44	6.84e-41	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
KIRC	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	15.55	1.13e-44	7.03e-41	0.59	0.57	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
KIRC	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	15.55	1.14e-44	7.09e-41	0.67	0.57	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	15.55	1.14e-44	7.09e-41	0.67	0.57	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
KIRC	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-15.54	1.17e-44	7.29e-41	-0.73	-0.57	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-15.54	1.19e-44	7.37e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-15.54	1.19e-44	7.39e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-15.54	1.23e-44	7.62e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-15.54	1.23e-44	7.62e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	15.53	1.33e-44	8.21e-41	0.74	0.57	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
KIRC	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	15.53	1.35e-44	8.34e-41	0.92	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
KIRC	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-15.53	1.39e-44	8.58e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-15.53	1.39e-44	8.58e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-15.53	1.39e-44	8.58e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-15.53	1.39e-44	8.58e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-15.53	1.4e-44	8.63e-41	-0.82	-0.57	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
KIRC	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-15.53	1.4e-44	8.66e-41	-0.61	-0.57	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
KIRC	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	15.52	1.45e-44	8.97e-41	0.92	0.57	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
KIRC	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	15.52	1.49e-44	9.18e-41	0.74	0.57	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
KIRC	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-15.52	1.51e-44	9.29e-41	-0.72	-0.57	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-15.52	1.51e-44	9.29e-41	-0.72	-0.57	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-15.52	1.51e-44	9.29e-41	-0.72	-0.57	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
KIRC	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	15.52	1.54e-44	9.5e-41	0.5	0.57	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
KIRC	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	15.52	1.56e-44	9.57e-41	0.83	0.57	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
KIRC	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-15.51	1.59e-44	9.76e-41	-0.58	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
KIRC	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-15.51	1.63e-44	9.98e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-15.51	1.63e-44	9.98e-41	-0.73	-0.57	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	15.51	1.63e-44	1e-40	0.74	0.57	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
KIRC	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-15.51	1.63e-44	1e-40	-0.81	-0.57	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-15.51	1.64e-44	1e-40	-0.82	-0.57	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
KIRC	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-15.51	1.64e-44	1e-40	-0.82	-0.57	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-15.51	1.64e-44	1e-40	-0.82	-0.57	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-15.51	1.64e-44	1e-40	-0.82	-0.57	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
KIRC	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	15.51	1.64e-44	1.01e-40	0.67	0.57	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	15.51	1.65e-44	1.01e-40	0.74	0.57	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	15.51	1.65e-44	1.01e-40	0.74	0.57	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
KIRC	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	15.51	1.75e-44	1.07e-40	0.5	0.57	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
KIRC	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-15.5	1.86e-44	1.14e-40	-0.74	-0.57	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
KIRC	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-15.49	1.98e-44	1.21e-40	-0.73	-0.57	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
KIRC	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	15.49	1.98e-44	1.21e-40	0.83	0.57	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
KIRC	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	15.49	2.1e-44	1.28e-40	0.76	0.57	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	15.49	2.1e-44	1.28e-40	0.76	0.57	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	15.49	2.13e-44	1.3e-40	0.75	0.57	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
KIRC	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	15.48	2.29e-44	1.39e-40	1.07	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	15.48	2.33e-44	1.42e-40	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
KIRC	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-15.48	2.35e-44	1.43e-40	-0.74	-0.57	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
KIRC	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	15.48	2.37e-44	1.44e-40	0.58	0.57	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
KIRC	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-15.48	2.38e-44	1.44e-40	-0.81	-0.57	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-15.48	2.38e-44	1.44e-40	-0.81	-0.57	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-15.48	2.38e-44	1.44e-40	-0.81	-0.57	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-15.48	2.38e-44	1.44e-40	-0.81	-0.57	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-15.47	2.41e-44	1.46e-40	-0.82	-0.57	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-15.47	2.49e-44	1.51e-40	-0.81	-0.57	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
KIRC	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	15.47	2.52e-44	1.53e-40	0.74	0.57	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	15.47	2.52e-44	1.53e-40	0.74	0.57	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
KIRC	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	15.47	2.53e-44	1.53e-40	0.92	0.57	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
KIRC	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-15.47	2.55e-44	1.54e-40	-0.81	-0.57	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-15.47	2.62e-44	1.58e-40	-0.81	-0.57	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
KIRC	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	15.46	2.68e-44	1.62e-40	0.83	0.57	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
KIRC	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	15.46	2.68e-44	1.62e-40	0.83	0.57	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
KIRC	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-15.46	2.7e-44	1.63e-40	-0.67	-0.57	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
KIRC	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	15.46	2.7e-44	1.63e-40	0.73	0.57	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
KIRC	cis	rs9457247	1	rs2013815	ENSG00000265828.1	MIR3939	15.46	2.8e-44	1.69e-40	0.64	0.57	Crohn's disease;	chr6:166960324	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-15.46	2.92e-44	1.76e-40	-0.81	-0.57	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-15.46	2.92e-44	1.76e-40	-0.81	-0.57	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-15.46	2.95e-44	1.78e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-15.46	2.95e-44	1.78e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
KIRC	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	15.45	3.03e-44	1.82e-40	1.04	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
KIRC	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	15.45	3.11e-44	1.87e-40	0.76	0.57	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
KIRC	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	15.45	3.16e-44	1.9e-40	0.91	0.57	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
KIRC	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	15.44	3.33e-44	2e-40	0.5	0.57	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
KIRC	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	15.44	3.41e-44	2.05e-40	0.93	0.57	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-15.44	3.42e-44	2.05e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-15.44	3.55e-44	2.13e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-15.43	3.79e-44	2.27e-40	-0.81	-0.57	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
KIRC	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	15.43	3.82e-44	2.29e-40	0.49	0.57	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
KIRC	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	15.43	4.01e-44	2.4e-40	0.71	0.57	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
KIRC	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-15.42	4.14e-44	2.48e-40	-0.81	-0.57	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-15.42	4.14e-44	2.48e-40	-0.81	-0.57	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
KIRC	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	15.42	4.29e-44	2.56e-40	0.5	0.57	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
KIRC	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	15.41	4.72e-44	2.81e-40	0.61	0.57	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
KIRC	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-15.4	5.02e-44	2.99e-40	-0.82	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
KIRC	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-15.4	5.06e-44	3.01e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-15.4	5.27e-44	3.14e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
KIRC	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-15.4	5.28e-44	3.14e-40	-0.7	-0.57	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-15.4	5.45e-44	3.24e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	15.4	5.5e-44	3.27e-40	0.76	0.57	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
KIRC	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	15.39	5.86e-44	3.48e-40	0.65	0.57	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
KIRC	cis	rs9457247	1	rs4710147	ENSG00000265828.1	MIR3939	15.39	5.9e-44	3.51e-40	0.64	0.57	Crohn's disease;	chr6:166960751	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.935	rs2757046	ENSG00000265828.1	MIR3939	15.39	5.9e-44	3.51e-40	0.64	0.57	Crohn's disease;	chr6:166960865	chr6:166997807~166997912:-
KIRC	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	15.39	5.95e-44	3.53e-40	0.5	0.57	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
KIRC	cis	rs9457247	1	rs2757047	ENSG00000265828.1	MIR3939	15.39	5.97e-44	3.54e-40	0.64	0.57	Crohn's disease;	chr6:166961001	chr6:166997807~166997912:-
KIRC	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	15.39	6.02e-44	3.57e-40	0.92	0.57	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
KIRC	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-15.39	6.03e-44	3.58e-40	-0.74	-0.57	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
KIRC	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-15.38	6.22e-44	3.69e-40	-0.81	-0.57	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
KIRC	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	15.38	6.41e-44	3.8e-40	0.66	0.57	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
KIRC	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-15.38	6.46e-44	3.83e-40	-0.69	-0.57	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
KIRC	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-15.38	6.49e-44	3.85e-40	-0.78	-0.57	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
KIRC	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	15.38	6.73e-44	3.98e-40	0.92	0.57	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
KIRC	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-15.38	6.79e-44	4.02e-40	-0.7	-0.57	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-15.38	6.79e-44	4.02e-40	-0.7	-0.57	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-15.38	6.79e-44	4.02e-40	-0.7	-0.57	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-15.38	6.81e-44	4.03e-40	-0.7	-0.57	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
KIRC	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-15.38	6.82e-44	4.03e-40	-0.64	-0.57	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
KIRC	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-15.37	7.02e-44	4.15e-40	-0.72	-0.57	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-15.37	7.02e-44	4.15e-40	-0.72	-0.57	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
KIRC	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	15.37	7.05e-44	4.17e-40	0.48	0.57	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
KIRC	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-15.37	7.12e-44	4.21e-40	-0.57	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
KIRC	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	15.37	7.44e-44	4.39e-40	0.73	0.57	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
KIRC	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	15.36	7.71e-44	4.55e-40	0.66	0.57	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	15.36	7.71e-44	4.55e-40	0.66	0.57	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	15.36	7.71e-44	4.55e-40	0.66	0.57	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
KIRC	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	15.36	7.93e-44	4.67e-40	0.85	0.57	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
KIRC	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-15.36	7.95e-44	4.68e-40	-0.81	-0.57	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-15.36	7.95e-44	4.68e-40	-0.81	-0.57	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-15.36	7.95e-44	4.68e-40	-0.81	-0.57	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-15.36	7.95e-44	4.68e-40	-0.81	-0.57	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-15.36	7.95e-44	4.68e-40	-0.81	-0.57	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
KIRC	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-15.36	8e-44	4.71e-40	-0.71	-0.57	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
KIRC	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	15.36	8.02e-44	4.72e-40	0.94	0.57	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
KIRC	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-15.36	8.14e-44	4.79e-40	-0.8	-0.57	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
KIRC	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-15.36	8.32e-44	4.89e-40	-0.78	-0.57	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
KIRC	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	15.35	8.44e-44	4.96e-40	0.67	0.57	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
KIRC	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-15.35	8.92e-44	5.24e-40	-0.73	-0.57	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
KIRC	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-15.35	8.92e-44	5.24e-40	-0.6	-0.57	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
KIRC	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-15.35	9.01e-44	5.29e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	15.35	9.19e-44	5.39e-40	0.74	0.57	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
KIRC	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-15.34	9.53e-44	5.58e-40	-0.81	-0.57	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
KIRC	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	15.34	9.54e-44	5.59e-40	0.7	0.57	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
KIRC	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-15.34	9.78e-44	5.73e-40	-0.81	-0.57	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
KIRC	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-15.34	9.79e-44	5.73e-40	-0.71	-0.57	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
KIRC	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-15.34	9.97e-44	5.84e-40	-0.81	-0.57	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
KIRC	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-15.34	1.02e-43	5.99e-40	-0.72	-0.57	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
KIRC	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	15.33	1.06e-43	6.18e-40	0.74	0.57	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
KIRC	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-15.33	1.06e-43	6.21e-40	-0.7	-0.57	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
KIRC	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	15.33	1.07e-43	6.25e-40	0.92	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	15.32	1.2e-43	7e-40	0.73	0.57	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
KIRC	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	15.32	1.23e-43	7.16e-40	0.66	0.57	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
KIRC	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.19e-40	-0.81	-0.57	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
KIRC	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-15.32	1.24e-43	7.24e-40	-0.81	-0.57	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-15.32	1.26e-43	7.32e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
KIRC	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-15.31	1.28e-43	7.46e-40	-0.61	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
KIRC	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	15.31	1.33e-43	7.73e-40	0.73	0.57	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
KIRC	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-15.31	1.36e-43	7.87e-40	-0.72	-0.57	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
KIRC	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-15.3	1.5e-43	8.7e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-15.3	1.5e-43	8.7e-40	-0.73	-0.57	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
KIRC	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-15.29	1.58e-43	9.15e-40	-0.81	-0.57	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
KIRC	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-15.29	1.72e-43	9.93e-40	-0.69	-0.57	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-15.28	1.78e-43	1.02e-39	-0.73	-0.57	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	15.28	1.81e-43	1.05e-39	0.75	0.57	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	15.28	1.81e-43	1.05e-39	0.75	0.57	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
KIRC	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-15.28	1.9e-43	1.1e-39	-0.57	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
KIRC	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-15.28	1.95e-43	1.12e-39	-0.78	-0.57	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-15.27	2.03e-43	1.17e-39	-0.78	-0.57	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-15.27	2.04e-43	1.17e-39	-0.77	-0.57	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-15.27	2.04e-43	1.17e-39	-0.77	-0.57	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
KIRC	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	15.27	2.06e-43	1.19e-39	0.84	0.57	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
KIRC	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-15.27	2.09e-43	1.2e-39	-0.71	-0.57	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.27	2.11e-43	1.21e-39	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
KIRC	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-15.27	2.11e-43	1.21e-39	-0.81	-0.57	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-15.27	2.11e-43	1.21e-39	-0.81	-0.57	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-15.27	2.11e-43	1.21e-39	-0.81	-0.57	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-15.27	2.11e-43	1.21e-39	-0.81	-0.57	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
KIRC	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	15.27	2.11e-43	1.21e-39	0.7	0.57	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
KIRC	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	15.27	2.12e-43	1.22e-39	0.7	0.57	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
KIRC	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-15.26	2.23e-43	1.28e-39	-0.71	-0.57	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
KIRC	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	15.26	2.32e-43	1.33e-39	0.7	0.57	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
KIRC	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	15.26	2.37e-43	1.36e-39	0.73	0.57	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
KIRC	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-15.26	2.39e-43	1.37e-39	-0.81	-0.57	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
KIRC	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-15.25	2.46e-43	1.41e-39	-0.48	-0.57	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
KIRC	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-15.25	2.48e-43	1.42e-39	-0.72	-0.57	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-15.25	2.48e-43	1.42e-39	-0.72	-0.57	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
KIRC	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	15.25	2.52e-43	1.44e-39	0.69	0.57	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
KIRC	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-15.25	2.59e-43	1.48e-39	-0.72	-0.57	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
KIRC	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-15.25	2.62e-43	1.5e-39	-0.72	-0.57	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
KIRC	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	15.24	2.73e-43	1.56e-39	0.66	0.57	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	15.24	2.73e-43	1.56e-39	0.66	0.57	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
KIRC	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-15.23	2.98e-43	1.7e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
KIRC	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-15.23	3e-43	1.71e-39	-0.69	-0.56	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	15.23	3.08e-43	1.76e-39	0.66	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-15.23	3.09e-43	1.76e-39	-0.71	-0.56	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-15.23	3.09e-43	1.76e-39	-0.71	-0.56	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
KIRC	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	15.23	3.2e-43	1.82e-39	0.7	0.56	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.22	3.28e-43	1.86e-39	-0.72	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
KIRC	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-15.22	3.29e-43	1.87e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
KIRC	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-15.22	3.36e-43	1.91e-39	-0.77	-0.56	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
KIRC	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-15.22	3.36e-43	1.91e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-15.22	3.38e-43	1.92e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
KIRC	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-15.22	3.4e-43	1.93e-39	-0.77	-0.56	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
KIRC	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-15.22	3.42e-43	1.94e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	15.22	3.43e-43	1.95e-39	0.68	0.56	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
KIRC	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-15.22	3.5e-43	1.98e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
KIRC	cis	rs9457247	1	rs2769354	ENSG00000265828.1	MIR3939	15.22	3.58e-43	2.02e-39	0.63	0.56	Crohn's disease;	chr6:166966283	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.846	rs2757052	ENSG00000265828.1	MIR3939	15.22	3.58e-43	2.02e-39	0.63	0.56	Crohn's disease;	chr6:166966686	chr6:166997807~166997912:-
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	15.22	3.62e-43	2.04e-39	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
KIRC	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-15.21	3.73e-43	2.11e-39	-0.8	-0.56	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
KIRC	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	15.21	3.77e-43	2.13e-39	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
KIRC	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-15.21	3.8e-43	2.15e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-15.21	3.82e-43	2.16e-39	-0.72	-0.56	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
KIRC	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-15.2	4.07e-43	2.3e-39	-0.81	-0.56	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-15.2	4.16e-43	2.34e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
KIRC	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	15.2	4.21e-43	2.37e-39	0.71	0.56	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
KIRC	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	15.2	4.21e-43	2.37e-39	0.71	0.56	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
KIRC	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	15.2	4.21e-43	2.37e-39	0.65	0.56	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	15.2	4.21e-43	2.37e-39	0.65	0.56	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
KIRC	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-15.2	4.27e-43	2.4e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-15.2	4.28e-43	2.41e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
KIRC	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-15.2	4.31e-43	2.42e-39	-0.8	-0.56	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	15.2	4.34e-43	2.44e-39	0.72	0.56	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	15.2	4.4e-43	2.47e-39	0.74	0.56	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
KIRC	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-15.2	4.43e-43	2.49e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
KIRC	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-15.19	4.58e-43	2.57e-39	-0.7	-0.56	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
KIRC	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-15.19	4.63e-43	2.6e-39	-0.85	-0.56	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
KIRC	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-15.19	4.67e-43	2.62e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-15.19	4.67e-43	2.62e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
KIRC	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	15.19	4.78e-43	2.68e-39	0.65	0.56	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
KIRC	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-15.19	4.86e-43	2.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
KIRC	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-15.19	4.91e-43	2.75e-39	-0.8	-0.56	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-15.19	4.96e-43	2.78e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-15.18	4.97e-43	2.78e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
KIRC	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	15.18	5.38e-43	3.01e-39	0.67	0.56	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
KIRC	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-15.18	5.5e-43	3.07e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
KIRC	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	15.17	5.51e-43	3.08e-39	0.66	0.56	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	15.17	5.54e-43	3.09e-39	0.74	0.56	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
KIRC	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	15.17	5.84e-43	3.26e-39	0.66	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	15.17	5.89e-43	3.28e-39	0.72	0.56	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
KIRC	cis	rs9457247	0.967	rs1211447	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166968491	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs1187532	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166968532	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs448060	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166969134	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs365189	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166971057	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs376551	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166971435	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs402749	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166972616	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs397713	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166973226	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.905	rs453184	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166973916	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs436707	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166975355	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs377753	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166976008	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs430477	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166976363	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs376574	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166976468	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs439237	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166977904	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs9457247	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166978686	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs405553	ENSG00000265828.1	MIR3939	-15.16	6.12e-43	3.4e-39	-0.63	-0.56	Crohn's disease;	chr6:166981570	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs2015864	ENSG00000265828.1	MIR3939	15.16	6.12e-43	3.4e-39	0.63	0.56	Crohn's disease;	chr6:166967988	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs385863	ENSG00000265828.1	MIR3939	-15.16	6.14e-43	3.41e-39	-0.63	-0.56	Crohn's disease;	chr6:166973127	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.935	rs1794697	ENSG00000265828.1	MIR3939	-15.16	6.15e-43	3.41e-39	-0.63	-0.56	Crohn's disease;	chr6:166981922	chr6:166997807~166997912:-
KIRC	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	15.16	6.27e-43	3.48e-39	1.11	0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	15.16	6.55e-43	3.63e-39	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
KIRC	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-15.16	6.57e-43	3.64e-39	-0.91	-0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
KIRC	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	15.16	6.57e-43	3.64e-39	0.7	0.56	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	15.16	6.57e-43	3.64e-39	0.7	0.56	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	15.16	6.57e-43	3.64e-39	0.7	0.56	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
KIRC	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	15.16	6.58e-43	3.64e-39	0.64	0.56	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
KIRC	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-15.16	6.59e-43	3.65e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
KIRC	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	15.15	6.99e-43	3.87e-39	0.7	0.56	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
KIRC	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-15.15	7.05e-43	3.9e-39	-0.77	-0.56	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
KIRC	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-15.15	7.47e-43	4.13e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-15.15	7.47e-43	4.13e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-15.15	7.47e-43	4.13e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
KIRC	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-15.15	7.47e-43	4.13e-39	-0.72	-0.56	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
KIRC	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-15.15	7.49e-43	4.13e-39	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
KIRC	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-15.15	7.5e-43	4.14e-39	-0.69	-0.56	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs2149090	ENSG00000265828.1	MIR3939	15.15	7.51e-43	4.15e-39	0.63	0.56	Crohn's disease;	chr6:166959276	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs2149091	ENSG00000265828.1	MIR3939	15.15	7.51e-43	4.15e-39	0.63	0.56	Crohn's disease;	chr6:166959298	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	15.14	7.71e-43	4.25e-39	0.72	0.56	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	15.14	7.73e-43	4.26e-39	0.72	0.56	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	15.14	7.73e-43	4.26e-39	0.72	0.56	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	15.14	7.73e-43	4.26e-39	0.72	0.56	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
KIRC	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-15.14	7.74e-43	4.26e-39	-0.77	-0.56	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
KIRC	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	15.14	8.05e-43	4.43e-39	0.7	0.56	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
KIRC	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-15.14	8.12e-43	4.47e-39	-0.73	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
KIRC	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-15.14	8.12e-43	4.47e-39	-0.73	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
KIRC	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	15.14	8.14e-43	4.47e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	15.14	8.14e-43	4.47e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	15.14	8.14e-43	4.47e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	15.14	8.14e-43	4.47e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	15.14	8.14e-43	4.47e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	15.14	8.16e-43	4.48e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	15.14	8.16e-43	4.48e-39	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
KIRC	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	15.13	8.37e-43	4.6e-39	0.69	0.56	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-15.13	8.41e-43	4.62e-39	-0.54	-0.56	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-15.13	8.56e-43	4.69e-39	-0.73	-0.56	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
KIRC	cis	rs9457247	0.967	rs443570	ENSG00000265828.1	MIR3939	-15.13	8.59e-43	4.71e-39	-0.63	-0.56	Crohn's disease;	chr6:166976437	chr6:166997807~166997912:-
KIRC	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	15.13	8.66e-43	4.75e-39	0.71	0.56	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
KIRC	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	15.13	8.69e-43	4.76e-39	0.69	0.56	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
KIRC	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-15.13	9.1e-43	4.99e-39	-0.71	-0.56	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
KIRC	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-15.12	9.29e-43	5.08e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
KIRC	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	15.12	9.48e-43	5.19e-39	0.89	0.56	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
KIRC	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-15.11	1.04e-42	5.66e-39	-0.79	-0.56	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-15.11	1.04e-42	5.66e-39	-0.79	-0.56	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
KIRC	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	15.11	1.06e-42	5.77e-39	0.73	0.56	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
KIRC	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	15.11	1.06e-42	5.8e-39	1.12	0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
KIRC	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	15.11	1.06e-42	5.8e-39	1.12	0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
KIRC	cis	rs9457247	0.935	rs1187530	ENSG00000265828.1	MIR3939	15.11	1.08e-42	5.92e-39	0.63	0.56	Crohn's disease;	chr6:166963324	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.935	rs2757050	ENSG00000265828.1	MIR3939	15.11	1.08e-42	5.92e-39	0.63	0.56	Crohn's disease;	chr6:166963677	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs1590257	ENSG00000265828.1	MIR3939	15.11	1.08e-42	5.92e-39	0.63	0.56	Crohn's disease;	chr6:166964294	chr6:166997807~166997912:-
KIRC	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	15.11	1.09e-42	5.93e-39	0.76	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	15.11	1.1e-42	5.98e-39	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
KIRC	cis	rs9457247	1	rs1819333	ENSG00000265828.1	MIR3939	-15.11	1.1e-42	5.99e-39	-0.63	-0.56	Crohn's disease;	chr6:166960059	chr6:166997807~166997912:-
KIRC	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-15.11	1.1e-42	6.02e-39	-0.49	-0.56	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
KIRC	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-15.11	1.12e-42	6.09e-39	-0.7	-0.56	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
KIRC	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-15.11	1.13e-42	6.15e-39	-0.54	-0.56	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-15.1	1.2e-42	6.51e-39	-0.73	-0.56	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
KIRC	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	15.1	1.2e-42	6.53e-39	0.67	0.56	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-15.1	1.23e-42	6.71e-39	-0.71	-0.56	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
KIRC	cis	rs9457247	0.902	rs34560498	ENSG00000265828.1	MIR3939	-15.1	1.27e-42	6.87e-39	-0.63	-0.56	Crohn's disease;	chr6:166982374	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	15.09	1.27e-42	6.89e-39	0.72	0.56	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
KIRC	cis	rs9457247	1	rs393727	ENSG00000265828.1	MIR3939	-15.09	1.28e-42	6.93e-39	-0.63	-0.56	Crohn's disease;	chr6:166985144	chr6:166997807~166997912:-
KIRC	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-15.09	1.28e-42	6.95e-39	-0.77	-0.56	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
KIRC	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-15.09	1.33e-42	7.2e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
KIRC	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	15.09	1.35e-42	7.32e-39	0.93	0.56	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
KIRC	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	15.09	1.36e-42	7.38e-39	0.7	0.56	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
KIRC	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	15.09	1.38e-42	7.48e-39	0.62	0.56	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
KIRC	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-15.08	1.42e-42	7.72e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
KIRC	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-15.08	1.43e-42	7.72e-39	-0.77	-0.56	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
KIRC	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	15.08	1.45e-42	7.87e-39	0.66	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
KIRC	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-15.08	1.46e-42	7.89e-39	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
KIRC	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-15.08	1.48e-42	8.02e-39	-0.79	-0.56	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
KIRC	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-15.08	1.53e-42	8.26e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-15.08	1.54e-42	8.3e-39	-0.72	-0.56	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
KIRC	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-15.08	1.54e-42	8.34e-39	-0.77	-0.56	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
KIRC	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	15.07	1.6e-42	8.62e-39	0.69	0.56	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
KIRC	cis	rs9457247	0.967	rs2149092	ENSG00000265828.1	MIR3939	15.07	1.62e-42	8.72e-39	0.63	0.56	Crohn's disease;	chr6:166959490	chr6:166997807~166997912:-
KIRC	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	15.07	1.62e-42	8.77e-39	0.68	0.56	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
KIRC	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	15.07	1.72e-42	9.31e-39	0.65	0.56	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
KIRC	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-15.06	1.78e-42	9.57e-39	-0.69	-0.56	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
KIRC	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-15.06	1.83e-42	9.84e-39	-0.71	-0.56	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
KIRC	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-15.05	1.94e-42	1.05e-38	-0.8	-0.56	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
KIRC	cis	rs9457247	1	rs2149085	ENSG00000265828.1	MIR3939	15.05	1.96e-42	1.05e-38	0.63	0.56	Crohn's disease;	chr6:166957622	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs2769347	ENSG00000265828.1	MIR3939	15.05	1.98e-42	1.07e-38	0.63	0.56	Crohn's disease;	chr6:166958249	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-15.05	2.02e-42	1.09e-38	-0.71	-0.56	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-15.05	2.03e-42	1.09e-38	-0.7	-0.56	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
KIRC	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-15.05	2.03e-42	1.09e-38	-0.66	-0.56	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
KIRC	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-15.05	2.09e-42	1.12e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
KIRC	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	15.05	2.1e-42	1.13e-38	0.73	0.56	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
KIRC	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-15.04	2.14e-42	1.15e-38	-0.77	-0.56	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
KIRC	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-15.04	2.16e-42	1.16e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
KIRC	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	15.04	2.19e-42	1.18e-38	0.72	0.56	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
KIRC	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-15.04	2.22e-42	1.19e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-15.04	2.22e-42	1.19e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	15.03	2.37e-42	1.26e-38	0.71	0.56	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
KIRC	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-15.03	2.45e-42	1.31e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
KIRC	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	15.03	2.47e-42	1.31e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
KIRC	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-15.03	2.47e-42	1.32e-38	-0.69	-0.56	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
KIRC	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	15.03	2.48e-42	1.32e-38	0.58	0.56	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
KIRC	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	15.03	2.51e-42	1.33e-38	0.81	0.56	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
KIRC	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-15.03	2.52e-42	1.34e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
KIRC	cis	rs73086581	0.891	rs73084555	ENSG00000229539.1	RP11-119B16.2	15.03	2.56e-42	1.36e-38	0.94	0.56	Response to antidepressants in depression;	chr20:3913153	chr20:3888239~3888868:-
KIRC	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	15.03	2.56e-42	1.36e-38	0.73	0.56	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
KIRC	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-15.03	2.57e-42	1.36e-38	-0.53	-0.56	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-15.03	2.61e-42	1.38e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
KIRC	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	15.02	2.65e-42	1.4e-38	0.91	0.56	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.967	rs2149083	ENSG00000265828.1	MIR3939	15.02	2.67e-42	1.42e-38	0.63	0.56	Crohn's disease;	chr6:166957483	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs2149084	ENSG00000265828.1	MIR3939	15.02	2.67e-42	1.42e-38	0.63	0.56	Crohn's disease;	chr6:166957500	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs2769346	ENSG00000265828.1	MIR3939	15.02	2.67e-42	1.42e-38	0.63	0.56	Crohn's disease;	chr6:166957511	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-15.02	2.69e-42	1.42e-38	-0.8	-0.56	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
KIRC	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-15.02	2.69e-42	1.42e-38	-0.54	-0.56	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
KIRC	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-15.02	2.72e-42	1.44e-38	-0.71	-0.56	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-15.02	2.72e-42	1.44e-38	-0.71	-0.56	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
KIRC	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	15.02	2.72e-42	1.44e-38	0.81	0.56	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
KIRC	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-15.02	2.76e-42	1.46e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
KIRC	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-15.02	2.83e-42	1.49e-38	-0.62	-0.56	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
KIRC	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-15.01	2.97e-42	1.57e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
KIRC	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-15.01	3.01e-42	1.59e-38	-0.7	-0.56	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
KIRC	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-15.01	3.05e-42	1.61e-38	-0.7	-0.56	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	15.01	3.07e-42	1.62e-38	0.72	0.56	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
KIRC	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-15.01	3.09e-42	1.63e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	15.01	3.16e-42	1.67e-38	0.72	0.56	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
KIRC	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-15.01	3.19e-42	1.68e-38	-0.54	-0.56	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-15	3.27e-42	1.72e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-15	3.27e-42	1.72e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
KIRC	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-15	3.32e-42	1.74e-38	-0.49	-0.56	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
KIRC	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	15	3.34e-42	1.75e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	15	3.35e-42	1.75e-38	0.71	0.56	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
KIRC	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-15	3.44e-42	1.8e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
KIRC	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-15	3.56e-42	1.85e-38	-0.69	-0.56	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
KIRC	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	15	3.57e-42	1.86e-38	0.56	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
KIRC	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-14.99	3.6e-42	1.88e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
KIRC	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-14.99	3.6e-42	1.88e-38	-0.57	-0.56	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
KIRC	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-14.99	3.71e-42	1.93e-38	-0.69	-0.56	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
KIRC	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-14.99	3.73e-42	1.94e-38	-0.69	-0.56	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
KIRC	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	14.99	3.76e-42	1.96e-38	1.12	0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
KIRC	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-14.99	3.79e-42	1.97e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
KIRC	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-14.99	3.94e-42	2.05e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
KIRC	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-14.98	4.01e-42	2.08e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
KIRC	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-14.98	4.09e-42	2.12e-38	-0.7	-0.56	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
KIRC	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-14.98	4.21e-42	2.19e-38	-0.69	-0.56	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
KIRC	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-14.98	4.27e-42	2.22e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
KIRC	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	14.97	4.47e-42	2.32e-38	0.66	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	14.97	4.57e-42	2.37e-38	0.72	0.56	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
KIRC	cis	rs9457247	1	rs393558	ENSG00000265828.1	MIR3939	-14.97	4.66e-42	2.41e-38	-0.62	-0.56	Crohn's disease;	chr6:166984262	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs394522	ENSG00000265828.1	MIR3939	-14.97	4.66e-42	2.41e-38	-0.62	-0.56	Crohn's disease;	chr6:166984583	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs408040	ENSG00000265828.1	MIR3939	-14.97	4.66e-42	2.41e-38	-0.62	-0.56	Crohn's disease;	chr6:166985415	chr6:166997807~166997912:-
KIRC	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	14.97	4.8e-42	2.47e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	14.97	4.8e-42	2.47e-38	0.91	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
KIRC	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-14.97	4.8e-42	2.47e-38	-0.54	-0.56	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
KIRC	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	14.97	4.82e-42	2.48e-38	0.72	0.56	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-14.96	4.93e-42	2.54e-38	-0.7	-0.56	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
KIRC	cis	rs9457247	1	rs364283	ENSG00000265828.1	MIR3939	-14.96	5.22e-42	2.69e-38	-0.63	-0.56	Crohn's disease;	chr6:166970262	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs429083	ENSG00000265828.1	MIR3939	-14.96	5.22e-42	2.69e-38	-0.63	-0.56	Crohn's disease;	chr6:166970484	chr6:166997807~166997912:-
KIRC	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-14.96	5.39e-42	2.77e-38	-0.69	-0.56	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
KIRC	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-14.95	5.45e-42	2.8e-38	-0.69	-0.56	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
KIRC	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-14.95	5.49e-42	2.82e-38	-0.7	-0.56	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
KIRC	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	14.95	5.6e-42	2.88e-38	0.39	0.56	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
KIRC	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-14.95	5.63e-42	2.89e-38	-0.54	-0.56	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-14.95	5.8e-42	2.98e-38	-0.54	-0.56	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
KIRC	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-14.95	5.97e-42	3.07e-38	-0.69	-0.56	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
KIRC	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-14.94	6.01e-42	3.08e-38	-0.8	-0.56	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
KIRC	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	14.94	6.02e-42	3.09e-38	0.68	0.56	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
KIRC	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-14.94	6.07e-42	3.11e-38	-0.69	-0.56	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-14.94	6.1e-42	3.12e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
KIRC	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	14.94	6.13e-42	3.14e-38	0.69	0.56	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
KIRC	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-14.94	6.14e-42	3.14e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
KIRC	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-14.94	6.18e-42	3.16e-38	-0.72	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
KIRC	cis	rs507080	0.733	rs497678	ENSG00000255422.1	AP002954.4	-14.94	6.25e-42	3.2e-38	-0.69	-0.56	Serum metabolite levels;	chr11:118697172	chr11:118704607~118750263:+
KIRC	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	14.94	6.26e-42	3.2e-38	0.82	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
KIRC	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	14.94	6.29e-42	3.22e-38	0.69	0.56	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
KIRC	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	14.94	6.59e-42	3.37e-38	0.9	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
KIRC	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	14.93	6.74e-42	3.44e-38	0.69	0.56	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
KIRC	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	14.93	6.82e-42	3.48e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
KIRC	cis	rs9457247	1	rs413232	ENSG00000265828.1	MIR3939	-14.93	6.88e-42	3.51e-38	-0.62	-0.56	Crohn's disease;	chr6:166987484	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs86755	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166989620	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs382009	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166989633	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs428805	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166989644	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.934	rs2345571	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166989912	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs385460	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166990400	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs385113	ENSG00000265828.1	MIR3939	-14.93	6.89e-42	3.52e-38	-0.62	-0.56	Crohn's disease;	chr6:166990483	chr6:166997807~166997912:-
KIRC	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-14.93	7.14e-42	3.64e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
KIRC	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	14.93	7.14e-42	3.64e-38	0.66	0.56	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
KIRC	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	14.93	7.16e-42	3.65e-38	0.87	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
KIRC	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-14.93	7.24e-42	3.69e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
KIRC	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-14.92	7.38e-42	3.75e-38	-0.66	-0.56	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
KIRC	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-14.92	7.46e-42	3.79e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
KIRC	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	14.92	7.58e-42	3.85e-38	0.69	0.56	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
KIRC	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	14.92	7.63e-42	3.88e-38	0.69	0.56	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
KIRC	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	14.92	7.77e-42	3.95e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
KIRC	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-14.92	8.08e-42	4.1e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
KIRC	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-14.91	8.17e-42	4.15e-38	-0.7	-0.56	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
KIRC	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-14.91	8.18e-42	4.15e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
KIRC	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	14.91	8.33e-42	4.23e-38	0.68	0.56	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
KIRC	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	14.91	8.36e-42	4.24e-38	0.67	0.56	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
KIRC	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	14.91	8.42e-42	4.27e-38	0.66	0.56	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-14.91	8.54e-42	4.33e-38	-0.69	-0.56	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
KIRC	cis	rs9457247	0.967	rs447042	ENSG00000265828.1	MIR3939	-14.91	8.56e-42	4.34e-38	-0.62	-0.56	Crohn's disease;	chr6:166991947	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs402191	ENSG00000265828.1	MIR3939	-14.91	8.56e-42	4.34e-38	-0.62	-0.56	Crohn's disease;	chr6:166992065	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs2769355	ENSG00000265828.1	MIR3939	14.91	8.94e-42	4.53e-38	0.63	0.56	Crohn's disease;	chr6:166967005	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs2757054	ENSG00000265828.1	MIR3939	14.91	8.94e-42	4.53e-38	0.63	0.56	Crohn's disease;	chr6:166967013	chr6:166997807~166997912:-
KIRC	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	14.91	8.95e-42	4.53e-38	0.56	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
KIRC	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-14.9	9.1e-42	4.6e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-14.9	9.12e-42	4.61e-38	-0.72	-0.56	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
KIRC	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	14.9	9.2e-42	4.65e-38	0.69	0.56	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
KIRC	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-14.9	9.23e-42	4.67e-38	-0.79	-0.56	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
KIRC	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	14.9	9.31e-42	4.71e-38	0.68	0.56	Depression;	chr6:28240757	chr6:28176188~28176674:+
KIRC	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-14.9	9.44e-42	4.76e-38	-0.69	-0.56	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-14.9	9.49e-42	4.79e-38	-0.79	-0.56	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.9	9.9e-42	4.99e-38	0.71	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
KIRC	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-14.89	1.03e-41	5.21e-38	-0.79	-0.56	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
KIRC	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	14.89	1.04e-41	5.23e-38	0.8	0.56	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
KIRC	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-14.89	1.05e-41	5.3e-38	-0.69	-0.56	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
KIRC	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-14.89	1.07e-41	5.38e-38	-0.69	-0.56	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-14.89	1.07e-41	5.38e-38	-0.69	-0.56	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	14.88	1.13e-41	5.69e-38	0.71	0.56	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
KIRC	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-14.88	1.14e-41	5.72e-38	-0.7	-0.56	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
KIRC	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-14.88	1.14e-41	5.72e-38	-0.53	-0.56	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-14.88	1.14e-41	5.72e-38	-0.53	-0.56	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	14.88	1.15e-41	5.77e-38	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
KIRC	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-14.88	1.16e-41	5.84e-38	-0.71	-0.56	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
KIRC	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	14.88	1.2e-41	6e-38	0.86	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
KIRC	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	14.88	1.2e-41	6.01e-38	0.69	0.56	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
KIRC	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-14.87	1.27e-41	6.33e-38	-0.54	-0.56	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
KIRC	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-14.87	1.27e-41	6.37e-38	-1.07	-0.56	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	14.87	1.3e-41	6.52e-38	0.62	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
KIRC	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-14.87	1.32e-41	6.58e-38	-0.53	-0.56	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-14.87	1.33e-41	6.62e-38	-0.54	-0.56	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-14.87	1.33e-41	6.62e-38	-0.54	-0.56	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-14.87	1.33e-41	6.62e-38	-0.54	-0.56	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
KIRC	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	14.87	1.33e-41	6.64e-38	0.88	0.56	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
KIRC	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-14.86	1.38e-41	6.9e-38	-0.67	-0.56	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
KIRC	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-14.86	1.42e-41	7.06e-38	-0.71	-0.56	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
KIRC	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	14.86	1.42e-41	7.08e-38	0.65	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
KIRC	cis	rs6085948	0.861	rs6117729	ENSG00000238102.1	RP11-19D2.1	-14.86	1.42e-41	7.09e-38	-0.62	-0.56	Interleukin-10 levels;	chr20:7267542	chr20:7256580~7258214:-
KIRC	cis	rs9457247	1	rs400063	ENSG00000265828.1	MIR3939	-14.86	1.44e-41	7.17e-38	-0.62	-0.56	Crohn's disease;	chr6:166973104	chr6:166997807~166997912:-
KIRC	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	14.86	1.45e-41	7.23e-38	1.05	0.56	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
KIRC	cis	rs5769707	0.967	rs8141807	ENSG00000235111.1	RP1-29C18.8	-14.86	1.46e-41	7.27e-38	-0.53	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49612657~49615716:-
KIRC	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	14.86	1.51e-41	7.52e-38	0.69	0.56	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
KIRC	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-14.85	1.53e-41	7.58e-38	-0.8	-0.56	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
KIRC	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-14.85	1.57e-41	7.78e-38	-0.73	-0.56	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
KIRC	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-14.85	1.58e-41	7.84e-38	-0.53	-0.56	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
KIRC	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	14.85	1.66e-41	8.23e-38	0.69	0.56	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	14.85	1.66e-41	8.23e-38	0.69	0.56	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	14.85	1.66e-41	8.23e-38	0.69	0.56	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs416131	ENSG00000265828.1	MIR3939	14.85	1.66e-41	8.25e-38	0.63	0.56	Crohn's disease;	chr6:166993056	chr6:166997807~166997912:-
KIRC	cis	rs6085948	0.861	rs11907461	ENSG00000238102.1	RP11-19D2.1	-14.85	1.68e-41	8.34e-38	-0.61	-0.56	Interleukin-10 levels;	chr20:7251766	chr20:7256580~7258214:-
KIRC	cis	rs9457247	1	rs932644	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166990699	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs10946198	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166990944	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs10946199	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166991004	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs1794694	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166991263	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs430293	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166991470	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs430097	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166991585	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs409356	ENSG00000265828.1	MIR3939	-14.84	1.7e-41	8.4e-38	-0.62	-0.56	Crohn's disease;	chr6:166991738	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs422094	ENSG00000265828.1	MIR3939	-14.84	1.74e-41	8.63e-38	-0.62	-0.55	Crohn's disease;	chr6:166983545	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-14.84	1.75e-41	8.67e-38	-0.79	-0.55	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
KIRC	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-14.84	1.75e-41	8.67e-38	-0.79	-0.55	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
KIRC	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-14.84	1.76e-41	8.68e-38	-0.71	-0.55	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-14.84	1.76e-41	8.68e-38	-0.71	-0.55	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-14.84	1.76e-41	8.68e-38	-0.71	-0.55	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
KIRC	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-14.84	1.77e-41	8.72e-38	-0.71	-0.55	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
KIRC	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	14.84	1.77e-41	8.74e-38	0.62	0.55	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
KIRC	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-14.84	1.81e-41	8.95e-38	-0.66	-0.55	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	14.83	1.89e-41	9.31e-38	0.69	0.55	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
KIRC	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-14.83	1.94e-41	9.56e-38	-0.62	-0.55	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
KIRC	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	14.83	1.94e-41	9.56e-38	0.72	0.55	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
KIRC	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	14.83	1.97e-41	9.71e-38	0.69	0.55	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
KIRC	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	14.83	1.99e-41	9.82e-38	0.63	0.55	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
KIRC	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-14.83	2e-41	9.87e-38	-0.69	-0.55	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	14.82	2.11e-41	1.04e-37	0.71	0.55	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	14.82	2.11e-41	1.04e-37	0.71	0.55	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
KIRC	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	14.82	2.11e-41	1.04e-37	0.71	0.55	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
KIRC	cis	rs9457247	1	rs408918	ENSG00000265828.1	MIR3939	-14.82	2.16e-41	1.06e-37	-0.62	-0.55	Crohn's disease;	chr6:166985794	chr6:166997807~166997912:-
KIRC	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-14.82	2.19e-41	1.08e-37	-0.88	-0.55	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
KIRC	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-14.82	2.21e-41	1.09e-37	-0.53	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
KIRC	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-14.82	2.22e-41	1.09e-37	-0.69	-0.55	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
KIRC	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-14.82	2.25e-41	1.1e-37	-0.65	-0.55	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
KIRC	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	14.82	2.25e-41	1.11e-37	0.64	0.55	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
KIRC	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-14.82	2.29e-41	1.12e-37	-0.79	-0.55	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
KIRC	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	14.81	2.32e-41	1.14e-37	0.63	0.55	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
KIRC	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	14.81	2.33e-41	1.14e-37	0.69	0.55	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
KIRC	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	14.81	2.37e-41	1.16e-37	0.8	0.55	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	14.81	2.48e-41	1.21e-37	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
KIRC	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-14.81	2.49e-41	1.22e-37	-0.53	-0.55	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
KIRC	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-14.81	2.5e-41	1.22e-37	-0.69	-0.55	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-14.81	2.5e-41	1.22e-37	-0.69	-0.55	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
KIRC	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-14.81	2.52e-41	1.24e-37	-0.49	-0.55	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
KIRC	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	14.8	2.55e-41	1.25e-37	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
KIRC	cis	rs9457247	0.902	rs366938	ENSG00000265828.1	MIR3939	-14.8	2.57e-41	1.26e-37	-0.62	-0.55	Crohn's disease;	chr6:166990050	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.871	rs1811121	ENSG00000265828.1	MIR3939	-14.8	2.57e-41	1.26e-37	-0.62	-0.55	Crohn's disease;	chr6:166990051	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	14.8	2.58e-41	1.26e-37	0.67	0.55	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-14.8	2.64e-41	1.29e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
KIRC	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-14.8	2.65e-41	1.29e-37	-0.8	-0.55	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
KIRC	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	14.79	2.82e-41	1.38e-37	0.68	0.55	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
KIRC	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-14.79	2.87e-41	1.4e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
KIRC	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-14.79	2.88e-41	1.41e-37	-0.69	-0.55	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-14.79	2.94e-41	1.43e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
KIRC	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-14.79	2.97e-41	1.45e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
KIRC	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	14.79	3.03e-41	1.48e-37	0.89	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.935	rs401260	ENSG00000265828.1	MIR3939	-14.79	3.06e-41	1.49e-37	-0.62	-0.55	Crohn's disease;	chr6:166992400	chr6:166997807~166997912:-
KIRC	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-14.79	3.08e-41	1.5e-37	-0.69	-0.55	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-14.79	3.08e-41	1.5e-37	-0.69	-0.55	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-14.79	3.08e-41	1.5e-37	-0.69	-0.55	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-14.79	3.08e-41	1.5e-37	-0.69	-0.55	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-14.78	3.15e-41	1.53e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
KIRC	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	14.78	3.18e-41	1.54e-37	0.65	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
KIRC	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-14.78	3.23e-41	1.56e-37	-0.53	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
KIRC	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-14.78	3.23e-41	1.57e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
KIRC	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	14.78	3.3e-41	1.6e-37	0.65	0.55	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
KIRC	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	14.78	3.35e-41	1.62e-37	0.68	0.55	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
KIRC	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-14.78	3.41e-41	1.65e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
KIRC	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	14.77	3.58e-41	1.73e-37	0.7	0.55	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
KIRC	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	14.77	3.65e-41	1.77e-37	0.65	0.55	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
KIRC	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-14.77	3.65e-41	1.77e-37	-0.54	-0.55	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-14.77	3.65e-41	1.77e-37	-0.54	-0.55	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-14.77	3.65e-41	1.77e-37	-0.54	-0.55	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-14.77	3.69e-41	1.78e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-14.77	3.7e-41	1.79e-37	-0.69	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
KIRC	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	14.77	3.7e-41	1.79e-37	0.77	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	14.77	3.7e-41	1.79e-37	0.77	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
KIRC	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	14.77	3.71e-41	1.79e-37	0.7	0.55	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
KIRC	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-14.77	3.73e-41	1.8e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
KIRC	cis	rs9457247	1	rs386548	ENSG00000265828.1	MIR3939	14.77	3.74e-41	1.8e-37	0.62	0.55	Crohn's disease;	chr6:166972045	chr6:166997807~166997912:-
KIRC	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-14.77	3.81e-41	1.84e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-14.77	3.81e-41	1.84e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-14.76	3.85e-41	1.86e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
KIRC	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-14.76	4.01e-41	1.93e-37	-0.66	-0.55	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
KIRC	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-14.76	4.15e-41	2e-37	-0.53	-0.55	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-14.76	4.15e-41	2e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
KIRC	cis	rs9457247	1	rs421214	ENSG00000265828.1	MIR3939	-14.76	4.2e-41	2.02e-37	-0.62	-0.55	Crohn's disease;	chr6:166983141	chr6:166997807~166997912:-
KIRC	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	14.76	4.21e-41	2.03e-37	0.64	0.55	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
KIRC	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	14.76	4.21e-41	2.03e-37	0.69	0.55	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
KIRC	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	14.75	4.28e-41	2.06e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
KIRC	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-14.75	4.33e-41	2.08e-37	-0.69	-0.55	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
KIRC	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-14.75	4.35e-41	2.09e-37	-0.69	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
KIRC	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	14.75	4.37e-41	2.1e-37	0.69	0.55	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
KIRC	cis	rs6085948	0.861	rs2224055	ENSG00000238102.1	RP11-19D2.1	-14.75	4.43e-41	2.13e-37	-0.6	-0.55	Interleukin-10 levels;	chr20:7253521	chr20:7256580~7258214:-
KIRC	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	14.75	4.44e-41	2.13e-37	0.89	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	14.75	4.44e-41	2.13e-37	0.89	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	14.75	4.44e-41	2.13e-37	0.89	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-14.75	4.53e-41	2.17e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-14.75	4.53e-41	2.17e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-14.75	4.53e-41	2.17e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
KIRC	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-14.75	4.58e-41	2.2e-37	-0.72	-0.55	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-14.75	4.58e-41	2.2e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
KIRC	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-14.75	4.68e-41	2.24e-37	-0.67	-0.55	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-14.75	4.68e-41	2.24e-37	-0.67	-0.55	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	14.74	4.83e-41	2.31e-37	0.69	0.55	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
KIRC	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-14.74	4.91e-41	2.35e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
KIRC	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	14.74	4.95e-41	2.36e-37	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
KIRC	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	14.74	4.96e-41	2.37e-37	0.69	0.55	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
KIRC	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-14.74	5.01e-41	2.39e-37	-0.53	-0.55	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
KIRC	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	14.74	5.22e-41	2.49e-37	0.71	0.55	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
KIRC	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	14.73	5.24e-41	2.5e-37	0.68	0.55	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
KIRC	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	14.73	5.27e-41	2.51e-37	0.77	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
KIRC	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-14.73	5.28e-41	2.51e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
KIRC	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	14.73	5.53e-41	2.63e-37	0.68	0.55	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
KIRC	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	14.73	5.55e-41	2.64e-37	0.62	0.55	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
KIRC	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-14.73	5.65e-41	2.69e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
KIRC	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	14.73	5.7e-41	2.71e-37	0.8	0.55	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
KIRC	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-14.72	5.82e-41	2.77e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
KIRC	cis	rs9457247	1	rs1794693	ENSG00000265828.1	MIR3939	-14.72	6.07e-41	2.88e-37	-0.62	-0.55	Crohn's disease;	chr6:166992182	chr6:166997807~166997912:-
KIRC	cis	rs6085948	0.817	rs17394645	ENSG00000238102.1	RP11-19D2.1	-14.72	6.3e-41	2.99e-37	-0.61	-0.55	Interleukin-10 levels;	chr20:7250193	chr20:7256580~7258214:-
KIRC	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	14.72	6.34e-41	3e-37	0.66	0.55	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	14.72	6.34e-41	3e-37	0.66	0.55	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
KIRC	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	14.72	6.38e-41	3.03e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
KIRC	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-14.71	6.62e-41	3.14e-37	-0.73	-0.55	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
KIRC	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	14.71	6.67e-41	3.16e-37	0.68	0.55	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
KIRC	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	14.71	6.73e-41	3.19e-37	0.69	0.55	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-14.71	6.81e-41	3.22e-37	-0.67	-0.55	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-14.71	6.81e-41	3.22e-37	-0.67	-0.55	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-14.71	6.81e-41	3.22e-37	-0.67	-0.55	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-14.71	6.81e-41	3.22e-37	-0.67	-0.55	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
KIRC	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	14.71	6.9e-41	3.26e-37	0.69	0.55	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
KIRC	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-14.71	6.96e-41	3.29e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-14.71	6.96e-41	3.29e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
KIRC	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-14.71	6.96e-41	3.29e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
KIRC	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	14.71	6.99e-41	3.3e-37	0.69	0.55	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-14.71	7.02e-41	3.32e-37	-0.53	-0.55	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-14.71	7.02e-41	3.32e-37	-0.53	-0.55	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	14.7	7.36e-41	3.48e-37	0.61	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
KIRC	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	14.7	7.54e-41	3.56e-37	0.65	0.55	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
KIRC	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-14.7	7.54e-41	3.56e-37	-0.52	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
KIRC	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-14.7	7.74e-41	3.65e-37	-0.55	-0.55	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
KIRC	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-14.7	7.76e-41	3.66e-37	-0.55	-0.55	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
KIRC	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	14.7	7.81e-41	3.68e-37	0.69	0.55	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
KIRC	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	14.7	7.84e-41	3.7e-37	0.69	0.55	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	14.7	7.85e-41	3.7e-37	0.7	0.55	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	14.7	7.85e-41	3.7e-37	0.7	0.55	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	14.7	7.85e-41	3.7e-37	0.7	0.55	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	14.7	7.85e-41	3.7e-37	0.7	0.55	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	14.7	7.85e-41	3.7e-37	0.7	0.55	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
KIRC	cis	rs9457247	0.756	rs1811123	ENSG00000265828.1	MIR3939	-14.69	7.92e-41	3.73e-37	-0.62	-0.55	Crohn's disease;	chr6:166989955	chr6:166997807~166997912:-
KIRC	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	14.69	7.97e-41	3.75e-37	0.89	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
KIRC	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-14.69	8.13e-41	3.82e-37	-0.53	-0.55	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
KIRC	cis	rs5769707	0.935	rs9616332	ENSG00000235111.1	RP1-29C18.8	-14.69	8.16e-41	3.84e-37	-0.53	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49612657~49615716:-
KIRC	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	14.69	8.4e-41	3.95e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
KIRC	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	14.69	8.42e-41	3.96e-37	0.69	0.55	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs439553	ENSG00000265828.1	MIR3939	-14.69	8.47e-41	3.98e-37	-0.61	-0.55	Crohn's disease;	chr6:166977724	chr6:166997807~166997912:-
KIRC	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-14.69	8.57e-41	4.03e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
KIRC	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-14.69	8.61e-41	4.05e-37	-0.95	-0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
KIRC	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-14.68	8.77e-41	4.12e-37	-0.53	-0.55	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
KIRC	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-14.68	8.91e-41	4.18e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
KIRC	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-14.68	9.07e-41	4.26e-37	-0.53	-0.55	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
KIRC	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-14.68	9.1e-41	4.27e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-14.68	9.11e-41	4.27e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
KIRC	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	14.68	9.27e-41	4.34e-37	0.62	0.55	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
KIRC	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-14.68	9.31e-41	4.36e-37	-0.53	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
KIRC	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	14.68	9.65e-41	4.51e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
KIRC	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-14.67	9.84e-41	4.6e-37	-0.53	-0.55	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
KIRC	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-14.67	9.91e-41	4.64e-37	-0.67	-0.55	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-14.67	9.91e-41	4.64e-37	-0.67	-0.55	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-14.67	9.91e-41	4.64e-37	-0.67	-0.55	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-14.67	9.92e-41	4.64e-37	-0.68	-0.55	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
KIRC	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	14.67	1.02e-40	4.74e-37	0.64	0.55	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
KIRC	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-14.67	1.02e-40	4.78e-37	-1.01	-0.55	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
KIRC	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-14.66	1.08e-40	5.02e-37	-0.54	-0.55	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
KIRC	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	14.66	1.08e-40	5.04e-37	0.7	0.55	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
KIRC	cis	rs9457247	1	rs408087	ENSG00000265828.1	MIR3939	-14.66	1.1e-40	5.12e-37	-0.61	-0.55	Crohn's disease;	chr6:166985464	chr6:166997807~166997912:-
KIRC	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-14.66	1.1e-40	5.13e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-14.66	1.1e-40	5.13e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-14.66	1.1e-40	5.13e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-14.66	1.1e-40	5.13e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-14.66	1.1e-40	5.13e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-14.66	1.1e-40	5.13e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
KIRC	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-14.66	1.11e-40	5.14e-37	-0.7	-0.55	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-14.66	1.11e-40	5.14e-37	-0.7	-0.55	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
KIRC	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-14.66	1.15e-40	5.34e-37	-0.63	-0.55	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
KIRC	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-14.66	1.15e-40	5.36e-37	-0.72	-0.55	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
KIRC	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-14.66	1.17e-40	5.45e-37	-0.68	-0.55	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	14.66	1.18e-40	5.48e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
KIRC	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	14.65	1.22e-40	5.64e-37	0.65	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-14.65	1.22e-40	5.66e-37	-0.67	-0.55	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
KIRC	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	14.65	1.28e-40	5.94e-37	0.87	0.55	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
KIRC	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-14.65	1.3e-40	6.01e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
KIRC	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-14.64	1.34e-40	6.19e-37	-0.64	-0.55	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-14.64	1.34e-40	6.19e-37	-0.64	-0.55	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
KIRC	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-14.64	1.38e-40	6.36e-37	-0.67	-0.55	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
KIRC	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	14.64	1.38e-40	6.38e-37	0.64	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
KIRC	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-14.64	1.39e-40	6.42e-37	-0.64	-0.55	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
KIRC	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-14.64	1.4e-40	6.48e-37	-0.65	-0.55	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
KIRC	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	14.64	1.41e-40	6.49e-37	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
KIRC	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-14.64	1.41e-40	6.51e-37	-0.53	-0.55	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
KIRC	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-14.64	1.41e-40	6.51e-37	-0.53	-0.55	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
KIRC	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-14.64	1.42e-40	6.54e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
KIRC	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-14.64	1.45e-40	6.7e-37	-0.69	-0.55	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-14.64	1.45e-40	6.7e-37	-0.53	-0.55	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
KIRC	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-14.63	1.49e-40	6.86e-37	-0.68	-0.55	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	14.63	1.53e-40	7.06e-37	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
KIRC	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	14.63	1.56e-40	7.16e-37	0.65	0.55	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
KIRC	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-14.63	1.56e-40	7.18e-37	-0.55	-0.55	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
KIRC	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-14.63	1.57e-40	7.21e-37	-0.49	-0.55	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
KIRC	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-14.63	1.59e-40	7.31e-37	-0.65	-0.55	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
KIRC	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	14.63	1.6e-40	7.38e-37	0.61	0.55	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
KIRC	cis	rs5769707	0.967	rs8141807	ENSG00000188511.11	C22orf34	14.63	1.61e-40	7.41e-37	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49414524~49657542:-
KIRC	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	14.62	1.62e-40	7.47e-37	0.64	0.55	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
KIRC	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	14.62	1.63e-40	7.51e-37	0.69	0.55	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-14.62	1.71e-40	7.88e-37	-0.53	-0.55	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
KIRC	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-14.62	1.74e-40	8.01e-37	-0.49	-0.55	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
KIRC	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-14.62	1.76e-40	8.09e-37	-0.95	-0.55	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
KIRC	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	14.62	1.76e-40	8.1e-37	0.68	0.55	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-14.62	1.79e-40	8.23e-37	-0.68	-0.55	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
KIRC	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	14.61	1.81e-40	8.31e-37	0.46	0.55	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
KIRC	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	14.61	1.81e-40	8.31e-37	0.46	0.55	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
KIRC	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-14.61	1.89e-40	8.67e-37	-0.79	-0.55	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
KIRC	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-14.61	1.9e-40	8.7e-37	-0.7	-0.55	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
KIRC	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-14.61	1.97e-40	9.02e-37	-0.67	-0.55	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-14.61	1.97e-40	9.02e-37	-0.67	-0.55	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	14.6	2.03e-40	9.31e-37	0.69	0.55	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	14.6	2.03e-40	9.31e-37	0.69	0.55	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
KIRC	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	14.6	2.07e-40	9.48e-37	0.69	0.55	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
KIRC	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-14.6	2.09e-40	9.56e-37	-0.53	-0.55	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
KIRC	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	14.6	2.11e-40	9.64e-37	0.68	0.55	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-14.6	2.12e-40	9.69e-37	-0.67	-0.55	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
KIRC	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	14.6	2.13e-40	9.75e-37	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
KIRC	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-14.6	2.15e-40	9.83e-37	-0.71	-0.55	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
KIRC	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-14.6	2.17e-40	9.93e-37	-0.7	-0.55	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
KIRC	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-14.59	2.24e-40	1.02e-36	-0.66	-0.55	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
KIRC	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	14.59	2.27e-40	1.04e-36	0.65	0.55	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
KIRC	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-14.59	2.28e-40	1.04e-36	-0.53	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
KIRC	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-14.59	2.31e-40	1.05e-36	-0.63	-0.55	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
KIRC	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-14.59	2.33e-40	1.06e-36	-0.7	-0.55	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
KIRC	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	14.59	2.38e-40	1.09e-36	1.1	0.55	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
KIRC	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-14.59	2.4e-40	1.09e-36	-0.65	-0.55	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
KIRC	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-14.58	2.47e-40	1.12e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
KIRC	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	14.58	2.47e-40	1.13e-36	0.68	0.55	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-14.58	2.48e-40	1.13e-36	-0.65	-0.55	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
KIRC	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-14.58	2.5e-40	1.14e-36	-0.54	-0.55	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
KIRC	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-14.58	2.52e-40	1.14e-36	-0.52	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
KIRC	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-14.58	2.52e-40	1.15e-36	-0.68	-0.55	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-14.58	2.55e-40	1.16e-36	-0.68	-0.55	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
KIRC	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	14.57	2.7e-40	1.23e-36	0.61	0.55	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
KIRC	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-14.57	2.73e-40	1.24e-36	-0.68	-0.55	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	14.57	2.77e-40	1.26e-36	0.74	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
KIRC	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-14.57	2.77e-40	1.26e-36	-0.61	-0.55	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
KIRC	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-14.57	2.84e-40	1.29e-36	-0.52	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
KIRC	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-14.57	2.86e-40	1.3e-36	-0.68	-0.55	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-14.57	2.86e-40	1.3e-36	-0.68	-0.55	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	14.57	2.88e-40	1.31e-36	0.69	0.55	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
KIRC	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	14.57	2.95e-40	1.34e-36	0.68	0.55	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
KIRC	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-14.56	3.01e-40	1.36e-36	-0.71	-0.55	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
KIRC	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-14.56	3.01e-40	1.36e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
KIRC	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-14.56	3.03e-40	1.37e-36	-0.68	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
KIRC	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-14.56	3.05e-40	1.38e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
KIRC	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-14.56	3.12e-40	1.41e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-14.56	3.12e-40	1.41e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-14.56	3.12e-40	1.41e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
KIRC	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-14.56	3.13e-40	1.41e-36	-0.55	-0.55	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
KIRC	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	14.56	3.17e-40	1.43e-36	0.68	0.55	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
KIRC	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-14.56	3.23e-40	1.46e-36	-0.55	-0.55	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
KIRC	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-14.56	3.27e-40	1.47e-36	-0.67	-0.55	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
KIRC	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	14.56	3.27e-40	1.48e-36	0.61	0.55	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
KIRC	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-14.55	3.43e-40	1.54e-36	-0.66	-0.55	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
KIRC	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-14.55	3.46e-40	1.56e-36	-0.71	-0.55	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
KIRC	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	14.55	3.52e-40	1.58e-36	0.97	0.55	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
KIRC	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-14.55	3.54e-40	1.59e-36	-0.63	-0.55	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
KIRC	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	14.55	3.63e-40	1.64e-36	0.76	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
KIRC	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-14.55	3.67e-40	1.65e-36	-0.71	-0.55	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
KIRC	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-14.54	3.7e-40	1.67e-36	-0.53	-0.55	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
KIRC	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-14.54	3.72e-40	1.67e-36	-0.65	-0.55	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-14.54	3.72e-40	1.67e-36	-0.65	-0.55	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-14.54	3.72e-40	1.67e-36	-0.65	-0.55	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-14.54	3.72e-40	1.67e-36	-0.65	-0.55	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-14.54	3.72e-40	1.67e-36	-0.65	-0.55	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
KIRC	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	14.54	3.74e-40	1.68e-36	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
KIRC	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-14.54	3.78e-40	1.7e-36	-0.66	-0.55	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	14.54	3.82e-40	1.72e-36	0.68	0.55	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	14.54	3.82e-40	1.72e-36	0.68	0.55	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-14.54	3.84e-40	1.72e-36	-0.68	-0.55	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-14.54	3.9e-40	1.75e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
KIRC	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	14.54	3.93e-40	1.76e-36	0.68	0.55	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
KIRC	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	14.54	3.99e-40	1.79e-36	0.83	0.55	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
KIRC	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-14.54	4.07e-40	1.82e-36	-0.67	-0.55	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	14.53	4.1e-40	1.84e-36	0.75	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
KIRC	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-14.53	4.14e-40	1.86e-36	-0.65	-0.55	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
KIRC	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-14.53	4.16e-40	1.87e-36	-0.67	-0.55	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-14.53	4.16e-40	1.87e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
KIRC	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-14.53	4.26e-40	1.91e-36	-0.71	-0.55	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
KIRC	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-14.53	4.3e-40	1.93e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
KIRC	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	14.53	4.4e-40	1.97e-36	0.86	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
KIRC	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	14.53	4.47e-40	2e-36	0.64	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
KIRC	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-14.53	4.48e-40	2.01e-36	-0.65	-0.55	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
KIRC	cis	rs9457247	1	rs415890	ENSG00000265828.1	MIR3939	14.52	4.59e-40	2.05e-36	0.61	0.55	Crohn's disease;	chr6:166993145	chr6:166997807~166997912:-
KIRC	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-14.52	4.62e-40	2.06e-36	-0.6	-0.55	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
KIRC	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	14.52	4.62e-40	2.06e-36	0.79	0.55	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
KIRC	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-14.52	4.65e-40	2.08e-36	-0.68	-0.55	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-14.52	4.68e-40	2.09e-36	-0.71	-0.55	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
KIRC	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	14.52	4.79e-40	2.14e-36	0.52	0.55	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-14.52	4.86e-40	2.17e-36	-0.6	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
KIRC	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-14.52	4.9e-40	2.18e-36	-0.68	-0.55	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-14.51	5.06e-40	2.25e-36	-0.67	-0.55	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-14.51	5.12e-40	2.28e-36	-0.68	-0.55	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	14.51	5.17e-40	2.3e-36	0.7	0.55	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	14.51	5.31e-40	2.36e-36	0.71	0.55	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
KIRC	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-14.51	5.31e-40	2.36e-36	-0.53	-0.55	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
KIRC	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-14.51	5.33e-40	2.37e-36	-0.68	-0.55	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-14.51	5.38e-40	2.39e-36	-0.74	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
KIRC	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	14.51	5.43e-40	2.42e-36	0.65	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
KIRC	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-14.51	5.51e-40	2.45e-36	-0.65	-0.55	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-14.5	5.54e-40	2.46e-36	-0.65	-0.55	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
KIRC	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	14.5	5.56e-40	2.47e-36	0.7	0.55	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
KIRC	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-14.5	5.6e-40	2.49e-36	-0.64	-0.55	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
KIRC	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-14.5	5.6e-40	2.49e-36	-0.78	-0.55	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
KIRC	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-14.5	5.64e-40	2.51e-36	-0.52	-0.55	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
KIRC	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	14.5	5.69e-40	2.53e-36	1.1	0.55	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
KIRC	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-14.5	5.7e-40	2.53e-36	-0.65	-0.55	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
KIRC	cis	rs6085948	0.861	rs6085947	ENSG00000238102.1	RP11-19D2.1	14.5	5.74e-40	2.55e-36	0.58	0.55	Interleukin-10 levels;	chr20:7252181	chr20:7256580~7258214:-
KIRC	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-14.5	6.1e-40	2.71e-36	-0.64	-0.55	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
KIRC	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	14.5	6.1e-40	2.71e-36	0.76	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
KIRC	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	14.49	6.38e-40	2.83e-36	0.68	0.55	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
KIRC	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-14.49	6.45e-40	2.86e-36	-0.69	-0.55	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-14.49	6.45e-40	2.86e-36	-0.69	-0.55	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
KIRC	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	14.49	6.51e-40	2.88e-36	0.86	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	14.49	6.51e-40	2.88e-36	0.86	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
KIRC	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-14.48	7.22e-40	3.19e-36	-0.65	-0.55	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
KIRC	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-14.48	7.26e-40	3.21e-36	-0.7	-0.55	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
KIRC	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	14.48	7.47e-40	3.3e-36	0.6	0.55	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
KIRC	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-14.47	7.62e-40	3.37e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-14.47	7.62e-40	3.37e-36	-0.68	-0.55	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
KIRC	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-14.47	7.66e-40	3.38e-36	-0.68	-0.55	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-14.47	7.66e-40	3.38e-36	-0.68	-0.55	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	14.47	7.74e-40	3.42e-36	0.67	0.55	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	14.47	7.74e-40	3.42e-36	0.67	0.55	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
KIRC	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-14.47	7.76e-40	3.43e-36	-0.52	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
KIRC	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-14.47	8.02e-40	3.54e-36	-0.65	-0.55	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
KIRC	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-14.47	8.05e-40	3.55e-36	-0.7	-0.55	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
KIRC	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-14.47	8.23e-40	3.63e-36	-0.65	-0.55	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
KIRC	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	14.46	8.39e-40	3.7e-36	0.69	0.55	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
KIRC	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	14.46	8.43e-40	3.72e-36	0.69	0.55	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	14.46	8.47e-40	3.73e-36	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	14.46	8.47e-40	3.73e-36	0.68	0.55	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
KIRC	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-14.46	8.68e-40	3.83e-36	-0.7	-0.54	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
KIRC	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-14.46	8.72e-40	3.84e-36	-0.67	-0.54	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-14.46	8.72e-40	3.84e-36	-0.69	-0.54	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-14.46	8.72e-40	3.84e-36	-0.69	-0.54	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
KIRC	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-14.46	8.8e-40	3.88e-36	-0.65	-0.54	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
KIRC	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-14.46	8.87e-40	3.91e-36	-0.68	-0.54	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-14.46	8.89e-40	3.91e-36	-0.68	-0.54	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-14.46	8.89e-40	3.91e-36	-0.68	-0.54	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
KIRC	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-14.46	8.9e-40	3.92e-36	-0.65	-0.54	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
KIRC	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-14.46	9.18e-40	4.04e-36	-0.67	-0.54	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-14.45	9.29e-40	4.09e-36	-0.7	-0.54	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
KIRC	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	14.45	9.52e-40	4.19e-36	0.67	0.54	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
KIRC	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-14.45	9.7e-40	4.26e-36	-0.67	-0.54	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
KIRC	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	14.45	9.74e-40	4.28e-36	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
KIRC	cis	rs9457247	0.935	rs1044059	ENSG00000265828.1	MIR3939	14.45	1.01e-39	4.43e-36	0.61	0.54	Crohn's disease;	chr6:166956409	chr6:166997807~166997912:-
KIRC	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-14.45	1.02e-39	4.46e-36	-0.65	-0.54	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-14.45	1.02e-39	4.46e-36	-0.65	-0.54	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-14.45	1.02e-39	4.46e-36	-0.65	-0.54	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-14.45	1.02e-39	4.46e-36	-0.65	-0.54	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
KIRC	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-14.45	1.02e-39	4.46e-36	-0.68	-0.54	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	14.44	1.03e-39	4.5e-36	0.68	0.54	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	14.44	1.1e-39	4.81e-36	0.84	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	14.44	1.1e-39	4.81e-36	0.84	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
KIRC	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-14.44	1.11e-39	4.85e-36	-0.71	-0.54	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
KIRC	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-14.44	1.11e-39	4.86e-36	-0.68	-0.54	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-14.44	1.12e-39	4.88e-36	-0.69	-0.54	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
KIRC	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	14.44	1.12e-39	4.89e-36	0.7	0.54	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
KIRC	cis	rs5769707	0.935	rs9616332	ENSG00000188511.11	C22orf34	14.43	1.15e-39	5.01e-36	0.64	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-14.43	1.22e-39	5.33e-36	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
KIRC	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-14.43	1.23e-39	5.34e-36	-0.67	-0.54	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-14.43	1.23e-39	5.34e-36	-0.67	-0.54	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-14.43	1.24e-39	5.42e-36	-0.68	-0.54	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	14.42	1.26e-39	5.48e-36	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-14.42	1.28e-39	5.59e-36	-0.68	-0.54	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	14.42	1.3e-39	5.67e-36	0.66	0.54	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs389946	ENSG00000265828.1	MIR3939	-14.42	1.31e-39	5.7e-36	-0.6	-0.54	Crohn's disease;	chr6:166993780	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs422694	ENSG00000265828.1	MIR3939	-14.42	1.32e-39	5.73e-36	-0.6	-0.54	Crohn's disease;	chr6:166992586	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs422780	ENSG00000265828.1	MIR3939	-14.42	1.32e-39	5.73e-36	-0.6	-0.54	Crohn's disease;	chr6:166992721	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs400176	ENSG00000265828.1	MIR3939	-14.42	1.32e-39	5.73e-36	-0.6	-0.54	Crohn's disease;	chr6:166992750	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs415842	ENSG00000265828.1	MIR3939	-14.42	1.32e-39	5.73e-36	-0.6	-0.54	Crohn's disease;	chr6:166993193	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs389956	ENSG00000265828.1	MIR3939	-14.42	1.32e-39	5.73e-36	-0.6	-0.54	Crohn's disease;	chr6:166993766	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-14.42	1.36e-39	5.92e-36	-0.66	-0.54	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
KIRC	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	14.42	1.36e-39	5.92e-36	0.7	0.54	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
KIRC	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-14.42	1.39e-39	6.02e-36	-0.63	-0.54	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-14.42	1.39e-39	6.02e-36	-0.63	-0.54	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-14.42	1.39e-39	6.02e-36	-0.63	-0.54	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
KIRC	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-14.41	1.4e-39	6.09e-36	-0.68	-0.54	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	14.41	1.4e-39	6.09e-36	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
KIRC	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-14.41	1.44e-39	6.24e-36	-0.69	-0.54	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
KIRC	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-14.41	1.49e-39	6.44e-36	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
KIRC	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-14.41	1.53e-39	6.63e-36	-0.67	-0.54	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-14.4	1.54e-39	6.66e-36	-0.67	-0.54	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
KIRC	cis	rs1155848	0.892	rs9574421	ENSG00000227354.5	RBM26-AS1	14.4	1.55e-39	6.69e-36	1.1	0.54	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406205	chr13:79406309~79424328:+
KIRC	cis	rs5769707	0.904	rs7288869	ENSG00000235111.1	RP1-29C18.8	-14.4	1.58e-39	6.84e-36	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49612657~49615716:-
KIRC	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-14.4	1.63e-39	7.05e-36	-0.74	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
KIRC	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	14.4	1.66e-39	7.17e-36	0.76	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
KIRC	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	14.4	1.7e-39	7.33e-36	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
KIRC	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-14.39	1.71e-39	7.4e-36	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
KIRC	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	14.39	1.72e-39	7.41e-36	0.62	0.54	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
KIRC	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	14.39	1.72e-39	7.44e-36	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	14.39	1.72e-39	7.44e-36	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	14.39	1.73e-39	7.48e-36	0.69	0.54	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
KIRC	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	14.39	1.76e-39	7.6e-36	0.66	0.54	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	14.39	1.76e-39	7.6e-36	0.66	0.54	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	14.39	1.76e-39	7.6e-36	0.66	0.54	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	14.39	1.76e-39	7.6e-36	0.66	0.54	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	14.39	1.84e-39	7.93e-36	0.69	0.54	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	14.39	1.84e-39	7.93e-36	0.69	0.54	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
KIRC	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	14.38	1.89e-39	8.13e-36	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-14.38	1.95e-39	8.38e-36	-0.68	-0.54	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	14.38	1.96e-39	8.41e-36	0.68	0.54	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
KIRC	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-14.38	1.99e-39	8.53e-36	-0.68	-0.54	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
KIRC	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-14.38	2.01e-39	8.62e-36	-0.68	-0.54	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
KIRC	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	14.38	2.04e-39	8.77e-36	0.67	0.54	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	14.38	2.04e-39	8.77e-36	0.67	0.54	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
KIRC	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	14.38	2.07e-39	8.87e-36	0.91	0.54	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	14.37	2.12e-39	9.07e-36	0.66	0.54	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	14.37	2.12e-39	9.07e-36	0.66	0.54	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
KIRC	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	14.37	2.17e-39	9.28e-36	0.67	0.54	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
KIRC	cis	rs6085948	0.861	rs11908494	ENSG00000238102.1	RP11-19D2.1	-14.37	2.18e-39	9.33e-36	-0.59	-0.54	Interleukin-10 levels;	chr20:7250266	chr20:7256580~7258214:-
KIRC	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-14.37	2.29e-39	9.8e-36	-0.68	-0.54	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
KIRC	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	14.37	2.31e-39	9.87e-36	0.69	0.54	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-14.36	2.33e-39	9.97e-36	-0.69	-0.54	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-14.36	2.35e-39	1e-35	-0.69	-0.54	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-14.36	2.35e-39	1e-35	-0.69	-0.54	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-14.36	2.35e-39	1e-35	-0.69	-0.54	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-14.36	2.35e-39	1e-35	-0.69	-0.54	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
KIRC	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	14.36	2.35e-39	1e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
KIRC	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-14.36	2.4e-39	1.03e-35	-0.7	-0.54	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
KIRC	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-14.36	2.5e-39	1.07e-35	-0.63	-0.54	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
KIRC	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-14.36	2.52e-39	1.07e-35	-0.65	-0.54	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
KIRC	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	14.36	2.55e-39	1.09e-35	0.68	0.54	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	14.36	2.55e-39	1.09e-35	0.68	0.54	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
KIRC	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	14.35	2.6e-39	1.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
KIRC	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	14.35	2.62e-39	1.12e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
KIRC	cis	rs5769707	1	rs5769707	ENSG00000235111.1	RP1-29C18.8	-14.35	2.71e-39	1.15e-35	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49612657~49615716:-
KIRC	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	14.35	2.79e-39	1.19e-35	0.68	0.54	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
KIRC	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	14.35	2.79e-39	1.19e-35	0.86	0.54	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
KIRC	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	14.34	2.83e-39	1.2e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	14.34	2.92e-39	1.24e-35	0.68	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
KIRC	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-14.34	3.02e-39	1.28e-35	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-14.34	3.02e-39	1.28e-35	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
KIRC	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	14.34	3.04e-39	1.29e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
KIRC	cis	rs6085948	0.861	rs6077169	ENSG00000238102.1	RP11-19D2.1	-14.34	3.11e-39	1.32e-35	-0.61	-0.54	Interleukin-10 levels;	chr20:7267815	chr20:7256580~7258214:-
KIRC	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-14.33	3.16e-39	1.34e-35	-0.68	-0.54	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
KIRC	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	14.33	3.19e-39	1.35e-35	0.67	0.54	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
KIRC	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.33	3.2e-39	1.35e-35	-0.75	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
KIRC	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-14.33	3.29e-39	1.39e-35	-0.74	-0.54	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-14.33	3.29e-39	1.39e-35	-0.74	-0.54	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
KIRC	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-14.33	3.31e-39	1.4e-35	-0.68	-0.54	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
KIRC	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	14.33	3.35e-39	1.42e-35	0.64	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
KIRC	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-14.33	3.44e-39	1.45e-35	-0.7	-0.54	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
KIRC	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	14.33	3.45e-39	1.46e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
KIRC	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-14.32	3.49e-39	1.47e-35	-0.65	-0.54	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
KIRC	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-14.32	3.64e-39	1.54e-35	-0.7	-0.54	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
KIRC	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	14.31	3.85e-39	1.62e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
KIRC	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	14.31	4.04e-39	1.7e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	14.31	4.04e-39	1.7e-35	0.83	0.54	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	14.31	4.04e-39	1.7e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	14.31	4.04e-39	1.7e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
KIRC	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-14.31	4.1e-39	1.72e-35	-0.7	-0.54	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
KIRC	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-14.3	4.37e-39	1.84e-35	-0.68	-0.54	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
KIRC	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-14.3	4.51e-39	1.89e-35	-0.64	-0.54	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
KIRC	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	14.29	4.71e-39	1.98e-35	0.69	0.54	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
KIRC	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-14.29	4.72e-39	1.98e-35	-0.69	-0.54	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
KIRC	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	14.29	4.79e-39	2.01e-35	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	14.29	4.93e-39	2.07e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
KIRC	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-14.29	4.93e-39	2.07e-35	-0.63	-0.54	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
KIRC	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-14.29	4.97e-39	2.08e-35	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
KIRC	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-14.29	4.97e-39	2.08e-35	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
KIRC	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	14.29	4.99e-39	2.09e-35	0.77	0.54	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
KIRC	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	14.29	5.04e-39	2.11e-35	0.85	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.935	rs9348211	ENSG00000265828.1	MIR3939	14.29	5.15e-39	2.16e-35	0.61	0.54	Crohn's disease;	chr6:166961685	chr6:166997807~166997912:-
KIRC	cis	rs6920364	1	rs6920364	ENSG00000265828.1	MIR3939	14.29	5.15e-39	2.16e-35	0.61	0.54	Lung cancer;	chr6:166962978	chr6:166997807~166997912:-
KIRC	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	14.29	5.2e-39	2.18e-35	0.66	0.54	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
KIRC	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	14.28	5.46e-39	2.28e-35	0.68	0.54	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-14.28	5.59e-39	2.34e-35	-0.69	-0.54	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
KIRC	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-14.28	5.6e-39	2.34e-35	-0.64	-0.54	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
KIRC	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-14.27	5.81e-39	2.43e-35	-0.52	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
KIRC	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-14.27	6.12e-39	2.55e-35	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
KIRC	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-14.27	6.2e-39	2.59e-35	-0.73	-0.54	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
KIRC	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	14.27	6.22e-39	2.6e-35	0.68	0.54	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-14.26	6.46e-39	2.69e-35	-0.67	-0.54	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
KIRC	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	14.26	6.52e-39	2.72e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
KIRC	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-14.26	6.69e-39	2.79e-35	-0.67	-0.54	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-14.26	6.69e-39	2.79e-35	-0.67	-0.54	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
KIRC	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-14.26	6.76e-39	2.82e-35	-0.65	-0.54	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-14.26	6.76e-39	2.82e-35	-0.65	-0.54	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
KIRC	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-14.26	6.81e-39	2.84e-35	-0.68	-0.54	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
KIRC	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-14.26	7.04e-39	2.93e-35	-0.65	-0.54	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-14.25	7.18e-39	2.99e-35	-0.7	-0.54	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
KIRC	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-14.25	7.26e-39	3.02e-35	-0.7	-0.54	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
KIRC	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	14.25	7.28e-39	3.03e-35	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
KIRC	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-14.25	7.47e-39	3.1e-35	-0.68	-0.54	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
KIRC	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	14.25	7.48e-39	3.11e-35	0.69	0.54	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-14.25	7.57e-39	3.15e-35	-0.65	-0.54	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
KIRC	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-14.24	8.22e-39	3.41e-35	-0.7	-0.54	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
KIRC	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	14.24	8.36e-39	3.46e-35	0.65	0.54	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-14.24	8.42e-39	3.49e-35	-0.69	-0.54	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
KIRC	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	14.24	8.43e-39	3.49e-35	0.68	0.54	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
KIRC	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	14.24	8.49e-39	3.51e-35	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
KIRC	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-14.24	8.51e-39	3.52e-35	-0.64	-0.54	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
KIRC	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	14.24	8.59e-39	3.56e-35	0.83	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
KIRC	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-14.23	8.75e-39	3.62e-35	-0.52	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
KIRC	cis	rs6085948	0.861	rs6054849	ENSG00000238102.1	RP11-19D2.1	-14.23	8.85e-39	3.66e-35	-0.58	-0.54	Interleukin-10 levels;	chr20:7251460	chr20:7256580~7258214:-
KIRC	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	14.23	9.1e-39	3.76e-35	0.75	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
KIRC	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-14.22	1.02e-38	4.2e-35	-0.75	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
KIRC	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	14.21	1.12e-38	4.62e-35	0.64	0.54	Depression;	chr6:28301886	chr6:28176188~28176674:+
KIRC	cis	rs9457247	1	rs406095	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166995599	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.646	rs4710160	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166995753	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs430145	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166996881	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs425039	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166997039	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs376097	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166997390	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs424185	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166997419	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs400837	ENSG00000265828.1	MIR3939	-14.21	1.13e-38	4.64e-35	-0.61	-0.54	Crohn's disease;	chr6:166997520	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	14.21	1.14e-38	4.69e-35	0.64	0.54	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
KIRC	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	14.21	1.14e-38	4.7e-35	0.69	0.54	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
KIRC	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-14.2	1.18e-38	4.85e-35	-0.62	-0.54	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
KIRC	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-14.2	1.24e-38	5.09e-35	-0.64	-0.54	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
KIRC	cis	rs9457247	1	rs2769352	ENSG00000265828.1	MIR3939	14.2	1.24e-38	5.12e-35	0.61	0.54	Crohn's disease;	chr6:166965131	chr6:166997807~166997912:-
KIRC	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	14.2	1.3e-38	5.33e-35	0.62	0.54	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
KIRC	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-14.19	1.34e-38	5.49e-35	-0.63	-0.54	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
KIRC	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	14.19	1.35e-38	5.54e-35	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
KIRC	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-14.19	1.37e-38	5.62e-35	-0.59	-0.54	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
KIRC	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	14.19	1.38e-38	5.63e-35	0.63	0.54	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
KIRC	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	14.18	1.46e-38	5.96e-35	0.7	0.54	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	14.18	1.48e-38	6.03e-35	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
KIRC	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-14.18	1.51e-38	6.16e-35	-0.75	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
KIRC	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	14.18	1.53e-38	6.25e-35	0.67	0.54	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	14.18	1.53e-38	6.25e-35	0.67	0.54	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-14.18	1.58e-38	6.44e-35	-0.68	-0.54	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
KIRC	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	14.18	1.58e-38	6.46e-35	0.67	0.54	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
KIRC	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	14.17	1.6e-38	6.52e-35	0.68	0.54	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	14.17	1.63e-38	6.64e-35	0.68	0.54	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	14.17	1.63e-38	6.64e-35	0.68	0.54	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
KIRC	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-14.17	1.69e-38	6.89e-35	-0.67	-0.54	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs2757042	ENSG00000265828.1	MIR3939	14.17	1.75e-38	7.12e-35	0.6	0.54	Crohn's disease;	chr6:166957746	chr6:166997807~166997912:-
KIRC	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.16	1.86e-38	7.55e-35	-0.81	-0.54	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
KIRC	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	14.16	1.9e-38	7.72e-35	0.73	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	14.16	1.9e-38	7.72e-35	0.73	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
KIRC	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	14.16	1.91e-38	7.77e-35	0.62	0.54	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
KIRC	cis	rs9457247	1	rs422562	ENSG00000265828.1	MIR3939	-14.16	1.93e-38	7.82e-35	-0.6	-0.54	Crohn's disease;	chr6:166992830	chr6:166997807~166997912:-
KIRC	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-14.15	2.12e-38	8.58e-35	-0.64	-0.54	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
KIRC	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-14.15	2.14e-38	8.65e-35	-0.73	-0.54	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
KIRC	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	14.15	2.14e-38	8.65e-35	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
KIRC	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-14.14	2.18e-38	8.83e-35	-0.74	-0.54	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-14.14	2.18e-38	8.83e-35	-0.74	-0.54	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
KIRC	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-14.14	2.2e-38	8.89e-35	-0.68	-0.54	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
KIRC	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	14.14	2.28e-38	9.23e-35	0.69	0.54	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-14.14	2.3e-38	9.3e-35	-0.68	-0.54	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
KIRC	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-14.14	2.35e-38	9.49e-35	-0.54	-0.54	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
KIRC	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	14.14	2.35e-38	9.49e-35	0.63	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
KIRC	cis	rs9457247	1	rs364451	ENSG00000265828.1	MIR3939	-14.14	2.37e-38	9.58e-35	-0.61	-0.54	Crohn's disease;	chr6:166971268	chr6:166997807~166997912:-
KIRC	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-14.14	2.38e-38	9.61e-35	-0.65	-0.54	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
KIRC	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	14.14	2.38e-38	9.63e-35	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	14.13	2.4e-38	9.68e-35	0.67	0.54	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
KIRC	cis	rs9457247	0.967	rs388406	ENSG00000265828.1	MIR3939	-14.13	2.42e-38	9.76e-35	-0.61	-0.54	Crohn's disease;	chr6:166996074	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.967	rs433191	ENSG00000265828.1	MIR3939	-14.13	2.42e-38	9.76e-35	-0.61	-0.54	Crohn's disease;	chr6:166996174	chr6:166997807~166997912:-
KIRC	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-14.13	2.48e-38	1e-34	-0.71	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
KIRC	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-14.13	2.58e-38	1.04e-34	-0.65	-0.54	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
KIRC	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-14.13	2.58e-38	1.04e-34	-0.65	-0.54	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
KIRC	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-14.13	2.58e-38	1.04e-34	-0.65	-0.54	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	14.13	2.62e-38	1.06e-34	0.69	0.54	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
KIRC	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-14.12	2.71e-38	1.09e-34	-0.76	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
KIRC	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	14.12	2.73e-38	1.1e-34	0.62	0.54	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
KIRC	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	14.12	2.73e-38	1.1e-34	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	14.12	2.73e-38	1.1e-34	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	14.12	2.73e-38	1.1e-34	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
KIRC	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	14.12	2.79e-38	1.12e-34	0.68	0.54	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	14.12	2.79e-38	1.12e-34	0.68	0.54	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	14.12	2.79e-38	1.12e-34	0.68	0.54	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	14.12	2.8e-38	1.12e-34	0.66	0.54	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
KIRC	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-14.12	2.84e-38	1.14e-34	-0.63	-0.54	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
KIRC	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-14.12	2.92e-38	1.17e-34	-0.64	-0.54	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-14.11	3.02e-38	1.21e-34	-0.66	-0.54	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-14.11	3.08e-38	1.23e-34	-0.53	-0.54	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
KIRC	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	14.11	3.11e-38	1.25e-34	0.82	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	14.11	3.17e-38	1.27e-34	0.63	0.54	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
KIRC	cis	rs9457247	0.935	rs2149093	ENSG00000265828.1	MIR3939	14.11	3.22e-38	1.29e-34	0.6	0.54	Crohn's disease;	chr6:166959557	chr6:166997807~166997912:-
KIRC	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	14.1	3.29e-38	1.32e-34	0.65	0.54	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
KIRC	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-14.1	3.3e-38	1.32e-34	-0.59	-0.54	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
KIRC	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-14.1	3.35e-38	1.34e-34	-0.68	-0.54	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
KIRC	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	14.09	3.63e-38	1.45e-34	0.64	0.54	Depression;	chr6:28303421	chr6:28176188~28176674:+
KIRC	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	14.09	3.66e-38	1.46e-34	0.74	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
KIRC	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	14.09	3.66e-38	1.46e-34	0.74	0.54	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
KIRC	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-14.09	3.73e-38	1.49e-34	-0.64	-0.54	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
KIRC	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-14.09	3.82e-38	1.52e-34	-0.78	-0.53	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
KIRC	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-14.09	3.94e-38	1.57e-34	-0.7	-0.53	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
KIRC	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-14.08	4e-38	1.59e-34	-0.75	-0.53	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
KIRC	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-14.08	4.01e-38	1.6e-34	-0.7	-0.53	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.08	4.05e-38	1.61e-34	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
KIRC	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-14.08	4.08e-38	1.62e-34	-0.68	-0.53	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
KIRC	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	14.08	4.12e-38	1.64e-34	0.67	0.53	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
KIRC	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	14.08	4.34e-38	1.73e-34	0.68	0.53	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	14.08	4.34e-38	1.73e-34	0.68	0.53	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-14.07	4.39e-38	1.75e-34	-0.65	-0.53	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
KIRC	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-14.07	4.52e-38	1.8e-34	-0.61	-0.53	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
KIRC	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-14.07	4.72e-38	1.88e-34	-0.55	-0.53	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
KIRC	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-14.07	4.84e-38	1.92e-34	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
KIRC	cis	rs9457247	1	rs444988	ENSG00000265828.1	MIR3939	-14.06	4.88e-38	1.94e-34	-0.61	-0.53	Crohn's disease;	chr6:166976186	chr6:166997807~166997912:-
KIRC	cis	rs9457247	1	rs408080	ENSG00000265828.1	MIR3939	-14.06	4.88e-38	1.94e-34	-0.61	-0.53	Crohn's disease;	chr6:166979034	chr6:166997807~166997912:-
KIRC	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-14.06	4.94e-38	1.96e-34	-0.52	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
KIRC	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-14.06	4.97e-38	1.97e-34	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
KIRC	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-14.06	5.03e-38	1.99e-34	-0.67	-0.53	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
KIRC	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-14.06	5.03e-38	1.99e-34	-0.67	-0.53	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
KIRC	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-14.06	5.33e-38	2.11e-34	-0.75	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
KIRC	cis	rs6085948	0.861	rs6054847	ENSG00000238102.1	RP11-19D2.1	-14.05	5.36e-38	2.12e-34	-0.58	-0.53	Interleukin-10 levels;	chr20:7249794	chr20:7256580~7258214:-
KIRC	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	14.05	5.38e-38	2.13e-34	0.66	0.53	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	14.05	5.38e-38	2.13e-34	0.66	0.53	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
KIRC	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-14.05	5.51e-38	2.18e-34	-0.71	-0.53	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-14.05	5.67e-38	2.24e-34	-0.71	-0.53	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-14.05	5.67e-38	2.24e-34	-0.71	-0.53	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-14.05	5.67e-38	2.24e-34	-0.71	-0.53	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
KIRC	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-14.05	5.68e-38	2.25e-34	-0.58	-0.53	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
KIRC	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	14.05	5.69e-38	2.25e-34	0.66	0.53	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
KIRC	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	14.04	5.99e-38	2.37e-34	0.63	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
KIRC	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-14.04	6.16e-38	2.44e-34	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
KIRC	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-14.04	6.2e-38	2.45e-34	-0.73	-0.53	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
KIRC	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	14.04	6.31e-38	2.49e-34	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
KIRC	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	14.03	6.76e-38	2.67e-34	0.64	0.53	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
KIRC	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	14.03	6.79e-38	2.68e-34	0.68	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
KIRC	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-14.03	6.88e-38	2.71e-34	-0.7	-0.53	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
KIRC	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	14.03	6.92e-38	2.73e-34	0.67	0.53	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	14.03	6.92e-38	2.73e-34	0.67	0.53	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
KIRC	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-14.03	6.95e-38	2.74e-34	-0.53	-0.53	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
KIRC	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-14.03	7.08e-38	2.79e-34	-0.63	-0.53	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-14.03	7.13e-38	2.8e-34	-0.63	-0.53	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
KIRC	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-14.02	7.36e-38	2.9e-34	-0.52	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
KIRC	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	14.02	7.43e-38	2.92e-34	0.65	0.53	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	14.02	7.43e-38	2.92e-34	0.65	0.53	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	14.02	7.48e-38	2.94e-34	0.66	0.53	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	14.02	7.54e-38	2.97e-34	0.66	0.53	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
KIRC	cis	rs9457247	1	rs407515	ENSG00000265828.1	MIR3939	-14.02	7.57e-38	2.98e-34	-0.61	-0.53	Crohn's disease;	chr6:166994056	chr6:166997807~166997912:-
KIRC	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-14.01	8.6e-38	3.37e-34	-0.72	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	14.01	8.62e-38	3.37e-34	0.66	0.53	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	14.01	8.74e-38	3.42e-34	0.65	0.53	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	14.01	8.74e-38	3.42e-34	0.65	0.53	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	14.01	8.74e-38	3.42e-34	0.65	0.53	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	14.01	8.74e-38	3.42e-34	0.65	0.53	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
KIRC	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-14	8.94e-38	3.5e-34	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
KIRC	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-14	8.96e-38	3.5e-34	-0.59	-0.53	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
KIRC	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	14	9.02e-38	3.52e-34	0.66	0.53	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	14	9.02e-38	3.52e-34	0.66	0.53	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	14	9.02e-38	3.52e-34	0.66	0.53	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	14	9.02e-38	3.52e-34	0.66	0.53	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14	9.22e-38	3.6e-34	0.68	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
KIRC	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	14	9.26e-38	3.61e-34	0.68	0.53	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
KIRC	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-14	9.29e-38	3.62e-34	-0.65	-0.53	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-14	9.37e-38	3.65e-34	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
KIRC	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-14	9.68e-38	3.77e-34	-0.68	-0.53	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
KIRC	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	14	9.75e-38	3.8e-34	0.66	0.53	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-13.99	9.86e-38	3.84e-34	-0.52	-0.53	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
KIRC	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	13.99	1.01e-37	3.95e-34	0.62	0.53	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
KIRC	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-13.99	1.01e-37	3.95e-34	-0.7	-0.53	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
KIRC	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	13.99	1.02e-37	3.97e-34	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
KIRC	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-13.99	1.03e-37	4e-34	-0.66	-0.53	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
KIRC	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-13.99	1.05e-37	4.09e-34	-0.74	-0.53	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
KIRC	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	13.99	1.06e-37	4.12e-34	0.66	0.53	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-13.99	1.06e-37	4.13e-34	-0.66	-0.53	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-13.99	1.06e-37	4.13e-34	-0.66	-0.53	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-13.99	1.06e-37	4.13e-34	-0.66	-0.53	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
KIRC	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.99	1.07e-37	4.17e-34	-0.68	-0.53	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.99	1.07e-37	4.17e-34	-0.68	-0.53	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.99	1.07e-37	4.17e-34	-0.68	-0.53	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
KIRC	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	13.99	1.08e-37	4.21e-34	0.73	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
KIRC	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.98	1.09e-37	4.23e-34	-0.68	-0.53	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.98	1.1e-37	4.26e-34	-0.68	-0.53	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
KIRC	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-13.97	1.22e-37	4.75e-34	-0.68	-0.53	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
KIRC	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-13.97	1.24e-37	4.82e-34	-0.64	-0.53	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
KIRC	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	13.97	1.29e-37	5e-34	0.65	0.53	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
KIRC	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.97	1.31e-37	5.08e-34	-0.67	-0.53	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.97	1.31e-37	5.08e-34	-0.67	-0.53	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.97	1.31e-37	5.08e-34	-0.67	-0.53	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
KIRC	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-13.96	1.37e-37	5.31e-34	-0.67	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
KIRC	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-13.96	1.4e-37	5.42e-34	-0.86	-0.53	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
KIRC	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-13.96	1.43e-37	5.52e-34	-0.59	-0.53	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
KIRC	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-13.96	1.44e-37	5.54e-34	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
KIRC	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	13.95	1.51e-37	5.81e-34	0.63	0.53	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
KIRC	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-13.95	1.52e-37	5.86e-34	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	13.95	1.62e-37	6.24e-34	0.65	0.53	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-13.94	1.63e-37	6.29e-34	-0.66	-0.53	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-13.94	1.69e-37	6.5e-34	-0.65	-0.53	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
KIRC	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-13.94	1.7e-37	6.52e-34	-0.65	-0.53	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-13.94	1.7e-37	6.53e-34	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	13.94	1.72e-37	6.62e-34	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
KIRC	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-13.94	1.73e-37	6.64e-34	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
KIRC	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	13.94	1.76e-37	6.76e-34	0.8	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	13.94	1.76e-37	6.76e-34	0.8	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
KIRC	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.94	1.76e-37	6.77e-34	-0.68	-0.53	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.94	1.76e-37	6.77e-34	-0.68	-0.53	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.94	1.76e-37	6.77e-34	-0.68	-0.53	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.94	1.76e-37	6.77e-34	-0.68	-0.53	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
KIRC	cis	rs9457247	0.534	rs933243	ENSG00000265828.1	MIR3939	-13.94	1.78e-37	6.82e-34	-0.62	-0.53	Crohn's disease;	chr6:166990385	chr6:166997807~166997912:-
KIRC	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-13.93	1.8e-37	6.92e-34	-0.52	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
KIRC	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-13.93	1.81e-37	6.94e-34	-0.73	-0.53	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
KIRC	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	13.93	1.85e-37	7.09e-34	0.67	0.53	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	13.93	1.85e-37	7.09e-34	0.66	0.53	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	13.93	1.85e-37	7.09e-34	0.66	0.53	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	13.93	1.85e-37	7.09e-34	0.66	0.53	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
KIRC	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	13.93	1.93e-37	7.39e-34	0.63	0.53	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
KIRC	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	13.93	1.97e-37	7.54e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	13.93	1.97e-37	7.54e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
KIRC	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-13.92	1.99e-37	7.62e-34	-0.71	-0.53	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
KIRC	cis	rs9457247	0.515	rs2757039	ENSG00000265828.1	MIR3939	13.92	2.05e-37	7.85e-34	0.62	0.53	Crohn's disease;	chr6:166956865	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.935	rs427824	ENSG00000265828.1	MIR3939	-13.92	2.09e-37	8e-34	-0.6	-0.53	Crohn's disease;	chr6:166990430	chr6:166997807~166997912:-
KIRC	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-13.92	2.13e-37	8.14e-34	-0.69	-0.53	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
KIRC	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	13.92	2.14e-37	8.19e-34	0.65	0.53	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	13.92	2.17e-37	8.3e-34	0.67	0.53	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-13.91	2.22e-37	8.46e-34	-0.66	-0.53	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
KIRC	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	13.91	2.23e-37	8.5e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	13.91	2.23e-37	8.5e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	13.91	2.23e-37	8.5e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	13.91	2.23e-37	8.5e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-13.91	2.24e-37	8.56e-34	-0.65	-0.53	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-13.91	2.24e-37	8.56e-34	-0.65	-0.53	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-13.91	2.25e-37	8.58e-34	-0.65	-0.53	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	13.91	2.28e-37	8.68e-34	0.65	0.53	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	13.91	2.28e-37	8.68e-34	0.65	0.53	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	13.91	2.28e-37	8.68e-34	0.65	0.53	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-13.91	2.3e-37	8.76e-34	-0.67	-0.53	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	13.91	2.32e-37	8.85e-34	0.65	0.53	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	13.91	2.32e-37	8.85e-34	0.65	0.53	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
KIRC	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	13.91	2.33e-37	8.88e-34	0.63	0.53	Depression;	chr6:28327262	chr6:28176188~28176674:+
KIRC	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-13.91	2.41e-37	9.18e-34	-0.65	-0.53	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-13.9	2.46e-37	9.38e-34	-0.65	-0.53	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
KIRC	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	13.9	2.49e-37	9.47e-34	0.71	0.53	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
KIRC	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	13.9	2.52e-37	9.6e-34	0.63	0.53	Depression;	chr6:28323463	chr6:28176188~28176674:+
KIRC	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	13.9	2.53e-37	9.61e-34	0.68	0.53	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	13.9	2.53e-37	9.61e-34	0.65	0.53	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
KIRC	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	13.9	2.54e-37	9.64e-34	0.58	0.53	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
KIRC	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	13.9	2.6e-37	9.87e-34	0.67	0.53	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
KIRC	cis	rs9355610	0.927	rs2757041	ENSG00000265828.1	MIR3939	13.9	2.61e-37	9.91e-34	0.62	0.53	Graves' disease;	chr6:166957044	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	13.9	2.62e-37	9.94e-34	0.65	0.53	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
KIRC	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-13.89	2.75e-37	1.04e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-13.89	2.89e-37	1.1e-33	-0.65	-0.53	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	13.89	2.94e-37	1.11e-33	0.65	0.53	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	13.89	2.94e-37	1.11e-33	0.65	0.53	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	13.89	2.94e-37	1.11e-33	0.65	0.53	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	13.89	2.94e-37	1.11e-33	0.65	0.53	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-13.89	2.94e-37	1.12e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
KIRC	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-13.88	2.98e-37	1.13e-33	-0.65	-0.53	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
KIRC	cis	rs9457247	1	rs398278	ENSG00000265828.1	MIR3939	-13.88	3.07e-37	1.16e-33	-0.6	-0.53	Crohn's disease;	chr6:166974681	chr6:166997807~166997912:-
KIRC	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	13.88	3.08e-37	1.17e-33	0.65	0.53	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-13.88	3.08e-37	1.17e-33	-0.65	-0.53	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	13.88	3.08e-37	1.17e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	13.88	3.08e-37	1.17e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	13.88	3.12e-37	1.18e-33	0.66	0.53	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	13.88	3.12e-37	1.18e-33	0.66	0.53	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	13.88	3.12e-37	1.18e-33	0.66	0.53	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	13.88	3.15e-37	1.19e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-13.88	3.15e-37	1.19e-33	-0.65	-0.53	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	13.88	3.24e-37	1.22e-33	0.66	0.53	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
KIRC	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	13.87	3.3e-37	1.25e-33	0.58	0.53	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
KIRC	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-13.87	3.31e-37	1.25e-33	-0.53	-0.53	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
KIRC	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	13.87	3.37e-37	1.27e-33	0.66	0.53	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
KIRC	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	13.87	3.37e-37	1.27e-33	0.66	0.53	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
KIRC	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-13.87	3.4e-37	1.28e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
KIRC	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	13.87	3.47e-37	1.31e-33	0.81	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
KIRC	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	13.87	3.49e-37	1.32e-33	0.65	0.53	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
KIRC	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.87	3.52e-37	1.33e-33	-0.67	-0.53	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.87	3.52e-37	1.33e-33	-0.67	-0.53	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.87	3.52e-37	1.33e-33	-0.67	-0.53	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
KIRC	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-13.87	3.57e-37	1.35e-33	-0.62	-0.53	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
KIRC	cis	rs9457247	0.905	rs377232	ENSG00000265828.1	MIR3939	-13.87	3.61e-37	1.36e-33	-0.6	-0.53	Crohn's disease;	chr6:166996150	chr6:166997807~166997912:-
KIRC	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	13.86	3.75e-37	1.41e-33	0.64	0.53	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-13.86	3.78e-37	1.42e-33	-0.68	-0.53	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
KIRC	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.86	3.91e-37	1.47e-33	0.67	0.53	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
KIRC	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-13.86	3.93e-37	1.48e-33	-0.71	-0.53	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
KIRC	cis	rs9457247	1	rs404222	ENSG00000265828.1	MIR3939	-13.85	4.25e-37	1.6e-33	-0.6	-0.53	Crohn's disease;	chr6:166988662	chr6:166997807~166997912:-
KIRC	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-13.85	4.25e-37	1.6e-33	-0.63	-0.53	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-13.85	4.25e-37	1.6e-33	-0.63	-0.53	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
KIRC	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-13.85	4.38e-37	1.65e-33	-0.65	-0.53	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
KIRC	cis	rs9355610	0.727	rs2247315	ENSG00000265828.1	MIR3939	13.85	4.41e-37	1.66e-33	0.62	0.53	Graves' disease;	chr6:166956723	chr6:166997807~166997912:-
KIRC	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	13.84	4.68e-37	1.76e-33	0.58	0.53	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
KIRC	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-13.84	4.69e-37	1.76e-33	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
KIRC	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-13.84	4.74e-37	1.78e-33	-0.67	-0.53	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
KIRC	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	13.84	4.78e-37	1.79e-33	0.65	0.53	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
KIRC	cis	rs9457247	0.967	rs1794696	ENSG00000265828.1	MIR3939	-13.84	4.85e-37	1.82e-33	-0.6	-0.53	Crohn's disease;	chr6:166982686	chr6:166997807~166997912:-
KIRC	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	13.84	4.86e-37	1.82e-33	0.81	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
KIRC	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	13.83	4.99e-37	1.87e-33	0.73	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	13.83	4.99e-37	1.87e-33	0.66	0.53	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	13.83	4.99e-37	1.87e-33	0.66	0.53	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	13.83	4.99e-37	1.87e-33	0.66	0.53	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	13.83	4.99e-37	1.87e-33	0.66	0.53	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	13.83	4.99e-37	1.87e-33	0.66	0.53	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	13.83	5.06e-37	1.89e-33	0.73	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	13.83	5.06e-37	1.89e-33	0.73	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-13.82	5.54e-37	2.07e-33	-0.65	-0.53	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
KIRC	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-13.82	5.56e-37	2.08e-33	-0.66	-0.53	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
KIRC	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	13.82	5.78e-37	2.16e-33	0.65	0.53	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	13.82	5.91e-37	2.21e-33	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
KIRC	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	13.81	6.3e-37	2.35e-33	0.63	0.53	Depression;	chr6:28317705	chr6:28176188~28176674:+
KIRC	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-13.81	6.33e-37	2.36e-33	-0.67	-0.53	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-13.81	6.33e-37	2.36e-33	-0.67	-0.53	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
KIRC	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	13.81	6.41e-37	2.39e-33	0.67	0.53	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
KIRC	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	13.81	6.45e-37	2.4e-33	0.62	0.53	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
KIRC	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-13.81	6.48e-37	2.41e-33	-0.74	-0.53	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	13.8	6.74e-37	2.51e-33	0.65	0.53	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
KIRC	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	13.8	7.18e-37	2.67e-33	0.82	0.53	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
KIRC	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	13.8	7.23e-37	2.69e-33	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
KIRC	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	13.79	7.72e-37	2.87e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	13.79	7.72e-37	2.87e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	13.79	7.73e-37	2.87e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	13.79	7.73e-37	2.87e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-13.79	7.78e-37	2.89e-33	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
KIRC	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-13.79	7.88e-37	2.93e-33	-0.65	-0.53	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-13.79	8.08e-37	3e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
KIRC	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-13.78	8.1e-37	3e-33	-0.51	-0.53	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
KIRC	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	13.78	8.19e-37	3.04e-33	0.65	0.53	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
KIRC	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	13.78	8.34e-37	3.09e-33	0.67	0.53	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	13.78	8.37e-37	3.1e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	13.78	8.66e-37	3.21e-33	0.65	0.53	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-13.78	8.8e-37	3.25e-33	-0.65	-0.53	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-13.77	9.16e-37	3.38e-33	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
KIRC	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	13.77	9.43e-37	3.48e-33	0.67	0.53	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	13.77	9.43e-37	3.48e-33	0.67	0.53	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	13.77	9.44e-37	3.48e-33	0.63	0.53	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
KIRC	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	13.77	9.45e-37	3.49e-33	0.67	0.53	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
KIRC	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	13.77	9.64e-37	3.55e-33	0.67	0.53	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	13.76	9.89e-37	3.65e-33	0.65	0.53	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	13.76	9.89e-37	3.65e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-13.76	9.95e-37	3.67e-33	-0.9	-0.53	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	13.76	1e-36	3.69e-33	0.66	0.53	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	13.76	1.01e-36	3.73e-33	0.67	0.53	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	13.76	1.02e-36	3.75e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	13.76	1.07e-36	3.93e-33	0.65	0.53	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	13.76	1.07e-36	3.93e-33	0.65	0.53	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
KIRC	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-13.76	1.07e-36	3.94e-33	-0.52	-0.53	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
KIRC	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	13.76	1.08e-36	3.96e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	13.76	1.09e-36	3.99e-33	0.65	0.53	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	13.76	1.09e-36	3.99e-33	0.65	0.53	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	13.76	1.09e-36	3.99e-33	0.65	0.53	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	13.76	1.09e-36	3.99e-33	0.8	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
KIRC	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	13.75	1.12e-36	4.1e-33	0.62	0.53	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	13.75	1.12e-36	4.1e-33	0.62	0.53	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	13.75	1.12e-36	4.1e-33	0.62	0.53	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	13.75	1.15e-36	4.21e-33	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
KIRC	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	13.75	1.16e-36	4.26e-33	0.82	0.53	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
KIRC	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	13.75	1.16e-36	4.26e-33	0.82	0.53	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
KIRC	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-13.75	1.2e-36	4.38e-33	-0.66	-0.53	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-13.74	1.29e-36	4.71e-33	-0.65	-0.53	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-13.74	1.29e-36	4.71e-33	-0.65	-0.53	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-13.74	1.29e-36	4.71e-33	-0.65	-0.53	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-13.74	1.32e-36	4.8e-33	-0.65	-0.53	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-13.74	1.32e-36	4.8e-33	-0.65	-0.53	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
KIRC	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-13.74	1.33e-36	4.85e-33	-0.52	-0.53	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
KIRC	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	13.73	1.34e-36	4.87e-33	0.68	0.53	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-13.73	1.35e-36	4.92e-33	-0.68	-0.53	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
KIRC	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-13.73	1.35e-36	4.93e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-13.73	1.35e-36	4.93e-33	-0.64	-0.53	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
KIRC	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-13.73	1.35e-36	4.94e-33	-0.62	-0.53	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
KIRC	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-13.73	1.36e-36	4.96e-33	-0.73	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
KIRC	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-13.73	1.38e-36	5.03e-33	-0.67	-0.53	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
KIRC	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	13.73	1.38e-36	5.03e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	13.73	1.39e-36	5.06e-33	0.65	0.53	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	13.73	1.39e-36	5.06e-33	0.65	0.53	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	13.73	1.39e-36	5.06e-33	0.65	0.53	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	13.73	1.39e-36	5.06e-33	0.65	0.53	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	13.73	1.41e-36	5.13e-33	0.65	0.53	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	13.73	1.41e-36	5.13e-33	0.65	0.53	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
KIRC	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	13.73	1.43e-36	5.2e-33	0.58	0.53	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
KIRC	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	13.73	1.46e-36	5.32e-33	0.67	0.53	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	13.73	1.47e-36	5.35e-33	0.67	0.53	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-13.72	1.49e-36	5.41e-33	-0.63	-0.53	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
KIRC	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	13.72	1.53e-36	5.56e-33	0.67	0.52	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
KIRC	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-13.72	1.57e-36	5.71e-33	-0.79	-0.52	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
KIRC	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	13.72	1.59e-36	5.76e-33	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
KIRC	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-13.72	1.62e-36	5.87e-33	-0.64	-0.52	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
KIRC	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	13.71	1.63e-36	5.92e-33	0.72	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
KIRC	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-13.71	1.64e-36	5.96e-33	-0.69	-0.52	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
KIRC	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	13.71	1.65e-36	5.97e-33	0.65	0.52	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
KIRC	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	13.71	1.67e-36	6.05e-33	0.58	0.52	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
KIRC	cis	rs9457247	0.967	rs387733	ENSG00000265828.1	MIR3939	13.7	1.84e-36	6.68e-33	0.6	0.52	Crohn's disease;	chr6:166996283	chr6:166997807~166997912:-
KIRC	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-13.7	1.9e-36	6.89e-33	-0.65	-0.52	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	13.7	1.98e-36	7.15e-33	0.68	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
KIRC	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-13.69	2.06e-36	7.43e-33	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
KIRC	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	13.69	2.09e-36	7.55e-33	0.7	0.52	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
KIRC	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	13.69	2.11e-36	7.64e-33	0.62	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
KIRC	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-13.69	2.14e-36	7.74e-33	-0.64	-0.52	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
KIRC	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	13.69	2.18e-36	7.86e-33	0.62	0.52	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
KIRC	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	13.69	2.19e-36	7.91e-33	0.74	0.52	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
KIRC	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	13.68	2.21e-36	7.99e-33	0.51	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
KIRC	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-13.68	2.25e-36	8.12e-33	-0.66	-0.52	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
KIRC	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	13.68	2.33e-36	8.41e-33	0.68	0.52	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
KIRC	cis	rs9457247	0.756	rs2345572	ENSG00000265828.1	MIR3939	-13.68	2.34e-36	8.42e-33	-0.6	-0.52	Crohn's disease;	chr6:166989953	chr6:166997807~166997912:-
KIRC	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	13.68	2.35e-36	8.46e-33	0.64	0.52	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
KIRC	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	13.68	2.38e-36	8.56e-33	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
KIRC	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	13.68	2.41e-36	8.67e-33	0.66	0.52	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
KIRC	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	13.68	2.41e-36	8.67e-33	0.66	0.52	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
KIRC	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-13.68	2.41e-36	8.67e-33	-0.49	-0.52	Breast cancer;	chr11:825777	chr11:779617~780755:+
KIRC	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	13.67	2.45e-36	8.82e-33	0.64	0.52	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
KIRC	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-13.67	2.56e-36	9.19e-33	-0.63	-0.52	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
KIRC	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	13.67	2.56e-36	9.19e-33	0.66	0.52	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.67	2.57e-36	9.22e-33	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
KIRC	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	13.67	2.62e-36	9.41e-33	0.63	0.52	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
KIRC	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-13.66	2.76e-36	9.89e-33	-0.51	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
KIRC	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	13.66	2.83e-36	1.02e-32	0.65	0.52	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
KIRC	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-13.66	2.84e-36	1.02e-32	-0.67	-0.52	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
KIRC	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	13.66	2.96e-36	1.06e-32	0.66	0.52	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
KIRC	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-13.65	3.01e-36	1.08e-32	-0.59	-0.52	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
KIRC	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	13.65	3.11e-36	1.11e-32	0.78	0.52	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
KIRC	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	13.65	3.14e-36	1.13e-32	0.82	0.52	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
KIRC	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	13.65	3.14e-36	1.13e-32	0.82	0.52	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
KIRC	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	13.65	3.17e-36	1.13e-32	0.66	0.52	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
KIRC	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	13.65	3.22e-36	1.15e-32	0.66	0.52	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	13.64	3.28e-36	1.17e-32	0.64	0.52	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-13.64	3.42e-36	1.22e-32	-0.65	-0.52	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
KIRC	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-13.64	3.51e-36	1.25e-32	-0.5	-0.52	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
KIRC	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	13.63	3.66e-36	1.31e-32	0.64	0.52	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	13.63	3.66e-36	1.31e-32	0.64	0.52	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
KIRC	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-13.63	3.74e-36	1.33e-32	-0.75	-0.52	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
KIRC	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-13.63	3.9e-36	1.39e-32	-0.57	-0.52	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
KIRC	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	13.63	3.92e-36	1.39e-32	0.66	0.52	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	13.63	3.98e-36	1.41e-32	0.64	0.52	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
KIRC	cis	rs9457247	0.646	rs239934	ENSG00000265828.1	MIR3939	-13.62	4.1e-36	1.46e-32	-0.6	-0.52	Crohn's disease;	chr6:166998560	chr6:166997807~166997912:-
KIRC	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	13.62	4.18e-36	1.49e-32	0.66	0.52	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
KIRC	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	13.62	4.23e-36	1.5e-32	0.81	0.52	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
KIRC	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-13.62	4.3e-36	1.53e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
KIRC	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-13.62	4.41e-36	1.56e-32	-0.72	-0.52	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
KIRC	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	13.61	4.43e-36	1.57e-32	0.64	0.52	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-13.61	4.57e-36	1.62e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-13.61	4.57e-36	1.62e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
KIRC	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-13.61	4.69e-36	1.66e-32	-0.66	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
KIRC	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	13.61	4.71e-36	1.67e-32	0.62	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
KIRC	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-13.6	4.88e-36	1.72e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
KIRC	cis	rs9355610	0.892	rs2247314	ENSG00000265828.1	MIR3939	13.6	4.97e-36	1.76e-32	0.61	0.52	Graves' disease;	chr6:166956742	chr6:166997807~166997912:-
KIRC	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-13.6	5.05e-36	1.78e-32	-0.71	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
KIRC	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-13.6	5.14e-36	1.81e-32	-0.64	-0.52	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
KIRC	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	13.6	5.14e-36	1.81e-32	0.64	0.52	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
KIRC	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	13.6	5.25e-36	1.85e-32	0.65	0.52	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
KIRC	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-13.6	5.26e-36	1.85e-32	-0.66	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
KIRC	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-13.59	5.53e-36	1.95e-32	-0.7	-0.52	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-13.59	5.59e-36	1.97e-32	-0.69	-0.52	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-13.59	5.59e-36	1.97e-32	-0.69	-0.52	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
KIRC	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	13.59	5.65e-36	1.99e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	13.59	5.68e-36	2e-32	0.64	0.52	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	13.59	5.7e-36	2e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	13.58	6.02e-36	2.11e-32	0.62	0.52	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
KIRC	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	13.58	6.05e-36	2.13e-32	0.62	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
KIRC	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	13.58	6.39e-36	2.24e-32	0.68	0.52	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
KIRC	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	13.58	6.51e-36	2.28e-32	0.67	0.52	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
KIRC	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	13.57	6.66e-36	2.33e-32	0.59	0.52	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
KIRC	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	13.57	6.69e-36	2.35e-32	0.61	0.52	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
KIRC	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-13.57	6.77e-36	2.37e-32	-0.59	-0.52	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	13.57	6.84e-36	2.4e-32	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
KIRC	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-13.57	7.08e-36	2.48e-32	-0.73	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
KIRC	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	13.57	7.19e-36	2.51e-32	0.64	0.52	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
KIRC	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	13.57	7.25e-36	2.53e-32	0.73	0.52	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-13.56	7.32e-36	2.56e-32	-0.64	-0.52	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
KIRC	cis	rs9457247	0.534	rs2757053	ENSG00000265828.1	MIR3939	13.56	7.51e-36	2.62e-32	0.61	0.52	Crohn's disease;	chr6:166966850	chr6:166997807~166997912:-
KIRC	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-13.56	7.79e-36	2.72e-32	-0.88	-0.52	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
KIRC	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-13.56	7.86e-36	2.74e-32	-0.71	-0.52	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	13.56	7.95e-36	2.77e-32	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
KIRC	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-13.55	8.24e-36	2.87e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
KIRC	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-13.55	8.37e-36	2.92e-32	-0.71	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
KIRC	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	13.55	8.47e-36	2.95e-32	0.66	0.52	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-13.55	8.73e-36	3.04e-32	-0.64	-0.52	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	13.55	8.8e-36	3.06e-32	0.67	0.52	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	13.55	8.8e-36	3.06e-32	0.67	0.52	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	13.54	8.92e-36	3.1e-32	0.65	0.52	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
KIRC	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-13.54	8.97e-36	3.12e-32	-0.7	-0.52	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
KIRC	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	13.54	9.06e-36	3.15e-32	0.65	0.52	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
KIRC	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	13.54	9.1e-36	3.16e-32	0.58	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
KIRC	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	13.54	9.14e-36	3.18e-32	0.67	0.52	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	13.54	9.47e-36	3.29e-32	0.62	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
KIRC	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	13.53	1e-35	3.48e-32	0.83	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
KIRC	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	13.53	1e-35	3.48e-32	0.67	0.52	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
KIRC	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-13.53	1.01e-35	3.48e-32	-0.52	-0.52	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
KIRC	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	13.53	1.03e-35	3.56e-32	0.64	0.52	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	13.53	1.05e-35	3.62e-32	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
KIRC	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-13.53	1.06e-35	3.67e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
KIRC	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-13.53	1.06e-35	3.67e-32	-0.58	-0.52	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
KIRC	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	13.53	1.06e-35	3.67e-32	0.61	0.52	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
KIRC	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-13.53	1.06e-35	3.68e-32	-0.64	-0.52	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
KIRC	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-13.52	1.09e-35	3.78e-32	-0.57	-0.52	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
KIRC	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	13.52	1.1e-35	3.8e-32	0.66	0.52	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	13.52	1.1e-35	3.81e-32	0.84	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
KIRC	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-13.52	1.12e-35	3.87e-32	-0.59	-0.52	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
KIRC	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	13.52	1.14e-35	3.95e-32	0.57	0.52	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-13.52	1.19e-35	4.11e-32	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
KIRC	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-13.51	1.2e-35	4.14e-32	-0.5	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
KIRC	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	13.51	1.23e-35	4.23e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	13.51	1.23e-35	4.23e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
KIRC	cis	rs944002	1	rs59643720	ENSG00000259444.1	RP11-736N17.8	13.5	1.34e-35	4.62e-32	0.56	0.52	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098470	chr14:103094723~103098885:+
KIRC	cis	rs944002	1	rs61462345	ENSG00000259444.1	RP11-736N17.8	13.5	1.34e-35	4.62e-32	0.56	0.52	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103098598	chr14:103094723~103098885:+
KIRC	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	13.5	1.37e-35	4.72e-32	0.66	0.52	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	13.5	1.41e-35	4.84e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	13.5	1.41e-35	4.84e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	13.5	1.41e-35	4.84e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	13.5	1.41e-35	4.84e-32	0.65	0.52	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-13.5	1.43e-35	4.9e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
KIRC	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	13.5	1.43e-35	4.91e-32	0.62	0.52	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
KIRC	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	13.5	1.43e-35	4.93e-32	0.76	0.52	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
KIRC	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-13.5	1.44e-35	4.95e-32	-0.65	-0.52	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
KIRC	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	13.49	1.5e-35	5.14e-32	0.79	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	13.49	1.51e-35	5.19e-32	0.66	0.52	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	13.49	1.51e-35	5.19e-32	0.66	0.52	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	13.49	1.52e-35	5.2e-32	0.65	0.52	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
KIRC	cis	rs9457247	0.534	rs9355610	ENSG00000265828.1	MIR3939	13.49	1.54e-35	5.29e-32	0.6	0.52	Crohn's disease;	chr6:166969587	chr6:166997807~166997912:-
KIRC	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	13.49	1.55e-35	5.33e-32	0.83	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
KIRC	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-13.49	1.58e-35	5.42e-32	-0.64	-0.52	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-13.48	1.68e-35	5.75e-32	-0.67	-0.52	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
KIRC	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-13.48	1.68e-35	5.76e-32	-0.75	-0.52	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
KIRC	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	13.48	1.69e-35	5.79e-32	0.58	0.52	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
KIRC	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-13.48	1.69e-35	5.8e-32	-0.67	-0.52	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	13.48	1.73e-35	5.9e-32	0.64	0.52	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
KIRC	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-13.48	1.77e-35	6.05e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
KIRC	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	13.47	1.79e-35	6.12e-32	0.62	0.52	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
KIRC	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-13.47	1.82e-35	6.23e-32	-0.68	-0.52	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
KIRC	cis	rs9457247	0.534	rs4710154	ENSG00000265828.1	MIR3939	13.47	1.84e-35	6.29e-32	0.6	0.52	Crohn's disease;	chr6:166981146	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	13.47	1.86e-35	6.34e-32	0.61	0.52	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
KIRC	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-13.47	1.87e-35	6.38e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
KIRC	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	13.46	2.02e-35	6.88e-32	0.63	0.52	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	13.46	2.05e-35	6.99e-32	0.67	0.52	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
KIRC	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	13.46	2.09e-35	7.11e-32	0.66	0.52	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	13.46	2.09e-35	7.12e-32	0.64	0.52	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
KIRC	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-13.46	2.1e-35	7.13e-32	-0.66	-0.52	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
KIRC	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-13.46	2.12e-35	7.2e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
KIRC	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	13.46	2.12e-35	7.2e-32	0.64	0.52	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
KIRC	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-13.45	2.18e-35	7.42e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
KIRC	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	13.45	2.18e-35	7.42e-32	0.65	0.52	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
KIRC	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-13.45	2.24e-35	7.61e-32	-0.57	-0.52	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
KIRC	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	13.45	2.25e-35	7.62e-32	0.65	0.52	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	13.45	2.26e-35	7.67e-32	0.66	0.52	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	13.45	2.27e-35	7.71e-32	0.66	0.52	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
KIRC	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	13.45	2.3e-35	7.81e-32	0.7	0.52	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
KIRC	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	13.45	2.31e-35	7.84e-32	0.61	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
KIRC	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-13.45	2.34e-35	7.95e-32	-0.75	-0.52	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
KIRC	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-13.45	2.35e-35	7.98e-32	-0.51	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
KIRC	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	13.45	2.37e-35	8.02e-32	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
KIRC	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-13.45	2.38e-35	8.03e-32	-0.63	-0.52	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
KIRC	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	13.44	2.39e-35	8.08e-32	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
KIRC	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-13.44	2.41e-35	8.14e-32	-0.67	-0.52	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
KIRC	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	13.44	2.46e-35	8.32e-32	0.58	0.52	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
KIRC	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	13.44	2.51e-35	8.49e-32	0.67	0.52	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
KIRC	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	13.44	2.55e-35	8.62e-32	0.65	0.52	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	13.44	2.55e-35	8.62e-32	0.65	0.52	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	13.44	2.55e-35	8.62e-32	0.65	0.52	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
KIRC	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	13.44	2.6e-35	8.76e-32	0.68	0.52	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
KIRC	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	13.43	2.76e-35	9.3e-32	0.63	0.52	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
KIRC	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-13.43	2.8e-35	9.42e-32	-0.75	-0.52	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
KIRC	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	13.43	2.8e-35	9.44e-32	0.65	0.52	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
KIRC	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-13.43	2.83e-35	9.53e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
KIRC	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-13.43	2.83e-35	9.53e-32	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
KIRC	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-13.43	2.87e-35	9.64e-32	-0.64	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-13.42	2.94e-35	9.87e-32	-0.65	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
KIRC	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	13.42	2.97e-35	9.97e-32	0.58	0.52	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
KIRC	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-13.42	3.06e-35	1.03e-31	-0.62	-0.52	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	13.42	3.07e-35	1.03e-31	0.64	0.52	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	13.42	3.07e-35	1.03e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	13.42	3.07e-35	1.03e-31	0.81	0.52	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
KIRC	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	13.42	3.08e-35	1.04e-31	0.65	0.52	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	13.42	3.11e-35	1.04e-31	0.64	0.52	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
KIRC	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	13.42	3.16e-35	1.06e-31	0.75	0.52	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
KIRC	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-13.42	3.18e-35	1.07e-31	-0.63	-0.52	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
KIRC	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	13.41	3.28e-35	1.1e-31	0.62	0.52	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
KIRC	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	13.41	3.31e-35	1.11e-31	0.73	0.52	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
KIRC	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	13.41	3.32e-35	1.11e-31	0.63	0.52	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
KIRC	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-13.41	3.33e-35	1.11e-31	-0.63	-0.52	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
KIRC	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	13.41	3.35e-35	1.12e-31	0.8	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
KIRC	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	13.41	3.36e-35	1.13e-31	0.64	0.52	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	13.41	3.36e-35	1.13e-31	0.64	0.52	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
KIRC	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-13.4	3.58e-35	1.2e-31	-0.67	-0.52	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
KIRC	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-13.4	3.59e-35	1.2e-31	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
KIRC	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-13.4	3.62e-35	1.21e-31	-0.58	-0.52	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
KIRC	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	13.4	3.67e-35	1.23e-31	0.64	0.52	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
KIRC	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	13.4	3.67e-35	1.23e-31	0.64	0.52	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	13.4	3.67e-35	1.23e-31	0.64	0.52	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
KIRC	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	13.4	3.74e-35	1.25e-31	0.75	0.52	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
KIRC	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	13.4	3.83e-35	1.27e-31	0.81	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
KIRC	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	13.39	3.94e-35	1.31e-31	0.64	0.52	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	13.39	3.94e-35	1.31e-31	0.64	0.52	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
KIRC	cis	rs6085948	0.953	rs6077166	ENSG00000238102.1	RP11-19D2.1	13.39	3.97e-35	1.32e-31	0.55	0.52	Interleukin-10 levels;	chr20:7252921	chr20:7256580~7258214:-
KIRC	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	13.39	4.16e-35	1.38e-31	0.8	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	13.39	4.18e-35	1.39e-31	0.61	0.52	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
KIRC	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	13.39	4.19e-35	1.39e-31	0.74	0.52	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
KIRC	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	13.39	4.23e-35	1.4e-31	0.64	0.52	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
KIRC	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	13.38	4.34e-35	1.44e-31	0.59	0.52	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
KIRC	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	13.38	4.41e-35	1.46e-31	0.65	0.52	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
KIRC	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	13.38	4.55e-35	1.51e-31	0.76	0.52	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	13.38	4.62e-35	1.53e-31	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
KIRC	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	13.38	4.68e-35	1.55e-31	0.8	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	13.37	4.91e-35	1.63e-31	0.65	0.52	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
KIRC	cis	rs6560039	1	rs6560039	ENSG00000234460.1	XXyac-YM21GA2.4	13.37	4.97e-35	1.65e-31	0.7	0.52	Gait variability;	chr9:87860031	chr9:87864166~87866290:+
KIRC	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-13.37	5.07e-35	1.68e-31	-0.64	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-13.37	5.1e-35	1.69e-31	-0.64	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-13.37	5.1e-35	1.69e-31	-0.64	-0.52	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
KIRC	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	13.37	5.18e-35	1.71e-31	0.59	0.51	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	13.37	5.18e-35	1.71e-31	0.59	0.51	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
KIRC	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	13.37	5.22e-35	1.73e-31	0.56	0.51	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
KIRC	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	13.37	5.24e-35	1.73e-31	0.65	0.51	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	13.36	5.35e-35	1.77e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	13.36	5.35e-35	1.77e-31	0.81	0.51	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	13.36	5.35e-35	1.77e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	13.36	5.35e-35	1.77e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.663	rs9459835	ENSG00000265828.1	MIR3939	-13.36	5.46e-35	1.8e-31	-0.6	-0.51	Crohn's disease;	chr6:167004063	chr6:166997807~166997912:-
KIRC	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	13.36	5.47e-35	1.8e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
KIRC	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-13.36	5.55e-35	1.83e-31	-0.71	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
KIRC	cis	rs9457247	0.534	rs12055488	ENSG00000265828.1	MIR3939	13.36	5.67e-35	1.87e-31	0.6	0.51	Crohn's disease;	chr6:166966082	chr6:166997807~166997912:-
KIRC	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	13.36	5.67e-35	1.87e-31	0.74	0.51	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
KIRC	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	13.36	5.67e-35	1.87e-31	0.74	0.51	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
KIRC	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	13.35	5.84e-35	1.92e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
KIRC	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-13.35	5.99e-35	1.97e-31	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
KIRC	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	13.35	6.12e-35	2.01e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
KIRC	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	13.35	6.28e-35	2.06e-31	0.6	0.51	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
KIRC	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-13.35	6.33e-35	2.08e-31	-0.51	-0.51	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
KIRC	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-13.35	6.35e-35	2.08e-31	-0.66	-0.51	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
KIRC	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	13.34	6.47e-35	2.12e-31	0.73	0.51	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
KIRC	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	13.34	6.47e-35	2.12e-31	0.73	0.51	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
KIRC	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-13.34	6.61e-35	2.17e-31	-0.49	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
KIRC	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-13.34	6.64e-35	2.18e-31	-0.51	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
KIRC	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-13.34	6.66e-35	2.19e-31	-0.78	-0.51	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
KIRC	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	13.34	6.77e-35	2.22e-31	0.65	0.51	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	13.34	6.81e-35	2.23e-31	0.61	0.51	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
KIRC	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	13.34	6.81e-35	2.23e-31	0.59	0.51	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
KIRC	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-13.33	7.11e-35	2.33e-31	-0.63	-0.51	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
KIRC	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	13.33	7.11e-35	2.33e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	13.33	7.15e-35	2.34e-31	0.65	0.51	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-13.33	7.59e-35	2.48e-31	-0.63	-0.51	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-13.33	7.66e-35	2.5e-31	-0.62	-0.51	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-13.33	7.66e-35	2.5e-31	-0.62	-0.51	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
KIRC	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	13.33	7.7e-35	2.51e-31	0.73	0.51	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
KIRC	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	13.33	7.71e-35	2.52e-31	0.81	0.51	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	13.32	7.95e-35	2.59e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
KIRC	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	13.32	8.04e-35	2.62e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
KIRC	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	13.32	8.36e-35	2.72e-31	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
KIRC	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-13.32	8.45e-35	2.75e-31	-0.57	-0.51	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
KIRC	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-13.32	8.46e-35	2.75e-31	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
KIRC	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-13.32	8.52e-35	2.77e-31	-0.65	-0.51	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
KIRC	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-13.32	8.62e-35	2.8e-31	-0.5	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
KIRC	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-13.32	8.63e-35	2.8e-31	-0.57	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
KIRC	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	13.31	8.65e-35	2.81e-31	0.65	0.51	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	13.31	8.65e-35	2.81e-31	0.65	0.51	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
KIRC	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-13.31	8.89e-35	2.89e-31	-0.72	-0.51	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
KIRC	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.31	8.92e-35	2.9e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
KIRC	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-13.31	8.93e-35	2.9e-31	-0.81	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	13.31	9.02e-35	2.93e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
KIRC	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	13.31	9.05e-35	2.93e-31	0.67	0.51	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	13.31	9.15e-35	2.97e-31	0.65	0.51	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
KIRC	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-13.31	9.18e-35	2.98e-31	-0.58	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
KIRC	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	13.31	9.19e-35	2.98e-31	0.67	0.51	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
KIRC	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-13.31	9.37e-35	3.04e-31	-0.58	-0.51	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
KIRC	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-13.31	9.46e-35	3.07e-31	-0.45	-0.51	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
KIRC	cis	rs944002	1	rs2297067	ENSG00000259444.1	RP11-736N17.8	-13.31	9.46e-35	3.07e-31	-0.54	-0.51	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100448	chr14:103094723~103098885:+
KIRC	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-13.31	9.51e-35	3.08e-31	-0.58	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
KIRC	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	13.3	9.53e-35	3.08e-31	0.59	0.51	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
KIRC	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	13.3	9.63e-35	3.12e-31	0.65	0.51	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
KIRC	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-13.3	9.92e-35	3.21e-31	-0.57	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
KIRC	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	13.3	9.98e-35	3.23e-31	0.82	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
KIRC	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	13.3	9.99e-35	3.23e-31	0.53	0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
KIRC	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	13.3	1.01e-34	3.26e-31	0.72	0.51	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
KIRC	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	13.3	1.01e-34	3.27e-31	0.72	0.51	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
KIRC	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	13.3	1.02e-34	3.3e-31	0.65	0.51	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
KIRC	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	13.29	1.07e-34	3.44e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	13.29	1.07e-34	3.47e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
KIRC	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-13.29	1.1e-34	3.54e-31	-0.66	-0.51	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
KIRC	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	13.29	1.1e-34	3.56e-31	0.63	0.51	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	13.29	1.1e-34	3.56e-31	0.63	0.51	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
KIRC	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	13.29	1.11e-34	3.58e-31	0.65	0.51	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
KIRC	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	13.29	1.11e-34	3.58e-31	0.65	0.51	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	13.29	1.12e-34	3.61e-31	0.65	0.51	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	13.29	1.12e-34	3.61e-31	0.65	0.51	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-13.29	1.14e-34	3.68e-31	-0.49	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
KIRC	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	13.29	1.15e-34	3.71e-31	0.72	0.51	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
KIRC	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-13.29	1.16e-34	3.73e-31	-0.64	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
KIRC	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	13.28	1.16e-34	3.74e-31	0.82	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	13.28	1.17e-34	3.77e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
KIRC	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	13.28	1.18e-34	3.79e-31	0.54	0.51	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
KIRC	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-13.28	1.22e-34	3.92e-31	-0.61	-0.51	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
KIRC	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	13.28	1.22e-34	3.93e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-13.28	1.26e-34	4.05e-31	-0.62	-0.51	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
KIRC	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	13.28	1.27e-34	4.08e-31	0.74	0.51	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
KIRC	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	13.28	1.27e-34	4.08e-31	0.82	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	13.27	1.29e-34	4.13e-31	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	13.27	1.29e-34	4.13e-31	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	13.27	1.29e-34	4.13e-31	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	13.27	1.35e-34	4.34e-31	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
KIRC	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	13.27	1.36e-34	4.37e-31	0.51	0.51	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
KIRC	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	13.27	1.37e-34	4.4e-31	0.59	0.51	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
KIRC	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	13.27	1.37e-34	4.4e-31	0.65	0.51	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
KIRC	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	13.27	1.38e-34	4.41e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
KIRC	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	13.27	1.38e-34	4.41e-31	0.59	0.51	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
KIRC	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	13.27	1.39e-34	4.44e-31	0.82	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.534	rs2345568	ENSG00000265828.1	MIR3939	13.27	1.39e-34	4.44e-31	0.6	0.51	Crohn's disease;	chr6:166968316	chr6:166997807~166997912:-
KIRC	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	13.27	1.41e-34	4.52e-31	0.65	0.51	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
KIRC	cis	rs9457247	0.534	rs4710149	ENSG00000265828.1	MIR3939	13.26	1.41e-34	4.53e-31	0.59	0.51	Crohn's disease;	chr6:166972858	chr6:166997807~166997912:-
KIRC	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	13.26	1.45e-34	4.64e-31	0.62	0.51	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
KIRC	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	13.26	1.49e-34	4.76e-31	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	13.26	1.49e-34	4.76e-31	0.61	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
KIRC	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	13.26	1.52e-34	4.86e-31	0.63	0.51	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	13.26	1.52e-34	4.86e-31	0.62	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
KIRC	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	13.26	1.52e-34	4.86e-31	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
KIRC	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-13.26	1.52e-34	4.87e-31	-0.59	-0.51	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
KIRC	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	13.26	1.53e-34	4.87e-31	0.67	0.51	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
KIRC	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	13.25	1.57e-34	5.01e-31	0.65	0.51	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	13.25	1.58e-34	5.05e-31	0.6	0.51	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
KIRC	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-13.25	1.59e-34	5.06e-31	-0.72	-0.51	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
KIRC	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	13.25	1.59e-34	5.07e-31	0.56	0.51	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
KIRC	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	13.25	1.61e-34	5.14e-31	0.62	0.51	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
KIRC	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-13.25	1.64e-34	5.22e-31	-0.5	-0.51	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
KIRC	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-13.25	1.67e-34	5.31e-31	-0.59	-0.51	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
KIRC	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	13.25	1.67e-34	5.31e-31	0.62	0.51	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
KIRC	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-13.25	1.72e-34	5.47e-31	-0.64	-0.51	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
KIRC	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-13.24	1.74e-34	5.54e-31	-0.63	-0.51	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
KIRC	cis	rs9457247	0.534	rs9347170	ENSG00000265828.1	MIR3939	13.24	1.74e-34	5.55e-31	0.6	0.51	Crohn's disease;	chr6:166991699	chr6:166997807~166997912:-
KIRC	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	13.24	1.77e-34	5.62e-31	0.57	0.51	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
KIRC	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	13.24	1.78e-34	5.66e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
KIRC	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	13.24	1.87e-34	5.93e-31	0.59	0.51	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
KIRC	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-13.24	1.88e-34	5.97e-31	-0.68	-0.51	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	13.24	1.89e-34	6e-31	0.67	0.51	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
KIRC	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	13.23	1.91e-34	6.06e-31	0.58	0.51	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	13.23	1.91e-34	6.06e-31	0.58	0.51	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
KIRC	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	13.23	1.98e-34	6.27e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
KIRC	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-13.23	2.06e-34	6.52e-31	-0.62	-0.51	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	13.22	2.14e-34	6.75e-31	0.64	0.51	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	13.22	2.14e-34	6.75e-31	0.64	0.51	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	13.22	2.14e-34	6.75e-31	0.64	0.51	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
KIRC	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-13.22	2.16e-34	6.82e-31	-0.64	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
KIRC	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-13.22	2.17e-34	6.85e-31	-0.51	-0.51	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
KIRC	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	13.21	2.34e-34	7.36e-31	0.78	0.51	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	13.21	2.34e-34	7.36e-31	0.78	0.51	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	13.21	2.34e-34	7.36e-31	0.78	0.51	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	13.21	2.34e-34	7.36e-31	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	13.21	2.35e-34	7.41e-31	0.6	0.51	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
KIRC	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	13.21	2.37e-34	7.48e-31	0.79	0.51	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
KIRC	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-13.21	2.39e-34	7.54e-31	-0.59	-0.51	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
KIRC	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	13.21	2.4e-34	7.57e-31	0.62	0.51	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	13.21	2.43e-34	7.64e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
KIRC	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-13.21	2.44e-34	7.67e-31	-0.7	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
KIRC	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-13.21	2.49e-34	7.84e-31	-0.64	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
KIRC	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-13.21	2.5e-34	7.87e-31	-0.69	-0.51	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
KIRC	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	13.21	2.52e-34	7.94e-31	0.59	0.51	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	13.21	2.53e-34	7.96e-31	0.59	0.51	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
KIRC	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	13.2	2.62e-34	8.24e-31	0.62	0.51	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
KIRC	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	13.2	2.65e-34	8.33e-31	0.78	0.51	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
KIRC	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-13.2	2.67e-34	8.38e-31	-0.69	-0.51	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-13.2	2.67e-34	8.38e-31	-0.69	-0.51	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-13.2	2.67e-34	8.38e-31	-0.69	-0.51	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
KIRC	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-13.2	2.68e-34	8.41e-31	-0.74	-0.51	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
KIRC	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	13.2	2.7e-34	8.47e-31	0.78	0.51	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
KIRC	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	13.2	2.7e-34	8.47e-31	0.58	0.51	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	13.2	2.7e-34	8.47e-31	0.58	0.51	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	13.2	2.7e-34	8.47e-31	0.58	0.51	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	13.2	2.7e-34	8.47e-31	0.58	0.51	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
KIRC	cis	rs9457247	0.534	rs9366078	ENSG00000265828.1	MIR3939	13.2	2.75e-34	8.63e-31	0.59	0.51	Crohn's disease;	chr6:166986024	chr6:166997807~166997912:-
KIRC	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	13.2	2.79e-34	8.74e-31	0.64	0.51	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
KIRC	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-13.19	2.84e-34	8.89e-31	-0.57	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
KIRC	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-13.19	2.91e-34	9.12e-31	-0.63	-0.51	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
KIRC	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	13.19	2.92e-34	9.14e-31	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	13.19	2.93e-34	9.17e-31	0.64	0.51	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	13.19	2.96e-34	9.24e-31	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-13.19	2.99e-34	9.32e-31	-0.61	-0.51	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	13.19	3.08e-34	9.61e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	13.19	3.08e-34	9.61e-31	0.61	0.51	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
KIRC	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	13.18	3.13e-34	9.76e-31	0.69	0.51	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
KIRC	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-13.18	3.16e-34	9.85e-31	-0.67	-0.51	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
KIRC	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	13.18	3.23e-34	1.01e-30	0.79	0.51	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
KIRC	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	13.18	3.28e-34	1.02e-30	0.78	0.51	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	13.18	3.4e-34	1.06e-30	0.78	0.51	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	13.18	3.4e-34	1.06e-30	0.78	0.51	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	13.18	3.4e-34	1.06e-30	0.78	0.51	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
KIRC	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	13.17	3.46e-34	1.08e-30	0.72	0.51	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
KIRC	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	13.17	3.46e-34	1.08e-30	0.72	0.51	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
KIRC	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	13.17	3.66e-34	1.14e-30	0.61	0.51	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
KIRC	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	13.17	3.72e-34	1.15e-30	0.79	0.51	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
KIRC	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	13.16	3.8e-34	1.18e-30	0.71	0.51	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
KIRC	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	13.16	3.8e-34	1.18e-30	0.62	0.51	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
KIRC	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	13.16	3.84e-34	1.19e-30	0.78	0.51	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
KIRC	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	13.16	3.85e-34	1.2e-30	0.61	0.51	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
KIRC	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-13.16	4e-34	1.24e-30	-0.64	-0.51	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-13.16	4e-34	1.24e-30	-0.64	-0.51	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
KIRC	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-13.16	4.09e-34	1.27e-30	-0.59	-0.51	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
KIRC	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	13.16	4.1e-34	1.27e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
KIRC	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-13.16	4.11e-34	1.27e-30	-0.5	-0.51	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
KIRC	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-13.15	4.19e-34	1.29e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
KIRC	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-13.15	4.23e-34	1.31e-30	-0.7	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
KIRC	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-13.15	4.25e-34	1.31e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
KIRC	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	13.15	4.27e-34	1.32e-30	0.72	0.51	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
KIRC	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	13.15	4.34e-34	1.34e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	13.15	4.34e-34	1.34e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	13.15	4.34e-34	1.34e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	13.15	4.34e-34	1.34e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.534	rs9356551	ENSG00000265828.1	MIR3939	13.15	4.41e-34	1.36e-30	0.59	0.51	Crohn's disease;	chr6:166986857	chr6:166997807~166997912:-
KIRC	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-13.15	4.51e-34	1.39e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
KIRC	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	13.15	4.52e-34	1.39e-30	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
KIRC	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	13.15	4.55e-34	1.4e-30	0.72	0.51	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
KIRC	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-13.14	4.6e-34	1.42e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-13.14	4.6e-34	1.42e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
KIRC	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	13.14	4.62e-34	1.42e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	13.14	4.62e-34	1.42e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	13.14	4.62e-34	1.42e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
KIRC	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-13.14	4.68e-34	1.44e-30	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-13.14	4.68e-34	1.44e-30	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-13.14	4.68e-34	1.44e-30	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
KIRC	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-13.14	4.75e-34	1.46e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-13.14	4.85e-34	1.49e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
KIRC	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-13.14	4.86e-34	1.5e-30	-0.58	-0.51	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
KIRC	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-13.14	4.88e-34	1.5e-30	-0.58	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
KIRC	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-13.14	4.91e-34	1.51e-30	-0.61	-0.51	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
KIRC	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-13.14	5.05e-34	1.55e-30	-0.8	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
KIRC	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	13.14	5.06e-34	1.55e-30	0.66	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
KIRC	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	13.13	5.08e-34	1.56e-30	0.63	0.51	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
KIRC	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	13.13	5.08e-34	1.56e-30	0.61	0.51	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
KIRC	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-13.13	5.14e-34	1.58e-30	-0.57	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
KIRC	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	13.13	5.2e-34	1.6e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	13.13	5.2e-34	1.6e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	13.13	5.23e-34	1.6e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
KIRC	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-13.13	5.24e-34	1.61e-30	-0.55	-0.51	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
KIRC	cis	rs9457247	0.534	rs7750593	ENSG00000265828.1	MIR3939	13.13	5.35e-34	1.64e-30	0.59	0.51	Crohn's disease;	chr6:166973871	chr6:166997807~166997912:-
KIRC	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-13.13	5.46e-34	1.67e-30	-0.67	-0.51	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
KIRC	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	13.13	5.57e-34	1.7e-30	0.69	0.51	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
KIRC	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-13.13	5.58e-34	1.71e-30	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-13.13	5.58e-34	1.71e-30	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
KIRC	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-13.12	5.66e-34	1.73e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-13.12	5.66e-34	1.73e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-13.12	5.66e-34	1.73e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-13.12	5.66e-34	1.73e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-13.12	5.66e-34	1.73e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
KIRC	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	13.12	5.66e-34	1.73e-30	0.6	0.51	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
KIRC	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-13.12	5.68e-34	1.74e-30	-0.59	-0.51	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
KIRC	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-13.12	5.8e-34	1.77e-30	-0.63	-0.51	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
KIRC	cis	rs944002	1	rs62006947	ENSG00000259444.1	RP11-736N17.8	13.12	5.92e-34	1.81e-30	0.55	0.51	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103099033	chr14:103094723~103098885:+
KIRC	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	13.12	6.01e-34	1.83e-30	0.8	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
KIRC	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	13.12	6.09e-34	1.86e-30	0.49	0.51	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
KIRC	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	13.11	6.31e-34	1.93e-30	0.6	0.51	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	13.11	6.4e-34	1.95e-30	0.65	0.51	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
KIRC	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-13.11	6.43e-34	1.96e-30	-0.58	-0.51	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
KIRC	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	13.11	6.51e-34	1.98e-30	0.57	0.51	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
KIRC	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	13.11	6.74e-34	2.05e-30	0.63	0.51	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	13.1	6.93e-34	2.11e-30	0.77	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
KIRC	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-13.1	7.14e-34	2.17e-30	-0.64	-0.51	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
KIRC	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	13.1	7.19e-34	2.18e-30	0.71	0.51	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
KIRC	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	13.1	7.32e-34	2.22e-30	0.71	0.51	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
KIRC	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	13.1	7.39e-34	2.24e-30	0.64	0.51	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
KIRC	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-13.1	7.46e-34	2.27e-30	-0.64	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
KIRC	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-13.09	7.56e-34	2.29e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
KIRC	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	13.09	7.83e-34	2.37e-30	0.59	0.51	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
KIRC	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	13.09	7.99e-34	2.42e-30	0.71	0.51	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
KIRC	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	13.09	8.03e-34	2.43e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	13.09	8.03e-34	2.43e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	13.09	8.05e-34	2.44e-30	0.66	0.51	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	13.09	8.05e-34	2.44e-30	0.66	0.51	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
KIRC	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-13.09	8.08e-34	2.45e-30	-0.56	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
KIRC	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-13.09	8.08e-34	2.45e-30	-0.56	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
KIRC	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	13.09	8.11e-34	2.46e-30	0.46	0.51	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
KIRC	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	13.09	8.12e-34	2.46e-30	0.58	0.51	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
KIRC	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-13.09	8.13e-34	2.46e-30	-0.55	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
KIRC	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	13.08	8.32e-34	2.52e-30	0.49	0.51	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
KIRC	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	13.08	8.47e-34	2.56e-30	0.66	0.51	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	13.08	8.59e-34	2.6e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	13.08	8.59e-34	2.6e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
KIRC	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	13.08	8.83e-34	2.67e-30	0.71	0.51	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
KIRC	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-13.07	9.18e-34	2.77e-30	-0.65	-0.51	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
KIRC	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-13.07	9.62e-34	2.9e-30	-0.59	-0.51	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-13.07	9.88e-34	2.97e-30	-0.59	-0.51	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-13.07	9.88e-34	2.97e-30	-0.59	-0.51	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	13.07	9.95e-34	2.99e-30	0.65	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
KIRC	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	13.07	9.99e-34	3e-30	0.62	0.51	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
KIRC	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-13.06	1.01e-33	3.04e-30	-0.64	-0.51	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
KIRC	cis	rs9457247	0.515	rs1951459	ENSG00000265828.1	MIR3939	13.06	1.03e-33	3.11e-30	0.59	0.51	Crohn's disease;	chr6:166989048	chr6:166997807~166997912:-
KIRC	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-13.06	1.06e-33	3.17e-30	-0.69	-0.51	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
KIRC	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-13.06	1.09e-33	3.28e-30	-0.63	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
KIRC	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-13.06	1.1e-33	3.29e-30	-0.62	-0.51	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
KIRC	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-13.05	1.12e-33	3.34e-30	-0.63	-0.51	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
KIRC	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-13.05	1.12e-33	3.34e-30	-0.78	-0.51	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
KIRC	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	13.05	1.13e-33	3.39e-30	0.66	0.51	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
KIRC	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-13.05	1.16e-33	3.49e-30	-0.59	-0.51	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
KIRC	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	13.05	1.19e-33	3.56e-30	0.63	0.51	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
KIRC	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	13.05	1.19e-33	3.56e-30	0.81	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
KIRC	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-13.04	1.23e-33	3.69e-30	-0.69	-0.51	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
KIRC	cis	rs9457247	0.765	rs6904946	ENSG00000265828.1	MIR3939	13.04	1.24e-33	3.72e-30	0.57	0.51	Crohn's disease;	chr6:167020460	chr6:166997807~166997912:-
KIRC	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	13.04	1.25e-33	3.74e-30	0.71	0.51	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
KIRC	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-13.04	1.27e-33	3.8e-30	-0.59	-0.51	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
KIRC	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	13.04	1.3e-33	3.88e-30	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	13.04	1.3e-33	3.88e-30	0.79	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
KIRC	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-13.03	1.36e-33	4.07e-30	-0.55	-0.51	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
KIRC	cis	rs6085948	1	rs6054856	ENSG00000238102.1	RP11-19D2.1	-13.03	1.37e-33	4.08e-30	-0.54	-0.51	Interleukin-10 levels;	chr20:7266592	chr20:7256580~7258214:-
KIRC	cis	rs9457247	0.588	rs35171809	ENSG00000265828.1	MIR3939	-13.03	1.37e-33	4.09e-30	-0.57	-0.51	Crohn's disease;	chr6:167019278	chr6:166997807~166997912:-
KIRC	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	13.03	1.43e-33	4.26e-30	0.63	0.51	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
KIRC	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	13.03	1.44e-33	4.31e-30	0.6	0.51	Depression;	chr6:28314871	chr6:28176188~28176674:+
KIRC	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-13.03	1.47e-33	4.39e-30	-0.62	-0.51	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
KIRC	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-13.02	1.49e-33	4.44e-30	-0.68	-0.51	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
KIRC	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-13.02	1.49e-33	4.45e-30	-0.6	-0.51	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
KIRC	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	13.02	1.52e-33	4.51e-30	0.78	0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	13.02	1.55e-33	4.62e-30	0.66	0.51	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	13.02	1.55e-33	4.62e-30	0.66	0.51	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
KIRC	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-13.02	1.57e-33	4.67e-30	-0.6	-0.51	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-13.02	1.57e-33	4.67e-30	-0.6	-0.51	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
KIRC	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	13.02	1.57e-33	4.68e-30	0.6	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
KIRC	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-13.02	1.58e-33	4.69e-30	-0.62	-0.51	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
KIRC	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-13.02	1.59e-33	4.73e-30	-0.64	-0.51	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
KIRC	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-13.02	1.59e-33	4.73e-30	-0.55	-0.51	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
KIRC	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-13.02	1.6e-33	4.74e-30	-0.67	-0.51	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
KIRC	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	13.02	1.62e-33	4.82e-30	0.62	0.5	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
KIRC	cis	rs9457247	0.663	rs9459839	ENSG00000265828.1	MIR3939	-13.01	1.65e-33	4.91e-30	-0.57	-0.5	Crohn's disease;	chr6:167018341	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-13.01	1.66e-33	4.92e-30	-0.71	-0.5	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-13.01	1.66e-33	4.92e-30	-0.71	-0.5	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
KIRC	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	13.01	1.71e-33	5.07e-30	0.6	0.5	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	13.01	1.71e-33	5.08e-30	0.78	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
KIRC	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	13.01	1.71e-33	5.08e-30	0.65	0.5	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	13.01	1.71e-33	5.08e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
KIRC	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	13.01	1.72e-33	5.11e-30	0.77	0.5	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
KIRC	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	13.01	1.73e-33	5.14e-30	0.64	0.5	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
KIRC	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	13.01	1.74e-33	5.15e-30	0.58	0.5	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
KIRC	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	13.01	1.74e-33	5.17e-30	0.65	0.5	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
KIRC	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-13.01	1.75e-33	5.19e-30	-0.6	-0.5	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	13.01	1.79e-33	5.3e-30	0.59	0.5	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
KIRC	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	13	1.86e-33	5.51e-30	0.6	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
KIRC	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-13	1.86e-33	5.51e-30	-0.63	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-13	1.89e-33	5.59e-30	-0.63	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-13	1.91e-33	5.65e-30	-0.64	-0.5	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
KIRC	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	13	1.93e-33	5.71e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
KIRC	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	13	1.96e-33	5.78e-30	0.63	0.5	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
KIRC	cis	rs944002	1	rs2297066	ENSG00000259444.1	RP11-736N17.8	13	1.96e-33	5.79e-30	0.53	0.5	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103100498	chr14:103094723~103098885:+
KIRC	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-12.99	2.02e-33	5.95e-30	-0.69	-0.5	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-12.99	2.04e-33	6.02e-30	-0.69	-0.5	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-12.99	2.08e-33	6.14e-30	-0.69	-0.5	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
KIRC	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-12.99	2.08e-33	6.14e-30	-0.69	-0.5	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
KIRC	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	12.99	2.12e-33	6.25e-30	0.34	0.5	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
KIRC	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-12.98	2.2e-33	6.48e-30	-0.61	-0.5	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
KIRC	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-12.98	2.21e-33	6.51e-30	-0.76	-0.5	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
KIRC	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-12.98	2.28e-33	6.71e-30	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
KIRC	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	12.98	2.28e-33	6.72e-30	0.64	0.5	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
KIRC	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-12.98	2.31e-33	6.82e-30	-0.5	-0.5	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
KIRC	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-12.98	2.36e-33	6.96e-30	-0.67	-0.5	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
KIRC	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-12.98	2.37e-33	6.98e-30	-0.7	-0.5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
KIRC	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	12.98	2.4e-33	7.07e-30	0.64	0.5	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	12.98	2.4e-33	7.07e-30	0.64	0.5	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
KIRC	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	12.97	2.42e-33	7.13e-30	0.61	0.5	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
KIRC	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-12.97	2.46e-33	7.25e-30	-0.49	-0.5	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
KIRC	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	12.97	2.55e-33	7.49e-30	0.6	0.5	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
KIRC	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	12.97	2.56e-33	7.53e-30	0.66	0.5	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
KIRC	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	12.97	2.57e-33	7.55e-30	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
KIRC	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-12.97	2.59e-33	7.62e-30	-0.64	-0.5	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
KIRC	cis	rs9326248	0.569	rs473172	ENSG00000254851.1	RP11-109L13.1	-12.97	2.61e-33	7.66e-30	-0.98	-0.5	Blood protein levels;	chr11:116937254	chr11:117135528~117138582:+
KIRC	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	12.97	2.63e-33	7.72e-30	0.57	0.5	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
KIRC	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-12.96	2.72e-33	7.98e-30	-0.65	-0.5	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-12.96	2.77e-33	8.12e-30	-0.63	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
KIRC	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	12.96	2.77e-33	8.13e-30	0.59	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
KIRC	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-12.96	2.83e-33	8.28e-30	-0.64	-0.5	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
KIRC	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	12.96	2.86e-33	8.39e-30	0.56	0.5	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
KIRC	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-12.96	2.89e-33	8.47e-30	-0.57	-0.5	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
KIRC	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-12.95	3.07e-33	8.98e-30	-0.58	-0.5	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
KIRC	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	12.95	3.1e-33	9.06e-30	0.63	0.5	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	12.95	3.19e-33	9.32e-30	0.65	0.5	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-12.95	3.19e-33	9.32e-30	-0.64	-0.5	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-12.95	3.19e-33	9.32e-30	-0.64	-0.5	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
KIRC	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-12.94	3.25e-33	9.49e-30	-0.58	-0.5	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
KIRC	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-12.94	3.35e-33	9.77e-30	-0.64	-0.5	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
KIRC	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	12.94	3.38e-33	9.84e-30	0.64	0.5	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
KIRC	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-12.94	3.42e-33	9.97e-30	-0.64	-0.5	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
KIRC	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-12.94	3.44e-33	1e-29	-0.63	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-12.94	3.44e-33	1e-29	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	12.94	3.56e-33	1.04e-29	0.66	0.5	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
KIRC	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	12.93	3.67e-33	1.07e-29	0.71	0.5	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
KIRC	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-12.93	3.77e-33	1.1e-29	-0.49	-0.5	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
KIRC	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-12.93	3.79e-33	1.1e-29	-0.62	-0.5	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
KIRC	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	12.93	3.82e-33	1.11e-29	0.61	0.5	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
KIRC	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	12.93	3.93e-33	1.14e-29	0.57	0.5	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
KIRC	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	12.92	3.96e-33	1.15e-29	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-12.92	3.99e-33	1.16e-29	-0.7	-0.5	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
KIRC	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	12.92	4.04e-33	1.17e-29	0.65	0.5	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	12.92	4.04e-33	1.17e-29	0.65	0.5	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	12.92	4.04e-33	1.17e-29	0.65	0.5	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
KIRC	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	12.92	4.05e-33	1.17e-29	0.6	0.5	Myopia;	chr6:28302807	chr6:28176188~28176674:+
KIRC	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-12.92	4.14e-33	1.2e-29	-0.64	-0.5	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
KIRC	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	12.92	4.25e-33	1.23e-29	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	12.92	4.25e-33	1.23e-29	0.61	0.5	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
KIRC	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	12.92	4.31e-33	1.25e-29	0.62	0.5	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
KIRC	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	12.91	4.42e-33	1.28e-29	0.64	0.5	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
KIRC	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-12.91	4.43e-33	1.28e-29	-0.6	-0.5	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-12.91	4.54e-33	1.31e-29	-0.58	-0.5	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
KIRC	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	12.91	4.58e-33	1.32e-29	0.57	0.5	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
KIRC	cis	rs9457247	0.663	rs1894603	ENSG00000265828.1	MIR3939	12.91	4.63e-33	1.34e-29	0.56	0.5	Crohn's disease;	chr6:167021198	chr6:166997807~166997912:-
KIRC	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	12.91	4.73e-33	1.37e-29	0.63	0.5	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	12.91	4.76e-33	1.37e-29	0.68	0.5	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	12.9	4.85e-33	1.4e-29	0.79	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	12.9	4.93e-33	1.42e-29	0.76	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
KIRC	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-12.9	4.99e-33	1.44e-29	-0.63	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
KIRC	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-12.9	5.05e-33	1.46e-29	-0.48	-0.5	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
KIRC	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-12.89	5.44e-33	1.57e-29	-0.59	-0.5	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
KIRC	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-12.89	5.45e-33	1.57e-29	-0.63	-0.5	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
KIRC	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	12.89	5.47e-33	1.57e-29	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
KIRC	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-12.89	5.56e-33	1.6e-29	-0.57	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
KIRC	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	12.89	5.79e-33	1.67e-29	0.61	0.5	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	12.88	5.8e-33	1.67e-29	0.61	0.5	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
KIRC	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-12.88	5.8e-33	1.67e-29	-0.55	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
KIRC	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	12.88	5.96e-33	1.71e-29	0.48	0.5	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
KIRC	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-12.88	5.98e-33	1.72e-29	-0.62	-0.5	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
KIRC	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-12.88	6.26e-33	1.8e-29	-0.57	-0.5	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
KIRC	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-12.88	6.36e-33	1.83e-29	-0.59	-0.5	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
KIRC	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	12.88	6.37e-33	1.83e-29	0.57	0.5	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
KIRC	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	12.88	6.38e-33	1.83e-29	0.61	0.5	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	12.87	6.64e-33	1.91e-29	0.62	0.5	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
KIRC	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-12.87	6.78e-33	1.95e-29	-0.63	-0.5	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-12.87	6.78e-33	1.95e-29	-0.63	-0.5	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-12.87	6.78e-33	1.95e-29	-0.63	-0.5	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
KIRC	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-12.87	6.88e-33	1.97e-29	-0.48	-0.5	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
KIRC	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-12.86	7.17e-33	2.05e-29	-0.57	-0.5	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
KIRC	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	12.86	7.3e-33	2.09e-29	0.6	0.5	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
KIRC	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	12.86	7.35e-33	2.1e-29	0.76	0.5	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	12.86	7.35e-33	2.1e-29	0.76	0.5	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	12.86	7.51e-33	2.15e-29	0.59	0.5	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
KIRC	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-12.86	7.55e-33	2.16e-29	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
KIRC	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	12.86	7.58e-33	2.17e-29	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	12.86	7.58e-33	2.17e-29	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	12.86	7.58e-33	2.17e-29	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
KIRC	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-12.86	7.6e-33	2.17e-29	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
KIRC	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	12.86	7.73e-33	2.21e-29	0.7	0.5	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
KIRC	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-12.85	8.13e-33	2.32e-29	-0.58	-0.5	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
KIRC	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	12.85	8.13e-33	2.32e-29	0.6	0.5	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
KIRC	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	12.85	8.17e-33	2.33e-29	0.63	0.5	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-12.85	8.17e-33	2.33e-29	-0.64	-0.5	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	12.85	8.25e-33	2.36e-29	0.58	0.5	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
KIRC	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	12.85	8.32e-33	2.38e-29	0.61	0.5	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	12.85	8.32e-33	2.38e-29	0.61	0.5	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
KIRC	cis	rs4273100	0.688	rs4143829	ENSG00000262319.1	CTC-457L16.2	12.85	8.39e-33	2.4e-29	0.56	0.5	Schizophrenia;	chr17:19338192	chr17:19141017~19143689:-
KIRC	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-12.84	8.55e-33	2.44e-29	-0.63	-0.5	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
KIRC	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	12.84	8.56e-33	2.44e-29	0.95	0.5	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
KIRC	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	12.84	8.75e-33	2.5e-29	0.6	0.5	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
KIRC	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	12.84	8.8e-33	2.51e-29	0.56	0.5	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
KIRC	cis	rs9457247	0.663	rs12526548	ENSG00000265828.1	MIR3939	-12.84	8.8e-33	2.51e-29	-0.57	-0.5	Crohn's disease;	chr6:167017659	chr6:166997807~166997912:-
KIRC	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-12.84	8.85e-33	2.52e-29	-0.6	-0.5	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
KIRC	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-12.84	9.08e-33	2.59e-29	-0.56	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
KIRC	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-12.84	9.11e-33	2.6e-29	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
KIRC	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	12.84	9.36e-33	2.67e-29	0.61	0.5	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
KIRC	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	12.84	9.4e-33	2.68e-29	0.74	0.5	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
KIRC	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-12.83	9.44e-33	2.69e-29	-0.54	-0.5	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
KIRC	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-12.83	9.93e-33	2.83e-29	-0.63	-0.5	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
KIRC	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-12.83	1.01e-32	2.89e-29	-0.6	-0.5	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
KIRC	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-12.82	1.04e-32	2.96e-29	-0.41	-0.5	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-12.82	1.04e-32	2.96e-29	-0.41	-0.5	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
KIRC	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	12.82	1.04e-32	2.96e-29	0.61	0.5	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	12.82	1.04e-32	2.96e-29	0.61	0.5	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
KIRC	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	12.82	1.06e-32	3.01e-29	0.62	0.5	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
KIRC	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-12.82	1.06e-32	3.01e-29	-0.63	-0.5	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
KIRC	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	12.82	1.06e-32	3.03e-29	0.58	0.5	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
KIRC	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	12.82	1.07e-32	3.05e-29	0.53	0.5	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
KIRC	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-12.82	1.13e-32	3.22e-29	-0.63	-0.5	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
KIRC	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-12.82	1.14e-32	3.24e-29	-0.58	-0.5	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
KIRC	cis	rs4273100	0.607	rs8072587	ENSG00000262319.1	CTC-457L16.2	12.82	1.14e-32	3.24e-29	0.56	0.5	Schizophrenia;	chr17:19307760	chr17:19141017~19143689:-
KIRC	cis	rs4273100	0.646	rs11652784	ENSG00000262319.1	CTC-457L16.2	12.82	1.14e-32	3.24e-29	0.56	0.5	Schizophrenia;	chr17:19313948	chr17:19141017~19143689:-
KIRC	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-12.81	1.17e-32	3.31e-29	-0.57	-0.5	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
KIRC	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-12.81	1.18e-32	3.35e-29	-0.5	-0.5	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
KIRC	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-12.81	1.19e-32	3.37e-29	-0.54	-0.5	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
KIRC	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-12.81	1.2e-32	3.41e-29	-0.67	-0.5	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
KIRC	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	12.81	1.22e-32	3.44e-29	0.59	0.5	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
KIRC	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	12.81	1.26e-32	3.55e-29	0.61	0.5	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
KIRC	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	12.8	1.28e-32	3.61e-29	0.64	0.5	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
KIRC	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	12.8	1.29e-32	3.65e-29	0.57	0.5	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
KIRC	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	12.8	1.33e-32	3.75e-29	0.77	0.5	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
KIRC	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-12.8	1.36e-32	3.85e-29	-0.63	-0.5	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
KIRC	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	12.79	1.4e-32	3.95e-29	0.62	0.5	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	12.79	1.4e-32	3.96e-29	0.6	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
KIRC	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	12.79	1.4e-32	3.96e-29	0.59	0.5	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
KIRC	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	12.79	1.43e-32	4.04e-29	0.61	0.5	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.79	1.45e-32	4.08e-29	0.61	0.5	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
KIRC	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.79	1.45e-32	4.08e-29	0.61	0.5	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
KIRC	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-12.79	1.47e-32	4.14e-29	-0.63	-0.5	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
KIRC	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	12.79	1.48e-32	4.18e-29	0.34	0.5	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
KIRC	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	12.79	1.51e-32	4.25e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	12.79	1.51e-32	4.25e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
KIRC	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	12.79	1.53e-32	4.3e-29	0.63	0.5	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
KIRC	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-12.78	1.56e-32	4.4e-29	-0.5	-0.5	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
KIRC	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	12.78	1.57e-32	4.43e-29	0.63	0.5	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	12.78	1.59e-32	4.47e-29	0.62	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
KIRC	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	12.78	1.61e-32	4.52e-29	0.6	0.5	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
KIRC	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	12.78	1.66e-32	4.66e-29	0.34	0.5	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
KIRC	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-12.78	1.68e-32	4.71e-29	-0.48	-0.5	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
KIRC	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-12.77	1.7e-32	4.78e-29	-0.58	-0.5	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
KIRC	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	12.77	1.74e-32	4.89e-29	0.61	0.5	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
KIRC	cis	rs10759883	0.539	rs609296	ENSG00000175611.10	LINC00476	12.77	1.79e-32	5.01e-29	0.56	0.5	Nicotine dependence;	chr9:95973604	chr9:95759231~95875977:-
KIRC	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-12.77	1.8e-32	5.05e-29	-0.73	-0.5	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
KIRC	cis	rs4273100	0.573	rs4924783	ENSG00000262319.1	CTC-457L16.2	12.77	1.84e-32	5.15e-29	0.55	0.5	Schizophrenia;	chr17:19350668	chr17:19141017~19143689:-
KIRC	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	12.77	1.85e-32	5.19e-29	0.6	0.5	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
KIRC	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	12.76	1.89e-32	5.3e-29	0.73	0.5	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
KIRC	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	12.76	1.89e-32	5.31e-29	0.57	0.5	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
KIRC	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	12.76	1.91e-32	5.34e-29	0.59	0.5	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
KIRC	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-12.76	1.91e-32	5.36e-29	-0.55	-0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
KIRC	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	12.76	1.93e-32	5.41e-29	0.57	0.5	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
KIRC	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-12.76	1.96e-32	5.48e-29	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
KIRC	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-12.76	2e-32	5.61e-29	-0.54	-0.5	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
KIRC	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	12.76	2e-32	5.61e-29	0.58	0.5	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	12.76	2.01e-32	5.62e-29	0.6	0.5	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
KIRC	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	12.76	2.02e-32	5.64e-29	0.93	0.5	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
KIRC	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	12.76	2.02e-32	5.64e-29	0.93	0.5	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
KIRC	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.07e-32	5.8e-29	-0.63	-0.5	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.07e-32	5.8e-29	-0.63	-0.5	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.07e-32	5.8e-29	-0.63	-0.5	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
KIRC	cis	rs4273100	0.646	rs1472932	ENSG00000262319.1	CTC-457L16.2	12.75	2.15e-32	6e-29	0.55	0.5	Schizophrenia;	chr17:19317353	chr17:19141017~19143689:-
KIRC	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-12.75	2.18e-32	6.1e-29	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
KIRC	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	12.75	2.2e-32	6.15e-29	0.6	0.5	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
KIRC	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	12.74	2.27e-32	6.34e-29	0.54	0.5	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
KIRC	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	12.74	2.36e-32	6.57e-29	0.62	0.5	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	12.74	2.36e-32	6.58e-29	0.62	0.5	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
KIRC	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-12.74	2.37e-32	6.61e-29	-0.67	-0.5	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
KIRC	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	12.74	2.38e-32	6.64e-29	0.6	0.5	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
KIRC	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-12.74	2.42e-32	6.75e-29	-0.57	-0.5	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
KIRC	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.78e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	12.74	2.44e-32	6.79e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
KIRC	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-12.74	2.44e-32	6.8e-29	-0.67	-0.5	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
KIRC	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	12.74	2.45e-32	6.81e-29	0.61	0.5	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
KIRC	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	12.74	2.45e-32	6.81e-29	0.61	0.5	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	12.74	2.45e-32	6.83e-29	0.62	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
KIRC	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	12.74	2.46e-32	6.83e-29	0.57	0.5	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	12.73	2.5e-32	6.96e-29	0.57	0.5	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
KIRC	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-12.73	2.57e-32	7.14e-29	-0.57	-0.5	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
KIRC	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	12.73	2.6e-32	7.22e-29	0.6	0.5	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
KIRC	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	12.73	2.6e-32	7.23e-29	0.71	0.5	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
KIRC	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-12.73	2.62e-32	7.28e-29	-0.48	-0.5	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
KIRC	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	12.73	2.63e-32	7.32e-29	0.59	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
KIRC	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-12.72	2.74e-32	7.6e-29	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-12.72	2.74e-32	7.6e-29	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-12.72	2.74e-32	7.6e-29	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
KIRC	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	12.72	2.78e-32	7.73e-29	0.64	0.5	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	12.72	2.79e-32	7.76e-29	0.62	0.5	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-12.72	2.83e-32	7.86e-29	-0.63	-0.5	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-12.72	2.83e-32	7.86e-29	-0.63	-0.5	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-12.72	2.83e-32	7.86e-29	-0.63	-0.5	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
KIRC	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-12.72	2.88e-32	8e-29	-0.48	-0.5	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
KIRC	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-12.72	2.9e-32	8.04e-29	-0.57	-0.5	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
KIRC	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	12.72	2.92e-32	8.1e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
KIRC	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-12.72	2.93e-32	8.12e-29	-0.59	-0.5	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
KIRC	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	12.72	2.93e-32	8.13e-29	0.6	0.5	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
KIRC	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	12.72	2.94e-32	8.15e-29	0.73	0.5	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
KIRC	cis	rs9457247	0.663	rs6456143	ENSG00000265828.1	MIR3939	-12.72	2.96e-32	8.19e-29	-0.57	-0.5	Crohn's disease;	chr6:167001952	chr6:166997807~166997912:-
KIRC	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	12.72	2.99e-32	8.29e-29	0.62	0.5	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-12.72	2.99e-32	8.3e-29	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-12.71	3.03e-32	8.4e-29	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-12.71	3.03e-32	8.4e-29	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-12.71	3.03e-32	8.4e-29	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	12.71	3.09e-32	8.56e-29	0.58	0.5	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
KIRC	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-12.71	3.19e-32	8.81e-29	-0.76	-0.5	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
KIRC	cis	rs944002	1	rs10131298	ENSG00000259444.1	RP11-736N17.8	12.71	3.21e-32	8.87e-29	0.53	0.5	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102277	chr14:103094723~103098885:+
KIRC	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	12.71	3.28e-32	9.07e-29	0.6	0.5	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	12.71	3.28e-32	9.08e-29	0.6	0.5	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-12.71	3.29e-32	9.08e-29	-0.62	-0.5	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-12.71	3.29e-32	9.08e-29	-0.62	-0.5	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
KIRC	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-12.71	3.29e-32	9.1e-29	-0.6	-0.5	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
KIRC	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-12.7	3.34e-32	9.22e-29	-0.48	-0.5	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
KIRC	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	12.7	3.41e-32	9.42e-29	0.56	0.5	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
KIRC	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	12.7	3.41e-32	9.42e-29	0.56	0.5	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
KIRC	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	12.7	3.56e-32	9.81e-29	0.94	0.5	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
KIRC	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-12.7	3.59e-32	9.9e-29	-0.54	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
KIRC	cis	rs9457247	0.765	rs1322077	ENSG00000265828.1	MIR3939	-12.69	3.76e-32	1.04e-28	-0.57	-0.5	Crohn's disease;	chr6:167010805	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.765	rs9457249	ENSG00000265828.1	MIR3939	-12.69	3.76e-32	1.04e-28	-0.57	-0.5	Crohn's disease;	chr6:167012950	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.765	rs9457251	ENSG00000265828.1	MIR3939	-12.69	3.76e-32	1.04e-28	-0.57	-0.5	Crohn's disease;	chr6:167013219	chr6:166997807~166997912:-
KIRC	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	12.69	3.77e-32	1.04e-28	0.63	0.5	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	12.69	3.78e-32	1.04e-28	0.6	0.5	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-12.69	3.8e-32	1.05e-28	-0.41	-0.5	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	12.69	3.81e-32	1.05e-28	0.62	0.5	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	12.69	3.84e-32	1.06e-28	0.61	0.5	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-12.69	3.86e-32	1.06e-28	-0.59	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
KIRC	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-12.69	3.87e-32	1.07e-28	-0.74	-0.5	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
KIRC	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-12.69	3.91e-32	1.08e-28	-0.54	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
KIRC	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-12.69	3.93e-32	1.08e-28	-0.63	-0.5	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
KIRC	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-12.69	3.93e-32	1.08e-28	-0.59	-0.5	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	12.68	4.08e-32	1.12e-28	0.59	0.5	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
KIRC	cis	rs5769707	0.642	rs4824070	ENSG00000235111.1	RP1-29C18.8	-12.68	4.18e-32	1.15e-28	-0.54	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49612657~49615716:-
KIRC	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	12.68	4.18e-32	1.15e-28	0.57	0.5	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
KIRC	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	12.68	4.2e-32	1.15e-28	0.61	0.5	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	12.68	4.2e-32	1.15e-28	0.61	0.5	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
KIRC	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	12.68	4.2e-32	1.15e-28	0.84	0.5	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
KIRC	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-12.68	4.22e-32	1.16e-28	-0.57	-0.5	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
KIRC	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	12.68	4.28e-32	1.17e-28	0.51	0.5	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-12.68	4.28e-32	1.18e-28	-0.41	-0.5	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
KIRC	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-12.68	4.36e-32	1.2e-28	-0.63	-0.5	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-12.68	4.36e-32	1.2e-28	-0.63	-0.5	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
KIRC	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-12.68	4.4e-32	1.21e-28	-0.59	-0.5	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
KIRC	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-12.67	4.6e-32	1.26e-28	-0.63	-0.49	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
KIRC	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-12.67	4.62e-32	1.27e-28	-0.52	-0.49	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
KIRC	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	12.67	4.66e-32	1.28e-28	0.41	0.49	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
KIRC	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-12.67	4.71e-32	1.29e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
KIRC	cis	rs944002	0.951	rs7150997	ENSG00000259444.1	RP11-736N17.8	12.67	4.75e-32	1.3e-28	0.54	0.49	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103105537	chr14:103094723~103098885:+
KIRC	cis	rs2919917	1	rs4739134	ENSG00000254352.1	RP11-578O24.2	12.67	4.75e-32	1.3e-28	0.58	0.49	Lymphocyte counts;	chr8:78643913	chr8:78723796~78724136:-
KIRC	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-12.66	4.89e-32	1.34e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
KIRC	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
KIRC	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-12.66	4.89e-32	1.34e-28	-0.63	-0.49	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
KIRC	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	12.66	4.95e-32	1.35e-28	0.78	0.49	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-12.66	4.95e-32	1.35e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
KIRC	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-12.66	5.07e-32	1.39e-28	-0.64	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
KIRC	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	12.66	5.15e-32	1.41e-28	0.5	0.49	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-12.66	5.18e-32	1.42e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
KIRC	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-12.66	5.18e-32	1.42e-28	-0.58	-0.49	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
KIRC	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-12.66	5.28e-32	1.44e-28	-0.62	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
KIRC	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	12.66	5.31e-32	1.45e-28	0.64	0.49	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	12.66	5.31e-32	1.45e-28	0.64	0.49	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
KIRC	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	12.65	5.36e-32	1.46e-28	0.61	0.49	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
KIRC	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-12.65	5.42e-32	1.48e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
KIRC	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	12.65	5.45e-32	1.49e-28	0.61	0.49	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-12.65	5.48e-32	1.5e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
KIRC	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-12.65	5.48e-32	1.5e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
KIRC	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	12.65	5.63e-32	1.54e-28	0.34	0.49	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
KIRC	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-12.65	5.84e-32	1.59e-28	-0.63	-0.49	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
KIRC	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	12.65	5.85e-32	1.6e-28	0.6	0.49	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	12.64	5.93e-32	1.61e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
KIRC	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-12.64	6e-32	1.63e-28	-0.55	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
KIRC	cis	rs4273100	0.688	rs4924980	ENSG00000262319.1	CTC-457L16.2	12.64	6e-32	1.63e-28	0.55	0.49	Schizophrenia;	chr17:19301550	chr17:19141017~19143689:-
KIRC	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-12.64	6.09e-32	1.66e-28	-0.58	-0.49	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
KIRC	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	12.64	6.11e-32	1.66e-28	0.58	0.49	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
KIRC	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.25e-32	1.7e-28	-0.63	-0.49	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.25e-32	1.7e-28	-0.62	-0.49	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.25e-32	1.7e-28	-0.62	-0.49	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.25e-32	1.7e-28	-0.62	-0.49	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.25e-32	1.7e-28	-0.62	-0.49	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-12.64	6.4e-32	1.74e-28	-0.62	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
KIRC	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-12.64	6.47e-32	1.76e-28	-0.74	-0.49	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
KIRC	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-12.64	6.47e-32	1.76e-28	-0.74	-0.49	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
KIRC	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-12.63	6.49e-32	1.76e-28	-0.62	-0.49	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-12.63	6.49e-32	1.76e-28	-0.62	-0.49	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-12.63	6.49e-32	1.76e-28	-0.62	-0.49	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-12.63	6.49e-32	1.76e-28	-0.62	-0.49	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-12.63	6.49e-32	1.76e-28	-0.62	-0.49	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
KIRC	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	12.63	6.53e-32	1.77e-28	0.63	0.49	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	12.63	6.61e-32	1.79e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	12.63	6.61e-32	1.79e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
KIRC	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	12.63	6.65e-32	1.8e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
KIRC	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	12.63	6.66e-32	1.81e-28	0.63	0.49	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
KIRC	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-12.63	6.7e-32	1.82e-28	-0.66	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
KIRC	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	12.63	6.85e-32	1.86e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	12.63	6.85e-32	1.86e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
KIRC	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	12.63	6.87e-32	1.86e-28	0.74	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
KIRC	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	12.63	6.94e-32	1.88e-28	0.56	0.49	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
KIRC	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	12.63	7e-32	1.89e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	12.63	7e-32	1.89e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
KIRC	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-12.63	7.13e-32	1.93e-28	-0.63	-0.49	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-12.63	7.13e-32	1.93e-28	-0.63	-0.49	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-12.63	7.13e-32	1.93e-28	-0.63	-0.49	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	12.62	7.4e-32	2e-28	0.61	0.49	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
KIRC	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	12.62	7.52e-32	2.03e-28	0.8	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
KIRC	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-12.62	7.63e-32	2.06e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
KIRC	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	12.62	7.7e-32	2.08e-28	0.63	0.49	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-12.62	7.7e-32	2.08e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
KIRC	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-12.62	7.78e-32	2.1e-28	-0.62	-0.49	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-12.62	7.82e-32	2.11e-28	-0.63	-0.49	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-12.62	7.82e-32	2.11e-28	-0.63	-0.49	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
KIRC	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	12.61	7.95e-32	2.15e-28	0.63	0.49	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
KIRC	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-12.61	8.03e-32	2.17e-28	-0.61	-0.49	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
KIRC	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	12.61	8.04e-32	2.17e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	12.61	8.04e-32	2.17e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
KIRC	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	12.61	8.11e-32	2.19e-28	0.63	0.49	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
KIRC	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-12.61	8.27e-32	2.23e-28	-0.6	-0.49	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
KIRC	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-12.61	8.3e-32	2.24e-28	-0.47	-0.49	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
KIRC	cis	rs4273100	0.607	rs1043809	ENSG00000262319.1	CTC-457L16.2	12.61	8.42e-32	2.27e-28	0.55	0.49	Schizophrenia;	chr17:19336119	chr17:19141017~19143689:-
KIRC	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-12.61	8.55e-32	2.3e-28	-0.62	-0.49	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-12.61	8.55e-32	2.3e-28	-0.62	-0.49	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-12.61	8.55e-32	2.3e-28	-0.62	-0.49	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-12.61	8.55e-32	2.3e-28	-0.62	-0.49	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-12.61	8.59e-32	2.31e-28	-0.62	-0.49	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	12.61	8.61e-32	2.32e-28	0.63	0.49	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
KIRC	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	12.6	8.68e-32	2.34e-28	0.63	0.49	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	12.6	8.69e-32	2.34e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-12.6	8.71e-32	2.34e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
KIRC	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-12.6	8.85e-32	2.38e-28	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
KIRC	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	12.6	8.86e-32	2.38e-28	0.61	0.49	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
KIRC	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-12.6	8.9e-32	2.39e-28	-0.61	-0.49	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
KIRC	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-12.6	8.91e-32	2.39e-28	-0.63	-0.49	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
KIRC	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-12.6	9.18e-32	2.46e-28	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
KIRC	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-12.6	9.28e-32	2.49e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-12.6	9.28e-32	2.49e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
KIRC	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-12.6	9.49e-32	2.55e-28	-0.58	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
KIRC	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	12.59	9.68e-32	2.59e-28	0.79	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	12.59	9.68e-32	2.59e-28	0.79	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	12.59	9.68e-32	2.59e-28	0.79	0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
KIRC	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-12.59	9.71e-32	2.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
KIRC	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-12.59	9.85e-32	2.64e-28	-0.48	-0.49	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-12.59	1.01e-31	2.71e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
KIRC	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-12.59	1.03e-31	2.75e-28	-0.74	-0.49	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
KIRC	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-12.59	1.03e-31	2.76e-28	-0.59	-0.49	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
KIRC	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-12.59	1.04e-31	2.77e-28	-0.59	-0.49	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	12.59	1.04e-31	2.78e-28	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
KIRC	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-12.59	1.04e-31	2.79e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
KIRC	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	12.58	1.05e-31	2.81e-28	0.62	0.49	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
KIRC	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-12.58	1.07e-31	2.85e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-12.58	1.12e-31	2.98e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
KIRC	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	12.58	1.12e-31	2.99e-28	0.86	0.49	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
KIRC	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	12.58	1.12e-31	2.99e-28	0.51	0.49	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
KIRC	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	12.58	1.13e-31	3.01e-28	0.87	0.49	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
KIRC	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-12.58	1.13e-31	3.02e-28	-0.63	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
KIRC	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	12.58	1.13e-31	3.02e-28	0.86	0.49	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
KIRC	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-12.58	1.15e-31	3.05e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
KIRC	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-12.57	1.18e-31	3.13e-28	-0.63	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
KIRC	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	12.57	1.19e-31	3.15e-28	0.63	0.49	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	12.57	1.19e-31	3.17e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
KIRC	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	12.57	1.22e-31	3.23e-28	0.6	0.49	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
KIRC	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	12.57	1.26e-31	3.33e-28	0.91	0.49	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
KIRC	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-12.57	1.26e-31	3.35e-28	-0.57	-0.49	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
KIRC	cis	rs9457247	0.663	rs2282861	ENSG00000265828.1	MIR3939	-12.57	1.27e-31	3.36e-28	-0.56	-0.49	Crohn's disease;	chr6:167026640	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.663	rs2282860	ENSG00000265828.1	MIR3939	-12.57	1.27e-31	3.36e-28	-0.56	-0.49	Crohn's disease;	chr6:167026756	chr6:166997807~166997912:-
KIRC	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-12.57	1.27e-31	3.37e-28	-0.59	-0.49	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	12.56	1.28e-31	3.38e-28	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
KIRC	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-12.56	1.29e-31	3.43e-28	-0.75	-0.49	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
KIRC	cis	rs9457247	0.579	rs2181059	ENSG00000265828.1	MIR3939	-12.56	1.3e-31	3.45e-28	-0.56	-0.49	Crohn's disease;	chr6:167028136	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.663	rs2237277	ENSG00000265828.1	MIR3939	-12.56	1.3e-31	3.45e-28	-0.56	-0.49	Crohn's disease;	chr6:167028619	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.663	rs9457258	ENSG00000265828.1	MIR3939	-12.56	1.3e-31	3.45e-28	-0.56	-0.49	Crohn's disease;	chr6:167030766	chr6:166997807~166997912:-
KIRC	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-12.56	1.31e-31	3.46e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
KIRC	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	12.56	1.32e-31	3.51e-28	0.61	0.49	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
KIRC	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	12.56	1.38e-31	3.65e-28	0.58	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
KIRC	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-12.56	1.38e-31	3.66e-28	-0.81	-0.49	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
KIRC	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	12.55	1.4e-31	3.72e-28	0.59	0.49	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
KIRC	cis	rs4273100	0.688	rs28582509	ENSG00000262319.1	CTC-457L16.2	-12.55	1.41e-31	3.72e-28	-0.56	-0.49	Schizophrenia;	chr17:19261866	chr17:19141017~19143689:-
KIRC	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-12.55	1.44e-31	3.81e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-12.55	1.44e-31	3.81e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
KIRC	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-12.55	1.44e-31	3.81e-28	-0.63	-0.49	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
KIRC	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-12.55	1.45e-31	3.82e-28	-0.41	-0.49	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	12.55	1.46e-31	3.85e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-12.55	1.46e-31	3.85e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-12.55	1.47e-31	3.88e-28	-0.6	-0.49	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
KIRC	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	12.55	1.48e-31	3.92e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
KIRC	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	12.55	1.49e-31	3.94e-28	0.85	0.49	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
KIRC	cis	rs4273100	0.646	rs4924987	ENSG00000262319.1	CTC-457L16.2	12.55	1.52e-31	4e-28	0.55	0.49	Schizophrenia;	chr17:19343762	chr17:19141017~19143689:-
KIRC	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	12.54	1.55e-31	4.1e-28	0.59	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
KIRC	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	12.54	1.56e-31	4.11e-28	0.59	0.49	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
KIRC	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	12.54	1.57e-31	4.15e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	12.54	1.57e-31	4.15e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	12.54	1.57e-31	4.15e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	12.54	1.58e-31	4.17e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	12.54	1.58e-31	4.17e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	12.54	1.58e-31	4.17e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
KIRC	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	12.54	1.59e-31	4.2e-28	0.59	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
KIRC	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-12.54	1.6e-31	4.23e-28	-0.47	-0.49	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
KIRC	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-12.54	1.62e-31	4.27e-28	-0.62	-0.49	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
KIRC	cis	rs4273100	0.688	rs4924967	ENSG00000262319.1	CTC-457L16.2	-12.54	1.64e-31	4.33e-28	-0.56	-0.49	Schizophrenia;	chr17:19268883	chr17:19141017~19143689:-
KIRC	cis	rs4273100	0.688	rs28760541	ENSG00000262319.1	CTC-457L16.2	-12.54	1.64e-31	4.33e-28	-0.56	-0.49	Schizophrenia;	chr17:19269192	chr17:19141017~19143689:-
KIRC	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	12.54	1.65e-31	4.36e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
KIRC	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	12.54	1.67e-31	4.39e-28	0.5	0.49	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	12.54	1.67e-31	4.39e-28	0.5	0.49	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	12.54	1.67e-31	4.39e-28	0.5	0.49	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-12.53	1.7e-31	4.48e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
KIRC	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-12.53	1.74e-31	4.58e-28	-0.59	-0.49	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
KIRC	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-12.53	1.75e-31	4.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-12.53	1.75e-31	4.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-12.53	1.75e-31	4.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-12.53	1.75e-31	4.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-12.53	1.75e-31	4.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
KIRC	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	12.53	1.78e-31	4.69e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	12.53	1.78e-31	4.69e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	12.53	1.78e-31	4.69e-28	0.58	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
KIRC	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	12.53	1.8e-31	4.72e-28	0.6	0.49	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
KIRC	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-12.53	1.8e-31	4.74e-28	-0.6	-0.49	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
KIRC	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	12.53	1.81e-31	4.76e-28	0.66	0.49	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
KIRC	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-12.53	1.83e-31	4.8e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-12.53	1.83e-31	4.8e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	12.53	1.84e-31	4.83e-28	0.57	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
KIRC	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-12.53	1.86e-31	4.88e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-12.53	1.86e-31	4.88e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
KIRC	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-12.52	1.87e-31	4.9e-28	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
KIRC	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-12.52	1.88e-31	4.92e-28	-0.57	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
KIRC	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-12.52	1.89e-31	4.97e-28	-0.6	-0.49	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
KIRC	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-12.52	1.91e-31	5.01e-28	-0.4	-0.49	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
KIRC	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-12.52	1.92e-31	5.03e-28	-0.56	-0.49	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
KIRC	cis	rs9457247	0.663	rs10946205	ENSG00000265828.1	MIR3939	-12.52	1.93e-31	5.06e-28	-0.56	-0.49	Crohn's disease;	chr6:167037823	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	12.52	2.03e-31	5.32e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
KIRC	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	12.52	2.04e-31	5.35e-28	0.63	0.49	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	12.52	2.04e-31	5.35e-28	0.63	0.49	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-12.51	2.06e-31	5.39e-28	-0.62	-0.49	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	12.51	2.07e-31	5.43e-28	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
KIRC	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-12.51	2.08e-31	5.43e-28	-0.6	-0.49	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
KIRC	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	12.51	2.08e-31	5.45e-28	0.4	0.49	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
KIRC	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	12.51	2.09e-31	5.46e-28	0.56	0.49	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	12.51	2.11e-31	5.51e-28	0.56	0.49	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	12.51	2.11e-31	5.51e-28	0.56	0.49	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
KIRC	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-12.51	2.16e-31	5.65e-28	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
KIRC	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.51	2.17e-31	5.67e-28	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
KIRC	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-12.51	2.19e-31	5.73e-28	-0.73	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
KIRC	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-12.5	2.27e-31	5.92e-28	-0.56	-0.49	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
KIRC	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	12.5	2.27e-31	5.93e-28	0.6	0.49	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	12.5	2.3e-31	6e-28	0.59	0.49	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	12.5	2.36e-31	6.14e-28	0.64	0.49	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
KIRC	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-12.5	2.4e-31	6.26e-28	-0.39	-0.49	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
KIRC	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-12.5	2.41e-31	6.27e-28	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
KIRC	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	12.5	2.42e-31	6.32e-28	0.38	0.49	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
KIRC	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-12.5	2.43e-31	6.34e-28	-0.61	-0.49	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
KIRC	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	12.5	2.44e-31	6.36e-28	0.57	0.49	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
KIRC	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	12.49	2.48e-31	6.47e-28	0.56	0.49	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
KIRC	cis	rs9457247	0.663	rs9459845	ENSG00000265828.1	MIR3939	-12.49	2.5e-31	6.5e-28	-0.55	-0.49	Crohn's disease;	chr6:167027013	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.663	rs9457257	ENSG00000265828.1	MIR3939	-12.49	2.5e-31	6.5e-28	-0.55	-0.49	Crohn's disease;	chr6:167027248	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.637	rs9459846	ENSG00000265828.1	MIR3939	-12.49	2.5e-31	6.5e-28	-0.55	-0.49	Crohn's disease;	chr6:167027535	chr6:166997807~166997912:-
KIRC	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-12.49	2.5e-31	6.51e-28	-0.62	-0.49	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-12.49	2.5e-31	6.51e-28	-0.62	-0.49	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
KIRC	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	12.49	2.51e-31	6.54e-28	0.61	0.49	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-12.49	2.54e-31	6.6e-28	-0.62	-0.49	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-12.49	2.54e-31	6.62e-28	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
KIRC	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-12.49	2.57e-31	6.68e-28	-0.52	-0.49	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
KIRC	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-12.49	2.62e-31	6.8e-28	-0.47	-0.49	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
KIRC	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	12.49	2.62e-31	6.81e-28	0.62	0.49	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
KIRC	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	12.49	2.67e-31	6.94e-28	0.6	0.49	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
KIRC	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-12.49	2.68e-31	6.96e-28	-0.48	-0.49	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
KIRC	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	12.49	2.69e-31	6.98e-28	0.57	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
KIRC	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-12.49	2.69e-31	6.98e-28	-0.48	-0.49	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
KIRC	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	12.49	2.72e-31	7.07e-28	0.87	0.49	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
KIRC	cis	rs9457247	0.663	rs9295384	ENSG00000265828.1	MIR3939	-12.48	2.75e-31	7.13e-28	-0.55	-0.49	Crohn's disease;	chr6:167034625	chr6:166997807~166997912:-
KIRC	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-12.48	2.79e-31	7.25e-28	-0.58	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
KIRC	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	12.48	2.8e-31	7.26e-28	0.57	0.49	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
KIRC	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	12.48	2.8e-31	7.26e-28	0.58	0.49	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
KIRC	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-12.48	2.85e-31	7.39e-28	-0.62	-0.49	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
KIRC	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-12.48	2.86e-31	7.41e-28	-0.58	-0.49	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	12.48	2.94e-31	7.6e-28	0.59	0.49	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
KIRC	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-12.48	2.96e-31	7.65e-28	-0.52	-0.49	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
KIRC	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-12.47	3.03e-31	7.83e-28	-0.62	-0.49	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
KIRC	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	12.47	3.07e-31	7.94e-28	0.5	0.49	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
KIRC	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-12.47	3.27e-31	8.43e-28	-0.42	-0.49	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
KIRC	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-12.46	3.34e-31	8.61e-28	-0.39	-0.49	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
KIRC	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-12.46	3.37e-31	8.69e-28	-0.61	-0.49	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
KIRC	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-12.46	3.41e-31	8.79e-28	-0.62	-0.49	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-12.46	3.41e-31	8.79e-28	-0.62	-0.49	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
KIRC	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-12.46	3.43e-31	8.84e-28	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
KIRC	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-12.46	3.44e-31	8.85e-28	-0.61	-0.49	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
KIRC	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-12.46	3.44e-31	8.85e-28	-0.62	-0.49	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
KIRC	cis	rs944002	0.857	rs77071436	ENSG00000259444.1	RP11-736N17.8	12.46	3.51e-31	9.03e-28	0.53	0.49	Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels;	chr14:103102644	chr14:103094723~103098885:+
KIRC	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	12.46	3.52e-31	9.06e-28	0.57	0.49	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
KIRC	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-12.45	3.67e-31	9.43e-28	-0.63	-0.49	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
KIRC	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-12.45	3.67e-31	9.43e-28	-0.61	-0.49	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-12.45	3.67e-31	9.43e-28	-0.61	-0.49	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
KIRC	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-12.45	3.79e-31	9.72e-28	-0.62	-0.49	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-12.45	3.79e-31	9.72e-28	-0.62	-0.49	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
KIRC	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	12.45	3.8e-31	9.75e-28	0.61	0.49	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
KIRC	cis	rs4273100	0.688	rs12939947	ENSG00000262319.1	CTC-457L16.2	-12.45	3.84e-31	9.86e-28	-0.55	-0.49	Schizophrenia;	chr17:19301218	chr17:19141017~19143689:-
KIRC	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	12.45	3.96e-31	1.02e-27	0.5	0.49	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	12.45	3.96e-31	1.02e-27	0.5	0.49	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
KIRC	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-12.44	4.01e-31	1.03e-27	-0.52	-0.49	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
KIRC	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-12.44	4.1e-31	1.05e-27	-0.56	-0.49	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
KIRC	cis	rs9457247	0.663	rs7749278	ENSG00000265828.1	MIR3939	12.44	4.16e-31	1.07e-27	0.56	0.49	Crohn's disease;	chr6:167021837	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	12.44	4.2e-31	1.08e-27	0.59	0.49	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
KIRC	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-12.44	4.26e-31	1.09e-27	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
KIRC	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-12.44	4.27e-31	1.09e-27	-0.62	-0.49	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
KIRC	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-12.44	4.31e-31	1.1e-27	-0.6	-0.49	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
KIRC	cis	rs9457247	0.663	rs2237274	ENSG00000265828.1	MIR3939	-12.44	4.32e-31	1.11e-27	-0.55	-0.49	Crohn's disease;	chr6:167029507	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.663	rs2301436	ENSG00000265828.1	MIR3939	-12.44	4.33e-31	1.11e-27	-0.56	-0.49	Crohn's disease;	chr6:167024500	chr6:166997807~166997912:-
KIRC	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-12.44	4.34e-31	1.11e-27	-0.4	-0.49	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
KIRC	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-12.44	4.39e-31	1.12e-27	-0.58	-0.49	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-12.43	4.44e-31	1.14e-27	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
KIRC	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-12.43	4.5e-31	1.15e-27	-0.52	-0.49	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
KIRC	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-12.43	4.55e-31	1.16e-27	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
KIRC	cis	rs9457247	0.765	rs9457252	ENSG00000265828.1	MIR3939	12.43	4.56e-31	1.17e-27	0.55	0.49	Crohn's disease;	chr6:167020437	chr6:166997807~166997912:-
KIRC	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-12.43	4.79e-31	1.22e-27	-0.5	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
KIRC	cis	rs9457247	0.765	rs6900701	ENSG00000265828.1	MIR3939	-12.42	4.84e-31	1.24e-27	-0.55	-0.49	Crohn's disease;	chr6:167020624	chr6:166997807~166997912:-
KIRC	cis	rs4273100	0.688	rs1533034	ENSG00000262319.1	CTC-457L16.2	-12.42	4.93e-31	1.26e-27	-0.56	-0.49	Schizophrenia;	chr17:19249862	chr17:19141017~19143689:-
KIRC	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	12.42	5.02e-31	1.28e-27	0.33	0.49	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
KIRC	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-12.42	5.06e-31	1.29e-27	-0.75	-0.49	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
KIRC	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-12.42	5.08e-31	1.3e-27	-0.53	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
KIRC	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	12.42	5.13e-31	1.31e-27	0.6	0.49	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-12.42	5.2e-31	1.33e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
KIRC	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-12.42	5.21e-31	1.33e-27	-0.56	-0.49	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
KIRC	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-12.42	5.32e-31	1.36e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
KIRC	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-12.41	5.34e-31	1.36e-27	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
KIRC	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
KIRC	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.4e-31	1.37e-27	-0.62	-0.49	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
KIRC	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-12.41	5.49e-31	1.4e-27	-0.53	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
KIRC	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-12.41	5.52e-31	1.41e-27	-0.62	-0.49	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
KIRC	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-12.41	5.55e-31	1.41e-27	-0.53	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
KIRC	cis	rs9457247	0.612	rs2237273	ENSG00000265828.1	MIR3939	-12.41	5.61e-31	1.43e-27	-0.55	-0.49	Crohn's disease;	chr6:167029529	chr6:166997807~166997912:-
KIRC	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-12.41	5.63e-31	1.43e-27	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
KIRC	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-12.41	5.74e-31	1.46e-27	-0.49	-0.49	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
KIRC	cis	rs4273100	0.605	rs28591622	ENSG00000262319.1	CTC-457L16.2	-12.4	5.89e-31	1.5e-27	-0.55	-0.49	Schizophrenia;	chr17:19272004	chr17:19141017~19143689:-
KIRC	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-12.4	5.96e-31	1.52e-27	-0.57	-0.49	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
KIRC	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-12.4	6e-31	1.52e-27	-0.61	-0.49	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
KIRC	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	12.4	6.07e-31	1.54e-27	0.59	0.49	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-12.4	6.31e-31	1.6e-27	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	12.39	6.46e-31	1.64e-27	0.59	0.49	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-12.39	6.62e-31	1.68e-27	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
KIRC	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	12.39	6.74e-31	1.71e-27	1.02	0.49	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	12.39	6.74e-31	1.71e-27	1.02	0.49	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
KIRC	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-12.39	6.75e-31	1.71e-27	-0.53	-0.49	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
KIRC	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	12.39	6.8e-31	1.72e-27	0.62	0.49	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
KIRC	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	12.39	6.92e-31	1.75e-27	0.61	0.49	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	12.39	6.92e-31	1.75e-27	0.61	0.49	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-12.39	7.08e-31	1.79e-27	-0.61	-0.49	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-12.38	7.12e-31	1.8e-27	-0.6	-0.49	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
KIRC	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-12.38	7.58e-31	1.91e-27	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-12.38	7.58e-31	1.91e-27	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
KIRC	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-12.38	7.75e-31	1.95e-27	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
KIRC	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	12.37	7.79e-31	1.96e-27	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	12.37	7.79e-31	1.96e-27	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	12.37	7.79e-31	1.96e-27	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	12.37	7.79e-31	1.96e-27	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	12.37	7.91e-31	1.99e-27	0.6	0.49	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-12.37	7.91e-31	1.99e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-12.37	7.91e-31	1.99e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-12.37	7.91e-31	1.99e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-12.37	7.91e-31	1.99e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-12.37	7.91e-31	1.99e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
KIRC	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-12.37	7.95e-31	2e-27	-0.47	-0.49	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
KIRC	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-12.37	8.12e-31	2.04e-27	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
KIRC	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-12.37	8.17e-31	2.05e-27	-0.62	-0.49	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
KIRC	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	12.37	8.21e-31	2.06e-27	0.62	0.49	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
KIRC	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-12.37	8.24e-31	2.07e-27	-0.6	-0.49	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
KIRC	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-12.37	8.35e-31	2.1e-27	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
KIRC	cis	rs9457247	0.73	rs9459841	ENSG00000265828.1	MIR3939	-12.37	8.46e-31	2.12e-27	-0.55	-0.49	Crohn's disease;	chr6:167018461	chr6:166997807~166997912:-
KIRC	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-12.37	8.53e-31	2.14e-27	-0.47	-0.49	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
KIRC	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-12.37	8.54e-31	2.14e-27	-0.52	-0.49	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
KIRC	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-12.36	8.71e-31	2.18e-27	-0.58	-0.49	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
KIRC	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	12.36	8.71e-31	2.18e-27	0.56	0.49	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-12.36	8.97e-31	2.25e-27	-0.6	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
KIRC	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-12.36	9.11e-31	2.28e-27	-0.62	-0.49	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
KIRC	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-12.36	9.11e-31	2.28e-27	-0.56	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
KIRC	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-12.36	9.13e-31	2.29e-27	-0.64	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
KIRC	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-12.36	9.14e-31	2.29e-27	-0.53	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
KIRC	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-12.36	9.16e-31	2.29e-27	-0.64	-0.49	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
KIRC	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	12.36	9.2e-31	2.31e-27	0.59	0.49	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-12.36	9.33e-31	2.33e-27	-0.62	-0.49	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.681	rs6009803	ENSG00000235111.1	RP1-29C18.8	-12.36	9.41e-31	2.35e-27	-0.53	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-12.35	9.43e-31	2.36e-27	-0.52	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
KIRC	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-12.35	9.52e-31	2.38e-27	-0.8	-0.49	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
KIRC	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	12.35	9.63e-31	2.41e-27	0.6	0.49	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
KIRC	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-12.35	9.65e-31	2.41e-27	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
KIRC	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-12.35	9.74e-31	2.44e-27	-0.59	-0.49	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	12.35	9.76e-31	2.44e-27	0.61	0.49	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
KIRC	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	12.35	9.99e-31	2.5e-27	0.54	0.49	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
KIRC	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-12.35	1.01e-30	2.52e-27	-0.59	-0.49	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
KIRC	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-12.35	1.02e-30	2.55e-27	-0.65	-0.49	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
KIRC	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-12.34	1.05e-30	2.62e-27	-0.4	-0.49	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
KIRC	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-12.34	1.07e-30	2.68e-27	-0.49	-0.49	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
KIRC	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-12.34	1.08e-30	2.69e-27	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
KIRC	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-12.34	1.08e-30	2.69e-27	-0.62	-0.49	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
KIRC	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-12.34	1.1e-30	2.73e-27	-0.56	-0.49	Temperament;	chr17:14075460	chr17:14024514~14025488:+
KIRC	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	12.34	1.1e-30	2.73e-27	0.61	0.49	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
KIRC	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-12.34	1.11e-30	2.78e-27	-0.64	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
KIRC	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	12.34	1.12e-30	2.8e-27	0.55	0.48	Temperament;	chr17:14068990	chr17:14024514~14025488:+
KIRC	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-12.33	1.14e-30	2.84e-27	-0.64	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
KIRC	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-12.33	1.15e-30	2.86e-27	-0.56	-0.48	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
KIRC	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-12.33	1.15e-30	2.87e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-12.33	1.15e-30	2.87e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
KIRC	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-12.33	1.16e-30	2.88e-27	-0.58	-0.48	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
KIRC	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-12.33	1.16e-30	2.89e-27	-0.73	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
KIRC	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-12.33	1.17e-30	2.91e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	12.33	1.17e-30	2.92e-27	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
KIRC	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-12.33	1.18e-30	2.93e-27	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
KIRC	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-12.33	1.19e-30	2.97e-27	-0.6	-0.48	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
KIRC	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-12.33	1.19e-30	2.97e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-12.33	1.19e-30	2.97e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
KIRC	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-12.33	1.2e-30	2.99e-27	-0.42	-0.48	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
KIRC	cis	rs904251	0.704	rs2776873	ENSG00000204110.6	RP1-153P14.8	-12.33	1.23e-30	3.06e-27	-0.7	-0.48	Cognitive performance;	chr6:37515366	chr6:37507348~37535616:+
KIRC	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-12.32	1.25e-30	3.11e-27	-0.69	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
KIRC	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	12.32	1.26e-30	3.12e-27	0.59	0.48	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
KIRC	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	12.32	1.28e-30	3.18e-27	0.59	0.48	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
KIRC	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	12.32	1.28e-30	3.19e-27	0.5	0.48	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
KIRC	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-12.32	1.32e-30	3.27e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-12.32	1.32e-30	3.27e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
KIRC	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-12.31	1.39e-30	3.44e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
KIRC	cis	rs4273100	0.688	rs1467028	ENSG00000262319.1	CTC-457L16.2	-12.31	1.4e-30	3.46e-27	-0.55	-0.48	Schizophrenia;	chr17:19271561	chr17:19141017~19143689:-
KIRC	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-12.31	1.41e-30	3.5e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
KIRC	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-12.31	1.42e-30	3.52e-27	-0.51	-0.48	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
KIRC	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-12.31	1.43e-30	3.55e-27	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
KIRC	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-12.31	1.43e-30	3.55e-27	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
KIRC	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-12.31	1.43e-30	3.55e-27	-0.56	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
KIRC	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-12.31	1.48e-30	3.66e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
KIRC	cis	rs732716	0.752	rs11085072	ENSG00000267769.1	CTB-50L17.9	-12.31	1.48e-30	3.67e-27	-0.53	-0.48	Mean corpuscular volume;	chr19:4368145	chr19:4454014~4455286:+
KIRC	cis	rs10256972	0.616	rs3802141	ENSG00000229043.2	AC091729.9	-12.31	1.48e-30	3.67e-27	-0.54	-0.48	Endometriosis;Longevity;	chr7:1091720	chr7:1160374~1165267:+
KIRC	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	12.31	1.51e-30	3.74e-27	0.59	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
KIRC	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-12.3	1.53e-30	3.78e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-12.3	1.53e-30	3.78e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-12.3	1.53e-30	3.78e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-12.3	1.53e-30	3.78e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
KIRC	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	12.3	1.53e-30	3.78e-27	0.55	0.48	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
KIRC	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-12.3	1.53e-30	3.79e-27	-0.64	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
KIRC	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	12.3	1.56e-30	3.86e-27	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
KIRC	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-12.3	1.59e-30	3.93e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-12.3	1.6e-30	3.95e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-12.3	1.6e-30	3.95e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	12.3	1.61e-30	3.97e-27	0.58	0.48	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	12.3	1.65e-30	4.09e-27	0.6	0.48	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
KIRC	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-12.3	1.66e-30	4.11e-27	-0.73	-0.48	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
KIRC	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-12.3	1.66e-30	4.11e-27	-0.53	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
KIRC	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	12.29	1.7e-30	4.19e-27	0.59	0.48	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
KIRC	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-12.29	1.76e-30	4.35e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-12.29	1.81e-30	4.47e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
KIRC	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-12.29	1.83e-30	4.51e-27	-0.47	-0.48	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
KIRC	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-12.28	1.87e-30	4.6e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
KIRC	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-12.28	1.91e-30	4.7e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-12.28	1.93e-30	4.74e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
KIRC	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	12.28	1.96e-30	4.82e-27	0.71	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
KIRC	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-12.27	2.04e-30	5e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
KIRC	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-12.27	2.04e-30	5e-27	-0.73	-0.48	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
KIRC	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	12.27	2.04e-30	5.01e-27	0.62	0.48	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
KIRC	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-12.27	2.06e-30	5.05e-27	-0.52	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
KIRC	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	12.27	2.09e-30	5.13e-27	0.58	0.48	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
KIRC	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-12.27	2.13e-30	5.23e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-12.27	2.13e-30	5.23e-27	-0.49	-0.48	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
KIRC	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-12.27	2.14e-30	5.25e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
KIRC	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	12.27	2.19e-30	5.37e-27	0.56	0.48	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
KIRC	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	12.27	2.19e-30	5.37e-27	0.64	0.48	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
KIRC	cis	rs9457247	0.555	rs2247325	ENSG00000265828.1	MIR3939	12.26	2.21e-30	5.42e-27	0.56	0.48	Crohn's disease;	chr6:166956504	chr6:166997807~166997912:-
KIRC	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	12.26	2.23e-30	5.46e-27	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
KIRC	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-12.26	2.24e-30	5.49e-27	-0.52	-0.48	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
KIRC	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-12.26	2.25e-30	5.5e-27	-0.52	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
KIRC	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-12.26	2.34e-30	5.72e-27	-0.59	-0.48	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	12.26	2.34e-30	5.74e-27	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
KIRC	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	12.26	2.34e-30	5.74e-27	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
KIRC	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	12.26	2.37e-30	5.81e-27	0.41	0.48	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
KIRC	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-12.26	2.41e-30	5.89e-27	-0.78	-0.48	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
KIRC	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-12.26	2.43e-30	5.93e-27	-0.6	-0.48	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-12.26	2.43e-30	5.93e-27	-0.6	-0.48	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
KIRC	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-12.25	2.45e-30	5.99e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-12.25	2.45e-30	5.99e-27	-0.59	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
KIRC	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	12.25	2.45e-30	6e-27	0.62	0.48	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
KIRC	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	12.25	2.47e-30	6.04e-27	0.98	0.48	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
KIRC	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	12.25	2.5e-30	6.11e-27	0.58	0.48	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	12.25	2.5e-30	6.11e-27	0.58	0.48	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-12.25	2.52e-30	6.15e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
KIRC	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-12.25	2.52e-30	6.16e-27	-0.53	-0.48	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
KIRC	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-12.25	2.55e-30	6.23e-27	-0.54	-0.48	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
KIRC	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	12.25	2.56e-30	6.26e-27	0.61	0.48	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-12.25	2.61e-30	6.38e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-12.25	2.61e-30	6.38e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-12.25	2.65e-30	6.47e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-12.25	2.65e-30	6.47e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-12.25	2.65e-30	6.47e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-12.25	2.66e-30	6.49e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	12.25	2.67e-30	6.5e-27	0.56	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
KIRC	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-12.24	2.73e-30	6.65e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
KIRC	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-12.24	2.73e-30	6.65e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
KIRC	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-12.24	2.73e-30	6.65e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
KIRC	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-12.24	2.73e-30	6.65e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
KIRC	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-12.24	2.73e-30	6.65e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
KIRC	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-12.24	2.87e-30	6.98e-27	-0.6	-0.48	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
KIRC	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	12.24	2.9e-30	7.06e-27	0.66	0.48	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
KIRC	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	12.24	2.91e-30	7.06e-27	0.59	0.48	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	12.24	2.91e-30	7.06e-27	0.59	0.48	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
KIRC	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	12.23	2.95e-30	7.16e-27	0.55	0.48	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
KIRC	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
KIRC	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-12.23	2.98e-30	7.22e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
KIRC	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-12.23	3e-30	7.26e-27	-0.44	-0.48	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
KIRC	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-12.23	3.01e-30	7.3e-27	-0.41	-0.48	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
KIRC	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-12.23	3.15e-30	7.63e-27	-0.47	-0.48	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
KIRC	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-12.23	3.19e-30	7.73e-27	-0.4	-0.48	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
KIRC	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-12.22	3.26e-30	7.89e-27	-0.53	-0.48	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
KIRC	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-12.22	3.28e-30	7.93e-27	-0.6	-0.48	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
KIRC	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	12.22	3.31e-30	8e-27	0.58	0.48	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
KIRC	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.22	3.37e-30	8.14e-27	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
KIRC	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.22	3.37e-30	8.14e-27	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
KIRC	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	12.22	3.4e-30	8.2e-27	0.59	0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
KIRC	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	12.21	3.58e-30	8.64e-27	0.58	0.48	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-12.21	3.64e-30	8.77e-27	-0.52	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-12.21	3.64e-30	8.77e-27	-0.52	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
KIRC	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	12.21	3.68e-30	8.87e-27	0.72	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
KIRC	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	12.21	3.83e-30	9.23e-27	0.68	0.48	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
KIRC	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	12.21	3.87e-30	9.31e-27	0.57	0.48	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	12.21	3.87e-30	9.31e-27	0.57	0.48	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
KIRC	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-12.21	3.89e-30	9.36e-27	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
KIRC	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-12.2	3.98e-30	9.58e-27	-0.42	-0.48	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
KIRC	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-12.2	4.04e-30	9.72e-27	-0.39	-0.48	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
KIRC	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-12.2	4.05e-30	9.73e-27	-0.53	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
KIRC	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	12.2	4.1e-30	9.85e-27	0.59	0.48	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
KIRC	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-12.2	4.14e-30	9.95e-27	-0.54	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
KIRC	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-12.2	4.15e-30	9.96e-27	-0.59	-0.48	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-12.2	4.25e-30	1.02e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
KIRC	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	12.2	4.26e-30	1.02e-26	0.48	0.48	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
KIRC	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-12.2	4.27e-30	1.03e-26	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
KIRC	cis	rs4273100	0.646	rs2296981	ENSG00000262319.1	CTC-457L16.2	12.19	4.29e-30	1.03e-26	0.53	0.48	Schizophrenia;	chr17:19310022	chr17:19141017~19143689:-
KIRC	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	12.19	4.32e-30	1.04e-26	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
KIRC	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	12.19	4.39e-30	1.05e-26	0.84	0.48	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
KIRC	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	12.19	4.39e-30	1.05e-26	0.84	0.48	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
KIRC	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	12.19	4.41e-30	1.06e-26	0.59	0.48	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
KIRC	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	12.19	4.41e-30	1.06e-26	0.56	0.48	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
KIRC	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-12.19	4.46e-30	1.07e-26	-0.51	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
KIRC	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	12.19	4.47e-30	1.07e-26	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
KIRC	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-12.19	4.56e-30	1.09e-26	-0.63	-0.48	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
KIRC	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-12.19	4.56e-30	1.09e-26	-0.5	-0.48	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
KIRC	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-12.19	4.58e-30	1.1e-26	-0.57	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
KIRC	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-12.19	4.61e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-12.19	4.62e-30	1.1e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	12.19	4.65e-30	1.11e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
KIRC	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	12.19	4.71e-30	1.12e-26	0.6	0.48	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	12.18	4.73e-30	1.13e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-12.18	4.75e-30	1.13e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-12.18	4.81e-30	1.15e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
KIRC	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-12.18	4.87e-30	1.16e-26	-0.63	-0.48	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-12.18	4.87e-30	1.16e-26	-0.63	-0.48	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-12.18	4.87e-30	1.16e-26	-0.63	-0.48	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-12.18	4.87e-30	1.16e-26	-0.63	-0.48	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-12.18	4.95e-30	1.18e-26	-0.63	-0.48	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
KIRC	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-12.18	4.97e-30	1.18e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-12.18	4.97e-30	1.18e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	12.18	5.01e-30	1.19e-26	0.58	0.48	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
KIRC	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-12.18	5.04e-30	1.2e-26	-0.64	-0.48	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
KIRC	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-12.18	5.07e-30	1.21e-26	-0.61	-0.48	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	12.18	5.11e-30	1.22e-26	0.6	0.48	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
KIRC	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-12.17	5.2e-30	1.24e-26	-0.64	-0.48	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
KIRC	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-12.17	5.43e-30	1.29e-26	-0.63	-0.48	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-12.17	5.43e-30	1.29e-26	-0.63	-0.48	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
KIRC	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-12.17	5.51e-30	1.31e-26	-0.48	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
KIRC	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	12.17	5.53e-30	1.31e-26	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
KIRC	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-12.17	5.65e-30	1.34e-26	-0.65	-0.48	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
KIRC	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-12.16	5.73e-30	1.36e-26	-0.54	-0.48	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
KIRC	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	12.16	5.74e-30	1.36e-26	0.58	0.48	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
KIRC	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.16	5.83e-30	1.38e-26	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
KIRC	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	12.16	5.92e-30	1.4e-26	0.57	0.48	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	12.16	5.93e-30	1.4e-26	0.59	0.48	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	12.16	5.93e-30	1.4e-26	0.59	0.48	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
KIRC	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-12.16	5.98e-30	1.42e-26	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
KIRC	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-12.16	5.99e-30	1.42e-26	-0.47	-0.48	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
KIRC	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-12.16	6e-30	1.42e-26	-0.62	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
KIRC	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-12.16	6.02e-30	1.43e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
KIRC	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	12.16	6.07e-30	1.44e-26	0.66	0.48	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
KIRC	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	12.16	6.11e-30	1.44e-26	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
KIRC	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-12.15	6.3e-30	1.49e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	12.15	6.31e-30	1.49e-26	0.58	0.48	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
KIRC	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	12.15	6.4e-30	1.51e-26	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
KIRC	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	12.15	6.42e-30	1.52e-26	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
KIRC	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-12.15	6.44e-30	1.52e-26	-0.61	-0.48	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
KIRC	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	12.15	6.49e-30	1.53e-26	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
KIRC	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-12.15	6.58e-30	1.55e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
KIRC	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-12.15	6.76e-30	1.6e-26	-0.67	-0.48	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
KIRC	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	12.15	6.78e-30	1.6e-26	0.48	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
KIRC	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-12.15	6.78e-30	1.6e-26	-0.38	-0.48	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-12.15	6.85e-30	1.62e-26	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
KIRC	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	12.15	6.86e-30	1.62e-26	0.62	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
KIRC	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-12.14	6.91e-30	1.63e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-12.14	6.94e-30	1.64e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
KIRC	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-12.14	6.94e-30	1.64e-26	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
KIRC	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	12.14	7e-30	1.65e-26	0.56	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	12.14	7e-30	1.65e-26	0.56	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	12.14	7.1e-30	1.67e-26	0.57	0.48	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	12.14	7.29e-30	1.72e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
KIRC	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	12.14	7.35e-30	1.73e-26	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
KIRC	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	12.14	7.42e-30	1.75e-26	0.45	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
KIRC	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	12.14	7.46e-30	1.76e-26	0.57	0.48	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-12.13	7.61e-30	1.79e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-12.13	7.61e-30	1.79e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-12.13	7.61e-30	1.79e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	12.13	7.63e-30	1.79e-26	0.59	0.48	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	12.13	7.63e-30	1.79e-26	0.59	0.48	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
KIRC	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	12.13	7.84e-30	1.84e-26	0.61	0.48	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
KIRC	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-12.13	7.93e-30	1.86e-26	-0.7	-0.48	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
KIRC	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	12.13	7.97e-30	1.87e-26	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
KIRC	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	12.13	8.23e-30	1.93e-26	0.72	0.48	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
KIRC	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-12.13	8.24e-30	1.93e-26	-0.6	-0.48	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-12.13	8.24e-30	1.93e-26	-0.6	-0.48	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
KIRC	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-12.13	8.25e-30	1.94e-26	-0.6	-0.48	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-12.13	8.25e-30	1.94e-26	-0.6	-0.48	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
KIRC	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-12.12	8.37e-30	1.96e-26	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
KIRC	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-12.12	8.38e-30	1.97e-26	-0.59	-0.48	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-12.12	8.43e-30	1.98e-26	-0.6	-0.48	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	12.12	8.65e-30	2.03e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-12.12	8.87e-30	2.08e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
KIRC	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	12.12	8.97e-30	2.1e-26	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
KIRC	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-12.12	9.07e-30	2.12e-26	-0.59	-0.48	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
KIRC	cis	rs4273100	0.541	rs7501702	ENSG00000262319.1	CTC-457L16.2	12.12	9.11e-30	2.13e-26	0.52	0.48	Schizophrenia;	chr17:19390414	chr17:19141017~19143689:-
KIRC	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-12.11	9.31e-30	2.18e-26	-0.6	-0.48	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
KIRC	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	12.11	9.34e-30	2.19e-26	0.45	0.48	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	12.11	9.34e-30	2.19e-26	0.45	0.48	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	12.11	9.39e-30	2.2e-26	0.45	0.48	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	12.11	9.39e-30	2.2e-26	0.45	0.48	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
KIRC	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-12.11	9.39e-30	2.2e-26	-0.6	-0.48	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
KIRC	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-12.11	9.42e-30	2.2e-26	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
KIRC	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-12.11	9.54e-30	2.23e-26	-0.72	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
KIRC	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	12.11	9.74e-30	2.28e-26	0.58	0.48	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
KIRC	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	12.11	9.88e-30	2.31e-26	0.45	0.48	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
KIRC	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-12.11	9.93e-30	2.32e-26	-0.38	-0.48	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
KIRC	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-12.11	1e-29	2.34e-26	-0.57	-0.48	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-12.1	1.01e-29	2.35e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	12.1	1.02e-29	2.39e-26	0.59	0.48	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
KIRC	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-12.1	1.06e-29	2.47e-26	-0.55	-0.48	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
KIRC	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	12.1	1.08e-29	2.51e-26	0.63	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
KIRC	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-12.1	1.08e-29	2.52e-26	-0.46	-0.48	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
KIRC	cis	rs4273100	0.512	rs1355128	ENSG00000262319.1	CTC-457L16.2	12.1	1.08e-29	2.52e-26	0.53	0.48	Schizophrenia;	chr17:19395831	chr17:19141017~19143689:-
KIRC	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-12.1	1.1e-29	2.56e-26	-0.46	-0.48	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
KIRC	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-12.09	1.11e-29	2.59e-26	-0.61	-0.48	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
KIRC	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-12.09	1.12e-29	2.6e-26	-0.49	-0.48	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
KIRC	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	12.09	1.14e-29	2.66e-26	0.59	0.48	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-12.09	1.16e-29	2.71e-26	-0.61	-0.48	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
KIRC	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-12.09	1.17e-29	2.73e-26	-0.61	-0.48	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
KIRC	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	12.09	1.18e-29	2.74e-26	0.58	0.48	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
KIRC	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-12.09	1.2e-29	2.8e-26	-0.55	-0.48	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
KIRC	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-12.09	1.21e-29	2.81e-26	-0.61	-0.48	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
KIRC	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	12.08	1.22e-29	2.83e-26	0.61	0.48	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
KIRC	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-12.08	1.23e-29	2.86e-26	-0.61	-0.48	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
KIRC	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	12.08	1.24e-29	2.88e-26	0.59	0.48	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	12.08	1.27e-29	2.95e-26	0.39	0.48	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	12.08	1.29e-29	3.01e-26	0.39	0.48	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
KIRC	cis	rs4273100	0.512	rs7502682	ENSG00000262319.1	CTC-457L16.2	12.08	1.3e-29	3.02e-26	0.52	0.48	Schizophrenia;	chr17:19392137	chr17:19141017~19143689:-
KIRC	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-12.08	1.31e-29	3.05e-26	-0.41	-0.48	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
KIRC	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-12.08	1.32e-29	3.05e-26	-0.51	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-12.08	1.32e-29	3.05e-26	-0.51	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
KIRC	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	12.07	1.34e-29	3.11e-26	0.61	0.48	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
KIRC	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-12.07	1.35e-29	3.12e-26	-0.53	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-12.07	1.36e-29	3.16e-26	-0.6	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
KIRC	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	12.07	1.37e-29	3.17e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	12.07	1.39e-29	3.22e-26	0.59	0.48	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
KIRC	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	12.07	1.39e-29	3.22e-26	0.58	0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
KIRC	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	12.07	1.39e-29	3.22e-26	0.58	0.48	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
KIRC	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-12.07	1.39e-29	3.23e-26	-0.55	-0.48	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
KIRC	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	12.07	1.43e-29	3.3e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	12.07	1.43e-29	3.3e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
KIRC	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	12.07	1.44e-29	3.34e-26	0.56	0.48	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	12.07	1.45e-29	3.35e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
KIRC	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	12.06	1.46e-29	3.39e-26	0.59	0.48	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
KIRC	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-12.06	1.49e-29	3.45e-26	-0.71	-0.48	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
KIRC	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	12.06	1.53e-29	3.54e-26	0.58	0.48	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
KIRC	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-12.06	1.58e-29	3.65e-26	-0.4	-0.48	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
KIRC	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-12.06	1.59e-29	3.68e-26	-0.46	-0.48	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
KIRC	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-12.05	1.61e-29	3.72e-26	-0.58	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
KIRC	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	12.05	1.74e-29	4.01e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	12.05	1.74e-29	4.01e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	12.05	1.74e-29	4.01e-26	0.57	0.48	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-12.05	1.74e-29	4.01e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
KIRC	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-12.04	1.76e-29	4.07e-26	-0.56	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
KIRC	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-12.04	1.78e-29	4.09e-26	-0.48	-0.48	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
KIRC	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-12.04	1.8e-29	4.14e-26	-0.67	-0.48	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
KIRC	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-12.04	1.82e-29	4.2e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-12.04	1.86e-29	4.28e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-12.04	1.86e-29	4.28e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-12.04	1.86e-29	4.28e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
KIRC	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-12.04	1.86e-29	4.29e-26	-0.52	-0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
KIRC	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-12.04	1.92e-29	4.42e-26	-0.47	-0.48	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
KIRC	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	12.04	1.93e-29	4.43e-26	0.54	0.48	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
KIRC	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	12.03	1.95e-29	4.48e-26	0.72	0.48	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
KIRC	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	12.03	1.99e-29	4.57e-26	0.58	0.48	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-12.03	2e-29	4.6e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
KIRC	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-12.03	2.01e-29	4.62e-26	-0.6	-0.48	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
KIRC	cis	rs4273100	0.512	rs2233072	ENSG00000262319.1	CTC-457L16.2	12.03	2.02e-29	4.64e-26	0.53	0.48	Schizophrenia;	chr17:19378515	chr17:19141017~19143689:-
KIRC	cis	rs9457247	0.765	rs2237276	ENSG00000265828.1	MIR3939	-12.03	2.03e-29	4.67e-26	-0.53	-0.48	Crohn's disease;	chr6:167028627	chr6:166997807~166997912:-
KIRC	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	12.03	2.05e-29	4.71e-26	0.33	0.48	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
KIRC	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-12.03	2.09e-29	4.8e-26	-0.55	-0.48	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
KIRC	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-12.03	2.1e-29	4.81e-26	-0.46	-0.48	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
KIRC	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-12.03	2.1e-29	4.82e-26	-0.6	-0.48	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
KIRC	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	12.02	2.13e-29	4.89e-26	0.32	0.48	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
KIRC	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	12.02	2.14e-29	4.92e-26	0.59	0.48	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
KIRC	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-12.02	2.17e-29	4.97e-26	-0.46	-0.48	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
KIRC	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	12.02	2.19e-29	5.02e-26	0.58	0.48	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	12.02	2.19e-29	5.02e-26	0.58	0.48	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
KIRC	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-12.02	2.2e-29	5.05e-26	-0.46	-0.48	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
KIRC	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-12.02	2.22e-29	5.1e-26	-0.68	-0.48	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
KIRC	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	12.02	2.24e-29	5.13e-26	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	12.02	2.24e-29	5.13e-26	0.58	0.48	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
KIRC	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-12.02	2.24e-29	5.14e-26	-0.63	-0.48	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
KIRC	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	12.02	2.25e-29	5.15e-26	0.51	0.48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
KIRC	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	12.02	2.25e-29	5.15e-26	0.54	0.48	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
KIRC	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	12.02	2.26e-29	5.18e-26	0.58	0.48	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	12.02	2.26e-29	5.18e-26	0.58	0.48	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	12.02	2.27e-29	5.21e-26	0.58	0.48	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	12.02	2.27e-29	5.21e-26	0.58	0.48	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	12.02	2.27e-29	5.21e-26	0.58	0.48	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	12.02	2.27e-29	5.21e-26	0.59	0.48	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-12.01	2.34e-29	5.36e-26	-0.99	-0.48	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-12.01	2.34e-29	5.37e-26	-0.39	-0.48	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
KIRC	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	12.01	2.37e-29	5.44e-26	0.32	0.48	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
KIRC	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	12.01	2.44e-29	5.58e-26	0.66	0.48	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
KIRC	cis	rs6964833	1	rs3846966	ENSG00000277053.3	GTF2IP1	-12.01	2.45e-29	5.61e-26	-0.63	-0.48	Menarche (age at onset);	chr7:74698811	chr7:75185385~75237696:-
KIRC	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	12.01	2.47e-29	5.66e-26	0.7	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	12.01	2.47e-29	5.66e-26	0.7	0.47	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
KIRC	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	12.01	2.48e-29	5.68e-26	0.59	0.47	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	12.01	2.48e-29	5.68e-26	0.49	0.47	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-12.01	2.52e-29	5.77e-26	-0.39	-0.47	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	12.01	2.55e-29	5.84e-26	0.59	0.47	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	12.01	2.56e-29	5.85e-26	0.72	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	12	2.6e-29	5.94e-26	0.72	0.47	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
KIRC	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	12	2.61e-29	5.97e-26	0.57	0.47	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	12	2.62e-29	5.98e-26	0.58	0.47	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-12	2.68e-29	6.13e-26	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
KIRC	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	12	2.75e-29	6.29e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
KIRC	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	11.99	2.89e-29	6.59e-26	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
KIRC	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-11.99	2.9e-29	6.61e-26	-0.4	-0.47	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
KIRC	cis	rs4273100	0.541	rs973649	ENSG00000262319.1	CTC-457L16.2	11.99	2.91e-29	6.65e-26	0.52	0.47	Schizophrenia;	chr17:19388755	chr17:19141017~19143689:-
KIRC	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-11.99	2.91e-29	6.65e-26	-0.44	-0.47	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
KIRC	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.99	2.95e-29	6.73e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
KIRC	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	11.99	2.97e-29	6.77e-26	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
KIRC	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-11.98	3.09e-29	7.05e-26	-0.53	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
KIRC	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-11.98	3.09e-29	7.05e-26	-0.71	-0.47	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
KIRC	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.98	3.15e-29	7.16e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.98	3.15e-29	7.16e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
KIRC	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-11.98	3.18e-29	7.25e-26	-0.46	-0.47	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
KIRC	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-11.98	3.2e-29	7.29e-26	-0.39	-0.47	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
KIRC	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	11.98	3.35e-29	7.62e-26	0.6	0.47	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
KIRC	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-11.98	3.37e-29	7.66e-26	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
KIRC	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	11.98	3.39e-29	7.7e-26	0.59	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.97	3.39e-29	7.71e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.97	3.39e-29	7.71e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.97	3.41e-29	7.74e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
KIRC	cis	rs9457247	0.715	rs6923582	ENSG00000265828.1	MIR3939	-11.97	3.42e-29	7.77e-26	-0.54	-0.47	Crohn's disease;	chr6:167023674	chr6:166997807~166997912:-
KIRC	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-11.97	3.5e-29	7.94e-26	-0.58	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-11.97	3.5e-29	7.94e-26	-0.58	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
KIRC	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	11.97	3.58e-29	8.13e-26	0.58	0.47	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
KIRC	cis	rs6964833	1	rs2301907	ENSG00000277053.3	GTF2IP1	-11.97	3.59e-29	8.14e-26	-0.63	-0.47	Menarche (age at onset);	chr7:74700517	chr7:75185385~75237696:-
KIRC	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	11.97	3.62e-29	8.22e-26	0.48	0.47	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
KIRC	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	11.96	3.72e-29	8.44e-26	0.44	0.47	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	11.96	3.72e-29	8.44e-26	0.44	0.47	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
KIRC	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	11.96	3.75e-29	8.5e-26	0.54	0.47	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-11.96	3.79e-29	8.59e-26	-0.39	-0.47	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
KIRC	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-11.96	3.8e-29	8.62e-26	-0.6	-0.47	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
KIRC	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-11.96	3.85e-29	8.71e-26	-0.47	-0.47	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
KIRC	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	11.96	3.85e-29	8.73e-26	0.71	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	11.96	3.85e-29	8.73e-26	0.71	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	11.96	3.85e-29	8.73e-26	0.71	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
KIRC	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.96	3.86e-29	8.75e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.96	3.86e-29	8.75e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
KIRC	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	11.96	3.87e-29	8.75e-26	0.57	0.47	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	11.96	3.9e-29	8.82e-26	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	11.96	3.95e-29	8.93e-26	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-11.96	4.05e-29	9.17e-26	-0.38	-0.47	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
KIRC	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.96	4.06e-29	9.18e-26	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	11.95	4.14e-29	9.36e-26	0.59	0.47	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	11.95	4.17e-29	9.42e-26	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
KIRC	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	11.95	4.18e-29	9.44e-26	0.58	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
KIRC	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	11.95	4.24e-29	9.58e-26	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
KIRC	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	11.95	4.24e-29	9.58e-26	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
KIRC	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	11.94	4.49e-29	1.01e-25	0.62	0.47	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-11.94	4.5e-29	1.02e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
KIRC	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	11.94	4.55e-29	1.02e-25	0.6	0.47	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
KIRC	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-11.94	4.69e-29	1.06e-25	-0.4	-0.47	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
KIRC	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-11.94	4.71e-29	1.06e-25	-0.67	-0.47	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
KIRC	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	11.94	4.71e-29	1.06e-25	0.58	0.47	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
KIRC	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	11.94	4.74e-29	1.07e-25	0.62	0.47	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-11.94	4.85e-29	1.09e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
KIRC	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-11.93	5.05e-29	1.13e-25	-0.53	-0.47	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
KIRC	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-11.93	5.1e-29	1.14e-25	-0.55	-0.47	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
KIRC	cis	rs5769707	0.632	rs5770601	ENSG00000235111.1	RP1-29C18.8	-11.93	5.25e-29	1.18e-25	-0.51	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49612657~49615716:-
KIRC	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-11.93	5.28e-29	1.18e-25	-0.62	-0.47	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
KIRC	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	11.93	5.34e-29	1.2e-25	0.6	0.47	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
KIRC	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-11.92	5.44e-29	1.22e-25	-0.61	-0.47	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
KIRC	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-11.92	5.45e-29	1.22e-25	-0.51	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
KIRC	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	11.92	5.55e-29	1.24e-25	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
KIRC	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-11.92	5.59e-29	1.25e-25	-0.48	-0.47	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
KIRC	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	11.92	5.63e-29	1.26e-25	0.44	0.47	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
KIRC	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-11.92	5.7e-29	1.28e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
KIRC	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	11.92	5.77e-29	1.29e-25	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
KIRC	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	11.92	5.77e-29	1.29e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
KIRC	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	11.92	5.88e-29	1.31e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
KIRC	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	11.92	5.9e-29	1.32e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
KIRC	cis	rs4273100	0.512	rs973650	ENSG00000262319.1	CTC-457L16.2	11.91	5.96e-29	1.33e-25	0.52	0.47	Schizophrenia;	chr17:19388472	chr17:19141017~19143689:-
KIRC	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	11.91	5.98e-29	1.34e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
KIRC	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	11.91	6.01e-29	1.34e-25	0.49	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
KIRC	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	11.91	6.05e-29	1.35e-25	0.58	0.47	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-11.91	6.23e-29	1.39e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-11.91	6.24e-29	1.39e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-11.91	6.24e-29	1.39e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
KIRC	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-11.91	6.25e-29	1.39e-25	-0.56	-0.47	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	11.91	6.26e-29	1.4e-25	0.59	0.47	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
KIRC	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	11.91	6.29e-29	1.4e-25	0.55	0.47	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
KIRC	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-11.91	6.32e-29	1.41e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
KIRC	cis	rs5769707	0.681	rs1107514	ENSG00000235111.1	RP1-29C18.8	-11.91	6.33e-29	1.41e-25	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49612657~49615716:-
KIRC	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	11.9	6.54e-29	1.46e-25	0.58	0.47	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	11.9	6.59e-29	1.47e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
KIRC	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	11.9	6.67e-29	1.49e-25	0.58	0.47	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
KIRC	cis	rs5769707	0.681	rs739236	ENSG00000235111.1	RP1-29C18.8	-11.9	6.7e-29	1.49e-25	-0.52	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49612657~49615716:-
KIRC	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-11.9	6.78e-29	1.51e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-11.9	6.78e-29	1.51e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-11.9	6.78e-29	1.51e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	11.9	6.82e-29	1.52e-25	0.58	0.47	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	11.9	6.95e-29	1.55e-25	0.58	0.47	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	11.9	6.97e-29	1.55e-25	0.57	0.47	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	11.9	6.97e-29	1.55e-25	0.57	0.47	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
KIRC	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	11.9	7.01e-29	1.56e-25	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
KIRC	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-11.9	7.09e-29	1.58e-25	-0.59	-0.47	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
KIRC	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	11.89	7.15e-29	1.59e-25	0.59	0.47	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
KIRC	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-11.89	7.16e-29	1.59e-25	-0.62	-0.47	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
KIRC	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-11.89	7.29e-29	1.62e-25	-0.48	-0.47	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
KIRC	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-11.89	7.37e-29	1.64e-25	-0.46	-0.47	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
KIRC	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	11.89	7.38e-29	1.64e-25	0.58	0.47	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
KIRC	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-11.89	7.45e-29	1.65e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-11.89	7.45e-29	1.65e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
KIRC	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	11.89	7.47e-29	1.66e-25	0.44	0.47	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
KIRC	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	11.89	7.48e-29	1.66e-25	0.62	0.47	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
KIRC	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	11.89	7.52e-29	1.67e-25	0.58	0.47	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
KIRC	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	11.89	7.57e-29	1.68e-25	0.56	0.47	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	11.89	7.57e-29	1.68e-25	0.6	0.47	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
KIRC	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-11.89	7.59e-29	1.69e-25	-0.62	-0.47	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-11.89	7.59e-29	1.69e-25	-0.62	-0.47	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-11.89	7.59e-29	1.69e-25	-0.62	-0.47	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
KIRC	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	11.89	7.61e-29	1.69e-25	0.58	0.47	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
KIRC	cis	rs10129255	0.517	rs11625572	ENSG00000211970.3	IGHV4-61	-11.89	7.64e-29	1.7e-25	-0.39	-0.47	Kawasaki disease;	chr14:106656426	chr14:106639119~106639657:-
KIRC	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-11.89	7.66e-29	1.7e-25	-0.47	-0.47	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
KIRC	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-11.89	7.68e-29	1.7e-25	-0.52	-0.47	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
KIRC	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	11.89	7.68e-29	1.71e-25	0.55	0.47	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
KIRC	cis	rs6964833	0.935	rs7795281	ENSG00000277053.3	GTF2IP1	-11.89	7.77e-29	1.72e-25	-0.63	-0.47	Menarche (age at onset);	chr7:74708523	chr7:75185385~75237696:-
KIRC	cis	rs6964833	0.935	rs7795282	ENSG00000277053.3	GTF2IP1	-11.89	7.77e-29	1.72e-25	-0.63	-0.47	Menarche (age at onset);	chr7:74708526	chr7:75185385~75237696:-
KIRC	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	11.88	7.85e-29	1.74e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
KIRC	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	11.88	7.93e-29	1.76e-25	0.62	0.47	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
KIRC	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	11.88	7.97e-29	1.77e-25	0.56	0.47	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
KIRC	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-11.88	8.07e-29	1.79e-25	-0.49	-0.47	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
KIRC	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-11.88	8.1e-29	1.8e-25	-0.55	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
KIRC	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-11.88	8.35e-29	1.85e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-11.88	8.35e-29	1.85e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-11.88	8.35e-29	1.85e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
KIRC	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-11.88	8.36e-29	1.85e-25	-0.54	-0.47	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
KIRC	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-11.88	8.37e-29	1.85e-25	-0.46	-0.47	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
KIRC	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-11.88	8.41e-29	1.86e-25	-0.51	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
KIRC	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	11.88	8.6e-29	1.9e-25	0.6	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
KIRC	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	11.87	8.66e-29	1.91e-25	0.71	0.47	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
KIRC	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-11.87	8.67e-29	1.92e-25	-0.47	-0.47	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
KIRC	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	11.87	8.76e-29	1.93e-25	0.39	0.47	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
KIRC	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-11.87	8.79e-29	1.94e-25	-0.4	-0.47	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
KIRC	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-11.87	8.79e-29	1.94e-25	-0.4	-0.47	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
KIRC	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	11.87	8.91e-29	1.97e-25	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
KIRC	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	11.87	8.97e-29	1.98e-25	0.58	0.47	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
KIRC	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-11.87	9.04e-29	1.99e-25	-0.53	-0.47	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000248763.2	RP13-644M16.5	-11.87	9.07e-29	2e-25	-0.71	-0.47	Obesity-related traits;	chr4:69107521	chr4:69066395~69069888:+
KIRC	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	11.87	9.1e-29	2.01e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
KIRC	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-11.87	9.16e-29	2.02e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-11.87	9.16e-29	2.02e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
KIRC	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	11.87	9.35e-29	2.06e-25	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
KIRC	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	11.87	9.36e-29	2.07e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
KIRC	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-11.87	9.37e-29	2.07e-25	-0.59	-0.47	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	11.87	9.37e-29	2.07e-25	0.59	0.47	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
KIRC	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	11.86	9.48e-29	2.09e-25	0.59	0.47	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	11.86	9.49e-29	2.09e-25	0.58	0.47	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
KIRC	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	11.86	9.61e-29	2.12e-25	0.58	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	11.86	9.61e-29	2.12e-25	0.58	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
KIRC	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-11.86	9.63e-29	2.12e-25	-0.62	-0.47	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
KIRC	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	11.86	9.68e-29	2.13e-25	0.73	0.47	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
KIRC	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-11.86	9.81e-29	2.16e-25	-0.64	-0.47	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
KIRC	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-11.86	9.87e-29	2.18e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	11.86	1.01e-28	2.22e-25	0.59	0.47	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
KIRC	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-11.86	1.01e-28	2.22e-25	-0.61	-0.47	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
KIRC	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-11.86	1.01e-28	2.23e-25	-0.56	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.85	1.04e-28	2.28e-25	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.85	1.04e-28	2.28e-25	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
KIRC	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-11.85	1.04e-28	2.29e-25	-0.82	-0.47	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000248763.2	RP13-644M16.5	-11.85	1.05e-28	2.3e-25	-0.71	-0.47	Obesity-related traits;	chr4:69101657	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000248763.2	RP13-644M16.5	-11.85	1.05e-28	2.3e-25	-0.71	-0.47	Obesity-related traits;	chr4:69102209	chr4:69066395~69069888:+
KIRC	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	11.85	1.06e-28	2.32e-25	0.59	0.47	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	11.85	1.06e-28	2.34e-25	0.58	0.47	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
KIRC	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.07e-28	2.35e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.07e-28	2.35e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.07e-28	2.35e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
KIRC	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	11.85	1.07e-28	2.36e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
KIRC	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.1e-28	2.42e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
KIRC	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	11.85	1.12e-28	2.45e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
KIRC	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	11.85	1.12e-28	2.45e-25	0.59	0.47	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
KIRC	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	11.85	1.13e-28	2.48e-25	0.62	0.47	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
KIRC	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-11.85	1.13e-28	2.48e-25	-0.52	-0.47	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
KIRC	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	11.84	1.15e-28	2.51e-25	0.71	0.47	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
KIRC	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-11.84	1.17e-28	2.56e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
KIRC	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	11.84	1.17e-28	2.57e-25	0.58	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
KIRC	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	11.84	1.18e-28	2.58e-25	0.62	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
KIRC	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	11.84	1.18e-28	2.58e-25	0.39	0.47	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
KIRC	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-11.84	1.18e-28	2.58e-25	-0.45	-0.47	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
KIRC	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	11.84	1.18e-28	2.59e-25	0.59	0.47	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	11.84	1.18e-28	2.59e-25	0.59	0.47	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
KIRC	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-11.84	1.19e-28	2.6e-25	-0.52	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
KIRC	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	11.84	1.21e-28	2.66e-25	0.56	0.47	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-11.84	1.21e-28	2.66e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-11.84	1.21e-28	2.66e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
KIRC	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	11.84	1.22e-28	2.68e-25	0.44	0.47	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
KIRC	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	11.84	1.24e-28	2.71e-25	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.83	1.27e-28	2.78e-25	0.68	0.47	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.83	1.27e-28	2.78e-25	0.68	0.47	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
KIRC	cis	rs9457247	0.74	rs13195812	ENSG00000265828.1	MIR3939	-11.83	1.28e-28	2.81e-25	-0.53	-0.47	Crohn's disease;	chr6:167030414	chr6:166997807~166997912:-
KIRC	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-11.83	1.29e-28	2.83e-25	-0.4	-0.47	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
KIRC	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	11.83	1.32e-28	2.89e-25	0.55	0.47	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
KIRC	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	11.83	1.33e-28	2.91e-25	0.54	0.47	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
KIRC	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	11.83	1.34e-28	2.93e-25	0.58	0.47	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	11.83	1.34e-28	2.93e-25	0.58	0.47	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000248763.2	RP13-644M16.5	-11.83	1.35e-28	2.95e-25	-0.71	-0.47	Obesity-related traits;	chr4:69104054	chr4:69066395~69069888:+
KIRC	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.83	1.36e-28	2.96e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
KIRC	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-11.83	1.37e-28	2.99e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
KIRC	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.82	1.37e-28	3e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
KIRC	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-11.82	1.38e-28	3e-25	-0.6	-0.47	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
KIRC	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	11.82	1.39e-28	3.04e-25	0.59	0.47	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	11.82	1.4e-28	3.06e-25	0.49	0.47	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
KIRC	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-11.82	1.41e-28	3.08e-25	-0.47	-0.47	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
KIRC	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-11.82	1.42e-28	3.1e-25	-0.7	-0.47	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
KIRC	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-11.82	1.43e-28	3.12e-25	-0.97	-0.47	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
KIRC	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	11.82	1.46e-28	3.17e-25	0.56	0.47	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	11.82	1.47e-28	3.2e-25	0.59	0.47	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	11.82	1.47e-28	3.2e-25	0.59	0.47	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
KIRC	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	11.82	1.47e-28	3.2e-25	0.58	0.47	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	11.82	1.47e-28	3.21e-25	0.61	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
KIRC	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	11.82	1.49e-28	3.25e-25	0.68	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	11.82	1.49e-28	3.25e-25	0.68	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
KIRC	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.82	1.49e-28	3.26e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
KIRC	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-11.82	1.5e-28	3.26e-25	-0.4	-0.47	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
KIRC	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-11.82	1.5e-28	3.26e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-11.82	1.5e-28	3.26e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
KIRC	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-11.81	1.52e-28	3.3e-25	-0.68	-0.47	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	11.81	1.53e-28	3.34e-25	0.58	0.47	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
KIRC	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-11.81	1.54e-28	3.36e-25	-0.57	-0.47	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
KIRC	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-11.81	1.54e-28	3.36e-25	-0.45	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
KIRC	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-11.81	1.55e-28	3.37e-25	-0.53	-0.47	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
KIRC	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	11.81	1.55e-28	3.37e-25	0.59	0.47	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
KIRC	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-11.81	1.56e-28	3.39e-25	-0.64	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
KIRC	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-11.81	1.63e-28	3.55e-25	-0.51	-0.47	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
KIRC	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-11.81	1.64e-28	3.56e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	11.8	1.66e-28	3.61e-25	0.57	0.47	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	11.8	1.68e-28	3.64e-25	0.57	0.47	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	11.8	1.68e-28	3.64e-25	0.57	0.47	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	11.8	1.68e-28	3.64e-25	0.57	0.47	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	11.8	1.7e-28	3.69e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	11.8	1.7e-28	3.69e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	11.8	1.7e-28	3.69e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	11.8	1.7e-28	3.69e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
KIRC	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	11.8	1.7e-28	3.69e-25	0.46	0.47	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
KIRC	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	11.8	1.7e-28	3.69e-25	0.43	0.47	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
KIRC	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-11.8	1.7e-28	3.7e-25	-0.48	-0.47	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
KIRC	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-11.8	1.72e-28	3.74e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	11.8	1.74e-28	3.77e-25	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
KIRC	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	11.8	1.75e-28	3.78e-25	0.57	0.47	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
KIRC	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-11.8	1.75e-28	3.79e-25	-0.62	-0.47	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
KIRC	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	11.8	1.75e-28	3.8e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
KIRC	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	11.8	1.76e-28	3.82e-25	0.48	0.47	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
KIRC	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	11.8	1.77e-28	3.84e-25	0.58	0.47	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
KIRC	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-11.8	1.78e-28	3.85e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
KIRC	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-11.8	1.78e-28	3.85e-25	-0.36	-0.47	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
KIRC	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-11.8	1.8e-28	3.89e-25	-0.6	-0.47	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
KIRC	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	11.8	1.8e-28	3.89e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
KIRC	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	11.79	1.82e-28	3.94e-25	0.44	0.47	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
KIRC	cis	rs9457247	0.765	rs1060404	ENSG00000265828.1	MIR3939	-11.79	1.84e-28	3.98e-25	-0.54	-0.47	Crohn's disease;	chr6:167015979	chr6:166997807~166997912:-
KIRC	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	11.79	1.88e-28	4.06e-25	0.53	0.47	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
KIRC	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	11.79	1.89e-28	4.09e-25	0.7	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
KIRC	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	11.79	1.89e-28	4.1e-25	0.47	0.47	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-11.79	1.9e-28	4.1e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	11.79	1.9e-28	4.11e-25	0.57	0.47	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	11.79	1.9e-28	4.11e-25	0.57	0.47	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
KIRC	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	11.79	1.91e-28	4.12e-25	0.4	0.47	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	11.79	1.92e-28	4.15e-25	0.54	0.47	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	11.79	1.96e-28	4.23e-25	0.58	0.47	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	11.79	1.97e-28	4.25e-25	0.69	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
KIRC	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-11.78	2e-28	4.32e-25	-0.52	-0.47	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
KIRC	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	11.78	2e-28	4.33e-25	0.56	0.47	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
KIRC	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-11.78	2.02e-28	4.36e-25	-0.54	-0.47	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
KIRC	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	11.78	2.02e-28	4.37e-25	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
KIRC	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-11.78	2.03e-28	4.39e-25	-0.58	-0.47	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
KIRC	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-11.78	2.04e-28	4.42e-25	-0.46	-0.47	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
KIRC	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	11.78	2.05e-28	4.42e-25	0.58	0.47	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	11.78	2.05e-28	4.42e-25	0.58	0.47	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
KIRC	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	11.78	2.05e-28	4.43e-25	0.8	0.47	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
KIRC	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	11.78	2.06e-28	4.44e-25	0.59	0.47	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	11.78	2.08e-28	4.49e-25	0.56	0.47	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-11.78	2.14e-28	4.62e-25	-0.39	-0.47	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
KIRC	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-11.78	2.16e-28	4.65e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-11.78	2.16e-28	4.65e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-11.78	2.16e-28	4.65e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
KIRC	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-11.77	2.18e-28	4.7e-25	-0.52	-0.47	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
KIRC	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	11.77	2.18e-28	4.7e-25	0.57	0.47	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	11.77	2.19e-28	4.72e-25	0.58	0.47	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-11.77	2.21e-28	4.77e-25	-0.55	-0.47	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	11.77	2.22e-28	4.79e-25	0.77	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
KIRC	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-11.77	2.24e-28	4.82e-25	-0.39	-0.47	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
KIRC	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	11.77	2.24e-28	4.83e-25	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
KIRC	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-11.77	2.26e-28	4.87e-25	-0.46	-0.47	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
KIRC	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-11.77	2.28e-28	4.91e-25	-0.45	-0.47	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
KIRC	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	11.77	2.28e-28	4.91e-25	0.58	0.47	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	11.77	2.29e-28	4.92e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
KIRC	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-11.77	2.32e-28	4.99e-25	-0.45	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
KIRC	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-11.77	2.32e-28	4.99e-25	-0.45	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
KIRC	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	11.77	2.33e-28	5.02e-25	0.58	0.47	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	11.77	2.33e-28	5.02e-25	0.58	0.47	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
KIRC	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	11.77	2.34e-28	5.03e-25	0.53	0.47	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
KIRC	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-11.77	2.34e-28	5.03e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-11.77	2.34e-28	5.03e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-11.77	2.34e-28	5.03e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-11.77	2.34e-28	5.03e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-11.77	2.34e-28	5.03e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
KIRC	cis	rs4273100	0.688	rs12938803	ENSG00000262319.1	CTC-457L16.2	11.77	2.37e-28	5.09e-25	0.51	0.47	Schizophrenia;	chr17:19301119	chr17:19141017~19143689:-
KIRC	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-11.77	2.38e-28	5.11e-25	-0.47	-0.47	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
KIRC	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-11.76	2.4e-28	5.16e-25	-0.45	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
KIRC	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	11.76	2.41e-28	5.18e-25	0.58	0.47	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
KIRC	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-11.76	2.43e-28	5.21e-25	-0.56	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
KIRC	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	11.76	2.45e-28	5.25e-25	0.71	0.47	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
KIRC	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	11.76	2.47e-28	5.3e-25	0.56	0.47	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	11.76	2.47e-28	5.31e-25	0.57	0.47	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
KIRC	cis	rs9457247	0.765	rs12212247	ENSG00000265828.1	MIR3939	-11.76	2.5e-28	5.37e-25	-0.54	-0.47	Crohn's disease;	chr6:167000051	chr6:166997807~166997912:-
KIRC	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	11.76	2.52e-28	5.4e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	11.76	2.52e-28	5.41e-25	0.58	0.47	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
KIRC	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-11.76	2.53e-28	5.42e-25	-0.84	-0.47	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
KIRC	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	11.76	2.54e-28	5.45e-25	0.48	0.47	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
KIRC	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	11.76	2.54e-28	5.45e-25	0.58	0.47	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
KIRC	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-11.76	2.54e-28	5.46e-25	-0.45	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
KIRC	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-11.76	2.58e-28	5.52e-25	-0.39	-0.47	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
KIRC	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-11.76	2.58e-28	5.52e-25	-0.39	-0.47	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
KIRC	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	11.75	2.63e-28	5.64e-25	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
KIRC	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	11.75	2.65e-28	5.69e-25	0.57	0.47	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
KIRC	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	11.75	2.67e-28	5.71e-25	0.53	0.47	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
KIRC	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-11.75	2.67e-28	5.72e-25	-0.59	-0.47	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
KIRC	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	11.75	2.68e-28	5.75e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-11.75	2.77e-28	5.92e-25	-0.67	-0.47	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
KIRC	cis	rs9457247	0.765	rs9459836	ENSG00000265828.1	MIR3939	-11.75	2.8e-28	5.99e-25	-0.54	-0.47	Crohn's disease;	chr6:167005617	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.765	rs9459838	ENSG00000265828.1	MIR3939	-11.75	2.8e-28	5.99e-25	-0.54	-0.47	Crohn's disease;	chr6:167013111	chr6:166997807~166997912:-
KIRC	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	11.75	2.81e-28	6.02e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
KIRC	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-11.75	2.83e-28	6.04e-25	-0.5	-0.47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
KIRC	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	11.75	2.84e-28	6.08e-25	0.68	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-11.75	2.84e-28	6.08e-25	-0.58	-0.47	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	11.75	2.87e-28	6.14e-25	0.49	0.47	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
KIRC	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	11.74	2.92e-28	6.24e-25	0.77	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
KIRC	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-11.74	2.93e-28	6.26e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	11.74	2.95e-28	6.29e-25	0.59	0.47	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	11.74	2.95e-28	6.29e-25	0.49	0.47	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
KIRC	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-11.74	2.96e-28	6.32e-25	-0.7	-0.47	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
KIRC	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	11.74	2.97e-28	6.33e-25	0.37	0.47	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
KIRC	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	11.74	2.97e-28	6.33e-25	0.56	0.47	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	11.74	3e-28	6.4e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	11.74	3e-28	6.4e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	11.74	3e-28	6.4e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	11.74	3.01e-28	6.41e-25	0.57	0.47	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	11.74	3.01e-28	6.41e-25	0.57	0.47	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	11.74	3.01e-28	6.41e-25	0.57	0.47	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	11.74	3.01e-28	6.41e-25	0.57	0.47	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	11.74	3.01e-28	6.41e-25	0.57	0.47	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	11.74	3.05e-28	6.51e-25	0.56	0.47	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
KIRC	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	11.74	3.07e-28	6.54e-25	0.52	0.47	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
KIRC	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-11.74	3.08e-28	6.57e-25	-0.45	-0.47	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-11.74	3.08e-28	6.57e-25	-0.45	-0.47	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
KIRC	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	11.74	3.1e-28	6.61e-25	0.47	0.47	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
KIRC	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	11.74	3.13e-28	6.66e-25	0.45	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
KIRC	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-11.74	3.15e-28	6.71e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	11.74	3.15e-28	6.71e-25	0.57	0.47	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	11.74	3.15e-28	6.71e-25	0.57	0.47	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	11.73	3.16e-28	6.72e-25	0.58	0.47	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	11.73	3.2e-28	6.8e-25	0.58	0.47	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
KIRC	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	11.73	3.21e-28	6.84e-25	0.54	0.47	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
KIRC	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	11.73	3.26e-28	6.92e-25	0.67	0.47	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
KIRC	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	11.73	3.26e-28	6.92e-25	0.67	0.47	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
KIRC	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	11.73	3.27e-28	6.94e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
KIRC	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	11.73	3.3e-28	7.02e-25	0.49	0.47	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	11.73	3.3e-28	7.02e-25	0.49	0.47	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
KIRC	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	11.73	3.33e-28	7.07e-25	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
KIRC	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-11.73	3.33e-28	7.07e-25	-0.69	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
KIRC	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	11.73	3.36e-28	7.14e-25	0.57	0.47	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
KIRC	cis	rs6085948	1	rs6085948	ENSG00000238102.1	RP11-19D2.1	11.73	3.41e-28	7.23e-25	0.49	0.47	Interleukin-10 levels;	chr20:7252703	chr20:7256580~7258214:-
KIRC	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	11.73	3.45e-28	7.32e-25	0.56	0.47	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
KIRC	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-11.73	3.46e-28	7.34e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
KIRC	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	11.72	3.52e-28	7.47e-25	0.56	0.47	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
KIRC	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	11.72	3.54e-28	7.51e-25	0.55	0.47	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
KIRC	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-11.72	3.56e-28	7.54e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-11.72	3.56e-28	7.54e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-11.72	3.56e-28	7.54e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	11.72	3.58e-28	7.59e-25	0.58	0.47	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
KIRC	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-11.72	3.61e-28	7.65e-25	-0.54	-0.47	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
KIRC	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	11.72	3.68e-28	7.78e-25	0.56	0.47	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
KIRC	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	11.72	3.72e-28	7.87e-25	0.48	0.47	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
KIRC	cis	rs9457247	0.765	rs3752520	ENSG00000265828.1	MIR3939	-11.72	3.72e-28	7.88e-25	-0.54	-0.47	Crohn's disease;	chr6:167022671	chr6:166997807~166997912:-
KIRC	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-11.72	3.75e-28	7.93e-25	-0.46	-0.47	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
KIRC	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	11.72	3.75e-28	7.93e-25	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
KIRC	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-11.71	3.8e-28	8.04e-25	-0.68	-0.47	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
KIRC	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	11.71	3.82e-28	8.08e-25	0.68	0.47	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
KIRC	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	11.71	3.82e-28	8.08e-25	0.68	0.47	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
KIRC	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	11.71	3.84e-28	8.11e-25	0.59	0.47	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	11.71	3.85e-28	8.14e-25	0.59	0.47	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
KIRC	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	11.71	3.91e-28	8.27e-25	0.56	0.47	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
KIRC	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	11.71	3.94e-28	8.33e-25	0.44	0.47	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.71	3.95e-28	8.34e-25	0.68	0.47	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.71	3.95e-28	8.34e-25	0.68	0.47	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
KIRC	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-11.71	3.96e-28	8.36e-25	-0.31	-0.47	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
KIRC	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	11.71	3.96e-28	8.37e-25	0.68	0.47	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
KIRC	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-11.71	3.99e-28	8.44e-25	-0.55	-0.47	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
KIRC	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-11.71	4e-28	8.44e-25	-0.52	-0.47	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
KIRC	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	11.71	4.02e-28	8.49e-25	0.43	0.47	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	11.71	4.03e-28	8.51e-25	0.59	0.47	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
KIRC	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-11.71	4.05e-28	8.54e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
KIRC	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.71	4.05e-28	8.55e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.71	4.05e-28	8.55e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.71	4.05e-28	8.55e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
KIRC	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	11.71	4.07e-28	8.58e-25	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
KIRC	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	11.71	4.07e-28	8.58e-25	0.7	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
KIRC	cis	rs9457247	0.765	rs9457256	ENSG00000265828.1	MIR3939	-11.71	4.09e-28	8.63e-25	-0.54	-0.47	Crohn's disease;	chr6:167022973	chr6:166997807~166997912:-
KIRC	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-11.71	4.11e-28	8.68e-25	-0.51	-0.47	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
KIRC	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-11.71	4.12e-28	8.69e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
KIRC	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-11.71	4.12e-28	8.69e-25	-0.53	-0.47	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
KIRC	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	11.7	4.18e-28	8.81e-25	0.49	0.47	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
KIRC	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	11.7	4.19e-28	8.82e-25	0.58	0.47	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	11.7	4.19e-28	8.82e-25	0.57	0.47	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
KIRC	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	11.7	4.2e-28	8.85e-25	0.7	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	11.7	4.2e-28	8.85e-25	0.7	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	11.7	4.21e-28	8.88e-25	0.58	0.47	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
KIRC	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-11.7	4.22e-28	8.89e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
KIRC	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-11.7	4.24e-28	8.93e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
KIRC	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-11.7	4.26e-28	8.96e-25	-0.49	-0.47	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
KIRC	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.7	4.27e-28	8.99e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.7	4.27e-28	8.99e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.7	4.27e-28	8.99e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.7	4.27e-28	8.99e-25	0.56	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
KIRC	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-11.7	4.29e-28	9.02e-25	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-11.7	4.29e-28	9.02e-25	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-11.7	4.29e-28	9.02e-25	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-11.7	4.29e-28	9.02e-25	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-11.7	4.3e-28	9.04e-25	-0.38	-0.47	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
KIRC	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-11.7	4.31e-28	9.07e-25	-0.57	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
KIRC	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-11.7	4.37e-28	9.2e-25	-0.47	-0.47	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
KIRC	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	11.7	4.4e-28	9.22e-25	0.47	0.47	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
KIRC	cis	rs5769707	0.681	rs4622843	ENSG00000235111.1	RP1-29C18.8	-11.7	4.48e-28	9.39e-25	-0.49	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49612657~49615716:-
KIRC	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	11.7	4.54e-28	9.53e-25	0.57	0.47	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	11.7	4.55e-28	9.53e-25	0.58	0.47	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
KIRC	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-11.7	4.56e-28	9.55e-25	-0.52	-0.47	Temperament;	chr17:14046511	chr17:14024514~14025488:+
KIRC	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-11.7	4.56e-28	9.55e-25	-0.52	-0.47	Temperament;	chr17:14048649	chr17:14024514~14025488:+
KIRC	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	11.69	4.57e-28	9.59e-25	0.77	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
KIRC	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-11.69	4.58e-28	9.59e-25	-0.58	-0.47	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	11.69	4.59e-28	9.62e-25	0.67	0.47	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
KIRC	cis	rs7182621	0.767	rs11247132	ENSG00000259363.4	CTD-2054N24.2	-11.69	4.59e-28	9.63e-25	-0.57	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99875536	chr15:99807023~99877148:+
KIRC	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-11.69	4.61e-28	9.66e-25	-0.98	-0.47	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
KIRC	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-11.69	4.62e-28	9.68e-25	-0.53	-0.47	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
KIRC	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-11.69	4.65e-28	9.73e-25	-0.54	-0.47	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
KIRC	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	11.69	4.72e-28	9.89e-25	0.69	0.47	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
KIRC	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	11.69	4.75e-28	9.95e-25	0.47	0.47	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	11.69	4.75e-28	9.95e-25	0.47	0.47	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
KIRC	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	11.69	4.8e-28	1e-24	0.57	0.47	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	11.69	4.8e-28	1e-24	0.57	0.47	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
KIRC	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	11.69	4.81e-28	1.01e-24	0.56	0.47	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
KIRC	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-11.69	4.82e-28	1.01e-24	-0.99	-0.47	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
KIRC	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-11.69	4.82e-28	1.01e-24	-0.39	-0.47	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
KIRC	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	11.69	4.83e-28	1.01e-24	0.58	0.47	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
KIRC	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-11.69	4.83e-28	1.01e-24	-0.47	-0.47	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
KIRC	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	11.69	4.84e-28	1.01e-24	0.59	0.47	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	11.69	4.85e-28	1.01e-24	0.32	0.47	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
KIRC	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	11.69	4.94e-28	1.03e-24	0.56	0.47	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
KIRC	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.69	4.94e-28	1.03e-24	0.55	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
KIRC	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	11.69	4.96e-28	1.04e-24	0.48	0.47	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	11.69	5e-28	1.04e-24	0.48	0.46	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	11.69	5e-28	1.04e-24	0.48	0.46	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
KIRC	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	11.68	5.01e-28	1.05e-24	0.58	0.46	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
KIRC	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	11.68	5.07e-28	1.06e-24	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	11.68	5.09e-28	1.06e-24	0.58	0.46	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
KIRC	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-11.68	5.11e-28	1.07e-24	-0.53	-0.46	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-11.68	5.13e-28	1.07e-24	-0.6	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
KIRC	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-11.68	5.18e-28	1.08e-24	-0.57	-0.46	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	11.68	5.21e-28	1.09e-24	0.57	0.46	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
KIRC	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	11.68	5.23e-28	1.09e-24	0.5	0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	11.68	5.24e-28	1.09e-24	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
KIRC	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	11.68	5.25e-28	1.09e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
KIRC	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-11.68	5.26e-28	1.1e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-11.68	5.26e-28	1.1e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-11.68	5.26e-28	1.1e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-11.68	5.26e-28	1.1e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
KIRC	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	11.68	5.35e-28	1.12e-24	0.64	0.46	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
KIRC	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-11.68	5.36e-28	1.12e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000250696.4	RP11-704M14.1	11.68	5.42e-28	1.13e-24	0.58	0.46	Obesity-related traits;	chr4:69101657	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000250696.4	RP11-704M14.1	11.68	5.42e-28	1.13e-24	0.58	0.46	Obesity-related traits;	chr4:69102209	chr4:69182100~69216766:+
KIRC	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-11.68	5.43e-28	1.13e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000250696.4	RP11-704M14.1	11.68	5.44e-28	1.13e-24	0.58	0.46	Obesity-related traits;	chr4:69107521	chr4:69182100~69216766:+
KIRC	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-11.67	5.58e-28	1.16e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	11.67	5.64e-28	1.17e-24	0.58	0.46	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	11.67	5.64e-28	1.17e-24	0.58	0.46	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	11.67	5.64e-28	1.17e-24	0.32	0.46	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
KIRC	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.66e-28	1.18e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.66e-28	1.18e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.66e-28	1.18e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.66e-28	1.18e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.66e-28	1.18e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
KIRC	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	11.67	5.66e-28	1.18e-24	0.56	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
KIRC	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
KIRC	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	11.67	5.7e-28	1.19e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
KIRC	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	11.67	5.72e-28	1.19e-24	0.58	0.46	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-11.67	5.72e-28	1.19e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-11.67	5.73e-28	1.19e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
KIRC	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.76e-28	1.2e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-11.67	5.8e-28	1.21e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
KIRC	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-11.67	5.8e-28	1.21e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
KIRC	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	11.67	5.81e-28	1.21e-24	0.57	0.46	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	11.67	5.81e-28	1.21e-24	0.57	0.46	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
KIRC	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	11.67	5.85e-28	1.22e-24	0.48	0.46	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	11.67	5.85e-28	1.22e-24	0.48	0.46	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
KIRC	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-11.67	5.95e-28	1.24e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
KIRC	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	11.67	5.95e-28	1.24e-24	0.58	0.46	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	11.67	6.01e-28	1.25e-24	0.58	0.46	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
KIRC	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.66	6.12e-28	1.27e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.66	6.12e-28	1.27e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.66	6.12e-28	1.27e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.66	6.12e-28	1.27e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
KIRC	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-11.66	6.29e-28	1.31e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
KIRC	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-11.66	6.32e-28	1.31e-24	-0.64	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
KIRC	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-11.66	6.36e-28	1.32e-24	-0.71	-0.46	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
KIRC	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	11.66	6.4e-28	1.33e-24	0.54	0.46	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
KIRC	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	11.66	6.4e-28	1.33e-24	0.54	0.46	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
KIRC	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-11.66	6.4e-28	1.33e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
KIRC	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	11.66	6.41e-28	1.33e-24	0.47	0.46	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
KIRC	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	11.66	6.41e-28	1.33e-24	0.68	0.46	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
KIRC	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	11.66	6.53e-28	1.35e-24	0.88	0.46	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
KIRC	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-11.66	6.54e-28	1.36e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
KIRC	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-11.66	6.6e-28	1.37e-24	-0.91	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
KIRC	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.65	6.67e-28	1.38e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.65	6.67e-28	1.38e-24	0.55	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
KIRC	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	11.65	6.76e-28	1.4e-24	0.67	0.46	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
KIRC	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	11.65	6.79e-28	1.41e-24	0.58	0.46	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
KIRC	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	11.65	6.79e-28	1.41e-24	0.58	0.46	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	11.65	6.82e-28	1.41e-24	0.58	0.46	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
KIRC	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-11.65	6.98e-28	1.45e-24	-0.58	-0.46	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
KIRC	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-11.65	7.05e-28	1.46e-24	-0.58	-0.46	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
KIRC	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-11.64	7.48e-28	1.55e-24	-0.44	-0.46	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
KIRC	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-11.64	7.52e-28	1.55e-24	-0.53	-0.46	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-11.64	7.64e-28	1.58e-24	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
KIRC	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-11.64	7.65e-28	1.58e-24	-0.62	-0.46	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
KIRC	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-11.64	7.65e-28	1.58e-24	-0.44	-0.46	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	11.64	7.68e-28	1.59e-24	0.38	0.46	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
KIRC	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-11.64	7.68e-28	1.59e-24	-0.53	-0.46	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
KIRC	cis	rs9457247	0.765	rs9459849	ENSG00000265828.1	MIR3939	-11.64	7.74e-28	1.6e-24	-0.53	-0.46	Crohn's disease;	chr6:167030672	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.765	rs9457259	ENSG00000265828.1	MIR3939	-11.64	7.74e-28	1.6e-24	-0.53	-0.46	Crohn's disease;	chr6:167030793	chr6:166997807~166997912:-
KIRC	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-11.64	7.75e-28	1.6e-24	-0.58	-0.46	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-11.64	7.75e-28	1.6e-24	-0.58	-0.46	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-11.64	7.75e-28	1.6e-24	-0.58	-0.46	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-11.64	7.82e-28	1.61e-24	-0.66	-0.46	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-11.64	7.82e-28	1.61e-24	-0.66	-0.46	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-11.64	7.82e-28	1.61e-24	-0.66	-0.46	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	11.64	7.85e-28	1.62e-24	0.57	0.46	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	11.64	7.85e-28	1.62e-24	0.57	0.46	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
KIRC	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	11.64	7.86e-28	1.62e-24	0.66	0.46	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	11.64	7.87e-28	1.62e-24	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
KIRC	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-11.64	7.88e-28	1.63e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
KIRC	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	11.64	7.93e-28	1.64e-24	0.56	0.46	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
KIRC	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	11.64	7.94e-28	1.64e-24	0.53	0.46	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
KIRC	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	11.63	8.13e-28	1.68e-24	0.67	0.46	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
KIRC	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	11.63	8.13e-28	1.68e-24	0.67	0.46	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
KIRC	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-11.63	8.25e-28	1.7e-24	-0.45	-0.46	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
KIRC	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-11.63	8.32e-28	1.72e-24	-0.57	-0.46	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
KIRC	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	11.63	8.46e-28	1.74e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	11.63	8.53e-28	1.76e-24	0.58	0.46	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
KIRC	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-11.63	8.54e-28	1.76e-24	-0.91	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
KIRC	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-11.63	8.54e-28	1.76e-24	-0.91	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	11.63	8.55e-28	1.76e-24	0.57	0.46	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
KIRC	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-11.63	8.61e-28	1.77e-24	-0.5	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
KIRC	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	11.63	8.63e-28	1.78e-24	0.43	0.46	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
KIRC	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	11.62	8.73e-28	1.8e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
KIRC	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-11.62	8.74e-28	1.8e-24	-0.58	-0.46	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
KIRC	cis	rs10129255	0.589	rs78599641	ENSG00000211970.3	IGHV4-61	-11.62	8.77e-28	1.8e-24	-0.4	-0.46	Kawasaki disease;	chr14:106637576	chr14:106639119~106639657:-
KIRC	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-11.62	8.89e-28	1.83e-24	-0.53	-0.46	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
KIRC	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	11.62	8.97e-28	1.85e-24	0.32	0.46	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
KIRC	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	11.62	9.04e-28	1.86e-24	0.57	0.46	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
KIRC	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	11.62	9.06e-28	1.86e-24	0.59	0.46	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	11.62	9.08e-28	1.87e-24	0.57	0.46	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	11.62	9.12e-28	1.87e-24	0.57	0.46	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
KIRC	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-11.62	9.14e-28	1.88e-24	-0.57	-0.46	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000250696.4	RP11-704M14.1	11.62	9.22e-28	1.89e-24	0.57	0.46	Obesity-related traits;	chr4:69104054	chr4:69182100~69216766:+
KIRC	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	11.62	9.36e-28	1.92e-24	0.6	0.46	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-11.62	9.37e-28	1.92e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
KIRC	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	11.62	9.4e-28	1.93e-24	0.47	0.46	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	11.62	9.4e-28	1.93e-24	0.47	0.46	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	11.62	9.4e-28	1.93e-24	0.47	0.46	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	11.62	9.4e-28	1.93e-24	0.47	0.46	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
KIRC	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	11.62	9.4e-28	1.93e-24	0.58	0.46	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	11.62	9.4e-28	1.93e-24	0.58	0.46	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	11.62	9.4e-28	1.93e-24	0.58	0.46	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-11.62	9.43e-28	1.94e-24	-0.57	-0.46	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
KIRC	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	11.62	9.44e-28	1.94e-24	0.56	0.46	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
KIRC	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	11.62	9.44e-28	1.94e-24	0.58	0.46	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	11.62	9.44e-28	1.94e-24	0.58	0.46	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-11.62	9.51e-28	1.95e-24	-0.91	-0.46	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
KIRC	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-11.61	9.55e-28	1.96e-24	-0.4	-0.46	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
KIRC	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	11.61	9.67e-28	1.98e-24	0.92	0.46	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
KIRC	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	11.61	9.76e-28	2e-24	0.66	0.46	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
KIRC	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	11.61	9.86e-28	2.02e-24	0.48	0.46	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
KIRC	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	11.61	9.88e-28	2.02e-24	0.61	0.46	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
KIRC	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-11.61	1.01e-27	2.07e-24	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	11.61	1.03e-27	2.11e-24	0.58	0.46	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
KIRC	cis	rs9457247	0.765	rs4710171	ENSG00000265828.1	MIR3939	-11.61	1.03e-27	2.12e-24	-0.54	-0.46	Crohn's disease;	chr6:167016698	chr6:166997807~166997912:-
KIRC	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	11.61	1.04e-27	2.14e-24	0.47	0.46	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
KIRC	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-11.6	1.05e-27	2.14e-24	-0.61	-0.46	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-11.6	1.05e-27	2.14e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
KIRC	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	11.6	1.07e-27	2.18e-24	0.6	0.46	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	11.6	1.07e-27	2.18e-24	0.6	0.46	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	11.6	1.08e-27	2.2e-24	0.61	0.46	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	11.6	1.08e-27	2.21e-24	0.67	0.46	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
KIRC	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	11.6	1.1e-27	2.24e-24	0.47	0.46	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
KIRC	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	11.6	1.1e-27	2.25e-24	0.58	0.46	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	11.6	1.1e-27	2.25e-24	0.58	0.46	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	11.6	1.11e-27	2.26e-24	0.58	0.46	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	11.6	1.11e-27	2.26e-24	0.57	0.46	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	11.6	1.11e-27	2.27e-24	0.71	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-11.6	1.12e-27	2.28e-24	-0.65	-0.46	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	11.6	1.12e-27	2.29e-24	0.57	0.46	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	11.6	1.12e-27	2.29e-24	0.57	0.46	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-11.6	1.12e-27	2.29e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
KIRC	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	11.6	1.12e-27	2.29e-24	0.58	0.46	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	11.6	1.12e-27	2.29e-24	0.58	0.46	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-11.6	1.12e-27	2.29e-24	-0.64	-0.46	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
KIRC	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	11.6	1.13e-27	2.31e-24	0.68	0.46	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
KIRC	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-11.6	1.13e-27	2.31e-24	-0.56	-0.46	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
KIRC	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-11.6	1.14e-27	2.33e-24	-0.94	-0.46	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
KIRC	cis	rs4963124	0.962	rs11246306	ENSG00000279672.1	CMB9-55F22.1	11.59	1.15e-27	2.34e-24	0.46	0.46	Proteinuria and chronic kidney disease;	chr11:761525	chr11:779617~780755:+
KIRC	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	11.59	1.15e-27	2.34e-24	0.57	0.46	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	11.59	1.16e-27	2.37e-24	0.58	0.46	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
KIRC	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-11.59	1.17e-27	2.38e-24	-0.45	-0.46	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
KIRC	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	11.59	1.17e-27	2.38e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	11.59	1.17e-27	2.38e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-11.59	1.19e-27	2.42e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
KIRC	cis	rs9457247	0.765	rs10946203	ENSG00000265828.1	MIR3939	-11.59	1.19e-27	2.43e-24	-0.53	-0.46	Crohn's disease;	chr6:167033247	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-11.59	1.2e-27	2.44e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
KIRC	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-11.59	1.2e-27	2.45e-24	-0.46	-0.46	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
KIRC	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	11.59	1.21e-27	2.47e-24	0.66	0.46	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	11.59	1.21e-27	2.47e-24	0.66	0.46	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
KIRC	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-11.59	1.21e-27	2.48e-24	-0.44	-0.46	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
KIRC	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-11.59	1.22e-27	2.49e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
KIRC	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	11.59	1.23e-27	2.5e-24	0.43	0.46	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
KIRC	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-11.59	1.23e-27	2.51e-24	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	11.59	1.24e-27	2.52e-24	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
KIRC	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	11.58	1.26e-27	2.57e-24	0.75	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
KIRC	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-11.58	1.28e-27	2.6e-24	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
KIRC	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	11.58	1.29e-27	2.61e-24	0.59	0.46	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
KIRC	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	11.58	1.3e-27	2.64e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-11.58	1.3e-27	2.64e-24	-0.39	-0.46	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
KIRC	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-11.58	1.32e-27	2.68e-24	-0.6	-0.46	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
KIRC	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-11.58	1.32e-27	2.69e-24	-0.71	-0.46	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
KIRC	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	11.58	1.33e-27	2.7e-24	0.39	0.46	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
KIRC	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	11.58	1.35e-27	2.73e-24	0.57	0.46	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
KIRC	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-11.58	1.35e-27	2.75e-24	-0.39	-0.46	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
KIRC	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	11.58	1.36e-27	2.76e-24	0.55	0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
KIRC	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	11.58	1.36e-27	2.76e-24	0.65	0.46	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
KIRC	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-11.58	1.37e-27	2.77e-24	-0.57	-0.46	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
KIRC	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	11.58	1.37e-27	2.79e-24	0.57	0.46	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	11.57	1.38e-27	2.81e-24	0.57	0.46	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
KIRC	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	11.57	1.39e-27	2.83e-24	0.68	0.46	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
KIRC	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-11.57	1.4e-27	2.84e-24	-0.39	-0.46	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
KIRC	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	11.57	1.41e-27	2.86e-24	0.57	0.46	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	11.57	1.42e-27	2.88e-24	0.65	0.46	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
KIRC	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-11.57	1.42e-27	2.88e-24	-0.44	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
KIRC	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	11.57	1.45e-27	2.94e-24	0.58	0.46	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	11.57	1.49e-27	3.02e-24	0.59	0.46	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
KIRC	cis	rs1823913	0.963	rs4146105	ENSG00000280083.1	RP11-317J9.1	-11.57	1.49e-27	3.02e-24	-0.45	-0.46	Obesity-related traits;	chr2:191245240	chr2:191154118~191156070:-
KIRC	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	11.56	1.51e-27	3.06e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	11.56	1.51e-27	3.06e-24	0.57	0.46	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	11.56	1.51e-27	3.06e-24	0.57	0.46	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	11.56	1.51e-27	3.06e-24	0.57	0.46	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
KIRC	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-11.56	1.52e-27	3.07e-24	-0.52	-0.46	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
KIRC	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-11.56	1.55e-27	3.14e-24	-0.44	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
KIRC	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-11.56	1.56e-27	3.16e-24	-0.6	-0.46	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
KIRC	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-11.56	1.57e-27	3.17e-24	-0.62	-0.46	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
KIRC	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-11.56	1.62e-27	3.27e-24	-0.57	-0.46	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
KIRC	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-11.56	1.64e-27	3.32e-24	-0.95	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
KIRC	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-11.55	1.66e-27	3.34e-24	-0.59	-0.46	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
KIRC	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	11.55	1.66e-27	3.34e-24	0.58	0.46	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-11.55	1.66e-27	3.35e-24	-0.47	-0.46	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
KIRC	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	11.55	1.68e-27	3.38e-24	0.58	0.46	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	11.55	1.68e-27	3.39e-24	0.58	0.46	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
KIRC	cis	rs1823913	1	rs68014803	ENSG00000280083.1	RP11-317J9.1	-11.55	1.7e-27	3.44e-24	-0.45	-0.46	Obesity-related traits;	chr2:191241877	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	11.55	1.71e-27	3.44e-24	0.58	0.46	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	11.55	1.71e-27	3.44e-24	0.58	0.46	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	11.55	1.71e-27	3.44e-24	0.58	0.46	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	11.55	1.72e-27	3.47e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
KIRC	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-11.55	1.73e-27	3.48e-24	-0.49	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
KIRC	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.55	1.73e-27	3.48e-24	0.67	0.46	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	11.55	1.75e-27	3.52e-24	0.56	0.46	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	11.55	1.75e-27	3.52e-24	0.56	0.46	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	11.55	1.75e-27	3.52e-24	0.56	0.46	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	11.55	1.76e-27	3.55e-24	0.58	0.46	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
KIRC	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	11.55	1.76e-27	3.55e-24	0.53	0.46	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	11.55	1.76e-27	3.55e-24	0.53	0.46	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
KIRC	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	11.55	1.78e-27	3.59e-24	0.58	0.46	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
KIRC	cis	rs9457247	0.534	rs1130033	ENSG00000265828.1	MIR3939	-11.55	1.79e-27	3.6e-24	-0.53	-0.46	Crohn's disease;	chr6:166972135	chr6:166997807~166997912:-
KIRC	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	11.55	1.79e-27	3.6e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	11.55	1.81e-27	3.64e-24	0.36	0.46	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	11.55	1.81e-27	3.64e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	11.55	1.81e-27	3.64e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	11.54	1.82e-27	3.65e-24	0.58	0.46	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	11.54	1.83e-27	3.69e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
KIRC	cis	rs1823913	1	rs13019004	ENSG00000280083.1	RP11-317J9.1	-11.54	1.85e-27	3.71e-24	-0.45	-0.46	Obesity-related traits;	chr2:191245493	chr2:191154118~191156070:-
KIRC	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	11.54	1.85e-27	3.73e-24	0.56	0.46	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	11.54	1.85e-27	3.73e-24	0.58	0.46	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	11.54	1.87e-27	3.76e-24	0.31	0.46	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
KIRC	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	11.54	1.87e-27	3.77e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
KIRC	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	11.54	1.88e-27	3.79e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
KIRC	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-11.54	1.93e-27	3.88e-24	-0.61	-0.46	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
KIRC	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-11.54	1.93e-27	3.88e-24	-0.61	-0.46	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
KIRC	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-11.54	1.95e-27	3.93e-24	-0.49	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
KIRC	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	11.54	1.95e-27	3.93e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-11.53	1.99e-27	4e-24	-1	-0.46	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
KIRC	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	11.53	2e-27	4.01e-24	0.32	0.46	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
KIRC	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-11.53	2.04e-27	4.09e-24	-0.6	-0.46	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
KIRC	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-11.53	2.09e-27	4.2e-24	-0.45	-0.46	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-11.53	2.09e-27	4.2e-24	-0.45	-0.46	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
KIRC	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-11.53	2.1e-27	4.21e-24	-0.53	-0.46	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	11.53	2.11e-27	4.23e-24	0.58	0.46	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	11.53	2.13e-27	4.28e-24	0.57	0.46	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
KIRC	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-11.53	2.15e-27	4.32e-24	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
KIRC	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	11.53	2.16e-27	4.33e-24	0.58	0.46	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	11.53	2.16e-27	4.34e-24	0.56	0.46	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	11.53	2.18e-27	4.37e-24	0.68	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	11.52	2.18e-27	4.38e-24	0.58	0.46	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
KIRC	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-11.52	2.18e-27	4.38e-24	-0.72	-0.46	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
KIRC	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-11.52	2.19e-27	4.39e-24	-0.39	-0.46	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
KIRC	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-11.52	2.22e-27	4.45e-24	-0.49	-0.46	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
KIRC	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-11.52	2.23e-27	4.47e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-11.52	2.23e-27	4.47e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
KIRC	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	11.52	2.24e-27	4.5e-24	0.53	0.46	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
KIRC	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	11.52	2.28e-27	4.56e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
KIRC	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	11.52	2.33e-27	4.65e-24	0.47	0.46	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
KIRC	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-11.52	2.33e-27	4.67e-24	-0.58	-0.46	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-11.52	2.34e-27	4.68e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	11.52	2.36e-27	4.71e-24	0.63	0.46	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
KIRC	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-11.52	2.36e-27	4.73e-24	-0.44	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
KIRC	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	11.52	2.38e-27	4.75e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	11.52	2.38e-27	4.75e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
KIRC	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-11.52	2.38e-27	4.75e-24	-0.46	-0.46	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
KIRC	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-11.52	2.38e-27	4.75e-24	-0.46	-0.46	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
KIRC	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	11.51	2.42e-27	4.83e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
KIRC	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	11.51	2.42e-27	4.84e-24	0.48	0.46	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
KIRC	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	11.51	2.42e-27	4.84e-24	0.43	0.46	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
KIRC	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-11.51	2.44e-27	4.87e-24	-0.63	-0.46	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
KIRC	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	11.51	2.45e-27	4.89e-24	0.56	0.46	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	11.51	2.45e-27	4.89e-24	0.56	0.46	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	11.51	2.45e-27	4.89e-24	0.56	0.46	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
KIRC	cis	rs9457247	0.765	rs10484531	ENSG00000265828.1	MIR3939	-11.51	2.46e-27	4.91e-24	-0.53	-0.46	Crohn's disease;	chr6:167040946	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	11.51	2.47e-27	4.93e-24	0.58	0.46	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	11.51	2.49e-27	4.97e-24	0.66	0.46	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
KIRC	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	11.51	2.5e-27	4.99e-24	0.56	0.46	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
KIRC	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-11.51	2.54e-27	5.06e-24	-0.49	-0.46	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
KIRC	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-11.51	2.54e-27	5.07e-24	-0.52	-0.46	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
KIRC	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	11.51	2.55e-27	5.09e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	11.51	2.55e-27	5.09e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	11.51	2.55e-27	5.09e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	11.51	2.55e-27	5.09e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
KIRC	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-11.51	2.56e-27	5.11e-24	-0.67	-0.46	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
KIRC	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	11.5	2.66e-27	5.31e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	11.5	2.69e-27	5.35e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
KIRC	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	11.5	2.7e-27	5.38e-24	0.58	0.46	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
KIRC	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-11.5	2.71e-27	5.39e-24	-0.59	-0.46	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
KIRC	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-11.5	2.71e-27	5.39e-24	-0.59	-0.46	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
KIRC	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-11.5	2.71e-27	5.4e-24	-0.37	-0.46	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
KIRC	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	11.5	2.72e-27	5.42e-24	0.67	0.46	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
KIRC	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-11.5	2.74e-27	5.46e-24	-0.57	-0.46	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
KIRC	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-11.5	2.79e-27	5.55e-24	-0.59	-0.46	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
KIRC	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-11.5	2.8e-27	5.56e-24	-0.59	-0.46	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
KIRC	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-11.5	2.8e-27	5.56e-24	-0.59	-0.46	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
KIRC	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	11.5	2.81e-27	5.58e-24	0.63	0.46	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	11.5	2.82e-27	5.6e-24	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
KIRC	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	11.5	2.82e-27	5.61e-24	0.47	0.46	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	11.5	2.82e-27	5.61e-24	0.47	0.46	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	11.5	2.82e-27	5.61e-24	0.47	0.46	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	11.5	2.84e-27	5.65e-24	0.47	0.46	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
KIRC	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-11.5	2.85e-27	5.67e-24	-0.51	-0.46	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
KIRC	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	11.49	2.88e-27	5.71e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
KIRC	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-11.49	2.9e-27	5.76e-24	-0.95	-0.46	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
KIRC	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	11.49	2.91e-27	5.78e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	11.49	2.92e-27	5.8e-24	0.58	0.46	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
KIRC	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-11.49	2.93e-27	5.81e-24	-0.63	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
KIRC	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	11.49	2.93e-27	5.82e-24	0.58	0.46	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
KIRC	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	11.49	2.93e-27	5.82e-24	0.51	0.46	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
KIRC	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-11.49	2.95e-27	5.85e-24	-0.59	-0.46	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
KIRC	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	11.49	3.02e-27	5.99e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
KIRC	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-11.49	3.04e-27	6.02e-24	-0.59	-0.46	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
KIRC	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	11.49	3.05e-27	6.04e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	11.49	3.05e-27	6.04e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	11.49	3.05e-27	6.04e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
KIRC	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	11.49	3.06e-27	6.07e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	11.49	3.06e-27	6.07e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	11.49	3.07e-27	6.09e-24	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
KIRC	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-11.49	3.09e-27	6.13e-24	-0.6	-0.46	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
KIRC	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-11.49	3.09e-27	6.13e-24	-0.6	-0.46	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
KIRC	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	11.49	3.1e-27	6.14e-24	0.6	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
KIRC	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	11.49	3.1e-27	6.14e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
KIRC	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-11.49	3.12e-27	6.18e-24	-0.44	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
KIRC	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-11.49	3.13e-27	6.19e-24	-0.43	-0.46	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
KIRC	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-11.49	3.13e-27	6.2e-24	-0.41	-0.46	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
KIRC	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-11.48	3.15e-27	6.23e-24	-0.52	-0.46	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
KIRC	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	11.48	3.27e-27	6.47e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	11.48	3.27e-27	6.47e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	11.48	3.27e-27	6.47e-24	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
KIRC	cis	rs1823913	0.927	rs1454761	ENSG00000280083.1	RP11-317J9.1	-11.48	3.29e-27	6.51e-24	-0.45	-0.46	Obesity-related traits;	chr2:191237092	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	11.48	3.3e-27	6.52e-24	0.58	0.46	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
KIRC	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-11.48	3.32e-27	6.56e-24	-0.42	-0.46	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
KIRC	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-11.48	3.35e-27	6.62e-24	-0.49	-0.46	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
KIRC	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-11.48	3.38e-27	6.68e-24	-0.44	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
KIRC	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	11.48	3.41e-27	6.74e-24	0.47	0.46	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	11.47	3.47e-27	6.85e-24	0.47	0.46	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
KIRC	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-11.47	3.5e-27	6.91e-24	-0.43	-0.46	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
KIRC	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-11.47	3.53e-27	6.97e-24	-0.38	-0.46	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
KIRC	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-11.47	3.53e-27	6.97e-24	-0.38	-0.46	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
KIRC	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	11.47	3.53e-27	6.97e-24	0.38	0.46	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
KIRC	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	11.47	3.54e-27	7e-24	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
KIRC	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	11.47	3.54e-27	7e-24	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
KIRC	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-11.47	3.62e-27	7.14e-24	-0.45	-0.46	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	11.47	3.68e-27	7.25e-24	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	11.47	3.68e-27	7.25e-24	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
KIRC	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	11.47	3.73e-27	7.35e-24	0.58	0.46	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
KIRC	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	11.46	3.79e-27	7.47e-24	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	11.46	3.79e-27	7.48e-24	0.57	0.46	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	11.46	3.79e-27	7.48e-24	0.57	0.46	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
KIRC	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	11.46	3.8e-27	7.49e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	11.46	3.8e-27	7.49e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	11.46	3.8e-27	7.49e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
KIRC	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-11.46	3.82e-27	7.53e-24	-0.48	-0.46	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
KIRC	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-11.46	3.88e-27	7.64e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-11.46	3.88e-27	7.64e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
KIRC	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-11.46	3.9e-27	7.69e-24	-0.38	-0.46	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
KIRC	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-11.46	3.92e-27	7.72e-24	-0.52	-0.46	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
KIRC	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	11.46	3.95e-27	7.79e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
KIRC	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-11.46	3.96e-27	7.79e-24	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
KIRC	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-11.46	3.98e-27	7.83e-24	-0.47	-0.46	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
KIRC	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	11.46	4.05e-27	7.97e-24	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
KIRC	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-11.46	4.07e-27	8.01e-24	-0.51	-0.46	Temperament;	chr17:14007232	chr17:14024514~14025488:+
KIRC	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	11.46	4.08e-27	8.01e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
KIRC	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	11.46	4.09e-27	8.04e-24	0.56	0.46	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
KIRC	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-11.46	4.11e-27	8.08e-24	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-11.46	4.11e-27	8.08e-24	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
KIRC	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-11.46	4.11e-27	8.08e-24	-0.56	-0.46	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-11.45	4.14e-27	8.13e-24	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	11.45	4.16e-27	8.18e-24	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
KIRC	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	11.45	4.17e-27	8.19e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	11.45	4.17e-27	8.19e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	11.45	4.17e-27	8.19e-24	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
KIRC	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	11.45	4.2e-27	8.25e-24	0.58	0.46	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	11.45	4.2e-27	8.25e-24	0.58	0.46	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
KIRC	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-11.45	4.24e-27	8.33e-24	-0.54	-0.46	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
KIRC	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-11.45	4.37e-27	8.57e-24	-0.5	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
KIRC	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	11.45	4.38e-27	8.6e-24	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
KIRC	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	11.45	4.39e-27	8.61e-24	0.56	0.46	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	11.45	4.39e-27	8.61e-24	0.56	0.46	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
KIRC	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-11.45	4.42e-27	8.66e-24	-0.39	-0.46	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
KIRC	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	11.45	4.43e-27	8.68e-24	0.58	0.46	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	11.45	4.46e-27	8.73e-24	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	11.45	4.46e-27	8.73e-24	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	11.45	4.46e-27	8.73e-24	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	11.45	4.46e-27	8.73e-24	0.74	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
KIRC	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-11.45	4.48e-27	8.78e-24	-0.61	-0.46	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
KIRC	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	11.45	4.5e-27	8.81e-24	0.57	0.46	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
KIRC	cis	rs6456156	0.586	rs12203510	ENSG00000265828.1	MIR3939	-11.44	4.54e-27	8.88e-24	-0.51	-0.46	Primary biliary cholangitis;	chr6:167059518	chr6:166997807~166997912:-
KIRC	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	11.44	4.56e-27	8.92e-24	0.76	0.46	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
KIRC	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	11.44	4.57e-27	8.94e-24	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
KIRC	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-11.44	4.57e-27	8.95e-24	-0.46	-0.46	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
KIRC	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-11.44	4.6e-27	9e-24	-0.48	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
KIRC	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-11.44	4.63e-27	9.06e-24	-0.57	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
KIRC	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	11.44	4.68e-27	9.16e-24	0.56	0.46	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
KIRC	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-11.44	4.74e-27	9.27e-24	-0.52	-0.46	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
KIRC	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	11.44	4.78e-27	9.35e-24	0.54	0.46	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	11.44	4.78e-27	9.35e-24	0.54	0.46	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-11.44	4.79e-27	9.35e-24	-0.36	-0.46	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
KIRC	cis	rs4963124	0.924	rs7478765	ENSG00000279672.1	CMB9-55F22.1	11.44	4.8e-27	9.38e-24	0.45	0.46	Proteinuria and chronic kidney disease;	chr11:752059	chr11:779617~780755:+
KIRC	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-11.44	4.86e-27	9.5e-24	-0.47	-0.46	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
KIRC	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-11.44	4.86e-27	9.5e-24	-0.47	-0.46	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-11.44	4.86e-27	9.5e-24	-0.47	-0.46	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
KIRC	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-11.44	4.86e-27	9.5e-24	-0.47	-0.46	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
KIRC	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-11.44	4.87e-27	9.51e-24	-0.38	-0.46	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	11.43	4.98e-27	9.72e-24	0.56	0.46	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
KIRC	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	11.43	5.09e-27	9.93e-24	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
KIRC	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-11.43	5.1e-27	9.95e-24	-0.45	-0.46	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
KIRC	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	11.43	5.13e-27	1e-23	0.56	0.46	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	11.43	5.19e-27	1.01e-23	0.57	0.46	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	11.43	5.19e-27	1.01e-23	0.57	0.46	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
KIRC	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-11.43	5.19e-27	1.01e-23	-0.52	-0.46	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
KIRC	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-11.43	5.31e-27	1.04e-23	-0.55	-0.46	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
KIRC	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.43	5.37e-27	1.05e-23	-0.98	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
KIRC	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	11.42	5.44e-27	1.06e-23	0.58	0.46	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
KIRC	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-11.42	5.51e-27	1.07e-23	-0.95	-0.46	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
KIRC	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-11.42	5.51e-27	1.07e-23	-0.52	-0.46	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
KIRC	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	11.42	5.57e-27	1.09e-23	0.43	0.46	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
KIRC	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	11.42	5.67e-27	1.1e-23	0.47	0.46	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
KIRC	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-11.42	5.68e-27	1.11e-23	-0.57	-0.46	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
KIRC	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-11.42	5.68e-27	1.11e-23	-0.52	-0.46	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
KIRC	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-11.42	5.75e-27	1.12e-23	-0.65	-0.46	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
KIRC	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	11.42	5.76e-27	1.12e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
KIRC	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	11.42	5.76e-27	1.12e-23	0.75	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	11.42	5.76e-27	1.12e-23	0.75	0.46	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
KIRC	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	11.42	5.77e-27	1.12e-23	0.52	0.46	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
KIRC	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	11.42	5.84e-27	1.14e-23	0.55	0.46	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
KIRC	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-11.42	5.87e-27	1.14e-23	-0.54	-0.46	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
KIRC	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-11.41	5.97e-27	1.16e-23	-0.53	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
KIRC	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	11.41	6.01e-27	1.17e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
KIRC	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	11.41	6.04e-27	1.17e-23	0.47	0.46	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	11.41	6.04e-27	1.17e-23	0.47	0.46	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-11.41	6.09e-27	1.18e-23	-0.38	-0.46	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
KIRC	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	11.41	6.1e-27	1.19e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
KIRC	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-11.41	6.13e-27	1.19e-23	-0.44	-0.46	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
KIRC	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-11.41	6.15e-27	1.19e-23	-0.91	-0.46	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
KIRC	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	11.41	6.33e-27	1.23e-23	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
KIRC	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	11.41	6.36e-27	1.23e-23	0.56	0.46	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	11.4	6.56e-27	1.27e-23	0.38	0.46	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
KIRC	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	11.4	6.56e-27	1.27e-23	0.57	0.46	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
KIRC	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	11.4	6.59e-27	1.28e-23	0.64	0.46	Migraine;	chr16:75350086	chr16:75379818~75381260:-
KIRC	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	11.4	6.63e-27	1.28e-23	0.66	0.46	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
KIRC	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-11.4	6.65e-27	1.29e-23	-0.52	-0.46	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
KIRC	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-11.4	6.82e-27	1.32e-23	-0.57	-0.46	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
KIRC	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	11.4	6.91e-27	1.34e-23	0.57	0.46	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
KIRC	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	11.4	6.95e-27	1.35e-23	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	11.4	6.95e-27	1.35e-23	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	11.4	6.95e-27	1.35e-23	0.55	0.46	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
KIRC	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-11.4	6.96e-27	1.35e-23	-0.52	-0.46	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
KIRC	cis	rs9457247	0.74	rs10946204	ENSG00000265828.1	MIR3939	-11.4	7e-27	1.35e-23	-0.52	-0.46	Crohn's disease;	chr6:167037641	chr6:166997807~166997912:-
KIRC	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	11.4	7.02e-27	1.36e-23	0.57	0.46	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	11.39	7.14e-27	1.38e-23	0.58	0.46	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
KIRC	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	11.39	7.31e-27	1.41e-23	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	11.39	7.37e-27	1.43e-23	0.65	0.46	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	11.39	7.37e-27	1.43e-23	0.65	0.46	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-11.39	7.43e-27	1.44e-23	-0.91	-0.46	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-11.39	7.43e-27	1.44e-23	-0.91	-0.46	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-11.39	7.43e-27	1.44e-23	-0.91	-0.46	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
KIRC	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-11.39	7.54e-27	1.46e-23	-0.43	-0.46	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
KIRC	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	11.39	7.56e-27	1.46e-23	0.57	0.46	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
KIRC	cis	rs9457247	0.765	rs10455982	ENSG00000265828.1	MIR3939	-11.39	7.68e-27	1.48e-23	-0.52	-0.46	Crohn's disease;	chr6:167035240	chr6:166997807~166997912:-
KIRC	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-11.39	7.72e-27	1.49e-23	-0.51	-0.46	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
KIRC	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	11.39	7.74e-27	1.5e-23	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
KIRC	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	11.39	7.78e-27	1.5e-23	0.47	0.46	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-11.38	7.9e-27	1.53e-23	-0.37	-0.46	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
KIRC	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-11.38	8.03e-27	1.55e-23	-0.45	-0.46	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-11.38	8.03e-27	1.55e-23	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
KIRC	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-11.38	8.11e-27	1.57e-23	-0.93	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	11.38	8.28e-27	1.6e-23	0.58	0.46	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
KIRC	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	11.38	8.31e-27	1.6e-23	0.52	0.46	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
KIRC	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	11.38	8.37e-27	1.61e-23	0.54	0.46	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-11.38	8.45e-27	1.63e-23	-0.38	-0.46	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-11.38	8.45e-27	1.63e-23	-0.38	-0.46	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
KIRC	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-11.37	8.58e-27	1.65e-23	-0.45	-0.46	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
KIRC	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-11.37	8.74e-27	1.68e-23	-0.51	-0.46	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
KIRC	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-11.37	9.21e-27	1.78e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
KIRC	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	11.37	9.33e-27	1.8e-23	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
KIRC	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-11.36	9.94e-27	1.91e-23	-0.59	-0.45	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
KIRC	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-11.36	9.94e-27	1.91e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-11.36	9.94e-27	1.91e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	11.36	9.95e-27	1.91e-23	0.65	0.45	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-11.36	9.96e-27	1.91e-23	-0.56	-0.45	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
KIRC	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-11.36	1.01e-26	1.94e-23	-0.51	-0.45	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
KIRC	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-11.36	1.01e-26	1.94e-23	-0.51	-0.45	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
KIRC	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-11.35	1.05e-26	2.01e-23	-0.59	-0.45	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
KIRC	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-11.35	1.05e-26	2.02e-23	-0.48	-0.45	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
KIRC	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	11.35	1.07e-26	2.05e-23	0.52	0.45	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
KIRC	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-11.35	1.07e-26	2.05e-23	-0.57	-0.45	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
KIRC	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-11.35	1.07e-26	2.05e-23	-0.36	-0.45	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	11.35	1.07e-26	2.05e-23	0.57	0.45	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
KIRC	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-11.35	1.08e-26	2.07e-23	-0.58	-0.45	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
KIRC	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	11.35	1.08e-26	2.08e-23	0.57	0.45	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	11.35	1.1e-26	2.11e-23	0.94	0.45	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	11.35	1.11e-26	2.13e-23	0.57	0.45	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
KIRC	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-11.35	1.12e-26	2.15e-23	-0.59	-0.45	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
KIRC	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	11.34	1.13e-26	2.16e-23	0.55	0.45	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	11.34	1.19e-26	2.28e-23	0.56	0.45	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	11.34	1.21e-26	2.31e-23	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
KIRC	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-11.33	1.28e-26	2.46e-23	-0.59	-0.45	QT interval;	chr16:28845498	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	11.33	1.28e-26	2.46e-23	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	11.33	1.28e-26	2.46e-23	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
KIRC	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-11.33	1.29e-26	2.46e-23	-0.3	-0.45	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
KIRC	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-11.33	1.31e-26	2.49e-23	-0.62	-0.45	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
KIRC	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-11.33	1.32e-26	2.51e-23	-0.54	-0.45	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
KIRC	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-11.33	1.33e-26	2.53e-23	-0.56	-0.45	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	11.33	1.33e-26	2.54e-23	0.37	0.45	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
KIRC	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-11.33	1.34e-26	2.55e-23	-0.57	-0.45	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
KIRC	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-11.33	1.34e-26	2.56e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-11.32	1.37e-26	2.62e-23	-0.65	-0.45	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
KIRC	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-11.32	1.38e-26	2.64e-23	-0.67	-0.45	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
KIRC	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-11.32	1.39e-26	2.64e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	11.32	1.4e-26	2.67e-23	0.59	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
KIRC	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	11.32	1.4e-26	2.68e-23	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
KIRC	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	11.32	1.42e-26	2.71e-23	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	11.32	1.42e-26	2.71e-23	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
KIRC	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-11.32	1.42e-26	2.72e-23	-0.3	-0.45	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
KIRC	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	11.32	1.42e-26	2.72e-23	0.32	0.45	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
KIRC	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	11.32	1.43e-26	2.72e-23	0.47	0.45	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
KIRC	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-11.32	1.43e-26	2.72e-23	-0.44	-0.45	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	11.32	1.45e-26	2.77e-23	0.57	0.45	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
KIRC	cis	rs10129255	0.642	rs11624918	ENSG00000211970.3	IGHV4-61	-11.32	1.46e-26	2.79e-23	-0.39	-0.45	Kawasaki disease;	chr14:106664672	chr14:106639119~106639657:-
KIRC	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-11.32	1.47e-26	2.8e-23	-0.48	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
KIRC	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	11.31	1.5e-26	2.85e-23	0.51	0.45	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
KIRC	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-11.31	1.53e-26	2.92e-23	-0.51	-0.45	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
KIRC	cis	rs6456156	0.586	rs13195158	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167067904	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs9457266	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167069067	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.565	rs7750209	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167069407	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs7746628	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167069747	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs2345753	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167070856	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.603	rs2345754	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167070873	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs7761977	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167072190	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs7742305	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167072235	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs7762156	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167072343	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs2001115	ENSG00000265828.1	MIR3939	-11.31	1.56e-26	2.97e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167072730	chr6:166997807~166997912:-
KIRC	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	11.31	1.57e-26	2.99e-23	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
KIRC	cis	rs6456156	0.586	rs9457261	ENSG00000265828.1	MIR3939	-11.31	1.58e-26	3e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167054191	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	11.31	1.58e-26	3.01e-23	0.57	0.45	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
KIRC	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	11.31	1.59e-26	3.02e-23	0.57	0.45	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
KIRC	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	11.31	1.6e-26	3.04e-23	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
KIRC	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	11.31	1.61e-26	3.05e-23	0.46	0.45	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
KIRC	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-11.31	1.61e-26	3.07e-23	-0.62	-0.45	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
KIRC	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-11.3	1.62e-26	3.08e-23	-0.94	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-11.3	1.62e-26	3.08e-23	-0.94	-0.45	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
KIRC	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-11.3	1.62e-26	3.08e-23	-0.55	-0.45	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
KIRC	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-11.3	1.66e-26	3.16e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-11.3	1.67e-26	3.16e-23	-0.52	-0.45	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
KIRC	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	11.3	1.67e-26	3.18e-23	0.55	0.45	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
KIRC	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-11.3	1.68e-26	3.2e-23	-0.61	-0.45	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
KIRC	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-11.3	1.72e-26	3.26e-23	-0.55	-0.45	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
KIRC	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-11.3	1.73e-26	3.29e-23	-0.6	-0.45	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
KIRC	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	11.3	1.75e-26	3.31e-23	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
KIRC	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	11.3	1.75e-26	3.31e-23	0.32	0.45	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
KIRC	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-11.29	1.77e-26	3.35e-23	-0.51	-0.45	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
KIRC	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-11.29	1.81e-26	3.44e-23	-0.47	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-11.29	1.81e-26	3.44e-23	-0.47	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
KIRC	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	11.29	1.85e-26	3.51e-23	0.55	0.45	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-11.29	1.91e-26	3.62e-23	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
KIRC	cis	rs6456156	0.586	rs1407315	ENSG00000265828.1	MIR3939	-11.29	1.92e-26	3.63e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167055171	chr6:166997807~166997912:-
KIRC	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-11.28	1.96e-26	3.71e-23	-0.57	-0.45	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
KIRC	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	11.28	2.02e-26	3.82e-23	0.53	0.45	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
KIRC	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	11.28	2.03e-26	3.84e-23	0.6	0.45	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
KIRC	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-11.28	2.03e-26	3.84e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-11.28	2.04e-26	3.86e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
KIRC	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-11.28	2.06e-26	3.89e-23	-0.69	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
KIRC	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-11.28	2.06e-26	3.9e-23	-0.69	-0.45	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
KIRC	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-11.28	2.09e-26	3.94e-23	-0.52	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
KIRC	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	11.28	2.1e-26	3.95e-23	0.56	0.45	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
KIRC	cis	rs6456156	0.528	rs6936261	ENSG00000265828.1	MIR3939	-11.27	2.14e-26	4.04e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167056188	chr6:166997807~166997912:-
KIRC	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-11.27	2.16e-26	4.08e-23	-0.57	-0.45	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
KIRC	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	11.27	2.18e-26	4.11e-23	0.43	0.45	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	11.27	2.18e-26	4.11e-23	0.43	0.45	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
KIRC	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-11.27	2.18e-26	4.11e-23	-0.67	-0.45	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	11.27	2.2e-26	4.14e-23	0.56	0.45	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-11.27	2.23e-26	4.21e-23	-0.93	-0.45	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
KIRC	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-11.27	2.24e-26	4.21e-23	-0.48	-0.45	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
KIRC	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-11.27	2.26e-26	4.25e-23	-0.53	-0.45	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
KIRC	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-11.27	2.28e-26	4.28e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
KIRC	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-11.27	2.28e-26	4.28e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
KIRC	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	11.27	2.29e-26	4.3e-23	0.35	0.45	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
KIRC	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	11.27	2.29e-26	4.31e-23	0.61	0.45	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	11.27	2.3e-26	4.33e-23	0.95	0.45	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-11.26	2.33e-26	4.37e-23	-0.92	-0.45	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
KIRC	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-11.26	2.33e-26	4.37e-23	-0.92	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
KIRC	cis	rs6456156	0.586	rs1358882	ENSG00000265828.1	MIR3939	-11.26	2.39e-26	4.49e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167053613	chr6:166997807~166997912:-
KIRC	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-11.26	2.43e-26	4.57e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-11.26	2.43e-26	4.57e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-11.26	2.43e-26	4.57e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-11.26	2.43e-26	4.57e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	11.26	2.45e-26	4.6e-23	0.57	0.45	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
KIRC	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	11.26	2.46e-26	4.61e-23	0.44	0.45	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
KIRC	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-11.26	2.46e-26	4.62e-23	-0.54	-0.45	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
KIRC	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	11.26	2.48e-26	4.65e-23	0.53	0.45	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
KIRC	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-11.26	2.49e-26	4.68e-23	-0.53	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
KIRC	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-11.26	2.5e-26	4.69e-23	-0.53	-0.45	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.26	2.5e-26	4.69e-23	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
KIRC	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-11.26	2.54e-26	4.76e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-11.26	2.54e-26	4.76e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-11.25	2.54e-26	4.76e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-11.25	2.57e-26	4.83e-23	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
KIRC	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-11.25	2.58e-26	4.84e-23	-0.6	-0.45	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
KIRC	cis	rs6456156	0.586	rs12527827	ENSG00000265828.1	MIR3939	-11.25	2.59e-26	4.84e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167055783	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.565	rs12529959	ENSG00000265828.1	MIR3939	-11.25	2.59e-26	4.84e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167055804	chr6:166997807~166997912:-
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	11.25	2.6e-26	4.87e-23	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
KIRC	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-11.25	2.62e-26	4.9e-23	-0.52	-0.45	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-11.25	2.64e-26	4.94e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-11.25	2.64e-26	4.94e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-11.25	2.64e-26	4.94e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
KIRC	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	11.25	2.64e-26	4.95e-23	0.52	0.45	Depression;	chr6:28273214	chr6:28176188~28176674:+
KIRC	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	11.25	2.64e-26	4.95e-23	0.52	0.45	Depression;	chr6:28273215	chr6:28176188~28176674:+
KIRC	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	11.25	2.67e-26	4.99e-23	0.52	0.45	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
KIRC	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	11.25	2.68e-26	5.01e-23	0.54	0.45	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
KIRC	cis	rs6456156	0.586	rs6456150	ENSG00000265828.1	MIR3939	-11.25	2.69e-26	5.04e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167055434	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	11.25	2.72e-26	5.08e-23	0.57	0.45	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	11.25	2.73e-26	5.11e-23	0.53	0.45	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
KIRC	cis	rs9457247	0.51	rs6456151	ENSG00000265828.1	MIR3939	-11.25	2.74e-26	5.12e-23	-0.51	-0.45	Crohn's disease;	chr6:167058363	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	11.25	2.74e-26	5.12e-23	0.58	0.45	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	11.25	2.75e-26	5.15e-23	0.91	0.45	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	11.25	2.76e-26	5.16e-23	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
KIRC	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	11.25	2.77e-26	5.18e-23	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
KIRC	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	11.24	2.78e-26	5.2e-23	0.47	0.45	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	11.24	2.78e-26	5.2e-23	0.47	0.45	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
KIRC	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-11.24	2.79e-26	5.21e-23	-0.38	-0.45	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
KIRC	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	11.24	2.8e-26	5.23e-23	0.57	0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
KIRC	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	11.24	2.82e-26	5.27e-23	0.65	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
KIRC	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-11.24	2.83e-26	5.29e-23	-0.51	-0.45	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
KIRC	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-11.24	2.84e-26	5.3e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-11.24	2.84e-26	5.3e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-11.24	2.84e-26	5.3e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
KIRC	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.24	2.89e-26	5.4e-23	0.53	0.45	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
KIRC	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	11.24	2.89e-26	5.4e-23	0.31	0.45	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
KIRC	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-11.24	2.92e-26	5.45e-23	-0.58	-0.45	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
KIRC	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-11.24	2.93e-26	5.47e-23	-0.91	-0.45	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
KIRC	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	11.24	2.94e-26	5.49e-23	0.54	0.45	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
KIRC	cis	rs6456156	0.586	rs911632	ENSG00000265828.1	MIR3939	-11.24	2.96e-26	5.53e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167057973	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs2017338	ENSG00000265828.1	MIR3939	-11.24	2.96e-26	5.53e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167058226	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.565	rs6456153	ENSG00000265828.1	MIR3939	-11.24	2.96e-26	5.53e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167058679	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs6456154	ENSG00000265828.1	MIR3939	-11.24	2.96e-26	5.53e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167058768	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs720325	ENSG00000265828.1	MIR3939	-11.24	2.97e-26	5.55e-23	-0.5	-0.45	Primary biliary cholangitis;	chr6:167053861	chr6:166997807~166997912:-
KIRC	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	11.24	3e-26	5.6e-23	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
KIRC	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.23	3.06e-26	5.71e-23	-0.56	-0.45	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
KIRC	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-11.23	3.09e-26	5.75e-23	-0.38	-0.45	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
KIRC	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	11.23	3.14e-26	5.85e-23	0.55	0.45	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
KIRC	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	11.23	3.21e-26	5.98e-23	0.52	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
KIRC	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-11.23	3.26e-26	6.07e-23	-0.52	-0.45	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
KIRC	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-11.23	3.3e-26	6.15e-23	-0.36	-0.45	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-11.23	3.32e-26	6.17e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
KIRC	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-11.22	3.33e-26	6.2e-23	-0.92	-0.45	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
KIRC	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-11.22	3.36e-26	6.25e-23	-0.58	-0.45	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
KIRC	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-11.22	3.39e-26	6.3e-23	-0.36	-0.45	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-11.22	3.44e-26	6.39e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	11.22	3.47e-26	6.45e-23	0.56	0.45	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	11.22	3.47e-26	6.45e-23	0.56	0.45	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
KIRC	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	11.21	3.64e-26	6.76e-23	0.54	0.45	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-11.21	3.69e-26	6.85e-23	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-11.21	3.69e-26	6.85e-23	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	11.21	3.71e-26	6.89e-23	0.57	0.45	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	11.21	3.72e-26	6.9e-23	0.57	0.45	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	11.21	3.75e-26	6.96e-23	0.57	0.45	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
KIRC	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	11.21	3.77e-26	6.99e-23	0.77	0.45	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
KIRC	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.21	3.78e-26	7.01e-23	0.67	0.45	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
KIRC	cis	rs2302464	1	rs16892289	ENSG00000214846.4	RP11-115L11.1	-11.21	3.78e-26	7.01e-23	-1.13	-0.45	Cerebrospinal fluid biomarker levels;	chr4:15730680	chr4:15730962~15731627:-
KIRC	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-11.21	3.81e-26	7.06e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-11.21	3.81e-26	7.06e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-11.21	3.81e-26	7.06e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
KIRC	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-11.21	3.91e-26	7.25e-23	-0.5	-0.45	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
KIRC	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	11.21	3.93e-26	7.29e-23	0.56	0.45	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
KIRC	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	11.2	4e-26	7.4e-23	0.54	0.45	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
KIRC	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	11.2	4.03e-26	7.46e-23	0.57	0.45	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
KIRC	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-11.2	4.05e-26	7.49e-23	-0.58	-0.45	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
KIRC	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-11.2	4.12e-26	7.61e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
KIRC	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-11.2	4.12e-26	7.63e-23	-0.51	-0.45	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
KIRC	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	11.2	4.15e-26	7.68e-23	0.56	0.45	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
KIRC	cis	rs6456156	0.586	rs9459853	ENSG00000265828.1	MIR3939	-11.2	4.16e-26	7.69e-23	-0.51	-0.45	Primary biliary cholangitis;	chr6:167052286	chr6:166997807~166997912:-
KIRC	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	11.2	4.21e-26	7.79e-23	0.55	0.45	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	11.2	4.26e-26	7.87e-23	0.37	0.45	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
KIRC	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-11.2	4.26e-26	7.88e-23	-0.44	-0.45	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	11.2	4.28e-26	7.91e-23	0.56	0.45	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
KIRC	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-11.2	4.33e-26	8.01e-23	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
KIRC	cis	rs9457247	0.765	rs9295385	ENSG00000265828.1	MIR3939	-11.2	4.33e-26	8.01e-23	-0.51	-0.45	Crohn's disease;	chr6:167034693	chr6:166997807~166997912:-
KIRC	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	11.2	4.34e-26	8.02e-23	0.42	0.45	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
KIRC	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	11.2	4.35e-26	8.04e-23	0.76	0.45	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
KIRC	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-11.2	4.35e-26	8.04e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
KIRC	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	11.19	4.38e-26	8.1e-23	0.44	0.45	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
KIRC	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-11.19	4.41e-26	8.15e-23	-0.58	-0.45	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
KIRC	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	11.19	4.51e-26	8.32e-23	0.56	0.45	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
KIRC	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-11.19	4.53e-26	8.37e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
KIRC	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-11.19	4.53e-26	8.37e-23	-0.37	-0.45	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
KIRC	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	11.19	4.54e-26	8.38e-23	0.52	0.45	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	11.19	4.54e-26	8.38e-23	0.56	0.45	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	11.19	4.54e-26	8.38e-23	0.56	0.45	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
KIRC	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	11.19	4.58e-26	8.45e-23	0.42	0.45	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	11.19	4.59e-26	8.48e-23	0.57	0.45	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
KIRC	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	11.19	4.63e-26	8.53e-23	0.76	0.45	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
KIRC	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	11.19	4.63e-26	8.53e-23	0.76	0.45	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
KIRC	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	11.19	4.63e-26	8.53e-23	0.76	0.45	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
KIRC	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	11.19	4.74e-26	8.74e-23	0.57	0.45	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	11.19	4.74e-26	8.74e-23	0.36	0.45	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
KIRC	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-11.19	4.75e-26	8.75e-23	-0.44	-0.45	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-11.19	4.75e-26	8.75e-23	-0.44	-0.45	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.19	4.76e-26	8.78e-23	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
KIRC	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-11.18	4.8e-26	8.84e-23	-0.36	-0.45	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-11.18	4.8e-26	8.84e-23	-0.36	-0.45	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-11.18	4.8e-26	8.84e-23	-0.36	-0.45	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	11.18	4.81e-26	8.86e-23	0.57	0.45	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-11.18	4.86e-26	8.94e-23	-0.58	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
KIRC	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-11.18	4.91e-26	9.03e-23	-0.5	-0.45	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
KIRC	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-11.18	4.97e-26	9.14e-23	-0.44	-0.45	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	11.18	4.97e-26	9.14e-23	0.57	0.45	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
KIRC	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	11.18	4.98e-26	9.16e-23	0.5	0.45	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
KIRC	cis	rs5769707	0.681	rs916360	ENSG00000235111.1	RP1-29C18.8	-11.18	4.99e-26	9.17e-23	-0.48	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49612657~49615716:-
KIRC	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-11.18	5.12e-26	9.4e-23	-0.54	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
KIRC	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-11.18	5.14e-26	9.45e-23	-0.52	-0.45	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
KIRC	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.29e-26	9.71e-23	-0.44	-0.45	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
KIRC	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	11.17	5.33e-26	9.77e-23	0.57	0.45	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-11.17	5.42e-26	9.94e-23	-0.56	-0.45	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
KIRC	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.49e-26	1.01e-22	-0.44	-0.45	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.49e-26	1.01e-22	-0.44	-0.45	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-11.17	5.51e-26	1.01e-22	-0.44	-0.45	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	11.17	5.7e-26	1.04e-22	0.37	0.45	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
KIRC	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	11.16	5.71e-26	1.05e-22	0.52	0.45	Depression;	chr6:28363475	chr6:28176188~28176674:+
KIRC	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	11.16	5.75e-26	1.05e-22	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
KIRC	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	11.16	5.76e-26	1.05e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	11.16	5.76e-26	1.05e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-11.16	5.88e-26	1.08e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	11.16	5.9e-26	1.08e-22	0.55	0.45	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
KIRC	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-11.16	5.9e-26	1.08e-22	-0.44	-0.45	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
KIRC	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	11.16	5.93e-26	1.08e-22	0.56	0.45	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
KIRC	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-11.16	5.95e-26	1.09e-22	-0.91	-0.45	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-11.16	5.99e-26	1.09e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-11.16	6.02e-26	1.1e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
KIRC	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-11.16	6.05e-26	1.1e-22	-0.9	-0.45	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-11.16	6.05e-26	1.11e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	11.16	6.08e-26	1.11e-22	0.65	0.45	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
KIRC	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-11.16	6.09e-26	1.11e-22	-0.91	-0.45	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
KIRC	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-11.16	6.19e-26	1.13e-22	-0.47	-0.45	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
KIRC	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-11.16	6.2e-26	1.13e-22	-0.45	-0.45	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
KIRC	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-11.15	6.26e-26	1.14e-22	-0.44	-0.45	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
KIRC	cis	rs6456156	0.586	rs13210649	ENSG00000265828.1	MIR3939	-11.15	6.33e-26	1.15e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167059705	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs12213801	ENSG00000265828.1	MIR3939	-11.15	6.33e-26	1.15e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167060596	chr6:166997807~166997912:-
KIRC	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	11.15	6.38e-26	1.16e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
KIRC	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-11.15	6.44e-26	1.17e-22	-0.55	-0.45	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
KIRC	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-11.15	6.44e-26	1.17e-22	-0.5	-0.45	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
KIRC	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	11.15	6.61e-26	1.2e-22	0.57	0.45	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	11.15	6.67e-26	1.21e-22	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	11.15	6.67e-26	1.21e-22	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
KIRC	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	11.15	6.67e-26	1.21e-22	0.74	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	11.15	6.68e-26	1.22e-22	0.56	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	11.15	6.68e-26	1.22e-22	0.56	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	11.15	6.8e-26	1.24e-22	0.31	0.45	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
KIRC	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	11.14	6.84e-26	1.24e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-11.14	6.88e-26	1.25e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-11.14	6.88e-26	1.25e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-11.14	6.88e-26	1.25e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
KIRC	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-11.14	6.88e-26	1.25e-22	-0.74	-0.45	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
KIRC	cis	rs4356975	0.842	rs6600899	ENSG00000250696.4	RP11-704M14.1	11.14	7.01e-26	1.27e-22	0.47	0.45	Obesity-related traits;	chr4:69132295	chr4:69182100~69216766:+
KIRC	cis	rs6456156	0.583	rs7748224	ENSG00000265828.1	MIR3939	-11.14	7.16e-26	1.3e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167043372	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	11.14	7.18e-26	1.3e-22	0.56	0.45	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
KIRC	cis	rs6456156	0.565	rs12529238	ENSG00000265828.1	MIR3939	-11.14	7.23e-26	1.31e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167052088	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.524	rs6932740	ENSG00000265828.1	MIR3939	-11.14	7.23e-26	1.31e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167052951	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.524	rs6934043	ENSG00000265828.1	MIR3939	-11.14	7.23e-26	1.31e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167052961	chr6:166997807~166997912:-
KIRC	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	11.14	7.27e-26	1.32e-22	0.54	0.45	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
KIRC	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-11.14	7.28e-26	1.32e-22	-0.61	-0.45	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
KIRC	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-11.14	7.43e-26	1.35e-22	-0.54	-0.45	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
KIRC	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-11.13	7.48e-26	1.36e-22	-0.39	-0.45	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
KIRC	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-11.13	7.51e-26	1.36e-22	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
KIRC	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	11.13	7.51e-26	1.36e-22	0.37	0.45	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	11.13	7.63e-26	1.38e-22	0.56	0.45	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	11.13	7.63e-26	1.38e-22	0.56	0.45	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	11.13	7.69e-26	1.4e-22	0.56	0.45	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-11.13	7.99e-26	1.45e-22	-0.59	-0.45	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	11.13	8.09e-26	1.47e-22	0.56	0.45	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	11.13	8.09e-26	1.47e-22	0.56	0.45	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
KIRC	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-11.13	8.13e-26	1.47e-22	-0.9	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
KIRC	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	11.13	8.14e-26	1.47e-22	0.46	0.45	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	11.13	8.14e-26	1.47e-22	0.46	0.45	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-11.12	8.27e-26	1.5e-22	-0.36	-0.45	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-11.12	8.27e-26	1.5e-22	-0.36	-0.45	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	11.12	8.28e-26	1.5e-22	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
KIRC	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-11.12	8.29e-26	1.5e-22	-0.66	-0.45	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
KIRC	cis	rs6456156	0.565	rs2181058	ENSG00000265828.1	MIR3939	-11.12	8.31e-26	1.5e-22	-0.51	-0.45	Primary biliary cholangitis;	chr6:167051842	chr6:166997807~166997912:-
KIRC	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	11.12	8.47e-26	1.53e-22	0.56	0.45	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
KIRC	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-11.12	8.51e-26	1.54e-22	-0.9	-0.45	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
KIRC	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-11.12	8.59e-26	1.55e-22	-0.68	-0.45	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
KIRC	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	11.12	8.6e-26	1.55e-22	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	11.11	8.99e-26	1.62e-22	0.56	0.45	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	11.11	8.99e-26	1.62e-22	0.56	0.45	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
KIRC	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-11.11	8.99e-26	1.62e-22	-0.45	-0.45	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
KIRC	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	11.11	9.08e-26	1.64e-22	0.62	0.45	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
KIRC	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	11.11	9.15e-26	1.65e-22	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
KIRC	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-11.11	9.17e-26	1.65e-22	-0.39	-0.45	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
KIRC	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-11.11	9.17e-26	1.66e-22	-0.56	-0.45	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	11.11	9.47e-26	1.71e-22	0.56	0.45	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	11.11	9.47e-26	1.71e-22	0.56	0.45	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	11.11	9.47e-26	1.71e-22	0.56	0.45	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
KIRC	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-11.11	9.52e-26	1.72e-22	-0.57	-0.45	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
KIRC	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-11.11	9.58e-26	1.73e-22	-0.58	-0.45	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
KIRC	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	11.11	9.61e-26	1.73e-22	0.66	0.45	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
KIRC	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-11.11	9.65e-26	1.74e-22	-0.48	-0.45	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
KIRC	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-11.1	9.85e-26	1.78e-22	-0.89	-0.45	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
KIRC	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-11.1	9.97e-26	1.8e-22	-0.44	-0.45	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
KIRC	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	11.1	1e-25	1.8e-22	0.41	0.45	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
KIRC	cis	rs6456156	0.586	rs6909180	ENSG00000265828.1	MIR3939	-11.1	1e-25	1.8e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167047049	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs12213683	ENSG00000265828.1	MIR3939	-11.1	1e-25	1.8e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167047230	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs12528323	ENSG00000265828.1	MIR3939	-11.1	1e-25	1.8e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167048157	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-11.1	1e-25	1.8e-22	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	11.1	1e-25	1.81e-22	0.56	0.45	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	11.1	1e-25	1.81e-22	0.56	0.45	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	11.1	1e-25	1.81e-22	0.56	0.45	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	11.1	1e-25	1.81e-22	0.56	0.45	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	11.1	1e-25	1.81e-22	0.56	0.45	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
KIRC	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-11.1	1.01e-25	1.81e-22	-0.7	-0.45	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
KIRC	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-11.1	1.01e-25	1.82e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
KIRC	cis	rs6456156	0.586	rs12529876	ENSG00000265828.1	MIR3939	-11.1	1.01e-25	1.82e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167048013	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs12528689	ENSG00000265828.1	MIR3939	-11.1	1.01e-25	1.82e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167048258	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs13208636	ENSG00000265828.1	MIR3939	-11.1	1.01e-25	1.82e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167048477	chr6:166997807~166997912:-
KIRC	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	11.1	1.02e-25	1.84e-22	0.31	0.45	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
KIRC	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-11.1	1.02e-25	1.84e-22	-0.35	-0.45	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-11.1	1.02e-25	1.84e-22	-0.35	-0.45	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-11.1	1.02e-25	1.84e-22	-0.35	-0.45	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
KIRC	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-11.1	1.02e-25	1.84e-22	-0.35	-0.45	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
KIRC	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	11.1	1.03e-25	1.85e-22	0.54	0.45	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
KIRC	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	11.1	1.03e-25	1.86e-22	0.55	0.45	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
KIRC	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-11.1	1.04e-25	1.86e-22	-0.44	-0.45	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
KIRC	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	11.1	1.04e-25	1.87e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	11.1	1.04e-25	1.87e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	11.1	1.04e-25	1.87e-22	0.58	0.45	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
KIRC	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	11.1	1.04e-25	1.88e-22	0.42	0.45	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	11.1	1.04e-25	1.88e-22	0.42	0.45	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.88e-22	0.56	0.45	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
KIRC	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.1	1.05e-25	1.89e-22	0.46	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
KIRC	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	11.1	1.05e-25	1.89e-22	0.56	0.45	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-11.1	1.07e-25	1.91e-22	-0.37	-0.45	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	11.09	1.09e-25	1.96e-22	0.63	0.45	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
KIRC	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	11.09	1.11e-25	1.99e-22	0.46	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
KIRC	cis	rs6456156	0.586	rs6456149	ENSG00000265828.1	MIR3939	-11.09	1.11e-25	1.99e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167050414	chr6:166997807~166997912:-
KIRC	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-11.09	1.11e-25	2e-22	-0.53	-0.45	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
KIRC	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	11.09	1.14e-25	2.05e-22	0.54	0.45	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
KIRC	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-11.09	1.14e-25	2.05e-22	-0.59	-0.45	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
KIRC	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	11.09	1.16e-25	2.09e-22	0.42	0.45	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
KIRC	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-11.08	1.17e-25	2.1e-22	-0.44	-0.45	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-11.08	1.17e-25	2.1e-22	-0.44	-0.45	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-11.08	1.22e-25	2.19e-22	-0.44	-0.45	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-11.08	1.23e-25	2.21e-22	-0.35	-0.45	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
KIRC	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	11.08	1.24e-25	2.22e-22	0.54	0.45	Height;	chr11:118703185	chr11:118688039~118690600:-
KIRC	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	11.08	1.24e-25	2.22e-22	0.54	0.45	Height;	chr11:118703207	chr11:118688039~118690600:-
KIRC	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	11.08	1.24e-25	2.22e-22	0.54	0.45	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.08	1.24e-25	2.22e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
KIRC	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-11.08	1.25e-25	2.25e-22	-0.48	-0.45	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
KIRC	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	11.08	1.26e-25	2.25e-22	0.57	0.45	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
KIRC	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	11.08	1.26e-25	2.26e-22	0.55	0.45	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
KIRC	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-11.08	1.27e-25	2.27e-22	-0.6	-0.45	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
KIRC	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.08	1.27e-25	2.28e-22	0.46	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
KIRC	cis	rs6456156	0.565	rs12525345	ENSG00000265828.1	MIR3939	-11.08	1.27e-25	2.28e-22	-0.5	-0.45	Primary biliary cholangitis;	chr6:167065387	chr6:166997807~166997912:-
KIRC	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-11.08	1.28e-25	2.29e-22	-0.61	-0.45	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
KIRC	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-11.07	1.28e-25	2.3e-22	-0.46	-0.45	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
KIRC	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	11.07	1.29e-25	2.31e-22	0.35	0.45	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
KIRC	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-11.07	1.3e-25	2.32e-22	-0.49	-0.45	Temperament;	chr17:14003617	chr17:14024514~14025488:+
KIRC	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	11.07	1.3e-25	2.33e-22	0.56	0.45	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	11.07	1.3e-25	2.33e-22	0.56	0.45	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
KIRC	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	11.07	1.31e-25	2.34e-22	0.57	0.45	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
KIRC	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	11.07	1.32e-25	2.35e-22	0.46	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
KIRC	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-11.07	1.35e-25	2.4e-22	-0.69	-0.45	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
KIRC	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	11.07	1.35e-25	2.4e-22	0.54	0.45	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	11.07	1.35e-25	2.41e-22	0.55	0.45	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
KIRC	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-11.07	1.35e-25	2.41e-22	-0.58	-0.45	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
KIRC	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	11.07	1.36e-25	2.43e-22	0.41	0.45	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
KIRC	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-11.07	1.36e-25	2.43e-22	-0.6	-0.45	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
KIRC	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-11.07	1.38e-25	2.47e-22	-0.39	-0.45	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
KIRC	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-11.07	1.39e-25	2.48e-22	-0.78	-0.45	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
KIRC	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	11.07	1.4e-25	2.49e-22	0.56	0.45	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
KIRC	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	11.06	1.42e-25	2.52e-22	0.52	0.45	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
KIRC	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	11.06	1.44e-25	2.57e-22	0.35	0.45	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
KIRC	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	11.06	1.45e-25	2.59e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	11.06	1.45e-25	2.59e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	11.06	1.45e-25	2.59e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	11.06	1.45e-25	2.59e-22	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
KIRC	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-11.06	1.46e-25	2.61e-22	-0.36	-0.45	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
KIRC	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-11.06	1.47e-25	2.62e-22	-0.6	-0.45	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
KIRC	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-11.06	1.53e-25	2.72e-22	-0.79	-0.44	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
KIRC	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-11.05	1.55e-25	2.76e-22	-0.55	-0.44	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
KIRC	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	11.05	1.56e-25	2.77e-22	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
KIRC	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-11.05	1.56e-25	2.77e-22	-0.42	-0.44	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
KIRC	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-11.05	1.56e-25	2.78e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-11.05	1.56e-25	2.78e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	11.05	1.59e-25	2.83e-22	0.56	0.44	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
KIRC	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-11.05	1.59e-25	2.83e-22	-0.6	-0.44	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
KIRC	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	11.05	1.6e-25	2.85e-22	0.57	0.44	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
KIRC	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-11.05	1.61e-25	2.86e-22	-0.52	-0.44	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
KIRC	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	11.05	1.61e-25	2.87e-22	0.54	0.44	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
KIRC	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-11.05	1.62e-25	2.87e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
KIRC	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-11.05	1.63e-25	2.9e-22	-0.91	-0.44	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
KIRC	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	11.05	1.63e-25	2.9e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
KIRC	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	11.05	1.67e-25	2.96e-22	0.55	0.44	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
KIRC	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-11.04	1.7e-25	3.01e-22	-0.42	-0.44	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
KIRC	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-11.04	1.7e-25	3.02e-22	-0.63	-0.44	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
KIRC	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	11.04	1.73e-25	3.07e-22	0.51	0.44	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
KIRC	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	11.04	1.74e-25	3.08e-22	0.55	0.44	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
KIRC	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11.04	1.76e-25	3.12e-22	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
KIRC	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	11.04	1.76e-25	3.12e-22	0.55	0.44	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	11.04	1.76e-25	3.12e-22	0.55	0.44	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	11.04	1.76e-25	3.12e-22	0.55	0.44	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	11.04	1.76e-25	3.12e-22	0.55	0.44	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	11.04	1.76e-25	3.12e-22	0.55	0.44	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
KIRC	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	11.04	1.79e-25	3.17e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
KIRC	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	11.04	1.79e-25	3.18e-22	0.56	0.44	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	11.04	1.79e-25	3.18e-22	0.56	0.44	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	11.04	1.8e-25	3.19e-22	0.37	0.44	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	11.04	1.82e-25	3.23e-22	0.56	0.44	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
KIRC	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-11.03	1.88e-25	3.32e-22	-0.5	-0.44	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
KIRC	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-11.03	1.88e-25	3.32e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
KIRC	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	11.03	1.92e-25	3.38e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-11.03	1.92e-25	3.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
KIRC	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-11.03	1.98e-25	3.49e-22	-0.58	-0.44	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
KIRC	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	11.02	2.01e-25	3.54e-22	0.61	0.44	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
KIRC	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-11.02	2.02e-25	3.56e-22	-0.73	-0.44	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
KIRC	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-11.02	2.04e-25	3.61e-22	-0.55	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
KIRC	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-11.02	2.06e-25	3.63e-22	-0.65	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
KIRC	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	11.02	2.06e-25	3.64e-22	0.52	0.44	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
KIRC	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-11.02	2.1e-25	3.71e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
KIRC	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-11.02	2.1e-25	3.71e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
KIRC	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-11.02	2.11e-25	3.72e-22	-0.5	-0.44	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
KIRC	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	11.02	2.16e-25	3.8e-22	0.6	0.44	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
KIRC	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	11.02	2.17e-25	3.82e-22	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
KIRC	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-11.02	2.17e-25	3.82e-22	-0.52	-0.44	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	11.02	2.18e-25	3.83e-22	0.52	0.44	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
KIRC	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-11.01	2.21e-25	3.88e-22	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
KIRC	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	11.01	2.22e-25	3.91e-22	0.51	0.44	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
KIRC	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-11.01	2.22e-25	3.91e-22	-0.53	-0.44	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
KIRC	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-11.01	2.24e-25	3.94e-22	-0.58	-0.44	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
KIRC	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	11.01	2.28e-25	4.01e-22	0.42	0.44	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
KIRC	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	11.01	2.28e-25	4.01e-22	0.36	0.44	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
KIRC	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	11.01	2.28e-25	4.02e-22	0.41	0.44	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
KIRC	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	11.01	2.3e-25	4.04e-22	0.42	0.44	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
KIRC	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	11.01	2.32e-25	4.08e-22	0.58	0.44	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
KIRC	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	11.01	2.33e-25	4.1e-22	0.42	0.44	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	11.01	2.35e-25	4.12e-22	0.59	0.44	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
KIRC	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	11.01	2.36e-25	4.14e-22	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
KIRC	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-11	2.41e-25	4.24e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
KIRC	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-11	2.44e-25	4.28e-22	-0.68	-0.44	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
KIRC	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	11	2.45e-25	4.3e-22	0.55	0.44	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
KIRC	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	11	2.45e-25	4.3e-22	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
KIRC	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-11	2.46e-25	4.32e-22	-0.54	-0.44	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
KIRC	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	11	2.47e-25	4.34e-22	0.41	0.44	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	11	2.47e-25	4.34e-22	0.41	0.44	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	11	2.47e-25	4.34e-22	0.41	0.44	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
KIRC	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-11	2.48e-25	4.36e-22	-0.44	-0.44	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
KIRC	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-11	2.49e-25	4.37e-22	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
KIRC	cis	rs4814920	0.818	rs6046387	ENSG00000275142.1	RP5-999L4.2	-11	2.49e-25	4.37e-22	-0.81	-0.44	Bipolar disorder (body mass index interaction);	chr20:19869186	chr20:19871891~19872284:+
KIRC	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-11	2.5e-25	4.38e-22	-0.37	-0.44	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
KIRC	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	11	2.53e-25	4.43e-22	0.63	0.44	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
KIRC	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	11	2.54e-25	4.45e-22	0.54	0.44	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
KIRC	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	11	2.55e-25	4.47e-22	0.56	0.44	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-11	2.55e-25	4.48e-22	-0.58	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
KIRC	cis	rs2919917	0.628	rs11776243	ENSG00000254352.1	RP11-578O24.2	11	2.59e-25	4.54e-22	0.57	0.44	Lymphocyte counts;	chr8:78648848	chr8:78723796~78724136:-
KIRC	cis	rs2919917	0.628	rs10110524	ENSG00000254352.1	RP11-578O24.2	11	2.59e-25	4.54e-22	0.57	0.44	Lymphocyte counts;	chr8:78648871	chr8:78723796~78724136:-
KIRC	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-11	2.6e-25	4.55e-22	-0.44	-0.44	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
KIRC	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-11	2.6e-25	4.55e-22	-0.46	-0.44	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
KIRC	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-11	2.61e-25	4.56e-22	-0.62	-0.44	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
KIRC	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-10.99	2.62e-25	4.59e-22	-0.45	-0.44	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
KIRC	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-10.99	2.65e-25	4.65e-22	-0.44	-0.44	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
KIRC	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	10.99	2.74e-25	4.78e-22	0.64	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
KIRC	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	10.99	2.79e-25	4.87e-22	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	10.99	2.79e-25	4.87e-22	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
KIRC	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-10.99	2.8e-25	4.9e-22	-0.43	-0.44	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
KIRC	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-10.99	2.82e-25	4.93e-22	-0.5	-0.44	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
KIRC	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.98	2.9e-25	5.06e-22	0.53	0.44	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
KIRC	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-10.98	2.91e-25	5.08e-22	-0.54	-0.44	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
KIRC	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-10.98	2.93e-25	5.12e-22	-0.44	-0.44	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
KIRC	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-10.98	2.95e-25	5.15e-22	-0.52	-0.44	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
KIRC	cis	rs1823913	1	rs10445782	ENSG00000280083.1	RP11-317J9.1	10.98	2.97e-25	5.18e-22	0.42	0.44	Obesity-related traits;	chr2:191236639	chr2:191154118~191156070:-
KIRC	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-10.98	3e-25	5.24e-22	-0.43	-0.44	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
KIRC	cis	rs1823913	0.926	rs12615901	ENSG00000280083.1	RP11-317J9.1	10.98	3.02e-25	5.28e-22	0.43	0.44	Obesity-related traits;	chr2:191233381	chr2:191154118~191156070:-
KIRC	cis	rs1823913	1	rs7574570	ENSG00000280083.1	RP11-317J9.1	10.98	3.02e-25	5.28e-22	0.43	0.44	Obesity-related traits;	chr2:191233790	chr2:191154118~191156070:-
KIRC	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-10.98	3.03e-25	5.29e-22	-0.46	-0.44	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
KIRC	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	10.98	3.04e-25	5.3e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	10.98	3.04e-25	5.3e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	10.98	3.04e-25	5.3e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	10.98	3.04e-25	5.3e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-10.98	3.05e-25	5.32e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
KIRC	cis	rs1823913	1	rs10445783	ENSG00000280083.1	RP11-317J9.1	10.98	3.1e-25	5.4e-22	0.42	0.44	Obesity-related traits;	chr2:191236772	chr2:191154118~191156070:-
KIRC	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-10.98	3.11e-25	5.43e-22	-0.45	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
KIRC	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	10.98	3.12e-25	5.43e-22	0.41	0.44	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
KIRC	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	10.97	3.13e-25	5.46e-22	0.51	0.44	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	10.97	3.13e-25	5.46e-22	0.51	0.44	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
KIRC	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-10.97	3.16e-25	5.5e-22	-0.87	-0.44	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-10.97	3.2e-25	5.57e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-10.97	3.2e-25	5.57e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-10.97	3.21e-25	5.59e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	10.97	3.21e-25	5.59e-22	0.63	0.44	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
KIRC	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-10.97	3.25e-25	5.66e-22	-0.53	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
KIRC	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-10.97	3.25e-25	5.66e-22	-0.51	-0.44	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-10.97	3.25e-25	5.66e-22	-0.51	-0.44	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-10.97	3.25e-25	5.66e-22	-0.51	-0.44	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	10.97	3.25e-25	5.66e-22	0.51	0.44	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	10.97	3.25e-25	5.66e-22	0.51	0.44	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
KIRC	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	10.97	3.29e-25	5.72e-22	0.66	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
KIRC	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-10.97	3.29e-25	5.73e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-10.97	3.3e-25	5.74e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-10.97	3.3e-25	5.74e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
KIRC	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	10.97	3.31e-25	5.75e-22	0.59	0.44	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
KIRC	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-10.97	3.32e-25	5.78e-22	-0.5	-0.44	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
KIRC	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	10.97	3.39e-25	5.89e-22	0.72	0.44	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
KIRC	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	10.97	3.39e-25	5.89e-22	0.63	0.44	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
KIRC	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	10.97	3.4e-25	5.92e-22	0.52	0.44	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
KIRC	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	10.96	3.43e-25	5.95e-22	0.45	0.44	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
KIRC	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	10.96	3.46e-25	6.02e-22	0.57	0.44	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
KIRC	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	10.96	3.5e-25	6.09e-22	0.41	0.44	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
KIRC	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-10.96	3.52e-25	6.11e-22	-0.45	-0.44	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
KIRC	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-10.96	3.52e-25	6.11e-22	-0.52	-0.44	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
KIRC	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	10.96	3.52e-25	6.12e-22	0.54	0.44	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
KIRC	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-10.96	3.62e-25	6.28e-22	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-10.96	3.62e-25	6.28e-22	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
KIRC	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	10.96	3.63e-25	6.3e-22	0.54	0.44	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	10.96	3.63e-25	6.3e-22	0.54	0.44	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	10.96	3.63e-25	6.3e-22	0.54	0.44	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	10.96	3.63e-25	6.3e-22	0.54	0.44	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	10.96	3.63e-25	6.3e-22	0.54	0.44	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
KIRC	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-10.96	3.64e-25	6.32e-22	-0.5	-0.44	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
KIRC	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	10.96	3.7e-25	6.42e-22	0.51	0.44	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
KIRC	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	10.95	3.74e-25	6.48e-22	0.65	0.44	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
KIRC	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	10.95	3.8e-25	6.59e-22	0.69	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
KIRC	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	10.95	3.87e-25	6.71e-22	0.5	0.44	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
KIRC	cis	rs6456156	0.586	rs1358883	ENSG00000265828.1	MIR3939	10.95	3.94e-25	6.82e-22	0.49	0.44	Primary biliary cholangitis;	chr6:167053945	chr6:166997807~166997912:-
KIRC	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	10.95	3.96e-25	6.86e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	10.95	3.96e-25	6.86e-22	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-10.95	4.03e-25	6.97e-22	-0.9	-0.44	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
KIRC	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-10.94	4.09e-25	7.09e-22	-0.51	-0.44	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
KIRC	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	10.94	4.14e-25	7.16e-22	0.56	0.44	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
KIRC	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	10.94	4.16e-25	7.2e-22	0.53	0.44	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
KIRC	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	10.94	4.2e-25	7.26e-22	0.46	0.44	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
KIRC	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-10.94	4.21e-25	7.28e-22	-0.54	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
KIRC	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	10.94	4.28e-25	7.4e-22	0.54	0.44	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
KIRC	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-10.94	4.28e-25	7.41e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
KIRC	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	10.94	4.31e-25	7.45e-22	0.63	0.44	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
KIRC	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.94	4.32e-25	7.47e-22	0.55	0.44	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
KIRC	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-10.94	4.36e-25	7.53e-22	-0.45	-0.44	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
KIRC	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-10.94	4.36e-25	7.53e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
KIRC	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	10.94	4.41e-25	7.62e-22	0.66	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
KIRC	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-10.94	4.42e-25	7.63e-22	-0.52	-0.44	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-10.94	4.42e-25	7.63e-22	-0.52	-0.44	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
KIRC	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-10.94	4.46e-25	7.69e-22	-0.45	-0.44	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
KIRC	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	10.93	4.46e-25	7.71e-22	0.58	0.44	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
KIRC	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-10.93	4.47e-25	7.72e-22	-0.54	-0.44	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
KIRC	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-10.93	4.48e-25	7.73e-22	-0.52	-0.44	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
KIRC	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	10.93	4.48e-25	7.73e-22	0.45	0.44	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
KIRC	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-10.93	4.48e-25	7.74e-22	-0.65	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
KIRC	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-10.93	4.52e-25	7.8e-22	-0.46	-0.44	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
KIRC	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-10.93	4.58e-25	7.91e-22	-0.43	-0.44	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
KIRC	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	10.93	4.58e-25	7.91e-22	0.45	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	10.93	4.58e-25	7.91e-22	0.45	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
KIRC	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-10.93	4.59e-25	7.91e-22	-0.55	-0.44	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
KIRC	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-10.93	4.6e-25	7.94e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-10.93	4.6e-25	7.94e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
KIRC	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-10.93	4.62e-25	7.97e-22	-0.53	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
KIRC	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-10.93	4.62e-25	7.97e-22	-0.53	-0.44	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
KIRC	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-10.93	4.64e-25	8e-22	-0.58	-0.44	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
KIRC	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	10.93	4.67e-25	8.06e-22	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
KIRC	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-10.93	4.68e-25	8.07e-22	-0.43	-0.44	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
KIRC	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	10.93	4.75e-25	8.18e-22	0.39	0.44	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
KIRC	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	10.93	4.76e-25	8.2e-22	0.71	0.44	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
KIRC	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-10.93	4.84e-25	8.34e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-10.93	4.84e-25	8.34e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-10.92	4.88e-25	8.4e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
KIRC	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-10.92	4.88e-25	8.4e-22	-0.54	-0.44	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	10.92	4.88e-25	8.41e-22	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
KIRC	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-10.92	4.95e-25	8.52e-22	-0.63	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
KIRC	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	10.92	4.97e-25	8.55e-22	0.71	0.44	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	10.92	4.97e-25	8.56e-22	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
KIRC	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-10.92	5.01e-25	8.63e-22	-0.36	-0.44	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
KIRC	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-10.92	5.06e-25	8.71e-22	-0.36	-0.44	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	10.92	5.12e-25	8.8e-22	0.35	0.44	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
KIRC	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-10.92	5.2e-25	8.94e-22	-0.5	-0.44	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-10.92	5.2e-25	8.94e-22	-0.5	-0.44	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
KIRC	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	10.92	5.26e-25	9.04e-22	0.54	0.44	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
KIRC	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-10.92	5.31e-25	9.12e-22	-0.91	-0.44	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-10.91	5.38e-25	9.24e-22	-0.35	-0.44	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	10.91	5.39e-25	9.25e-22	0.62	0.44	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
KIRC	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-10.91	5.4e-25	9.26e-22	-0.46	-0.44	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
KIRC	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-10.91	5.42e-25	9.29e-22	-0.37	-0.44	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.91	5.56e-25	9.54e-22	0.56	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
KIRC	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	10.91	5.66e-25	9.7e-22	0.31	0.44	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
KIRC	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	10.91	5.75e-25	9.85e-22	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
KIRC	cis	rs6456156	0.586	rs2285148	ENSG00000265828.1	MIR3939	-10.91	5.76e-25	9.86e-22	-0.51	-0.44	Primary biliary cholangitis;	chr6:167077511	chr6:166997807~166997912:-
KIRC	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-10.9	5.87e-25	1e-21	-0.53	-0.44	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-10.9	5.89e-25	1.01e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
KIRC	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-10.9	5.91e-25	1.01e-21	-0.63	-0.44	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
KIRC	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-10.9	5.93e-25	1.01e-21	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-10.9	5.93e-25	1.01e-21	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-10.9	5.93e-25	1.01e-21	-0.52	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
KIRC	cis	rs13236243	0.673	rs4721596	ENSG00000236318.1	AC019117.1	10.9	5.95e-25	1.02e-21	0.59	0.44	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17380483	chr7:17374867~17466664:+
KIRC	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	10.9	5.95e-25	1.02e-21	0.72	0.44	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
KIRC	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	10.9	5.96e-25	1.02e-21	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	10.9	5.96e-25	1.02e-21	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	10.9	6.06e-25	1.04e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	10.9	6.06e-25	1.04e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-10.9	6.07e-25	1.04e-21	-0.89	-0.44	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
KIRC	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-10.9	6.12e-25	1.05e-21	-0.58	-0.44	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
KIRC	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-10.9	6.12e-25	1.05e-21	-0.56	-0.44	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
KIRC	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-10.9	6.18e-25	1.06e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	10.9	6.18e-25	1.06e-21	0.36	0.44	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
KIRC	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-10.9	6.23e-25	1.06e-21	-0.45	-0.44	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
KIRC	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	10.9	6.24e-25	1.07e-21	0.52	0.44	Height;	chr11:118786602	chr11:118688039~118690600:-
KIRC	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	10.9	6.25e-25	1.07e-21	0.63	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
KIRC	cis	rs1823913	1	rs4853559	ENSG00000280083.1	RP11-317J9.1	10.89	6.4e-25	1.09e-21	0.42	0.44	Obesity-related traits;	chr2:191235965	chr2:191154118~191156070:-
KIRC	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	10.89	6.42e-25	1.1e-21	0.66	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
KIRC	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	10.89	6.44e-25	1.1e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
KIRC	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-10.89	6.46e-25	1.1e-21	-0.47	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
KIRC	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	10.89	6.54e-25	1.12e-21	0.51	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
KIRC	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	10.89	6.56e-25	1.12e-21	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	10.89	6.56e-25	1.12e-21	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
KIRC	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-10.89	6.58e-25	1.12e-21	-0.57	-0.44	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
KIRC	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	10.89	6.59e-25	1.12e-21	0.59	0.44	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
KIRC	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	10.89	6.61e-25	1.13e-21	0.53	0.44	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
KIRC	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-10.89	6.71e-25	1.14e-21	-0.43	-0.44	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
KIRC	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-10.89	6.78e-25	1.16e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-10.89	6.78e-25	1.16e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-10.89	6.78e-25	1.16e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
KIRC	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	10.89	6.79e-25	1.16e-21	0.66	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
KIRC	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	10.89	6.81e-25	1.16e-21	0.44	0.44	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
KIRC	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-10.88	6.97e-25	1.19e-21	-0.56	-0.44	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
KIRC	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-10.88	7.18e-25	1.22e-21	-0.43	-0.44	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
KIRC	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-10.88	7.2e-25	1.23e-21	-0.69	-0.44	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
KIRC	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	10.88	7.2e-25	1.23e-21	0.53	0.44	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	10.88	7.2e-25	1.23e-21	0.53	0.44	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
KIRC	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-10.88	7.24e-25	1.23e-21	-0.45	-0.44	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
KIRC	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-10.88	7.26e-25	1.23e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-10.88	7.27e-25	1.24e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-10.88	7.27e-25	1.24e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-10.88	7.27e-25	1.24e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-10.88	7.27e-25	1.24e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-10.88	7.27e-25	1.24e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
KIRC	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	10.88	7.27e-25	1.24e-21	0.51	0.44	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	10.88	7.27e-25	1.24e-21	0.51	0.44	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
KIRC	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	10.87	7.64e-25	1.3e-21	0.53	0.44	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000251284.2	RP13-644M16.1	-10.87	7.68e-25	1.3e-21	-0.63	-0.44	Obesity-related traits;	chr4:69104054	chr4:69125274~69126451:+
KIRC	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	10.87	7.72e-25	1.31e-21	0.43	0.44	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
KIRC	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-10.87	7.75e-25	1.32e-21	-0.46	-0.44	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
KIRC	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	10.87	7.84e-25	1.33e-21	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
KIRC	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-10.87	7.93e-25	1.34e-21	-0.89	-0.44	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	10.87	8.01e-25	1.36e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
KIRC	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-10.87	8.08e-25	1.37e-21	-0.56	-0.44	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
KIRC	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-10.87	8.25e-25	1.4e-21	-0.51	-0.44	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
KIRC	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	10.87	8.27e-25	1.4e-21	0.74	0.44	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
KIRC	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	10.86	8.37e-25	1.42e-21	0.52	0.44	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
KIRC	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-10.86	8.38e-25	1.42e-21	-0.56	-0.44	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
KIRC	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	10.86	8.39e-25	1.42e-21	0.64	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
KIRC	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	10.86	8.48e-25	1.44e-21	0.56	0.44	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-10.86	8.62e-25	1.46e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
KIRC	cis	rs2698530	0.607	rs1019686	ENSG00000225889.6	AC074289.1	-10.86	8.64e-25	1.46e-21	-0.44	-0.44	Iron status biomarkers;	chr2:64234988	chr2:64143239~64252859:+
KIRC	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-10.86	8.69e-25	1.47e-21	-0.37	-0.44	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-10.86	8.69e-25	1.47e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-10.86	8.69e-25	1.47e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-10.86	8.69e-25	1.47e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
KIRC	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	10.86	8.7e-25	1.47e-21	0.51	0.44	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
KIRC	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	10.86	8.81e-25	1.49e-21	0.51	0.44	Height;	chr11:118773873	chr11:118688039~118690600:-
KIRC	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	10.86	8.82e-25	1.49e-21	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
KIRC	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-10.86	8.89e-25	1.5e-21	-0.51	-0.44	Height;	chr11:118758322	chr11:118688039~118690600:-
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	10.86	8.9e-25	1.51e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000251284.2	RP13-644M16.1	-10.86	8.98e-25	1.52e-21	-0.62	-0.44	Obesity-related traits;	chr4:69107521	chr4:69125274~69126451:+
KIRC	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-10.86	9.04e-25	1.53e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
KIRC	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-10.85	9.07e-25	1.53e-21	-0.68	-0.44	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
KIRC	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-10.85	9.11e-25	1.54e-21	-0.34	-0.44	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
KIRC	cis	rs4356975	0.697	rs66666893	ENSG00000250696.4	RP11-704M14.1	10.85	9.22e-25	1.56e-21	0.46	0.44	Obesity-related traits;	chr4:69133393	chr4:69182100~69216766:+
KIRC	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	10.85	9.22e-25	1.56e-21	0.54	0.44	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
KIRC	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	10.85	9.3e-25	1.57e-21	0.39	0.44	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
KIRC	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	10.85	9.33e-25	1.57e-21	0.66	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
KIRC	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	10.85	9.62e-25	1.62e-21	0.55	0.44	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
KIRC	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-10.85	9.64e-25	1.62e-21	-0.51	-0.44	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
KIRC	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-10.85	9.65e-25	1.62e-21	-0.7	-0.44	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
KIRC	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	10.85	9.74e-25	1.64e-21	0.72	0.44	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
KIRC	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-10.85	9.85e-25	1.66e-21	-0.57	-0.44	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
KIRC	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-10.84	9.99e-25	1.68e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
KIRC	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-10.84	1e-24	1.68e-21	-0.68	-0.44	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
KIRC	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	10.84	1.02e-24	1.71e-21	0.53	0.44	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
KIRC	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-10.84	1.02e-24	1.72e-21	-0.47	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-10.84	1.02e-24	1.72e-21	-0.47	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-10.84	1.02e-24	1.72e-21	-0.47	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-10.84	1.02e-24	1.72e-21	-0.47	-0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
KIRC	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	10.84	1.04e-24	1.74e-21	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
KIRC	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	10.84	1.04e-24	1.74e-21	0.45	0.44	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
KIRC	cis	rs6456156	0.586	rs12198816	ENSG00000265828.1	MIR3939	-10.84	1.04e-24	1.75e-21	-0.51	-0.44	Primary biliary cholangitis;	chr6:167070058	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.586	rs2001114	ENSG00000265828.1	MIR3939	-10.84	1.04e-24	1.75e-21	-0.51	-0.44	Primary biliary cholangitis;	chr6:167073090	chr6:166997807~166997912:-
KIRC	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	10.84	1.06e-24	1.78e-21	0.51	0.44	Height;	chr11:118781100	chr11:118688039~118690600:-
KIRC	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	10.84	1.07e-24	1.79e-21	0.51	0.44	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	10.84	1.07e-24	1.79e-21	0.51	0.44	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	10.84	1.07e-24	1.79e-21	0.51	0.44	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
KIRC	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	10.84	1.08e-24	1.8e-21	0.39	0.44	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
KIRC	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-10.84	1.08e-24	1.81e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-10.84	1.08e-24	1.81e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-10.84	1.08e-24	1.81e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
KIRC	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-10.83	1.09e-24	1.82e-21	-0.63	-0.44	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
KIRC	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-10.83	1.1e-24	1.84e-21	-0.43	-0.44	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
KIRC	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-10.83	1.1e-24	1.84e-21	-0.58	-0.44	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
KIRC	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	10.83	1.12e-24	1.87e-21	0.49	0.44	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
KIRC	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	10.83	1.12e-24	1.87e-21	0.51	0.44	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	10.83	1.12e-24	1.88e-21	0.37	0.44	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
KIRC	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	10.83	1.12e-24	1.88e-21	0.39	0.44	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
KIRC	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	10.83	1.13e-24	1.89e-21	0.57	0.44	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
KIRC	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	10.83	1.14e-24	1.91e-21	0.56	0.44	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
KIRC	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	10.83	1.15e-24	1.92e-21	0.54	0.44	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
KIRC	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	10.83	1.15e-24	1.92e-21	0.56	0.44	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
KIRC	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	10.83	1.15e-24	1.92e-21	0.39	0.44	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	10.83	1.15e-24	1.92e-21	0.39	0.44	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
KIRC	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	10.83	1.15e-24	1.93e-21	0.55	0.44	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
KIRC	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	10.83	1.15e-24	1.93e-21	0.54	0.44	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
KIRC	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	10.83	1.16e-24	1.93e-21	0.53	0.44	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	10.83	1.16e-24	1.93e-21	0.53	0.44	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
KIRC	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	10.83	1.17e-24	1.95e-21	0.62	0.44	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
KIRC	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-10.83	1.17e-24	1.96e-21	-0.59	-0.44	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000251284.2	RP13-644M16.1	-10.83	1.17e-24	1.96e-21	-0.62	-0.44	Obesity-related traits;	chr4:69101657	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000251284.2	RP13-644M16.1	-10.83	1.17e-24	1.96e-21	-0.62	-0.44	Obesity-related traits;	chr4:69102209	chr4:69125274~69126451:+
KIRC	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-10.83	1.18e-24	1.97e-21	-0.56	-0.44	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
KIRC	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-10.82	1.21e-24	2.01e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
KIRC	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	10.82	1.22e-24	2.04e-21	0.39	0.44	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
KIRC	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	10.82	1.22e-24	2.04e-21	0.53	0.44	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
KIRC	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-10.82	1.23e-24	2.06e-21	-0.92	-0.44	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
KIRC	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	10.82	1.24e-24	2.07e-21	0.53	0.44	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	10.82	1.24e-24	2.07e-21	0.53	0.44	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
KIRC	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	10.82	1.24e-24	2.07e-21	0.67	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
KIRC	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	10.82	1.24e-24	2.07e-21	0.62	0.44	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
KIRC	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	10.82	1.24e-24	2.07e-21	0.62	0.44	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
KIRC	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-10.82	1.25e-24	2.09e-21	-0.49	-0.44	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
KIRC	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-10.82	1.25e-24	2.09e-21	-0.49	-0.44	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
KIRC	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	10.82	1.26e-24	2.09e-21	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
KIRC	cis	rs6456156	0.586	rs10946209	ENSG00000265828.1	MIR3939	-10.82	1.28e-24	2.12e-21	-0.5	-0.44	Primary biliary cholangitis;	chr6:167067503	chr6:166997807~166997912:-
KIRC	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	10.81	1.3e-24	2.17e-21	0.96	0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
KIRC	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	10.81	1.3e-24	2.17e-21	0.39	0.44	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
KIRC	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-10.81	1.31e-24	2.18e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
KIRC	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	10.81	1.31e-24	2.18e-21	0.53	0.44	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
KIRC	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	10.81	1.32e-24	2.19e-21	0.65	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
KIRC	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	10.81	1.33e-24	2.2e-21	0.41	0.44	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
KIRC	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-10.81	1.33e-24	2.21e-21	-0.59	-0.44	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
KIRC	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-10.81	1.34e-24	2.22e-21	-0.39	-0.44	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
KIRC	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	10.81	1.34e-24	2.22e-21	0.67	0.44	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-10.81	1.35e-24	2.25e-21	-0.64	-0.44	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
KIRC	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-10.81	1.36e-24	2.26e-21	-0.72	-0.44	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
KIRC	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	10.81	1.37e-24	2.28e-21	0.36	0.44	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
KIRC	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	10.81	1.38e-24	2.3e-21	0.52	0.44	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
KIRC	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	10.81	1.39e-24	2.3e-21	0.44	0.44	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
KIRC	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-10.81	1.39e-24	2.31e-21	-0.45	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
KIRC	cis	rs4273100	1	rs12602286	ENSG00000262319.1	CTC-457L16.2	10.81	1.4e-24	2.32e-21	0.54	0.44	Schizophrenia;	chr17:19333641	chr17:19141017~19143689:-
KIRC	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.81	1.4e-24	2.32e-21	0.54	0.44	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
KIRC	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-10.81	1.41e-24	2.33e-21	-0.49	-0.44	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
KIRC	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-10.8	1.44e-24	2.39e-21	-0.45	-0.44	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
KIRC	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-10.8	1.45e-24	2.4e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
KIRC	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	10.8	1.47e-24	2.43e-21	0.51	0.44	Height;	chr11:118764443	chr11:118688039~118690600:-
KIRC	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	10.8	1.49e-24	2.46e-21	0.6	0.44	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	10.8	1.49e-24	2.46e-21	0.56	0.44	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
KIRC	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-10.8	1.49e-24	2.47e-21	-0.9	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
KIRC	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	10.8	1.5e-24	2.48e-21	0.56	0.44	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
KIRC	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	10.8	1.51e-24	2.5e-21	0.53	0.44	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
KIRC	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	10.8	1.52e-24	2.51e-21	0.53	0.44	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
KIRC	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	10.8	1.52e-24	2.52e-21	0.52	0.44	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
KIRC	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	10.79	1.55e-24	2.57e-21	0.39	0.44	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-10.79	1.56e-24	2.57e-21	-0.58	-0.44	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
KIRC	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-10.79	1.56e-24	2.58e-21	-0.54	-0.44	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
KIRC	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	10.79	1.57e-24	2.6e-21	0.56	0.44	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
KIRC	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-10.79	1.58e-24	2.61e-21	-0.63	-0.44	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
KIRC	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	10.79	1.59e-24	2.62e-21	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
KIRC	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-10.79	1.6e-24	2.64e-21	-0.36	-0.44	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
KIRC	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-10.79	1.62e-24	2.68e-21	-0.59	-0.44	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
KIRC	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	10.79	1.65e-24	2.72e-21	0.57	0.44	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
KIRC	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-10.79	1.65e-24	2.73e-21	-0.55	-0.44	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
KIRC	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-10.79	1.67e-24	2.76e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
KIRC	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	10.78	1.68e-24	2.78e-21	0.39	0.44	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	10.78	1.68e-24	2.78e-21	0.39	0.44	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
KIRC	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	10.78	1.68e-24	2.78e-21	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
KIRC	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	10.78	1.7e-24	2.81e-21	0.53	0.44	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
KIRC	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	10.78	1.71e-24	2.83e-21	0.53	0.44	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
KIRC	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-10.78	1.73e-24	2.86e-21	-0.67	-0.44	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
KIRC	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-10.78	1.75e-24	2.88e-21	-0.45	-0.44	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
KIRC	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-10.78	1.77e-24	2.92e-21	-0.64	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
KIRC	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	10.78	1.77e-24	2.92e-21	0.5	0.44	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
KIRC	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-10.78	1.78e-24	2.93e-21	-0.57	-0.44	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
KIRC	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	10.78	1.78e-24	2.94e-21	0.51	0.44	Height;	chr11:118761813	chr11:118688039~118690600:-
KIRC	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	10.78	1.79e-24	2.95e-21	0.89	0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-10.78	1.79e-24	2.96e-21	-0.34	-0.44	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
KIRC	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-10.78	1.83e-24	3.01e-21	-0.52	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
KIRC	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-10.77	1.84e-24	3.03e-21	-0.65	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
KIRC	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-10.77	1.84e-24	3.04e-21	-0.46	-0.44	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
KIRC	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	10.77	1.87e-24	3.09e-21	0.86	0.44	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
KIRC	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	10.77	1.89e-24	3.11e-21	0.53	0.44	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
KIRC	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	10.77	1.9e-24	3.12e-21	0.58	0.44	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
KIRC	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	10.77	1.9e-24	3.13e-21	0.53	0.44	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
KIRC	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-10.77	1.9e-24	3.13e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-10.77	1.91e-24	3.14e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	10.77	1.92e-24	3.17e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	10.77	1.92e-24	3.17e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000248763.2	RP13-644M16.5	-10.77	1.94e-24	3.2e-21	-0.55	-0.44	Obesity-related traits;	chr4:69069866	chr4:69066395~69069888:+
KIRC	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	10.77	1.96e-24	3.23e-21	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
KIRC	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-10.77	1.97e-24	3.25e-21	-0.57	-0.44	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	10.77	1.99e-24	3.27e-21	0.54	0.44	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	10.77	1.99e-24	3.27e-21	0.54	0.44	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
KIRC	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	10.77	1.99e-24	3.28e-21	0.58	0.44	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
KIRC	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	10.77	2e-24	3.29e-21	0.52	0.44	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-10.76	2.03e-24	3.34e-21	-0.36	-0.44	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
KIRC	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	10.76	2.07e-24	3.4e-21	0.62	0.44	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-10.76	2.09e-24	3.42e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
KIRC	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-10.76	2.09e-24	3.43e-21	-0.54	-0.44	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	10.76	2.1e-24	3.44e-21	0.54	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
KIRC	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-10.76	2.1e-24	3.44e-21	-0.52	-0.44	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
KIRC	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-10.76	2.11e-24	3.47e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-10.76	2.11e-24	3.47e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.76	2.13e-24	3.49e-21	0.54	0.44	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
KIRC	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-10.76	2.13e-24	3.5e-21	-0.35	-0.44	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
KIRC	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-10.76	2.14e-24	3.5e-21	-0.67	-0.44	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
KIRC	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-10.76	2.17e-24	3.55e-21	-0.56	-0.44	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
KIRC	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	10.76	2.17e-24	3.56e-21	0.5	0.44	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
KIRC	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	10.75	2.19e-24	3.59e-21	0.39	0.44	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
KIRC	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	10.75	2.21e-24	3.62e-21	0.52	0.44	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	10.75	2.25e-24	3.69e-21	0.35	0.44	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	10.75	2.27e-24	3.71e-21	0.52	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
KIRC	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	10.75	2.28e-24	3.72e-21	0.53	0.44	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
KIRC	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-10.75	2.28e-24	3.73e-21	-0.38	-0.44	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
KIRC	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.75	2.3e-24	3.76e-21	0.55	0.44	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
KIRC	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-10.75	2.33e-24	3.81e-21	-0.43	-0.43	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
KIRC	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	10.75	2.35e-24	3.84e-21	0.57	0.43	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
KIRC	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	10.75	2.36e-24	3.84e-21	0.44	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
KIRC	cis	rs2302464	1	rs4342183	ENSG00000214846.4	RP11-115L11.1	10.75	2.36e-24	3.86e-21	1.18	0.43	Cerebrospinal fluid biomarker levels;	chr4:15733817	chr4:15730962~15731627:-
KIRC	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-10.74	2.4e-24	3.92e-21	-0.43	-0.43	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
KIRC	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-10.74	2.4e-24	3.92e-21	-0.63	-0.43	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
KIRC	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	10.74	2.42e-24	3.94e-21	0.86	0.43	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	10.74	2.42e-24	3.94e-21	0.55	0.43	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
KIRC	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	10.74	2.44e-24	3.98e-21	0.58	0.43	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
KIRC	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-10.74	2.48e-24	4.04e-21	-0.88	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
KIRC	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-10.74	2.48e-24	4.04e-21	-0.88	-0.43	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-10.74	2.48e-24	4.04e-21	-0.35	-0.43	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-10.74	2.48e-24	4.04e-21	-0.35	-0.43	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-10.74	2.48e-24	4.04e-21	-0.35	-0.43	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
KIRC	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	10.74	2.49e-24	4.06e-21	0.64	0.43	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
KIRC	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	10.74	2.5e-24	4.07e-21	0.68	0.43	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
KIRC	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	10.74	2.54e-24	4.13e-21	0.44	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
KIRC	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	10.74	2.54e-24	4.14e-21	0.73	0.43	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
KIRC	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-10.74	2.6e-24	4.23e-21	-0.5	-0.43	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
KIRC	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	10.74	2.6e-24	4.24e-21	0.5	0.43	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
KIRC	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	10.73	2.65e-24	4.32e-21	0.56	0.43	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
KIRC	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	10.73	2.72e-24	4.42e-21	0.57	0.43	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
KIRC	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	10.73	2.72e-24	4.43e-21	0.5	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
KIRC	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-10.73	2.74e-24	4.45e-21	-0.55	-0.43	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69071281	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69071328	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69071698	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072135	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072143	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072154	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072229	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072402	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072745	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69072777	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69073025	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69073381	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000248763.2	RP13-644M16.5	-10.73	2.75e-24	4.47e-21	-0.55	-0.43	Obesity-related traits;	chr4:69073429	chr4:69066395~69069888:+
KIRC	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	10.73	2.76e-24	4.48e-21	0.54	0.43	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	10.73	2.76e-24	4.48e-21	0.58	0.43	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
KIRC	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-10.73	2.76e-24	4.48e-21	-0.52	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
KIRC	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-10.73	2.77e-24	4.49e-21	-0.44	-0.43	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
KIRC	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-10.73	2.77e-24	4.49e-21	-0.86	-0.43	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
KIRC	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-10.73	2.79e-24	4.53e-21	-0.67	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
KIRC	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.73	2.84e-24	4.6e-21	0.54	0.43	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-10.73	2.84e-24	4.61e-21	-0.61	-0.43	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
KIRC	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-10.72	2.86e-24	4.64e-21	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
KIRC	cis	rs6456156	0.586	rs4710176	ENSG00000265828.1	MIR3939	-10.72	2.9e-24	4.7e-21	-0.51	-0.43	Primary biliary cholangitis;	chr6:167078151	chr6:166997807~166997912:-
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000248763.2	RP13-644M16.5	-10.72	2.9e-24	4.71e-21	-0.55	-0.43	Obesity-related traits;	chr4:69069614	chr4:69066395~69069888:+
KIRC	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	10.72	2.92e-24	4.74e-21	0.51	0.43	Height;	chr11:118749988	chr11:118688039~118690600:-
KIRC	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	10.72	2.93e-24	4.75e-21	0.39	0.43	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
KIRC	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	10.72	2.94e-24	4.76e-21	0.44	0.43	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000248763.2	RP13-644M16.5	-10.72	2.94e-24	4.77e-21	-0.55	-0.43	Obesity-related traits;	chr4:69073715	chr4:69066395~69069888:+
KIRC	cis	rs9457247	0.602	rs12209395	ENSG00000265828.1	MIR3939	-10.72	2.96e-24	4.8e-21	-0.5	-0.43	Crohn's disease;	chr6:167050426	chr6:166997807~166997912:-
KIRC	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	10.72	2.96e-24	4.8e-21	0.44	0.43	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	10.72	2.96e-24	4.8e-21	0.44	0.43	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	10.72	2.96e-24	4.8e-21	0.44	0.43	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	10.72	2.96e-24	4.8e-21	0.44	0.43	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
KIRC	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	10.72	2.98e-24	4.82e-21	0.34	0.43	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
KIRC	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-10.72	2.98e-24	4.82e-21	-0.66	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
KIRC	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-10.72	3.02e-24	4.89e-21	-0.46	-0.43	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
KIRC	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	10.72	3.03e-24	4.91e-21	0.53	0.43	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	10.72	3.03e-24	4.91e-21	0.53	0.43	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
KIRC	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	10.72	3.08e-24	4.99e-21	0.39	0.43	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.72	3.08e-24	4.99e-21	0.55	0.43	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
KIRC	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	10.71	3.14e-24	5.08e-21	0.39	0.43	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
KIRC	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	10.71	3.16e-24	5.11e-21	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
KIRC	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	10.71	3.18e-24	5.15e-21	0.5	0.43	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-10.71	3.21e-24	5.19e-21	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
KIRC	cis	rs9399135	0.743	rs7745098	ENSG00000232876.1	CTA-212D2.2	-10.71	3.24e-24	5.23e-21	-0.59	-0.43	Red blood cell count;	chr6:135093866	chr6:135055033~135060550:+
KIRC	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	10.71	3.27e-24	5.28e-21	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
KIRC	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	10.71	3.27e-24	5.29e-21	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
KIRC	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	10.71	3.27e-24	5.29e-21	1.14	0.43	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
KIRC	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	10.71	3.27e-24	5.29e-21	1.14	0.43	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
KIRC	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	10.71	3.27e-24	5.29e-21	1.14	0.43	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	10.71	3.27e-24	5.29e-21	1.14	0.43	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	10.71	3.28e-24	5.29e-21	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
KIRC	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-10.71	3.3e-24	5.33e-21	-0.63	-0.43	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
KIRC	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-10.71	3.32e-24	5.37e-21	-0.42	-0.43	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
KIRC	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	10.71	3.37e-24	5.45e-21	0.39	0.43	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	10.71	3.37e-24	5.45e-21	0.39	0.43	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
KIRC	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-10.71	3.39e-24	5.46e-21	-0.5	-0.43	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
KIRC	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-10.7	3.48e-24	5.62e-21	-0.67	-0.43	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
KIRC	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-10.7	3.48e-24	5.62e-21	-0.48	-0.43	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
KIRC	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-10.7	3.5e-24	5.64e-21	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
KIRC	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-10.7	3.53e-24	5.69e-21	-0.63	-0.43	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
KIRC	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	10.7	3.55e-24	5.72e-21	0.55	0.43	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
KIRC	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	10.7	3.57e-24	5.75e-21	0.63	0.43	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
KIRC	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.7	3.57e-24	5.75e-21	0.54	0.43	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
KIRC	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	10.7	3.59e-24	5.79e-21	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
KIRC	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-10.7	3.6e-24	5.8e-21	-0.49	-0.43	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
KIRC	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-10.7	3.63e-24	5.85e-21	-0.44	-0.43	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
KIRC	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-10.7	3.63e-24	5.85e-21	-0.53	-0.43	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
KIRC	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	10.7	3.63e-24	5.85e-21	0.67	0.43	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
KIRC	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-10.7	3.66e-24	5.89e-21	-0.52	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000248763.2	RP13-644M16.5	-10.7	3.69e-24	5.95e-21	-0.55	-0.43	Obesity-related traits;	chr4:69070955	chr4:69066395~69069888:+
KIRC	cis	rs2698530	0.634	rs2555438	ENSG00000225889.6	AC074289.1	-10.69	3.73e-24	6.01e-21	-0.43	-0.43	Iron status biomarkers;	chr2:64248986	chr2:64143239~64252859:+
KIRC	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	10.69	3.75e-24	6.03e-21	0.67	0.43	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
KIRC	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-10.69	3.83e-24	6.16e-21	-0.44	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
KIRC	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-10.69	3.83e-24	6.16e-21	-0.44	-0.43	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
KIRC	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	10.69	3.83e-24	6.17e-21	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
KIRC	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	10.69	3.92e-24	6.3e-21	0.37	0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
KIRC	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	10.69	4.02e-24	6.46e-21	0.44	0.43	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	10.69	4.02e-24	6.46e-21	0.44	0.43	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	10.69	4.02e-24	6.46e-21	0.44	0.43	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
KIRC	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-10.69	4.03e-24	6.48e-21	-0.53	-0.43	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
KIRC	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	10.68	4.05e-24	6.51e-21	0.34	0.43	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-10.68	4.05e-24	6.52e-21	-0.61	-0.43	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-10.68	4.05e-24	6.52e-21	-0.61	-0.43	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-10.68	4.05e-24	6.52e-21	-0.61	-0.43	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
KIRC	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-10.68	4.07e-24	6.54e-21	-0.48	-0.43	Temperament;	chr17:14013482	chr17:14024514~14025488:+
KIRC	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-10.68	4.07e-24	6.55e-21	-0.56	-0.43	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-10.68	4.07e-24	6.55e-21	-0.56	-0.43	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
KIRC	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-10.68	4.08e-24	6.55e-21	-0.48	-0.43	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
KIRC	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-10.68	4.09e-24	6.57e-21	-0.58	-0.43	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
KIRC	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-10.68	4.09e-24	6.58e-21	-0.54	-0.43	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
KIRC	cis	rs79040073	0.53	rs113085328	ENSG00000259531.2	RP11-295H24.3	10.68	4.11e-24	6.6e-21	0.54	0.43	Lung cancer in ever smokers;	chr15:49223704	chr15:49365124~49366685:-
KIRC	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	10.68	4.23e-24	6.79e-21	0.51	0.43	Height;	chr11:118760944	chr11:118688039~118690600:-
KIRC	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-10.68	4.24e-24	6.8e-21	-0.93	-0.43	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
KIRC	cis	rs79040073	0.563	rs73392233	ENSG00000259531.2	RP11-295H24.3	10.68	4.25e-24	6.82e-21	0.53	0.43	Lung cancer in ever smokers;	chr15:49214881	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.53	rs79452929	ENSG00000259531.2	RP11-295H24.3	10.68	4.25e-24	6.82e-21	0.53	0.43	Lung cancer in ever smokers;	chr15:49216166	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.53	rs57560518	ENSG00000259531.2	RP11-295H24.3	10.68	4.25e-24	6.82e-21	0.53	0.43	Lung cancer in ever smokers;	chr15:49218760	chr15:49365124~49366685:-
KIRC	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-10.68	4.26e-24	6.84e-21	-0.87	-0.43	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
KIRC	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	10.68	4.3e-24	6.9e-21	0.71	0.43	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
KIRC	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-10.68	4.31e-24	6.91e-21	-0.6	-0.43	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
KIRC	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	10.68	4.35e-24	6.98e-21	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	10.68	4.35e-24	6.98e-21	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.68	4.37e-24	7e-21	-0.55	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000248763.2	RP13-644M16.5	-10.67	4.41e-24	7.07e-21	-0.55	-0.43	Obesity-related traits;	chr4:69071215	chr4:69066395~69069888:+
KIRC	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	10.67	4.44e-24	7.11e-21	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000248763.2	RP13-644M16.5	10.67	4.5e-24	7.21e-21	0.55	0.43	Obesity-related traits;	chr4:69075436	chr4:69066395~69069888:+
KIRC	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-10.67	4.59e-24	7.34e-21	-0.37	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
KIRC	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	10.67	4.6e-24	7.36e-21	0.56	0.43	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
KIRC	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-10.67	4.65e-24	7.44e-21	-0.44	-0.43	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
KIRC	cis	rs5760092	0.627	rs6519489	ENSG00000231271.1	AP000350.8	-10.67	4.66e-24	7.47e-21	-0.67	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23949918~23954042:+
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000248763.2	RP13-644M16.5	-10.67	4.69e-24	7.5e-21	-0.55	-0.43	Obesity-related traits;	chr4:69069420	chr4:69066395~69069888:+
KIRC	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	10.67	4.69e-24	7.5e-21	0.48	0.43	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
KIRC	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-10.67	4.76e-24	7.62e-21	-0.93	-0.43	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
KIRC	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-10.67	4.78e-24	7.64e-21	-0.53	-0.43	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
KIRC	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	10.67	4.78e-24	7.64e-21	0.58	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
KIRC	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	10.67	4.79e-24	7.66e-21	0.58	0.43	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
KIRC	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	10.66	4.84e-24	7.74e-21	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	10.66	4.84e-24	7.74e-21	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
KIRC	cis	rs5760092	0.755	rs11090298	ENSG00000231271.1	AP000350.8	-10.66	4.91e-24	7.85e-21	-0.66	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23949918~23954042:+
KIRC	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	10.66	4.99e-24	7.97e-21	0.53	0.43	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
KIRC	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-10.66	5e-24	7.98e-21	-0.54	-0.43	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
KIRC	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	10.66	5.07e-24	8.1e-21	0.51	0.43	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
KIRC	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	10.66	5.07e-24	8.1e-21	0.62	0.43	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
KIRC	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-10.65	5.27e-24	8.41e-21	-0.47	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-10.65	5.27e-24	8.41e-21	-0.47	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-10.65	5.27e-24	8.41e-21	-0.47	-0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
KIRC	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10.65	5.28e-24	8.42e-21	-0.56	-0.43	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-10.65	5.3e-24	8.45e-21	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
KIRC	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	10.65	5.3e-24	8.46e-21	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
KIRC	cis	rs11079159	0.628	rs884303	ENSG00000263096.1	RP11-515O17.2	10.65	5.34e-24	8.52e-21	0.54	0.43	QRS duration;	chr17:55289939	chr17:55271504~55273653:-
KIRC	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-10.65	5.35e-24	8.53e-21	-0.64	-0.43	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
KIRC	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	10.65	5.38e-24	8.57e-21	0.57	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
KIRC	cis	rs11079159	0.628	rs884301	ENSG00000263096.1	RP11-515O17.2	10.65	5.4e-24	8.61e-21	0.54	0.43	QRS duration;	chr17:55290103	chr17:55271504~55273653:-
KIRC	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-10.65	5.48e-24	8.74e-21	-0.34	-0.43	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
KIRC	cis	rs6456156	0.586	rs10946208	ENSG00000265828.1	MIR3939	-10.65	5.51e-24	8.78e-21	-0.5	-0.43	Primary biliary cholangitis;	chr6:167046108	chr6:166997807~166997912:-
KIRC	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-10.65	5.54e-24	8.82e-21	-0.61	-0.43	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
KIRC	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	10.65	5.54e-24	8.82e-21	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	10.65	5.54e-24	8.82e-21	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
KIRC	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	10.65	5.59e-24	8.9e-21	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000248763.2	RP13-644M16.5	-10.65	5.63e-24	8.97e-21	-0.55	-0.43	Obesity-related traits;	chr4:69069219	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000248763.2	RP13-644M16.5	-10.65	5.63e-24	8.97e-21	-0.55	-0.43	Obesity-related traits;	chr4:69069397	chr4:69066395~69069888:+
KIRC	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	10.65	5.69e-24	9.06e-21	0.67	0.43	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
KIRC	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
KIRC	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
KIRC	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	10.65	5.7e-24	9.07e-21	1.13	0.43	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
KIRC	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-10.64	5.77e-24	9.18e-21	-0.66	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
KIRC	cis	rs6456156	0.586	rs12525855	ENSG00000265828.1	MIR3939	-10.64	5.79e-24	9.22e-21	-0.5	-0.43	Primary biliary cholangitis;	chr6:167066525	chr6:166997807~166997912:-
KIRC	cis	rs5760092	0.755	rs11090298	ENSG00000250470.1	AP000351.3	-10.64	5.94e-24	9.44e-21	-0.67	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23976904~23977585:-
KIRC	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	10.64	5.99e-24	9.52e-21	0.44	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
KIRC	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-10.64	6e-24	9.53e-21	-0.55	-0.43	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	10.64	6.01e-24	9.54e-21	0.34	0.43	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
KIRC	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-10.64	6.03e-24	9.57e-21	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
KIRC	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-10.64	6.03e-24	9.57e-21	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
KIRC	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	10.64	6.04e-24	9.6e-21	0.54	0.43	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
KIRC	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	10.64	6.1e-24	9.7e-21	0.49	0.43	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
KIRC	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-10.64	6.18e-24	9.81e-21	-0.47	-0.43	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
KIRC	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-10.64	6.21e-24	9.86e-21	-0.5	-0.43	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-10.64	6.21e-24	9.86e-21	-0.5	-0.43	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
KIRC	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-10.64	6.23e-24	9.89e-21	-0.53	-0.43	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
KIRC	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	10.63	6.28e-24	9.97e-21	0.54	0.43	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
KIRC	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-10.63	6.33e-24	1e-20	-0.67	-0.43	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-10.63	6.33e-24	1e-20	-0.67	-0.43	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
KIRC	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	10.63	6.42e-24	1.02e-20	0.57	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
KIRC	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-10.63	6.48e-24	1.03e-20	-0.52	-0.43	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
KIRC	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	10.63	6.5e-24	1.03e-20	0.68	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
KIRC	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	10.63	6.55e-24	1.04e-20	0.69	0.43	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
KIRC	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-10.63	6.6e-24	1.05e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
KIRC	cis	rs2698530	0.634	rs2059634	ENSG00000225889.6	AC074289.1	-10.63	6.66e-24	1.05e-20	-0.43	-0.43	Iron status biomarkers;	chr2:64234480	chr2:64143239~64252859:+
KIRC	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	10.63	6.79e-24	1.08e-20	0.39	0.43	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
KIRC	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	10.62	6.83e-24	1.08e-20	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
KIRC	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-10.62	6.85e-24	1.08e-20	-0.5	-0.43	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
KIRC	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	10.62	6.91e-24	1.09e-20	1.1	0.43	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
KIRC	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	10.62	6.91e-24	1.09e-20	0.52	0.43	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.53	rs17396612	ENSG00000259531.2	RP11-295H24.3	10.62	6.91e-24	1.09e-20	0.52	0.43	Lung cancer in ever smokers;	chr15:49257746	chr15:49365124~49366685:-
KIRC	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	10.62	6.93e-24	1.1e-20	0.44	0.43	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
KIRC	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-10.62	6.97e-24	1.1e-20	-0.56	-0.43	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
KIRC	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	10.62	7e-24	1.11e-20	0.43	0.43	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	10.62	7e-24	1.11e-20	0.43	0.43	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	10.62	7e-24	1.11e-20	0.43	0.43	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
KIRC	cis	rs79040073	0.53	rs8029506	ENSG00000259531.2	RP11-295H24.3	10.62	7.06e-24	1.12e-20	0.53	0.43	Lung cancer in ever smokers;	chr15:49274543	chr15:49365124~49366685:-
KIRC	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	10.62	7.24e-24	1.14e-20	0.39	0.43	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
KIRC	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	10.62	7.27e-24	1.15e-20	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	10.62	7.27e-24	1.15e-20	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
KIRC	cis	rs7115242	0.699	rs72645459	ENSG00000254851.1	RP11-109L13.1	10.62	7.29e-24	1.15e-20	0.96	0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891441	chr11:117135528~117138582:+
KIRC	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	10.62	7.36e-24	1.16e-20	0.51	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
KIRC	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-10.61	7.5e-24	1.19e-20	-0.58	-0.43	QT interval;	chr16:28824579	chr16:28700294~28701540:-
KIRC	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	10.61	7.58e-24	1.2e-20	0.4	0.43	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
KIRC	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-10.61	7.78e-24	1.23e-20	-0.56	-0.43	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
KIRC	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	10.61	7.83e-24	1.24e-20	0.48	0.43	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
KIRC	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	10.61	7.86e-24	1.24e-20	0.57	0.43	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
KIRC	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-10.61	7.87e-24	1.24e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000248763.2	RP13-644M16.5	-10.61	7.98e-24	1.26e-20	-0.55	-0.43	Obesity-related traits;	chr4:69072070	chr4:69066395~69069888:+
KIRC	cis	rs79040073	0.53	rs17475228	ENSG00000259531.2	RP11-295H24.3	10.61	7.99e-24	1.26e-20	0.52	0.43	Lung cancer in ever smokers;	chr15:49269619	chr15:49365124~49366685:-
KIRC	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	10.6	8.28e-24	1.31e-20	0.53	0.43	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
KIRC	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-10.6	8.29e-24	1.31e-20	-0.53	-0.43	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
KIRC	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	10.6	8.33e-24	1.31e-20	0.5	0.43	Height;	chr11:118742526	chr11:118688039~118690600:-
KIRC	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	10.6	8.33e-24	1.31e-20	0.51	0.43	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
KIRC	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.6	8.35e-24	1.32e-20	0.33	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
KIRC	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-10.6	8.41e-24	1.33e-20	-0.33	-0.43	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
KIRC	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-10.6	8.52e-24	1.34e-20	-0.89	-0.43	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
KIRC	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-10.6	8.62e-24	1.36e-20	-0.49	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
KIRC	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-10.6	8.67e-24	1.37e-20	-0.64	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-10.6	8.67e-24	1.37e-20	-0.64	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-10.6	8.67e-24	1.37e-20	-0.64	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
KIRC	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	10.6	8.69e-24	1.37e-20	0.64	0.43	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
KIRC	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-10.6	8.71e-24	1.37e-20	-0.51	-0.43	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
KIRC	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-10.6	8.75e-24	1.38e-20	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
KIRC	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-10.6	8.83e-24	1.39e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
KIRC	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-10.59	8.87e-24	1.4e-20	-0.33	-0.43	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
KIRC	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-10.59	8.99e-24	1.41e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-10.59	8.99e-24	1.41e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-10.59	8.99e-24	1.41e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
KIRC	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	10.59	9.03e-24	1.42e-20	0.85	0.43	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
KIRC	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-10.59	9.1e-24	1.43e-20	-0.5	-0.43	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
KIRC	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	10.59	9.15e-24	1.44e-20	0.39	0.43	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
KIRC	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-10.59	9.22e-24	1.45e-20	-0.64	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
KIRC	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	10.59	9.27e-24	1.46e-20	0.55	0.43	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
KIRC	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-10.59	9.27e-24	1.46e-20	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
KIRC	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	10.59	9.34e-24	1.47e-20	0.5	0.43	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000248763.2	RP13-644M16.5	-10.59	9.39e-24	1.48e-20	-0.55	-0.43	Obesity-related traits;	chr4:69068460	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000248763.2	RP13-644M16.5	-10.59	9.39e-24	1.48e-20	-0.55	-0.43	Obesity-related traits;	chr4:69068643	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000248763.2	RP13-644M16.5	-10.59	9.39e-24	1.48e-20	-0.55	-0.43	Obesity-related traits;	chr4:69068755	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000248763.2	RP13-644M16.5	-10.59	9.39e-24	1.48e-20	-0.55	-0.43	Obesity-related traits;	chr4:69069090	chr4:69066395~69069888:+
KIRC	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	10.59	9.6e-24	1.51e-20	0.58	0.43	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
KIRC	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-10.58	9.68e-24	1.52e-20	-0.36	-0.43	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-10.58	9.71e-24	1.52e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-10.58	9.71e-24	1.52e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-10.58	9.81e-24	1.54e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
KIRC	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-10.58	9.82e-24	1.54e-20	-0.51	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000248763.2	RP13-644M16.5	-10.58	9.86e-24	1.55e-20	-0.55	-0.43	Obesity-related traits;	chr4:69075473	chr4:69066395~69069888:+
KIRC	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	10.58	9.89e-24	1.55e-20	0.66	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
KIRC	cis	rs2698530	0.634	rs1019685	ENSG00000225889.6	AC074289.1	-10.58	1e-23	1.57e-20	-0.43	-0.43	Iron status biomarkers;	chr2:64233984	chr2:64143239~64252859:+
KIRC	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-10.58	1e-23	1.57e-20	-0.5	-0.43	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
KIRC	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	10.58	1.01e-23	1.59e-20	0.55	0.43	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
KIRC	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	10.58	1.01e-23	1.59e-20	0.52	0.43	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
KIRC	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	10.58	1.02e-23	1.6e-20	0.53	0.43	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
KIRC	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-10.58	1.03e-23	1.61e-20	-0.63	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
KIRC	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-10.58	1.03e-23	1.62e-20	-0.5	-0.43	Height;	chr11:118703185	chr11:118704607~118750263:+
KIRC	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-10.58	1.03e-23	1.62e-20	-0.5	-0.43	Height;	chr11:118703207	chr11:118704607~118750263:+
KIRC	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-10.58	1.03e-23	1.62e-20	-0.5	-0.43	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
KIRC	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	10.58	1.04e-23	1.63e-20	0.63	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
KIRC	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	10.58	1.05e-23	1.64e-20	0.55	0.43	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
KIRC	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	10.58	1.05e-23	1.65e-20	0.53	0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
KIRC	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	10.57	1.06e-23	1.66e-20	0.65	0.43	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
KIRC	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	10.57	1.06e-23	1.66e-20	0.63	0.43	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
KIRC	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	10.57	1.07e-23	1.67e-20	0.39	0.43	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
KIRC	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-10.57	1.07e-23	1.67e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-10.57	1.07e-23	1.67e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-10.57	1.07e-23	1.67e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
KIRC	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	10.57	1.07e-23	1.68e-20	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	10.57	1.07e-23	1.68e-20	0.53	0.43	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
KIRC	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-10.57	1.09e-23	1.7e-20	-0.56	-0.43	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
KIRC	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	10.57	1.11e-23	1.73e-20	0.5	0.43	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
KIRC	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	10.57	1.12e-23	1.75e-20	0.48	0.43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
KIRC	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-10.57	1.14e-23	1.78e-20	-0.62	-0.43	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
KIRC	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-10.57	1.15e-23	1.79e-20	-0.64	-0.43	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
KIRC	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-10.56	1.16e-23	1.81e-20	-0.36	-0.43	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
KIRC	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-10.56	1.18e-23	1.84e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
KIRC	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	10.56	1.18e-23	1.85e-20	0.55	0.43	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
KIRC	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-10.56	1.19e-23	1.86e-20	-0.35	-0.43	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
KIRC	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	10.56	1.2e-23	1.88e-20	0.56	0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
KIRC	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	10.56	1.22e-23	1.9e-20	0.43	0.43	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
KIRC	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-10.56	1.22e-23	1.91e-20	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
KIRC	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-10.56	1.22e-23	1.91e-20	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
KIRC	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-10.56	1.24e-23	1.94e-20	-0.92	-0.43	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	10.56	1.25e-23	1.95e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
KIRC	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	10.55	1.27e-23	1.98e-20	0.63	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
KIRC	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	10.55	1.32e-23	2.05e-20	0.52	0.43	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
KIRC	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-10.55	1.32e-23	2.06e-20	-0.67	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000248763.2	RP13-644M16.5	-10.55	1.33e-23	2.06e-20	-0.54	-0.43	Obesity-related traits;	chr4:69079224	chr4:69066395~69069888:+
KIRC	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	10.55	1.34e-23	2.08e-20	0.55	0.43	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
KIRC	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	10.54	1.38e-23	2.15e-20	0.38	0.43	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
KIRC	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-10.54	1.39e-23	2.17e-20	-0.37	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
KIRC	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.54	1.44e-23	2.24e-20	0.54	0.43	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
KIRC	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-10.54	1.47e-23	2.28e-20	-0.62	-0.43	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-10.54	1.47e-23	2.28e-20	-0.62	-0.43	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
KIRC	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-10.54	1.47e-23	2.29e-20	-0.5	-0.43	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
KIRC	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	10.54	1.48e-23	2.29e-20	0.55	0.43	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
KIRC	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	10.54	1.48e-23	2.3e-20	0.39	0.43	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
KIRC	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-10.53	1.5e-23	2.32e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
KIRC	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	10.53	1.5e-23	2.33e-20	0.56	0.43	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
KIRC	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-10.53	1.51e-23	2.35e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-10.53	1.51e-23	2.35e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
KIRC	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.53	1.52e-23	2.36e-20	0.32	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
KIRC	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.53	1.52e-23	2.36e-20	0.32	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
KIRC	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	10.53	1.56e-23	2.41e-20	0.44	0.43	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	10.53	1.56e-23	2.41e-20	0.44	0.43	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
KIRC	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	10.53	1.59e-23	2.46e-20	0.51	0.43	Height;	chr11:118737916	chr11:118688039~118690600:-
KIRC	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-10.53	1.63e-23	2.52e-20	-0.62	-0.43	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
KIRC	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-10.52	1.63e-23	2.53e-20	-0.48	-0.43	Temperament;	chr17:14015466	chr17:14024514~14025488:+
KIRC	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	10.52	1.64e-23	2.54e-20	0.5	0.43	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
KIRC	cis	rs6456156	0.586	rs9459862	ENSG00000265828.1	MIR3939	10.52	1.65e-23	2.55e-20	0.49	0.43	Primary biliary cholangitis;	chr6:167073523	chr6:166997807~166997912:-
KIRC	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	10.52	1.65e-23	2.55e-20	0.38	0.43	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
KIRC	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	10.52	1.65e-23	2.55e-20	0.44	0.43	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
KIRC	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	10.52	1.68e-23	2.6e-20	0.3	0.43	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
KIRC	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-10.52	1.68e-23	2.6e-20	-0.48	-0.43	Temperament;	chr17:14033087	chr17:14024514~14025488:+
KIRC	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-10.52	1.69e-23	2.61e-20	-0.63	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
KIRC	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	10.52	1.69e-23	2.61e-20	0.5	0.43	Height;	chr11:118791319	chr11:118688039~118690600:-
KIRC	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-10.52	1.69e-23	2.62e-20	-0.6	-0.43	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
KIRC	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-10.52	1.69e-23	2.62e-20	-0.6	-0.43	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
KIRC	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-10.52	1.7e-23	2.63e-20	-0.65	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
KIRC	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-10.52	1.77e-23	2.72e-20	-0.62	-0.43	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
KIRC	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	10.52	1.77e-23	2.73e-20	0.5	0.43	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-10.51	1.78e-23	2.75e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	10.51	1.79e-23	2.76e-20	0.51	0.43	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
KIRC	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-10.51	1.81e-23	2.78e-20	-0.73	-0.43	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
KIRC	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	10.51	1.88e-23	2.89e-20	0.57	0.43	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	10.51	1.88e-23	2.9e-20	0.56	0.43	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	10.51	1.89e-23	2.91e-20	0.54	0.43	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
KIRC	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	10.51	1.93e-23	2.96e-20	0.44	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
KIRC	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-10.51	1.93e-23	2.97e-20	-0.63	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
KIRC	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-10.51	1.94e-23	2.98e-20	-0.59	-0.43	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
KIRC	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	10.51	1.94e-23	2.98e-20	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
KIRC	cis	rs5760092	0.627	rs6519489	ENSG00000250470.1	AP000351.3	-10.5	1.95e-23	3e-20	-0.67	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23976904~23977585:-
KIRC	cis	rs7115242	0.567	rs10047462	ENSG00000254851.1	RP11-109L13.1	-10.5	1.95e-23	3e-20	-0.95	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116851325	chr11:117135528~117138582:+
KIRC	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	10.5	1.96e-23	3.01e-20	0.44	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
KIRC	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	10.5	2.03e-23	3.12e-20	0.49	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
KIRC	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	10.5	2.03e-23	3.13e-20	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
KIRC	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-10.5	2.07e-23	3.18e-20	-0.55	-0.43	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
KIRC	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	10.5	2.07e-23	3.18e-20	0.54	0.43	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
KIRC	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-10.5	2.08e-23	3.19e-20	-0.55	-0.43	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
KIRC	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-10.5	2.08e-23	3.19e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-10.5	2.08e-23	3.19e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-10.5	2.08e-23	3.19e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-10.5	2.08e-23	3.19e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-10.5	2.08e-23	3.19e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
KIRC	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	10.5	2.09e-23	3.21e-20	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-10.5	2.09e-23	3.21e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-10.5	2.1e-23	3.22e-20	-0.35	-0.43	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
KIRC	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	10.5	2.11e-23	3.24e-20	0.51	0.43	Height;	chr11:118737823	chr11:118688039~118690600:-
KIRC	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-10.49	2.13e-23	3.26e-20	-0.52	-0.43	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
KIRC	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	10.49	2.14e-23	3.29e-20	0.48	0.43	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
KIRC	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	10.49	2.18e-23	3.34e-20	0.57	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
KIRC	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	10.49	2.19e-23	3.36e-20	0.55	0.43	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
KIRC	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	10.49	2.2e-23	3.36e-20	0.5	0.43	Height;	chr11:118747911	chr11:118688039~118690600:-
KIRC	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	10.49	2.2e-23	3.37e-20	0.43	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
KIRC	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-10.49	2.22e-23	3.4e-20	-0.64	-0.43	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-10.49	2.22e-23	3.4e-20	-0.64	-0.43	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
KIRC	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	10.49	2.22e-23	3.4e-20	0.49	0.43	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
KIRC	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	10.49	2.25e-23	3.44e-20	0.38	0.43	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-10.49	2.26e-23	3.46e-20	-0.6	-0.43	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
KIRC	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-10.48	2.31e-23	3.53e-20	-0.51	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
KIRC	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-10.48	2.32e-23	3.55e-20	-0.39	-0.43	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
KIRC	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-10.48	2.34e-23	3.58e-20	-0.43	-0.43	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
KIRC	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	10.48	2.34e-23	3.58e-20	0.69	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
KIRC	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	10.48	2.37e-23	3.63e-20	0.72	0.43	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
KIRC	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	10.48	2.38e-23	3.64e-20	0.56	0.43	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
KIRC	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-10.48	2.39e-23	3.64e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-10.48	2.39e-23	3.64e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-10.48	2.39e-23	3.64e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-10.48	2.39e-23	3.64e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-10.48	2.39e-23	3.64e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
KIRC	cis	rs4356975	0.697	rs5002700	ENSG00000250696.4	RP11-704M14.1	10.48	2.39e-23	3.66e-20	0.44	0.43	Obesity-related traits;	chr4:69155637	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.697	rs6849081	ENSG00000250696.4	RP11-704M14.1	10.48	2.41e-23	3.68e-20	0.44	0.43	Obesity-related traits;	chr4:69144840	chr4:69182100~69216766:+
KIRC	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-10.48	2.46e-23	3.75e-20	-0.32	-0.43	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
KIRC	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-10.48	2.47e-23	3.76e-20	-0.41	-0.43	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
KIRC	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-10.47	2.53e-23	3.86e-20	-0.51	-0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
KIRC	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	10.47	2.53e-23	3.87e-20	0.52	0.43	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
KIRC	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	10.47	2.53e-23	3.87e-20	0.44	0.43	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
KIRC	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-10.47	2.55e-23	3.89e-20	-0.35	-0.43	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
KIRC	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-10.47	2.6e-23	3.96e-20	-0.35	-0.43	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
KIRC	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-10.47	2.61e-23	3.97e-20	-0.49	-0.43	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	10.47	2.63e-23	4e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000248763.2	RP13-644M16.5	-10.47	2.65e-23	4.03e-20	-0.54	-0.43	Obesity-related traits;	chr4:69074077	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000248763.2	RP13-644M16.5	-10.47	2.65e-23	4.03e-20	-0.54	-0.43	Obesity-related traits;	chr4:69075085	chr4:69066395~69069888:+
KIRC	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-10.47	2.66e-23	4.05e-20	-0.4	-0.43	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
KIRC	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-10.47	2.68e-23	4.08e-20	-0.55	-0.43	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
KIRC	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	10.47	2.69e-23	4.09e-20	0.49	0.43	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
KIRC	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-10.47	2.71e-23	4.13e-20	-0.89	-0.43	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
KIRC	cis	rs11079159	0.606	rs876720	ENSG00000263096.1	RP11-515O17.2	-10.46	2.77e-23	4.22e-20	-0.54	-0.43	QRS duration;	chr17:55289154	chr17:55271504~55273653:-
KIRC	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-10.46	2.81e-23	4.27e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	10.46	2.84e-23	4.32e-20	0.57	0.43	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
KIRC	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-10.46	2.88e-23	4.38e-20	-0.51	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
KIRC	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	10.46	2.91e-23	4.41e-20	0.38	0.43	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
KIRC	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	10.46	2.96e-23	4.49e-20	0.63	0.43	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
KIRC	cis	rs4356975	0.697	rs58039330	ENSG00000250696.4	RP11-704M14.1	10.46	2.96e-23	4.49e-20	0.43	0.43	Obesity-related traits;	chr4:69149529	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.66	rs60567038	ENSG00000250696.4	RP11-704M14.1	10.46	2.96e-23	4.49e-20	0.43	0.43	Obesity-related traits;	chr4:69150135	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.697	rs58366569	ENSG00000250696.4	RP11-704M14.1	10.46	2.96e-23	4.49e-20	0.43	0.43	Obesity-related traits;	chr4:69150626	chr4:69182100~69216766:+
KIRC	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	10.46	2.96e-23	4.49e-20	0.52	0.43	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
KIRC	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-10.46	2.98e-23	4.52e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
KIRC	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	10.45	2.99e-23	4.53e-20	0.57	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
KIRC	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-10.45	2.99e-23	4.54e-20	-0.49	-0.43	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
KIRC	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-10.45	2.99e-23	4.54e-20	-0.66	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
KIRC	cis	rs72901758	0.768	rs72901762	ENSG00000267676.1	THA1P	10.45	3.01e-23	4.56e-20	0.51	0.43	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78248845	chr17:78248493~78254416:-
KIRC	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	10.45	3.03e-23	4.59e-20	0.38	0.43	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
KIRC	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-10.45	3.03e-23	4.59e-20	-0.54	-0.43	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
KIRC	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-10.45	3.03e-23	4.6e-20	-0.5	-0.43	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-10.45	3.04e-23	4.6e-20	-0.34	-0.43	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
KIRC	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	10.45	3.07e-23	4.64e-20	0.79	0.43	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
KIRC	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	10.45	3.08e-23	4.67e-20	0.5	0.43	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
KIRC	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	10.45	3.09e-23	4.67e-20	0.63	0.43	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
KIRC	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-10.45	3.1e-23	4.7e-20	-0.33	-0.43	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
KIRC	cis	rs2698530	0.634	rs1582792	ENSG00000225889.6	AC074289.1	-10.45	3.13e-23	4.74e-20	-0.42	-0.43	Iron status biomarkers;	chr2:64250409	chr2:64143239~64252859:+
KIRC	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	10.45	3.15e-23	4.76e-20	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
KIRC	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-10.45	3.17e-23	4.8e-20	-0.47	-0.43	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
KIRC	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	10.45	3.17e-23	4.8e-20	0.5	0.43	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
KIRC	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-10.45	3.18e-23	4.81e-20	-0.49	-0.43	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
KIRC	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	10.45	3.19e-23	4.82e-20	0.43	0.43	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
KIRC	cis	rs9847710	0.967	rs2244552	ENSG00000280417.1	RP11-5O17.1	-10.45	3.23e-23	4.88e-20	-0.49	-0.43	Ulcerative colitis;	chr3:53021506	chr3:53046166~53048122:+
KIRC	cis	rs9457247	0.602	rs2157388	ENSG00000265828.1	MIR3939	-10.45	3.23e-23	4.89e-20	-0.49	-0.42	Crohn's disease;	chr6:167068424	chr6:166997807~166997912:-
KIRC	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-10.45	3.25e-23	4.91e-20	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-10.45	3.25e-23	4.91e-20	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
KIRC	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	10.44	3.3e-23	4.99e-20	0.52	0.42	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
KIRC	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	10.44	3.33e-23	5.03e-20	0.52	0.42	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000248763.2	RP13-644M16.5	-10.44	3.35e-23	5.06e-20	-0.54	-0.42	Obesity-related traits;	chr4:69079704	chr4:69066395~69069888:+
KIRC	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-10.44	3.36e-23	5.07e-20	-0.33	-0.42	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
KIRC	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-10.44	3.36e-23	5.08e-20	-0.49	-0.42	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
KIRC	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-10.44	3.39e-23	5.11e-20	-0.35	-0.42	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
KIRC	cis	rs9457247	0.602	rs2239827	ENSG00000265828.1	MIR3939	-10.44	3.39e-23	5.12e-20	-0.49	-0.42	Crohn's disease;	chr6:167077457	chr6:166997807~166997912:-
KIRC	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-10.44	3.39e-23	5.12e-20	-0.49	-0.42	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
KIRC	cis	rs4356975	0.649	rs59421013	ENSG00000250696.4	RP11-704M14.1	10.44	3.53e-23	5.33e-20	0.43	0.42	Obesity-related traits;	chr4:69149131	chr4:69182100~69216766:+
KIRC	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-10.43	3.57e-23	5.38e-20	-0.64	-0.42	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
KIRC	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-10.43	3.6e-23	5.43e-20	-0.41	-0.42	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
KIRC	cis	rs72901758	0.768	rs1567237	ENSG00000267676.1	THA1P	-10.43	3.62e-23	5.46e-20	-0.51	-0.42	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78250213	chr17:78248493~78254416:-
KIRC	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-10.43	3.66e-23	5.52e-20	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-10.43	3.66e-23	5.52e-20	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
KIRC	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-10.43	3.66e-23	5.52e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
KIRC	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-10.43	3.68e-23	5.54e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
KIRC	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	10.43	3.69e-23	5.56e-20	0.43	0.42	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
KIRC	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	10.43	3.7e-23	5.57e-20	0.43	0.42	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
KIRC	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-10.43	3.72e-23	5.6e-20	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
KIRC	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-10.43	3.72e-23	5.61e-20	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
KIRC	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	10.43	3.75e-23	5.64e-20	0.43	0.42	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
KIRC	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	10.43	3.77e-23	5.67e-20	0.52	0.42	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	10.43	3.77e-23	5.67e-20	0.52	0.42	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	10.43	3.77e-23	5.67e-20	0.52	0.42	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	10.43	3.77e-23	5.67e-20	0.52	0.42	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
KIRC	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	10.43	3.78e-23	5.68e-20	0.44	0.42	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	10.43	3.78e-23	5.68e-20	0.44	0.42	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
KIRC	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	10.43	3.85e-23	5.79e-20	0.55	0.42	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-10.42	3.88e-23	5.83e-20	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
KIRC	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	10.42	3.89e-23	5.85e-20	0.84	0.42	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
KIRC	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-10.42	3.91e-23	5.88e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
KIRC	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-10.42	3.92e-23	5.89e-20	-0.65	-0.42	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
KIRC	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	10.42	3.97e-23	5.97e-20	0.53	0.42	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
KIRC	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-10.42	4.01e-23	6.02e-20	-0.56	-0.42	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
KIRC	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	10.42	4.01e-23	6.02e-20	0.53	0.42	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
KIRC	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	10.42	4.02e-23	6.03e-20	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
KIRC	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-10.42	4.03e-23	6.05e-20	-0.51	-0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
KIRC	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-10.42	4.03e-23	6.05e-20	-0.47	-0.42	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
KIRC	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	10.42	4.05e-23	6.08e-20	0.55	0.42	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
KIRC	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	10.42	4.05e-23	6.08e-20	0.55	0.42	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
KIRC	cis	rs2698530	0.634	rs871776	ENSG00000225889.6	AC074289.1	-10.42	4.06e-23	6.09e-20	-0.43	-0.42	Iron status biomarkers;	chr2:64228540	chr2:64143239~64252859:+
KIRC	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-10.42	4.06e-23	6.09e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
KIRC	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-10.42	4.06e-23	6.09e-20	-0.49	-0.42	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.42	4.13e-23	6.19e-20	-0.56	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
KIRC	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-10.42	4.15e-23	6.23e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
KIRC	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-10.42	4.19e-23	6.29e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
KIRC	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	10.42	4.19e-23	6.29e-20	0.77	0.42	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
KIRC	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	10.42	4.19e-23	6.29e-20	0.77	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
KIRC	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-10.42	4.2e-23	6.29e-20	-0.36	-0.42	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
KIRC	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-10.41	4.24e-23	6.35e-20	-0.51	-0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
KIRC	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	10.41	4.27e-23	6.41e-20	0.63	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
KIRC	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-10.41	4.27e-23	6.41e-20	-0.35	-0.42	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-10.41	4.27e-23	6.41e-20	-0.35	-0.42	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
KIRC	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-10.41	4.28e-23	6.41e-20	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000248763.2	RP13-644M16.5	-10.41	4.33e-23	6.49e-20	-0.54	-0.42	Obesity-related traits;	chr4:69075351	chr4:69066395~69069888:+
KIRC	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	10.41	4.34e-23	6.5e-20	0.54	0.42	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	10.41	4.35e-23	6.52e-20	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
KIRC	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	10.41	4.35e-23	6.53e-20	0.38	0.42	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
KIRC	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	10.41	4.37e-23	6.55e-20	0.5	0.42	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
KIRC	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	10.41	4.39e-23	6.57e-20	0.55	0.42	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
KIRC	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-10.41	4.39e-23	6.58e-20	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
KIRC	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-10.41	4.42e-23	6.62e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
KIRC	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-10.41	4.44e-23	6.65e-20	-0.49	-0.42	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
KIRC	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	10.41	4.45e-23	6.66e-20	0.57	0.42	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
KIRC	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-10.41	4.53e-23	6.78e-20	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-10.41	4.53e-23	6.78e-20	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
KIRC	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	10.41	4.54e-23	6.79e-20	0.75	0.42	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
KIRC	cis	rs5769707	0.681	rs6009803	ENSG00000188511.11	C22orf34	10.41	4.57e-23	6.84e-20	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49657359	chr22:49414524~49657542:-
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000248763.2	RP13-644M16.5	-10.4	4.63e-23	6.93e-20	-0.53	-0.42	Obesity-related traits;	chr4:69079291	chr4:69066395~69069888:+
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	10.4	4.63e-23	6.93e-20	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
KIRC	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-10.4	4.65e-23	6.95e-20	-0.32	-0.42	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
KIRC	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-10.4	4.66e-23	6.97e-20	-0.48	-0.42	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
KIRC	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	10.4	4.7e-23	7.03e-20	0.52	0.42	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	10.4	4.7e-23	7.03e-20	0.52	0.42	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	10.4	4.7e-23	7.03e-20	0.52	0.42	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
KIRC	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.4	4.75e-23	7.1e-20	0.32	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
KIRC	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-10.4	4.75e-23	7.1e-20	-0.48	-0.42	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
KIRC	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-10.4	4.76e-23	7.11e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
KIRC	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-10.4	4.86e-23	7.26e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-10.4	4.86e-23	7.26e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
KIRC	cis	rs2698530	0.634	rs1025210	ENSG00000225889.6	AC074289.1	-10.4	4.9e-23	7.32e-20	-0.43	-0.42	Iron status biomarkers;	chr2:64251945	chr2:64143239~64252859:+
KIRC	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-10.4	4.92e-23	7.36e-20	-0.45	-0.42	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
KIRC	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-10.4	4.95e-23	7.4e-20	-0.63	-0.42	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
KIRC	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	10.39	5.06e-23	7.55e-20	0.38	0.42	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
KIRC	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-10.39	5.08e-23	7.58e-20	-0.51	-0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
KIRC	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	10.39	5.09e-23	7.6e-20	1.11	0.42	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	10.39	5.09e-23	7.6e-20	1.11	0.42	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
KIRC	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-10.39	5.14e-23	7.67e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
KIRC	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	10.39	5.15e-23	7.69e-20	0.44	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
KIRC	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-10.39	5.18e-23	7.72e-20	-0.66	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
KIRC	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-10.39	5.18e-23	7.72e-20	-0.47	-0.42	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
KIRC	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-10.39	5.2e-23	7.75e-20	-0.41	-0.42	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
KIRC	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	10.39	5.22e-23	7.78e-20	0.44	0.42	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	10.39	5.22e-23	7.78e-20	0.44	0.42	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
KIRC	cis	rs7115242	0.699	rs17174502	ENSG00000254851.1	RP11-109L13.1	10.39	5.23e-23	7.79e-20	0.92	0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116888939	chr11:117135528~117138582:+
KIRC	cis	rs4356975	1	rs4356975	ENSG00000248763.2	RP13-644M16.5	-10.39	5.24e-23	7.81e-20	-0.54	-0.42	Obesity-related traits;	chr4:69106745	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000248763.2	RP13-644M16.5	-10.39	5.3e-23	7.9e-20	-0.54	-0.42	Obesity-related traits;	chr4:69075937	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000248763.2	RP13-644M16.5	-10.39	5.3e-23	7.9e-20	-0.54	-0.42	Obesity-related traits;	chr4:69075944	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000248763.2	RP13-644M16.5	-10.39	5.3e-23	7.9e-20	-0.54	-0.42	Obesity-related traits;	chr4:69076309	chr4:69066395~69069888:+
KIRC	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-10.39	5.31e-23	7.91e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
KIRC	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-10.39	5.35e-23	7.97e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-10.39	5.35e-23	7.97e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-10.39	5.35e-23	7.97e-20	-0.34	-0.42	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
KIRC	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	10.39	5.35e-23	7.97e-20	0.59	0.42	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000248763.2	RP13-644M16.5	-10.39	5.37e-23	8e-20	-0.54	-0.42	Obesity-related traits;	chr4:69078113	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000248763.2	RP13-644M16.5	-10.39	5.37e-23	8e-20	-0.54	-0.42	Obesity-related traits;	chr4:69078247	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000248763.2	RP13-644M16.5	-10.39	5.37e-23	8e-20	-0.54	-0.42	Obesity-related traits;	chr4:69078533	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000248763.2	RP13-644M16.5	-10.39	5.37e-23	8e-20	-0.54	-0.42	Obesity-related traits;	chr4:69078868	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000248763.2	RP13-644M16.5	-10.39	5.37e-23	8e-20	-0.54	-0.42	Obesity-related traits;	chr4:69078897	chr4:69066395~69069888:+
KIRC	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	10.39	5.39e-23	8.02e-20	0.53	0.42	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
KIRC	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-10.39	5.45e-23	8.11e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
KIRC	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-10.38	5.48e-23	8.15e-20	-0.54	-0.42	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
KIRC	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-10.38	5.5e-23	8.18e-20	-0.45	-0.42	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
KIRC	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-10.38	5.52e-23	8.2e-20	-0.49	-0.42	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
KIRC	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	10.38	5.52e-23	8.2e-20	0.44	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
KIRC	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	10.38	5.53e-23	8.23e-20	0.54	0.42	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
KIRC	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-10.38	5.53e-23	8.23e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-10.38	5.53e-23	8.23e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-10.38	5.53e-23	8.23e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-10.38	5.53e-23	8.23e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-10.38	5.53e-23	8.23e-20	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
KIRC	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-10.38	5.6e-23	8.33e-20	-0.42	-0.42	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
KIRC	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-10.38	5.62e-23	8.35e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
KIRC	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	10.38	5.62e-23	8.35e-20	0.42	0.42	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
KIRC	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-10.38	5.62e-23	8.35e-20	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
KIRC	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	10.38	5.67e-23	8.43e-20	0.43	0.42	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
KIRC	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	10.38	5.69e-23	8.45e-20	0.49	0.42	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
KIRC	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	10.38	5.69e-23	8.45e-20	0.43	0.42	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
KIRC	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-10.38	5.69e-23	8.46e-20	-0.35	-0.42	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
KIRC	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	10.38	5.73e-23	8.5e-20	0.49	0.42	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
KIRC	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	10.38	5.73e-23	8.52e-20	0.5	0.42	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
KIRC	cis	rs79040073	0.53	rs73394357	ENSG00000259531.2	RP11-295H24.3	10.38	5.74e-23	8.52e-20	0.51	0.42	Lung cancer in ever smokers;	chr15:49300314	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.53	rs3784630	ENSG00000259531.2	RP11-295H24.3	10.38	5.74e-23	8.52e-20	0.51	0.42	Lung cancer in ever smokers;	chr15:49322952	chr15:49365124~49366685:-
KIRC	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	10.38	5.74e-23	8.52e-20	0.51	0.42	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
KIRC	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-10.38	5.75e-23	8.54e-20	-0.45	-0.42	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
KIRC	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	10.38	5.85e-23	8.68e-20	0.57	0.42	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	10.38	5.89e-23	8.74e-20	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
KIRC	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-10.38	5.94e-23	8.81e-20	-0.49	-0.42	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
KIRC	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	10.37	6.04e-23	8.95e-20	0.43	0.42	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000248763.2	RP13-644M16.5	-10.37	6.04e-23	8.95e-20	-0.54	-0.42	Obesity-related traits;	chr4:69079387	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000248763.2	RP13-644M16.5	-10.37	6.04e-23	8.95e-20	-0.54	-0.42	Obesity-related traits;	chr4:69079446	chr4:69066395~69069888:+
KIRC	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-10.37	6.12e-23	9.07e-20	-0.51	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
KIRC	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-10.37	6.15e-23	9.12e-20	-0.61	-0.42	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
KIRC	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	10.37	6.15e-23	9.12e-20	0.44	0.42	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	10.37	6.15e-23	9.12e-20	0.44	0.42	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
KIRC	cis	rs2698530	0.634	rs1025209	ENSG00000225889.6	AC074289.1	-10.37	6.2e-23	9.18e-20	-0.42	-0.42	Iron status biomarkers;	chr2:64251926	chr2:64143239~64252859:+
KIRC	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.37	6.21e-23	9.19e-20	0.54	0.42	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000248763.2	RP13-644M16.5	-10.37	6.22e-23	9.21e-20	-0.54	-0.42	Obesity-related traits;	chr4:69079589	chr4:69066395~69069888:+
KIRC	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	10.37	6.23e-23	9.23e-20	0.39	0.42	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
KIRC	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-10.37	6.23e-23	9.23e-20	-0.51	-0.42	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
KIRC	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	10.37	6.26e-23	9.27e-20	0.29	0.42	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
KIRC	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-10.37	6.32e-23	9.35e-20	-0.51	-0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
KIRC	cis	rs9457247	0.668	rs2236313	ENSG00000265828.1	MIR3939	-10.37	6.37e-23	9.42e-20	-0.48	-0.42	Crohn's disease;	chr6:166946901	chr6:166997807~166997912:-
KIRC	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	10.37	6.39e-23	9.46e-20	0.54	0.42	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
KIRC	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-10.37	6.4e-23	9.46e-20	-0.59	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
KIRC	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-10.36	6.5e-23	9.61e-20	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
KIRC	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	10.36	6.58e-23	9.74e-20	0.52	0.42	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
KIRC	cis	rs7188445	0.651	rs4889014	ENSG00000261390.4	RP11-345M22.2	10.36	6.64e-23	9.81e-20	0.48	0.42	Urate levels;	chr16:79684556	chr16:79715232~79770563:-
KIRC	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	10.36	6.64e-23	9.81e-20	0.48	0.42	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
KIRC	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	10.36	6.65e-23	9.83e-20	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
KIRC	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	10.36	6.77e-23	1e-19	0.52	0.42	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
KIRC	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.36	6.83e-23	1.01e-19	0.32	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
KIRC	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-10.36	6.85e-23	1.01e-19	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
KIRC	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-10.36	6.87e-23	1.01e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-10.36	6.87e-23	1.01e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-10.36	6.88e-23	1.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-10.36	6.88e-23	1.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-10.36	6.97e-23	1.03e-19	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
KIRC	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-10.36	6.98e-23	1.03e-19	-0.54	-0.42	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
KIRC	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-10.36	7e-23	1.03e-19	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
KIRC	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-10.36	7.06e-23	1.04e-19	-0.41	-0.42	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
KIRC	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	10.35	7.08e-23	1.04e-19	0.62	0.42	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
KIRC	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.35	7.17e-23	1.06e-19	0.52	0.42	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000248763.2	RP13-644M16.5	-10.35	7.21e-23	1.06e-19	-0.55	-0.42	Obesity-related traits;	chr4:69063770	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-10.35	7.22e-23	1.06e-19	-0.35	-0.42	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	10.35	7.29e-23	1.08e-19	0.55	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
KIRC	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-10.35	7.3e-23	1.08e-19	-0.49	-0.42	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
KIRC	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	10.35	7.34e-23	1.08e-19	0.52	0.42	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
KIRC	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-10.35	7.4e-23	1.09e-19	-0.63	-0.42	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-10.35	7.4e-23	1.09e-19	-0.63	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
KIRC	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-10.35	7.44e-23	1.1e-19	-0.42	-0.42	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
KIRC	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	10.35	7.47e-23	1.1e-19	0.54	0.42	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
KIRC	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	10.35	7.51e-23	1.11e-19	0.38	0.42	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
KIRC	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	10.35	7.52e-23	1.11e-19	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
KIRC	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	10.34	7.75e-23	1.14e-19	0.43	0.42	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
KIRC	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	10.34	7.75e-23	1.14e-19	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
KIRC	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	10.34	7.8e-23	1.15e-19	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
KIRC	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-10.34	7.84e-23	1.15e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
KIRC	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-10.34	7.91e-23	1.16e-19	-0.65	-0.42	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-10.34	7.91e-23	1.16e-19	-0.65	-0.42	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
KIRC	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	10.34	7.92e-23	1.16e-19	0.4	0.42	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
KIRC	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-10.34	7.95e-23	1.17e-19	-0.56	-0.42	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
KIRC	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-10.34	7.97e-23	1.17e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
KIRC	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	10.34	8.01e-23	1.18e-19	0.47	0.42	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
KIRC	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.05e-23	1.18e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.05e-23	1.18e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.05e-23	1.18e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.05e-23	1.18e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.05e-23	1.18e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
KIRC	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-10.34	8.19e-23	1.2e-19	-0.55	-0.42	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
KIRC	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	10.34	8.2e-23	1.2e-19	0.55	0.42	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
KIRC	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-10.34	8.2e-23	1.2e-19	-0.51	-0.42	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
KIRC	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.21e-23	1.2e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
KIRC	cis	rs2698530	0.624	rs2247947	ENSG00000225889.6	AC074289.1	-10.34	8.23e-23	1.21e-19	-0.42	-0.42	Iron status biomarkers;	chr2:64249344	chr2:64143239~64252859:+
KIRC	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	10.34	8.26e-23	1.21e-19	0.84	0.42	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
KIRC	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-10.34	8.3e-23	1.22e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
KIRC	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-10.34	8.35e-23	1.22e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
KIRC	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-10.34	8.37e-23	1.23e-19	-0.63	-0.42	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
KIRC	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-10.33	8.4e-23	1.23e-19	-0.41	-0.42	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
KIRC	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-10.33	8.4e-23	1.23e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
KIRC	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	10.33	8.42e-23	1.24e-19	0.39	0.42	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
KIRC	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	10.33	8.49e-23	1.24e-19	0.8	0.42	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
KIRC	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	10.33	8.5e-23	1.25e-19	0.54	0.42	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
KIRC	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	10.33	8.53e-23	1.25e-19	0.44	0.42	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
KIRC	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.33	8.58e-23	1.26e-19	0.52	0.42	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
KIRC	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.33	8.58e-23	1.26e-19	0.52	0.42	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
KIRC	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-10.33	8.71e-23	1.28e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-10.33	8.72e-23	1.28e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
KIRC	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	10.33	8.72e-23	1.28e-19	0.81	0.42	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
KIRC	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	10.33	8.72e-23	1.28e-19	0.81	0.42	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
KIRC	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-10.33	8.72e-23	1.28e-19	-0.55	-0.42	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-10.33	8.72e-23	1.28e-19	-0.55	-0.42	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
KIRC	cis	rs9457247	0.561	rs916331	ENSG00000265828.1	MIR3939	-10.33	8.77e-23	1.28e-19	-0.48	-0.42	Crohn's disease;	chr6:167057071	chr6:166997807~166997912:-
KIRC	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-10.33	8.79e-23	1.29e-19	-0.45	-0.42	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
KIRC	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	10.33	8.8e-23	1.29e-19	0.48	0.42	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
KIRC	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-10.33	9.05e-23	1.32e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
KIRC	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	10.33	9.06e-23	1.32e-19	0.43	0.42	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
KIRC	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-10.32	9.18e-23	1.34e-19	-0.29	-0.42	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
KIRC	cis	rs9847710	0.967	rs2581778	ENSG00000280417.1	RP11-5O17.1	-10.32	9.19e-23	1.34e-19	-0.48	-0.42	Ulcerative colitis;	chr3:53021295	chr3:53046166~53048122:+
KIRC	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-10.32	9.24e-23	1.35e-19	-0.56	-0.42	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
KIRC	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-10.32	9.26e-23	1.35e-19	-0.48	-0.42	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
KIRC	cis	rs7188445	0.712	rs6564688	ENSG00000261390.4	RP11-345M22.2	10.32	9.27e-23	1.36e-19	0.48	0.42	Urate levels;	chr16:79680061	chr16:79715232~79770563:-
KIRC	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-10.32	9.4e-23	1.37e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
KIRC	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-10.32	9.52e-23	1.39e-19	-0.63	-0.42	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
KIRC	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	10.32	9.53e-23	1.39e-19	0.47	0.42	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	10.32	9.53e-23	1.39e-19	0.47	0.42	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	10.32	9.6e-23	1.4e-19	0.47	0.42	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000248763.2	RP13-644M16.5	-10.32	9.61e-23	1.4e-19	-0.53	-0.42	Obesity-related traits;	chr4:69074144	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000248763.2	RP13-644M16.5	-10.32	9.61e-23	1.4e-19	-0.53	-0.42	Obesity-related traits;	chr4:69074157	chr4:69066395~69069888:+
KIRC	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-10.32	9.69e-23	1.41e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
KIRC	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-10.32	9.89e-23	1.44e-19	-0.32	-0.42	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
KIRC	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-10.32	9.89e-23	1.44e-19	-0.32	-0.42	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
KIRC	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-10.32	9.91e-23	1.45e-19	-0.64	-0.42	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-10.32	9.91e-23	1.45e-19	-0.64	-0.42	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
KIRC	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-10.31	9.98e-23	1.46e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
KIRC	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	10.31	1e-22	1.46e-19	0.51	0.42	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
KIRC	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	10.31	1.03e-22	1.51e-19	0.56	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
KIRC	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	10.31	1.04e-22	1.52e-19	0.39	0.42	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
KIRC	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-10.31	1.04e-22	1.52e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
KIRC	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-10.31	1.05e-22	1.52e-19	-0.62	-0.42	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
KIRC	cis	rs9457247	0.602	rs13204839	ENSG00000265828.1	MIR3939	-10.31	1.05e-22	1.53e-19	-0.48	-0.42	Crohn's disease;	chr6:167057631	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.602	rs6456152	ENSG00000265828.1	MIR3939	-10.31	1.05e-22	1.53e-19	-0.48	-0.42	Crohn's disease;	chr6:167058574	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.602	rs9457262	ENSG00000265828.1	MIR3939	-10.31	1.05e-22	1.53e-19	-0.48	-0.42	Crohn's disease;	chr6:167060197	chr6:166997807~166997912:-
KIRC	cis	rs3093024	0.595	rs4412174	ENSG00000265828.1	MIR3939	-10.31	1.05e-22	1.53e-19	-0.48	-0.42	Rheumatoid arthritis;	chr6:167062578	chr6:166997807~166997912:-
KIRC	cis	rs3093024	0.595	rs4458654	ENSG00000265828.1	MIR3939	-10.31	1.05e-22	1.53e-19	-0.48	-0.42	Rheumatoid arthritis;	chr6:167062580	chr6:166997807~166997912:-
KIRC	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	10.31	1.06e-22	1.54e-19	0.47	0.42	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
KIRC	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-10.31	1.06e-22	1.54e-19	-0.63	-0.42	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
KIRC	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-10.31	1.07e-22	1.55e-19	-0.47	-0.42	Temperament;	chr17:14042870	chr17:14024514~14025488:+
KIRC	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-10.31	1.08e-22	1.57e-19	-0.63	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
KIRC	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-10.3	1.09e-22	1.58e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
KIRC	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	10.3	1.11e-22	1.61e-19	0.52	0.42	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
KIRC	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	10.3	1.11e-22	1.62e-19	0.43	0.42	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	10.3	1.11e-22	1.62e-19	0.43	0.42	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
KIRC	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	10.3	1.12e-22	1.62e-19	0.39	0.42	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
KIRC	cis	rs2698530	0.634	rs6750096	ENSG00000225889.6	AC074289.1	-10.3	1.13e-22	1.64e-19	-0.42	-0.42	Iron status biomarkers;	chr2:64246935	chr2:64143239~64252859:+
KIRC	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	10.3	1.13e-22	1.64e-19	0.39	0.42	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
KIRC	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-10.3	1.13e-22	1.64e-19	-0.51	-0.42	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
KIRC	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-10.3	1.14e-22	1.66e-19	-0.5	-0.42	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-10.3	1.14e-22	1.66e-19	-0.5	-0.42	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-10.3	1.14e-22	1.66e-19	-0.5	-0.42	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
KIRC	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	10.3	1.15e-22	1.66e-19	0.56	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	10.3	1.15e-22	1.66e-19	0.56	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
KIRC	cis	rs4356975	1	rs4356975	ENSG00000250696.4	RP11-704M14.1	10.3	1.16e-22	1.69e-19	0.44	0.42	Obesity-related traits;	chr4:69106745	chr4:69182100~69216766:+
KIRC	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	10.3	1.17e-22	1.7e-19	0.48	0.42	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
KIRC	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	10.3	1.17e-22	1.7e-19	0.48	0.42	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
KIRC	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-10.3	1.17e-22	1.7e-19	-0.81	-0.42	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
KIRC	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-10.3	1.18e-22	1.71e-19	-0.52	-0.42	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
KIRC	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-10.3	1.18e-22	1.71e-19	-0.59	-0.42	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
KIRC	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-10.3	1.18e-22	1.71e-19	-0.5	-0.42	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-10.29	1.2e-22	1.73e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-10.29	1.2e-22	1.73e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
KIRC	cis	rs9847710	0.967	rs4687694	ENSG00000280417.1	RP11-5O17.1	-10.29	1.2e-22	1.74e-19	-0.48	-0.42	Ulcerative colitis;	chr3:53015031	chr3:53046166~53048122:+
KIRC	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	10.29	1.21e-22	1.76e-19	0.49	0.42	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
KIRC	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	10.29	1.24e-22	1.79e-19	0.55	0.42	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	10.29	1.26e-22	1.83e-19	0.49	0.42	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
KIRC	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-10.29	1.27e-22	1.83e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
KIRC	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-10.28	1.3e-22	1.87e-19	-0.52	-0.42	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
KIRC	cis	rs2698530	0.634	rs2555426	ENSG00000225889.6	AC074289.1	-10.28	1.3e-22	1.88e-19	-0.42	-0.42	Iron status biomarkers;	chr2:64243051	chr2:64143239~64252859:+
KIRC	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	10.28	1.31e-22	1.89e-19	0.49	0.42	Height;	chr11:118746590	chr11:118688039~118690600:-
KIRC	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	10.28	1.32e-22	1.91e-19	0.45	0.42	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
KIRC	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	10.28	1.32e-22	1.91e-19	0.83	0.42	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
KIRC	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-10.28	1.34e-22	1.94e-19	-0.49	-0.42	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
KIRC	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-10.28	1.34e-22	1.94e-19	-0.49	-0.42	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
KIRC	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.28	1.35e-22	1.95e-19	-0.57	-0.42	QT interval;	chr16:28857143	chr16:28700294~28701540:-
KIRC	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-10.28	1.36e-22	1.96e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-10.28	1.36e-22	1.96e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-10.28	1.36e-22	1.96e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
KIRC	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-10.28	1.37e-22	1.98e-19	-0.67	-0.42	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
KIRC	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-10.28	1.38e-22	1.99e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-10.28	1.38e-22	1.99e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
KIRC	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-10.28	1.38e-22	1.99e-19	-0.5	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
KIRC	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-10.28	1.39e-22	2e-19	-0.43	-0.42	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
KIRC	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-10.27	1.43e-22	2.06e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-10.27	1.43e-22	2.06e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-10.27	1.43e-22	2.06e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
KIRC	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-10.27	1.44e-22	2.08e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-10.27	1.44e-22	2.08e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-10.27	1.44e-22	2.08e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-10.27	1.44e-22	2.08e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
KIRC	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-10.27	1.44e-22	2.08e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
KIRC	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	10.27	1.48e-22	2.13e-19	0.47	0.42	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
KIRC	cis	rs79040073	0.53	rs73396206	ENSG00000259531.2	RP11-295H24.3	10.27	1.5e-22	2.17e-19	0.51	0.42	Lung cancer in ever smokers;	chr15:49323632	chr15:49365124~49366685:-
KIRC	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-10.27	1.51e-22	2.17e-19	-0.45	-0.42	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
KIRC	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-10.26	1.53e-22	2.21e-19	-0.32	-0.42	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
KIRC	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-10.26	1.54e-22	2.22e-19	-0.32	-0.42	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
KIRC	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	10.26	1.55e-22	2.23e-19	0.38	0.42	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
KIRC	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	10.26	1.55e-22	2.24e-19	0.53	0.42	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
KIRC	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-10.26	1.57e-22	2.26e-19	-0.4	-0.42	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
KIRC	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
KIRC	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-10.26	1.57e-22	2.27e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
KIRC	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-10.26	1.59e-22	2.28e-19	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-10.26	1.59e-22	2.28e-19	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-10.26	1.59e-22	2.28e-19	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-10.26	1.59e-22	2.28e-19	-0.39	-0.42	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	10.26	1.59e-22	2.28e-19	0.39	0.42	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
KIRC	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	10.26	1.59e-22	2.28e-19	0.65	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
KIRC	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	10.26	1.59e-22	2.28e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
KIRC	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-10.26	1.6e-22	2.3e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
KIRC	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	10.26	1.61e-22	2.31e-19	0.38	0.42	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
KIRC	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-10.26	1.61e-22	2.31e-19	-0.55	-0.42	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
KIRC	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-10.26	1.63e-22	2.34e-19	-0.31	-0.42	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
KIRC	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-10.26	1.64e-22	2.35e-19	-0.44	-0.42	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-10.26	1.65e-22	2.36e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
KIRC	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-10.26	1.65e-22	2.37e-19	-0.32	-0.42	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
KIRC	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-10.26	1.66e-22	2.38e-19	-0.56	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
KIRC	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-10.25	1.67e-22	2.39e-19	-0.64	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
KIRC	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	10.25	1.67e-22	2.4e-19	0.43	0.42	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
KIRC	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-10.25	1.68e-22	2.41e-19	-0.45	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
KIRC	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	10.25	1.69e-22	2.42e-19	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	10.25	1.69e-22	2.42e-19	0.57	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
KIRC	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	10.25	1.7e-22	2.43e-19	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
KIRC	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	10.25	1.73e-22	2.48e-19	0.39	0.42	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
KIRC	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.25	1.73e-22	2.49e-19	0.52	0.42	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
KIRC	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	10.25	1.74e-22	2.5e-19	0.43	0.42	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
KIRC	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	10.25	1.75e-22	2.5e-19	0.8	0.42	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
KIRC	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	10.25	1.75e-22	2.5e-19	0.52	0.42	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
KIRC	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	10.25	1.76e-22	2.52e-19	0.51	0.42	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
KIRC	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	10.25	1.78e-22	2.55e-19	0.55	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
KIRC	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	10.24	1.83e-22	2.62e-19	0.49	0.42	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
KIRC	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-10.24	1.85e-22	2.65e-19	-0.66	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
KIRC	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	10.24	1.89e-22	2.7e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	10.24	1.89e-22	2.7e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
KIRC	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	10.24	1.9e-22	2.71e-19	0.43	0.42	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-10.24	1.93e-22	2.75e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-10.24	1.93e-22	2.75e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-10.24	1.93e-22	2.75e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
KIRC	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-10.24	1.96e-22	2.8e-19	-0.35	-0.42	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
KIRC	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-10.24	1.96e-22	2.8e-19	-0.35	-0.42	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
KIRC	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-10.24	1.97e-22	2.81e-19	-0.68	-0.42	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
KIRC	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-10.24	1.97e-22	2.82e-19	-0.63	-0.42	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
KIRC	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	10.23	2e-22	2.85e-19	0.47	0.42	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
KIRC	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	10.23	2.01e-22	2.86e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	10.23	2.01e-22	2.86e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	10.23	2.01e-22	2.86e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-10.23	2.01e-22	2.87e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	10.23	2.02e-22	2.89e-19	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
KIRC	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-10.23	2.03e-22	2.89e-19	-0.33	-0.42	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
KIRC	cis	rs2698530	0.634	rs2555425	ENSG00000225889.6	AC074289.1	-10.23	2.03e-22	2.89e-19	-0.42	-0.42	Iron status biomarkers;	chr2:64239648	chr2:64143239~64252859:+
KIRC	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	10.23	2.05e-22	2.92e-19	0.47	0.42	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
KIRC	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-10.23	2.08e-22	2.96e-19	-0.33	-0.42	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
KIRC	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	10.23	2.09e-22	2.98e-19	0.54	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
KIRC	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	10.23	2.09e-22	2.98e-19	0.41	0.42	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
KIRC	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-10.23	2.1e-22	3e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
KIRC	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	10.23	2.1e-22	3e-19	0.49	0.42	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
KIRC	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-10.23	2.12e-22	3.02e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
KIRC	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-10.22	2.15e-22	3.06e-19	-0.63	-0.42	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
KIRC	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	10.22	2.16e-22	3.07e-19	0.47	0.42	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
KIRC	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	10.22	2.17e-22	3.08e-19	0.52	0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
KIRC	cis	rs9457247	0.624	rs9457260	ENSG00000265828.1	MIR3939	-10.22	2.17e-22	3.09e-19	-0.48	-0.42	Crohn's disease;	chr6:167053177	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.624	rs17524252	ENSG00000265828.1	MIR3939	-10.22	2.17e-22	3.09e-19	-0.48	-0.42	Crohn's disease;	chr6:167053490	chr6:166997807~166997912:-
KIRC	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-10.22	2.18e-22	3.1e-19	-0.31	-0.42	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
KIRC	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-10.22	2.2e-22	3.12e-19	-0.5	-0.42	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
KIRC	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-10.22	2.21e-22	3.14e-19	-0.54	-0.42	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
KIRC	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	10.22	2.27e-22	3.23e-19	0.56	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
KIRC	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-10.22	2.29e-22	3.25e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
KIRC	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-10.22	2.3e-22	3.26e-19	-0.32	-0.42	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
KIRC	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	10.22	2.32e-22	3.3e-19	0.48	0.42	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
KIRC	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	10.22	2.33e-22	3.3e-19	0.53	0.42	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
KIRC	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	10.22	2.34e-22	3.32e-19	0.59	0.42	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
KIRC	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	10.21	2.36e-22	3.36e-19	0.63	0.42	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
KIRC	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-10.21	2.39e-22	3.39e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	10.21	2.41e-22	3.42e-19	0.55	0.42	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
KIRC	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.41	0.42	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.43	0.42	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.43	0.42	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.43	0.42	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.43	0.42	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	10.21	2.43e-22	3.45e-19	0.43	0.42	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
KIRC	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	10.21	2.47e-22	3.5e-19	0.53	0.42	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
KIRC	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	10.21	2.47e-22	3.5e-19	0.53	0.42	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000248763.2	RP13-644M16.5	-10.21	2.49e-22	3.52e-19	-0.53	-0.42	Obesity-related traits;	chr4:69077628	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000248763.2	RP13-644M16.5	-10.21	2.49e-22	3.52e-19	-0.53	-0.42	Obesity-related traits;	chr4:69077631	chr4:69066395~69069888:+
KIRC	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-10.21	2.49e-22	3.52e-19	-0.49	-0.42	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
KIRC	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-10.21	2.5e-22	3.54e-19	-0.62	-0.42	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
KIRC	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	10.21	2.5e-22	3.54e-19	0.54	0.42	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
KIRC	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	10.21	2.52e-22	3.56e-19	0.31	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
KIRC	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	10.21	2.52e-22	3.57e-19	0.39	0.42	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
KIRC	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-10.21	2.54e-22	3.6e-19	-0.36	-0.42	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
KIRC	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	10.21	2.54e-22	3.6e-19	0.42	0.42	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	10.21	2.54e-22	3.6e-19	0.42	0.42	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
KIRC	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-10.2	2.58e-22	3.65e-19	-0.49	-0.42	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
KIRC	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-10.2	2.58e-22	3.65e-19	-0.49	-0.42	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
KIRC	cis	rs11079159	0.606	rs1114603	ENSG00000263096.1	RP11-515O17.2	10.2	2.59e-22	3.66e-19	0.54	0.42	QRS duration;	chr17:55291706	chr17:55271504~55273653:-
KIRC	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-10.2	2.6e-22	3.68e-19	-0.41	-0.42	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
KIRC	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-10.2	2.6e-22	3.68e-19	-0.41	-0.42	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
KIRC	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	10.2	2.64e-22	3.73e-19	0.43	0.42	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
KIRC	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	10.2	2.64e-22	3.73e-19	0.58	0.42	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
KIRC	cis	rs2698530	0.634	rs1365482	ENSG00000225889.6	AC074289.1	10.2	2.65e-22	3.75e-19	0.41	0.42	Iron status biomarkers;	chr2:64248838	chr2:64143239~64252859:+
KIRC	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	10.2	2.66e-22	3.76e-19	0.38	0.42	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	10.2	2.66e-22	3.76e-19	0.38	0.42	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	10.2	2.66e-22	3.76e-19	0.38	0.42	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-10.2	2.67e-22	3.77e-19	-0.51	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
KIRC	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	10.2	2.69e-22	3.8e-19	0.38	0.42	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	10.2	2.69e-22	3.8e-19	0.39	0.42	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
KIRC	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-10.2	2.7e-22	3.81e-19	-0.5	-0.42	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
KIRC	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-10.2	2.7e-22	3.82e-19	-0.49	-0.42	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
KIRC	cis	rs9457247	0.602	rs9459854	ENSG00000265828.1	MIR3939	-10.19	2.79e-22	3.93e-19	-0.48	-0.42	Crohn's disease;	chr6:167052394	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.582	rs9459855	ENSG00000265828.1	MIR3939	-10.19	2.79e-22	3.93e-19	-0.48	-0.42	Crohn's disease;	chr6:167052662	chr6:166997807~166997912:-
KIRC	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	10.19	2.8e-22	3.96e-19	0.38	0.42	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
KIRC	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-10.19	2.83e-22	3.99e-19	-0.82	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
KIRC	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-10.19	2.84e-22	4e-19	-0.78	-0.42	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
KIRC	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-10.19	2.84e-22	4.01e-19	-0.35	-0.42	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
KIRC	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	10.19	2.86e-22	4.04e-19	0.47	0.42	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
KIRC	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-10.19	2.93e-22	4.14e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
KIRC	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-10.19	2.94e-22	4.15e-19	-0.31	-0.42	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
KIRC	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	10.19	2.99e-22	4.21e-19	0.56	0.42	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	10.19	2.99e-22	4.21e-19	0.56	0.42	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
KIRC	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-10.19	3e-22	4.23e-19	-0.47	-0.42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000250696.4	RP11-704M14.1	-10.18	3.03e-22	4.27e-19	-0.43	-0.42	Obesity-related traits;	chr4:69075436	chr4:69182100~69216766:+
KIRC	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-10.18	3.09e-22	4.35e-19	-0.44	-0.42	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
KIRC	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	10.18	3.13e-22	4.41e-19	0.51	0.42	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
KIRC	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-10.18	3.14e-22	4.43e-19	-0.47	-0.42	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
KIRC	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	10.18	3.18e-22	4.47e-19	0.53	0.42	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
KIRC	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-10.18	3.18e-22	4.48e-19	-0.5	-0.42	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-10.18	3.2e-22	4.5e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-10.18	3.2e-22	4.5e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-10.18	3.2e-22	4.5e-19	-0.52	-0.42	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
KIRC	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-10.18	3.23e-22	4.54e-19	-0.48	-0.42	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	10.18	3.24e-22	4.56e-19	0.52	0.42	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
KIRC	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.18	3.26e-22	4.59e-19	0.47	0.42	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
KIRC	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-10.18	3.26e-22	4.59e-19	-0.44	-0.42	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-10.17	3.31e-22	4.65e-19	-0.33	-0.42	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
KIRC	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	10.17	3.32e-22	4.67e-19	0.48	0.42	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	10.17	3.32e-22	4.67e-19	0.48	0.42	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
KIRC	cis	rs9457247	0.565	rs2038580	ENSG00000265828.1	MIR3939	-10.17	3.34e-22	4.69e-19	-0.48	-0.42	Crohn's disease;	chr6:167043002	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.602	rs12208359	ENSG00000265828.1	MIR3939	-10.17	3.35e-22	4.71e-19	-0.48	-0.42	Crohn's disease;	chr6:167044967	chr6:166997807~166997912:-
KIRC	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	10.17	3.35e-22	4.72e-19	0.79	0.42	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
KIRC	cis	rs9457247	0.544	rs6920858	ENSG00000265828.1	MIR3939	-10.17	3.35e-22	4.72e-19	-0.48	-0.42	Crohn's disease;	chr6:167051142	chr6:166997807~166997912:-
KIRC	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	10.17	3.41e-22	4.79e-19	0.56	0.42	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
KIRC	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-10.17	3.41e-22	4.8e-19	-0.34	-0.42	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
KIRC	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	10.17	3.45e-22	4.84e-19	0.47	0.42	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
KIRC	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	10.17	3.45e-22	4.85e-19	0.51	0.42	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
KIRC	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	10.17	3.45e-22	4.85e-19	0.51	0.42	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
KIRC	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	10.17	3.48e-22	4.89e-19	0.56	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
KIRC	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-10.17	3.51e-22	4.93e-19	-0.32	-0.42	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
KIRC	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	10.17	3.51e-22	4.93e-19	0.42	0.42	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
KIRC	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-10.17	3.53e-22	4.95e-19	-0.47	-0.42	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
KIRC	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-10.17	3.53e-22	4.96e-19	-0.55	-0.42	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
KIRC	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-10.16	3.58e-22	5.03e-19	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-10.16	3.58e-22	5.03e-19	-0.51	-0.42	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
KIRC	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	10.16	3.65e-22	5.12e-19	0.73	0.42	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
KIRC	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-10.16	3.65e-22	5.12e-19	-0.56	-0.42	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
KIRC	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	10.16	3.66e-22	5.13e-19	0.37	0.42	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
KIRC	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	10.16	3.66e-22	5.13e-19	0.37	0.42	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	10.16	3.66e-22	5.13e-19	0.37	0.42	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
KIRC	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-10.16	3.67e-22	5.15e-19	-0.54	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
KIRC	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	10.16	3.74e-22	5.24e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
KIRC	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-10.16	3.77e-22	5.28e-19	-0.54	-0.42	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
KIRC	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-10.16	3.77e-22	5.28e-19	-0.51	-0.42	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
KIRC	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-10.16	3.78e-22	5.3e-19	-0.48	-0.42	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
KIRC	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	10.16	3.81e-22	5.34e-19	0.32	0.42	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
KIRC	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-10.16	3.86e-22	5.41e-19	-0.47	-0.42	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
KIRC	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-10.16	3.88e-22	5.43e-19	-0.48	-0.42	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
KIRC	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-10.16	3.88e-22	5.43e-19	-0.52	-0.42	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
KIRC	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-10.15	4e-22	5.6e-19	-0.52	-0.42	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
KIRC	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	10.15	4.04e-22	5.65e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
KIRC	cis	rs9457247	0.602	rs10484530	ENSG00000265828.1	MIR3939	-10.15	4.05e-22	5.66e-19	-0.48	-0.42	Crohn's disease;	chr6:167048074	chr6:166997807~166997912:-
KIRC	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	10.15	4.11e-22	5.74e-19	0.54	0.42	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
KIRC	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	10.15	4.12e-22	5.76e-19	0.5	0.42	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
KIRC	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	10.15	4.21e-22	5.88e-19	0.55	0.41	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
KIRC	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	10.15	4.21e-22	5.88e-19	0.55	0.41	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
KIRC	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	10.15	4.21e-22	5.88e-19	0.55	0.41	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
KIRC	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	10.15	4.21e-22	5.89e-19	0.42	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
KIRC	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-10.14	4.3e-22	6.01e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
KIRC	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	10.14	4.32e-22	6.04e-19	0.38	0.41	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
KIRC	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-10.14	4.33e-22	6.04e-19	-0.45	-0.41	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
KIRC	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	10.14	4.42e-22	6.17e-19	0.52	0.41	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
KIRC	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	10.14	4.46e-22	6.22e-19	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
KIRC	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	10.14	4.5e-22	6.28e-19	0.42	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
KIRC	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-10.14	4.6e-22	6.42e-19	-0.5	-0.41	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
KIRC	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	10.14	4.61e-22	6.42e-19	0.42	0.41	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-10.13	4.66e-22	6.5e-19	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
KIRC	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	10.13	4.68e-22	6.53e-19	0.49	0.41	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
KIRC	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-10.13	4.69e-22	6.54e-19	-0.62	-0.41	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
KIRC	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-10.13	4.69e-22	6.54e-19	-0.54	-0.41	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
KIRC	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	10.13	4.89e-22	6.81e-19	0.41	0.41	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
KIRC	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-10.13	4.91e-22	6.84e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-10.13	4.92e-22	6.84e-19	-0.46	-0.41	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-10.13	4.92e-22	6.84e-19	-0.46	-0.41	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-10.13	4.92e-22	6.84e-19	-0.46	-0.41	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-10.13	4.92e-22	6.84e-19	-0.46	-0.41	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
KIRC	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.13	4.98e-22	6.93e-19	0.46	0.41	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.13	4.98e-22	6.93e-19	0.46	0.41	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.13	4.98e-22	6.93e-19	0.46	0.41	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.13	4.98e-22	6.93e-19	0.46	0.41	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
KIRC	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.13	4.98e-22	6.93e-19	0.43	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
KIRC	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	10.12	5.04e-22	7.01e-19	0.46	0.41	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
KIRC	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	10.12	5.06e-22	7.04e-19	0.51	0.41	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
KIRC	cis	rs189798	0.807	rs330910	ENSG00000254340.1	RP11-10A14.3	10.12	5.07e-22	7.04e-19	0.56	0.41	Myopia (pathological);	chr8:9138245	chr8:9141424~9145435:+
KIRC	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	10.12	5.08e-22	7.07e-19	0.56	0.41	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
KIRC	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	10.12	5.13e-22	7.13e-19	0.54	0.41	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000250696.4	RP11-704M14.1	10.12	5.15e-22	7.15e-19	0.43	0.41	Obesity-related traits;	chr4:69079224	chr4:69182100~69216766:+
KIRC	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-10.12	5.17e-22	7.18e-19	-0.35	-0.41	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
KIRC	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-10.12	5.18e-22	7.19e-19	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
KIRC	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	10.12	5.26e-22	7.31e-19	0.54	0.41	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
KIRC	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-10.12	5.34e-22	7.41e-19	-0.33	-0.41	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
KIRC	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-10.12	5.34e-22	7.41e-19	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
KIRC	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	10.12	5.39e-22	7.48e-19	0.49	0.41	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
KIRC	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-10.12	5.45e-22	7.57e-19	-0.61	-0.41	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
KIRC	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	10.11	5.48e-22	7.6e-19	0.51	0.41	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
KIRC	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	10.11	5.5e-22	7.63e-19	0.42	0.41	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
KIRC	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	10.11	5.58e-22	7.74e-19	0.47	0.41	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
KIRC	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	10.11	5.6e-22	7.77e-19	0.55	0.41	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
KIRC	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-10.11	5.62e-22	7.79e-19	-0.52	-0.41	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
KIRC	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-10.11	5.63e-22	7.81e-19	-0.39	-0.41	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
KIRC	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	10.11	5.7e-22	7.9e-19	0.56	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
KIRC	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	10.11	5.71e-22	7.91e-19	0.58	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
KIRC	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-10.11	5.79e-22	8.02e-19	-0.59	-0.41	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
KIRC	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	10.11	5.83e-22	8.07e-19	0.42	0.41	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
KIRC	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-10.11	5.83e-22	8.07e-19	-0.48	-0.41	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
KIRC	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-10.11	5.83e-22	8.07e-19	-0.48	-0.41	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
KIRC	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-10.11	5.86e-22	8.11e-19	-0.63	-0.41	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
KIRC	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	10.11	5.88e-22	8.14e-19	0.38	0.41	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
KIRC	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	10.11	5.88e-22	8.14e-19	0.42	0.41	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
KIRC	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-10.11	5.92e-22	8.19e-19	-0.55	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
KIRC	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	10.11	5.95e-22	8.24e-19	0.41	0.41	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
KIRC	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-10.11	5.95e-22	8.24e-19	-0.61	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
KIRC	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	10.1	5.98e-22	8.27e-19	0.54	0.41	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
KIRC	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	10.1	6e-22	8.3e-19	0.42	0.41	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
KIRC	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-10.1	6.14e-22	8.49e-19	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
KIRC	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	10.1	6.15e-22	8.5e-19	0.53	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
KIRC	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-10.1	6.16e-22	8.51e-19	-0.55	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
KIRC	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	10.1	6.2e-22	8.57e-19	0.55	0.41	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
KIRC	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-10.1	6.39e-22	8.82e-19	-0.62	-0.41	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
KIRC	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-10.1	6.43e-22	8.88e-19	-0.43	-0.41	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
KIRC	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-10.1	6.45e-22	8.91e-19	-0.39	-0.41	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
KIRC	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-10.09	6.5e-22	8.98e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-10.09	6.5e-22	8.98e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-10.09	6.5e-22	8.98e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-10.09	6.5e-22	8.98e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-10.09	6.5e-22	8.98e-19	-0.51	-0.41	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
KIRC	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-10.09	6.51e-22	8.99e-19	-0.42	-0.41	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
KIRC	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-10.09	6.57e-22	9.07e-19	-0.69	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
KIRC	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	10.09	6.62e-22	9.14e-19	0.51	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
KIRC	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-10.09	6.62e-22	9.14e-19	-0.42	-0.41	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
KIRC	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-10.09	6.63e-22	9.16e-19	-0.4	-0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
KIRC	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	10.09	6.68e-22	9.21e-19	0.54	0.41	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
KIRC	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-10.09	6.73e-22	9.29e-19	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
KIRC	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-10.09	6.8e-22	9.38e-19	-0.55	-0.41	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
KIRC	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-10.09	6.82e-22	9.4e-19	-0.72	-0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
KIRC	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-10.09	6.82e-22	9.41e-19	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
KIRC	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-10.09	6.83e-22	9.42e-19	-0.54	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
KIRC	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	10.09	6.84e-22	9.43e-19	0.42	0.41	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
KIRC	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-10.09	6.9e-22	9.51e-19	-0.48	-0.41	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
KIRC	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-10.09	6.92e-22	9.54e-19	-0.47	-0.41	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
KIRC	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-10.09	6.93e-22	9.55e-19	-0.57	-0.41	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
KIRC	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-10.09	6.94e-22	9.56e-19	-0.57	-0.41	QT interval;	chr16:28884339	chr16:28700294~28701540:-
KIRC	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-10.09	6.98e-22	9.61e-19	-0.61	-0.41	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
KIRC	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-10.08	7.16e-22	9.86e-19	-0.62	-0.41	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
KIRC	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	10.08	7.17e-22	9.86e-19	0.54	0.41	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	10.08	7.17e-22	9.86e-19	0.54	0.41	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
KIRC	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	10.08	7.19e-22	9.9e-19	0.46	0.41	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
KIRC	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	10.08	7.29e-22	1e-18	0.53	0.41	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
KIRC	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	10.08	7.3e-22	1e-18	0.46	0.41	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
KIRC	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-10.08	7.35e-22	1.01e-18	-0.47	-0.41	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
KIRC	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	10.08	7.38e-22	1.01e-18	0.52	0.41	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
KIRC	cis	rs9457247	0.566	rs10946207	ENSG00000265828.1	MIR3939	-10.08	7.47e-22	1.03e-18	-0.48	-0.41	Crohn's disease;	chr6:167042548	chr6:166997807~166997912:-
KIRC	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-10.08	7.53e-22	1.03e-18	-0.47	-0.41	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
KIRC	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	10.08	7.53e-22	1.03e-18	0.52	0.41	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
KIRC	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-10.08	7.59e-22	1.04e-18	-0.5	-0.41	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
KIRC	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-10.08	7.67e-22	1.05e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-10.08	7.67e-22	1.05e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-10.08	7.67e-22	1.05e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
KIRC	cis	rs2698530	0.634	rs2698523	ENSG00000225889.6	AC074289.1	-10.07	7.75e-22	1.06e-18	-0.41	-0.41	Iron status biomarkers;	chr2:64249202	chr2:64143239~64252859:+
KIRC	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-10.07	7.83e-22	1.08e-18	-0.51	-0.41	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
KIRC	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-10.07	7.89e-22	1.08e-18	-0.46	-0.41	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
KIRC	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	10.07	7.9e-22	1.09e-18	0.51	0.41	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
KIRC	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	10.07	7.95e-22	1.09e-18	0.42	0.41	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
KIRC	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	10.07	8.01e-22	1.1e-18	0.49	0.41	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
KIRC	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-10.07	8.01e-22	1.1e-18	-0.49	-0.41	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
KIRC	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-10.07	8.02e-22	1.1e-18	-0.62	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
KIRC	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-10.07	8.04e-22	1.1e-18	-0.43	-0.41	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
KIRC	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	10.07	8.1e-22	1.11e-18	0.42	0.41	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
KIRC	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-10.07	8.12e-22	1.11e-18	-0.62	-0.41	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
KIRC	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-10.07	8.14e-22	1.12e-18	-0.48	-0.41	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-10.07	8.19e-22	1.12e-18	-0.48	-0.41	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
KIRC	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-10.06	8.51e-22	1.17e-18	-0.43	-0.41	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
KIRC	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	10.06	8.7e-22	1.19e-18	0.55	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
KIRC	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-10.06	8.7e-22	1.19e-18	-0.38	-0.41	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
KIRC	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	10.06	8.71e-22	1.19e-18	0.47	0.41	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
KIRC	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	10.06	8.75e-22	1.2e-18	0.51	0.41	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
KIRC	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-10.06	8.94e-22	1.22e-18	-0.47	-0.41	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
KIRC	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	10.06	8.99e-22	1.23e-18	0.99	0.41	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
KIRC	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	10.06	9.01e-22	1.23e-18	0.58	0.41	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
KIRC	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-10.06	9.01e-22	1.23e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
KIRC	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	10.06	9.05e-22	1.24e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
KIRC	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	10.06	9.05e-22	1.24e-18	0.38	0.41	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
KIRC	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	10.05	9.12e-22	1.25e-18	0.61	0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
KIRC	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-10.05	9.13e-22	1.25e-18	-0.53	-0.41	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
KIRC	cis	rs9457247	0.624	rs2239826	ENSG00000265828.1	MIR3939	-10.05	9.21e-22	1.26e-18	-0.47	-0.41	Crohn's disease;	chr6:167091392	chr6:166997807~166997912:-
KIRC	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	10.05	9.29e-22	1.27e-18	0.6	0.41	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
KIRC	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-10.05	9.31e-22	1.27e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-10.05	9.4e-22	1.28e-18	-0.52	-0.41	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	10.05	9.5e-22	1.3e-18	0.32	0.41	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
KIRC	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	10.05	9.53e-22	1.3e-18	0.5	0.41	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
KIRC	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	10.05	9.63e-22	1.31e-18	0.53	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	10.05	9.63e-22	1.31e-18	0.53	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
KIRC	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-10.05	9.78e-22	1.33e-18	-0.48	-0.41	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-10.05	9.78e-22	1.33e-18	-0.48	-0.41	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
KIRC	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-10.05	9.79e-22	1.34e-18	-0.56	-0.41	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
KIRC	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-10.05	9.84e-22	1.34e-18	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
KIRC	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-10.05	9.84e-22	1.34e-18	-0.61	-0.41	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
KIRC	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	10.05	9.86e-22	1.35e-18	0.38	0.41	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
KIRC	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-10.04	9.94e-22	1.36e-18	-0.48	-0.41	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
KIRC	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-10.04	9.97e-22	1.36e-18	-0.38	-0.41	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
KIRC	cis	rs5769707	0.681	rs739236	ENSG00000188511.11	C22orf34	10.04	1e-21	1.37e-18	0.56	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49647954	chr22:49414524~49657542:-
KIRC	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-10.04	1e-21	1.37e-18	-0.38	-0.41	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
KIRC	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-10.04	1.02e-21	1.39e-18	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
KIRC	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-10.04	1.02e-21	1.39e-18	-0.48	-0.41	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
KIRC	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-10.04	1.02e-21	1.39e-18	-0.42	-0.41	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
KIRC	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-10.04	1.03e-21	1.4e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
KIRC	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	10.04	1.04e-21	1.41e-18	0.42	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
KIRC	cis	rs13236243	0.747	rs7811989	ENSG00000236318.1	AC019117.1	10.04	1.04e-21	1.41e-18	0.56	0.41	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17331739	chr7:17374867~17466664:+
KIRC	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	10.04	1.04e-21	1.42e-18	0.39	0.41	Height;	chr4:55527164	chr4:55363971~55395847:-
KIRC	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	10.04	1.04e-21	1.42e-18	0.38	0.41	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
KIRC	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-10.04	1.05e-21	1.43e-18	-0.31	-0.41	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
KIRC	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-10.04	1.05e-21	1.43e-18	-0.5	-0.41	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
KIRC	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-10.04	1.06e-21	1.44e-18	-0.56	-0.41	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
KIRC	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-10.04	1.07e-21	1.46e-18	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
KIRC	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	10.03	1.09e-21	1.48e-18	0.42	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
KIRC	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-10.03	1.09e-21	1.48e-18	-0.54	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
KIRC	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-10.03	1.09e-21	1.48e-18	-0.54	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
KIRC	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-10.03	1.09e-21	1.48e-18	-0.54	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
KIRC	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-10.03	1.09e-21	1.49e-18	-0.52	-0.41	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
KIRC	cis	rs13236243	0.673	rs11764350	ENSG00000236318.1	AC019117.1	-10.03	1.1e-21	1.5e-18	-0.53	-0.41	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17382489	chr7:17374867~17466664:+
KIRC	cis	rs9847710	0.933	rs1529544	ENSG00000280417.1	RP11-5O17.1	10.03	1.11e-21	1.52e-18	0.47	0.41	Ulcerative colitis;	chr3:53005439	chr3:53046166~53048122:+
KIRC	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-10.03	1.13e-21	1.54e-18	-0.58	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
KIRC	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-10.03	1.13e-21	1.54e-18	-0.62	-0.41	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
KIRC	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-10.03	1.16e-21	1.58e-18	-0.48	-0.41	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
KIRC	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	10.03	1.16e-21	1.58e-18	0.77	0.41	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
KIRC	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-10.03	1.17e-21	1.59e-18	-0.47	-0.41	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
KIRC	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-10.02	1.17e-21	1.59e-18	-0.47	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
KIRC	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	10.02	1.18e-21	1.6e-18	0.39	0.41	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
KIRC	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	10.02	1.18e-21	1.6e-18	0.38	0.41	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
KIRC	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	10.02	1.18e-21	1.6e-18	0.53	0.41	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
KIRC	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	10.02	1.19e-21	1.62e-18	0.4	0.41	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
KIRC	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-10.02	1.2e-21	1.62e-18	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
KIRC	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-10.02	1.2e-21	1.63e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-10.02	1.2e-21	1.63e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
KIRC	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	10.02	1.21e-21	1.64e-18	0.54	0.41	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
KIRC	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-10.02	1.23e-21	1.67e-18	-0.48	-0.41	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-10.02	1.23e-21	1.67e-18	-0.48	-0.41	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
KIRC	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	10.02	1.24e-21	1.68e-18	0.51	0.41	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
KIRC	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-10.02	1.24e-21	1.68e-18	-0.58	-0.41	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
KIRC	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	10.02	1.25e-21	1.69e-18	0.45	0.41	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
KIRC	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-10.02	1.26e-21	1.7e-18	-0.48	-0.41	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
KIRC	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	10.02	1.26e-21	1.71e-18	0.78	0.41	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
KIRC	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	10.02	1.26e-21	1.71e-18	0.54	0.41	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
KIRC	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-10.01	1.28e-21	1.73e-18	-0.5	-0.41	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
KIRC	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-10.01	1.28e-21	1.73e-18	-0.55	-0.41	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
KIRC	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-10.01	1.29e-21	1.75e-18	-0.6	-0.41	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
KIRC	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-10.01	1.29e-21	1.75e-18	-0.34	-0.41	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
KIRC	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-10.01	1.3e-21	1.76e-18	-0.5	-0.41	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
KIRC	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	10.01	1.3e-21	1.76e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
KIRC	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	10.01	1.3e-21	1.76e-18	0.52	0.41	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
KIRC	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-10.01	1.31e-21	1.78e-18	-0.46	-0.41	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
KIRC	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	10.01	1.32e-21	1.79e-18	0.5	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
KIRC	cis	rs5769707	0.681	rs1107514	ENSG00000188511.11	C22orf34	10.01	1.32e-21	1.79e-18	0.56	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49648735	chr22:49414524~49657542:-
KIRC	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	10.01	1.33e-21	1.8e-18	0.42	0.41	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
KIRC	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-10.01	1.33e-21	1.8e-18	-0.58	-0.41	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
KIRC	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	10.01	1.34e-21	1.82e-18	0.59	0.41	Height;	chr6:109381443	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	10.01	1.34e-21	1.82e-18	0.59	0.41	Height;	chr6:109382480	chr6:109382795~109383666:+
KIRC	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-10.01	1.34e-21	1.82e-18	-0.61	-0.41	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
KIRC	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-10.01	1.34e-21	1.82e-18	-0.43	-0.41	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
KIRC	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-10.01	1.36e-21	1.84e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	10.01	1.36e-21	1.85e-18	0.33	0.41	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
KIRC	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-10.01	1.38e-21	1.86e-18	-0.54	-0.41	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
KIRC	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-10.01	1.38e-21	1.87e-18	-0.53	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
KIRC	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	10	1.39e-21	1.87e-18	0.61	0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
KIRC	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-10	1.42e-21	1.91e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
KIRC	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-10	1.42e-21	1.92e-18	-0.38	-0.41	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
KIRC	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-10	1.42e-21	1.92e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
KIRC	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	10	1.44e-21	1.95e-18	0.41	0.41	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
KIRC	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-10	1.45e-21	1.96e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
KIRC	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-10	1.47e-21	1.98e-18	-0.46	-0.41	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
KIRC	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-10	1.49e-21	2.01e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
KIRC	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	10	1.5e-21	2.02e-18	0.5	0.41	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
KIRC	cis	rs72901758	0.696	rs72909029	ENSG00000267676.1	THA1P	9.99	1.51e-21	2.04e-18	0.49	0.41	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78253370	chr17:78248493~78254416:-
KIRC	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	9.99	1.52e-21	2.05e-18	0.83	0.41	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	9.99	1.52e-21	2.05e-18	0.83	0.41	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
KIRC	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-9.99	1.54e-21	2.08e-18	-0.51	-0.41	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
KIRC	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	9.99	1.55e-21	2.09e-18	0.53	0.41	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	9.99	1.58e-21	2.13e-18	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	9.99	1.58e-21	2.13e-18	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
KIRC	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	9.99	1.58e-21	2.13e-18	0.42	0.41	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
KIRC	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	9.99	1.59e-21	2.14e-18	0.38	0.41	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	9.99	1.59e-21	2.14e-18	0.38	0.41	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
KIRC	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	9.99	1.61e-21	2.17e-18	0.55	0.41	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
KIRC	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	9.99	1.61e-21	2.17e-18	0.42	0.41	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
KIRC	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	9.98	1.65e-21	2.22e-18	0.6	0.41	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
KIRC	cis	rs72901758	0.669	rs17641275	ENSG00000267676.1	THA1P	-9.98	1.65e-21	2.23e-18	-0.48	-0.41	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78251715	chr17:78248493~78254416:-
KIRC	cis	rs9457247	0.602	rs4710175	ENSG00000265828.1	MIR3939	-9.98	1.67e-21	2.25e-18	-0.47	-0.41	Crohn's disease;	chr6:167054312	chr6:166997807~166997912:-
KIRC	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-9.98	1.68e-21	2.26e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-9.98	1.68e-21	2.26e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-9.98	1.68e-21	2.26e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-9.98	1.68e-21	2.26e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-9.98	1.68e-21	2.26e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
KIRC	cis	rs2301436	0.512	rs6925969	ENSG00000265828.1	MIR3939	-9.98	1.68e-21	2.26e-18	-0.47	-0.41	Crohn's disease;	chr6:167088250	chr6:166997807~166997912:-
KIRC	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	9.98	1.68e-21	2.27e-18	0.38	0.41	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
KIRC	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-9.98	1.69e-21	2.27e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
KIRC	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-9.98	1.69e-21	2.27e-18	-0.55	-0.41	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
KIRC	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	9.98	1.71e-21	2.3e-18	0.54	0.41	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
KIRC	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	9.98	1.72e-21	2.31e-18	0.3	0.41	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
KIRC	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	9.98	1.72e-21	2.31e-18	0.52	0.41	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
KIRC	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	9.98	1.74e-21	2.34e-18	0.5	0.41	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
KIRC	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-9.98	1.75e-21	2.35e-18	-0.61	-0.41	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
KIRC	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	9.98	1.76e-21	2.36e-18	0.5	0.41	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
KIRC	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	9.97	1.78e-21	2.4e-18	0.45	0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
KIRC	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	9.97	1.79e-21	2.4e-18	0.41	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
KIRC	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	9.97	1.79e-21	2.4e-18	0.54	0.41	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
KIRC	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	9.97	1.79e-21	2.4e-18	0.5	0.41	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
KIRC	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-9.97	1.79e-21	2.4e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-9.97	1.79e-21	2.4e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-9.97	1.79e-21	2.4e-18	-0.51	-0.41	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
KIRC	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-9.97	1.8e-21	2.41e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
KIRC	cis	rs72901758	0.768	rs11657271	ENSG00000267676.1	THA1P	9.97	1.8e-21	2.42e-18	0.49	0.41	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78253601	chr17:78248493~78254416:-
KIRC	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-9.97	1.81e-21	2.42e-18	-0.47	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
KIRC	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-9.97	1.82e-21	2.44e-18	-0.6	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
KIRC	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-9.97	1.83e-21	2.45e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-9.97	1.83e-21	2.45e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-9.97	1.83e-21	2.45e-18	-0.51	-0.41	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
KIRC	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	9.97	1.83e-21	2.46e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
KIRC	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	9.97	1.83e-21	2.46e-18	0.48	0.41	Depression;	chr6:28399886	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	9.97	1.83e-21	2.46e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
KIRC	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	9.97	1.83e-21	2.46e-18	0.5	0.41	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
KIRC	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	9.97	1.85e-21	2.48e-18	0.39	0.41	Height;	chr4:55415153	chr4:55363971~55395847:-
KIRC	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-9.97	1.85e-21	2.49e-18	-0.47	-0.41	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
KIRC	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	9.97	1.86e-21	2.49e-18	0.59	0.41	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
KIRC	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-9.97	1.9e-21	2.54e-18	-0.48	-0.41	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
KIRC	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	9.97	1.9e-21	2.55e-18	0.42	0.41	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
KIRC	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-9.97	1.91e-21	2.56e-18	-0.52	-0.41	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
KIRC	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-9.97	1.93e-21	2.59e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
KIRC	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	9.97	1.93e-21	2.59e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
KIRC	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-9.96	1.95e-21	2.61e-18	-0.5	-0.41	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
KIRC	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	9.96	1.95e-21	2.62e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
KIRC	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	9.96	1.99e-21	2.66e-18	0.59	0.41	Height;	chr6:109387972	chr6:109382795~109383666:+
KIRC	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	9.96	1.99e-21	2.66e-18	0.59	0.41	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
KIRC	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	9.96	2.02e-21	2.7e-18	0.5	0.41	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	9.96	2.02e-21	2.7e-18	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
KIRC	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-9.96	2.03e-21	2.72e-18	-0.41	-0.41	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
KIRC	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-9.96	2.03e-21	2.72e-18	-0.41	-0.41	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
KIRC	cis	rs2302464	1	rs60913985	ENSG00000214846.4	RP11-115L11.1	9.96	2.05e-21	2.74e-18	0.99	0.41	Cerebrospinal fluid biomarker levels;	chr4:15726671	chr4:15730962~15731627:-
KIRC	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-9.96	2.08e-21	2.78e-18	-0.47	-0.41	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-9.96	2.08e-21	2.78e-18	-0.47	-0.41	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-9.96	2.09e-21	2.79e-18	-0.47	-0.41	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
KIRC	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	9.96	2.09e-21	2.79e-18	0.41	0.41	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
KIRC	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-9.96	2.09e-21	2.8e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-9.96	2.09e-21	2.8e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-9.96	2.09e-21	2.8e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
KIRC	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	9.96	2.1e-21	2.81e-18	0.49	0.41	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
KIRC	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-9.95	2.11e-21	2.81e-18	-0.31	-0.41	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
KIRC	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	9.95	2.12e-21	2.83e-18	0.54	0.41	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
KIRC	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	9.95	2.12e-21	2.83e-18	0.37	0.41	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
KIRC	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	9.95	2.13e-21	2.85e-18	0.54	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
KIRC	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	9.95	2.15e-21	2.87e-18	0.42	0.41	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
KIRC	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-9.95	2.16e-21	2.88e-18	-0.51	-0.41	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
KIRC	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-9.95	2.17e-21	2.9e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-9.95	2.17e-21	2.9e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
KIRC	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	9.95	2.18e-21	2.91e-18	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
KIRC	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	9.95	2.18e-21	2.91e-18	0.4	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
KIRC	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-9.95	2.19e-21	2.92e-18	-0.61	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
KIRC	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-9.95	2.21e-21	2.94e-18	-0.47	-0.41	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
KIRC	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-9.95	2.21e-21	2.95e-18	-0.49	-0.41	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
KIRC	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-9.95	2.21e-21	2.95e-18	-0.49	-0.41	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
KIRC	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	9.95	2.22e-21	2.96e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
KIRC	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-9.95	2.23e-21	2.97e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-9.95	2.23e-21	2.97e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
KIRC	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-9.95	2.24e-21	2.98e-18	-0.58	-0.41	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-9.95	2.24e-21	2.98e-18	-0.58	-0.41	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-9.95	2.24e-21	2.98e-18	-0.58	-0.41	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-9.95	2.24e-21	2.99e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
KIRC	cis	rs72901758	0.661	rs56683270	ENSG00000267676.1	THA1P	9.95	2.26e-21	3.01e-18	0.49	0.41	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78251746	chr17:78248493~78254416:-
KIRC	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	9.95	2.29e-21	3.05e-18	0.34	0.41	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
KIRC	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	9.95	2.29e-21	3.05e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
KIRC	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	9.94	2.3e-21	3.06e-18	0.38	0.41	Height;	chr4:55517185	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	9.94	2.3e-21	3.06e-18	0.38	0.41	Height;	chr4:55522229	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	9.94	2.33e-21	3.1e-18	0.38	0.41	Height;	chr4:55440988	chr4:55363971~55395847:-
KIRC	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	9.94	2.33e-21	3.1e-18	0.76	0.41	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
KIRC	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	9.94	2.33e-21	3.11e-18	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
KIRC	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	9.94	2.34e-21	3.12e-18	0.59	0.41	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
KIRC	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	9.94	2.35e-21	3.12e-18	0.52	0.41	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
KIRC	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-9.94	2.35e-21	3.13e-18	-0.51	-0.41	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
KIRC	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-9.94	2.35e-21	3.13e-18	-0.5	-0.41	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
KIRC	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	9.94	2.35e-21	3.13e-18	0.49	0.41	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
KIRC	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-9.94	2.36e-21	3.14e-18	-0.47	-0.41	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
KIRC	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-9.94	2.36e-21	3.15e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
KIRC	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-9.94	2.38e-21	3.16e-18	-0.47	-0.41	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
KIRC	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	9.94	2.38e-21	3.16e-18	0.53	0.41	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
KIRC	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-9.94	2.39e-21	3.18e-18	-0.4	-0.41	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
KIRC	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-9.94	2.39e-21	3.18e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
KIRC	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-9.94	2.4e-21	3.19e-18	-0.52	-0.41	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
KIRC	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	9.94	2.43e-21	3.23e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
KIRC	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-9.94	2.44e-21	3.24e-18	-0.52	-0.41	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
KIRC	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	9.94	2.47e-21	3.28e-18	0.73	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
KIRC	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-9.93	2.49e-21	3.31e-18	-0.47	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
KIRC	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-9.93	2.51e-21	3.34e-18	-0.45	-0.41	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
KIRC	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	9.93	2.54e-21	3.37e-18	0.52	0.41	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
KIRC	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-9.93	2.56e-21	3.4e-18	-0.5	-0.41	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
KIRC	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-9.93	2.57e-21	3.41e-18	-0.55	-0.41	QT interval;	chr16:28877088	chr16:28700294~28701540:-
KIRC	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-9.93	2.58e-21	3.42e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-9.93	2.58e-21	3.42e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-9.93	2.58e-21	3.42e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-9.93	2.58e-21	3.42e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-9.93	2.58e-21	3.42e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
KIRC	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-9.93	2.59e-21	3.44e-18	-0.53	-0.41	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
KIRC	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-9.93	2.6e-21	3.45e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
KIRC	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	9.93	2.63e-21	3.49e-18	0.5	0.41	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
KIRC	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	9.93	2.63e-21	3.49e-18	0.49	0.41	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
KIRC	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-9.93	2.63e-21	3.49e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-9.93	2.63e-21	3.49e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
KIRC	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	9.93	2.64e-21	3.5e-18	0.52	0.41	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
KIRC	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	9.93	2.64e-21	3.5e-18	0.5	0.41	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
KIRC	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	9.93	2.66e-21	3.53e-18	0.41	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
KIRC	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	9.93	2.66e-21	3.53e-18	0.41	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
KIRC	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	9.93	2.7e-21	3.58e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	9.93	2.7e-21	3.58e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	9.93	2.7e-21	3.58e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	9.93	2.7e-21	3.58e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
KIRC	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	9.92	2.74e-21	3.63e-18	0.46	0.41	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
KIRC	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	9.92	2.75e-21	3.65e-18	0.5	0.41	Depression;	chr6:28402301	chr6:28176188~28176674:+
KIRC	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-9.92	2.76e-21	3.65e-18	-0.53	-0.41	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
KIRC	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-9.92	2.77e-21	3.66e-18	-0.53	-0.41	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
KIRC	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-9.92	2.79e-21	3.7e-18	-0.54	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
KIRC	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	9.92	2.8e-21	3.7e-18	0.55	0.41	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
KIRC	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-9.92	2.85e-21	3.77e-18	-0.45	-0.41	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
KIRC	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	9.92	2.85e-21	3.77e-18	0.46	0.41	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	9.92	2.85e-21	3.77e-18	0.46	0.41	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
KIRC	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
KIRC	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	9.92	2.86e-21	3.79e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
KIRC	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-9.92	2.86e-21	3.79e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-9.92	2.86e-21	3.79e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
KIRC	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-9.92	2.9e-21	3.83e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
KIRC	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	9.92	2.9e-21	3.84e-18	0.51	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
KIRC	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	9.92	2.9e-21	3.84e-18	0.54	0.41	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
KIRC	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-9.92	2.91e-21	3.85e-18	-0.46	-0.41	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
KIRC	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-9.92	2.91e-21	3.85e-18	-0.42	-0.41	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
KIRC	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-9.92	2.93e-21	3.88e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
KIRC	cis	rs9457247	0.602	rs17615336	ENSG00000265828.1	MIR3939	-9.92	2.93e-21	3.88e-18	-0.47	-0.41	Crohn's disease;	chr6:167093246	chr6:166997807~166997912:-
KIRC	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-9.91	2.94e-21	3.89e-18	-0.52	-0.41	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
KIRC	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-9.91	2.95e-21	3.89e-18	-0.47	-0.41	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
KIRC	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-9.91	2.95e-21	3.91e-18	-0.46	-0.41	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
KIRC	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-9.91	2.96e-21	3.91e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
KIRC	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-9.91	2.96e-21	3.91e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
KIRC	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	9.91	2.96e-21	3.91e-18	0.38	0.41	Height;	chr4:55516548	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	9.91	2.96e-21	3.91e-18	0.38	0.41	Height;	chr4:55516744	chr4:55363971~55395847:-
KIRC	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	9.91	2.98e-21	3.94e-18	0.41	0.41	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
KIRC	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-9.91	2.98e-21	3.94e-18	-1	-0.41	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
KIRC	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	9.91	2.99e-21	3.95e-18	0.41	0.41	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
KIRC	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-9.91	3e-21	3.96e-18	-0.79	-0.41	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
KIRC	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-9.91	3.02e-21	3.99e-18	-0.46	-0.41	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-9.91	3.03e-21	4e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
KIRC	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-9.91	3.04e-21	4.01e-18	-0.49	-0.41	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
KIRC	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-9.91	3.05e-21	4.02e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-9.91	3.05e-21	4.02e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
KIRC	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	9.91	3.05e-21	4.03e-18	0.5	0.41	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
KIRC	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	9.91	3.05e-21	4.03e-18	0.5	0.41	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
KIRC	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	9.91	3.05e-21	4.03e-18	0.59	0.41	Height;	chr6:109441837	chr6:109382795~109383666:+
KIRC	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-9.91	3.05e-21	4.03e-18	-0.33	-0.41	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
KIRC	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	9.91	3.06e-21	4.04e-18	0.41	0.41	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-9.91	3.15e-21	4.15e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
KIRC	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	9.91	3.16e-21	4.17e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
KIRC	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	9.91	3.16e-21	4.17e-18	0.38	0.41	Height;	chr4:55486718	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	9.91	3.17e-21	4.17e-18	0.51	0.41	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
KIRC	cis	rs904251	0.523	rs2797799	ENSG00000227920.2	RP1-153P14.5	-9.9	3.22e-21	4.24e-18	-0.45	-0.41	Cognitive performance;	chr6:37515844	chr6:37545145~37550860:+
KIRC	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	9.9	3.23e-21	4.26e-18	0.45	0.41	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
KIRC	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-9.9	3.24e-21	4.27e-18	-0.47	-0.41	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
KIRC	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	9.9	3.28e-21	4.32e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	9.9	3.28e-21	4.32e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	9.9	3.28e-21	4.32e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	9.9	3.28e-21	4.32e-18	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
KIRC	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	9.9	3.28e-21	4.33e-18	0.51	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
KIRC	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	9.9	3.29e-21	4.33e-18	0.38	0.41	Height;	chr4:55508982	chr4:55363971~55395847:-
KIRC	cis	rs904251	0.523	rs2776872	ENSG00000227920.2	RP1-153P14.5	-9.9	3.3e-21	4.34e-18	-0.44	-0.41	Cognitive performance;	chr6:37515011	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.523	rs1757191	ENSG00000227920.2	RP1-153P14.5	-9.9	3.3e-21	4.34e-18	-0.44	-0.41	Cognitive performance;	chr6:37515095	chr6:37545145~37550860:+
KIRC	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-9.9	3.32e-21	4.37e-18	-0.49	-0.41	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
KIRC	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-9.9	3.32e-21	4.37e-18	-0.49	-0.41	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
KIRC	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-9.9	3.33e-21	4.39e-18	-0.77	-0.41	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
KIRC	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	9.9	3.36e-21	4.42e-18	0.5	0.41	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
KIRC	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	9.9	3.38e-21	4.45e-18	0.52	0.41	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
KIRC	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-9.9	3.44e-21	4.52e-18	-0.75	-0.41	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
KIRC	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-9.9	3.44e-21	4.52e-18	-0.5	-0.41	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	9.9	3.44e-21	4.52e-18	0.5	0.41	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
KIRC	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-9.9	3.45e-21	4.54e-18	-0.49	-0.41	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
KIRC	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-9.9	3.45e-21	4.54e-18	-0.6	-0.41	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
KIRC	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-9.9	3.46e-21	4.55e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
KIRC	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	9.89	3.49e-21	4.59e-18	0.59	0.41	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	9.89	3.49e-21	4.59e-18	0.59	0.41	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	9.89	3.55e-21	4.66e-18	0.59	0.41	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	9.89	3.55e-21	4.67e-18	0.58	0.41	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
KIRC	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	9.89	3.55e-21	4.67e-18	0.4	0.41	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
KIRC	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-9.89	3.56e-21	4.67e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
KIRC	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-9.89	3.56e-21	4.68e-18	-0.47	-0.41	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
KIRC	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-9.89	3.56e-21	4.68e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-9.89	3.56e-21	4.68e-18	-0.41	-0.41	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
KIRC	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-9.89	3.59e-21	4.71e-18	-0.52	-0.41	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
KIRC	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	9.89	3.59e-21	4.72e-18	0.41	0.41	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
KIRC	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-9.89	3.61e-21	4.74e-18	-0.5	-0.41	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
KIRC	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-9.89	3.65e-21	4.8e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
KIRC	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	9.89	3.67e-21	4.81e-18	0.57	0.41	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
KIRC	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	9.89	3.67e-21	4.82e-18	0.59	0.41	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	9.89	3.67e-21	4.82e-18	0.59	0.41	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
KIRC	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	9.89	3.68e-21	4.83e-18	0.74	0.41	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
KIRC	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	9.89	3.69e-21	4.85e-18	0.46	0.41	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
KIRC	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	9.89	3.71e-21	4.87e-18	0.59	0.41	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
KIRC	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-9.89	3.71e-21	4.87e-18	-0.57	-0.41	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
KIRC	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	9.89	3.72e-21	4.88e-18	0.42	0.41	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
KIRC	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	9.89	3.75e-21	4.92e-18	0.37	0.41	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
KIRC	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-9.89	3.75e-21	4.92e-18	-0.35	-0.41	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
KIRC	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-9.89	3.76e-21	4.92e-18	-0.45	-0.41	Temperament;	chr17:14007316	chr17:14024514~14025488:+
KIRC	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-9.88	3.81e-21	4.99e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-9.88	3.81e-21	4.99e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
KIRC	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-9.88	3.82e-21	5.01e-18	-0.47	-0.41	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
KIRC	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	9.88	3.84e-21	5.04e-18	0.43	0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
KIRC	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	9.88	3.86e-21	5.06e-18	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	9.88	3.86e-21	5.06e-18	0.51	0.41	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
KIRC	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-9.88	3.86e-21	5.06e-18	-0.45	-0.41	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
KIRC	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-9.88	3.87e-21	5.08e-18	-0.79	-0.41	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
KIRC	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	9.88	3.92e-21	5.13e-18	0.38	0.41	Height;	chr4:55514802	chr4:55363971~55395847:-
KIRC	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	9.88	3.93e-21	5.14e-18	0.42	0.41	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
KIRC	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	9.88	3.94e-21	5.17e-18	0.58	0.41	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	9.88	3.94e-21	5.17e-18	0.58	0.41	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
KIRC	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-9.88	3.96e-21	5.19e-18	-0.6	-0.41	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
KIRC	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	9.88	3.97e-21	5.19e-18	0.42	0.41	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
KIRC	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-9.88	3.98e-21	5.21e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-9.88	3.98e-21	5.21e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-9.88	3.98e-21	5.21e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-9.88	3.98e-21	5.21e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
KIRC	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-9.88	3.98e-21	5.21e-18	-0.45	-0.41	Temperament;	chr17:14007198	chr17:14024514~14025488:+
KIRC	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	9.88	3.98e-21	5.21e-18	0.42	0.41	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
KIRC	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	9.88	4.09e-21	5.36e-18	0.59	0.41	Height;	chr6:109403951	chr6:109382795~109383666:+
KIRC	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-9.87	4.11e-21	5.38e-18	-0.38	-0.41	Height;	chr4:55514317	chr4:55363971~55395847:-
KIRC	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-9.87	4.12e-21	5.39e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
KIRC	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	9.87	4.14e-21	5.42e-18	0.41	0.41	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
KIRC	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-9.87	4.15e-21	5.43e-18	-0.51	-0.41	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
KIRC	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	9.87	4.16e-21	5.44e-18	0.38	0.41	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
KIRC	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	9.87	4.17e-21	5.46e-18	0.46	0.41	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
KIRC	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	9.87	4.22e-21	5.52e-18	0.38	0.41	Height;	chr4:55509442	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	9.87	4.22e-21	5.52e-18	0.38	0.41	Height;	chr4:55510177	chr4:55363971~55395847:-
KIRC	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	9.87	4.24e-21	5.54e-18	0.58	0.41	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	9.87	4.24e-21	5.54e-18	0.58	0.41	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
KIRC	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-9.87	4.24e-21	5.54e-18	-0.5	-0.41	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
KIRC	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-9.87	4.24e-21	5.55e-18	-0.45	-0.41	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
KIRC	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-9.87	4.26e-21	5.57e-18	-0.53	-0.41	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
KIRC	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-9.87	4.33e-21	5.66e-18	-0.4	-0.41	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
KIRC	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	9.87	4.39e-21	5.74e-18	0.53	0.41	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
KIRC	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-9.87	4.41e-21	5.76e-18	-0.79	-0.41	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
KIRC	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	9.86	4.46e-21	5.83e-18	0.57	0.41	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
KIRC	cis	rs6456156	0.565	rs6921588	ENSG00000265828.1	MIR3939	-9.86	4.47e-21	5.84e-18	-0.47	-0.41	Primary biliary cholangitis;	chr6:167080909	chr6:166997807~166997912:-
KIRC	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	9.86	4.51e-21	5.88e-18	0.82	0.41	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
KIRC	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	9.86	4.52e-21	5.9e-18	0.41	0.41	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
KIRC	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-9.86	4.57e-21	5.96e-18	-0.52	-0.41	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
KIRC	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	9.86	4.59e-21	5.98e-18	0.41	0.41	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
KIRC	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-9.86	4.63e-21	6.03e-18	-0.53	-0.41	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
KIRC	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-9.86	4.63e-21	6.04e-18	-0.59	-0.41	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
KIRC	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	9.86	4.64e-21	6.05e-18	0.38	0.41	Height;	chr4:55483718	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	9.86	4.64e-21	6.05e-18	0.38	0.41	Height;	chr4:55490176	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	9.86	4.64e-21	6.05e-18	0.38	0.41	Height;	chr4:55495262	chr4:55363971~55395847:-
KIRC	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-9.86	4.66e-21	6.07e-18	-0.5	-0.41	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
KIRC	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-9.86	4.67e-21	6.09e-18	-0.47	-0.41	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-9.86	4.67e-21	6.09e-18	-0.47	-0.41	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
KIRC	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-9.86	4.68e-21	6.1e-18	-0.46	-0.41	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
KIRC	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	9.86	4.74e-21	6.18e-18	0.54	0.41	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
KIRC	cis	rs904251	0.504	rs9380677	ENSG00000227920.2	RP1-153P14.5	-9.86	4.75e-21	6.19e-18	-0.44	-0.41	Cognitive performance;	chr6:37512590	chr6:37545145~37550860:+
KIRC	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-9.86	4.76e-21	6.2e-18	-0.5	-0.41	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
KIRC	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-9.86	4.77e-21	6.22e-18	-0.44	-0.41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
KIRC	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	9.86	4.82e-21	6.27e-18	0.5	0.41	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
KIRC	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	9.86	4.82e-21	6.27e-18	0.38	0.41	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
KIRC	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-9.86	4.83e-21	6.29e-18	-0.5	-0.41	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-9.86	4.83e-21	6.29e-18	-0.5	-0.41	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
KIRC	cis	rs4356975	0.842	rs6600899	ENSG00000248763.2	RP13-644M16.5	-9.85	4.92e-21	6.4e-18	-0.52	-0.4	Obesity-related traits;	chr4:69132295	chr4:69066395~69069888:+
KIRC	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	9.85	4.96e-21	6.45e-18	0.5	0.4	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
KIRC	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	9.85	4.96e-21	6.45e-18	0.5	0.4	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
KIRC	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	9.85	4.97e-21	6.47e-18	0.39	0.4	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	9.85	4.98e-21	6.47e-18	0.41	0.4	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	9.85	4.98e-21	6.47e-18	0.41	0.4	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
KIRC	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-9.85	4.98e-21	6.48e-18	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.872	rs10133674	ENSG00000211970.3	IGHV4-61	-9.85	4.98e-21	6.48e-18	-0.34	-0.4	Kawasaki disease;	chr14:106692788	chr14:106639119~106639657:-
KIRC	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-9.85	5e-21	6.5e-18	-0.53	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
KIRC	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-9.85	5.01e-21	6.52e-18	-0.41	-0.4	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
KIRC	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-9.85	5.07e-21	6.58e-18	-0.59	-0.4	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
KIRC	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-9.85	5.09e-21	6.61e-18	-0.49	-0.4	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
KIRC	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	9.85	5.09e-21	6.62e-18	0.4	0.4	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
KIRC	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-9.85	5.11e-21	6.64e-18	-0.45	-0.4	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
KIRC	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	9.85	5.17e-21	6.71e-18	0.59	0.4	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
KIRC	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-9.85	5.17e-21	6.72e-18	-0.57	-0.4	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
KIRC	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-9.85	5.19e-21	6.73e-18	-0.43	-0.4	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
KIRC	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-9.85	5.24e-21	6.8e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
KIRC	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-9.85	5.25e-21	6.81e-18	-0.57	-0.4	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
KIRC	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-9.85	5.25e-21	6.81e-18	-0.46	-0.4	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-9.85	5.25e-21	6.81e-18	-0.46	-0.4	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
KIRC	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	9.84	5.29e-21	6.86e-18	0.38	0.4	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
KIRC	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	9.84	5.34e-21	6.92e-18	0.38	0.4	Height;	chr4:55570843	chr4:55363971~55395847:-
KIRC	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	9.84	5.42e-21	7.02e-18	0.41	0.4	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	9.84	5.42e-21	7.02e-18	0.41	0.4	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
KIRC	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	9.84	5.44e-21	7.05e-18	0.69	0.4	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
KIRC	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	9.84	5.5e-21	7.12e-18	0.46	0.4	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	9.84	5.5e-21	7.12e-18	0.46	0.4	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
KIRC	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	9.84	5.6e-21	7.24e-18	0.39	0.4	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.84	5.64e-21	7.3e-18	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
KIRC	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-9.84	5.64e-21	7.3e-18	-0.46	-0.4	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
KIRC	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-9.84	5.68e-21	7.35e-18	-0.31	-0.4	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
KIRC	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	9.84	5.68e-21	7.36e-18	0.37	0.4	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	9.84	5.68e-21	7.36e-18	0.37	0.4	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
KIRC	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-9.84	5.7e-21	7.38e-18	-0.45	-0.4	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
KIRC	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-9.84	5.71e-21	7.38e-18	-0.59	-0.4	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
KIRC	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	9.83	5.74e-21	7.42e-18	0.46	0.4	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
KIRC	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	9.83	5.79e-21	7.49e-18	0.39	0.4	Height;	chr4:55501955	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	9.83	5.8e-21	7.51e-18	0.5	0.4	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
KIRC	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	9.83	5.84e-21	7.56e-18	0.41	0.4	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	9.83	5.84e-21	7.56e-18	0.41	0.4	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	9.83	5.89e-21	7.61e-18	0.39	0.4	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
KIRC	cis	rs904251	0.523	rs2776871	ENSG00000227920.2	RP1-153P14.5	-9.83	5.92e-21	7.65e-18	-0.44	-0.4	Cognitive performance;	chr6:37513983	chr6:37545145~37550860:+
KIRC	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	9.83	5.93e-21	7.66e-18	0.52	0.4	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
KIRC	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	9.83	5.93e-21	7.67e-18	0.38	0.4	Height;	chr4:55490228	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	9.83	5.93e-21	7.67e-18	0.38	0.4	Height;	chr4:55491150	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	9.83	5.93e-21	7.67e-18	0.38	0.4	Height;	chr4:55493557	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	9.83	5.93e-21	7.67e-18	0.38	0.4	Height;	chr4:55502504	chr4:55363971~55395847:-
KIRC	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	9.83	5.96e-21	7.71e-18	0.58	0.4	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	9.83	5.96e-21	7.71e-18	0.58	0.4	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
KIRC	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-9.83	5.98e-21	7.73e-18	-0.44	-0.4	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
KIRC	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	9.83	6e-21	7.76e-18	0.55	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
KIRC	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-9.83	6.01e-21	7.76e-18	-0.45	-0.4	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
KIRC	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-9.83	6.01e-21	7.76e-18	-0.45	-0.4	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
KIRC	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-9.83	6.02e-21	7.77e-18	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
KIRC	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	9.83	6.02e-21	7.78e-18	0.4	0.4	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
KIRC	cis	rs904251	0.523	rs1776454	ENSG00000227920.2	RP1-153P14.5	-9.83	6.03e-21	7.78e-18	-0.44	-0.4	Cognitive performance;	chr6:37514323	chr6:37545145~37550860:+
KIRC	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-9.83	6.05e-21	7.81e-18	-0.35	-0.4	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
KIRC	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-9.83	6.14e-21	7.93e-18	-0.57	-0.4	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
KIRC	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-9.82	6.23e-21	8.04e-18	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-9.82	6.26e-21	8.07e-18	-0.35	-0.4	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
KIRC	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-9.82	6.26e-21	8.08e-18	-0.43	-0.4	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
KIRC	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	9.82	6.27e-21	8.09e-18	0.51	0.4	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
KIRC	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-9.82	6.35e-21	8.19e-18	-0.74	-0.4	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
KIRC	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	9.82	6.39e-21	8.23e-18	0.51	0.4	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	9.82	6.43e-21	8.28e-18	0.54	0.4	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
KIRC	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9.82	6.49e-21	8.35e-18	-0.4	-0.4	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
KIRC	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-9.82	6.5e-21	8.36e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-9.82	6.5e-21	8.36e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-9.82	6.5e-21	8.36e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-9.82	6.5e-21	8.36e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-9.82	6.5e-21	8.37e-18	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
KIRC	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-9.82	6.51e-21	8.38e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-9.82	6.51e-21	8.38e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
KIRC	cis	rs904251	0.523	rs2776870	ENSG00000227920.2	RP1-153P14.5	-9.82	6.52e-21	8.39e-18	-0.44	-0.4	Cognitive performance;	chr6:37513588	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.523	rs2797798	ENSG00000227920.2	RP1-153P14.5	-9.82	6.52e-21	8.39e-18	-0.44	-0.4	Cognitive performance;	chr6:37513661	chr6:37545145~37550860:+
KIRC	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-9.82	6.54e-21	8.42e-18	-0.48	-0.4	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-9.82	6.54e-21	8.42e-18	-0.48	-0.4	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-9.82	6.54e-21	8.42e-18	-0.48	-0.4	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-9.82	6.54e-21	8.42e-18	-0.48	-0.4	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-9.82	6.54e-21	8.42e-18	-0.48	-0.4	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-9.82	6.57e-21	8.46e-18	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
KIRC	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-9.82	6.58e-21	8.47e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-9.82	6.58e-21	8.47e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
KIRC	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-9.82	6.6e-21	8.49e-18	-0.51	-0.4	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
KIRC	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	9.82	6.69e-21	8.6e-18	0.46	0.4	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
KIRC	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	9.82	6.7e-21	8.62e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
KIRC	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-9.82	6.72e-21	8.64e-18	-0.74	-0.4	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
KIRC	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	9.82	6.74e-21	8.66e-18	0.37	0.4	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
KIRC	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-9.82	6.76e-21	8.68e-18	-0.34	-0.4	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
KIRC	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-9.81	6.82e-21	8.76e-18	-0.36	-0.4	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
KIRC	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-9.81	6.84e-21	8.79e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
KIRC	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-9.81	6.91e-21	8.87e-18	-0.52	-0.4	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
KIRC	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-9.81	6.93e-21	8.9e-18	-0.45	-0.4	Temperament;	chr17:14018109	chr17:14024514~14025488:+
KIRC	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-9.81	6.93e-21	8.9e-18	-0.53	-0.4	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
KIRC	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	9.81	6.98e-21	8.96e-18	0.39	0.4	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
KIRC	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-9.81	6.98e-21	8.96e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
KIRC	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	9.81	6.99e-21	8.97e-18	0.46	0.4	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	9.81	6.99e-21	8.97e-18	0.46	0.4	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	9.81	6.99e-21	8.97e-18	0.46	0.4	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
KIRC	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-9.81	7e-21	8.99e-18	-0.46	-0.4	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
KIRC	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-9.81	7.03e-21	9.03e-18	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
KIRC	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-9.81	7.06e-21	9.06e-18	-0.53	-0.4	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
KIRC	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-9.81	7.1e-21	9.11e-18	-0.53	-0.4	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
KIRC	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	9.81	7.16e-21	9.19e-18	0.52	0.4	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	9.81	7.18e-21	9.21e-18	0.31	0.4	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
KIRC	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-9.81	7.18e-21	9.21e-18	-0.73	-0.4	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
KIRC	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	9.81	7.2e-21	9.23e-18	0.53	0.4	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
KIRC	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-9.81	7.2e-21	9.23e-18	-0.33	-0.4	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
KIRC	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-9.81	7.23e-21	9.26e-18	-0.49	-0.4	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
KIRC	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-9.81	7.29e-21	9.33e-18	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-9.81	7.29e-21	9.33e-18	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-9.81	7.29e-21	9.33e-18	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
KIRC	cis	rs904251	0.523	rs914348	ENSG00000227920.2	RP1-153P14.5	-9.81	7.32e-21	9.38e-18	-0.44	-0.4	Cognitive performance;	chr6:37516953	chr6:37545145~37550860:+
KIRC	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	9.81	7.33e-21	9.38e-18	0.41	0.4	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	9.81	7.33e-21	9.38e-18	0.41	0.4	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	9.81	7.33e-21	9.38e-18	0.41	0.4	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
KIRC	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-9.8	7.37e-21	9.43e-18	-0.47	-0.4	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
KIRC	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-9.8	7.39e-21	9.46e-18	-0.39	-0.4	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
KIRC	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-9.8	7.41e-21	9.48e-18	-0.45	-0.4	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
KIRC	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-9.8	7.45e-21	9.53e-18	-0.54	-0.4	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
KIRC	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-9.8	7.59e-21	9.71e-18	-0.34	-0.4	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
KIRC	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-9.8	7.63e-21	9.76e-18	-0.47	-0.4	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
KIRC	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	9.8	7.67e-21	9.81e-18	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
KIRC	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	9.8	7.71e-21	9.86e-18	0.52	0.4	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
KIRC	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-9.8	7.74e-21	9.9e-18	-0.56	-0.4	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
KIRC	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-9.8	7.79e-21	9.96e-18	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-9.8	7.81e-21	9.98e-18	-0.33	-0.4	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
KIRC	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	9.8	7.83e-21	1e-17	0.6	0.4	Height;	chr6:109573151	chr6:109382795~109383666:+
KIRC	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-9.8	7.85e-21	1e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-9.8	7.85e-21	1e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
KIRC	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-9.8	7.86e-21	1e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
KIRC	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	9.8	7.96e-21	1.02e-17	0.5	0.4	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
KIRC	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-9.79	7.99e-21	1.02e-17	-0.83	-0.4	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
KIRC	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-9.79	7.99e-21	1.02e-17	-0.43	-0.4	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
KIRC	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	9.79	8e-21	1.02e-17	0.38	0.4	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	9.79	8.02e-21	1.02e-17	0.38	0.4	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	9.79	8.02e-21	1.02e-17	0.38	0.4	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	9.79	8.02e-21	1.02e-17	0.38	0.4	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	9.79	8.02e-21	1.02e-17	0.38	0.4	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
KIRC	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	9.79	8.06e-21	1.03e-17	0.59	0.4	Height;	chr6:109436760	chr6:109382795~109383666:+
KIRC	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-9.79	8.08e-21	1.03e-17	-0.31	-0.4	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
KIRC	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-9.79	8.13e-21	1.04e-17	-0.39	-0.4	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
KIRC	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-9.79	8.18e-21	1.04e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
KIRC	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-9.79	8.19e-21	1.04e-17	-0.46	-0.4	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
KIRC	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-9.79	8.22e-21	1.05e-17	-0.53	-0.4	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
KIRC	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	9.79	8.31e-21	1.06e-17	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
KIRC	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-9.79	8.31e-21	1.06e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
KIRC	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	9.79	8.31e-21	1.06e-17	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
KIRC	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	9.79	8.32e-21	1.06e-17	0.37	0.4	Height;	chr4:55409063	chr4:55363971~55395847:-
KIRC	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	9.79	8.33e-21	1.06e-17	0.46	0.4	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	9.79	8.33e-21	1.06e-17	0.46	0.4	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
KIRC	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	9.79	8.36e-21	1.07e-17	0.59	0.4	Height;	chr6:109427303	chr6:109382795~109383666:+
KIRC	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	9.79	8.43e-21	1.07e-17	0.41	0.4	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
KIRC	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	9.79	8.43e-21	1.07e-17	0.37	0.4	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
KIRC	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-9.79	8.45e-21	1.08e-17	-0.59	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
KIRC	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	9.79	8.47e-21	1.08e-17	0.38	0.4	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
KIRC	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	9.79	8.49e-21	1.08e-17	0.51	0.4	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	9.79	8.49e-21	1.08e-17	0.51	0.4	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
KIRC	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	9.79	8.5e-21	1.08e-17	0.37	0.4	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	9.79	8.5e-21	1.08e-17	0.37	0.4	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
KIRC	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-9.79	8.52e-21	1.09e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-9.79	8.52e-21	1.09e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-9.79	8.52e-21	1.09e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-9.79	8.52e-21	1.09e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-9.79	8.52e-21	1.09e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
KIRC	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-9.79	8.53e-21	1.09e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-9.79	8.53e-21	1.09e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
KIRC	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	9.79	8.56e-21	1.09e-17	0.55	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
KIRC	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	9.79	8.6e-21	1.1e-17	0.6	0.4	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
KIRC	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-9.78	8.69e-21	1.11e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
KIRC	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	9.78	8.82e-21	1.12e-17	0.37	0.4	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
KIRC	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-9.78	8.89e-21	1.13e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
KIRC	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-9.78	8.89e-21	1.13e-17	-0.47	-0.4	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-9.78	8.89e-21	1.13e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
KIRC	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-9.78	8.89e-21	1.13e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
KIRC	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-9.78	8.89e-21	1.13e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
KIRC	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	9.78	8.9e-21	1.13e-17	0.51	0.4	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
KIRC	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	9.78	8.91e-21	1.13e-17	0.41	0.4	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
KIRC	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	9.78	8.94e-21	1.14e-17	0.37	0.4	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
KIRC	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	9.78	8.97e-21	1.14e-17	0.51	0.4	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
KIRC	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	9.78	9.06e-21	1.15e-17	0.52	0.4	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
KIRC	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	9.78	9.09e-21	1.15e-17	0.41	0.4	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	9.78	9.09e-21	1.15e-17	0.41	0.4	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
KIRC	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	9.78	9.09e-21	1.16e-17	0.57	0.4	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
KIRC	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-9.78	9.17e-21	1.17e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
KIRC	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-9.78	9.21e-21	1.17e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000248763.2	RP13-644M16.5	-9.78	9.23e-21	1.17e-17	-0.51	-0.4	Obesity-related traits;	chr4:69062256	chr4:69066395~69069888:+
KIRC	cis	rs4273100	1	rs868698	ENSG00000228157.4	AC007952.5	9.78	9.26e-21	1.18e-17	0.68	0.4	Schizophrenia;	chr17:19281898	chr17:19092974~19096837:+
KIRC	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-9.78	9.31e-21	1.18e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
KIRC	cis	rs4963124	0.886	rs10902216	ENSG00000279672.1	CMB9-55F22.1	9.78	9.35e-21	1.19e-17	0.43	0.4	Proteinuria and chronic kidney disease;	chr11:739392	chr11:779617~780755:+
KIRC	cis	rs904251	0.523	rs10947675	ENSG00000227920.2	RP1-153P14.5	-9.78	9.35e-21	1.19e-17	-0.45	-0.4	Cognitive performance;	chr6:37512196	chr6:37545145~37550860:+
KIRC	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-9.78	9.41e-21	1.19e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-9.78	9.41e-21	1.19e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-9.78	9.41e-21	1.19e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-9.78	9.41e-21	1.19e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-9.78	9.41e-21	1.19e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
KIRC	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	9.77	9.46e-21	1.2e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
KIRC	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-9.77	9.47e-21	1.2e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
KIRC	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-9.77	9.53e-21	1.21e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-9.77	9.53e-21	1.21e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-9.77	9.53e-21	1.21e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
KIRC	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	9.77	9.53e-21	1.21e-17	0.47	0.4	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
KIRC	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	9.77	9.55e-21	1.21e-17	0.38	0.4	Height;	chr4:55528801	chr4:55363971~55395847:-
KIRC	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	9.77	9.57e-21	1.21e-17	0.42	0.4	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
KIRC	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-9.77	9.58e-21	1.22e-17	-0.49	-0.4	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
KIRC	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	9.77	9.64e-21	1.22e-17	0.46	0.4	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
KIRC	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	9.77	9.67e-21	1.23e-17	0.38	0.4	Height;	chr4:55548666	chr4:55363971~55395847:-
KIRC	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	9.77	9.68e-21	1.23e-17	0.37	0.4	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
KIRC	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	9.77	9.7e-21	1.23e-17	0.38	0.4	Height;	chr4:55482360	chr4:55363971~55395847:-
KIRC	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	9.77	9.74e-21	1.24e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
KIRC	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-9.77	9.76e-21	1.24e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
KIRC	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-9.77	9.76e-21	1.24e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
KIRC	cis	rs904251	0.504	rs1757188	ENSG00000227920.2	RP1-153P14.5	-9.77	9.76e-21	1.24e-17	-0.44	-0.4	Cognitive performance;	chr6:37516032	chr6:37545145~37550860:+
KIRC	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	9.77	9.79e-21	1.24e-17	0.51	0.4	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-9.77	9.95e-21	1.26e-17	-0.31	-0.4	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
KIRC	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	9.77	9.96e-21	1.26e-17	0.53	0.4	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
KIRC	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-9.77	1e-20	1.27e-17	-0.51	-0.4	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
KIRC	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-9.77	1e-20	1.27e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
KIRC	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-9.77	1.01e-20	1.27e-17	-0.56	-0.4	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
KIRC	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	9.77	1.01e-20	1.28e-17	0.53	0.4	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
KIRC	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-9.77	1.01e-20	1.28e-17	-0.38	-0.4	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
KIRC	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	9.77	1.02e-20	1.29e-17	0.37	0.4	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	9.77	1.02e-20	1.29e-17	0.37	0.4	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000250696.4	RP11-704M14.1	9.77	1.02e-20	1.29e-17	0.42	0.4	Obesity-related traits;	chr4:69079704	chr4:69182100~69216766:+
KIRC	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-9.76	1.02e-20	1.3e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
KIRC	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-9.76	1.02e-20	1.3e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-9.76	1.02e-20	1.3e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
KIRC	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-9.76	1.05e-20	1.32e-17	-0.5	-0.4	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
KIRC	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	9.76	1.05e-20	1.33e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
KIRC	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-9.76	1.06e-20	1.34e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
KIRC	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-9.76	1.07e-20	1.35e-17	-0.45	-0.4	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
KIRC	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	9.76	1.07e-20	1.36e-17	0.53	0.4	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
KIRC	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-9.76	1.07e-20	1.36e-17	-0.52	-0.4	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
KIRC	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	9.76	1.08e-20	1.36e-17	0.46	0.4	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
KIRC	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-9.76	1.08e-20	1.36e-17	-0.53	-0.4	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
KIRC	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-9.76	1.08e-20	1.36e-17	-0.51	-0.4	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
KIRC	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-9.76	1.08e-20	1.36e-17	-0.35	-0.4	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
KIRC	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-9.76	1.08e-20	1.36e-17	-0.35	-0.4	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
KIRC	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-9.76	1.08e-20	1.36e-17	-0.35	-0.4	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
KIRC	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-9.76	1.08e-20	1.36e-17	-0.35	-0.4	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-9.76	1.08e-20	1.36e-17	-0.35	-0.4	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
KIRC	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-9.76	1.09e-20	1.37e-17	-0.47	-0.4	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
KIRC	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	9.76	1.09e-20	1.37e-17	0.41	0.4	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
KIRC	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	9.76	1.09e-20	1.38e-17	0.49	0.4	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
KIRC	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-9.76	1.09e-20	1.38e-17	-0.45	-0.4	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
KIRC	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	9.76	1.09e-20	1.38e-17	0.41	0.4	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
KIRC	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	9.76	1.11e-20	1.4e-17	0.47	0.4	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
KIRC	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-9.75	1.11e-20	1.4e-17	-0.4	-0.4	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
KIRC	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	9.75	1.12e-20	1.41e-17	0.49	0.4	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
KIRC	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-9.75	1.12e-20	1.42e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.83	rs6600868	ENSG00000248763.2	RP13-644M16.5	-9.75	1.13e-20	1.42e-17	-0.5	-0.4	Obesity-related traits;	chr4:69075923	chr4:69066395~69069888:+
KIRC	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	9.75	1.13e-20	1.42e-17	0.39	0.4	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
KIRC	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	9.75	1.13e-20	1.43e-17	0.38	0.4	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
KIRC	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	9.75	1.13e-20	1.43e-17	0.44	0.4	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
KIRC	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-9.75	1.14e-20	1.44e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
KIRC	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-9.75	1.15e-20	1.44e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
KIRC	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	9.75	1.15e-20	1.45e-17	0.46	0.4	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
KIRC	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-9.75	1.15e-20	1.45e-17	-0.53	-0.4	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
KIRC	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-9.75	1.16e-20	1.46e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
KIRC	cis	rs11089937	0.926	rs5750601	ENSG00000211639.2	IGLV4-60	9.75	1.16e-20	1.47e-17	0.39	0.4	Periodontitis (PAL4Q3);	chr22:22144396	chr22:22162199~22162681:+
KIRC	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	9.75	1.17e-20	1.47e-17	0.49	0.4	Depression;	chr6:28364057	chr6:28176188~28176674:+
KIRC	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	9.75	1.17e-20	1.48e-17	0.51	0.4	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
KIRC	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-9.75	1.18e-20	1.48e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
KIRC	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	9.75	1.18e-20	1.49e-17	0.84	0.4	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
KIRC	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	9.75	1.19e-20	1.5e-17	0.41	0.4	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	9.75	1.19e-20	1.5e-17	0.41	0.4	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
KIRC	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-9.75	1.19e-20	1.5e-17	-0.47	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
KIRC	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-9.75	1.2e-20	1.5e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
KIRC	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	9.75	1.2e-20	1.51e-17	0.41	0.4	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	9.75	1.2e-20	1.51e-17	0.41	0.4	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	9.75	1.2e-20	1.51e-17	0.41	0.4	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	9.75	1.2e-20	1.51e-17	0.41	0.4	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
KIRC	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	9.75	1.21e-20	1.52e-17	0.46	0.4	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
KIRC	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-9.74	1.21e-20	1.52e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
KIRC	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-9.74	1.21e-20	1.52e-17	-0.41	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
KIRC	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	9.74	1.21e-20	1.52e-17	0.37	0.4	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
KIRC	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	9.74	1.21e-20	1.53e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	9.74	1.23e-20	1.54e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
KIRC	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-9.74	1.23e-20	1.54e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-9.74	1.23e-20	1.54e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-9.74	1.23e-20	1.54e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-9.74	1.23e-20	1.54e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-9.74	1.23e-20	1.54e-17	-0.5	-0.4	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
KIRC	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-9.74	1.23e-20	1.54e-17	-0.54	-0.4	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-9.74	1.23e-20	1.54e-17	-0.54	-0.4	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
KIRC	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-9.74	1.23e-20	1.54e-17	-0.48	-0.4	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
KIRC	cis	rs2698530	0.762	rs2251764	ENSG00000225889.6	AC074289.1	-9.74	1.23e-20	1.55e-17	-0.41	-0.4	Iron status biomarkers;	chr2:64258331	chr2:64143239~64252859:+
KIRC	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	9.74	1.23e-20	1.55e-17	0.38	0.4	Height;	chr4:55529387	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	9.74	1.23e-20	1.55e-17	0.38	0.4	Height;	chr4:55529786	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	9.74	1.23e-20	1.55e-17	0.38	0.4	Height;	chr4:55532542	chr4:55363971~55395847:-
KIRC	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	9.74	1.23e-20	1.55e-17	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
KIRC	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-9.74	1.25e-20	1.57e-17	-0.43	-0.4	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
KIRC	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	9.74	1.26e-20	1.58e-17	0.37	0.4	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
KIRC	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	9.74	1.26e-20	1.58e-17	0.38	0.4	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
KIRC	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	9.74	1.26e-20	1.58e-17	0.31	0.4	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
KIRC	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-9.74	1.27e-20	1.59e-17	-0.45	-0.4	Temperament;	chr17:14019308	chr17:14024514~14025488:+
KIRC	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-9.74	1.27e-20	1.59e-17	-0.67	-0.4	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
KIRC	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-9.74	1.27e-20	1.59e-17	-0.5	-0.4	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
KIRC	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	9.74	1.28e-20	1.6e-17	0.46	0.4	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
KIRC	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-9.74	1.28e-20	1.6e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
KIRC	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	9.74	1.28e-20	1.61e-17	0.49	0.4	Depression;	chr6:28399846	chr6:28176188~28176674:+
KIRC	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	9.74	1.28e-20	1.61e-17	0.49	0.4	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
KIRC	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	9.74	1.29e-20	1.61e-17	0.55	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
KIRC	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	9.74	1.29e-20	1.62e-17	0.56	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
KIRC	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-9.74	1.3e-20	1.63e-17	-0.29	-0.4	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
KIRC	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-9.74	1.3e-20	1.63e-17	-0.5	-0.4	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
KIRC	cis	rs11079159	0.5	rs7223165	ENSG00000263096.1	RP11-515O17.2	9.73	1.31e-20	1.65e-17	0.53	0.4	QRS duration;	chr17:55286477	chr17:55271504~55273653:-
KIRC	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	9.73	1.31e-20	1.65e-17	0.4	0.4	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	9.73	1.31e-20	1.65e-17	0.4	0.4	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	9.73	1.31e-20	1.65e-17	0.4	0.4	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
KIRC	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	9.73	1.32e-20	1.65e-17	0.39	0.4	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
KIRC	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	9.73	1.32e-20	1.66e-17	0.41	0.4	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
KIRC	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-9.73	1.34e-20	1.67e-17	-0.47	-0.4	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
KIRC	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	9.73	1.34e-20	1.67e-17	0.36	0.4	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
KIRC	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	9.73	1.34e-20	1.68e-17	0.37	0.4	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	9.73	1.34e-20	1.68e-17	0.37	0.4	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	9.73	1.34e-20	1.68e-17	0.37	0.4	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	9.73	1.34e-20	1.68e-17	0.37	0.4	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	9.73	1.34e-20	1.68e-17	0.37	0.4	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
KIRC	cis	rs904251	0.522	rs882322	ENSG00000227920.2	RP1-153P14.5	-9.73	1.35e-20	1.69e-17	-0.44	-0.4	Cognitive performance;	chr6:37516327	chr6:37545145~37550860:+
KIRC	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	9.73	1.35e-20	1.69e-17	0.57	0.4	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
KIRC	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-9.73	1.36e-20	1.7e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
KIRC	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-9.73	1.36e-20	1.71e-17	-0.51	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
KIRC	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	9.73	1.37e-20	1.71e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
KIRC	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-9.73	1.37e-20	1.71e-17	-0.47	-0.4	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-9.73	1.37e-20	1.71e-17	-0.47	-0.4	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
KIRC	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	9.73	1.37e-20	1.71e-17	0.39	0.4	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
KIRC	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-9.73	1.38e-20	1.72e-17	-0.4	-0.4	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
KIRC	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	9.73	1.39e-20	1.74e-17	0.49	0.4	Depression;	chr6:28407125	chr6:28176188~28176674:+
KIRC	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	9.73	1.42e-20	1.77e-17	0.51	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
KIRC	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-9.73	1.42e-20	1.77e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
KIRC	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-9.73	1.42e-20	1.77e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
KIRC	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	9.73	1.42e-20	1.78e-17	0.41	0.4	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
KIRC	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	9.72	1.43e-20	1.78e-17	0.46	0.4	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
KIRC	cis	rs2745572	0.515	rs2250686	ENSG00000272279.1	RP11-157J24.2	-9.72	1.43e-20	1.79e-17	-0.57	-0.4	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548909	chr6:1528364~1528911:-
KIRC	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	9.72	1.44e-20	1.8e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
KIRC	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	9.72	1.44e-20	1.8e-17	0.41	0.4	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	9.72	1.44e-20	1.8e-17	0.41	0.4	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	9.72	1.44e-20	1.8e-17	0.41	0.4	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	9.72	1.44e-20	1.8e-17	0.41	0.4	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	9.72	1.44e-20	1.8e-17	0.4	0.4	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
KIRC	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-9.72	1.45e-20	1.81e-17	-0.47	-0.4	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
KIRC	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-9.72	1.45e-20	1.81e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-9.72	1.45e-20	1.81e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
KIRC	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-9.72	1.45e-20	1.81e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
KIRC	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	9.72	1.46e-20	1.82e-17	0.39	0.4	Height;	chr4:55413708	chr4:55363971~55395847:-
KIRC	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	9.72	1.46e-20	1.83e-17	0.48	0.4	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
KIRC	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-9.72	1.46e-20	1.83e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-9.72	1.46e-20	1.83e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
KIRC	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	9.72	1.47e-20	1.83e-17	0.41	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
KIRC	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	9.72	1.47e-20	1.83e-17	0.37	0.4	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
KIRC	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-9.72	1.47e-20	1.84e-17	-0.47	-0.4	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
KIRC	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-9.72	1.48e-20	1.84e-17	-0.48	-0.4	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
KIRC	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	9.72	1.48e-20	1.84e-17	0.37	0.4	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
KIRC	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	9.72	1.48e-20	1.85e-17	0.4	0.4	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
KIRC	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	9.72	1.49e-20	1.86e-17	0.4	0.4	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
KIRC	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	9.72	1.5e-20	1.87e-17	0.76	0.4	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
KIRC	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-9.72	1.51e-20	1.88e-17	-0.53	-0.4	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
KIRC	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-9.72	1.52e-20	1.89e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
KIRC	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-9.72	1.52e-20	1.89e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
KIRC	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	9.72	1.52e-20	1.9e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
KIRC	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	9.72	1.52e-20	1.9e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
KIRC	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-9.72	1.53e-20	1.9e-17	-0.53	-0.4	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
KIRC	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	9.72	1.53e-20	1.91e-17	0.52	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
KIRC	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	9.72	1.53e-20	1.91e-17	0.41	0.4	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	9.72	1.53e-20	1.91e-17	0.41	0.4	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	9.72	1.53e-20	1.91e-17	0.41	0.4	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	9.72	1.53e-20	1.91e-17	0.41	0.4	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
KIRC	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	9.72	1.54e-20	1.92e-17	0.41	0.4	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
KIRC	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	9.72	1.54e-20	1.92e-17	0.41	0.4	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
KIRC	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	9.72	1.54e-20	1.92e-17	0.4	0.4	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
KIRC	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	9.72	1.54e-20	1.92e-17	0.45	0.4	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
KIRC	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	9.72	1.54e-20	1.92e-17	0.41	0.4	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
KIRC	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	9.72	1.55e-20	1.93e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
KIRC	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	9.71	1.55e-20	1.93e-17	0.39	0.4	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
KIRC	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-9.71	1.55e-20	1.93e-17	-0.34	-0.4	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
KIRC	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-9.71	1.56e-20	1.94e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-9.71	1.56e-20	1.94e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-9.71	1.56e-20	1.94e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
KIRC	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-9.71	1.56e-20	1.95e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
KIRC	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-9.71	1.56e-20	1.95e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
KIRC	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-9.71	1.56e-20	1.95e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-9.71	1.56e-20	1.95e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-9.71	1.56e-20	1.95e-17	-0.34	-0.4	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-9.71	1.56e-20	1.95e-17	-0.34	-0.4	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
KIRC	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-9.71	1.57e-20	1.96e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
KIRC	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-9.71	1.57e-20	1.96e-17	-0.43	-0.4	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
KIRC	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-9.71	1.6e-20	1.99e-17	-0.54	-0.4	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-9.71	1.6e-20	1.99e-17	-0.54	-0.4	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
KIRC	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	9.71	1.61e-20	2.01e-17	0.45	0.4	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
KIRC	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-9.71	1.62e-20	2.02e-17	-0.59	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
KIRC	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-9.71	1.62e-20	2.02e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
KIRC	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	9.71	1.63e-20	2.02e-17	0.56	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
KIRC	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-9.71	1.64e-20	2.03e-17	-0.49	-0.4	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
KIRC	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	9.71	1.64e-20	2.04e-17	0.3	0.4	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
KIRC	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	9.71	1.65e-20	2.05e-17	0.37	0.4	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
KIRC	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-9.71	1.65e-20	2.06e-17	-0.46	-0.4	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
KIRC	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-9.71	1.66e-20	2.06e-17	-0.3	-0.4	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
KIRC	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-9.71	1.66e-20	2.06e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
KIRC	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	9.71	1.66e-20	2.07e-17	0.53	0.4	QT interval;	chr16:28860645	chr16:28700294~28701540:-
KIRC	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-9.71	1.67e-20	2.07e-17	-0.3	-0.4	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
KIRC	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	9.71	1.68e-20	2.08e-17	0.37	0.4	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	9.71	1.68e-20	2.08e-17	0.37	0.4	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	9.71	1.68e-20	2.08e-17	0.37	0.4	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
KIRC	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	9.7	1.69e-20	2.09e-17	0.57	0.4	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
KIRC	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-9.7	1.69e-20	2.1e-17	-0.53	-0.4	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-9.7	1.69e-20	2.1e-17	-0.53	-0.4	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-9.7	1.69e-20	2.1e-17	-0.35	-0.4	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
KIRC	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	9.7	1.7e-20	2.11e-17	0.4	0.4	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-9.7	1.7e-20	2.11e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
KIRC	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	9.7	1.7e-20	2.11e-17	0.4	0.4	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
KIRC	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	9.7	1.71e-20	2.12e-17	0.89	0.4	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
KIRC	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-9.7	1.71e-20	2.12e-17	-0.37	-0.4	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
KIRC	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-9.7	1.72e-20	2.13e-17	-0.55	-0.4	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-9.7	1.72e-20	2.13e-17	-0.55	-0.4	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
KIRC	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	9.7	1.73e-20	2.15e-17	0.52	0.4	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
KIRC	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-9.7	1.73e-20	2.15e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
KIRC	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-9.7	1.75e-20	2.17e-17	-0.34	-0.4	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
KIRC	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	9.7	1.75e-20	2.17e-17	0.49	0.4	Depression;	chr6:28391932	chr6:28176188~28176674:+
KIRC	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-9.7	1.76e-20	2.18e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
KIRC	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	9.7	1.76e-20	2.19e-17	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
KIRC	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-9.7	1.77e-20	2.19e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-9.7	1.77e-20	2.2e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
KIRC	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-9.7	1.78e-20	2.2e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
KIRC	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-9.7	1.78e-20	2.21e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-9.7	1.78e-20	2.21e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
KIRC	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	9.7	1.78e-20	2.21e-17	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
KIRC	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-9.7	1.79e-20	2.21e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
KIRC	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-9.7	1.79e-20	2.22e-17	-0.5	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
KIRC	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-9.7	1.79e-20	2.22e-17	-0.39	-0.4	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
KIRC	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-9.7	1.79e-20	2.22e-17	-0.43	-0.4	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
KIRC	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	9.7	1.81e-20	2.24e-17	0.52	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
KIRC	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	9.7	1.81e-20	2.24e-17	0.37	0.4	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
KIRC	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-9.7	1.82e-20	2.25e-17	-0.5	-0.4	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
KIRC	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-9.7	1.82e-20	2.25e-17	-0.5	-0.4	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
KIRC	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-9.7	1.82e-20	2.26e-17	-0.3	-0.4	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
KIRC	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-9.69	1.85e-20	2.29e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
KIRC	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-9.69	1.86e-20	2.3e-17	-0.63	-0.4	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
KIRC	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	9.69	1.86e-20	2.31e-17	0.34	0.4	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
KIRC	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	9.69	1.87e-20	2.31e-17	0.39	0.4	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
KIRC	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-9.69	1.87e-20	2.32e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
KIRC	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-9.69	1.87e-20	2.32e-17	-0.37	-0.4	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
KIRC	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-9.69	1.87e-20	2.32e-17	-0.34	-0.4	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
KIRC	cis	rs9457247	0.508	rs9459874	ENSG00000265828.1	MIR3939	9.69	1.87e-20	2.32e-17	0.45	0.4	Crohn's disease;	chr6:167090639	chr6:166997807~166997912:-
KIRC	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	9.69	1.88e-20	2.33e-17	0.49	0.4	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
KIRC	cis	rs4356975	0.83	rs7666894	ENSG00000248763.2	RP13-644M16.5	-9.69	1.9e-20	2.35e-17	-0.5	-0.4	Obesity-related traits;	chr4:69078780	chr4:69066395~69069888:+
KIRC	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	9.69	1.91e-20	2.37e-17	0.4	0.4	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
KIRC	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-9.69	1.91e-20	2.37e-17	-0.52	-0.4	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
KIRC	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-9.69	1.92e-20	2.37e-17	-0.34	-0.4	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
KIRC	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-9.69	1.93e-20	2.39e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-9.69	1.93e-20	2.39e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
KIRC	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-9.69	1.93e-20	2.39e-17	-0.44	-0.4	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-9.69	1.93e-20	2.39e-17	-0.44	-0.4	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
KIRC	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-9.69	1.93e-20	2.39e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
KIRC	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-9.69	1.94e-20	2.39e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
KIRC	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-9.69	1.94e-20	2.39e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
KIRC	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-9.69	1.94e-20	2.39e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
KIRC	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-9.69	1.94e-20	2.4e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
KIRC	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	9.69	1.94e-20	2.4e-17	0.58	0.4	Height;	chr6:109416945	chr6:109382795~109383666:+
KIRC	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	9.69	1.94e-20	2.41e-17	0.41	0.4	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-9.69	1.95e-20	2.41e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
KIRC	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-9.69	1.95e-20	2.42e-17	-0.54	-0.4	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
KIRC	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-9.69	1.96e-20	2.42e-17	-0.52	-0.4	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.795	rs4694599	ENSG00000248763.2	RP13-644M16.5	-9.69	1.97e-20	2.44e-17	-0.5	-0.4	Obesity-related traits;	chr4:69070858	chr4:69066395~69069888:+
KIRC	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	9.69	1.97e-20	2.44e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
KIRC	cis	rs4356975	0.697	rs58039330	ENSG00000248763.2	RP13-644M16.5	-9.69	1.98e-20	2.45e-17	-0.49	-0.4	Obesity-related traits;	chr4:69149529	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.66	rs60567038	ENSG00000248763.2	RP13-644M16.5	-9.69	1.98e-20	2.45e-17	-0.49	-0.4	Obesity-related traits;	chr4:69150135	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.697	rs58366569	ENSG00000248763.2	RP13-644M16.5	-9.69	1.98e-20	2.45e-17	-0.49	-0.4	Obesity-related traits;	chr4:69150626	chr4:69066395~69069888:+
KIRC	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-9.68	1.99e-20	2.45e-17	-0.58	-0.4	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
KIRC	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-9.68	2e-20	2.47e-17	-0.4	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
KIRC	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-9.68	2.01e-20	2.48e-17	-0.43	-0.4	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-9.68	2.01e-20	2.48e-17	-0.43	-0.4	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
KIRC	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-9.68	2.02e-20	2.49e-17	-0.54	-0.4	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-9.68	2.02e-20	2.49e-17	-0.54	-0.4	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
KIRC	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-9.68	2.03e-20	2.5e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
KIRC	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	9.68	2.04e-20	2.51e-17	0.47	0.4	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
KIRC	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-9.68	2.04e-20	2.51e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
KIRC	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-9.68	2.04e-20	2.51e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
KIRC	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	9.68	2.06e-20	2.54e-17	0.39	0.4	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	9.68	2.06e-20	2.54e-17	0.39	0.4	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
KIRC	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	9.68	2.07e-20	2.55e-17	0.53	0.4	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
KIRC	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	9.68	2.07e-20	2.56e-17	0.56	0.4	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
KIRC	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	9.68	2.08e-20	2.56e-17	0.37	0.4	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
KIRC	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-9.68	2.08e-20	2.57e-17	-0.37	-0.4	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
KIRC	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	9.68	2.09e-20	2.58e-17	0.88	0.4	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	9.68	2.09e-20	2.58e-17	0.88	0.4	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
KIRC	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-9.68	2.09e-20	2.58e-17	-0.33	-0.4	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
KIRC	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-9.68	2.11e-20	2.6e-17	-0.52	-0.4	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
KIRC	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	9.68	2.11e-20	2.6e-17	0.37	0.4	Height;	chr4:55542243	chr4:55363971~55395847:-
KIRC	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-9.68	2.11e-20	2.6e-17	-0.34	-0.4	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
KIRC	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	9.68	2.11e-20	2.61e-17	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
KIRC	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	9.68	2.12e-20	2.62e-17	0.37	0.4	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
KIRC	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55436423	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55437438	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55452295	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55454900	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55454938	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55455102	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	9.68	2.14e-20	2.64e-17	0.37	0.4	Height;	chr4:55460485	chr4:55363971~55395847:-
KIRC	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-9.68	2.14e-20	2.64e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
KIRC	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-9.68	2.14e-20	2.64e-17	-0.46	-0.4	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
KIRC	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	9.67	2.16e-20	2.66e-17	0.41	0.4	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
KIRC	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	9.67	2.16e-20	2.66e-17	0.55	0.4	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
KIRC	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	9.67	2.16e-20	2.67e-17	0.45	0.4	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
KIRC	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	9.67	2.17e-20	2.67e-17	0.54	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
KIRC	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.67	2.18e-20	2.69e-17	-0.42	-0.4	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000250696.4	RP11-704M14.1	9.67	2.19e-20	2.69e-17	0.42	0.4	Obesity-related traits;	chr4:69069866	chr4:69182100~69216766:+
KIRC	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-9.67	2.2e-20	2.71e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
KIRC	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	9.67	2.2e-20	2.71e-17	0.28	0.4	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
KIRC	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	9.67	2.21e-20	2.72e-17	0.49	0.4	Depression;	chr6:28386473	chr6:28176188~28176674:+
KIRC	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	9.67	2.22e-20	2.73e-17	0.38	0.4	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
KIRC	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-9.67	2.22e-20	2.74e-17	-0.4	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
KIRC	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	9.67	2.25e-20	2.76e-17	0.28	0.4	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
KIRC	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-9.67	2.25e-20	2.77e-17	-0.57	-0.4	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
KIRC	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	9.67	2.26e-20	2.78e-17	0.46	0.4	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
KIRC	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	9.67	2.28e-20	2.81e-17	0.28	0.4	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
KIRC	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	9.67	2.28e-20	2.81e-17	0.51	0.4	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
KIRC	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	9.67	2.32e-20	2.85e-17	0.52	0.4	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
KIRC	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	9.66	2.34e-20	2.87e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
KIRC	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	9.66	2.34e-20	2.88e-17	0.39	0.4	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
KIRC	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-9.66	2.34e-20	2.88e-17	-0.58	-0.4	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
KIRC	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	9.66	2.35e-20	2.89e-17	0.4	0.4	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
KIRC	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-9.66	2.35e-20	2.89e-17	-0.35	-0.4	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
KIRC	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	9.66	2.36e-20	2.9e-17	0.57	0.4	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
KIRC	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-9.66	2.36e-20	2.9e-17	-0.43	-0.4	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
KIRC	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	9.66	2.37e-20	2.91e-17	0.45	0.4	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
KIRC	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	9.66	2.37e-20	2.91e-17	0.58	0.4	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	9.66	2.37e-20	2.91e-17	0.58	0.4	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
KIRC	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	9.66	2.37e-20	2.91e-17	0.27	0.4	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	9.66	2.37e-20	2.91e-17	0.27	0.4	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
KIRC	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	9.66	2.37e-20	2.92e-17	0.43	0.4	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
KIRC	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-9.66	2.38e-20	2.92e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
KIRC	cis	rs10028773	0.632	rs34481394	ENSG00000245958.5	RP11-33B1.1	-9.66	2.38e-20	2.92e-17	-0.33	-0.4	Educational attainment;	chr4:119327219	chr4:119454791~119552025:+
KIRC	cis	rs10028773	0.666	rs35231872	ENSG00000245958.5	RP11-33B1.1	-9.66	2.38e-20	2.92e-17	-0.33	-0.4	Educational attainment;	chr4:119327221	chr4:119454791~119552025:+
KIRC	cis	rs10028773	0.7	rs35653026	ENSG00000245958.5	RP11-33B1.1	-9.66	2.38e-20	2.92e-17	-0.33	-0.4	Educational attainment;	chr4:119327223	chr4:119454791~119552025:+
KIRC	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-9.66	2.38e-20	2.92e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
KIRC	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-9.66	2.38e-20	2.92e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
KIRC	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	9.66	2.38e-20	2.93e-17	0.4	0.4	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
KIRC	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	9.66	2.38e-20	2.93e-17	0.45	0.4	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
KIRC	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-9.66	2.41e-20	2.96e-17	-0.54	-0.4	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-9.66	2.41e-20	2.96e-17	-0.54	-0.4	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
KIRC	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	9.66	2.41e-20	2.96e-17	0.39	0.4	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	9.66	2.41e-20	2.96e-17	0.39	0.4	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
KIRC	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-9.66	2.42e-20	2.97e-17	-0.45	-0.4	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
KIRC	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	9.66	2.42e-20	2.97e-17	0.5	0.4	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
KIRC	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	9.66	2.44e-20	2.99e-17	0.45	0.4	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
KIRC	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-9.66	2.44e-20	2.99e-17	-0.55	-0.4	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
KIRC	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	9.66	2.46e-20	3.02e-17	0.48	0.4	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
KIRC	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	9.66	2.47e-20	3.03e-17	0.53	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
KIRC	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-9.66	2.47e-20	3.03e-17	-0.33	-0.4	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
KIRC	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	9.66	2.48e-20	3.04e-17	0.39	0.4	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	9.66	2.48e-20	3.04e-17	0.39	0.4	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
KIRC	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-9.66	2.48e-20	3.04e-17	-0.4	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
KIRC	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-9.66	2.49e-20	3.05e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-9.66	2.49e-20	3.05e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-9.66	2.49e-20	3.05e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-9.66	2.49e-20	3.05e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
KIRC	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	9.66	2.51e-20	3.08e-17	0.28	0.4	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
KIRC	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	9.66	2.53e-20	3.1e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
KIRC	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-9.65	2.57e-20	3.15e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
KIRC	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	9.65	2.58e-20	3.16e-17	0.37	0.4	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
KIRC	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-9.65	2.59e-20	3.17e-17	-0.33	-0.4	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
KIRC	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-9.65	2.6e-20	3.19e-17	-0.33	-0.4	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
KIRC	cis	rs11089937	0.963	rs5757078	ENSG00000211639.2	IGLV4-60	9.65	2.62e-20	3.2e-17	0.38	0.4	Periodontitis (PAL4Q3);	chr22:22145526	chr22:22162199~22162681:+
KIRC	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	9.65	2.63e-20	3.22e-17	0.5	0.4	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
KIRC	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	9.65	2.64e-20	3.23e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	9.65	2.64e-20	3.23e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	9.65	2.64e-20	3.23e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	9.65	2.64e-20	3.23e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
KIRC	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-9.65	2.67e-20	3.26e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-9.65	2.67e-20	3.26e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-9.65	2.67e-20	3.26e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
KIRC	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	9.65	2.67e-20	3.26e-17	0.51	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
KIRC	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	9.65	2.67e-20	3.26e-17	0.58	0.4	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
KIRC	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-9.65	2.67e-20	3.27e-17	-0.59	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
KIRC	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	9.65	2.67e-20	3.27e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
KIRC	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-9.65	2.68e-20	3.28e-17	-0.61	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
KIRC	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	9.65	2.68e-20	3.28e-17	0.4	0.4	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
KIRC	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-9.65	2.69e-20	3.29e-17	-0.33	-0.4	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
KIRC	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	9.65	2.71e-20	3.31e-17	0.44	0.4	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
KIRC	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	9.65	2.73e-20	3.33e-17	0.48	0.4	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
KIRC	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	9.65	2.74e-20	3.34e-17	0.37	0.4	Height;	chr4:55573424	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	9.65	2.74e-20	3.35e-17	0.38	0.4	Height;	chr4:55575856	chr4:55363971~55395847:-
KIRC	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-9.65	2.75e-20	3.36e-17	-0.44	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
KIRC	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	9.64	2.76e-20	3.38e-17	0.45	0.4	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
KIRC	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-9.64	2.8e-20	3.42e-17	-0.47	-0.4	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
KIRC	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	9.64	2.82e-20	3.44e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
KIRC	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	9.64	2.82e-20	3.44e-17	0.51	0.4	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
KIRC	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	9.64	2.82e-20	3.44e-17	0.45	0.4	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
KIRC	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	9.64	2.83e-20	3.45e-17	0.37	0.4	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
KIRC	cis	rs1005277	0.522	rs289650	ENSG00000151963.4	RP11-775A3.1	-9.64	2.83e-20	3.46e-17	-0.44	-0.4	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:37883594~37884109:+
KIRC	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	9.64	2.84e-20	3.47e-17	0.45	0.4	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
KIRC	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-9.64	2.85e-20	3.48e-17	-0.74	-0.4	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
KIRC	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-9.64	2.86e-20	3.49e-17	-0.3	-0.4	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
KIRC	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-9.64	2.86e-20	3.49e-17	-0.33	-0.4	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
KIRC	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	9.64	2.88e-20	3.52e-17	0.53	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	9.64	2.88e-20	3.52e-17	0.53	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	9.64	2.88e-20	3.52e-17	0.53	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
KIRC	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-9.64	2.89e-20	3.52e-17	-0.44	-0.4	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
KIRC	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-9.64	2.9e-20	3.53e-17	-0.53	-0.4	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
KIRC	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-9.64	2.91e-20	3.55e-17	-0.63	-0.4	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
KIRC	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	9.64	2.92e-20	3.56e-17	0.76	0.4	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
KIRC	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-9.64	2.93e-20	3.58e-17	-0.43	-0.4	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
KIRC	cis	rs1757171	0.542	rs3818985	ENSG00000227920.2	RP1-153P14.5	-9.64	2.95e-20	3.6e-17	-0.44	-0.4	Cognitive performance;	chr6:37516438	chr6:37545145~37550860:+
KIRC	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	9.64	2.96e-20	3.61e-17	0.37	0.4	Height;	chr4:55544621	chr4:55363971~55395847:-
KIRC	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-9.64	2.96e-20	3.61e-17	-0.5	-0.4	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
KIRC	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	9.64	2.98e-20	3.63e-17	0.45	0.4	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
KIRC	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-9.64	2.98e-20	3.64e-17	-0.48	-0.4	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
KIRC	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-9.63	3e-20	3.65e-17	-0.55	-0.4	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-9.63	3e-20	3.65e-17	-0.55	-0.4	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-9.63	3e-20	3.65e-17	-0.55	-0.4	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
KIRC	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-9.63	3e-20	3.65e-17	-0.54	-0.4	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-9.63	3e-20	3.65e-17	-0.54	-0.4	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-9.63	3e-20	3.65e-17	-0.54	-0.4	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-9.63	3e-20	3.65e-17	-0.54	-0.4	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
KIRC	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-9.63	3e-20	3.66e-17	-0.57	-0.4	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
KIRC	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	9.63	3.01e-20	3.67e-17	0.37	0.4	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
KIRC	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	9.63	3.01e-20	3.67e-17	0.81	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
KIRC	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	9.63	3.02e-20	3.68e-17	0.37	0.4	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
KIRC	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-9.63	3.02e-20	3.68e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-9.63	3.02e-20	3.68e-17	-0.52	-0.4	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-9.63	3.03e-20	3.69e-17	-0.33	-0.4	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-9.63	3.03e-20	3.69e-17	-0.33	-0.4	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
KIRC	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	9.63	3.05e-20	3.71e-17	0.4	0.4	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	9.63	3.05e-20	3.71e-17	0.4	0.4	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	9.63	3.05e-20	3.71e-17	0.4	0.4	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	9.63	3.06e-20	3.72e-17	0.4	0.4	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	9.63	3.06e-20	3.72e-17	0.4	0.4	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
KIRC	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-9.63	3.08e-20	3.75e-17	-0.34	-0.4	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
KIRC	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-9.63	3.08e-20	3.75e-17	-0.42	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
KIRC	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-9.63	3.08e-20	3.75e-17	-0.42	-0.4	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
KIRC	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-9.63	3.12e-20	3.79e-17	-0.52	-0.4	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
KIRC	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	9.63	3.13e-20	3.81e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	9.63	3.13e-20	3.81e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	9.63	3.13e-20	3.81e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
KIRC	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	9.63	3.15e-20	3.83e-17	0.45	0.4	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
KIRC	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	9.63	3.17e-20	3.85e-17	0.41	0.4	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
KIRC	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	9.63	3.18e-20	3.86e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	9.63	3.18e-20	3.86e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
KIRC	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	9.63	3.18e-20	3.87e-17	0.44	0.4	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
KIRC	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-9.63	3.18e-20	3.87e-17	-0.44	-0.4	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
KIRC	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	9.63	3.19e-20	3.87e-17	0.37	0.4	Height;	chr4:55452921	chr4:55363971~55395847:-
KIRC	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-9.63	3.21e-20	3.9e-17	-0.47	-0.4	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
KIRC	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-9.63	3.21e-20	3.9e-17	-0.52	-0.4	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
KIRC	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	9.63	3.22e-20	3.91e-17	0.4	0.4	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
KIRC	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-9.63	3.22e-20	3.91e-17	-0.51	-0.4	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
KIRC	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	9.63	3.22e-20	3.91e-17	0.4	0.4	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	9.63	3.22e-20	3.91e-17	0.4	0.4	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
KIRC	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	9.62	3.25e-20	3.94e-17	0.39	0.4	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
KIRC	cis	rs919433	1	rs1346649	ENSG00000231621.1	AC013264.2	9.62	3.25e-20	3.95e-17	0.42	0.4	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301393	chr2:197197991~197199273:+
KIRC	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	9.62	3.26e-20	3.95e-17	0.53	0.4	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
KIRC	cis	rs4356975	0.649	rs59421013	ENSG00000248763.2	RP13-644M16.5	-9.62	3.29e-20	3.99e-17	-0.49	-0.4	Obesity-related traits;	chr4:69149131	chr4:69066395~69069888:+
KIRC	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-9.62	3.32e-20	4.03e-17	-0.55	-0.4	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
KIRC	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-9.62	3.35e-20	4.06e-17	-0.4	-0.4	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
KIRC	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-9.62	3.36e-20	4.07e-17	-0.3	-0.4	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
KIRC	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-9.62	3.36e-20	4.07e-17	-0.37	-0.4	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
KIRC	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-9.62	3.38e-20	4.1e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-9.62	3.38e-20	4.1e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-9.62	3.38e-20	4.1e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-9.62	3.38e-20	4.1e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-9.62	3.38e-20	4.1e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	9.62	3.39e-20	4.11e-17	0.52	0.4	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
KIRC	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-9.62	3.4e-20	4.12e-17	-0.47	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
KIRC	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-9.62	3.41e-20	4.14e-17	-0.33	-0.4	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
KIRC	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	9.62	3.42e-20	4.14e-17	0.43	0.4	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
KIRC	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	9.62	3.42e-20	4.14e-17	0.45	0.4	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	9.62	3.42e-20	4.14e-17	0.45	0.4	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	9.62	3.42e-20	4.14e-17	0.45	0.4	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	9.62	3.42e-20	4.14e-17	0.45	0.4	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
KIRC	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-9.62	3.44e-20	4.16e-17	-0.54	-0.4	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
KIRC	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-9.62	3.45e-20	4.18e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
KIRC	cis	rs9847710	1	rs2564956	ENSG00000280417.1	RP11-5O17.1	-9.62	3.47e-20	4.2e-17	-0.46	-0.4	Ulcerative colitis;	chr3:53036446	chr3:53046166~53048122:+
KIRC	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-9.62	3.47e-20	4.2e-17	-0.43	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
KIRC	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	9.62	3.49e-20	4.23e-17	0.59	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
KIRC	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-9.62	3.5e-20	4.24e-17	-0.38	-0.4	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
KIRC	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	9.62	3.5e-20	4.24e-17	0.5	0.4	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
KIRC	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-9.61	3.55e-20	4.3e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
KIRC	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	9.61	3.56e-20	4.3e-17	0.47	0.4	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
KIRC	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	9.61	3.57e-20	4.31e-17	0.4	0.4	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	9.61	3.58e-20	4.33e-17	0.4	0.4	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
KIRC	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-9.61	3.58e-20	4.33e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-9.61	3.58e-20	4.33e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-9.61	3.58e-20	4.33e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
KIRC	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-9.61	3.6e-20	4.36e-17	-0.45	-0.4	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-9.61	3.63e-20	4.38e-17	-0.33	-0.4	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
KIRC	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-9.61	3.63e-20	4.39e-17	-0.46	-0.4	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
KIRC	cis	rs5769707	0.681	rs916360	ENSG00000188511.11	C22orf34	9.61	3.65e-20	4.41e-17	0.52	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49648324	chr22:49414524~49657542:-
KIRC	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-9.61	3.67e-20	4.44e-17	-0.59	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
KIRC	cis	rs904251	0.523	rs1776455	ENSG00000227920.2	RP1-153P14.5	-9.61	3.68e-20	4.45e-17	-0.43	-0.4	Cognitive performance;	chr6:37515147	chr6:37545145~37550860:+
KIRC	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	9.61	3.69e-20	4.46e-17	0.27	0.4	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
KIRC	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	9.61	3.72e-20	4.5e-17	0.37	0.4	Height;	chr4:55489895	chr4:55363971~55395847:-
KIRC	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	9.61	3.73e-20	4.5e-17	0.39	0.4	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
KIRC	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	9.61	3.76e-20	4.54e-17	0.45	0.4	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
KIRC	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-9.61	3.78e-20	4.57e-17	-0.35	-0.4	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
KIRC	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-9.6	3.82e-20	4.62e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-9.6	3.82e-20	4.62e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-9.6	3.82e-20	4.62e-17	-0.41	-0.4	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
KIRC	cis	rs9457247	0.508	rs2285147	ENSG00000265828.1	MIR3939	-9.6	3.83e-20	4.62e-17	-0.45	-0.4	Crohn's disease;	chr6:167092060	chr6:166997807~166997912:-
KIRC	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	9.6	3.85e-20	4.65e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	9.6	3.85e-20	4.65e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
KIRC	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	9.6	3.86e-20	4.65e-17	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
KIRC	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	9.6	3.86e-20	4.65e-17	0.47	0.4	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
KIRC	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-9.6	3.86e-20	4.66e-17	-0.33	-0.4	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-9.6	3.86e-20	4.66e-17	-0.33	-0.4	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-9.6	3.86e-20	4.66e-17	-0.33	-0.4	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-9.6	3.86e-20	4.66e-17	-0.33	-0.4	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
KIRC	cis	rs2302464	1	rs58978163	ENSG00000214846.4	RP11-115L11.1	9.6	3.87e-20	4.66e-17	0.97	0.4	Cerebrospinal fluid biomarker levels;	chr4:15726385	chr4:15730962~15731627:-
KIRC	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-9.6	3.87e-20	4.67e-17	-0.42	-0.4	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
KIRC	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-9.6	3.91e-20	4.71e-17	-0.53	-0.4	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
KIRC	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-9.6	3.93e-20	4.74e-17	-0.5	-0.4	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
KIRC	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	9.6	3.93e-20	4.74e-17	0.33	0.4	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
KIRC	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-9.6	3.94e-20	4.75e-17	-0.45	-0.4	Height;	chr11:118737823	chr11:118704607~118750263:+
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000250696.4	RP11-704M14.1	9.6	3.96e-20	4.77e-17	0.42	0.4	Obesity-related traits;	chr4:69071215	chr4:69182100~69216766:+
KIRC	cis	rs1757171	0.504	rs11969056	ENSG00000227920.2	RP1-153P14.5	-9.6	3.96e-20	4.77e-17	-0.44	-0.4	Cognitive performance;	chr6:37516509	chr6:37545145~37550860:+
KIRC	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-9.6	3.96e-20	4.78e-17	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-9.6	3.98e-20	4.79e-17	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
KIRC	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-9.6	4.02e-20	4.84e-17	-0.4	-0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
KIRC	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	9.6	4.02e-20	4.85e-17	0.45	0.4	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
KIRC	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	9.6	4.02e-20	4.85e-17	0.45	0.4	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
KIRC	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	9.6	4.03e-20	4.85e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	9.6	4.03e-20	4.85e-17	0.46	0.4	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
KIRC	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	9.6	4.05e-20	4.88e-17	0.51	0.4	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
KIRC	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-9.6	4.09e-20	4.92e-17	-0.51	-0.4	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
KIRC	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	9.6	4.09e-20	4.92e-17	0.57	0.4	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
KIRC	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	9.59	4.15e-20	5e-17	0.38	0.4	Height;	chr4:55577294	chr4:55363971~55395847:-
KIRC	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-9.59	4.17e-20	5.01e-17	-0.44	-0.4	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
KIRC	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	9.59	4.19e-20	5.04e-17	0.4	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
KIRC	cis	rs2302464	1	rs73123615	ENSG00000214846.4	RP11-115L11.1	9.59	4.19e-20	5.04e-17	0.96	0.4	Cerebrospinal fluid biomarker levels;	chr4:15726553	chr4:15730962~15731627:-
KIRC	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	9.59	4.2e-20	5.05e-17	0.37	0.4	Height;	chr4:55564241	chr4:55363971~55395847:-
KIRC	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	9.59	4.21e-20	5.06e-17	0.61	0.4	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
KIRC	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	9.59	4.21e-20	5.06e-17	0.61	0.4	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
KIRC	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-9.59	4.23e-20	5.09e-17	-0.5	-0.4	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
KIRC	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	9.59	4.26e-20	5.12e-17	0.45	0.4	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	9.59	4.26e-20	5.12e-17	0.45	0.4	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	9.59	4.26e-20	5.12e-17	0.45	0.4	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
KIRC	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-9.59	4.26e-20	5.13e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-9.59	4.26e-20	5.13e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
KIRC	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	9.59	4.28e-20	5.14e-17	0.52	0.4	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
KIRC	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	9.59	4.29e-20	5.15e-17	0.48	0.4	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
KIRC	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	9.59	4.3e-20	5.17e-17	0.38	0.4	Height;	chr4:55401306	chr4:55363971~55395847:-
KIRC	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	9.59	4.32e-20	5.19e-17	0.39	0.4	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
KIRC	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	9.59	4.32e-20	5.19e-17	0.67	0.4	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
KIRC	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	9.59	4.32e-20	5.2e-17	0.51	0.4	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
KIRC	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	9.59	4.33e-20	5.2e-17	0.37	0.4	Height;	chr4:55465165	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	9.59	4.36e-20	5.24e-17	0.37	0.4	Height;	chr4:55561053	chr4:55363971~55395847:-
KIRC	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	9.59	4.36e-20	5.24e-17	0.55	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
KIRC	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-9.59	4.38e-20	5.26e-17	-0.44	-0.4	Temperament;	chr17:13999319	chr17:14024514~14025488:+
KIRC	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-9.59	4.38e-20	5.26e-17	-0.49	-0.4	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
KIRC	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-9.59	4.38e-20	5.27e-17	-0.5	-0.4	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
KIRC	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-9.59	4.38e-20	5.27e-17	-0.5	-0.4	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
KIRC	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-9.59	4.41e-20	5.29e-17	-0.45	-0.4	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
KIRC	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	9.59	4.46e-20	5.36e-17	0.62	0.4	Height;	chr6:109548647	chr6:109382795~109383666:+
KIRC	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	9.59	4.48e-20	5.38e-17	0.5	0.4	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
KIRC	cis	rs4356975	0.697	rs6849081	ENSG00000248763.2	RP13-644M16.5	-9.58	4.53e-20	5.43e-17	-0.49	-0.4	Obesity-related traits;	chr4:69144840	chr4:69066395~69069888:+
KIRC	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-9.58	4.55e-20	5.46e-17	-0.5	-0.4	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
KIRC	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.58	4.57e-20	5.48e-17	0.45	0.4	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
KIRC	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	9.58	4.59e-20	5.5e-17	0.48	0.4	Depression;	chr6:28379133	chr6:28176188~28176674:+
KIRC	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	9.58	4.59e-20	5.5e-17	0.48	0.4	Depression;	chr6:28379168	chr6:28176188~28176674:+
KIRC	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-9.58	4.62e-20	5.54e-17	-0.57	-0.4	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
KIRC	cis	rs2698530	0.762	rs2698541	ENSG00000225889.6	AC074289.1	-9.58	4.64e-20	5.56e-17	-0.4	-0.4	Iron status biomarkers;	chr2:64261545	chr2:64143239~64252859:+
KIRC	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-9.58	4.68e-20	5.61e-17	-0.45	-0.4	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
KIRC	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	9.58	4.69e-20	5.63e-17	0.77	0.4	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69071281	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69071328	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69071698	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072135	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072143	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072154	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072229	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072402	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072745	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69072777	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69073025	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69073381	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000250696.4	RP11-704M14.1	9.58	4.73e-20	5.67e-17	0.41	0.4	Obesity-related traits;	chr4:69073429	chr4:69182100~69216766:+
KIRC	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-9.58	4.74e-20	5.67e-17	-0.45	-0.4	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
KIRC	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	9.58	4.74e-20	5.68e-17	0.27	0.4	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
KIRC	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	9.58	4.74e-20	5.68e-17	0.52	0.4	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
KIRC	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	9.58	4.77e-20	5.71e-17	0.4	0.4	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
KIRC	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-9.58	4.79e-20	5.73e-17	-0.5	-0.4	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
KIRC	cis	rs904251	0.504	rs12202664	ENSG00000227920.2	RP1-153P14.5	-9.58	4.79e-20	5.74e-17	-0.44	-0.4	Cognitive performance;	chr6:37513422	chr6:37545145~37550860:+
KIRC	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	9.58	4.81e-20	5.76e-17	0.39	0.4	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
KIRC	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-9.58	4.83e-20	5.78e-17	-0.33	-0.4	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-9.58	4.83e-20	5.78e-17	-0.33	-0.4	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-9.58	4.83e-20	5.78e-17	-0.33	-0.4	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-9.58	4.83e-20	5.78e-17	-0.33	-0.4	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
KIRC	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	9.58	4.83e-20	5.79e-17	0.45	0.4	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000250696.4	RP11-704M14.1	9.58	4.84e-20	5.8e-17	0.42	0.4	Obesity-related traits;	chr4:69077628	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000250696.4	RP11-704M14.1	9.58	4.84e-20	5.8e-17	0.42	0.4	Obesity-related traits;	chr4:69077631	chr4:69182100~69216766:+
KIRC	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-9.58	4.84e-20	5.8e-17	-0.42	-0.4	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-9.58	4.84e-20	5.8e-17	-0.42	-0.4	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
KIRC	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	9.58	4.86e-20	5.81e-17	0.58	0.4	Height;	chr6:109415050	chr6:109382795~109383666:+
KIRC	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-9.57	4.88e-20	5.84e-17	-0.43	-0.4	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
KIRC	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	9.57	4.9e-20	5.86e-17	0.97	0.4	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs11944132	ENSG00000214846.4	RP11-115L11.1	9.57	4.9e-20	5.86e-17	0.97	0.4	Cerebrospinal fluid biomarker levels;	chr4:15724291	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	9.57	4.9e-20	5.86e-17	0.97	0.4	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
KIRC	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	9.57	4.9e-20	5.86e-17	0.97	0.4	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
KIRC	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-9.57	4.92e-20	5.89e-17	-0.37	-0.4	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
KIRC	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	9.57	4.92e-20	5.89e-17	0.44	0.4	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	9.57	4.95e-20	5.93e-17	0.43	0.4	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	9.57	4.95e-20	5.93e-17	0.43	0.4	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	9.57	4.95e-20	5.93e-17	0.43	0.4	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000250696.4	RP11-704M14.1	9.57	4.96e-20	5.93e-17	0.41	0.4	Obesity-related traits;	chr4:69079589	chr4:69182100~69216766:+
KIRC	cis	rs904251	0.861	rs1757183	ENSG00000227920.2	RP1-153P14.5	9.57	4.96e-20	5.93e-17	0.46	0.4	Cognitive performance;	chr6:37517014	chr6:37545145~37550860:+
KIRC	cis	rs1005277	0.522	rs289649	ENSG00000151963.4	RP11-775A3.1	-9.57	4.96e-20	5.93e-17	-0.44	-0.4	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:37883594~37884109:+
KIRC	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	9.57	5.03e-20	6.01e-17	0.5	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
KIRC	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-9.57	5.1e-20	6.09e-17	-0.5	-0.4	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
KIRC	cis	rs6456156	0.692	rs9457270	ENSG00000265828.1	MIR3939	-9.57	5.12e-20	6.12e-17	-0.45	-0.4	Primary biliary cholangitis;	chr6:167099440	chr6:166997807~166997912:-
KIRC	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-9.57	5.13e-20	6.13e-17	-0.42	-0.4	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
KIRC	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	9.57	5.13e-20	6.13e-17	0.45	0.4	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
KIRC	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	9.57	5.14e-20	6.14e-17	0.48	0.4	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-9.57	5.15e-20	6.15e-17	-0.51	-0.4	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-9.57	5.18e-20	6.18e-17	-0.35	-0.4	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
KIRC	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-9.57	5.18e-20	6.18e-17	-0.54	-0.4	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
KIRC	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-9.57	5.22e-20	6.23e-17	-0.31	-0.4	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-9.57	5.22e-20	6.23e-17	-0.31	-0.4	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
KIRC	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	9.57	5.26e-20	6.27e-17	0.39	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
KIRC	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-9.57	5.28e-20	6.3e-17	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
KIRC	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	9.56	5.31e-20	6.34e-17	0.42	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
KIRC	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	9.56	5.32e-20	6.35e-17	0.38	0.39	Height;	chr4:55578154	chr4:55363971~55395847:-
KIRC	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	9.56	5.34e-20	6.37e-17	0.55	0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000250696.4	RP11-704M14.1	9.56	5.37e-20	6.4e-17	0.41	0.39	Obesity-related traits;	chr4:69073715	chr4:69182100~69216766:+
KIRC	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	9.56	5.38e-20	6.41e-17	0.36	0.39	Height;	chr4:55363436	chr4:55363971~55395847:-
KIRC	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	9.56	5.41e-20	6.45e-17	0.41	0.39	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
KIRC	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-9.56	5.43e-20	6.46e-17	-0.51	-0.39	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
KIRC	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	9.56	5.46e-20	6.5e-17	0.3	0.39	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
KIRC	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-9.56	5.46e-20	6.5e-17	-0.55	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-9.56	5.46e-20	6.5e-17	-0.55	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
KIRC	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	9.56	5.47e-20	6.52e-17	0.45	0.39	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
KIRC	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-9.56	5.49e-20	6.54e-17	-0.45	-0.39	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
KIRC	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	9.56	5.5e-20	6.55e-17	0.37	0.39	Height;	chr4:55561218	chr4:55363971~55395847:-
KIRC	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-9.56	5.52e-20	6.57e-17	-0.36	-0.39	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
KIRC	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	9.56	5.54e-20	6.6e-17	0.46	0.39	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
KIRC	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-9.56	5.56e-20	6.62e-17	-0.5	-0.39	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
KIRC	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-9.56	5.58e-20	6.65e-17	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
KIRC	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	9.56	5.58e-20	6.65e-17	0.4	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
KIRC	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	9.56	5.59e-20	6.65e-17	0.39	0.39	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000250696.4	RP11-704M14.1	9.56	5.65e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69078113	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000250696.4	RP11-704M14.1	9.56	5.65e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69078247	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000250696.4	RP11-704M14.1	9.56	5.65e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69078533	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000250696.4	RP11-704M14.1	9.56	5.65e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69078868	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000250696.4	RP11-704M14.1	9.56	5.65e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69078897	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000250696.4	RP11-704M14.1	9.56	5.66e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69079387	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000250696.4	RP11-704M14.1	9.56	5.66e-20	6.73e-17	0.41	0.39	Obesity-related traits;	chr4:69079446	chr4:69182100~69216766:+
KIRC	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	9.56	5.66e-20	6.73e-17	0.46	0.39	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	9.56	5.66e-20	6.73e-17	0.46	0.39	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
KIRC	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-9.56	5.69e-20	6.77e-17	-0.46	-0.39	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
KIRC	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	9.56	5.72e-20	6.8e-17	0.45	0.39	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
KIRC	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	9.55	5.75e-20	6.84e-17	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
KIRC	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	9.55	5.75e-20	6.84e-17	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
KIRC	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-9.55	5.75e-20	6.84e-17	-0.4	-0.39	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
KIRC	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-9.55	5.8e-20	6.9e-17	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-9.55	5.8e-20	6.9e-17	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
KIRC	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	9.55	5.83e-20	6.93e-17	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
KIRC	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	9.55	5.85e-20	6.95e-17	0.4	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
KIRC	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-9.55	5.86e-20	6.97e-17	-0.31	-0.39	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
KIRC	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-9.55	5.91e-20	7.02e-17	-0.33	-0.39	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
KIRC	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-9.55	5.93e-20	7.05e-17	-0.47	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
KIRC	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-9.55	6e-20	7.12e-17	-0.41	-0.39	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
KIRC	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-9.55	6e-20	7.13e-17	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
KIRC	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	9.55	6.05e-20	7.18e-17	0.49	0.39	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
KIRC	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-9.55	6.05e-20	7.18e-17	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
KIRC	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-9.55	6.05e-20	7.18e-17	-0.42	-0.39	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
KIRC	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-9.55	6.08e-20	7.22e-17	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-9.55	6.08e-20	7.22e-17	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-9.55	6.08e-20	7.22e-17	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-9.55	6.08e-20	7.22e-17	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
KIRC	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	9.55	6.09e-20	7.22e-17	0.55	0.39	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
KIRC	cis	rs919433	1	rs6741380	ENSG00000231621.1	AC013264.2	-9.55	6.09e-20	7.22e-17	-0.41	-0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197300397	chr2:197197991~197199273:+
KIRC	cis	rs9457247	0.508	rs6902119	ENSG00000265828.1	MIR3939	-9.55	6.1e-20	7.24e-17	-0.45	-0.39	Crohn's disease;	chr6:167092303	chr6:166997807~166997912:-
KIRC	cis	rs9457247	0.508	rs6918286	ENSG00000265828.1	MIR3939	-9.55	6.1e-20	7.24e-17	-0.45	-0.39	Crohn's disease;	chr6:167092341	chr6:166997807~166997912:-
KIRC	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-9.55	6.12e-20	7.27e-17	-0.47	-0.39	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-9.55	6.12e-20	7.27e-17	-0.47	-0.39	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
KIRC	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-9.55	6.16e-20	7.3e-17	-0.37	-0.39	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
KIRC	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	9.55	6.22e-20	7.37e-17	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
KIRC	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-9.55	6.23e-20	7.39e-17	-0.37	-0.39	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
KIRC	cis	rs9457247	0.508	rs9457268	ENSG00000265828.1	MIR3939	-9.54	6.27e-20	7.43e-17	-0.45	-0.39	Crohn's disease;	chr6:167090151	chr6:166997807~166997912:-
KIRC	cis	rs2698530	0.791	rs2555442	ENSG00000225889.6	AC074289.1	-9.54	6.37e-20	7.55e-17	-0.4	-0.39	Iron status biomarkers;	chr2:64262157	chr2:64143239~64252859:+
KIRC	cis	rs11603023	1	rs11603023	ENSG00000255422.1	AP002954.4	-9.54	6.4e-20	7.58e-17	-0.45	-0.39	Cholesterol, total;	chr11:118615352	chr11:118704607~118750263:+
KIRC	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	9.54	6.42e-20	7.6e-17	0.49	0.39	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
KIRC	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-9.54	6.46e-20	7.65e-17	-0.39	-0.39	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-9.54	6.49e-20	7.69e-17	-0.39	-0.39	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
KIRC	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	9.54	6.49e-20	7.69e-17	0.36	0.39	Height;	chr4:55370412	chr4:55363971~55395847:-
KIRC	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-9.54	6.52e-20	7.72e-17	-0.59	-0.39	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
KIRC	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	9.54	6.53e-20	7.73e-17	0.5	0.39	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
KIRC	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	9.54	6.55e-20	7.76e-17	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
KIRC	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-9.54	6.57e-20	7.78e-17	-0.33	-0.39	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
KIRC	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	9.54	6.58e-20	7.79e-17	0.45	0.39	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000250696.4	RP11-704M14.1	9.54	6.59e-20	7.8e-17	0.41	0.39	Obesity-related traits;	chr4:69072070	chr4:69182100~69216766:+
KIRC	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-9.54	6.63e-20	7.84e-17	-0.53	-0.39	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
KIRC	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	9.54	6.64e-20	7.86e-17	0.49	0.39	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
KIRC	cis	rs13113518	1	rs13132420	ENSG00000249700.7	SRD5A3-AS1	-9.54	6.64e-20	7.86e-17	-0.35	-0.39	Height;	chr4:55526646	chr4:55363971~55395847:-
KIRC	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	9.54	6.69e-20	7.92e-17	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
KIRC	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	9.53	6.76e-20	8e-17	0.43	0.39	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
KIRC	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	9.53	6.77e-20	8.01e-17	0.53	0.39	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
KIRC	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-9.53	6.8e-20	8.04e-17	-0.49	-0.39	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
KIRC	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	9.53	6.8e-20	8.04e-17	0.51	0.39	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
KIRC	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-9.53	6.82e-20	8.06e-17	-0.41	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
KIRC	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	9.53	6.9e-20	8.15e-17	0.5	0.39	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
KIRC	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	9.53	6.92e-20	8.18e-17	0.47	0.39	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
KIRC	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	9.53	7e-20	8.27e-17	0.44	0.39	Temperament;	chr17:13996939	chr17:14024514~14025488:+
KIRC	cis	rs904251	0.797	rs1776460	ENSG00000227920.2	RP1-153P14.5	-9.53	7.01e-20	8.28e-17	-0.46	-0.39	Cognitive performance;	chr6:37517708	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.523	rs10807184	ENSG00000227920.2	RP1-153P14.5	-9.53	7.09e-20	8.37e-17	-0.44	-0.39	Cognitive performance;	chr6:37515937	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.561	rs1757189	ENSG00000227920.2	RP1-153P14.5	-9.53	7.09e-20	8.37e-17	-0.44	-0.39	Cognitive performance;	chr6:37515951	chr6:37545145~37550860:+
KIRC	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-9.53	7.15e-20	8.44e-17	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
KIRC	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-9.53	7.16e-20	8.45e-17	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
KIRC	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	9.53	7.18e-20	8.47e-17	0.5	0.39	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
KIRC	cis	rs10759883	0.612	rs2943532	ENSG00000175611.10	LINC00476	9.53	7.24e-20	8.54e-17	0.46	0.39	Nicotine dependence;	chr9:96024975	chr9:95759231~95875977:-
KIRC	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	9.53	7.31e-20	8.62e-17	0.48	0.39	Height;	chr11:118808920	chr11:118688039~118690600:-
KIRC	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-9.53	7.32e-20	8.62e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000250696.4	RP11-704M14.1	9.52	7.34e-20	8.65e-17	0.41	0.39	Obesity-related traits;	chr4:69075937	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000250696.4	RP11-704M14.1	9.52	7.34e-20	8.65e-17	0.41	0.39	Obesity-related traits;	chr4:69075944	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000250696.4	RP11-704M14.1	9.52	7.34e-20	8.65e-17	0.41	0.39	Obesity-related traits;	chr4:69076309	chr4:69182100~69216766:+
KIRC	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	9.52	7.34e-20	8.65e-17	0.3	0.39	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
KIRC	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-9.52	7.38e-20	8.7e-17	-0.47	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
KIRC	cis	rs950776	0.518	rs4887062	ENSG00000261762.1	RP11-650L12.2	-9.52	7.41e-20	8.73e-17	-0.51	-0.39	Sudden cardiac arrest;	chr15:78545459	chr15:78589123~78591276:-
KIRC	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-9.52	7.47e-20	8.79e-17	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
KIRC	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-9.52	7.48e-20	8.8e-17	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
KIRC	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	9.52	7.49e-20	8.82e-17	0.37	0.39	Height;	chr4:55540928	chr4:55363971~55395847:-
KIRC	cis	rs79040073	0.637	rs112792737	ENSG00000259531.2	RP11-295H24.3	9.52	7.54e-20	8.88e-17	0.52	0.39	Lung cancer in ever smokers;	chr15:49198849	chr15:49365124~49366685:-
KIRC	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.52	7.56e-20	8.89e-17	-0.45	-0.39	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
KIRC	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-9.52	7.58e-20	8.92e-17	-0.34	-0.39	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
KIRC	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	9.52	7.58e-20	8.92e-17	0.28	0.39	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
KIRC	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	9.52	7.61e-20	8.96e-17	0.45	0.39	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
KIRC	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	9.52	7.63e-20	8.98e-17	0.45	0.39	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
KIRC	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-9.52	7.68e-20	9.03e-17	-0.53	-0.39	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
KIRC	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-9.52	7.73e-20	9.1e-17	-0.54	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
KIRC	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	9.52	7.85e-20	9.23e-17	0.4	0.39	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
KIRC	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-9.52	7.9e-20	9.29e-17	-0.54	-0.39	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
KIRC	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	9.52	7.91e-20	9.3e-17	0.51	0.39	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	9.52	7.92e-20	9.32e-17	0.3	0.39	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
KIRC	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-9.51	7.96e-20	9.35e-17	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
KIRC	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-9.51	7.96e-20	9.35e-17	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
KIRC	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-9.51	7.96e-20	9.36e-17	-0.45	-0.39	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
KIRC	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	9.51	7.97e-20	9.36e-17	0.39	0.39	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
KIRC	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	9.51	7.97e-20	9.36e-17	0.54	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
KIRC	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-9.51	8e-20	9.4e-17	-0.3	-0.39	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
KIRC	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	9.51	8e-20	9.41e-17	0.47	0.39	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
KIRC	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-9.51	8.1e-20	9.52e-17	-0.42	-0.39	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
KIRC	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	9.51	8.11e-20	9.54e-17	0.45	0.39	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
KIRC	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-9.51	8.19e-20	9.63e-17	-0.43	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
KIRC	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-9.51	8.27e-20	9.72e-17	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
KIRC	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	9.51	8.3e-20	9.74e-17	0.37	0.39	Height;	chr4:55407965	chr4:55363971~55395847:-
KIRC	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.51	8.46e-20	9.92e-17	-0.45	-0.39	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
KIRC	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-9.51	8.47e-20	9.94e-17	-0.32	-0.39	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-9.51	8.53e-20	1e-16	-0.31	-0.39	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
KIRC	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-9.51	8.56e-20	1e-16	-0.45	-0.39	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
KIRC	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	9.51	8.57e-20	1e-16	0.52	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	9.51	8.57e-20	1e-16	0.52	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	9.51	8.57e-20	1e-16	0.52	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
KIRC	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	9.51	8.57e-20	1e-16	0.52	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
KIRC	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-9.5	8.63e-20	1.01e-16	-0.55	-0.39	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
KIRC	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-9.5	8.65e-20	1.01e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-9.5	8.65e-20	1.01e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
KIRC	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	9.5	8.66e-20	1.02e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000250696.4	RP11-704M14.1	9.5	8.69e-20	1.02e-16	0.41	0.39	Obesity-related traits;	chr4:69075351	chr4:69182100~69216766:+
KIRC	cis	rs904251	0.861	rs1757180	ENSG00000227920.2	RP1-153P14.5	-9.5	8.71e-20	1.02e-16	-0.46	-0.39	Cognitive performance;	chr6:37518369	chr6:37545145~37550860:+
KIRC	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-9.5	8.72e-20	1.02e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
KIRC	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	9.5	8.75e-20	1.03e-16	0.47	0.39	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000250696.4	RP11-704M14.1	9.5	8.84e-20	1.03e-16	0.41	0.39	Obesity-related traits;	chr4:69074077	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000250696.4	RP11-704M14.1	9.5	8.84e-20	1.03e-16	0.41	0.39	Obesity-related traits;	chr4:69075085	chr4:69182100~69216766:+
KIRC	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-9.5	8.87e-20	1.04e-16	-0.51	-0.39	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000250919.1	RP11-813N20.3	-9.5	8.95e-20	1.05e-16	-0.42	-0.39	Obesity-related traits;	chr4:69070955	chr4:69027831~69044578:+
KIRC	cis	rs9457247	0.565	rs12193698	ENSG00000265828.1	MIR3939	-9.5	8.97e-20	1.05e-16	-0.45	-0.39	Crohn's disease;	chr6:167098585	chr6:166997807~166997912:-
KIRC	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	9.5	9.01e-20	1.05e-16	0.46	0.39	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
KIRC	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-9.5	9.05e-20	1.06e-16	-0.33	-0.39	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
KIRC	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	9.5	9.09e-20	1.06e-16	0.53	0.39	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
KIRC	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-9.5	9.12e-20	1.07e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-9.5	9.12e-20	1.07e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
KIRC	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-9.5	9.18e-20	1.07e-16	-0.51	-0.39	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
KIRC	cis	rs919433	1	rs2889363	ENSG00000231621.1	AC013264.2	9.5	9.19e-20	1.07e-16	0.41	0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298975	chr2:197197991~197199273:+
KIRC	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	9.5	9.25e-20	1.08e-16	0.34	0.39	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
KIRC	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	9.5	9.27e-20	1.08e-16	0.54	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
KIRC	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	9.5	9.28e-20	1.09e-16	0.54	0.39	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
KIRC	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	9.5	9.34e-20	1.09e-16	0.39	0.39	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
KIRC	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	9.49	9.41e-20	1.1e-16	0.44	0.39	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
KIRC	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-9.49	9.42e-20	1.1e-16	-0.55	-0.39	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
KIRC	cis	rs904251	0.828	rs1757178	ENSG00000227920.2	RP1-153P14.5	9.49	9.45e-20	1.1e-16	0.45	0.39	Cognitive performance;	chr6:37518534	chr6:37545145~37550860:+
KIRC	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	9.49	9.53e-20	1.11e-16	0.52	0.39	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
KIRC	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-9.49	9.55e-20	1.12e-16	-0.39	-0.39	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000250919.1	RP11-813N20.3	-9.49	9.58e-20	1.12e-16	-0.42	-0.39	Obesity-related traits;	chr4:69069614	chr4:69027831~69044578:+
KIRC	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	9.49	9.6e-20	1.12e-16	0.45	0.39	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
KIRC	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	9.49	9.67e-20	1.13e-16	0.48	0.39	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
KIRC	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	9.49	9.76e-20	1.14e-16	0.3	0.39	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
KIRC	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-9.49	9.78e-20	1.14e-16	-0.38	-0.39	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
KIRC	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-9.49	9.78e-20	1.14e-16	-0.42	-0.39	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
KIRC	cis	rs11079159	0.606	rs4239192	ENSG00000263096.1	RP11-515O17.2	9.49	9.87e-20	1.15e-16	0.5	0.39	QRS duration;	chr17:55299143	chr17:55271504~55273653:-
KIRC	cis	rs919433	1	rs6761919	ENSG00000231621.1	AC013264.2	9.49	9.88e-20	1.15e-16	0.41	0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298604	chr2:197197991~197199273:+
KIRC	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-9.49	9.9e-20	1.16e-16	-0.48	-0.39	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
KIRC	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	9.49	9.97e-20	1.16e-16	0.37	0.39	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
KIRC	cis	rs2749592	1	rs2749592	ENSG00000151963.4	RP11-775A3.1	-9.49	1e-19	1.17e-16	-0.5	-0.39	Age-related hearing impairment (SNP x SNP interaction);	chr10:37969914	chr10:37883594~37884109:+
KIRC	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-9.49	1.01e-19	1.17e-16	-0.31	-0.39	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
KIRC	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	9.49	1.01e-19	1.18e-16	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
KIRC	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	9.49	1.01e-19	1.18e-16	0.38	0.39	Height;	chr4:55566291	chr4:55363971~55395847:-
KIRC	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.49	1.01e-19	1.18e-16	-0.39	-0.39	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
KIRC	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.49	1.01e-19	1.18e-16	-0.39	-0.39	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
KIRC	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-9.48	1.02e-19	1.19e-16	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
KIRC	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	9.48	1.02e-19	1.19e-16	0.61	0.39	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
KIRC	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-9.48	1.02e-19	1.19e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
KIRC	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-9.48	1.02e-19	1.19e-16	-0.39	-0.39	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
KIRC	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	9.48	1.02e-19	1.19e-16	0.45	0.39	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
KIRC	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	9.48	1.03e-19	1.2e-16	0.45	0.39	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
KIRC	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	9.48	1.03e-19	1.2e-16	0.58	0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
KIRC	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	9.48	1.04e-19	1.21e-16	0.44	0.39	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
KIRC	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-9.48	1.05e-19	1.22e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-9.48	1.05e-19	1.22e-16	-0.49	-0.39	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
KIRC	cis	rs10129255	0.646	rs55995061	ENSG00000211970.3	IGHV4-61	-9.48	1.05e-19	1.23e-16	-0.33	-0.39	Kawasaki disease;	chr14:106799309	chr14:106639119~106639657:-
KIRC	cis	rs919433	1	rs2195510	ENSG00000231621.1	AC013264.2	9.48	1.06e-19	1.24e-16	0.4	0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197296471	chr2:197197991~197199273:+
KIRC	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-9.48	1.07e-19	1.25e-16	-0.42	-0.39	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
KIRC	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	9.48	1.07e-19	1.25e-16	0.5	0.39	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-9.48	1.07e-19	1.25e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-9.48	1.07e-19	1.25e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
KIRC	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	9.48	1.07e-19	1.25e-16	0.52	0.39	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
KIRC	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	9.48	1.07e-19	1.25e-16	0.52	0.39	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
KIRC	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-9.48	1.07e-19	1.25e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
KIRC	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-9.48	1.08e-19	1.25e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-9.48	1.08e-19	1.26e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
KIRC	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-9.48	1.09e-19	1.27e-16	-0.46	-0.39	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
KIRC	cis	rs9457247	0.565	rs12178491	ENSG00000265828.1	MIR3939	-9.48	1.1e-19	1.28e-16	-0.45	-0.39	Crohn's disease;	chr6:167098986	chr6:166997807~166997912:-
KIRC	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-9.47	1.11e-19	1.29e-16	-0.54	-0.39	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
KIRC	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	9.47	1.11e-19	1.29e-16	0.4	0.39	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
KIRC	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-9.47	1.11e-19	1.29e-16	-0.32	-0.39	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000250696.4	RP11-704M14.1	9.47	1.11e-19	1.29e-16	0.41	0.39	Obesity-related traits;	chr4:69070955	chr4:69182100~69216766:+
KIRC	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	9.47	1.11e-19	1.29e-16	0.39	0.39	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
KIRC	cis	rs904251	0.861	rs1776456	ENSG00000227920.2	RP1-153P14.5	-9.47	1.11e-19	1.29e-16	-0.45	-0.39	Cognitive performance;	chr6:37516922	chr6:37545145~37550860:+
KIRC	cis	rs1005277	0.54	rs1987431	ENSG00000151963.4	RP11-775A3.1	-9.47	1.12e-19	1.31e-16	-0.44	-0.39	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:37883594~37884109:+
KIRC	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	9.47	1.13e-19	1.31e-16	0.75	0.39	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
KIRC	cis	rs1005277	0.522	rs9417256	ENSG00000151963.4	RP11-775A3.1	-9.47	1.13e-19	1.31e-16	-0.44	-0.39	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:37883594~37884109:+
KIRC	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	9.47	1.13e-19	1.32e-16	0.56	0.39	Height;	chr6:109373851	chr6:109382795~109383666:+
KIRC	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	9.47	1.14e-19	1.32e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
KIRC	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	9.47	1.14e-19	1.33e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
KIRC	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	9.47	1.14e-19	1.33e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
KIRC	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-9.47	1.15e-19	1.33e-16	-0.45	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
KIRC	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-9.47	1.15e-19	1.34e-16	-0.39	-0.39	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	9.47	1.16e-19	1.34e-16	0.39	0.39	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	9.47	1.16e-19	1.34e-16	0.39	0.39	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
KIRC	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-9.47	1.16e-19	1.34e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-9.47	1.16e-19	1.34e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
KIRC	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	9.47	1.16e-19	1.35e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
KIRC	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	9.47	1.17e-19	1.36e-16	0.45	0.39	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
KIRC	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	9.47	1.17e-19	1.36e-16	0.45	0.39	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
KIRC	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-9.47	1.17e-19	1.36e-16	-0.48	-0.39	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
KIRC	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-9.47	1.18e-19	1.37e-16	-0.41	-0.39	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
KIRC	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	9.47	1.19e-19	1.38e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	9.47	1.19e-19	1.38e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	9.47	1.19e-19	1.38e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
KIRC	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-9.47	1.19e-19	1.38e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
KIRC	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	9.47	1.19e-19	1.38e-16	0.6	0.39	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
KIRC	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	9.46	1.2e-19	1.39e-16	0.39	0.39	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
KIRC	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	9.46	1.2e-19	1.39e-16	0.49	0.39	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
KIRC	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	9.46	1.22e-19	1.41e-16	0.45	0.39	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
KIRC	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-9.46	1.22e-19	1.41e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
KIRC	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-9.46	1.22e-19	1.41e-16	-0.52	-0.39	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
KIRC	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	9.46	1.22e-19	1.41e-16	0.45	0.39	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	9.46	1.22e-19	1.41e-16	0.45	0.39	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
KIRC	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-9.46	1.22e-19	1.42e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-9.46	1.22e-19	1.42e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-9.46	1.22e-19	1.42e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
KIRC	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-9.46	1.22e-19	1.42e-16	-0.41	-0.39	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
KIRC	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-9.46	1.23e-19	1.42e-16	-0.48	-0.39	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
KIRC	cis	rs2749592	0.55	rs7081464	ENSG00000151963.4	RP11-775A3.1	9.46	1.24e-19	1.44e-16	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:37883594~37884109:+
KIRC	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-9.46	1.24e-19	1.44e-16	-0.32	-0.39	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
KIRC	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	9.46	1.24e-19	1.44e-16	0.45	0.39	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
KIRC	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	9.46	1.24e-19	1.44e-16	0.39	0.39	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	9.46	1.24e-19	1.44e-16	0.39	0.39	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
KIRC	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-9.46	1.26e-19	1.46e-16	-0.44	-0.39	Height;	chr11:118737916	chr11:118704607~118750263:+
KIRC	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	9.46	1.28e-19	1.48e-16	0.39	0.39	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-9.46	1.28e-19	1.48e-16	-0.47	-0.39	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
KIRC	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	9.46	1.28e-19	1.48e-16	0.44	0.39	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
KIRC	cis	rs904251	0.797	rs1757181	ENSG00000227920.2	RP1-153P14.5	9.46	1.28e-19	1.49e-16	0.45	0.39	Cognitive performance;	chr6:37517952	chr6:37545145~37550860:+
KIRC	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	9.45	1.29e-19	1.5e-16	0.53	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
KIRC	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	9.45	1.3e-19	1.5e-16	0.29	0.39	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
KIRC	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	9.45	1.3e-19	1.5e-16	0.45	0.39	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
KIRC	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-9.45	1.3e-19	1.51e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
KIRC	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	9.45	1.3e-19	1.51e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
KIRC	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-9.45	1.3e-19	1.51e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-9.45	1.3e-19	1.51e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
KIRC	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	9.45	1.31e-19	1.51e-16	0.48	0.39	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
KIRC	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	9.45	1.31e-19	1.52e-16	0.5	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
KIRC	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	9.45	1.31e-19	1.52e-16	0.49	0.39	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
KIRC	cis	rs904251	0.737	rs914347	ENSG00000227920.2	RP1-153P14.5	-9.45	1.33e-19	1.54e-16	-0.46	-0.39	Cognitive performance;	chr6:37517194	chr6:37545145~37550860:+
KIRC	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	9.45	1.34e-19	1.55e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
KIRC	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	9.45	1.35e-19	1.57e-16	0.39	0.39	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	9.45	1.35e-19	1.57e-16	0.39	0.39	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-9.45	1.36e-19	1.57e-16	-0.39	-0.39	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
KIRC	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-9.45	1.36e-19	1.57e-16	-0.39	-0.39	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000250696.4	RP11-704M14.1	9.45	1.36e-19	1.57e-16	0.41	0.39	Obesity-related traits;	chr4:69069219	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000250696.4	RP11-704M14.1	9.45	1.36e-19	1.57e-16	0.41	0.39	Obesity-related traits;	chr4:69069397	chr4:69182100~69216766:+
KIRC	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-9.45	1.37e-19	1.58e-16	-0.61	-0.39	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
KIRC	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	9.45	1.37e-19	1.59e-16	0.41	0.39	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
KIRC	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	9.45	1.38e-19	1.6e-16	0.44	0.39	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
KIRC	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-9.45	1.39e-19	1.61e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
KIRC	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	9.45	1.39e-19	1.61e-16	0.38	0.39	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	9.45	1.4e-19	1.61e-16	0.39	0.39	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
KIRC	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	9.44	1.41e-19	1.63e-16	0.43	0.39	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
KIRC	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	9.44	1.42e-19	1.64e-16	0.38	0.39	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
KIRC	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	9.44	1.42e-19	1.64e-16	0.46	0.39	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
KIRC	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	9.44	1.43e-19	1.65e-16	0.37	0.39	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
KIRC	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-9.44	1.43e-19	1.66e-16	-0.39	-0.39	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
KIRC	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-9.44	1.44e-19	1.66e-16	-0.5	-0.39	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
KIRC	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-9.44	1.44e-19	1.66e-16	-0.54	-0.39	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
KIRC	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	9.44	1.45e-19	1.67e-16	0.5	0.39	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
KIRC	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-9.44	1.45e-19	1.68e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-9.44	1.45e-19	1.68e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-9.44	1.45e-19	1.68e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-9.44	1.45e-19	1.68e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-9.44	1.45e-19	1.68e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
KIRC	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-9.44	1.45e-19	1.68e-16	-0.53	-0.39	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000250919.1	RP11-813N20.3	-9.44	1.45e-19	1.68e-16	-0.42	-0.39	Obesity-related traits;	chr4:69069866	chr4:69027831~69044578:+
KIRC	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	9.44	1.46e-19	1.68e-16	0.52	0.39	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
KIRC	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	9.44	1.46e-19	1.68e-16	0.33	0.39	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
KIRC	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	9.44	1.46e-19	1.69e-16	0.39	0.39	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
KIRC	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-9.44	1.46e-19	1.69e-16	-0.33	-0.39	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
KIRC	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-9.44	1.47e-19	1.7e-16	-0.39	-0.39	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
KIRC	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-9.44	1.48e-19	1.7e-16	-0.45	-0.39	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
KIRC	cis	rs9457247	0.565	rs2239824	ENSG00000265828.1	MIR3939	-9.44	1.51e-19	1.74e-16	-0.45	-0.39	Crohn's disease;	chr6:167098311	chr6:166997807~166997912:-
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000250696.4	RP11-704M14.1	9.44	1.51e-19	1.74e-16	0.41	0.39	Obesity-related traits;	chr4:69074144	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000250696.4	RP11-704M14.1	9.44	1.51e-19	1.74e-16	0.41	0.39	Obesity-related traits;	chr4:69074157	chr4:69182100~69216766:+
KIRC	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-9.44	1.52e-19	1.75e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
KIRC	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	9.44	1.52e-19	1.75e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
KIRC	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-9.43	1.53e-19	1.76e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-9.43	1.53e-19	1.76e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-9.43	1.53e-19	1.76e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-9.43	1.53e-19	1.76e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-9.43	1.53e-19	1.76e-16	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
KIRC	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	9.43	1.54e-19	1.78e-16	0.52	0.39	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
KIRC	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-9.43	1.55e-19	1.78e-16	-0.4	-0.39	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
KIRC	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-9.43	1.55e-19	1.78e-16	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
KIRC	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-9.43	1.56e-19	1.79e-16	-0.41	-0.39	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
KIRC	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-9.43	1.56e-19	1.8e-16	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
KIRC	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-9.43	1.57e-19	1.8e-16	-0.49	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
KIRC	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	9.43	1.57e-19	1.81e-16	0.38	0.39	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
KIRC	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-9.43	1.57e-19	1.81e-16	-0.69	-0.39	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
KIRC	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-9.43	1.58e-19	1.81e-16	-0.32	-0.39	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
KIRC	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.43	1.58e-19	1.81e-16	-0.32	-0.39	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
KIRC	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-9.43	1.59e-19	1.82e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
KIRC	cis	rs919433	0.963	rs1366837	ENSG00000231621.1	AC013264.2	9.43	1.59e-19	1.83e-16	0.4	0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197295777	chr2:197197991~197199273:+
KIRC	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-9.43	1.59e-19	1.83e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
KIRC	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	9.43	1.59e-19	1.83e-16	0.48	0.39	Depression;	chr6:28428413	chr6:28176188~28176674:+
KIRC	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-9.43	1.6e-19	1.84e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-9.43	1.61e-19	1.85e-16	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
KIRC	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-9.43	1.61e-19	1.85e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-9.43	1.61e-19	1.85e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
KIRC	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9.43	1.61e-19	1.85e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
KIRC	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	9.43	1.61e-19	1.85e-16	0.75	0.39	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
KIRC	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-9.43	1.62e-19	1.86e-16	-0.56	-0.39	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
KIRC	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	9.43	1.62e-19	1.86e-16	0.39	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
KIRC	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	9.43	1.63e-19	1.88e-16	0.46	0.39	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
KIRC	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	9.43	1.64e-19	1.88e-16	0.44	0.39	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	9.43	1.64e-19	1.88e-16	0.44	0.39	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
KIRC	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	9.43	1.64e-19	1.89e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
KIRC	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	9.43	1.65e-19	1.89e-16	0.6	0.39	Height;	chr6:109564272	chr6:109382795~109383666:+
KIRC	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-9.42	1.65e-19	1.9e-16	-0.43	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
KIRC	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	9.42	1.65e-19	1.9e-16	0.56	0.39	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
KIRC	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-9.42	1.67e-19	1.91e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
KIRC	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	9.42	1.68e-19	1.92e-16	0.43	0.39	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
KIRC	cis	rs9847710	1	rs12488768	ENSG00000280417.1	RP11-5O17.1	9.42	1.68e-19	1.93e-16	0.45	0.39	Ulcerative colitis;	chr3:53052218	chr3:53046166~53048122:+
KIRC	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-9.42	1.69e-19	1.94e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-9.42	1.69e-19	1.94e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
KIRC	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	9.42	1.69e-19	1.94e-16	0.37	0.39	Height;	chr4:55361200	chr4:55363971~55395847:-
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000250919.1	RP11-813N20.3	-9.42	1.69e-19	1.94e-16	-0.42	-0.39	Obesity-related traits;	chr4:69072070	chr4:69027831~69044578:+
KIRC	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.42	1.69e-19	1.94e-16	-0.44	-0.39	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
KIRC	cis	rs4356975	0.795	rs4694599	ENSG00000250919.1	RP11-813N20.3	-9.42	1.69e-19	1.94e-16	-0.41	-0.39	Obesity-related traits;	chr4:69070858	chr4:69027831~69044578:+
KIRC	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-9.42	1.69e-19	1.94e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
KIRC	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-9.42	1.7e-19	1.95e-16	-0.51	-0.39	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
KIRC	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-9.42	1.7e-19	1.95e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
KIRC	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	9.42	1.7e-19	1.95e-16	0.43	0.39	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
KIRC	cis	rs1823913	1	rs13019004	ENSG00000227542.1	AC092614.2	9.42	1.72e-19	1.97e-16	0.37	0.39	Obesity-related traits;	chr2:191245493	chr2:191229165~191246172:-
KIRC	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-9.42	1.72e-19	1.97e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
KIRC	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-9.42	1.74e-19	2e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
KIRC	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	9.42	1.74e-19	2e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000250696.4	RP11-704M14.1	9.42	1.75e-19	2.01e-16	0.41	0.39	Obesity-related traits;	chr4:69069614	chr4:69182100~69216766:+
KIRC	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	9.42	1.75e-19	2.01e-16	0.48	0.39	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
KIRC	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-9.42	1.76e-19	2.01e-16	-0.53	-0.39	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
KIRC	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-9.42	1.76e-19	2.01e-16	-0.44	-0.39	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
KIRC	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	9.42	1.76e-19	2.01e-16	0.48	0.39	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
KIRC	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-9.42	1.76e-19	2.02e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-9.42	1.76e-19	2.02e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-9.42	1.76e-19	2.02e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-9.42	1.76e-19	2.02e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
KIRC	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-9.42	1.77e-19	2.02e-16	-0.37	-0.39	Asthma;	chr2:102438096	chr2:102438713~102440475:+
KIRC	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-9.42	1.77e-19	2.03e-16	-0.45	-0.39	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
KIRC	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-9.42	1.78e-19	2.03e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-9.42	1.78e-19	2.03e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
KIRC	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-9.42	1.78e-19	2.03e-16	-0.5	-0.39	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
KIRC	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	9.42	1.78e-19	2.04e-16	0.47	0.39	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
KIRC	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	9.42	1.78e-19	2.04e-16	0.36	0.39	Height;	chr4:55387515	chr4:55363971~55395847:-
KIRC	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-9.42	1.79e-19	2.04e-16	-0.41	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
KIRC	cis	rs2302464	1	rs16892272	ENSG00000214846.4	RP11-115L11.1	9.42	1.79e-19	2.05e-16	0.95	0.39	Cerebrospinal fluid biomarker levels;	chr4:15726456	chr4:15730962~15731627:-
KIRC	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	9.41	1.79e-19	2.05e-16	0.38	0.39	Height;	chr4:55457922	chr4:55363971~55395847:-
KIRC	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	9.41	1.79e-19	2.05e-16	0.39	0.39	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
KIRC	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	9.41	1.8e-19	2.05e-16	0.46	0.39	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	9.41	1.8e-19	2.05e-16	0.46	0.39	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	9.41	1.8e-19	2.05e-16	0.46	0.39	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	9.41	1.8e-19	2.05e-16	0.46	0.39	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
KIRC	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-9.41	1.8e-19	2.06e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
KIRC	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-9.41	1.82e-19	2.08e-16	-0.5	-0.39	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000250919.1	RP11-813N20.3	-9.41	1.83e-19	2.09e-16	-0.42	-0.39	Obesity-related traits;	chr4:69071215	chr4:69027831~69044578:+
KIRC	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	9.41	1.83e-19	2.09e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
KIRC	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	9.41	1.87e-19	2.14e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
KIRC	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-9.41	1.87e-19	2.14e-16	-0.41	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
KIRC	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-9.41	1.88e-19	2.14e-16	-0.39	-0.39	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
KIRC	cis	rs4356975	0.697	rs66666893	ENSG00000248763.2	RP13-644M16.5	-9.41	1.89e-19	2.16e-16	-0.49	-0.39	Obesity-related traits;	chr4:69133393	chr4:69066395~69069888:+
KIRC	cis	rs2749592	0.55	rs7917262	ENSG00000151963.4	RP11-775A3.1	9.41	1.9e-19	2.17e-16	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:37883594~37884109:+
KIRC	cis	rs4273100	1	rs4924986	ENSG00000262319.1	CTC-457L16.2	9.41	1.91e-19	2.18e-16	0.54	0.39	Schizophrenia;	chr17:19339154	chr17:19141017~19143689:-
KIRC	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	9.41	1.91e-19	2.18e-16	0.44	0.39	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69071281	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69071328	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69071698	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072135	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072143	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072154	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072229	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072402	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072745	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69072777	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69073025	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69073381	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000250919.1	RP11-813N20.3	-9.41	1.93e-19	2.2e-16	-0.41	-0.39	Obesity-related traits;	chr4:69073429	chr4:69027831~69044578:+
KIRC	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-9.41	1.94e-19	2.21e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000250696.4	RP11-704M14.1	9.4	1.96e-19	2.23e-16	0.41	0.39	Obesity-related traits;	chr4:69069420	chr4:69182100~69216766:+
KIRC	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	9.4	1.96e-19	2.24e-16	0.4	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
KIRC	cis	rs9457247	0.565	rs2239823	ENSG00000265828.1	MIR3939	-9.4	1.96e-19	2.24e-16	-0.45	-0.39	Crohn's disease;	chr6:167098643	chr6:166997807~166997912:-
KIRC	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-9.4	1.96e-19	2.24e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
KIRC	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	9.4	1.97e-19	2.24e-16	0.44	0.39	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
KIRC	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-9.4	1.97e-19	2.24e-16	-0.57	-0.39	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
KIRC	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	9.4	1.98e-19	2.25e-16	0.56	0.39	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
KIRC	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	9.4	1.98e-19	2.26e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
KIRC	cis	rs904251	0.861	rs914349	ENSG00000227920.2	RP1-153P14.5	-9.4	1.98e-19	2.26e-16	-0.45	-0.39	Cognitive performance;	chr6:37516939	chr6:37545145~37550860:+
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000250919.1	RP11-813N20.3	-9.4	1.98e-19	2.26e-16	-0.42	-0.39	Obesity-related traits;	chr4:69069420	chr4:69027831~69044578:+
KIRC	cis	rs4380275	0.965	rs12621177	ENSG00000223751.1	AC116609.2	9.4	1.99e-19	2.27e-16	0.49	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:742488~747767:+
KIRC	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-9.4	1.99e-19	2.27e-16	-0.44	-0.39	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
KIRC	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-9.4	2.01e-19	2.29e-16	-0.52	-0.39	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
KIRC	cis	rs950776	0.518	rs12914694	ENSG00000261762.1	RP11-650L12.2	9.4	2.03e-19	2.31e-16	0.51	0.39	Sudden cardiac arrest;	chr15:78522102	chr15:78589123~78591276:-
KIRC	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-9.4	2.04e-19	2.32e-16	-0.43	-0.39	Height;	chr11:118781100	chr11:118704607~118750263:+
KIRC	cis	rs11079159	0.606	rs4239193	ENSG00000263096.1	RP11-515O17.2	9.4	2.04e-19	2.32e-16	0.49	0.39	QRS duration;	chr17:55299163	chr17:55271504~55273653:-
KIRC	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	9.4	2.07e-19	2.36e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
KIRC	cis	rs2698530	0.664	rs2555434	ENSG00000225889.6	AC074289.1	-9.4	2.07e-19	2.36e-16	-0.4	-0.39	Iron status biomarkers;	chr2:64225156	chr2:64143239~64252859:+
KIRC	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-9.4	2.08e-19	2.36e-16	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
KIRC	cis	rs904251	0.523	rs9369005	ENSG00000227920.2	RP1-153P14.5	-9.4	2.09e-19	2.37e-16	-0.43	-0.39	Cognitive performance;	chr6:37515333	chr6:37545145~37550860:+
KIRC	cis	rs79040073	0.637	rs111375880	ENSG00000259531.2	RP11-295H24.3	9.4	2.1e-19	2.38e-16	0.52	0.39	Lung cancer in ever smokers;	chr15:49120197	chr15:49365124~49366685:-
KIRC	cis	rs4356975	0.83	rs7666894	ENSG00000250919.1	RP11-813N20.3	-9.4	2.1e-19	2.39e-16	-0.41	-0.39	Obesity-related traits;	chr4:69078780	chr4:69027831~69044578:+
KIRC	cis	rs1823913	0.927	rs35092718	ENSG00000227542.1	AC092614.2	9.4	2.1e-19	2.39e-16	0.36	0.39	Obesity-related traits;	chr2:191243882	chr2:191229165~191246172:-
KIRC	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-9.4	2.1e-19	2.39e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
KIRC	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-9.39	2.11e-19	2.4e-16	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
KIRC	cis	rs2749592	0.55	rs9733309	ENSG00000151963.4	RP11-775A3.1	9.39	2.12e-19	2.41e-16	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:37883594~37884109:+
KIRC	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	9.39	2.12e-19	2.41e-16	0.37	0.39	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
KIRC	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-9.39	2.13e-19	2.42e-16	-0.5	-0.39	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000250696.4	RP11-704M14.1	9.39	2.13e-19	2.42e-16	0.41	0.39	Obesity-related traits;	chr4:69068460	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000250696.4	RP11-704M14.1	9.39	2.13e-19	2.42e-16	0.41	0.39	Obesity-related traits;	chr4:69068643	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000250696.4	RP11-704M14.1	9.39	2.13e-19	2.42e-16	0.41	0.39	Obesity-related traits;	chr4:69068755	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000250696.4	RP11-704M14.1	9.39	2.13e-19	2.42e-16	0.41	0.39	Obesity-related traits;	chr4:69069090	chr4:69182100~69216766:+
KIRC	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-9.39	2.14e-19	2.43e-16	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
KIRC	cis	rs4380275	1	rs4854376	ENSG00000223751.1	AC116609.2	9.39	2.14e-19	2.44e-16	0.49	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:742488~747767:+
KIRC	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-9.39	2.16e-19	2.45e-16	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
KIRC	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-9.39	2.16e-19	2.46e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
KIRC	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	9.39	2.16e-19	2.46e-16	0.38	0.39	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
KIRC	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	9.39	2.16e-19	2.46e-16	0.4	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
KIRC	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	9.39	2.17e-19	2.46e-16	0.48	0.39	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
KIRC	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	9.39	2.17e-19	2.46e-16	0.39	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
KIRC	cis	rs4273100	0.834	rs59415593	ENSG00000262319.1	CTC-457L16.2	-9.39	2.17e-19	2.47e-16	-0.55	-0.39	Schizophrenia;	chr17:19319911	chr17:19141017~19143689:-
KIRC	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-9.39	2.17e-19	2.47e-16	-0.52	-0.39	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-9.39	2.17e-19	2.47e-16	-0.52	-0.39	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
KIRC	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-9.39	2.18e-19	2.47e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
KIRC	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	9.39	2.18e-19	2.47e-16	0.47	0.39	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000250919.1	RP11-813N20.3	-9.39	2.19e-19	2.48e-16	-0.41	-0.39	Obesity-related traits;	chr4:69073715	chr4:69027831~69044578:+
KIRC	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	9.39	2.19e-19	2.49e-16	0.4	0.39	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
KIRC	cis	rs2658782	0.704	rs2658766	ENSG00000279684.1	RP11-755E23.2	-9.39	2.2e-19	2.49e-16	-0.57	-0.39	Pulmonary function decline;	chr11:93499063	chr11:93286629~93288903:-
KIRC	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-9.39	2.2e-19	2.5e-16	-0.44	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
KIRC	cis	rs9847710	1	rs13088455	ENSG00000280417.1	RP11-5O17.1	9.39	2.2e-19	2.5e-16	0.45	0.39	Ulcerative colitis;	chr3:53053466	chr3:53046166~53048122:+
KIRC	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	9.39	2.22e-19	2.51e-16	0.4	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
KIRC	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-9.39	2.23e-19	2.53e-16	-0.36	-0.39	Height;	chr3:53074760	chr3:53064283~53065091:-
KIRC	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-9.39	2.24e-19	2.54e-16	-0.52	-0.39	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-9.39	2.24e-19	2.54e-16	-0.52	-0.39	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
KIRC	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-9.39	2.24e-19	2.54e-16	-0.49	-0.39	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
KIRC	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-9.39	2.24e-19	2.54e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
KIRC	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-9.39	2.26e-19	2.56e-16	-0.39	-0.39	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
KIRC	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-9.39	2.26e-19	2.56e-16	-0.5	-0.39	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
KIRC	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	9.39	2.27e-19	2.57e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
KIRC	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-9.38	2.28e-19	2.58e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
KIRC	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	9.38	2.29e-19	2.59e-16	0.52	0.39	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
KIRC	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	9.38	2.29e-19	2.59e-16	0.49	0.39	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
KIRC	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	9.38	2.29e-19	2.6e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
KIRC	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-9.38	2.3e-19	2.61e-16	-0.44	-0.39	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
KIRC	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-9.38	2.3e-19	2.61e-16	-0.44	-0.39	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
KIRC	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-9.38	2.31e-19	2.61e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-9.38	2.31e-19	2.61e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
KIRC	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	9.38	2.31e-19	2.61e-16	0.56	0.39	Height;	chr6:109712525	chr6:109382795~109383666:+
KIRC	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-9.38	2.31e-19	2.61e-16	-0.44	-0.39	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
KIRC	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-9.38	2.31e-19	2.61e-16	-0.33	-0.39	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
KIRC	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-9.38	2.31e-19	2.62e-16	-0.36	-0.39	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
KIRC	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	9.38	2.33e-19	2.64e-16	0.55	0.39	Height;	chr6:109351533	chr6:109382795~109383666:+
KIRC	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	9.38	2.34e-19	2.65e-16	0.46	0.39	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
KIRC	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-9.38	2.35e-19	2.67e-16	-0.45	-0.39	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
KIRC	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	9.38	2.38e-19	2.69e-16	0.48	0.39	Depression;	chr6:28431469	chr6:28176188~28176674:+
KIRC	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-9.38	2.39e-19	2.7e-16	-0.52	-0.39	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
KIRC	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	9.38	2.39e-19	2.7e-16	0.55	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
KIRC	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	9.38	2.41e-19	2.73e-16	0.5	0.39	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
KIRC	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	9.38	2.41e-19	2.73e-16	0.43	0.39	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	9.38	2.41e-19	2.73e-16	0.43	0.39	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
KIRC	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-9.38	2.41e-19	2.73e-16	-0.46	-0.39	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
KIRC	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-9.38	2.42e-19	2.73e-16	-0.45	-0.39	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
KIRC	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-9.38	2.42e-19	2.74e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
KIRC	cis	rs1823913	0.963	rs4146105	ENSG00000227542.1	AC092614.2	9.38	2.42e-19	2.74e-16	0.37	0.39	Obesity-related traits;	chr2:191245240	chr2:191229165~191246172:-
KIRC	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-9.38	2.42e-19	2.74e-16	-0.47	-0.39	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
KIRC	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	9.38	2.46e-19	2.78e-16	0.47	0.39	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
KIRC	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	9.38	2.46e-19	2.79e-16	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
KIRC	cis	rs4356975	0.83	rs6600868	ENSG00000250919.1	RP11-813N20.3	-9.38	2.47e-19	2.79e-16	-0.4	-0.39	Obesity-related traits;	chr4:69075923	chr4:69027831~69044578:+
KIRC	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	9.37	2.47e-19	2.79e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
KIRC	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	9.37	2.47e-19	2.8e-16	0.43	0.39	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
KIRC	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-9.37	2.48e-19	2.8e-16	-0.39	-0.39	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
KIRC	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-9.37	2.49e-19	2.81e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
KIRC	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-9.37	2.49e-19	2.81e-16	-0.39	-0.39	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-9.37	2.49e-19	2.81e-16	-0.39	-0.39	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-9.37	2.49e-19	2.81e-16	-0.39	-0.39	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
KIRC	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	9.37	2.5e-19	2.83e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
KIRC	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-9.37	2.52e-19	2.85e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
KIRC	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-9.37	2.52e-19	2.85e-16	-0.37	-0.39	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
KIRC	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-9.37	2.6e-19	2.93e-16	-0.51	-0.39	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
KIRC	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-9.37	2.61e-19	2.94e-16	-0.5	-0.39	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
KIRC	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-9.37	2.62e-19	2.95e-16	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
KIRC	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-9.37	2.62e-19	2.95e-16	-0.49	-0.39	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000250919.1	RP11-813N20.3	-9.37	2.62e-19	2.95e-16	-0.42	-0.39	Obesity-related traits;	chr4:69069219	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000250919.1	RP11-813N20.3	-9.37	2.62e-19	2.95e-16	-0.42	-0.39	Obesity-related traits;	chr4:69069397	chr4:69027831~69044578:+
KIRC	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	9.37	2.62e-19	2.96e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
KIRC	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	9.37	2.63e-19	2.97e-16	0.4	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
KIRC	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-9.37	2.64e-19	2.97e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
KIRC	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-9.37	2.64e-19	2.98e-16	-0.52	-0.39	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
KIRC	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.37	2.65e-19	2.99e-16	0.4	0.39	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
KIRC	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-9.37	2.65e-19	2.99e-16	-0.33	-0.39	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
KIRC	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-9.37	2.66e-19	3e-16	-0.51	-0.39	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
KIRC	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-9.36	2.68e-19	3.02e-16	-0.57	-0.39	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
KIRC	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-9.36	2.68e-19	3.02e-16	-0.57	-0.39	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
KIRC	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-9.36	2.68e-19	3.02e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
KIRC	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-9.36	2.68e-19	3.02e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
KIRC	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-9.36	2.68e-19	3.02e-16	-0.52	-0.39	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
KIRC	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	9.36	2.69e-19	3.03e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
KIRC	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	9.36	2.69e-19	3.03e-16	0.51	0.39	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
KIRC	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	9.36	2.71e-19	3.05e-16	0.37	0.39	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
KIRC	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-9.36	2.72e-19	3.06e-16	-0.33	-0.39	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
KIRC	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	9.36	2.73e-19	3.07e-16	0.44	0.39	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
KIRC	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-9.36	2.76e-19	3.1e-16	-0.5	-0.39	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
KIRC	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	9.36	2.77e-19	3.12e-16	0.61	0.39	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
KIRC	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	9.36	2.77e-19	3.12e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
KIRC	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	9.36	2.78e-19	3.12e-16	0.56	0.39	Height;	chr6:109372084	chr6:109382795~109383666:+
KIRC	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-9.36	2.78e-19	3.12e-16	-0.52	-0.39	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
KIRC	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-9.36	2.78e-19	3.13e-16	-0.43	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
KIRC	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-9.36	2.78e-19	3.13e-16	-0.52	-0.39	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
KIRC	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-9.36	2.79e-19	3.13e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
KIRC	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	9.36	2.79e-19	3.14e-16	0.57	0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
KIRC	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-9.36	2.79e-19	3.14e-16	-0.5	-0.39	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
KIRC	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	9.36	2.79e-19	3.14e-16	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
KIRC	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	9.36	2.81e-19	3.16e-16	0.38	0.39	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
KIRC	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-9.36	2.81e-19	3.16e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
KIRC	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-9.36	2.82e-19	3.17e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
KIRC	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	9.36	2.82e-19	3.17e-16	0.63	0.39	Height;	chr6:109479488	chr6:109382795~109383666:+
KIRC	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-9.36	2.85e-19	3.2e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
KIRC	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	9.36	2.88e-19	3.23e-16	0.48	0.39	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
KIRC	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	9.35	2.9e-19	3.26e-16	0.56	0.39	Height;	chr6:109375848	chr6:109382795~109383666:+
KIRC	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	9.35	2.9e-19	3.26e-16	0.46	0.39	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
KIRC	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	9.35	2.91e-19	3.27e-16	0.45	0.39	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
KIRC	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-9.35	2.91e-19	3.27e-16	-0.39	-0.39	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
KIRC	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-9.35	2.92e-19	3.28e-16	-0.41	-0.39	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
KIRC	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-9.35	2.93e-19	3.29e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-9.35	2.93e-19	3.29e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-9.35	2.93e-19	3.29e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-9.35	2.93e-19	3.29e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-9.35	2.93e-19	3.29e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
KIRC	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-9.35	2.93e-19	3.29e-16	-0.38	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
KIRC	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-9.35	2.94e-19	3.3e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
KIRC	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-9.35	2.94e-19	3.31e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
KIRC	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-9.35	2.96e-19	3.32e-16	-0.39	-0.39	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
KIRC	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	9.35	2.97e-19	3.33e-16	0.61	0.39	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
KIRC	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-9.35	2.98e-19	3.34e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-9.35	2.98e-19	3.34e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-9.35	2.98e-19	3.34e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-9.35	2.98e-19	3.34e-16	-0.38	-0.39	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
KIRC	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-9.35	2.98e-19	3.34e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
KIRC	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-9.35	2.99e-19	3.35e-16	-0.38	-0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
KIRC	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-9.35	3.01e-19	3.38e-16	-0.45	-0.39	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
KIRC	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	9.35	3.02e-19	3.39e-16	0.86	0.39	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
KIRC	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	9.35	3.04e-19	3.41e-16	0.37	0.39	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
KIRC	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	9.35	3.04e-19	3.41e-16	0.37	0.39	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
KIRC	cis	rs950027	0.967	rs2486280	ENSG00000259520.4	CTD-2651B20.3	-9.35	3.04e-19	3.41e-16	-0.48	-0.39	Response to fenofibrate (adiponectin levels);	chr15:45459691	chr15:45251580~45279251:-
KIRC	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-9.35	3.05e-19	3.42e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
KIRC	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	9.35	3.06e-19	3.43e-16	0.36	0.39	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
KIRC	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-9.35	3.12e-19	3.49e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
KIRC	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	9.35	3.13e-19	3.51e-16	0.51	0.39	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
KIRC	cis	rs2749592	0.505	rs7915670	ENSG00000151963.4	RP11-775A3.1	9.35	3.13e-19	3.51e-16	0.44	0.39	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:37883594~37884109:+
KIRC	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	9.35	3.13e-19	3.51e-16	0.48	0.39	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
KIRC	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-9.35	3.14e-19	3.52e-16	-0.52	-0.39	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
KIRC	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-9.34	3.14e-19	3.52e-16	-0.51	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
KIRC	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	9.34	3.15e-19	3.53e-16	0.51	0.39	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
KIRC	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-9.34	3.17e-19	3.55e-16	-0.44	-0.39	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
KIRC	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	9.34	3.18e-19	3.56e-16	0.48	0.39	Depression;	chr6:28430971	chr6:28176188~28176674:+
KIRC	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-9.34	3.21e-19	3.59e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-9.34	3.21e-19	3.59e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
KIRC	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	9.34	3.22e-19	3.61e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
KIRC	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	9.34	3.24e-19	3.62e-16	0.51	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
KIRC	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-9.34	3.24e-19	3.63e-16	-0.39	-0.39	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
KIRC	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-9.34	3.24e-19	3.63e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
KIRC	cis	rs6600671	1	rs4844381	ENSG00000227082.1	CH17-437K3.1	-9.34	3.25e-19	3.64e-16	-0.43	-0.39	Hip geometry;	chr1:121443040	chr1:121396754~121463129:+
KIRC	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	9.34	3.26e-19	3.65e-16	0.45	0.39	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
KIRC	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-9.34	3.28e-19	3.66e-16	-0.41	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
KIRC	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	9.34	3.28e-19	3.67e-16	0.43	0.39	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
KIRC	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-9.34	3.29e-19	3.69e-16	-0.51	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
KIRC	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-9.34	3.31e-19	3.7e-16	-0.49	-0.39	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
KIRC	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-9.34	3.33e-19	3.73e-16	-0.34	-0.39	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
KIRC	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	9.34	3.33e-19	3.73e-16	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
KIRC	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-9.34	3.34e-19	3.73e-16	-0.45	-0.39	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
KIRC	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-9.34	3.34e-19	3.73e-16	-0.52	-0.39	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
KIRC	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-9.34	3.34e-19	3.74e-16	-0.43	-0.39	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
KIRC	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	9.34	3.37e-19	3.76e-16	0.39	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
KIRC	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-9.34	3.37e-19	3.77e-16	-0.51	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
KIRC	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	9.34	3.38e-19	3.77e-16	0.56	0.39	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
KIRC	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	9.34	3.38e-19	3.77e-16	0.56	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
KIRC	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	9.34	3.4e-19	3.8e-16	0.27	0.39	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
KIRC	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-9.34	3.4e-19	3.8e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
KIRC	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	9.34	3.4e-19	3.8e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
KIRC	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	9.34	3.4e-19	3.8e-16	0.51	0.39	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
KIRC	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-9.33	3.44e-19	3.84e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
KIRC	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-9.33	3.44e-19	3.84e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
KIRC	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	9.33	3.48e-19	3.88e-16	0.49	0.39	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
KIRC	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	9.33	3.48e-19	3.89e-16	0.6	0.39	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
KIRC	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-9.33	3.49e-19	3.89e-16	-0.42	-0.39	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
KIRC	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-9.33	3.52e-19	3.92e-16	-0.43	-0.39	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
KIRC	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	9.33	3.52e-19	3.93e-16	0.58	0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
KIRC	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-9.33	3.52e-19	3.93e-16	-0.52	-0.39	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-9.33	3.52e-19	3.93e-16	-0.52	-0.39	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-9.33	3.52e-19	3.93e-16	-0.52	-0.39	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
KIRC	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	9.33	3.53e-19	3.94e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	9.33	3.53e-19	3.94e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	9.33	3.53e-19	3.94e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	9.33	3.53e-19	3.94e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	9.33	3.53e-19	3.94e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
KIRC	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-9.33	3.53e-19	3.94e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
KIRC	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	9.33	3.54e-19	3.95e-16	0.49	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
KIRC	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-9.33	3.54e-19	3.95e-16	-0.41	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000250919.1	RP11-813N20.3	-9.33	3.54e-19	3.95e-16	-0.41	-0.39	Obesity-related traits;	chr4:69068460	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000250919.1	RP11-813N20.3	-9.33	3.54e-19	3.95e-16	-0.41	-0.39	Obesity-related traits;	chr4:69068643	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000250919.1	RP11-813N20.3	-9.33	3.54e-19	3.95e-16	-0.41	-0.39	Obesity-related traits;	chr4:69068755	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000250919.1	RP11-813N20.3	-9.33	3.54e-19	3.95e-16	-0.41	-0.39	Obesity-related traits;	chr4:69069090	chr4:69027831~69044578:+
KIRC	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	9.33	3.55e-19	3.96e-16	0.49	0.39	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
KIRC	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	9.33	3.57e-19	3.98e-16	0.4	0.39	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
KIRC	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	9.33	3.58e-19	3.99e-16	0.4	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
KIRC	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	9.33	3.58e-19	3.99e-16	0.36	0.39	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
KIRC	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	9.33	3.59e-19	4e-16	0.45	0.39	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
KIRC	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-9.33	3.6e-19	4.01e-16	-0.39	-0.39	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
KIRC	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	9.33	3.63e-19	4.04e-16	0.45	0.39	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
KIRC	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-9.33	3.65e-19	4.07e-16	-0.41	-0.39	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
KIRC	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	9.33	3.66e-19	4.07e-16	0.36	0.39	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
KIRC	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-9.33	3.66e-19	4.08e-16	-0.39	-0.39	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
KIRC	cis	rs899997	1	rs7182993	ENSG00000261143.1	ADAMTS7P3	9.33	3.66e-19	4.08e-16	0.46	0.39	Coronary artery disease or large artery stroke;	chr15:78752672	chr15:77976042~77993057:+
KIRC	cis	rs899997	1	rs7182694	ENSG00000261143.1	ADAMTS7P3	9.33	3.66e-19	4.08e-16	0.46	0.39	Coronary artery disease or large artery stroke;	chr15:78752688	chr15:77976042~77993057:+
KIRC	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	9.33	3.67e-19	4.09e-16	0.38	0.39	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
KIRC	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	9.32	3.7e-19	4.12e-16	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
KIRC	cis	rs1823913	1	rs68014803	ENSG00000227542.1	AC092614.2	9.32	3.77e-19	4.19e-16	0.37	0.39	Obesity-related traits;	chr2:191241877	chr2:191229165~191246172:-
KIRC	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	9.32	3.8e-19	4.22e-16	0.56	0.39	Height;	chr6:109713188	chr6:109382795~109383666:+
KIRC	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-9.32	3.85e-19	4.28e-16	-0.39	-0.39	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
KIRC	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	9.32	3.88e-19	4.32e-16	0.36	0.39	Height;	chr4:55451489	chr4:55363971~55395847:-
KIRC	cis	rs79040073	0.637	rs12913966	ENSG00000259531.2	RP11-295H24.3	9.32	3.89e-19	4.33e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49214290	chr15:49365124~49366685:-
KIRC	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-9.32	3.9e-19	4.34e-16	-0.39	-0.39	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
KIRC	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-9.32	3.91e-19	4.35e-16	-0.41	-0.39	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
KIRC	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	9.32	3.92e-19	4.36e-16	0.61	0.39	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
KIRC	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	9.32	3.94e-19	4.38e-16	0.55	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
KIRC	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
KIRC	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-9.32	3.94e-19	4.38e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
KIRC	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-9.32	3.95e-19	4.39e-16	-0.33	-0.39	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
KIRC	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-9.32	3.96e-19	4.4e-16	-0.39	-0.39	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
KIRC	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-9.32	3.97e-19	4.41e-16	-0.49	-0.39	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
KIRC	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-9.31	4e-19	4.45e-16	-0.39	-0.39	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
KIRC	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-9.31	4.02e-19	4.47e-16	-0.4	-0.39	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
KIRC	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	9.31	4.04e-19	4.49e-16	0.66	0.39	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
KIRC	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	9.31	4.1e-19	4.55e-16	0.36	0.39	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
KIRC	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-9.31	4.1e-19	4.55e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
KIRC	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-9.31	4.11e-19	4.56e-16	-0.4	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
KIRC	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	9.31	4.12e-19	4.58e-16	0.45	0.39	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
KIRC	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	9.31	4.14e-19	4.59e-16	0.38	0.39	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
KIRC	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-9.31	4.15e-19	4.61e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-9.31	4.15e-19	4.61e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-9.31	4.15e-19	4.61e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-9.31	4.15e-19	4.61e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
KIRC	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-9.31	4.16e-19	4.62e-16	-0.36	-0.39	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
KIRC	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-9.31	4.17e-19	4.62e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
KIRC	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	9.31	4.17e-19	4.63e-16	0.44	0.39	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
KIRC	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-9.31	4.22e-19	4.68e-16	-0.38	-0.39	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
KIRC	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	9.31	4.25e-19	4.71e-16	0.39	0.39	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
KIRC	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	9.31	4.25e-19	4.71e-16	0.55	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
KIRC	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-9.31	4.25e-19	4.71e-16	-0.3	-0.39	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
KIRC	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-9.31	4.27e-19	4.73e-16	-0.31	-0.39	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
KIRC	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-9.31	4.27e-19	4.73e-16	-0.31	-0.39	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
KIRC	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-9.31	4.3e-19	4.76e-16	-0.49	-0.39	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
KIRC	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	9.31	4.3e-19	4.76e-16	0.44	0.39	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
KIRC	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-9.31	4.31e-19	4.77e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-9.31	4.31e-19	4.77e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
KIRC	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-9.31	4.32e-19	4.78e-16	-0.38	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
KIRC	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	9.3	4.34e-19	4.8e-16	0.37	0.39	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
KIRC	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-9.3	4.35e-19	4.81e-16	-0.34	-0.39	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
KIRC	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-9.3	4.38e-19	4.84e-16	-0.49	-0.39	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
KIRC	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-9.3	4.46e-19	4.93e-16	-0.37	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
KIRC	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	9.3	4.49e-19	4.96e-16	0.49	0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
KIRC	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-9.3	4.49e-19	4.97e-16	-0.54	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
KIRC	cis	rs10262624	0.967	rs7804966	ENSG00000234286.1	AC006026.13	-9.3	4.5e-19	4.98e-16	-0.45	-0.39	Schizophrenia;	chr7:23865141	chr7:23680195~23680786:-
KIRC	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	9.3	4.51e-19	4.98e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.599	rs73394331	ENSG00000259531.2	RP11-295H24.3	9.3	4.51e-19	4.98e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49278236	chr15:49365124~49366685:-
KIRC	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-9.3	4.51e-19	4.98e-16	-0.46	-0.39	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
KIRC	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-9.3	4.52e-19	4.99e-16	-0.49	-0.39	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
KIRC	cis	rs79040073	0.637	rs77813839	ENSG00000259531.2	RP11-295H24.3	9.3	4.53e-19	5e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49172799	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs77965410	ENSG00000259531.2	RP11-295H24.3	9.3	4.53e-19	5e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49194450	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs75391491	ENSG00000259531.2	RP11-295H24.3	9.3	4.53e-19	5e-16	0.51	0.39	Lung cancer in ever smokers;	chr15:49210376	chr15:49365124~49366685:-
KIRC	cis	rs919433	0.929	rs10931779	ENSG00000231621.1	AC013264.2	9.3	4.55e-19	5.02e-16	0.39	0.39	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197302101	chr2:197197991~197199273:+
KIRC	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	9.3	4.56e-19	5.04e-16	0.56	0.39	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
KIRC	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-9.3	4.59e-19	5.07e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
KIRC	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-9.3	4.6e-19	5.07e-16	-0.52	-0.39	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	9.3	4.6e-19	5.08e-16	0.51	0.39	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
KIRC	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-9.3	4.6e-19	5.08e-16	-0.41	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
KIRC	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-9.3	4.61e-19	5.09e-16	-0.39	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
KIRC	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	9.3	4.62e-19	5.1e-16	0.36	0.39	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
KIRC	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	9.3	4.63e-19	5.1e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	9.3	4.63e-19	5.1e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
KIRC	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	9.3	4.63e-19	5.11e-16	0.47	0.39	Depression;	chr6:28432562	chr6:28176188~28176674:+
KIRC	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	9.3	4.65e-19	5.13e-16	0.27	0.39	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
KIRC	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	9.29	4.7e-19	5.18e-16	0.45	0.39	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
KIRC	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-9.29	4.7e-19	5.18e-16	-0.38	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
KIRC	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	9.29	4.74e-19	5.22e-16	0.47	0.39	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
KIRC	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	9.29	4.76e-19	5.24e-16	0.58	0.39	Height;	chr6:109618283	chr6:109382795~109383666:+
KIRC	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-9.29	4.78e-19	5.27e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-9.29	4.78e-19	5.27e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-9.29	4.78e-19	5.27e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-9.29	4.78e-19	5.27e-16	-0.48	-0.39	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
KIRC	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-9.29	4.83e-19	5.32e-16	-0.4	-0.39	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
KIRC	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	9.29	4.86e-19	5.36e-16	0.58	0.39	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
KIRC	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-9.29	4.89e-19	5.38e-16	-0.5	-0.39	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
KIRC	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-9.29	4.89e-19	5.38e-16	-0.33	-0.39	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
KIRC	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-9.29	4.9e-19	5.4e-16	-0.49	-0.39	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
KIRC	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	9.29	4.91e-19	5.41e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
KIRC	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	9.29	4.91e-19	5.41e-16	0.55	0.39	Height;	chr6:109359125	chr6:109382795~109383666:+
KIRC	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	9.29	4.93e-19	5.43e-16	0.35	0.39	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
KIRC	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-9.29	4.99e-19	5.49e-16	-0.51	-0.39	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
KIRC	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-9.29	4.99e-19	5.49e-16	-0.49	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
KIRC	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	9.29	5e-19	5.5e-16	0.71	0.39	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
KIRC	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-9.29	5.01e-19	5.51e-16	-0.45	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
KIRC	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-9.29	5.03e-19	5.53e-16	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
KIRC	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-9.29	5.04e-19	5.54e-16	-0.5	-0.39	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
KIRC	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	9.29	5.05e-19	5.55e-16	0.49	0.39	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
KIRC	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	9.29	5.08e-19	5.58e-16	0.49	0.39	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
KIRC	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	9.28	5.09e-19	5.6e-16	0.39	0.39	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
KIRC	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	9.28	5.1e-19	5.61e-16	0.44	0.39	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
KIRC	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	9.28	5.14e-19	5.65e-16	0.41	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
KIRC	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	9.28	5.14e-19	5.65e-16	0.41	0.39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
KIRC	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	9.28	5.16e-19	5.67e-16	0.51	0.39	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
KIRC	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-9.28	5.2e-19	5.71e-16	-0.51	-0.39	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
KIRC	cis	rs1823913	0.927	rs1454761	ENSG00000227542.1	AC092614.2	9.28	5.21e-19	5.72e-16	0.36	0.39	Obesity-related traits;	chr2:191237092	chr2:191229165~191246172:-
KIRC	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	9.28	5.21e-19	5.72e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
KIRC	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-9.28	5.23e-19	5.74e-16	-0.3	-0.39	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
KIRC	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	9.28	5.23e-19	5.75e-16	0.55	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
KIRC	cis	rs10971721	0.643	rs10971701	ENSG00000260947.1	RP11-384P7.7	9.28	5.24e-19	5.76e-16	0.85	0.38	Body mass index;	chr9:33781900	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.643	rs10971702	ENSG00000260947.1	RP11-384P7.7	9.28	5.24e-19	5.76e-16	0.85	0.38	Body mass index;	chr9:33784104	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.643	rs12375483	ENSG00000260947.1	RP11-384P7.7	9.28	5.24e-19	5.76e-16	0.85	0.38	Body mass index;	chr9:33784910	chr9:33697459~33700986:+
KIRC	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	9.28	5.25e-19	5.77e-16	0.5	0.38	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
KIRC	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-9.28	5.27e-19	5.79e-16	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
KIRC	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	9.28	5.29e-19	5.81e-16	0.61	0.38	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
KIRC	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	9.28	5.29e-19	5.81e-16	0.5	0.38	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-9.28	5.3e-19	5.81e-16	-0.3	-0.38	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
KIRC	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	9.28	5.3e-19	5.82e-16	0.44	0.38	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
KIRC	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-9.28	5.32e-19	5.84e-16	-0.49	-0.38	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-9.28	5.32e-19	5.84e-16	-0.49	-0.38	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-9.28	5.32e-19	5.84e-16	-0.49	-0.38	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
KIRC	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-9.28	5.33e-19	5.85e-16	-0.4	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
KIRC	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-9.28	5.36e-19	5.88e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
KIRC	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-9.28	5.36e-19	5.88e-16	-0.45	-0.38	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
KIRC	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-9.28	5.36e-19	5.89e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
KIRC	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	9.28	5.41e-19	5.93e-16	0.36	0.38	Asthma;	chr2:102440033	chr2:102438713~102440475:+
KIRC	cis	rs4356975	0.83	rs72851348	ENSG00000248763.2	RP13-644M16.5	-9.28	5.42e-19	5.94e-16	-0.49	-0.38	Obesity-related traits;	chr4:69054305	chr4:69066395~69069888:+
KIRC	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-9.28	5.45e-19	5.97e-16	-0.56	-0.38	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
KIRC	cis	rs4356975	0.83	rs6422322	ENSG00000248763.2	RP13-644M16.5	-9.28	5.45e-19	5.98e-16	-0.49	-0.38	Obesity-related traits;	chr4:69055571	chr4:69066395~69069888:+
KIRC	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	9.28	5.46e-19	5.99e-16	0.36	0.38	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
KIRC	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-9.28	5.48e-19	6.01e-16	-0.68	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
KIRC	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	9.27	5.51e-19	6.04e-16	0.46	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
KIRC	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-9.27	5.55e-19	6.08e-16	-0.49	-0.38	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-9.27	5.55e-19	6.08e-16	-0.49	-0.38	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
KIRC	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	9.27	5.56e-19	6.09e-16	0.55	0.38	Height;	chr6:109339681	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	9.27	5.57e-19	6.1e-16	0.55	0.38	Height;	chr6:109708527	chr6:109382795~109383666:+
KIRC	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-9.27	5.57e-19	6.1e-16	-0.35	-0.38	Height;	chr4:55477866	chr4:55363971~55395847:-
KIRC	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	9.27	5.6e-19	6.13e-16	0.55	0.38	Height;	chr6:109360679	chr6:109382795~109383666:+
KIRC	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	9.27	5.6e-19	6.14e-16	0.48	0.38	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
KIRC	cis	rs2749592	0.531	rs994804	ENSG00000151963.4	RP11-775A3.1	9.27	5.61e-19	6.14e-16	0.44	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:37883594~37884109:+
KIRC	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-9.27	5.62e-19	6.16e-16	-0.47	-0.38	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
KIRC	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-9.27	5.64e-19	6.18e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
KIRC	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	9.27	5.65e-19	6.18e-16	0.41	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
KIRC	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	9.27	5.65e-19	6.18e-16	0.41	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
KIRC	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-9.27	5.69e-19	6.22e-16	-0.49	-0.38	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
KIRC	cis	rs10971721	0.643	rs72711741	ENSG00000260947.1	RP11-384P7.7	9.27	5.69e-19	6.22e-16	0.85	0.38	Body mass index;	chr9:33785113	chr9:33697459~33700986:+
KIRC	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-9.27	5.71e-19	6.25e-16	-0.47	-0.38	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
KIRC	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-9.27	5.72e-19	6.26e-16	-0.37	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
KIRC	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	9.27	5.72e-19	6.26e-16	0.72	0.38	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
KIRC	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-9.27	5.75e-19	6.29e-16	-0.4	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
KIRC	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	9.27	5.76e-19	6.3e-16	0.44	0.38	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	9.27	5.76e-19	6.3e-16	0.44	0.38	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	9.27	5.76e-19	6.3e-16	0.44	0.38	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
KIRC	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	9.27	5.76e-19	6.3e-16	0.38	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
KIRC	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	9.27	5.76e-19	6.3e-16	0.4	0.38	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
KIRC	cis	rs2698530	0.791	rs890481	ENSG00000225889.6	AC074289.1	-9.27	5.77e-19	6.31e-16	-0.39	-0.38	Iron status biomarkers;	chr2:64265382	chr2:64143239~64252859:+
KIRC	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-9.27	5.79e-19	6.34e-16	-0.4	-0.38	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
KIRC	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	9.27	5.79e-19	6.34e-16	0.5	0.38	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
KIRC	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	9.27	5.81e-19	6.35e-16	0.38	0.38	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
KIRC	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-9.27	5.81e-19	6.35e-16	-0.42	-0.38	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
KIRC	cis	rs72901758	0.662	rs56326958	ENSG00000267676.1	THA1P	9.27	5.86e-19	6.41e-16	0.48	0.38	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78254358	chr17:78248493~78254416:-
KIRC	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	9.27	5.91e-19	6.46e-16	0.51	0.38	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
KIRC	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-9.27	5.91e-19	6.47e-16	-0.45	-0.38	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
KIRC	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	9.27	5.92e-19	6.47e-16	0.38	0.38	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
KIRC	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	9.27	5.94e-19	6.5e-16	0.36	0.38	Asthma;	chr2:102446466	chr2:102438713~102440475:+
KIRC	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	9.27	5.96e-19	6.51e-16	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
KIRC	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	9.27	5.96e-19	6.51e-16	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
KIRC	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-9.26	5.98e-19	6.53e-16	-0.43	-0.38	Height;	chr11:118747911	chr11:118704607~118750263:+
KIRC	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-9.26	5.99e-19	6.54e-16	-0.36	-0.38	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
KIRC	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	9.26	6.05e-19	6.61e-16	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
KIRC	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-9.26	6.08e-19	6.64e-16	-0.31	-0.38	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
KIRC	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-9.26	6.09e-19	6.64e-16	-0.47	-0.38	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-9.26	6.09e-19	6.64e-16	-0.47	-0.38	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
KIRC	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	9.26	6.09e-19	6.64e-16	0.44	0.38	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	9.26	6.09e-19	6.64e-16	0.44	0.38	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
KIRC	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	9.26	6.11e-19	6.66e-16	0.55	0.38	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
KIRC	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-9.26	6.13e-19	6.69e-16	-0.57	-0.38	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
KIRC	cis	rs72901758	0.768	rs55782477	ENSG00000267676.1	THA1P	9.26	6.14e-19	6.7e-16	0.48	0.38	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:78254622	chr17:78248493~78254416:-
KIRC	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-9.26	6.17e-19	6.73e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
KIRC	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-9.26	6.2e-19	6.76e-16	-0.44	-0.38	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-9.26	6.2e-19	6.76e-16	-0.44	-0.38	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
KIRC	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-9.26	6.28e-19	6.84e-16	-0.33	-0.38	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
KIRC	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	9.26	6.28e-19	6.85e-16	0.55	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
KIRC	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	9.26	6.28e-19	6.85e-16	0.48	0.38	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
KIRC	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	9.26	6.31e-19	6.88e-16	0.51	0.38	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	9.26	6.31e-19	6.88e-16	0.51	0.38	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	9.26	6.31e-19	6.88e-16	0.51	0.38	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	9.26	6.31e-19	6.88e-16	0.51	0.38	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
KIRC	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	9.26	6.33e-19	6.89e-16	0.44	0.38	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
KIRC	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	9.26	6.33e-19	6.9e-16	0.44	0.38	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
KIRC	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	9.26	6.34e-19	6.91e-16	0.39	0.38	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
KIRC	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-9.26	6.36e-19	6.92e-16	-0.55	-0.38	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
KIRC	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	9.26	6.36e-19	6.93e-16	0.44	0.38	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	9.26	6.36e-19	6.93e-16	0.44	0.38	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	9.26	6.36e-19	6.93e-16	0.44	0.38	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	9.26	6.36e-19	6.93e-16	0.44	0.38	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	9.26	6.36e-19	6.93e-16	0.44	0.38	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
KIRC	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	9.26	6.38e-19	6.95e-16	0.44	0.38	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	9.26	6.38e-19	6.95e-16	0.44	0.38	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	9.26	6.38e-19	6.95e-16	0.44	0.38	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	9.26	6.38e-19	6.95e-16	0.44	0.38	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	9.26	6.38e-19	6.95e-16	0.44	0.38	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
KIRC	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-9.26	6.39e-19	6.96e-16	-0.49	-0.38	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
KIRC	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	9.26	6.4e-19	6.97e-16	0.55	0.38	Height;	chr6:109365409	chr6:109382795~109383666:+
KIRC	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	9.26	6.41e-19	6.97e-16	0.44	0.38	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
KIRC	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-9.26	6.42e-19	6.99e-16	-0.33	-0.38	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
KIRC	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	9.26	6.42e-19	6.99e-16	0.37	0.38	Asthma;	chr2:102431747	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	9.26	6.42e-19	6.99e-16	0.37	0.38	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	9.26	6.42e-19	6.99e-16	0.37	0.38	Asthma;	chr2:102432120	chr2:102438713~102440475:+
KIRC	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	9.26	6.42e-19	6.99e-16	0.41	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
KIRC	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-9.26	6.43e-19	7e-16	-0.53	-0.38	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
KIRC	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	9.25	6.46e-19	7.01e-16	0.47	0.38	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
KIRC	cis	rs904251	0.797	rs1757177	ENSG00000227920.2	RP1-153P14.5	-9.25	6.47e-19	7.01e-16	-0.45	-0.38	Cognitive performance;	chr6:37518594	chr6:37545145~37550860:+
KIRC	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-9.25	6.5e-19	7.04e-16	-0.44	-0.38	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
KIRC	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	9.25	6.51e-19	7.06e-16	0.49	0.38	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
KIRC	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-9.25	6.52e-19	7.06e-16	-0.32	-0.38	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
KIRC	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-9.25	6.52e-19	7.07e-16	-0.42	-0.38	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
KIRC	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-9.25	6.52e-19	7.07e-16	-0.56	-0.38	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
KIRC	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-9.25	6.55e-19	7.1e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-9.25	6.55e-19	7.1e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-9.25	6.55e-19	7.1e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
KIRC	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	9.25	6.56e-19	7.11e-16	0.36	0.38	Height;	chr4:55587104	chr4:55363971~55395847:-
KIRC	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-9.25	6.59e-19	7.14e-16	-0.49	-0.38	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
KIRC	cis	rs2749592	0.55	rs10764135	ENSG00000151963.4	RP11-775A3.1	9.25	6.59e-19	7.14e-16	0.44	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:37883594~37884109:+
KIRC	cis	rs2749592	0.55	rs12255038	ENSG00000151963.4	RP11-775A3.1	9.25	6.59e-19	7.14e-16	0.44	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:37883594~37884109:+
KIRC	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	9.25	6.62e-19	7.17e-16	0.44	0.38	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	9.25	6.62e-19	7.17e-16	0.44	0.38	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
KIRC	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	9.25	6.66e-19	7.22e-16	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
KIRC	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-9.25	6.68e-19	7.24e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-9.25	6.68e-19	7.24e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-9.25	6.72e-19	7.28e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
KIRC	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	9.25	6.76e-19	7.32e-16	0.72	0.38	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
KIRC	cis	rs79040073	0.637	rs73390360	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49171265	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73390362	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49172292	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.599	rs73390384	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49180905	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.6	rs57785991	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49188443	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs7177624	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49189515	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11635814	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49195028	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs78298181	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49213350	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73392236	ENSG00000259531.2	RP11-295H24.3	9.25	6.79e-19	7.35e-16	0.5	0.38	Lung cancer in ever smokers;	chr15:49216829	chr15:49365124~49366685:-
KIRC	cis	rs4356975	0.697	rs5002700	ENSG00000248763.2	RP13-644M16.5	-9.25	6.89e-19	7.46e-16	-0.48	-0.38	Obesity-related traits;	chr4:69155637	chr4:69066395~69069888:+
KIRC	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-9.25	6.92e-19	7.49e-16	-0.44	-0.38	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
KIRC	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	9.25	6.93e-19	7.49e-16	0.71	0.38	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
KIRC	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	9.25	6.94e-19	7.5e-16	0.39	0.38	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
KIRC	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	9.25	6.97e-19	7.53e-16	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
KIRC	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-9.25	6.99e-19	7.56e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
KIRC	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	9.25	6.99e-19	7.56e-16	0.5	0.38	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
KIRC	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	9.24	7e-19	7.57e-16	0.54	0.38	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
KIRC	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-9.24	7.05e-19	7.62e-16	-0.4	-0.38	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
KIRC	cis	rs9847710	1	rs4687697	ENSG00000280417.1	RP11-5O17.1	9.24	7.05e-19	7.62e-16	0.44	0.38	Ulcerative colitis;	chr3:53056474	chr3:53046166~53048122:+
KIRC	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	9.24	7.05e-19	7.62e-16	0.47	0.38	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-9.24	7.07e-19	7.64e-16	-0.49	-0.38	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
KIRC	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-9.24	7.08e-19	7.65e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
KIRC	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-9.24	7.09e-19	7.66e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
KIRC	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	9.24	7.11e-19	7.69e-16	0.53	0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
KIRC	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-9.24	7.12e-19	7.7e-16	-0.38	-0.38	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
KIRC	cis	rs904251	0.766	rs1757175	ENSG00000227920.2	RP1-153P14.5	-9.24	7.13e-19	7.7e-16	-0.45	-0.38	Cognitive performance;	chr6:37518918	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.828	rs1757174	ENSG00000227920.2	RP1-153P14.5	-9.24	7.13e-19	7.7e-16	-0.45	-0.38	Cognitive performance;	chr6:37518919	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.861	rs1757173	ENSG00000227920.2	RP1-153P14.5	-9.24	7.13e-19	7.7e-16	-0.45	-0.38	Cognitive performance;	chr6:37519176	chr6:37545145~37550860:+
KIRC	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-9.24	7.15e-19	7.73e-16	-0.43	-0.38	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
KIRC	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-9.24	7.15e-19	7.73e-16	-0.4	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
KIRC	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-9.24	7.18e-19	7.76e-16	-0.44	-0.38	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
KIRC	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-9.24	7.21e-19	7.79e-16	-0.44	-0.38	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-9.24	7.21e-19	7.79e-16	-0.44	-0.38	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-9.24	7.21e-19	7.79e-16	-0.44	-0.38	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-9.24	7.21e-19	7.79e-16	-0.44	-0.38	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
KIRC	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-9.24	7.21e-19	7.79e-16	-0.44	-0.38	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
KIRC	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-9.24	7.21e-19	7.79e-16	-0.41	-0.38	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
KIRC	cis	rs904251	0.861	rs1757171	ENSG00000227920.2	RP1-153P14.5	-9.24	7.22e-19	7.8e-16	-0.45	-0.38	Cognitive performance;	chr6:37519268	chr6:37545145~37550860:+
KIRC	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	9.24	7.22e-19	7.8e-16	0.47	0.38	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	9.24	7.22e-19	7.8e-16	0.47	0.38	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
KIRC	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	9.24	7.23e-19	7.81e-16	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
KIRC	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-9.24	7.24e-19	7.81e-16	-0.44	-0.38	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
KIRC	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-9.24	7.26e-19	7.84e-16	-0.33	-0.38	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
KIRC	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	9.24	7.27e-19	7.84e-16	0.51	0.38	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
KIRC	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-9.24	7.27e-19	7.85e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-9.24	7.28e-19	7.85e-16	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
KIRC	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	9.24	7.28e-19	7.86e-16	0.36	0.38	Height;	chr3:53073764	chr3:53064283~53065091:-
KIRC	cis	rs189798	0.845	rs330904	ENSG00000254340.1	RP11-10A14.3	-9.24	7.3e-19	7.87e-16	-0.51	-0.38	Myopia (pathological);	chr8:9134315	chr8:9141424~9145435:+
KIRC	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-9.24	7.32e-19	7.9e-16	-0.37	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
KIRC	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	9.24	7.33e-19	7.91e-16	0.51	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
KIRC	cis	rs79040073	0.637	rs79979867	ENSG00000259531.2	RP11-295H24.3	9.24	7.33e-19	7.91e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49177261	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs80214300	ENSG00000259531.2	RP11-295H24.3	9.24	7.33e-19	7.91e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49180767	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs79723325	ENSG00000259531.2	RP11-295H24.3	9.24	7.33e-19	7.91e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49193423	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs77815234	ENSG00000259531.2	RP11-295H24.3	9.24	7.33e-19	7.91e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49193495	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs75691966	ENSG00000259531.2	RP11-295H24.3	9.24	7.33e-19	7.91e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49214743	chr15:49365124~49366685:-
KIRC	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	9.24	7.34e-19	7.92e-16	0.35	0.38	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
KIRC	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	9.24	7.35e-19	7.93e-16	0.37	0.38	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
KIRC	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	9.24	7.37e-19	7.94e-16	0.44	0.38	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
KIRC	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-9.24	7.37e-19	7.95e-16	-0.49	-0.38	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
KIRC	cis	rs17361889	0.613	rs4721484	ENSG00000224683.1	RPL36AP29	9.24	7.39e-19	7.97e-16	0.47	0.38	Pediatric bone mineral content (hip);	chr7:16242778	chr7:16208945~16209265:+
KIRC	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	9.24	7.44e-19	8.02e-16	0.36	0.38	Asthma;	chr2:102446780	chr2:102438713~102440475:+
KIRC	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-9.24	7.45e-19	8.02e-16	-0.44	-0.38	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
KIRC	cis	rs899997	1	rs7182567	ENSG00000261143.1	ADAMTS7P3	9.24	7.46e-19	8.04e-16	0.45	0.38	Coronary artery disease or large artery stroke;	chr15:78752712	chr15:77976042~77993057:+
KIRC	cis	rs2749592	0.725	rs9417245	ENSG00000151963.4	RP11-775A3.1	9.24	7.47e-19	8.04e-16	0.48	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37537394	chr10:37883594~37884109:+
KIRC	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-9.24	7.48e-19	8.06e-16	-0.43	-0.38	Height;	chr5:36861889	chr5:36666214~36725195:-
KIRC	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	9.24	7.49e-19	8.07e-16	0.36	0.38	Asthma;	chr2:102432614	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	9.24	7.49e-19	8.07e-16	0.36	0.38	Asthma;	chr2:102433405	chr2:102438713~102440475:+
KIRC	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	9.24	7.49e-19	8.07e-16	0.45	0.38	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
KIRC	cis	rs950776	0.518	rs62008194	ENSG00000261762.1	RP11-650L12.2	9.24	7.5e-19	8.08e-16	0.5	0.38	Sudden cardiac arrest;	chr15:78521463	chr15:78589123~78591276:-
KIRC	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-9.24	7.53e-19	8.11e-16	-0.48	-0.38	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
KIRC	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-9.23	7.59e-19	8.17e-16	-0.42	-0.38	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
KIRC	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	9.23	7.6e-19	8.18e-16	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	9.23	7.6e-19	8.18e-16	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
KIRC	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-9.23	7.68e-19	8.26e-16	-0.47	-0.38	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
KIRC	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-9.23	7.71e-19	8.29e-16	-0.44	-0.38	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-9.23	7.71e-19	8.29e-16	-0.44	-0.38	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-9.23	7.71e-19	8.29e-16	-0.44	-0.38	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
KIRC	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-9.23	7.74e-19	8.33e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-9.23	7.74e-19	8.33e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-9.23	7.74e-19	8.33e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000250919.1	RP11-813N20.3	-9.23	7.74e-19	8.33e-16	-0.41	-0.38	Obesity-related traits;	chr4:69075473	chr4:69027831~69044578:+
KIRC	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-9.23	7.74e-19	8.33e-16	-0.33	-0.38	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
KIRC	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-9.23	7.75e-19	8.34e-16	-0.43	-0.38	Height;	chr11:118746590	chr11:118704607~118750263:+
KIRC	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	9.23	7.78e-19	8.37e-16	0.73	0.38	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
KIRC	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	9.23	7.83e-19	8.42e-16	0.71	0.38	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
KIRC	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-9.23	7.91e-19	8.5e-16	-0.49	-0.38	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
KIRC	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-9.23	7.93e-19	8.52e-16	-0.34	-0.38	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
KIRC	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-9.23	7.97e-19	8.57e-16	-0.39	-0.38	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
KIRC	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	9.23	7.98e-19	8.57e-16	0.41	0.38	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
KIRC	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	9.23	7.98e-19	8.57e-16	0.44	0.38	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	9.23	7.98e-19	8.57e-16	0.44	0.38	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	9.23	7.98e-19	8.57e-16	0.44	0.38	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	9.23	7.98e-19	8.57e-16	0.44	0.38	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
KIRC	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-9.23	8.04e-19	8.63e-16	-0.51	-0.38	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
KIRC	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	9.23	8.05e-19	8.65e-16	0.43	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
KIRC	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-9.23	8.1e-19	8.69e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
KIRC	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	9.23	8.11e-19	8.71e-16	0.74	0.38	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
KIRC	cis	rs4356975	0.83	rs7435274	ENSG00000248763.2	RP13-644M16.5	-9.23	8.12e-19	8.72e-16	-0.49	-0.38	Obesity-related traits;	chr4:69050281	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs7438808	ENSG00000248763.2	RP13-644M16.5	-9.23	8.12e-19	8.72e-16	-0.49	-0.38	Obesity-related traits;	chr4:69050666	chr4:69066395~69069888:+
KIRC	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-9.23	8.12e-19	8.72e-16	-0.44	-0.38	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
KIRC	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	9.23	8.14e-19	8.74e-16	0.44	0.38	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
KIRC	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-9.23	8.15e-19	8.75e-16	-0.47	-0.38	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-9.23	8.15e-19	8.75e-16	-0.47	-0.38	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-9.23	8.15e-19	8.75e-16	-0.47	-0.38	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
KIRC	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-9.23	8.16e-19	8.75e-16	-0.44	-0.38	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
KIRC	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	9.23	8.19e-19	8.79e-16	0.55	0.38	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
KIRC	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	9.23	8.2e-19	8.8e-16	0.46	0.38	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
KIRC	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-9.22	8.23e-19	8.83e-16	-0.42	-0.38	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
KIRC	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-9.22	8.24e-19	8.84e-16	-0.44	-0.38	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
KIRC	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-9.22	8.25e-19	8.85e-16	-0.44	-0.38	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-9.22	8.25e-19	8.85e-16	-0.44	-0.38	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
KIRC	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	9.22	8.31e-19	8.91e-16	0.65	0.38	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
KIRC	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	9.22	8.33e-19	8.93e-16	0.32	0.38	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
KIRC	cis	rs4356975	0.83	rs4422474	ENSG00000248763.2	RP13-644M16.5	-9.22	8.34e-19	8.94e-16	-0.49	-0.38	Obesity-related traits;	chr4:69051322	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs4377650	ENSG00000248763.2	RP13-644M16.5	-9.22	8.34e-19	8.94e-16	-0.49	-0.38	Obesity-related traits;	chr4:69051355	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs72851338	ENSG00000248763.2	RP13-644M16.5	-9.22	8.34e-19	8.94e-16	-0.49	-0.38	Obesity-related traits;	chr4:69052555	chr4:69066395~69069888:+
KIRC	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-9.22	8.35e-19	8.95e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
KIRC	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-9.22	8.37e-19	8.97e-16	-0.36	-0.38	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
KIRC	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-9.22	8.39e-19	8.99e-16	-0.52	-0.38	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
KIRC	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	9.22	8.4e-19	9.01e-16	0.56	0.38	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
KIRC	cis	rs4356975	0.83	rs10012215	ENSG00000248763.2	RP13-644M16.5	-9.22	8.41e-19	9.01e-16	-0.48	-0.38	Obesity-related traits;	chr4:69048448	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs10012240	ENSG00000248763.2	RP13-644M16.5	-9.22	8.41e-19	9.01e-16	-0.48	-0.38	Obesity-related traits;	chr4:69048519	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs10012607	ENSG00000248763.2	RP13-644M16.5	-9.22	8.41e-19	9.01e-16	-0.48	-0.38	Obesity-related traits;	chr4:69048866	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-9.22	8.49e-19	9.09e-16	-0.3	-0.38	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
KIRC	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	9.22	8.52e-19	9.12e-16	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
KIRC	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	9.22	8.55e-19	9.15e-16	0.51	0.38	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
KIRC	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	9.22	8.56e-19	9.17e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
KIRC	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-9.22	8.61e-19	9.22e-16	-0.4	-0.38	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
KIRC	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	9.22	8.63e-19	9.24e-16	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
KIRC	cis	rs79040073	0.637	rs57252806	ENSG00000259531.2	RP11-295H24.3	9.22	8.63e-19	9.24e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49352188	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11633981	ENSG00000259531.2	RP11-295H24.3	9.22	8.63e-19	9.24e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49360903	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11633282	ENSG00000259531.2	RP11-295H24.3	9.22	8.63e-19	9.24e-16	0.51	0.38	Lung cancer in ever smokers;	chr15:49372472	chr15:49365124~49366685:-
KIRC	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	9.22	8.76e-19	9.37e-16	0.39	0.38	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
KIRC	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	9.22	8.76e-19	9.37e-16	0.39	0.38	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
KIRC	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-9.22	8.8e-19	9.42e-16	-0.56	-0.38	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
KIRC	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	9.22	8.81e-19	9.42e-16	0.58	0.38	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000250696.4	RP11-704M14.1	9.21	8.89e-19	9.5e-16	0.41	0.38	Obesity-related traits;	chr4:69063770	chr4:69182100~69216766:+
KIRC	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-9.21	8.89e-19	9.5e-16	-0.46	-0.38	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
KIRC	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	9.21	8.93e-19	9.55e-16	0.44	0.38	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
KIRC	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-9.21	8.97e-19	9.59e-16	-0.33	-0.38	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
KIRC	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	9.21	8.99e-19	9.6e-16	0.4	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
KIRC	cis	rs1005277	0.505	rs13503	ENSG00000151963.4	RP11-775A3.1	9.21	9e-19	9.62e-16	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:37883594~37884109:+
KIRC	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-9.21	9e-19	9.62e-16	-0.46	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
KIRC	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-9.21	9.03e-19	9.64e-16	-0.48	-0.38	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
KIRC	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-9.21	9.05e-19	9.66e-16	-0.38	-0.38	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
KIRC	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	9.21	9.06e-19	9.68e-16	0.6	0.38	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
KIRC	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-9.21	9.07e-19	9.69e-16	-0.47	-0.38	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
KIRC	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	9.21	9.09e-19	9.71e-16	0.39	0.38	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
KIRC	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-9.21	9.1e-19	9.72e-16	-0.37	-0.38	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
KIRC	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-9.21	9.11e-19	9.72e-16	-0.96	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
KIRC	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-9.21	9.12e-19	9.73e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-9.21	9.12e-19	9.73e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-9.21	9.12e-19	9.73e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-9.21	9.12e-19	9.73e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-9.21	9.12e-19	9.73e-16	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
KIRC	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-9.21	9.14e-19	9.75e-16	-0.48	-0.38	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
KIRC	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-9.21	9.18e-19	9.8e-16	-0.37	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
KIRC	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	9.21	9.21e-19	9.82e-16	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
KIRC	cis	rs4356975	0.83	rs57386454	ENSG00000248763.2	RP13-644M16.5	-9.21	9.25e-19	9.86e-16	-0.48	-0.38	Obesity-related traits;	chr4:69052968	chr4:69066395~69069888:+
KIRC	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-9.21	9.33e-19	9.95e-16	-0.5	-0.38	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
KIRC	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	9.21	9.36e-19	9.98e-16	0.65	0.38	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
KIRC	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	9.21	9.36e-19	9.98e-16	0.65	0.38	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
KIRC	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-9.21	9.41e-19	1e-15	-0.36	-0.38	Asthma;	chr2:102374909	chr2:102438713~102440475:+
KIRC	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-9.21	9.41e-19	1e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
KIRC	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-9.21	9.42e-19	1e-15	-0.45	-0.38	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
KIRC	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-9.21	9.46e-19	1.01e-15	-0.4	-0.38	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-9.21	9.46e-19	1.01e-15	-0.4	-0.38	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
KIRC	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-9.21	9.48e-19	1.01e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
KIRC	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	9.21	9.5e-19	1.01e-15	0.51	0.38	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
KIRC	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-9.21	9.5e-19	1.01e-15	-0.47	-0.38	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-9.21	9.54e-19	1.02e-15	-0.47	-0.38	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
KIRC	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	9.21	9.56e-19	1.02e-15	0.4	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
KIRC	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-9.21	9.57e-19	1.02e-15	-0.36	-0.38	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
KIRC	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-9.21	9.59e-19	1.02e-15	-0.49	-0.38	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
KIRC	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-9.2	9.62e-19	1.02e-15	-0.44	-0.38	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
KIRC	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-9.2	9.64e-19	1.03e-15	-0.51	-0.38	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
KIRC	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	9.2	9.68e-19	1.03e-15	0.51	0.38	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
KIRC	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-9.2	9.73e-19	1.03e-15	-0.44	-0.38	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
KIRC	cis	rs950776	0.518	rs12916483	ENSG00000261762.1	RP11-650L12.2	9.2	9.88e-19	1.05e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78540055	chr15:78589123~78591276:-
KIRC	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	9.2	9.91e-19	1.05e-15	0.55	0.38	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
KIRC	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-9.2	9.91e-19	1.05e-15	-0.5	-0.38	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
KIRC	cis	rs904251	0.523	rs12202055	ENSG00000227920.2	RP1-153P14.5	-9.2	9.93e-19	1.06e-15	-0.43	-0.38	Cognitive performance;	chr6:37518304	chr6:37545145~37550860:+
KIRC	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	9.2	9.94e-19	1.06e-15	0.62	0.38	Height;	chr6:109455700	chr6:109382795~109383666:+
KIRC	cis	rs1005277	0.505	rs7069702	ENSG00000151963.4	RP11-775A3.1	9.2	1e-18	1.06e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:37883594~37884109:+
KIRC	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	9.2	1e-18	1.07e-15	0.38	0.38	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	9.2	1e-18	1.07e-15	0.38	0.38	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
KIRC	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	9.2	1.01e-18	1.07e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	9.2	1.01e-18	1.07e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
KIRC	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-9.2	1.01e-18	1.07e-15	-0.56	-0.38	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
KIRC	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-9.2	1.01e-18	1.07e-15	-0.48	-0.38	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-9.2	1.01e-18	1.07e-15	-0.48	-0.38	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
KIRC	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	9.2	1.01e-18	1.08e-15	0.23	0.38	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
KIRC	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-9.2	1.02e-18	1.08e-15	-0.48	-0.38	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
KIRC	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	9.2	1.02e-18	1.08e-15	0.5	0.38	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
KIRC	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	9.2	1.02e-18	1.08e-15	0.5	0.38	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
KIRC	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	9.2	1.02e-18	1.08e-15	0.38	0.38	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
KIRC	cis	rs6600671	0.967	rs4844613	ENSG00000227082.1	CH17-437K3.1	-9.2	1.02e-18	1.08e-15	-0.43	-0.38	Hip geometry;	chr1:121431913	chr1:121396754~121463129:+
KIRC	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-9.2	1.03e-18	1.09e-15	-0.49	-0.38	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
KIRC	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-9.2	1.03e-18	1.09e-15	-0.47	-0.38	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
KIRC	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-9.2	1.03e-18	1.1e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
KIRC	cis	rs2698530	0.583	rs2698527	ENSG00000225889.6	AC074289.1	-9.2	1.04e-18	1.1e-15	-0.38	-0.38	Iron status biomarkers;	chr2:64272495	chr2:64143239~64252859:+
KIRC	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	9.19	1.05e-18	1.11e-15	0.43	0.38	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
KIRC	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	9.19	1.05e-18	1.11e-15	0.35	0.38	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
KIRC	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-9.19	1.05e-18	1.12e-15	-0.49	-0.38	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
KIRC	cis	rs79040073	0.637	rs73394333	ENSG00000259531.2	RP11-295H24.3	9.19	1.05e-18	1.12e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49278719	chr15:49365124~49366685:-
KIRC	cis	rs950776	0.518	rs952216	ENSG00000261762.1	RP11-650L12.2	9.19	1.07e-18	1.13e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78526860	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.506	rs12915366	ENSG00000261762.1	RP11-650L12.2	9.19	1.07e-18	1.13e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78539411	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.531	rs12915652	ENSG00000261762.1	RP11-650L12.2	9.19	1.07e-18	1.13e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78539586	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs3813572	ENSG00000261762.1	RP11-650L12.2	9.19	1.07e-18	1.13e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78540246	chr15:78589123~78591276:-
KIRC	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-9.19	1.07e-18	1.13e-15	-0.34	-0.38	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
KIRC	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	9.19	1.07e-18	1.13e-15	0.44	0.38	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000250919.1	RP11-813N20.3	-9.19	1.07e-18	1.14e-15	-0.41	-0.38	Obesity-related traits;	chr4:69075351	chr4:69027831~69044578:+
KIRC	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-9.19	1.07e-18	1.14e-15	-0.42	-0.38	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-9.19	1.08e-18	1.14e-15	-0.41	-0.38	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
KIRC	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-9.19	1.08e-18	1.14e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
KIRC	cis	rs79040073	0.637	rs11638606	ENSG00000259531.2	RP11-295H24.3	9.19	1.08e-18	1.14e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49372564	chr15:49365124~49366685:-
KIRC	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	9.19	1.09e-18	1.15e-15	0.49	0.38	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
KIRC	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	9.19	1.09e-18	1.15e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
KIRC	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	9.19	1.09e-18	1.16e-15	0.44	0.38	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
KIRC	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.19	1.09e-18	1.16e-15	0.31	0.38	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
KIRC	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	9.19	1.1e-18	1.16e-15	0.51	0.38	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
KIRC	cis	rs79040073	0.637	rs73390343	ENSG00000259531.2	RP11-295H24.3	9.19	1.1e-18	1.17e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49164026	chr15:49365124~49366685:-
KIRC	cis	rs950776	0.518	rs11636131	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78529264	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs11632604	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78529572	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12910289	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78529723	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12910100	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78530325	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12915428	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78531026	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs11630349	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78532266	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12906284	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78532763	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12906846	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78532953	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12907169	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78533156	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12906951	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78533220	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs56007453	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78533897	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12916999	ENSG00000261762.1	RP11-650L12.2	9.19	1.11e-18	1.17e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78534570	chr15:78589123~78591276:-
KIRC	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	9.19	1.11e-18	1.17e-15	0.5	0.38	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
KIRC	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	9.19	1.12e-18	1.18e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
KIRC	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	9.19	1.12e-18	1.18e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
KIRC	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-9.19	1.12e-18	1.18e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-9.19	1.12e-18	1.18e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-9.19	1.12e-18	1.18e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
KIRC	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	9.19	1.12e-18	1.18e-15	0.43	0.38	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	9.19	1.12e-18	1.18e-15	0.43	0.38	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	9.19	1.12e-18	1.18e-15	0.43	0.38	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
KIRC	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-9.19	1.13e-18	1.19e-15	-0.57	-0.38	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
KIRC	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-9.18	1.13e-18	1.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000250919.1	RP11-813N20.3	-9.18	1.13e-18	1.2e-15	-0.41	-0.38	Obesity-related traits;	chr4:69074144	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000250919.1	RP11-813N20.3	-9.18	1.13e-18	1.2e-15	-0.41	-0.38	Obesity-related traits;	chr4:69074157	chr4:69027831~69044578:+
KIRC	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	9.18	1.14e-18	1.2e-15	0.51	0.38	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	9.18	1.14e-18	1.2e-15	0.51	0.38	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	9.18	1.14e-18	1.2e-15	0.51	0.38	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
KIRC	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-9.18	1.14e-18	1.2e-15	-0.37	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
KIRC	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	9.18	1.14e-18	1.21e-15	0.51	0.38	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
KIRC	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-9.18	1.15e-18	1.21e-15	-0.44	-0.38	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
KIRC	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-9.18	1.15e-18	1.21e-15	-0.5	-0.38	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
KIRC	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	9.18	1.15e-18	1.22e-15	0.39	0.38	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
KIRC	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-9.18	1.15e-18	1.22e-15	-0.44	-0.38	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
KIRC	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	9.18	1.16e-18	1.22e-15	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
KIRC	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	9.18	1.16e-18	1.23e-15	0.47	0.38	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
KIRC	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	9.18	1.16e-18	1.23e-15	0.37	0.38	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	9.18	1.16e-18	1.23e-15	0.37	0.38	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	9.18	1.16e-18	1.23e-15	0.37	0.38	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
KIRC	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-9.18	1.17e-18	1.24e-15	-0.33	-0.38	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	9.18	1.18e-18	1.24e-15	0.5	0.38	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
KIRC	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-9.18	1.18e-18	1.25e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
KIRC	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.18	1.19e-18	1.25e-15	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
KIRC	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-9.18	1.19e-18	1.25e-15	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
KIRC	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-9.18	1.19e-18	1.25e-15	-0.49	-0.38	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
KIRC	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	9.18	1.19e-18	1.25e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
KIRC	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	9.18	1.19e-18	1.26e-15	0.48	0.38	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
KIRC	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.18	1.2e-18	1.26e-15	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
KIRC	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-9.18	1.2e-18	1.26e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
KIRC	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	9.18	1.2e-18	1.26e-15	0.29	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
KIRC	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	9.18	1.2e-18	1.26e-15	0.5	0.38	Height;	chr6:109494237	chr6:109382795~109383666:+
KIRC	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-9.18	1.21e-18	1.27e-15	-0.5	-0.38	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
KIRC	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	9.18	1.21e-18	1.27e-15	0.5	0.38	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
KIRC	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	9.18	1.21e-18	1.27e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
KIRC	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-9.18	1.21e-18	1.27e-15	-0.51	-0.38	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
KIRC	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-9.18	1.21e-18	1.28e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-9.18	1.21e-18	1.28e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-9.18	1.21e-18	1.28e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-9.18	1.21e-18	1.28e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
KIRC	cis	rs79040073	0.637	rs61442055	ENSG00000259531.2	RP11-295H24.3	9.18	1.22e-18	1.28e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49156901	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11632211	ENSG00000259531.2	RP11-295H24.3	9.18	1.22e-18	1.28e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49159178	chr15:49365124~49366685:-
KIRC	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	9.18	1.22e-18	1.28e-15	0.51	0.38	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	9.18	1.22e-18	1.28e-15	0.51	0.38	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
KIRC	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	9.18	1.22e-18	1.28e-15	0.43	0.38	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
KIRC	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-9.18	1.22e-18	1.28e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
KIRC	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	9.17	1.23e-18	1.29e-15	0.38	0.38	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
KIRC	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.17	1.23e-18	1.29e-15	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
KIRC	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	9.17	1.23e-18	1.29e-15	0.51	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
KIRC	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	9.17	1.24e-18	1.31e-15	0.36	0.38	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
KIRC	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	9.17	1.24e-18	1.31e-15	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
KIRC	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-9.17	1.25e-18	1.31e-15	-0.38	-0.38	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
KIRC	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	9.17	1.25e-18	1.31e-15	0.6	0.38	Height;	chr6:109352277	chr6:109382795~109383666:+
KIRC	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	9.17	1.25e-18	1.31e-15	0.36	0.38	Asthma;	chr2:102402540	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	9.17	1.25e-18	1.31e-15	0.36	0.38	Asthma;	chr2:102402571	chr2:102438713~102440475:+
KIRC	cis	rs950776	0.518	rs12903129	ENSG00000261762.1	RP11-650L12.2	9.17	1.25e-18	1.32e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78527264	chr15:78589123~78591276:-
KIRC	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-9.17	1.25e-18	1.32e-15	-0.55	-0.38	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
KIRC	cis	rs79040073	0.679	rs76231511	ENSG00000259531.2	RP11-295H24.3	9.17	1.25e-18	1.32e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:49222243	chr15:49365124~49366685:-
KIRC	cis	rs3813579	0.517	rs9928324	ENSG00000261390.4	RP11-345M22.2	9.17	1.27e-18	1.33e-15	0.46	0.38	Thyroid volume;	chr16:79711089	chr16:79715232~79770563:-
KIRC	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-9.17	1.27e-18	1.33e-15	-0.46	-0.38	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
KIRC	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-9.17	1.27e-18	1.33e-15	-0.36	-0.38	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
KIRC	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-9.17	1.27e-18	1.33e-15	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-9.17	1.27e-18	1.33e-15	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
KIRC	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	9.17	1.27e-18	1.33e-15	0.55	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
KIRC	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-9.17	1.27e-18	1.34e-15	-0.44	-0.38	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
KIRC	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	9.17	1.28e-18	1.34e-15	0.56	0.38	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	9.17	1.28e-18	1.34e-15	0.56	0.38	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
KIRC	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	9.17	1.28e-18	1.34e-15	0.36	0.38	Asthma;	chr2:102403325	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-9.17	1.28e-18	1.34e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
KIRC	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-9.17	1.28e-18	1.35e-15	-0.48	-0.38	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
KIRC	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	9.17	1.29e-18	1.35e-15	0.26	0.38	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
KIRC	cis	rs4356975	0.83	rs4481286	ENSG00000248763.2	RP13-644M16.5	-9.17	1.29e-18	1.35e-15	-0.48	-0.38	Obesity-related traits;	chr4:69056631	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs4583828	ENSG00000248763.2	RP13-644M16.5	-9.17	1.29e-18	1.35e-15	-0.48	-0.38	Obesity-related traits;	chr4:69056669	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs4235113	ENSG00000248763.2	RP13-644M16.5	-9.17	1.29e-18	1.35e-15	-0.48	-0.38	Obesity-related traits;	chr4:69056739	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs4235114	ENSG00000248763.2	RP13-644M16.5	-9.17	1.29e-18	1.35e-15	-0.48	-0.38	Obesity-related traits;	chr4:69056953	chr4:69066395~69069888:+
KIRC	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	9.17	1.29e-18	1.36e-15	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
KIRC	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-9.17	1.3e-18	1.36e-15	-0.49	-0.38	Height;	chr6:109501793	chr6:109382795~109383666:+
KIRC	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-9.17	1.3e-18	1.37e-15	-0.44	-0.38	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
KIRC	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	9.17	1.3e-18	1.37e-15	0.55	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
KIRC	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	9.17	1.31e-18	1.37e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
KIRC	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-9.17	1.31e-18	1.37e-15	-0.36	-0.38	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
KIRC	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	9.17	1.31e-18	1.37e-15	0.36	0.38	Asthma;	chr2:102404807	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	9.17	1.31e-18	1.37e-15	0.36	0.38	Asthma;	chr2:102407218	chr2:102438713~102440475:+
KIRC	cis	rs79040073	0.637	rs17473568	ENSG00000259531.2	RP11-295H24.3	9.17	1.31e-18	1.37e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49149326	chr15:49365124~49366685:-
KIRC	cis	rs4273100	1	rs57433322	ENSG00000262319.1	CTC-457L16.2	-9.17	1.31e-18	1.37e-15	-0.55	-0.38	Schizophrenia;	chr17:19238269	chr17:19141017~19143689:-
KIRC	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-9.17	1.32e-18	1.38e-15	-0.51	-0.38	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
KIRC	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-9.17	1.32e-18	1.38e-15	-0.57	-0.38	Height;	chr6:109625358	chr6:109382795~109383666:+
KIRC	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	9.16	1.32e-18	1.38e-15	0.43	0.38	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000250919.1	RP11-813N20.3	-9.16	1.32e-18	1.39e-15	-0.41	-0.38	Obesity-related traits;	chr4:69075937	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000250919.1	RP11-813N20.3	-9.16	1.32e-18	1.39e-15	-0.41	-0.38	Obesity-related traits;	chr4:69075944	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000250919.1	RP11-813N20.3	-9.16	1.32e-18	1.39e-15	-0.41	-0.38	Obesity-related traits;	chr4:69076309	chr4:69027831~69044578:+
KIRC	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-9.16	1.33e-18	1.39e-15	-0.42	-0.38	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
KIRC	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-9.16	1.33e-18	1.39e-15	-0.3	-0.38	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
KIRC	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	9.16	1.34e-18	1.4e-15	0.39	0.38	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
KIRC	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	9.16	1.34e-18	1.4e-15	0.36	0.38	Asthma;	chr2:102403679	chr2:102438713~102440475:+
KIRC	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-9.16	1.34e-18	1.4e-15	-0.46	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
KIRC	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-9.16	1.35e-18	1.41e-15	-0.42	-0.38	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-9.16	1.35e-18	1.41e-15	-0.42	-0.38	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
KIRC	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-9.16	1.35e-18	1.41e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-9.16	1.35e-18	1.41e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
KIRC	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-9.16	1.35e-18	1.41e-15	-0.42	-0.38	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000250919.1	RP11-813N20.3	-9.16	1.35e-18	1.41e-15	-0.4	-0.38	Obesity-related traits;	chr4:69074077	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000250919.1	RP11-813N20.3	-9.16	1.35e-18	1.41e-15	-0.4	-0.38	Obesity-related traits;	chr4:69075085	chr4:69027831~69044578:+
KIRC	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	9.16	1.36e-18	1.42e-15	0.53	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
KIRC	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-9.16	1.36e-18	1.42e-15	-0.44	-0.38	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
KIRC	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-9.16	1.36e-18	1.42e-15	-0.38	-0.38	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
KIRC	cis	rs79040073	0.637	rs17394420	ENSG00000259531.2	RP11-295H24.3	9.16	1.36e-18	1.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:49128619	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs17473148	ENSG00000259531.2	RP11-295H24.3	9.16	1.36e-18	1.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:49137213	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs74798636	ENSG00000259531.2	RP11-295H24.3	9.16	1.36e-18	1.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:49143146	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs79455310	ENSG00000259531.2	RP11-295H24.3	9.16	1.36e-18	1.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:49146918	chr15:49365124~49366685:-
KIRC	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	9.16	1.36e-18	1.42e-15	0.37	0.38	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
KIRC	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-9.16	1.36e-18	1.43e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
KIRC	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-9.16	1.37e-18	1.43e-15	-0.35	-0.38	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
KIRC	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	9.16	1.37e-18	1.43e-15	0.43	0.38	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
KIRC	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-9.16	1.37e-18	1.43e-15	-0.47	-0.38	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
KIRC	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	9.16	1.37e-18	1.43e-15	0.47	0.38	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
KIRC	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	9.16	1.37e-18	1.43e-15	0.76	0.38	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
KIRC	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-9.16	1.38e-18	1.44e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
KIRC	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	9.16	1.38e-18	1.44e-15	0.58	0.38	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
KIRC	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	9.16	1.38e-18	1.44e-15	0.58	0.38	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
KIRC	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-9.16	1.39e-18	1.45e-15	-0.44	-0.38	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-9.16	1.39e-18	1.45e-15	-0.44	-0.38	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
KIRC	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	9.16	1.39e-18	1.45e-15	0.27	0.38	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
KIRC	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-9.16	1.4e-18	1.46e-15	-0.45	-0.38	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
KIRC	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	9.16	1.4e-18	1.46e-15	0.44	0.38	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
KIRC	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	9.16	1.4e-18	1.46e-15	0.39	0.38	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
KIRC	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-9.16	1.41e-18	1.47e-15	-0.49	-0.38	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
KIRC	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-9.16	1.42e-18	1.48e-15	-0.43	-0.38	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
KIRC	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-9.16	1.42e-18	1.48e-15	-0.51	-0.38	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
KIRC	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	9.16	1.42e-18	1.49e-15	0.74	0.38	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
KIRC	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	9.16	1.43e-18	1.49e-15	0.67	0.38	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
KIRC	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-9.15	1.43e-18	1.5e-15	-0.4	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
KIRC	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	9.15	1.44e-18	1.51e-15	0.75	0.38	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
KIRC	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
KIRC	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
KIRC	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
KIRC	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
KIRC	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-9.15	1.45e-18	1.51e-15	-0.43	-0.38	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
KIRC	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-9.15	1.45e-18	1.51e-15	-0.37	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
KIRC	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-9.15	1.45e-18	1.52e-15	-0.48	-0.38	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
KIRC	cis	rs919433	0.963	rs10199410	ENSG00000231621.1	AC013264.2	9.15	1.46e-18	1.52e-15	0.4	0.38	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197291052	chr2:197197991~197199273:+
KIRC	cis	rs1005277	0.505	rs10827835	ENSG00000151963.4	RP11-775A3.1	9.15	1.47e-18	1.54e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:37883594~37884109:+
KIRC	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-9.15	1.47e-18	1.54e-15	-0.5	-0.38	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
KIRC	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	9.15	1.48e-18	1.54e-15	0.5	0.38	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
KIRC	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-9.15	1.48e-18	1.55e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
KIRC	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-9.15	1.5e-18	1.56e-15	-0.35	-0.38	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
KIRC	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	9.15	1.5e-18	1.57e-15	0.5	0.38	Height;	chr6:109586733	chr6:109382795~109383666:+
KIRC	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-9.15	1.51e-18	1.57e-15	-0.32	-0.38	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
KIRC	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	9.15	1.51e-18	1.57e-15	0.43	0.38	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
KIRC	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-9.15	1.51e-18	1.57e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
KIRC	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	9.15	1.51e-18	1.58e-15	0.51	0.38	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
KIRC	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	9.15	1.52e-18	1.58e-15	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
KIRC	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	9.15	1.52e-18	1.58e-15	0.54	0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
KIRC	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-9.15	1.53e-18	1.59e-15	-0.48	-0.38	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
KIRC	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	9.15	1.54e-18	1.6e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
KIRC	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	9.15	1.54e-18	1.6e-15	0.53	0.38	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
KIRC	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-9.15	1.55e-18	1.61e-15	-0.55	-0.38	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
KIRC	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-9.14	1.55e-18	1.61e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
KIRC	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-9.14	1.55e-18	1.61e-15	-0.38	-0.38	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
KIRC	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	9.14	1.55e-18	1.61e-15	0.44	0.38	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
KIRC	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	9.14	1.56e-18	1.62e-15	0.48	0.38	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
KIRC	cis	rs2698530	0.634	rs1816618	ENSG00000225889.6	AC074289.1	-9.14	1.57e-18	1.63e-15	-0.39	-0.38	Iron status biomarkers;	chr2:64220750	chr2:64143239~64252859:+
KIRC	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	9.14	1.57e-18	1.63e-15	0.58	0.38	Height;	chr6:109645257	chr6:109382795~109383666:+
KIRC	cis	rs1005277	0.54	rs1814077	ENSG00000151963.4	RP11-775A3.1	-9.14	1.57e-18	1.63e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:37883594~37884109:+
KIRC	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	9.14	1.57e-18	1.64e-15	0.51	0.38	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
KIRC	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-9.14	1.58e-18	1.64e-15	-0.44	-0.38	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
KIRC	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-9.14	1.59e-18	1.66e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
KIRC	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-9.14	1.6e-18	1.66e-15	-0.35	-0.38	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
KIRC	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	9.14	1.6e-18	1.66e-15	0.68	0.38	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
KIRC	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-9.14	1.6e-18	1.66e-15	-0.45	-0.38	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
KIRC	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-9.14	1.6e-18	1.66e-15	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
KIRC	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-9.14	1.6e-18	1.66e-15	-0.39	-0.38	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
KIRC	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	9.14	1.6e-18	1.67e-15	0.57	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
KIRC	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	9.14	1.6e-18	1.67e-15	0.57	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
KIRC	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	9.14	1.61e-18	1.67e-15	0.47	0.38	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
KIRC	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	9.14	1.61e-18	1.67e-15	0.54	0.38	Height;	chr6:109764163	chr6:109382795~109383666:+
KIRC	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	9.14	1.61e-18	1.67e-15	0.36	0.38	Asthma;	chr2:102412435	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	9.14	1.61e-18	1.67e-15	0.36	0.38	Asthma;	chr2:102412461	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	9.14	1.61e-18	1.67e-15	0.36	0.38	Asthma;	chr2:102412524	chr2:102438713~102440475:+
KIRC	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	9.14	1.62e-18	1.68e-15	0.51	0.38	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
KIRC	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-9.14	1.62e-18	1.69e-15	-0.33	-0.38	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
KIRC	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	9.14	1.63e-18	1.69e-15	0.48	0.38	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
KIRC	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	9.14	1.63e-18	1.69e-15	0.39	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
KIRC	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	9.14	1.64e-18	1.7e-15	0.44	0.38	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
KIRC	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	9.14	1.65e-18	1.71e-15	0.48	0.38	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
KIRC	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	9.14	1.65e-18	1.71e-15	0.38	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
KIRC	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	9.14	1.66e-18	1.72e-15	0.44	0.38	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
KIRC	cis	rs4356975	0.83	rs60212682	ENSG00000248763.2	RP13-644M16.5	-9.14	1.66e-18	1.72e-15	-0.48	-0.38	Obesity-related traits;	chr4:69052849	chr4:69066395~69069888:+
KIRC	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-9.14	1.66e-18	1.73e-15	-0.44	-0.38	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
KIRC	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-9.14	1.67e-18	1.73e-15	-0.35	-0.38	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
KIRC	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-9.14	1.67e-18	1.73e-15	-0.65	-0.38	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
KIRC	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.14	1.67e-18	1.74e-15	-0.46	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
KIRC	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	9.13	1.68e-18	1.74e-15	0.46	0.38	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
KIRC	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-9.13	1.68e-18	1.74e-15	-0.44	-0.38	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
KIRC	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-9.13	1.68e-18	1.74e-15	-0.44	-0.38	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
KIRC	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	9.13	1.68e-18	1.74e-15	0.36	0.38	Asthma;	chr2:102410644	chr2:102438713~102440475:+
KIRC	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	9.13	1.69e-18	1.75e-15	0.44	0.38	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	9.13	1.69e-18	1.75e-15	0.44	0.38	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	9.13	1.69e-18	1.75e-15	0.44	0.38	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
KIRC	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-9.13	1.69e-18	1.75e-15	-0.31	-0.38	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
KIRC	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-9.13	1.7e-18	1.76e-15	-0.49	-0.38	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
KIRC	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-9.13	1.7e-18	1.76e-15	-0.5	-0.38	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
KIRC	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	9.13	1.7e-18	1.76e-15	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
KIRC	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	9.13	1.7e-18	1.76e-15	0.81	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
KIRC	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	9.13	1.71e-18	1.77e-15	0.37	0.38	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
KIRC	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	9.13	1.71e-18	1.77e-15	0.71	0.38	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
KIRC	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-9.13	1.71e-18	1.77e-15	-0.52	-0.38	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-9.13	1.71e-18	1.77e-15	-0.52	-0.38	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
KIRC	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-9.13	1.71e-18	1.77e-15	-0.39	-0.38	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
KIRC	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-9.13	1.71e-18	1.77e-15	-0.4	-0.38	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
KIRC	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	9.13	1.72e-18	1.78e-15	0.44	0.38	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000250919.1	RP11-813N20.3	-9.13	1.73e-18	1.79e-15	-0.41	-0.38	Obesity-related traits;	chr4:69077628	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000250919.1	RP11-813N20.3	-9.13	1.73e-18	1.79e-15	-0.41	-0.38	Obesity-related traits;	chr4:69077631	chr4:69027831~69044578:+
KIRC	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	9.13	1.73e-18	1.79e-15	0.74	0.38	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
KIRC	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-9.13	1.73e-18	1.79e-15	-0.4	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
KIRC	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-9.13	1.73e-18	1.79e-15	-0.42	-0.38	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
KIRC	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	9.13	1.74e-18	1.8e-15	0.36	0.38	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
KIRC	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-9.13	1.74e-18	1.8e-15	-0.77	-0.38	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
KIRC	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-9.13	1.75e-18	1.81e-15	-0.48	-0.38	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
KIRC	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	9.13	1.75e-18	1.81e-15	0.43	0.38	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
KIRC	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-9.13	1.77e-18	1.83e-15	-0.44	-0.38	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
KIRC	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-9.13	1.77e-18	1.83e-15	-0.37	-0.38	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
KIRC	cis	rs1005277	0.522	rs11011343	ENSG00000151963.4	RP11-775A3.1	-9.13	1.78e-18	1.84e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:37883594~37884109:+
KIRC	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-9.13	1.78e-18	1.84e-15	-0.34	-0.38	Height;	chr4:55364952	chr4:55363971~55395847:-
KIRC	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	9.13	1.8e-18	1.86e-15	0.32	0.38	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
KIRC	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	9.13	1.8e-18	1.86e-15	0.66	0.38	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
KIRC	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-9.12	1.82e-18	1.88e-15	-0.49	-0.38	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
KIRC	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	9.12	1.82e-18	1.88e-15	0.39	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
KIRC	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-9.12	1.83e-18	1.89e-15	-0.4	-0.38	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
KIRC	cis	rs6600671	1	rs4844607	ENSG00000227082.1	CH17-437K3.1	9.12	1.83e-18	1.89e-15	0.43	0.38	Hip geometry;	chr1:121442201	chr1:121396754~121463129:+
KIRC	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	9.12	1.85e-18	1.91e-15	0.38	0.38	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
KIRC	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	9.12	1.85e-18	1.91e-15	0.48	0.38	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
KIRC	cis	rs1005277	0.522	rs7090858	ENSG00000151963.4	RP11-775A3.1	9.12	1.85e-18	1.91e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:37883594~37884109:+
KIRC	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-9.12	1.86e-18	1.92e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-9.12	1.86e-18	1.92e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
KIRC	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-9.12	1.88e-18	1.94e-15	-0.68	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
KIRC	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	9.12	1.88e-18	1.94e-15	0.49	0.38	Height;	chr6:109490935	chr6:109382795~109383666:+
KIRC	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	9.12	1.88e-18	1.95e-15	0.44	0.38	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
KIRC	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	9.12	1.9e-18	1.96e-15	0.42	0.38	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	9.12	1.9e-18	1.96e-15	0.42	0.38	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	9.12	1.9e-18	1.96e-15	0.42	0.38	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
KIRC	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	9.12	1.91e-18	1.97e-15	0.49	0.38	Height;	chr6:109494148	chr6:109382795~109383666:+
KIRC	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-9.12	1.92e-18	1.98e-15	-0.38	-0.38	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
KIRC	cis	rs1200821	0.535	rs1938417	ENSG00000151963.4	RP11-775A3.1	9.12	1.92e-18	1.99e-15	0.43	0.38	Hemostatic factors and hematological phenotypes;	chr10:37398592	chr10:37883594~37884109:+
KIRC	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	9.12	1.93e-18	1.99e-15	0.36	0.38	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
KIRC	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-9.12	1.93e-18	1.99e-15	-0.42	-0.38	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
KIRC	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	9.12	1.94e-18	2e-15	0.34	0.38	Height;	chr4:55537960	chr4:55363971~55395847:-
KIRC	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	9.12	1.94e-18	2e-15	0.6	0.38	Height;	chr6:109369898	chr6:109382795~109383666:+
KIRC	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	9.12	1.94e-18	2e-15	0.34	0.38	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
KIRC	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-9.12	1.94e-18	2e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
KIRC	cis	rs79040073	0.637	rs73408143	ENSG00000259531.2	RP11-295H24.3	9.12	1.95e-18	2.01e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49126771	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs3088333	ENSG00000259531.2	RP11-295H24.3	9.12	1.95e-18	2.01e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49140891	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs17394970	ENSG00000259531.2	RP11-295H24.3	9.12	1.95e-18	2.01e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49145371	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11635455	ENSG00000259531.2	RP11-295H24.3	9.12	1.95e-18	2.01e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49147216	chr15:49365124~49366685:-
KIRC	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	9.12	1.95e-18	2.01e-15	0.51	0.38	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
KIRC	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-9.12	1.96e-18	2.02e-15	-0.44	-0.38	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
KIRC	cis	rs1005277	0.505	rs1208689	ENSG00000151963.4	RP11-775A3.1	-9.11	1.97e-18	2.02e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:37883594~37884109:+
KIRC	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	9.11	1.97e-18	2.02e-15	0.53	0.38	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	9.11	1.97e-18	2.02e-15	0.53	0.38	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
KIRC	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	9.11	1.98e-18	2.04e-15	0.37	0.38	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
KIRC	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-9.11	1.99e-18	2.04e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
KIRC	cis	rs950776	0.507	rs12912673	ENSG00000261762.1	RP11-650L12.2	9.11	1.99e-18	2.04e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78517874	chr15:78589123~78591276:-
KIRC	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-9.11	2e-18	2.06e-15	-0.43	-0.38	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
KIRC	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-9.11	2e-18	2.06e-15	-0.44	-0.38	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
KIRC	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-9.11	2.01e-18	2.06e-15	-0.52	-0.38	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
KIRC	cis	rs79040073	0.637	rs73392249	ENSG00000259531.2	RP11-295H24.3	9.11	2.01e-18	2.07e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49224264	chr15:49365124~49366685:-
KIRC	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	9.11	2.01e-18	2.07e-15	0.43	0.38	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
KIRC	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-9.11	2.03e-18	2.09e-15	-0.35	-0.38	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
KIRC	cis	rs2698530	0.791	rs2698526	ENSG00000225889.6	AC074289.1	9.11	2.03e-18	2.09e-15	0.38	0.38	Iron status biomarkers;	chr2:64272389	chr2:64143239~64252859:+
KIRC	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-9.11	2.04e-18	2.09e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-9.11	2.04e-18	2.09e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-9.11	2.04e-18	2.09e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-9.11	2.04e-18	2.09e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	9.11	2.04e-18	2.09e-15	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
KIRC	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-9.11	2.05e-18	2.1e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-9.11	2.05e-18	2.1e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-9.11	2.05e-18	2.1e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
KIRC	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	9.11	2.05e-18	2.1e-15	0.49	0.38	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
KIRC	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	9.11	2.05e-18	2.11e-15	0.44	0.38	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	9.11	2.05e-18	2.11e-15	0.44	0.38	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
KIRC	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-9.11	2.06e-18	2.11e-15	-0.5	-0.38	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.83	rs6600865	ENSG00000248763.2	RP13-644M16.5	-9.11	2.06e-18	2.11e-15	-0.47	-0.38	Obesity-related traits;	chr4:69057904	chr4:69066395~69069888:+
KIRC	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-9.11	2.06e-18	2.11e-15	-0.43	-0.38	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
KIRC	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	9.11	2.06e-18	2.12e-15	0.48	0.38	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
KIRC	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-9.11	2.07e-18	2.13e-15	-0.52	-0.38	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-9.11	2.07e-18	2.13e-15	-0.52	-0.38	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
KIRC	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-9.11	2.07e-18	2.13e-15	-0.51	-0.38	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
KIRC	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-9.11	2.08e-18	2.13e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-9.11	2.08e-18	2.13e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-9.11	2.08e-18	2.13e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-9.11	2.08e-18	2.13e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-9.11	2.08e-18	2.13e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000250919.1	RP11-813N20.3	-9.11	2.08e-18	2.13e-15	-0.4	-0.38	Obesity-related traits;	chr4:69078113	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000250919.1	RP11-813N20.3	-9.11	2.08e-18	2.13e-15	-0.4	-0.38	Obesity-related traits;	chr4:69078247	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000250919.1	RP11-813N20.3	-9.11	2.08e-18	2.13e-15	-0.4	-0.38	Obesity-related traits;	chr4:69078533	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000250919.1	RP11-813N20.3	-9.11	2.08e-18	2.13e-15	-0.4	-0.38	Obesity-related traits;	chr4:69078868	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000250919.1	RP11-813N20.3	-9.11	2.08e-18	2.13e-15	-0.4	-0.38	Obesity-related traits;	chr4:69078897	chr4:69027831~69044578:+
KIRC	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-9.11	2.09e-18	2.14e-15	-0.42	-0.38	Height;	chr11:118764443	chr11:118704607~118750263:+
KIRC	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	9.11	2.09e-18	2.14e-15	0.36	0.38	Asthma;	chr2:102399227	chr2:102438713~102440475:+
KIRC	cis	rs79040073	0.599	rs17396536	ENSG00000259531.2	RP11-295H24.3	9.11	2.09e-18	2.14e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49256871	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs78881953	ENSG00000259531.2	RP11-295H24.3	9.11	2.09e-18	2.14e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49269019	chr15:49365124~49366685:-
KIRC	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	9.11	2.1e-18	2.15e-15	0.44	0.38	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
KIRC	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-9.11	2.11e-18	2.16e-15	-0.48	-0.38	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
KIRC	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-9.11	2.12e-18	2.17e-15	-0.48	-0.38	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
KIRC	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	9.11	2.12e-18	2.18e-15	0.36	0.38	Asthma;	chr2:102379885	chr2:102438713~102440475:+
KIRC	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	9.1	2.12e-18	2.18e-15	0.3	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
KIRC	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	9.1	2.13e-18	2.18e-15	0.54	0.38	Height;	chr6:109762861	chr6:109382795~109383666:+
KIRC	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-9.1	2.13e-18	2.19e-15	-0.35	-0.38	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
KIRC	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-9.1	2.15e-18	2.2e-15	-0.52	-0.38	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
KIRC	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	9.1	2.15e-18	2.2e-15	0.44	0.38	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
KIRC	cis	rs9457247	0.508	rs7760495	ENSG00000265828.1	MIR3939	-9.1	2.15e-18	2.21e-15	-0.43	-0.38	Crohn's disease;	chr6:167093307	chr6:166997807~166997912:-
KIRC	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-9.1	2.17e-18	2.22e-15	-0.43	-0.38	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
KIRC	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-9.1	2.18e-18	2.23e-15	-0.29	-0.38	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
KIRC	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-9.1	2.19e-18	2.24e-15	-0.43	-0.38	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
KIRC	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	9.1	2.19e-18	2.24e-15	0.51	0.38	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	9.1	2.19e-18	2.24e-15	0.51	0.38	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
KIRC	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-9.1	2.19e-18	2.24e-15	-0.36	-0.38	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
KIRC	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	9.1	2.19e-18	2.24e-15	0.36	0.38	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
KIRC	cis	rs2749592	0.918	rs11011388	ENSG00000151963.4	RP11-775A3.1	9.1	2.21e-18	2.25e-15	0.49	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37866282	chr10:37883594~37884109:+
KIRC	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	9.1	2.21e-18	2.26e-15	0.26	0.38	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
KIRC	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	9.1	2.21e-18	2.26e-15	0.5	0.38	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
KIRC	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-9.1	2.22e-18	2.27e-15	-0.35	-0.38	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
KIRC	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-9.1	2.23e-18	2.27e-15	-0.42	-0.38	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-9.1	2.23e-18	2.27e-15	-0.42	-0.38	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-9.1	2.23e-18	2.27e-15	-0.42	-0.38	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
KIRC	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	9.1	2.23e-18	2.27e-15	0.29	0.38	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	9.1	2.23e-18	2.27e-15	0.29	0.38	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	9.1	2.23e-18	2.27e-15	0.29	0.38	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
KIRC	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-9.1	2.23e-18	2.28e-15	-0.43	-0.38	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
KIRC	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-9.1	2.24e-18	2.29e-15	-0.43	-0.38	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
KIRC	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-9.1	2.25e-18	2.3e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
KIRC	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	9.1	2.25e-18	2.3e-15	0.36	0.38	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
KIRC	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	9.1	2.26e-18	2.31e-15	0.26	0.38	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
KIRC	cis	rs4356975	0.798	rs4694588	ENSG00000248763.2	RP13-644M16.5	9.1	2.27e-18	2.32e-15	0.48	0.38	Obesity-related traits;	chr4:69044664	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs6422321	ENSG00000248763.2	RP13-644M16.5	9.1	2.27e-18	2.32e-15	0.48	0.38	Obesity-related traits;	chr4:69044911	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.768	rs4518318	ENSG00000248763.2	RP13-644M16.5	9.1	2.27e-18	2.32e-15	0.48	0.38	Obesity-related traits;	chr4:69045479	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs4351079	ENSG00000248763.2	RP13-644M16.5	9.1	2.27e-18	2.32e-15	0.48	0.38	Obesity-related traits;	chr4:69045631	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.798	rs4607293	ENSG00000248763.2	RP13-644M16.5	9.1	2.27e-18	2.32e-15	0.48	0.38	Obesity-related traits;	chr4:69045714	chr4:69066395~69069888:+
KIRC	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-9.1	2.28e-18	2.33e-15	-0.49	-0.38	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
KIRC	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-9.1	2.29e-18	2.33e-15	-0.48	-0.38	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-9.1	2.29e-18	2.34e-15	-0.48	-0.38	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
KIRC	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	9.09	2.31e-18	2.35e-15	0.41	0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
KIRC	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	9.09	2.31e-18	2.36e-15	0.44	0.38	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
KIRC	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	9.09	2.32e-18	2.36e-15	0.42	0.38	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
KIRC	cis	rs1005277	0.54	rs2145487	ENSG00000151963.4	RP11-775A3.1	-9.09	2.33e-18	2.37e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:37883594~37884109:+
KIRC	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	9.09	2.33e-18	2.37e-15	0.44	0.38	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
KIRC	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-9.09	2.33e-18	2.37e-15	-0.42	-0.38	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
KIRC	cis	rs904251	0.861	rs1757169	ENSG00000227920.2	RP1-153P14.5	-9.09	2.33e-18	2.37e-15	-0.44	-0.38	Cognitive performance;	chr6:37519300	chr6:37545145~37550860:+
KIRC	cis	rs79040073	0.637	rs73398223	ENSG00000259531.2	RP11-295H24.3	9.09	2.33e-18	2.37e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49379505	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs60594237	ENSG00000259531.2	RP11-295H24.3	9.09	2.33e-18	2.37e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49379916	chr15:49365124~49366685:-
KIRC	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-9.09	2.34e-18	2.38e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
KIRC	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	9.09	2.34e-18	2.38e-15	0.44	0.38	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
KIRC	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	9.09	2.34e-18	2.38e-15	0.35	0.38	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
KIRC	cis	rs950776	0.518	rs12591557	ENSG00000261762.1	RP11-650L12.2	9.09	2.34e-18	2.38e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78519390	chr15:78589123~78591276:-
KIRC	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	9.09	2.35e-18	2.39e-15	0.44	0.38	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	9.09	2.35e-18	2.39e-15	0.44	0.38	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-9.09	2.35e-18	2.39e-15	-0.29	-0.38	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
KIRC	cis	rs904251	0.523	rs2776874	ENSG00000227920.2	RP1-153P14.5	-9.09	2.35e-18	2.39e-15	-0.41	-0.38	Cognitive performance;	chr6:37515421	chr6:37545145~37550860:+
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000250919.1	RP11-813N20.3	9.09	2.37e-18	2.41e-15	0.4	0.38	Obesity-related traits;	chr4:69075436	chr4:69027831~69044578:+
KIRC	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	9.09	2.4e-18	2.44e-15	0.43	0.38	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
KIRC	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	9.09	2.4e-18	2.44e-15	0.34	0.38	Height;	chr4:55485974	chr4:55363971~55395847:-
KIRC	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	9.09	2.41e-18	2.44e-15	0.36	0.38	Asthma;	chr2:102423587	chr2:102438713~102440475:+
KIRC	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-9.09	2.41e-18	2.45e-15	-0.37	-0.38	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
KIRC	cis	rs9457247	0.508	rs6941355	ENSG00000265828.1	MIR3939	-9.09	2.41e-18	2.45e-15	-0.43	-0.38	Crohn's disease;	chr6:167092750	chr6:166997807~166997912:-
KIRC	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-9.09	2.43e-18	2.47e-15	-0.51	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
KIRC	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-9.09	2.44e-18	2.48e-15	-0.43	-0.38	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
KIRC	cis	rs79040073	0.637	rs76069611	ENSG00000259531.2	RP11-295H24.3	9.09	2.44e-18	2.48e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49281322	chr15:49365124~49366685:-
KIRC	cis	rs899997	1	rs11632672	ENSG00000261143.1	ADAMTS7P3	9.09	2.45e-18	2.48e-15	0.45	0.38	Coronary artery disease or large artery stroke;	chr15:78751988	chr15:77976042~77993057:+
KIRC	cis	rs79040073	0.564	rs34606419	ENSG00000259531.2	RP11-295H24.3	9.09	2.46e-18	2.49e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49240390	chr15:49365124~49366685:-
KIRC	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	9.09	2.46e-18	2.5e-15	0.61	0.38	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
KIRC	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	9.09	2.47e-18	2.5e-15	0.61	0.38	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
KIRC	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-9.09	2.47e-18	2.51e-15	-0.4	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
KIRC	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	9.09	2.48e-18	2.51e-15	0.53	0.38	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
KIRC	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-9.08	2.49e-18	2.52e-15	-0.5	-0.38	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
KIRC	cis	rs79040073	0.51	rs111307556	ENSG00000259531.2	RP11-295H24.3	9.08	2.5e-18	2.53e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49339858	chr15:49365124~49366685:-
KIRC	cis	rs950776	0.518	rs12900783	ENSG00000261762.1	RP11-650L12.2	9.08	2.51e-18	2.54e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78523181	chr15:78589123~78591276:-
KIRC	cis	rs4356975	0.83	rs7693166	ENSG00000248763.2	RP13-644M16.5	9.08	2.53e-18	2.56e-15	0.48	0.38	Obesity-related traits;	chr4:69044866	chr4:69066395~69069888:+
KIRC	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	9.08	2.53e-18	2.56e-15	0.42	0.38	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
KIRC	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-9.08	2.55e-18	2.58e-15	-0.48	-0.38	Height;	chr6:109497253	chr6:109382795~109383666:+
KIRC	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-9.08	2.56e-18	2.59e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-9.08	2.56e-18	2.59e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
KIRC	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	9.08	2.57e-18	2.6e-15	0.49	0.38	Height;	chr6:109501402	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	9.08	2.57e-18	2.6e-15	0.49	0.38	Height;	chr6:109501429	chr6:109382795~109383666:+
KIRC	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-9.08	2.58e-18	2.6e-15	-0.44	-0.38	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
KIRC	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-9.08	2.58e-18	2.61e-15	-0.42	-0.38	Height;	chr11:118761813	chr11:118704607~118750263:+
KIRC	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	9.08	2.59e-18	2.62e-15	0.51	0.38	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
KIRC	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	9.08	2.59e-18	2.62e-15	0.56	0.38	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
KIRC	cis	rs2749592	0.55	rs4934881	ENSG00000151963.4	RP11-775A3.1	9.08	2.6e-18	2.63e-15	0.43	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:37883594~37884109:+
KIRC	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-9.08	2.61e-18	2.64e-15	-0.39	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
KIRC	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-9.08	2.62e-18	2.65e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
KIRC	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	9.08	2.62e-18	2.65e-15	0.5	0.38	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
KIRC	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-9.08	2.63e-18	2.66e-15	-0.39	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
KIRC	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	9.08	2.63e-18	2.66e-15	0.6	0.38	Height;	chr6:109409645	chr6:109382795~109383666:+
KIRC	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	9.08	2.64e-18	2.67e-15	0.55	0.38	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
KIRC	cis	rs1005277	0.505	rs200939	ENSG00000151963.4	RP11-775A3.1	-9.08	2.65e-18	2.67e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:37883594~37884109:+
KIRC	cis	rs950776	0.518	rs12594391	ENSG00000261762.1	RP11-650L12.2	9.08	2.65e-18	2.68e-15	0.49	0.38	Sudden cardiac arrest;	chr15:78523898	chr15:78589123~78591276:-
KIRC	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	9.08	2.66e-18	2.68e-15	0.36	0.38	Asthma;	chr2:102426252	chr2:102438713~102440475:+
KIRC	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	9.08	2.66e-18	2.69e-15	0.5	0.38	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000250919.1	RP11-813N20.3	-9.08	2.67e-18	2.69e-15	-0.4	-0.38	Obesity-related traits;	chr4:69079387	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000250919.1	RP11-813N20.3	-9.08	2.67e-18	2.69e-15	-0.4	-0.38	Obesity-related traits;	chr4:69079446	chr4:69027831~69044578:+
KIRC	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-9.08	2.68e-18	2.7e-15	-0.43	-0.38	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
KIRC	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	9.08	2.68e-18	2.71e-15	0.44	0.38	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
KIRC	cis	rs950776	0.518	rs62008174	ENSG00000261762.1	RP11-650L12.2	9.08	2.69e-18	2.71e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78516605	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.518	rs12910978	ENSG00000261762.1	RP11-650L12.2	9.08	2.69e-18	2.71e-15	0.5	0.38	Sudden cardiac arrest;	chr15:78517675	chr15:78589123~78591276:-
KIRC	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	9.08	2.69e-18	2.71e-15	0.47	0.38	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
KIRC	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-9.07	2.7e-18	2.73e-15	-0.47	-0.38	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
KIRC	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	9.07	2.71e-18	2.73e-15	0.36	0.38	Asthma;	chr2:102427407	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	9.07	2.71e-18	2.73e-15	0.36	0.38	Asthma;	chr2:102427715	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	9.07	2.71e-18	2.73e-15	0.36	0.38	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	9.07	2.71e-18	2.73e-15	0.36	0.38	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	9.07	2.71e-18	2.73e-15	0.36	0.38	Asthma;	chr2:102423717	chr2:102438713~102440475:+
KIRC	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-9.07	2.71e-18	2.74e-15	-0.41	-0.38	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
KIRC	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	9.07	2.72e-18	2.74e-15	0.51	0.38	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	9.07	2.72e-18	2.74e-15	0.51	0.38	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
KIRC	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-9.07	2.72e-18	2.75e-15	-0.46	-0.38	Depression;	chr6:28422360	chr6:28176188~28176674:+
KIRC	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	9.07	2.73e-18	2.75e-15	0.44	0.38	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
KIRC	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-9.07	2.73e-18	2.75e-15	-0.68	-0.38	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
KIRC	cis	rs2698530	0.791	rs869739	ENSG00000225889.6	AC074289.1	-9.07	2.74e-18	2.76e-15	-0.38	-0.38	Iron status biomarkers;	chr2:64266012	chr2:64143239~64252859:+
KIRC	cis	rs79040073	0.637	rs11632575	ENSG00000259531.2	RP11-295H24.3	9.07	2.74e-18	2.77e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49380758	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.594	rs59112977	ENSG00000259531.2	RP11-295H24.3	9.07	2.74e-18	2.77e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49382342	chr15:49365124~49366685:-
KIRC	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	9.07	2.75e-18	2.77e-15	0.42	0.38	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
KIRC	cis	rs1200821	0.529	rs4934856	ENSG00000151963.4	RP11-775A3.1	9.07	2.75e-18	2.78e-15	0.43	0.38	Hemostatic factors and hematological phenotypes;	chr10:37518919	chr10:37883594~37884109:+
KIRC	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	9.07	2.76e-18	2.79e-15	0.36	0.38	Asthma;	chr2:102419875	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	9.07	2.76e-18	2.79e-15	0.36	0.38	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	9.07	2.76e-18	2.79e-15	0.36	0.38	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	9.07	2.76e-18	2.79e-15	0.36	0.38	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	9.07	2.76e-18	2.79e-15	0.36	0.38	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
KIRC	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-9.07	2.78e-18	2.8e-15	-0.31	-0.38	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
KIRC	cis	rs1005277	0.522	rs1208767	ENSG00000151963.4	RP11-775A3.1	-9.07	2.78e-18	2.8e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:37883594~37884109:+
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000250696.4	RP11-704M14.1	9.07	2.78e-18	2.8e-15	0.39	0.38	Obesity-related traits;	chr4:69079291	chr4:69182100~69216766:+
KIRC	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-9.07	2.78e-18	2.8e-15	-0.37	-0.38	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
KIRC	cis	rs1005277	0.54	rs4934907	ENSG00000151963.4	RP11-775A3.1	-9.07	2.79e-18	2.81e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:37883594~37884109:+
KIRC	cis	rs1005277	0.54	rs11011351	ENSG00000151963.4	RP11-775A3.1	-9.07	2.79e-18	2.81e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:37883594~37884109:+
KIRC	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-9.07	2.81e-18	2.83e-15	-0.43	-0.38	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
KIRC	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-9.07	2.81e-18	2.83e-15	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
KIRC	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	9.07	2.81e-18	2.83e-15	0.34	0.38	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
KIRC	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	9.07	2.82e-18	2.84e-15	0.36	0.38	Asthma;	chr2:102419319	chr2:102438713~102440475:+
KIRC	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.07	2.83e-18	2.85e-15	-0.31	-0.38	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
KIRC	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	9.07	2.83e-18	2.85e-15	0.48	0.38	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
KIRC	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.07	2.83e-18	2.85e-15	0.31	0.38	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
KIRC	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-9.07	2.84e-18	2.85e-15	-0.48	-0.38	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
KIRC	cis	rs1005277	0.505	rs7099777	ENSG00000151963.4	RP11-775A3.1	9.07	2.85e-18	2.87e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:37883594~37884109:+
KIRC	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-9.07	2.86e-18	2.88e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-9.07	2.86e-18	2.88e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-9.07	2.86e-18	2.88e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
KIRC	cis	rs1005277	0.505	rs7917943	ENSG00000151963.4	RP11-775A3.1	9.07	2.86e-18	2.88e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:37883594~37884109:+
KIRC	cis	rs1005277	0.505	rs10827836	ENSG00000151963.4	RP11-775A3.1	9.07	2.87e-18	2.89e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:37883594~37884109:+
KIRC	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	9.07	2.9e-18	2.91e-15	0.5	0.38	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
KIRC	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-9.07	2.9e-18	2.92e-15	-0.51	-0.38	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
KIRC	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	9.07	2.91e-18	2.92e-15	0.35	0.38	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
KIRC	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-9.06	2.92e-18	2.93e-15	-0.42	-0.38	Height;	chr11:118749988	chr11:118704607~118750263:+
KIRC	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-9.06	2.92e-18	2.94e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
KIRC	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-9.06	2.93e-18	2.95e-15	-0.49	-0.38	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
KIRC	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	9.06	2.94e-18	2.95e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
KIRC	cis	rs1005277	0.577	rs4934906	ENSG00000151963.4	RP11-775A3.1	-9.06	2.94e-18	2.95e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37883594~37884109:+
KIRC	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	9.06	2.95e-18	2.96e-15	0.49	0.38	Height;	chr6:109494760	chr6:109382795~109383666:+
KIRC	cis	rs79040073	0.637	rs113885253	ENSG00000259531.2	RP11-295H24.3	9.06	2.95e-18	2.97e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49402615	chr15:49365124~49366685:-
KIRC	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-9.06	2.95e-18	2.97e-15	-0.47	-0.38	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-9.06	2.95e-18	2.97e-15	-0.47	-0.38	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-9.06	2.95e-18	2.97e-15	-0.47	-0.38	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
KIRC	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	9.06	2.97e-18	2.99e-15	0.43	0.38	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
KIRC	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	9.06	3.02e-18	3.03e-15	0.55	0.38	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	9.06	3.02e-18	3.03e-15	0.55	0.38	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
KIRC	cis	rs10916248	0.511	rs10916512	ENSG00000232628.4	RP11-365O16.3	9.06	3.02e-18	3.04e-15	0.61	0.38	QT interval (drug interaction);	chr1:224220968	chr1:224208747~224213279:-
KIRC	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-9.06	3.03e-18	3.04e-15	-0.43	-0.38	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
KIRC	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	9.06	3.04e-18	3.05e-15	0.43	0.38	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
KIRC	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-9.06	3.06e-18	3.07e-15	-0.43	-0.38	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
KIRC	cis	rs904251	0.861	rs2776875	ENSG00000227920.2	RP1-153P14.5	-9.06	3.07e-18	3.08e-15	-0.44	-0.38	Cognitive performance;	chr6:37519020	chr6:37545145~37550860:+
KIRC	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	9.06	3.07e-18	3.08e-15	0.44	0.38	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
KIRC	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-9.06	3.08e-18	3.09e-15	-0.47	-0.38	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-9.06	3.08e-18	3.09e-15	-0.47	-0.38	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
KIRC	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	9.06	3.08e-18	3.09e-15	0.4	0.38	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
KIRC	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-9.06	3.08e-18	3.09e-15	-0.58	-0.38	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
KIRC	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-9.06	3.08e-18	3.09e-15	-0.43	-0.38	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
KIRC	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-9.06	3.09e-18	3.09e-15	-0.38	-0.38	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
KIRC	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-9.06	3.1e-18	3.11e-15	-0.57	-0.38	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
KIRC	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	9.06	3.1e-18	3.11e-15	0.5	0.38	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
KIRC	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-9.06	3.12e-18	3.12e-15	-0.37	-0.38	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000250696.4	RP11-704M14.1	9.06	3.15e-18	3.15e-15	0.39	0.38	Obesity-related traits;	chr4:69062256	chr4:69182100~69216766:+
KIRC	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-9.05	3.16e-18	3.17e-15	-0.51	-0.38	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
KIRC	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-9.05	3.18e-18	3.18e-15	-0.42	-0.38	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
KIRC	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-9.05	3.18e-18	3.18e-15	-0.42	-0.38	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
KIRC	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-9.05	3.19e-18	3.19e-15	-0.44	-0.38	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
KIRC	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	9.05	3.19e-18	3.2e-15	0.38	0.38	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000250919.1	RP11-813N20.3	-9.05	3.2e-18	3.2e-15	-0.4	-0.38	Obesity-related traits;	chr4:69079589	chr4:69027831~69044578:+
KIRC	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	9.05	3.21e-18	3.21e-15	0.55	0.38	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
KIRC	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	9.05	3.23e-18	3.23e-15	0.3	0.38	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
KIRC	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	9.05	3.23e-18	3.23e-15	0.48	0.38	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
KIRC	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	9.05	3.23e-18	3.23e-15	0.34	0.38	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	9.05	3.23e-18	3.23e-15	0.34	0.38	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
KIRC	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-9.05	3.24e-18	3.24e-15	-0.42	-0.38	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
KIRC	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-9.05	3.24e-18	3.24e-15	-0.49	-0.38	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
KIRC	cis	rs79040073	0.637	rs73396235	ENSG00000259531.2	RP11-295H24.3	9.05	3.26e-18	3.26e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49346956	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73396238	ENSG00000259531.2	RP11-295H24.3	9.05	3.26e-18	3.26e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49347146	chr15:49365124~49366685:-
KIRC	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-9.05	3.26e-18	3.26e-15	-0.43	-0.38	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
KIRC	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	9.05	3.27e-18	3.27e-15	0.36	0.38	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	9.05	3.27e-18	3.27e-15	0.36	0.38	Asthma;	chr2:102388870	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	9.05	3.27e-18	3.27e-15	0.36	0.38	Asthma;	chr2:102389644	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	9.05	3.27e-18	3.27e-15	0.36	0.38	Asthma;	chr2:102389988	chr2:102438713~102440475:+
KIRC	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-9.05	3.28e-18	3.28e-15	-0.48	-0.38	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
KIRC	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-9.05	3.29e-18	3.29e-15	-0.44	-0.38	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
KIRC	cis	rs79040073	0.637	rs73394339	ENSG00000259531.2	RP11-295H24.3	9.05	3.31e-18	3.31e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49279601	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs17397211	ENSG00000259531.2	RP11-295H24.3	9.05	3.31e-18	3.31e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49279746	chr15:49365124~49366685:-
KIRC	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	9.05	3.34e-18	3.33e-15	0.52	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
KIRC	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-9.05	3.39e-18	3.39e-15	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
KIRC	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-9.05	3.41e-18	3.4e-15	-0.37	-0.38	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
KIRC	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	9.04	3.41e-18	3.4e-15	0.36	0.38	Asthma;	chr2:102411180	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	9.04	3.41e-18	3.4e-15	0.36	0.38	Asthma;	chr2:102411191	chr2:102438713~102440475:+
KIRC	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-9.04	3.43e-18	3.42e-15	-0.47	-0.38	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
KIRC	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-9.04	3.44e-18	3.43e-15	-0.43	-0.38	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
KIRC	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	9.04	3.45e-18	3.45e-15	0.49	0.38	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	9.04	3.45e-18	3.45e-15	0.49	0.38	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	9.04	3.45e-18	3.45e-15	0.49	0.38	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	9.04	3.47e-18	3.46e-15	0.49	0.38	Height;	chr6:109503623	chr6:109382795~109383666:+
KIRC	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-9.04	3.47e-18	3.47e-15	-0.49	-0.38	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
KIRC	cis	rs79040073	0.637	rs8030457	ENSG00000259531.2	RP11-295H24.3	9.04	3.49e-18	3.48e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49392809	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.599	rs17477722	ENSG00000259531.2	RP11-295H24.3	9.04	3.49e-18	3.48e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49394220	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73398243	ENSG00000259531.2	RP11-295H24.3	9.04	3.49e-18	3.48e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49394344	chr15:49365124~49366685:-
KIRC	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	9.04	3.51e-18	3.5e-15	0.36	0.38	Asthma;	chr2:102437614	chr2:102438713~102440475:+
KIRC	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	9.04	3.52e-18	3.51e-15	0.42	0.38	Height;	chr11:118758322	chr11:118704607~118750263:+
KIRC	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-9.04	3.52e-18	3.51e-15	-0.64	-0.38	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
KIRC	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	9.04	3.53e-18	3.52e-15	0.59	0.38	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
KIRC	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	9.04	3.57e-18	3.56e-15	0.44	0.38	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	9.04	3.57e-18	3.56e-15	0.44	0.38	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	9.04	3.57e-18	3.56e-15	0.44	0.38	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
KIRC	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-9.04	3.6e-18	3.59e-15	-0.53	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
KIRC	cis	rs2698530	0.791	rs890482	ENSG00000225889.6	AC074289.1	9.04	3.64e-18	3.62e-15	0.38	0.38	Iron status biomarkers;	chr2:64265801	chr2:64143239~64252859:+
KIRC	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-9.04	3.64e-18	3.63e-15	-0.48	-0.38	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
KIRC	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-9.04	3.66e-18	3.64e-15	-0.48	-0.38	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
KIRC	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-9.04	3.66e-18	3.65e-15	-0.43	-0.38	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
KIRC	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	9.04	3.67e-18	3.65e-15	0.33	0.38	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
KIRC	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-9.04	3.68e-18	3.66e-15	-0.47	-0.38	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
KIRC	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	9.04	3.68e-18	3.66e-15	0.48	0.38	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
KIRC	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-9.03	3.71e-18	3.69e-15	-0.43	-0.38	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
KIRC	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	9.03	3.71e-18	3.69e-15	0.36	0.38	Asthma;	chr2:102415109	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	9.03	3.71e-18	3.69e-15	0.36	0.38	Asthma;	chr2:102417501	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	9.03	3.71e-18	3.69e-15	0.36	0.38	Asthma;	chr2:102418383	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	9.03	3.71e-18	3.69e-15	0.36	0.38	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
KIRC	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.36	-0.38	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
KIRC	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-9.03	3.72e-18	3.7e-15	-0.47	-0.38	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
KIRC	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-9.03	3.72e-18	3.7e-15	-0.35	-0.38	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
KIRC	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-9.03	3.75e-18	3.73e-15	-0.48	-0.38	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
KIRC	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	9.03	3.75e-18	3.73e-15	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
KIRC	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	9.03	3.76e-18	3.74e-15	0.44	0.38	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
KIRC	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	9.03	3.77e-18	3.75e-15	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
KIRC	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	9.03	3.78e-18	3.75e-15	0.32	0.38	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
KIRC	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	9.03	3.78e-18	3.75e-15	0.32	0.38	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
KIRC	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	9.03	3.78e-18	3.76e-15	0.49	0.38	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
KIRC	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-9.03	3.8e-18	3.78e-15	-0.43	-0.38	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
KIRC	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-9.03	3.82e-18	3.79e-15	-0.44	-0.38	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
KIRC	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	9.03	3.82e-18	3.8e-15	0.45	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
KIRC	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-9.03	3.83e-18	3.81e-15	-0.47	-0.38	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
KIRC	cis	rs1005277	0.505	rs719569	ENSG00000151963.4	RP11-775A3.1	9.03	3.83e-18	3.81e-15	0.43	0.38	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:37883594~37884109:+
KIRC	cis	rs1005277	0.522	rs200943	ENSG00000151963.4	RP11-775A3.1	-9.03	3.83e-18	3.81e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:37883594~37884109:+
KIRC	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-9.03	3.83e-18	3.81e-15	-0.48	-0.38	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000250919.1	RP11-813N20.3	-9.03	3.84e-18	3.81e-15	-0.41	-0.38	Obesity-related traits;	chr4:69063770	chr4:69027831~69044578:+
KIRC	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-9.03	3.84e-18	3.82e-15	-0.47	-0.38	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
KIRC	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	9.03	3.85e-18	3.83e-15	0.38	0.38	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
KIRC	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	9.03	3.86e-18	3.83e-15	0.36	0.38	Asthma;	chr2:102381261	chr2:102438713~102440475:+
KIRC	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	9.03	3.87e-18	3.84e-15	0.39	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
KIRC	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	9.03	3.88e-18	3.85e-15	0.42	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
KIRC	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-9.03	3.9e-18	3.86e-15	-0.3	-0.38	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
KIRC	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	9.03	3.91e-18	3.87e-15	0.57	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
KIRC	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	9.03	3.91e-18	3.87e-15	0.57	0.38	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
KIRC	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	9.03	3.91e-18	3.87e-15	0.57	0.38	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
KIRC	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	9.03	3.92e-18	3.89e-15	0.5	0.38	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
KIRC	cis	rs1005277	0.505	rs200937	ENSG00000151963.4	RP11-775A3.1	-9.03	3.92e-18	3.89e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:37883594~37884109:+
KIRC	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-9.03	3.93e-18	3.89e-15	-0.49	-0.38	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
KIRC	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	9.03	3.94e-18	3.91e-15	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
KIRC	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	9.03	3.94e-18	3.91e-15	0.47	0.38	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
KIRC	cis	rs79040073	0.637	rs78050772	ENSG00000259531.2	RP11-295H24.3	9.03	3.96e-18	3.92e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49286380	chr15:49365124~49366685:-
KIRC	cis	rs2749592	0.531	rs10764134	ENSG00000151963.4	RP11-775A3.1	9.03	3.97e-18	3.93e-15	0.43	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:37883594~37884109:+
KIRC	cis	rs4356975	0.83	rs3922514	ENSG00000248763.2	RP13-644M16.5	-9.03	3.98e-18	3.94e-15	-0.47	-0.38	Obesity-related traits;	chr4:69060905	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.83	rs28775401	ENSG00000248763.2	RP13-644M16.5	-9.03	3.98e-18	3.94e-15	-0.47	-0.38	Obesity-related traits;	chr4:69060999	chr4:69066395~69069888:+
KIRC	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.02	4e-18	3.96e-15	0.49	0.38	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
KIRC	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	9.02	4e-18	3.96e-15	0.36	0.38	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
KIRC	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-9.02	4e-18	3.96e-15	-0.39	-0.38	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
KIRC	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	9.02	4.01e-18	3.97e-15	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
KIRC	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	9.02	4.01e-18	3.98e-15	0.36	0.38	Asthma;	chr2:102374753	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-9.02	4.02e-18	3.98e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-9.02	4.02e-18	3.98e-15	-0.41	-0.38	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
KIRC	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-9.02	4.02e-18	3.98e-15	-0.48	-0.38	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
KIRC	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-9.02	4.02e-18	3.98e-15	-0.49	-0.38	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
KIRC	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	9.02	4.02e-18	3.98e-15	0.36	0.38	Asthma;	chr2:102381819	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	9.02	4.02e-18	3.98e-15	0.36	0.38	Asthma;	chr2:102382514	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	9.02	4.02e-18	3.98e-15	0.36	0.38	Asthma;	chr2:102382943	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	9.02	4.02e-18	3.98e-15	0.36	0.38	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	9.02	4.02e-18	3.98e-15	0.36	0.38	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
KIRC	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-9.02	4.02e-18	3.98e-15	-0.49	-0.38	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
KIRC	cis	rs1005277	0.505	rs200936	ENSG00000151963.4	RP11-775A3.1	-9.02	4.07e-18	4.03e-15	-0.43	-0.38	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:37883594~37884109:+
KIRC	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	9.02	4.07e-18	4.03e-15	0.66	0.38	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
KIRC	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-9.02	4.09e-18	4.04e-15	-0.36	-0.38	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
KIRC	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-9.02	4.1e-18	4.06e-15	-0.41	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
KIRC	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-9.02	4.1e-18	4.06e-15	-0.41	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-9.02	4.1e-18	4.06e-15	-0.41	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
KIRC	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-9.02	4.11e-18	4.06e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
KIRC	cis	rs79040073	0.637	rs8027094	ENSG00000259531.2	RP11-295H24.3	9.02	4.13e-18	4.09e-15	0.5	0.38	Lung cancer in ever smokers;	chr15:49388639	chr15:49365124~49366685:-
KIRC	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-9.02	4.14e-18	4.1e-15	-0.41	-0.38	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
KIRC	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	9.02	4.15e-18	4.11e-15	0.59	0.38	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
KIRC	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	9.02	4.16e-18	4.11e-15	0.39	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
KIRC	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	9.02	4.16e-18	4.12e-15	0.42	0.38	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
KIRC	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-9.02	4.17e-18	4.12e-15	-0.41	-0.38	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
KIRC	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-9.02	4.17e-18	4.13e-15	-0.37	-0.38	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
KIRC	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
KIRC	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-9.02	4.2e-18	4.15e-15	-0.44	-0.38	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
KIRC	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	9.02	4.21e-18	4.16e-15	0.26	0.38	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
KIRC	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-9.02	4.25e-18	4.19e-15	-0.34	-0.38	Height;	chr4:55487920	chr4:55363971~55395847:-
KIRC	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	9.02	4.25e-18	4.19e-15	0.38	0.38	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
KIRC	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	9.02	4.26e-18	4.21e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
KIRC	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	9.02	4.26e-18	4.21e-15	0.46	0.38	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
KIRC	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.02	4.26e-18	4.21e-15	-0.43	-0.38	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
KIRC	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	9.02	4.28e-18	4.23e-15	0.47	0.38	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
KIRC	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	9.01	4.31e-18	4.26e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
KIRC	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	9.01	4.32e-18	4.26e-15	0.34	0.38	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	9.01	4.32e-18	4.27e-15	0.48	0.38	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
KIRC	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	9.01	4.33e-18	4.27e-15	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
KIRC	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-9.01	4.37e-18	4.31e-15	-0.41	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
KIRC	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	9.01	4.37e-18	4.32e-15	0.47	0.38	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	9.01	4.37e-18	4.32e-15	0.47	0.38	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
KIRC	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	9.01	4.37e-18	4.32e-15	0.7	0.38	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
KIRC	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-9.01	4.38e-18	4.32e-15	-0.49	-0.38	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
KIRC	cis	rs79040073	0.637	rs73398250	ENSG00000259531.2	RP11-295H24.3	9.01	4.38e-18	4.33e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49404829	chr15:49365124~49366685:-
KIRC	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-9.01	4.4e-18	4.34e-15	-0.3	-0.38	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
KIRC	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-9.01	4.4e-18	4.34e-15	-0.3	-0.38	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
KIRC	cis	rs4356975	0.83	rs4413468	ENSG00000248763.2	RP13-644M16.5	-9.01	4.44e-18	4.38e-15	-0.47	-0.38	Obesity-related traits;	chr4:69061845	chr4:69066395~69069888:+
KIRC	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	9.01	4.5e-18	4.43e-15	0.27	0.38	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
KIRC	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-9.01	4.5e-18	4.43e-15	-0.37	-0.38	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
KIRC	cis	rs904251	0.6	rs12211110	ENSG00000227920.2	RP1-153P14.5	-9.01	4.5e-18	4.43e-15	-0.41	-0.38	Cognitive performance;	chr6:37498456	chr6:37545145~37550860:+
KIRC	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	9.01	4.55e-18	4.48e-15	0.36	0.38	Asthma;	chr2:102415289	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	9.01	4.55e-18	4.48e-15	0.36	0.38	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
KIRC	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	9.01	4.56e-18	4.49e-15	0.47	0.38	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
KIRC	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-9.01	4.56e-18	4.5e-15	-0.38	-0.38	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
KIRC	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	9.01	4.58e-18	4.51e-15	0.4	0.38	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
KIRC	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	9.01	4.58e-18	4.51e-15	0.43	0.38	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
KIRC	cis	rs2749592	0.513	rs9417249	ENSG00000151963.4	RP11-775A3.1	9.01	4.58e-18	4.52e-15	0.43	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:37883594~37884109:+
KIRC	cis	rs6600671	1	rs12047116	ENSG00000227082.1	CH17-437K3.1	-9.01	4.59e-18	4.53e-15	-0.42	-0.38	Hip geometry;	chr1:121443912	chr1:121396754~121463129:+
KIRC	cis	rs6600671	0.967	rs11249347	ENSG00000227082.1	CH17-437K3.1	-9.01	4.59e-18	4.53e-15	-0.42	-0.38	Hip geometry;	chr1:121446489	chr1:121396754~121463129:+
KIRC	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-9.01	4.64e-18	4.57e-15	-0.43	-0.38	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-9.01	4.64e-18	4.57e-15	-0.43	-0.38	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	9.01	4.65e-18	4.58e-15	0.43	0.38	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
KIRC	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-9.01	4.65e-18	4.58e-15	-0.42	-0.38	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
KIRC	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-9	4.7e-18	4.62e-15	-0.47	-0.38	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
KIRC	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-9	4.7e-18	4.62e-15	-0.42	-0.38	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
KIRC	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-9	4.7e-18	4.63e-15	-0.56	-0.38	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
KIRC	cis	rs4273100	1	rs16960158	ENSG00000228157.4	AC007952.5	9	4.72e-18	4.64e-15	0.66	0.38	Schizophrenia;	chr17:19259739	chr17:19092974~19096837:+
KIRC	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-9	4.74e-18	4.66e-15	-0.43	-0.38	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
KIRC	cis	rs12458462	0.851	rs62097746	ENSG00000274828.1	RP11-567M16.6	9	4.74e-18	4.66e-15	0.38	0.38	Monocyte count;	chr18:79727508	chr18:79677287~79679358:-
KIRC	cis	rs12458462	0.851	rs60298379	ENSG00000274828.1	RP11-567M16.6	9	4.74e-18	4.66e-15	0.38	0.38	Monocyte count;	chr18:79728422	chr18:79677287~79679358:-
KIRC	cis	rs12458462	0.812	rs36073957	ENSG00000274828.1	RP11-567M16.6	9	4.74e-18	4.66e-15	0.38	0.38	Monocyte count;	chr18:79728441	chr18:79677287~79679358:-
KIRC	cis	rs12458462	0.851	rs2169249	ENSG00000274828.1	RP11-567M16.6	9	4.74e-18	4.66e-15	0.38	0.38	Monocyte count;	chr18:79729649	chr18:79677287~79679358:-
KIRC	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	9	4.79e-18	4.71e-15	0.49	0.38	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
KIRC	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-9	4.79e-18	4.71e-15	-0.48	-0.38	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
KIRC	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-9	4.8e-18	4.72e-15	-0.43	-0.38	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
KIRC	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	9	4.82e-18	4.74e-15	0.49	0.38	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
KIRC	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-9	4.86e-18	4.77e-15	-0.3	-0.37	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
KIRC	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	9	4.86e-18	4.78e-15	0.37	0.37	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
KIRC	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	9	4.91e-18	4.82e-15	0.48	0.37	Height;	chr6:109507364	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	9	4.91e-18	4.82e-15	0.48	0.37	Height;	chr6:109507366	chr6:109382795~109383666:+
KIRC	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	9	4.92e-18	4.83e-15	0.47	0.37	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	9	4.92e-18	4.83e-15	0.47	0.37	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	9	4.92e-18	4.83e-15	0.47	0.37	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
KIRC	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-9	4.93e-18	4.84e-15	-0.49	-0.37	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
KIRC	cis	rs1005277	0.522	rs289648	ENSG00000151963.4	RP11-775A3.1	-9	4.93e-18	4.84e-15	-0.42	-0.37	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:37883594~37884109:+
KIRC	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-9	4.94e-18	4.85e-15	-0.44	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
KIRC	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-9	4.96e-18	4.87e-15	-0.37	-0.37	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
KIRC	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	9	4.97e-18	4.88e-15	0.48	0.37	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
KIRC	cis	rs1200821	0.529	rs2505707	ENSG00000151963.4	RP11-775A3.1	-9	5.01e-18	4.92e-15	-0.42	-0.37	Hemostatic factors and hematological phenotypes;	chr10:37512326	chr10:37883594~37884109:+
KIRC	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	9	5.01e-18	4.92e-15	0.36	0.37	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
KIRC	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	9	5.03e-18	4.93e-15	0.61	0.37	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
KIRC	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-8.99	5.04e-18	4.95e-15	-0.43	-0.37	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
KIRC	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	8.99	5.06e-18	4.97e-15	0.39	0.37	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
KIRC	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	8.99	5.08e-18	4.98e-15	0.5	0.37	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
KIRC	cis	rs79040073	0.637	rs10519221	ENSG00000259531.2	RP11-295H24.3	8.99	5.08e-18	4.98e-15	0.49	0.37	Lung cancer in ever smokers;	chr15:49286377	chr15:49365124~49366685:-
KIRC	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-8.99	5.09e-18	4.99e-15	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-8.99	5.09e-18	4.99e-15	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
KIRC	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-8.99	5.12e-18	5.02e-15	-0.41	-0.37	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
KIRC	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	8.99	5.14e-18	5.04e-15	0.42	0.37	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	8.99	5.14e-18	5.04e-15	0.42	0.37	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
KIRC	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	8.99	5.14e-18	5.04e-15	0.48	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
KIRC	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	8.99	5.15e-18	5.05e-15	0.48	0.37	Height;	chr6:109500687	chr6:109382795~109383666:+
KIRC	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-8.99	5.15e-18	5.05e-15	-0.43	-0.37	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
KIRC	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-8.99	5.17e-18	5.06e-15	-0.49	-0.37	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
KIRC	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-8.99	5.17e-18	5.06e-15	-0.49	-0.37	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
KIRC	cis	rs1005277	0.522	rs289647	ENSG00000151963.4	RP11-775A3.1	-8.99	5.17e-18	5.07e-15	-0.41	-0.37	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:37883594~37884109:+
KIRC	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-8.99	5.2e-18	5.1e-15	-0.41	-0.37	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
KIRC	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	8.99	5.22e-18	5.11e-15	0.48	0.37	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	8.99	5.23e-18	5.12e-15	0.49	0.37	Height;	chr6:109507271	chr6:109382795~109383666:+
KIRC	cis	rs6600671	1	rs10903159	ENSG00000227082.1	CH17-437K3.1	-8.99	5.24e-18	5.13e-15	-0.42	-0.37	Hip geometry;	chr1:121440138	chr1:121396754~121463129:+
KIRC	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-8.99	5.24e-18	5.13e-15	-0.44	-0.37	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
KIRC	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-8.99	5.25e-18	5.14e-15	-0.43	-0.37	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
KIRC	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-8.99	5.26e-18	5.15e-15	-0.35	-0.37	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
KIRC	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	8.99	5.26e-18	5.15e-15	0.34	0.37	Height;	chr4:55487368	chr4:55363971~55395847:-
KIRC	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-8.99	5.27e-18	5.16e-15	-0.5	-0.37	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
KIRC	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	8.99	5.27e-18	5.16e-15	0.37	0.37	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
KIRC	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-8.99	5.29e-18	5.18e-15	-0.43	-0.37	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
KIRC	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-8.99	5.31e-18	5.2e-15	-0.44	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
KIRC	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-8.99	5.32e-18	5.2e-15	-0.41	-0.37	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
KIRC	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-8.99	5.35e-18	5.23e-15	-0.61	-0.37	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
KIRC	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-8.99	5.35e-18	5.23e-15	-0.6	-0.37	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
KIRC	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.99	5.37e-18	5.25e-15	-0.51	-0.37	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
KIRC	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	8.99	5.37e-18	5.25e-15	0.43	0.37	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
KIRC	cis	rs1005277	0.505	rs200910	ENSG00000151963.4	RP11-775A3.1	-8.99	5.38e-18	5.26e-15	-0.42	-0.37	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:37883594~37884109:+
KIRC	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.99	5.39e-18	5.26e-15	-0.46	-0.37	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
KIRC	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.99	5.4e-18	5.27e-15	0.44	0.37	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.99	5.4e-18	5.27e-15	0.44	0.37	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
KIRC	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	8.98	5.45e-18	5.33e-15	0.49	0.37	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
KIRC	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-8.98	5.48e-18	5.35e-15	-0.42	-0.37	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
KIRC	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	8.98	5.5e-18	5.37e-15	0.48	0.37	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	8.98	5.52e-18	5.39e-15	0.54	0.37	Height;	chr6:109775693	chr6:109382795~109383666:+
KIRC	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-8.98	5.52e-18	5.39e-15	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
KIRC	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	8.98	5.52e-18	5.39e-15	0.45	0.37	Height;	chr11:118809363	chr11:118688039~118690600:-
KIRC	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-8.98	5.52e-18	5.39e-15	-0.36	-0.37	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
KIRC	cis	rs4273100	1	rs57433322	ENSG00000228157.4	AC007952.5	8.98	5.53e-18	5.4e-15	0.67	0.37	Schizophrenia;	chr17:19238269	chr17:19092974~19096837:+
KIRC	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-8.98	5.56e-18	5.43e-15	-0.49	-0.37	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-8.98	5.63e-18	5.49e-15	-0.49	-0.37	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
KIRC	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-8.98	5.64e-18	5.5e-15	-0.49	-0.37	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
KIRC	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-8.98	5.64e-18	5.5e-15	-0.49	-0.37	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
KIRC	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	8.98	5.65e-18	5.5e-15	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
KIRC	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-8.98	5.65e-18	5.51e-15	-0.56	-0.37	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
KIRC	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-8.98	5.68e-18	5.54e-15	-0.56	-0.37	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
KIRC	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-8.98	5.71e-18	5.56e-15	-0.44	-0.37	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
KIRC	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-8.98	5.72e-18	5.58e-15	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
KIRC	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	8.98	5.73e-18	5.58e-15	0.56	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
KIRC	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	8.98	5.74e-18	5.59e-15	0.47	0.37	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
KIRC	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	8.98	5.75e-18	5.6e-15	0.41	0.37	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-8.98	5.75e-18	5.61e-15	-0.36	-0.37	Asthma;	chr2:102374328	chr2:102438713~102440475:+
KIRC	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	8.98	5.75e-18	5.61e-15	0.79	0.37	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
KIRC	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-8.98	5.79e-18	5.64e-15	-0.57	-0.37	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
KIRC	cis	rs79040073	0.637	rs117582142	ENSG00000259531.2	RP11-295H24.3	8.98	5.8e-18	5.65e-15	0.5	0.37	Lung cancer in ever smokers;	chr15:49228624	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.565	rs11638515	ENSG00000259531.2	RP11-295H24.3	8.98	5.8e-18	5.65e-15	0.5	0.37	Lung cancer in ever smokers;	chr15:49233530	chr15:49365124~49366685:-
KIRC	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	8.98	5.83e-18	5.68e-15	0.47	0.37	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
KIRC	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	8.98	5.83e-18	5.68e-15	0.62	0.37	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
KIRC	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	8.98	5.85e-18	5.69e-15	0.47	0.37	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
KIRC	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	8.98	5.85e-18	5.69e-15	0.27	0.37	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
KIRC	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	8.98	5.85e-18	5.69e-15	0.49	0.37	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
KIRC	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-8.98	5.85e-18	5.7e-15	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
KIRC	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	8.98	5.89e-18	5.73e-15	0.48	0.37	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
KIRC	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	8.98	5.89e-18	5.73e-15	0.36	0.37	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
KIRC	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-8.97	5.92e-18	5.76e-15	-0.41	-0.37	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
KIRC	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-8.97	5.94e-18	5.78e-15	-0.41	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
KIRC	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-8.97	5.98e-18	5.81e-15	-0.42	-0.37	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
KIRC	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-8.97	6e-18	5.83e-15	-0.42	-0.37	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
KIRC	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	8.97	6e-18	5.84e-15	0.34	0.37	Height;	chr4:55518776	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	8.97	6e-18	5.84e-15	0.34	0.37	Height;	chr4:55518922	chr4:55363971~55395847:-
KIRC	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	8.97	6e-18	5.84e-15	0.34	0.37	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	8.97	6.06e-18	5.89e-15	0.47	0.37	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	8.97	6.06e-18	5.89e-15	0.47	0.37	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
KIRC	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-8.97	6.09e-18	5.91e-15	-0.48	-0.37	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
KIRC	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	8.97	6.09e-18	5.92e-15	0.48	0.37	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
KIRC	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	8.97	6.09e-18	5.92e-15	0.48	0.37	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
KIRC	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-8.97	6.1e-18	5.92e-15	-0.32	-0.37	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
KIRC	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	8.97	6.11e-18	5.94e-15	0.32	0.37	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	8.97	6.11e-18	5.94e-15	0.32	0.37	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
KIRC	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	8.97	6.13e-18	5.95e-15	0.47	0.37	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
KIRC	cis	rs4356975	0.842	rs6600899	ENSG00000196472.4	RP13-644M16.4	8.97	6.13e-18	5.96e-15	0.43	0.37	Obesity-related traits;	chr4:69132295	chr4:69181660~69182372:+
KIRC	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	8.97	6.15e-18	5.97e-15	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	8.97	6.15e-18	5.97e-15	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	8.97	6.15e-18	5.97e-15	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	8.97	6.15e-18	5.97e-15	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
KIRC	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-8.97	6.18e-18	6e-15	-0.41	-0.37	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
KIRC	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-8.97	6.19e-18	6.01e-15	-0.4	-0.37	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
KIRC	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-8.97	6.2e-18	6.02e-15	-0.32	-0.37	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
KIRC	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	8.97	6.2e-18	6.02e-15	0.38	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
KIRC	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	8.97	6.26e-18	6.08e-15	0.47	0.37	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
KIRC	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	8.97	6.3e-18	6.11e-15	0.34	0.37	Height;	chr4:55515292	chr4:55363971~55395847:-
KIRC	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	8.97	6.31e-18	6.12e-15	0.42	0.37	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
KIRC	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-8.97	6.32e-18	6.13e-15	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
KIRC	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-8.97	6.33e-18	6.14e-15	-0.49	-0.37	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
KIRC	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	8.97	6.35e-18	6.16e-15	0.4	0.37	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
KIRC	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	8.97	6.35e-18	6.16e-15	0.48	0.37	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
KIRC	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-8.96	6.38e-18	6.18e-15	-0.48	-0.37	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	8.96	6.38e-18	6.19e-15	0.29	0.37	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
KIRC	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	8.96	6.38e-18	6.19e-15	0.29	0.37	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
KIRC	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-8.96	6.46e-18	6.26e-15	-0.48	-0.37	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
KIRC	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-8.96	6.46e-18	6.26e-15	-0.35	-0.37	Asthma;	chr2:102401592	chr2:102438713~102440475:+
KIRC	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	8.96	6.49e-18	6.29e-15	0.45	0.37	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
KIRC	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	8.96	6.53e-18	6.33e-15	0.34	0.37	Height;	chr4:55501479	chr4:55363971~55395847:-
KIRC	cis	rs1005277	0.522	rs1208684	ENSG00000151963.4	RP11-775A3.1	-8.96	6.56e-18	6.36e-15	-0.42	-0.37	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:37883594~37884109:+
KIRC	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	8.96	6.6e-18	6.39e-15	0.64	0.37	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	8.96	6.6e-18	6.39e-15	0.64	0.37	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
KIRC	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-8.96	6.61e-18	6.4e-15	-0.42	-0.37	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
KIRC	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	8.96	6.69e-18	6.47e-15	0.55	0.37	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
KIRC	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-8.96	6.7e-18	6.48e-15	-0.43	-0.37	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
KIRC	cis	rs6600671	1	rs4844616	ENSG00000227082.1	CH17-437K3.1	-8.96	6.7e-18	6.48e-15	-0.42	-0.37	Hip geometry;	chr1:121429348	chr1:121396754~121463129:+
KIRC	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	8.96	6.71e-18	6.49e-15	0.42	0.37	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
KIRC	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-8.96	6.71e-18	6.5e-15	-0.56	-0.37	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
KIRC	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-8.96	6.73e-18	6.51e-15	-0.42	-0.37	Height;	chr11:118742526	chr11:118704607~118750263:+
KIRC	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-8.96	6.73e-18	6.51e-15	-0.35	-0.37	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-8.96	6.73e-18	6.51e-15	-0.35	-0.37	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-8.96	6.73e-18	6.51e-15	-0.35	-0.37	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-8.96	6.73e-18	6.51e-15	-0.35	-0.37	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
KIRC	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-8.96	6.79e-18	6.56e-15	-0.39	-0.37	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
KIRC	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-8.96	6.81e-18	6.59e-15	-0.47	-0.37	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
KIRC	cis	rs9355610	0.609	rs9366076	ENSG00000265828.1	MIR3939	8.96	6.84e-18	6.61e-15	0.52	0.37	Graves' disease;	chr6:166960220	chr6:166997807~166997912:-
KIRC	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-8.96	6.86e-18	6.63e-15	-0.42	-0.37	Height;	chr11:118773873	chr11:118704607~118750263:+
KIRC	cis	rs11671005	0.569	rs73068335	ENSG00000269600.1	AC016629.3	-8.95	6.9e-18	6.67e-15	-0.61	-0.37	Mean platelet volume;	chr19:58577941	chr19:58593896~58599355:-
KIRC	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-8.95	6.9e-18	6.67e-15	-0.48	-0.37	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
KIRC	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-8.95	6.91e-18	6.68e-15	-0.47	-0.37	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
KIRC	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	8.95	6.94e-18	6.7e-15	0.41	0.37	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
KIRC	cis	rs1200821	0.535	rs1208783	ENSG00000151963.4	RP11-775A3.1	-8.95	6.95e-18	6.71e-15	-0.43	-0.37	Hemostatic factors and hematological phenotypes;	chr10:37478539	chr10:37883594~37884109:+
KIRC	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	8.95	6.95e-18	6.71e-15	0.48	0.37	Height;	chr6:109499759	chr6:109382795~109383666:+
KIRC	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	8.95	6.96e-18	6.72e-15	0.33	0.37	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
KIRC	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-8.95	6.97e-18	6.73e-15	-0.47	-0.37	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-8.95	6.97e-18	6.73e-15	-0.47	-0.37	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-8.95	6.97e-18	6.73e-15	-0.47	-0.37	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
KIRC	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	8.95	6.97e-18	6.73e-15	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
KIRC	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-8.95	6.98e-18	6.73e-15	-0.35	-0.37	Asthma;	chr2:102393077	chr2:102438713~102440475:+
KIRC	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-8.95	7.02e-18	6.78e-15	-0.29	-0.37	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
KIRC	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-8.95	7.03e-18	6.78e-15	-0.43	-0.37	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
KIRC	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	8.95	7.03e-18	6.79e-15	0.33	0.37	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
KIRC	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	8.95	7.04e-18	6.79e-15	0.29	0.37	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
KIRC	cis	rs2754412	1	rs2754412	ENSG00000263064.2	RP11-291L22.7	8.95	7.1e-18	6.85e-15	0.45	0.37	Breast cancer;	chr10:38338906	chr10:38448689~38448949:+
KIRC	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-8.95	7.18e-18	6.92e-15	-0.35	-0.37	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
KIRC	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	8.95	7.18e-18	6.92e-15	0.62	0.37	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
KIRC	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-8.95	7.22e-18	6.96e-15	-0.36	-0.37	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
KIRC	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55506498	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55507248	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55507729	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55508587	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55509367	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55510352	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	8.95	7.22e-18	6.96e-15	0.34	0.37	Height;	chr4:55511198	chr4:55363971~55395847:-
KIRC	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	8.95	7.23e-18	6.97e-15	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
KIRC	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-8.95	7.23e-18	6.97e-15	-0.42	-0.37	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-8.95	7.23e-18	6.97e-15	-0.42	-0.37	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
KIRC	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-8.95	7.25e-18	6.98e-15	-0.48	-0.37	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
KIRC	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-8.95	7.27e-18	7e-15	-0.35	-0.37	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
KIRC	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	8.95	7.28e-18	7.01e-15	0.29	0.37	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
KIRC	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-8.95	7.28e-18	7.01e-15	-0.43	-0.37	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
KIRC	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	8.95	7.29e-18	7.02e-15	0.43	0.37	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
KIRC	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-8.95	7.29e-18	7.02e-15	-0.4	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
KIRC	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	8.95	7.31e-18	7.04e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
KIRC	cis	rs919433	0.963	rs10153881	ENSG00000231621.1	AC013264.2	8.95	7.32e-18	7.04e-15	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306374	chr2:197197991~197199273:+
KIRC	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-8.95	7.32e-18	7.04e-15	-0.37	-0.37	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
KIRC	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	8.95	7.32e-18	7.04e-15	0.49	0.37	Height;	chr6:109498586	chr6:109382795~109383666:+
KIRC	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	8.95	7.36e-18	7.08e-15	0.38	0.37	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
KIRC	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	8.95	7.36e-18	7.08e-15	0.38	0.37	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
KIRC	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	8.95	7.36e-18	7.08e-15	0.38	0.37	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
KIRC	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	8.95	7.37e-18	7.1e-15	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
KIRC	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	8.95	7.37e-18	7.1e-15	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
KIRC	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	8.95	7.4e-18	7.12e-15	0.42	0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
KIRC	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-8.95	7.41e-18	7.13e-15	-0.43	-0.37	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
KIRC	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	8.95	7.42e-18	7.13e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
KIRC	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	8.95	7.44e-18	7.16e-15	0.67	0.37	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
KIRC	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	8.95	7.44e-18	7.16e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
KIRC	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-8.94	7.45e-18	7.17e-15	-0.36	-0.37	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
KIRC	cis	rs4273100	0.79	rs60166680	ENSG00000262319.1	CTC-457L16.2	-8.94	7.48e-18	7.2e-15	-0.52	-0.37	Schizophrenia;	chr17:19374231	chr17:19141017~19143689:-
KIRC	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	8.94	7.52e-18	7.23e-15	0.34	0.37	Height;	chr4:55484534	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	8.94	7.52e-18	7.23e-15	0.34	0.37	Height;	chr4:55489310	chr4:55363971~55395847:-
KIRC	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-8.94	7.53e-18	7.24e-15	-0.47	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
KIRC	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-8.94	7.54e-18	7.25e-15	-0.47	-0.37	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
KIRC	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	8.94	7.54e-18	7.25e-15	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
KIRC	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	8.94	7.55e-18	7.26e-15	0.42	0.37	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
KIRC	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-8.94	7.57e-18	7.27e-15	-0.56	-0.37	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
KIRC	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-8.94	7.58e-18	7.28e-15	-0.3	-0.37	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
KIRC	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-8.94	7.58e-18	7.28e-15	-0.3	-0.37	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
KIRC	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	8.94	7.58e-18	7.28e-15	0.3	0.37	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000250919.1	RP11-813N20.3	-8.94	7.61e-18	7.31e-15	-0.4	-0.37	Obesity-related traits;	chr4:69079704	chr4:69027831~69044578:+
KIRC	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	8.94	7.63e-18	7.33e-15	0.38	0.37	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
KIRC	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-8.94	7.67e-18	7.37e-15	-0.43	-0.37	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
KIRC	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-8.94	7.71e-18	7.41e-15	-0.47	-0.37	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
KIRC	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	8.94	7.72e-18	7.41e-15	0.49	0.37	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
KIRC	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	8.94	7.74e-18	7.43e-15	0.46	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
KIRC	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	8.94	7.75e-18	7.44e-15	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
KIRC	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-8.94	7.82e-18	7.51e-15	-0.37	-0.37	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
KIRC	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	8.94	7.87e-18	7.55e-15	0.55	0.37	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
KIRC	cis	rs12460587	0.568	rs8113376	ENSG00000275055.1	CTC-471J1.11	-8.94	7.91e-18	7.59e-15	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090170	chr19:52049007~52049754:+
KIRC	cis	rs71007656	1	rs71007656	ENSG00000151963.4	RP11-775A3.1	-8.94	7.95e-18	7.62e-15	-0.41	-0.37	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:37883594~37884109:+
KIRC	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-8.94	8e-18	7.67e-15	-0.36	-0.37	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
KIRC	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	8.94	8e-18	7.67e-15	0.5	0.37	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
KIRC	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	8.94	8e-18	7.67e-15	0.54	0.37	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
KIRC	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	8.94	8.01e-18	7.68e-15	0.49	0.37	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
KIRC	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-8.94	8.02e-18	7.69e-15	-0.35	-0.37	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
KIRC	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.93	8.08e-18	7.74e-15	0.43	0.37	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.93	8.08e-18	7.74e-15	0.43	0.37	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.93	8.08e-18	7.74e-15	0.43	0.37	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
KIRC	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	8.93	8.09e-18	7.75e-15	0.35	0.37	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	8.93	8.09e-18	7.75e-15	0.35	0.37	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	8.93	8.09e-18	7.75e-15	0.35	0.37	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	8.93	8.09e-18	7.75e-15	0.35	0.37	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	8.93	8.09e-18	7.75e-15	0.35	0.37	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
KIRC	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-8.93	8.11e-18	7.77e-15	-0.43	-0.37	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
KIRC	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	8.93	8.12e-18	7.77e-15	0.29	0.37	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
KIRC	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-8.93	8.17e-18	7.82e-15	-0.35	-0.37	Asthma;	chr2:102399682	chr2:102438713~102440475:+
KIRC	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	8.93	8.24e-18	7.88e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
KIRC	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-8.93	8.25e-18	7.89e-15	-0.42	-0.37	Height;	chr11:118786602	chr11:118704607~118750263:+
KIRC	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	8.93	8.25e-18	7.9e-15	0.43	0.37	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
KIRC	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	8.93	8.29e-18	7.93e-15	0.46	0.37	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
KIRC	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	8.93	8.31e-18	7.95e-15	0.4	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
KIRC	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.93	8.34e-18	7.98e-15	-0.42	-0.37	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.93	8.34e-18	7.98e-15	-0.42	-0.37	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
KIRC	cis	rs1061377	0.748	rs1036033	ENSG00000249685.1	RP11-360F5.3	8.93	8.34e-18	7.98e-15	0.34	0.37	Uric acid levels;	chr4:39105295	chr4:39133913~39135608:+
KIRC	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	8.93	8.37e-18	8.01e-15	0.35	0.37	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
KIRC	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	8.93	8.41e-18	8.04e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
KIRC	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	8.93	8.41e-18	8.05e-15	0.26	0.37	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
KIRC	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-8.93	8.44e-18	8.07e-15	-0.35	-0.37	Asthma;	chr2:102394777	chr2:102438713~102440475:+
KIRC	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	8.93	8.48e-18	8.11e-15	0.39	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
KIRC	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	8.93	8.49e-18	8.12e-15	0.47	0.37	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
KIRC	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	8.93	8.5e-18	8.13e-15	0.35	0.37	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	8.93	8.5e-18	8.13e-15	0.35	0.37	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	8.93	8.5e-18	8.13e-15	0.35	0.37	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	8.93	8.5e-18	8.13e-15	0.35	0.37	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
KIRC	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-8.93	8.54e-18	8.16e-15	-0.46	-0.37	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
KIRC	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	8.93	8.54e-18	8.16e-15	0.46	0.37	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
KIRC	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	8.93	8.54e-18	8.16e-15	0.35	0.37	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
KIRC	cis	rs7189233	0.531	rs1861353	ENSG00000279344.1	RP11-44F14.7	8.93	8.56e-18	8.18e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53418169	chr16:53478957~53481550:-
KIRC	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	8.93	8.56e-18	8.18e-15	0.35	0.37	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
KIRC	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	8.93	8.57e-18	8.19e-15	0.35	0.37	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	8.93	8.57e-18	8.19e-15	0.35	0.37	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	8.93	8.58e-18	8.2e-15	0.47	0.37	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
KIRC	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-8.93	8.66e-18	8.27e-15	-0.35	-0.37	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
KIRC	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	8.93	8.67e-18	8.27e-15	0.34	0.37	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000250919.1	RP11-813N20.3	-8.92	8.71e-18	8.31e-15	-0.39	-0.37	Obesity-related traits;	chr4:69079224	chr4:69027831~69044578:+
KIRC	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55482317	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55491628	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55495801	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55496737	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55496933	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55497842	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55500224	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55501629	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55501726	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55501788	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55504176	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	8.92	8.71e-18	8.31e-15	0.34	0.37	Height;	chr4:55504201	chr4:55363971~55395847:-
KIRC	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-8.92	8.71e-18	8.31e-15	-0.35	-0.37	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-8.92	8.71e-18	8.31e-15	-0.35	-0.37	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
KIRC	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-8.92	8.72e-18	8.32e-15	-0.47	-0.37	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
KIRC	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	8.92	8.76e-18	8.35e-15	0.4	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	8.92	8.76e-18	8.35e-15	0.4	0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
KIRC	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-8.92	8.82e-18	8.41e-15	-0.44	-0.37	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-8.92	8.82e-18	8.41e-15	-0.44	-0.37	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
KIRC	cis	rs1061377	0.748	rs1964345	ENSG00000249685.1	RP11-360F5.3	8.92	8.84e-18	8.43e-15	0.34	0.37	Uric acid levels;	chr4:39104793	chr4:39133913~39135608:+
KIRC	cis	rs79040073	0.637	rs77408643	ENSG00000259531.2	RP11-295H24.3	8.92	8.85e-18	8.44e-15	0.5	0.37	Lung cancer in ever smokers;	chr15:49377226	chr15:49365124~49366685:-
KIRC	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-8.92	8.87e-18	8.46e-15	-0.35	-0.37	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
KIRC	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	8.92	8.88e-18	8.46e-15	0.47	0.37	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
KIRC	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	8.92	8.89e-18	8.47e-15	0.35	0.37	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
KIRC	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	8.92	8.89e-18	8.47e-15	0.35	0.37	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	8.92	8.89e-18	8.47e-15	0.35	0.37	Asthma;	chr2:102394452	chr2:102438713~102440475:+
KIRC	cis	rs2698530	0.762	rs2555441	ENSG00000225889.6	AC074289.1	-8.92	8.91e-18	8.49e-15	-0.39	-0.37	Iron status biomarkers;	chr2:64261741	chr2:64143239~64252859:+
KIRC	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-8.92	8.91e-18	8.5e-15	-0.47	-0.37	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
KIRC	cis	rs6600671	1	rs11249350	ENSG00000227082.1	CH17-437K3.1	-8.92	9.01e-18	8.59e-15	-0.42	-0.37	Hip geometry;	chr1:121436587	chr1:121396754~121463129:+
KIRC	cis	rs79040073	0.637	rs79365293	ENSG00000259531.2	RP11-295H24.3	8.92	9.04e-18	8.61e-15	0.5	0.37	Lung cancer in ever smokers;	chr15:49402268	chr15:49365124~49366685:-
KIRC	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.92	9.05e-18	8.62e-15	-0.43	-0.37	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
KIRC	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-8.92	9.09e-18	8.66e-15	-0.57	-0.37	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	8.92	9.11e-18	8.67e-15	0.48	0.37	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
KIRC	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-8.92	9.11e-18	8.67e-15	-0.47	-0.37	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
KIRC	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-8.92	9.13e-18	8.69e-15	-0.54	-0.37	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
KIRC	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-8.92	9.18e-18	8.74e-15	-0.36	-0.37	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
KIRC	cis	rs4853012	1	rs4853012	ENSG00000257800.1	FNBP1P1	8.92	9.2e-18	8.75e-15	0.5	0.37	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74120680~74123218:+
KIRC	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	8.92	9.21e-18	8.76e-15	0.48	0.37	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
KIRC	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-8.92	9.21e-18	8.77e-15	-0.48	-0.37	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
KIRC	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	8.92	9.24e-18	8.79e-15	0.37	0.37	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
KIRC	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	8.92	9.3e-18	8.84e-15	0.54	0.37	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
KIRC	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	8.92	9.31e-18	8.86e-15	0.34	0.37	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
KIRC	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-8.92	9.33e-18	8.88e-15	-0.38	-0.37	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
KIRC	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	8.92	9.35e-18	8.89e-15	0.48	0.37	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
KIRC	cis	rs4273100	0.79	rs2048230	ENSG00000262319.1	CTC-457L16.2	-8.92	9.35e-18	8.89e-15	-0.51	-0.37	Schizophrenia;	chr17:19372886	chr17:19141017~19143689:-
KIRC	cis	rs4273100	0.79	rs60606605	ENSG00000262319.1	CTC-457L16.2	-8.92	9.35e-18	8.89e-15	-0.51	-0.37	Schizophrenia;	chr17:19373831	chr17:19141017~19143689:-
KIRC	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-8.92	9.4e-18	8.93e-15	-0.36	-0.37	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
KIRC	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-8.91	9.44e-18	8.97e-15	-0.38	-0.37	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
KIRC	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	8.91	9.46e-18	8.99e-15	0.34	0.37	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
KIRC	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-8.91	9.49e-18	9.02e-15	-0.45	-0.37	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
KIRC	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-8.91	9.57e-18	9.09e-15	-0.57	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
KIRC	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-8.91	9.63e-18	9.14e-15	-0.43	-0.37	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
KIRC	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	8.91	9.64e-18	9.15e-15	0.54	0.37	Height;	chr6:109737797	chr6:109382795~109383666:+
KIRC	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	8.91	9.69e-18	9.2e-15	0.35	0.37	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
KIRC	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-8.91	9.71e-18	9.22e-15	-0.52	-0.37	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
KIRC	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-8.91	9.72e-18	9.23e-15	-0.36	-0.37	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
KIRC	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-8.91	9.73e-18	9.24e-15	-0.56	-0.37	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-8.91	9.75e-18	9.26e-15	-0.49	-0.37	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	8.91	9.76e-18	9.26e-15	0.48	0.37	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
KIRC	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-8.91	9.89e-18	9.38e-15	-0.48	-0.37	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	8.91	9.9e-18	9.39e-15	0.48	0.37	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
KIRC	cis	rs1529102	0.899	rs1358624	ENSG00000225889.6	AC074289.1	8.91	9.91e-18	9.4e-15	0.34	0.37	Breast size;	chr2:64259365	chr2:64143239~64252859:+
KIRC	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	8.91	9.94e-18	9.43e-15	0.34	0.37	Height;	chr4:55524246	chr4:55363971~55395847:-
KIRC	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	8.91	9.96e-18	9.45e-15	0.49	0.37	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
KIRC	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.91	1e-17	9.48e-15	0.43	0.37	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
KIRC	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	8.91	1e-17	9.49e-15	0.47	0.37	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	8.91	1e-17	9.5e-15	0.45	0.37	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
KIRC	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	8.91	1e-17	9.53e-15	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
KIRC	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-8.91	1.01e-17	9.59e-15	-0.57	-0.37	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
KIRC	cis	rs1200821	0.559	rs9418267	ENSG00000151963.4	RP11-775A3.1	8.91	1.01e-17	9.59e-15	0.42	0.37	Hemostatic factors and hematological phenotypes;	chr10:37531023	chr10:37883594~37884109:+
KIRC	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-8.91	1.01e-17	9.61e-15	-0.36	-0.37	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-8.91	1.01e-17	9.61e-15	-0.36	-0.37	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
KIRC	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-8.91	1.02e-17	9.62e-15	-0.49	-0.37	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
KIRC	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	8.91	1.02e-17	9.62e-15	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
KIRC	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-8.9	1.02e-17	9.64e-15	-0.46	-0.37	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
KIRC	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	8.9	1.03e-17	9.71e-15	0.35	0.37	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
KIRC	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	8.9	1.03e-17	9.71e-15	0.46	0.37	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
KIRC	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	8.9	1.03e-17	9.76e-15	0.34	0.37	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
KIRC	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	8.9	1.03e-17	9.8e-15	0.5	0.37	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
KIRC	cis	rs79040073	0.637	rs77296528	ENSG00000259531.2	RP11-295H24.3	8.9	1.04e-17	9.81e-15	0.5	0.37	Lung cancer in ever smokers;	chr15:49381827	chr15:49365124~49366685:-
KIRC	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.9	1.04e-17	9.84e-15	-0.38	-0.37	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
KIRC	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	8.9	1.05e-17	9.89e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
KIRC	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	8.9	1.05e-17	9.89e-15	0.48	0.37	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
KIRC	cis	rs189798	0.592	rs10111263	ENSG00000254340.1	RP11-10A14.3	-8.9	1.05e-17	9.91e-15	-0.48	-0.37	Myopia (pathological);	chr8:9111923	chr8:9141424~9145435:+
KIRC	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-8.9	1.05e-17	9.94e-15	-0.48	-0.37	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
KIRC	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	8.9	1.05e-17	9.96e-15	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
KIRC	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-8.9	1.06e-17	1e-14	-0.48	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
KIRC	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	8.9	1.06e-17	1e-14	0.39	0.37	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
KIRC	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	8.9	1.06e-17	1e-14	0.47	0.37	Height;	chr6:109498751	chr6:109382795~109383666:+
KIRC	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	8.9	1.06e-17	1e-14	0.34	0.37	Height;	chr4:55548261	chr4:55363971~55395847:-
KIRC	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	8.9	1.06e-17	1.01e-14	0.48	0.37	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
KIRC	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-8.9	1.07e-17	1.01e-14	-0.43	-0.37	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
KIRC	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-8.9	1.07e-17	1.01e-14	-0.43	-0.37	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
KIRC	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-8.9	1.07e-17	1.01e-14	-0.47	-0.37	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-8.9	1.07e-17	1.01e-14	-0.47	-0.37	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-8.9	1.07e-17	1.01e-14	-0.47	-0.37	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
KIRC	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	8.9	1.08e-17	1.02e-14	0.34	0.37	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
KIRC	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	8.9	1.08e-17	1.02e-14	0.35	0.37	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
KIRC	cis	rs6600671	1	rs7532615	ENSG00000227082.1	CH17-437K3.1	8.9	1.08e-17	1.02e-14	0.42	0.37	Hip geometry;	chr1:121430980	chr1:121396754~121463129:+
KIRC	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-8.9	1.09e-17	1.02e-14	-0.58	-0.37	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
KIRC	cis	rs919433	0.857	rs36071109	ENSG00000231621.1	AC013264.2	8.9	1.09e-17	1.02e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197197991~197199273:+
KIRC	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	8.9	1.09e-17	1.03e-14	0.41	0.37	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
KIRC	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-8.9	1.09e-17	1.03e-14	-0.46	-0.37	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
KIRC	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	8.9	1.09e-17	1.03e-14	0.35	0.37	Asthma;	chr2:102418659	chr2:102438713~102440475:+
KIRC	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	8.9	1.09e-17	1.03e-14	0.52	0.37	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
KIRC	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-8.9	1.09e-17	1.03e-14	-0.41	-0.37	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
KIRC	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-8.9	1.1e-17	1.03e-14	-0.34	-0.37	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
KIRC	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.89	1.11e-17	1.05e-14	-0.42	-0.37	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
KIRC	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	8.89	1.11e-17	1.05e-14	0.48	0.37	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
KIRC	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	8.89	1.12e-17	1.06e-14	0.44	0.37	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
KIRC	cis	rs1005277	0.522	rs289645	ENSG00000151963.4	RP11-775A3.1	-8.89	1.13e-17	1.07e-14	-0.41	-0.37	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:37883594~37884109:+
KIRC	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-8.89	1.14e-17	1.07e-14	-0.47	-0.37	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
KIRC	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	8.89	1.14e-17	1.08e-14	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
KIRC	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	8.89	1.14e-17	1.08e-14	0.32	0.37	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
KIRC	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.08e-14	0.34	0.37	Height;	chr4:55520278	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.08e-14	0.34	0.37	Height;	chr4:55523835	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.08e-14	0.34	0.37	Height;	chr4:55525589	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.08e-14	0.34	0.37	Height;	chr4:55525781	chr4:55363971~55395847:-
KIRC	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	8.89	1.15e-17	1.08e-14	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
KIRC	cis	rs58873874	0.737	rs80320835	ENSG00000251405.2	CTB-109A12.1	8.89	1.15e-17	1.08e-14	0.74	0.37	Bipolar disorder (body mass index interaction);	chr5:157389887	chr5:157362615~157460078:-
KIRC	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-8.89	1.15e-17	1.08e-14	-0.35	-0.37	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
KIRC	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-8.89	1.15e-17	1.08e-14	-0.5	-0.37	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
KIRC	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.89	1.15e-17	1.08e-14	-0.43	-0.37	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
KIRC	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.09e-14	0.34	0.37	Height;	chr4:55534166	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	8.89	1.15e-17	1.09e-14	0.34	0.37	Height;	chr4:55534180	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	8.89	1.16e-17	1.09e-14	0.34	0.37	Height;	chr4:55546002	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	8.89	1.16e-17	1.09e-14	0.34	0.37	Height;	chr4:55546378	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	8.89	1.16e-17	1.09e-14	0.47	0.37	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
KIRC	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	8.89	1.17e-17	1.1e-14	0.33	0.37	Height;	chr4:55479069	chr4:55363971~55395847:-
KIRC	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	8.89	1.17e-17	1.1e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
KIRC	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	8.89	1.17e-17	1.1e-14	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
KIRC	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	8.89	1.17e-17	1.1e-14	0.34	0.37	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
KIRC	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	8.89	1.18e-17	1.11e-14	0.56	0.37	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
KIRC	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.89	1.18e-17	1.11e-14	-0.42	-0.37	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
KIRC	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-8.89	1.18e-17	1.11e-14	-0.34	-0.37	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
KIRC	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-8.89	1.19e-17	1.11e-14	-0.46	-0.37	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
KIRC	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	8.88	1.19e-17	1.12e-14	0.34	0.37	Height;	chr4:55531150	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	8.88	1.19e-17	1.12e-14	0.34	0.37	Height;	chr4:55531218	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	8.88	1.19e-17	1.12e-14	0.34	0.37	Height;	chr4:55531811	chr4:55363971~55395847:-
KIRC	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-8.88	1.19e-17	1.12e-14	-0.37	-0.37	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
KIRC	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	8.88	1.19e-17	1.12e-14	0.47	0.37	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
KIRC	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-8.88	1.2e-17	1.13e-14	-0.47	-0.37	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
KIRC	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	8.88	1.2e-17	1.13e-14	0.49	0.37	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
KIRC	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	8.88	1.2e-17	1.13e-14	0.33	0.37	Height;	chr4:55479339	chr4:55363971~55395847:-
KIRC	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-8.88	1.21e-17	1.13e-14	-0.22	-0.37	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
KIRC	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-8.88	1.21e-17	1.13e-14	-0.54	-0.37	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
KIRC	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	8.88	1.21e-17	1.14e-14	0.88	0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
KIRC	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-8.88	1.21e-17	1.14e-14	-0.46	-0.37	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
KIRC	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	8.88	1.21e-17	1.14e-14	0.36	0.37	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
KIRC	cis	rs79040073	0.637	rs73398276	ENSG00000259531.2	RP11-295H24.3	8.88	1.21e-17	1.14e-14	0.49	0.37	Lung cancer in ever smokers;	chr15:49418782	chr15:49365124~49366685:-
KIRC	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	8.88	1.21e-17	1.14e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
KIRC	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	8.88	1.22e-17	1.14e-14	0.35	0.37	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
KIRC	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	8.88	1.23e-17	1.16e-14	0.53	0.37	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
KIRC	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-8.88	1.23e-17	1.16e-14	-0.48	-0.37	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
KIRC	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	8.88	1.24e-17	1.16e-14	0.34	0.37	Height;	chr4:55526514	chr4:55363971~55395847:-
KIRC	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	8.88	1.24e-17	1.16e-14	0.51	0.37	Height;	chr6:109486036	chr6:109382795~109383666:+
KIRC	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	8.88	1.24e-17	1.16e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
KIRC	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	8.88	1.24e-17	1.16e-14	0.38	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
KIRC	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	8.88	1.24e-17	1.17e-14	0.44	0.37	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
KIRC	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	8.88	1.24e-17	1.17e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
KIRC	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-8.88	1.25e-17	1.17e-14	-0.36	-0.37	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
KIRC	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-8.88	1.25e-17	1.17e-14	-0.32	-0.37	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	8.88	1.25e-17	1.17e-14	0.48	0.37	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
KIRC	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	8.88	1.25e-17	1.17e-14	0.33	0.37	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
KIRC	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-8.88	1.25e-17	1.18e-14	-0.41	-0.37	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
KIRC	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-8.88	1.26e-17	1.18e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
KIRC	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-8.88	1.26e-17	1.18e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
KIRC	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	8.88	1.26e-17	1.18e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	8.88	1.26e-17	1.18e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	8.88	1.26e-17	1.18e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
KIRC	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	8.88	1.26e-17	1.18e-14	0.39	0.37	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
KIRC	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.88	1.26e-17	1.18e-14	-0.38	-0.37	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
KIRC	cis	rs1005277	0.54	rs7903942	ENSG00000151963.4	RP11-775A3.1	8.88	1.26e-17	1.18e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:37883594~37884109:+
KIRC	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8.88	1.26e-17	1.19e-14	0.48	0.37	Height;	chr6:109407238	chr6:109382795~109383666:+
KIRC	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	8.88	1.27e-17	1.19e-14	0.26	0.37	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
KIRC	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-8.88	1.27e-17	1.19e-14	-0.47	-0.37	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
KIRC	cis	rs79040073	0.637	rs11634636	ENSG00000259531.2	RP11-295H24.3	8.88	1.27e-17	1.19e-14	0.49	0.37	Lung cancer in ever smokers;	chr15:49315407	chr15:49365124~49366685:-
KIRC	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	8.88	1.27e-17	1.19e-14	0.42	0.37	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
KIRC	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	8.88	1.27e-17	1.19e-14	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
KIRC	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.88	1.27e-17	1.19e-14	-0.42	-0.37	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
KIRC	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-8.88	1.28e-17	1.19e-14	-0.47	-0.37	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
KIRC	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-8.88	1.28e-17	1.2e-14	-0.35	-0.37	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
KIRC	cis	rs4273100	1	rs16960499	ENSG00000262319.1	CTC-457L16.2	-8.88	1.28e-17	1.2e-14	-0.53	-0.37	Schizophrenia;	chr17:19299719	chr17:19141017~19143689:-
KIRC	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-8.88	1.28e-17	1.2e-14	-0.48	-0.37	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
KIRC	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	8.87	1.29e-17	1.21e-14	0.58	0.37	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
KIRC	cis	rs79040073	0.637	rs17476361	ENSG00000259531.2	RP11-295H24.3	8.87	1.29e-17	1.21e-14	0.49	0.37	Lung cancer in ever smokers;	chr15:49302255	chr15:49365124~49366685:-
KIRC	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	8.87	1.29e-17	1.21e-14	0.47	0.37	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	8.87	1.3e-17	1.21e-14	0.55	0.37	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
KIRC	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-8.87	1.3e-17	1.22e-14	-0.54	-0.37	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
KIRC	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	8.87	1.3e-17	1.22e-14	0.48	0.37	Height;	chr6:109518783	chr6:109382795~109383666:+
KIRC	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	8.87	1.31e-17	1.22e-14	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
KIRC	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-8.87	1.31e-17	1.23e-14	-0.35	-0.37	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
KIRC	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-8.87	1.31e-17	1.23e-14	-0.91	-0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
KIRC	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-8.87	1.31e-17	1.23e-14	-0.43	-0.37	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
KIRC	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-8.87	1.32e-17	1.23e-14	-0.47	-0.37	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-8.87	1.32e-17	1.23e-14	-0.47	-0.37	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
KIRC	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-8.87	1.32e-17	1.24e-14	-0.47	-0.37	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
KIRC	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-8.87	1.32e-17	1.24e-14	-0.46	-0.37	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
KIRC	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-8.87	1.33e-17	1.24e-14	-0.44	-0.37	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
KIRC	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-8.87	1.33e-17	1.24e-14	-0.48	-0.37	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
KIRC	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-8.87	1.33e-17	1.24e-14	-0.42	-0.37	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
KIRC	cis	rs79040073	0.637	rs73398272	ENSG00000259531.2	RP11-295H24.3	8.87	1.33e-17	1.25e-14	0.48	0.37	Lung cancer in ever smokers;	chr15:49416426	chr15:49365124~49366685:-
KIRC	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	8.87	1.34e-17	1.25e-14	0.47	0.37	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	8.87	1.34e-17	1.25e-14	0.48	0.37	Height;	chr6:109526846	chr6:109382795~109383666:+
KIRC	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-8.87	1.34e-17	1.25e-14	-0.41	-0.37	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
KIRC	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-8.87	1.34e-17	1.25e-14	-0.35	-0.37	Asthma;	chr2:102377873	chr2:102438713~102440475:+
KIRC	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-8.87	1.36e-17	1.27e-14	-0.41	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
KIRC	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-8.87	1.36e-17	1.27e-14	-0.41	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
KIRC	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	8.87	1.36e-17	1.27e-14	0.48	0.37	Height;	chr6:109496073	chr6:109382795~109383666:+
KIRC	cis	rs1005277	0.522	rs289643	ENSG00000151963.4	RP11-775A3.1	-8.87	1.38e-17	1.29e-14	-0.41	-0.37	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:37883594~37884109:+
KIRC	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	8.87	1.38e-17	1.29e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
KIRC	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	8.87	1.38e-17	1.29e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
KIRC	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	8.87	1.39e-17	1.29e-14	0.48	0.37	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
KIRC	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-8.87	1.39e-17	1.29e-14	-0.41	-0.37	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
KIRC	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-8.86	1.39e-17	1.29e-14	-0.43	-0.37	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
KIRC	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-8.86	1.39e-17	1.3e-14	-0.47	-0.37	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
KIRC	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-8.86	1.4e-17	1.31e-14	-0.41	-0.37	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
KIRC	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	8.86	1.41e-17	1.31e-14	0.35	0.37	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	8.86	1.41e-17	1.31e-14	0.35	0.37	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
KIRC	cis	rs1061377	0.748	rs1964347	ENSG00000249685.1	RP11-360F5.3	8.86	1.41e-17	1.31e-14	0.34	0.37	Uric acid levels;	chr4:39104956	chr4:39133913~39135608:+
KIRC	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	8.86	1.41e-17	1.31e-14	0.38	0.37	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
KIRC	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	8.86	1.41e-17	1.32e-14	0.59	0.37	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
KIRC	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	8.86	1.42e-17	1.32e-14	0.53	0.37	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
KIRC	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-8.86	1.42e-17	1.33e-14	-0.48	-0.37	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
KIRC	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.86	1.43e-17	1.33e-14	0.43	0.37	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
KIRC	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.86	1.43e-17	1.33e-14	-0.42	-0.37	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
KIRC	cis	rs904251	0.861	rs2776877	ENSG00000227920.2	RP1-153P14.5	-8.86	1.43e-17	1.33e-14	-0.43	-0.37	Cognitive performance;	chr6:37519359	chr6:37545145~37550860:+
KIRC	cis	rs904251	0.864	rs2797801	ENSG00000227920.2	RP1-153P14.5	-8.86	1.43e-17	1.33e-14	-0.43	-0.37	Cognitive performance;	chr6:37519385	chr6:37545145~37550860:+
KIRC	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	8.86	1.44e-17	1.34e-14	0.32	0.37	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	8.86	1.44e-17	1.34e-14	0.32	0.37	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
KIRC	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-8.86	1.45e-17	1.35e-14	-0.39	-0.37	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
KIRC	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-8.86	1.45e-17	1.35e-14	-0.47	-0.37	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
KIRC	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-8.86	1.45e-17	1.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-8.86	1.45e-17	1.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-8.86	1.45e-17	1.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-8.86	1.45e-17	1.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-8.86	1.45e-17	1.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
KIRC	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-8.86	1.46e-17	1.36e-14	-0.47	-0.37	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
KIRC	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	8.86	1.46e-17	1.36e-14	0.42	0.37	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
KIRC	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-8.86	1.46e-17	1.36e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
KIRC	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	8.86	1.47e-17	1.36e-14	0.44	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
KIRC	cis	rs899997	0.954	rs4887091	ENSG00000261143.1	ADAMTS7P3	8.86	1.48e-17	1.37e-14	0.44	0.37	Coronary artery disease or large artery stroke;	chr15:78751238	chr15:77976042~77993057:+
KIRC	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	8.86	1.48e-17	1.38e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
KIRC	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-8.86	1.49e-17	1.39e-14	-0.45	-0.37	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
KIRC	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-8.86	1.49e-17	1.39e-14	-0.46	-0.37	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
KIRC	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	8.85	1.5e-17	1.39e-14	0.48	0.37	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
KIRC	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-8.85	1.5e-17	1.39e-14	-0.3	-0.37	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
KIRC	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	8.85	1.51e-17	1.4e-14	0.38	0.37	Height;	chr3:53091453	chr3:53064283~53065091:-
KIRC	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-8.85	1.51e-17	1.4e-14	-0.47	-0.37	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
KIRC	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-8.85	1.51e-17	1.41e-14	-0.41	-0.37	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
KIRC	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-8.85	1.52e-17	1.41e-14	-0.45	-0.37	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
KIRC	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-8.85	1.52e-17	1.41e-14	-0.48	-0.37	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
KIRC	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	8.85	1.52e-17	1.42e-14	0.47	0.37	Height;	chr6:109497088	chr6:109382795~109383666:+
KIRC	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-8.85	1.53e-17	1.42e-14	-0.42	-0.37	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
KIRC	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-8.85	1.54e-17	1.43e-14	-0.47	-0.37	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-8.85	1.54e-17	1.43e-14	-0.47	-0.37	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
KIRC	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-8.85	1.55e-17	1.44e-14	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
KIRC	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.85	1.56e-17	1.44e-14	0.43	0.37	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
KIRC	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-8.85	1.56e-17	1.45e-14	-0.53	-0.37	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
KIRC	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	8.85	1.56e-17	1.45e-14	0.46	0.37	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
KIRC	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.85	1.56e-17	1.45e-14	0.43	0.37	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
KIRC	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	8.85	1.56e-17	1.45e-14	0.48	0.37	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
KIRC	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	8.85	1.56e-17	1.45e-14	0.56	0.37	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
KIRC	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-8.85	1.56e-17	1.45e-14	-0.47	-0.37	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
KIRC	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	8.85	1.57e-17	1.46e-14	0.22	0.37	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
KIRC	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-8.85	1.57e-17	1.46e-14	-0.47	-0.37	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
KIRC	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	8.85	1.58e-17	1.47e-14	0.46	0.37	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
KIRC	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.85	1.59e-17	1.47e-14	0.42	0.37	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
KIRC	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-8.85	1.59e-17	1.48e-14	-0.47	-0.37	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
KIRC	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-8.85	1.6e-17	1.49e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-8.85	1.6e-17	1.49e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
KIRC	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-8.85	1.61e-17	1.49e-14	-0.43	-0.37	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
KIRC	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	8.85	1.62e-17	1.5e-14	0.43	0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
KIRC	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-8.84	1.63e-17	1.51e-14	-0.39	-0.37	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
KIRC	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	8.84	1.63e-17	1.51e-14	0.34	0.37	Height;	chr4:55515118	chr4:55363971~55395847:-
KIRC	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	8.84	1.63e-17	1.52e-14	0.56	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
KIRC	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	8.84	1.64e-17	1.52e-14	0.36	0.37	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
KIRC	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	8.84	1.64e-17	1.52e-14	0.53	0.37	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
KIRC	cis	rs79040073	0.636	rs74339964	ENSG00000259531.2	RP11-295H24.3	8.84	1.64e-17	1.52e-14	0.49	0.37	Lung cancer in ever smokers;	chr15:49329916	chr15:49365124~49366685:-
KIRC	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-8.84	1.65e-17	1.52e-14	-0.55	-0.37	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	8.84	1.65e-17	1.53e-14	0.48	0.37	Height;	chr6:109546439	chr6:109382795~109383666:+
KIRC	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	8.84	1.65e-17	1.53e-14	0.48	0.37	Height;	chr6:109551060	chr6:109382795~109383666:+
KIRC	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	8.84	1.65e-17	1.53e-14	0.54	0.37	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
KIRC	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	8.84	1.67e-17	1.55e-14	0.32	0.37	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	8.84	1.67e-17	1.55e-14	0.32	0.37	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
KIRC	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-8.84	1.68e-17	1.55e-14	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
KIRC	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-8.84	1.68e-17	1.56e-14	-0.48	-0.37	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	8.84	1.68e-17	1.56e-14	0.46	0.37	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
KIRC	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	8.84	1.69e-17	1.56e-14	0.49	0.37	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
KIRC	cis	rs1005277	0.505	rs200935	ENSG00000151963.4	RP11-775A3.1	-8.84	1.69e-17	1.57e-14	-0.42	-0.37	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:37883594~37884109:+
KIRC	cis	rs6600671	1	rs1591882	ENSG00000227082.1	CH17-437K3.1	-8.84	1.7e-17	1.57e-14	-0.41	-0.37	Hip geometry;	chr1:121441455	chr1:121396754~121463129:+
KIRC	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	8.84	1.7e-17	1.57e-14	0.32	0.37	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
KIRC	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	8.84	1.7e-17	1.57e-14	0.57	0.37	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
KIRC	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	8.84	1.7e-17	1.58e-14	0.33	0.37	Height;	chr4:55450662	chr4:55363971~55395847:-
KIRC	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	8.84	1.71e-17	1.58e-14	0.41	0.37	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
KIRC	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-8.84	1.71e-17	1.59e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
KIRC	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-8.84	1.71e-17	1.59e-14	-0.26	-0.37	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
KIRC	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	8.84	1.72e-17	1.59e-14	0.37	0.37	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
KIRC	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	8.84	1.72e-17	1.59e-14	0.59	0.37	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
KIRC	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	8.84	1.73e-17	1.6e-14	0.36	0.37	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
KIRC	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-8.84	1.74e-17	1.61e-14	-0.33	-0.37	Height;	chr4:55542948	chr4:55363971~55395847:-
KIRC	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-8.84	1.74e-17	1.61e-14	-0.69	-0.37	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
KIRC	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-8.84	1.74e-17	1.61e-14	-0.46	-0.37	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
KIRC	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	8.84	1.75e-17	1.61e-14	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
KIRC	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	8.83	1.75e-17	1.62e-14	0.29	0.37	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
KIRC	cis	rs6061231	0.583	rs2427313	ENSG00000273619.1	RP5-908M14.9	-8.83	1.75e-17	1.62e-14	-0.3	-0.37	Colorectal cancer;	chr20:62395619	chr20:62386303~62386970:-
KIRC	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	8.83	1.75e-17	1.62e-14	0.55	0.37	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
KIRC	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	8.83	1.76e-17	1.62e-14	0.5	0.37	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
KIRC	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	8.83	1.76e-17	1.62e-14	0.49	0.37	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
KIRC	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	8.83	1.76e-17	1.62e-14	0.49	0.37	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
KIRC	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	8.83	1.79e-17	1.65e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
KIRC	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	8.83	1.79e-17	1.65e-14	0.42	0.37	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
KIRC	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-8.83	1.79e-17	1.65e-14	-0.48	-0.37	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
KIRC	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	8.83	1.8e-17	1.66e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
KIRC	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-8.83	1.81e-17	1.67e-14	-0.49	-0.37	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
KIRC	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-8.83	1.81e-17	1.67e-14	-0.46	-0.37	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
KIRC	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-8.83	1.81e-17	1.67e-14	-0.36	-0.37	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
KIRC	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	8.83	1.82e-17	1.68e-14	0.46	0.37	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
KIRC	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-8.83	1.83e-17	1.68e-14	-0.26	-0.37	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
KIRC	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-8.83	1.83e-17	1.69e-14	-0.48	-0.37	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
KIRC	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	8.83	1.84e-17	1.69e-14	0.5	0.37	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
KIRC	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-8.83	1.84e-17	1.7e-14	-0.52	-0.37	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
KIRC	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	8.83	1.85e-17	1.7e-14	0.47	0.37	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
KIRC	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	8.83	1.85e-17	1.7e-14	0.5	0.37	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
KIRC	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	8.83	1.86e-17	1.71e-14	0.48	0.37	Height;	chr6:109533040	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	8.83	1.86e-17	1.71e-14	0.48	0.37	Height;	chr6:109534269	chr6:109382795~109383666:+
KIRC	cis	rs919433	0.963	rs12693815	ENSG00000231621.1	AC013264.2	8.83	1.86e-17	1.71e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197303679	chr2:197197991~197199273:+
KIRC	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-8.83	1.86e-17	1.71e-14	-0.34	-0.37	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
KIRC	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	8.83	1.86e-17	1.72e-14	0.37	0.37	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
KIRC	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	8.83	1.87e-17	1.72e-14	0.34	0.37	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
KIRC	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	8.83	1.87e-17	1.72e-14	0.49	0.37	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
KIRC	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	8.83	1.87e-17	1.72e-14	0.37	0.37	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
KIRC	cis	rs1200821	0.529	rs2475206	ENSG00000151963.4	RP11-775A3.1	8.83	1.87e-17	1.73e-14	0.42	0.37	Hemostatic factors and hematological phenotypes;	chr10:37513604	chr10:37883594~37884109:+
KIRC	cis	rs4819052	0.851	rs7275468	ENSG00000223768.1	LINC00205	-8.83	1.88e-17	1.73e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45293285~45297354:+
KIRC	cis	rs79040073	0.637	rs73394355	ENSG00000259531.2	RP11-295H24.3	8.83	1.88e-17	1.73e-14	0.47	0.37	Lung cancer in ever smokers;	chr15:49299893	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs73394359	ENSG00000259531.2	RP11-295H24.3	8.83	1.88e-17	1.73e-14	0.47	0.37	Lung cancer in ever smokers;	chr15:49300941	chr15:49365124~49366685:-
KIRC	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	8.83	1.88e-17	1.73e-14	0.48	0.37	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
KIRC	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-8.83	1.88e-17	1.73e-14	-0.47	-0.37	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
KIRC	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-8.82	1.9e-17	1.75e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-8.82	1.9e-17	1.75e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
KIRC	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-8.82	1.91e-17	1.75e-14	-0.42	-0.37	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
KIRC	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-8.82	1.91e-17	1.76e-14	-0.48	-0.37	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
KIRC	cis	rs4356975	1	rs4356975	ENSG00000196472.4	RP13-644M16.4	8.82	1.91e-17	1.76e-14	0.42	0.37	Obesity-related traits;	chr4:69106745	chr4:69181660~69182372:+
KIRC	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	8.82	1.92e-17	1.76e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
KIRC	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	8.82	1.92e-17	1.76e-14	0.48	0.37	Height;	chr6:109564443	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	8.82	1.92e-17	1.76e-14	0.48	0.37	Height;	chr6:109571489	chr6:109382795~109383666:+
KIRC	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	8.82	1.92e-17	1.77e-14	0.43	0.37	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
KIRC	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	8.82	1.93e-17	1.77e-14	0.35	0.37	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
KIRC	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	8.82	1.93e-17	1.78e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
KIRC	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-8.82	1.93e-17	1.78e-14	-0.46	-0.37	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
KIRC	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-8.82	1.93e-17	1.78e-14	-0.4	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
KIRC	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	8.82	1.94e-17	1.78e-14	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
KIRC	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	8.82	1.94e-17	1.78e-14	0.48	0.37	Height;	chr6:109576414	chr6:109382795~109383666:+
KIRC	cis	rs1005277	0.54	rs289638	ENSG00000151963.4	RP11-775A3.1	-8.82	1.94e-17	1.79e-14	-0.41	-0.37	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:37883594~37884109:+
KIRC	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	8.82	1.94e-17	1.79e-14	0.45	0.37	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
KIRC	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	8.82	1.95e-17	1.79e-14	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
KIRC	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-8.82	1.95e-17	1.79e-14	-0.34	-0.37	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
KIRC	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-8.82	1.95e-17	1.79e-14	-0.33	-0.37	Height;	chr4:55547636	chr4:55363971~55395847:-
KIRC	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.82	1.95e-17	1.79e-14	-0.43	-0.37	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
KIRC	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	8.82	1.95e-17	1.79e-14	0.47	0.37	Height;	chr6:109495102	chr6:109382795~109383666:+
KIRC	cis	rs2749592	0.918	rs1208653	ENSG00000151963.4	RP11-775A3.1	8.82	1.96e-17	1.8e-14	0.47	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr10:37964898	chr10:37883594~37884109:+
KIRC	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-8.82	1.96e-17	1.8e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-8.82	1.96e-17	1.8e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-8.82	1.96e-17	1.8e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-8.82	1.96e-17	1.8e-14	-0.41	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
KIRC	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-8.82	1.97e-17	1.81e-14	-0.33	-0.37	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
KIRC	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-8.82	1.97e-17	1.81e-14	-0.34	-0.37	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-8.82	1.97e-17	1.81e-14	-0.34	-0.37	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
KIRC	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	8.82	1.97e-17	1.81e-14	0.48	0.37	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
KIRC	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	8.82	1.98e-17	1.82e-14	0.41	0.37	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
KIRC	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	8.82	1.99e-17	1.82e-14	0.54	0.37	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
KIRC	cis	rs919433	0.963	rs4850428	ENSG00000231621.1	AC013264.2	8.82	1.99e-17	1.83e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305048	chr2:197197991~197199273:+
KIRC	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-8.82	1.99e-17	1.83e-14	-0.49	-0.37	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
KIRC	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.82	1.99e-17	1.83e-14	-0.42	-0.37	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.82	1.99e-17	1.83e-14	-0.42	-0.37	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
KIRC	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	8.82	1.99e-17	1.83e-14	0.45	0.37	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	8.82	1.99e-17	1.83e-14	0.45	0.37	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
KIRC	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	8.82	2e-17	1.83e-14	0.48	0.37	Height;	chr6:109588639	chr6:109382795~109383666:+
KIRC	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	8.82	2.01e-17	1.85e-14	0.33	0.37	Height;	chr4:55479996	chr4:55363971~55395847:-
KIRC	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-8.82	2.01e-17	1.85e-14	-0.42	-0.37	Migraine;	chr4:56853383	chr4:56960927~56961373:-
KIRC	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-8.82	2.03e-17	1.86e-14	-0.43	-0.37	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
KIRC	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-8.82	2.03e-17	1.86e-14	-0.43	-0.37	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
KIRC	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-8.82	2.03e-17	1.86e-14	-0.43	-0.37	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
KIRC	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-8.82	2.03e-17	1.86e-14	-0.42	-0.37	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
KIRC	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-8.81	2.04e-17	1.87e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-8.81	2.04e-17	1.87e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-8.81	2.04e-17	1.87e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
KIRC	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-8.81	2.06e-17	1.89e-14	-0.42	-0.37	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
KIRC	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-8.81	2.06e-17	1.89e-14	-0.47	-0.37	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
KIRC	cis	rs904251	0.797	rs2776878	ENSG00000227920.2	RP1-153P14.5	-8.81	2.06e-17	1.89e-14	-0.43	-0.37	Cognitive performance;	chr6:37519497	chr6:37545145~37550860:+
KIRC	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	8.81	2.07e-17	1.89e-14	0.45	0.37	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
KIRC	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	8.81	2.08e-17	1.91e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	8.81	2.08e-17	1.91e-14	0.4	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
KIRC	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	8.81	2.08e-17	1.91e-14	0.48	0.37	Height;	chr6:109584789	chr6:109382795~109383666:+
KIRC	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-8.81	2.09e-17	1.91e-14	-0.4	-0.37	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-8.81	2.09e-17	1.91e-14	-0.4	-0.37	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
KIRC	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	8.81	2.09e-17	1.91e-14	0.58	0.37	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
KIRC	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	8.81	2.09e-17	1.91e-14	0.48	0.37	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
KIRC	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	8.81	2.09e-17	1.91e-14	0.48	0.37	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
KIRC	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-8.81	2.09e-17	1.91e-14	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
KIRC	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-8.81	2.09e-17	1.92e-14	-0.46	-0.37	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
KIRC	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-8.81	2.1e-17	1.92e-14	-0.46	-0.37	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
KIRC	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	8.81	2.1e-17	1.93e-14	0.37	0.37	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
KIRC	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	8.81	2.12e-17	1.94e-14	0.38	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	8.81	2.12e-17	1.94e-14	0.38	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
KIRC	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	8.81	2.13e-17	1.95e-14	0.65	0.37	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
KIRC	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-8.81	2.13e-17	1.95e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
KIRC	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	8.81	2.13e-17	1.95e-14	0.47	0.37	Height;	chr6:109496680	chr6:109382795~109383666:+
KIRC	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	8.81	2.13e-17	1.95e-14	0.5	0.37	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
KIRC	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-8.81	2.13e-17	1.95e-14	-0.48	-0.37	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
KIRC	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	8.81	2.14e-17	1.96e-14	0.41	0.37	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
KIRC	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-8.81	2.16e-17	1.98e-14	-0.34	-0.37	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
KIRC	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	8.81	2.17e-17	1.98e-14	0.65	0.37	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
KIRC	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	8.81	2.18e-17	1.99e-14	0.34	0.37	Height;	chr4:55533481	chr4:55363971~55395847:-
KIRC	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	8.81	2.19e-17	2e-14	0.37	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	8.81	2.19e-17	2e-14	0.37	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
KIRC	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-8.81	2.19e-17	2e-14	-0.37	-0.37	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
KIRC	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	8.8	2.22e-17	2.03e-14	0.45	0.37	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
KIRC	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-8.8	2.23e-17	2.03e-14	-0.43	-0.37	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
KIRC	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-8.8	2.23e-17	2.03e-14	-0.41	-0.37	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
KIRC	cis	rs8396	1	rs9410	ENSG00000271817.2	U3	8.8	2.23e-17	2.03e-14	0.35	0.37	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158710839	chr4:158700691~158700909:+
KIRC	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	8.8	2.23e-17	2.04e-14	0.35	0.37	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
KIRC	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.8	2.23e-17	2.04e-14	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
KIRC	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.8	2.23e-17	2.04e-14	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
KIRC	cis	rs11096990	0.613	rs12643415	ENSG00000249207.1	RP11-360F5.1	8.8	2.24e-17	2.04e-14	0.37	0.37	Cognitive function;	chr4:39270375	chr4:39112677~39126818:-
KIRC	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	8.8	2.24e-17	2.04e-14	0.46	0.37	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	8.8	2.24e-17	2.05e-14	0.46	0.37	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	8.8	2.24e-17	2.05e-14	0.46	0.37	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	8.8	2.24e-17	2.05e-14	0.46	0.37	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	8.8	2.24e-17	2.05e-14	0.46	0.37	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
KIRC	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	8.8	2.24e-17	2.05e-14	0.42	0.37	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
KIRC	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-8.8	2.25e-17	2.06e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
KIRC	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-8.8	2.26e-17	2.06e-14	-0.47	-0.37	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
KIRC	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-8.8	2.27e-17	2.07e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
KIRC	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	8.8	2.27e-17	2.07e-14	0.56	0.37	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-8.8	2.27e-17	2.08e-14	-0.45	-0.37	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
KIRC	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-8.8	2.28e-17	2.08e-14	-0.54	-0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
KIRC	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	8.8	2.29e-17	2.09e-14	0.26	0.37	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
KIRC	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	8.8	2.29e-17	2.09e-14	0.65	0.37	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
KIRC	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-8.8	2.3e-17	2.1e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
KIRC	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-8.8	2.3e-17	2.1e-14	-0.41	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
KIRC	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	8.8	2.3e-17	2.1e-14	0.45	0.37	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	8.8	2.3e-17	2.1e-14	0.45	0.37	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	8.8	2.3e-17	2.1e-14	0.45	0.37	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
KIRC	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.8	2.31e-17	2.11e-14	-0.42	-0.37	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.8	2.31e-17	2.11e-14	-0.42	-0.37	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.8	2.31e-17	2.11e-14	-0.42	-0.37	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
KIRC	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	8.8	2.32e-17	2.11e-14	0.54	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
KIRC	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	8.8	2.32e-17	2.12e-14	0.38	0.37	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
KIRC	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	8.8	2.33e-17	2.12e-14	0.52	0.37	Height;	chr6:109331033	chr6:109382795~109383666:+
KIRC	cis	rs6600671	1	rs1856572	ENSG00000227082.1	CH17-437K3.1	-8.8	2.33e-17	2.12e-14	-0.41	-0.37	Hip geometry;	chr1:121427719	chr1:121396754~121463129:+
KIRC	cis	rs9388451	0.626	rs1739384	ENSG00000237742.5	RP11-624M8.1	-8.8	2.34e-17	2.13e-14	-0.42	-0.37	Brugada syndrome;	chr6:125778100	chr6:125578558~125749190:-
KIRC	cis	rs9388451	0.587	rs1739385	ENSG00000237742.5	RP11-624M8.1	-8.8	2.34e-17	2.13e-14	-0.42	-0.37	Brugada syndrome;	chr6:125778793	chr6:125578558~125749190:-
KIRC	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	8.8	2.36e-17	2.15e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
KIRC	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	8.8	2.37e-17	2.16e-14	0.33	0.37	Height;	chr4:55425312	chr4:55363971~55395847:-
KIRC	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-8.8	2.38e-17	2.17e-14	-0.33	-0.37	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
KIRC	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-8.8	2.38e-17	2.17e-14	-0.35	-0.37	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	8.79	2.38e-17	2.17e-14	0.34	0.37	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
KIRC	cis	rs6600671	1	rs10794671	ENSG00000227082.1	CH17-437K3.1	-8.79	2.39e-17	2.17e-14	-0.41	-0.37	Hip geometry;	chr1:121426382	chr1:121396754~121463129:+
KIRC	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-8.79	2.4e-17	2.18e-14	-0.43	-0.37	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
KIRC	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	8.79	2.41e-17	2.19e-14	0.33	0.37	Height;	chr4:55534788	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	8.79	2.41e-17	2.19e-14	0.33	0.37	Height;	chr4:55535489	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	8.79	2.41e-17	2.19e-14	0.33	0.37	Height;	chr4:55536421	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	8.79	2.41e-17	2.19e-14	0.33	0.37	Height;	chr4:55537080	chr4:55363971~55395847:-
KIRC	cis	rs2749592	0.918	rs4934590	ENSG00000151963.4	RP11-775A3.1	8.79	2.41e-17	2.19e-14	0.47	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr10:37588641	chr10:37883594~37884109:+
KIRC	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-8.79	2.41e-17	2.19e-14	-0.4	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
KIRC	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	8.79	2.41e-17	2.19e-14	0.33	0.37	Height;	chr4:55545574	chr4:55363971~55395847:-
KIRC	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	8.79	2.41e-17	2.2e-14	0.41	0.37	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
KIRC	cis	rs79040073	0.637	rs57749497	ENSG00000259531.2	RP11-295H24.3	8.79	2.41e-17	2.2e-14	0.47	0.37	Lung cancer in ever smokers;	chr15:49297661	chr15:49365124~49366685:-
KIRC	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	8.79	2.42e-17	2.21e-14	0.48	0.37	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
KIRC	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-8.79	2.42e-17	2.21e-14	-0.58	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
KIRC	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-8.79	2.43e-17	2.21e-14	-0.43	-0.37	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
KIRC	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	8.79	2.43e-17	2.21e-14	0.34	0.37	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-8.79	2.43e-17	2.21e-14	-0.34	-0.37	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
KIRC	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	8.79	2.43e-17	2.21e-14	0.33	0.37	Height;	chr4:55541259	chr4:55363971~55395847:-
KIRC	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	8.79	2.43e-17	2.22e-14	0.28	0.37	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
KIRC	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	8.79	2.45e-17	2.23e-14	0.55	0.37	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
KIRC	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	8.79	2.45e-17	2.23e-14	0.66	0.37	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
KIRC	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.79	2.45e-17	2.23e-14	-0.43	-0.37	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
KIRC	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	8.79	2.45e-17	2.23e-14	0.48	0.37	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
KIRC	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	8.79	2.45e-17	2.23e-14	0.47	0.37	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
KIRC	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.79	2.45e-17	2.23e-14	-0.42	-0.37	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000250696.4	RP11-704M14.1	8.79	2.46e-17	2.24e-14	0.39	0.37	Obesity-related traits;	chr4:69075473	chr4:69182100~69216766:+
KIRC	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	8.79	2.47e-17	2.25e-14	0.49	0.37	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
KIRC	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	8.79	2.48e-17	2.26e-14	0.39	0.37	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	8.79	2.48e-17	2.26e-14	0.39	0.37	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	8.79	2.49e-17	2.27e-14	0.39	0.37	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
KIRC	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-8.79	2.49e-17	2.27e-14	-0.35	-0.37	Asthma;	chr2:102392894	chr2:102438713~102440475:+
KIRC	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-8.79	2.5e-17	2.27e-14	-0.42	-0.37	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
KIRC	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	8.79	2.5e-17	2.27e-14	0.34	0.37	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	8.79	2.5e-17	2.27e-14	0.34	0.37	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	8.79	2.5e-17	2.27e-14	0.34	0.37	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	8.79	2.5e-17	2.27e-14	0.34	0.37	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
KIRC	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	8.79	2.5e-17	2.27e-14	0.47	0.37	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
KIRC	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-8.79	2.51e-17	2.28e-14	-0.45	-0.37	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
KIRC	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-8.79	2.51e-17	2.28e-14	-0.47	-0.37	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
KIRC	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	8.79	2.52e-17	2.29e-14	0.45	0.37	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
KIRC	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	8.79	2.53e-17	2.3e-14	0.53	0.37	Height;	chr6:109732047	chr6:109382795~109383666:+
KIRC	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	8.79	2.54e-17	2.3e-14	0.39	0.37	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
KIRC	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	8.79	2.54e-17	2.31e-14	0.37	0.37	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
KIRC	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	8.79	2.55e-17	2.31e-14	0.34	0.37	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
KIRC	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	8.79	2.55e-17	2.31e-14	0.49	0.37	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
KIRC	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	8.79	2.55e-17	2.31e-14	0.47	0.37	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
KIRC	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	8.79	2.55e-17	2.32e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
KIRC	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	8.79	2.56e-17	2.32e-14	0.6	0.37	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	8.79	2.56e-17	2.32e-14	0.6	0.37	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
KIRC	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-8.79	2.56e-17	2.33e-14	-0.48	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
KIRC	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.78	2.58e-17	2.34e-14	-0.42	-0.37	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.78	2.58e-17	2.34e-14	-0.42	-0.37	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.78	2.58e-17	2.34e-14	-0.42	-0.37	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
KIRC	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	8.78	2.59e-17	2.35e-14	0.47	0.37	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
KIRC	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-8.78	2.59e-17	2.35e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
KIRC	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	8.78	2.59e-17	2.35e-14	0.48	0.37	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
KIRC	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-8.78	2.6e-17	2.36e-14	-0.41	-0.37	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
KIRC	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	8.78	2.6e-17	2.36e-14	0.48	0.37	Height;	chr6:109589051	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	8.78	2.6e-17	2.36e-14	0.48	0.37	Height;	chr6:109592105	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	8.78	2.6e-17	2.36e-14	0.48	0.37	Height;	chr6:109608105	chr6:109382795~109383666:+
KIRC	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	8.78	2.6e-17	2.36e-14	0.43	0.37	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
KIRC	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-8.78	2.61e-17	2.37e-14	-0.42	-0.37	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
KIRC	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-8.78	2.63e-17	2.38e-14	-0.46	-0.37	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
KIRC	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-8.78	2.64e-17	2.39e-14	-0.47	-0.37	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
KIRC	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	8.78	2.65e-17	2.4e-14	0.33	0.37	Height;	chr4:55459921	chr4:55363971~55395847:-
KIRC	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	8.78	2.65e-17	2.4e-14	0.48	0.37	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
KIRC	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-8.78	2.66e-17	2.41e-14	-0.49	-0.37	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
KIRC	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	8.78	2.66e-17	2.41e-14	0.33	0.37	Height;	chr4:55476736	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	8.78	2.66e-17	2.41e-14	0.33	0.37	Height;	chr4:55477426	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	8.78	2.66e-17	2.41e-14	0.33	0.37	Height;	chr4:55477545	chr4:55363971~55395847:-
KIRC	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	8.78	2.67e-17	2.42e-14	0.43	0.37	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
KIRC	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	8.78	2.67e-17	2.42e-14	0.37	0.37	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
KIRC	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-8.78	2.67e-17	2.42e-14	-0.43	-0.37	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
KIRC	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-8.78	2.68e-17	2.42e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
KIRC	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-8.78	2.68e-17	2.43e-14	-0.56	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
KIRC	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	8.78	2.68e-17	2.43e-14	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	8.78	2.69e-17	2.44e-14	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
KIRC	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	8.78	2.7e-17	2.45e-14	0.35	0.37	Height;	chr4:55611014	chr4:55363971~55395847:-
KIRC	cis	rs4356975	0.83	rs7438033	ENSG00000248763.2	RP13-644M16.5	8.78	2.71e-17	2.46e-14	0.45	0.37	Obesity-related traits;	chr4:69059343	chr4:69066395~69069888:+
KIRC	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-8.78	2.72e-17	2.47e-14	-0.41	-0.37	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-8.78	2.72e-17	2.47e-14	-0.41	-0.37	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
KIRC	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-8.78	2.73e-17	2.47e-14	-0.45	-0.37	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
KIRC	cis	rs10129255	0.912	rs61996059	ENSG00000211970.3	IGHV4-61	-8.78	2.73e-17	2.47e-14	-0.32	-0.37	Kawasaki disease;	chr14:106716897	chr14:106639119~106639657:-
KIRC	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-8.78	2.73e-17	2.47e-14	-0.58	-0.37	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
KIRC	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	8.78	2.73e-17	2.47e-14	0.46	0.37	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
KIRC	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-8.78	2.73e-17	2.47e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
KIRC	cis	rs919433	0.963	rs4850786	ENSG00000231621.1	AC013264.2	-8.78	2.74e-17	2.48e-14	-0.4	-0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313884	chr2:197197991~197199273:+
KIRC	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-8.78	2.76e-17	2.5e-14	-0.49	-0.37	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
KIRC	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	8.78	2.77e-17	2.51e-14	0.47	0.37	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	8.77	2.78e-17	2.52e-14	0.35	0.37	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
KIRC	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	8.77	2.79e-17	2.53e-14	0.48	0.37	Height;	chr6:109634150	chr6:109382795~109383666:+
KIRC	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	8.77	2.8e-17	2.53e-14	0.46	0.37	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
KIRC	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-8.77	2.81e-17	2.54e-14	-0.39	-0.37	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
KIRC	cis	rs11671005	0.568	rs55987239	ENSG00000269600.1	AC016629.3	-8.77	2.81e-17	2.55e-14	-0.59	-0.37	Mean platelet volume;	chr19:58573678	chr19:58593896~58599355:-
KIRC	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.77	2.82e-17	2.55e-14	-0.42	-0.37	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
KIRC	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.77	2.82e-17	2.55e-14	0.41	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
KIRC	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-8.77	2.82e-17	2.55e-14	-0.53	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
KIRC	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	8.77	2.82e-17	2.55e-14	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
KIRC	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-8.77	2.83e-17	2.56e-14	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
KIRC	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	8.77	2.84e-17	2.56e-14	0.39	0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
KIRC	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-8.77	2.84e-17	2.57e-14	-0.46	-0.37	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
KIRC	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	8.77	2.85e-17	2.57e-14	0.48	0.37	Height;	chr6:109618620	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	8.77	2.85e-17	2.57e-14	0.48	0.37	Height;	chr6:109620772	chr6:109382795~109383666:+
KIRC	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	8.77	2.85e-17	2.58e-14	0.47	0.37	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	8.77	2.86e-17	2.59e-14	0.48	0.37	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
KIRC	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-8.77	2.86e-17	2.59e-14	-0.41	-0.37	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
KIRC	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	8.77	2.87e-17	2.59e-14	0.47	0.37	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	8.77	2.87e-17	2.59e-14	0.47	0.37	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
KIRC	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.77	2.87e-17	2.6e-14	-0.42	-0.37	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
KIRC	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	8.77	2.87e-17	2.6e-14	0.52	0.37	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
KIRC	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-8.77	2.9e-17	2.62e-14	-0.88	-0.37	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
KIRC	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	8.77	2.9e-17	2.62e-14	0.22	0.37	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
KIRC	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	8.77	2.9e-17	2.62e-14	0.47	0.37	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
KIRC	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-8.77	2.9e-17	2.62e-14	-0.42	-0.37	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
KIRC	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	8.77	2.91e-17	2.62e-14	0.43	0.37	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
KIRC	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-8.77	2.92e-17	2.63e-14	-0.41	-0.37	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
KIRC	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-8.77	2.92e-17	2.63e-14	-0.4	-0.37	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
KIRC	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55435912	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55436576	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55436985	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55439472	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55439652	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55440643	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55441110	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55441567	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55441907	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55450812	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55452853	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55454154	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55455650	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55456620	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55457027	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55457086	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55461320	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55462689	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55463606	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55466010	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55467308	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55470266	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55470874	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55474259	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	8.77	2.92e-17	2.63e-14	0.33	0.37	Height;	chr4:55475130	chr4:55363971~55395847:-
KIRC	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-8.77	2.93e-17	2.64e-14	-0.46	-0.37	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
KIRC	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	8.77	2.93e-17	2.64e-14	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
KIRC	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	8.77	2.94e-17	2.65e-14	0.43	0.37	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	8.77	2.94e-17	2.65e-14	0.43	0.37	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
KIRC	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-8.77	2.94e-17	2.65e-14	-0.45	-0.37	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
KIRC	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-8.77	2.94e-17	2.65e-14	-0.38	-0.37	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
KIRC	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55429416	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55430596	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55430730	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55430740	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55431595	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	8.77	2.96e-17	2.67e-14	0.33	0.37	Height;	chr4:55434518	chr4:55363971~55395847:-
KIRC	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-8.77	2.97e-17	2.67e-14	-0.59	-0.37	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
KIRC	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	8.77	2.97e-17	2.67e-14	0.5	0.37	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
KIRC	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	8.77	2.98e-17	2.68e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
KIRC	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-8.77	2.98e-17	2.68e-14	-0.48	-0.37	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
KIRC	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-8.77	2.98e-17	2.68e-14	-0.26	-0.37	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
KIRC	cis	rs1476679	1	rs34919929	ENSG00000078319.8	PMS2P1	8.77	2.98e-17	2.69e-14	0.46	0.37	Alzheimer's disease (late onset);	chr7:100414711	chr7:100320992~100341908:-
KIRC	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	8.76	3.01e-17	2.71e-14	0.39	0.37	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
KIRC	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	8.76	3.02e-17	2.72e-14	0.49	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
KIRC	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	8.76	3.04e-17	2.74e-14	0.34	0.37	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
KIRC	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-8.76	3.04e-17	2.74e-14	-0.47	-0.37	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
KIRC	cis	rs6600671	1	rs2185281	ENSG00000227082.1	CH17-437K3.1	-8.76	3.04e-17	2.74e-14	-0.41	-0.37	Hip geometry;	chr1:121438132	chr1:121396754~121463129:+
KIRC	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-8.76	3.04e-17	2.74e-14	-0.37	-0.37	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
KIRC	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-8.76	3.05e-17	2.74e-14	-0.39	-0.37	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
KIRC	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	8.76	3.05e-17	2.75e-14	0.26	0.37	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
KIRC	cis	rs919433	1	rs919433	ENSG00000231621.1	AC013264.2	8.76	3.06e-17	2.75e-14	0.39	0.37	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197197991~197199273:+
KIRC	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	8.76	3.07e-17	2.76e-14	0.44	0.37	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
KIRC	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-8.76	3.07e-17	2.76e-14	-0.37	-0.37	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	8.76	3.08e-17	2.78e-14	0.45	0.37	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
KIRC	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	8.76	3.09e-17	2.78e-14	0.4	0.37	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
KIRC	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	8.76	3.09e-17	2.78e-14	0.4	0.37	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
KIRC	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	8.76	3.09e-17	2.78e-14	0.61	0.37	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
KIRC	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-8.76	3.1e-17	2.79e-14	-0.61	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
KIRC	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-8.76	3.12e-17	2.81e-14	-0.31	-0.37	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	8.76	3.13e-17	2.81e-14	0.47	0.37	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	8.76	3.14e-17	2.83e-14	0.47	0.37	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	8.76	3.14e-17	2.83e-14	0.49	0.37	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
KIRC	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-8.76	3.16e-17	2.84e-14	-0.4	-0.37	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
KIRC	cis	rs1200821	0.535	rs1208784	ENSG00000151963.4	RP11-775A3.1	-8.76	3.17e-17	2.85e-14	-0.42	-0.37	Hemostatic factors and hematological phenotypes;	chr10:37479505	chr10:37883594~37884109:+
KIRC	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	8.76	3.18e-17	2.85e-14	0.33	0.37	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
KIRC	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	8.76	3.19e-17	2.87e-14	0.47	0.37	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	8.76	3.19e-17	2.87e-14	0.47	0.37	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
KIRC	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-8.76	3.2e-17	2.87e-14	-0.42	-0.37	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
KIRC	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-8.76	3.21e-17	2.88e-14	-0.34	-0.37	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
KIRC	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	8.76	3.22e-17	2.89e-14	0.55	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
KIRC	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	8.75	3.24e-17	2.91e-14	0.47	0.37	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	8.75	3.24e-17	2.91e-14	0.47	0.37	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
KIRC	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-8.75	3.25e-17	2.92e-14	-0.57	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
KIRC	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	8.75	3.26e-17	2.93e-14	0.46	0.37	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
KIRC	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	8.75	3.26e-17	2.93e-14	0.73	0.37	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
KIRC	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	8.75	3.27e-17	2.94e-14	0.41	0.37	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
KIRC	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.75	3.28e-17	2.94e-14	0.36	0.37	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
KIRC	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-8.75	3.28e-17	2.94e-14	-0.53	-0.37	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
KIRC	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-8.75	3.29e-17	2.96e-14	-0.59	-0.37	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
KIRC	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	8.75	3.31e-17	2.97e-14	0.47	0.37	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
KIRC	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	8.75	3.32e-17	2.98e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
KIRC	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	8.75	3.32e-17	2.98e-14	0.47	0.37	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
KIRC	cis	rs9355610	0.609	rs62436424	ENSG00000265828.1	MIR3939	8.75	3.33e-17	2.98e-14	0.52	0.37	Graves' disease;	chr6:166960770	chr6:166997807~166997912:-
KIRC	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-8.75	3.34e-17	2.99e-14	-0.36	-0.37	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
KIRC	cis	rs5769707	0.521	rs74351010	ENSG00000235111.1	RP1-29C18.8	8.75	3.37e-17	3.02e-14	0.46	0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49612657~49615716:-
KIRC	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-8.75	3.38e-17	3.03e-14	-0.4	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
KIRC	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-8.75	3.38e-17	3.03e-14	-0.4	-0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
KIRC	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-8.75	3.38e-17	3.03e-14	-0.38	-0.37	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
KIRC	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	8.75	3.39e-17	3.03e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
KIRC	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-8.75	3.39e-17	3.04e-14	-0.43	-0.37	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
KIRC	cis	rs9388451	0.626	rs1268074	ENSG00000237742.5	RP11-624M8.1	-8.75	3.41e-17	3.06e-14	-0.42	-0.37	Brugada syndrome;	chr6:125786645	chr6:125578558~125749190:-
KIRC	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	8.75	3.42e-17	3.06e-14	0.46	0.37	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
KIRC	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	8.75	3.42e-17	3.07e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
KIRC	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	8.75	3.42e-17	3.07e-14	0.46	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
KIRC	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.75	3.43e-17	3.07e-14	-0.47	-0.37	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
KIRC	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	8.75	3.43e-17	3.07e-14	0.46	0.37	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
KIRC	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	8.75	3.43e-17	3.08e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	8.75	3.43e-17	3.08e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
KIRC	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	8.75	3.45e-17	3.09e-14	0.26	0.37	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
KIRC	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.75	3.46e-17	3.1e-14	-0.41	-0.37	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.75	3.46e-17	3.1e-14	-0.41	-0.37	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
KIRC	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	8.75	3.47e-17	3.11e-14	0.47	0.37	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
KIRC	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	8.75	3.49e-17	3.12e-14	0.69	0.37	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
KIRC	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	8.75	3.49e-17	3.12e-14	0.69	0.37	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
KIRC	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-8.74	3.51e-17	3.14e-14	-0.41	-0.37	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
KIRC	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	8.74	3.51e-17	3.14e-14	0.43	0.37	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
KIRC	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-8.74	3.52e-17	3.15e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
KIRC	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-8.74	3.52e-17	3.15e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
KIRC	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-8.74	3.52e-17	3.15e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
KIRC	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	8.74	3.53e-17	3.16e-14	0.46	0.37	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
KIRC	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	8.74	3.55e-17	3.17e-14	0.33	0.37	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
KIRC	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-8.74	3.55e-17	3.17e-14	-0.33	-0.37	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
KIRC	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-8.74	3.55e-17	3.18e-14	-0.6	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
KIRC	cis	rs8396	0.96	rs17843919	ENSG00000271817.2	U3	8.74	3.57e-17	3.19e-14	0.35	0.37	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158717814	chr4:158700691~158700909:+
KIRC	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	8.74	3.57e-17	3.19e-14	0.34	0.37	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
KIRC	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	8.74	3.58e-17	3.2e-14	0.33	0.37	Height;	chr4:55442184	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	8.74	3.58e-17	3.2e-14	0.33	0.37	Height;	chr4:55442875	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	8.74	3.58e-17	3.2e-14	0.33	0.37	Height;	chr4:55444253	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	8.74	3.58e-17	3.2e-14	0.33	0.37	Height;	chr4:55446869	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	8.74	3.58e-17	3.2e-14	0.33	0.37	Height;	chr4:55447523	chr4:55363971~55395847:-
KIRC	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	8.74	3.6e-17	3.22e-14	0.64	0.37	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	8.74	3.6e-17	3.22e-14	0.64	0.37	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	8.74	3.61e-17	3.22e-14	0.45	0.37	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	8.74	3.61e-17	3.22e-14	0.45	0.37	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	8.74	3.61e-17	3.22e-14	0.45	0.37	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	8.74	3.61e-17	3.22e-14	0.45	0.37	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
KIRC	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	8.74	3.63e-17	3.24e-14	0.49	0.37	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
KIRC	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	8.74	3.63e-17	3.24e-14	0.33	0.37	Height;	chr4:55538228	chr4:55363971~55395847:-
KIRC	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	8.74	3.63e-17	3.24e-14	0.65	0.37	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.83	rs3922514	ENSG00000250919.1	RP11-813N20.3	-8.74	3.63e-17	3.25e-14	-0.38	-0.37	Obesity-related traits;	chr4:69060905	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs28775401	ENSG00000250919.1	RP11-813N20.3	-8.74	3.63e-17	3.25e-14	-0.38	-0.37	Obesity-related traits;	chr4:69060999	chr4:69027831~69044578:+
KIRC	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-8.74	3.64e-17	3.25e-14	-0.34	-0.37	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
KIRC	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-8.74	3.64e-17	3.25e-14	-0.48	-0.37	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
KIRC	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-8.74	3.65e-17	3.26e-14	-0.47	-0.37	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
KIRC	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-8.74	3.65e-17	3.26e-14	-0.38	-0.37	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-8.74	3.65e-17	3.26e-14	-0.38	-0.37	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-8.74	3.65e-17	3.26e-14	-0.38	-0.37	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
KIRC	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	8.74	3.65e-17	3.26e-14	0.56	0.37	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
KIRC	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	8.74	3.65e-17	3.26e-14	0.33	0.37	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
KIRC	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	8.74	3.66e-17	3.27e-14	0.38	0.37	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
KIRC	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	8.74	3.66e-17	3.27e-14	0.33	0.37	Height;	chr4:55451955	chr4:55363971~55395847:-
KIRC	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-8.74	3.66e-17	3.27e-14	-0.33	-0.37	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
KIRC	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	8.74	3.67e-17	3.27e-14	0.52	0.37	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
KIRC	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-8.74	3.67e-17	3.28e-14	-0.34	-0.37	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-8.74	3.67e-17	3.28e-14	-0.34	-0.37	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
KIRC	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	8.74	3.69e-17	3.29e-14	0.48	0.37	Height;	chr6:109693890	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	8.74	3.69e-17	3.29e-14	0.48	0.37	Height;	chr6:109694672	chr6:109382795~109383666:+
KIRC	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.74	3.7e-17	3.3e-14	0.36	0.37	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
KIRC	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-8.74	3.7e-17	3.3e-14	-0.41	-0.37	Height;	chr11:118791319	chr11:118704607~118750263:+
KIRC	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-8.74	3.71e-17	3.31e-14	-0.41	-0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
KIRC	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	8.74	3.72e-17	3.32e-14	0.45	0.37	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
KIRC	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	8.74	3.72e-17	3.32e-14	0.48	0.37	Height;	chr6:109558247	chr6:109382795~109383666:+
KIRC	cis	rs11671005	0.568	rs73068329	ENSG00000269600.1	AC016629.3	-8.74	3.73e-17	3.32e-14	-0.59	-0.37	Mean platelet volume;	chr19:58568958	chr19:58593896~58599355:-
KIRC	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	8.74	3.74e-17	3.33e-14	0.64	0.37	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	8.74	3.74e-17	3.33e-14	0.64	0.37	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	8.74	3.74e-17	3.33e-14	0.64	0.37	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
KIRC	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	8.74	3.76e-17	3.35e-14	0.34	0.37	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
KIRC	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.73	3.78e-17	3.37e-14	-0.43	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
KIRC	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-8.73	3.79e-17	3.37e-14	-0.28	-0.37	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	8.73	3.82e-17	3.4e-14	0.46	0.37	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
KIRC	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-8.73	3.82e-17	3.4e-14	-0.45	-0.37	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
KIRC	cis	rs1005277	0.522	rs9418276	ENSG00000151963.4	RP11-775A3.1	-8.73	3.83e-17	3.41e-14	-0.4	-0.37	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:37883594~37884109:+
KIRC	cis	rs1005277	0.522	rs7072977	ENSG00000151963.4	RP11-775A3.1	-8.73	3.83e-17	3.41e-14	-0.4	-0.37	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:37883594~37884109:+
KIRC	cis	rs748404	0.578	rs2244746	ENSG00000249839.1	AC011330.5	-8.73	3.83e-17	3.41e-14	-0.46	-0.37	Lung cancer;	chr15:43402885	chr15:43663654~43684339:-
KIRC	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	8.73	3.84e-17	3.42e-14	0.44	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
KIRC	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-8.73	3.84e-17	3.42e-14	-0.35	-0.37	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
KIRC	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	8.73	3.85e-17	3.42e-14	0.48	0.37	Height;	chr6:109690255	chr6:109382795~109383666:+
KIRC	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	8.73	3.85e-17	3.42e-14	0.39	0.37	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
KIRC	cis	rs79040073	0.637	rs11635354	ENSG00000259531.2	RP11-295H24.3	8.73	3.85e-17	3.43e-14	0.48	0.37	Lung cancer in ever smokers;	chr15:49419413	chr15:49365124~49366685:-
KIRC	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-8.73	3.85e-17	3.43e-14	-0.48	-0.37	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
KIRC	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-8.73	3.85e-17	3.43e-14	-0.42	-0.37	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
KIRC	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	8.73	3.86e-17	3.43e-14	0.66	0.37	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
KIRC	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	8.73	3.86e-17	3.43e-14	0.47	0.37	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
KIRC	cis	rs9388451	0.537	rs1739383	ENSG00000237742.5	RP11-624M8.1	-8.73	3.86e-17	3.43e-14	-0.42	-0.37	Brugada syndrome;	chr6:125777769	chr6:125578558~125749190:-
KIRC	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-8.73	3.86e-17	3.44e-14	-0.45	-0.37	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
KIRC	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	8.73	3.86e-17	3.44e-14	0.33	0.37	Height;	chr4:55562653	chr4:55363971~55395847:-
KIRC	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-8.73	3.87e-17	3.44e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-8.73	3.87e-17	3.44e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
KIRC	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	8.73	3.88e-17	3.45e-14	0.47	0.37	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
KIRC	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.73	3.88e-17	3.45e-14	0.36	0.37	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
KIRC	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	8.73	3.89e-17	3.46e-14	0.54	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
KIRC	cis	rs9388451	0.559	rs1777210	ENSG00000237742.5	RP11-624M8.1	-8.73	3.9e-17	3.47e-14	-0.42	-0.37	Brugada syndrome;	chr6:125777770	chr6:125578558~125749190:-
KIRC	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	8.73	3.91e-17	3.48e-14	0.36	0.37	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
KIRC	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-8.73	3.92e-17	3.48e-14	-0.36	-0.37	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
KIRC	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	8.73	3.92e-17	3.48e-14	0.36	0.37	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
KIRC	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-8.73	3.92e-17	3.48e-14	-0.6	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
KIRC	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-8.73	3.93e-17	3.49e-14	-0.34	-0.37	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
KIRC	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	8.73	3.93e-17	3.49e-14	0.53	0.37	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
KIRC	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-8.73	3.95e-17	3.51e-14	-0.5	-0.37	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
KIRC	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	8.73	3.95e-17	3.51e-14	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	8.73	3.95e-17	3.51e-14	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	8.73	3.95e-17	3.51e-14	0.33	0.37	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
KIRC	cis	rs4356975	0.83	rs4413468	ENSG00000250919.1	RP11-813N20.3	-8.73	3.97e-17	3.53e-14	-0.38	-0.37	Obesity-related traits;	chr4:69061845	chr4:69027831~69044578:+
KIRC	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	8.73	3.97e-17	3.53e-14	0.35	0.37	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
KIRC	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	8.73	3.99e-17	3.54e-14	0.37	0.37	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
KIRC	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	8.73	4e-17	3.55e-14	0.4	0.37	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
KIRC	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-8.73	4.01e-17	3.56e-14	-0.34	-0.37	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
KIRC	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	8.73	4.02e-17	3.57e-14	0.36	0.37	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
KIRC	cis	rs10612751	1	rs10612751	ENSG00000277863.1	RP11-282A11.4	8.73	4.02e-17	3.57e-14	0.42	0.37	Lobe attachment (rater-scored or self-reported);	chr13:106993686	chr13:106903150~106904099:-
KIRC	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	8.73	4.03e-17	3.58e-14	0.34	0.37	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
KIRC	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-8.73	4.03e-17	3.58e-14	-0.48	-0.37	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
KIRC	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	8.73	4.04e-17	3.59e-14	0.47	0.37	Height;	chr6:109391084	chr6:109382795~109383666:+
KIRC	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	8.73	4.05e-17	3.6e-14	0.64	0.37	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
KIRC	cis	rs1823913	1	rs4853559	ENSG00000227542.1	AC092614.2	-8.73	4.06e-17	3.6e-14	-0.34	-0.37	Obesity-related traits;	chr2:191235965	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-8.73	4.07e-17	3.61e-14	-0.34	-0.37	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-8.73	4.07e-17	3.61e-14	-0.34	-0.37	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
KIRC	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	8.73	4.07e-17	3.61e-14	0.4	0.37	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
KIRC	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-8.73	4.08e-17	3.62e-14	-0.49	-0.37	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
KIRC	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-8.72	4.08e-17	3.62e-14	-0.4	-0.37	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
KIRC	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-8.72	4.1e-17	3.64e-14	-0.51	-0.37	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
KIRC	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-8.72	4.12e-17	3.65e-14	-0.41	-0.37	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-8.72	4.12e-17	3.65e-14	-0.41	-0.37	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-8.72	4.12e-17	3.65e-14	-0.41	-0.37	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-8.72	4.12e-17	3.65e-14	-0.41	-0.37	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
KIRC	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	8.72	4.13e-17	3.66e-14	0.48	0.37	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
KIRC	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-8.72	4.13e-17	3.66e-14	-0.59	-0.37	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
KIRC	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-8.72	4.13e-17	3.66e-14	-0.48	-0.37	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
KIRC	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	8.72	4.13e-17	3.66e-14	0.47	0.37	Height;	chr6:109646187	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	8.72	4.13e-17	3.66e-14	0.47	0.37	Height;	chr6:109652694	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	8.72	4.13e-17	3.66e-14	0.47	0.37	Height;	chr6:109655791	chr6:109382795~109383666:+
KIRC	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	8.72	4.13e-17	3.66e-14	0.54	0.37	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
KIRC	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	8.72	4.15e-17	3.68e-14	0.4	0.37	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
KIRC	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-8.72	4.16e-17	3.69e-14	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
KIRC	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	8.72	4.17e-17	3.69e-14	0.32	0.36	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
KIRC	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	8.72	4.18e-17	3.7e-14	0.47	0.36	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
KIRC	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	8.72	4.19e-17	3.71e-14	0.4	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
KIRC	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	8.72	4.19e-17	3.71e-14	0.41	0.36	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	8.72	4.19e-17	3.71e-14	0.41	0.36	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	8.72	4.19e-17	3.71e-14	0.41	0.36	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
KIRC	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-8.72	4.22e-17	3.73e-14	-0.46	-0.36	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
KIRC	cis	rs2749592	0.531	rs1208559	ENSG00000151963.4	RP11-775A3.1	8.72	4.22e-17	3.73e-14	0.42	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:37883594~37884109:+
KIRC	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-8.72	4.22e-17	3.74e-14	-0.41	-0.36	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
KIRC	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	8.72	4.23e-17	3.75e-14	0.48	0.36	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
KIRC	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	8.72	4.26e-17	3.77e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
KIRC	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-8.72	4.27e-17	3.78e-14	-0.36	-0.36	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000250919.1	RP11-813N20.3	-8.72	4.28e-17	3.79e-14	-0.38	-0.36	Obesity-related traits;	chr4:69079291	chr4:69027831~69044578:+
KIRC	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	8.72	4.36e-17	3.85e-14	0.54	0.36	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
KIRC	cis	rs6061231	0.556	rs6121571	ENSG00000273619.1	RP5-908M14.9	-8.72	4.36e-17	3.86e-14	-0.29	-0.36	Colorectal cancer;	chr20:62402267	chr20:62386303~62386970:-
KIRC	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	8.72	4.37e-17	3.86e-14	0.46	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
KIRC	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	8.72	4.37e-17	3.86e-14	0.46	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
KIRC	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	8.72	4.37e-17	3.87e-14	0.46	0.36	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
KIRC	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-8.72	4.39e-17	3.89e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
KIRC	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-8.72	4.4e-17	3.89e-14	-0.47	-0.36	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
KIRC	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	8.72	4.4e-17	3.89e-14	0.48	0.36	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
KIRC	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-8.71	4.42e-17	3.91e-14	-0.41	-0.36	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
KIRC	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	8.71	4.43e-17	3.92e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
KIRC	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	8.71	4.44e-17	3.92e-14	0.29	0.36	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
KIRC	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	8.71	4.44e-17	3.92e-14	0.45	0.36	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
KIRC	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	8.71	4.45e-17	3.93e-14	0.32	0.36	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
KIRC	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	8.71	4.47e-17	3.95e-14	0.61	0.36	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
KIRC	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-8.71	4.49e-17	3.97e-14	-0.41	-0.36	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-8.71	4.49e-17	3.97e-14	-0.41	-0.36	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
KIRC	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	8.71	4.51e-17	3.98e-14	0.33	0.36	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
KIRC	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	8.71	4.51e-17	3.98e-14	0.46	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
KIRC	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	8.71	4.51e-17	3.98e-14	0.46	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
KIRC	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-8.71	4.51e-17	3.98e-14	-0.34	-0.36	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
KIRC	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-8.71	4.51e-17	3.98e-14	-0.34	-0.36	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
KIRC	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-8.71	4.52e-17	3.99e-14	-0.51	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
KIRC	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	8.71	4.52e-17	3.99e-14	0.48	0.36	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
KIRC	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-8.71	4.52e-17	3.99e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
KIRC	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-8.71	4.53e-17	4e-14	-0.41	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
KIRC	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-8.71	4.54e-17	4.01e-14	-0.51	-0.36	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
KIRC	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-8.71	4.58e-17	4.04e-14	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
KIRC	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	8.71	4.58e-17	4.04e-14	0.38	0.36	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
KIRC	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	8.71	4.59e-17	4.05e-14	0.36	0.36	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
KIRC	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-8.71	4.6e-17	4.06e-14	-0.43	-0.36	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
KIRC	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-8.71	4.61e-17	4.07e-14	-0.41	-0.36	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
KIRC	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	8.71	4.61e-17	4.07e-14	0.38	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
KIRC	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	8.71	4.62e-17	4.08e-14	0.45	0.36	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	8.71	4.62e-17	4.08e-14	0.45	0.36	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
KIRC	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-8.71	4.64e-17	4.09e-14	-0.41	-0.36	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-8.71	4.64e-17	4.09e-14	-0.41	-0.36	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
KIRC	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	8.71	4.65e-17	4.1e-14	0.6	0.36	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
KIRC	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	8.71	4.66e-17	4.11e-14	0.55	0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
KIRC	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	8.71	4.67e-17	4.12e-14	0.48	0.36	Height;	chr6:109357369	chr6:109382795~109383666:+
KIRC	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	8.71	4.68e-17	4.12e-14	0.46	0.36	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
KIRC	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	8.71	4.68e-17	4.12e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
KIRC	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-8.71	4.69e-17	4.13e-14	-0.71	-0.36	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
KIRC	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-8.71	4.72e-17	4.16e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
KIRC	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	8.71	4.72e-17	4.16e-14	0.45	0.36	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	8.71	4.72e-17	4.16e-14	0.45	0.36	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
KIRC	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-8.71	4.73e-17	4.17e-14	-0.38	-0.36	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
KIRC	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	8.71	4.74e-17	4.17e-14	0.45	0.36	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
KIRC	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	8.71	4.74e-17	4.18e-14	0.41	0.36	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
KIRC	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-8.71	4.74e-17	4.18e-14	-0.32	-0.36	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
KIRC	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-8.7	4.76e-17	4.2e-14	-0.48	-0.36	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
KIRC	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-8.7	4.76e-17	4.2e-14	-0.48	-0.36	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
KIRC	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-8.7	4.76e-17	4.2e-14	-0.44	-0.36	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
KIRC	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	8.7	4.77e-17	4.2e-14	0.47	0.36	Height;	chr6:109642186	chr6:109382795~109383666:+
KIRC	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	8.7	4.78e-17	4.21e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
KIRC	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-8.7	4.78e-17	4.21e-14	-0.38	-0.36	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
KIRC	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	8.7	4.82e-17	4.25e-14	0.36	0.36	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
KIRC	cis	rs4273100	0.85	rs11204306	ENSG00000262319.1	CTC-457L16.2	-8.7	4.83e-17	4.25e-14	-0.5	-0.36	Schizophrenia;	chr17:19364058	chr17:19141017~19143689:-
KIRC	cis	rs2302464	1	rs6828144	ENSG00000214846.4	RP11-115L11.1	8.7	4.83e-17	4.25e-14	0.97	0.36	Cerebrospinal fluid biomarker levels;	chr4:15725766	chr4:15730962~15731627:-
KIRC	cis	rs79040073	0.637	rs61259878	ENSG00000259531.2	RP11-295H24.3	8.7	4.85e-17	4.27e-14	0.48	0.36	Lung cancer in ever smokers;	chr15:49432564	chr15:49365124~49366685:-
KIRC	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	8.7	4.86e-17	4.28e-14	0.67	0.36	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
KIRC	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	8.7	4.87e-17	4.28e-14	0.34	0.36	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
KIRC	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-8.7	4.87e-17	4.29e-14	-0.51	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
KIRC	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	8.7	4.88e-17	4.29e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
KIRC	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	8.7	4.88e-17	4.29e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
KIRC	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-8.7	4.89e-17	4.3e-14	-0.45	-0.36	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
KIRC	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	8.7	4.9e-17	4.31e-14	0.29	0.36	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
KIRC	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	8.7	4.92e-17	4.33e-14	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	8.7	4.92e-17	4.33e-14	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
KIRC	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	8.7	4.94e-17	4.34e-14	0.47	0.36	Height;	chr6:109640141	chr6:109382795~109383666:+
KIRC	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	8.7	5.01e-17	4.41e-14	0.45	0.36	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
KIRC	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	8.7	5.03e-17	4.42e-14	0.33	0.36	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
KIRC	cis	rs1823913	0.926	rs12615901	ENSG00000227542.1	AC092614.2	-8.7	5.05e-17	4.44e-14	-0.34	-0.36	Obesity-related traits;	chr2:191233381	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs7574570	ENSG00000227542.1	AC092614.2	-8.7	5.05e-17	4.44e-14	-0.34	-0.36	Obesity-related traits;	chr2:191233790	chr2:191229165~191246172:-
KIRC	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	8.7	5.05e-17	4.44e-14	0.45	0.36	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	8.7	5.05e-17	4.44e-14	0.45	0.36	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
KIRC	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	8.7	5.07e-17	4.45e-14	0.33	0.36	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
KIRC	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-8.7	5.07e-17	4.46e-14	-0.4	-0.36	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
KIRC	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	8.7	5.1e-17	4.48e-14	0.42	0.36	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
KIRC	cis	rs11079159	0.565	rs4794563	ENSG00000263096.1	RP11-515O17.2	8.69	5.13e-17	4.51e-14	0.45	0.36	QRS duration;	chr17:55304524	chr17:55271504~55273653:-
KIRC	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	8.69	5.14e-17	4.52e-14	0.35	0.36	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
KIRC	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	8.69	5.14e-17	4.52e-14	0.37	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
KIRC	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	8.69	5.15e-17	4.53e-14	0.44	0.36	Height;	chr4:55387515	chr4:55387949~55388271:+
KIRC	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	8.69	5.16e-17	4.53e-14	0.35	0.36	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
KIRC	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-8.69	5.17e-17	4.54e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
KIRC	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-8.69	5.19e-17	4.56e-14	-0.4	-0.36	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	8.69	5.2e-17	4.56e-14	0.46	0.36	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
KIRC	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	8.69	5.21e-17	4.58e-14	0.35	0.36	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
KIRC	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	8.69	5.23e-17	4.59e-14	0.45	0.36	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
KIRC	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	8.69	5.25e-17	4.61e-14	0.42	0.36	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	8.69	5.25e-17	4.61e-14	0.42	0.36	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	8.69	5.26e-17	4.61e-14	0.42	0.36	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
KIRC	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	8.69	5.26e-17	4.61e-14	0.42	0.36	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
KIRC	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	8.69	5.27e-17	4.62e-14	0.56	0.36	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	8.69	5.27e-17	4.62e-14	0.56	0.36	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
KIRC	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-8.69	5.27e-17	4.63e-14	-0.31	-0.36	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-8.69	5.27e-17	4.63e-14	-0.31	-0.36	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
KIRC	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	8.69	5.3e-17	4.65e-14	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
KIRC	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-8.69	5.3e-17	4.65e-14	-0.38	-0.36	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
KIRC	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	8.69	5.3e-17	4.65e-14	0.47	0.36	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
KIRC	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-8.69	5.3e-17	4.65e-14	-0.47	-0.36	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	8.69	5.31e-17	4.66e-14	0.45	0.36	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
KIRC	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-8.69	5.33e-17	4.68e-14	-0.47	-0.36	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
KIRC	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	8.69	5.34e-17	4.69e-14	0.34	0.36	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
KIRC	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	8.69	5.35e-17	4.69e-14	0.35	0.36	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
KIRC	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	8.69	5.36e-17	4.7e-14	0.45	0.36	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
KIRC	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	8.69	5.36e-17	4.7e-14	0.55	0.36	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
KIRC	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	8.69	5.37e-17	4.71e-14	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
KIRC	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	8.69	5.37e-17	4.71e-14	0.45	0.36	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	8.69	5.37e-17	4.71e-14	0.45	0.36	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	8.69	5.37e-17	4.71e-14	0.45	0.36	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
KIRC	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.69	5.4e-17	4.73e-14	-0.47	-0.36	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
KIRC	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	8.69	5.4e-17	4.73e-14	0.47	0.36	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
KIRC	cis	rs58873874	0.737	rs10515750	ENSG00000251405.2	CTB-109A12.1	8.69	5.4e-17	4.73e-14	0.68	0.36	Bipolar disorder (body mass index interaction);	chr5:157383064	chr5:157362615~157460078:-
KIRC	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	8.69	5.41e-17	4.74e-14	0.48	0.36	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
KIRC	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	8.69	5.49e-17	4.81e-14	0.33	0.36	Height;	chr4:55578787	chr4:55363971~55395847:-
KIRC	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	8.69	5.5e-17	4.81e-14	0.48	0.36	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
KIRC	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-8.69	5.52e-17	4.83e-14	-0.39	-0.36	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
KIRC	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-8.69	5.53e-17	4.84e-14	-0.41	-0.36	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	8.69	5.53e-17	4.84e-14	0.48	0.36	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
KIRC	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	8.69	5.53e-17	4.84e-14	0.33	0.36	Height;	chr4:55574959	chr4:55363971~55395847:-
KIRC	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	8.68	5.54e-17	4.85e-14	0.32	0.36	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
KIRC	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	8.68	5.58e-17	4.88e-14	0.45	0.36	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
KIRC	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-8.68	5.58e-17	4.88e-14	-0.5	-0.36	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
KIRC	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	8.68	5.61e-17	4.91e-14	0.35	0.36	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
KIRC	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	8.68	5.61e-17	4.91e-14	0.35	0.36	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	8.68	5.61e-17	4.91e-14	0.35	0.36	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
KIRC	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-8.68	5.61e-17	4.91e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
KIRC	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	8.68	5.62e-17	4.92e-14	0.48	0.36	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	8.68	5.62e-17	4.92e-14	0.47	0.36	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
KIRC	cis	rs1476679	0.927	rs2405442	ENSG00000078319.8	PMS2P1	8.68	5.62e-17	4.92e-14	0.46	0.36	Alzheimer's disease (late onset);	chr7:100373690	chr7:100320992~100341908:-
KIRC	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	8.68	5.63e-17	4.92e-14	0.22	0.36	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
KIRC	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	8.68	5.64e-17	4.93e-14	0.39	0.36	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
KIRC	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	8.68	5.64e-17	4.93e-14	0.39	0.36	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
KIRC	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	8.68	5.68e-17	4.96e-14	0.64	0.36	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	8.68	5.68e-17	4.96e-14	0.64	0.36	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	8.68	5.68e-17	4.96e-14	0.64	0.36	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
KIRC	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-8.68	5.7e-17	4.98e-14	-0.46	-0.36	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
KIRC	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-8.68	5.7e-17	4.98e-14	-0.58	-0.36	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
KIRC	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	8.68	5.71e-17	4.99e-14	0.39	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
KIRC	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	8.68	5.72e-17	4.99e-14	0.51	0.36	Height;	chr6:109769861	chr6:109382795~109383666:+
KIRC	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	8.68	5.75e-17	5.03e-14	0.47	0.36	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
KIRC	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	8.68	5.79e-17	5.05e-14	0.39	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
KIRC	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-8.68	5.79e-17	5.06e-14	-0.47	-0.36	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	8.68	5.81e-17	5.07e-14	0.45	0.36	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
KIRC	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-8.68	5.83e-17	5.09e-14	-0.39	-0.36	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
KIRC	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	8.68	5.83e-17	5.09e-14	0.37	0.36	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
KIRC	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-8.68	5.84e-17	5.1e-14	-0.27	-0.36	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
KIRC	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-8.68	5.84e-17	5.1e-14	-0.4	-0.36	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
KIRC	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-8.68	5.84e-17	5.1e-14	-0.4	-0.36	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
KIRC	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-8.68	5.84e-17	5.1e-14	-0.44	-0.36	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
KIRC	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	8.68	5.85e-17	5.1e-14	0.47	0.36	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	8.68	5.86e-17	5.11e-14	0.45	0.36	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	8.68	5.86e-17	5.11e-14	0.45	0.36	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	8.68	5.86e-17	5.11e-14	0.45	0.36	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
KIRC	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	8.68	5.86e-17	5.11e-14	0.34	0.36	Height;	chr4:55558258	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	8.68	5.86e-17	5.11e-14	0.34	0.36	Height;	chr4:55558259	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	8.68	5.86e-17	5.11e-14	0.34	0.36	Height;	chr4:55558261	chr4:55363971~55395847:-
KIRC	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-8.68	5.87e-17	5.12e-14	-0.41	-0.36	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
KIRC	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-8.68	5.87e-17	5.12e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-8.68	5.87e-17	5.12e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
KIRC	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-8.68	5.89e-17	5.14e-14	-0.43	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
KIRC	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	8.68	5.9e-17	5.14e-14	0.46	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
KIRC	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	8.68	5.9e-17	5.14e-14	0.55	0.36	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
KIRC	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-8.68	5.91e-17	5.15e-14	-0.37	-0.36	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
KIRC	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	8.68	5.92e-17	5.16e-14	0.45	0.36	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
KIRC	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	8.68	5.93e-17	5.17e-14	0.33	0.36	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
KIRC	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	8.68	5.94e-17	5.17e-14	0.48	0.36	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
KIRC	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	8.68	5.94e-17	5.18e-14	0.37	0.36	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
KIRC	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-8.68	5.94e-17	5.18e-14	-0.42	-0.36	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
KIRC	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-8.68	5.96e-17	5.19e-14	-0.49	-0.36	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
KIRC	cis	rs9322193	0.887	rs4870139	ENSG00000223701.3	RAET1E-AS1	8.67	6e-17	5.23e-14	0.47	0.36	Lung cancer;	chr6:149575182	chr6:149884431~149919508:+
KIRC	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	8.67	6.01e-17	5.24e-14	0.33	0.36	Height;	chr4:55570311	chr4:55363971~55395847:-
KIRC	cis	rs3096299	0.967	rs3102383	ENSG00000274627.1	RP11-104N10.2	8.67	6.03e-17	5.25e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89344887	chr16:89516797~89522217:+
KIRC	cis	rs79040073	0.637	rs11638314	ENSG00000259531.2	RP11-295H24.3	8.67	6.03e-17	5.25e-14	0.48	0.36	Lung cancer in ever smokers;	chr15:49421747	chr15:49365124~49366685:-
KIRC	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	8.67	6.07e-17	5.28e-14	0.5	0.36	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
KIRC	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-8.67	6.08e-17	5.29e-14	-0.38	-0.36	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
KIRC	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	8.67	6.08e-17	5.3e-14	0.45	0.36	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
KIRC	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.67	6.09e-17	5.3e-14	-0.42	-0.36	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
KIRC	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-8.67	6.11e-17	5.32e-14	-0.48	-0.36	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
KIRC	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-8.67	6.11e-17	5.32e-14	-0.48	-0.36	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
KIRC	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	8.67	6.15e-17	5.35e-14	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
KIRC	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	8.67	6.18e-17	5.38e-14	0.59	0.36	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
KIRC	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	8.67	6.19e-17	5.39e-14	0.45	0.36	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	8.67	6.19e-17	5.39e-14	0.45	0.36	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	8.67	6.19e-17	5.39e-14	0.45	0.36	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	8.67	6.22e-17	5.41e-14	0.35	0.36	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
KIRC	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-8.67	6.23e-17	5.42e-14	-0.47	-0.36	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-8.67	6.24e-17	5.43e-14	-0.45	-0.36	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
KIRC	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-8.67	6.24e-17	5.43e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
KIRC	cis	rs11671005	0.568	rs73068325	ENSG00000269600.1	AC016629.3	-8.67	6.25e-17	5.43e-14	-0.59	-0.36	Mean platelet volume;	chr19:58567729	chr19:58593896~58599355:-
KIRC	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-8.67	6.27e-17	5.45e-14	-0.47	-0.36	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
KIRC	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	8.67	6.28e-17	5.46e-14	0.65	0.36	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
KIRC	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	8.67	6.29e-17	5.47e-14	0.4	0.36	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
KIRC	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	8.67	6.3e-17	5.48e-14	0.45	0.36	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	8.67	6.3e-17	5.48e-14	0.45	0.36	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	8.67	6.31e-17	5.48e-14	0.45	0.36	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	8.67	6.31e-17	5.48e-14	0.45	0.36	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
KIRC	cis	rs4273100	0.79	rs60166680	ENSG00000228157.4	AC007952.5	8.67	6.31e-17	5.49e-14	0.62	0.36	Schizophrenia;	chr17:19374231	chr17:19092974~19096837:+
KIRC	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	8.67	6.32e-17	5.49e-14	0.29	0.36	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
KIRC	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	8.67	6.37e-17	5.53e-14	0.55	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
KIRC	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-8.67	6.38e-17	5.54e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
KIRC	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-8.67	6.38e-17	5.54e-14	-0.43	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
KIRC	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	8.67	6.38e-17	5.54e-14	0.45	0.36	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
KIRC	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-8.67	6.38e-17	5.54e-14	-0.39	-0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
KIRC	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	8.67	6.38e-17	5.55e-14	0.41	0.36	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
KIRC	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	8.67	6.39e-17	5.55e-14	0.64	0.36	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
KIRC	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	8.67	6.39e-17	5.55e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	8.67	6.39e-17	5.55e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	8.67	6.39e-17	5.55e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	8.67	6.39e-17	5.55e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	8.67	6.39e-17	5.55e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	8.67	6.4e-17	5.55e-14	0.41	0.36	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
KIRC	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	8.67	6.41e-17	5.56e-14	0.54	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
KIRC	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	8.67	6.41e-17	5.56e-14	0.4	0.36	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
KIRC	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-8.67	6.44e-17	5.59e-14	-0.47	-0.36	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
KIRC	cis	rs7176527	0.579	rs366717	ENSG00000188388.10	GOLGA6L3	8.66	6.48e-17	5.62e-14	0.43	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85240472~85247170:+
KIRC	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	8.66	6.49e-17	5.63e-14	0.48	0.36	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
KIRC	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-8.66	6.53e-17	5.66e-14	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
KIRC	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-8.66	6.53e-17	5.66e-14	-0.54	-0.36	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
KIRC	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-8.66	6.56e-17	5.69e-14	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
KIRC	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-8.66	6.58e-17	5.71e-14	-0.4	-0.36	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
KIRC	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-8.66	6.62e-17	5.74e-14	-0.56	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
KIRC	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.66	6.67e-17	5.78e-14	-0.41	-0.36	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
KIRC	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	8.66	6.69e-17	5.79e-14	0.37	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	8.66	6.69e-17	5.79e-14	0.37	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	8.66	6.69e-17	5.79e-14	0.37	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
KIRC	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-8.66	6.7e-17	5.81e-14	-0.33	-0.36	Height;	chr4:55537550	chr4:55363971~55395847:-
KIRC	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-8.66	6.75e-17	5.85e-14	-0.49	-0.36	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
KIRC	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	8.66	6.75e-17	5.85e-14	0.45	0.36	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
KIRC	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	8.66	6.78e-17	5.87e-14	0.46	0.36	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	8.66	6.8e-17	5.89e-14	0.54	0.36	Height;	chr6:109741085	chr6:109382795~109383666:+
KIRC	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	8.66	6.81e-17	5.9e-14	0.47	0.36	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
KIRC	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-8.66	6.83e-17	5.91e-14	-0.24	-0.36	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	8.66	6.84e-17	5.92e-14	0.46	0.36	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
KIRC	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	8.66	6.9e-17	5.97e-14	0.47	0.36	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
KIRC	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	8.66	6.91e-17	5.98e-14	0.4	0.36	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	8.66	6.91e-17	5.98e-14	0.4	0.36	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
KIRC	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-8.66	6.93e-17	6e-14	-0.38	-0.36	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
KIRC	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.66	6.93e-17	6e-14	-0.56	-0.36	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
KIRC	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-8.66	6.95e-17	6.02e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
KIRC	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	8.65	6.98e-17	6.04e-14	0.5	0.36	Height;	chr6:109333018	chr6:109382795~109383666:+
KIRC	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-8.65	7.06e-17	6.1e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
KIRC	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-8.65	7.06e-17	6.1e-14	-0.39	-0.36	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
KIRC	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	8.65	7.1e-17	6.13e-14	0.35	0.36	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
KIRC	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-8.65	7.1e-17	6.13e-14	-0.64	-0.36	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
KIRC	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-8.65	7.11e-17	6.15e-14	-0.44	-0.36	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
KIRC	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-8.65	7.11e-17	6.15e-14	-0.44	-0.36	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
KIRC	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	8.65	7.11e-17	6.15e-14	0.45	0.36	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
KIRC	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-8.65	7.12e-17	6.16e-14	-0.38	-0.36	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
KIRC	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-8.65	7.22e-17	6.24e-14	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
KIRC	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-8.65	7.24e-17	6.25e-14	-0.49	-0.36	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
KIRC	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	8.65	7.25e-17	6.26e-14	0.52	0.36	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	8.65	7.25e-17	6.26e-14	0.46	0.36	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
KIRC	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	8.65	7.26e-17	6.27e-14	0.67	0.36	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.509	rs5014975	ENSG00000250696.4	RP11-704M14.1	8.65	7.27e-17	6.28e-14	0.39	0.36	Obesity-related traits;	chr4:69130244	chr4:69182100~69216766:+
KIRC	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	8.65	7.28e-17	6.29e-14	0.48	0.36	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
KIRC	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	8.65	7.29e-17	6.29e-14	0.26	0.36	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
KIRC	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	8.65	7.29e-17	6.3e-14	0.31	0.36	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
KIRC	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-8.65	7.33e-17	6.33e-14	-0.4	-0.36	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
KIRC	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-8.65	7.34e-17	6.33e-14	-0.54	-0.36	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
KIRC	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	8.65	7.34e-17	6.34e-14	0.64	0.36	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	8.65	7.34e-17	6.34e-14	0.64	0.36	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	8.65	7.34e-17	6.34e-14	0.64	0.36	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
KIRC	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	8.65	7.37e-17	6.36e-14	0.37	0.36	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	8.65	7.37e-17	6.36e-14	0.37	0.36	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	8.65	7.37e-17	6.36e-14	0.37	0.36	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
KIRC	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	8.65	7.39e-17	6.38e-14	0.46	0.36	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
KIRC	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	8.65	7.5e-17	6.47e-14	0.72	0.36	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000196472.4	RP13-644M16.4	8.65	7.51e-17	6.47e-14	0.41	0.36	Obesity-related traits;	chr4:69079224	chr4:69181660~69182372:+
KIRC	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	8.64	7.51e-17	6.48e-14	0.47	0.36	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
KIRC	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	8.64	7.55e-17	6.51e-14	0.38	0.36	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
KIRC	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-8.64	7.6e-17	6.55e-14	-0.59	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
KIRC	cis	rs453301	0.624	rs2915251	ENSG00000253893.2	FAM85B	-8.64	7.61e-17	6.56e-14	-0.47	-0.36	Joint mobility (Beighton score);	chr8:9009901	chr8:8167819~8226614:-
KIRC	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	8.64	7.63e-17	6.57e-14	0.39	0.36	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
KIRC	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	8.64	7.65e-17	6.6e-14	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
KIRC	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-8.64	7.66e-17	6.6e-14	-0.36	-0.36	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
KIRC	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	8.64	7.7e-17	6.63e-14	0.32	0.36	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
KIRC	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-8.64	7.73e-17	6.66e-14	-0.37	-0.36	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
KIRC	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	8.64	7.73e-17	6.66e-14	0.39	0.36	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
KIRC	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	8.64	7.74e-17	6.67e-14	0.46	0.36	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
KIRC	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-8.64	7.75e-17	6.68e-14	-0.41	-0.36	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	8.64	7.75e-17	6.68e-14	0.51	0.36	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	8.64	7.77e-17	6.7e-14	0.47	0.36	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
KIRC	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	8.64	7.79e-17	6.71e-14	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
KIRC	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	8.64	7.82e-17	6.73e-14	0.39	0.36	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
KIRC	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-8.64	7.84e-17	6.75e-14	-0.42	-0.36	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
KIRC	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-8.64	7.85e-17	6.76e-14	-0.48	-0.36	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
KIRC	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-8.64	7.85e-17	6.76e-14	-0.48	-0.36	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	8.64	7.86e-17	6.77e-14	0.46	0.36	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
KIRC	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	8.64	7.87e-17	6.78e-14	0.41	0.36	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
KIRC	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-8.64	7.87e-17	6.78e-14	-0.41	-0.36	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
KIRC	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	8.64	7.88e-17	6.78e-14	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
KIRC	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	8.64	7.88e-17	6.79e-14	0.4	0.36	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
KIRC	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	8.64	7.89e-17	6.79e-14	0.45	0.36	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
KIRC	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-8.64	7.91e-17	6.81e-14	-0.41	-0.36	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
KIRC	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-8.64	7.91e-17	6.81e-14	-0.36	-0.36	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
KIRC	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	8.64	7.93e-17	6.83e-14	0.4	0.36	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
KIRC	cis	rs919433	0.963	rs1896857	ENSG00000231621.1	AC013264.2	8.64	7.97e-17	6.86e-14	0.38	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197299806	chr2:197197991~197199273:+
KIRC	cis	rs12893668	0.514	rs3212090	ENSG00000269910.1	RP11-73M18.10	8.64	7.98e-17	6.87e-14	0.26	0.36	Reticulocyte count;	chr14:103702526	chr14:103694516~103695050:-
KIRC	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	8.64	7.99e-17	6.88e-14	0.66	0.36	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
KIRC	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	8.64	8.01e-17	6.89e-14	0.47	0.36	Height;	chr6:109374782	chr6:109382795~109383666:+
KIRC	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-8.64	8.03e-17	6.9e-14	-0.58	-0.36	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
KIRC	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-8.64	8.07e-17	6.94e-14	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
KIRC	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-8.64	8.09e-17	6.96e-14	-0.41	-0.36	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
KIRC	cis	rs2283792	0.765	rs9607241	ENSG00000224086.5	LL22NC03-86G7.1	-8.64	8.1e-17	6.96e-14	-0.3	-0.36	Multiple sclerosis;	chr22:21750584	chr22:21938293~21977632:+
KIRC	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	8.63	8.1e-17	6.97e-14	0.45	0.36	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	8.63	8.1e-17	6.97e-14	0.45	0.36	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
KIRC	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	8.63	8.11e-17	6.97e-14	0.48	0.36	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	8.63	8.11e-17	6.97e-14	0.48	0.36	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	8.63	8.11e-17	6.97e-14	0.48	0.36	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	8.63	8.11e-17	6.97e-14	0.48	0.36	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
KIRC	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	8.63	8.11e-17	6.97e-14	0.45	0.36	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	8.63	8.11e-17	6.97e-14	0.45	0.36	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	8.63	8.11e-17	6.97e-14	0.45	0.36	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	8.63	8.11e-17	6.97e-14	0.45	0.36	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	8.63	8.11e-17	6.97e-14	0.45	0.36	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
KIRC	cis	rs4936099	0.646	rs4937514	ENSG00000175773.11	RP11-121M22.1	8.63	8.12e-17	6.98e-14	0.37	0.36	Optic cup area;Vertical cup-disc ratio;	chr11:130394620	chr11:130314993~130403657:+
KIRC	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-8.63	8.16e-17	7.02e-14	-0.44	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
KIRC	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-8.63	8.16e-17	7.02e-14	-0.6	-0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
KIRC	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-8.63	8.17e-17	7.02e-14	-0.47	-0.36	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
KIRC	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	8.63	8.2e-17	7.05e-14	0.47	0.36	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
KIRC	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	8.63	8.21e-17	7.05e-14	0.64	0.36	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
KIRC	cis	rs6908034	0.607	rs73378506	ENSG00000228412.5	RP4-625H18.2	8.63	8.23e-17	7.07e-14	0.72	0.36	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19802164~19804752:-
KIRC	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	8.63	8.23e-17	7.08e-14	0.33	0.36	Height;	chr4:55540912	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	8.63	8.23e-17	7.08e-14	0.33	0.36	Height;	chr4:55540972	chr4:55363971~55395847:-
KIRC	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-8.63	8.27e-17	7.11e-14	-0.43	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
KIRC	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	8.63	8.31e-17	7.14e-14	0.42	0.36	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
KIRC	cis	rs12893668	0.543	rs1799796	ENSG00000269910.1	RP11-73M18.10	8.63	8.31e-17	7.14e-14	0.26	0.36	Reticulocyte count;	chr14:103699590	chr14:103694516~103695050:-
KIRC	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-8.63	8.32e-17	7.14e-14	-0.36	-0.36	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
KIRC	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-8.63	8.36e-17	7.18e-14	-0.31	-0.36	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
KIRC	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-8.63	8.41e-17	7.22e-14	-0.53	-0.36	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
KIRC	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-8.63	8.43e-17	7.24e-14	-0.47	-0.36	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
KIRC	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	8.63	8.44e-17	7.24e-14	0.49	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
KIRC	cis	rs4356975	0.527	rs60423649	ENSG00000250696.4	RP11-704M14.1	8.63	8.5e-17	7.3e-14	0.38	0.36	Obesity-related traits;	chr4:69127952	chr4:69182100~69216766:+
KIRC	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-8.63	8.52e-17	7.31e-14	-0.31	-0.36	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
KIRC	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-8.63	8.52e-17	7.31e-14	-0.31	-0.36	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
KIRC	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-8.63	8.54e-17	7.33e-14	-0.49	-0.36	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
KIRC	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	8.63	8.58e-17	7.36e-14	0.4	0.36	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
KIRC	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-8.63	8.58e-17	7.36e-14	-0.43	-0.36	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
KIRC	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	8.63	8.61e-17	7.39e-14	0.38	0.36	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
KIRC	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-8.63	8.63e-17	7.4e-14	-0.4	-0.36	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
KIRC	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-8.63	8.63e-17	7.4e-14	-0.5	-0.36	Height;	chr6:109485060	chr6:109382795~109383666:+
KIRC	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-8.63	8.64e-17	7.41e-14	-0.37	-0.36	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
KIRC	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	8.63	8.66e-17	7.43e-14	0.52	0.36	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
KIRC	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-8.63	8.67e-17	7.43e-14	-0.46	-0.36	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	8.63	8.68e-17	7.44e-14	0.4	0.36	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
KIRC	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	8.63	8.69e-17	7.45e-14	0.37	0.36	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
KIRC	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	8.63	8.71e-17	7.47e-14	0.68	0.36	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
KIRC	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	8.63	8.73e-17	7.48e-14	0.42	0.36	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
KIRC	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	8.63	8.74e-17	7.49e-14	0.26	0.36	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
KIRC	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-8.62	8.76e-17	7.51e-14	-0.34	-0.36	Height;	chr4:55593918	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	8.62	8.76e-17	7.51e-14	0.46	0.36	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
KIRC	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-8.62	8.77e-17	7.52e-14	-0.41	-0.36	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
KIRC	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	8.62	8.82e-17	7.55e-14	0.48	0.36	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
KIRC	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	8.62	8.84e-17	7.57e-14	0.45	0.36	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
KIRC	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	8.62	8.84e-17	7.57e-14	0.37	0.36	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
KIRC	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	8.62	8.85e-17	7.58e-14	0.59	0.36	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
KIRC	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-8.62	8.88e-17	7.61e-14	-0.47	-0.36	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
KIRC	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	8.62	8.92e-17	7.64e-14	0.55	0.36	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
KIRC	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-8.62	8.95e-17	7.67e-14	-0.33	-0.36	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-8.62	8.96e-17	7.67e-14	-0.36	-0.36	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
KIRC	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	8.62	8.98e-17	7.69e-14	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
KIRC	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	8.62	9e-17	7.71e-14	0.76	0.36	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
KIRC	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	8.62	9.01e-17	7.71e-14	0.38	0.36	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
KIRC	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-8.62	9.01e-17	7.71e-14	-0.48	-0.36	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	8.62	9.1e-17	7.79e-14	0.4	0.36	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
KIRC	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	8.62	9.11e-17	7.8e-14	0.54	0.36	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
KIRC	cis	rs9457247	0.529	rs6907666	ENSG00000265828.1	MIR3939	8.62	9.19e-17	7.86e-14	0.4	0.36	Crohn's disease;	chr6:167109907	chr6:166997807~166997912:-
KIRC	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-8.62	9.21e-17	7.88e-14	-0.46	-0.36	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
KIRC	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	8.62	9.24e-17	7.9e-14	0.47	0.36	Height;	chr6:109367528	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	8.62	9.24e-17	7.9e-14	0.47	0.36	Height;	chr6:109368704	chr6:109382795~109383666:+
KIRC	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-8.62	9.25e-17	7.91e-14	-0.4	-0.36	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
KIRC	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	8.62	9.28e-17	7.94e-14	0.46	0.36	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
KIRC	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	8.62	9.35e-17	7.99e-14	0.47	0.36	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
KIRC	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-8.62	9.38e-17	8.02e-14	-0.49	-0.36	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
KIRC	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-8.62	9.38e-17	8.02e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-8.62	9.38e-17	8.02e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
KIRC	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	8.62	9.39e-17	8.02e-14	0.34	0.36	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
KIRC	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	8.62	9.4e-17	8.04e-14	0.45	0.36	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
KIRC	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	8.62	9.42e-17	8.05e-14	0.48	0.36	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
KIRC	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-8.62	9.42e-17	8.05e-14	-0.28	-0.36	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
KIRC	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-8.61	9.43e-17	8.06e-14	-0.48	-0.36	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
KIRC	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	8.61	9.44e-17	8.06e-14	0.34	0.36	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
KIRC	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-8.61	9.44e-17	8.06e-14	-0.5	-0.36	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
KIRC	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	8.61	9.49e-17	8.1e-14	0.45	0.36	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
KIRC	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	8.61	9.53e-17	8.14e-14	0.71	0.36	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
KIRC	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-8.61	9.59e-17	8.19e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
KIRC	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	8.61	9.6e-17	8.2e-14	0.47	0.36	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
KIRC	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-8.61	9.63e-17	8.22e-14	-0.38	-0.36	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
KIRC	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-8.61	9.68e-17	8.26e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
KIRC	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-8.61	9.68e-17	8.26e-14	-0.5	-0.36	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
KIRC	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-8.61	9.81e-17	8.37e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
KIRC	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	8.61	9.82e-17	8.37e-14	0.22	0.36	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
KIRC	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	8.61	9.84e-17	8.39e-14	0.45	0.36	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
KIRC	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	8.61	9.85e-17	8.4e-14	0.33	0.36	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
KIRC	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	8.61	9.86e-17	8.4e-14	0.63	0.36	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	8.61	9.87e-17	8.41e-14	0.45	0.36	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
KIRC	cis	rs1200821	0.535	rs1208789	ENSG00000151963.4	RP11-775A3.1	-8.61	9.92e-17	8.46e-14	-0.41	-0.36	Hemostatic factors and hematological phenotypes;	chr10:37433544	chr10:37883594~37884109:+
KIRC	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	8.61	9.95e-17	8.48e-14	0.36	0.36	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	8.61	9.95e-17	8.48e-14	0.36	0.36	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	8.61	9.95e-17	8.48e-14	0.36	0.36	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
KIRC	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-8.61	9.97e-17	8.5e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
KIRC	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	8.61	1.01e-16	8.57e-14	0.34	0.36	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
KIRC	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	8.61	1.01e-16	8.6e-14	0.47	0.36	Height;	chr6:109634847	chr6:109382795~109383666:+
KIRC	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-8.61	1.01e-16	8.62e-14	-0.43	-0.36	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
KIRC	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-8.61	1.01e-16	8.63e-14	-0.48	-0.36	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
KIRC	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	8.61	1.02e-16	8.65e-14	0.46	0.36	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	8.61	1.02e-16	8.65e-14	0.46	0.36	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
KIRC	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	8.6	1.02e-16	8.67e-14	0.39	0.36	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
KIRC	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	8.6	1.02e-16	8.67e-14	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
KIRC	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	8.6	1.02e-16	8.69e-14	0.25	0.36	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
KIRC	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	8.6	1.02e-16	8.7e-14	0.47	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
KIRC	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.6	1.02e-16	8.72e-14	0.41	0.36	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.6	1.02e-16	8.72e-14	-0.41	-0.36	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
KIRC	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-8.6	1.03e-16	8.72e-14	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
KIRC	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.6	1.03e-16	8.73e-14	0.48	0.36	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
KIRC	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	8.6	1.03e-16	8.74e-14	0.37	0.36	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
KIRC	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-8.6	1.03e-16	8.77e-14	-0.48	-0.36	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
KIRC	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-8.6	1.03e-16	8.77e-14	-0.48	-0.36	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	8.6	1.04e-16	8.82e-14	0.35	0.36	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
KIRC	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-8.6	1.04e-16	8.86e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
KIRC	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	8.6	1.04e-16	8.87e-14	0.33	0.36	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
KIRC	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-8.6	1.05e-16	8.93e-14	-0.29	-0.36	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
KIRC	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	8.6	1.06e-16	8.97e-14	0.42	0.36	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
KIRC	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-8.6	1.06e-16	9.02e-14	-0.4	-0.36	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
KIRC	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-8.6	1.06e-16	9.04e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-8.6	1.06e-16	9.04e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-8.6	1.06e-16	9.04e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-8.6	1.06e-16	9.04e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs11488879	ENSG00000274576.2	IGHV2-70	-8.6	1.06e-16	9.04e-14	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106786097	chr14:106770577~106771020:-
KIRC	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-8.6	1.07e-16	9.05e-14	-0.48	-0.36	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
KIRC	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-8.6	1.07e-16	9.09e-14	-0.41	-0.36	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
KIRC	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	8.6	1.07e-16	9.1e-14	0.36	0.36	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
KIRC	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	8.6	1.07e-16	9.12e-14	0.4	0.36	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	8.6	1.07e-16	9.12e-14	0.4	0.36	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	8.6	1.08e-16	9.15e-14	0.45	0.36	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
KIRC	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-8.6	1.08e-16	9.17e-14	-0.47	-0.36	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
KIRC	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-8.6	1.08e-16	9.17e-14	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-8.6	1.08e-16	9.17e-14	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-8.6	1.08e-16	9.17e-14	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
KIRC	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-8.6	1.09e-16	9.24e-14	-0.4	-0.36	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
KIRC	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-8.6	1.09e-16	9.26e-14	-0.54	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
KIRC	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	8.6	1.09e-16	9.27e-14	0.58	0.36	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
KIRC	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	8.59	1.1e-16	9.31e-14	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	8.59	1.1e-16	9.31e-14	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
KIRC	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	8.59	1.11e-16	9.41e-14	0.4	0.36	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
KIRC	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-8.59	1.11e-16	9.42e-14	-0.29	-0.36	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
KIRC	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	8.59	1.12e-16	9.53e-14	0.36	0.36	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	8.59	1.12e-16	9.53e-14	0.36	0.36	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
KIRC	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	8.59	1.13e-16	9.54e-14	0.46	0.36	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	8.59	1.13e-16	9.54e-14	0.46	0.36	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
KIRC	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	8.59	1.13e-16	9.55e-14	0.51	0.36	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
KIRC	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-8.59	1.13e-16	9.57e-14	-0.4	-0.36	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
KIRC	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	8.59	1.14e-16	9.62e-14	0.4	0.36	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
KIRC	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	8.59	1.14e-16	9.66e-14	0.44	0.36	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	8.59	1.14e-16	9.68e-14	0.45	0.36	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
KIRC	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	8.59	1.14e-16	9.68e-14	0.41	0.36	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
KIRC	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	8.59	1.14e-16	9.68e-14	0.42	0.36	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
KIRC	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	8.59	1.15e-16	9.7e-14	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	8.59	1.15e-16	9.7e-14	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	8.59	1.15e-16	9.72e-14	0.46	0.36	Height;	chr6:109405536	chr6:109382795~109383666:+
KIRC	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	8.59	1.15e-16	9.75e-14	0.38	0.36	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.83	rs4481286	ENSG00000250919.1	RP11-813N20.3	-8.59	1.15e-16	9.76e-14	-0.38	-0.36	Obesity-related traits;	chr4:69056631	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs4583828	ENSG00000250919.1	RP11-813N20.3	-8.59	1.15e-16	9.76e-14	-0.38	-0.36	Obesity-related traits;	chr4:69056669	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs4235113	ENSG00000250919.1	RP11-813N20.3	-8.59	1.15e-16	9.76e-14	-0.38	-0.36	Obesity-related traits;	chr4:69056739	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs4235114	ENSG00000250919.1	RP11-813N20.3	-8.59	1.15e-16	9.76e-14	-0.38	-0.36	Obesity-related traits;	chr4:69056953	chr4:69027831~69044578:+
KIRC	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	8.59	1.16e-16	9.77e-14	0.4	0.36	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
KIRC	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-8.59	1.16e-16	9.79e-14	-0.46	-0.36	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
KIRC	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	8.59	1.16e-16	9.81e-14	0.45	0.36	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
KIRC	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	8.59	1.16e-16	9.81e-14	0.47	0.36	Height;	chr6:109424139	chr6:109382795~109383666:+
KIRC	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	8.59	1.16e-16	9.82e-14	0.37	0.36	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
KIRC	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-8.59	1.16e-16	9.82e-14	-0.46	-0.36	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
KIRC	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-8.59	1.16e-16	9.83e-14	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
KIRC	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	8.59	1.16e-16	9.83e-14	0.43	0.36	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
KIRC	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-8.59	1.17e-16	9.85e-14	-0.32	-0.36	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
KIRC	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	8.59	1.17e-16	9.85e-14	0.38	0.36	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
KIRC	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-8.59	1.17e-16	9.86e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-8.59	1.17e-16	9.86e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-8.59	1.17e-16	9.86e-14	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
KIRC	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.59	1.17e-16	9.88e-14	0.47	0.36	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
KIRC	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	8.59	1.17e-16	9.91e-14	0.49	0.36	Height;	chr6:109430398	chr6:109382795~109383666:+
KIRC	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	8.59	1.18e-16	9.92e-14	0.45	0.36	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
KIRC	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
KIRC	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	8.59	1.18e-16	9.92e-14	0.67	0.36	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
KIRC	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	8.59	1.18e-16	9.93e-14	0.47	0.36	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
KIRC	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	8.59	1.18e-16	9.94e-14	0.45	0.36	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
KIRC	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	8.59	1.18e-16	9.94e-14	0.44	0.36	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
KIRC	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	8.59	1.18e-16	9.98e-14	0.4	0.36	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	8.58	1.19e-16	1e-13	0.45	0.36	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
KIRC	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-8.58	1.19e-16	1e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-8.58	1.19e-16	1e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-8.58	1.19e-16	1e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
KIRC	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-8.58	1.19e-16	1.01e-13	-0.43	-0.36	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
KIRC	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	8.58	1.19e-16	1.01e-13	0.46	0.36	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
KIRC	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	8.58	1.2e-16	1.01e-13	0.68	0.36	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
KIRC	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-8.58	1.2e-16	1.01e-13	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
KIRC	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	8.58	1.2e-16	1.01e-13	0.67	0.36	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
KIRC	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-8.58	1.2e-16	1.01e-13	-0.33	-0.36	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
KIRC	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	8.58	1.2e-16	1.01e-13	0.46	0.36	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
KIRC	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-8.58	1.22e-16	1.03e-13	-0.42	-0.36	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-8.58	1.22e-16	1.03e-13	-0.42	-0.36	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
KIRC	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	8.58	1.22e-16	1.03e-13	0.45	0.36	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
KIRC	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-8.58	1.22e-16	1.03e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
KIRC	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	8.58	1.23e-16	1.04e-13	0.38	0.36	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
KIRC	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-8.58	1.23e-16	1.04e-13	-0.45	-0.36	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
KIRC	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-8.58	1.24e-16	1.04e-13	-0.4	-0.36	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
KIRC	cis	rs6600671	1	rs1986111	ENSG00000227082.1	CH17-437K3.1	-8.58	1.24e-16	1.04e-13	-0.41	-0.36	Hip geometry;	chr1:121462934	chr1:121396754~121463129:+
KIRC	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	8.58	1.24e-16	1.04e-13	0.33	0.36	Height;	chr4:55476159	chr4:55363971~55395847:-
KIRC	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-8.58	1.24e-16	1.04e-13	-0.47	-0.36	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
KIRC	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-8.58	1.24e-16	1.04e-13	-0.5	-0.36	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
KIRC	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-8.58	1.24e-16	1.04e-13	-0.33	-0.36	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
KIRC	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-8.58	1.25e-16	1.05e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
KIRC	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-8.58	1.25e-16	1.05e-13	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
KIRC	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-8.58	1.25e-16	1.05e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-8.58	1.25e-16	1.05e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-8.58	1.25e-16	1.05e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
KIRC	cis	rs1005277	0.522	rs1208681	ENSG00000151963.4	RP11-775A3.1	-8.58	1.25e-16	1.05e-13	-0.4	-0.36	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:37883594~37884109:+
KIRC	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-8.58	1.25e-16	1.05e-13	-0.4	-0.36	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
KIRC	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	8.58	1.25e-16	1.05e-13	0.25	0.36	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
KIRC	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	8.58	1.26e-16	1.06e-13	0.33	0.36	Height;	chr4:55559957	chr4:55363971~55395847:-
KIRC	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	8.58	1.26e-16	1.06e-13	0.41	0.36	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
KIRC	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-8.58	1.26e-16	1.06e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-8.58	1.26e-16	1.06e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
KIRC	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	8.58	1.26e-16	1.06e-13	0.47	0.36	Height;	chr6:109706514	chr6:109382795~109383666:+
KIRC	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	8.58	1.26e-16	1.06e-13	0.46	0.36	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
KIRC	cis	rs9322193	0.961	rs4870144	ENSG00000223701.3	RAET1E-AS1	8.58	1.26e-16	1.06e-13	0.45	0.36	Lung cancer;	chr6:149575540	chr6:149884431~149919508:+
KIRC	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-8.58	1.27e-16	1.06e-13	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
KIRC	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	8.58	1.27e-16	1.06e-13	0.33	0.36	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
KIRC	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-8.57	1.28e-16	1.07e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
KIRC	cis	rs4356975	0.563	rs12506962	ENSG00000250696.4	RP11-704M14.1	8.57	1.28e-16	1.07e-13	0.38	0.36	Obesity-related traits;	chr4:69100306	chr4:69182100~69216766:+
KIRC	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	8.57	1.28e-16	1.08e-13	0.56	0.36	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
KIRC	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-8.57	1.28e-16	1.08e-13	-0.42	-0.36	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
KIRC	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-8.57	1.28e-16	1.08e-13	-0.46	-0.36	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	8.57	1.28e-16	1.08e-13	0.35	0.36	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
KIRC	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-8.57	1.29e-16	1.08e-13	-0.43	-0.36	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
KIRC	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	8.57	1.29e-16	1.08e-13	0.45	0.36	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
KIRC	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-8.57	1.29e-16	1.08e-13	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
KIRC	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	8.57	1.29e-16	1.08e-13	0.46	0.36	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
KIRC	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-8.57	1.3e-16	1.09e-13	-0.43	-0.36	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
KIRC	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-8.57	1.3e-16	1.09e-13	-0.4	-0.36	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
KIRC	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	8.57	1.31e-16	1.1e-13	0.45	0.36	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
KIRC	cis	rs1529102	1	rs2433388	ENSG00000225889.6	AC074289.1	-8.57	1.31e-16	1.1e-13	-0.34	-0.36	Breast size;	chr2:64266485	chr2:64143239~64252859:+
KIRC	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	8.57	1.31e-16	1.1e-13	0.45	0.36	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
KIRC	cis	rs9355610	0.609	rs3756838	ENSG00000265828.1	MIR3939	8.57	1.32e-16	1.1e-13	0.51	0.36	Graves' disease;	chr6:166957763	chr6:166997807~166997912:-
KIRC	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-8.57	1.32e-16	1.1e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-8.57	1.32e-16	1.1e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-8.57	1.32e-16	1.1e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-8.57	1.32e-16	1.1e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
KIRC	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	8.57	1.32e-16	1.11e-13	0.73	0.36	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
KIRC	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	8.57	1.32e-16	1.11e-13	0.45	0.36	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	8.57	1.32e-16	1.11e-13	0.45	0.36	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
KIRC	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-8.57	1.33e-16	1.11e-13	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
KIRC	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-8.57	1.34e-16	1.12e-13	-0.58	-0.36	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
KIRC	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-8.57	1.34e-16	1.12e-13	-0.58	-0.36	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
KIRC	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-8.57	1.34e-16	1.12e-13	-0.25	-0.36	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
KIRC	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	8.57	1.34e-16	1.12e-13	0.43	0.36	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
KIRC	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-8.57	1.34e-16	1.13e-13	-0.31	-0.36	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
KIRC	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	8.57	1.34e-16	1.13e-13	0.45	0.36	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
KIRC	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	8.57	1.34e-16	1.13e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
KIRC	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	8.57	1.35e-16	1.13e-13	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
KIRC	cis	rs2749592	0.513	rs1208708	ENSG00000151963.4	RP11-775A3.1	-8.57	1.35e-16	1.13e-13	-0.41	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37883594~37884109:+
KIRC	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	8.57	1.35e-16	1.13e-13	0.68	0.36	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
KIRC	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-8.57	1.36e-16	1.14e-13	-0.47	-0.36	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
KIRC	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	8.57	1.36e-16	1.14e-13	0.46	0.36	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
KIRC	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	8.57	1.36e-16	1.14e-13	0.7	0.36	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
KIRC	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	8.57	1.37e-16	1.14e-13	0.48	0.36	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
KIRC	cis	rs6600671	1	rs6600669	ENSG00000227082.1	CH17-437K3.1	-8.57	1.37e-16	1.14e-13	-0.41	-0.36	Hip geometry;	chr1:121471785	chr1:121396754~121463129:+
KIRC	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	8.57	1.37e-16	1.14e-13	0.46	0.36	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	8.57	1.37e-16	1.14e-13	0.46	0.36	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
KIRC	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	8.57	1.37e-16	1.15e-13	0.29	0.36	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
KIRC	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	8.57	1.38e-16	1.15e-13	0.32	0.36	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
KIRC	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-8.57	1.38e-16	1.15e-13	-0.52	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
KIRC	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	8.57	1.38e-16	1.15e-13	0.46	0.36	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	8.56	1.38e-16	1.15e-13	0.46	0.36	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	8.56	1.38e-16	1.15e-13	0.45	0.36	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
KIRC	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
KIRC	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-8.56	1.39e-16	1.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
KIRC	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	8.56	1.39e-16	1.16e-13	0.48	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
KIRC	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-8.56	1.39e-16	1.16e-13	-0.46	-0.36	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
KIRC	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	8.56	1.39e-16	1.16e-13	0.38	0.36	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
KIRC	cis	rs79040073	0.637	rs11635308	ENSG00000259531.2	RP11-295H24.3	8.56	1.39e-16	1.16e-13	0.47	0.36	Lung cancer in ever smokers;	chr15:49426531	chr15:49365124~49366685:-
KIRC	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-8.56	1.39e-16	1.16e-13	-0.37	-0.36	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
KIRC	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-8.56	1.41e-16	1.18e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-8.56	1.41e-16	1.18e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-8.56	1.41e-16	1.18e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
KIRC	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	8.56	1.42e-16	1.18e-13	0.66	0.36	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
KIRC	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	8.56	1.42e-16	1.19e-13	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
KIRC	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-8.56	1.42e-16	1.19e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
KIRC	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-8.56	1.42e-16	1.19e-13	-0.41	-0.36	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
KIRC	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-8.56	1.43e-16	1.19e-13	-0.41	-0.36	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
KIRC	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	8.56	1.43e-16	1.19e-13	0.31	0.36	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
KIRC	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	8.56	1.43e-16	1.2e-13	0.33	0.36	Height;	chr4:55553396	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	8.56	1.43e-16	1.2e-13	0.33	0.36	Height;	chr4:55554025	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	8.56	1.43e-16	1.2e-13	0.33	0.36	Height;	chr4:55554380	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	8.56	1.43e-16	1.2e-13	0.33	0.36	Height;	chr4:55554456	chr4:55363971~55395847:-
KIRC	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-8.56	1.43e-16	1.2e-13	-0.39	-0.36	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
KIRC	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	8.56	1.44e-16	1.2e-13	0.41	0.36	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
KIRC	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-8.56	1.44e-16	1.2e-13	-0.4	-0.36	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
KIRC	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-8.56	1.45e-16	1.21e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
KIRC	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	8.56	1.45e-16	1.21e-13	0.47	0.36	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
KIRC	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-8.56	1.46e-16	1.22e-13	-0.38	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
KIRC	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	8.56	1.47e-16	1.23e-13	0.65	0.36	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000250919.1	RP11-813N20.3	-8.56	1.48e-16	1.23e-13	-0.38	-0.36	Obesity-related traits;	chr4:69062256	chr4:69027831~69044578:+
KIRC	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	8.56	1.48e-16	1.24e-13	0.38	0.36	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
KIRC	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-8.55	1.49e-16	1.24e-13	-0.43	-0.36	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
KIRC	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	8.55	1.49e-16	1.24e-13	0.43	0.36	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
KIRC	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-8.55	1.49e-16	1.24e-13	-0.41	-0.36	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
KIRC	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	8.55	1.49e-16	1.24e-13	0.72	0.36	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
KIRC	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-8.55	1.49e-16	1.24e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
KIRC	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-8.55	1.5e-16	1.25e-13	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
KIRC	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-8.55	1.5e-16	1.25e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-8.55	1.5e-16	1.25e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
KIRC	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-8.55	1.5e-16	1.25e-13	-0.43	-0.36	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
KIRC	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-8.55	1.5e-16	1.25e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
KIRC	cis	rs79040073	0.637	rs78323502	ENSG00000259531.2	RP11-295H24.3	8.55	1.51e-16	1.26e-13	0.48	0.36	Lung cancer in ever smokers;	chr15:49436634	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.517	rs118069527	ENSG00000259531.2	RP11-295H24.3	8.55	1.51e-16	1.26e-13	0.48	0.36	Lung cancer in ever smokers;	chr15:49436684	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs79404431	ENSG00000259531.2	RP11-295H24.3	8.55	1.51e-16	1.26e-13	0.48	0.36	Lung cancer in ever smokers;	chr15:49436689	chr15:49365124~49366685:-
KIRC	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-8.55	1.51e-16	1.26e-13	-0.53	-0.36	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-8.55	1.52e-16	1.27e-13	-0.47	-0.36	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
KIRC	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	8.55	1.52e-16	1.27e-13	0.42	0.36	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
KIRC	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	8.55	1.52e-16	1.27e-13	0.39	0.36	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
KIRC	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	8.55	1.53e-16	1.28e-13	0.44	0.36	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
KIRC	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-8.55	1.53e-16	1.28e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
KIRC	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-8.55	1.53e-16	1.28e-13	-0.39	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
KIRC	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-8.55	1.54e-16	1.28e-13	-0.43	-0.36	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
KIRC	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-8.55	1.55e-16	1.29e-13	-0.45	-0.36	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
KIRC	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	8.55	1.55e-16	1.29e-13	0.39	0.36	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
KIRC	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	8.55	1.55e-16	1.29e-13	0.39	0.36	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
KIRC	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	8.55	1.55e-16	1.29e-13	0.33	0.36	Height;	chr4:55551447	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	8.55	1.55e-16	1.29e-13	0.33	0.36	Height;	chr4:55551845	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	8.55	1.56e-16	1.29e-13	0.46	0.36	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
KIRC	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	8.55	1.56e-16	1.3e-13	0.54	0.36	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
KIRC	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-8.55	1.57e-16	1.3e-13	-0.44	-0.36	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
KIRC	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-8.55	1.57e-16	1.3e-13	-0.47	-0.36	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
KIRC	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-8.55	1.58e-16	1.31e-13	-0.45	-0.36	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
KIRC	cis	rs4356975	0.563	rs4293848	ENSG00000250696.4	RP11-704M14.1	8.55	1.58e-16	1.31e-13	0.37	0.36	Obesity-related traits;	chr4:69099784	chr4:69182100~69216766:+
KIRC	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	8.55	1.58e-16	1.31e-13	0.33	0.36	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
KIRC	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	8.55	1.59e-16	1.32e-13	0.47	0.36	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
KIRC	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-8.55	1.59e-16	1.32e-13	-0.39	-0.36	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
KIRC	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	8.54	1.6e-16	1.33e-13	0.48	0.36	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
KIRC	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	8.54	1.6e-16	1.33e-13	0.41	0.36	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
KIRC	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	8.54	1.6e-16	1.33e-13	0.41	0.36	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
KIRC	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	8.54	1.61e-16	1.33e-13	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
KIRC	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	8.54	1.61e-16	1.34e-13	0.46	0.36	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
KIRC	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.54	1.61e-16	1.34e-13	-0.41	-0.36	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
KIRC	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	8.54	1.62e-16	1.35e-13	0.46	0.36	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
KIRC	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-8.54	1.62e-16	1.35e-13	-0.4	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
KIRC	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	8.54	1.63e-16	1.35e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
KIRC	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-8.54	1.63e-16	1.35e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
KIRC	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-8.54	1.63e-16	1.36e-13	-0.4	-0.36	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
KIRC	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.54	1.63e-16	1.36e-13	0.25	0.36	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
KIRC	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	8.54	1.65e-16	1.37e-13	0.68	0.36	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
KIRC	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	8.54	1.65e-16	1.37e-13	0.47	0.36	Height;	chr6:109715504	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	8.54	1.65e-16	1.37e-13	0.47	0.36	Height;	chr6:109715560	chr6:109382795~109383666:+
KIRC	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	8.54	1.65e-16	1.37e-13	0.4	0.36	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
KIRC	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-8.54	1.65e-16	1.37e-13	-0.34	-0.36	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
KIRC	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-8.54	1.66e-16	1.38e-13	-0.4	-0.36	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
KIRC	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-8.54	1.67e-16	1.38e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
KIRC	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-8.54	1.67e-16	1.38e-13	-0.5	-0.36	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
KIRC	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	8.54	1.67e-16	1.39e-13	0.47	0.36	Height;	chr6:109740895	chr6:109382795~109383666:+
KIRC	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	8.54	1.68e-16	1.39e-13	0.46	0.36	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
KIRC	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	8.54	1.68e-16	1.39e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
KIRC	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-8.54	1.68e-16	1.4e-13	-0.46	-0.36	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-8.54	1.69e-16	1.4e-13	-0.45	-0.36	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
KIRC	cis	rs7017914	0.934	rs7814274	ENSG00000254031.4	RP11-326E22.1	-8.54	1.69e-16	1.4e-13	-0.39	-0.36	Bone mineral density;	chr8:70658176	chr8:71155457~71204223:+
KIRC	cis	rs904251	0.6	rs1874736	ENSG00000227920.2	RP1-153P14.5	-8.54	1.7e-16	1.41e-13	-0.39	-0.36	Cognitive performance;	chr6:37480218	chr6:37545145~37550860:+
KIRC	cis	rs950027	0.62	rs1145076	ENSG00000235390.4	CTD-2651B20.5	-8.54	1.7e-16	1.41e-13	-0.34	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45321077~45321692:-
KIRC	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-8.54	1.7e-16	1.41e-13	-0.39	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
KIRC	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-8.54	1.7e-16	1.41e-13	-0.36	-0.36	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
KIRC	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	8.54	1.7e-16	1.41e-13	0.47	0.36	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
KIRC	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	8.54	1.7e-16	1.41e-13	0.39	0.36	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
KIRC	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-8.54	1.71e-16	1.42e-13	-0.44	-0.36	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-8.54	1.71e-16	1.42e-13	-0.44	-0.36	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
KIRC	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-8.54	1.71e-16	1.42e-13	-0.37	-0.36	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.563	rs4554144	ENSG00000250696.4	RP11-704M14.1	8.54	1.71e-16	1.42e-13	0.37	0.36	Obesity-related traits;	chr4:69094837	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7438135	ENSG00000250696.4	RP11-704M14.1	8.54	1.72e-16	1.42e-13	0.37	0.36	Obesity-related traits;	chr4:69095621	chr4:69182100~69216766:+
KIRC	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-8.54	1.72e-16	1.42e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
KIRC	cis	rs11089937	0.597	rs4821774	ENSG00000211638.2	IGLV8-61	-8.54	1.72e-16	1.43e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22098700~22099212:+
KIRC	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	8.54	1.72e-16	1.43e-13	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
KIRC	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	8.54	1.72e-16	1.43e-13	0.5	0.36	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
KIRC	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	8.53	1.73e-16	1.43e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
KIRC	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	8.53	1.73e-16	1.43e-13	0.47	0.36	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
KIRC	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-8.53	1.73e-16	1.43e-13	-0.39	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
KIRC	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-8.53	1.73e-16	1.44e-13	-0.4	-0.36	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-8.53	1.73e-16	1.44e-13	-0.4	-0.36	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
KIRC	cis	rs7169304	0.559	rs117818498	ENSG00000259531.2	RP11-295H24.3	8.53	1.74e-16	1.44e-13	0.47	0.36	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49436685	chr15:49365124~49366685:-
KIRC	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	8.53	1.74e-16	1.44e-13	0.36	0.36	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	8.53	1.74e-16	1.44e-13	0.44	0.36	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.563	rs7676472	ENSG00000250696.4	RP11-704M14.1	8.53	1.75e-16	1.45e-13	0.37	0.36	Obesity-related traits;	chr4:69090226	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7663584	ENSG00000250696.4	RP11-704M14.1	8.53	1.75e-16	1.45e-13	0.37	0.36	Obesity-related traits;	chr4:69090392	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600876	ENSG00000250696.4	RP11-704M14.1	8.53	1.75e-16	1.45e-13	0.37	0.36	Obesity-related traits;	chr4:69091212	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.583	rs6600877	ENSG00000250696.4	RP11-704M14.1	8.53	1.75e-16	1.45e-13	0.37	0.36	Obesity-related traits;	chr4:69091505	chr4:69182100~69216766:+
KIRC	cis	rs79040073	0.679	rs78135084	ENSG00000259531.2	RP11-295H24.3	8.53	1.75e-16	1.45e-13	0.49	0.36	Lung cancer in ever smokers;	chr15:49169895	chr15:49365124~49366685:-
KIRC	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	8.53	1.75e-16	1.45e-13	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
KIRC	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	8.53	1.76e-16	1.45e-13	0.31	0.36	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
KIRC	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-8.53	1.76e-16	1.45e-13	-0.47	-0.36	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
KIRC	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-8.53	1.76e-16	1.45e-13	-0.47	-0.36	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
KIRC	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-8.53	1.76e-16	1.46e-13	-0.33	-0.36	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
KIRC	cis	rs4356975	0.83	rs6422322	ENSG00000250919.1	RP11-813N20.3	-8.53	1.76e-16	1.46e-13	-0.38	-0.36	Obesity-related traits;	chr4:69055571	chr4:69027831~69044578:+
KIRC	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-8.53	1.76e-16	1.46e-13	-0.66	-0.36	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
KIRC	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.53	1.76e-16	1.46e-13	-0.46	-0.36	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
KIRC	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	8.53	1.76e-16	1.46e-13	0.46	0.36	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	8.53	1.77e-16	1.46e-13	0.5	0.36	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
KIRC	cis	rs4356975	0.563	rs6600878	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69092618	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.583	rs6819757	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69092946	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs57216626	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69093105	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs59415892	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69093191	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs62296942	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69093401	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7437039	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69093758	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7439792	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69093881	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs62296944	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69094492	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600879	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69094669	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600880	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69094762	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4538548	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69094951	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600883	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69094953	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4455491	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69095215	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs11940220	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69095222	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs11940316	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69095409	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7668258	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69096360	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs12647681	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69097442	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs12647682	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69097450	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs58544196	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69097740	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7439326	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69098462	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7438244	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69098491	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7441750	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69098803	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7441774	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69098836	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs7434332	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.37	0.36	Obesity-related traits;	chr4:69099141	chr4:69182100~69216766:+
KIRC	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-8.53	1.77e-16	1.46e-13	-0.47	-0.36	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.563	rs6858558	ENSG00000250696.4	RP11-704M14.1	8.53	1.77e-16	1.46e-13	0.38	0.36	Obesity-related traits;	chr4:69103825	chr4:69182100~69216766:+
KIRC	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	8.53	1.78e-16	1.47e-13	0.53	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
KIRC	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	8.53	1.78e-16	1.47e-13	0.44	0.36	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
KIRC	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	8.53	1.78e-16	1.47e-13	0.25	0.36	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
KIRC	cis	rs4356975	1	rs4356975	ENSG00000250919.1	RP11-813N20.3	-8.53	1.78e-16	1.47e-13	-0.38	-0.36	Obesity-related traits;	chr4:69106745	chr4:69027831~69044578:+
KIRC	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	8.53	1.8e-16	1.49e-13	0.25	0.36	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
KIRC	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	8.53	1.81e-16	1.49e-13	0.44	0.36	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
KIRC	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	8.53	1.81e-16	1.49e-13	0.4	0.36	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
KIRC	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	8.53	1.81e-16	1.5e-13	0.45	0.36	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
KIRC	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	8.53	1.81e-16	1.5e-13	0.44	0.36	Height;	chr4:55490228	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	8.53	1.81e-16	1.5e-13	0.44	0.36	Height;	chr4:55491150	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	8.53	1.81e-16	1.5e-13	0.44	0.36	Height;	chr4:55493557	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	8.53	1.81e-16	1.5e-13	0.44	0.36	Height;	chr4:55502504	chr4:55387949~55388271:+
KIRC	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	8.53	1.81e-16	1.5e-13	0.53	0.36	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	8.53	1.81e-16	1.5e-13	0.45	0.36	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
KIRC	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	8.53	1.82e-16	1.5e-13	0.46	0.36	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
KIRC	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	8.53	1.82e-16	1.5e-13	0.4	0.36	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
KIRC	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-8.53	1.82e-16	1.5e-13	-0.4	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000196472.4	RP13-644M16.4	8.53	1.82e-16	1.5e-13	0.48	0.36	Obesity-related traits;	chr4:69101657	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000196472.4	RP13-644M16.4	8.53	1.82e-16	1.5e-13	0.48	0.36	Obesity-related traits;	chr4:69102209	chr4:69181660~69182372:+
KIRC	cis	rs79040073	0.637	rs11630318	ENSG00000259531.2	RP11-295H24.3	-8.53	1.82e-16	1.5e-13	-0.46	-0.36	Lung cancer in ever smokers;	chr15:49312606	chr15:49365124~49366685:-
KIRC	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	8.53	1.82e-16	1.51e-13	0.31	0.36	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
KIRC	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	8.53	1.83e-16	1.51e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
KIRC	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	8.53	1.83e-16	1.51e-13	0.46	0.36	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
KIRC	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-8.53	1.84e-16	1.52e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	8.53	1.85e-16	1.52e-13	0.46	0.36	Height;	chr6:109506513	chr6:109382795~109383666:+
KIRC	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	8.53	1.85e-16	1.52e-13	0.52	0.36	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
KIRC	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	8.53	1.85e-16	1.53e-13	0.64	0.36	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.83	rs6600865	ENSG00000250919.1	RP11-813N20.3	-8.53	1.85e-16	1.53e-13	-0.38	-0.36	Obesity-related traits;	chr4:69057904	chr4:69027831~69044578:+
KIRC	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	8.53	1.85e-16	1.53e-13	0.5	0.36	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
KIRC	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-8.53	1.85e-16	1.53e-13	-0.43	-0.36	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
KIRC	cis	rs919433	0.963	rs1896854	ENSG00000231621.1	AC013264.2	8.52	1.86e-16	1.54e-13	0.37	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283052	chr2:197197991~197199273:+
KIRC	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	8.52	1.86e-16	1.54e-13	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
KIRC	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	8.52	1.86e-16	1.54e-13	0.38	0.36	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
KIRC	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-8.52	1.87e-16	1.54e-13	-0.39	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
KIRC	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	8.52	1.87e-16	1.54e-13	0.47	0.36	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
KIRC	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	8.52	1.88e-16	1.55e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
KIRC	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-8.52	1.89e-16	1.56e-13	-0.41	-0.36	Migraine;	chr4:56851192	chr4:56960927~56961373:-
KIRC	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-8.52	1.89e-16	1.56e-13	-0.41	-0.36	Migraine;	chr4:56852087	chr4:56960927~56961373:-
KIRC	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	8.52	1.89e-16	1.56e-13	0.45	0.36	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	8.52	1.89e-16	1.56e-13	0.45	0.36	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	8.52	1.89e-16	1.56e-13	0.45	0.36	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
KIRC	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-8.52	1.91e-16	1.57e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-8.52	1.92e-16	1.58e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
KIRC	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	8.52	1.92e-16	1.58e-13	0.58	0.36	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	8.52	1.92e-16	1.58e-13	0.58	0.36	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	8.52	1.92e-16	1.58e-13	0.58	0.36	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	8.52	1.92e-16	1.58e-13	0.58	0.36	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
KIRC	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	8.52	1.92e-16	1.58e-13	0.45	0.36	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
KIRC	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	8.52	1.93e-16	1.59e-13	0.4	0.36	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	8.52	1.93e-16	1.59e-13	0.4	0.36	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
KIRC	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	8.52	1.93e-16	1.59e-13	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
KIRC	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-8.52	1.93e-16	1.59e-13	-0.37	-0.36	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
KIRC	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-8.52	1.94e-16	1.59e-13	-0.3	-0.36	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
KIRC	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-8.52	1.94e-16	1.6e-13	-0.32	-0.36	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
KIRC	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-8.52	1.94e-16	1.6e-13	-0.29	-0.36	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
KIRC	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-8.52	1.94e-16	1.6e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
KIRC	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-8.52	1.94e-16	1.6e-13	-0.3	-0.36	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
KIRC	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	8.52	1.94e-16	1.6e-13	0.47	0.36	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
KIRC	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	8.52	1.95e-16	1.61e-13	0.4	0.36	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	8.52	1.95e-16	1.61e-13	0.4	0.36	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	8.52	1.95e-16	1.61e-13	0.45	0.36	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	8.52	1.95e-16	1.61e-13	0.46	0.36	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
KIRC	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	8.52	1.96e-16	1.61e-13	0.28	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
KIRC	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	8.52	1.96e-16	1.61e-13	0.44	0.36	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
KIRC	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-8.52	1.96e-16	1.61e-13	-0.39	-0.36	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
KIRC	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	8.52	1.97e-16	1.62e-13	0.48	0.36	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
KIRC	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	8.52	1.98e-16	1.63e-13	0.4	0.36	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-8.52	1.98e-16	1.63e-13	-0.48	-0.36	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
KIRC	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	8.52	1.98e-16	1.63e-13	0.31	0.36	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
KIRC	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	8.52	1.98e-16	1.63e-13	0.62	0.36	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
KIRC	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-8.52	1.99e-16	1.63e-13	-0.52	-0.36	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
KIRC	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-8.52	1.99e-16	1.64e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
KIRC	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	8.52	1.99e-16	1.64e-13	0.44	0.36	Height;	chr4:55483718	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	8.52	1.99e-16	1.64e-13	0.44	0.36	Height;	chr4:55490176	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	8.52	1.99e-16	1.64e-13	0.44	0.36	Height;	chr4:55495262	chr4:55387949~55388271:+
KIRC	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-8.52	2e-16	1.65e-13	-0.42	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
KIRC	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	8.51	2.01e-16	1.65e-13	0.63	0.36	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	8.51	2.01e-16	1.65e-13	0.63	0.36	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	8.51	2.01e-16	1.65e-13	0.63	0.36	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
KIRC	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	8.51	2.02e-16	1.66e-13	0.44	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
KIRC	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	8.51	2.02e-16	1.66e-13	0.45	0.36	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
KIRC	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	8.51	2.02e-16	1.66e-13	0.68	0.36	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	8.51	2.02e-16	1.66e-13	0.68	0.36	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
KIRC	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	8.51	2.03e-16	1.67e-13	0.58	0.36	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
KIRC	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	8.51	2.05e-16	1.68e-13	0.63	0.36	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	8.51	2.05e-16	1.68e-13	0.63	0.36	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	8.51	2.05e-16	1.68e-13	0.63	0.36	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	8.51	2.05e-16	1.68e-13	0.63	0.36	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	8.51	2.05e-16	1.68e-13	0.63	0.36	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
KIRC	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	8.51	2.05e-16	1.68e-13	0.53	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
KIRC	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-8.51	2.06e-16	1.69e-13	-0.4	-0.36	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
KIRC	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	8.51	2.06e-16	1.69e-13	0.29	0.36	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
KIRC	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-8.51	2.07e-16	1.7e-13	-0.47	-0.36	Height;	chr6:109731677	chr6:109382795~109383666:+
KIRC	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-8.51	2.08e-16	1.7e-13	-0.35	-0.36	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
KIRC	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	8.51	2.08e-16	1.71e-13	0.5	0.36	Height;	chr6:109773423	chr6:109382795~109383666:+
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000196472.4	RP13-644M16.4	-8.51	2.08e-16	1.71e-13	-0.41	-0.36	Obesity-related traits;	chr4:69075436	chr4:69181660~69182372:+
KIRC	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-8.51	2.09e-16	1.71e-13	-0.32	-0.36	Height;	chr11:118786602	chr11:118791254~118793137:+
KIRC	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-8.51	2.1e-16	1.72e-13	-0.53	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	8.51	2.1e-16	1.72e-13	0.44	0.36	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	8.51	2.1e-16	1.72e-13	0.44	0.36	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.83	rs72851348	ENSG00000250919.1	RP11-813N20.3	-8.51	2.1e-16	1.72e-13	-0.38	-0.36	Obesity-related traits;	chr4:69054305	chr4:69027831~69044578:+
KIRC	cis	rs9355610	0.609	rs7772112	ENSG00000265828.1	MIR3939	8.51	2.12e-16	1.74e-13	0.53	0.36	Graves' disease;	chr6:166995408	chr6:166997807~166997912:-
KIRC	cis	rs3820928	0.874	rs10167086	ENSG00000212391.1	SNORA48	8.51	2.12e-16	1.74e-13	0.42	0.36	Pulmonary function;	chr2:226928013	chr2:226968989~226969122:-
KIRC	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	8.51	2.13e-16	1.74e-13	0.42	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
KIRC	cis	rs1823913	1	rs10445782	ENSG00000227542.1	AC092614.2	-8.51	2.13e-16	1.74e-13	-0.33	-0.36	Obesity-related traits;	chr2:191236639	chr2:191229165~191246172:-
KIRC	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-8.51	2.13e-16	1.75e-13	-0.44	-0.36	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
KIRC	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	8.51	2.13e-16	1.75e-13	0.38	0.36	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
KIRC	cis	rs79040073	0.682	rs12592277	ENSG00000259531.2	RP11-295H24.3	8.51	2.14e-16	1.76e-13	0.45	0.36	Lung cancer in ever smokers;	chr15:49436562	chr15:49365124~49366685:-
KIRC	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-8.51	2.14e-16	1.76e-13	-0.29	-0.36	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
KIRC	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	8.51	2.14e-16	1.76e-13	0.54	0.36	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
KIRC	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	8.51	2.15e-16	1.76e-13	0.39	0.36	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
KIRC	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	8.51	2.15e-16	1.76e-13	0.51	0.36	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
KIRC	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	8.51	2.15e-16	1.76e-13	0.43	0.36	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	8.51	2.15e-16	1.76e-13	0.43	0.36	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	8.51	2.15e-16	1.76e-13	0.43	0.36	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
KIRC	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	8.51	2.16e-16	1.76e-13	0.43	0.36	Height;	chr4:55440988	chr4:55387949~55388271:+
KIRC	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-8.51	2.16e-16	1.77e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
KIRC	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	8.5	2.17e-16	1.77e-13	0.49	0.36	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
KIRC	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	8.5	2.17e-16	1.77e-13	0.46	0.36	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
KIRC	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	8.5	2.17e-16	1.78e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
KIRC	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-8.5	2.18e-16	1.78e-13	-0.5	-0.36	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
KIRC	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-8.5	2.18e-16	1.78e-13	-0.5	-0.36	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
KIRC	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	8.5	2.18e-16	1.78e-13	0.46	0.36	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
KIRC	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	8.5	2.18e-16	1.78e-13	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-8.5	2.18e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-8.5	2.18e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-8.5	2.18e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-8.5	2.18e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
KIRC	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-8.5	2.19e-16	1.79e-13	-0.25	-0.36	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
KIRC	cis	rs4273100	1	rs16960158	ENSG00000262319.1	CTC-457L16.2	-8.5	2.19e-16	1.79e-13	-0.51	-0.36	Schizophrenia;	chr17:19259739	chr17:19141017~19143689:-
KIRC	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-8.5	2.19e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-8.5	2.19e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-8.5	2.19e-16	1.79e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	8.5	2.19e-16	1.79e-13	0.44	0.36	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	8.5	2.19e-16	1.79e-13	0.44	0.36	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
KIRC	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-8.5	2.2e-16	1.8e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-8.5	2.2e-16	1.8e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-8.5	2.2e-16	1.8e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-8.5	2.2e-16	1.8e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
KIRC	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-8.5	2.2e-16	1.8e-13	-0.46	-0.36	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
KIRC	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-8.5	2.2e-16	1.8e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
KIRC	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	8.5	2.2e-16	1.8e-13	0.45	0.36	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
KIRC	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-8.5	2.2e-16	1.8e-13	-0.4	-0.36	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
KIRC	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-8.5	2.21e-16	1.81e-13	-0.38	-0.36	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-8.5	2.21e-16	1.81e-13	-0.48	-0.36	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
KIRC	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	8.5	2.22e-16	1.82e-13	0.44	0.36	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
KIRC	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	8.5	2.22e-16	1.82e-13	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
KIRC	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	8.5	2.22e-16	1.82e-13	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
KIRC	cis	rs4356975	0.697	rs66666893	ENSG00000196472.4	RP13-644M16.4	8.5	2.22e-16	1.82e-13	0.4	0.36	Obesity-related traits;	chr4:69133393	chr4:69181660~69182372:+
KIRC	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-8.5	2.23e-16	1.82e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
KIRC	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-8.5	2.23e-16	1.82e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-8.5	2.23e-16	1.82e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-8.5	2.23e-16	1.82e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
KIRC	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-8.5	2.23e-16	1.82e-13	-0.3	-0.36	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
KIRC	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-8.5	2.23e-16	1.83e-13	-0.38	-0.36	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
KIRC	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	8.5	2.24e-16	1.83e-13	0.53	0.36	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
KIRC	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	8.5	2.25e-16	1.83e-13	0.58	0.36	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
KIRC	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-8.5	2.25e-16	1.84e-13	-0.49	-0.36	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
KIRC	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	8.5	2.28e-16	1.86e-13	0.47	0.36	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	8.5	2.29e-16	1.87e-13	0.44	0.36	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
KIRC	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-8.5	2.3e-16	1.87e-13	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
KIRC	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	8.5	2.3e-16	1.88e-13	0.53	0.36	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
KIRC	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	8.5	2.3e-16	1.88e-13	0.43	0.36	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
KIRC	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-8.5	2.3e-16	1.88e-13	-0.52	-0.36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
KIRC	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-8.5	2.3e-16	1.88e-13	-0.29	-0.36	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
KIRC	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	8.5	2.3e-16	1.88e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
KIRC	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	8.5	2.3e-16	1.88e-13	0.53	0.36	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
KIRC	cis	rs4356975	0.527	rs57102579	ENSG00000250696.4	RP11-704M14.1	8.5	2.31e-16	1.88e-13	0.38	0.36	Obesity-related traits;	chr4:69125476	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.527	rs4385139	ENSG00000250696.4	RP11-704M14.1	8.5	2.31e-16	1.88e-13	0.38	0.36	Obesity-related traits;	chr4:69125911	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.527	rs4694645	ENSG00000250696.4	RP11-704M14.1	8.5	2.31e-16	1.88e-13	0.38	0.36	Obesity-related traits;	chr4:69127200	chr4:69182100~69216766:+
KIRC	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	8.5	2.31e-16	1.89e-13	0.38	0.36	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
KIRC	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-8.5	2.31e-16	1.89e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
KIRC	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	8.5	2.32e-16	1.89e-13	0.4	0.36	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
KIRC	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	8.5	2.32e-16	1.89e-13	0.48	0.36	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
KIRC	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-8.5	2.32e-16	1.89e-13	-0.42	-0.36	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
KIRC	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-8.5	2.33e-16	1.9e-13	-0.45	-0.36	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
KIRC	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	8.5	2.33e-16	1.9e-13	0.33	0.36	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
KIRC	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	8.5	2.33e-16	1.9e-13	0.49	0.36	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
KIRC	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-8.49	2.34e-16	1.91e-13	-0.36	-0.36	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
KIRC	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-8.49	2.35e-16	1.92e-13	-0.41	-0.36	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
KIRC	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-8.49	2.35e-16	1.92e-13	-0.48	-0.36	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-8.49	2.35e-16	1.92e-13	-0.48	-0.36	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
KIRC	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	8.49	2.35e-16	1.92e-13	0.48	0.36	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	8.49	2.35e-16	1.92e-13	0.48	0.36	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
KIRC	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	8.49	2.36e-16	1.92e-13	0.38	0.36	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
KIRC	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	8.49	2.36e-16	1.92e-13	0.44	0.36	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
KIRC	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	8.49	2.36e-16	1.92e-13	0.32	0.36	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
KIRC	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-8.49	2.36e-16	1.93e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
KIRC	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-8.49	2.37e-16	1.93e-13	-0.3	-0.36	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
KIRC	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-8.49	2.37e-16	1.93e-13	-0.41	-0.36	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
KIRC	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	8.49	2.37e-16	1.94e-13	0.33	0.36	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
KIRC	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	8.49	2.38e-16	1.94e-13	0.62	0.36	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
KIRC	cis	rs904251	0.6	rs9380673	ENSG00000227920.2	RP1-153P14.5	-8.49	2.38e-16	1.94e-13	-0.38	-0.36	Cognitive performance;	chr6:37447349	chr6:37545145~37550860:+
KIRC	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-8.49	2.38e-16	1.94e-13	-0.44	-0.36	Height;	chr4:55514317	chr4:55387949~55388271:+
KIRC	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	8.49	2.38e-16	1.94e-13	0.42	0.36	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
KIRC	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-8.49	2.39e-16	1.94e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
KIRC	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-8.49	2.4e-16	1.95e-13	-0.46	-0.36	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-8.49	2.4e-16	1.95e-13	-0.46	-0.36	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
KIRC	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	8.49	2.4e-16	1.95e-13	0.37	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
KIRC	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	8.49	2.4e-16	1.95e-13	0.45	0.36	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
KIRC	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-8.49	2.4e-16	1.95e-13	-0.42	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
KIRC	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	8.49	2.4e-16	1.95e-13	0.4	0.36	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
KIRC	cis	rs4356975	0.563	rs4327554	ENSG00000250696.4	RP11-704M14.1	-8.49	2.41e-16	1.97e-13	-0.37	-0.36	Obesity-related traits;	chr4:69120690	chr4:69182100~69216766:+
KIRC	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	8.49	2.42e-16	1.97e-13	0.31	0.36	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
KIRC	cis	rs4356975	0.563	rs7662029	ENSG00000250696.4	RP11-704M14.1	8.49	2.42e-16	1.97e-13	0.37	0.36	Obesity-related traits;	chr4:69096194	chr4:69182100~69216766:+
KIRC	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-8.49	2.43e-16	1.98e-13	-0.31	-0.36	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
KIRC	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-8.49	2.44e-16	1.98e-13	-0.4	-0.36	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	8.49	2.44e-16	1.98e-13	0.4	0.36	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
KIRC	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-8.49	2.44e-16	1.99e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
KIRC	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-8.49	2.44e-16	1.99e-13	-0.48	-0.36	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
KIRC	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-8.49	2.45e-16	1.99e-13	-0.41	-0.36	Migraine;	chr4:56852029	chr4:56960927~56961373:-
KIRC	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-8.49	2.47e-16	2.01e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
KIRC	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	8.49	2.47e-16	2.01e-13	0.45	0.36	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
KIRC	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-8.49	2.47e-16	2.01e-13	-0.46	-0.36	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
KIRC	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	8.49	2.47e-16	2.01e-13	0.44	0.36	Height;	chr4:55516548	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	8.49	2.47e-16	2.01e-13	0.44	0.36	Height;	chr4:55516744	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	8.49	2.48e-16	2.01e-13	0.45	0.36	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
KIRC	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	8.49	2.48e-16	2.02e-13	0.38	0.36	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
KIRC	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	8.49	2.49e-16	2.02e-13	0.38	0.36	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
KIRC	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-8.49	2.49e-16	2.03e-13	-0.33	-0.36	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
KIRC	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	8.49	2.5e-16	2.03e-13	0.46	0.36	Height;	chr6:109676091	chr6:109382795~109383666:+
KIRC	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-8.49	2.5e-16	2.03e-13	-0.54	-0.36	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
KIRC	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	8.49	2.5e-16	2.04e-13	0.32	0.36	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
KIRC	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-8.49	2.5e-16	2.04e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
KIRC	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	8.49	2.51e-16	2.04e-13	0.41	0.36	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	8.49	2.51e-16	2.04e-13	0.41	0.36	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
KIRC	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	8.49	2.51e-16	2.04e-13	0.48	0.36	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
KIRC	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-8.48	2.52e-16	2.05e-13	-0.39	-0.36	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
KIRC	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	8.48	2.53e-16	2.06e-13	0.42	0.36	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
KIRC	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-8.48	2.53e-16	2.06e-13	-0.44	-0.36	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	8.48	2.54e-16	2.06e-13	0.44	0.36	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
KIRC	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	8.48	2.54e-16	2.06e-13	0.61	0.36	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
KIRC	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	8.48	2.55e-16	2.07e-13	0.4	0.36	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
KIRC	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-8.48	2.56e-16	2.08e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
KIRC	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	8.48	2.57e-16	2.08e-13	0.47	0.36	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
KIRC	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	8.48	2.57e-16	2.09e-13	0.65	0.36	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
KIRC	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	8.48	2.57e-16	2.09e-13	0.39	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
KIRC	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	8.48	2.57e-16	2.09e-13	0.63	0.36	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	8.48	2.57e-16	2.09e-13	0.63	0.36	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	8.48	2.57e-16	2.09e-13	0.63	0.36	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
KIRC	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-8.48	2.58e-16	2.09e-13	-0.42	-0.36	Height;	chr4:55364952	chr4:55387949~55388271:+
KIRC	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	8.48	2.59e-16	2.1e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.563	rs12642938	ENSG00000248763.2	RP13-644M16.5	-8.48	2.59e-16	2.1e-13	-0.46	-0.36	Obesity-related traits;	chr4:69110499	chr4:69066395~69069888:+
KIRC	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	8.48	2.59e-16	2.1e-13	0.39	0.36	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
KIRC	cis	rs904251	0.828	rs2797803	ENSG00000227920.2	RP1-153P14.5	-8.48	2.6e-16	2.11e-13	-0.42	-0.36	Cognitive performance;	chr6:37519564	chr6:37545145~37550860:+
KIRC	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-8.48	2.61e-16	2.12e-13	-0.42	-0.36	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
KIRC	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	8.48	2.62e-16	2.13e-13	0.31	0.36	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
KIRC	cis	rs950027	0.62	rs1145084	ENSG00000235390.4	CTD-2651B20.5	-8.48	2.62e-16	2.13e-13	-0.34	-0.36	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45321077~45321692:-
KIRC	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	8.48	2.62e-16	2.13e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	8.48	2.62e-16	2.13e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	8.48	2.62e-16	2.13e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	8.48	2.62e-16	2.13e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
KIRC	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-8.48	2.62e-16	2.13e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
KIRC	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-8.48	2.62e-16	2.13e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
KIRC	cis	rs7945705	0.875	rs10769955	ENSG00000254860.4	TMEM9B-AS1	-8.48	2.63e-16	2.13e-13	-0.38	-0.36	Hemoglobin concentration;	chr11:8763100	chr11:8964675~8977527:+
KIRC	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-8.48	2.63e-16	2.13e-13	-0.46	-0.36	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
KIRC	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	8.48	2.64e-16	2.14e-13	0.4	0.36	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
KIRC	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-8.48	2.64e-16	2.14e-13	-0.37	-0.36	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
KIRC	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	8.48	2.65e-16	2.15e-13	0.49	0.36	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
KIRC	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-8.48	2.65e-16	2.15e-13	-0.4	-0.36	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
KIRC	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	8.48	2.66e-16	2.15e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	8.48	2.66e-16	2.15e-13	0.45	0.36	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	8.48	2.66e-16	2.15e-13	0.45	0.36	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
KIRC	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	8.48	2.67e-16	2.16e-13	0.47	0.36	Height;	chr6:109747119	chr6:109382795~109383666:+
KIRC	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	8.48	2.67e-16	2.16e-13	0.47	0.36	Height;	chr6:109747411	chr6:109382795~109383666:+
KIRC	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	8.48	2.67e-16	2.16e-13	0.47	0.36	Height;	chr6:109748819	chr6:109382795~109383666:+
KIRC	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	8.48	2.67e-16	2.16e-13	0.47	0.36	Height;	chr6:109749564	chr6:109382795~109383666:+
KIRC	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	8.48	2.67e-16	2.16e-13	0.47	0.36	Height;	chr6:109763331	chr6:109382795~109383666:+
KIRC	cis	rs1823913	1	rs10445783	ENSG00000227542.1	AC092614.2	-8.48	2.67e-16	2.16e-13	-0.33	-0.36	Obesity-related traits;	chr2:191236772	chr2:191229165~191246172:-
KIRC	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-8.48	2.67e-16	2.16e-13	-0.43	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
KIRC	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	8.48	2.68e-16	2.17e-13	0.49	0.36	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	8.48	2.68e-16	2.17e-13	0.49	0.36	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
KIRC	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	8.48	2.68e-16	2.17e-13	0.61	0.36	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
KIRC	cis	rs919433	0.927	rs1429418	ENSG00000231621.1	AC013264.2	8.48	2.68e-16	2.17e-13	0.39	0.36	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293427	chr2:197197991~197199273:+
KIRC	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	8.48	2.68e-16	2.17e-13	0.37	0.36	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	8.48	2.68e-16	2.17e-13	0.37	0.36	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-8.48	2.68e-16	2.17e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
KIRC	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	8.48	2.69e-16	2.18e-13	0.4	0.36	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
KIRC	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	8.48	2.69e-16	2.18e-13	0.4	0.36	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
KIRC	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	8.48	2.7e-16	2.18e-13	0.65	0.36	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
KIRC	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	8.48	2.71e-16	2.19e-13	0.44	0.36	Height;	chr4:55486718	chr4:55387949~55388271:+
KIRC	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-8.47	2.71e-16	2.2e-13	-0.42	-0.36	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
KIRC	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-8.47	2.72e-16	2.2e-13	-0.42	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
KIRC	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	8.47	2.73e-16	2.21e-13	0.44	0.36	Height;	chr4:55517185	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	8.47	2.73e-16	2.21e-13	0.44	0.36	Height;	chr4:55522229	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	8.47	2.74e-16	2.22e-13	0.43	0.36	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	8.47	2.74e-16	2.22e-13	0.43	0.36	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	8.47	2.74e-16	2.22e-13	0.43	0.36	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
KIRC	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	8.47	2.75e-16	2.22e-13	0.59	0.36	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
KIRC	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	8.47	2.75e-16	2.23e-13	0.44	0.36	Height;	chr4:55514802	chr4:55387949~55388271:+
KIRC	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-8.47	2.76e-16	2.23e-13	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	8.47	2.76e-16	2.23e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
KIRC	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-8.47	2.76e-16	2.23e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
KIRC	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	8.47	2.76e-16	2.24e-13	0.46	0.36	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
KIRC	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	8.47	2.78e-16	2.25e-13	0.65	0.36	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
KIRC	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	8.47	2.78e-16	2.25e-13	0.49	0.36	Height;	chr6:109482392	chr6:109382795~109383666:+
KIRC	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-8.47	2.78e-16	2.25e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
KIRC	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8.47	2.78e-16	2.25e-13	-0.41	-0.36	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8.47	2.78e-16	2.25e-13	-0.41	-0.36	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8.47	2.78e-16	2.25e-13	-0.41	-0.36	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
KIRC	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-8.47	2.79e-16	2.26e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
KIRC	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-8.47	2.8e-16	2.26e-13	-0.25	-0.36	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
KIRC	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-8.47	2.8e-16	2.26e-13	-0.45	-0.36	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-8.47	2.8e-16	2.26e-13	-0.45	-0.36	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-8.47	2.8e-16	2.26e-13	-0.45	-0.36	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
KIRC	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-8.47	2.8e-16	2.27e-13	-0.32	-0.36	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
KIRC	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	8.47	2.81e-16	2.27e-13	0.46	0.36	Height;	chr6:109672088	chr6:109382795~109383666:+
KIRC	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-8.47	2.82e-16	2.28e-13	-0.39	-0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
KIRC	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	8.47	2.82e-16	2.28e-13	0.53	0.36	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
KIRC	cis	rs904251	0.6	rs11756241	ENSG00000227920.2	RP1-153P14.5	-8.47	2.84e-16	2.29e-13	-0.39	-0.36	Cognitive performance;	chr6:37477325	chr6:37545145~37550860:+
KIRC	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-8.47	2.84e-16	2.29e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-8.47	2.84e-16	2.29e-13	-0.37	-0.36	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
KIRC	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-8.47	2.84e-16	2.29e-13	-0.37	-0.36	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
KIRC	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	8.47	2.84e-16	2.3e-13	0.46	0.36	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
KIRC	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	8.47	2.84e-16	2.3e-13	0.36	0.36	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
KIRC	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-8.47	2.85e-16	2.3e-13	-0.46	-0.36	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
KIRC	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	8.47	2.85e-16	2.3e-13	0.63	0.36	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	8.47	2.86e-16	2.31e-13	0.65	0.36	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
KIRC	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	8.47	2.86e-16	2.31e-13	0.36	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
KIRC	cis	rs7916697	0.52	rs12246624	ENSG00000233590.1	RP11-153K11.3	-8.47	2.87e-16	2.32e-13	-0.4	-0.36	Optic disc area;	chr10:68276805	chr10:68233251~68242379:-
KIRC	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-8.47	2.88e-16	2.33e-13	-0.48	-0.36	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
KIRC	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-8.47	2.88e-16	2.33e-13	-0.32	-0.36	Height;	chr11:118749988	chr11:118791254~118793137:+
KIRC	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	8.47	2.89e-16	2.33e-13	0.4	0.36	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
KIRC	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-8.47	2.91e-16	2.35e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-8.47	2.91e-16	2.35e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
KIRC	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-8.47	2.91e-16	2.35e-13	-0.47	-0.36	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
KIRC	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	8.47	2.91e-16	2.35e-13	0.48	0.36	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	8.47	2.92e-16	2.35e-13	0.5	0.36	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
KIRC	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	8.47	2.92e-16	2.35e-13	0.46	0.36	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	8.46	2.93e-16	2.37e-13	0.35	0.36	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
KIRC	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-8.46	2.94e-16	2.37e-13	-0.38	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
KIRC	cis	rs4356975	0.83	rs4422474	ENSG00000250919.1	RP11-813N20.3	-8.46	2.94e-16	2.37e-13	-0.38	-0.36	Obesity-related traits;	chr4:69051322	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs4377650	ENSG00000250919.1	RP11-813N20.3	-8.46	2.94e-16	2.37e-13	-0.38	-0.36	Obesity-related traits;	chr4:69051355	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs72851338	ENSG00000250919.1	RP11-813N20.3	-8.46	2.94e-16	2.37e-13	-0.38	-0.36	Obesity-related traits;	chr4:69052555	chr4:69027831~69044578:+
KIRC	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-8.46	2.94e-16	2.37e-13	-0.45	-0.36	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
KIRC	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	8.46	2.94e-16	2.37e-13	0.4	0.36	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
KIRC	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	8.46	2.95e-16	2.38e-13	0.44	0.36	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	8.46	2.95e-16	2.38e-13	0.44	0.36	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	8.46	2.96e-16	2.38e-13	0.35	0.36	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
KIRC	cis	rs7017914	0.967	rs2100908	ENSG00000254031.4	RP11-326E22.1	8.46	2.96e-16	2.39e-13	0.39	0.36	Bone mineral density;	chr8:70671075	chr8:71155457~71204223:+
KIRC	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	8.46	2.96e-16	2.39e-13	0.62	0.36	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
KIRC	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	8.46	2.97e-16	2.4e-13	0.41	0.36	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
KIRC	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	8.46	2.98e-16	2.4e-13	0.44	0.36	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
KIRC	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-8.46	2.98e-16	2.4e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
KIRC	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-8.46	2.98e-16	2.4e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
KIRC	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-8.46	2.98e-16	2.4e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
KIRC	cis	rs12893668	0.572	rs11846404	ENSG00000269910.1	RP11-73M18.10	8.46	2.98e-16	2.4e-13	0.25	0.36	Reticulocyte count;	chr14:103689771	chr14:103694516~103695050:-
KIRC	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	8.46	2.99e-16	2.41e-13	0.53	0.36	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
KIRC	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	8.46	3e-16	2.42e-13	0.53	0.36	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
KIRC	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-8.46	3.01e-16	2.43e-13	-0.4	-0.36	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
KIRC	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	8.46	3.01e-16	2.43e-13	0.48	0.36	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
KIRC	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	8.46	3.02e-16	2.43e-13	0.34	0.36	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
KIRC	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	8.46	3.02e-16	2.43e-13	0.36	0.36	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
KIRC	cis	rs79040073	0.563	rs17478618	ENSG00000259531.2	RP11-295H24.3	-8.46	3.02e-16	2.43e-13	-0.46	-0.36	Lung cancer in ever smokers;	chr15:49444621	chr15:49365124~49366685:-
KIRC	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	8.46	3.04e-16	2.45e-13	0.35	0.36	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	8.46	3.04e-16	2.45e-13	0.35	0.36	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-8.46	3.04e-16	2.45e-13	-0.43	-0.36	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
KIRC	cis	rs899997	1	rs11072793	ENSG00000261143.1	ADAMTS7P3	8.46	3.05e-16	2.45e-13	0.42	0.36	Coronary artery disease or large artery stroke;	chr15:78714100	chr15:77976042~77993057:+
KIRC	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-8.46	3.05e-16	2.46e-13	-0.54	-0.36	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
KIRC	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-8.46	3.07e-16	2.47e-13	-0.42	-0.36	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
KIRC	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	8.46	3.07e-16	2.48e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	8.46	3.07e-16	2.48e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
KIRC	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	8.46	3.08e-16	2.48e-13	0.57	0.36	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
KIRC	cis	rs904251	0.6	rs2270687	ENSG00000227920.2	RP1-153P14.5	-8.46	3.08e-16	2.48e-13	-0.38	-0.36	Cognitive performance;	chr6:37450487	chr6:37545145~37550860:+
KIRC	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-8.46	3.09e-16	2.49e-13	-0.39	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
KIRC	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	8.46	3.1e-16	2.5e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	8.46	3.1e-16	2.5e-13	0.38	0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
KIRC	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	8.46	3.11e-16	2.5e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000196472.4	RP13-644M16.4	8.46	3.12e-16	2.51e-13	0.48	0.36	Obesity-related traits;	chr4:69104054	chr4:69181660~69182372:+
KIRC	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-8.46	3.12e-16	2.51e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-8.46	3.12e-16	2.51e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
KIRC	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	8.46	3.13e-16	2.52e-13	0.45	0.36	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
KIRC	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-8.46	3.15e-16	2.53e-13	-0.38	-0.36	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-8.45	3.17e-16	2.55e-13	-0.47	-0.36	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.83	rs57386454	ENSG00000250919.1	RP11-813N20.3	-8.45	3.17e-16	2.55e-13	-0.38	-0.36	Obesity-related traits;	chr4:69052968	chr4:69027831~69044578:+
KIRC	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	8.45	3.19e-16	2.56e-13	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
KIRC	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	8.45	3.19e-16	2.57e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	8.45	3.19e-16	2.57e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	8.45	3.19e-16	2.57e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	8.45	3.19e-16	2.57e-13	0.63	0.36	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
KIRC	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-8.45	3.2e-16	2.57e-13	-0.43	-0.36	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
KIRC	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	8.45	3.2e-16	2.57e-13	0.44	0.36	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
KIRC	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-8.45	3.21e-16	2.58e-13	-0.4	-0.36	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
KIRC	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	8.45	3.21e-16	2.58e-13	0.38	0.36	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
KIRC	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-8.45	3.22e-16	2.58e-13	-0.36	-0.36	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
KIRC	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	8.45	3.22e-16	2.59e-13	0.4	0.36	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
KIRC	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-8.45	3.23e-16	2.59e-13	-0.29	-0.36	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
KIRC	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-8.45	3.23e-16	2.6e-13	-0.39	-0.36	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
KIRC	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	8.45	3.24e-16	2.6e-13	0.48	0.36	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
KIRC	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	8.45	3.24e-16	2.61e-13	0.44	0.36	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
KIRC	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	8.45	3.25e-16	2.61e-13	0.41	0.36	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
KIRC	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	8.45	3.25e-16	2.61e-13	0.69	0.36	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
KIRC	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-8.45	3.25e-16	2.61e-13	-0.46	-0.36	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
KIRC	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	8.45	3.26e-16	2.62e-13	0.36	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
KIRC	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	8.45	3.26e-16	2.62e-13	0.39	0.36	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
KIRC	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-8.45	3.26e-16	2.62e-13	-0.54	-0.36	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
KIRC	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	8.45	3.26e-16	2.62e-13	0.42	0.36	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
KIRC	cis	rs3820928	0.874	rs4675130	ENSG00000212391.1	SNORA48	-8.45	3.28e-16	2.64e-13	-0.42	-0.36	Pulmonary function;	chr2:226963024	chr2:226968989~226969122:-
KIRC	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-8.45	3.29e-16	2.64e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
KIRC	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-8.45	3.29e-16	2.64e-13	-0.38	-0.36	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-8.45	3.29e-16	2.64e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-8.45	3.29e-16	2.64e-13	-0.38	-0.36	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
KIRC	cis	rs6600671	0.934	rs11249429	ENSG00000227082.1	CH17-437K3.1	8.45	3.3e-16	2.65e-13	0.4	0.36	Hip geometry;	chr1:121549282	chr1:121396754~121463129:+
KIRC	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	8.45	3.34e-16	2.68e-13	0.36	0.35	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
KIRC	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-8.45	3.34e-16	2.68e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
KIRC	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	8.45	3.34e-16	2.68e-13	0.39	0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
KIRC	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-8.45	3.35e-16	2.68e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-8.45	3.35e-16	2.68e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-8.45	3.35e-16	2.68e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-8.45	3.35e-16	2.68e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-8.45	3.35e-16	2.68e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	8.45	3.35e-16	2.69e-13	0.34	0.35	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-8.45	3.35e-16	2.69e-13	-0.4	-0.35	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	8.45	3.35e-16	2.69e-13	0.48	0.35	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
KIRC	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-8.45	3.36e-16	2.69e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
KIRC	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-8.45	3.37e-16	2.7e-13	-0.86	-0.35	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
KIRC	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-8.45	3.37e-16	2.7e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	8.45	3.37e-16	2.7e-13	0.54	0.35	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	8.45	3.38e-16	2.71e-13	0.46	0.35	Height;	chr6:109358652	chr6:109382795~109383666:+
KIRC	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	8.45	3.39e-16	2.71e-13	0.46	0.35	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8.45	3.39e-16	2.71e-13	0.46	0.35	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
KIRC	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-8.45	3.39e-16	2.71e-13	-0.35	-0.35	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
KIRC	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	8.45	3.39e-16	2.71e-13	0.65	0.35	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
KIRC	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-8.45	3.39e-16	2.72e-13	-0.37	-0.35	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
KIRC	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	8.44	3.4e-16	2.72e-13	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
KIRC	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	8.44	3.4e-16	2.73e-13	0.37	0.35	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs4819041	ENSG00000223768.1	LINC00205	-8.44	3.41e-16	2.73e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-8.44	3.41e-16	2.73e-13	-0.48	-0.35	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
KIRC	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	8.44	3.42e-16	2.74e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	8.44	3.42e-16	2.74e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
KIRC	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-8.44	3.43e-16	2.75e-13	-0.54	-0.35	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-8.44	3.43e-16	2.75e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-8.44	3.43e-16	2.75e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-8.44	3.43e-16	2.75e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-8.44	3.43e-16	2.75e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
KIRC	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	8.44	3.43e-16	2.75e-13	0.69	0.35	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
KIRC	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	8.44	3.45e-16	2.76e-13	0.45	0.35	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
KIRC	cis	rs7017914	0.934	rs17689585	ENSG00000254031.4	RP11-326E22.1	8.44	3.47e-16	2.77e-13	0.39	0.35	Bone mineral density;	chr8:70906566	chr8:71155457~71204223:+
KIRC	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	8.44	3.47e-16	2.78e-13	0.55	0.35	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
KIRC	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-8.44	3.47e-16	2.78e-13	-0.49	-0.35	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
KIRC	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-8.44	3.47e-16	2.78e-13	-0.41	-0.35	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
KIRC	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	8.44	3.51e-16	2.81e-13	0.36	0.35	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
KIRC	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	8.44	3.51e-16	2.81e-13	0.53	0.35	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
KIRC	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	8.44	3.52e-16	2.81e-13	0.4	0.35	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
KIRC	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-8.44	3.53e-16	2.82e-13	-0.37	-0.35	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
KIRC	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	8.44	3.56e-16	2.85e-13	0.46	0.35	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
KIRC	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-8.44	3.56e-16	2.85e-13	-0.38	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
KIRC	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-8.44	3.58e-16	2.86e-13	-0.43	-0.35	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-8.44	3.58e-16	2.86e-13	-0.43	-0.35	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
KIRC	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	8.44	3.58e-16	2.86e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	8.44	3.58e-16	2.86e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
KIRC	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-8.44	3.58e-16	2.86e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
KIRC	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-8.44	3.58e-16	2.86e-13	-0.32	-0.35	Height;	chr11:118742526	chr11:118791254~118793137:+
KIRC	cis	rs950027	0.62	rs1049518	ENSG00000235390.4	CTD-2651B20.5	-8.44	3.59e-16	2.87e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.584	rs1145086	ENSG00000235390.4	CTD-2651B20.5	-8.44	3.59e-16	2.87e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.62	rs1153857	ENSG00000235390.4	CTD-2651B20.5	-8.44	3.59e-16	2.87e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.62	rs1153855	ENSG00000235390.4	CTD-2651B20.5	-8.44	3.59e-16	2.87e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.62	rs2486274	ENSG00000235390.4	CTD-2651B20.5	-8.44	3.59e-16	2.87e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45321077~45321692:-
KIRC	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	8.44	3.6e-16	2.87e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	8.44	3.6e-16	2.87e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
KIRC	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-8.44	3.6e-16	2.88e-13	-0.4	-0.35	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
KIRC	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	8.44	3.61e-16	2.88e-13	0.3	0.35	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	8.44	3.61e-16	2.88e-13	0.3	0.35	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
KIRC	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	8.44	3.61e-16	2.88e-13	0.38	0.35	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
KIRC	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-8.44	3.61e-16	2.89e-13	-0.48	-0.35	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
KIRC	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	8.44	3.61e-16	2.89e-13	0.38	0.35	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
KIRC	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	8.44	3.62e-16	2.89e-13	0.38	0.35	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
KIRC	cis	rs4356975	0.527	rs62296943	ENSG00000250696.4	RP11-704M14.1	8.44	3.63e-16	2.9e-13	0.37	0.35	Obesity-related traits;	chr4:69093465	chr4:69182100~69216766:+
KIRC	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	8.44	3.64e-16	2.9e-13	0.43	0.35	Height;	chr4:55570843	chr4:55387949~55388271:+
KIRC	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-8.44	3.64e-16	2.91e-13	-0.48	-0.35	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
KIRC	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-8.44	3.65e-16	2.92e-13	-0.46	-0.35	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	8.43	3.67e-16	2.93e-13	0.46	0.35	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
KIRC	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-8.43	3.68e-16	2.94e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-8.43	3.68e-16	2.94e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-8.43	3.68e-16	2.94e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
KIRC	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	8.43	3.68e-16	2.94e-13	0.76	0.35	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
KIRC	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	8.43	3.69e-16	2.95e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
KIRC	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	8.43	3.7e-16	2.95e-13	0.44	0.35	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	8.43	3.7e-16	2.95e-13	0.44	0.35	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
KIRC	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	8.43	3.7e-16	2.96e-13	0.45	0.35	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
KIRC	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-8.43	3.7e-16	2.96e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
KIRC	cis	rs7017914	0.967	rs7814648	ENSG00000254031.4	RP11-326E22.1	8.43	3.7e-16	2.96e-13	0.39	0.35	Bone mineral density;	chr8:70691749	chr8:71155457~71204223:+
KIRC	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	8.43	3.71e-16	2.96e-13	0.4	0.35	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-8.43	3.71e-16	2.96e-13	-0.4	-0.35	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
KIRC	cis	rs950027	0.62	rs1145080	ENSG00000235390.4	CTD-2651B20.5	-8.43	3.72e-16	2.97e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45321077~45321692:-
KIRC	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	8.43	3.73e-16	2.97e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
KIRC	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-8.43	3.73e-16	2.98e-13	-0.45	-0.35	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
KIRC	cis	rs4356975	0.563	rs6600893	ENSG00000250696.4	RP11-704M14.1	8.43	3.74e-16	2.98e-13	0.37	0.35	Obesity-related traits;	chr4:69113183	chr4:69182100~69216766:+
KIRC	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	8.43	3.75e-16	2.99e-13	0.48	0.35	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	8.43	3.75e-16	2.99e-13	0.48	0.35	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	8.43	3.75e-16	2.99e-13	0.48	0.35	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
KIRC	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-8.43	3.75e-16	2.99e-13	-0.45	-0.35	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
KIRC	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	8.43	3.75e-16	2.99e-13	0.35	0.35	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
KIRC	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-8.43	3.76e-16	3e-13	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-8.43	3.76e-16	3e-13	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
KIRC	cis	rs919433	1	rs1560277	ENSG00000231621.1	AC013264.2	-8.43	3.76e-16	3e-13	-0.38	-0.35	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197197991~197199273:+
KIRC	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	8.43	3.76e-16	3e-13	0.37	0.35	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	8.43	3.76e-16	3e-13	0.37	0.35	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
KIRC	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-8.43	3.77e-16	3e-13	-0.25	-0.35	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
KIRC	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	8.43	3.77e-16	3e-13	0.4	0.35	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
KIRC	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	8.43	3.78e-16	3.01e-13	0.46	0.35	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
KIRC	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	8.43	3.78e-16	3.01e-13	0.46	0.35	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
KIRC	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-8.43	3.79e-16	3.02e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
KIRC	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-8.43	3.8e-16	3.03e-13	-0.45	-0.35	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
KIRC	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	8.43	3.81e-16	3.03e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	8.43	3.81e-16	3.03e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	8.43	3.81e-16	3.03e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	8.43	3.81e-16	3.03e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
KIRC	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-8.43	3.81e-16	3.04e-13	-0.32	-0.35	Height;	chr11:118791319	chr11:118791254~118793137:+
KIRC	cis	rs6600671	1	rs4844380	ENSG00000227082.1	CH17-437K3.1	-8.43	3.83e-16	3.05e-13	-0.4	-0.35	Hip geometry;	chr1:121451764	chr1:121396754~121463129:+
KIRC	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-8.43	3.83e-16	3.05e-13	-0.44	-0.35	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
KIRC	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	8.43	3.83e-16	3.05e-13	0.44	0.35	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
KIRC	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-8.43	3.83e-16	3.05e-13	-0.42	-0.35	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
KIRC	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	8.43	3.85e-16	3.07e-13	0.47	0.35	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
KIRC	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	8.43	3.85e-16	3.07e-13	0.53	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
KIRC	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-8.43	3.85e-16	3.07e-13	-0.4	-0.35	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	8.43	3.86e-16	3.07e-13	0.45	0.35	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
KIRC	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	8.43	3.87e-16	3.08e-13	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
KIRC	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	8.43	3.87e-16	3.08e-13	0.41	0.35	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
KIRC	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	8.43	3.89e-16	3.1e-13	0.39	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
KIRC	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-8.43	3.89e-16	3.1e-13	-0.36	-0.35	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
KIRC	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-8.43	3.89e-16	3.1e-13	-0.36	-0.35	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000196472.4	RP13-644M16.4	8.43	3.9e-16	3.1e-13	0.48	0.35	Obesity-related traits;	chr4:69107521	chr4:69181660~69182372:+
KIRC	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	8.43	3.9e-16	3.11e-13	0.47	0.35	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	8.43	3.9e-16	3.11e-13	0.44	0.35	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
KIRC	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	8.43	3.91e-16	3.11e-13	0.69	0.35	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
KIRC	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	8.43	3.91e-16	3.12e-13	0.48	0.35	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
KIRC	cis	rs9847710	0.818	rs6445558	ENSG00000280417.1	RP11-5O17.1	8.43	3.92e-16	3.12e-13	0.4	0.35	Ulcerative colitis;	chr3:53063644	chr3:53046166~53048122:+
KIRC	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-8.43	3.94e-16	3.14e-13	-0.41	-0.35	Migraine;	chr4:56850720	chr4:56960927~56961373:-
KIRC	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-8.42	3.94e-16	3.14e-13	-0.38	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
KIRC	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	8.42	3.97e-16	3.16e-13	0.45	0.35	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
KIRC	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	8.42	3.99e-16	3.17e-13	0.65	0.35	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
KIRC	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-8.42	3.99e-16	3.17e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
KIRC	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	8.42	3.99e-16	3.17e-13	0.62	0.35	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	8.42	3.99e-16	3.17e-13	0.62	0.35	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
KIRC	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	8.42	4.02e-16	3.2e-13	0.3	0.35	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	8.42	4.02e-16	3.2e-13	0.3	0.35	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
KIRC	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-8.42	4.02e-16	3.2e-13	-0.46	-0.35	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
KIRC	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-8.42	4.02e-16	3.2e-13	-0.47	-0.35	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
KIRC	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-8.42	4.03e-16	3.2e-13	-0.42	-0.35	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
KIRC	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	8.42	4.04e-16	3.21e-13	0.28	0.35	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
KIRC	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	8.42	4.04e-16	3.21e-13	0.44	0.35	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
KIRC	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-8.42	4.05e-16	3.22e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
KIRC	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	8.42	4.06e-16	3.23e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	8.42	4.06e-16	3.23e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	8.42	4.06e-16	3.23e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	8.42	4.06e-16	3.23e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	8.42	4.06e-16	3.23e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
KIRC	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	8.42	4.09e-16	3.25e-13	0.49	0.35	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
KIRC	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-8.42	4.09e-16	3.25e-13	-0.39	-0.35	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
KIRC	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	8.42	4.09e-16	3.25e-13	0.43	0.35	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
KIRC	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-8.42	4.1e-16	3.26e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
KIRC	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	8.42	4.12e-16	3.27e-13	0.33	0.35	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
KIRC	cis	rs4380275	1	rs7562792	ENSG00000223751.1	AC116609.2	8.42	4.12e-16	3.27e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:742488~747767:+
KIRC	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-8.42	4.13e-16	3.28e-13	-0.45	-0.35	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
KIRC	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	8.42	4.13e-16	3.28e-13	0.34	0.35	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	8.42	4.13e-16	3.28e-13	0.34	0.35	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
KIRC	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-8.42	4.14e-16	3.28e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
KIRC	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-8.42	4.14e-16	3.29e-13	-0.43	-0.35	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
KIRC	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-8.42	4.15e-16	3.3e-13	-0.39	-0.35	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	8.42	4.15e-16	3.3e-13	0.44	0.35	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
KIRC	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	8.42	4.16e-16	3.3e-13	0.33	0.35	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
KIRC	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	8.42	4.16e-16	3.3e-13	0.65	0.35	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
KIRC	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	8.42	4.16e-16	3.31e-13	0.44	0.35	Height;	chr4:55509442	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	8.42	4.16e-16	3.31e-13	0.44	0.35	Height;	chr4:55510177	chr4:55387949~55388271:+
KIRC	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	8.42	4.16e-16	3.31e-13	0.66	0.35	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
KIRC	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	8.42	4.18e-16	3.32e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
KIRC	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-8.42	4.19e-16	3.33e-13	-0.4	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
KIRC	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	8.42	4.19e-16	3.33e-13	0.45	0.35	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
KIRC	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	8.42	4.2e-16	3.33e-13	0.44	0.35	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
KIRC	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-8.42	4.2e-16	3.33e-13	-0.39	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
KIRC	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-8.42	4.21e-16	3.34e-13	-0.43	-0.35	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
KIRC	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	8.42	4.22e-16	3.35e-13	0.45	0.35	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
KIRC	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	8.42	4.22e-16	3.35e-13	0.37	0.35	Height;	chr3:53085313	chr3:53064283~53065091:-
KIRC	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-8.42	4.24e-16	3.36e-13	-0.4	-0.35	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
KIRC	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	8.42	4.24e-16	3.36e-13	0.37	0.35	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
KIRC	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-8.41	4.25e-16	3.37e-13	-0.48	-0.35	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
KIRC	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	8.41	4.26e-16	3.38e-13	0.43	0.35	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
KIRC	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	8.41	4.26e-16	3.38e-13	0.3	0.35	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
KIRC	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	8.41	4.27e-16	3.38e-13	0.47	0.35	Height;	chr6:109739615	chr6:109382795~109383666:+
KIRC	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-8.41	4.28e-16	3.39e-13	-0.39	-0.35	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
KIRC	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-8.41	4.29e-16	3.4e-13	-0.43	-0.35	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
KIRC	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-8.41	4.29e-16	3.4e-13	-0.51	-0.35	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
KIRC	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	8.41	4.32e-16	3.42e-13	0.47	0.35	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
KIRC	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	8.41	4.32e-16	3.43e-13	0.28	0.35	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	8.41	4.33e-16	3.43e-13	0.51	0.35	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
KIRC	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-8.41	4.33e-16	3.43e-13	-0.43	-0.35	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
KIRC	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-8.41	4.34e-16	3.44e-13	-0.4	-0.35	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
KIRC	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	8.41	4.35e-16	3.45e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	8.41	4.35e-16	3.45e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
KIRC	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	8.41	4.35e-16	3.45e-13	0.44	0.35	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
KIRC	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-8.41	4.37e-16	3.46e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-8.41	4.37e-16	3.46e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
KIRC	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	8.41	4.38e-16	3.47e-13	0.46	0.35	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
KIRC	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-8.41	4.38e-16	3.47e-13	-0.39	-0.35	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
KIRC	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	8.41	4.39e-16	3.47e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	8.41	4.39e-16	3.47e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
KIRC	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-8.41	4.39e-16	3.48e-13	-0.43	-0.35	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
KIRC	cis	rs950027	0.62	rs1426932	ENSG00000235390.4	CTD-2651B20.5	-8.41	4.39e-16	3.48e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45321077~45321692:-
KIRC	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-8.41	4.39e-16	3.48e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.563	rs6851533	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69113032	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7666195	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69113765	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7685151	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69114055	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.583	rs11936822	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69114229	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs34814736	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69114760	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs11933459	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69116045	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600895	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69117694	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4508963	ENSG00000250696.4	RP11-704M14.1	8.41	4.4e-16	3.49e-13	0.37	0.35	Obesity-related traits;	chr4:69118770	chr4:69182100~69216766:+
KIRC	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	8.41	4.41e-16	3.49e-13	0.45	0.35	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	8.41	4.42e-16	3.5e-13	0.44	0.35	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
KIRC	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	8.41	4.42e-16	3.5e-13	0.48	0.35	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	8.41	4.42e-16	3.5e-13	0.48	0.35	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-8.41	4.42e-16	3.5e-13	-0.48	-0.35	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
KIRC	cis	rs4819052	0.851	rs1999334	ENSG00000223768.1	LINC00205	-8.41	4.43e-16	3.5e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45293285~45297354:+
KIRC	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-8.41	4.43e-16	3.51e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
KIRC	cis	rs3820928	0.874	rs55959848	ENSG00000212391.1	SNORA48	-8.41	4.44e-16	3.51e-13	-0.42	-0.35	Pulmonary function;	chr2:226940710	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs10933163	ENSG00000212391.1	SNORA48	-8.41	4.44e-16	3.51e-13	-0.42	-0.35	Pulmonary function;	chr2:226950570	chr2:226968989~226969122:-
KIRC	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	8.41	4.44e-16	3.52e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
KIRC	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	8.41	4.45e-16	3.52e-13	0.61	0.35	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
KIRC	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	8.41	4.45e-16	3.52e-13	0.48	0.35	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
KIRC	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-8.41	4.46e-16	3.53e-13	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
KIRC	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-8.41	4.47e-16	3.53e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
KIRC	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	8.41	4.47e-16	3.54e-13	0.36	0.35	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
KIRC	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-8.41	4.48e-16	3.54e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-8.41	4.49e-16	3.55e-13	-0.47	-0.35	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-8.41	4.49e-16	3.55e-13	-0.4	-0.35	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
KIRC	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-8.41	4.49e-16	3.55e-13	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
KIRC	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-8.41	4.49e-16	3.56e-13	-0.45	-0.35	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
KIRC	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.41	4.5e-16	3.56e-13	0.45	0.35	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.41	4.5e-16	3.56e-13	0.45	0.35	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
KIRC	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-8.41	4.5e-16	3.56e-13	-0.24	-0.35	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
KIRC	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	8.41	4.51e-16	3.56e-13	0.38	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
KIRC	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-8.41	4.52e-16	3.57e-13	-0.4	-0.35	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	8.41	4.53e-16	3.58e-13	0.36	0.35	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
KIRC	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	8.41	4.54e-16	3.59e-13	0.7	0.35	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
KIRC	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	8.41	4.54e-16	3.59e-13	0.7	0.35	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
KIRC	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	8.41	4.55e-16	3.6e-13	0.43	0.35	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
KIRC	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	8.41	4.56e-16	3.6e-13	0.32	0.35	Height;	chr4:55582068	chr4:55363971~55395847:-
KIRC	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	8.41	4.57e-16	3.61e-13	0.32	0.35	Height;	chr4:55589624	chr4:55363971~55395847:-
KIRC	cis	rs1150668	1	rs1150668	ENSG00000204709.4	LINC01556	8.41	4.57e-16	3.62e-13	0.46	0.35	Pubertal anthropometrics;	chr6:28162011	chr6:28943877~28944537:+
KIRC	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	8.4	4.58e-16	3.62e-13	0.52	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
KIRC	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-8.4	4.59e-16	3.62e-13	-0.31	-0.35	Height;	chr11:118764443	chr11:118791254~118793137:+
KIRC	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-8.4	4.59e-16	3.63e-13	-0.29	-0.35	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
KIRC	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	8.4	4.59e-16	3.63e-13	0.44	0.35	Height;	chr4:55508982	chr4:55387949~55388271:+
KIRC	cis	rs4819052	0.851	rs35560973	ENSG00000223768.1	LINC00205	-8.4	4.61e-16	3.64e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45293285~45297354:+
KIRC	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	8.4	4.61e-16	3.64e-13	0.43	0.35	Height;	chr4:55409063	chr4:55387949~55388271:+
KIRC	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	8.4	4.62e-16	3.65e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
KIRC	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	8.4	4.63e-16	3.66e-13	0.45	0.35	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
KIRC	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-8.4	4.64e-16	3.67e-13	-0.42	-0.35	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
KIRC	cis	rs1529102	0.844	rs2698533	ENSG00000225889.6	AC074289.1	-8.4	4.66e-16	3.68e-13	-0.32	-0.35	Breast size;	chr2:64271271	chr2:64143239~64252859:+
KIRC	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	8.4	4.69e-16	3.71e-13	0.38	0.35	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
KIRC	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-8.4	4.71e-16	3.72e-13	-0.45	-0.35	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
KIRC	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	8.4	4.74e-16	3.74e-13	0.36	0.35	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
KIRC	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	8.4	4.75e-16	3.75e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
KIRC	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	8.4	4.78e-16	3.77e-13	0.57	0.35	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
KIRC	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	8.4	4.8e-16	3.79e-13	0.43	0.35	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
KIRC	cis	rs9847710	0.967	rs2564934	ENSG00000280417.1	RP11-5O17.1	-8.4	4.81e-16	3.79e-13	-0.41	-0.35	Ulcerative colitis;	chr3:52990564	chr3:53046166~53048122:+
KIRC	cis	rs9847710	0.901	rs2564937	ENSG00000280417.1	RP11-5O17.1	-8.4	4.81e-16	3.79e-13	-0.41	-0.35	Ulcerative colitis;	chr3:52991843	chr3:53046166~53048122:+
KIRC	cis	rs7017914	0.967	rs13271442	ENSG00000254031.4	RP11-326E22.1	8.4	4.81e-16	3.79e-13	0.39	0.35	Bone mineral density;	chr8:70672934	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs34558600	ENSG00000254031.4	RP11-326E22.1	8.4	4.81e-16	3.79e-13	0.39	0.35	Bone mineral density;	chr8:70673917	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6472538	ENSG00000254031.4	RP11-326E22.1	8.4	4.81e-16	3.79e-13	0.39	0.35	Bone mineral density;	chr8:70674736	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7001162	ENSG00000254031.4	RP11-326E22.1	8.4	4.81e-16	3.79e-13	0.39	0.35	Bone mineral density;	chr8:70675235	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs56112621	ENSG00000254031.4	RP11-326E22.1	8.4	4.81e-16	3.79e-13	0.39	0.35	Bone mineral density;	chr8:70676159	chr8:71155457~71204223:+
KIRC	cis	rs13113518	1	rs13132420	ENSG00000273257.1	RP11-177J6.1	-8.4	4.82e-16	3.8e-13	-0.41	-0.35	Height;	chr4:55526646	chr4:55387949~55388271:+
KIRC	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	8.4	4.82e-16	3.8e-13	0.41	0.35	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
KIRC	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	8.4	4.83e-16	3.81e-13	0.32	0.35	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
KIRC	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-8.4	4.83e-16	3.81e-13	-0.36	-0.35	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	8.4	4.85e-16	3.83e-13	0.51	0.35	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
KIRC	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-8.4	4.87e-16	3.84e-13	-0.42	-0.35	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
KIRC	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	8.4	4.87e-16	3.84e-13	0.48	0.35	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
KIRC	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-8.4	4.87e-16	3.84e-13	-0.41	-0.35	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
KIRC	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-8.4	4.87e-16	3.84e-13	-0.42	-0.35	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
KIRC	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-8.4	4.87e-16	3.84e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-8.4	4.87e-16	3.84e-13	-0.48	-0.35	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.83	rs7438033	ENSG00000250919.1	RP11-813N20.3	8.4	4.88e-16	3.84e-13	0.37	0.35	Obesity-related traits;	chr4:69059343	chr4:69027831~69044578:+
KIRC	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	8.4	4.88e-16	3.85e-13	0.3	0.35	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
KIRC	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	8.4	4.89e-16	3.85e-13	0.44	0.35	Shingles;	chr7:38346957	chr7:38358512~38359162:-
KIRC	cis	rs9847710	0.967	rs2564931	ENSG00000280417.1	RP11-5O17.1	-8.4	4.91e-16	3.87e-13	-0.41	-0.35	Ulcerative colitis;	chr3:52986543	chr3:53046166~53048122:+
KIRC	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-8.4	4.92e-16	3.88e-13	-0.43	-0.35	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
KIRC	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-8.4	4.92e-16	3.88e-13	-0.43	-0.35	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
KIRC	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-8.39	4.93e-16	3.89e-13	-0.42	-0.35	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-8.39	4.93e-16	3.89e-13	-0.42	-0.35	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-8.39	4.93e-16	3.89e-13	-0.42	-0.35	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
KIRC	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	8.39	4.94e-16	3.89e-13	0.69	0.35	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
KIRC	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	8.39	4.94e-16	3.89e-13	0.69	0.35	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	8.39	4.94e-16	3.89e-13	0.69	0.35	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	8.39	4.94e-16	3.89e-13	0.69	0.35	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
KIRC	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-8.39	4.95e-16	3.9e-13	-0.31	-0.35	Height;	chr11:118761813	chr11:118791254~118793137:+
KIRC	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-8.39	4.97e-16	3.91e-13	-0.47	-0.35	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
KIRC	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-8.39	4.97e-16	3.92e-13	-0.4	-0.35	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
KIRC	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	8.39	4.98e-16	3.93e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
KIRC	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55436423	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55437438	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55452295	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55454900	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55454938	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55455102	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	8.39	4.99e-16	3.93e-13	0.43	0.35	Height;	chr4:55460485	chr4:55387949~55388271:+
KIRC	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	8.39	5e-16	3.94e-13	0.49	0.35	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
KIRC	cis	rs950027	0.62	rs1145093	ENSG00000235390.4	CTD-2651B20.5	-8.39	5.04e-16	3.97e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45321077~45321692:-
KIRC	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-8.39	5.05e-16	3.97e-13	-0.4	-0.35	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
KIRC	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	8.39	5.07e-16	3.99e-13	0.37	0.35	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
KIRC	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	8.39	5.07e-16	3.99e-13	0.49	0.35	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
KIRC	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-8.39	5.09e-16	4e-13	-0.44	-0.35	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
KIRC	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	8.39	5.09e-16	4.01e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
KIRC	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-8.39	5.1e-16	4.01e-13	-0.45	-0.35	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
KIRC	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-8.39	5.1e-16	4.01e-13	-0.44	-0.35	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
KIRC	cis	rs904251	0.525	rs12200378	ENSG00000227920.2	RP1-153P14.5	-8.39	5.11e-16	4.02e-13	-0.38	-0.35	Cognitive performance;	chr6:37457528	chr6:37545145~37550860:+
KIRC	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	8.39	5.12e-16	4.03e-13	0.3	0.35	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
KIRC	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-8.39	5.13e-16	4.03e-13	-0.28	-0.35	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
KIRC	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	8.39	5.13e-16	4.04e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
KIRC	cis	rs1529102	1	rs1529102	ENSG00000225889.6	AC074289.1	-8.39	5.14e-16	4.04e-13	-0.32	-0.35	Breast size;	chr2:64268493	chr2:64143239~64252859:+
KIRC	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	8.39	5.15e-16	4.05e-13	0.62	0.35	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	8.39	5.15e-16	4.05e-13	0.62	0.35	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	8.39	5.15e-16	4.05e-13	0.62	0.35	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
KIRC	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	8.39	5.18e-16	4.08e-13	0.47	0.35	Height;	chr6:109732518	chr6:109382795~109383666:+
KIRC	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-8.39	5.19e-16	4.08e-13	-0.29	-0.35	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
KIRC	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-8.39	5.19e-16	4.08e-13	-0.43	-0.35	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
KIRC	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	8.39	5.19e-16	4.08e-13	0.43	0.35	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
KIRC	cis	rs4356975	0.563	rs4356974	ENSG00000248763.2	RP13-644M16.5	-8.39	5.19e-16	4.08e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106696	chr4:69066395~69069888:+
KIRC	cis	rs2698530	0.554	rs10496110	ENSG00000225889.6	AC074289.1	-8.39	5.2e-16	4.09e-13	-0.35	-0.35	Iron status biomarkers;	chr2:64223221	chr2:64143239~64252859:+
KIRC	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	8.39	5.21e-16	4.1e-13	0.53	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
KIRC	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	8.39	5.22e-16	4.1e-13	0.49	0.35	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
KIRC	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	8.39	5.23e-16	4.11e-13	0.31	0.35	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
KIRC	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	8.39	5.24e-16	4.11e-13	0.46	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
KIRC	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	8.39	5.25e-16	4.12e-13	0.48	0.35	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.527	rs57102579	ENSG00000248763.2	RP13-644M16.5	-8.39	5.25e-16	4.13e-13	-0.45	-0.35	Obesity-related traits;	chr4:69125476	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.527	rs4385139	ENSG00000248763.2	RP13-644M16.5	-8.39	5.25e-16	4.13e-13	-0.45	-0.35	Obesity-related traits;	chr4:69125911	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.527	rs4694645	ENSG00000248763.2	RP13-644M16.5	-8.39	5.25e-16	4.13e-13	-0.45	-0.35	Obesity-related traits;	chr4:69127200	chr4:69066395~69069888:+
KIRC	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-8.39	5.26e-16	4.13e-13	-0.25	-0.35	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
KIRC	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-8.39	5.27e-16	4.14e-13	-0.46	-0.35	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-8.39	5.27e-16	4.14e-13	-0.46	-0.35	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
KIRC	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	8.39	5.27e-16	4.14e-13	0.47	0.35	Height;	chr6:109738307	chr6:109382795~109383666:+
KIRC	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	8.39	5.27e-16	4.14e-13	0.36	0.35	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
KIRC	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	8.39	5.28e-16	4.14e-13	0.3	0.35	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
KIRC	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	8.39	5.29e-16	4.16e-13	0.47	0.35	Height;	chr6:109346560	chr6:109382795~109383666:+
KIRC	cis	rs7672749	1	rs11733405	ENSG00000249973.2	CHCHD2P7	8.39	5.29e-16	4.16e-13	0.66	0.35	TB-LM or TBLH-BMD (pleiotropy);	chr4:87877498	chr4:87785920~87786371:-
KIRC	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-8.39	5.31e-16	4.17e-13	-0.39	-0.35	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
KIRC	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-8.38	5.32e-16	4.18e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-8.38	5.32e-16	4.18e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
KIRC	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	8.38	5.33e-16	4.18e-13	0.37	0.35	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
KIRC	cis	rs13113518	0.678	rs13149568	ENSG00000273257.1	RP11-177J6.1	8.38	5.33e-16	4.18e-13	0.42	0.35	Height;	chr4:55370412	chr4:55387949~55388271:+
KIRC	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-8.38	5.33e-16	4.18e-13	-0.41	-0.35	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
KIRC	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	8.38	5.34e-16	4.19e-13	0.37	0.35	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	8.38	5.34e-16	4.19e-13	0.37	0.35	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	8.38	5.34e-16	4.19e-13	0.37	0.35	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
KIRC	cis	rs4356975	0.563	rs7698846	ENSG00000248763.2	RP13-644M16.5	-8.38	5.34e-16	4.19e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106278	chr4:69066395~69069888:+
KIRC	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	8.38	5.34e-16	4.19e-13	0.37	0.35	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
KIRC	cis	rs4380275	1	rs4450634	ENSG00000223751.1	AC116609.2	8.38	5.35e-16	4.19e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:742488~747767:+
KIRC	cis	rs4380275	1	rs4380275	ENSG00000223751.1	AC116609.2	8.38	5.35e-16	4.19e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:742488~747767:+
KIRC	cis	rs4380275	1	rs6548253	ENSG00000223751.1	AC116609.2	8.38	5.35e-16	4.19e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:742488~747767:+
KIRC	cis	rs4380275	1	rs73143802	ENSG00000223751.1	AC116609.2	8.38	5.35e-16	4.19e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:742488~747767:+
KIRC	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	8.38	5.35e-16	4.2e-13	0.34	0.35	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
KIRC	cis	rs11671005	0.652	rs56225452	ENSG00000269600.1	AC016629.3	-8.38	5.36e-16	4.2e-13	-0.58	-0.35	Mean platelet volume;	chr19:58513279	chr19:58593896~58599355:-
KIRC	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	8.38	5.37e-16	4.21e-13	0.47	0.35	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
KIRC	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	8.38	5.37e-16	4.22e-13	0.32	0.35	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
KIRC	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	8.38	5.38e-16	4.22e-13	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
KIRC	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	8.38	5.39e-16	4.23e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
KIRC	cis	rs13423976	0.631	rs4566347	ENSG00000231367.4	AC016995.3	8.38	5.41e-16	4.24e-13	0.45	0.35	Gut microbiome composition (summer);	chr2:38515498	chr2:38406719~38515740:-
KIRC	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	8.38	5.41e-16	4.24e-13	0.3	0.35	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
KIRC	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	8.38	5.41e-16	4.24e-13	0.36	0.35	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
KIRC	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	8.38	5.43e-16	4.26e-13	0.39	0.35	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
KIRC	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-8.38	5.43e-16	4.26e-13	-0.42	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
KIRC	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-8.38	5.44e-16	4.26e-13	-0.41	-0.35	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
KIRC	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	8.38	5.47e-16	4.28e-13	0.46	0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
KIRC	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-8.38	5.48e-16	4.3e-13	-0.29	-0.35	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
KIRC	cis	rs4356975	0.563	rs6600891	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69105878	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs7693957	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106078	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7698645	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106192	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs12513195	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106368	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4541594	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106554	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.583	rs4351080	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69106601	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs5013211	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107059	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4292394	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107231	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4337789	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107326	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4521414	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107807	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4314345	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107922	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4588522	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107949	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4364327	ENSG00000248763.2	RP13-644M16.5	-8.38	5.51e-16	4.32e-13	-0.46	-0.35	Obesity-related traits;	chr4:69107974	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	8.38	5.52e-16	4.33e-13	0.34	0.35	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
KIRC	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-8.38	5.52e-16	4.33e-13	-0.42	-0.35	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-8.38	5.55e-16	4.35e-13	-0.41	-0.35	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
KIRC	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	8.38	5.55e-16	4.35e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	8.38	5.55e-16	4.35e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
KIRC	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-8.38	5.56e-16	4.35e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
KIRC	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	8.38	5.57e-16	4.36e-13	0.62	0.35	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	8.38	5.57e-16	4.36e-13	0.62	0.35	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	8.38	5.57e-16	4.36e-13	0.62	0.35	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	8.38	5.57e-16	4.36e-13	0.62	0.35	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
KIRC	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-8.38	5.57e-16	4.36e-13	-0.47	-0.35	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
KIRC	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	8.38	5.59e-16	4.38e-13	0.72	0.35	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
KIRC	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	8.38	5.6e-16	4.39e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
KIRC	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	8.38	5.62e-16	4.39e-13	0.44	0.35	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
KIRC	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	8.38	5.63e-16	4.41e-13	0.44	0.35	Height;	chr4:55407965	chr4:55387949~55388271:+
KIRC	cis	rs9847710	0.967	rs2564938	ENSG00000280417.1	RP11-5O17.1	-8.38	5.65e-16	4.42e-13	-0.41	-0.35	Ulcerative colitis;	chr3:52992368	chr3:53046166~53048122:+
KIRC	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	8.38	5.66e-16	4.43e-13	0.62	0.35	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
KIRC	cis	rs950027	0.62	rs1145076	ENSG00000259433.2	CTD-2651B20.4	-8.38	5.67e-16	4.43e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45330209~45332634:-
KIRC	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	8.38	5.67e-16	4.44e-13	0.38	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
KIRC	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	8.38	5.69e-16	4.45e-13	0.63	0.35	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
KIRC	cis	rs4380275	0.965	rs4315562	ENSG00000223751.1	AC116609.2	8.38	5.69e-16	4.45e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:742488~747767:+
KIRC	cis	rs6479901	0.512	rs11817169	ENSG00000232075.1	MRPL35P2	8.38	5.7e-16	4.45e-13	0.56	0.35	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63634317~63634827:-
KIRC	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	8.38	5.71e-16	4.47e-13	0.37	0.35	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
KIRC	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	8.38	5.71e-16	4.47e-13	0.37	0.35	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
KIRC	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	8.38	5.71e-16	4.47e-13	0.44	0.35	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
KIRC	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	8.38	5.72e-16	4.47e-13	0.43	0.35	Height;	chr4:55489895	chr4:55387949~55388271:+
KIRC	cis	rs7017914	1	rs7017914	ENSG00000254031.4	RP11-326E22.1	8.37	5.72e-16	4.47e-13	0.39	0.35	Bone mineral density;	chr8:70678968	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13256250	ENSG00000254031.4	RP11-326E22.1	8.37	5.72e-16	4.47e-13	0.39	0.35	Bone mineral density;	chr8:70683958	chr8:71155457~71204223:+
KIRC	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	8.37	5.73e-16	4.48e-13	0.52	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
KIRC	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-8.37	5.73e-16	4.48e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-8.37	5.73e-16	4.48e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-8.37	5.73e-16	4.48e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-8.37	5.73e-16	4.48e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
KIRC	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-8.37	5.76e-16	4.5e-13	-0.34	-0.35	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
KIRC	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-8.37	5.76e-16	4.5e-13	-0.25	-0.35	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
KIRC	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	8.37	5.77e-16	4.51e-13	0.43	0.35	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
KIRC	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-8.37	5.77e-16	4.51e-13	-0.46	-0.35	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
KIRC	cis	rs3820928	0.874	rs55748731	ENSG00000212391.1	SNORA48	-8.37	5.79e-16	4.52e-13	-0.42	-0.35	Pulmonary function;	chr2:226953913	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	8.37	5.8e-16	4.53e-13	0.36	0.35	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
KIRC	cis	rs904251	0.6	rs4714068	ENSG00000227920.2	RP1-153P14.5	-8.37	5.8e-16	4.53e-13	-0.38	-0.35	Cognitive performance;	chr6:37487866	chr6:37545145~37550860:+
KIRC	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	8.37	5.81e-16	4.54e-13	0.47	0.35	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
KIRC	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	8.37	5.86e-16	4.57e-13	0.32	0.35	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
KIRC	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-8.37	5.88e-16	4.59e-13	-0.28	-0.35	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
KIRC	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-8.37	5.88e-16	4.59e-13	-0.28	-0.35	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
KIRC	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-8.37	5.88e-16	4.59e-13	-0.28	-0.35	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
KIRC	cis	rs7017914	0.967	rs59992214	ENSG00000254031.4	RP11-326E22.1	8.37	5.88e-16	4.59e-13	0.39	0.35	Bone mineral density;	chr8:70687310	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.935	rs35564237	ENSG00000254031.4	RP11-326E22.1	8.37	5.88e-16	4.59e-13	0.39	0.35	Bone mineral density;	chr8:70688239	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6987007	ENSG00000254031.4	RP11-326E22.1	8.37	5.88e-16	4.59e-13	0.39	0.35	Bone mineral density;	chr8:70688707	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs62530772	ENSG00000254031.4	RP11-326E22.1	8.37	5.88e-16	4.59e-13	0.39	0.35	Bone mineral density;	chr8:70689306	chr8:71155457~71204223:+
KIRC	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	8.37	5.91e-16	4.61e-13	0.45	0.35	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
KIRC	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	8.37	5.93e-16	4.62e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	8.37	5.93e-16	4.62e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	8.37	5.93e-16	4.62e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	8.37	5.93e-16	4.62e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
KIRC	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	8.37	5.93e-16	4.62e-13	0.31	0.35	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
KIRC	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-8.37	5.97e-16	4.65e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
KIRC	cis	rs7017914	0.967	rs6991329	ENSG00000254031.4	RP11-326E22.1	8.37	5.98e-16	4.66e-13	0.39	0.35	Bone mineral density;	chr8:70681190	chr8:71155457~71204223:+
KIRC	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	8.37	5.99e-16	4.67e-13	0.46	0.35	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
KIRC	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	8.37	6e-16	4.68e-13	0.46	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
KIRC	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-8.37	6.03e-16	4.7e-13	-0.31	-0.35	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
KIRC	cis	rs4380275	0.965	rs4375894	ENSG00000223751.1	AC116609.2	8.37	6.05e-16	4.72e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:742488~747767:+
KIRC	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	8.37	6.09e-16	4.74e-13	0.43	0.35	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	8.37	6.09e-16	4.74e-13	0.43	0.35	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	8.37	6.09e-16	4.74e-13	0.43	0.35	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	8.37	6.09e-16	4.74e-13	0.44	0.35	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
KIRC	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-8.37	6.1e-16	4.75e-13	-0.47	-0.35	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
KIRC	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	8.37	6.1e-16	4.75e-13	0.38	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.563	rs6600893	ENSG00000248763.2	RP13-644M16.5	-8.37	6.11e-16	4.76e-13	-0.45	-0.35	Obesity-related traits;	chr4:69113183	chr4:69066395~69069888:+
KIRC	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-8.37	6.12e-16	4.77e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
KIRC	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	8.37	6.12e-16	4.77e-13	0.57	0.35	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
KIRC	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-8.37	6.12e-16	4.77e-13	-0.24	-0.35	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
KIRC	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-8.37	6.16e-16	4.79e-13	-0.45	-0.35	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
KIRC	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	8.36	6.17e-16	4.8e-13	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
KIRC	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	8.36	6.18e-16	4.81e-13	0.71	0.35	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
KIRC	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-8.36	6.2e-16	4.82e-13	-0.39	-0.35	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
KIRC	cis	rs10754283	0.84	rs1215502	ENSG00000231613.1	RP5-943J3.1	8.36	6.2e-16	4.83e-13	0.37	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89627456	chr1:89788914~89790492:+
KIRC	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.36	6.2e-16	4.83e-13	-0.35	-0.35	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.563	rs6600885	ENSG00000248763.2	RP13-644M16.5	-8.36	6.22e-16	4.84e-13	-0.45	-0.35	Obesity-related traits;	chr4:69103949	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7375178	ENSG00000248763.2	RP13-644M16.5	-8.36	6.22e-16	4.84e-13	-0.45	-0.35	Obesity-related traits;	chr4:69103961	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs35402056	ENSG00000248763.2	RP13-644M16.5	-8.36	6.22e-16	4.84e-13	-0.45	-0.35	Obesity-related traits;	chr4:69108549	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4694177	ENSG00000248763.2	RP13-644M16.5	-8.36	6.22e-16	4.84e-13	-0.45	-0.35	Obesity-related traits;	chr4:69110141	chr4:69066395~69069888:+
KIRC	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	8.36	6.24e-16	4.85e-13	0.44	0.35	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
KIRC	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-8.36	6.24e-16	4.86e-13	-0.45	-0.35	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
KIRC	cis	rs950027	0.62	rs1145089	ENSG00000235390.4	CTD-2651B20.5	-8.36	6.25e-16	4.86e-13	-0.34	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45321077~45321692:-
KIRC	cis	rs7017914	0.967	rs1477944	ENSG00000254031.4	RP11-326E22.1	8.36	6.25e-16	4.86e-13	0.38	0.35	Bone mineral density;	chr8:70703365	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs17760497	ENSG00000254031.4	RP11-326E22.1	8.36	6.25e-16	4.86e-13	0.38	0.35	Bone mineral density;	chr8:70704810	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs34677078	ENSG00000254031.4	RP11-326E22.1	8.36	6.25e-16	4.86e-13	0.38	0.35	Bone mineral density;	chr8:70705480	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	8.36	6.28e-16	4.89e-13	0.35	0.35	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.563	rs12512526	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69100700	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs34386959	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69100837	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs55834557	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69100876	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs56388229	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69100940	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs34318523	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69101135	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.583	rs34630750	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69101208	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs12508257	ENSG00000250696.4	RP11-704M14.1	8.36	6.3e-16	4.9e-13	0.37	0.35	Obesity-related traits;	chr4:69101921	chr4:69182100~69216766:+
KIRC	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-8.36	6.31e-16	4.9e-13	-0.48	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
KIRC	cis	rs12893668	0.572	rs1606	ENSG00000269910.1	RP11-73M18.10	8.36	6.31e-16	4.91e-13	0.25	0.35	Reticulocyte count;	chr14:103694944	chr14:103694516~103695050:-
KIRC	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	8.36	6.32e-16	4.91e-13	0.47	0.35	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
KIRC	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-8.36	6.32e-16	4.92e-13	-0.48	-0.35	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
KIRC	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-8.36	6.34e-16	4.93e-13	-0.48	-0.35	Depression;	chr6:28131566	chr6:28115628~28116551:+
KIRC	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-8.36	6.35e-16	4.94e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-8.36	6.35e-16	4.94e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
KIRC	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	8.36	6.37e-16	4.95e-13	0.43	0.35	Height;	chr4:55465165	chr4:55387949~55388271:+
KIRC	cis	rs4380275	1	rs4359695	ENSG00000223751.1	AC116609.2	8.36	6.39e-16	4.97e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:742488~747767:+
KIRC	cis	rs4380275	0.931	rs4538239	ENSG00000223751.1	AC116609.2	8.36	6.39e-16	4.97e-13	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:742488~747767:+
KIRC	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-8.36	6.41e-16	4.98e-13	-0.4	-0.35	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
KIRC	cis	rs13423976	0.572	rs11893988	ENSG00000231367.4	AC016995.3	8.36	6.43e-16	5e-13	0.45	0.35	Gut microbiome composition (summer);	chr2:38515630	chr2:38406719~38515740:-
KIRC	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	8.36	6.43e-16	5e-13	0.5	0.35	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
KIRC	cis	rs13113518	0.812	rs13140173	ENSG00000273257.1	RP11-177J6.1	8.36	6.45e-16	5.01e-13	0.44	0.35	Height;	chr4:55527164	chr4:55387949~55388271:+
KIRC	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-8.36	6.47e-16	5.02e-13	-0.36	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
KIRC	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-8.36	6.49e-16	5.04e-13	-0.39	-0.35	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
KIRC	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	8.36	6.51e-16	5.05e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
KIRC	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	8.36	6.52e-16	5.06e-13	0.46	0.35	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
KIRC	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	8.36	6.52e-16	5.07e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	8.36	6.52e-16	5.07e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
KIRC	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-8.36	6.55e-16	5.09e-13	-0.29	-0.35	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
KIRC	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	8.36	6.56e-16	5.09e-13	0.67	0.35	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
KIRC	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	8.36	6.56e-16	5.09e-13	0.54	0.35	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
KIRC	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-8.36	6.56e-16	5.09e-13	-0.4	-0.35	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
KIRC	cis	rs6600671	0.966	rs6600664	ENSG00000227082.1	CH17-437K3.1	-8.36	6.57e-16	5.1e-13	-0.4	-0.35	Hip geometry;	chr1:121480638	chr1:121396754~121463129:+
KIRC	cis	rs6600671	0.932	rs6600663	ENSG00000227082.1	CH17-437K3.1	-8.36	6.57e-16	5.1e-13	-0.4	-0.35	Hip geometry;	chr1:121480639	chr1:121396754~121463129:+
KIRC	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	8.36	6.58e-16	5.11e-13	0.42	0.35	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
KIRC	cis	rs4356975	0.527	rs60423649	ENSG00000248763.2	RP13-644M16.5	-8.36	6.6e-16	5.12e-13	-0.45	-0.35	Obesity-related traits;	chr4:69127952	chr4:69066395~69069888:+
KIRC	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	8.36	6.6e-16	5.12e-13	0.48	0.35	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
KIRC	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	8.36	6.61e-16	5.13e-13	0.47	0.35	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	8.36	6.61e-16	5.13e-13	0.47	0.35	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
KIRC	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-8.36	6.62e-16	5.14e-13	-0.42	-0.35	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
KIRC	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	8.36	6.63e-16	5.14e-13	0.51	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
KIRC	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-8.36	6.63e-16	5.14e-13	-0.49	-0.35	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
KIRC	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.35	6.64e-16	5.15e-13	0.45	0.35	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
KIRC	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	8.35	6.64e-16	5.15e-13	0.38	0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
KIRC	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-8.35	6.64e-16	5.15e-13	-0.33	-0.35	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
KIRC	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	8.35	6.65e-16	5.15e-13	0.4	0.35	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
KIRC	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-8.35	6.66e-16	5.17e-13	-0.47	-0.35	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
KIRC	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	8.35	6.71e-16	5.2e-13	0.31	0.35	Height;	chr11:118758322	chr11:118791254~118793137:+
KIRC	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	8.35	6.72e-16	5.21e-13	0.36	0.35	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	8.35	6.72e-16	5.21e-13	0.36	0.35	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	8.35	6.72e-16	5.21e-13	0.36	0.35	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	8.35	6.72e-16	5.21e-13	0.36	0.35	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	8.35	6.72e-16	5.21e-13	0.36	0.35	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
KIRC	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	8.35	6.74e-16	5.23e-13	0.39	0.35	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
KIRC	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	8.35	6.74e-16	5.23e-13	0.24	0.35	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
KIRC	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-8.35	6.75e-16	5.23e-13	-0.46	-0.35	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
KIRC	cis	rs4273100	1	rs868698	ENSG00000262319.1	CTC-457L16.2	-8.35	6.78e-16	5.25e-13	-0.48	-0.35	Schizophrenia;	chr17:19281898	chr17:19141017~19143689:-
KIRC	cis	rs950027	0.62	rs1145084	ENSG00000259433.2	CTD-2651B20.4	-8.35	6.8e-16	5.27e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45330209~45332634:-
KIRC	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-8.35	6.81e-16	5.27e-13	-0.62	-0.35	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
KIRC	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-8.35	6.82e-16	5.28e-13	-0.41	-0.35	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
KIRC	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-8.35	6.84e-16	5.3e-13	-0.39	-0.35	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
KIRC	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-8.35	6.84e-16	5.3e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
KIRC	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-8.35	6.85e-16	5.3e-13	-0.47	-0.35	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
KIRC	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	8.35	6.88e-16	5.33e-13	0.37	0.35	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
KIRC	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	8.35	6.88e-16	5.33e-13	0.3	0.35	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
KIRC	cis	rs4356975	0.563	rs6851533	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69113032	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7666195	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69113765	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7685151	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69114055	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.583	rs11936822	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69114229	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs34814736	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69114760	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs11933459	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69116045	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600895	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69117694	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4508963	ENSG00000248763.2	RP13-644M16.5	-8.35	6.9e-16	5.34e-13	-0.45	-0.35	Obesity-related traits;	chr4:69118770	chr4:69066395~69069888:+
KIRC	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-8.35	6.9e-16	5.34e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
KIRC	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	8.35	6.91e-16	5.35e-13	0.35	0.35	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
KIRC	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	8.35	6.92e-16	5.35e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	8.35	6.95e-16	5.38e-13	0.46	0.35	Height;	chr6:109392096	chr6:109382795~109383666:+
KIRC	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	8.35	6.99e-16	5.4e-13	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
KIRC	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-8.35	7e-16	5.41e-13	-0.35	-0.35	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-8.35	7e-16	5.41e-13	-0.35	-0.35	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
KIRC	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-8.35	7.04e-16	5.45e-13	-0.54	-0.35	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
KIRC	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-8.35	7.04e-16	5.45e-13	-0.42	-0.35	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
KIRC	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-8.35	7.08e-16	5.47e-13	-0.36	-0.35	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
KIRC	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	8.35	7.09e-16	5.48e-13	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
KIRC	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-8.35	7.1e-16	5.49e-13	-0.46	-0.35	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
KIRC	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-8.35	7.1e-16	5.49e-13	-0.51	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
KIRC	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-8.35	7.11e-16	5.5e-13	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
KIRC	cis	rs4356975	0.83	rs7435274	ENSG00000250919.1	RP11-813N20.3	-8.35	7.12e-16	5.51e-13	-0.37	-0.35	Obesity-related traits;	chr4:69050281	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs7438808	ENSG00000250919.1	RP11-813N20.3	-8.35	7.12e-16	5.51e-13	-0.37	-0.35	Obesity-related traits;	chr4:69050666	chr4:69027831~69044578:+
KIRC	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-8.35	7.14e-16	5.52e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
KIRC	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	8.34	7.15e-16	5.53e-13	0.64	0.35	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
KIRC	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-8.34	7.16e-16	5.53e-13	-0.41	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
KIRC	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	8.34	7.17e-16	5.54e-13	0.38	0.35	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	8.34	7.17e-16	5.54e-13	0.38	0.35	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	8.34	7.17e-16	5.54e-13	0.38	0.35	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
KIRC	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-8.34	7.18e-16	5.55e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
KIRC	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	8.34	7.18e-16	5.55e-13	0.39	0.35	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
KIRC	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	8.34	7.18e-16	5.55e-13	0.39	0.35	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
KIRC	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	8.34	7.19e-16	5.55e-13	0.43	0.35	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
KIRC	cis	rs12594515	0.587	rs8033024	ENSG00000273972.1	CTD-2306A12.1	-8.34	7.2e-16	5.57e-13	-0.38	-0.35	Weight;Waist circumference;	chr15:45705898	chr15:45702640~45703183:+
KIRC	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	8.34	7.22e-16	5.58e-13	0.44	0.35	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	8.34	7.22e-16	5.58e-13	0.44	0.35	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
KIRC	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-8.34	7.22e-16	5.58e-13	-0.42	-0.35	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
KIRC	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	8.34	7.22e-16	5.58e-13	0.45	0.35	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
KIRC	cis	rs950027	0.62	rs1617634	ENSG00000259433.2	CTD-2651B20.4	-8.34	7.26e-16	5.61e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45330209~45332634:-
KIRC	cis	rs4819052	0.851	rs4819049	ENSG00000223768.1	LINC00205	-8.34	7.27e-16	5.61e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45293285~45297354:+
KIRC	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	8.34	7.27e-16	5.61e-13	0.64	0.35	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
KIRC	cis	rs10916248	0.511	rs10916515	ENSG00000232628.4	RP11-365O16.3	8.34	7.28e-16	5.62e-13	0.56	0.35	QT interval (drug interaction);	chr1:224222121	chr1:224208747~224213279:-
KIRC	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	8.34	7.29e-16	5.63e-13	0.43	0.35	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000196472.4	RP13-644M16.4	8.34	7.29e-16	5.63e-13	0.4	0.35	Obesity-related traits;	chr4:69077628	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000196472.4	RP13-644M16.4	8.34	7.29e-16	5.63e-13	0.4	0.35	Obesity-related traits;	chr4:69077631	chr4:69181660~69182372:+
KIRC	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-8.34	7.32e-16	5.65e-13	-0.44	-0.35	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
KIRC	cis	rs6600671	0.934	rs12060031	ENSG00000227082.1	CH17-437K3.1	8.34	7.32e-16	5.66e-13	0.4	0.35	Hip geometry;	chr1:121501652	chr1:121396754~121463129:+
KIRC	cis	rs4356975	0.563	rs12505466	ENSG00000250696.4	RP11-704M14.1	8.34	7.33e-16	5.66e-13	0.37	0.35	Obesity-related traits;	chr4:69119944	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600896	ENSG00000250696.4	RP11-704M14.1	8.34	7.33e-16	5.66e-13	0.37	0.35	Obesity-related traits;	chr4:69121000	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600897	ENSG00000250696.4	RP11-704M14.1	8.34	7.33e-16	5.66e-13	0.37	0.35	Obesity-related traits;	chr4:69121531	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4274916	ENSG00000250696.4	RP11-704M14.1	8.34	7.33e-16	5.66e-13	0.37	0.35	Obesity-related traits;	chr4:69122660	chr4:69182100~69216766:+
KIRC	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	8.34	7.33e-16	5.66e-13	0.39	0.35	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
KIRC	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-8.34	7.33e-16	5.66e-13	-0.28	-0.35	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
KIRC	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-8.34	7.34e-16	5.67e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
KIRC	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-8.34	7.36e-16	5.69e-13	-0.4	-0.35	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
KIRC	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-8.34	7.37e-16	5.69e-13	-0.24	-0.35	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
KIRC	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-8.34	7.41e-16	5.72e-13	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
KIRC	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	8.34	7.42e-16	5.72e-13	0.44	0.35	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	8.34	7.42e-16	5.72e-13	0.44	0.35	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	8.34	7.42e-16	5.72e-13	0.44	0.35	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
KIRC	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	8.34	7.46e-16	5.76e-13	0.43	0.35	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
KIRC	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-8.34	7.48e-16	5.77e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
KIRC	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-8.34	7.52e-16	5.8e-13	-0.5	-0.35	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
KIRC	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	8.34	7.52e-16	5.8e-13	0.43	0.35	Height;	chr4:55452921	chr4:55387949~55388271:+
KIRC	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-8.34	7.54e-16	5.81e-13	-0.31	-0.35	Height;	chr11:118773873	chr11:118791254~118793137:+
KIRC	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-8.34	7.54e-16	5.82e-13	-0.38	-0.35	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
KIRC	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-8.34	7.55e-16	5.82e-13	-0.44	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
KIRC	cis	rs7017914	0.967	rs17689955	ENSG00000254031.4	RP11-326E22.1	8.34	7.59e-16	5.85e-13	0.38	0.35	Bone mineral density;	chr8:70936629	chr8:71155457~71204223:+
KIRC	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-8.34	7.6e-16	5.86e-13	-0.41	-0.35	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
KIRC	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-8.34	7.62e-16	5.87e-13	-0.37	-0.35	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
KIRC	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-8.34	7.64e-16	5.89e-13	-0.34	-0.35	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
KIRC	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	8.34	7.64e-16	5.89e-13	0.38	0.35	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
KIRC	cis	rs7017914	0.934	rs6987313	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70658754	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs35580034	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70659838	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs17760050	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70662016	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs35214141	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70662329	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs10504479	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70665280	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs35109143	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70665665	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs13269513	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70665844	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs34282253	ENSG00000254031.4	RP11-326E22.1	8.34	7.65e-16	5.9e-13	0.38	0.35	Bone mineral density;	chr8:70670131	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	8.34	7.68e-16	5.92e-13	0.35	0.35	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	8.34	7.68e-16	5.92e-13	0.35	0.35	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	8.34	7.68e-16	5.92e-13	0.35	0.35	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
KIRC	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	8.33	7.7e-16	5.94e-13	0.45	0.35	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
KIRC	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	8.33	7.71e-16	5.94e-13	0.47	0.35	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
KIRC	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-8.33	7.73e-16	5.96e-13	-0.38	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
KIRC	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-8.33	7.74e-16	5.96e-13	-0.35	-0.35	Height;	chr3:53085518	chr3:53064283~53065091:-
KIRC	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.33	7.74e-16	5.96e-13	-0.39	-0.35	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
KIRC	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-8.33	7.78e-16	5.99e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
KIRC	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-8.33	7.79e-16	6e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
KIRC	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	8.33	7.81e-16	6.01e-13	0.62	0.35	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	8.33	7.81e-16	6.01e-13	0.62	0.35	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	8.33	7.81e-16	6.01e-13	0.62	0.35	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	8.33	7.81e-16	6.01e-13	0.62	0.35	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	8.33	7.83e-16	6.03e-13	0.61	0.35	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
KIRC	cis	rs4273100	1	rs12602286	ENSG00000228157.4	AC007952.5	-8.33	7.9e-16	6.08e-13	-0.54	-0.35	Schizophrenia;	chr17:19333641	chr17:19092974~19096837:+
KIRC	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	8.33	7.9e-16	6.08e-13	0.57	0.35	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
KIRC	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	8.33	7.91e-16	6.09e-13	0.45	0.35	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
KIRC	cis	rs4356975	0.563	rs7658752	ENSG00000250696.4	RP11-704M14.1	8.33	7.91e-16	6.09e-13	0.37	0.35	Obesity-related traits;	chr4:69112350	chr4:69182100~69216766:+
KIRC	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	8.33	7.93e-16	6.1e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
KIRC	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	8.33	7.94e-16	6.11e-13	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
KIRC	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	8.33	7.95e-16	6.12e-13	0.49	0.35	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
KIRC	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-8.33	7.97e-16	6.13e-13	-0.26	-0.35	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
KIRC	cis	rs4819052	0.851	rs4819040	ENSG00000223768.1	LINC00205	-8.33	7.98e-16	6.14e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45293285~45297354:+
KIRC	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-8.33	7.98e-16	6.14e-13	-0.5	-0.35	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
KIRC	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	8.33	8.03e-16	6.18e-13	0.46	0.35	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	8.33	8.03e-16	6.18e-13	0.46	0.35	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
KIRC	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	8.33	8.04e-16	6.18e-13	0.4	0.35	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
KIRC	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-8.33	8.04e-16	6.19e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-8.33	8.04e-16	6.19e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-8.33	8.04e-16	6.19e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
KIRC	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	8.33	8.05e-16	6.19e-13	0.45	0.35	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	8.33	8.05e-16	6.19e-13	0.45	0.35	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
KIRC	cis	rs13113518	0.812	rs4507426	ENSG00000273257.1	RP11-177J6.1	8.33	8.11e-16	6.24e-13	0.43	0.35	Height;	chr4:55529387	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	8.33	8.11e-16	6.24e-13	0.43	0.35	Height;	chr4:55529786	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	8.33	8.11e-16	6.24e-13	0.43	0.35	Height;	chr4:55532542	chr4:55387949~55388271:+
KIRC	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	8.33	8.14e-16	6.26e-13	0.61	0.35	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.563	rs7439152	ENSG00000248763.2	RP13-644M16.5	-8.33	8.17e-16	6.28e-13	-0.45	-0.35	Obesity-related traits;	chr4:69103288	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	8.33	8.18e-16	6.29e-13	0.43	0.35	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	8.33	8.18e-16	6.29e-13	0.43	0.35	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	8.33	8.18e-16	6.29e-13	0.43	0.35	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	8.33	8.18e-16	6.29e-13	0.43	0.35	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	8.33	8.18e-16	6.29e-13	0.43	0.35	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
KIRC	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-8.33	8.19e-16	6.29e-13	-0.47	-0.35	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
KIRC	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	8.33	8.2e-16	6.3e-13	0.52	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
KIRC	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-8.33	8.22e-16	6.31e-13	-0.39	-0.35	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
KIRC	cis	rs79040073	0.607	rs7168316	ENSG00000259531.2	RP11-295H24.3	8.33	8.24e-16	6.33e-13	0.44	0.35	Lung cancer in ever smokers;	chr15:49441549	chr15:49365124~49366685:-
KIRC	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	8.33	8.27e-16	6.35e-13	0.47	0.35	Height;	chr6:109429207	chr6:109382795~109383666:+
KIRC	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	8.33	8.27e-16	6.35e-13	0.71	0.35	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
KIRC	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	8.33	8.27e-16	6.36e-13	0.64	0.35	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
KIRC	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	8.33	8.29e-16	6.37e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	8.33	8.29e-16	6.37e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-8.32	8.31e-16	6.38e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-8.32	8.31e-16	6.38e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.563	rs6600887	ENSG00000248763.2	RP13-644M16.5	-8.32	8.35e-16	6.41e-13	-0.45	-0.35	Obesity-related traits;	chr4:69104070	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs6600888	ENSG00000248763.2	RP13-644M16.5	-8.32	8.35e-16	6.41e-13	-0.45	-0.35	Obesity-related traits;	chr4:69104141	chr4:69066395~69069888:+
KIRC	cis	rs950027	0.596	rs2467853	ENSG00000235390.4	CTD-2651B20.5	-8.32	8.35e-16	6.42e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45321077~45321692:-
KIRC	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-8.32	8.36e-16	6.42e-13	-0.43	-0.35	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
KIRC	cis	rs4356975	0.563	rs11249527	ENSG00000250696.4	RP11-704M14.1	8.32	8.38e-16	6.44e-13	0.37	0.35	Obesity-related traits;	chr4:69089267	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6846298	ENSG00000250696.4	RP11-704M14.1	8.32	8.38e-16	6.44e-13	0.37	0.35	Obesity-related traits;	chr4:69089278	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs11249528	ENSG00000250696.4	RP11-704M14.1	8.32	8.38e-16	6.44e-13	0.37	0.35	Obesity-related traits;	chr4:69089337	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs55757747	ENSG00000250696.4	RP11-704M14.1	8.32	8.38e-16	6.44e-13	0.37	0.35	Obesity-related traits;	chr4:69089919	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs56217918	ENSG00000250696.4	RP11-704M14.1	8.32	8.38e-16	6.44e-13	0.37	0.35	Obesity-related traits;	chr4:69089925	chr4:69182100~69216766:+
KIRC	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	8.32	8.39e-16	6.44e-13	0.35	0.35	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	8.32	8.39e-16	6.44e-13	0.35	0.35	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	8.32	8.39e-16	6.44e-13	0.35	0.35	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	8.32	8.39e-16	6.44e-13	0.35	0.35	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	8.32	8.39e-16	6.44e-13	0.35	0.35	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
KIRC	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	8.32	8.41e-16	6.45e-13	0.43	0.35	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
KIRC	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-8.32	8.43e-16	6.47e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
KIRC	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-8.32	8.48e-16	6.51e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
KIRC	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	8.32	8.5e-16	6.52e-13	0.44	0.35	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
KIRC	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-8.32	8.5e-16	6.53e-13	-0.45	-0.35	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-8.32	8.5e-16	6.53e-13	-0.45	-0.35	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
KIRC	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-8.32	8.51e-16	6.53e-13	-0.44	-0.35	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
KIRC	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	8.32	8.53e-16	6.54e-13	0.35	0.35	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
KIRC	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	8.32	8.53e-16	6.54e-13	0.42	0.35	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
KIRC	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	8.32	8.57e-16	6.57e-13	0.33	0.35	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
KIRC	cis	rs950027	0.62	rs1145089	ENSG00000259433.2	CTD-2651B20.4	-8.32	8.57e-16	6.57e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45330209~45332634:-
KIRC	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-8.32	8.57e-16	6.57e-13	-0.39	-0.35	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
KIRC	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	8.32	8.57e-16	6.57e-13	0.5	0.35	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
KIRC	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	8.32	8.58e-16	6.58e-13	0.39	0.35	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	8.32	8.59e-16	6.58e-13	0.43	0.35	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.83	rs60212682	ENSG00000250919.1	RP11-813N20.3	-8.32	8.62e-16	6.61e-13	-0.37	-0.35	Obesity-related traits;	chr4:69052849	chr4:69027831~69044578:+
KIRC	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	8.32	8.63e-16	6.62e-13	0.5	0.35	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
KIRC	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-8.32	8.63e-16	6.62e-13	-0.39	-0.35	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-8.32	8.64e-16	6.62e-13	-0.36	-0.35	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
KIRC	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-8.32	8.64e-16	6.62e-13	-0.24	-0.35	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
KIRC	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.32	8.64e-16	6.62e-13	0.53	0.35	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
KIRC	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-8.32	8.67e-16	6.64e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.527	rs62296943	ENSG00000248763.2	RP13-644M16.5	-8.32	8.67e-16	6.65e-13	-0.45	-0.35	Obesity-related traits;	chr4:69093465	chr4:69066395~69069888:+
KIRC	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-8.32	8.69e-16	6.66e-13	-0.39	-0.35	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
KIRC	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	8.32	8.7e-16	6.66e-13	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
KIRC	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	8.32	8.7e-16	6.67e-13	0.61	0.35	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
KIRC	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-8.32	8.71e-16	6.68e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-8.32	8.71e-16	6.68e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
KIRC	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	8.32	8.74e-16	6.7e-13	0.35	0.35	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
KIRC	cis	rs3820928	0.874	rs4461255	ENSG00000212391.1	SNORA48	8.32	8.77e-16	6.72e-13	0.41	0.35	Pulmonary function;	chr2:226981808	chr2:226968989~226969122:-
KIRC	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
KIRC	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-8.32	8.78e-16	6.73e-13	-0.35	-0.35	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
KIRC	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.4	-0.35	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-8.32	8.79e-16	6.73e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
KIRC	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-8.32	8.8e-16	6.74e-13	-0.42	-0.35	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-8.32	8.8e-16	6.74e-13	-0.42	-0.35	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
KIRC	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	8.32	8.83e-16	6.76e-13	0.46	0.35	Height;	chr6:109738751	chr6:109382795~109383666:+
KIRC	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-8.32	8.87e-16	6.79e-13	-0.33	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
KIRC	cis	rs755249	0.701	rs1180342	ENSG00000237624.1	OXCT2P1	-8.32	8.9e-16	6.81e-13	-0.44	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39514956~39516490:+
KIRC	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	8.32	8.91e-16	6.82e-13	0.3	0.35	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	8.32	8.91e-16	6.82e-13	0.3	0.35	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	8.32	8.91e-16	6.82e-13	0.3	0.35	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	8.32	8.91e-16	6.82e-13	0.3	0.35	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	8.32	8.91e-16	6.82e-13	0.3	0.35	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
KIRC	cis	rs13113518	0.812	rs2035692	ENSG00000273257.1	RP11-177J6.1	8.31	8.93e-16	6.84e-13	0.43	0.35	Height;	chr4:55528801	chr4:55387949~55388271:+
KIRC	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.31	8.94e-16	6.84e-13	-0.39	-0.35	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
KIRC	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	8.31	8.95e-16	6.85e-13	0.3	0.35	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
KIRC	cis	rs4356975	0.563	rs6600886	ENSG00000248763.2	RP13-644M16.5	-8.31	8.98e-16	6.87e-13	-0.45	-0.35	Obesity-related traits;	chr4:69104017	chr4:69066395~69069888:+
KIRC	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-8.31	8.98e-16	6.87e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	8.31	9e-16	6.88e-13	0.46	0.35	Height;	chr6:109706740	chr6:109382795~109383666:+
KIRC	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-8.31	9e-16	6.89e-13	-0.38	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.649	rs59421013	ENSG00000250919.1	RP11-813N20.3	-8.31	9.02e-16	6.9e-13	-0.36	-0.35	Obesity-related traits;	chr4:69149131	chr4:69027831~69044578:+
KIRC	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-8.31	9.03e-16	6.91e-13	-0.42	-0.35	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
KIRC	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	8.31	9.03e-16	6.91e-13	0.37	0.35	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
KIRC	cis	rs10754283	0.84	rs1215501	ENSG00000231613.1	RP5-943J3.1	8.31	9.06e-16	6.93e-13	0.37	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89630131	chr1:89788914~89790492:+
KIRC	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-8.31	9.07e-16	6.93e-13	-0.46	-0.35	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
KIRC	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	8.31	9.1e-16	6.95e-13	0.3	0.35	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	8.31	9.1e-16	6.95e-13	0.3	0.35	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
KIRC	cis	rs4356975	0.563	rs12642938	ENSG00000250696.4	RP11-704M14.1	8.31	9.12e-16	6.97e-13	0.37	0.35	Obesity-related traits;	chr4:69110499	chr4:69182100~69216766:+
KIRC	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-8.31	9.15e-16	7e-13	-0.4	-0.35	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
KIRC	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	8.31	9.21e-16	7.04e-13	0.39	0.35	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
KIRC	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	8.31	9.24e-16	7.06e-13	0.74	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
KIRC	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	8.31	9.26e-16	7.07e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-8.31	9.26e-16	7.07e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-8.31	9.26e-16	7.07e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-8.31	9.26e-16	7.07e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-8.31	9.26e-16	7.07e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
KIRC	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-8.31	9.26e-16	7.07e-13	-0.47	-0.35	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
KIRC	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-8.31	9.27e-16	7.08e-13	-0.3	-0.35	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
KIRC	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-8.31	9.27e-16	7.08e-13	-0.3	-0.35	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
KIRC	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	8.31	9.28e-16	7.09e-13	0.51	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
KIRC	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-8.31	9.31e-16	7.11e-13	-0.24	-0.35	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
KIRC	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	8.31	9.33e-16	7.12e-13	0.36	0.35	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
KIRC	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	8.31	9.34e-16	7.13e-13	0.47	0.35	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
KIRC	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-8.31	9.39e-16	7.17e-13	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
KIRC	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	8.31	9.4e-16	7.18e-13	0.76	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
KIRC	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-8.31	9.4e-16	7.18e-13	-0.48	-0.35	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
KIRC	cis	rs4356975	0.697	rs58039330	ENSG00000250919.1	RP11-813N20.3	-8.31	9.42e-16	7.19e-13	-0.36	-0.35	Obesity-related traits;	chr4:69149529	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.66	rs60567038	ENSG00000250919.1	RP11-813N20.3	-8.31	9.42e-16	7.19e-13	-0.36	-0.35	Obesity-related traits;	chr4:69150135	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.697	rs58366569	ENSG00000250919.1	RP11-813N20.3	-8.31	9.42e-16	7.19e-13	-0.36	-0.35	Obesity-related traits;	chr4:69150626	chr4:69027831~69044578:+
KIRC	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	8.31	9.43e-16	7.2e-13	0.44	0.35	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	8.31	9.43e-16	7.2e-13	0.44	0.35	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
KIRC	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-8.31	9.44e-16	7.2e-13	-0.34	-0.35	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
KIRC	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	8.31	9.45e-16	7.21e-13	0.37	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
KIRC	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	8.31	9.47e-16	7.23e-13	0.37	0.35	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
KIRC	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	8.31	9.49e-16	7.24e-13	0.46	0.35	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
KIRC	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	8.31	9.49e-16	7.24e-13	0.31	0.35	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
KIRC	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	8.31	9.49e-16	7.24e-13	0.65	0.35	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000196472.4	RP13-644M16.4	8.31	9.5e-16	7.25e-13	0.4	0.35	Obesity-related traits;	chr4:69079704	chr4:69181660~69182372:+
KIRC	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-8.31	9.5e-16	7.25e-13	-0.44	-0.35	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
KIRC	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-8.31	9.5e-16	7.25e-13	-0.5	-0.35	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-8.31	9.5e-16	7.25e-13	-0.5	-0.35	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
KIRC	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-8.31	9.52e-16	7.26e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	8.31	9.53e-16	7.27e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	8.31	9.53e-16	7.27e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	8.31	9.53e-16	7.27e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-8.31	9.53e-16	7.27e-13	-0.39	-0.35	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
KIRC	cis	rs904251	0.965	rs62406516	ENSG00000227920.2	RP1-153P14.5	-8.31	9.55e-16	7.28e-13	-0.39	-0.35	Cognitive performance;	chr6:37471588	chr6:37545145~37550860:+
KIRC	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-8.31	9.55e-16	7.29e-13	-0.42	-0.35	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
KIRC	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-8.31	9.56e-16	7.29e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
KIRC	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-8.31	9.58e-16	7.3e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
KIRC	cis	rs12893668	0.572	rs7148857	ENSG00000269910.1	RP11-73M18.10	8.31	9.58e-16	7.31e-13	0.25	0.35	Reticulocyte count;	chr14:103676900	chr14:103694516~103695050:-
KIRC	cis	rs12893668	0.572	rs2273175	ENSG00000269910.1	RP11-73M18.10	8.3	9.65e-16	7.36e-13	0.25	0.35	Reticulocyte count;	chr14:103693804	chr14:103694516~103695050:-
KIRC	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-8.3	9.66e-16	7.36e-13	-0.42	-0.35	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
KIRC	cis	rs1560104	0.597	rs12708758	ENSG00000274834.1	CTD-3037G24.5	8.3	9.66e-16	7.36e-13	0.38	0.35	Obesity-related traits;	chr16:12616844	chr16:12614451~12614852:+
KIRC	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-8.3	9.67e-16	7.37e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000196472.4	RP13-644M16.4	8.3	9.68e-16	7.38e-13	0.4	0.35	Obesity-related traits;	chr4:69079387	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000196472.4	RP13-644M16.4	8.3	9.68e-16	7.38e-13	0.4	0.35	Obesity-related traits;	chr4:69079446	chr4:69181660~69182372:+
KIRC	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	8.3	9.69e-16	7.38e-13	0.34	0.35	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
KIRC	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	8.3	9.72e-16	7.41e-13	0.64	0.35	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
KIRC	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-8.3	9.75e-16	7.43e-13	-0.36	-0.35	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
KIRC	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-8.3	9.78e-16	7.46e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-8.3	9.78e-16	7.46e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-8.3	9.78e-16	7.46e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-8.3	9.78e-16	7.46e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
KIRC	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-8.3	9.82e-16	7.48e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
KIRC	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	8.3	9.82e-16	7.48e-13	0.61	0.35	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
KIRC	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-8.3	9.83e-16	7.49e-13	-0.38	-0.35	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
KIRC	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-8.3	9.9e-16	7.54e-13	-0.38	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
KIRC	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-8.3	9.91e-16	7.54e-13	-0.34	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
KIRC	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-8.3	9.91e-16	7.55e-13	-0.39	-0.35	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
KIRC	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	8.3	9.91e-16	7.55e-13	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
KIRC	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	8.3	9.92e-16	7.55e-13	0.37	0.35	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
KIRC	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	8.3	9.93e-16	7.56e-13	0.59	0.35	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
KIRC	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-8.3	9.94e-16	7.56e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
KIRC	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	8.3	9.94e-16	7.57e-13	0.66	0.35	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
KIRC	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-8.3	9.97e-16	7.59e-13	-0.49	-0.35	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
KIRC	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	8.3	9.99e-16	7.6e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
KIRC	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	8.3	1e-15	7.61e-13	0.77	0.35	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
KIRC	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	8.3	1e-15	7.62e-13	0.59	0.35	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
KIRC	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	8.3	1e-15	7.63e-13	0.43	0.35	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
KIRC	cis	rs4819052	0.807	rs7283915	ENSG00000223768.1	LINC00205	-8.3	1e-15	7.63e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs2838850	ENSG00000223768.1	LINC00205	-8.3	1e-15	7.63e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs8130285	ENSG00000223768.1	LINC00205	-8.3	1e-15	7.63e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs13050359	ENSG00000223768.1	LINC00205	-8.3	1e-15	7.63e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45293285~45297354:+
KIRC	cis	rs4356975	0.503	rs11938761	ENSG00000248763.2	RP13-644M16.5	-8.3	1e-15	7.63e-13	-0.45	-0.35	Obesity-related traits;	chr4:69083992	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs11935886	ENSG00000248763.2	RP13-644M16.5	-8.3	1e-15	7.63e-13	-0.45	-0.35	Obesity-related traits;	chr4:69083994	chr4:69066395~69069888:+
KIRC	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	8.3	1e-15	7.64e-13	0.47	0.35	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	8.3	1e-15	7.64e-13	0.47	0.35	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
KIRC	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	8.3	1.01e-15	7.65e-13	0.63	0.35	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
KIRC	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	8.3	1.01e-15	7.66e-13	0.52	0.35	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
KIRC	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	8.3	1.01e-15	7.68e-13	0.37	0.35	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
KIRC	cis	rs950027	0.62	rs2461700	ENSG00000235390.4	CTD-2651B20.5	-8.3	1.01e-15	7.71e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.62	rs2453533	ENSG00000235390.4	CTD-2651B20.5	-8.3	1.01e-15	7.71e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45321077~45321692:-
KIRC	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	8.3	1.01e-15	7.71e-13	0.36	0.35	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
KIRC	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	8.3	1.02e-15	7.73e-13	0.61	0.35	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
KIRC	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	8.3	1.02e-15	7.73e-13	0.54	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
KIRC	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-8.3	1.02e-15	7.74e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
KIRC	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-8.3	1.02e-15	7.74e-13	-0.42	-0.35	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
KIRC	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-8.3	1.02e-15	7.75e-13	-0.44	-0.35	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
KIRC	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-8.3	1.02e-15	7.77e-13	-0.38	-0.35	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
KIRC	cis	rs9847710	0.967	rs2581824	ENSG00000280417.1	RP11-5O17.1	8.3	1.02e-15	7.78e-13	0.41	0.35	Ulcerative colitis;	chr3:52988392	chr3:53046166~53048122:+
KIRC	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-8.3	1.02e-15	7.78e-13	-0.55	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
KIRC	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-8.3	1.03e-15	7.81e-13	-0.36	-0.35	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
KIRC	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	8.3	1.03e-15	7.82e-13	0.5	0.35	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
KIRC	cis	rs950027	0.596	rs2467865	ENSG00000235390.4	CTD-2651B20.5	-8.3	1.03e-15	7.83e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45321077~45321692:-
KIRC	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-8.3	1.03e-15	7.83e-13	-0.42	-0.35	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
KIRC	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	8.29	1.04e-15	7.87e-13	0.24	0.35	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
KIRC	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-8.29	1.04e-15	7.88e-13	-0.36	-0.35	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
KIRC	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-8.29	1.04e-15	7.88e-13	-0.36	-0.35	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
KIRC	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	8.29	1.04e-15	7.89e-13	0.69	0.35	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
KIRC	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-8.29	1.04e-15	7.89e-13	-0.24	-0.35	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
KIRC	cis	rs4819052	0.851	rs2838845	ENSG00000223768.1	LINC00205	-8.29	1.04e-15	7.89e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-8.29	1.04e-15	7.89e-13	-0.39	-0.35	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
KIRC	cis	rs7017914	0.935	rs6472551	ENSG00000254031.4	RP11-326E22.1	8.29	1.04e-15	7.9e-13	0.38	0.35	Bone mineral density;	chr8:70869614	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs1993862	ENSG00000254031.4	RP11-326E22.1	8.29	1.04e-15	7.92e-13	0.38	0.35	Bone mineral density;	chr8:70667127	chr8:71155457~71204223:+
KIRC	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-8.29	1.04e-15	7.92e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
KIRC	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-8.29	1.04e-15	7.93e-13	-0.39	-0.35	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
KIRC	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	8.29	1.04e-15	7.93e-13	0.69	0.35	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
KIRC	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	8.29	1.05e-15	7.94e-13	0.37	0.35	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
KIRC	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	8.29	1.05e-15	7.96e-13	0.49	0.35	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
KIRC	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-8.29	1.05e-15	7.97e-13	-0.49	-0.35	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
KIRC	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-8.29	1.05e-15	7.97e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
KIRC	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-8.29	1.05e-15	7.98e-13	-0.49	-0.35	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
KIRC	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-8.29	1.05e-15	8e-13	-0.35	-0.35	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
KIRC	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-8.29	1.05e-15	8e-13	-0.42	-0.35	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-8.29	1.05e-15	8e-13	-0.42	-0.35	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
KIRC	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	8.29	1.06e-15	8.05e-13	0.75	0.35	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
KIRC	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-8.29	1.06e-15	8.05e-13	-0.5	-0.35	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
KIRC	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	8.29	1.06e-15	8.06e-13	0.59	0.35	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
KIRC	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-8.29	1.06e-15	8.07e-13	-0.39	-0.35	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
KIRC	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	8.29	1.07e-15	8.09e-13	0.36	0.35	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000196472.4	RP13-644M16.4	8.29	1.07e-15	8.1e-13	0.4	0.35	Obesity-related traits;	chr4:69079589	chr4:69181660~69182372:+
KIRC	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	8.29	1.08e-15	8.16e-13	0.31	0.35	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
KIRC	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-8.29	1.08e-15	8.2e-13	-0.46	-0.35	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
KIRC	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-8.29	1.08e-15	8.22e-13	-0.39	-0.35	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-8.29	1.08e-15	8.22e-13	-0.39	-0.35	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-8.29	1.08e-15	8.22e-13	-0.39	-0.35	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
KIRC	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	8.29	1.09e-15	8.26e-13	0.36	0.35	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.545	rs11249525	ENSG00000248763.2	RP13-644M16.5	-8.29	1.09e-15	8.26e-13	-0.45	-0.35	Obesity-related traits;	chr4:69080923	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4443355	ENSG00000248763.2	RP13-644M16.5	-8.29	1.09e-15	8.26e-13	-0.45	-0.35	Obesity-related traits;	chr4:69083026	chr4:69066395~69069888:+
KIRC	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	8.29	1.09e-15	8.26e-13	0.68	0.35	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	8.29	1.09e-15	8.26e-13	0.68	0.35	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
KIRC	cis	rs950027	0.62	rs1145077	ENSG00000235390.4	CTD-2651B20.5	8.29	1.09e-15	8.27e-13	0.33	0.35	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45321077~45321692:-
KIRC	cis	rs950027	0.62	rs1426932	ENSG00000259433.2	CTD-2651B20.4	-8.29	1.09e-15	8.27e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45330209~45332634:-
KIRC	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	8.29	1.09e-15	8.27e-13	0.48	0.35	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
KIRC	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	8.29	1.09e-15	8.28e-13	0.53	0.35	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
KIRC	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	8.29	1.1e-15	8.31e-13	0.46	0.35	Height;	chr6:109347707	chr6:109382795~109383666:+
KIRC	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	8.29	1.1e-15	8.32e-13	0.48	0.35	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
KIRC	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-8.29	1.1e-15	8.33e-13	-0.25	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
KIRC	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-8.29	1.1e-15	8.33e-13	-0.42	-0.35	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
KIRC	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	8.29	1.1e-15	8.35e-13	0.45	0.35	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
KIRC	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-8.29	1.1e-15	8.36e-13	-0.26	-0.35	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
KIRC	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-8.29	1.1e-15	8.37e-13	-0.44	-0.35	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
KIRC	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	8.29	1.11e-15	8.38e-13	0.24	0.35	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
KIRC	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	8.29	1.11e-15	8.41e-13	0.31	0.35	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
KIRC	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-8.29	1.11e-15	8.41e-13	-0.35	-0.35	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
KIRC	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	8.28	1.12e-15	8.46e-13	0.44	0.35	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
KIRC	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	8.28	1.12e-15	8.47e-13	0.45	0.35	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
KIRC	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	8.28	1.12e-15	8.48e-13	0.37	0.35	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
KIRC	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	8.28	1.12e-15	8.48e-13	0.32	0.35	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
KIRC	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-8.28	1.12e-15	8.49e-13	-0.41	-0.35	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
KIRC	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	8.28	1.12e-15	8.49e-13	0.37	0.35	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
KIRC	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	8.28	1.12e-15	8.51e-13	0.48	0.35	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	8.28	1.12e-15	8.51e-13	0.48	0.35	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-8.28	1.12e-15	8.51e-13	-0.47	-0.35	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
KIRC	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-8.28	1.12e-15	8.51e-13	-0.3	-0.35	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
KIRC	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-8.28	1.13e-15	8.54e-13	-0.32	-0.35	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
KIRC	cis	rs7017914	0.967	rs6472539	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70717575	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs3954897	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70723720	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.811	rs4272413	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70723952	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.935	rs6981435	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70724913	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6999739	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70724977	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7013657	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70725324	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs7006615	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70727572	chr8:71155457~71204223:+
KIRC	cis	rs7017914	1	rs7007450	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70728034	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs11989553	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70728664	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13272523	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70729237	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs62530826	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70729408	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs35295900	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70729826	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs35115527	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70730774	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs11991273	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70733625	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.869	rs11987511	ENSG00000254031.4	RP11-326E22.1	8.28	1.13e-15	8.57e-13	0.38	0.35	Bone mineral density;	chr8:70733636	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-8.28	1.13e-15	8.58e-13	-0.47	-0.35	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
KIRC	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	8.28	1.14e-15	8.63e-13	0.4	0.35	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
KIRC	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-8.28	1.14e-15	8.64e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
KIRC	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	8.28	1.15e-15	8.66e-13	0.4	0.35	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
KIRC	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-8.28	1.15e-15	8.67e-13	-0.39	-0.35	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
KIRC	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-8.28	1.15e-15	8.67e-13	-0.52	-0.35	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-8.28	1.15e-15	8.68e-13	-0.47	-0.35	Height;	chr6:109636120	chr6:109382795~109383666:+
KIRC	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-8.28	1.15e-15	8.68e-13	-0.4	-0.35	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
KIRC	cis	rs4356975	0.563	rs12505466	ENSG00000248763.2	RP13-644M16.5	-8.28	1.15e-15	8.69e-13	-0.45	-0.35	Obesity-related traits;	chr4:69119944	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600896	ENSG00000248763.2	RP13-644M16.5	-8.28	1.15e-15	8.69e-13	-0.45	-0.35	Obesity-related traits;	chr4:69121000	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600897	ENSG00000248763.2	RP13-644M16.5	-8.28	1.15e-15	8.69e-13	-0.45	-0.35	Obesity-related traits;	chr4:69121531	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4274916	ENSG00000248763.2	RP13-644M16.5	-8.28	1.15e-15	8.69e-13	-0.45	-0.35	Obesity-related traits;	chr4:69122660	chr4:69066395~69069888:+
KIRC	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	8.28	1.15e-15	8.7e-13	0.51	0.35	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
KIRC	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-8.28	1.15e-15	8.71e-13	-0.47	-0.35	Depression;	chr6:28133900	chr6:28115628~28116551:+
KIRC	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-8.28	1.15e-15	8.71e-13	-0.42	-0.35	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
KIRC	cis	rs4356975	0.697	rs66666893	ENSG00000250919.1	RP11-813N20.3	-8.28	1.15e-15	8.73e-13	-0.37	-0.35	Obesity-related traits;	chr4:69133393	chr4:69027831~69044578:+
KIRC	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	8.28	1.16e-15	8.74e-13	0.69	0.35	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
KIRC	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-8.28	1.16e-15	8.74e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
KIRC	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	8.28	1.16e-15	8.75e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-8.28	1.16e-15	8.75e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-8.28	1.16e-15	8.75e-13	-0.53	-0.35	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-8.28	1.16e-15	8.75e-13	-0.53	-0.35	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-8.28	1.16e-15	8.75e-13	-0.53	-0.35	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
KIRC	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	8.28	1.16e-15	8.75e-13	0.37	0.35	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
KIRC	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	8.28	1.16e-15	8.76e-13	0.44	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
KIRC	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	8.28	1.16e-15	8.78e-13	0.43	0.35	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
KIRC	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-8.28	1.16e-15	8.79e-13	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
KIRC	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	8.28	1.16e-15	8.8e-13	0.46	0.35	Height;	chr6:109741670	chr6:109382795~109383666:+
KIRC	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	8.28	1.17e-15	8.81e-13	0.56	0.35	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
KIRC	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	8.28	1.17e-15	8.81e-13	0.48	0.35	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
KIRC	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-8.28	1.17e-15	8.81e-13	-0.47	-0.35	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
KIRC	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-8.28	1.17e-15	8.82e-13	-0.45	-0.35	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
KIRC	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-8.28	1.17e-15	8.83e-13	-0.42	-0.35	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
KIRC	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	8.28	1.17e-15	8.86e-13	0.42	0.35	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
KIRC	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-8.28	1.18e-15	8.88e-13	-0.43	-0.35	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
KIRC	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	8.28	1.18e-15	8.9e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
KIRC	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-8.28	1.18e-15	8.91e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-8.28	1.18e-15	8.91e-13	-0.45	-0.35	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
KIRC	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	8.28	1.18e-15	8.94e-13	0.54	0.35	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
KIRC	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	8.28	1.19e-15	8.95e-13	0.37	0.35	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
KIRC	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	8.28	1.19e-15	8.96e-13	0.42	0.35	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
KIRC	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	8.28	1.19e-15	8.96e-13	0.75	0.35	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
KIRC	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-8.28	1.19e-15	8.98e-13	-0.36	-0.35	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
KIRC	cis	rs950027	0.62	rs1145080	ENSG00000259433.2	CTD-2651B20.4	-8.28	1.19e-15	8.98e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45330209~45332634:-
KIRC	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	8.28	1.19e-15	8.99e-13	0.37	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
KIRC	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	8.28	1.19e-15	9e-13	0.36	0.35	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
KIRC	cis	rs950027	0.62	rs2467862	ENSG00000235390.4	CTD-2651B20.5	-8.28	1.19e-15	9e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45321077~45321692:-
KIRC	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-8.28	1.2e-15	9.03e-13	-0.31	-0.35	Height;	chr11:118746590	chr11:118791254~118793137:+
KIRC	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	8.28	1.2e-15	9.03e-13	0.37	0.35	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
KIRC	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	8.27	1.2e-15	9.06e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	8.27	1.2e-15	9.06e-13	0.23	0.35	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
KIRC	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	8.27	1.2e-15	9.08e-13	0.58	0.35	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
KIRC	cis	rs3820928	0.874	rs4144328	ENSG00000212391.1	SNORA48	-8.27	1.21e-15	9.12e-13	-0.41	-0.35	Pulmonary function;	chr2:226925471	chr2:226968989~226969122:-
KIRC	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	8.27	1.21e-15	9.13e-13	0.45	0.35	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
KIRC	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	8.27	1.21e-15	9.13e-13	0.3	0.35	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
KIRC	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	8.27	1.21e-15	9.14e-13	0.35	0.35	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
KIRC	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	8.27	1.21e-15	9.14e-13	0.48	0.35	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
KIRC	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	8.27	1.21e-15	9.15e-13	0.48	0.35	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
KIRC	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-8.27	1.21e-15	9.15e-13	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
KIRC	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	8.27	1.22e-15	9.16e-13	0.39	0.35	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
KIRC	cis	rs2486288	0.539	rs2433601	ENSG00000235390.4	CTD-2651B20.5	-8.27	1.22e-15	9.16e-13	-0.33	-0.35	Glomerular filtration rate;	chr15:45424227	chr15:45321077~45321692:-
KIRC	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	8.27	1.22e-15	9.17e-13	0.53	0.35	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
KIRC	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-8.27	1.22e-15	9.17e-13	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-8.27	1.22e-15	9.17e-13	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
KIRC	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-8.27	1.22e-15	9.19e-13	-0.39	-0.35	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
KIRC	cis	rs7829975	0.777	rs6989926	ENSG00000253893.2	FAM85B	8.27	1.22e-15	9.21e-13	0.45	0.35	Mood instability;	chr8:8689803	chr8:8167819~8226614:-
KIRC	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	8.27	1.22e-15	9.22e-13	0.43	0.35	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
KIRC	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	8.27	1.22e-15	9.22e-13	0.48	0.35	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
KIRC	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	8.27	1.22e-15	9.23e-13	0.46	0.35	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
KIRC	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-8.27	1.23e-15	9.24e-13	-0.39	-0.35	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-8.27	1.23e-15	9.24e-13	-0.39	-0.35	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
KIRC	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	8.27	1.23e-15	9.27e-13	0.39	0.35	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
KIRC	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	8.27	1.23e-15	9.29e-13	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	8.27	1.23e-15	9.29e-13	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
KIRC	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-8.27	1.23e-15	9.29e-13	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
KIRC	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-8.27	1.24e-15	9.35e-13	-0.39	-0.35	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
KIRC	cis	rs950027	0.595	rs2486288	ENSG00000235390.4	CTD-2651B20.5	-8.27	1.24e-15	9.37e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45321077~45321692:-
KIRC	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-8.27	1.25e-15	9.38e-13	-0.42	-0.35	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
KIRC	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-8.27	1.25e-15	9.39e-13	-0.5	-0.35	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
KIRC	cis	rs4356975	0.563	rs7439152	ENSG00000250696.4	RP11-704M14.1	8.27	1.25e-15	9.4e-13	0.37	0.35	Obesity-related traits;	chr4:69103288	chr4:69182100~69216766:+
KIRC	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-8.27	1.25e-15	9.4e-13	-0.44	-0.35	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
KIRC	cis	rs7017914	0.967	rs2732087	ENSG00000254031.4	RP11-326E22.1	8.27	1.25e-15	9.41e-13	0.37	0.35	Bone mineral density;	chr8:70948204	chr8:71155457~71204223:+
KIRC	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-8.27	1.25e-15	9.43e-13	-0.35	-0.35	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
KIRC	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-8.27	1.25e-15	9.43e-13	-0.35	-0.35	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
KIRC	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-8.27	1.25e-15	9.43e-13	-0.35	-0.35	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
KIRC	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-8.27	1.25e-15	9.44e-13	-0.34	-0.35	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
KIRC	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-8.27	1.26e-15	9.46e-13	-0.33	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
KIRC	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-8.27	1.26e-15	9.48e-13	-0.42	-0.35	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
KIRC	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-8.27	1.26e-15	9.5e-13	-0.5	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-8.27	1.26e-15	9.5e-13	-0.5	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
KIRC	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	8.27	1.26e-15	9.51e-13	0.75	0.35	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
KIRC	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-8.27	1.27e-15	9.52e-13	-0.39	-0.35	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-8.27	1.27e-15	9.52e-13	-0.39	-0.35	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
KIRC	cis	rs950027	0.62	rs35861938	ENSG00000235390.4	CTD-2651B20.5	-8.27	1.27e-15	9.57e-13	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45321077~45321692:-
KIRC	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-8.27	1.27e-15	9.59e-13	-0.54	-0.35	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
KIRC	cis	rs7017914	0.934	rs13255886	ENSG00000254031.4	RP11-326E22.1	8.27	1.28e-15	9.6e-13	0.38	0.35	Bone mineral density;	chr8:70653719	chr8:71155457~71204223:+
KIRC	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-8.27	1.28e-15	9.61e-13	-0.6	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
KIRC	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-8.27	1.28e-15	9.63e-13	-0.46	-0.35	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
KIRC	cis	rs4356975	0.563	rs4327554	ENSG00000248763.2	RP13-644M16.5	8.27	1.28e-15	9.63e-13	0.44	0.35	Obesity-related traits;	chr4:69120690	chr4:69066395~69069888:+
KIRC	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-8.27	1.28e-15	9.64e-13	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
KIRC	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-8.27	1.28e-15	9.66e-13	-0.38	-0.35	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
KIRC	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-8.27	1.29e-15	9.67e-13	-0.42	-0.35	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
KIRC	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-8.27	1.29e-15	9.7e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
KIRC	cis	rs950027	0.62	rs1153860	ENSG00000235390.4	CTD-2651B20.5	8.27	1.29e-15	9.71e-13	0.33	0.35	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45321077~45321692:-
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000196472.4	RP13-644M16.4	8.26	1.29e-15	9.72e-13	0.4	0.35	Obesity-related traits;	chr4:69078113	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000196472.4	RP13-644M16.4	8.26	1.29e-15	9.72e-13	0.4	0.35	Obesity-related traits;	chr4:69078247	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000196472.4	RP13-644M16.4	8.26	1.29e-15	9.72e-13	0.4	0.35	Obesity-related traits;	chr4:69078533	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000196472.4	RP13-644M16.4	8.26	1.29e-15	9.72e-13	0.4	0.35	Obesity-related traits;	chr4:69078868	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000196472.4	RP13-644M16.4	8.26	1.29e-15	9.72e-13	0.4	0.35	Obesity-related traits;	chr4:69078897	chr4:69181660~69182372:+
KIRC	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	8.26	1.29e-15	9.72e-13	0.38	0.35	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
KIRC	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	8.26	1.3e-15	9.73e-13	0.3	0.35	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
KIRC	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	8.26	1.3e-15	9.75e-13	0.43	0.35	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
KIRC	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	8.26	1.3e-15	9.79e-13	0.52	0.35	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.503	rs11938761	ENSG00000250696.4	RP11-704M14.1	8.26	1.31e-15	9.82e-13	0.37	0.35	Obesity-related traits;	chr4:69083992	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs11935886	ENSG00000250696.4	RP11-704M14.1	8.26	1.31e-15	9.82e-13	0.37	0.35	Obesity-related traits;	chr4:69083994	chr4:69182100~69216766:+
KIRC	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	8.26	1.31e-15	9.87e-13	0.62	0.35	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
KIRC	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-8.26	1.32e-15	9.88e-13	-0.39	-0.35	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
KIRC	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	8.26	1.32e-15	9.89e-13	0.6	0.35	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
KIRC	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	8.26	1.32e-15	9.9e-13	0.46	0.35	Height;	chr6:109424122	chr6:109382795~109383666:+
KIRC	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	8.26	1.32e-15	9.91e-13	0.34	0.35	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
KIRC	cis	rs950027	0.62	rs2467862	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.32e-15	9.92e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45330209~45332634:-
KIRC	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-8.26	1.32e-15	9.93e-13	-0.39	-0.35	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
KIRC	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	8.26	1.32e-15	9.94e-13	0.64	0.35	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	8.26	1.32e-15	9.94e-13	0.64	0.35	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	8.26	1.32e-15	9.94e-13	0.64	0.35	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
KIRC	cis	rs950027	0.62	rs1049518	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.33e-15	9.95e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45330209~45332634:-
KIRC	cis	rs950027	0.584	rs1145086	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.33e-15	9.95e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45330209~45332634:-
KIRC	cis	rs950027	0.62	rs1153857	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.33e-15	9.95e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45330209~45332634:-
KIRC	cis	rs950027	0.62	rs1153855	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.33e-15	9.95e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45330209~45332634:-
KIRC	cis	rs950027	0.62	rs2486274	ENSG00000259433.2	CTD-2651B20.4	-8.26	1.33e-15	9.95e-13	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45330209~45332634:-
KIRC	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-8.26	1.33e-15	9.95e-13	-0.35	-0.35	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
KIRC	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-8.26	1.33e-15	9.96e-13	-0.51	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
KIRC	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-8.26	1.33e-15	9.97e-13	-0.36	-0.35	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
KIRC	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-8.26	1.33e-15	9.97e-13	-0.38	-0.35	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
KIRC	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	8.26	1.33e-15	1e-12	0.31	0.35	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
KIRC	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-8.26	1.34e-15	1e-12	-0.34	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
KIRC	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-8.26	1.34e-15	1e-12	-0.39	-0.35	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
KIRC	cis	rs13113518	0.812	rs12500601	ENSG00000273257.1	RP11-177J6.1	8.26	1.34e-15	1e-12	0.43	0.35	Height;	chr4:55451489	chr4:55387949~55388271:+
KIRC	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	8.26	1.34e-15	1.01e-12	0.25	0.35	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
KIRC	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	8.26	1.34e-15	1.01e-12	0.64	0.35	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	8.26	1.34e-15	1.01e-12	0.64	0.35	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	8.26	1.34e-15	1.01e-12	0.64	0.35	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	8.26	1.34e-15	1.01e-12	0.64	0.35	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
KIRC	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	8.26	1.34e-15	1.01e-12	0.38	0.35	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
KIRC	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-8.26	1.35e-15	1.01e-12	-0.26	-0.35	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
KIRC	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-8.26	1.35e-15	1.01e-12	-0.29	-0.35	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
KIRC	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	8.26	1.35e-15	1.01e-12	0.45	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
KIRC	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-8.26	1.35e-15	1.01e-12	-0.25	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
KIRC	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	8.26	1.36e-15	1.02e-12	0.48	0.35	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
KIRC	cis	rs3820928	0.874	rs1917125	ENSG00000212391.1	SNORA48	-8.26	1.36e-15	1.02e-12	-0.41	-0.35	Pulmonary function;	chr2:226934265	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs67513858	ENSG00000212391.1	SNORA48	-8.26	1.36e-15	1.02e-12	-0.41	-0.35	Pulmonary function;	chr2:226940103	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs7562776	ENSG00000212391.1	SNORA48	-8.26	1.36e-15	1.02e-12	-0.41	-0.35	Pulmonary function;	chr2:226941834	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs4234062	ENSG00000212391.1	SNORA48	-8.26	1.36e-15	1.02e-12	-0.41	-0.35	Pulmonary function;	chr2:226954334	chr2:226968989~226969122:-
KIRC	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	8.26	1.36e-15	1.02e-12	0.5	0.35	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
KIRC	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	8.26	1.36e-15	1.02e-12	0.62	0.35	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	8.26	1.36e-15	1.02e-12	0.62	0.35	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
KIRC	cis	rs10754283	0.84	rs990040	ENSG00000231613.1	RP5-943J3.1	8.26	1.37e-15	1.03e-12	0.36	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89628800	chr1:89788914~89790492:+
KIRC	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-8.26	1.38e-15	1.03e-12	-0.41	-0.35	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
KIRC	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	8.26	1.38e-15	1.03e-12	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
KIRC	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-8.26	1.38e-15	1.03e-12	-0.39	-0.35	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
KIRC	cis	rs12893668	0.603	rs12896171	ENSG00000269910.1	RP11-73M18.10	8.26	1.38e-15	1.04e-12	0.25	0.35	Reticulocyte count;	chr14:103669629	chr14:103694516~103695050:-
KIRC	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.25	1.39e-15	1.04e-12	0.45	0.35	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
KIRC	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-8.25	1.39e-15	1.04e-12	-0.35	-0.35	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
KIRC	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	8.25	1.4e-15	1.05e-12	0.45	0.35	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
KIRC	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-8.25	1.4e-15	1.05e-12	-0.37	-0.35	Height;	chr3:53093751	chr3:53064283~53065091:-
KIRC	cis	rs12893668	0.572	rs4906350	ENSG00000269910.1	RP11-73M18.10	8.25	1.4e-15	1.05e-12	0.25	0.35	Reticulocyte count;	chr14:103645457	chr14:103694516~103695050:-
KIRC	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	8.25	1.4e-15	1.05e-12	0.36	0.35	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	8.25	1.41e-15	1.05e-12	0.36	0.35	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	8.25	1.41e-15	1.05e-12	0.36	0.35	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	8.25	1.41e-15	1.05e-12	0.36	0.35	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
KIRC	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-8.25	1.41e-15	1.05e-12	-0.66	-0.35	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
KIRC	cis	rs7017914	0.967	rs13255735	ENSG00000254031.4	RP11-326E22.1	8.25	1.41e-15	1.05e-12	0.38	0.35	Bone mineral density;	chr8:70947504	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	8.25	1.41e-15	1.06e-12	0.47	0.35	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
KIRC	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-8.25	1.42e-15	1.06e-12	-0.37	-0.35	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
KIRC	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	8.25	1.42e-15	1.07e-12	0.76	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	8.25	1.43e-15	1.07e-12	0.47	0.35	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
KIRC	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	8.25	1.44e-15	1.08e-12	0.67	0.35	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
KIRC	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	8.25	1.44e-15	1.08e-12	0.67	0.35	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
KIRC	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	8.25	1.44e-15	1.08e-12	0.36	0.35	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
KIRC	cis	rs904251	1	rs12212090	ENSG00000227920.2	RP1-153P14.5	-8.25	1.45e-15	1.09e-12	-0.38	-0.35	Cognitive performance;	chr6:37464032	chr6:37545145~37550860:+
KIRC	cis	rs4356975	0.563	rs7442453	ENSG00000248763.2	RP13-644M16.5	-8.25	1.45e-15	1.09e-12	-0.44	-0.35	Obesity-related traits;	chr4:69103462	chr4:69066395~69069888:+
KIRC	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	8.25	1.47e-15	1.1e-12	0.35	0.35	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
KIRC	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-8.25	1.48e-15	1.1e-12	-0.48	-0.35	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
KIRC	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-8.25	1.48e-15	1.1e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
KIRC	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-8.25	1.48e-15	1.1e-12	-0.44	-0.35	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-8.25	1.48e-15	1.11e-12	-0.47	-0.35	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
KIRC	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-8.25	1.49e-15	1.11e-12	-0.42	-0.35	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
KIRC	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-8.25	1.49e-15	1.11e-12	-0.34	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
KIRC	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-8.24	1.5e-15	1.12e-12	-0.34	-0.35	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
KIRC	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-8.24	1.51e-15	1.13e-12	-0.4	-0.35	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
KIRC	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-8.24	1.51e-15	1.13e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
KIRC	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	8.24	1.51e-15	1.13e-12	0.35	0.35	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
KIRC	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-8.24	1.52e-15	1.13e-12	-0.35	-0.35	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
KIRC	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	8.24	1.52e-15	1.13e-12	0.75	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
KIRC	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-8.24	1.52e-15	1.14e-12	-0.44	-0.35	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
KIRC	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	8.24	1.53e-15	1.14e-12	0.31	0.35	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
KIRC	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	8.24	1.53e-15	1.14e-12	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
KIRC	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-8.24	1.53e-15	1.14e-12	-0.42	-0.35	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
KIRC	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.24	1.53e-15	1.14e-12	-0.56	-0.35	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
KIRC	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	8.24	1.54e-15	1.15e-12	0.36	0.35	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
KIRC	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	8.24	1.54e-15	1.15e-12	0.35	0.35	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
KIRC	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	8.24	1.54e-15	1.15e-12	0.48	0.35	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
KIRC	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-8.24	1.54e-15	1.15e-12	-0.39	-0.35	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
KIRC	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-8.24	1.54e-15	1.15e-12	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
KIRC	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	8.24	1.55e-15	1.15e-12	0.61	0.35	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
KIRC	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-8.24	1.55e-15	1.15e-12	-0.34	-0.35	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-8.24	1.55e-15	1.15e-12	-0.34	-0.35	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
KIRC	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	8.24	1.55e-15	1.15e-12	0.42	0.35	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
KIRC	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	8.24	1.55e-15	1.16e-12	0.68	0.35	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	8.24	1.55e-15	1.16e-12	0.68	0.35	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	8.24	1.55e-15	1.16e-12	0.68	0.35	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
KIRC	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	8.24	1.55e-15	1.16e-12	0.44	0.35	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
KIRC	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	8.24	1.55e-15	1.16e-12	0.33	0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
KIRC	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	8.24	1.56e-15	1.16e-12	0.52	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
KIRC	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-8.24	1.56e-15	1.16e-12	-0.39	-0.35	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-8.24	1.56e-15	1.16e-12	-0.39	-0.35	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
KIRC	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	8.24	1.56e-15	1.16e-12	0.37	0.35	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	8.24	1.56e-15	1.16e-12	0.37	0.35	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	8.24	1.56e-15	1.16e-12	0.37	0.35	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
KIRC	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	8.24	1.56e-15	1.16e-12	0.37	0.35	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
KIRC	cis	rs526231	0.819	rs2288788	ENSG00000175749.11	EIF3KP1	8.24	1.57e-15	1.17e-12	0.43	0.35	Primary biliary cholangitis;	chr5:103264868	chr5:103032376~103033031:+
KIRC	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	8.24	1.57e-15	1.17e-12	0.42	0.35	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
KIRC	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	8.24	1.57e-15	1.17e-12	0.42	0.35	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
KIRC	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-8.24	1.58e-15	1.18e-12	-0.38	-0.35	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
KIRC	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	8.24	1.58e-15	1.18e-12	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
KIRC	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-8.24	1.58e-15	1.18e-12	-0.34	-0.35	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
KIRC	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.24	1.58e-15	1.18e-12	0.68	0.35	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
KIRC	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-8.24	1.58e-15	1.18e-12	-0.5	-0.35	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
KIRC	cis	rs4356975	0.697	rs6849081	ENSG00000250919.1	RP11-813N20.3	-8.24	1.59e-15	1.18e-12	-0.36	-0.35	Obesity-related traits;	chr4:69144840	chr4:69027831~69044578:+
KIRC	cis	rs950027	0.596	rs2467853	ENSG00000259433.2	CTD-2651B20.4	-8.24	1.59e-15	1.18e-12	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45330209~45332634:-
KIRC	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-8.24	1.59e-15	1.18e-12	-0.5	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
KIRC	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	8.24	1.6e-15	1.19e-12	0.43	0.35	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
KIRC	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-8.24	1.6e-15	1.19e-12	-0.42	-0.35	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
KIRC	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	8.24	1.6e-15	1.19e-12	0.37	0.35	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
KIRC	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-8.24	1.6e-15	1.19e-12	-0.39	-0.35	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
KIRC	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-8.24	1.6e-15	1.19e-12	-0.39	-0.35	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
KIRC	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-8.24	1.61e-15	1.2e-12	-0.48	-0.35	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
KIRC	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-8.24	1.61e-15	1.2e-12	-0.39	-0.35	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
KIRC	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-8.23	1.61e-15	1.2e-12	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-8.23	1.61e-15	1.2e-12	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
KIRC	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	8.23	1.62e-15	1.2e-12	0.5	0.35	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
KIRC	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-8.23	1.62e-15	1.2e-12	-0.38	-0.35	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
KIRC	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	8.23	1.62e-15	1.21e-12	0.38	0.35	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
KIRC	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-8.23	1.63e-15	1.21e-12	-0.45	-0.35	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.563	rs11932131	ENSG00000250696.4	RP11-704M14.1	8.23	1.63e-15	1.21e-12	0.37	0.35	Obesity-related traits;	chr4:69083829	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs35297888	ENSG00000250696.4	RP11-704M14.1	8.23	1.63e-15	1.21e-12	0.37	0.35	Obesity-related traits;	chr4:69083855	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs35749478	ENSG00000250696.4	RP11-704M14.1	8.23	1.63e-15	1.21e-12	0.37	0.35	Obesity-related traits;	chr4:69083862	chr4:69182100~69216766:+
KIRC	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-8.23	1.63e-15	1.22e-12	-0.37	-0.35	Height;	chr3:53094335	chr3:53064283~53065091:-
KIRC	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	8.23	1.63e-15	1.22e-12	0.46	0.35	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
KIRC	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-8.23	1.64e-15	1.22e-12	-0.48	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
KIRC	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.23	1.64e-15	1.22e-12	-0.43	-0.35	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
KIRC	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-8.23	1.64e-15	1.22e-12	-0.36	-0.35	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
KIRC	cis	rs4356975	0.563	rs6422324	ENSG00000250696.4	RP11-704M14.1	8.23	1.64e-15	1.22e-12	0.37	0.35	Obesity-related traits;	chr4:69087385	chr4:69182100~69216766:+
KIRC	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-8.23	1.65e-15	1.22e-12	-0.36	-0.35	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
KIRC	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	8.23	1.65e-15	1.23e-12	0.52	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
KIRC	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	8.23	1.66e-15	1.23e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	8.23	1.66e-15	1.23e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
KIRC	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	8.23	1.66e-15	1.23e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	8.23	1.66e-15	1.23e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	8.23	1.66e-15	1.23e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	8.23	1.66e-15	1.23e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
KIRC	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-8.23	1.66e-15	1.24e-12	-0.42	-0.35	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
KIRC	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-8.23	1.66e-15	1.24e-12	-0.42	-0.35	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
KIRC	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-8.23	1.67e-15	1.24e-12	-0.33	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
KIRC	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	8.23	1.67e-15	1.24e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
KIRC	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	8.23	1.68e-15	1.25e-12	0.27	0.35	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
KIRC	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	8.23	1.68e-15	1.25e-12	0.62	0.35	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	8.23	1.68e-15	1.25e-12	0.62	0.35	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	8.23	1.68e-15	1.25e-12	0.62	0.35	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	8.23	1.68e-15	1.25e-12	0.62	0.35	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
KIRC	cis	rs1560104	0.597	rs12708757	ENSG00000274834.1	CTD-3037G24.5	8.23	1.68e-15	1.25e-12	0.37	0.35	Obesity-related traits;	chr16:12616724	chr16:12614451~12614852:+
KIRC	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	8.23	1.69e-15	1.25e-12	0.36	0.35	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
KIRC	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	8.23	1.69e-15	1.25e-12	0.43	0.35	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
KIRC	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	8.23	1.69e-15	1.25e-12	0.36	0.35	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
KIRC	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-8.23	1.69e-15	1.26e-12	-0.44	-0.35	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
KIRC	cis	rs4356975	0.583	rs4632729	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69080286	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs11249524	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69080653	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs11249526	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69080934	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.602	rs7674851	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69081113	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7679550	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69081187	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4478248	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69081498	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7680709	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69081745	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4131317	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69083280	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4540108	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69083614	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.545	rs4640729	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69083642	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4522933	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69083780	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs11937683	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69084102	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7659306	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69084560	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4454000	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69084853	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4273534	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69084927	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs4642304	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69085832	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4446391	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69086364	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7437174	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69086885	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6600874	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69087695	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6843382	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69087884	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4694171	ENSG00000250696.4	RP11-704M14.1	8.23	1.69e-15	1.26e-12	0.37	0.35	Obesity-related traits;	chr4:69088579	chr4:69182100~69216766:+
KIRC	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	8.23	1.69e-15	1.26e-12	0.27	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
KIRC	cis	rs950027	0.62	rs1346267	ENSG00000235390.4	CTD-2651B20.5	-8.23	1.7e-15	1.26e-12	-0.33	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45321077~45321692:-
KIRC	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	8.23	1.7e-15	1.26e-12	0.35	0.35	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.563	rs4535394	ENSG00000250696.4	RP11-704M14.1	-8.23	1.7e-15	1.26e-12	-0.36	-0.35	Obesity-related traits;	chr4:69122735	chr4:69182100~69216766:+
KIRC	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	8.23	1.71e-15	1.27e-12	0.53	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
KIRC	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-8.23	1.71e-15	1.27e-12	-0.41	-0.35	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-8.23	1.71e-15	1.27e-12	-0.42	-0.35	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
KIRC	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	8.23	1.72e-15	1.27e-12	0.43	0.35	Height;	chr4:55573424	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	8.23	1.72e-15	1.27e-12	0.36	0.35	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	8.23	1.72e-15	1.27e-12	0.36	0.35	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	8.23	1.72e-15	1.27e-12	0.36	0.35	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.563	rs4293848	ENSG00000248763.2	RP13-644M16.5	-8.23	1.72e-15	1.27e-12	-0.44	-0.35	Obesity-related traits;	chr4:69099784	chr4:69066395~69069888:+
KIRC	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-8.23	1.72e-15	1.28e-12	-0.59	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
KIRC	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-8.23	1.72e-15	1.28e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
KIRC	cis	rs4356975	0.563	rs6600885	ENSG00000250696.4	RP11-704M14.1	8.23	1.72e-15	1.28e-12	0.37	0.35	Obesity-related traits;	chr4:69103949	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7375178	ENSG00000250696.4	RP11-704M14.1	8.23	1.72e-15	1.28e-12	0.37	0.35	Obesity-related traits;	chr4:69103961	chr4:69182100~69216766:+
KIRC	cis	rs7017914	0.934	rs1389202	ENSG00000254031.4	RP11-326E22.1	8.23	1.72e-15	1.28e-12	0.37	0.35	Bone mineral density;	chr8:70940050	chr8:71155457~71204223:+
KIRC	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-8.23	1.72e-15	1.28e-12	-0.39	-0.35	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
KIRC	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	8.23	1.72e-15	1.28e-12	0.61	0.35	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
KIRC	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-8.23	1.73e-15	1.28e-12	-0.47	-0.35	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-8.23	1.73e-15	1.28e-12	-0.47	-0.35	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-8.23	1.73e-15	1.28e-12	-0.47	-0.35	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
KIRC	cis	rs12893668	0.572	rs11540512	ENSG00000269910.1	RP11-73M18.10	8.22	1.73e-15	1.29e-12	0.25	0.35	Reticulocyte count;	chr14:103681040	chr14:103694516~103695050:-
KIRC	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-8.22	1.74e-15	1.29e-12	-0.35	-0.35	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
KIRC	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	8.22	1.74e-15	1.29e-12	0.55	0.35	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
KIRC	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	8.22	1.74e-15	1.29e-12	0.3	0.35	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
KIRC	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-8.22	1.74e-15	1.29e-12	-0.35	-0.35	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
KIRC	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-8.22	1.75e-15	1.3e-12	-0.24	-0.35	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
KIRC	cis	rs10754283	0.84	rs1229992	ENSG00000231613.1	RP5-943J3.1	8.22	1.75e-15	1.3e-12	0.36	0.35	Amyotrophic lateral sclerosis (sporadic);	chr1:89628669	chr1:89788914~89790492:+
KIRC	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-8.22	1.75e-15	1.3e-12	-0.34	-0.35	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
KIRC	cis	rs12893668	0.572	rs35011804	ENSG00000269910.1	RP11-73M18.10	8.22	1.75e-15	1.3e-12	0.25	0.35	Reticulocyte count;	chr14:103685063	chr14:103694516~103695050:-
KIRC	cis	rs12893668	0.572	rs4900591	ENSG00000269910.1	RP11-73M18.10	8.22	1.75e-15	1.3e-12	0.25	0.35	Reticulocyte count;	chr14:103688541	chr14:103694516~103695050:-
KIRC	cis	rs4356975	0.563	rs7658752	ENSG00000248763.2	RP13-644M16.5	-8.22	1.76e-15	1.3e-12	-0.45	-0.35	Obesity-related traits;	chr4:69112350	chr4:69066395~69069888:+
KIRC	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-8.22	1.76e-15	1.3e-12	-0.42	-0.35	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
KIRC	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	8.22	1.76e-15	1.3e-12	0.69	0.35	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
KIRC	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-8.22	1.77e-15	1.31e-12	-0.46	-0.35	Height;	chr6:109432968	chr6:109382795~109383666:+
KIRC	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	8.22	1.77e-15	1.31e-12	0.49	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
KIRC	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-8.22	1.78e-15	1.32e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.583	rs62296935	ENSG00000248763.2	RP13-644M16.5	-8.22	1.78e-15	1.32e-12	-0.45	-0.35	Obesity-related traits;	chr4:69082878	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs62296936	ENSG00000248763.2	RP13-644M16.5	-8.22	1.78e-15	1.32e-12	-0.45	-0.35	Obesity-related traits;	chr4:69082903	chr4:69066395~69069888:+
KIRC	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	8.22	1.78e-15	1.32e-12	0.31	0.35	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
KIRC	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-8.22	1.79e-15	1.33e-12	-0.41	-0.35	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
KIRC	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-8.22	1.79e-15	1.33e-12	-0.5	-0.35	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
KIRC	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
KIRC	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	8.22	1.8e-15	1.33e-12	0.34	0.35	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
KIRC	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-8.22	1.8e-15	1.33e-12	-0.36	-0.35	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
KIRC	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-8.22	1.8e-15	1.33e-12	-0.39	-0.35	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
KIRC	cis	rs950027	0.62	rs1145093	ENSG00000259433.2	CTD-2651B20.4	-8.22	1.81e-15	1.34e-12	-0.25	-0.35	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45330209~45332634:-
KIRC	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	8.22	1.81e-15	1.34e-12	0.42	0.35	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
KIRC	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	8.22	1.81e-15	1.34e-12	0.42	0.35	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
KIRC	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-8.22	1.81e-15	1.34e-12	-0.38	-0.35	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
KIRC	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	8.22	1.81e-15	1.34e-12	0.51	0.35	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
KIRC	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-8.22	1.82e-15	1.35e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
KIRC	cis	rs4356975	0.563	rs6422324	ENSG00000248763.2	RP13-644M16.5	-8.22	1.82e-15	1.35e-12	-0.44	-0.35	Obesity-related traits;	chr4:69087385	chr4:69066395~69069888:+
KIRC	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-8.22	1.83e-15	1.35e-12	-0.48	-0.35	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
KIRC	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-8.22	1.83e-15	1.36e-12	-0.33	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
KIRC	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	8.22	1.83e-15	1.36e-12	0.44	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000196472.4	RP13-644M16.4	8.22	1.83e-15	1.36e-12	0.4	0.35	Obesity-related traits;	chr4:69069866	chr4:69181660~69182372:+
KIRC	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	8.22	1.84e-15	1.36e-12	0.66	0.35	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
KIRC	cis	rs3820928	0.874	rs7563644	ENSG00000212391.1	SNORA48	-8.22	1.84e-15	1.36e-12	-0.41	-0.35	Pulmonary function;	chr2:226982216	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs7605032	ENSG00000212391.1	SNORA48	-8.22	1.84e-15	1.36e-12	-0.41	-0.35	Pulmonary function;	chr2:226982914	chr2:226968989~226969122:-
KIRC	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.22	1.85e-15	1.37e-12	-0.43	-0.35	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
KIRC	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	8.22	1.85e-15	1.37e-12	0.68	0.35	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
KIRC	cis	rs4356975	0.583	rs4632729	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69080286	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs11249524	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69080653	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs11249526	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69080934	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.602	rs7674851	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69081113	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7679550	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69081187	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4478248	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69081498	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7680709	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69081745	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4131317	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083280	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4540108	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083614	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs4640729	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083642	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4522933	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083780	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs11937683	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69084102	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7659306	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69084560	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4454000	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69084853	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4273534	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69084927	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs4642304	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69085832	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4446391	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69086364	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7437174	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69086885	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600874	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69087695	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6843382	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69087884	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4694171	ENSG00000248763.2	RP13-644M16.5	-8.22	1.85e-15	1.37e-12	-0.44	-0.35	Obesity-related traits;	chr4:69088579	chr4:69066395~69069888:+
KIRC	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	8.22	1.86e-15	1.37e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
KIRC	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	8.22	1.86e-15	1.37e-12	0.35	0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
KIRC	cis	rs7017914	0.967	rs6982406	ENSG00000254031.4	RP11-326E22.1	8.21	1.87e-15	1.38e-12	0.38	0.35	Bone mineral density;	chr8:70742373	chr8:71155457~71204223:+
KIRC	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-8.21	1.87e-15	1.38e-12	-0.39	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
KIRC	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-8.21	1.88e-15	1.39e-12	-0.41	-0.35	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
KIRC	cis	rs4356975	0.563	rs4535394	ENSG00000248763.2	RP13-644M16.5	8.21	1.89e-15	1.39e-12	0.44	0.35	Obesity-related traits;	chr4:69122735	chr4:69066395~69069888:+
KIRC	cis	rs3820928	0.874	rs10169717	ENSG00000212391.1	SNORA48	-8.21	1.89e-15	1.4e-12	-0.41	-0.35	Pulmonary function;	chr2:226932195	chr2:226968989~226969122:-
KIRC	cis	rs7017914	1	rs13253842	ENSG00000254031.4	RP11-326E22.1	8.21	1.9e-15	1.4e-12	0.38	0.35	Bone mineral density;	chr8:70713268	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13254908	ENSG00000254031.4	RP11-326E22.1	8.21	1.9e-15	1.4e-12	0.38	0.35	Bone mineral density;	chr8:70713863	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13264669	ENSG00000254031.4	RP11-326E22.1	8.21	1.9e-15	1.4e-12	0.38	0.35	Bone mineral density;	chr8:70714537	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs34508469	ENSG00000254031.4	RP11-326E22.1	8.21	1.9e-15	1.4e-12	0.38	0.35	Bone mineral density;	chr8:70716228	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs56043721	ENSG00000254031.4	RP11-326E22.1	8.21	1.9e-15	1.4e-12	0.38	0.35	Bone mineral density;	chr8:70718192	chr8:71155457~71204223:+
KIRC	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-8.21	1.9e-15	1.4e-12	-0.36	-0.35	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-8.21	1.9e-15	1.4e-12	-0.35	-0.35	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
KIRC	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	8.21	1.9e-15	1.41e-12	0.5	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
KIRC	cis	rs7017914	0.934	rs7015035	ENSG00000254031.4	RP11-326E22.1	8.21	1.91e-15	1.41e-12	0.38	0.35	Bone mineral density;	chr8:70741366	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs34905858	ENSG00000254031.4	RP11-326E22.1	8.21	1.91e-15	1.41e-12	0.38	0.35	Bone mineral density;	chr8:70747215	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs6998024	ENSG00000254031.4	RP11-326E22.1	8.21	1.91e-15	1.41e-12	0.38	0.35	Bone mineral density;	chr8:70748605	chr8:71155457~71204223:+
KIRC	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-8.21	1.91e-15	1.41e-12	-0.28	-0.35	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
KIRC	cis	rs4356975	0.563	rs11932131	ENSG00000248763.2	RP13-644M16.5	-8.21	1.91e-15	1.41e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083829	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs35297888	ENSG00000248763.2	RP13-644M16.5	-8.21	1.91e-15	1.41e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083855	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs35749478	ENSG00000248763.2	RP13-644M16.5	-8.21	1.91e-15	1.41e-12	-0.44	-0.35	Obesity-related traits;	chr4:69083862	chr4:69066395~69069888:+
KIRC	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-8.21	1.92e-15	1.41e-12	-0.37	-0.35	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
KIRC	cis	rs3820928	0.869	rs2396436	ENSG00000212391.1	SNORA48	-8.21	1.92e-15	1.41e-12	-0.4	-0.35	Pulmonary function;	chr2:226930748	chr2:226968989~226969122:-
KIRC	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	8.21	1.92e-15	1.41e-12	0.44	0.35	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
KIRC	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.21	1.92e-15	1.42e-12	0.45	0.35	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
KIRC	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	8.21	1.92e-15	1.42e-12	0.46	0.35	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
KIRC	cis	rs755249	0.701	rs1180342	ENSG00000182109.6	RP11-69E11.4	-8.21	1.93e-15	1.42e-12	-0.26	-0.35	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39522280~39546187:-
KIRC	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-8.21	1.94e-15	1.43e-12	-0.5	-0.35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
KIRC	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-8.21	1.94e-15	1.43e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	8.21	1.94e-15	1.43e-12	0.43	0.35	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
KIRC	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	8.21	1.94e-15	1.43e-12	0.45	0.35	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
KIRC	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	8.21	1.95e-15	1.44e-12	0.45	0.35	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
KIRC	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-8.21	1.95e-15	1.44e-12	-0.28	-0.35	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
KIRC	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.21	1.96e-15	1.45e-12	0.56	0.35	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
KIRC	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	8.21	1.96e-15	1.45e-12	0.43	0.35	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
KIRC	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	8.21	1.97e-15	1.45e-12	0.43	0.35	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
KIRC	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	8.21	1.97e-15	1.45e-12	0.49	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
KIRC	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	8.21	1.98e-15	1.46e-12	0.46	0.35	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
KIRC	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-8.21	1.98e-15	1.46e-12	-0.42	-0.35	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
KIRC	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	8.21	1.98e-15	1.46e-12	0.38	0.35	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	8.21	1.98e-15	1.46e-12	0.38	0.35	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
KIRC	cis	rs79040073	0.593	rs11632038	ENSG00000259531.2	RP11-295H24.3	8.21	1.98e-15	1.46e-12	0.47	0.35	Lung cancer in ever smokers;	chr15:49314101	chr15:49365124~49366685:-
KIRC	cis	rs4356975	0.83	rs10012215	ENSG00000250919.1	RP11-813N20.3	-8.21	1.98e-15	1.46e-12	-0.37	-0.35	Obesity-related traits;	chr4:69048448	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs10012240	ENSG00000250919.1	RP11-813N20.3	-8.21	1.98e-15	1.46e-12	-0.37	-0.35	Obesity-related traits;	chr4:69048519	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs10012607	ENSG00000250919.1	RP11-813N20.3	-8.21	1.98e-15	1.46e-12	-0.37	-0.35	Obesity-related traits;	chr4:69048866	chr4:69027831~69044578:+
KIRC	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	8.21	1.98e-15	1.46e-12	0.52	0.35	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
KIRC	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	8.21	2e-15	1.47e-12	0.38	0.35	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
KIRC	cis	rs4356975	0.545	rs11249525	ENSG00000250696.4	RP11-704M14.1	8.21	2e-15	1.47e-12	0.36	0.35	Obesity-related traits;	chr4:69080923	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4443355	ENSG00000250696.4	RP11-704M14.1	8.21	2e-15	1.47e-12	0.36	0.35	Obesity-related traits;	chr4:69083026	chr4:69182100~69216766:+
KIRC	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-8.2	2.01e-15	1.48e-12	-0.47	-0.35	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
KIRC	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-8.2	2.02e-15	1.49e-12	-0.59	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
KIRC	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-8.2	2.02e-15	1.49e-12	-0.39	-0.35	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-8.2	2.02e-15	1.49e-12	-0.39	-0.35	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
KIRC	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-8.2	2.02e-15	1.49e-12	-0.39	-0.35	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
KIRC	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	8.2	2.02e-15	1.49e-12	0.64	0.35	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	8.2	2.02e-15	1.49e-12	0.43	0.35	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
KIRC	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-8.2	2.02e-15	1.49e-12	-0.3	-0.35	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
KIRC	cis	rs7017914	0.967	rs62530792	ENSG00000254031.4	RP11-326E22.1	8.2	2.03e-15	1.49e-12	0.38	0.35	Bone mineral density;	chr8:70706532	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs35893260	ENSG00000254031.4	RP11-326E22.1	8.2	2.03e-15	1.49e-12	0.38	0.35	Bone mineral density;	chr8:70707838	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs34882924	ENSG00000254031.4	RP11-326E22.1	8.2	2.03e-15	1.49e-12	0.38	0.35	Bone mineral density;	chr8:70654073	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	8.2	2.03e-15	1.49e-12	0.43	0.35	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
KIRC	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	8.2	2.03e-15	1.49e-12	0.69	0.35	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
KIRC	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	8.2	2.03e-15	1.49e-12	0.69	0.35	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
KIRC	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	8.2	2.03e-15	1.49e-12	0.69	0.35	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
KIRC	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	8.2	2.03e-15	1.49e-12	0.42	0.35	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
KIRC	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	8.2	2.03e-15	1.49e-12	0.31	0.35	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
KIRC	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-8.2	2.04e-15	1.5e-12	-0.44	-0.35	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
KIRC	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-8.2	2.04e-15	1.5e-12	-0.43	-0.35	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
KIRC	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-8.2	2.05e-15	1.5e-12	-0.36	-0.35	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
KIRC	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-8.2	2.05e-15	1.5e-12	-0.34	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
KIRC	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	8.2	2.05e-15	1.51e-12	0.72	0.35	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
KIRC	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	8.2	2.05e-15	1.51e-12	0.61	0.35	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
KIRC	cis	rs12893668	0.572	rs4906356	ENSG00000269910.1	RP11-73M18.10	8.2	2.05e-15	1.51e-12	0.25	0.35	Reticulocyte count;	chr14:103672364	chr14:103694516~103695050:-
KIRC	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	8.2	2.06e-15	1.51e-12	0.5	0.35	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
KIRC	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	8.2	2.06e-15	1.51e-12	0.63	0.35	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
KIRC	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	8.2	2.06e-15	1.51e-12	0.43	0.35	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
KIRC	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	8.2	2.06e-15	1.51e-12	0.28	0.35	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
KIRC	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	8.2	2.07e-15	1.52e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	8.2	2.07e-15	1.52e-12	0.23	0.35	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
KIRC	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-8.2	2.08e-15	1.53e-12	-0.31	-0.35	Height;	chr11:118781100	chr11:118791254~118793137:+
KIRC	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	8.2	2.08e-15	1.53e-12	0.61	0.35	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	8.2	2.08e-15	1.53e-12	0.61	0.35	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	8.2	2.08e-15	1.53e-12	0.61	0.35	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
KIRC	cis	rs3820928	0.874	rs10207404	ENSG00000212391.1	SNORA48	-8.2	2.09e-15	1.53e-12	-0.4	-0.35	Pulmonary function;	chr2:226929704	chr2:226968989~226969122:-
KIRC	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	8.2	2.09e-15	1.53e-12	0.44	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
KIRC	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-8.2	2.09e-15	1.53e-12	-0.38	-0.35	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
KIRC	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	8.2	2.09e-15	1.54e-12	0.28	0.35	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
KIRC	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-8.2	2.09e-15	1.54e-12	-0.42	-0.35	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
KIRC	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.2	2.12e-15	1.55e-12	0.45	0.35	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
KIRC	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	8.2	2.13e-15	1.56e-12	0.3	0.35	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
KIRC	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	8.2	2.13e-15	1.56e-12	0.61	0.35	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
KIRC	cis	rs12893668	0.572	rs12590968	ENSG00000269910.1	RP11-73M18.10	8.2	2.13e-15	1.56e-12	0.25	0.35	Reticulocyte count;	chr14:103670296	chr14:103694516~103695050:-
KIRC	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	8.2	2.13e-15	1.56e-12	0.28	0.35	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
KIRC	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-8.2	2.13e-15	1.56e-12	-0.35	-0.35	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-8.2	2.13e-15	1.56e-12	-0.35	-0.35	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
KIRC	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	8.2	2.13e-15	1.56e-12	0.43	0.35	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
KIRC	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	8.2	2.14e-15	1.57e-12	0.48	0.35	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
KIRC	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-8.2	2.15e-15	1.58e-12	-0.3	-0.35	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
KIRC	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-8.2	2.16e-15	1.58e-12	-0.6	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
KIRC	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-8.2	2.16e-15	1.58e-12	-0.33	-0.35	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
KIRC	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-8.2	2.16e-15	1.58e-12	-0.4	-0.35	Height;	chr11:118808920	chr11:118704607~118750263:+
KIRC	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	8.19	2.16e-15	1.58e-12	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	8.19	2.16e-15	1.58e-12	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
KIRC	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	8.19	2.17e-15	1.59e-12	0.42	0.35	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
KIRC	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-8.19	2.17e-15	1.59e-12	-0.42	-0.35	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
KIRC	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	8.19	2.17e-15	1.59e-12	0.52	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
KIRC	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	8.19	2.17e-15	1.59e-12	0.49	0.35	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
KIRC	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	8.19	2.18e-15	1.6e-12	0.46	0.35	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
KIRC	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	8.19	2.19e-15	1.6e-12	0.29	0.35	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
KIRC	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	8.19	2.2e-15	1.61e-12	0.45	0.35	Height;	chr6:109391534	chr6:109382795~109383666:+
KIRC	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.19	2.2e-15	1.61e-12	-0.54	-0.35	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
KIRC	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-8.19	2.2e-15	1.61e-12	-0.45	-0.35	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
KIRC	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	8.19	2.21e-15	1.62e-12	0.47	0.35	Height;	chr6:109423238	chr6:109382795~109383666:+
KIRC	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-8.19	2.21e-15	1.62e-12	-0.59	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
KIRC	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.19	2.21e-15	1.62e-12	0.45	0.35	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
KIRC	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	8.19	2.21e-15	1.62e-12	0.49	0.35	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
KIRC	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-8.19	2.21e-15	1.62e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-8.19	2.21e-15	1.62e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-8.19	2.21e-15	1.62e-12	-0.37	-0.35	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
KIRC	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	8.19	2.21e-15	1.62e-12	0.63	0.35	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	8.19	2.21e-15	1.62e-12	0.63	0.35	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	8.19	2.21e-15	1.62e-12	0.63	0.35	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	8.19	2.21e-15	1.62e-12	0.63	0.35	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	8.19	2.21e-15	1.62e-12	0.63	0.35	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	8.19	2.22e-15	1.62e-12	0.34	0.35	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	8.19	2.22e-15	1.62e-12	0.34	0.35	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	8.19	2.22e-15	1.62e-12	0.34	0.35	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
KIRC	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	8.19	2.22e-15	1.62e-12	0.6	0.35	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	8.19	2.22e-15	1.62e-12	0.6	0.35	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
KIRC	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	8.19	2.22e-15	1.62e-12	0.36	0.35	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
KIRC	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	8.19	2.22e-15	1.62e-12	0.29	0.35	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	8.19	2.22e-15	1.62e-12	0.29	0.35	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
KIRC	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	8.19	2.22e-15	1.63e-12	0.48	0.35	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
KIRC	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-8.19	2.23e-15	1.63e-12	-0.34	-0.35	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
KIRC	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	8.19	2.24e-15	1.63e-12	0.31	0.35	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
KIRC	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	8.19	2.24e-15	1.63e-12	0.46	0.35	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
KIRC	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	8.19	2.24e-15	1.64e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	8.19	2.24e-15	1.64e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	8.19	2.24e-15	1.64e-12	0.38	0.35	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
KIRC	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-8.19	2.24e-15	1.64e-12	-0.39	-0.35	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
KIRC	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-8.19	2.24e-15	1.64e-12	-0.39	-0.35	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
KIRC	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-8.19	2.24e-15	1.64e-12	-0.39	-0.35	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
KIRC	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	8.19	2.25e-15	1.65e-12	0.44	0.35	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
KIRC	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-8.19	2.26e-15	1.65e-12	-0.44	-0.35	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
KIRC	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	8.19	2.27e-15	1.65e-12	0.38	0.35	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
KIRC	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	8.19	2.27e-15	1.66e-12	0.74	0.35	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
KIRC	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-8.19	2.27e-15	1.66e-12	-0.29	-0.35	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
KIRC	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-8.19	2.27e-15	1.66e-12	-0.48	-0.35	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
KIRC	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	8.19	2.29e-15	1.68e-12	0.34	0.35	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
KIRC	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	8.19	2.3e-15	1.68e-12	0.45	0.35	Height;	chr6:109393881	chr6:109382795~109383666:+
KIRC	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.19	2.3e-15	1.68e-12	-0.34	-0.35	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
KIRC	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	8.19	2.3e-15	1.68e-12	0.49	0.35	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
KIRC	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	8.19	2.3e-15	1.68e-12	0.3	0.35	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	8.19	2.3e-15	1.68e-12	0.3	0.35	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	8.19	2.3e-15	1.68e-12	0.3	0.35	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
KIRC	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	8.19	2.3e-15	1.68e-12	0.3	0.35	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
KIRC	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	8.19	2.3e-15	1.68e-12	0.46	0.35	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
KIRC	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	8.19	2.31e-15	1.68e-12	0.41	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
KIRC	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	8.19	2.31e-15	1.69e-12	0.36	0.35	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	8.19	2.31e-15	1.69e-12	0.36	0.35	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	8.19	2.31e-15	1.69e-12	0.36	0.35	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	8.19	2.31e-15	1.69e-12	0.36	0.35	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.798	rs4694588	ENSG00000250919.1	RP11-813N20.3	8.19	2.32e-15	1.69e-12	0.37	0.35	Obesity-related traits;	chr4:69044664	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs6422321	ENSG00000250919.1	RP11-813N20.3	8.19	2.32e-15	1.69e-12	0.37	0.35	Obesity-related traits;	chr4:69044911	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.768	rs4518318	ENSG00000250919.1	RP11-813N20.3	8.19	2.32e-15	1.69e-12	0.37	0.35	Obesity-related traits;	chr4:69045479	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.83	rs4351079	ENSG00000250919.1	RP11-813N20.3	8.19	2.32e-15	1.69e-12	0.37	0.35	Obesity-related traits;	chr4:69045631	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.798	rs4607293	ENSG00000250919.1	RP11-813N20.3	8.19	2.32e-15	1.69e-12	0.37	0.35	Obesity-related traits;	chr4:69045714	chr4:69027831~69044578:+
KIRC	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-8.19	2.32e-15	1.69e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
KIRC	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-8.18	2.33e-15	1.7e-12	-0.36	-0.35	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
KIRC	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	8.18	2.33e-15	1.7e-12	0.35	0.35	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
KIRC	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-8.18	2.33e-15	1.7e-12	-0.42	-0.35	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
KIRC	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	8.18	2.33e-15	1.7e-12	0.65	0.35	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
KIRC	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	8.18	2.34e-15	1.71e-12	0.44	0.35	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
KIRC	cis	rs6600671	0.899	rs6674392	ENSG00000227082.1	CH17-437K3.1	-8.18	2.35e-15	1.71e-12	-0.39	-0.35	Hip geometry;	chr1:121518864	chr1:121396754~121463129:+
KIRC	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	8.18	2.36e-15	1.72e-12	0.25	0.35	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
KIRC	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	8.18	2.36e-15	1.72e-12	0.22	0.35	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	8.18	2.36e-15	1.72e-12	0.22	0.35	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
KIRC	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	8.18	2.38e-15	1.73e-12	0.47	0.35	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
KIRC	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-8.18	2.38e-15	1.73e-12	-0.41	-0.35	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
KIRC	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	8.18	2.38e-15	1.73e-12	0.44	0.35	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	8.18	2.38e-15	1.73e-12	0.44	0.35	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
KIRC	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	8.18	2.39e-15	1.74e-12	0.74	0.35	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
KIRC	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	8.18	2.39e-15	1.74e-12	0.36	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
KIRC	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	8.18	2.39e-15	1.74e-12	0.49	0.35	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
KIRC	cis	rs6479901	0.947	rs7358191	ENSG00000232075.1	MRPL35P2	-8.18	2.39e-15	1.74e-12	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63519028	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7358152	ENSG00000232075.1	MRPL35P2	-8.18	2.39e-15	1.74e-12	-0.45	-0.35	Intelligence (multi-trait analysis);	chr10:63519138	chr10:63634317~63634827:-
KIRC	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	8.18	2.41e-15	1.75e-12	0.42	0.35	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
KIRC	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	8.18	2.41e-15	1.75e-12	0.36	0.35	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	8.18	2.41e-15	1.75e-12	0.36	0.35	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
KIRC	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	8.18	2.41e-15	1.75e-12	0.49	0.35	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
KIRC	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	8.18	2.41e-15	1.76e-12	0.68	0.35	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	8.18	2.41e-15	1.76e-12	0.68	0.35	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
KIRC	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-8.18	2.41e-15	1.76e-12	-0.44	-0.35	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
KIRC	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	8.18	2.41e-15	1.76e-12	0.29	0.35	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
KIRC	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	8.18	2.41e-15	1.76e-12	0.29	0.35	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
KIRC	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	8.18	2.42e-15	1.76e-12	0.3	0.35	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
KIRC	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-8.18	2.42e-15	1.76e-12	-0.38	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
KIRC	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	8.18	2.43e-15	1.77e-12	0.5	0.35	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
KIRC	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	8.18	2.44e-15	1.78e-12	0.44	0.35	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
KIRC	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	8.18	2.46e-15	1.79e-12	0.38	0.34	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
KIRC	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	8.18	2.46e-15	1.79e-12	0.3	0.34	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
KIRC	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	8.18	2.46e-15	1.79e-12	0.42	0.34	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
KIRC	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	8.18	2.46e-15	1.79e-12	0.43	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
KIRC	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-8.18	2.46e-15	1.79e-12	-0.35	-0.34	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
KIRC	cis	rs3820928	0.874	rs7423610	ENSG00000212391.1	SNORA48	-8.18	2.46e-15	1.79e-12	-0.41	-0.34	Pulmonary function;	chr2:226971546	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	8.18	2.47e-15	1.8e-12	0.35	0.34	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-8.18	2.48e-15	1.8e-12	-0.47	-0.34	Depression;	chr6:28096855	chr6:28115628~28116551:+
KIRC	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-8.18	2.48e-15	1.8e-12	-0.46	-0.34	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-8.18	2.48e-15	1.8e-12	-0.46	-0.34	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
KIRC	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	8.18	2.48e-15	1.8e-12	0.36	0.34	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	8.18	2.48e-15	1.8e-12	0.36	0.34	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	8.18	2.48e-15	1.8e-12	0.36	0.34	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
KIRC	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	8.18	2.49e-15	1.81e-12	0.45	0.34	Height;	chr6:109360263	chr6:109382795~109383666:+
KIRC	cis	rs7017914	0.967	rs1902614	ENSG00000254031.4	RP11-326E22.1	8.18	2.5e-15	1.82e-12	0.38	0.34	Bone mineral density;	chr8:70743932	chr8:71155457~71204223:+
KIRC	cis	rs4356975	0.83	rs7693166	ENSG00000250919.1	RP11-813N20.3	8.18	2.5e-15	1.82e-12	0.37	0.34	Obesity-related traits;	chr4:69044866	chr4:69027831~69044578:+
KIRC	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-8.17	2.5e-15	1.82e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-8.17	2.5e-15	1.82e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
KIRC	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-8.17	2.51e-15	1.83e-12	-0.5	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
KIRC	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-8.17	2.52e-15	1.83e-12	-0.38	-0.34	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
KIRC	cis	rs13113518	0.812	rs56055342	ENSG00000273257.1	RP11-177J6.1	8.17	2.52e-15	1.83e-12	0.43	0.34	Height;	chr4:55540928	chr4:55387949~55388271:+
KIRC	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	8.17	2.53e-15	1.84e-12	0.3	0.34	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
KIRC	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-8.17	2.55e-15	1.85e-12	-0.47	-0.34	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
KIRC	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	8.17	2.55e-15	1.85e-12	0.61	0.34	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	8.17	2.55e-15	1.85e-12	0.61	0.34	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	8.17	2.55e-15	1.85e-12	0.61	0.34	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	8.17	2.55e-15	1.85e-12	0.61	0.34	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	8.17	2.55e-15	1.85e-12	0.61	0.34	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
KIRC	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	8.17	2.56e-15	1.86e-12	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
KIRC	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-8.17	2.56e-15	1.86e-12	-0.24	-0.34	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
KIRC	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-8.17	2.56e-15	1.86e-12	-0.46	-0.34	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
KIRC	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-8.17	2.56e-15	1.86e-12	-0.38	-0.34	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
KIRC	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	8.17	2.57e-15	1.87e-12	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
KIRC	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Depression;	chr6:28123153	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Depression;	chr6:28124529	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Depression;	chr6:28126588	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Depression;	chr6:28126953	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-8.17	2.57e-15	1.87e-12	-0.47	-0.34	Depression;	chr6:28127577	chr6:28115628~28116551:+
KIRC	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	8.17	2.57e-15	1.87e-12	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
KIRC	cis	rs3820928	0.874	rs1917122	ENSG00000212391.1	SNORA48	-8.17	2.58e-15	1.87e-12	-0.41	-0.34	Pulmonary function;	chr2:226970965	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs1996998	ENSG00000212391.1	SNORA48	-8.17	2.58e-15	1.87e-12	-0.41	-0.34	Pulmonary function;	chr2:226975578	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	8.17	2.61e-15	1.89e-12	0.43	0.34	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.563	rs3924192	ENSG00000248763.2	RP13-644M16.5	8.17	2.61e-15	1.9e-12	0.44	0.34	Obesity-related traits;	chr4:69105246	chr4:69066395~69069888:+
KIRC	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	8.17	2.62e-15	1.9e-12	0.35	0.34	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.563	rs6600878	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69092618	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.583	rs6819757	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69092946	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs57216626	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69093105	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs59415892	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69093191	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs62296942	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69093401	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7437039	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69093758	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7439792	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69093881	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs62296944	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094492	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600879	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094669	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600880	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094762	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4538548	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094951	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600883	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094953	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs4455491	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69095215	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs11940220	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69095222	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs11940316	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69095409	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7668258	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69096360	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs12647681	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69097442	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs12647682	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69097450	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs58544196	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69097740	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7439326	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69098462	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7438244	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69098491	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7441750	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69098803	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7441774	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69098836	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs7434332	ENSG00000248763.2	RP13-644M16.5	-8.17	2.62e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69099141	chr4:69066395~69069888:+
KIRC	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-8.17	2.62e-15	1.9e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
KIRC	cis	rs4356975	0.563	rs7676472	ENSG00000248763.2	RP13-644M16.5	-8.17	2.63e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69090226	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs7663584	ENSG00000248763.2	RP13-644M16.5	-8.17	2.63e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69090392	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600876	ENSG00000248763.2	RP13-644M16.5	-8.17	2.63e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69091212	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.583	rs6600877	ENSG00000248763.2	RP13-644M16.5	-8.17	2.63e-15	1.9e-12	-0.44	-0.34	Obesity-related traits;	chr4:69091505	chr4:69066395~69069888:+
KIRC	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	8.17	2.63e-15	1.9e-12	0.27	0.34	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
KIRC	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	8.17	2.64e-15	1.91e-12	0.4	0.34	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
KIRC	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	8.17	2.64e-15	1.91e-12	0.53	0.34	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
KIRC	cis	rs4356975	0.563	rs4554144	ENSG00000248763.2	RP13-644M16.5	-8.17	2.64e-15	1.91e-12	-0.44	-0.34	Obesity-related traits;	chr4:69094837	chr4:69066395~69069888:+
KIRC	cis	rs3820928	0.874	rs11685983	ENSG00000212391.1	SNORA48	-8.17	2.64e-15	1.92e-12	-0.41	-0.34	Pulmonary function;	chr2:226935137	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.839	rs4675123	ENSG00000212391.1	SNORA48	-8.17	2.64e-15	1.92e-12	-0.41	-0.34	Pulmonary function;	chr2:226935489	chr2:226968989~226969122:-
KIRC	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	8.17	2.64e-15	1.92e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
KIRC	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	8.17	2.66e-15	1.92e-12	0.59	0.34	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	8.17	2.66e-15	1.92e-12	0.59	0.34	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
KIRC	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-8.17	2.66e-15	1.93e-12	-0.33	-0.34	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
KIRC	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-8.17	2.66e-15	1.93e-12	-0.35	-0.34	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
KIRC	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	8.17	2.67e-15	1.93e-12	0.46	0.34	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
KIRC	cis	rs4356975	0.563	rs7438135	ENSG00000248763.2	RP13-644M16.5	-8.17	2.68e-15	1.94e-12	-0.44	-0.34	Obesity-related traits;	chr4:69095621	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	8.17	2.68e-15	1.94e-12	0.43	0.34	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
KIRC	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	8.17	2.68e-15	1.94e-12	0.43	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	8.17	2.69e-15	1.94e-12	0.34	0.34	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
KIRC	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	8.16	2.69e-15	1.95e-12	0.3	0.34	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
KIRC	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	8.16	2.7e-15	1.95e-12	0.43	0.34	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
KIRC	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	8.16	2.7e-15	1.95e-12	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
KIRC	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	8.16	2.7e-15	1.95e-12	0.38	0.34	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
KIRC	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	8.16	2.71e-15	1.96e-12	0.42	0.34	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
KIRC	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	8.16	2.72e-15	1.96e-12	0.45	0.34	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
KIRC	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-8.16	2.72e-15	1.96e-12	-0.45	-0.34	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-8.16	2.72e-15	1.96e-12	-0.45	-0.34	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
KIRC	cis	rs2734839	0.964	rs7122246	ENSG00000270179.1	RP11-159N11.4	-8.16	2.72e-15	1.96e-12	-0.36	-0.34	Information processing speed;	chr11:113433735	chr11:113368478~113369117:+
KIRC	cis	rs2486288	0.539	rs2433601	ENSG00000259433.2	CTD-2651B20.4	-8.16	2.72e-15	1.97e-12	-0.25	-0.34	Glomerular filtration rate;	chr15:45424227	chr15:45330209~45332634:-
KIRC	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-8.16	2.73e-15	1.97e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-8.16	2.73e-15	1.97e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-8.16	2.73e-15	1.97e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
KIRC	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-8.16	2.73e-15	1.97e-12	-0.44	-0.34	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
KIRC	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	8.16	2.73e-15	1.98e-12	0.34	0.34	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
KIRC	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-8.16	2.73e-15	1.98e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-8.16	2.73e-15	1.98e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
KIRC	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-8.16	2.73e-15	1.98e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
KIRC	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-8.16	2.74e-15	1.98e-12	-0.4	-0.34	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
KIRC	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	8.16	2.74e-15	1.98e-12	0.48	0.34	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
KIRC	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-8.16	2.75e-15	1.99e-12	-0.4	-0.34	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
KIRC	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-8.16	2.76e-15	1.99e-12	-0.24	-0.34	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
KIRC	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-8.16	2.76e-15	1.99e-12	-0.48	-0.34	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
KIRC	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	8.16	2.76e-15	1.99e-12	0.68	0.34	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	8.16	2.76e-15	1.99e-12	0.68	0.34	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	8.16	2.76e-15	1.99e-12	0.68	0.34	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
KIRC	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	8.16	2.76e-15	1.99e-12	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
KIRC	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-8.16	2.77e-15	2e-12	-0.47	-0.34	Depression;	chr6:28137418	chr6:28115628~28116551:+
KIRC	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-8.16	2.77e-15	2e-12	-0.28	-0.34	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
KIRC	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-8.16	2.78e-15	2.01e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
KIRC	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	8.16	2.78e-15	2.01e-12	0.44	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
KIRC	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-8.16	2.79e-15	2.01e-12	-0.38	-0.34	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
KIRC	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-8.16	2.79e-15	2.02e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
KIRC	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-8.16	2.8e-15	2.02e-12	-0.41	-0.34	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-8.16	2.8e-15	2.02e-12	-0.41	-0.34	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
KIRC	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-8.16	2.8e-15	2.02e-12	-0.48	-0.34	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
KIRC	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	8.16	2.81e-15	2.03e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
KIRC	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	8.16	2.81e-15	2.03e-12	0.34	0.34	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
KIRC	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-8.16	2.81e-15	2.03e-12	-0.34	-0.34	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
KIRC	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	8.16	2.82e-15	2.04e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
KIRC	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-8.16	2.83e-15	2.04e-12	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	8.16	2.83e-15	2.04e-12	0.43	0.34	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
KIRC	cis	rs1560104	0.576	rs11640886	ENSG00000274834.1	CTD-3037G24.5	8.16	2.84e-15	2.05e-12	0.37	0.34	Obesity-related traits;	chr16:12615377	chr16:12614451~12614852:+
KIRC	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Depression;	chr6:28136698	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Depression;	chr6:28136856	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Depression;	chr6:28138363	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Depression;	chr6:28138981	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-8.16	2.85e-15	2.06e-12	-0.46	-0.34	Depression;	chr6:28139012	chr6:28115628~28116551:+
KIRC	cis	rs950027	0.595	rs2486288	ENSG00000259433.2	CTD-2651B20.4	-8.16	2.85e-15	2.06e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45330209~45332634:-
KIRC	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-8.16	2.86e-15	2.06e-12	-0.44	-0.34	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
KIRC	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-8.16	2.86e-15	2.06e-12	-0.34	-0.34	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
KIRC	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-8.16	2.86e-15	2.06e-12	-0.3	-0.34	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
KIRC	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-8.16	2.87e-15	2.07e-12	-0.5	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-8.16	2.87e-15	2.07e-12	-0.5	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
KIRC	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	8.16	2.87e-15	2.07e-12	0.45	0.34	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
KIRC	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-8.16	2.89e-15	2.08e-12	-0.33	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
KIRC	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-8.16	2.89e-15	2.08e-12	-0.44	-0.34	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
KIRC	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-8.16	2.89e-15	2.08e-12	-0.51	-0.34	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
KIRC	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	8.15	2.9e-15	2.09e-12	0.67	0.34	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
KIRC	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-8.15	2.9e-15	2.09e-12	-0.53	-0.34	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
KIRC	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-8.15	2.92e-15	2.1e-12	-0.48	-0.34	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
KIRC	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	8.15	2.92e-15	2.1e-12	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
KIRC	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-8.15	2.92e-15	2.1e-12	-0.39	-0.34	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
KIRC	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	8.15	2.93e-15	2.11e-12	0.48	0.34	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
KIRC	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-8.15	2.93e-15	2.11e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
KIRC	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-8.15	2.93e-15	2.11e-12	-0.39	-0.34	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
KIRC	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-8.15	2.93e-15	2.11e-12	-0.43	-0.34	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
KIRC	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-8.15	2.93e-15	2.11e-12	-0.47	-0.34	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
KIRC	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	8.15	2.94e-15	2.12e-12	0.36	0.34	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
KIRC	cis	rs3820928	0.804	rs4144327	ENSG00000212391.1	SNORA48	-8.15	2.94e-15	2.12e-12	-0.4	-0.34	Pulmonary function;	chr2:226925546	chr2:226968989~226969122:-
KIRC	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	8.15	2.94e-15	2.12e-12	0.41	0.34	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
KIRC	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	8.15	2.95e-15	2.13e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
KIRC	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	8.15	2.95e-15	2.13e-12	0.22	0.34	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
KIRC	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-8.15	2.95e-15	2.13e-12	-0.34	-0.34	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
KIRC	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-8.15	2.96e-15	2.13e-12	-0.45	-0.34	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	8.15	2.96e-15	2.13e-12	0.5	0.34	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
KIRC	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	8.15	2.96e-15	2.13e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-8.15	2.96e-15	2.13e-12	-0.46	-0.34	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
KIRC	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-8.15	2.97e-15	2.14e-12	-0.44	-0.34	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
KIRC	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	8.15	2.97e-15	2.14e-12	0.42	0.34	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
KIRC	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-8.15	2.97e-15	2.14e-12	-0.51	-0.34	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
KIRC	cis	rs3820928	0.839	rs13404750	ENSG00000212391.1	SNORA48	-8.15	3e-15	2.16e-12	-0.4	-0.34	Pulmonary function;	chr2:227011413	chr2:226968989~226969122:-
KIRC	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-8.15	3e-15	2.16e-12	-0.48	-0.34	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
KIRC	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-8.15	3.01e-15	2.16e-12	-0.29	-0.34	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
KIRC	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	8.15	3.01e-15	2.17e-12	0.38	0.34	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
KIRC	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	8.15	3.02e-15	2.17e-12	0.43	0.34	Height;	chr4:55575856	chr4:55387949~55388271:+
KIRC	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	8.15	3.04e-15	2.19e-12	0.49	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
KIRC	cis	rs1560104	0.556	rs59670495	ENSG00000274834.1	CTD-3037G24.5	8.15	3.04e-15	2.19e-12	0.38	0.34	Obesity-related traits;	chr16:12617241	chr16:12614451~12614852:+
KIRC	cis	rs4819052	0.851	rs2255774	ENSG00000223768.1	LINC00205	-8.15	3.05e-15	2.19e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45293285~45297354:+
KIRC	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-8.15	3.05e-15	2.2e-12	-0.46	-0.34	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
KIRC	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	8.15	3.05e-15	2.2e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
KIRC	cis	rs3820928	0.874	rs10210963	ENSG00000212391.1	SNORA48	-8.15	3.06e-15	2.2e-12	-0.4	-0.34	Pulmonary function;	chr2:226957129	chr2:226968989~226969122:-
KIRC	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	8.15	3.07e-15	2.2e-12	0.65	0.34	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
KIRC	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-8.15	3.07e-15	2.21e-12	-0.47	-0.34	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
KIRC	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	8.15	3.08e-15	2.21e-12	0.49	0.34	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	8.15	3.11e-15	2.23e-12	0.36	0.34	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
KIRC	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	8.15	3.11e-15	2.23e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	8.15	3.11e-15	2.23e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	8.15	3.11e-15	2.23e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
KIRC	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	8.15	3.11e-15	2.23e-12	0.38	0.34	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
KIRC	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-8.14	3.12e-15	2.24e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
KIRC	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	8.14	3.12e-15	2.24e-12	0.76	0.34	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
KIRC	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	8.14	3.13e-15	2.24e-12	0.35	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
KIRC	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-8.14	3.13e-15	2.25e-12	-0.37	-0.34	Height;	chr3:53097932	chr3:53064283~53065091:-
KIRC	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	8.14	3.15e-15	2.26e-12	0.44	0.34	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000196472.4	RP13-644M16.4	8.14	3.15e-15	2.26e-12	0.4	0.34	Obesity-related traits;	chr4:69063770	chr4:69181660~69182372:+
KIRC	cis	rs950027	0.62	rs2461700	ENSG00000259433.2	CTD-2651B20.4	-8.14	3.15e-15	2.26e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45330209~45332634:-
KIRC	cis	rs950027	0.62	rs2453533	ENSG00000259433.2	CTD-2651B20.4	-8.14	3.15e-15	2.26e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45330209~45332634:-
KIRC	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	8.14	3.16e-15	2.26e-12	0.39	0.34	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
KIRC	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	8.14	3.16e-15	2.26e-12	0.35	0.34	Height;	chr3:53073584	chr3:53064283~53065091:-
KIRC	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	8.14	3.16e-15	2.27e-12	0.32	0.34	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
KIRC	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	8.14	3.17e-15	2.27e-12	0.43	0.34	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
KIRC	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	8.14	3.18e-15	2.28e-12	0.49	0.34	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
KIRC	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	8.14	3.19e-15	2.29e-12	0.48	0.34	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
KIRC	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-8.14	3.19e-15	2.29e-12	-0.47	-0.34	Depression;	chr6:28108492	chr6:28115628~28116551:+
KIRC	cis	rs3820928	0.874	rs10178731	ENSG00000212391.1	SNORA48	-8.14	3.19e-15	2.29e-12	-0.4	-0.34	Pulmonary function;	chr2:227009516	chr2:226968989~226969122:-
KIRC	cis	rs79040073	0.598	rs11636296	ENSG00000259531.2	RP11-295H24.3	8.14	3.19e-15	2.29e-12	0.46	0.34	Lung cancer in ever smokers;	chr15:49034864	chr15:49365124~49366685:-
KIRC	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-8.14	3.21e-15	2.3e-12	-0.51	-0.34	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
KIRC	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	8.14	3.21e-15	2.3e-12	0.44	0.34	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	8.14	3.22e-15	2.31e-12	0.35	0.34	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
KIRC	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-8.14	3.23e-15	2.32e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
KIRC	cis	rs4356975	0.697	rs5002700	ENSG00000250919.1	RP11-813N20.3	-8.14	3.24e-15	2.32e-12	-0.36	-0.34	Obesity-related traits;	chr4:69155637	chr4:69027831~69044578:+
KIRC	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	8.14	3.25e-15	2.33e-12	0.35	0.34	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
KIRC	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	8.14	3.26e-15	2.33e-12	0.46	0.34	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
KIRC	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	8.14	3.26e-15	2.33e-12	0.5	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
KIRC	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	8.14	3.26e-15	2.34e-12	0.51	0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
KIRC	cis	rs7017914	0.967	rs13257800	ENSG00000254031.4	RP11-326E22.1	8.14	3.27e-15	2.34e-12	0.38	0.34	Bone mineral density;	chr8:70801898	chr8:71155457~71204223:+
KIRC	cis	rs1150668	0.965	rs1654774	ENSG00000204709.4	LINC01556	8.14	3.27e-15	2.34e-12	0.45	0.34	Pubertal anthropometrics;	chr6:28128502	chr6:28943877~28944537:+
KIRC	cis	rs950027	0.596	rs2467865	ENSG00000259433.2	CTD-2651B20.4	-8.14	3.28e-15	2.35e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45330209~45332634:-
KIRC	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-8.14	3.29e-15	2.36e-12	-0.44	-0.34	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
KIRC	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-8.14	3.29e-15	2.36e-12	-0.48	-0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
KIRC	cis	rs12893668	0.543	rs12147645	ENSG00000269910.1	RP11-73M18.10	8.14	3.29e-15	2.36e-12	0.25	0.34	Reticulocyte count;	chr14:103633871	chr14:103694516~103695050:-
KIRC	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	8.14	3.3e-15	2.36e-12	0.37	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
KIRC	cis	rs6600671	0.934	rs11249348	ENSG00000227082.1	CH17-437K3.1	-8.14	3.31e-15	2.37e-12	-0.38	-0.34	Hip geometry;	chr1:121446444	chr1:121396754~121463129:+
KIRC	cis	rs3820928	0.839	rs10197773	ENSG00000212391.1	SNORA48	-8.14	3.32e-15	2.37e-12	-0.41	-0.34	Pulmonary function;	chr2:226960119	chr2:226968989~226969122:-
KIRC	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-8.14	3.32e-15	2.37e-12	-0.39	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	8.14	3.32e-15	2.37e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
KIRC	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	8.14	3.33e-15	2.38e-12	0.42	0.34	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	8.14	3.33e-15	2.39e-12	0.43	0.34	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	8.14	3.33e-15	2.39e-12	0.43	0.34	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
KIRC	cis	rs4819052	0.765	rs2838868	ENSG00000223768.1	LINC00205	8.14	3.34e-15	2.39e-12	0.37	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45293285~45297354:+
KIRC	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	8.14	3.34e-15	2.39e-12	0.45	0.34	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
KIRC	cis	rs79040073	0.607	rs17400706	ENSG00000259531.2	RP11-295H24.3	8.13	3.35e-15	2.4e-12	0.45	0.34	Lung cancer in ever smokers;	chr15:49455148	chr15:49365124~49366685:-
KIRC	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-8.13	3.35e-15	2.4e-12	-0.47	-0.34	Depression;	chr6:28110254	chr6:28115628~28116551:+
KIRC	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	8.13	3.35e-15	2.4e-12	0.42	0.34	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
KIRC	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	8.13	3.35e-15	2.4e-12	0.62	0.34	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
KIRC	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	8.13	3.35e-15	2.4e-12	0.48	0.34	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
KIRC	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	8.13	3.36e-15	2.4e-12	0.29	0.34	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
KIRC	cis	rs4356975	0.563	rs12506962	ENSG00000248763.2	RP13-644M16.5	-8.13	3.36e-15	2.41e-12	-0.43	-0.34	Obesity-related traits;	chr4:69100306	chr4:69066395~69069888:+
KIRC	cis	rs7731783	1	rs7731783	ENSG00000249849.1	RP11-1101H11.1	-8.13	3.36e-15	2.41e-12	-0.38	-0.34	Methadone dose in opioid dependence;	chr5:177633311	chr5:177682294~177713969:+
KIRC	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-8.13	3.36e-15	2.41e-12	-0.47	-0.34	Depression;	chr6:28096077	chr6:28115628~28116551:+
KIRC	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	8.13	3.38e-15	2.42e-12	0.44	0.34	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
KIRC	cis	rs6479901	0.947	rs10761780	ENSG00000232075.1	MRPL35P2	-8.13	3.38e-15	2.42e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	8.13	3.39e-15	2.42e-12	0.42	0.34	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
KIRC	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	8.13	3.39e-15	2.42e-12	0.42	0.34	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	8.13	3.39e-15	2.43e-12	0.46	0.34	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
KIRC	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	8.13	3.4e-15	2.43e-12	0.65	0.34	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
KIRC	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-8.13	3.4e-15	2.43e-12	-0.39	-0.34	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
KIRC	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-8.13	3.4e-15	2.43e-12	-0.41	-0.34	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
KIRC	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	8.13	3.41e-15	2.44e-12	0.3	0.34	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	8.13	3.41e-15	2.44e-12	0.3	0.34	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
KIRC	cis	rs3820928	0.874	rs13385711	ENSG00000212391.1	SNORA48	-8.13	3.41e-15	2.44e-12	-0.41	-0.34	Pulmonary function;	chr2:226965698	chr2:226968989~226969122:-
KIRC	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	8.13	3.42e-15	2.44e-12	0.51	0.34	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
KIRC	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-8.13	3.42e-15	2.44e-12	-0.38	-0.34	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
KIRC	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	8.13	3.43e-15	2.45e-12	0.47	0.34	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
KIRC	cis	rs6479901	0.947	rs10822167	ENSG00000232075.1	MRPL35P2	-8.13	3.44e-15	2.46e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63398991	chr10:63634317~63634827:-
KIRC	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-8.13	3.45e-15	2.46e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
KIRC	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-8.13	3.45e-15	2.46e-12	-0.59	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
KIRC	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	8.13	3.45e-15	2.47e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
KIRC	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	8.13	3.46e-15	2.47e-12	0.35	0.34	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
KIRC	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-8.13	3.47e-15	2.48e-12	-0.45	-0.34	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
KIRC	cis	rs6600671	0.967	rs12069545	ENSG00000227082.1	CH17-437K3.1	-8.13	3.47e-15	2.48e-12	-0.38	-0.34	Hip geometry;	chr1:121430343	chr1:121396754~121463129:+
KIRC	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	8.13	3.47e-15	2.48e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	8.13	3.47e-15	2.48e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
KIRC	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-8.13	3.48e-15	2.49e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-8.13	3.48e-15	2.49e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
KIRC	cis	rs4380275	1	rs4268954	ENSG00000223751.1	AC116609.2	8.13	3.48e-15	2.49e-12	0.44	0.34	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:742488~747767:+
KIRC	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-8.13	3.48e-15	2.49e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-8.13	3.48e-15	2.49e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-8.13	3.48e-15	2.49e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-8.13	3.48e-15	2.49e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
KIRC	cis	rs1560104	0.619	rs3829519	ENSG00000274834.1	CTD-3037G24.5	8.13	3.49e-15	2.49e-12	0.37	0.34	Obesity-related traits;	chr16:12614854	chr16:12614451~12614852:+
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000196472.4	RP13-644M16.4	8.13	3.49e-15	2.49e-12	0.39	0.34	Obesity-related traits;	chr4:69075937	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000196472.4	RP13-644M16.4	8.13	3.49e-15	2.49e-12	0.39	0.34	Obesity-related traits;	chr4:69075944	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000196472.4	RP13-644M16.4	8.13	3.49e-15	2.49e-12	0.39	0.34	Obesity-related traits;	chr4:69076309	chr4:69181660~69182372:+
KIRC	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-8.13	3.5e-15	2.5e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
KIRC	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	8.13	3.51e-15	2.5e-12	0.75	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
KIRC	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-8.13	3.51e-15	2.51e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
KIRC	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	8.13	3.52e-15	2.51e-12	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
KIRC	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-8.13	3.52e-15	2.52e-12	-0.35	-0.34	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
KIRC	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-8.13	3.53e-15	2.52e-12	-0.31	-0.34	Height;	chr11:118760944	chr11:118791254~118793137:+
KIRC	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-8.13	3.54e-15	2.53e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
KIRC	cis	rs950027	0.62	rs1346267	ENSG00000259433.2	CTD-2651B20.4	-8.13	3.54e-15	2.53e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45330209~45332634:-
KIRC	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-8.13	3.54e-15	2.53e-12	-0.38	-0.34	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
KIRC	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-8.13	3.56e-15	2.54e-12	-0.49	-0.34	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
KIRC	cis	rs3858145	0.5	rs4633337	ENSG00000233590.1	RP11-153K11.3	8.13	3.56e-15	2.54e-12	0.44	0.34	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285970	chr10:68233251~68242379:-
KIRC	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-8.13	3.58e-15	2.55e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
KIRC	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	8.13	3.58e-15	2.55e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
KIRC	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-8.13	3.58e-15	2.56e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
KIRC	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-8.13	3.59e-15	2.56e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
KIRC	cis	rs1345301	0.905	rs2310243	ENSG00000234389.1	AC007278.3	-8.13	3.59e-15	2.56e-12	-0.34	-0.34	Waist circumference;	chr2:102261100	chr2:102438713~102440475:+
KIRC	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	8.13	3.59e-15	2.56e-12	0.43	0.34	Height;	chr4:55548666	chr4:55387949~55388271:+
KIRC	cis	rs6479901	0.947	rs10740128	ENSG00000232075.1	MRPL35P2	-8.12	3.6e-15	2.57e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63634317~63634827:-
KIRC	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-8.12	3.61e-15	2.58e-12	-0.51	-0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
KIRC	cis	rs4356975	0.842	rs6600899	ENSG00000250919.1	RP11-813N20.3	-8.12	3.62e-15	2.58e-12	-0.37	-0.34	Obesity-related traits;	chr4:69132295	chr4:69027831~69044578:+
KIRC	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
KIRC	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-8.12	3.63e-15	2.59e-12	-0.38	-0.34	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
KIRC	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-8.12	3.63e-15	2.59e-12	-0.41	-0.34	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
KIRC	cis	rs11089937	0.895	rs5756985	ENSG00000211639.2	IGLV4-60	8.12	3.64e-15	2.59e-12	0.32	0.34	Periodontitis (PAL4Q3);	chr22:22131847	chr22:22162199~22162681:+
KIRC	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	8.12	3.64e-15	2.59e-12	0.3	0.34	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	8.12	3.64e-15	2.59e-12	0.3	0.34	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
KIRC	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	8.12	3.64e-15	2.59e-12	0.35	0.34	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	8.12	3.64e-15	2.59e-12	0.35	0.34	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
KIRC	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	8.12	3.64e-15	2.59e-12	0.35	0.34	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
KIRC	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-8.12	3.65e-15	2.6e-12	-0.27	-0.34	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
KIRC	cis	rs950027	0.62	rs35861938	ENSG00000259433.2	CTD-2651B20.4	-8.12	3.66e-15	2.61e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45330209~45332634:-
KIRC	cis	rs4356975	0.563	rs7442453	ENSG00000250696.4	RP11-704M14.1	8.12	3.67e-15	2.61e-12	0.36	0.34	Obesity-related traits;	chr4:69103462	chr4:69182100~69216766:+
KIRC	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	8.12	3.67e-15	2.61e-12	0.44	0.34	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	8.12	3.67e-15	2.61e-12	0.44	0.34	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
KIRC	cis	rs7017914	0.935	rs56289931	ENSG00000254031.4	RP11-326E22.1	8.12	3.67e-15	2.61e-12	0.37	0.34	Bone mineral density;	chr8:70925519	chr8:71155457~71204223:+
KIRC	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-8.12	3.67e-15	2.61e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
KIRC	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-8.12	3.67e-15	2.61e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000196472.4	RP13-644M16.4	8.12	3.67e-15	2.62e-12	0.39	0.34	Obesity-related traits;	chr4:69074144	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000196472.4	RP13-644M16.4	8.12	3.67e-15	2.62e-12	0.39	0.34	Obesity-related traits;	chr4:69074157	chr4:69181660~69182372:+
KIRC	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-8.12	3.7e-15	2.63e-12	-0.32	-0.34	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
KIRC	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-8.12	3.7e-15	2.64e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	8.12	3.7e-15	2.64e-12	0.36	0.34	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
KIRC	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-8.12	3.7e-15	2.64e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-8.12	3.7e-15	2.64e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
KIRC	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	8.12	3.7e-15	2.64e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	8.12	3.7e-15	2.64e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	8.12	3.7e-15	2.64e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
KIRC	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-8.12	3.71e-15	2.64e-12	-0.46	-0.34	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-8.12	3.71e-15	2.64e-12	-0.46	-0.34	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
KIRC	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-8.12	3.72e-15	2.65e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
KIRC	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-8.12	3.73e-15	2.65e-12	-0.36	-0.34	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
KIRC	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-8.12	3.73e-15	2.66e-12	-0.45	-0.34	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
KIRC	cis	rs3096299	0.73	rs3114895	ENSG00000274627.1	RP11-104N10.2	8.12	3.74e-15	2.66e-12	0.25	0.34	Multiple myeloma (IgH translocation);	chr16:89328402	chr16:89516797~89522217:+
KIRC	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	8.12	3.75e-15	2.67e-12	0.65	0.34	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
KIRC	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-8.12	3.75e-15	2.67e-12	-0.38	-0.34	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
KIRC	cis	rs950027	0.62	rs1153862	ENSG00000235390.4	CTD-2651B20.5	-8.12	3.75e-15	2.67e-12	-0.33	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45321077~45321692:-
KIRC	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-8.12	3.76e-15	2.68e-12	-0.24	-0.34	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
KIRC	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-8.12	3.76e-15	2.68e-12	-0.24	-0.34	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
KIRC	cis	rs6600671	0.934	rs12131379	ENSG00000227082.1	CH17-437K3.1	-8.12	3.77e-15	2.68e-12	-0.38	-0.34	Hip geometry;	chr1:121551639	chr1:121396754~121463129:+
KIRC	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	8.12	3.77e-15	2.68e-12	0.45	0.34	Height;	chr6:109371524	chr6:109382795~109383666:+
KIRC	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	8.12	3.77e-15	2.68e-12	0.42	0.34	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
KIRC	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	8.12	3.78e-15	2.69e-12	0.3	0.34	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
KIRC	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-8.12	3.78e-15	2.69e-12	-0.37	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
KIRC	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	8.12	3.78e-15	2.69e-12	0.47	0.34	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
KIRC	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	8.12	3.78e-15	2.69e-12	0.36	0.34	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
KIRC	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	8.12	3.79e-15	2.7e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
KIRC	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-8.12	3.79e-15	2.7e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-8.12	3.79e-15	2.7e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
KIRC	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-8.12	3.79e-15	2.7e-12	-0.37	-0.34	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
KIRC	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-8.12	3.79e-15	2.7e-12	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
KIRC	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	8.12	3.8e-15	2.7e-12	0.3	0.34	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
KIRC	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	8.12	3.81e-15	2.71e-12	0.42	0.34	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
KIRC	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-8.12	3.81e-15	2.71e-12	-0.4	-0.34	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
KIRC	cis	rs950027	0.62	rs1153862	ENSG00000259433.2	CTD-2651B20.4	-8.12	3.81e-15	2.71e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45330209~45332634:-
KIRC	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	8.12	3.81e-15	2.71e-12	0.43	0.34	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
KIRC	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	8.12	3.82e-15	2.71e-12	0.42	0.34	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
KIRC	cis	rs3820928	0.874	rs6718057	ENSG00000212391.1	SNORA48	-8.12	3.82e-15	2.71e-12	-0.41	-0.34	Pulmonary function;	chr2:226969633	chr2:226968989~226969122:-
KIRC	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	8.12	3.82e-15	2.72e-12	0.46	0.34	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
KIRC	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-8.12	3.84e-15	2.73e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
KIRC	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	8.12	3.85e-15	2.73e-12	0.44	0.34	Height;	chr4:55415153	chr4:55387949~55388271:+
KIRC	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	8.12	3.85e-15	2.73e-12	0.46	0.34	Height;	chr6:109428824	chr6:109382795~109383666:+
KIRC	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-8.12	3.85e-15	2.73e-12	-0.6	-0.34	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
KIRC	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-8.12	3.85e-15	2.74e-12	-0.44	-0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
KIRC	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-8.12	3.85e-15	2.74e-12	-0.44	-0.34	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
KIRC	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-8.12	3.86e-15	2.74e-12	-0.36	-0.34	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
KIRC	cis	rs1560104	0.597	rs12162081	ENSG00000274834.1	CTD-3037G24.5	8.12	3.86e-15	2.74e-12	0.37	0.34	Obesity-related traits;	chr16:12616425	chr16:12614451~12614852:+
KIRC	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-8.11	3.88e-15	2.76e-12	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
KIRC	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	8.11	3.89e-15	2.76e-12	0.42	0.34	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
KIRC	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-8.11	3.89e-15	2.76e-12	-0.41	-0.34	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
KIRC	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	8.11	3.89e-15	2.76e-12	0.44	0.34	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
KIRC	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28111382	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28111650	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28112175	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28113616	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28113851	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28114487	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28114933	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28115743	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Depression;	chr6:28116411	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-8.11	3.89e-15	2.76e-12	-0.47	-0.34	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
KIRC	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	8.11	3.89e-15	2.77e-12	0.24	0.34	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
KIRC	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	8.11	3.9e-15	2.77e-12	0.43	0.34	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
KIRC	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-8.11	3.9e-15	2.77e-12	-0.41	-0.34	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
KIRC	cis	rs3820928	0.845	rs13415319	ENSG00000212391.1	SNORA48	-8.11	3.93e-15	2.79e-12	-0.4	-0.34	Pulmonary function;	chr2:227014220	chr2:226968989~226969122:-
KIRC	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	8.11	3.93e-15	2.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	8.11	3.93e-15	2.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	8.11	3.93e-15	2.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	8.11	3.93e-15	2.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	8.11	3.93e-15	2.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
KIRC	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	8.11	3.93e-15	2.79e-12	0.49	0.34	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	8.11	3.93e-15	2.79e-12	0.49	0.34	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
KIRC	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-8.11	3.93e-15	2.79e-12	-0.44	-0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
KIRC	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-8.11	3.94e-15	2.8e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
KIRC	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-8.11	3.95e-15	2.8e-12	-0.46	-0.34	Depression;	chr6:28139049	chr6:28115628~28116551:+
KIRC	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-8.11	3.95e-15	2.81e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
KIRC	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	8.11	3.96e-15	2.81e-12	0.38	0.34	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
KIRC	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-8.11	3.96e-15	2.81e-12	-0.41	-0.34	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
KIRC	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-8.11	3.97e-15	2.82e-12	-0.35	-0.34	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
KIRC	cis	rs6479901	0.947	rs7097698	ENSG00000232075.1	MRPL35P2	-8.11	3.97e-15	2.82e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63513635	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7068144	ENSG00000232075.1	MRPL35P2	-8.11	3.97e-15	2.82e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63514500	chr10:63634317~63634827:-
KIRC	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-8.11	3.97e-15	2.82e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
KIRC	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	8.11	3.98e-15	2.82e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	8.11	3.98e-15	2.82e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
KIRC	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	8.11	3.98e-15	2.82e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	8.11	3.99e-15	2.83e-12	0.42	0.34	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
KIRC	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	8.11	4e-15	2.84e-12	0.3	0.34	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
KIRC	cis	rs950027	0.62	rs872192	ENSG00000259433.2	CTD-2651B20.4	-8.11	4.01e-15	2.84e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45330209~45332634:-
KIRC	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-8.11	4.01e-15	2.84e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
KIRC	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-8.11	4.02e-15	2.85e-12	-0.38	-0.34	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
KIRC	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-8.11	4.03e-15	2.85e-12	-0.47	-0.34	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
KIRC	cis	rs4356975	0.563	rs4356974	ENSG00000250696.4	RP11-704M14.1	8.11	4.04e-15	2.86e-12	0.36	0.34	Obesity-related traits;	chr4:69106696	chr4:69182100~69216766:+
KIRC	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	8.11	4.05e-15	2.87e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
KIRC	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-8.11	4.06e-15	2.87e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
KIRC	cis	rs7829975	0.533	rs35900578	ENSG00000253893.2	FAM85B	-8.11	4.06e-15	2.87e-12	-0.46	-0.34	Mood instability;	chr8:8862003	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	8.11	4.09e-15	2.9e-12	0.35	0.34	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
KIRC	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-8.11	4.1e-15	2.9e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
KIRC	cis	rs12893668	0.572	rs4900590	ENSG00000269910.1	RP11-73M18.10	8.11	4.11e-15	2.91e-12	0.25	0.34	Reticulocyte count;	chr14:103680084	chr14:103694516~103695050:-
KIRC	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-8.11	4.11e-15	2.91e-12	-0.41	-0.34	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
KIRC	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	8.11	4.11e-15	2.91e-12	0.46	0.34	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
KIRC	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	8.11	4.11e-15	2.91e-12	0.46	0.34	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
KIRC	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-8.11	4.13e-15	2.92e-12	-0.49	-0.34	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
KIRC	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	8.11	4.13e-15	2.92e-12	0.44	0.34	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	8.11	4.13e-15	2.92e-12	0.44	0.34	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
KIRC	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	8.11	4.13e-15	2.92e-12	0.35	0.34	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	8.11	4.13e-15	2.92e-12	0.35	0.34	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	8.11	4.13e-15	2.92e-12	0.35	0.34	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
KIRC	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	8.11	4.13e-15	2.93e-12	0.45	0.34	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	8.11	4.13e-15	2.93e-12	0.45	0.34	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	8.11	4.13e-15	2.93e-12	0.45	0.34	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
KIRC	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	8.11	4.16e-15	2.95e-12	0.42	0.34	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
KIRC	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-8.1	4.17e-15	2.95e-12	-0.44	-0.34	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000196472.4	RP13-644M16.4	8.1	4.17e-15	2.95e-12	0.39	0.34	Obesity-related traits;	chr4:69075351	chr4:69181660~69182372:+
KIRC	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-8.1	4.17e-15	2.95e-12	-0.34	-0.34	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
KIRC	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-8.1	4.18e-15	2.96e-12	-0.24	-0.34	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
KIRC	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-8.1	4.18e-15	2.96e-12	-0.24	-0.34	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
KIRC	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	8.1	4.18e-15	2.96e-12	0.37	0.34	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
KIRC	cis	rs4356975	0.563	rs6600891	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69105878	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs7693957	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69106078	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs7698645	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69106192	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs12513195	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69106368	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4541594	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69106554	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.583	rs4351080	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69106601	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs5013211	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107059	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4292394	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107231	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4337789	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107326	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4521414	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107807	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4314345	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107922	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4588522	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107949	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4364327	ENSG00000250696.4	RP11-704M14.1	8.1	4.2e-15	2.97e-12	0.36	0.34	Obesity-related traits;	chr4:69107974	chr4:69182100~69216766:+
KIRC	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	8.1	4.2e-15	2.97e-12	0.44	0.34	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
KIRC	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-8.1	4.2e-15	2.97e-12	-0.36	-0.34	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
KIRC	cis	rs4356975	0.563	rs7698846	ENSG00000250696.4	RP11-704M14.1	8.1	4.21e-15	2.98e-12	0.36	0.34	Obesity-related traits;	chr4:69106278	chr4:69182100~69216766:+
KIRC	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	8.1	4.21e-15	2.98e-12	0.45	0.34	Height;	chr6:109375548	chr6:109382795~109383666:+
KIRC	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	8.1	4.21e-15	2.98e-12	0.48	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
KIRC	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	8.1	4.21e-15	2.98e-12	0.48	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
KIRC	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-8.1	4.23e-15	2.99e-12	-0.35	-0.34	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-8.1	4.23e-15	2.99e-12	-0.35	-0.34	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
KIRC	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	8.1	4.23e-15	2.99e-12	0.62	0.34	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
KIRC	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	8.1	4.24e-15	2.99e-12	0.36	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
KIRC	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-8.1	4.24e-15	2.99e-12	-0.41	-0.34	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-8.1	4.24e-15	2.99e-12	-0.41	-0.34	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
KIRC	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-8.1	4.24e-15	3e-12	-0.44	-0.34	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
KIRC	cis	rs4356975	0.563	rs35402056	ENSG00000250696.4	RP11-704M14.1	8.1	4.25e-15	3.01e-12	0.36	0.34	Obesity-related traits;	chr4:69108549	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs4694177	ENSG00000250696.4	RP11-704M14.1	8.1	4.25e-15	3.01e-12	0.36	0.34	Obesity-related traits;	chr4:69110141	chr4:69182100~69216766:+
KIRC	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	8.1	4.28e-15	3.03e-12	0.6	0.34	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	8.1	4.28e-15	3.03e-12	0.42	0.34	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	8.1	4.28e-15	3.03e-12	0.42	0.34	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
KIRC	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-8.1	4.29e-15	3.03e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
KIRC	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-8.1	4.29e-15	3.03e-12	-0.42	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
KIRC	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	8.1	4.31e-15	3.04e-12	0.3	0.34	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
KIRC	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-8.1	4.31e-15	3.04e-12	-0.33	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
KIRC	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	8.1	4.33e-15	3.06e-12	0.44	0.34	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000196472.4	RP13-644M16.4	8.1	4.33e-15	3.06e-12	0.39	0.34	Obesity-related traits;	chr4:69068460	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000196472.4	RP13-644M16.4	8.1	4.33e-15	3.06e-12	0.39	0.34	Obesity-related traits;	chr4:69068643	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000196472.4	RP13-644M16.4	8.1	4.33e-15	3.06e-12	0.39	0.34	Obesity-related traits;	chr4:69068755	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000196472.4	RP13-644M16.4	8.1	4.33e-15	3.06e-12	0.39	0.34	Obesity-related traits;	chr4:69069090	chr4:69181660~69182372:+
KIRC	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-8.1	4.34e-15	3.06e-12	-0.41	-0.34	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
KIRC	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	8.1	4.35e-15	3.07e-12	0.32	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
KIRC	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-8.1	4.35e-15	3.07e-12	-0.24	-0.34	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
KIRC	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	8.1	4.37e-15	3.08e-12	0.44	0.34	Height;	chr6:109382188	chr6:109382795~109383666:+
KIRC	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-8.1	4.37e-15	3.08e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
KIRC	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	8.1	4.39e-15	3.1e-12	0.45	0.34	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
KIRC	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-8.1	4.39e-15	3.1e-12	-0.48	-0.34	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
KIRC	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-8.1	4.39e-15	3.1e-12	-0.37	-0.34	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
KIRC	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-8.1	4.4e-15	3.11e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-8.1	4.4e-15	3.11e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
KIRC	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	8.1	4.42e-15	3.12e-12	0.38	0.34	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
KIRC	cis	rs6600671	1	rs11249351	ENSG00000227082.1	CH17-437K3.1	-8.1	4.43e-15	3.12e-12	-0.38	-0.34	Hip geometry;	chr1:121430082	chr1:121396754~121463129:+
KIRC	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	8.1	4.43e-15	3.12e-12	0.35	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
KIRC	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	8.1	4.44e-15	3.13e-12	0.43	0.34	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
KIRC	cis	rs13236243	0.501	rs2158041	ENSG00000236318.1	AC019117.1	8.1	4.44e-15	3.13e-12	0.49	0.34	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17328796	chr7:17374867~17466664:+
KIRC	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-8.1	4.44e-15	3.13e-12	-0.41	-0.34	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
KIRC	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	8.1	4.45e-15	3.14e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
KIRC	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-8.1	4.45e-15	3.14e-12	-0.46	-0.34	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
KIRC	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	8.1	4.46e-15	3.14e-12	0.36	0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
KIRC	cis	rs950027	0.62	rs1719246	ENSG00000259433.2	CTD-2651B20.4	-8.1	4.46e-15	3.14e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45330209~45332634:-
KIRC	cis	rs7017914	0.902	rs7831792	ENSG00000254031.4	RP11-326E22.1	8.1	4.46e-15	3.14e-12	0.38	0.34	Bone mineral density;	chr8:70653121	chr8:71155457~71204223:+
KIRC	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	8.1	4.47e-15	3.15e-12	0.47	0.34	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
KIRC	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	8.1	4.47e-15	3.15e-12	0.47	0.34	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
KIRC	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	8.1	4.47e-15	3.15e-12	0.6	0.34	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
KIRC	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	8.1	4.47e-15	3.15e-12	0.44	0.34	Height;	chr6:109367335	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	8.1	4.47e-15	3.15e-12	0.44	0.34	Height;	chr6:109368228	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	8.1	4.47e-15	3.15e-12	0.44	0.34	Height;	chr6:109370741	chr6:109382795~109383666:+
KIRC	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-8.09	4.48e-15	3.16e-12	-0.41	-0.34	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
KIRC	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	8.09	4.5e-15	3.17e-12	0.35	0.34	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
KIRC	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	8.09	4.5e-15	3.17e-12	0.49	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
KIRC	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	8.09	4.51e-15	3.17e-12	0.45	0.34	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
KIRC	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	8.09	4.51e-15	3.18e-12	0.36	0.34	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
KIRC	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	8.09	4.51e-15	3.18e-12	0.66	0.34	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	8.09	4.51e-15	3.18e-12	0.66	0.34	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
KIRC	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	8.09	4.52e-15	3.18e-12	0.48	0.34	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
KIRC	cis	rs6479901	1	rs10740133	ENSG00000232075.1	MRPL35P2	-8.09	4.52e-15	3.18e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63517676	chr10:63634317~63634827:-
KIRC	cis	rs950027	0.62	rs1617984	ENSG00000259433.2	CTD-2651B20.4	-8.09	4.52e-15	3.18e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45330209~45332634:-
KIRC	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	8.09	4.52e-15	3.19e-12	0.42	0.34	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
KIRC	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	8.09	4.53e-15	3.19e-12	0.45	0.34	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
KIRC	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-8.09	4.54e-15	3.19e-12	-0.41	-0.34	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
KIRC	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	8.09	4.54e-15	3.2e-12	0.46	0.34	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
KIRC	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	8.09	4.55e-15	3.21e-12	0.42	0.34	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	8.09	4.56e-15	3.21e-12	0.35	0.34	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	8.09	4.56e-15	3.21e-12	0.35	0.34	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
KIRC	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	8.09	4.56e-15	3.21e-12	0.75	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-8.09	4.56e-15	3.21e-12	-0.35	-0.34	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
KIRC	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	8.09	4.57e-15	3.21e-12	0.66	0.34	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	8.09	4.57e-15	3.21e-12	0.66	0.34	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	8.09	4.57e-15	3.21e-12	0.66	0.34	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
KIRC	cis	rs3820928	0.874	rs10189579	ENSG00000212391.1	SNORA48	-8.09	4.57e-15	3.21e-12	-0.4	-0.34	Pulmonary function;	chr2:227000160	chr2:226968989~226969122:-
KIRC	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.09	4.58e-15	3.22e-12	0.61	0.34	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
KIRC	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-8.09	4.58e-15	3.22e-12	-0.31	-0.34	Height;	chr11:118737916	chr11:118791254~118793137:+
KIRC	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-8.09	4.59e-15	3.23e-12	-0.38	-0.34	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-8.09	4.59e-15	3.23e-12	-0.38	-0.34	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
KIRC	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-8.09	4.59e-15	3.23e-12	-0.38	-0.34	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
KIRC	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-8.09	4.59e-15	3.23e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-8.09	4.59e-15	3.23e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	8.09	4.6e-15	3.23e-12	0.42	0.34	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	8.09	4.6e-15	3.23e-12	0.42	0.34	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	8.09	4.6e-15	3.23e-12	0.42	0.34	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
KIRC	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	8.09	4.6e-15	3.23e-12	0.63	0.34	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
KIRC	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-8.09	4.6e-15	3.24e-12	-0.41	-0.34	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
KIRC	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	8.09	4.61e-15	3.25e-12	0.49	0.34	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
KIRC	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	8.09	4.63e-15	3.25e-12	0.53	0.34	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
KIRC	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-8.09	4.64e-15	3.26e-12	-0.39	-0.34	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
KIRC	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-8.09	4.64e-15	3.26e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
KIRC	cis	rs7916697	0.52	rs4745957	ENSG00000233590.1	RP11-153K11.3	8.09	4.65e-15	3.27e-12	0.38	0.34	Optic disc area;	chr10:68284945	chr10:68233251~68242379:-
KIRC	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-8.09	4.65e-15	3.27e-12	-0.43	-0.34	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
KIRC	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	8.09	4.66e-15	3.28e-12	0.35	0.34	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.563	rs12512526	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69100700	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs34386959	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69100837	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs55834557	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69100876	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.522	rs56388229	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69100940	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs34318523	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69101135	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.583	rs34630750	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69101208	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs12508257	ENSG00000248763.2	RP13-644M16.5	-8.09	4.67e-15	3.28e-12	-0.43	-0.34	Obesity-related traits;	chr4:69101921	chr4:69066395~69069888:+
KIRC	cis	rs6479901	0.947	rs7082076	ENSG00000232075.1	MRPL35P2	-8.09	4.67e-15	3.28e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63517185	chr10:63634317~63634827:-
KIRC	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-8.09	4.69e-15	3.29e-12	-0.37	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
KIRC	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	8.09	4.69e-15	3.3e-12	0.23	0.34	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
KIRC	cis	rs4356975	0.509	rs5014975	ENSG00000248763.2	RP13-644M16.5	-8.09	4.7e-15	3.3e-12	-0.44	-0.34	Obesity-related traits;	chr4:69130244	chr4:69066395~69069888:+
KIRC	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-8.09	4.71e-15	3.31e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
KIRC	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	8.09	4.71e-15	3.31e-12	0.43	0.34	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
KIRC	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	8.09	4.71e-15	3.31e-12	0.61	0.34	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
KIRC	cis	rs6479901	0.947	rs10822179	ENSG00000232075.1	MRPL35P2	-8.09	4.74e-15	3.33e-12	-0.45	-0.34	Intelligence (multi-trait analysis);	chr10:63520404	chr10:63634317~63634827:-
KIRC	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	8.09	4.74e-15	3.33e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
KIRC	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-8.09	4.74e-15	3.33e-12	-0.38	-0.34	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
KIRC	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-8.09	4.75e-15	3.34e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-8.09	4.75e-15	3.34e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-8.09	4.75e-15	3.34e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-8.09	4.75e-15	3.34e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
KIRC	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	8.09	4.75e-15	3.34e-12	0.47	0.34	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
KIRC	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-8.09	4.76e-15	3.34e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
KIRC	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-8.09	4.78e-15	3.36e-12	-0.38	-0.34	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
KIRC	cis	rs3820928	0.845	rs1917126	ENSG00000212391.1	SNORA48	-8.09	4.78e-15	3.36e-12	-0.41	-0.34	Pulmonary function;	chr2:226976207	chr2:226968989~226969122:-
KIRC	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	8.09	4.79e-15	3.36e-12	0.53	0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
KIRC	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-8.09	4.79e-15	3.36e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-8.09	4.79e-15	3.36e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-8.09	4.79e-15	3.36e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-8.09	4.79e-15	3.36e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	8.09	4.8e-15	3.36e-12	0.45	0.34	Height;	chr6:109358227	chr6:109382795~109383666:+
KIRC	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-8.09	4.81e-15	3.37e-12	-0.38	-0.34	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
KIRC	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-8.08	4.82e-15	3.38e-12	-0.38	-0.34	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
KIRC	cis	rs6479901	1	rs6479901	ENSG00000232075.1	MRPL35P2	-8.08	4.83e-15	3.39e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63421016	chr10:63634317~63634827:-
KIRC	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	8.08	4.83e-15	3.39e-12	0.41	0.34	Height;	chr4:55363436	chr4:55387949~55388271:+
KIRC	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	8.08	4.83e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	8.08	4.83e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
KIRC	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	8.08	4.84e-15	3.39e-12	0.66	0.34	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
KIRC	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-8.08	4.85e-15	3.4e-12	-0.48	-0.34	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-8.08	4.85e-15	3.4e-12	-0.48	-0.34	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
KIRC	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	8.08	4.86e-15	3.41e-12	0.44	0.34	Height;	chr6:109383239	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	8.08	4.86e-15	3.41e-12	0.44	0.34	Height;	chr6:109383248	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	8.08	4.86e-15	3.41e-12	0.44	0.34	Height;	chr6:109384807	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	8.08	4.86e-15	3.41e-12	0.44	0.34	Height;	chr6:109390116	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	8.08	4.86e-15	3.41e-12	0.44	0.34	Height;	chr6:109390638	chr6:109382795~109383666:+
KIRC	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	8.08	4.86e-15	3.41e-12	0.37	0.34	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
KIRC	cis	rs11089937	0.54	rs2329931	ENSG00000211638.2	IGLV8-61	-8.08	4.86e-15	3.41e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.568	rs2876996	ENSG00000211638.2	IGLV8-61	-8.08	4.86e-15	3.41e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22098700~22099212:+
KIRC	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-8.08	4.89e-15	3.42e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
KIRC	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-8.08	4.89e-15	3.43e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7915680	ENSG00000232075.1	MRPL35P2	-8.08	4.89e-15	3.43e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.583	rs62296935	ENSG00000250696.4	RP11-704M14.1	8.08	4.91e-15	3.44e-12	0.36	0.34	Obesity-related traits;	chr4:69082878	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs62296936	ENSG00000250696.4	RP11-704M14.1	8.08	4.91e-15	3.44e-12	0.36	0.34	Obesity-related traits;	chr4:69082903	chr4:69182100~69216766:+
KIRC	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	8.08	4.91e-15	3.44e-12	0.48	0.34	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000196472.4	RP13-644M16.4	8.08	4.92e-15	3.45e-12	0.39	0.34	Obesity-related traits;	chr4:69072070	chr4:69181660~69182372:+
KIRC	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	8.08	4.92e-15	3.45e-12	0.4	0.34	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
KIRC	cis	rs3820928	0.874	rs1320407	ENSG00000212391.1	SNORA48	-8.08	4.93e-15	3.45e-12	-0.4	-0.34	Pulmonary function;	chr2:227002669	chr2:226968989~226969122:-
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000196472.4	RP13-644M16.4	8.08	4.94e-15	3.46e-12	0.39	0.34	Obesity-related traits;	chr4:69074077	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000196472.4	RP13-644M16.4	8.08	4.94e-15	3.46e-12	0.39	0.34	Obesity-related traits;	chr4:69075085	chr4:69181660~69182372:+
KIRC	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	8.08	4.95e-15	3.46e-12	0.42	0.34	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	8.08	4.95e-15	3.46e-12	0.35	0.34	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
KIRC	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	8.08	4.95e-15	3.47e-12	0.46	0.34	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
KIRC	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-8.08	4.95e-15	3.47e-12	-0.38	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
KIRC	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	8.08	4.95e-15	3.47e-12	0.43	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
KIRC	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	8.08	4.95e-15	3.47e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
KIRC	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-8.08	4.96e-15	3.47e-12	-0.47	-0.34	Depression;	chr6:28139876	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-8.08	4.96e-15	3.47e-12	-0.47	-0.34	Depression;	chr6:28139998	chr6:28115628~28116551:+
KIRC	cis	rs10853057	0.717	rs11079553	ENSG00000214174.7	AMZ2P1	-8.08	4.98e-15	3.48e-12	-0.56	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061877	chr17:64966550~64975576:-
KIRC	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-8.08	4.98e-15	3.48e-12	-0.38	-0.34	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
KIRC	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	8.08	5e-15	3.5e-12	0.3	0.34	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
KIRC	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	8.08	5.01e-15	3.51e-12	0.42	0.34	Height;	chr4:55561218	chr4:55387949~55388271:+
KIRC	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-8.08	5.01e-15	3.51e-12	-0.44	-0.34	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
KIRC	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	8.08	5.04e-15	3.52e-12	0.45	0.34	Height;	chr6:109397362	chr6:109382795~109383666:+
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000196472.4	RP13-644M16.4	8.08	5.05e-15	3.53e-12	0.39	0.34	Obesity-related traits;	chr4:69069219	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000196472.4	RP13-644M16.4	8.08	5.05e-15	3.53e-12	0.39	0.34	Obesity-related traits;	chr4:69069397	chr4:69181660~69182372:+
KIRC	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-8.08	5.05e-15	3.53e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
KIRC	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	8.08	5.05e-15	3.53e-12	0.56	0.34	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
KIRC	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	8.08	5.05e-15	3.53e-12	0.32	0.34	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
KIRC	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-8.08	5.06e-15	3.54e-12	-0.36	-0.34	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
KIRC	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	8.08	5.07e-15	3.54e-12	0.29	0.34	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
KIRC	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-8.08	5.08e-15	3.55e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-8.08	5.08e-15	3.55e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
KIRC	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	8.08	5.09e-15	3.56e-12	0.37	0.34	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
KIRC	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28089816	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28090857	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28091242	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28091439	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28091659	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28093966	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-8.08	5.1e-15	3.56e-12	-0.47	-0.34	Depression;	chr6:28094014	chr6:28115628~28116551:+
KIRC	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-8.08	5.11e-15	3.57e-12	-0.41	-0.34	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
KIRC	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	8.08	5.12e-15	3.57e-12	0.44	0.34	Height;	chr6:109361200	chr6:109382795~109383666:+
KIRC	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	8.08	5.13e-15	3.58e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
KIRC	cis	rs7250849	0.79	rs73052830	ENSG00000273837.1	LLNLR-470E3.1	-8.08	5.13e-15	3.58e-12	-0.65	-0.34	Blood protein levels;	chr19:51657512	chr19:51639478~51639931:-
KIRC	cis	rs72627509	1	rs72627509	ENSG00000269949.1	RP11-738E22.3	8.08	5.13e-15	3.58e-12	0.5	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972885	chr4:56960927~56961373:-
KIRC	cis	rs7017914	0.934	rs7830550	ENSG00000254031.4	RP11-326E22.1	8.08	5.14e-15	3.59e-12	0.38	0.34	Bone mineral density;	chr8:70658196	chr8:71155457~71204223:+
KIRC	cis	rs4356975	0.697	rs6849081	ENSG00000196472.4	RP13-644M16.4	8.08	5.15e-15	3.59e-12	0.38	0.34	Obesity-related traits;	chr4:69144840	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.697	rs58039330	ENSG00000196472.4	RP13-644M16.4	8.08	5.16e-15	3.6e-12	0.38	0.34	Obesity-related traits;	chr4:69149529	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.66	rs60567038	ENSG00000196472.4	RP13-644M16.4	8.08	5.16e-15	3.6e-12	0.38	0.34	Obesity-related traits;	chr4:69150135	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.697	rs58366569	ENSG00000196472.4	RP13-644M16.4	8.08	5.16e-15	3.6e-12	0.38	0.34	Obesity-related traits;	chr4:69150626	chr4:69181660~69182372:+
KIRC	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-8.08	5.17e-15	3.61e-12	-0.27	-0.34	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
KIRC	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	8.07	5.18e-15	3.62e-12	0.43	0.34	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
KIRC	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-8.07	5.19e-15	3.62e-12	-0.34	-0.34	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
KIRC	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-8.07	5.21e-15	3.64e-12	-0.57	-0.34	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
KIRC	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-8.07	5.21e-15	3.64e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
KIRC	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	8.07	5.21e-15	3.64e-12	0.45	0.34	Depression;	chr6:28363475	chr6:28943877~28944537:+
KIRC	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-8.07	5.22e-15	3.64e-12	-0.35	-0.34	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
KIRC	cis	rs12893668	0.572	rs34000399	ENSG00000269910.1	RP11-73M18.10	8.07	5.24e-15	3.65e-12	0.25	0.34	Reticulocyte count;	chr14:103635080	chr14:103694516~103695050:-
KIRC	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-8.07	5.26e-15	3.67e-12	-0.42	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000196472.4	RP13-644M16.4	8.07	5.27e-15	3.67e-12	0.39	0.34	Obesity-related traits;	chr4:69062256	chr4:69181660~69182372:+
KIRC	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-8.07	5.27e-15	3.68e-12	-0.48	-0.34	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
KIRC	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	8.07	5.29e-15	3.69e-12	0.44	0.34	Height;	chr6:109402736	chr6:109382795~109383666:+
KIRC	cis	rs1560104	0.518	rs11645483	ENSG00000274834.1	CTD-3037G24.5	8.07	5.3e-15	3.7e-12	0.37	0.34	Obesity-related traits;	chr16:12615400	chr16:12614451~12614852:+
KIRC	cis	rs710913	0.738	rs1180347	ENSG00000182109.6	RP11-69E11.4	-8.07	5.3e-15	3.7e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39522280~39546187:-
KIRC	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-8.07	5.31e-15	3.7e-12	-0.42	-0.34	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
KIRC	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-8.07	5.32e-15	3.71e-12	-0.37	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.697	rs5002700	ENSG00000196472.4	RP13-644M16.4	8.07	5.32e-15	3.71e-12	0.38	0.34	Obesity-related traits;	chr4:69155637	chr4:69181660~69182372:+
KIRC	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	8.07	5.32e-15	3.71e-12	0.45	0.34	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	8.07	5.33e-15	3.72e-12	0.42	0.34	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
KIRC	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-8.07	5.34e-15	3.72e-12	-0.32	-0.34	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
KIRC	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	8.07	5.34e-15	3.72e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
KIRC	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	8.07	5.36e-15	3.74e-12	0.24	0.34	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
KIRC	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-8.07	5.38e-15	3.75e-12	-0.32	-0.34	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
KIRC	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-8.07	5.39e-15	3.76e-12	-0.38	-0.34	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
KIRC	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-8.07	5.39e-15	3.76e-12	-0.38	-0.34	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
KIRC	cis	rs3820928	0.874	rs56324594	ENSG00000212391.1	SNORA48	-8.07	5.4e-15	3.76e-12	-0.4	-0.34	Pulmonary function;	chr2:227004138	chr2:226968989~226969122:-
KIRC	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	8.07	5.4e-15	3.76e-12	0.49	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
KIRC	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-8.07	5.41e-15	3.77e-12	-0.38	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
KIRC	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	8.07	5.42e-15	3.78e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	8.07	5.42e-15	3.78e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
KIRC	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	8.07	5.44e-15	3.79e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
KIRC	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	8.07	5.45e-15	3.79e-12	0.52	0.34	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
KIRC	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	8.07	5.45e-15	3.8e-12	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	8.07	5.45e-15	3.8e-12	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	8.07	5.45e-15	3.8e-12	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000196472.4	RP13-644M16.4	8.07	5.47e-15	3.81e-12	0.39	0.34	Obesity-related traits;	chr4:69071215	chr4:69181660~69182372:+
KIRC	cis	rs7945705	0.818	rs10769948	ENSG00000254860.4	TMEM9B-AS1	8.07	5.47e-15	3.81e-12	0.36	0.34	Hemoglobin concentration;	chr11:8740235	chr11:8964675~8977527:+
KIRC	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	8.07	5.48e-15	3.82e-12	0.44	0.34	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
KIRC	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-8.07	5.49e-15	3.82e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
KIRC	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	8.07	5.49e-15	3.82e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
KIRC	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-8.07	5.49e-15	3.82e-12	-0.46	-0.34	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-8.07	5.49e-15	3.82e-12	-0.46	-0.34	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
KIRC	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	8.07	5.51e-15	3.84e-12	0.24	0.34	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
KIRC	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-8.07	5.52e-15	3.84e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
KIRC	cis	rs755249	0.727	rs2242500	ENSG00000182109.6	RP11-69E11.4	8.07	5.54e-15	3.85e-12	0.26	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	8.07	5.54e-15	3.85e-12	0.26	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
KIRC	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	8.07	5.54e-15	3.85e-12	0.47	0.34	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
KIRC	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-8.07	5.56e-15	3.86e-12	-0.27	-0.34	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
KIRC	cis	rs79040073	0.563	rs17479003	ENSG00000259531.2	RP11-295H24.3	8.07	5.56e-15	3.87e-12	0.43	0.34	Lung cancer in ever smokers;	chr15:49453223	chr15:49365124~49366685:-
KIRC	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	8.06	5.57e-15	3.87e-12	0.43	0.34	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
KIRC	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	8.06	5.59e-15	3.89e-12	0.42	0.34	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	8.06	5.59e-15	3.89e-12	0.42	0.34	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
KIRC	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	8.06	5.6e-15	3.89e-12	0.37	0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
KIRC	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	8.06	5.6e-15	3.89e-12	0.38	0.34	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
KIRC	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-8.06	5.64e-15	3.92e-12	-0.36	-0.34	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
KIRC	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	8.06	5.65e-15	3.92e-12	0.37	0.34	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
KIRC	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	8.06	5.65e-15	3.93e-12	0.44	0.34	Height;	chr6:109383848	chr6:109382795~109383666:+
KIRC	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	8.06	5.65e-15	3.93e-12	0.6	0.34	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	8.06	5.65e-15	3.93e-12	0.6	0.34	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	8.06	5.65e-15	3.93e-12	0.6	0.34	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	8.06	5.65e-15	3.93e-12	0.6	0.34	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	8.06	5.65e-15	3.93e-12	0.33	0.34	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
KIRC	cis	rs950027	0.62	rs1719245	ENSG00000259433.2	CTD-2651B20.4	-8.06	5.67e-15	3.94e-12	-0.25	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45330209~45332634:-
KIRC	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	8.06	5.68e-15	3.94e-12	0.43	0.34	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
KIRC	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	8.06	5.69e-15	3.96e-12	0.24	0.34	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
KIRC	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	8.06	5.69e-15	3.96e-12	0.24	0.34	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
KIRC	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-8.06	5.7e-15	3.96e-12	-0.43	-0.34	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
KIRC	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	8.06	5.7e-15	3.96e-12	0.42	0.34	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	8.06	5.7e-15	3.96e-12	0.42	0.34	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
KIRC	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	8.06	5.71e-15	3.97e-12	0.3	0.34	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
KIRC	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	8.06	5.72e-15	3.97e-12	0.62	0.34	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
KIRC	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	8.06	5.73e-15	3.98e-12	0.56	0.34	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
KIRC	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-8.06	5.74e-15	3.99e-12	-0.45	-0.34	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
KIRC	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	8.06	5.76e-15	4e-12	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
KIRC	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	8.06	5.78e-15	4.01e-12	0.64	0.34	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
KIRC	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	8.06	5.78e-15	4.01e-12	0.64	0.34	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
KIRC	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-8.06	5.79e-15	4.02e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
KIRC	cis	rs3820928	0.839	rs4673174	ENSG00000212391.1	SNORA48	-8.06	5.8e-15	4.02e-12	-0.4	-0.34	Pulmonary function;	chr2:226936600	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.804	rs4675125	ENSG00000212391.1	SNORA48	-8.06	5.8e-15	4.02e-12	-0.4	-0.34	Pulmonary function;	chr2:226937783	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs55743026	ENSG00000212391.1	SNORA48	-8.06	5.8e-15	4.02e-12	-0.4	-0.34	Pulmonary function;	chr2:226938097	chr2:226968989~226969122:-
KIRC	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-8.06	5.8e-15	4.03e-12	-0.48	-0.34	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	8.06	5.8e-15	4.03e-12	0.48	0.34	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
KIRC	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-8.06	5.81e-15	4.03e-12	-0.45	-0.34	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
KIRC	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-8.06	5.82e-15	4.04e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
KIRC	cis	rs5771242	0.845	rs4838859	ENSG00000273253.2	RP3-402G11.26	-8.06	5.83e-15	4.04e-12	-0.41	-0.34	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50174773	chr22:50199090~50200837:-
KIRC	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-8.06	5.83e-15	4.04e-12	-0.36	-0.34	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
KIRC	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	8.06	5.83e-15	4.04e-12	0.4	0.34	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
KIRC	cis	rs4819052	0.851	rs2838844	ENSG00000223768.1	LINC00205	-8.06	5.84e-15	4.05e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45293285~45297354:+
KIRC	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	8.06	5.84e-15	4.05e-12	0.61	0.34	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
KIRC	cis	rs13113518	0.783	rs2171618	ENSG00000273257.1	RP11-177J6.1	8.06	5.85e-15	4.06e-12	0.42	0.34	Height;	chr4:55564241	chr4:55387949~55388271:+
KIRC	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	8.06	5.86e-15	4.06e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
KIRC	cis	rs6061231	0.74	rs11698650	ENSG00000275437.1	RP5-908M14.10	8.06	5.87e-15	4.07e-12	0.27	0.34	Colorectal cancer;	chr20:62383318	chr20:62402236~62405935:-
KIRC	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-8.06	5.89e-15	4.08e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
KIRC	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8.06	5.89e-15	4.08e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
KIRC	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-8.06	5.89e-15	4.09e-12	-0.46	-0.34	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	8.06	5.9e-15	4.09e-12	0.35	0.34	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
KIRC	cis	rs3820928	0.904	rs4129884	ENSG00000212391.1	SNORA48	-8.06	5.9e-15	4.09e-12	-0.4	-0.34	Pulmonary function;	chr2:226956227	chr2:226968989~226969122:-
KIRC	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-8.06	5.91e-15	4.1e-12	-0.43	-0.34	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
KIRC	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	8.06	5.94e-15	4.11e-12	0.48	0.34	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
KIRC	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-8.06	5.94e-15	4.12e-12	-0.27	-0.34	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
KIRC	cis	rs1560104	0.576	rs11645674	ENSG00000274834.1	CTD-3037G24.5	-8.06	5.95e-15	4.12e-12	-0.36	-0.34	Obesity-related traits;	chr16:12615117	chr16:12614451~12614852:+
KIRC	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	8.06	5.95e-15	4.12e-12	0.38	0.34	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
KIRC	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	8.06	5.95e-15	4.12e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
KIRC	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	8.06	5.96e-15	4.13e-12	0.59	0.34	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	8.06	5.96e-15	4.13e-12	0.59	0.34	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
KIRC	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	8.06	5.96e-15	4.13e-12	0.29	0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
KIRC	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-8.06	5.97e-15	4.13e-12	-0.47	-0.34	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
KIRC	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-8.05	5.98e-15	4.14e-12	-0.25	-0.34	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-8.05	5.98e-15	4.14e-12	-0.25	-0.34	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
KIRC	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	8.05	5.98e-15	4.14e-12	0.48	0.34	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
KIRC	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	8.05	5.99e-15	4.14e-12	0.35	0.34	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-8.05	6e-15	4.15e-12	-0.46	-0.34	Depression;	chr6:28135913	chr6:28115628~28116551:+
KIRC	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	8.05	6e-15	4.15e-12	0.58	0.34	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
KIRC	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-8.05	6e-15	4.16e-12	-0.38	-0.34	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
KIRC	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-8.05	6.01e-15	4.16e-12	-0.35	-0.34	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
KIRC	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	8.05	6.02e-15	4.17e-12	0.3	0.34	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
KIRC	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-8.05	6.03e-15	4.17e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
KIRC	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-8.05	6.03e-15	4.17e-12	-0.29	-0.34	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
KIRC	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	8.05	6.05e-15	4.18e-12	0.43	0.34	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
KIRC	cis	rs4356975	0.563	rs11249527	ENSG00000248763.2	RP13-644M16.5	-8.05	6.06e-15	4.19e-12	-0.43	-0.34	Obesity-related traits;	chr4:69089267	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6846298	ENSG00000248763.2	RP13-644M16.5	-8.05	6.06e-15	4.19e-12	-0.43	-0.34	Obesity-related traits;	chr4:69089278	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs11249528	ENSG00000248763.2	RP13-644M16.5	-8.05	6.06e-15	4.19e-12	-0.43	-0.34	Obesity-related traits;	chr4:69089337	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.545	rs55757747	ENSG00000248763.2	RP13-644M16.5	-8.05	6.06e-15	4.19e-12	-0.43	-0.34	Obesity-related traits;	chr4:69089919	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs56217918	ENSG00000248763.2	RP13-644M16.5	-8.05	6.06e-15	4.19e-12	-0.43	-0.34	Obesity-related traits;	chr4:69089925	chr4:69066395~69069888:+
KIRC	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-8.05	6.09e-15	4.21e-12	-0.37	-0.34	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
KIRC	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	8.05	6.11e-15	4.23e-12	0.63	0.34	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
KIRC	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.05	6.11e-15	4.23e-12	-0.42	-0.34	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
KIRC	cis	rs3820928	0.874	rs6728239	ENSG00000212391.1	SNORA48	-8.05	6.13e-15	4.24e-12	-0.4	-0.34	Pulmonary function;	chr2:226991836	chr2:226968989~226969122:-
KIRC	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-8.05	6.13e-15	4.24e-12	-0.43	-0.34	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
KIRC	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-8.05	6.14e-15	4.24e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
KIRC	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-8.05	6.14e-15	4.25e-12	-0.46	-0.34	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
KIRC	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	8.05	6.14e-15	4.25e-12	0.34	0.34	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
KIRC	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	8.05	6.16e-15	4.26e-12	0.31	0.34	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
KIRC	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	8.05	6.17e-15	4.26e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
KIRC	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-8.05	6.17e-15	4.27e-12	-0.38	-0.34	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
KIRC	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-8.05	6.18e-15	4.27e-12	-0.32	-0.34	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
KIRC	cis	rs710913	0.738	rs755247	ENSG00000237624.1	OXCT2P1	-8.05	6.23e-15	4.3e-12	-0.42	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39514956~39516490:+
KIRC	cis	rs1560104	0.576	rs7186185	ENSG00000274834.1	CTD-3037G24.5	8.05	6.23e-15	4.31e-12	0.37	0.34	Obesity-related traits;	chr16:12614985	chr16:12614451~12614852:+
KIRC	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-8.05	6.24e-15	4.31e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
KIRC	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-8.05	6.26e-15	4.32e-12	-0.41	-0.34	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
KIRC	cis	rs10028773	0.632	rs34481394	ENSG00000248280.1	RP11-33B1.2	8.05	6.28e-15	4.34e-12	0.35	0.34	Educational attainment;	chr4:119327219	chr4:119440561~119450157:-
KIRC	cis	rs10028773	0.666	rs35231872	ENSG00000248280.1	RP11-33B1.2	8.05	6.28e-15	4.34e-12	0.35	0.34	Educational attainment;	chr4:119327221	chr4:119440561~119450157:-
KIRC	cis	rs10028773	0.7	rs35653026	ENSG00000248280.1	RP11-33B1.2	8.05	6.28e-15	4.34e-12	0.35	0.34	Educational attainment;	chr4:119327223	chr4:119440561~119450157:-
KIRC	cis	rs7672749	0.73	rs61064865	ENSG00000249973.2	CHCHD2P7	8.05	6.28e-15	4.34e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87873356	chr4:87785920~87786371:-
KIRC	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	8.05	6.3e-15	4.35e-12	0.6	0.34	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	8.05	6.31e-15	4.36e-12	0.6	0.34	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-8.05	6.32e-15	4.36e-12	-0.41	-0.34	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
KIRC	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-8.05	6.32e-15	4.36e-12	-0.25	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
KIRC	cis	rs4819052	0.851	rs875621	ENSG00000223768.1	LINC00205	-8.05	6.36e-15	4.39e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45293285~45297354:+
KIRC	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-8.05	6.36e-15	4.39e-12	-0.38	-0.34	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
KIRC	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-8.05	6.36e-15	4.39e-12	-0.48	-0.34	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-8.05	6.36e-15	4.39e-12	-0.48	-0.34	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-8.05	6.36e-15	4.39e-12	-0.48	-0.34	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-8.05	6.36e-15	4.39e-12	-0.48	-0.34	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
KIRC	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	8.05	6.36e-15	4.39e-12	0.53	0.34	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
KIRC	cis	rs3820928	0.874	rs13419455	ENSG00000212391.1	SNORA48	-8.05	6.4e-15	4.42e-12	-0.4	-0.34	Pulmonary function;	chr2:226985749	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs7576081	ENSG00000212391.1	SNORA48	-8.05	6.41e-15	4.42e-12	-0.41	-0.34	Pulmonary function;	chr2:226978918	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.839	rs35068645	ENSG00000212391.1	SNORA48	-8.05	6.41e-15	4.42e-12	-0.41	-0.34	Pulmonary function;	chr2:226979549	chr2:226968989~226969122:-
KIRC	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	8.05	6.42e-15	4.43e-12	0.46	0.34	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	8.05	6.42e-15	4.43e-12	0.46	0.34	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
KIRC	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-8.04	6.45e-15	4.45e-12	-0.32	-0.34	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
KIRC	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	8.04	6.45e-15	4.45e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
KIRC	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	8.04	6.46e-15	4.45e-12	0.24	0.34	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
KIRC	cis	rs7017914	0.967	rs35960437	ENSG00000254031.4	RP11-326E22.1	8.04	6.46e-15	4.46e-12	0.38	0.34	Bone mineral density;	chr8:70749725	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs34409123	ENSG00000254031.4	RP11-326E22.1	8.04	6.46e-15	4.46e-12	0.38	0.34	Bone mineral density;	chr8:70749881	chr8:71155457~71204223:+
KIRC	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	8.04	6.47e-15	4.46e-12	0.36	0.34	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
KIRC	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-8.04	6.47e-15	4.46e-12	-0.5	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
KIRC	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	8.04	6.47e-15	4.47e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
KIRC	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	8.04	6.49e-15	4.47e-12	0.59	0.34	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
KIRC	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-8.04	6.51e-15	4.49e-12	-0.38	-0.34	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
KIRC	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-8.04	6.53e-15	4.5e-12	-0.36	-0.34	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
KIRC	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-8.04	6.54e-15	4.51e-12	-0.43	-0.34	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
KIRC	cis	rs904251	1	rs10947673	ENSG00000227920.2	RP1-153P14.5	-8.04	6.55e-15	4.51e-12	-0.38	-0.34	Cognitive performance;	chr6:37477303	chr6:37545145~37550860:+
KIRC	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	8.04	6.56e-15	4.52e-12	0.35	0.34	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	8.04	6.56e-15	4.52e-12	0.35	0.34	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	8.04	6.56e-15	4.52e-12	0.35	0.34	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
KIRC	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	8.04	6.57e-15	4.53e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
KIRC	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	8.04	6.58e-15	4.53e-12	0.61	0.34	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
KIRC	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-8.04	6.6e-15	4.55e-12	-0.41	-0.34	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
KIRC	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-8.04	6.61e-15	4.55e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
KIRC	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	8.04	6.62e-15	4.56e-12	0.47	0.34	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	8.04	6.63e-15	4.56e-12	0.42	0.34	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
KIRC	cis	rs6479901	0.947	rs7083823	ENSG00000232075.1	MRPL35P2	-8.04	6.63e-15	4.56e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63634317~63634827:-
KIRC	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-8.04	6.63e-15	4.57e-12	-0.37	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
KIRC	cis	rs2337406	0.789	rs9324095	ENSG00000274576.2	IGHV2-70	-8.04	6.65e-15	4.58e-12	-0.37	-0.34	Alzheimer's disease (late onset);	chr14:106795885	chr14:106770577~106771020:-
KIRC	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	8.04	6.66e-15	4.58e-12	0.34	0.34	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
KIRC	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	8.04	6.69e-15	4.6e-12	0.31	0.34	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
KIRC	cis	rs9847710	1	rs6770152	ENSG00000280417.1	RP11-5O17.1	-8.04	6.7e-15	4.6e-12	-0.37	-0.34	Ulcerative colitis;	chr3:53066198	chr3:53046166~53048122:+
KIRC	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-8.04	6.7e-15	4.61e-12	-0.37	-0.34	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
KIRC	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-8.04	6.71e-15	4.61e-12	-0.38	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
KIRC	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	8.04	6.75e-15	4.64e-12	0.24	0.34	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
KIRC	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-8.04	6.75e-15	4.64e-12	-0.37	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-8.04	6.75e-15	4.64e-12	-0.37	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
KIRC	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-8.04	6.77e-15	4.65e-12	-0.56	-0.34	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
KIRC	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	8.04	6.81e-15	4.68e-12	0.41	0.34	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
KIRC	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-8.04	6.81e-15	4.68e-12	-0.47	-0.34	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
KIRC	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-8.04	6.81e-15	4.68e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-8.04	6.81e-15	4.68e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
KIRC	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	8.04	6.83e-15	4.69e-12	0.24	0.34	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
KIRC	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	8.04	6.83e-15	4.69e-12	0.31	0.34	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
KIRC	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	8.04	6.83e-15	4.69e-12	0.43	0.34	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
KIRC	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-8.04	6.83e-15	4.69e-12	-0.37	-0.34	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-8.04	6.83e-15	4.69e-12	-0.37	-0.34	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
KIRC	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-8.04	6.83e-15	4.69e-12	-0.37	-0.34	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
KIRC	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-8.04	6.83e-15	4.69e-12	-0.37	-0.34	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
KIRC	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-8.04	6.83e-15	4.69e-12	-0.32	-0.34	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
KIRC	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	8.04	6.84e-15	4.7e-12	0.27	0.34	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
KIRC	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	8.04	6.85e-15	4.7e-12	0.44	0.34	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
KIRC	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-8.04	6.85e-15	4.7e-12	-0.46	-0.34	Depression;	chr6:28092227	chr6:28115628~28116551:+
KIRC	cis	rs6600671	1	rs10903161	ENSG00000227082.1	CH17-437K3.1	-8.04	6.85e-15	4.71e-12	-0.38	-0.34	Hip geometry;	chr1:121436882	chr1:121396754~121463129:+
KIRC	cis	rs6061231	0.755	rs11699160	ENSG00000275437.1	RP5-908M14.10	8.04	6.87e-15	4.72e-12	0.27	0.34	Colorectal cancer;	chr20:62383595	chr20:62402236~62405935:-
KIRC	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	8.04	6.87e-15	4.72e-12	0.41	0.34	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
KIRC	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	8.04	6.87e-15	4.72e-12	0.46	0.34	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
KIRC	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-8.04	6.88e-15	4.72e-12	-0.36	-0.34	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
KIRC	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-8.04	6.88e-15	4.73e-12	-0.44	-0.34	Height;	chr6:109531713	chr6:109382795~109383666:+
KIRC	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-8.04	6.89e-15	4.73e-12	-0.35	-0.34	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
KIRC	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	8.04	6.89e-15	4.73e-12	0.43	0.34	Height;	chr4:55457922	chr4:55387949~55388271:+
KIRC	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	8.04	6.9e-15	4.74e-12	0.53	0.34	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
KIRC	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-8.04	6.91e-15	4.74e-12	-0.36	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
KIRC	cis	rs3820928	0.81	rs10175929	ENSG00000212391.1	SNORA48	-8.03	6.91e-15	4.75e-12	-0.4	-0.34	Pulmonary function;	chr2:226993893	chr2:226968989~226969122:-
KIRC	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	8.03	6.93e-15	4.76e-12	0.71	0.34	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
KIRC	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-8.03	6.94e-15	4.76e-12	-0.29	-0.34	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
KIRC	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	8.03	6.95e-15	4.77e-12	0.48	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
KIRC	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	8.03	6.95e-15	4.77e-12	0.42	0.34	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
KIRC	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	8.03	6.95e-15	4.77e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
KIRC	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-8.03	6.96e-15	4.77e-12	-0.44	-0.34	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
KIRC	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	8.03	6.97e-15	4.78e-12	0.49	0.34	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
KIRC	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-8.03	7e-15	4.8e-12	-0.46	-0.34	Height;	chr6:109380015	chr6:109382795~109383666:+
KIRC	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-8.03	7.02e-15	4.81e-12	-0.47	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
KIRC	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	8.03	7.04e-15	4.83e-12	0.53	0.34	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
KIRC	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	8.03	7.04e-15	4.83e-12	0.34	0.34	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
KIRC	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	8.03	7.06e-15	4.84e-12	0.38	0.34	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
KIRC	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-8.03	7.07e-15	4.85e-12	-0.24	-0.34	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
KIRC	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	8.03	7.08e-15	4.85e-12	0.7	0.34	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
KIRC	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-8.03	7.09e-15	4.86e-12	-0.38	-0.34	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
KIRC	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	8.03	7.11e-15	4.87e-12	0.65	0.34	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
KIRC	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	8.03	7.11e-15	4.87e-12	0.44	0.34	Height;	chr6:109403734	chr6:109382795~109383666:+
KIRC	cis	rs7017914	0.967	rs12675271	ENSG00000254031.4	RP11-326E22.1	8.03	7.12e-15	4.88e-12	0.37	0.34	Bone mineral density;	chr8:70689774	chr8:71155457~71204223:+
KIRC	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-8.03	7.12e-15	4.88e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
KIRC	cis	rs4356975	0.563	rs6600886	ENSG00000250696.4	RP11-704M14.1	8.03	7.12e-15	4.88e-12	0.36	0.34	Obesity-related traits;	chr4:69104017	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.563	rs6858558	ENSG00000248763.2	RP13-644M16.5	-8.03	7.13e-15	4.89e-12	-0.43	-0.34	Obesity-related traits;	chr4:69103825	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.563	rs6600887	ENSG00000250696.4	RP11-704M14.1	8.03	7.13e-15	4.89e-12	0.36	0.34	Obesity-related traits;	chr4:69104070	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.522	rs6600888	ENSG00000250696.4	RP11-704M14.1	8.03	7.13e-15	4.89e-12	0.36	0.34	Obesity-related traits;	chr4:69104141	chr4:69182100~69216766:+
KIRC	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-8.03	7.13e-15	4.89e-12	-0.38	-0.34	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
KIRC	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	8.03	7.13e-15	4.89e-12	0.48	0.34	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
KIRC	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-8.03	7.15e-15	4.9e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
KIRC	cis	rs4356975	0.649	rs59421013	ENSG00000196472.4	RP13-644M16.4	8.03	7.17e-15	4.92e-12	0.38	0.34	Obesity-related traits;	chr4:69149131	chr4:69181660~69182372:+
KIRC	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-8.03	7.2e-15	4.93e-12	-0.47	-0.34	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
KIRC	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-8.03	7.2e-15	4.94e-12	-0.4	-0.34	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	8.03	7.21e-15	4.94e-12	0.35	0.34	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
KIRC	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-8.03	7.22e-15	4.94e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
KIRC	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-8.03	7.22e-15	4.95e-12	-0.37	-0.34	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
KIRC	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-8.03	7.24e-15	4.96e-12	-0.47	-0.34	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69071281	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69071328	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69071698	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072135	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072143	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072154	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072229	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072402	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072745	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69072777	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69073025	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69073381	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000196472.4	RP13-644M16.4	8.03	7.24e-15	4.96e-12	0.39	0.34	Obesity-related traits;	chr4:69073429	chr4:69181660~69182372:+
KIRC	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	8.03	7.25e-15	4.96e-12	0.42	0.34	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
KIRC	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-8.03	7.26e-15	4.97e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
KIRC	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	8.03	7.26e-15	4.97e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	8.03	7.26e-15	4.97e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
KIRC	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	8.03	7.26e-15	4.97e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
KIRC	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	8.03	7.29e-15	4.99e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	8.03	7.29e-15	4.99e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
KIRC	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-8.03	7.3e-15	4.99e-12	-0.36	-0.34	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
KIRC	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	8.03	7.3e-15	4.99e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	8.03	7.3e-15	4.99e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	8.03	7.3e-15	4.99e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
KIRC	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	8.03	7.3e-15	4.99e-12	0.43	0.34	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
KIRC	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-8.03	7.3e-15	5e-12	-0.29	-0.34	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
KIRC	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	8.03	7.31e-15	5e-12	0.44	0.34	Height;	chr6:109354092	chr6:109382795~109383666:+
KIRC	cis	rs7017914	0.967	rs1348535	ENSG00000254031.4	RP11-326E22.1	8.03	7.31e-15	5.01e-12	0.37	0.34	Bone mineral density;	chr8:70750506	chr8:71155457~71204223:+
KIRC	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-8.03	7.33e-15	5.01e-12	-0.38	-0.34	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
KIRC	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-8.03	7.33e-15	5.02e-12	-0.34	-0.34	Height;	chr3:53084188	chr3:53064283~53065091:-
KIRC	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	8.03	7.37e-15	5.04e-12	0.43	0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
KIRC	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	8.03	7.4e-15	5.06e-12	0.35	0.34	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
KIRC	cis	rs6479901	0.894	rs9919452	ENSG00000232075.1	MRPL35P2	-8.03	7.4e-15	5.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10761776	ENSG00000232075.1	MRPL35P2	-8.03	7.4e-15	5.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7910662	ENSG00000232075.1	MRPL35P2	-8.03	7.4e-15	5.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.624	rs10822175	ENSG00000232075.1	MRPL35P2	-8.03	7.4e-15	5.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63634317~63634827:-
KIRC	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-8.02	7.43e-15	5.08e-12	-0.31	-0.34	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
KIRC	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	8.02	7.43e-15	5.08e-12	0.37	0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
KIRC	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-8.02	7.43e-15	5.08e-12	-0.44	-0.34	Height;	chr6:109360458	chr6:109382795~109383666:+
KIRC	cis	rs13113518	0.812	rs12500456	ENSG00000273257.1	RP11-177J6.1	8.02	7.44e-15	5.09e-12	0.42	0.34	Height;	chr4:55561053	chr4:55387949~55388271:+
KIRC	cis	rs950776	0.695	rs1878399	ENSG00000261762.1	RP11-650L12.2	-8.02	7.45e-15	5.09e-12	-0.45	-0.34	Sudden cardiac arrest;	chr15:78619661	chr15:78589123~78591276:-
KIRC	cis	rs7672749	0.73	rs17013355	ENSG00000249973.2	CHCHD2P7	8.02	7.47e-15	5.1e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867091	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs4334720	ENSG00000249973.2	CHCHD2P7	8.02	7.47e-15	5.1e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867772	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs1870963	ENSG00000249973.2	CHCHD2P7	8.02	7.47e-15	5.1e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87867882	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs17013369	ENSG00000249973.2	CHCHD2P7	8.02	7.47e-15	5.1e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87868465	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs68078763	ENSG00000249973.2	CHCHD2P7	8.02	7.47e-15	5.1e-12	0.7	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87868787	chr4:87785920~87786371:-
KIRC	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.02	7.47e-15	5.11e-12	-0.51	-0.34	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
KIRC	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	8.02	7.48e-15	5.11e-12	0.39	0.34	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
KIRC	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-8.02	7.48e-15	5.11e-12	-0.6	-0.34	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
KIRC	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	8.02	7.5e-15	5.12e-12	0.46	0.34	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000196472.4	RP13-644M16.4	8.02	7.55e-15	5.16e-12	0.39	0.34	Obesity-related traits;	chr4:69073715	chr4:69181660~69182372:+
KIRC	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-8.02	7.55e-15	5.16e-12	-0.47	-0.34	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-8.02	7.55e-15	5.16e-12	-0.47	-0.34	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-8.02	7.55e-15	5.16e-12	-0.47	-0.34	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-8.02	7.55e-15	5.16e-12	-0.47	-0.34	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
KIRC	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	8.02	7.59e-15	5.18e-12	0.32	0.34	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
KIRC	cis	rs3820928	0.874	rs59630650	ENSG00000212391.1	SNORA48	-8.02	7.6e-15	5.19e-12	-0.4	-0.34	Pulmonary function;	chr2:226921798	chr2:226968989~226969122:-
KIRC	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	8.02	7.61e-15	5.19e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	8.02	7.61e-15	5.19e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	8.02	7.61e-15	5.19e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
KIRC	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-8.02	7.62e-15	5.2e-12	-0.4	-0.34	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
KIRC	cis	rs899997	1	rs11072800	ENSG00000261143.1	ADAMTS7P3	-8.02	7.62e-15	5.2e-12	-0.4	-0.34	Coronary artery disease or large artery stroke;	chr15:78753515	chr15:77976042~77993057:+
KIRC	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	8.02	7.62e-15	5.2e-12	0.6	0.34	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
KIRC	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	8.02	7.62e-15	5.2e-12	0.6	0.34	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
KIRC	cis	rs4356975	0.563	rs7657423	ENSG00000250696.4	RP11-704M14.1	-8.02	7.64e-15	5.21e-12	-0.36	-0.34	Obesity-related traits;	chr4:69090196	chr4:69182100~69216766:+
KIRC	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-8.02	7.65e-15	5.22e-12	-0.39	-0.34	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
KIRC	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	8.02	7.66e-15	5.23e-12	0.52	0.34	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
KIRC	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	8.02	7.67e-15	5.23e-12	0.3	0.34	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
KIRC	cis	rs1560104	0.549	rs7201160	ENSG00000274834.1	CTD-3037G24.5	8.02	7.69e-15	5.25e-12	0.37	0.34	Obesity-related traits;	chr16:12614022	chr16:12614451~12614852:+
KIRC	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-8.02	7.69e-15	5.25e-12	-0.38	-0.34	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
KIRC	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	8.02	7.73e-15	5.27e-12	0.57	0.34	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
KIRC	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-8.02	7.76e-15	5.29e-12	-0.45	-0.34	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
KIRC	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	8.02	7.77e-15	5.3e-12	0.46	0.34	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
KIRC	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	8.02	7.8e-15	5.32e-12	0.32	0.34	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
KIRC	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	8.02	7.81e-15	5.33e-12	0.27	0.34	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
KIRC	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	8.02	7.82e-15	5.33e-12	0.48	0.34	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
KIRC	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-8.02	7.83e-15	5.33e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
KIRC	cis	rs2337406	0.866	rs58154560	ENSG00000274576.2	IGHV2-70	-8.02	7.84e-15	5.34e-12	-0.37	-0.34	Alzheimer's disease (late onset);	chr14:106799601	chr14:106770577~106771020:-
KIRC	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	8.02	7.84e-15	5.35e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
KIRC	cis	rs79040073	0.607	rs10519227	ENSG00000259531.2	RP11-295H24.3	8.02	7.85e-15	5.35e-12	0.43	0.34	Lung cancer in ever smokers;	chr15:49454167	chr15:49365124~49366685:-
KIRC	cis	rs1560104	0.576	rs7202727	ENSG00000274834.1	CTD-3037G24.5	8.02	7.86e-15	5.35e-12	0.37	0.34	Obesity-related traits;	chr16:12614087	chr16:12614451~12614852:+
KIRC	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	8.02	7.86e-15	5.35e-12	0.6	0.34	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
KIRC	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-8.02	7.87e-15	5.36e-12	-0.38	-0.34	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
KIRC	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-8.02	7.88e-15	5.37e-12	-0.38	-0.34	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
KIRC	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	8.02	7.89e-15	5.38e-12	0.61	0.34	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
KIRC	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-8.02	7.9e-15	5.38e-12	-0.47	-0.34	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
KIRC	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-8.02	7.91e-15	5.39e-12	-0.37	-0.34	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
KIRC	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-8.02	7.92e-15	5.39e-12	-0.36	-0.34	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
KIRC	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-8.02	7.93e-15	5.4e-12	-0.42	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
KIRC	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	8.02	7.94e-15	5.4e-12	0.42	0.34	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
KIRC	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	8.02	7.95e-15	5.41e-12	0.52	0.34	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
KIRC	cis	rs526231	0.963	rs12187443	ENSG00000175749.11	EIF3KP1	8.02	7.95e-15	5.41e-12	0.44	0.34	Primary biliary cholangitis;	chr5:103324699	chr5:103032376~103033031:+
KIRC	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	8.02	7.95e-15	5.42e-12	0.37	0.34	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
KIRC	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-8.02	7.98e-15	5.43e-12	-0.59	-0.34	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
KIRC	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-8.01	7.99e-15	5.44e-12	-0.38	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
KIRC	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-8.01	8.01e-15	5.45e-12	-0.38	-0.34	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-8.01	8.01e-15	5.45e-12	-0.38	-0.34	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
KIRC	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-8.01	8.02e-15	5.46e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
KIRC	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	8.01	8.02e-15	5.46e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
KIRC	cis	rs8396	1	rs11737481	ENSG00000271817.2	U3	-8.01	8.02e-15	5.46e-12	-0.31	-0.34	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700098	chr4:158700691~158700909:+
KIRC	cis	rs710913	0.816	rs1727098	ENSG00000237624.1	OXCT2P1	-8.01	8.04e-15	5.47e-12	-0.42	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39514956~39516490:+
KIRC	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-8.01	8.09e-15	5.5e-12	-0.35	-0.34	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
KIRC	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-8.01	8.11e-15	5.52e-12	-0.41	-0.34	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
KIRC	cis	rs1560104	0.597	rs12162027	ENSG00000274834.1	CTD-3037G24.5	8.01	8.12e-15	5.52e-12	0.37	0.34	Obesity-related traits;	chr16:12616235	chr16:12614451~12614852:+
KIRC	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	8.01	8.14e-15	5.53e-12	0.43	0.34	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	8.01	8.14e-15	5.53e-12	0.43	0.34	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	8.01	8.14e-15	5.53e-12	0.43	0.34	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
KIRC	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	8.01	8.14e-15	5.53e-12	0.42	0.34	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
KIRC	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-8.01	8.14e-15	5.54e-12	-0.24	-0.34	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
KIRC	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-8.01	8.14e-15	5.54e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
KIRC	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	8.01	8.16e-15	5.55e-12	0.31	0.34	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
KIRC	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-8.01	8.18e-15	5.56e-12	-0.45	-0.34	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
KIRC	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	8.01	8.2e-15	5.57e-12	0.29	0.34	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
KIRC	cis	rs7224610	1	rs7224610	ENSG00000263096.1	RP11-515O17.2	8.01	8.2e-15	5.58e-12	0.44	0.34	Urate levels;	chr17:55287427	chr17:55271504~55273653:-
KIRC	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-8.01	8.22e-15	5.59e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
KIRC	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.01	8.26e-15	5.61e-12	-0.49	-0.34	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
KIRC	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	8.01	8.27e-15	5.62e-12	0.35	0.34	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
KIRC	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	8.01	8.28e-15	5.62e-12	0.64	0.34	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
KIRC	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	8.01	8.28e-15	5.63e-12	0.41	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
KIRC	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-8.01	8.29e-15	5.64e-12	-0.39	-0.34	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
KIRC	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.01	8.35e-15	5.67e-12	-0.51	-0.34	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-8.01	8.35e-15	5.68e-12	-0.43	-0.34	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
KIRC	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	8.01	8.4e-15	5.71e-12	0.58	0.34	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	8.01	8.4e-15	5.71e-12	0.58	0.34	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
KIRC	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	8.01	8.43e-15	5.73e-12	0.43	0.34	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
KIRC	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	8.01	8.44e-15	5.73e-12	0.42	0.34	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
KIRC	cis	rs4819052	0.851	rs1999335	ENSG00000223768.1	LINC00205	-8.01	8.44e-15	5.73e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45293285~45297354:+
KIRC	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-8.01	8.47e-15	5.75e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
KIRC	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	8.01	8.52e-15	5.78e-12	0.56	0.34	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
KIRC	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-8.01	8.52e-15	5.78e-12	-0.38	-0.34	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-8.01	8.52e-15	5.78e-12	-0.38	-0.34	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-8.01	8.52e-15	5.78e-12	-0.38	-0.34	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
KIRC	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-8.01	8.52e-15	5.78e-12	-0.45	-0.34	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
KIRC	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	8.01	8.53e-15	5.79e-12	0.58	0.34	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
KIRC	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-8.01	8.53e-15	5.79e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-8.01	8.53e-15	5.79e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-8.01	8.53e-15	5.79e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-8.01	8.53e-15	5.79e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-8.01	8.53e-15	5.79e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
KIRC	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-8.01	8.56e-15	5.81e-12	-0.44	-0.34	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
KIRC	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	8.01	8.58e-15	5.82e-12	0.37	0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
KIRC	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	8	8.58e-15	5.82e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
KIRC	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-8	8.58e-15	5.82e-12	-0.38	-0.34	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
KIRC	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	8	8.6e-15	5.83e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
KIRC	cis	rs950027	0.62	rs1153860	ENSG00000259433.2	CTD-2651B20.4	8	8.61e-15	5.84e-12	0.25	0.34	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45330209~45332634:-
KIRC	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	8	8.63e-15	5.86e-12	0.39	0.34	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
KIRC	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	8	8.65e-15	5.87e-12	0.3	0.34	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
KIRC	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-8	8.7e-15	5.9e-12	-0.45	-0.34	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
KIRC	cis	rs11079159	0.651	rs2287223	ENSG00000263096.1	RP11-515O17.2	8	8.72e-15	5.91e-12	0.41	0.34	QRS duration;	chr17:55315491	chr17:55271504~55273653:-
KIRC	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	8	8.73e-15	5.92e-12	0.43	0.34	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
KIRC	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-8	8.74e-15	5.93e-12	-0.3	-0.34	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
KIRC	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-8	8.76e-15	5.94e-12	-0.36	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
KIRC	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	8	8.77e-15	5.94e-12	0.43	0.34	Height;	chr4:55501955	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	8	8.77e-15	5.94e-12	0.35	0.34	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	8	8.77e-15	5.94e-12	0.35	0.34	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	8	8.77e-15	5.94e-12	0.35	0.34	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
KIRC	cis	rs12460587	0.587	rs55899235	ENSG00000275055.1	CTC-471J1.11	-8	8.79e-15	5.96e-12	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52099871	chr19:52049007~52049754:+
KIRC	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-8	8.8e-15	5.96e-12	-0.33	-0.34	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
KIRC	cis	rs3820928	0.874	rs7582251	ENSG00000212391.1	SNORA48	-8	8.8e-15	5.96e-12	-0.39	-0.34	Pulmonary function;	chr2:226926987	chr2:226968989~226969122:-
KIRC	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	8	8.84e-15	5.99e-12	0.45	0.34	Height;	chr6:109407148	chr6:109382795~109383666:+
KIRC	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-8	8.84e-15	5.99e-12	-0.41	-0.34	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
KIRC	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-8	8.85e-15	6e-12	-0.38	-0.34	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
KIRC	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	8	8.87e-15	6.01e-12	0.36	0.34	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
KIRC	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-8	8.87e-15	6.01e-12	-0.29	-0.34	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
KIRC	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-8	8.89e-15	6.02e-12	-0.46	-0.34	Depression;	chr6:28070115	chr6:28115628~28116551:+
KIRC	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-8	8.95e-15	6.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-8	8.95e-15	6.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-8	8.95e-15	6.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-8	8.95e-15	6.06e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
KIRC	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-8	8.95e-15	6.06e-12	-0.59	-0.34	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
KIRC	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-8	8.97e-15	6.07e-12	-0.38	-0.34	Migraine;	chr4:56956882	chr4:56960927~56961373:-
KIRC	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-8	8.97e-15	6.07e-12	-0.38	-0.34	Migraine;	chr4:56957291	chr4:56960927~56961373:-
KIRC	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-8	8.98e-15	6.08e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-8	8.98e-15	6.08e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	8	8.99e-15	6.08e-12	0.35	0.34	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	8	8.99e-15	6.08e-12	0.35	0.34	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	8	8.99e-15	6.08e-12	0.35	0.34	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
KIRC	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8	9e-15	6.09e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
KIRC	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	8	9.01e-15	6.1e-12	0.37	0.34	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
KIRC	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	8	9.01e-15	6.1e-12	0.37	0.34	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
KIRC	cis	rs6479901	0.947	rs10761755	ENSG00000232075.1	MRPL35P2	-8	9.01e-15	6.1e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63412212	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs10761757	ENSG00000232075.1	MRPL35P2	-8	9.01e-15	6.1e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63412790	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.846	rs10761761	ENSG00000232075.1	MRPL35P2	-8	9.01e-15	6.1e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63419398	chr10:63634317~63634827:-
KIRC	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-8	9.02e-15	6.1e-12	-0.41	-0.34	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
KIRC	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8	9.02e-15	6.11e-12	0.5	0.34	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
KIRC	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	8	9.03e-15	6.11e-12	0.3	0.34	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
KIRC	cis	rs7017914	0.934	rs2639921	ENSG00000254031.4	RP11-326E22.1	8	9.04e-15	6.12e-12	0.36	0.34	Bone mineral density;	chr8:70962599	chr8:71155457~71204223:+
KIRC	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	8	9.05e-15	6.13e-12	0.49	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
KIRC	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-8	9.07e-15	6.14e-12	-0.29	-0.34	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
KIRC	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	8	9.07e-15	6.14e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
KIRC	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-8	9.09e-15	6.15e-12	-0.33	-0.34	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
KIRC	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8	9.12e-15	6.17e-12	-0.52	-0.34	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
KIRC	cis	rs6479901	0.947	rs7074735	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.802	rs7075205	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.894	rs1061259	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.894	rs10761773	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.894	rs2393978	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs10822173	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs7085862	ENSG00000232075.1	MRPL35P2	-8	9.13e-15	6.17e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63634317~63634827:-
KIRC	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-8	9.13e-15	6.18e-12	-0.47	-0.34	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
KIRC	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8	9.15e-15	6.18e-12	0.37	0.34	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	8	9.15e-15	6.18e-12	0.37	0.34	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
KIRC	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-8	9.18e-15	6.2e-12	-0.43	-0.34	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
KIRC	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-7.99	9.23e-15	6.24e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
KIRC	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	7.99	9.23e-15	6.24e-12	0.38	0.34	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
KIRC	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.99	9.24e-15	6.24e-12	-0.37	-0.34	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.99	9.24e-15	6.24e-12	-0.37	-0.34	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
KIRC	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-7.99	9.26e-15	6.26e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
KIRC	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	7.99	9.27e-15	6.26e-12	0.34	0.34	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	7.99	9.27e-15	6.26e-12	0.34	0.34	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
KIRC	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-7.99	9.28e-15	6.27e-12	-0.56	-0.34	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
KIRC	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	7.99	9.32e-15	6.3e-12	0.42	0.34	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	7.99	9.32e-15	6.3e-12	0.42	0.34	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	7.99	9.32e-15	6.3e-12	0.42	0.34	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	7.99	9.32e-15	6.3e-12	0.42	0.34	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	7.99	9.32e-15	6.3e-12	0.42	0.34	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
KIRC	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	7.99	9.33e-15	6.3e-12	0.43	0.34	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
KIRC	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	7.99	9.34e-15	6.31e-12	0.57	0.34	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
KIRC	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-7.99	9.35e-15	6.32e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
KIRC	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28082231	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28082261	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28082984	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28083994	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28084025	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-7.99	9.37e-15	6.33e-12	-0.46	-0.34	Depression;	chr6:28085319	chr6:28115628~28116551:+
KIRC	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	7.99	9.39e-15	6.34e-12	0.37	0.34	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
KIRC	cis	rs4356975	0.527	rs12643840	ENSG00000250696.4	RP11-704M14.1	7.99	9.43e-15	6.37e-12	0.36	0.34	Obesity-related traits;	chr4:69082245	chr4:69182100~69216766:+
KIRC	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	7.99	9.46e-15	6.38e-12	0.4	0.34	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
KIRC	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-7.99	9.5e-15	6.41e-12	-0.46	-0.34	Depression;	chr6:28140307	chr6:28115628~28116551:+
KIRC	cis	rs950027	0.62	rs1719245	ENSG00000235390.4	CTD-2651B20.5	-7.99	9.5e-15	6.41e-12	-0.32	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45321077~45321692:-
KIRC	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-7.99	9.5e-15	6.41e-12	-0.38	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
KIRC	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	7.99	9.52e-15	6.42e-12	0.57	0.34	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
KIRC	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	7.99	9.52e-15	6.43e-12	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
KIRC	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-7.99	9.52e-15	6.43e-12	-0.47	-0.34	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
KIRC	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.99	9.54e-15	6.44e-12	0.5	0.34	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
KIRC	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-7.99	9.55e-15	6.44e-12	-0.44	-0.34	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
KIRC	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	7.99	9.56e-15	6.45e-12	0.45	0.34	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
KIRC	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	7.99	9.59e-15	6.47e-12	0.46	0.34	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
KIRC	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	7.99	9.6e-15	6.48e-12	0.56	0.34	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	7.99	9.6e-15	6.48e-12	0.56	0.34	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
KIRC	cis	rs7592578	0.723	rs4371384	ENSG00000272979.1	RP11-647K16.1	7.99	9.61e-15	6.48e-12	0.49	0.34	Diastolic blood pressure;	chr2:190566015	chr2:190454092~190454521:-
KIRC	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-7.99	9.68e-15	6.53e-12	-0.66	-0.34	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
KIRC	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-7.99	9.68e-15	6.53e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
KIRC	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-7.99	9.69e-15	6.54e-12	-0.35	-0.34	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-7.99	9.7e-15	6.54e-12	-0.33	-0.34	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	7.99	9.7e-15	6.54e-12	0.35	0.34	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
KIRC	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	7.99	9.7e-15	6.54e-12	0.45	0.34	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
KIRC	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.99	9.7e-15	6.54e-12	-0.33	-0.34	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
KIRC	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-7.99	9.7e-15	6.54e-12	-0.36	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-7.99	9.7e-15	6.54e-12	-0.45	-0.34	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
KIRC	cis	rs950776	0.518	rs28438420	ENSG00000261762.1	RP11-650L12.2	-7.99	9.74e-15	6.57e-12	-0.42	-0.34	Sudden cardiac arrest;	chr15:78543946	chr15:78589123~78591276:-
KIRC	cis	rs4356975	0.527	rs12643840	ENSG00000248763.2	RP13-644M16.5	-7.99	9.79e-15	6.6e-12	-0.44	-0.34	Obesity-related traits;	chr4:69082245	chr4:69066395~69069888:+
KIRC	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	7.99	9.8e-15	6.6e-12	0.41	0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
KIRC	cis	rs7017914	0.967	rs2639919	ENSG00000254031.4	RP11-326E22.1	7.99	9.83e-15	6.62e-12	0.36	0.34	Bone mineral density;	chr8:70962893	chr8:71155457~71204223:+
KIRC	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.99	9.83e-15	6.62e-12	0.24	0.34	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
KIRC	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	7.98	9.9e-15	6.67e-12	0.44	0.34	Height;	chr6:109409679	chr6:109382795~109383666:+
KIRC	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	7.98	9.91e-15	6.67e-12	0.58	0.34	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	7.98	9.91e-15	6.67e-12	0.58	0.34	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	7.98	9.91e-15	6.67e-12	0.58	0.34	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
KIRC	cis	rs13113518	0.783	rs13111128	ENSG00000273257.1	RP11-177J6.1	7.98	9.92e-15	6.68e-12	0.42	0.34	Height;	chr4:55578154	chr4:55387949~55388271:+
KIRC	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-7.98	9.92e-15	6.68e-12	-0.26	-0.34	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
KIRC	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-7.98	9.97e-15	6.72e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
KIRC	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-7.98	9.99e-15	6.72e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
KIRC	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-7.98	9.99e-15	6.72e-12	-0.45	-0.34	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
KIRC	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-7.98	9.99e-15	6.73e-12	-0.33	-0.34	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
KIRC	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	7.98	1.01e-14	6.77e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	7.98	1.01e-14	6.77e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	7.98	1.01e-14	6.77e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
KIRC	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	7.98	1.01e-14	6.77e-12	0.44	0.34	Height;	chr6:109424305	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	7.98	1.01e-14	6.77e-12	0.44	0.34	Height;	chr6:109425054	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	7.98	1.01e-14	6.77e-12	0.44	0.34	Height;	chr6:109426518	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	7.98	1.01e-14	6.77e-12	0.44	0.34	Height;	chr6:109427644	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	7.98	1.01e-14	6.77e-12	0.44	0.34	Height;	chr6:109430292	chr6:109382795~109383666:+
KIRC	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	7.98	1.01e-14	6.78e-12	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
KIRC	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	7.98	1.01e-14	6.78e-12	0.43	0.34	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
KIRC	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	7.98	1.01e-14	6.79e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
KIRC	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-7.98	1.01e-14	6.8e-12	-0.37	-0.34	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
KIRC	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	7.98	1.01e-14	6.81e-12	0.47	0.34	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
KIRC	cis	rs7017914	0.967	rs1493198	ENSG00000254031.4	RP11-326E22.1	7.98	1.01e-14	6.82e-12	0.36	0.34	Bone mineral density;	chr8:70939722	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs13255152	ENSG00000254031.4	RP11-326E22.1	7.98	1.01e-14	6.82e-12	0.36	0.34	Bone mineral density;	chr8:70947384	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-7.98	1.02e-14	6.86e-12	-0.47	-0.34	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-7.98	1.02e-14	6.86e-12	-0.47	-0.34	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-7.98	1.02e-14	6.86e-12	-0.47	-0.34	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
KIRC	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	7.98	1.02e-14	6.87e-12	0.56	0.34	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	7.98	1.02e-14	6.87e-12	0.56	0.34	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	7.98	1.02e-14	6.87e-12	0.56	0.34	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	7.98	1.02e-14	6.87e-12	0.56	0.34	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
KIRC	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	7.98	1.02e-14	6.89e-12	0.3	0.34	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
KIRC	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	7.98	1.03e-14	6.91e-12	0.35	0.34	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-7.98	1.04e-14	7e-12	-0.47	-0.34	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
KIRC	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	7.98	1.04e-14	7.01e-12	0.59	0.34	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
KIRC	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.98	1.05e-14	7.02e-12	0.29	0.34	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
KIRC	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	7.98	1.05e-14	7.03e-12	0.45	0.34	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
KIRC	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	7.98	1.05e-14	7.03e-12	0.47	0.34	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
KIRC	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	7.98	1.05e-14	7.05e-12	0.45	0.34	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
KIRC	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-7.98	1.05e-14	7.08e-12	-0.37	-0.34	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
KIRC	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-7.98	1.05e-14	7.09e-12	-0.33	-0.34	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
KIRC	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	7.98	1.06e-14	7.1e-12	0.44	0.34	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
KIRC	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	7.98	1.06e-14	7.13e-12	0.41	0.34	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	7.98	1.06e-14	7.13e-12	0.35	0.34	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	7.98	1.06e-14	7.13e-12	0.35	0.34	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
KIRC	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-7.98	1.06e-14	7.14e-12	-0.35	-0.34	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
KIRC	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-7.97	1.07e-14	7.15e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
KIRC	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-7.97	1.07e-14	7.18e-12	-0.48	-0.34	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
KIRC	cis	rs1560104	0.597	rs7187433	ENSG00000274834.1	CTD-3037G24.5	7.97	1.07e-14	7.2e-12	0.36	0.34	Obesity-related traits;	chr16:12615251	chr16:12614451~12614852:+
KIRC	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	7.97	1.07e-14	7.21e-12	0.6	0.34	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
KIRC	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-7.97	1.07e-14	7.21e-12	-0.66	-0.34	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
KIRC	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	7.97	1.08e-14	7.22e-12	0.48	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
KIRC	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-7.97	1.08e-14	7.22e-12	-0.46	-0.34	Depression;	chr6:28140454	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-7.97	1.08e-14	7.22e-12	-0.46	-0.34	Depression;	chr6:28141189	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-7.97	1.08e-14	7.22e-12	-0.46	-0.34	Depression;	chr6:28141484	chr6:28115628~28116551:+
KIRC	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	7.97	1.08e-14	7.23e-12	0.52	0.34	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
KIRC	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	7.97	1.08e-14	7.24e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
KIRC	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-7.97	1.08e-14	7.25e-12	-0.41	-0.34	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
KIRC	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-7.97	1.08e-14	7.25e-12	-0.37	-0.34	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
KIRC	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-7.97	1.08e-14	7.25e-12	-0.35	-0.34	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
KIRC	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	7.97	1.08e-14	7.27e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	7.97	1.08e-14	7.27e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
KIRC	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	7.97	1.08e-14	7.27e-12	0.35	0.34	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	7.97	1.08e-14	7.27e-12	0.35	0.34	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	7.97	1.08e-14	7.27e-12	0.35	0.34	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
KIRC	cis	rs11018904	0.861	rs4589254	ENSG00000280385.1	AP000648.5	7.97	1.09e-14	7.28e-12	0.38	0.34	Intelligence (multi-trait analysis);	chr11:90230187	chr11:90193614~90198120:+
KIRC	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-7.97	1.09e-14	7.28e-12	-0.33	-0.34	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
KIRC	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-7.97	1.09e-14	7.29e-12	-0.38	-0.34	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
KIRC	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-7.97	1.09e-14	7.31e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	7.97	1.09e-14	7.31e-12	0.48	0.34	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
KIRC	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	7.97	1.09e-14	7.32e-12	0.38	0.34	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
KIRC	cis	rs13113518	0.783	rs12510400	ENSG00000273257.1	RP11-177J6.1	7.97	1.09e-14	7.32e-12	0.42	0.34	Height;	chr4:55577294	chr4:55387949~55388271:+
KIRC	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	7.97	1.09e-14	7.33e-12	0.62	0.34	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
KIRC	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	7.97	1.09e-14	7.33e-12	0.34	0.34	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
KIRC	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	7.97	1.1e-14	7.34e-12	0.48	0.34	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
KIRC	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	7.97	1.1e-14	7.36e-12	0.38	0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
KIRC	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	7.97	1.1e-14	7.36e-12	0.3	0.34	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000196472.4	RP13-644M16.4	7.97	1.11e-14	7.43e-12	0.39	0.34	Obesity-related traits;	chr4:69069420	chr4:69181660~69182372:+
KIRC	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	7.97	1.11e-14	7.44e-12	0.42	0.34	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
KIRC	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	7.97	1.11e-14	7.44e-12	0.44	0.34	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
KIRC	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	7.97	1.12e-14	7.51e-12	0.42	0.34	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
KIRC	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	7.97	1.13e-14	7.55e-12	0.47	0.34	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
KIRC	cis	rs7017914	0.905	rs10091471	ENSG00000254031.4	RP11-326E22.1	7.97	1.13e-14	7.55e-12	0.37	0.34	Bone mineral density;	chr8:71041520	chr8:71155457~71204223:+
KIRC	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	7.97	1.13e-14	7.55e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	7.97	1.13e-14	7.55e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	7.97	1.13e-14	7.55e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
KIRC	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-7.97	1.13e-14	7.57e-12	-0.41	-0.34	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
KIRC	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-7.97	1.14e-14	7.6e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
KIRC	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-7.97	1.14e-14	7.6e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
KIRC	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-7.97	1.14e-14	7.61e-12	-0.3	-0.34	Height;	chr11:118747911	chr11:118791254~118793137:+
KIRC	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-7.97	1.14e-14	7.62e-12	-0.37	-0.34	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-7.97	1.14e-14	7.62e-12	-0.37	-0.34	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
KIRC	cis	rs1560104	0.536	rs12708760	ENSG00000274834.1	CTD-3037G24.5	7.97	1.14e-14	7.62e-12	0.37	0.34	Obesity-related traits;	chr16:12617071	chr16:12614451~12614852:+
KIRC	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	7.97	1.14e-14	7.62e-12	0.35	0.34	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
KIRC	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	7.97	1.14e-14	7.64e-12	0.57	0.34	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	7.97	1.14e-14	7.64e-12	0.57	0.34	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	7.97	1.14e-14	7.64e-12	0.57	0.34	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
KIRC	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	7.96	1.14e-14	7.65e-12	0.48	0.34	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
KIRC	cis	rs1560104	0.597	rs4781300	ENSG00000274834.1	CTD-3037G24.5	7.96	1.14e-14	7.66e-12	0.37	0.34	Obesity-related traits;	chr16:12613866	chr16:12614451~12614852:+
KIRC	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	7.96	1.15e-14	7.66e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
KIRC	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-7.96	1.15e-14	7.67e-12	-0.29	-0.34	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
KIRC	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-7.96	1.15e-14	7.67e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-7.96	1.15e-14	7.67e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
KIRC	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	7.96	1.15e-14	7.68e-12	0.3	0.34	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000196472.4	RP13-644M16.4	7.96	1.15e-14	7.7e-12	0.39	0.34	Obesity-related traits;	chr4:69069614	chr4:69181660~69182372:+
KIRC	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-7.96	1.15e-14	7.71e-12	-0.38	-0.34	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
KIRC	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	7.96	1.16e-14	7.73e-12	0.45	0.34	Height;	chr6:109477209	chr6:109382795~109383666:+
KIRC	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-7.96	1.16e-14	7.74e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
KIRC	cis	rs3820928	0.904	rs59135978	ENSG00000212391.1	SNORA48	-7.96	1.16e-14	7.74e-12	-0.4	-0.34	Pulmonary function;	chr2:226993047	chr2:226968989~226969122:-
KIRC	cis	rs7672749	0.73	rs6822777	ENSG00000249973.2	CHCHD2P7	-7.96	1.16e-14	7.74e-12	-0.69	-0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87870243	chr4:87785920~87786371:-
KIRC	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-7.96	1.16e-14	7.75e-12	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-7.96	1.16e-14	7.75e-12	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
KIRC	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-7.96	1.17e-14	7.8e-12	-0.38	-0.34	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
KIRC	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-7.96	1.17e-14	7.81e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-7.96	1.17e-14	7.81e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
KIRC	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	7.96	1.17e-14	7.84e-12	0.27	0.34	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
KIRC	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-7.96	1.18e-14	7.85e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-7.96	1.18e-14	7.85e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-7.96	1.18e-14	7.85e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
KIRC	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	7.96	1.18e-14	7.85e-12	0.52	0.34	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
KIRC	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-7.96	1.18e-14	7.85e-12	-0.41	-0.34	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
KIRC	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	7.96	1.18e-14	7.86e-12	0.45	0.34	Height;	chr6:109476101	chr6:109382795~109383666:+
KIRC	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	7.96	1.18e-14	7.89e-12	0.61	0.34	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
KIRC	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-7.96	1.18e-14	7.9e-12	-0.47	-0.34	Depression;	chr6:28099759	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-7.96	1.18e-14	7.9e-12	-0.47	-0.34	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-7.96	1.18e-14	7.9e-12	-0.47	-0.34	Depression;	chr6:28100648	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-7.96	1.18e-14	7.9e-12	-0.47	-0.34	Depression;	chr6:28107222	chr6:28115628~28116551:+
KIRC	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-7.96	1.19e-14	7.92e-12	-0.47	-0.34	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
KIRC	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	7.96	1.19e-14	7.93e-12	0.52	0.34	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
KIRC	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.96	1.19e-14	7.93e-12	0.37	0.34	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
KIRC	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.96	1.19e-14	7.93e-12	0.37	0.34	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
KIRC	cis	rs6504950	0.783	rs7211787	ENSG00000275710.1	RP11-257O5.4	7.96	1.19e-14	7.94e-12	0.47	0.34	Breast cancer;	chr17:55157551	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.783	rs12936639	ENSG00000275710.1	RP11-257O5.4	7.96	1.19e-14	7.94e-12	0.47	0.34	Breast cancer;	chr17:55158621	chr17:54964474~54964679:+
KIRC	cis	rs1560104	0.597	rs13338316	ENSG00000274834.1	CTD-3037G24.5	7.96	1.19e-14	7.95e-12	0.36	0.34	Obesity-related traits;	chr16:12617168	chr16:12614451~12614852:+
KIRC	cis	rs1560104	0.597	rs13333850	ENSG00000274834.1	CTD-3037G24.5	7.96	1.19e-14	7.95e-12	0.36	0.34	Obesity-related traits;	chr16:12617231	chr16:12614451~12614852:+
KIRC	cis	rs1560104	0.597	rs13334919	ENSG00000274834.1	CTD-3037G24.5	7.96	1.19e-14	7.95e-12	0.36	0.34	Obesity-related traits;	chr16:12617300	chr16:12614451~12614852:+
KIRC	cis	rs1560104	0.597	rs13338716	ENSG00000274834.1	CTD-3037G24.5	7.96	1.19e-14	7.95e-12	0.36	0.34	Obesity-related traits;	chr16:12617477	chr16:12614451~12614852:+
KIRC	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	7.96	1.19e-14	7.96e-12	0.45	0.34	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
KIRC	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-7.96	1.19e-14	7.96e-12	-0.38	-0.34	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
KIRC	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	7.96	1.19e-14	7.96e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
KIRC	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-7.96	1.19e-14	7.97e-12	-0.39	-0.34	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
KIRC	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	7.96	1.2e-14	7.98e-12	0.35	0.34	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	7.96	1.2e-14	7.98e-12	0.35	0.34	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
KIRC	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-7.96	1.2e-14	7.99e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
KIRC	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	7.96	1.2e-14	8e-12	0.41	0.34	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
KIRC	cis	rs4356975	0.563	rs7662029	ENSG00000248763.2	RP13-644M16.5	-7.96	1.2e-14	8e-12	-0.43	-0.34	Obesity-related traits;	chr4:69096194	chr4:69066395~69069888:+
KIRC	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-7.96	1.2e-14	8.01e-12	-0.41	-0.34	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
KIRC	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-7.96	1.2e-14	8.01e-12	-0.4	-0.34	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
KIRC	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	7.96	1.2e-14	8.01e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
KIRC	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	7.96	1.21e-14	8.04e-12	0.49	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
KIRC	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	7.96	1.21e-14	8.05e-12	0.51	0.34	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	7.96	1.21e-14	8.05e-12	0.45	0.34	Height;	chr6:109416225	chr6:109382795~109383666:+
KIRC	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	7.96	1.21e-14	8.06e-12	0.31	0.34	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
KIRC	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-7.96	1.21e-14	8.06e-12	-0.26	-0.34	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
KIRC	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	7.96	1.21e-14	8.07e-12	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
KIRC	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-7.96	1.21e-14	8.07e-12	-0.38	-0.34	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
KIRC	cis	rs62025270	0.547	rs1026722	ENSG00000202081.1	RNU6-1280P	7.96	1.21e-14	8.08e-12	0.38	0.34	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85651522~85651628:-
KIRC	cis	rs1560104	0.597	rs4781299	ENSG00000274834.1	CTD-3037G24.5	7.96	1.21e-14	8.09e-12	0.36	0.34	Obesity-related traits;	chr16:12613756	chr16:12614451~12614852:+
KIRC	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	7.96	1.22e-14	8.1e-12	0.37	0.34	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
KIRC	cis	rs13434995	0.589	rs499110	ENSG00000273257.1	RP11-177J6.1	-7.96	1.22e-14	8.11e-12	-0.45	-0.34	Adiponectin levels;	chr4:55381628	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	7.96	1.22e-14	8.12e-12	0.34	0.34	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
KIRC	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	7.96	1.22e-14	8.13e-12	0.45	0.34	Height;	chr6:109613205	chr6:109382795~109383666:+
KIRC	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-7.96	1.22e-14	8.15e-12	-0.33	-0.34	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
KIRC	cis	rs950027	0.62	rs1617634	ENSG00000235390.4	CTD-2651B20.5	-7.96	1.22e-14	8.15e-12	-0.32	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45321077~45321692:-
KIRC	cis	rs1345301	1	rs13405355	ENSG00000234389.1	AC007278.3	-7.96	1.23e-14	8.16e-12	-0.33	-0.34	Waist circumference;	chr2:102261746	chr2:102438713~102440475:+
KIRC	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28071237	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28074687	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28076559	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28076704	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28078391	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28079011	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28080757	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-7.96	1.23e-14	8.17e-12	-0.46	-0.34	Depression;	chr6:28080760	chr6:28115628~28116551:+
KIRC	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	7.96	1.23e-14	8.17e-12	0.61	0.34	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	7.96	1.23e-14	8.17e-12	0.61	0.34	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	7.96	1.23e-14	8.17e-12	0.61	0.34	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
KIRC	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	7.96	1.23e-14	8.17e-12	0.47	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
KIRC	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	7.96	1.23e-14	8.17e-12	0.47	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
KIRC	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.95	1.24e-14	8.22e-12	-0.34	-0.34	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
KIRC	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-7.95	1.24e-14	8.25e-12	-0.46	-0.34	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
KIRC	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	7.95	1.24e-14	8.25e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
KIRC	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	7.95	1.24e-14	8.25e-12	0.63	0.34	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
KIRC	cis	rs950027	0.62	rs1617984	ENSG00000235390.4	CTD-2651B20.5	-7.95	1.24e-14	8.25e-12	-0.32	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45321077~45321692:-
KIRC	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-7.95	1.24e-14	8.25e-12	-0.42	-0.34	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
KIRC	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-7.95	1.24e-14	8.26e-12	-0.4	-0.34	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
KIRC	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-7.95	1.24e-14	8.27e-12	-0.22	-0.34	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
KIRC	cis	rs3820928	0.935	rs12151597	ENSG00000212391.1	SNORA48	-7.95	1.25e-14	8.28e-12	-0.39	-0.34	Pulmonary function;	chr2:226994508	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.839	rs12151848	ENSG00000212391.1	SNORA48	-7.95	1.25e-14	8.28e-12	-0.39	-0.34	Pulmonary function;	chr2:226994610	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	7.95	1.25e-14	8.29e-12	0.35	0.34	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
KIRC	cis	rs1560104	0.576	rs12708761	ENSG00000274834.1	CTD-3037G24.5	7.95	1.25e-14	8.3e-12	0.36	0.34	Obesity-related traits;	chr16:12617077	chr16:12614451~12614852:+
KIRC	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.95	1.25e-14	8.31e-12	0.29	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
KIRC	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	7.95	1.25e-14	8.33e-12	0.35	0.34	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
KIRC	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-7.95	1.26e-14	8.36e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-7.95	1.26e-14	8.36e-12	-0.33	-0.34	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
KIRC	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	7.95	1.26e-14	8.39e-12	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
KIRC	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	7.95	1.26e-14	8.39e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	7.95	1.26e-14	8.39e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
KIRC	cis	rs647097	0.614	rs4797332	ENSG00000272788.1	RP11-674N23.4	-7.95	1.26e-14	8.4e-12	-0.42	-0.34	Chronic obstructive pulmonary disease;	chr18:8801283	chr18:8801656~8802305:+
KIRC	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-7.95	1.26e-14	8.41e-12	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
KIRC	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-7.95	1.27e-14	8.42e-12	-0.36	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
KIRC	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-7.95	1.27e-14	8.42e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-7.95	1.27e-14	8.42e-12	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
KIRC	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	7.95	1.27e-14	8.44e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	7.95	1.27e-14	8.44e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
KIRC	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-7.95	1.27e-14	8.45e-12	-0.4	-0.34	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
KIRC	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-7.95	1.27e-14	8.45e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
KIRC	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-7.95	1.28e-14	8.48e-12	-0.4	-0.34	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
KIRC	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	7.95	1.28e-14	8.48e-12	0.3	0.34	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	7.95	1.28e-14	8.48e-12	0.3	0.34	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
KIRC	cis	rs2734839	0.964	rs12364051	ENSG00000270179.1	RP11-159N11.4	-7.95	1.28e-14	8.48e-12	-0.35	-0.34	Information processing speed;	chr11:113434592	chr11:113368478~113369117:+
KIRC	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-7.95	1.28e-14	8.49e-12	-0.35	-0.34	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
KIRC	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	7.95	1.28e-14	8.5e-12	0.35	0.34	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
KIRC	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	7.95	1.28e-14	8.51e-12	0.39	0.34	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
KIRC	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	7.95	1.28e-14	8.51e-12	0.45	0.34	Height;	chr6:109414295	chr6:109382795~109383666:+
KIRC	cis	rs4356975	0.563	rs3924192	ENSG00000250696.4	RP11-704M14.1	-7.95	1.28e-14	8.53e-12	-0.35	-0.34	Obesity-related traits;	chr4:69105246	chr4:69182100~69216766:+
KIRC	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-7.95	1.29e-14	8.57e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
KIRC	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-7.95	1.29e-14	8.58e-12	-0.37	-0.34	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
KIRC	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	7.95	1.29e-14	8.58e-12	0.42	0.34	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	7.95	1.3e-14	8.6e-12	0.35	0.34	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	7.95	1.3e-14	8.6e-12	0.37	0.34	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
KIRC	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	7.95	1.3e-14	8.6e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	7.95	1.3e-14	8.6e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
KIRC	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	7.95	1.3e-14	8.61e-12	0.37	0.34	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
KIRC	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	7.95	1.3e-14	8.62e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
KIRC	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-7.95	1.3e-14	8.63e-12	-0.31	-0.34	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
KIRC	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	7.95	1.31e-14	8.68e-12	0.52	0.34	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
KIRC	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	7.95	1.31e-14	8.68e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	7.95	1.31e-14	8.7e-12	0.34	0.34	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	7.95	1.31e-14	8.7e-12	0.34	0.34	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
KIRC	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-7.95	1.31e-14	8.71e-12	-0.38	-0.34	Migraine;	chr4:56950140	chr4:56960927~56961373:-
KIRC	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-7.95	1.31e-14	8.72e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-7.95	1.31e-14	8.72e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-7.95	1.31e-14	8.72e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-7.95	1.31e-14	8.72e-12	-0.35	-0.34	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
KIRC	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-7.95	1.32e-14	8.74e-12	-0.38	-0.34	Migraine;	chr4:56937339	chr4:56960927~56961373:-
KIRC	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-7.95	1.32e-14	8.74e-12	-0.28	-0.34	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
KIRC	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	7.95	1.32e-14	8.75e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	7.94	1.32e-14	8.75e-12	0.35	0.34	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	7.94	1.32e-14	8.75e-12	0.35	0.34	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
KIRC	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-7.94	1.32e-14	8.76e-12	-0.34	-0.34	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
KIRC	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-7.94	1.32e-14	8.76e-12	-0.41	-0.34	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
KIRC	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-7.94	1.32e-14	8.77e-12	-0.43	-0.34	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
KIRC	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-7.94	1.32e-14	8.78e-12	-0.38	-0.34	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
KIRC	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	7.94	1.32e-14	8.78e-12	0.45	0.34	Height;	chr6:109656105	chr6:109382795~109383666:+
KIRC	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	7.94	1.33e-14	8.81e-12	0.44	0.34	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
KIRC	cis	rs4356975	0.509	rs6600884	ENSG00000248763.2	RP13-644M16.5	-7.94	1.33e-14	8.81e-12	-0.44	-0.34	Obesity-related traits;	chr4:69102348	chr4:69066395~69069888:+
KIRC	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	7.94	1.33e-14	8.82e-12	0.35	0.34	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	7.94	1.33e-14	8.82e-12	0.35	0.34	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
KIRC	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	7.94	1.33e-14	8.83e-12	0.3	0.34	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	7.94	1.33e-14	8.83e-12	0.3	0.34	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
KIRC	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-7.94	1.33e-14	8.84e-12	-0.48	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
KIRC	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-7.94	1.33e-14	8.84e-12	-0.41	-0.34	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-7.94	1.33e-14	8.84e-12	-0.41	-0.34	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
KIRC	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	7.94	1.33e-14	8.84e-12	0.42	0.34	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	7.94	1.33e-14	8.84e-12	0.42	0.34	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
KIRC	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	7.94	1.34e-14	8.86e-12	0.52	0.34	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
KIRC	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	7.94	1.34e-14	8.88e-12	0.34	0.34	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
KIRC	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	7.94	1.34e-14	8.89e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	7.94	1.34e-14	8.89e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	7.94	1.34e-14	8.89e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	7.94	1.34e-14	8.89e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	7.94	1.34e-14	8.89e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
KIRC	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-7.94	1.35e-14	8.91e-12	-0.34	-0.34	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
KIRC	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	7.94	1.35e-14	8.92e-12	0.34	0.34	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
KIRC	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	7.94	1.35e-14	8.95e-12	0.35	0.34	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
KIRC	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	7.94	1.35e-14	8.96e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
KIRC	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-7.94	1.35e-14	8.96e-12	-0.37	-0.34	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
KIRC	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-7.94	1.35e-14	8.96e-12	-0.65	-0.34	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	7.94	1.36e-14	8.97e-12	0.34	0.34	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	7.94	1.36e-14	8.98e-12	0.45	0.34	Depression;	chr6:28086929	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-7.94	1.36e-14	9e-12	-0.46	-0.34	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
KIRC	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	7.94	1.36e-14	9.01e-12	0.24	0.34	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
KIRC	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-7.94	1.37e-14	9.03e-12	-0.47	-0.34	Depression;	chr6:28104824	chr6:28115628~28116551:+
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000196472.4	RP13-644M16.4	7.94	1.37e-14	9.03e-12	0.39	0.34	Obesity-related traits;	chr4:69070955	chr4:69181660~69182372:+
KIRC	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	7.94	1.37e-14	9.04e-12	0.43	0.34	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
KIRC	cis	rs7945705	0.846	rs905290	ENSG00000254860.4	TMEM9B-AS1	-7.94	1.37e-14	9.06e-12	-0.36	-0.34	Hemoglobin concentration;	chr11:8732182	chr11:8964675~8977527:+
KIRC	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	7.94	1.37e-14	9.07e-12	0.42	0.34	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	7.94	1.38e-14	9.1e-12	0.46	0.34	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
KIRC	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	7.94	1.38e-14	9.12e-12	0.3	0.34	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	7.94	1.38e-14	9.12e-12	0.3	0.34	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	7.94	1.38e-14	9.12e-12	0.3	0.34	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
KIRC	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	7.94	1.38e-14	9.12e-12	0.3	0.34	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
KIRC	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-7.94	1.38e-14	9.12e-12	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
KIRC	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	7.94	1.38e-14	9.12e-12	0.42	0.34	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
KIRC	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-7.94	1.38e-14	9.13e-12	-0.78	-0.34	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
KIRC	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	7.94	1.38e-14	9.14e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
KIRC	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	7.94	1.39e-14	9.16e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
KIRC	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	7.94	1.39e-14	9.19e-12	0.35	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
KIRC	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-7.94	1.39e-14	9.19e-12	-0.37	-0.34	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-7.94	1.39e-14	9.19e-12	-0.37	-0.34	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-7.94	1.39e-14	9.19e-12	-0.37	-0.34	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-7.94	1.39e-14	9.19e-12	-0.37	-0.34	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-7.94	1.39e-14	9.19e-12	-0.37	-0.34	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
KIRC	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-7.94	1.39e-14	9.2e-12	-0.43	-0.34	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
KIRC	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	7.94	1.39e-14	9.2e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
KIRC	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-7.94	1.4e-14	9.25e-12	-0.41	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
KIRC	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	7.94	1.4e-14	9.26e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	7.94	1.4e-14	9.26e-12	0.48	0.34	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
KIRC	cis	rs4356975	0.83	rs6600868	ENSG00000250696.4	RP11-704M14.1	7.94	1.4e-14	9.27e-12	0.34	0.34	Obesity-related traits;	chr4:69075923	chr4:69182100~69216766:+
KIRC	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	7.94	1.4e-14	9.27e-12	0.5	0.34	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
KIRC	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	7.94	1.4e-14	9.27e-12	0.42	0.34	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
KIRC	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	7.94	1.4e-14	9.28e-12	0.43	0.34	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
KIRC	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	7.94	1.41e-14	9.3e-12	0.51	0.34	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
KIRC	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	7.94	1.41e-14	9.3e-12	0.26	0.34	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
KIRC	cis	rs1560104	0.536	rs9933641	ENSG00000274834.1	CTD-3037G24.5	7.94	1.41e-14	9.3e-12	0.36	0.34	Obesity-related traits;	chr16:12615413	chr16:12614451~12614852:+
KIRC	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	7.94	1.41e-14	9.31e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
KIRC	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	7.94	1.41e-14	9.32e-12	0.26	0.34	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
KIRC	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-7.94	1.42e-14	9.34e-12	-0.34	-0.34	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
KIRC	cis	rs9532669	0.926	rs4356344	ENSG00000176268.5	CYCSP34	7.94	1.42e-14	9.35e-12	0.36	0.34	Cervical cancer;	chr13:40874086	chr13:40863599~40863902:-
KIRC	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	7.93	1.42e-14	9.37e-12	0.36	0.34	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
KIRC	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	7.93	1.42e-14	9.37e-12	0.36	0.34	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
KIRC	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-7.93	1.42e-14	9.39e-12	-0.4	-0.34	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
KIRC	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	7.93	1.42e-14	9.4e-12	0.27	0.34	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
KIRC	cis	rs4356975	0.509	rs10006452	ENSG00000248763.2	RP13-644M16.5	-7.93	1.43e-14	9.41e-12	-0.43	-0.34	Obesity-related traits;	chr4:69112090	chr4:69066395~69069888:+
KIRC	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	7.93	1.43e-14	9.41e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
KIRC	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-7.93	1.43e-14	9.43e-12	-0.48	-0.34	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
KIRC	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.93	1.43e-14	9.45e-12	-0.35	-0.34	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.93	1.43e-14	9.45e-12	-0.35	-0.34	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
KIRC	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.93	1.43e-14	9.45e-12	-0.35	-0.34	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.93	1.43e-14	9.45e-12	-0.35	-0.34	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.93	1.43e-14	9.45e-12	-0.35	-0.34	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
KIRC	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	7.93	1.43e-14	9.46e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
KIRC	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-7.93	1.44e-14	9.47e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-7.93	1.44e-14	9.47e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
KIRC	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	7.93	1.44e-14	9.48e-12	0.44	0.34	Height;	chr6:109447092	chr6:109382795~109383666:+
KIRC	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-7.93	1.44e-14	9.48e-12	-0.36	-0.34	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
KIRC	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-7.93	1.44e-14	9.48e-12	-0.38	-0.34	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
KIRC	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	7.93	1.44e-14	9.5e-12	0.22	0.34	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
KIRC	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	7.93	1.44e-14	9.5e-12	0.34	0.34	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	7.93	1.44e-14	9.5e-12	0.34	0.34	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	7.93	1.44e-14	9.5e-12	0.34	0.34	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	7.93	1.44e-14	9.5e-12	0.34	0.34	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	7.93	1.44e-14	9.5e-12	0.34	0.34	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
KIRC	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	7.93	1.44e-14	9.51e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
KIRC	cis	rs919433	0.854	rs13013049	ENSG00000231621.1	AC013264.2	7.93	1.45e-14	9.54e-12	0.38	0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343940	chr2:197197991~197199273:+
KIRC	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	7.93	1.45e-14	9.55e-12	0.45	0.34	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
KIRC	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	7.93	1.45e-14	9.57e-12	0.3	0.34	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
KIRC	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	7.93	1.45e-14	9.58e-12	0.52	0.34	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
KIRC	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	7.93	1.45e-14	9.58e-12	0.43	0.34	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
KIRC	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	7.93	1.46e-14	9.59e-12	0.53	0.34	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
KIRC	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	7.93	1.46e-14	9.64e-12	0.49	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
KIRC	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	7.93	1.47e-14	9.65e-12	0.48	0.34	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
KIRC	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	7.93	1.47e-14	9.66e-12	0.44	0.34	Height;	chr6:109530435	chr6:109382795~109383666:+
KIRC	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	7.93	1.47e-14	9.67e-12	0.38	0.34	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
KIRC	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-7.93	1.47e-14	9.7e-12	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	7.93	1.48e-14	9.71e-12	0.34	0.34	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
KIRC	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	7.93	1.48e-14	9.71e-12	0.37	0.34	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
KIRC	cis	rs950027	0.572	rs12910764	ENSG00000259433.2	CTD-2651B20.4	7.93	1.48e-14	9.71e-12	0.24	0.34	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45330209~45332634:-
KIRC	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	7.93	1.48e-14	9.72e-12	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
KIRC	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-7.93	1.48e-14	9.74e-12	-0.41	-0.34	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
KIRC	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.93	1.48e-14	9.76e-12	0.41	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
KIRC	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	7.93	1.48e-14	9.76e-12	0.35	0.34	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
KIRC	cis	rs950027	0.62	rs1145077	ENSG00000259433.2	CTD-2651B20.4	7.93	1.48e-14	9.76e-12	0.24	0.34	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45330209~45332634:-
KIRC	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-7.93	1.48e-14	9.77e-12	-0.44	-0.34	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
KIRC	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-7.93	1.48e-14	9.77e-12	-0.38	-0.34	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
KIRC	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-7.93	1.49e-14	9.77e-12	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
KIRC	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	7.93	1.49e-14	9.78e-12	0.26	0.34	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
KIRC	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	7.93	1.49e-14	9.79e-12	0.35	0.34	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	7.93	1.49e-14	9.79e-12	0.35	0.34	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	7.93	1.49e-14	9.79e-12	0.35	0.34	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
KIRC	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-7.93	1.49e-14	9.79e-12	-0.44	-0.34	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
KIRC	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	7.93	1.49e-14	9.8e-12	0.42	0.34	Height;	chr4:55482360	chr4:55387949~55388271:+
KIRC	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	7.93	1.49e-14	9.8e-12	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
KIRC	cis	rs13434995	0.589	rs861029	ENSG00000273257.1	RP11-177J6.1	-7.93	1.49e-14	9.81e-12	-0.45	-0.34	Adiponectin levels;	chr4:55379470	chr4:55387949~55388271:+
KIRC	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-7.93	1.49e-14	9.82e-12	-0.4	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
KIRC	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	7.93	1.5e-14	9.85e-12	0.29	0.34	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
KIRC	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-7.93	1.5e-14	9.86e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
KIRC	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-7.93	1.5e-14	9.88e-12	-0.36	-0.34	Height;	chr3:53080524	chr3:53064283~53065091:-
KIRC	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	7.93	1.51e-14	9.9e-12	0.27	0.34	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
KIRC	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-7.93	1.51e-14	9.9e-12	-0.34	-0.34	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
KIRC	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-7.93	1.51e-14	9.93e-12	-0.5	-0.34	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	7.93	1.51e-14	9.93e-12	0.34	0.34	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
KIRC	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	7.93	1.52e-14	9.96e-12	0.41	0.34	Height;	chr4:55542243	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	7.93	1.52e-14	9.98e-12	0.34	0.34	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
KIRC	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	7.92	1.52e-14	1e-11	0.47	0.34	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
KIRC	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	7.92	1.52e-14	1e-11	0.23	0.34	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
KIRC	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	7.92	1.53e-14	1e-11	0.3	0.34	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
KIRC	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-7.92	1.53e-14	1.01e-11	-0.3	-0.34	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
KIRC	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	7.92	1.53e-14	1.01e-11	0.41	0.34	Height;	chr4:55544621	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	7.92	1.54e-14	1.01e-11	0.35	0.34	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
KIRC	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-7.92	1.54e-14	1.01e-11	-0.23	-0.34	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
KIRC	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	7.92	1.54e-14	1.01e-11	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
KIRC	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-7.92	1.54e-14	1.01e-11	-0.49	-0.34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
KIRC	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	7.92	1.54e-14	1.01e-11	0.59	0.34	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
KIRC	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-7.92	1.54e-14	1.01e-11	-0.38	-0.34	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
KIRC	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	7.92	1.55e-14	1.01e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
KIRC	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	7.92	1.55e-14	1.02e-11	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	7.92	1.55e-14	1.02e-11	0.34	0.34	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	7.92	1.55e-14	1.02e-11	0.34	0.34	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	7.92	1.55e-14	1.02e-11	0.34	0.34	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
KIRC	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-7.92	1.55e-14	1.02e-11	-0.38	-0.34	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
KIRC	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-7.92	1.55e-14	1.02e-11	-0.38	-0.34	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
KIRC	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-7.92	1.55e-14	1.02e-11	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
KIRC	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	7.92	1.55e-14	1.02e-11	0.57	0.34	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	7.92	1.55e-14	1.02e-11	0.57	0.34	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
KIRC	cis	rs3820928	0.874	rs2177593	ENSG00000212391.1	SNORA48	-7.92	1.55e-14	1.02e-11	-0.4	-0.34	Pulmonary function;	chr2:226969153	chr2:226968989~226969122:-
KIRC	cis	rs7017914	0.905	rs2639957	ENSG00000254031.4	RP11-326E22.1	7.92	1.55e-14	1.02e-11	0.36	0.34	Bone mineral density;	chr8:71010967	chr8:71155457~71204223:+
KIRC	cis	rs200986	1	rs200986	ENSG00000216901.1	AL022393.7	7.92	1.55e-14	1.02e-11	0.43	0.34	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28176188~28176674:+
KIRC	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-7.92	1.56e-14	1.03e-11	-0.41	-0.34	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
KIRC	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	7.92	1.56e-14	1.03e-11	0.27	0.34	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
KIRC	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	7.92	1.56e-14	1.03e-11	0.3	0.34	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
KIRC	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	7.92	1.56e-14	1.03e-11	0.46	0.34	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
KIRC	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	7.92	1.56e-14	1.03e-11	0.46	0.34	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
KIRC	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	7.92	1.56e-14	1.03e-11	0.46	0.34	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
KIRC	cis	rs6600671	0.899	rs11249432	ENSG00000227082.1	CH17-437K3.1	-7.92	1.57e-14	1.03e-11	-0.38	-0.34	Hip geometry;	chr1:121541678	chr1:121396754~121463129:+
KIRC	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	7.92	1.57e-14	1.03e-11	0.26	0.34	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
KIRC	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-7.92	1.57e-14	1.03e-11	-0.38	-0.34	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
KIRC	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-7.92	1.57e-14	1.03e-11	-0.43	-0.34	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
KIRC	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-7.92	1.58e-14	1.04e-11	-0.38	-0.34	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
KIRC	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	7.92	1.59e-14	1.04e-11	0.45	0.34	Height;	chr6:109581800	chr6:109382795~109383666:+
KIRC	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	7.92	1.59e-14	1.04e-11	0.43	0.34	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	7.92	1.59e-14	1.04e-11	0.43	0.34	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
KIRC	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	7.92	1.59e-14	1.04e-11	0.51	0.34	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
KIRC	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	7.92	1.59e-14	1.04e-11	0.24	0.34	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
KIRC	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-7.92	1.59e-14	1.04e-11	-0.37	-0.34	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
KIRC	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-7.92	1.59e-14	1.04e-11	-0.37	-0.34	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
KIRC	cis	rs2236295	1	rs2236295	ENSG00000238280.1	RP11-436D10.3	-7.92	1.59e-14	1.04e-11	-0.42	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62805132	chr10:62793562~62805887:-
KIRC	cis	rs950027	0.62	rs1719246	ENSG00000235390.4	CTD-2651B20.5	-7.92	1.59e-14	1.04e-11	-0.32	-0.34	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45321077~45321692:-
KIRC	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-7.92	1.59e-14	1.04e-11	-0.45	-0.34	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
KIRC	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.92	1.6e-14	1.05e-11	-0.35	-0.34	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
KIRC	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	7.92	1.6e-14	1.05e-11	0.33	0.34	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
KIRC	cis	rs4819052	0.851	rs10470246	ENSG00000223768.1	LINC00205	-7.92	1.61e-14	1.05e-11	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs10470247	ENSG00000223768.1	LINC00205	-7.92	1.61e-14	1.05e-11	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4819043	ENSG00000223768.1	LINC00205	-7.92	1.61e-14	1.05e-11	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4819044	ENSG00000223768.1	LINC00205	-7.92	1.61e-14	1.05e-11	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45293285~45297354:+
KIRC	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	7.92	1.61e-14	1.05e-11	0.51	0.34	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
KIRC	cis	rs7672749	0.643	rs11728139	ENSG00000249973.2	CHCHD2P7	7.92	1.61e-14	1.05e-11	0.69	0.34	TB-LM or TBLH-BMD (pleiotropy);	chr4:87871286	chr4:87785920~87786371:-
KIRC	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	7.92	1.61e-14	1.06e-11	0.47	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
KIRC	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	7.92	1.61e-14	1.06e-11	0.37	0.34	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
KIRC	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-7.92	1.61e-14	1.06e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-7.92	1.61e-14	1.06e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-7.92	1.61e-14	1.06e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-7.92	1.61e-14	1.06e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
KIRC	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	7.92	1.62e-14	1.06e-11	0.38	0.34	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
KIRC	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	7.92	1.62e-14	1.06e-11	0.65	0.34	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
KIRC	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	7.92	1.62e-14	1.06e-11	0.65	0.34	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
KIRC	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-7.92	1.62e-14	1.06e-11	-0.25	-0.34	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
KIRC	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	7.92	1.62e-14	1.06e-11	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
KIRC	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	7.92	1.62e-14	1.06e-11	0.45	0.34	Height;	chr6:109395761	chr6:109382795~109383666:+
KIRC	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	7.92	1.63e-14	1.07e-11	0.51	0.34	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
KIRC	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-7.92	1.63e-14	1.07e-11	-0.39	-0.34	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
KIRC	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-7.91	1.64e-14	1.07e-11	-0.45	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
KIRC	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-7.91	1.64e-14	1.07e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
KIRC	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	7.91	1.65e-14	1.08e-11	0.32	0.34	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
KIRC	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.91	1.65e-14	1.08e-11	0.29	0.34	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
KIRC	cis	rs12922317	0.681	rs2869492	ENSG00000260488.1	RP11-166B2.7	7.91	1.65e-14	1.08e-11	0.32	0.34	Schizophrenia;	chr16:11977484	chr16:11976851~11977850:-
KIRC	cis	rs950027	0.549	rs12909409	ENSG00000259433.2	CTD-2651B20.4	7.91	1.65e-14	1.08e-11	0.24	0.34	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45330209~45332634:-
KIRC	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	7.91	1.65e-14	1.08e-11	0.38	0.34	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
KIRC	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-7.91	1.65e-14	1.08e-11	-0.38	-0.34	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
KIRC	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	7.91	1.66e-14	1.08e-11	0.44	0.34	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
KIRC	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	7.91	1.66e-14	1.09e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
KIRC	cis	rs7017914	0.967	rs6993170	ENSG00000254031.4	RP11-326E22.1	7.91	1.67e-14	1.09e-11	0.37	0.34	Bone mineral density;	chr8:70781284	chr8:71155457~71204223:+
KIRC	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	7.91	1.67e-14	1.09e-11	0.47	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
KIRC	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	7.91	1.67e-14	1.09e-11	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-7.91	1.67e-14	1.09e-11	-0.48	-0.34	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
KIRC	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	7.91	1.67e-14	1.09e-11	0.4	0.34	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
KIRC	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	7.91	1.67e-14	1.09e-11	0.56	0.34	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
KIRC	cis	rs12456021	1	rs12456021	ENSG00000267257.1	RP11-1151B14.4	-7.91	1.67e-14	1.09e-11	-0.33	-0.34	Multiple sclerosis;	chr18:58546158	chr18:58535415~58538552:+
KIRC	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-7.91	1.68e-14	1.1e-11	-0.31	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
KIRC	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	7.91	1.68e-14	1.1e-11	0.48	0.34	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
KIRC	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	7.91	1.68e-14	1.1e-11	0.78	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
KIRC	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-7.91	1.69e-14	1.1e-11	-0.38	-0.34	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
KIRC	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	7.91	1.69e-14	1.11e-11	0.52	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
KIRC	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	7.91	1.7e-14	1.11e-11	0.6	0.33	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
KIRC	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	7.91	1.7e-14	1.11e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
KIRC	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-7.91	1.7e-14	1.11e-11	-0.27	-0.33	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
KIRC	cis	rs8396	1	rs12505475	ENSG00000271817.2	U3	-7.91	1.7e-14	1.11e-11	-0.31	-0.33	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158714092	chr4:158700691~158700909:+
KIRC	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	7.91	1.7e-14	1.11e-11	0.45	0.33	Height;	chr6:109380457	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	7.91	1.7e-14	1.11e-11	0.45	0.33	Height;	chr6:109380990	chr6:109382795~109383666:+
KIRC	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-7.91	1.7e-14	1.11e-11	-0.44	-0.33	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
KIRC	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-7.91	1.7e-14	1.11e-11	-0.48	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000196472.4	RP13-644M16.4	7.91	1.71e-14	1.12e-11	0.38	0.33	Obesity-related traits;	chr4:69079291	chr4:69181660~69182372:+
KIRC	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-7.91	1.71e-14	1.12e-11	-0.36	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.808	rs2838825	ENSG00000223768.1	LINC00205	-7.91	1.71e-14	1.12e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45293285~45297354:+
KIRC	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-7.91	1.71e-14	1.12e-11	-0.33	-0.33	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
KIRC	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-7.91	1.71e-14	1.12e-11	-0.48	-0.33	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
KIRC	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	7.91	1.71e-14	1.12e-11	0.41	0.33	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
KIRC	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	7.91	1.72e-14	1.12e-11	0.52	0.33	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
KIRC	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-7.91	1.72e-14	1.12e-11	-0.38	-0.33	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
KIRC	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-7.91	1.72e-14	1.12e-11	-0.38	-0.33	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
KIRC	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-7.91	1.72e-14	1.12e-11	-0.33	-0.33	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
KIRC	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-7.91	1.72e-14	1.12e-11	-0.28	-0.33	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
KIRC	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-7.91	1.73e-14	1.13e-11	-0.33	-0.33	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
KIRC	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-7.91	1.73e-14	1.13e-11	-0.3	-0.33	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
KIRC	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	7.91	1.74e-14	1.13e-11	0.46	0.33	Height;	chr6:109694120	chr6:109382795~109383666:+
KIRC	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	7.91	1.74e-14	1.13e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
KIRC	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-7.91	1.75e-14	1.14e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
KIRC	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-7.91	1.75e-14	1.14e-11	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
KIRC	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	7.91	1.75e-14	1.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
KIRC	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	7.9	1.76e-14	1.14e-11	0.46	0.33	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	7.9	1.76e-14	1.15e-11	0.47	0.33	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
KIRC	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	7.9	1.76e-14	1.15e-11	0.6	0.33	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
KIRC	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	7.9	1.77e-14	1.15e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
KIRC	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.9	1.77e-14	1.15e-11	-0.35	-0.33	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
KIRC	cis	rs1345301	1	rs12475055	ENSG00000234389.1	AC007278.3	7.9	1.77e-14	1.15e-11	0.33	0.33	Waist circumference;	chr2:102262431	chr2:102438713~102440475:+
KIRC	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-7.9	1.77e-14	1.16e-11	-0.43	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
KIRC	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	7.9	1.78e-14	1.16e-11	0.46	0.33	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
KIRC	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	7.9	1.78e-14	1.16e-11	0.34	0.33	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
KIRC	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-7.9	1.79e-14	1.16e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
KIRC	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-7.9	1.79e-14	1.16e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
KIRC	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-7.9	1.79e-14	1.16e-11	-0.42	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
KIRC	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	7.9	1.79e-14	1.17e-11	0.42	0.33	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
KIRC	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-7.9	1.79e-14	1.17e-11	-0.33	-0.33	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
KIRC	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	7.9	1.79e-14	1.17e-11	0.45	0.33	Height;	chr6:109617741	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	7.9	1.79e-14	1.17e-11	0.45	0.33	Height;	chr6:109619295	chr6:109382795~109383666:+
KIRC	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-7.9	1.79e-14	1.17e-11	-0.29	-0.33	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
KIRC	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	7.9	1.8e-14	1.17e-11	0.5	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
KIRC	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	7.9	1.8e-14	1.17e-11	0.42	0.33	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
KIRC	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-7.9	1.8e-14	1.17e-11	-0.47	-0.33	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
KIRC	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-7.9	1.8e-14	1.17e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-7.9	1.8e-14	1.17e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-7.9	1.8e-14	1.17e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-7.9	1.8e-14	1.17e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-7.9	1.81e-14	1.18e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
KIRC	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-7.9	1.81e-14	1.18e-11	-0.48	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
KIRC	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	7.9	1.81e-14	1.18e-11	0.34	0.33	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
KIRC	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-7.9	1.82e-14	1.18e-11	-0.42	-0.33	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
KIRC	cis	rs1345301	1	rs1345301	ENSG00000234389.1	AC007278.3	-7.9	1.82e-14	1.18e-11	-0.33	-0.33	Waist circumference;	chr2:102259127	chr2:102438713~102440475:+
KIRC	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	7.9	1.83e-14	1.19e-11	0.47	0.33	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
KIRC	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	7.9	1.83e-14	1.19e-11	0.52	0.33	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
KIRC	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-7.9	1.83e-14	1.19e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
KIRC	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-7.9	1.83e-14	1.19e-11	-0.41	-0.33	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
KIRC	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-7.9	1.84e-14	1.19e-11	-0.21	-0.33	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
KIRC	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-7.9	1.84e-14	1.2e-11	-0.36	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
KIRC	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	7.9	1.84e-14	1.2e-11	0.27	0.33	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
KIRC	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-7.9	1.84e-14	1.2e-11	-0.46	-0.33	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
KIRC	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	7.9	1.85e-14	1.2e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
KIRC	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	7.9	1.85e-14	1.2e-11	0.51	0.33	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
KIRC	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-7.9	1.86e-14	1.21e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
KIRC	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	7.9	1.86e-14	1.21e-11	0.35	0.33	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
KIRC	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-7.9	1.86e-14	1.21e-11	-0.39	-0.33	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
KIRC	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	7.9	1.86e-14	1.21e-11	0.47	0.33	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
KIRC	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	7.9	1.86e-14	1.21e-11	0.4	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
KIRC	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	7.9	1.87e-14	1.22e-11	0.42	0.33	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
KIRC	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	7.9	1.87e-14	1.22e-11	0.57	0.33	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
KIRC	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	7.9	1.87e-14	1.22e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
KIRC	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-7.9	1.87e-14	1.22e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
KIRC	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-7.9	1.88e-14	1.22e-11	-0.35	-0.33	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
KIRC	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	7.9	1.88e-14	1.22e-11	0.54	0.33	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
KIRC	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-7.9	1.88e-14	1.22e-11	-0.57	-0.33	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
KIRC	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	7.89	1.89e-14	1.22e-11	0.53	0.33	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	7.89	1.89e-14	1.22e-11	0.53	0.33	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
KIRC	cis	rs13423976	0.631	rs11888984	ENSG00000231367.4	AC016995.3	-7.89	1.89e-14	1.23e-11	-0.43	-0.33	Gut microbiome composition (summer);	chr2:38517250	chr2:38406719~38515740:-
KIRC	cis	rs3820928	0.874	rs13403281	ENSG00000212391.1	SNORA48	-7.89	1.89e-14	1.23e-11	-0.39	-0.33	Pulmonary function;	chr2:227016053	chr2:226968989~226969122:-
KIRC	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	7.89	1.9e-14	1.23e-11	0.44	0.33	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
KIRC	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	7.89	1.9e-14	1.23e-11	0.68	0.33	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
KIRC	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	7.89	1.9e-14	1.24e-11	0.42	0.33	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
KIRC	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-7.89	1.9e-14	1.24e-11	-0.41	-0.33	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
KIRC	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	7.89	1.91e-14	1.24e-11	0.25	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
KIRC	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	7.89	1.91e-14	1.24e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
KIRC	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	7.89	1.92e-14	1.24e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	7.89	1.92e-14	1.24e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	7.89	1.92e-14	1.24e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
KIRC	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-7.89	1.92e-14	1.25e-11	-0.34	-0.33	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
KIRC	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-7.89	1.92e-14	1.25e-11	-0.34	-0.33	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
KIRC	cis	rs7672749	1	rs72879198	ENSG00000249973.2	CHCHD2P7	7.89	1.92e-14	1.25e-11	0.64	0.33	TB-LM or TBLH-BMD (pleiotropy);	chr4:87883468	chr4:87785920~87786371:-
KIRC	cis	rs7672749	1	rs66735573	ENSG00000249973.2	CHCHD2P7	7.89	1.92e-14	1.25e-11	0.64	0.33	TB-LM or TBLH-BMD (pleiotropy);	chr4:87883746	chr4:87785920~87786371:-
KIRC	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	7.89	1.93e-14	1.25e-11	0.44	0.33	Height;	chr6:109470427	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	7.89	1.93e-14	1.25e-11	0.44	0.33	Height;	chr6:109470900	chr6:109382795~109383666:+
KIRC	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	7.89	1.94e-14	1.26e-11	0.25	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
KIRC	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-7.89	1.94e-14	1.26e-11	-0.35	-0.33	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
KIRC	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	7.89	1.94e-14	1.26e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
KIRC	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-7.89	1.94e-14	1.26e-11	-0.45	-0.33	Height;	chr6:109405874	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	7.89	1.95e-14	1.26e-11	0.46	0.33	Height;	chr6:109479396	chr6:109382795~109383666:+
KIRC	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.89	1.95e-14	1.26e-11	0.37	0.33	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
KIRC	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-7.89	1.95e-14	1.26e-11	-0.4	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
KIRC	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	7.89	1.95e-14	1.26e-11	0.46	0.33	Depression;	chr6:28142370	chr6:28115628~28116551:+
KIRC	cis	rs1560104	0.576	rs7186154	ENSG00000274834.1	CTD-3037G24.5	7.89	1.95e-14	1.26e-11	0.36	0.33	Obesity-related traits;	chr16:12615650	chr16:12614451~12614852:+
KIRC	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-7.89	1.95e-14	1.27e-11	-0.26	-0.33	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
KIRC	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	7.89	1.96e-14	1.27e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
KIRC	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-7.89	1.96e-14	1.27e-11	-0.5	-0.33	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
KIRC	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	7.89	1.97e-14	1.27e-11	0.44	0.33	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
KIRC	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-7.89	1.97e-14	1.27e-11	-0.45	-0.33	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
KIRC	cis	rs6600671	1	rs1832558	ENSG00000227082.1	CH17-437K3.1	-7.89	1.97e-14	1.28e-11	-0.37	-0.33	Hip geometry;	chr1:121435521	chr1:121396754~121463129:+
KIRC	cis	rs6600671	0.967	rs11249349	ENSG00000227082.1	CH17-437K3.1	-7.89	1.97e-14	1.28e-11	-0.37	-0.33	Hip geometry;	chr1:121437310	chr1:121396754~121463129:+
KIRC	cis	rs12922317	0.964	rs12930612	ENSG00000260488.1	RP11-166B2.7	7.89	1.97e-14	1.28e-11	0.36	0.33	Schizophrenia;	chr16:11978346	chr16:11976851~11977850:-
KIRC	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
KIRC	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-7.89	1.97e-14	1.28e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
KIRC	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-7.89	1.98e-14	1.28e-11	-0.6	-0.33	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
KIRC	cis	rs2361718	0.501	rs12944619	ENSG00000279259.1	RP11-334C17.3	7.89	1.98e-14	1.28e-11	0.36	0.33	Yeast infection;	chr17:80170310	chr17:80147250~80148596:+
KIRC	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-7.89	1.99e-14	1.29e-11	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
KIRC	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	7.89	1.99e-14	1.29e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
KIRC	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	7.89	1.99e-14	1.29e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
KIRC	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	7.89	1.99e-14	1.29e-11	0.45	0.33	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
KIRC	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	7.89	1.99e-14	1.29e-11	0.32	0.33	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
KIRC	cis	rs7224610	0.966	rs3794748	ENSG00000263096.1	RP11-515O17.2	7.89	1.99e-14	1.29e-11	0.44	0.33	Urate levels;	chr17:55287811	chr17:55271504~55273653:-
KIRC	cis	rs6061231	0.654	rs2427322	ENSG00000275437.1	RP5-908M14.10	7.89	2e-14	1.29e-11	0.26	0.33	Colorectal cancer;	chr20:62404314	chr20:62402236~62405935:-
KIRC	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	7.89	2e-14	1.29e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
KIRC	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	7.89	2e-14	1.3e-11	0.3	0.33	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	7.89	2e-14	1.3e-11	0.3	0.33	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
KIRC	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-7.89	2e-14	1.3e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
KIRC	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	7.89	2.01e-14	1.3e-11	0.5	0.33	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	7.89	2.01e-14	1.3e-11	0.5	0.33	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
KIRC	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	7.89	2.01e-14	1.3e-11	0.5	0.33	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
KIRC	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	7.89	2.02e-14	1.3e-11	0.3	0.33	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
KIRC	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	7.89	2.02e-14	1.3e-11	0.48	0.33	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
KIRC	cis	rs7017914	0.846	rs6472561	ENSG00000254031.4	RP11-326E22.1	-7.89	2.02e-14	1.31e-11	-0.37	-0.33	Bone mineral density;	chr8:71042948	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs4074909	ENSG00000254031.4	RP11-326E22.1	-7.89	2.02e-14	1.31e-11	-0.37	-0.33	Bone mineral density;	chr8:71043592	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs4078067	ENSG00000254031.4	RP11-326E22.1	-7.89	2.02e-14	1.31e-11	-0.37	-0.33	Bone mineral density;	chr8:71044236	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs4504667	ENSG00000254031.4	RP11-326E22.1	-7.89	2.02e-14	1.31e-11	-0.37	-0.33	Bone mineral density;	chr8:71044557	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs4571761	ENSG00000254031.4	RP11-326E22.1	-7.89	2.02e-14	1.31e-11	-0.37	-0.33	Bone mineral density;	chr8:71044938	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	7.89	2.02e-14	1.31e-11	0.34	0.33	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
KIRC	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-7.89	2.02e-14	1.31e-11	-0.36	-0.33	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
KIRC	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	7.88	2.02e-14	1.31e-11	0.37	0.33	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
KIRC	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	7.88	2.03e-14	1.31e-11	0.49	0.33	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
KIRC	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	7.88	2.04e-14	1.32e-11	0.52	0.33	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
KIRC	cis	rs7672749	1	rs11724215	ENSG00000249973.2	CHCHD2P7	7.88	2.04e-14	1.32e-11	0.66	0.33	TB-LM or TBLH-BMD (pleiotropy);	chr4:87880479	chr4:87785920~87786371:-
KIRC	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	7.88	2.04e-14	1.32e-11	0.31	0.33	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
KIRC	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-7.88	2.05e-14	1.32e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-7.88	2.05e-14	1.32e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
KIRC	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	7.88	2.05e-14	1.32e-11	0.53	0.33	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	7.88	2.05e-14	1.32e-11	0.53	0.33	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	7.88	2.05e-14	1.32e-11	0.53	0.33	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	7.88	2.05e-14	1.32e-11	0.53	0.33	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
KIRC	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-7.88	2.06e-14	1.33e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
KIRC	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-7.88	2.06e-14	1.33e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
KIRC	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-7.88	2.06e-14	1.33e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
KIRC	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-7.88	2.06e-14	1.33e-11	-0.45	-0.33	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
KIRC	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	7.88	2.06e-14	1.33e-11	0.45	0.33	Height;	chr6:109640682	chr6:109382795~109383666:+
KIRC	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-7.88	2.06e-14	1.33e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-7.88	2.06e-14	1.33e-11	-0.48	-0.33	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
KIRC	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	7.88	2.07e-14	1.34e-11	0.52	0.33	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
KIRC	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	7.88	2.07e-14	1.34e-11	0.3	0.33	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	7.88	2.07e-14	1.34e-11	0.3	0.33	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
KIRC	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-7.88	2.07e-14	1.34e-11	-0.29	-0.33	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
KIRC	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-7.88	2.08e-14	1.34e-11	-0.4	-0.33	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
KIRC	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-7.88	2.08e-14	1.34e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
KIRC	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	7.88	2.09e-14	1.35e-11	0.42	0.33	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
KIRC	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	7.88	2.09e-14	1.35e-11	0.29	0.33	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
KIRC	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	7.88	2.09e-14	1.35e-11	0.34	0.33	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
KIRC	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	7.88	2.1e-14	1.35e-11	0.45	0.33	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
KIRC	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-7.88	2.1e-14	1.35e-11	-0.31	-0.33	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
KIRC	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-7.88	2.1e-14	1.36e-11	-0.36	-0.33	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
KIRC	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-7.88	2.1e-14	1.36e-11	-0.43	-0.33	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
KIRC	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	7.88	2.1e-14	1.36e-11	0.37	0.33	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
KIRC	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	7.88	2.11e-14	1.36e-11	0.37	0.33	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
KIRC	cis	rs1345301	1	rs10200410	ENSG00000234389.1	AC007278.3	-7.88	2.11e-14	1.36e-11	-0.33	-0.33	Waist circumference;	chr2:102254411	chr2:102438713~102440475:+
KIRC	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-7.88	2.11e-14	1.36e-11	-0.33	-0.33	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
KIRC	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	7.88	2.12e-14	1.37e-11	0.24	0.33	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	7.88	2.12e-14	1.37e-11	0.24	0.33	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
KIRC	cis	rs3745672	1	rs78398345	ENSG00000219665.7	CTD-2006C1.2	-7.88	2.12e-14	1.37e-11	-0.57	-0.33	Multiple sclerosis;	chr19:12043633	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs111259072	ENSG00000219665.7	CTD-2006C1.2	-7.88	2.12e-14	1.37e-11	-0.57	-0.33	Multiple sclerosis;	chr19:12045754	chr19:11987617~12046275:+
KIRC	cis	rs3745672	0.661	rs112152876	ENSG00000219665.7	CTD-2006C1.2	-7.88	2.12e-14	1.37e-11	-0.57	-0.33	Multiple sclerosis;	chr19:12045864	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs10417006	ENSG00000219665.7	CTD-2006C1.2	-7.88	2.12e-14	1.37e-11	-0.57	-0.33	Multiple sclerosis;	chr19:12046438	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs7255420	ENSG00000219665.7	CTD-2006C1.2	-7.88	2.12e-14	1.37e-11	-0.57	-0.33	Multiple sclerosis;	chr19:12047024	chr19:11987617~12046275:+
KIRC	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	7.88	2.12e-14	1.37e-11	0.3	0.33	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
KIRC	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	7.88	2.12e-14	1.37e-11	0.3	0.33	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	7.88	2.12e-14	1.37e-11	0.3	0.33	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	7.88	2.12e-14	1.37e-11	0.3	0.33	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
KIRC	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-7.88	2.12e-14	1.37e-11	-0.4	-0.33	Height;	chr4:55477866	chr4:55387949~55388271:+
KIRC	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-7.88	2.12e-14	1.37e-11	-0.38	-0.33	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
KIRC	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	7.88	2.13e-14	1.37e-11	0.58	0.33	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
KIRC	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-7.88	2.13e-14	1.37e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
KIRC	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-7.88	2.14e-14	1.38e-11	-0.34	-0.33	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
KIRC	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	7.88	2.14e-14	1.38e-11	0.44	0.33	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
KIRC	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	7.88	2.14e-14	1.38e-11	0.53	0.33	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	7.88	2.14e-14	1.38e-11	0.53	0.33	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
KIRC	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-7.88	2.14e-14	1.38e-11	-0.58	-0.33	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
KIRC	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	7.88	2.14e-14	1.38e-11	0.6	0.33	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
KIRC	cis	rs12456021	1	rs62096279	ENSG00000267257.1	RP11-1151B14.4	-7.88	2.14e-14	1.38e-11	-0.33	-0.33	Multiple sclerosis;	chr18:58547294	chr18:58535415~58538552:+
KIRC	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	7.88	2.14e-14	1.38e-11	0.34	0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
KIRC	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	7.88	2.15e-14	1.38e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
KIRC	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	7.88	2.15e-14	1.39e-11	0.4	0.33	Height;	chr4:55574959	chr4:55387949~55388271:+
KIRC	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	7.88	2.15e-14	1.39e-11	0.45	0.33	Height;	chr6:109446728	chr6:109382795~109383666:+
KIRC	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-7.88	2.15e-14	1.39e-11	-0.54	-0.33	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
KIRC	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	7.88	2.15e-14	1.39e-11	0.5	0.33	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
KIRC	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-7.88	2.16e-14	1.39e-11	-0.43	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
KIRC	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	7.88	2.16e-14	1.39e-11	0.31	0.33	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
KIRC	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	7.88	2.16e-14	1.39e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
KIRC	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	7.88	2.16e-14	1.39e-11	0.48	0.33	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
KIRC	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-7.88	2.17e-14	1.4e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
KIRC	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-7.88	2.17e-14	1.4e-11	-0.3	-0.33	Height;	chr11:118737823	chr11:118791254~118793137:+
KIRC	cis	rs1560104	0.556	rs7188416	ENSG00000274834.1	CTD-3037G24.5	7.88	2.17e-14	1.4e-11	0.36	0.33	Obesity-related traits;	chr16:12615754	chr16:12614451~12614852:+
KIRC	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-7.87	2.18e-14	1.4e-11	-0.33	-0.33	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
KIRC	cis	rs4819052	0.807	rs1075788	ENSG00000223768.1	LINC00205	-7.87	2.18e-14	1.4e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45293285~45297354:+
KIRC	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	7.87	2.18e-14	1.4e-11	0.46	0.33	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
KIRC	cis	rs7592578	0.771	rs4439990	ENSG00000272979.1	RP11-647K16.1	-7.87	2.18e-14	1.4e-11	-0.48	-0.33	Diastolic blood pressure;	chr2:190533627	chr2:190454092~190454521:-
KIRC	cis	rs1520333	0.602	rs967426	ENSG00000254352.1	RP11-578O24.2	7.87	2.18e-14	1.4e-11	0.37	0.33	Multiple sclerosis;	chr8:78585664	chr8:78723796~78724136:-
KIRC	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	7.87	2.18e-14	1.41e-11	0.31	0.33	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
KIRC	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	7.87	2.18e-14	1.41e-11	0.31	0.33	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
KIRC	cis	rs7017914	0.967	rs13274381	ENSG00000254031.4	RP11-326E22.1	7.87	2.19e-14	1.41e-11	0.37	0.33	Bone mineral density;	chr8:70852859	chr8:71155457~71204223:+
KIRC	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	7.87	2.19e-14	1.41e-11	0.45	0.33	Height;	chr6:109438349	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	7.87	2.19e-14	1.41e-11	0.45	0.33	Height;	chr6:109441033	chr6:109382795~109383666:+
KIRC	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	7.87	2.19e-14	1.41e-11	0.34	0.33	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
KIRC	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-7.87	2.19e-14	1.41e-11	-0.28	-0.33	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
KIRC	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-7.87	2.19e-14	1.41e-11	-0.28	-0.33	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
KIRC	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-7.87	2.2e-14	1.42e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
KIRC	cis	rs2108622	0.64	rs58858790	ENSG00000267453.5	AC004791.2	-7.87	2.2e-14	1.42e-11	-0.41	-0.33	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15863463	chr19:15851993~15864904:-
KIRC	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-7.87	2.2e-14	1.42e-11	-0.35	-0.33	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
KIRC	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	7.87	2.2e-14	1.42e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	7.87	2.21e-14	1.42e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
KIRC	cis	rs1345301	1	rs1345302	ENSG00000234389.1	AC007278.3	-7.87	2.22e-14	1.43e-11	-0.33	-0.33	Waist circumference;	chr2:102256909	chr2:102438713~102440475:+
KIRC	cis	rs1345301	1	rs13431601	ENSG00000234389.1	AC007278.3	-7.87	2.22e-14	1.43e-11	-0.33	-0.33	Waist circumference;	chr2:102257253	chr2:102438713~102440475:+
KIRC	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	7.87	2.22e-14	1.43e-11	0.36	0.33	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
KIRC	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	7.87	2.23e-14	1.43e-11	0.4	0.33	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
KIRC	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-7.87	2.23e-14	1.43e-11	-0.33	-0.33	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
KIRC	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	7.87	2.23e-14	1.44e-11	0.52	0.33	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
KIRC	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	7.87	2.23e-14	1.44e-11	0.34	0.33	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
KIRC	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-7.87	2.23e-14	1.44e-11	-0.52	-0.33	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
KIRC	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-7.87	2.24e-14	1.44e-11	-0.26	-0.33	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
KIRC	cis	rs7592578	0.771	rs4258824	ENSG00000272979.1	RP11-647K16.1	-7.87	2.24e-14	1.44e-11	-0.47	-0.33	Diastolic blood pressure;	chr2:190530301	chr2:190454092~190454521:-
KIRC	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-7.87	2.24e-14	1.44e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
KIRC	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-7.87	2.24e-14	1.44e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
KIRC	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-7.87	2.24e-14	1.44e-11	-0.32	-0.33	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
KIRC	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	7.87	2.24e-14	1.44e-11	0.34	0.33	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	7.87	2.25e-14	1.45e-11	0.34	0.33	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
KIRC	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	7.87	2.26e-14	1.45e-11	0.44	0.33	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	7.87	2.26e-14	1.45e-11	0.34	0.33	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
KIRC	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-7.87	2.27e-14	1.46e-11	-0.48	-0.33	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
KIRC	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-7.87	2.27e-14	1.46e-11	-0.32	-0.33	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
KIRC	cis	rs2734839	0.964	rs4587762	ENSG00000270179.1	RP11-159N11.4	-7.87	2.28e-14	1.46e-11	-0.35	-0.33	Information processing speed;	chr11:113436171	chr11:113368478~113369117:+
KIRC	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	7.87	2.28e-14	1.46e-11	0.34	0.33	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
KIRC	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-7.87	2.28e-14	1.47e-11	-0.36	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
KIRC	cis	rs897984	0.762	rs8062719	ENSG00000260911.2	RP11-196G11.2	-7.87	2.28e-14	1.47e-11	-0.22	-0.33	Dementia with Lewy bodies;	chr16:30991343	chr16:31043150~31049868:+
KIRC	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-7.87	2.29e-14	1.47e-11	-0.34	-0.33	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
KIRC	cis	rs710913	0.738	rs1180347	ENSG00000237624.1	OXCT2P1	-7.87	2.29e-14	1.47e-11	-0.42	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39514956~39516490:+
KIRC	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	7.87	2.3e-14	1.48e-11	0.34	0.33	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
KIRC	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-7.87	2.31e-14	1.48e-11	-0.4	-0.33	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
KIRC	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	7.87	2.31e-14	1.48e-11	0.4	0.33	Height;	chr4:55501479	chr4:55387949~55388271:+
KIRC	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-7.86	2.33e-14	1.5e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
KIRC	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	7.86	2.34e-14	1.5e-11	0.24	0.33	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
KIRC	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-7.86	2.34e-14	1.5e-11	-0.31	-0.33	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
KIRC	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	7.86	2.34e-14	1.5e-11	0.41	0.33	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
KIRC	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	7.86	2.36e-14	1.51e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
KIRC	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-7.86	2.37e-14	1.52e-11	-0.38	-0.33	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
KIRC	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-7.86	2.38e-14	1.53e-11	-0.37	-0.33	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
KIRC	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	7.86	2.4e-14	1.54e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
KIRC	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	7.86	2.4e-14	1.54e-11	0.45	0.33	Height;	chr6:109382524	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	7.86	2.4e-14	1.54e-11	0.45	0.33	Height;	chr6:109384228	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	7.86	2.4e-14	1.54e-11	0.45	0.33	Height;	chr6:109385087	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	7.86	2.4e-14	1.54e-11	0.45	0.33	Height;	chr6:109387685	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	7.86	2.4e-14	1.54e-11	0.45	0.33	Height;	chr6:109388256	chr6:109382795~109383666:+
KIRC	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	7.86	2.4e-14	1.54e-11	0.29	0.33	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
KIRC	cis	rs6600671	0.764	rs6600673	ENSG00000227082.1	CH17-437K3.1	-7.86	2.4e-14	1.54e-11	-0.38	-0.33	Hip geometry;	chr1:121426988	chr1:121396754~121463129:+
KIRC	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-7.86	2.4e-14	1.54e-11	-0.4	-0.33	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
KIRC	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-7.86	2.41e-14	1.55e-11	-0.35	-0.33	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
KIRC	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-7.86	2.42e-14	1.55e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
KIRC	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-7.86	2.42e-14	1.55e-11	-0.38	-0.33	Migraine;	chr4:56943905	chr4:56960927~56961373:-
KIRC	cis	rs7017914	0.902	rs1373480	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70774732	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs10448014	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70775930	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7000647	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70776173	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13254801	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70776749	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.783	rs13252584	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70776796	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.84	rs13254851	ENSG00000254031.4	RP11-326E22.1	7.86	2.43e-14	1.56e-11	0.37	0.33	Bone mineral density;	chr8:70776799	chr8:71155457~71204223:+
KIRC	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	7.86	2.43e-14	1.56e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	7.86	2.43e-14	1.56e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
KIRC	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-7.86	2.43e-14	1.56e-11	-0.48	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-7.86	2.43e-14	1.56e-11	-0.48	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
KIRC	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-7.86	2.43e-14	1.56e-11	-0.38	-0.33	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
KIRC	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-7.86	2.44e-14	1.56e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
KIRC	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	7.86	2.44e-14	1.56e-11	0.51	0.33	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
KIRC	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-7.86	2.44e-14	1.56e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
KIRC	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-7.86	2.45e-14	1.57e-11	-0.35	-0.33	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
KIRC	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	7.86	2.46e-14	1.57e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	7.86	2.46e-14	1.57e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
KIRC	cis	rs7017914	0.967	rs12679261	ENSG00000254031.4	RP11-326E22.1	7.86	2.46e-14	1.57e-11	0.36	0.33	Bone mineral density;	chr8:70932414	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs10089583	ENSG00000254031.4	RP11-326E22.1	7.86	2.46e-14	1.57e-11	0.36	0.33	Bone mineral density;	chr8:70937249	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.37	0.33	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.37	0.33	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.37	0.33	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.37	0.33	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
KIRC	cis	rs647097	0.655	rs9965713	ENSG00000272788.1	RP11-674N23.4	-7.86	2.47e-14	1.58e-11	-0.41	-0.33	Chronic obstructive pulmonary disease;	chr18:8803253	chr18:8801656~8802305:+
KIRC	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.38	0.33	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	7.86	2.47e-14	1.58e-11	0.38	0.33	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	7.86	2.47e-14	1.58e-11	0.45	0.33	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
KIRC	cis	rs904251	1	rs904251	ENSG00000227920.2	RP1-153P14.5	-7.86	2.47e-14	1.58e-11	-0.37	-0.33	Cognitive performance;	chr6:37483920	chr6:37545145~37550860:+
KIRC	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-7.86	2.49e-14	1.59e-11	-0.28	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
KIRC	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	7.86	2.5e-14	1.6e-11	0.34	0.33	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	7.86	2.5e-14	1.6e-11	0.34	0.33	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
KIRC	cis	rs12456021	1	rs62096278	ENSG00000267257.1	RP11-1151B14.4	-7.86	2.5e-14	1.6e-11	-0.33	-0.33	Multiple sclerosis;	chr18:58546777	chr18:58535415~58538552:+
KIRC	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	7.85	2.51e-14	1.6e-11	0.46	0.33	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
KIRC	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	7.85	2.52e-14	1.61e-11	0.44	0.33	Height;	chr6:109351795	chr6:109382795~109383666:+
KIRC	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-7.85	2.52e-14	1.61e-11	-0.36	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
KIRC	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-7.85	2.52e-14	1.61e-11	-0.36	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
KIRC	cis	rs7224610	0.898	rs4299205	ENSG00000263096.1	RP11-515O17.2	7.85	2.52e-14	1.61e-11	0.45	0.33	Urate levels;	chr17:55288785	chr17:55271504~55273653:-
KIRC	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	7.85	2.52e-14	1.61e-11	0.43	0.33	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
KIRC	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-7.85	2.53e-14	1.61e-11	-0.35	-0.33	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
KIRC	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-7.85	2.53e-14	1.62e-11	-0.33	-0.33	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
KIRC	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-7.85	2.53e-14	1.62e-11	-0.48	-0.33	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-7.85	2.53e-14	1.62e-11	-0.48	-0.33	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-7.85	2.53e-14	1.62e-11	-0.48	-0.33	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
KIRC	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-7.85	2.53e-14	1.62e-11	-0.47	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
KIRC	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	7.85	2.53e-14	1.62e-11	0.31	0.33	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	7.85	2.54e-14	1.62e-11	0.31	0.33	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
KIRC	cis	rs4819052	0.851	rs7279011	ENSG00000223768.1	LINC00205	-7.85	2.54e-14	1.62e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45293285~45297354:+
KIRC	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-7.85	2.55e-14	1.63e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
KIRC	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-7.85	2.55e-14	1.63e-11	-0.4	-0.33	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
KIRC	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	7.85	2.55e-14	1.63e-11	0.56	0.33	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
KIRC	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-7.85	2.55e-14	1.63e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
KIRC	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	7.85	2.55e-14	1.63e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
KIRC	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	7.85	2.56e-14	1.63e-11	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
KIRC	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	7.85	2.56e-14	1.64e-11	0.3	0.33	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
KIRC	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	7.85	2.57e-14	1.64e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
KIRC	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	7.85	2.58e-14	1.65e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
KIRC	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	7.85	2.58e-14	1.65e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
KIRC	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	7.85	2.58e-14	1.65e-11	0.34	0.33	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
KIRC	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	7.85	2.58e-14	1.65e-11	0.35	0.33	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
KIRC	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	7.85	2.58e-14	1.65e-11	0.43	0.33	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	7.85	2.58e-14	1.65e-11	0.43	0.33	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
KIRC	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-7.85	2.6e-14	1.66e-11	-0.45	-0.33	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
KIRC	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-7.85	2.6e-14	1.66e-11	-0.4	-0.33	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
KIRC	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-7.85	2.6e-14	1.66e-11	-0.41	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
KIRC	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-7.85	2.6e-14	1.66e-11	-0.41	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
KIRC	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	7.85	2.61e-14	1.67e-11	0.43	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
KIRC	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	7.85	2.61e-14	1.67e-11	0.34	0.33	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
KIRC	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	7.85	2.61e-14	1.67e-11	0.43	0.33	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
KIRC	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	7.85	2.61e-14	1.67e-11	0.43	0.33	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
KIRC	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-7.85	2.61e-14	1.67e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
KIRC	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	7.85	2.62e-14	1.67e-11	0.37	0.33	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
KIRC	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-7.85	2.62e-14	1.67e-11	-0.37	-0.33	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
KIRC	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	7.85	2.63e-14	1.68e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	7.85	2.63e-14	1.68e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
KIRC	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-7.85	2.63e-14	1.68e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
KIRC	cis	rs755249	0.583	rs61779328	ENSG00000237624.1	OXCT2P1	7.85	2.64e-14	1.68e-11	0.56	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39514956~39516490:+
KIRC	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	7.85	2.64e-14	1.68e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
KIRC	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-7.85	2.64e-14	1.68e-11	-0.39	-0.33	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
KIRC	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	7.85	2.64e-14	1.68e-11	0.37	0.33	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
KIRC	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	7.85	2.64e-14	1.68e-11	0.38	0.33	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
KIRC	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-7.85	2.65e-14	1.69e-11	-0.37	-0.33	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
KIRC	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	7.85	2.66e-14	1.69e-11	0.24	0.33	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
KIRC	cis	rs1345301	0.935	rs11691721	ENSG00000234389.1	AC007278.3	-7.85	2.67e-14	1.7e-11	-0.33	-0.33	Waist circumference;	chr2:102260219	chr2:102438713~102440475:+
KIRC	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	7.85	2.68e-14	1.71e-11	0.4	0.33	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
KIRC	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-7.85	2.68e-14	1.71e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
KIRC	cis	rs4819052	0.851	rs1999333	ENSG00000223768.1	LINC00205	-7.84	2.69e-14	1.72e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45293285~45297354:+
KIRC	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-7.84	2.69e-14	1.72e-11	-0.39	-0.33	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
KIRC	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-7.84	2.7e-14	1.72e-11	-0.61	-0.33	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
KIRC	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	7.84	2.71e-14	1.72e-11	0.37	0.33	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
KIRC	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-7.84	2.71e-14	1.73e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
KIRC	cis	rs7592578	0.825	rs12477369	ENSG00000272979.1	RP11-647K16.1	7.84	2.71e-14	1.73e-11	0.49	0.33	Diastolic blood pressure;	chr2:190590898	chr2:190454092~190454521:-
KIRC	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	7.84	2.73e-14	1.74e-11	0.44	0.33	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
KIRC	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	7.84	2.74e-14	1.74e-11	0.36	0.33	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
KIRC	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	7.84	2.74e-14	1.74e-11	0.36	0.33	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
KIRC	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	7.84	2.74e-14	1.75e-11	0.43	0.33	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
KIRC	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-7.84	2.74e-14	1.75e-11	-0.26	-0.33	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
KIRC	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	7.84	2.74e-14	1.75e-11	0.37	0.33	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	7.84	2.74e-14	1.75e-11	0.37	0.33	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	7.84	2.75e-14	1.75e-11	0.37	0.33	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	7.84	2.75e-14	1.75e-11	0.37	0.33	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	7.84	2.75e-14	1.75e-11	0.37	0.33	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
KIRC	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-7.84	2.76e-14	1.76e-11	-0.39	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
KIRC	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	7.84	2.76e-14	1.76e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
KIRC	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-7.84	2.76e-14	1.76e-11	-0.37	-0.33	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-7.84	2.76e-14	1.76e-11	-0.37	-0.33	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
KIRC	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-7.84	2.77e-14	1.76e-11	-0.37	-0.33	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
KIRC	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-7.84	2.77e-14	1.76e-11	-0.34	-0.33	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-7.84	2.77e-14	1.76e-11	-0.34	-0.33	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
KIRC	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	7.84	2.77e-14	1.76e-11	0.44	0.33	Height;	chr6:109454233	chr6:109382795~109383666:+
KIRC	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	7.84	2.77e-14	1.76e-11	0.4	0.33	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
KIRC	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	7.84	2.77e-14	1.77e-11	0.34	0.33	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	7.84	2.78e-14	1.77e-11	0.32	0.33	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	7.84	2.78e-14	1.77e-11	0.32	0.33	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
KIRC	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	7.84	2.78e-14	1.77e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	7.84	2.78e-14	1.77e-11	0.41	0.33	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	7.84	2.78e-14	1.77e-11	0.34	0.33	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	7.84	2.78e-14	1.77e-11	0.34	0.33	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
KIRC	cis	rs12922317	0.927	rs12923439	ENSG00000260488.1	RP11-166B2.7	7.84	2.78e-14	1.77e-11	0.36	0.33	Schizophrenia;	chr16:11980101	chr16:11976851~11977850:-
KIRC	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-7.84	2.78e-14	1.77e-11	-0.39	-0.33	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-7.84	2.79e-14	1.77e-11	-0.4	-0.33	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
KIRC	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	7.84	2.8e-14	1.78e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
KIRC	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	7.84	2.8e-14	1.78e-11	0.61	0.33	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
KIRC	cis	rs7017914	0.902	rs10504481	ENSG00000254031.4	RP11-326E22.1	7.84	2.8e-14	1.78e-11	0.37	0.33	Bone mineral density;	chr8:70787282	chr8:71155457~71204223:+
KIRC	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	7.84	2.8e-14	1.78e-11	0.4	0.33	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
KIRC	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-7.84	2.81e-14	1.78e-11	-0.46	-0.33	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
KIRC	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-7.84	2.82e-14	1.79e-11	-0.47	-0.33	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
KIRC	cis	rs12456021	1	rs62096282	ENSG00000267257.1	RP11-1151B14.4	-7.84	2.82e-14	1.79e-11	-0.33	-0.33	Multiple sclerosis;	chr18:58548694	chr18:58535415~58538552:+
KIRC	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-7.84	2.83e-14	1.8e-11	-0.46	-0.33	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	7.84	2.84e-14	1.81e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
KIRC	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.84	2.85e-14	1.81e-11	-0.38	-0.33	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
KIRC	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	7.84	2.85e-14	1.81e-11	0.48	0.33	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
KIRC	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	7.84	2.86e-14	1.82e-11	0.34	0.33	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	7.84	2.86e-14	1.82e-11	0.34	0.33	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
KIRC	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-7.84	2.86e-14	1.82e-11	-0.34	-0.33	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-7.84	2.86e-14	1.82e-11	-0.34	-0.33	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
KIRC	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	7.84	2.86e-14	1.82e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
KIRC	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	7.84	2.86e-14	1.82e-11	0.35	0.33	Height;	chr3:53072864	chr3:53064283~53065091:-
KIRC	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	7.84	2.87e-14	1.82e-11	0.34	0.33	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
KIRC	cis	rs7592578	0.664	rs10931461	ENSG00000272979.1	RP11-647K16.1	7.84	2.87e-14	1.82e-11	0.47	0.33	Diastolic blood pressure;	chr2:190540554	chr2:190454092~190454521:-
KIRC	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	7.84	2.87e-14	1.82e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
KIRC	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	7.84	2.87e-14	1.82e-11	0.44	0.33	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
KIRC	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-7.84	2.88e-14	1.83e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-7.84	2.88e-14	1.83e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
KIRC	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-7.84	2.88e-14	1.83e-11	-0.48	-0.33	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
KIRC	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-7.84	2.88e-14	1.83e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-7.84	2.88e-14	1.83e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
KIRC	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	7.84	2.88e-14	1.83e-11	0.54	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
KIRC	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-7.83	2.89e-14	1.83e-11	-0.4	-0.33	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
KIRC	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	7.83	2.9e-14	1.84e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	7.83	2.9e-14	1.84e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	7.83	2.9e-14	1.84e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
KIRC	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-7.83	2.9e-14	1.84e-11	-0.37	-0.33	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
KIRC	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	7.83	2.9e-14	1.84e-11	0.42	0.33	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	7.83	2.9e-14	1.84e-11	0.42	0.33	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
KIRC	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	7.83	2.9e-14	1.84e-11	0.42	0.33	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
KIRC	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-7.83	2.9e-14	1.84e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
KIRC	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-7.83	2.91e-14	1.84e-11	-0.39	-0.33	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
KIRC	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-7.83	2.91e-14	1.84e-11	-0.35	-0.33	Height;	chr3:52989619	chr3:53064283~53065091:-
KIRC	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	7.83	2.91e-14	1.85e-11	0.45	0.33	Height;	chr6:109452743	chr6:109382795~109383666:+
KIRC	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	7.83	2.91e-14	1.85e-11	0.43	0.33	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
KIRC	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	7.83	2.94e-14	1.86e-11	0.35	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
KIRC	cis	rs7017914	0.967	rs7842851	ENSG00000254031.4	RP11-326E22.1	7.83	2.94e-14	1.86e-11	0.36	0.33	Bone mineral density;	chr8:70751570	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs4738105	ENSG00000254031.4	RP11-326E22.1	-7.83	2.94e-14	1.87e-11	-0.37	-0.33	Bone mineral density;	chr8:71046683	chr8:71155457~71204223:+
KIRC	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	7.83	2.95e-14	1.87e-11	0.43	0.33	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
KIRC	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-7.83	2.95e-14	1.87e-11	-0.6	-0.33	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
KIRC	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-7.83	2.96e-14	1.87e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-7.83	2.96e-14	1.88e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
KIRC	cis	rs4356975	0.509	rs4371688	ENSG00000248763.2	RP13-644M16.5	-7.83	2.96e-14	1.88e-11	-0.43	-0.33	Obesity-related traits;	chr4:69124323	chr4:69066395~69069888:+
KIRC	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-7.83	2.96e-14	1.88e-11	-0.36	-0.33	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
KIRC	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-7.83	2.96e-14	1.88e-11	-0.46	-0.33	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
KIRC	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	7.83	2.97e-14	1.88e-11	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
KIRC	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	7.83	2.97e-14	1.88e-11	0.37	0.33	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
KIRC	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	7.83	2.97e-14	1.88e-11	0.45	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
KIRC	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	7.83	2.98e-14	1.89e-11	0.37	0.33	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
KIRC	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	7.83	2.99e-14	1.9e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	7.83	2.99e-14	1.9e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
KIRC	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-7.83	3e-14	1.9e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
KIRC	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	7.83	3e-14	1.9e-11	0.37	0.33	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
KIRC	cis	rs10971721	0.631	rs56278960	ENSG00000260947.1	RP11-384P7.7	7.83	3e-14	1.9e-11	0.61	0.33	Body mass index;	chr9:34073416	chr9:33697459~33700986:+
KIRC	cis	rs7017914	0.905	rs4434651	ENSG00000254031.4	RP11-326E22.1	7.83	3e-14	1.9e-11	0.37	0.33	Bone mineral density;	chr8:71034952	chr8:71155457~71204223:+
KIRC	cis	rs79040073	0.607	rs17479205	ENSG00000259531.2	RP11-295H24.3	7.83	3e-14	1.9e-11	0.42	0.33	Lung cancer in ever smokers;	chr15:49456065	chr15:49365124~49366685:-
KIRC	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	7.83	3e-14	1.9e-11	0.26	0.33	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
KIRC	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	7.83	3.01e-14	1.9e-11	0.36	0.33	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
KIRC	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	7.83	3.01e-14	1.9e-11	0.44	0.33	Height;	chr6:109464011	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	7.83	3.01e-14	1.9e-11	0.44	0.33	Height;	chr6:109465777	chr6:109382795~109383666:+
KIRC	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	7.83	3.01e-14	1.91e-11	0.42	0.33	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
KIRC	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-7.83	3.01e-14	1.91e-11	-0.39	-0.33	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
KIRC	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-7.83	3.01e-14	1.91e-11	-0.35	-0.33	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
KIRC	cis	rs10971721	0.818	rs10971708	ENSG00000260947.1	RP11-384P7.7	7.83	3.02e-14	1.91e-11	0.66	0.33	Body mass index;	chr9:33803273	chr9:33697459~33700986:+
KIRC	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	7.83	3.02e-14	1.91e-11	0.4	0.33	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
KIRC	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	7.83	3.03e-14	1.92e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
KIRC	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	7.83	3.03e-14	1.92e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	7.83	3.03e-14	1.92e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	7.83	3.04e-14	1.92e-11	0.41	0.33	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
KIRC	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-7.83	3.05e-14	1.93e-11	-0.41	-0.33	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
KIRC	cis	rs11018904	0.906	rs12793836	ENSG00000280385.1	AP000648.5	-7.83	3.05e-14	1.93e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90193614~90198120:+
KIRC	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	7.83	3.05e-14	1.93e-11	0.43	0.33	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
KIRC	cis	rs1757171	0.534	rs2797793	ENSG00000227920.2	RP1-153P14.5	7.83	3.06e-14	1.93e-11	0.36	0.33	Cognitive performance;	chr6:37509486	chr6:37545145~37550860:+
KIRC	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	7.83	3.07e-14	1.95e-11	0.37	0.33	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
KIRC	cis	rs2230624	1	rs76823085	ENSG00000242349.4	NPPA-AS1	-7.83	3.07e-14	1.95e-11	-0.54	-0.33	Mosquito bite size;	chr1:11823491	chr1:11841017~11848079:+
KIRC	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	7.83	3.09e-14	1.95e-11	0.24	0.33	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
KIRC	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-7.82	3.1e-14	1.96e-11	-0.4	-0.33	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
KIRC	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	7.82	3.1e-14	1.96e-11	0.4	0.33	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
KIRC	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	7.82	3.1e-14	1.96e-11	0.31	0.33	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
KIRC	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	7.82	3.11e-14	1.96e-11	0.29	0.33	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
KIRC	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	7.82	3.11e-14	1.97e-11	0.46	0.33	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
KIRC	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-7.82	3.11e-14	1.97e-11	-0.35	-0.33	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
KIRC	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	7.82	3.12e-14	1.97e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
KIRC	cis	rs13434995	0.635	rs1818461	ENSG00000273257.1	RP11-177J6.1	-7.82	3.12e-14	1.97e-11	-0.45	-0.33	Adiponectin levels;	chr4:55379156	chr4:55387949~55388271:+
KIRC	cis	rs4356975	0.509	rs6422323	ENSG00000248763.2	RP13-644M16.5	-7.82	3.12e-14	1.97e-11	-0.43	-0.33	Obesity-related traits;	chr4:69087362	chr4:69066395~69069888:+
KIRC	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	7.82	3.13e-14	1.98e-11	0.58	0.33	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
KIRC	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-7.82	3.13e-14	1.98e-11	-0.43	-0.33	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
KIRC	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	7.82	3.13e-14	1.98e-11	0.31	0.33	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
KIRC	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	7.82	3.13e-14	1.98e-11	0.46	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
KIRC	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	7.82	3.14e-14	1.98e-11	0.37	0.33	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
KIRC	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	7.82	3.14e-14	1.98e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	7.82	3.14e-14	1.98e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
KIRC	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	7.82	3.14e-14	1.98e-11	0.46	0.33	Height;	chr6:109480428	chr6:109382795~109383666:+
KIRC	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-7.82	3.15e-14	1.99e-11	-0.43	-0.33	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
KIRC	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-7.82	3.16e-14	2e-11	-0.42	-0.33	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
KIRC	cis	rs3820928	0.874	rs10195072	ENSG00000212391.1	SNORA48	-7.82	3.18e-14	2.01e-11	-0.39	-0.33	Pulmonary function;	chr2:226929736	chr2:226968989~226969122:-
KIRC	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-7.82	3.19e-14	2.01e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
KIRC	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	7.82	3.19e-14	2.01e-11	0.45	0.33	Height;	chr6:109454855	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	7.82	3.19e-14	2.02e-11	0.44	0.33	Height;	chr6:109443332	chr6:109382795~109383666:+
KIRC	cis	rs13113518	0.783	rs1586555	ENSG00000273257.1	RP11-177J6.1	7.82	3.2e-14	2.02e-11	0.41	0.33	Height;	chr4:55587104	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	7.82	3.21e-14	2.03e-11	0.46	0.33	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
KIRC	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	7.82	3.22e-14	2.03e-11	0.43	0.33	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
KIRC	cis	rs10129255	0.576	rs2157616	ENSG00000211972.2	IGHV3-66	7.82	3.22e-14	2.03e-11	0.26	0.33	Kawasaki disease;	chr14:106767802	chr14:106675017~106675544:-
KIRC	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	7.82	3.22e-14	2.03e-11	0.36	0.33	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
KIRC	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	7.82	3.22e-14	2.03e-11	0.44	0.33	Height;	chr6:109440234	chr6:109382795~109383666:+
KIRC	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	7.82	3.23e-14	2.04e-11	0.41	0.33	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
KIRC	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	7.82	3.24e-14	2.04e-11	0.33	0.33	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
KIRC	cis	rs9532669	0.889	rs7320344	ENSG00000176268.5	CYCSP34	7.82	3.25e-14	2.05e-11	0.36	0.33	Cervical cancer;	chr13:40885502	chr13:40863599~40863902:-
KIRC	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-7.82	3.25e-14	2.05e-11	-0.66	-0.33	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
KIRC	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	7.82	3.26e-14	2.05e-11	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
KIRC	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	7.82	3.26e-14	2.06e-11	0.45	0.33	Height;	chr6:109449796	chr6:109382795~109383666:+
KIRC	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-7.82	3.26e-14	2.06e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-7.82	3.26e-14	2.06e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
KIRC	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-7.82	3.26e-14	2.06e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
KIRC	cis	rs1345301	1	rs11686567	ENSG00000234389.1	AC007278.3	-7.82	3.26e-14	2.06e-11	-0.33	-0.33	Waist circumference;	chr2:102260149	chr2:102438713~102440475:+
KIRC	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-7.82	3.27e-14	2.06e-11	-0.33	-0.33	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-7.82	3.27e-14	2.06e-11	-0.37	-0.33	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	7.82	3.27e-14	2.06e-11	0.34	0.33	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	7.82	3.28e-14	2.07e-11	0.34	0.33	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	7.82	3.28e-14	2.07e-11	0.37	0.33	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
KIRC	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-7.82	3.28e-14	2.07e-11	-0.42	-0.33	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
KIRC	cis	rs4356975	0.509	rs4587017	ENSG00000248763.2	RP13-644M16.5	-7.82	3.3e-14	2.08e-11	-0.43	-0.33	Obesity-related traits;	chr4:69081680	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.509	rs4458521	ENSG00000248763.2	RP13-644M16.5	-7.82	3.3e-14	2.08e-11	-0.43	-0.33	Obesity-related traits;	chr4:69086240	chr4:69066395~69069888:+
KIRC	cis	rs4356975	0.509	rs4694169	ENSG00000248763.2	RP13-644M16.5	-7.82	3.3e-14	2.08e-11	-0.43	-0.33	Obesity-related traits;	chr4:69088433	chr4:69066395~69069888:+
KIRC	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-7.82	3.3e-14	2.08e-11	-0.32	-0.33	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
KIRC	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	7.82	3.3e-14	2.08e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	7.82	3.3e-14	2.08e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
KIRC	cis	rs7017914	0.967	rs34042354	ENSG00000254031.4	RP11-326E22.1	7.82	3.3e-14	2.08e-11	0.37	0.33	Bone mineral density;	chr8:70818726	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13261712	ENSG00000254031.4	RP11-326E22.1	7.82	3.3e-14	2.08e-11	0.37	0.33	Bone mineral density;	chr8:70820029	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs13274062	ENSG00000254031.4	RP11-326E22.1	7.82	3.3e-14	2.08e-11	0.37	0.33	Bone mineral density;	chr8:70824852	chr8:71155457~71204223:+
KIRC	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-7.82	3.31e-14	2.08e-11	-0.45	-0.33	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
KIRC	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-7.82	3.31e-14	2.08e-11	-0.45	-0.33	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
KIRC	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	7.82	3.31e-14	2.09e-11	0.43	0.33	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
KIRC	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	7.81	3.33e-14	2.09e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
KIRC	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-7.81	3.33e-14	2.1e-11	-0.4	-0.33	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
KIRC	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	7.81	3.35e-14	2.11e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	7.81	3.35e-14	2.11e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
KIRC	cis	rs4819052	0.851	rs7279182	ENSG00000223768.1	LINC00205	-7.81	3.35e-14	2.11e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.765	rs2838827	ENSG00000223768.1	LINC00205	-7.81	3.35e-14	2.11e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45293285~45297354:+
KIRC	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	7.81	3.35e-14	2.11e-11	0.31	0.33	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
KIRC	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	7.81	3.35e-14	2.11e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
KIRC	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-7.81	3.36e-14	2.12e-11	-0.4	-0.33	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
KIRC	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	7.81	3.36e-14	2.12e-11	0.42	0.33	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
KIRC	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.81	3.37e-14	2.12e-11	-0.37	-0.33	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
KIRC	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	7.81	3.37e-14	2.12e-11	0.47	0.33	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
KIRC	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	7.81	3.37e-14	2.12e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	7.81	3.37e-14	2.12e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
KIRC	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-7.81	3.39e-14	2.13e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
KIRC	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-7.81	3.39e-14	2.13e-11	-0.45	-0.33	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
KIRC	cis	rs10971721	0.543	rs72729378	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34059927	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.543	rs68113313	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34059988	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs117965906	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34063843	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs55943129	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34064796	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs72729385	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34065401	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs10971882	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34066186	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs10971883	ENSG00000260947.1	RP11-384P7.7	7.81	3.39e-14	2.13e-11	0.6	0.33	Body mass index;	chr9:34066487	chr9:33697459~33700986:+
KIRC	cis	rs7017914	1	rs13252719	ENSG00000254031.4	RP11-326E22.1	7.81	3.4e-14	2.14e-11	0.37	0.33	Bone mineral density;	chr8:70822334	chr8:71155457~71204223:+
KIRC	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-7.81	3.4e-14	2.14e-11	-0.4	-0.33	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
KIRC	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.81	3.4e-14	2.14e-11	-0.34	-0.33	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
KIRC	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	7.81	3.4e-14	2.14e-11	0.45	0.33	Height;	chr6:109655182	chr6:109382795~109383666:+
KIRC	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-7.81	3.41e-14	2.14e-11	-0.35	-0.33	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
KIRC	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	7.81	3.42e-14	2.15e-11	0.4	0.33	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
KIRC	cis	rs7017914	0.967	rs35207116	ENSG00000254031.4	RP11-326E22.1	7.81	3.42e-14	2.15e-11	0.37	0.33	Bone mineral density;	chr8:70796736	chr8:71155457~71204223:+
KIRC	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-7.81	3.43e-14	2.16e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
KIRC	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-7.81	3.43e-14	2.16e-11	-0.45	-0.33	Depression;	chr6:28143758	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-7.81	3.43e-14	2.16e-11	-0.45	-0.33	Depression;	chr6:28144784	chr6:28115628~28116551:+
KIRC	cis	rs440932	0.717	rs330944	ENSG00000254340.1	RP11-10A14.3	7.81	3.44e-14	2.16e-11	0.43	0.33	High light scatter reticulocyte percentage of red cells;	chr8:9163783	chr8:9141424~9145435:+
KIRC	cis	rs7672749	0.73	rs6532027	ENSG00000249973.2	CHCHD2P7	7.81	3.44e-14	2.16e-11	0.69	0.33	TB-LM or TBLH-BMD (pleiotropy);	chr4:87875291	chr4:87785920~87786371:-
KIRC	cis	rs1345301	1	rs1420093	ENSG00000234389.1	AC007278.3	-7.81	3.44e-14	2.16e-11	-0.33	-0.33	Waist circumference;	chr2:102253998	chr2:102438713~102440475:+
KIRC	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-7.81	3.45e-14	2.17e-11	-0.4	-0.33	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-7.81	3.45e-14	2.17e-11	-0.4	-0.33	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-7.81	3.45e-14	2.17e-11	-0.4	-0.33	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
KIRC	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	7.81	3.45e-14	2.17e-11	0.75	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	7.81	3.46e-14	2.17e-11	0.32	0.33	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
KIRC	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-7.81	3.46e-14	2.18e-11	-0.37	-0.33	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-7.81	3.46e-14	2.18e-11	-0.37	-0.33	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
KIRC	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	7.81	3.47e-14	2.18e-11	0.34	0.33	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
KIRC	cis	rs710913	0.816	rs1180341	ENSG00000237624.1	OXCT2P1	-7.81	3.47e-14	2.18e-11	-0.41	-0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39514956~39516490:+
KIRC	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	7.81	3.47e-14	2.18e-11	0.51	0.33	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
KIRC	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	7.81	3.47e-14	2.18e-11	0.44	0.33	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
KIRC	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-7.81	3.48e-14	2.18e-11	-0.37	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
KIRC	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-7.81	3.48e-14	2.19e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
KIRC	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-7.81	3.49e-14	2.19e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
KIRC	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-7.81	3.49e-14	2.19e-11	-0.51	-0.33	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
KIRC	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	7.81	3.49e-14	2.19e-11	0.38	0.33	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
KIRC	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-7.81	3.49e-14	2.19e-11	-0.32	-0.33	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
KIRC	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	7.81	3.5e-14	2.2e-11	0.41	0.33	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
KIRC	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	7.81	3.5e-14	2.2e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
KIRC	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	7.81	3.5e-14	2.2e-11	0.4	0.33	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
KIRC	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	7.81	3.51e-14	2.2e-11	0.43	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
KIRC	cis	rs58873874	0.737	rs75326191	ENSG00000251405.2	CTB-109A12.1	7.81	3.51e-14	2.2e-11	0.62	0.33	Bipolar disorder (body mass index interaction);	chr5:157445797	chr5:157362615~157460078:-
KIRC	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	7.81	3.51e-14	2.21e-11	0.43	0.33	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
KIRC	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-7.81	3.52e-14	2.21e-11	-0.33	-0.33	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
KIRC	cis	rs7017914	0.967	rs62508819	ENSG00000254031.4	RP11-326E22.1	7.81	3.52e-14	2.21e-11	0.37	0.33	Bone mineral density;	chr8:70805871	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-7.81	3.53e-14	2.22e-11	-0.36	-0.33	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
KIRC	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-7.81	3.53e-14	2.22e-11	-0.6	-0.33	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
KIRC	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-7.81	3.54e-14	2.22e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
KIRC	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-7.81	3.56e-14	2.23e-11	-0.36	-0.33	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
KIRC	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	7.81	3.56e-14	2.24e-11	0.45	0.33	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	7.8	3.57e-14	2.24e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
KIRC	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-7.8	3.57e-14	2.24e-11	-0.4	-0.33	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-7.8	3.57e-14	2.24e-11	-0.4	-0.33	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
KIRC	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	7.8	3.58e-14	2.25e-11	0.37	0.33	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
KIRC	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-7.8	3.6e-14	2.26e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
KIRC	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-7.8	3.6e-14	2.26e-11	-0.33	-0.33	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
KIRC	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-7.8	3.61e-14	2.27e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
KIRC	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-7.8	3.62e-14	2.27e-11	-0.47	-0.33	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
KIRC	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	7.8	3.62e-14	2.27e-11	0.37	0.33	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
KIRC	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	7.8	3.63e-14	2.27e-11	0.51	0.33	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
KIRC	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-7.8	3.63e-14	2.28e-11	-0.46	-0.33	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-7.8	3.63e-14	2.28e-11	-0.46	-0.33	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
KIRC	cis	rs7945705	0.846	rs11042055	ENSG00000254860.4	TMEM9B-AS1	-7.8	3.63e-14	2.28e-11	-0.35	-0.33	Hemoglobin concentration;	chr11:8735309	chr11:8964675~8977527:+
KIRC	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-7.8	3.64e-14	2.28e-11	-0.33	-0.33	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
KIRC	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	7.8	3.64e-14	2.28e-11	0.27	0.33	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
KIRC	cis	rs7592578	0.771	rs10432434	ENSG00000272979.1	RP11-647K16.1	-7.8	3.65e-14	2.28e-11	-0.47	-0.33	Diastolic blood pressure;	chr2:190522353	chr2:190454092~190454521:-
KIRC	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	7.8	3.68e-14	2.3e-11	0.49	0.33	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
KIRC	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-7.8	3.68e-14	2.31e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
KIRC	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	7.8	3.69e-14	2.31e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
KIRC	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	7.8	3.69e-14	2.31e-11	0.52	0.33	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
KIRC	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-7.8	3.69e-14	2.31e-11	-0.36	-0.33	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
KIRC	cis	rs3096299	0.838	rs3102384	ENSG00000274627.1	RP11-104N10.2	7.8	3.71e-14	2.32e-11	0.23	0.33	Multiple myeloma (IgH translocation);	chr16:89345253	chr16:89516797~89522217:+
KIRC	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-7.8	3.73e-14	2.34e-11	-0.43	-0.33	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
KIRC	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-7.8	3.74e-14	2.34e-11	-0.34	-0.33	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
KIRC	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-7.8	3.75e-14	2.34e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
KIRC	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-7.8	3.75e-14	2.34e-11	-0.48	-0.33	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
KIRC	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-7.8	3.75e-14	2.34e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-7.8	3.75e-14	2.34e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
KIRC	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	7.8	3.76e-14	2.35e-11	0.45	0.33	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
KIRC	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-7.8	3.76e-14	2.35e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
KIRC	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	7.8	3.76e-14	2.35e-11	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
KIRC	cis	rs7017914	0.934	rs62508771	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70780453	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6998786	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70782395	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs12680988	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70783655	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs1596566	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70786341	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6993115	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70786948	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs6992879	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70787048	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs1838393	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70790356	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.935	rs7826483	ENSG00000254031.4	RP11-326E22.1	7.8	3.76e-14	2.35e-11	0.37	0.33	Bone mineral density;	chr8:70790658	chr8:71155457~71204223:+
KIRC	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	7.8	3.77e-14	2.36e-11	0.34	0.33	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
KIRC	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	7.8	3.77e-14	2.36e-11	0.37	0.33	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
KIRC	cis	rs3820928	0.874	rs10210997	ENSG00000212391.1	SNORA48	-7.8	3.77e-14	2.36e-11	-0.39	-0.33	Pulmonary function;	chr2:226994392	chr2:226968989~226969122:-
KIRC	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	7.8	3.77e-14	2.36e-11	0.5	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
KIRC	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	7.8	3.77e-14	2.36e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
KIRC	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-7.8	3.77e-14	2.36e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
KIRC	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	7.8	3.77e-14	2.36e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	7.8	3.77e-14	2.36e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	7.8	3.77e-14	2.36e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	7.8	3.77e-14	2.36e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
KIRC	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	7.8	3.77e-14	2.36e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	7.8	3.77e-14	2.36e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	7.8	3.77e-14	2.36e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	7.8	3.77e-14	2.36e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
KIRC	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-7.8	3.78e-14	2.36e-11	-0.35	-0.33	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
KIRC	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-7.8	3.78e-14	2.36e-11	-0.41	-0.33	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
KIRC	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	7.8	3.78e-14	2.36e-11	0.42	0.33	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
KIRC	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-7.8	3.8e-14	2.37e-11	-0.32	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
KIRC	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	7.8	3.8e-14	2.37e-11	0.34	0.33	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	7.8	3.8e-14	2.37e-11	0.47	0.33	Depression;	chr6:28428413	chr6:28943877~28944537:+
KIRC	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	7.8	3.8e-14	2.38e-11	0.29	0.33	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
KIRC	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-7.8	3.81e-14	2.38e-11	-0.48	-0.33	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
KIRC	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-7.8	3.81e-14	2.38e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-7.8	3.81e-14	2.38e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
KIRC	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	7.8	3.82e-14	2.39e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	7.8	3.83e-14	2.39e-11	0.37	0.33	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	7.79	3.83e-14	2.39e-11	0.4	0.33	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
KIRC	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	7.79	3.85e-14	2.4e-11	0.39	0.33	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
KIRC	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-7.79	3.86e-14	2.41e-11	-0.34	-0.33	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
KIRC	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	7.79	3.87e-14	2.42e-11	0.51	0.33	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
KIRC	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-7.79	3.88e-14	2.42e-11	-0.34	-0.33	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
KIRC	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-7.79	3.89e-14	2.43e-11	-0.37	-0.33	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
KIRC	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-7.79	3.89e-14	2.43e-11	-0.37	-0.33	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
KIRC	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	7.79	3.89e-14	2.43e-11	0.43	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
KIRC	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	7.79	3.89e-14	2.43e-11	0.46	0.33	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
KIRC	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	7.79	3.9e-14	2.43e-11	0.45	0.33	Depression;	chr6:28110525	chr6:28115628~28116551:+
KIRC	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-7.79	3.9e-14	2.43e-11	-0.46	-0.33	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
KIRC	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-7.79	3.9e-14	2.43e-11	-0.46	-0.33	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
KIRC	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-7.79	3.9e-14	2.44e-11	-0.42	-0.33	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
KIRC	cis	rs9601248	0.756	rs9601251	ENSG00000227676.3	LINC01068	-7.79	3.91e-14	2.44e-11	-0.4	-0.33	Major depressive disorder;	chr13:79615582	chr13:79566727~79571436:+
KIRC	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	7.79	3.91e-14	2.44e-11	0.45	0.33	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
KIRC	cis	rs79040073	0.607	rs73400205	ENSG00000259531.2	RP11-295H24.3	7.79	3.91e-14	2.44e-11	0.43	0.33	Lung cancer in ever smokers;	chr15:49442346	chr15:49365124~49366685:-
KIRC	cis	rs7017914	0.905	rs12542300	ENSG00000254031.4	RP11-326E22.1	-7.79	3.92e-14	2.44e-11	-0.36	-0.33	Bone mineral density;	chr8:71039160	chr8:71155457~71204223:+
KIRC	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	7.79	3.92e-14	2.44e-11	0.46	0.33	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
KIRC	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	7.79	3.92e-14	2.45e-11	0.42	0.33	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
KIRC	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-7.79	3.92e-14	2.45e-11	-0.26	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
KIRC	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	7.79	3.93e-14	2.45e-11	0.37	0.33	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	7.79	3.93e-14	2.45e-11	0.37	0.33	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
KIRC	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	7.79	3.93e-14	2.45e-11	0.44	0.33	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
KIRC	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.79	3.94e-14	2.46e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
KIRC	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	7.79	3.94e-14	2.46e-11	0.3	0.33	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
KIRC	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	7.79	3.95e-14	2.46e-11	0.37	0.33	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	7.79	3.95e-14	2.46e-11	0.37	0.33	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	7.79	3.95e-14	2.46e-11	0.37	0.33	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	7.79	3.95e-14	2.46e-11	0.37	0.33	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
KIRC	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	7.79	3.95e-14	2.46e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
KIRC	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-7.79	3.95e-14	2.47e-11	-0.39	-0.33	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
KIRC	cis	rs2734839	0.964	rs4938017	ENSG00000270179.1	RP11-159N11.4	7.79	3.98e-14	2.48e-11	0.34	0.33	Information processing speed;	chr11:113433207	chr11:113368478~113369117:+
KIRC	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-7.79	3.99e-14	2.49e-11	-0.52	-0.33	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
KIRC	cis	rs2018683	1	rs2018683	ENSG00000228421.2	AC005013.5	7.79	4e-14	2.49e-11	0.34	0.33	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28957667~28959345:+
KIRC	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-7.79	4e-14	2.5e-11	-0.4	-0.33	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
KIRC	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.79	4.02e-14	2.5e-11	0.25	0.33	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
KIRC	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	7.79	4.02e-14	2.5e-11	0.4	0.33	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
KIRC	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-7.79	4.02e-14	2.51e-11	-0.4	-0.33	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
KIRC	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	7.79	4.03e-14	2.51e-11	0.37	0.33	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
KIRC	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	7.79	4.03e-14	2.51e-11	0.56	0.33	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
KIRC	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	7.79	4.03e-14	2.51e-11	0.42	0.33	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
KIRC	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	7.79	4.03e-14	2.51e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
KIRC	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-7.79	4.03e-14	2.51e-11	-0.52	-0.33	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
KIRC	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-7.79	4.03e-14	2.51e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
KIRC	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	7.79	4.03e-14	2.51e-11	0.48	0.33	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
KIRC	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	7.79	4.04e-14	2.51e-11	0.42	0.33	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
KIRC	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	7.79	4.07e-14	2.53e-11	0.48	0.33	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
KIRC	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-7.79	4.07e-14	2.53e-11	-0.31	-0.33	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
KIRC	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	7.79	4.07e-14	2.54e-11	0.45	0.33	Height;	chr6:109469907	chr6:109382795~109383666:+
KIRC	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	7.79	4.08e-14	2.54e-11	0.41	0.33	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
KIRC	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-7.79	4.08e-14	2.54e-11	-0.4	-0.33	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
KIRC	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-7.79	4.08e-14	2.54e-11	-0.41	-0.33	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
KIRC	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-7.79	4.08e-14	2.54e-11	-0.48	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
KIRC	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-7.79	4.09e-14	2.54e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-7.79	4.09e-14	2.54e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	7.79	4.1e-14	2.55e-11	0.37	0.33	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
KIRC	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	7.78	4.11e-14	2.56e-11	0.36	0.33	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
KIRC	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-7.78	4.12e-14	2.56e-11	-0.37	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
KIRC	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	7.78	4.13e-14	2.57e-11	0.37	0.33	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
KIRC	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-7.78	4.13e-14	2.57e-11	-0.33	-0.33	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
KIRC	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-7.78	4.13e-14	2.57e-11	-0.46	-0.33	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
KIRC	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	7.78	4.13e-14	2.57e-11	0.34	0.33	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	7.78	4.14e-14	2.57e-11	0.33	0.33	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
KIRC	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-7.78	4.14e-14	2.57e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
KIRC	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	7.78	4.14e-14	2.58e-11	0.34	0.33	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	7.78	4.14e-14	2.58e-11	0.34	0.33	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-7.78	4.15e-14	2.58e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
KIRC	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-7.78	4.18e-14	2.6e-11	-0.42	-0.33	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-7.78	4.18e-14	2.6e-11	-0.42	-0.33	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
KIRC	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	7.78	4.18e-14	2.6e-11	0.45	0.33	Height;	chr6:109582583	chr6:109382795~109383666:+
KIRC	cis	rs13113518	0.507	rs11943456	ENSG00000249700.7	SRD5A3-AS1	7.78	4.21e-14	2.61e-11	0.29	0.33	Height;	chr4:55410167	chr4:55363971~55395847:-
KIRC	cis	rs3820928	0.874	rs4675138	ENSG00000212391.1	SNORA48	-7.78	4.21e-14	2.62e-11	-0.38	-0.33	Pulmonary function;	chr2:227019402	chr2:226968989~226969122:-
KIRC	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	7.78	4.21e-14	2.62e-11	0.44	0.33	Height;	chr6:109462738	chr6:109382795~109383666:+
KIRC	cis	rs10971721	0.631	rs10971891	ENSG00000260947.1	RP11-384P7.7	7.78	4.21e-14	2.62e-11	0.6	0.33	Body mass index;	chr9:34076593	chr9:33697459~33700986:+
KIRC	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-7.78	4.21e-14	2.62e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
KIRC	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-7.78	4.21e-14	2.62e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
KIRC	cis	rs13113518	0.507	rs4549456	ENSG00000249700.7	SRD5A3-AS1	7.78	4.22e-14	2.62e-11	0.3	0.33	Height;	chr4:55398586	chr4:55363971~55395847:-
KIRC	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-7.78	4.23e-14	2.63e-11	-0.4	-0.33	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
KIRC	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.78	4.23e-14	2.63e-11	-0.39	-0.33	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
KIRC	cis	rs9601248	0.756	rs7997134	ENSG00000227676.3	LINC01068	-7.78	4.24e-14	2.63e-11	-0.4	-0.33	Major depressive disorder;	chr13:79619594	chr13:79566727~79571436:+
KIRC	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-7.78	4.25e-14	2.64e-11	-0.41	-0.33	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	7.78	4.25e-14	2.64e-11	0.41	0.33	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	7.78	4.25e-14	2.64e-11	0.41	0.33	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	7.78	4.25e-14	2.64e-11	0.41	0.33	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
KIRC	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	7.78	4.25e-14	2.64e-11	0.43	0.33	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
KIRC	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-7.78	4.26e-14	2.64e-11	-0.43	-0.33	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
KIRC	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	7.78	4.26e-14	2.64e-11	0.43	0.33	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
KIRC	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	7.78	4.26e-14	2.64e-11	0.32	0.33	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
KIRC	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	7.78	4.27e-14	2.65e-11	0.37	0.33	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
KIRC	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	7.78	4.27e-14	2.65e-11	0.25	0.33	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
KIRC	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	7.78	4.27e-14	2.65e-11	0.25	0.33	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
KIRC	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	7.78	4.27e-14	2.65e-11	0.25	0.33	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
KIRC	cis	rs11647589	0.911	rs7194098	ENSG00000262995.1	CTD-2194A8.2	-7.78	4.28e-14	2.66e-11	-0.35	-0.33	Blood metabolite levels;	chr16:20453028	chr16:20440266~20447000:-
KIRC	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	7.78	4.28e-14	2.66e-11	0.46	0.33	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
KIRC	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-7.78	4.29e-14	2.66e-11	-0.4	-0.33	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
KIRC	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	7.78	4.29e-14	2.66e-11	0.56	0.33	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
KIRC	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	7.78	4.29e-14	2.66e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
KIRC	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	7.78	4.29e-14	2.66e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
KIRC	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-7.78	4.3e-14	2.67e-11	-0.37	-0.33	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
KIRC	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.78	4.31e-14	2.67e-11	-0.36	-0.33	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.78	4.31e-14	2.67e-11	-0.36	-0.33	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.78	4.31e-14	2.67e-11	-0.36	-0.33	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
KIRC	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	7.78	4.31e-14	2.67e-11	0.31	0.33	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
KIRC	cis	rs17772222	0.682	rs10132554	ENSG00000222990.1	RNU4-22P	7.78	4.31e-14	2.68e-11	0.35	0.33	Coronary artery calcification;	chr14:88473090	chr14:88513498~88513663:+
KIRC	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-7.78	4.31e-14	2.68e-11	-0.45	-0.33	Depression;	chr6:28159666	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-7.78	4.31e-14	2.68e-11	-0.45	-0.33	Depression;	chr6:28162598	chr6:28115628~28116551:+
KIRC	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	7.78	4.31e-14	2.68e-11	0.47	0.33	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
KIRC	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	7.78	4.32e-14	2.68e-11	0.37	0.33	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	7.78	4.32e-14	2.68e-11	0.37	0.33	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
KIRC	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	7.78	4.32e-14	2.68e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	7.78	4.32e-14	2.68e-11	0.46	0.33	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	7.78	4.32e-14	2.68e-11	0.46	0.33	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	7.78	4.32e-14	2.68e-11	0.46	0.33	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
KIRC	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-7.78	4.32e-14	2.68e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
KIRC	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	7.78	4.33e-14	2.68e-11	0.35	0.33	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
KIRC	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	7.78	4.33e-14	2.68e-11	0.63	0.33	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
KIRC	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.78	4.33e-14	2.69e-11	-0.38	-0.33	Migraine;	chr4:56879851	chr4:56960927~56961373:-
KIRC	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	7.78	4.35e-14	2.69e-11	0.34	0.33	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	7.78	4.35e-14	2.69e-11	0.34	0.33	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
KIRC	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-7.78	4.35e-14	2.7e-11	-0.43	-0.33	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
KIRC	cis	rs4356975	0.83	rs7666894	ENSG00000250696.4	RP11-704M14.1	7.78	4.36e-14	2.7e-11	0.34	0.33	Obesity-related traits;	chr4:69078780	chr4:69182100~69216766:+
KIRC	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.78	4.36e-14	2.7e-11	-0.38	-0.33	Migraine;	chr4:56880007	chr4:56960927~56961373:-
KIRC	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.78	4.36e-14	2.7e-11	-0.38	-0.33	Migraine;	chr4:56880190	chr4:56960927~56961373:-
KIRC	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.78	4.36e-14	2.7e-11	-0.38	-0.33	Migraine;	chr4:56880659	chr4:56960927~56961373:-
KIRC	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-7.78	4.36e-14	2.7e-11	-0.45	-0.33	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
KIRC	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	7.78	4.36e-14	2.7e-11	0.3	0.33	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-7.78	4.36e-14	2.7e-11	-0.37	-0.33	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
KIRC	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-7.78	4.37e-14	2.71e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
KIRC	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	7.78	4.37e-14	2.71e-11	0.44	0.33	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
KIRC	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	7.78	4.39e-14	2.72e-11	0.58	0.33	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	7.78	4.39e-14	2.72e-11	0.58	0.33	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
KIRC	cis	rs3096299	0.73	rs11076780	ENSG00000274627.1	RP11-104N10.2	7.78	4.39e-14	2.72e-11	0.24	0.33	Multiple myeloma (IgH translocation);	chr16:89331546	chr16:89516797~89522217:+
KIRC	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-7.78	4.4e-14	2.73e-11	-0.45	-0.33	Depression;	chr6:28161802	chr6:28115628~28116551:+
KIRC	cis	rs6600671	0.934	rs67718113	ENSG00000227082.1	CH17-437K3.1	7.78	4.4e-14	2.73e-11	0.37	0.33	Hip geometry;	chr1:121497112	chr1:121396754~121463129:+
KIRC	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-7.78	4.4e-14	2.73e-11	-0.21	-0.33	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
KIRC	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	7.78	4.41e-14	2.73e-11	0.47	0.33	Depression;	chr6:28431469	chr6:28943877~28944537:+
KIRC	cis	rs12922317	0.964	rs16958789	ENSG00000260488.1	RP11-166B2.7	7.77	4.42e-14	2.73e-11	0.36	0.33	Schizophrenia;	chr16:11981791	chr16:11976851~11977850:-
KIRC	cis	rs12922317	1	rs16958792	ENSG00000260488.1	RP11-166B2.7	7.77	4.42e-14	2.73e-11	0.36	0.33	Schizophrenia;	chr16:11981827	chr16:11976851~11977850:-
KIRC	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	7.77	4.42e-14	2.74e-11	0.37	0.33	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
KIRC	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	7.77	4.43e-14	2.74e-11	0.45	0.33	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
KIRC	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-7.77	4.43e-14	2.74e-11	-0.45	-0.33	Depression;	chr6:28145952	chr6:28115628~28116551:+
KIRC	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-7.77	4.43e-14	2.74e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
KIRC	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	7.77	4.46e-14	2.76e-11	0.58	0.33	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
KIRC	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-7.77	4.46e-14	2.76e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
KIRC	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	7.77	4.48e-14	2.77e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
KIRC	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	7.77	4.49e-14	2.78e-11	0.43	0.33	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
KIRC	cis	rs12922317	0.927	rs3851005	ENSG00000260488.1	RP11-166B2.7	7.77	4.49e-14	2.78e-11	0.36	0.33	Schizophrenia;	chr16:11977356	chr16:11976851~11977850:-
KIRC	cis	rs6600671	0.902	rs2222371	ENSG00000227082.1	CH17-437K3.1	7.77	4.51e-14	2.79e-11	0.37	0.33	Hip geometry;	chr1:121547320	chr1:121396754~121463129:+
KIRC	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	7.77	4.52e-14	2.8e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	7.77	4.52e-14	2.8e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
KIRC	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	7.77	4.53e-14	2.8e-11	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
KIRC	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	7.77	4.53e-14	2.8e-11	0.64	0.33	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
KIRC	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-7.77	4.53e-14	2.8e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
KIRC	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	7.77	4.53e-14	2.8e-11	0.42	0.33	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
KIRC	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-7.77	4.54e-14	2.81e-11	-0.48	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
KIRC	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	7.77	4.55e-14	2.81e-11	0.45	0.33	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
KIRC	cis	rs2486288	0.656	rs9921035	ENSG00000259433.2	CTD-2651B20.4	7.77	4.56e-14	2.82e-11	0.23	0.33	Glomerular filtration rate;	chr15:45254462	chr15:45330209~45332634:-
KIRC	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-7.77	4.56e-14	2.82e-11	-0.35	-0.33	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
KIRC	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	7.77	4.57e-14	2.82e-11	0.31	0.33	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
KIRC	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-7.77	4.57e-14	2.82e-11	-0.27	-0.33	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
KIRC	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	7.77	4.57e-14	2.82e-11	0.34	0.33	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
KIRC	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	7.77	4.58e-14	2.83e-11	0.36	0.33	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
KIRC	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-7.77	4.59e-14	2.84e-11	-0.34	-0.33	Height;	chr3:53069965	chr3:53064283~53065091:-
KIRC	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-7.77	4.59e-14	2.84e-11	-0.37	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
KIRC	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	7.77	4.6e-14	2.84e-11	0.51	0.33	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
KIRC	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-7.77	4.6e-14	2.84e-11	-0.45	-0.33	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
KIRC	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-7.77	4.61e-14	2.85e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	7.77	4.62e-14	2.86e-11	0.45	0.33	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
KIRC	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	7.77	4.62e-14	2.86e-11	0.42	0.33	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
KIRC	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	7.77	4.66e-14	2.88e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
KIRC	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-7.77	4.66e-14	2.88e-11	-0.4	-0.33	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-7.77	4.66e-14	2.88e-11	-0.4	-0.33	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
KIRC	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-7.77	4.66e-14	2.88e-11	-0.29	-0.33	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
KIRC	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	7.77	4.66e-14	2.88e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	7.77	4.66e-14	2.88e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
KIRC	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-7.77	4.66e-14	2.88e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
KIRC	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-7.77	4.66e-14	2.88e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-7.77	4.66e-14	2.88e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
KIRC	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	7.77	4.67e-14	2.88e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
KIRC	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	7.77	4.67e-14	2.89e-11	0.42	0.33	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
KIRC	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	7.77	4.68e-14	2.89e-11	0.45	0.33	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
KIRC	cis	rs7017914	0.967	rs2933853	ENSG00000254031.4	RP11-326E22.1	7.77	4.69e-14	2.89e-11	0.36	0.33	Bone mineral density;	chr8:70996987	chr8:71155457~71204223:+
KIRC	cis	rs3096299	0.757	rs3102372	ENSG00000274627.1	RP11-104N10.2	7.77	4.69e-14	2.89e-11	0.24	0.33	Multiple myeloma (IgH translocation);	chr16:89331863	chr16:89516797~89522217:+
KIRC	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-7.77	4.69e-14	2.89e-11	-0.45	-0.33	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
KIRC	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	7.77	4.7e-14	2.9e-11	0.51	0.33	Cancer;	chr7:142407435	chr7:142554836~142555318:+
KIRC	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-7.77	4.7e-14	2.9e-11	-0.35	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
KIRC	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	7.77	4.7e-14	2.9e-11	0.31	0.33	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
KIRC	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	7.77	4.7e-14	2.9e-11	0.43	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
KIRC	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-7.77	4.7e-14	2.9e-11	-0.37	-0.33	Height;	chr11:118809363	chr11:118704607~118750263:+
KIRC	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	7.77	4.72e-14	2.91e-11	0.39	0.33	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
KIRC	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-7.77	4.73e-14	2.92e-11	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
KIRC	cis	rs4819052	0.851	rs2838826	ENSG00000223768.1	LINC00205	-7.77	4.73e-14	2.92e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45293285~45297354:+
KIRC	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	7.76	4.76e-14	2.93e-11	0.41	0.33	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
KIRC	cis	rs12893668	0.603	rs61637848	ENSG00000269910.1	RP11-73M18.10	7.76	4.76e-14	2.94e-11	0.24	0.33	Reticulocyte count;	chr14:103629694	chr14:103694516~103695050:-
KIRC	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-7.76	4.77e-14	2.94e-11	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
KIRC	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	7.76	4.77e-14	2.94e-11	0.33	0.33	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	7.76	4.77e-14	2.94e-11	0.33	0.33	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	7.76	4.77e-14	2.94e-11	0.33	0.33	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	7.76	4.77e-14	2.94e-11	0.33	0.33	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	7.76	4.77e-14	2.94e-11	0.33	0.33	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	7.76	4.78e-14	2.95e-11	0.37	0.33	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	7.76	4.79e-14	2.96e-11	0.37	0.33	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	7.76	4.8e-14	2.96e-11	0.45	0.33	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
KIRC	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-7.76	4.81e-14	2.97e-11	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
KIRC	cis	rs7017914	0.905	rs2732102	ENSG00000254031.4	RP11-326E22.1	-7.76	4.81e-14	2.97e-11	-0.36	-0.33	Bone mineral density;	chr8:71010637	chr8:71155457~71204223:+
KIRC	cis	rs12922317	1	rs12922317	ENSG00000260488.1	RP11-166B2.7	7.76	4.84e-14	2.98e-11	0.36	0.33	Schizophrenia;	chr16:11983775	chr16:11976851~11977850:-
KIRC	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	7.76	4.84e-14	2.98e-11	0.41	0.33	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
KIRC	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-7.76	4.84e-14	2.98e-11	-0.39	-0.33	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
KIRC	cis	rs34375054	1	rs34375054	ENSG00000279233.1	RP11-158L12.4	7.76	4.84e-14	2.98e-11	0.26	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125181350	chr12:125138245~125141711:+
KIRC	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	7.76	4.84e-14	2.98e-11	0.58	0.33	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
KIRC	cis	rs13113518	0.729	rs12641881	ENSG00000273257.1	RP11-177J6.1	7.76	4.85e-14	2.99e-11	0.42	0.33	Height;	chr4:55401306	chr4:55387949~55388271:+
KIRC	cis	rs7017914	0.902	rs6472542	ENSG00000254031.4	RP11-326E22.1	-7.76	4.85e-14	2.99e-11	-0.36	-0.33	Bone mineral density;	chr8:70741852	chr8:71155457~71204223:+
KIRC	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	7.76	4.86e-14	3e-11	0.57	0.33	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
KIRC	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28154567	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28156691	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28158424	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28159056	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28159925	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28159932	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28162053	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28163375	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28163759	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28164580	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28164825	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28164948	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28165025	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28165528	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28168434	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28169019	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28169249	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28169676	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28169755	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28169791	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-7.76	4.86e-14	3e-11	-0.45	-0.33	Depression;	chr6:28170075	chr6:28115628~28116551:+
KIRC	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-7.76	4.88e-14	3e-11	-0.57	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
KIRC	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-7.76	4.88e-14	3.01e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-7.76	4.88e-14	3.01e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
KIRC	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-7.76	4.91e-14	3.02e-11	-0.45	-0.33	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
KIRC	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	7.76	4.91e-14	3.02e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
KIRC	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	7.76	4.92e-14	3.03e-11	0.24	0.33	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	7.76	4.92e-14	3.03e-11	0.24	0.33	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	7.76	4.92e-14	3.03e-11	0.24	0.33	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	7.76	4.92e-14	3.03e-11	0.24	0.33	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
KIRC	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-7.76	4.92e-14	3.03e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
KIRC	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-7.76	4.95e-14	3.04e-11	-0.41	-0.33	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
KIRC	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	7.76	4.95e-14	3.04e-11	0.43	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
KIRC	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	7.76	4.95e-14	3.05e-11	0.31	0.33	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
KIRC	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-7.76	4.96e-14	3.05e-11	-0.28	-0.33	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
KIRC	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-7.76	4.96e-14	3.05e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
KIRC	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-7.76	4.97e-14	3.06e-11	-0.62	-0.33	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	7.76	4.98e-14	3.07e-11	0.37	0.33	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
KIRC	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	7.76	4.99e-14	3.07e-11	0.49	0.33	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
KIRC	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	7.76	5.01e-14	3.08e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
KIRC	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-7.76	5.02e-14	3.08e-11	-0.41	-0.33	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
KIRC	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-7.76	5.02e-14	3.08e-11	-0.66	-0.33	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
KIRC	cis	rs12922317	0.964	rs8061496	ENSG00000260488.1	RP11-166B2.7	7.76	5.02e-14	3.08e-11	0.36	0.33	Schizophrenia;	chr16:11982895	chr16:11976851~11977850:-
KIRC	cis	rs12922317	0.964	rs8043644	ENSG00000260488.1	RP11-166B2.7	7.76	5.02e-14	3.08e-11	0.36	0.33	Schizophrenia;	chr16:11983267	chr16:11976851~11977850:-
KIRC	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	7.76	5.02e-14	3.09e-11	0.43	0.33	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
KIRC	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	7.76	5.02e-14	3.09e-11	0.37	0.33	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
KIRC	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-7.76	5.03e-14	3.09e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
KIRC	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.76	5.03e-14	3.09e-11	-0.34	-0.33	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
KIRC	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-7.76	5.04e-14	3.1e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
KIRC	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	7.76	5.04e-14	3.1e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
KIRC	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	7.76	5.05e-14	3.1e-11	0.34	0.33	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
KIRC	cis	rs7017914	0.967	rs17688313	ENSG00000254031.4	RP11-326E22.1	-7.76	5.06e-14	3.11e-11	-0.36	-0.33	Bone mineral density;	chr8:70771629	chr8:71155457~71204223:+
KIRC	cis	rs2486288	0.656	rs7162022	ENSG00000235390.4	CTD-2651B20.5	7.76	5.07e-14	3.12e-11	0.31	0.33	Glomerular filtration rate;	chr15:45273055	chr15:45321077~45321692:-
KIRC	cis	rs4819052	0.959	rs9976074	ENSG00000223768.1	LINC00205	-7.75	5.07e-14	3.12e-11	-0.35	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45293285~45297354:+
KIRC	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	7.75	5.08e-14	3.12e-11	0.33	0.33	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
KIRC	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-7.75	5.08e-14	3.12e-11	-0.31	-0.33	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
KIRC	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	7.75	5.09e-14	3.13e-11	0.49	0.33	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
KIRC	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	7.75	5.09e-14	3.13e-11	0.42	0.33	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
KIRC	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	7.75	5.1e-14	3.13e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
KIRC	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-7.75	5.1e-14	3.13e-11	-0.35	-0.33	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
KIRC	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-7.75	5.1e-14	3.14e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
KIRC	cis	rs12456021	0.941	rs62096277	ENSG00000267257.1	RP11-1151B14.4	-7.75	5.11e-14	3.14e-11	-0.33	-0.33	Multiple sclerosis;	chr18:58544313	chr18:58535415~58538552:+
KIRC	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-7.75	5.11e-14	3.14e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
KIRC	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	7.75	5.11e-14	3.14e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	7.75	5.11e-14	3.14e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
KIRC	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	7.75	5.12e-14	3.14e-11	0.39	0.33	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
KIRC	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-7.75	5.12e-14	3.14e-11	-0.3	-0.33	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
KIRC	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	7.75	5.12e-14	3.14e-11	0.34	0.33	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
KIRC	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	7.75	5.12e-14	3.15e-11	0.46	0.33	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
KIRC	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-7.75	5.14e-14	3.16e-11	-0.39	-0.33	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
KIRC	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-7.75	5.15e-14	3.16e-11	-0.47	-0.33	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
KIRC	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-7.75	5.15e-14	3.16e-11	-0.47	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
KIRC	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-7.75	5.16e-14	3.17e-11	-0.4	-0.33	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
KIRC	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	7.75	5.16e-14	3.17e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	7.75	5.19e-14	3.19e-11	0.37	0.33	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
KIRC	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-7.75	5.2e-14	3.19e-11	-0.43	-0.33	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
KIRC	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-7.75	5.21e-14	3.2e-11	-0.32	-0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
KIRC	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	7.75	5.22e-14	3.2e-11	0.29	0.33	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
KIRC	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	7.75	5.23e-14	3.21e-11	0.36	0.33	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
KIRC	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	7.75	5.23e-14	3.21e-11	0.39	0.33	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	7.75	5.23e-14	3.21e-11	0.39	0.33	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
KIRC	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	7.75	5.24e-14	3.21e-11	0.34	0.33	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
KIRC	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-7.75	5.27e-14	3.23e-11	-0.42	-0.33	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
KIRC	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	7.75	5.27e-14	3.23e-11	0.59	0.33	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
KIRC	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-7.75	5.27e-14	3.23e-11	-0.4	-0.33	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
KIRC	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-7.75	5.28e-14	3.24e-11	-0.4	-0.33	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
KIRC	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	7.75	5.3e-14	3.25e-11	0.42	0.33	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
KIRC	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-7.75	5.3e-14	3.25e-11	-0.45	-0.33	Depression;	chr6:28071808	chr6:28115628~28116551:+
KIRC	cis	rs9532669	0.819	rs9532652	ENSG00000176268.5	CYCSP34	7.75	5.3e-14	3.25e-11	0.36	0.33	Cervical cancer;	chr13:40903300	chr13:40863599~40863902:-
KIRC	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	7.75	5.31e-14	3.26e-11	0.46	0.33	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
KIRC	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	7.75	5.32e-14	3.26e-11	0.44	0.33	Height;	chr6:109375003	chr6:109382795~109383666:+
KIRC	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	7.75	5.32e-14	3.26e-11	0.36	0.33	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
KIRC	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-7.75	5.32e-14	3.26e-11	-0.41	-0.33	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
KIRC	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-7.75	5.33e-14	3.27e-11	-0.37	-0.33	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
KIRC	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	7.75	5.33e-14	3.27e-11	0.37	0.33	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
KIRC	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	7.75	5.33e-14	3.27e-11	0.41	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
KIRC	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-7.75	5.33e-14	3.27e-11	-0.4	-0.33	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
KIRC	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	7.75	5.34e-14	3.27e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
KIRC	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	7.75	5.35e-14	3.28e-11	0.46	0.33	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
KIRC	cis	rs58873874	0.737	rs75022277	ENSG00000251405.2	CTB-109A12.1	7.75	5.36e-14	3.28e-11	0.61	0.33	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157362615~157460078:-
KIRC	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-7.75	5.36e-14	3.28e-11	-0.39	-0.33	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
KIRC	cis	rs7017914	0.87	rs3098883	ENSG00000254031.4	RP11-326E22.1	7.75	5.38e-14	3.29e-11	0.36	0.33	Bone mineral density;	chr8:71031332	chr8:71155457~71204223:+
KIRC	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	7.75	5.38e-14	3.29e-11	0.36	0.33	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
KIRC	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	7.75	5.38e-14	3.3e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
KIRC	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	7.75	5.39e-14	3.3e-11	0.41	0.33	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	7.75	5.39e-14	3.3e-11	0.34	0.33	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
KIRC	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	7.75	5.42e-14	3.32e-11	0.27	0.33	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
KIRC	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	7.75	5.42e-14	3.32e-11	0.32	0.33	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-7.75	5.42e-14	3.32e-11	-0.45	-0.33	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
KIRC	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-7.75	5.42e-14	3.32e-11	-0.31	-0.33	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-7.75	5.42e-14	3.32e-11	-0.31	-0.33	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
KIRC	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	7.75	5.42e-14	3.32e-11	0.33	0.33	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-7.75	5.42e-14	3.32e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
KIRC	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	7.75	5.43e-14	3.32e-11	0.45	0.33	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
KIRC	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	7.75	5.43e-14	3.32e-11	0.41	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
KIRC	cis	rs3820928	0.874	rs10174073	ENSG00000212391.1	SNORA48	-7.75	5.44e-14	3.33e-11	-0.38	-0.33	Pulmonary function;	chr2:226930228	chr2:226968989~226969122:-
KIRC	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-7.74	5.45e-14	3.33e-11	-0.42	-0.33	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
KIRC	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	7.74	5.45e-14	3.34e-11	0.26	0.33	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
KIRC	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	7.74	5.47e-14	3.34e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
KIRC	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-7.74	5.47e-14	3.34e-11	-0.39	-0.33	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
KIRC	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	7.74	5.48e-14	3.35e-11	0.31	0.33	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
KIRC	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	7.74	5.49e-14	3.36e-11	0.44	0.33	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
KIRC	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-7.74	5.51e-14	3.37e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
KIRC	cis	rs904251	0.58	rs62408367	ENSG00000227920.2	RP1-153P14.5	-7.74	5.52e-14	3.38e-11	-0.35	-0.33	Cognitive performance;	chr6:37477037	chr6:37545145~37550860:+
KIRC	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	7.74	5.53e-14	3.38e-11	0.42	0.33	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
KIRC	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	7.74	5.54e-14	3.39e-11	0.31	0.33	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-7.74	5.55e-14	3.39e-11	-0.31	-0.33	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
KIRC	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	7.74	5.55e-14	3.39e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
KIRC	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	7.74	5.55e-14	3.39e-11	0.34	0.33	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
KIRC	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	7.74	5.56e-14	3.4e-11	0.36	0.33	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	7.74	5.56e-14	3.4e-11	0.36	0.33	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	7.74	5.56e-14	3.4e-11	0.33	0.33	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
KIRC	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	7.74	5.56e-14	3.4e-11	0.36	0.33	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
KIRC	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-7.74	5.57e-14	3.41e-11	-0.37	-0.33	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-7.74	5.57e-14	3.41e-11	-0.37	-0.33	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
KIRC	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	7.74	5.6e-14	3.42e-11	0.42	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	7.74	5.6e-14	3.42e-11	0.42	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
KIRC	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	7.74	5.61e-14	3.42e-11	0.45	0.33	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	7.74	5.61e-14	3.42e-11	0.45	0.33	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
KIRC	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	7.74	5.62e-14	3.43e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
KIRC	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-7.74	5.62e-14	3.43e-11	-0.42	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
KIRC	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-7.74	5.63e-14	3.44e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
KIRC	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	7.74	5.64e-14	3.45e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
KIRC	cis	rs9409565	0.502	rs509022	ENSG00000231806.2	PCAT7	7.74	5.65e-14	3.45e-11	0.4	0.33	Colorectal cancer (alcohol consumption interaction);	chr9:94566989	chr9:94555069~94568127:+
KIRC	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	7.74	5.65e-14	3.45e-11	0.46	0.33	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
KIRC	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-7.74	5.65e-14	3.45e-11	-0.28	-0.33	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
KIRC	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	7.74	5.66e-14	3.46e-11	0.46	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
KIRC	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	7.74	5.66e-14	3.46e-11	0.54	0.33	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	7.74	5.66e-14	3.46e-11	0.54	0.33	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
KIRC	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-7.74	5.68e-14	3.46e-11	-0.58	-0.33	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
KIRC	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	7.74	5.68e-14	3.47e-11	0.31	0.33	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
KIRC	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	7.74	5.69e-14	3.47e-11	0.5	0.33	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
KIRC	cis	rs2486288	0.656	rs7162022	ENSG00000259433.2	CTD-2651B20.4	7.74	5.69e-14	3.47e-11	0.24	0.33	Glomerular filtration rate;	chr15:45273055	chr15:45330209~45332634:-
KIRC	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	7.74	5.72e-14	3.49e-11	0.46	0.33	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	7.74	5.72e-14	3.49e-11	0.46	0.33	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
KIRC	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-7.74	5.73e-14	3.49e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-7.74	5.73e-14	3.49e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
KIRC	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-7.74	5.73e-14	3.5e-11	-0.36	-0.33	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
KIRC	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-7.74	5.75e-14	3.51e-11	-0.45	-0.33	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
KIRC	cis	rs2486288	0.656	rs2413768	ENSG00000259433.2	CTD-2651B20.4	7.74	5.75e-14	3.51e-11	0.24	0.33	Glomerular filtration rate;	chr15:45269786	chr15:45330209~45332634:-
KIRC	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	7.74	5.77e-14	3.52e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	7.74	5.77e-14	3.52e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-7.74	5.78e-14	3.52e-11	-0.34	-0.33	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	7.74	5.78e-14	3.52e-11	0.36	0.33	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
KIRC	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	7.74	5.8e-14	3.54e-11	0.36	0.33	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-7.74	5.8e-14	3.54e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
KIRC	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	7.74	5.8e-14	3.54e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	7.74	5.81e-14	3.54e-11	0.33	0.33	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
KIRC	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	7.74	5.81e-14	3.54e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
KIRC	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	7.74	5.83e-14	3.55e-11	0.4	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
KIRC	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	7.73	5.84e-14	3.56e-11	0.34	0.33	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
KIRC	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	7.73	5.84e-14	3.56e-11	0.37	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
KIRC	cis	rs2288884	0.708	rs11665783	ENSG00000275055.1	CTC-471J1.11	-7.73	5.84e-14	3.56e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52049007~52049754:+
KIRC	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	7.73	5.85e-14	3.56e-11	0.46	0.33	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
KIRC	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	7.73	5.86e-14	3.57e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
KIRC	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	7.73	5.86e-14	3.57e-11	0.36	0.33	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
KIRC	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-7.73	5.87e-14	3.58e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-7.73	5.87e-14	3.58e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
KIRC	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-7.73	5.87e-14	3.58e-11	-0.45	-0.33	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
KIRC	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-7.73	5.87e-14	3.58e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
KIRC	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	7.73	5.89e-14	3.59e-11	0.33	0.33	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
KIRC	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-7.73	5.89e-14	3.59e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
KIRC	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-7.73	5.9e-14	3.59e-11	-0.6	-0.33	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
KIRC	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	7.73	5.9e-14	3.6e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
KIRC	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-7.73	5.91e-14	3.6e-11	-0.45	-0.33	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
KIRC	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	7.73	5.93e-14	3.61e-11	0.58	0.33	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
KIRC	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	7.73	5.94e-14	3.62e-11	0.28	0.33	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
KIRC	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	7.73	5.96e-14	3.63e-11	0.34	0.33	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
KIRC	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	7.73	5.96e-14	3.63e-11	0.57	0.33	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
KIRC	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	7.73	5.97e-14	3.64e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
KIRC	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	7.73	5.97e-14	3.64e-11	0.4	0.33	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
KIRC	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	7.73	5.98e-14	3.64e-11	0.43	0.33	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	7.73	5.98e-14	3.64e-11	0.43	0.33	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	7.73	5.98e-14	3.64e-11	0.41	0.33	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
KIRC	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	7.73	5.99e-14	3.64e-11	0.29	0.33	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
KIRC	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	7.73	5.99e-14	3.64e-11	0.51	0.33	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
KIRC	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	7.73	5.99e-14	3.65e-11	0.36	0.33	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
KIRC	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.73	6.01e-14	3.66e-11	0.28	0.33	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
KIRC	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-7.73	6.02e-14	3.66e-11	-0.37	-0.33	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
KIRC	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-7.73	6.03e-14	3.67e-11	-0.46	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	7.73	6.04e-14	3.67e-11	0.41	0.33	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
KIRC	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-7.73	6.04e-14	3.67e-11	-0.6	-0.33	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
KIRC	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	7.73	6.04e-14	3.68e-11	0.26	0.33	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
KIRC	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	7.73	6.08e-14	3.7e-11	0.31	0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
KIRC	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-7.73	6.08e-14	3.7e-11	-0.45	-0.33	Depression;	chr6:28176973	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-7.73	6.08e-14	3.7e-11	-0.45	-0.33	Depression;	chr6:28180209	chr6:28115628~28116551:+
KIRC	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	7.73	6.08e-14	3.7e-11	0.49	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
KIRC	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	7.73	6.09e-14	3.7e-11	0.36	0.33	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	7.73	6.09e-14	3.7e-11	0.36	0.33	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	7.73	6.09e-14	3.7e-11	0.36	0.33	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	7.73	6.09e-14	3.7e-11	0.36	0.33	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
KIRC	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	7.73	6.1e-14	3.71e-11	0.31	0.33	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
KIRC	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-7.73	6.1e-14	3.71e-11	-0.45	-0.33	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-7.73	6.1e-14	3.71e-11	-0.45	-0.33	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
KIRC	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	7.73	6.11e-14	3.71e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	7.73	6.11e-14	3.71e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	7.73	6.11e-14	3.71e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	7.73	6.11e-14	3.71e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
KIRC	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-7.73	6.13e-14	3.73e-11	-0.39	-0.33	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
KIRC	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	7.73	6.14e-14	3.73e-11	0.26	0.33	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
KIRC	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	7.73	6.15e-14	3.74e-11	0.3	0.33	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
KIRC	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	7.73	6.15e-14	3.74e-11	0.3	0.33	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
KIRC	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.73	6.16e-14	3.74e-11	-0.24	-0.33	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
KIRC	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	7.73	6.16e-14	3.74e-11	0.37	0.33	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	7.73	6.17e-14	3.75e-11	0.37	0.33	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	7.73	6.17e-14	3.75e-11	0.37	0.33	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	7.73	6.17e-14	3.75e-11	0.37	0.33	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	7.73	6.17e-14	3.75e-11	0.37	0.33	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	7.73	6.17e-14	3.75e-11	0.37	0.33	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
KIRC	cis	rs79040073	0.637	rs1023683	ENSG00000259531.2	RP11-295H24.3	7.73	6.18e-14	3.75e-11	0.41	0.33	Lung cancer in ever smokers;	chr15:49415250	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.637	rs11639423	ENSG00000259531.2	RP11-295H24.3	7.73	6.18e-14	3.75e-11	0.41	0.33	Lung cancer in ever smokers;	chr15:49415448	chr15:49365124~49366685:-
KIRC	cis	rs1431005	0.928	rs4623072	ENSG00000250620.1	RP11-91J3.3	7.73	6.18e-14	3.76e-11	0.43	0.33	Response to statin therapy;	chr4:187459164	chr4:187413564~187415697:+
KIRC	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-7.73	6.19e-14	3.76e-11	-0.29	-0.33	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
KIRC	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-7.73	6.19e-14	3.76e-11	-0.41	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
KIRC	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	7.73	6.19e-14	3.76e-11	0.34	0.33	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
KIRC	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	7.73	6.22e-14	3.78e-11	0.29	0.33	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
KIRC	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	7.73	6.23e-14	3.78e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
KIRC	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-7.73	6.23e-14	3.78e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
KIRC	cis	rs12456021	0.941	rs12454835	ENSG00000267257.1	RP11-1151B14.4	-7.73	6.23e-14	3.78e-11	-0.33	-0.33	Multiple sclerosis;	chr18:58544608	chr18:58535415~58538552:+
KIRC	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-7.73	6.23e-14	3.79e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-7.73	6.23e-14	3.79e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-7.73	6.23e-14	3.79e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
KIRC	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	7.73	6.24e-14	3.79e-11	0.4	0.33	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
KIRC	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	7.73	6.25e-14	3.79e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
KIRC	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	7.73	6.25e-14	3.8e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
KIRC	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	7.73	6.26e-14	3.8e-11	0.46	0.33	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
KIRC	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	7.72	6.27e-14	3.8e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
KIRC	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	7.72	6.28e-14	3.81e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
KIRC	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-7.72	6.28e-14	3.81e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
KIRC	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	7.72	6.29e-14	3.82e-11	0.42	0.33	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
KIRC	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-7.72	6.29e-14	3.82e-11	-0.4	-0.33	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
KIRC	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-7.72	6.29e-14	3.82e-11	-0.26	-0.33	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-7.72	6.29e-14	3.82e-11	-0.26	-0.33	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	7.72	6.29e-14	3.82e-11	0.52	0.33	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	7.72	6.29e-14	3.82e-11	0.52	0.33	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
KIRC	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-7.72	6.32e-14	3.84e-11	-0.32	-0.33	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-7.72	6.32e-14	3.84e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-7.72	6.32e-14	3.84e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
KIRC	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-7.72	6.34e-14	3.84e-11	-0.41	-0.33	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
KIRC	cis	rs11512640	1	rs11220136	ENSG00000254671.2	STT3A-AS1	7.72	6.35e-14	3.85e-11	0.68	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125582185	chr11:125570284~125592568:-
KIRC	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	7.72	6.35e-14	3.85e-11	0.38	0.33	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
KIRC	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	7.72	6.36e-14	3.85e-11	0.28	0.33	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
KIRC	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	7.72	6.36e-14	3.86e-11	0.34	0.33	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
KIRC	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	7.72	6.37e-14	3.86e-11	0.41	0.33	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	7.72	6.37e-14	3.86e-11	0.41	0.33	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	7.72	6.37e-14	3.86e-11	0.41	0.33	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
KIRC	cis	rs10971721	0.658	rs55656643	ENSG00000260947.1	RP11-384P7.7	7.72	6.38e-14	3.87e-11	0.6	0.33	Body mass index;	chr9:34058497	chr9:33697459~33700986:+
KIRC	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-7.72	6.38e-14	3.87e-11	-0.26	-0.33	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-7.72	6.38e-14	3.87e-11	-0.26	-0.33	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
KIRC	cis	rs7592578	0.882	rs16832765	ENSG00000272979.1	RP11-647K16.1	-7.72	6.39e-14	3.87e-11	-0.49	-0.33	Diastolic blood pressure;	chr2:190604036	chr2:190454092~190454521:-
KIRC	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	7.72	6.39e-14	3.87e-11	0.46	0.33	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
KIRC	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	7.72	6.39e-14	3.87e-11	0.46	0.33	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
KIRC	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-7.72	6.41e-14	3.88e-11	-0.39	-0.33	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
KIRC	cis	rs526231	0.926	rs35805	ENSG00000175749.11	EIF3KP1	7.72	6.42e-14	3.89e-11	0.42	0.33	Primary biliary cholangitis;	chr5:103337432	chr5:103032376~103033031:+
KIRC	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	7.72	6.46e-14	3.91e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
KIRC	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	7.72	6.46e-14	3.91e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
KIRC	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	7.72	6.47e-14	3.92e-11	0.34	0.33	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
KIRC	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	7.72	6.47e-14	3.92e-11	0.34	0.33	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
KIRC	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-7.72	6.48e-14	3.92e-11	-0.25	-0.33	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
KIRC	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	7.72	6.48e-14	3.93e-11	0.45	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
KIRC	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	7.72	6.48e-14	3.93e-11	0.28	0.33	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
KIRC	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.72	6.49e-14	3.93e-11	0.43	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
KIRC	cis	rs4356975	0.509	rs28375964	ENSG00000248763.2	RP13-644M16.5	-7.72	6.5e-14	3.94e-11	-0.42	-0.33	Obesity-related traits;	chr4:69098070	chr4:69066395~69069888:+
KIRC	cis	rs11018904	0.817	rs11606060	ENSG00000280385.1	AP000648.5	-7.72	6.5e-14	3.94e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90193614~90198120:+
KIRC	cis	rs11018904	0.906	rs11603498	ENSG00000280385.1	AP000648.5	-7.72	6.5e-14	3.94e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90193614~90198120:+
KIRC	cis	rs950027	0.572	rs12910764	ENSG00000235390.4	CTD-2651B20.5	7.72	6.51e-14	3.94e-11	0.31	0.33	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45321077~45321692:-
KIRC	cis	rs10971721	0.584	rs10971900	ENSG00000260947.1	RP11-384P7.7	7.72	6.51e-14	3.94e-11	0.59	0.33	Body mass index;	chr9:34085079	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971901	ENSG00000260947.1	RP11-384P7.7	7.72	6.51e-14	3.94e-11	0.59	0.33	Body mass index;	chr9:34085149	chr9:33697459~33700986:+
KIRC	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-7.72	6.51e-14	3.94e-11	-0.45	-0.33	Depression;	chr6:28173770	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-7.72	6.51e-14	3.94e-11	-0.45	-0.33	Depression;	chr6:28174809	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-7.72	6.51e-14	3.94e-11	-0.45	-0.33	Depression;	chr6:28175233	chr6:28115628~28116551:+
KIRC	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
KIRC	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	7.72	6.52e-14	3.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	7.72	6.53e-14	3.96e-11	0.33	0.33	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
KIRC	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	7.72	6.55e-14	3.96e-11	0.24	0.33	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
KIRC	cis	rs9388451	1	rs9388451	ENSG00000237742.5	RP11-624M8.1	-7.72	6.55e-14	3.97e-11	-0.4	-0.33	Brugada syndrome;	chr6:125769231	chr6:125578558~125749190:-
KIRC	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	7.72	6.56e-14	3.97e-11	0.35	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
KIRC	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-7.72	6.58e-14	3.98e-11	-0.38	-0.33	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
KIRC	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-7.72	6.59e-14	3.99e-11	-0.43	-0.33	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
KIRC	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-7.72	6.6e-14	3.99e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
KIRC	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	7.72	6.6e-14	3.99e-11	0.43	0.33	Height;	chr6:109478720	chr6:109382795~109383666:+
KIRC	cis	rs647097	0.655	rs1876220	ENSG00000272788.1	RP11-674N23.4	-7.72	6.6e-14	3.99e-11	-0.4	-0.33	Chronic obstructive pulmonary disease;	chr18:8800549	chr18:8801656~8802305:+
KIRC	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-7.72	6.6e-14	3.99e-11	-0.44	-0.33	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
KIRC	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	7.72	6.61e-14	4e-11	0.42	0.33	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
KIRC	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	7.72	6.65e-14	4.02e-11	0.34	0.33	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
KIRC	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-7.72	6.65e-14	4.02e-11	-0.35	-0.33	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
KIRC	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	7.72	6.65e-14	4.02e-11	0.26	0.33	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
KIRC	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-7.72	6.66e-14	4.03e-11	-0.37	-0.33	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
KIRC	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	7.72	6.67e-14	4.03e-11	0.32	0.33	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
KIRC	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-7.72	6.67e-14	4.03e-11	-0.32	-0.33	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
KIRC	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	7.72	6.68e-14	4.04e-11	0.3	0.33	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
KIRC	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-7.72	6.69e-14	4.05e-11	-0.33	-0.33	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
KIRC	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	7.72	6.71e-14	4.05e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	7.72	6.71e-14	4.05e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
KIRC	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	7.72	6.71e-14	4.05e-11	0.53	0.33	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
KIRC	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-7.71	6.72e-14	4.06e-11	-0.41	-0.33	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
KIRC	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-7.71	6.72e-14	4.06e-11	-0.41	-0.33	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
KIRC	cis	rs7672749	1	rs7672749	ENSG00000249973.2	CHCHD2P7	7.71	6.73e-14	4.07e-11	0.6	0.33	TB-LM or TBLH-BMD (pleiotropy);	chr4:87877132	chr4:87785920~87786371:-
KIRC	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-7.71	6.74e-14	4.07e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-7.71	6.74e-14	4.07e-11	-0.38	-0.33	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
KIRC	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	7.71	6.75e-14	4.08e-11	0.26	0.33	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
KIRC	cis	rs10276381	0.786	rs73300665	ENSG00000234336.5	JAZF1-AS1	-7.71	6.76e-14	4.08e-11	-0.6	-0.33	Crohn's disease;	chr7:28187405	chr7:28180322~28243917:+
KIRC	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	7.71	6.76e-14	4.09e-11	0.31	0.33	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
KIRC	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-7.71	6.76e-14	4.09e-11	-0.31	-0.33	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
KIRC	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-7.71	6.76e-14	4.09e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
KIRC	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	7.71	6.77e-14	4.09e-11	0.42	0.33	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
KIRC	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-7.71	6.77e-14	4.09e-11	-0.37	-0.33	Migraine;	chr4:56940917	chr4:56960927~56961373:-
KIRC	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	7.71	6.78e-14	4.09e-11	0.31	0.33	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	7.71	6.78e-14	4.09e-11	0.31	0.33	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	7.71	6.78e-14	4.09e-11	0.31	0.33	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
KIRC	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-7.71	6.8e-14	4.11e-11	-0.45	-0.33	Depression;	chr6:28159843	chr6:28115628~28116551:+
KIRC	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.71	6.8e-14	4.11e-11	-0.33	-0.33	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
KIRC	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	7.71	6.82e-14	4.12e-11	0.36	0.33	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	7.71	6.82e-14	4.12e-11	0.36	0.33	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	7.71	6.82e-14	4.12e-11	0.36	0.33	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
KIRC	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-7.71	6.82e-14	4.12e-11	-0.58	-0.33	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
KIRC	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	7.71	6.84e-14	4.13e-11	0.3	0.33	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
KIRC	cis	rs7592578	0.771	rs12053190	ENSG00000272979.1	RP11-647K16.1	-7.71	6.84e-14	4.13e-11	-0.47	-0.33	Diastolic blood pressure;	chr2:190518622	chr2:190454092~190454521:-
KIRC	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	7.71	6.86e-14	4.14e-11	0.46	0.33	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
KIRC	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	7.71	6.87e-14	4.15e-11	0.36	0.33	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
KIRC	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-7.71	6.87e-14	4.15e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
KIRC	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.71	6.87e-14	4.15e-11	0.24	0.33	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
KIRC	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	7.71	6.88e-14	4.15e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
KIRC	cis	rs2486288	0.656	rs11639420	ENSG00000259433.2	CTD-2651B20.4	7.71	6.88e-14	4.16e-11	0.23	0.33	Glomerular filtration rate;	chr15:45267070	chr15:45330209~45332634:-
KIRC	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	7.71	6.88e-14	4.16e-11	0.29	0.33	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
KIRC	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-7.71	6.89e-14	4.16e-11	-0.41	-0.33	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
KIRC	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	7.71	6.9e-14	4.17e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
KIRC	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	7.71	6.91e-14	4.17e-11	0.3	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
KIRC	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	7.71	6.93e-14	4.19e-11	0.29	0.33	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
KIRC	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	7.71	6.94e-14	4.19e-11	0.42	0.33	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
KIRC	cis	rs3745672	1	rs7248680	ENSG00000219665.7	CTD-2006C1.2	7.71	6.95e-14	4.2e-11	0.53	0.33	Multiple sclerosis;	chr19:12054955	chr19:11987617~12046275:+
KIRC	cis	rs1823913	0.513	rs4334520	ENSG00000280083.1	RP11-317J9.1	-7.71	6.96e-14	4.2e-11	-0.32	-0.33	Obesity-related traits;	chr2:191329200	chr2:191154118~191156070:-
KIRC	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-7.71	6.98e-14	4.21e-11	-0.3	-0.33	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
KIRC	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	7.71	7e-14	4.22e-11	0.31	0.33	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
KIRC	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-7.71	7.04e-14	4.25e-11	-0.39	-0.33	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
KIRC	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	7.71	7.08e-14	4.27e-11	0.42	0.33	Height;	chr4:55413708	chr4:55387949~55388271:+
KIRC	cis	rs950027	0.549	rs11636114	ENSG00000235390.4	CTD-2651B20.5	-7.71	7.08e-14	4.27e-11	-0.31	-0.33	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45321077~45321692:-
KIRC	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	7.71	7.08e-14	4.27e-11	0.4	0.33	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
KIRC	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-7.71	7.08e-14	4.27e-11	-0.26	-0.33	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
KIRC	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-7.71	7.08e-14	4.27e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
KIRC	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.71	7.1e-14	4.28e-11	-0.57	-0.33	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
KIRC	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-7.71	7.1e-14	4.28e-11	-0.35	-0.33	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
KIRC	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-7.71	7.1e-14	4.28e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
KIRC	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-7.71	7.11e-14	4.29e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-7.71	7.11e-14	4.29e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
KIRC	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-7.71	7.15e-14	4.31e-11	-0.4	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
KIRC	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	7.71	7.15e-14	4.31e-11	0.42	0.33	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
KIRC	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	7.71	7.17e-14	4.32e-11	0.38	0.33	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
KIRC	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-7.71	7.18e-14	4.33e-11	-0.42	-0.33	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
KIRC	cis	rs1077773	0.509	rs6461315	ENSG00000236318.1	AC019117.1	7.71	7.2e-14	4.34e-11	0.44	0.33	Ulcerative colitis;Inflammatory bowel disease;	chr7:17408820	chr7:17374867~17466664:+
KIRC	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-7.7	7.22e-14	4.35e-11	-0.46	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
KIRC	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	7.7	7.22e-14	4.35e-11	0.54	0.33	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
KIRC	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	7.7	7.23e-14	4.36e-11	0.24	0.33	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
KIRC	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	7.7	7.23e-14	4.36e-11	0.4	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
KIRC	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	7.7	7.26e-14	4.37e-11	0.45	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
KIRC	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	7.7	7.28e-14	4.39e-11	0.44	0.33	Height;	chr6:109371573	chr6:109382795~109383666:+
KIRC	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-7.7	7.28e-14	4.39e-11	-0.37	-0.33	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
KIRC	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-7.7	7.28e-14	4.39e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
KIRC	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-7.7	7.29e-14	4.39e-11	-0.4	-0.33	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
KIRC	cis	rs2032366	0.63	rs1894094	ENSG00000267279.1	RP11-879F14.2	-7.7	7.29e-14	4.39e-11	-0.42	-0.33	Obesity-related traits;	chr18:61606390	chr18:61585746~61606916:-
KIRC	cis	rs950027	0.549	rs12909409	ENSG00000235390.4	CTD-2651B20.5	7.7	7.3e-14	4.4e-11	0.31	0.33	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45321077~45321692:-
KIRC	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	7.7	7.3e-14	4.4e-11	0.39	0.33	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	7.7	7.3e-14	4.4e-11	0.39	0.33	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
KIRC	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-7.7	7.31e-14	4.4e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
KIRC	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-7.7	7.31e-14	4.4e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-7.7	7.31e-14	4.4e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
KIRC	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-7.7	7.33e-14	4.41e-11	-0.26	-0.33	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
KIRC	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-7.7	7.33e-14	4.41e-11	-0.53	-0.33	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
KIRC	cis	rs7017914	0.875	rs2732107	ENSG00000254031.4	RP11-326E22.1	7.7	7.33e-14	4.41e-11	0.36	0.33	Bone mineral density;	chr8:71013073	chr8:71155457~71204223:+
KIRC	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-7.7	7.35e-14	4.43e-11	-0.48	-0.33	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
KIRC	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	7.7	7.35e-14	4.43e-11	0.33	0.33	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
KIRC	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	7.7	7.38e-14	4.44e-11	0.56	0.33	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
KIRC	cis	rs6600671	0.934	rs11249431	ENSG00000227082.1	CH17-437K3.1	7.7	7.38e-14	4.44e-11	0.37	0.33	Hip geometry;	chr1:121544405	chr1:121396754~121463129:+
KIRC	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	7.7	7.4e-14	4.45e-11	0.44	0.33	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
KIRC	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	7.7	7.4e-14	4.45e-11	0.45	0.33	Height;	chr6:109465229	chr6:109382795~109383666:+
KIRC	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-7.7	7.41e-14	4.46e-11	-0.45	-0.33	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
KIRC	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	7.7	7.41e-14	4.46e-11	0.41	0.33	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
KIRC	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	7.7	7.43e-14	4.47e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
KIRC	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	7.7	7.44e-14	4.47e-11	0.42	0.33	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
KIRC	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	7.7	7.45e-14	4.48e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
KIRC	cis	rs3820928	0.874	rs10194663	ENSG00000212391.1	SNORA48	-7.7	7.46e-14	4.48e-11	-0.38	-0.33	Pulmonary function;	chr2:227010653	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	7.7	7.46e-14	4.48e-11	0.33	0.33	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
KIRC	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	7.7	7.47e-14	4.49e-11	0.35	0.33	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
KIRC	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-7.7	7.48e-14	4.49e-11	-0.26	-0.33	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
KIRC	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-7.7	7.5e-14	4.5e-11	-0.35	-0.33	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
KIRC	cis	rs6061231	0.631	rs2427310	ENSG00000275437.1	RP5-908M14.10	7.7	7.52e-14	4.51e-11	0.25	0.33	Colorectal cancer;	chr20:62394873	chr20:62402236~62405935:-
KIRC	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-7.7	7.53e-14	4.52e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
KIRC	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-7.7	7.54e-14	4.52e-11	-0.26	-0.33	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
KIRC	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-7.7	7.55e-14	4.53e-11	-0.43	-0.33	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
KIRC	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-7.7	7.55e-14	4.53e-11	-0.31	-0.33	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	7.7	7.55e-14	4.53e-11	0.46	0.33	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
KIRC	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	7.7	7.55e-14	4.53e-11	0.59	0.33	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
KIRC	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-7.7	7.55e-14	4.53e-11	-0.47	-0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	7.7	7.58e-14	4.55e-11	0.33	0.33	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
KIRC	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-7.7	7.59e-14	4.55e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
KIRC	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-7.7	7.59e-14	4.55e-11	-0.26	-0.33	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
KIRC	cis	rs6600671	1	rs12145080	ENSG00000227082.1	CH17-437K3.1	7.7	7.6e-14	4.56e-11	0.37	0.33	Hip geometry;	chr1:121443673	chr1:121396754~121463129:+
KIRC	cis	rs950776	0.518	rs2869055	ENSG00000261762.1	RP11-650L12.2	-7.7	7.61e-14	4.57e-11	-0.41	-0.33	Sudden cardiac arrest;	chr15:78530046	chr15:78589123~78591276:-
KIRC	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	7.7	7.62e-14	4.57e-11	0.35	0.33	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
KIRC	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	7.7	7.62e-14	4.57e-11	0.34	0.33	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
KIRC	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-7.7	7.63e-14	4.57e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
KIRC	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-7.7	7.64e-14	4.58e-11	-0.26	-0.33	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
KIRC	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	7.7	7.64e-14	4.58e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
KIRC	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	7.7	7.65e-14	4.58e-11	0.45	0.33	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	7.7	7.65e-14	4.58e-11	0.45	0.33	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
KIRC	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.7	7.65e-14	4.59e-11	0.73	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
KIRC	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-7.7	7.66e-14	4.59e-11	-0.41	-0.33	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
KIRC	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-7.7	7.66e-14	4.59e-11	-0.35	-0.33	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
KIRC	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	7.7	7.66e-14	4.59e-11	0.32	0.33	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
KIRC	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	7.7	7.67e-14	4.59e-11	0.45	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
KIRC	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-7.7	7.67e-14	4.6e-11	-0.4	-0.33	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
KIRC	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-7.7	7.68e-14	4.6e-11	-0.36	-0.33	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
KIRC	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	7.7	7.68e-14	4.6e-11	0.45	0.33	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
KIRC	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-7.7	7.69e-14	4.61e-11	-0.37	-0.33	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
KIRC	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	7.7	7.69e-14	4.61e-11	0.43	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
KIRC	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	7.7	7.69e-14	4.61e-11	0.43	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
KIRC	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	7.7	7.71e-14	4.62e-11	0.37	0.33	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
KIRC	cis	rs3858145	0.505	rs12765827	ENSG00000233590.1	RP11-153K11.3	7.7	7.71e-14	4.62e-11	0.42	0.33	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68286821	chr10:68233251~68242379:-
KIRC	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	7.69	7.74e-14	4.63e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
KIRC	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	7.69	7.74e-14	4.64e-11	0.33	0.33	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
KIRC	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-7.69	7.74e-14	4.64e-11	-0.4	-0.33	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
KIRC	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	7.69	7.8e-14	4.67e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
KIRC	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	7.69	7.82e-14	4.68e-11	0.48	0.33	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
KIRC	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	7.69	7.82e-14	4.68e-11	0.39	0.33	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
KIRC	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	7.69	7.83e-14	4.69e-11	0.25	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
KIRC	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-7.69	7.85e-14	4.7e-11	-0.39	-0.33	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
KIRC	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	7.69	7.86e-14	4.7e-11	0.45	0.33	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
KIRC	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	7.69	7.86e-14	4.7e-11	0.22	0.33	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
KIRC	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-7.69	7.86e-14	4.7e-11	-0.39	-0.33	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
KIRC	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-7.69	7.86e-14	4.7e-11	-0.39	-0.33	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
KIRC	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	7.69	7.86e-14	4.7e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
KIRC	cis	rs7592578	0.771	rs1128723	ENSG00000272979.1	RP11-647K16.1	-7.69	7.88e-14	4.71e-11	-0.47	-0.33	Diastolic blood pressure;	chr2:190501981	chr2:190454092~190454521:-
KIRC	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-7.69	7.9e-14	4.73e-11	-0.46	-0.33	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
KIRC	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	7.69	7.93e-14	4.74e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
KIRC	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	7.69	7.93e-14	4.74e-11	0.33	0.33	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
KIRC	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-7.69	7.94e-14	4.75e-11	-0.34	-0.33	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
KIRC	cis	rs4713118	0.539	rs510987	ENSG00000216901.1	AL022393.7	7.69	7.94e-14	4.75e-11	0.42	0.33	Parkinson's disease;	chr6:27879739	chr6:28176188~28176674:+
KIRC	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	7.69	7.95e-14	4.76e-11	0.41	0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
KIRC	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-7.69	7.95e-14	4.76e-11	-0.33	-0.33	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
KIRC	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-7.69	7.95e-14	4.76e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000196472.4	RP13-644M16.4	7.69	7.96e-14	4.76e-11	0.37	0.33	Obesity-related traits;	chr4:69075473	chr4:69181660~69182372:+
KIRC	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	7.69	7.96e-14	4.76e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
KIRC	cis	rs6496044	0.963	rs11853972	ENSG00000202081.1	RNU6-1280P	7.69	7.97e-14	4.76e-11	0.35	0.33	Interstitial lung disease;	chr15:85519209	chr15:85651522~85651628:-
KIRC	cis	rs6479891	0.686	rs61855876	ENSG00000232075.1	MRPL35P2	7.69	7.97e-14	4.77e-11	0.49	0.33	Arthritis (juvenile idiopathic);	chr10:63597781	chr10:63634317~63634827:-
KIRC	cis	rs6908034	0.556	rs113071446	ENSG00000228412.5	RP4-625H18.2	7.69	7.99e-14	4.78e-11	0.75	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19802164~19804752:-
KIRC	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-7.69	7.99e-14	4.78e-11	-0.62	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
KIRC	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.01e-14	4.79e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
KIRC	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	7.69	8.01e-14	4.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
KIRC	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	7.69	8.02e-14	4.79e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	7.69	8.02e-14	4.79e-11	0.46	0.33	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
KIRC	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	7.69	8.03e-14	4.8e-11	0.24	0.33	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
KIRC	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	7.69	8.05e-14	4.81e-11	0.46	0.33	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
KIRC	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	7.69	8.08e-14	4.83e-11	0.28	0.33	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
KIRC	cis	rs4072705	1	rs7874367	ENSG00000224020.1	MIR181A2HG	7.69	8.1e-14	4.84e-11	0.33	0.33	Menarche (age at onset);	chr9:124615501	chr9:124658467~124698631:+
KIRC	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	7.69	8.1e-14	4.84e-11	0.58	0.33	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	7.69	8.1e-14	4.84e-11	0.58	0.33	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	7.69	8.1e-14	4.84e-11	0.55	0.33	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
KIRC	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-7.69	8.11e-14	4.84e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-7.69	8.11e-14	4.84e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-7.69	8.11e-14	4.84e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-7.69	8.11e-14	4.84e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
KIRC	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	7.69	8.14e-14	4.86e-11	0.36	0.33	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
KIRC	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-7.69	8.15e-14	4.87e-11	-0.33	-0.33	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
KIRC	cis	rs2486288	0.656	rs2413768	ENSG00000235390.4	CTD-2651B20.5	7.69	8.16e-14	4.87e-11	0.31	0.33	Glomerular filtration rate;	chr15:45269786	chr15:45321077~45321692:-
KIRC	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	7.69	8.16e-14	4.87e-11	0.26	0.33	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
KIRC	cis	rs6908034	0.607	rs77386860	ENSG00000228412.5	RP4-625H18.2	7.69	8.17e-14	4.88e-11	0.75	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19802164~19804752:-
KIRC	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-7.69	8.18e-14	4.88e-11	-0.32	-0.33	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
KIRC	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	7.69	8.19e-14	4.89e-11	0.42	0.33	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
KIRC	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.19e-14	4.89e-11	-0.3	-0.33	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
KIRC	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-7.69	8.21e-14	4.9e-11	-0.43	-0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
KIRC	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	7.69	8.21e-14	4.9e-11	0.34	0.33	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
KIRC	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	7.69	8.21e-14	4.9e-11	0.42	0.33	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
KIRC	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-7.69	8.24e-14	4.92e-11	-0.26	-0.33	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
KIRC	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-7.69	8.24e-14	4.92e-11	-0.31	-0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
KIRC	cis	rs13113518	0.545	rs6810483	ENSG00000249700.7	SRD5A3-AS1	7.69	8.24e-14	4.92e-11	0.29	0.33	Height;	chr4:55424406	chr4:55363971~55395847:-
KIRC	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-7.69	8.25e-14	4.92e-11	-0.36	-0.33	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-7.69	8.25e-14	4.92e-11	-0.36	-0.33	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-7.69	8.25e-14	4.92e-11	-0.36	-0.33	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	7.69	8.25e-14	4.92e-11	0.34	0.33	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
KIRC	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	7.69	8.25e-14	4.92e-11	0.24	0.33	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
KIRC	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-7.69	8.27e-14	4.93e-11	-0.42	-0.33	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
KIRC	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-7.69	8.27e-14	4.93e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
KIRC	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	7.69	8.27e-14	4.93e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	7.69	8.27e-14	4.93e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	7.69	8.27e-14	4.93e-11	0.21	0.33	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
KIRC	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7.69	8.28e-14	4.94e-11	-0.4	-0.33	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
KIRC	cis	rs2018683	1	rs160837	ENSG00000228421.2	AC005013.5	7.68	8.28e-14	4.94e-11	0.33	0.33	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28957667~28959345:+
KIRC	cis	rs6061231	0.556	rs6121571	ENSG00000275437.1	RP5-908M14.10	7.68	8.28e-14	4.94e-11	0.26	0.33	Colorectal cancer;	chr20:62402267	chr20:62402236~62405935:-
KIRC	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-7.68	8.29e-14	4.94e-11	-0.47	-0.33	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
KIRC	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-7.68	8.3e-14	4.95e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
KIRC	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-7.68	8.3e-14	4.95e-11	-0.41	-0.33	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
KIRC	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	7.68	8.35e-14	4.98e-11	0.41	0.33	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
KIRC	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	7.68	8.37e-14	4.99e-11	0.29	0.33	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
KIRC	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	7.68	8.38e-14	4.99e-11	0.23	0.33	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
KIRC	cis	rs7017914	0.902	rs3098866	ENSG00000254031.4	RP11-326E22.1	7.68	8.39e-14	5e-11	0.35	0.33	Bone mineral density;	chr8:71004339	chr8:71155457~71204223:+
KIRC	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	7.68	8.41e-14	5.01e-11	0.24	0.33	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	7.68	8.41e-14	5.01e-11	0.24	0.33	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
KIRC	cis	rs13423976	0.586	rs12617556	ENSG00000231367.4	AC016995.3	7.68	8.45e-14	5.03e-11	0.42	0.33	Gut microbiome composition (summer);	chr2:38514972	chr2:38406719~38515740:-
KIRC	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-7.68	8.45e-14	5.03e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
KIRC	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-7.68	8.46e-14	5.04e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-7.68	8.46e-14	5.04e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-7.68	8.46e-14	5.04e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-7.68	8.46e-14	5.04e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-7.68	8.46e-14	5.04e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
KIRC	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	7.68	8.46e-14	5.04e-11	0.41	0.33	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
KIRC	cis	rs1560104	0.597	rs4781297	ENSG00000274834.1	CTD-3037G24.5	7.68	8.5e-14	5.06e-11	0.35	0.33	Obesity-related traits;	chr16:12613347	chr16:12614451~12614852:+
KIRC	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	7.68	8.51e-14	5.07e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	7.68	8.51e-14	5.07e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	7.68	8.51e-14	5.07e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	7.68	8.51e-14	5.07e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-7.68	8.52e-14	5.07e-11	-0.41	-0.33	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
KIRC	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	7.68	8.53e-14	5.08e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
KIRC	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-7.68	8.56e-14	5.09e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-7.68	8.56e-14	5.09e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-7.68	8.56e-14	5.09e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
KIRC	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-7.68	8.6e-14	5.12e-11	-0.37	-0.33	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
KIRC	cis	rs890448	0.726	rs1530259	ENSG00000254531.1	FLJ20021	-7.68	8.6e-14	5.12e-11	-0.33	-0.33	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101303753	chr4:101347780~101348883:+
KIRC	cis	rs12456021	0.941	rs12456543	ENSG00000267257.1	RP11-1151B14.4	-7.68	8.6e-14	5.12e-11	-0.32	-0.33	Multiple sclerosis;	chr18:58549725	chr18:58535415~58538552:+
KIRC	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	7.68	8.61e-14	5.12e-11	0.37	0.33	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
KIRC	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	7.68	8.64e-14	5.14e-11	0.33	0.33	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	7.68	8.67e-14	5.16e-11	0.33	0.33	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
KIRC	cis	rs7592578	0.713	rs60915953	ENSG00000272979.1	RP11-647K16.1	-7.68	8.7e-14	5.17e-11	-0.49	-0.33	Diastolic blood pressure;	chr2:190466578	chr2:190454092~190454521:-
KIRC	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-7.68	8.7e-14	5.17e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-7.68	8.7e-14	5.17e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-7.68	8.7e-14	5.17e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-7.68	8.7e-14	5.17e-11	-0.33	-0.33	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
KIRC	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	7.68	8.73e-14	5.19e-11	0.55	0.33	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	7.68	8.73e-14	5.19e-11	0.55	0.33	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
KIRC	cis	rs13423976	0.546	rs10184164	ENSG00000231367.4	AC016995.3	7.68	8.73e-14	5.19e-11	0.42	0.33	Gut microbiome composition (summer);	chr2:38514411	chr2:38406719~38515740:-
KIRC	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-7.68	8.73e-14	5.19e-11	-0.32	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
KIRC	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-7.68	8.75e-14	5.2e-11	-0.62	-0.33	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
KIRC	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-7.68	8.75e-14	5.2e-11	-0.26	-0.33	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
KIRC	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	7.68	8.77e-14	5.21e-11	0.33	0.33	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
KIRC	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	7.68	8.78e-14	5.22e-11	0.44	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
KIRC	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-7.68	8.8e-14	5.23e-11	-0.3	-0.33	Height;	chr11:118809363	chr11:118791254~118793137:+
KIRC	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	7.68	8.8e-14	5.23e-11	0.46	0.33	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
KIRC	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-7.68	8.83e-14	5.25e-11	-0.48	-0.33	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
KIRC	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	7.68	8.85e-14	5.26e-11	0.3	0.33	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
KIRC	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	7.68	8.85e-14	5.26e-11	0.58	0.33	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
KIRC	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-7.68	8.85e-14	5.26e-11	-0.4	-0.33	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
KIRC	cis	rs6600671	0.967	rs12069545	ENSG00000270231.3	NBPF8P	7.68	8.88e-14	5.27e-11	0.25	0.33	Hip geometry;	chr1:121430343	chr1:120436353~120467739:+
KIRC	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-7.68	8.88e-14	5.27e-11	-0.46	-0.33	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
KIRC	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.67	8.89e-14	5.28e-11	0.3	0.33	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
KIRC	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	7.67	8.9e-14	5.29e-11	0.44	0.33	Height;	chr6:109354040	chr6:109382795~109383666:+
KIRC	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	7.67	8.9e-14	5.29e-11	0.45	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
KIRC	cis	rs7017914	0.967	rs1471114	ENSG00000254031.4	RP11-326E22.1	7.67	8.91e-14	5.29e-11	0.36	0.33	Bone mineral density;	chr8:70763312	chr8:71155457~71204223:+
KIRC	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.67	8.94e-14	5.31e-11	-0.3	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.67	8.94e-14	5.31e-11	-0.3	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
KIRC	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	7.67	8.94e-14	5.31e-11	0.44	0.33	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
KIRC	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	7.67	8.94e-14	5.31e-11	0.49	0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
KIRC	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-7.67	8.95e-14	5.31e-11	-0.37	-0.33	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
KIRC	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-7.67	8.96e-14	5.32e-11	-0.26	-0.33	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
KIRC	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.67	8.96e-14	5.32e-11	-0.33	-0.33	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
KIRC	cis	rs6600671	0.899	rs2319971	ENSG00000227082.1	CH17-437K3.1	-7.67	8.97e-14	5.32e-11	-0.37	-0.33	Hip geometry;	chr1:121485184	chr1:121396754~121463129:+
KIRC	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	7.67	8.98e-14	5.33e-11	0.43	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
KIRC	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	7.67	8.98e-14	5.33e-11	0.41	0.33	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
KIRC	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-7.67	8.98e-14	5.33e-11	-0.41	-0.33	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
KIRC	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	7.67	8.99e-14	5.34e-11	0.39	0.33	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
KIRC	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-7.67	9.04e-14	5.36e-11	-0.4	-0.33	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-7.67	9.04e-14	5.36e-11	-0.4	-0.33	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
KIRC	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-7.67	9.05e-14	5.37e-11	-0.42	-0.33	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
KIRC	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	7.67	9.05e-14	5.37e-11	0.47	0.33	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	7.67	9.06e-14	5.37e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
KIRC	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	7.67	9.06e-14	5.37e-11	0.42	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
KIRC	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	7.67	9.07e-14	5.38e-11	0.39	0.33	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
KIRC	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-7.67	9.09e-14	5.39e-11	-0.35	-0.33	Height;	chr3:52975027	chr3:53064283~53065091:-
KIRC	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-7.67	9.09e-14	5.39e-11	-0.26	-0.33	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
KIRC	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	7.67	9.1e-14	5.4e-11	0.45	0.33	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
KIRC	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-7.67	9.11e-14	5.4e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-7.67	9.11e-14	5.4e-11	-0.31	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
KIRC	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	7.67	9.12e-14	5.41e-11	0.33	0.33	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
KIRC	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	7.67	9.12e-14	5.41e-11	0.36	0.33	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
KIRC	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	7.67	9.13e-14	5.41e-11	0.25	0.33	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000251284.2	RP13-644M16.1	7.67	9.14e-14	5.42e-11	0.39	0.33	Obesity-related traits;	chr4:69075436	chr4:69125274~69126451:+
KIRC	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-7.67	9.14e-14	5.42e-11	-0.4	-0.33	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
KIRC	cis	rs3820928	1	rs1346618	ENSG00000212391.1	SNORA48	7.67	9.15e-14	5.42e-11	0.38	0.33	Pulmonary function;	chr2:226907272	chr2:226968989~226969122:-
KIRC	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-7.67	9.15e-14	5.42e-11	-0.39	-0.33	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
KIRC	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-7.67	9.16e-14	5.43e-11	-0.39	-0.33	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
KIRC	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-7.67	9.2e-14	5.45e-11	-0.36	-0.33	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
KIRC	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	7.67	9.23e-14	5.47e-11	0.59	0.33	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
KIRC	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	7.67	9.23e-14	5.47e-11	0.38	0.33	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
KIRC	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	7.67	9.24e-14	5.47e-11	0.4	0.33	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	7.67	9.24e-14	5.47e-11	0.4	0.33	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	7.67	9.28e-14	5.5e-11	0.41	0.33	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
KIRC	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-7.67	9.3e-14	5.5e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
KIRC	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	7.67	9.31e-14	5.51e-11	0.4	0.33	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
KIRC	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-7.67	9.31e-14	5.51e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
KIRC	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	7.67	9.32e-14	5.52e-11	0.44	0.33	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
KIRC	cis	rs7592578	0.766	rs62182865	ENSG00000272979.1	RP11-647K16.1	-7.67	9.33e-14	5.53e-11	-0.49	-0.33	Diastolic blood pressure;	chr2:190569454	chr2:190454092~190454521:-
KIRC	cis	rs12893668	0.542	rs12884809	ENSG00000269910.1	RP11-73M18.10	7.67	9.34e-14	5.53e-11	0.23	0.33	Reticulocyte count;	chr14:103628983	chr14:103694516~103695050:-
KIRC	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	7.67	9.36e-14	5.54e-11	0.46	0.33	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
KIRC	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	7.67	9.39e-14	5.55e-11	0.36	0.33	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
KIRC	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	7.67	9.42e-14	5.57e-11	0.43	0.33	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
KIRC	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-7.67	9.42e-14	5.57e-11	-0.41	-0.33	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
KIRC	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	7.67	9.43e-14	5.58e-11	0.46	0.33	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
KIRC	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	7.67	9.44e-14	5.58e-11	0.46	0.33	Depression;	chr6:28430971	chr6:28943877~28944537:+
KIRC	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	7.67	9.44e-14	5.58e-11	0.39	0.33	Height;	chr4:55485974	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	7.67	9.45e-14	5.59e-11	0.34	0.33	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
KIRC	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-7.67	9.46e-14	5.6e-11	-0.41	-0.33	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
KIRC	cis	rs10971721	0.596	rs9650704	ENSG00000260947.1	RP11-384P7.7	7.67	9.47e-14	5.6e-11	0.58	0.33	Body mass index;	chr9:34141956	chr9:33697459~33700986:+
KIRC	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	7.67	9.48e-14	5.61e-11	0.48	0.33	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
KIRC	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	7.67	9.48e-14	5.61e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	7.67	9.49e-14	5.62e-11	0.33	0.33	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
KIRC	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-7.67	9.5e-14	5.62e-11	-0.3	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
KIRC	cis	rs13423976	0.6	rs35776111	ENSG00000231367.4	AC016995.3	7.67	9.5e-14	5.62e-11	0.42	0.33	Gut microbiome composition (summer);	chr2:38515087	chr2:38406719~38515740:-
KIRC	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-7.67	9.5e-14	5.62e-11	-0.4	-0.33	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
KIRC	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.51e-14	5.63e-11	-0.33	-0.33	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
KIRC	cis	rs2288884	0.708	rs61574510	ENSG00000275055.1	CTC-471J1.11	-7.67	9.52e-14	5.63e-11	-0.41	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52049007~52049754:+
KIRC	cis	rs950027	0.549	rs11636114	ENSG00000259433.2	CTD-2651B20.4	-7.66	9.53e-14	5.64e-11	-0.23	-0.33	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45330209~45332634:-
KIRC	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-7.66	9.53e-14	5.64e-11	-0.57	-0.33	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	7.66	9.53e-14	5.64e-11	0.57	0.33	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	7.66	9.53e-14	5.64e-11	0.57	0.33	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	7.66	9.53e-14	5.64e-11	0.57	0.33	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
KIRC	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	7.66	9.54e-14	5.64e-11	0.27	0.33	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
KIRC	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	7.66	9.54e-14	5.64e-11	0.31	0.33	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
KIRC	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	7.66	9.55e-14	5.65e-11	0.45	0.33	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
KIRC	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	7.66	9.55e-14	5.65e-11	0.44	0.33	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
KIRC	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-7.66	9.55e-14	5.65e-11	-0.47	-0.33	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
KIRC	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-7.66	9.55e-14	5.65e-11	-0.47	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
KIRC	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	7.66	9.57e-14	5.66e-11	0.33	0.33	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	7.66	9.57e-14	5.66e-11	0.33	0.33	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	7.66	9.57e-14	5.66e-11	0.36	0.33	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
KIRC	cis	rs6908034	0.546	rs74514942	ENSG00000228412.5	RP4-625H18.2	7.66	9.58e-14	5.66e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19802164~19804752:-
KIRC	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-7.66	9.59e-14	5.67e-11	-0.35	-0.33	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
KIRC	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	7.66	9.59e-14	5.67e-11	0.45	0.33	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	7.66	9.59e-14	5.67e-11	0.45	0.33	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	7.66	9.59e-14	5.67e-11	0.45	0.33	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
KIRC	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-7.66	9.61e-14	5.68e-11	-0.41	-0.33	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
KIRC	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-7.66	9.65e-14	5.7e-11	-0.4	-0.33	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-7.66	9.65e-14	5.7e-11	-0.4	-0.33	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
KIRC	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-7.66	9.68e-14	5.72e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
KIRC	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	7.66	9.68e-14	5.72e-11	0.41	0.33	Height;	chr4:55361200	chr4:55387949~55388271:+
KIRC	cis	rs7017914	0.905	rs2732094	ENSG00000254031.4	RP11-326E22.1	7.66	9.68e-14	5.72e-11	0.35	0.33	Bone mineral density;	chr8:71007683	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732095	ENSG00000254031.4	RP11-326E22.1	7.66	9.68e-14	5.72e-11	0.35	0.33	Bone mineral density;	chr8:71007711	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs2732096	ENSG00000254031.4	RP11-326E22.1	7.66	9.68e-14	5.72e-11	0.35	0.33	Bone mineral density;	chr8:71007745	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.935	rs2732097	ENSG00000254031.4	RP11-326E22.1	7.66	9.68e-14	5.72e-11	0.35	0.33	Bone mineral density;	chr8:71007778	chr8:71155457~71204223:+
KIRC	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	7.66	9.7e-14	5.73e-11	0.46	0.33	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
KIRC	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	7.66	9.72e-14	5.74e-11	0.37	0.33	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
KIRC	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	7.66	9.72e-14	5.74e-11	0.44	0.33	Height;	chr6:109353355	chr6:109382795~109383666:+
KIRC	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	7.66	9.72e-14	5.74e-11	0.71	0.33	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
KIRC	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	7.66	9.72e-14	5.74e-11	0.71	0.33	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
KIRC	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-7.66	9.73e-14	5.75e-11	-0.39	-0.33	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
KIRC	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-7.66	9.73e-14	5.75e-11	-0.3	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
KIRC	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	7.66	9.74e-14	5.75e-11	0.45	0.33	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
KIRC	cis	rs7017914	0.967	rs12680166	ENSG00000254031.4	RP11-326E22.1	7.66	9.75e-14	5.76e-11	0.36	0.33	Bone mineral density;	chr8:70766403	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	7.66	9.76e-14	5.77e-11	0.34	0.33	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
KIRC	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-7.66	9.77e-14	5.77e-11	-0.36	-0.33	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
KIRC	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-7.66	9.78e-14	5.77e-11	-0.35	-0.33	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
KIRC	cis	rs6600671	1	rs11249351	ENSG00000270231.3	NBPF8P	7.66	9.78e-14	5.78e-11	0.25	0.33	Hip geometry;	chr1:121430082	chr1:120436353~120467739:+
KIRC	cis	rs13113518	0.507	rs11943456	ENSG00000273257.1	RP11-177J6.1	7.66	9.8e-14	5.79e-11	0.38	0.33	Height;	chr4:55410167	chr4:55387949~55388271:+
KIRC	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	7.66	9.8e-14	5.79e-11	0.35	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
KIRC	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	7.66	9.8e-14	5.79e-11	0.45	0.33	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	7.66	9.8e-14	5.79e-11	0.45	0.33	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	7.66	9.8e-14	5.79e-11	0.33	0.33	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
KIRC	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	7.66	9.81e-14	5.79e-11	0.22	0.33	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
KIRC	cis	rs6908034	0.607	rs78402429	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs77791009	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs75060331	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs77753186	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs79162793	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs76245225	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs75110577	ENSG00000228412.5	RP4-625H18.2	7.66	9.81e-14	5.79e-11	0.74	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19802164~19804752:-
KIRC	cis	rs13113518	0.557	rs13142096	ENSG00000273257.1	RP11-177J6.1	7.66	9.81e-14	5.79e-11	0.42	0.33	Height;	chr4:55566291	chr4:55387949~55388271:+
KIRC	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-7.66	9.83e-14	5.8e-11	-0.6	-0.33	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
KIRC	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-7.66	9.85e-14	5.81e-11	-0.33	-0.33	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
KIRC	cis	rs12922317	0.681	rs393329	ENSG00000260488.1	RP11-166B2.7	-7.66	9.85e-14	5.81e-11	-0.31	-0.33	Schizophrenia;	chr16:11976565	chr16:11976851~11977850:-
KIRC	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	7.66	9.86e-14	5.82e-11	0.36	0.33	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
KIRC	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	7.66	9.88e-14	5.83e-11	0.3	0.33	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
KIRC	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-7.66	9.89e-14	5.84e-11	-0.31	-0.33	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
KIRC	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-7.66	9.9e-14	5.84e-11	-0.34	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
KIRC	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	7.66	9.91e-14	5.85e-11	0.43	0.33	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
KIRC	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	7.66	9.91e-14	5.85e-11	0.36	0.33	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	7.66	9.91e-14	5.85e-11	0.36	0.33	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
KIRC	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-7.66	9.95e-14	5.87e-11	-0.3	-0.33	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
KIRC	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-7.66	9.96e-14	5.87e-11	-0.42	-0.33	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
KIRC	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-7.66	9.97e-14	5.88e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-7.66	9.97e-14	5.88e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-7.66	9.97e-14	5.88e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-7.66	9.97e-14	5.88e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
KIRC	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-7.66	9.97e-14	5.88e-11	-0.4	-0.33	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
KIRC	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-7.66	1e-13	5.9e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
KIRC	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	7.66	1e-13	5.9e-11	0.46	0.33	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	7.66	1e-13	5.9e-11	0.46	0.33	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
KIRC	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	7.66	1e-13	5.91e-11	0.39	0.33	Height;	chr4:55578787	chr4:55387949~55388271:+
KIRC	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-7.66	1e-13	5.91e-11	-0.41	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
KIRC	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	7.66	1e-13	5.91e-11	0.33	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
KIRC	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	7.66	1e-13	5.92e-11	0.46	0.33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
KIRC	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-7.66	1e-13	5.92e-11	-0.3	-0.33	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
KIRC	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-7.66	1.01e-13	5.93e-11	-0.43	-0.33	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-7.66	1.01e-13	5.93e-11	-0.43	-0.33	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
KIRC	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-7.66	1.01e-13	5.94e-11	-0.26	-0.33	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
KIRC	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	7.66	1.01e-13	5.95e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	7.66	1.01e-13	5.95e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
KIRC	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-7.66	1.01e-13	5.95e-11	-0.35	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-7.66	1.01e-13	5.95e-11	-0.35	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
KIRC	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.66	1.01e-13	5.95e-11	0.24	0.33	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
KIRC	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	7.66	1.01e-13	5.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	7.66	1.01e-13	5.95e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	7.66	1.01e-13	5.98e-11	0.31	0.33	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
KIRC	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	7.66	1.01e-13	5.98e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
KIRC	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-7.66	1.02e-13	5.99e-11	-0.31	-0.33	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
KIRC	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	7.66	1.02e-13	6e-11	0.31	0.33	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
KIRC	cis	rs11018904	0.817	rs11601793	ENSG00000280385.1	AP000648.5	-7.66	1.02e-13	6.01e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90193614~90198120:+
KIRC	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	7.65	1.02e-13	6.01e-11	0.68	0.33	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
KIRC	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-7.65	1.02e-13	6.02e-11	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
KIRC	cis	rs7017914	0.935	rs2732093	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71006844	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639899	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71007227	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.875	rs2639897	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71008441	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639896	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71008548	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs1353057	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71009862	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639960	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71009904	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639958	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71009915	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs1908036	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71010089	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs1908035	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71010173	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs1908034	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71010319	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs1908033	ENSG00000254031.4	RP11-326E22.1	7.65	1.02e-13	6.02e-11	0.35	0.33	Bone mineral density;	chr8:71010564	chr8:71155457~71204223:+
KIRC	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-7.65	1.02e-13	6.03e-11	-0.33	-0.33	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
KIRC	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	7.65	1.03e-13	6.03e-11	0.46	0.33	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
KIRC	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-7.65	1.03e-13	6.04e-11	-0.35	-0.33	Height;	chr3:52977358	chr3:53064283~53065091:-
KIRC	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-7.65	1.03e-13	6.04e-11	-0.24	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
KIRC	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55482317	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55491628	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55495801	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55496737	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55496933	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55497842	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55500224	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55501629	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55501726	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55501788	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55504176	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	7.65	1.03e-13	6.04e-11	0.39	0.33	Height;	chr4:55504201	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	7.65	1.03e-13	6.07e-11	0.47	0.33	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
KIRC	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	7.65	1.03e-13	6.07e-11	0.68	0.33	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
KIRC	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	7.65	1.03e-13	6.08e-11	0.45	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
KIRC	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-7.65	1.03e-13	6.08e-11	-0.38	-0.33	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
KIRC	cis	rs7017914	0.905	rs2732103	ENSG00000254031.4	RP11-326E22.1	7.65	1.03e-13	6.08e-11	0.35	0.33	Bone mineral density;	chr8:71011261	chr8:71155457~71204223:+
KIRC	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-7.65	1.03e-13	6.08e-11	-0.28	-0.33	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
KIRC	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	7.65	1.04e-13	6.09e-11	0.43	0.33	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
KIRC	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	7.65	1.04e-13	6.09e-11	0.43	0.33	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
KIRC	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	7.65	1.04e-13	6.09e-11	0.35	0.33	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
KIRC	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	7.65	1.04e-13	6.1e-11	0.46	0.33	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
KIRC	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.04e-13	6.1e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.04e-13	6.1e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.04e-13	6.1e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.04e-13	6.1e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
KIRC	cis	rs3820928	0.874	rs2177594	ENSG00000212391.1	SNORA48	-7.65	1.04e-13	6.1e-11	-0.39	-0.33	Pulmonary function;	chr2:226971523	chr2:226968989~226969122:-
KIRC	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-7.65	1.04e-13	6.11e-11	-0.38	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
KIRC	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-7.65	1.04e-13	6.11e-11	-0.61	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
KIRC	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-7.65	1.05e-13	6.14e-11	-0.37	-0.33	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
KIRC	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	7.65	1.05e-13	6.15e-11	0.32	0.33	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	7.65	1.05e-13	6.15e-11	0.32	0.33	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
KIRC	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	7.65	1.05e-13	6.17e-11	0.38	0.33	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
KIRC	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-7.65	1.05e-13	6.17e-11	-0.33	-0.33	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
KIRC	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.65	1.05e-13	6.17e-11	0.28	0.33	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
KIRC	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-7.65	1.05e-13	6.18e-11	-0.3	-0.33	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
KIRC	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-7.65	1.05e-13	6.19e-11	-0.31	-0.33	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
KIRC	cis	rs7017914	0.967	rs7825446	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70751939	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs6472543	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70752173	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7819332	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70756030	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7012404	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70756463	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7018381	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70757882	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs13258584	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70759344	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs7009297	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70760131	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs7014012	ENSG00000254031.4	RP11-326E22.1	7.65	1.05e-13	6.19e-11	0.36	0.33	Bone mineral density;	chr8:70760508	chr8:71155457~71204223:+
KIRC	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-7.65	1.05e-13	6.2e-11	-0.41	-0.33	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
KIRC	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	7.65	1.06e-13	6.2e-11	0.36	0.33	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
KIRC	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	7.65	1.06e-13	6.2e-11	0.43	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
KIRC	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-7.65	1.06e-13	6.2e-11	-0.43	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
KIRC	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	7.65	1.06e-13	6.22e-11	0.5	0.33	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
KIRC	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-7.65	1.06e-13	6.23e-11	-0.26	-0.33	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
KIRC	cis	rs4356975	0.795	rs4694599	ENSG00000250696.4	RP11-704M14.1	7.65	1.06e-13	6.25e-11	0.34	0.33	Obesity-related traits;	chr4:69070858	chr4:69182100~69216766:+
KIRC	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	7.65	1.07e-13	6.26e-11	0.33	0.33	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
KIRC	cis	rs755249	1	rs17513135	ENSG00000182109.6	RP11-69E11.4	7.65	1.07e-13	6.27e-11	0.28	0.33	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39522280~39546187:-
KIRC	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-7.65	1.07e-13	6.27e-11	-0.39	-0.33	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
KIRC	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	7.65	1.07e-13	6.27e-11	0.49	0.33	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
KIRC	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	7.65	1.07e-13	6.28e-11	0.41	0.33	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
KIRC	cis	rs7017914	0.934	rs2732092	ENSG00000254031.4	RP11-326E22.1	7.65	1.07e-13	6.29e-11	0.35	0.33	Bone mineral density;	chr8:71006364	chr8:71155457~71204223:+
KIRC	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-7.65	1.07e-13	6.29e-11	-0.3	-0.33	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
KIRC	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	7.65	1.07e-13	6.31e-11	0.37	0.33	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	7.65	1.08e-13	6.31e-11	0.41	0.33	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
KIRC	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	7.65	1.08e-13	6.31e-11	0.38	0.33	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
KIRC	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-7.65	1.08e-13	6.32e-11	-0.39	-0.33	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
KIRC	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	7.65	1.08e-13	6.32e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
KIRC	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	7.65	1.08e-13	6.33e-11	0.46	0.33	Depression;	chr6:28432562	chr6:28943877~28944537:+
KIRC	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	7.65	1.08e-13	6.34e-11	0.39	0.33	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
KIRC	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	7.65	1.08e-13	6.34e-11	0.46	0.33	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	7.65	1.08e-13	6.34e-11	0.46	0.33	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
KIRC	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	7.65	1.08e-13	6.35e-11	0.37	0.33	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	7.65	1.08e-13	6.35e-11	0.37	0.33	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
KIRC	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	7.65	1.08e-13	6.35e-11	0.37	0.33	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	7.65	1.08e-13	6.35e-11	0.37	0.33	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
KIRC	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	7.65	1.08e-13	6.35e-11	0.44	0.33	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
KIRC	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-7.65	1.08e-13	6.35e-11	-0.39	-0.33	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
KIRC	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	7.65	1.08e-13	6.36e-11	0.4	0.33	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
KIRC	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.08e-13	6.36e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-7.65	1.08e-13	6.36e-11	-0.29	-0.33	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
KIRC	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	7.65	1.09e-13	6.37e-11	0.41	0.33	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
KIRC	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-7.65	1.09e-13	6.37e-11	-0.35	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
KIRC	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-7.65	1.09e-13	6.38e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
KIRC	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-7.65	1.09e-13	6.39e-11	-0.3	-0.32	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
KIRC	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-7.65	1.09e-13	6.41e-11	-0.39	-0.32	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
KIRC	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	7.64	1.1e-13	6.42e-11	0.44	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
KIRC	cis	rs2337406	0.925	rs34064152	ENSG00000274576.2	IGHV2-70	-7.64	1.1e-13	6.42e-11	-0.43	-0.32	Alzheimer's disease (late onset);	chr14:106700364	chr14:106770577~106771020:-
KIRC	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-7.64	1.1e-13	6.43e-11	-0.39	-0.32	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
KIRC	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	7.64	1.1e-13	6.44e-11	0.39	0.32	Height;	chr4:55484534	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	7.64	1.1e-13	6.44e-11	0.39	0.32	Height;	chr4:55489310	chr4:55387949~55388271:+
KIRC	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	7.64	1.1e-13	6.44e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
KIRC	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	7.64	1.1e-13	6.44e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
KIRC	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	7.64	1.1e-13	6.44e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	7.64	1.1e-13	6.44e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	7.64	1.1e-13	6.44e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
KIRC	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	7.64	1.1e-13	6.44e-11	0.42	0.32	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
KIRC	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-7.64	1.1e-13	6.45e-11	-0.3	-0.32	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
KIRC	cis	rs890448	0.694	rs2583398	ENSG00000254531.1	FLJ20021	-7.64	1.1e-13	6.45e-11	-0.33	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101307539	chr4:101347780~101348883:+
KIRC	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	7.64	1.1e-13	6.46e-11	0.36	0.32	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
KIRC	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-7.64	1.1e-13	6.46e-11	-0.37	-0.32	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
KIRC	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.64	1.1e-13	6.46e-11	-0.33	-0.32	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
KIRC	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-7.64	1.1e-13	6.46e-11	-0.47	-0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
KIRC	cis	rs17772222	0.682	rs2401751	ENSG00000222990.1	RNU4-22P	-7.64	1.1e-13	6.47e-11	-0.35	-0.32	Coronary artery calcification;	chr14:88480278	chr14:88513498~88513663:+
KIRC	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	7.64	1.1e-13	6.47e-11	0.44	0.32	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
KIRC	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-7.64	1.11e-13	6.49e-11	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
KIRC	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	7.64	1.11e-13	6.5e-11	0.46	0.32	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
KIRC	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
KIRC	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	7.64	1.11e-13	6.5e-11	0.68	0.32	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
KIRC	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-7.64	1.11e-13	6.51e-11	-0.37	-0.32	Migraine;	chr4:56879297	chr4:56960927~56961373:-
KIRC	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-7.64	1.11e-13	6.51e-11	-0.26	-0.32	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
KIRC	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-7.64	1.11e-13	6.52e-11	-0.31	-0.32	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
KIRC	cis	rs7592578	0.766	rs12472081	ENSG00000272979.1	RP11-647K16.1	-7.64	1.11e-13	6.52e-11	-0.49	-0.32	Diastolic blood pressure;	chr2:190533819	chr2:190454092~190454521:-
KIRC	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-7.64	1.12e-13	6.53e-11	-0.26	-0.32	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
KIRC	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-7.64	1.12e-13	6.56e-11	-0.34	-0.32	Height;	chr3:52989412	chr3:53064283~53065091:-
KIRC	cis	rs755249	0.959	rs72663520	ENSG00000182109.6	RP11-69E11.4	7.64	1.12e-13	6.57e-11	0.28	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39522280~39546187:-
KIRC	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-7.64	1.12e-13	6.57e-11	-0.4	-0.32	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-7.64	1.12e-13	6.57e-11	-0.4	-0.32	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-7.64	1.12e-13	6.57e-11	-0.4	-0.32	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-7.64	1.12e-13	6.57e-11	-0.4	-0.32	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
KIRC	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	7.64	1.12e-13	6.58e-11	0.46	0.32	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
KIRC	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-7.64	1.13e-13	6.58e-11	-0.38	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
KIRC	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	7.64	1.13e-13	6.61e-11	0.46	0.32	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	7.64	1.13e-13	6.61e-11	0.46	0.32	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	7.64	1.13e-13	6.61e-11	0.46	0.32	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
KIRC	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-7.64	1.13e-13	6.63e-11	-0.47	-0.32	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
KIRC	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-7.64	1.13e-13	6.63e-11	-0.4	-0.32	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
KIRC	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-7.64	1.13e-13	6.64e-11	-0.3	-0.32	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
KIRC	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-7.64	1.14e-13	6.64e-11	-0.31	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
KIRC	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-7.64	1.14e-13	6.64e-11	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
KIRC	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	7.64	1.14e-13	6.65e-11	0.44	0.32	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
KIRC	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-7.64	1.14e-13	6.66e-11	-0.59	-0.32	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
KIRC	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.64	1.14e-13	6.66e-11	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
KIRC	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	7.64	1.14e-13	6.66e-11	0.4	0.32	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
KIRC	cis	rs75422866	0.764	rs73104177	ENSG00000280054.1	RP1-197B17.7	7.64	1.14e-13	6.67e-11	0.71	0.32	Pneumonia;	chr12:47713550	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.764	rs73104184	ENSG00000280054.1	RP1-197B17.7	7.64	1.14e-13	6.67e-11	0.71	0.32	Pneumonia;	chr12:47715623	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.764	rs73104188	ENSG00000280054.1	RP1-197B17.7	7.64	1.14e-13	6.67e-11	0.71	0.32	Pneumonia;	chr12:47715885	chr12:47728151~47730598:-
KIRC	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	7.64	1.14e-13	6.67e-11	0.39	0.32	Height;	chr4:55534166	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	7.64	1.14e-13	6.67e-11	0.39	0.32	Height;	chr4:55534180	chr4:55387949~55388271:+
KIRC	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	7.64	1.14e-13	6.67e-11	0.47	0.32	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
KIRC	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	7.64	1.14e-13	6.69e-11	0.52	0.32	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
KIRC	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	7.64	1.14e-13	6.69e-11	0.52	0.32	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
KIRC	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	7.64	1.15e-13	6.71e-11	0.41	0.32	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
KIRC	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	7.64	1.15e-13	6.71e-11	0.36	0.32	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
KIRC	cis	rs10971721	0.584	rs55857848	ENSG00000260947.1	RP11-384P7.7	7.64	1.15e-13	6.71e-11	0.58	0.32	Body mass index;	chr9:34121512	chr9:33697459~33700986:+
KIRC	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	7.64	1.15e-13	6.72e-11	0.47	0.32	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
KIRC	cis	rs10971721	0.584	rs72731226	ENSG00000260947.1	RP11-384P7.7	7.64	1.16e-13	6.75e-11	0.58	0.32	Body mass index;	chr9:34128832	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971944	ENSG00000260947.1	RP11-384P7.7	7.64	1.16e-13	6.75e-11	0.58	0.32	Body mass index;	chr9:34129008	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.631	rs74450404	ENSG00000260947.1	RP11-384P7.7	7.64	1.16e-13	6.75e-11	0.58	0.32	Body mass index;	chr9:34134666	chr9:33697459~33700986:+
KIRC	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	7.64	1.16e-13	6.75e-11	0.45	0.32	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
KIRC	cis	rs17801127	0.748	rs12989809	ENSG00000231969.1	AC144449.1	7.64	1.16e-13	6.78e-11	0.56	0.32	Liver enzyme levels (alanine transaminase);	chr2:149670312	chr2:149587196~149848233:+
KIRC	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-7.64	1.16e-13	6.78e-11	-0.34	-0.32	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
KIRC	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-7.64	1.16e-13	6.79e-11	-0.28	-0.32	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
KIRC	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	7.64	1.16e-13	6.8e-11	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
KIRC	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	7.64	1.16e-13	6.8e-11	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
KIRC	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	7.64	1.17e-13	6.84e-11	0.61	0.32	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	7.64	1.17e-13	6.84e-11	0.61	0.32	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
KIRC	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-7.64	1.17e-13	6.84e-11	-0.4	-0.32	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
KIRC	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-7.64	1.17e-13	6.84e-11	-0.4	-0.32	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
KIRC	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-7.64	1.17e-13	6.84e-11	-0.43	-0.32	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
KIRC	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	7.63	1.17e-13	6.85e-11	0.44	0.32	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	7.63	1.17e-13	6.85e-11	0.44	0.32	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	7.63	1.17e-13	6.85e-11	0.44	0.32	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
KIRC	cis	rs11018904	0.861	rs12786959	ENSG00000280385.1	AP000648.5	-7.63	1.17e-13	6.85e-11	-0.37	-0.32	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90193614~90198120:+
KIRC	cis	rs11018904	0.861	rs12787117	ENSG00000280385.1	AP000648.5	-7.63	1.17e-13	6.85e-11	-0.37	-0.32	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90193614~90198120:+
KIRC	cis	rs11018904	0.906	rs35129016	ENSG00000280385.1	AP000648.5	-7.63	1.17e-13	6.85e-11	-0.37	-0.32	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90193614~90198120:+
KIRC	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	7.63	1.18e-13	6.86e-11	0.3	0.32	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
KIRC	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-7.63	1.18e-13	6.87e-11	-0.35	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-7.63	1.18e-13	6.87e-11	-0.35	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
KIRC	cis	rs17772222	0.655	rs816072	ENSG00000222990.1	RNU4-22P	-7.63	1.18e-13	6.88e-11	-0.34	-0.32	Coronary artery calcification;	chr14:88484335	chr14:88513498~88513663:+
KIRC	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	7.63	1.18e-13	6.88e-11	0.4	0.32	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	7.63	1.18e-13	6.88e-11	0.4	0.32	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	7.63	1.18e-13	6.88e-11	0.4	0.32	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	7.63	1.18e-13	6.88e-11	0.4	0.32	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	7.63	1.18e-13	6.88e-11	0.4	0.32	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
KIRC	cis	rs3820928	0.874	rs10933165	ENSG00000212391.1	SNORA48	7.63	1.18e-13	6.9e-11	0.38	0.32	Pulmonary function;	chr2:227018932	chr2:226968989~226969122:-
KIRC	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	7.63	1.18e-13	6.9e-11	0.45	0.32	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	7.63	1.18e-13	6.9e-11	0.45	0.32	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
KIRC	cis	rs2486288	0.656	rs11637838	ENSG00000259433.2	CTD-2651B20.4	7.63	1.18e-13	6.9e-11	0.23	0.32	Glomerular filtration rate;	chr15:45258459	chr15:45330209~45332634:-
KIRC	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-7.63	1.19e-13	6.91e-11	-0.33	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
KIRC	cis	rs1528149	0.504	rs10227232	ENSG00000224683.1	RPL36AP29	-7.63	1.19e-13	6.91e-11	-0.4	-0.32	Sitting height ratio;	chr7:16138475	chr7:16208945~16209265:+
KIRC	cis	rs4819052	1	rs9984901	ENSG00000223768.1	LINC00205	-7.63	1.19e-13	6.91e-11	-0.35	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45293285~45297354:+
KIRC	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	7.63	1.19e-13	6.92e-11	0.41	0.32	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	7.63	1.19e-13	6.92e-11	0.41	0.32	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
KIRC	cis	rs7592578	0.766	rs62182885	ENSG00000272979.1	RP11-647K16.1	-7.63	1.19e-13	6.94e-11	-0.49	-0.32	Diastolic blood pressure;	chr2:190572298	chr2:190454092~190454521:-
KIRC	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	7.63	1.19e-13	6.96e-11	0.58	0.32	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	7.63	1.19e-13	6.96e-11	0.58	0.32	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	7.63	1.19e-13	6.96e-11	0.58	0.32	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
KIRC	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	7.63	1.19e-13	6.96e-11	0.42	0.32	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
KIRC	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	7.63	1.19e-13	6.97e-11	0.43	0.32	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
KIRC	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	7.63	1.2e-13	6.97e-11	0.4	0.32	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
KIRC	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	7.63	1.2e-13	6.99e-11	0.25	0.32	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	7.63	1.2e-13	6.99e-11	0.25	0.32	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
KIRC	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	7.63	1.2e-13	7.01e-11	0.43	0.32	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
KIRC	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-7.63	1.2e-13	7.01e-11	-0.26	-0.32	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
KIRC	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	7.63	1.2e-13	7.01e-11	0.4	0.32	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
KIRC	cis	rs4789693	0.546	rs7220204	ENSG00000265458.1	RP13-20L14.6	7.63	1.21e-13	7.03e-11	0.44	0.32	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82454273~82458521:-
KIRC	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	7.63	1.21e-13	7.03e-11	0.45	0.32	Depression;	chr6:28109824	chr6:28115628~28116551:+
KIRC	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	7.63	1.21e-13	7.04e-11	0.38	0.32	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
KIRC	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-7.63	1.21e-13	7.04e-11	-0.3	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
KIRC	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	7.63	1.21e-13	7.07e-11	0.44	0.32	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
KIRC	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.63	1.22e-13	7.09e-11	0.4	0.32	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
KIRC	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	7.63	1.22e-13	7.09e-11	0.61	0.32	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
KIRC	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	7.63	1.22e-13	7.1e-11	0.45	0.32	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
KIRC	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	7.63	1.22e-13	7.1e-11	0.62	0.32	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
KIRC	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-7.63	1.22e-13	7.1e-11	-0.39	-0.32	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
KIRC	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-7.63	1.22e-13	7.12e-11	-0.28	-0.32	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-7.63	1.22e-13	7.12e-11	-0.28	-0.32	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
KIRC	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-7.63	1.22e-13	7.13e-11	-0.39	-0.32	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
KIRC	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-7.63	1.23e-13	7.16e-11	-0.36	-0.32	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
KIRC	cis	rs950027	0.549	rs11070452	ENSG00000259433.2	CTD-2651B20.4	7.63	1.23e-13	7.17e-11	0.24	0.32	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45330209~45332634:-
KIRC	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	7.63	1.23e-13	7.17e-11	0.39	0.32	Height;	chr4:55479069	chr4:55387949~55388271:+
KIRC	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-7.63	1.24e-13	7.19e-11	-0.3	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
KIRC	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	7.63	1.24e-13	7.19e-11	0.44	0.32	Height;	chr6:109352852	chr6:109382795~109383666:+
KIRC	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	7.63	1.24e-13	7.2e-11	0.24	0.32	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
KIRC	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	7.63	1.24e-13	7.2e-11	0.61	0.32	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	7.63	1.24e-13	7.21e-11	0.52	0.32	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
KIRC	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	7.63	1.24e-13	7.22e-11	0.39	0.32	Height;	chr4:55515118	chr4:55387949~55388271:+
KIRC	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	7.63	1.24e-13	7.23e-11	0.39	0.32	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
KIRC	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	7.63	1.24e-13	7.23e-11	0.45	0.32	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	7.63	1.24e-13	7.23e-11	0.45	0.32	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
KIRC	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	7.63	1.24e-13	7.24e-11	0.59	0.32	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
KIRC	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	7.63	1.25e-13	7.25e-11	0.47	0.32	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
KIRC	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-7.63	1.25e-13	7.25e-11	-0.39	-0.32	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
KIRC	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	7.63	1.25e-13	7.26e-11	0.35	0.32	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
KIRC	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-7.63	1.25e-13	7.27e-11	-0.35	-0.32	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
KIRC	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	7.62	1.26e-13	7.31e-11	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
KIRC	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	7.62	1.26e-13	7.31e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
KIRC	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	7.62	1.26e-13	7.31e-11	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
KIRC	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	7.62	1.26e-13	7.33e-11	0.42	0.32	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
KIRC	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	7.62	1.26e-13	7.33e-11	0.42	0.32	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
KIRC	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-7.62	1.26e-13	7.33e-11	-0.35	-0.32	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
KIRC	cis	rs890448	0.726	rs2583396	ENSG00000254531.1	FLJ20021	-7.62	1.26e-13	7.34e-11	-0.33	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308621	chr4:101347780~101348883:+
KIRC	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	7.62	1.26e-13	7.34e-11	0.36	0.32	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
KIRC	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	7.62	1.27e-13	7.35e-11	0.38	0.32	Height;	chr4:55479339	chr4:55387949~55388271:+
KIRC	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-7.62	1.27e-13	7.35e-11	-0.32	-0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
KIRC	cis	rs7017914	0.967	rs4628281	ENSG00000254031.4	RP11-326E22.1	7.62	1.27e-13	7.35e-11	0.36	0.32	Bone mineral density;	chr8:70926929	chr8:71155457~71204223:+
KIRC	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	7.62	1.27e-13	7.35e-11	0.33	0.32	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
KIRC	cis	rs950027	0.62	rs872192	ENSG00000235390.4	CTD-2651B20.5	-7.62	1.27e-13	7.37e-11	-0.31	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45321077~45321692:-
KIRC	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
KIRC	cis	rs950027	0.549	rs2899375	ENSG00000259433.2	CTD-2651B20.4	7.62	1.27e-13	7.37e-11	0.24	0.32	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45330209~45332634:-
KIRC	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.27e-13	7.37e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
KIRC	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.62	1.27e-13	7.38e-11	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
KIRC	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-7.62	1.27e-13	7.38e-11	-0.31	-0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
KIRC	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	7.62	1.27e-13	7.39e-11	0.44	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
KIRC	cis	rs4660214	0.627	rs61779282	ENSG00000237624.1	OXCT2P1	7.62	1.27e-13	7.39e-11	0.59	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39514956~39516490:+
KIRC	cis	rs904251	0.704	rs2776873	ENSG00000227920.2	RP1-153P14.5	-7.62	1.28e-13	7.41e-11	-0.41	-0.32	Cognitive performance;	chr6:37515366	chr6:37545145~37550860:+
KIRC	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	7.62	1.29e-13	7.46e-11	0.28	0.32	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
KIRC	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	7.62	1.29e-13	7.49e-11	0.58	0.32	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
KIRC	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	7.62	1.29e-13	7.5e-11	0.46	0.32	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
KIRC	cis	rs755249	0.917	rs61779331	ENSG00000182109.6	RP11-69E11.4	7.62	1.3e-13	7.51e-11	0.28	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39522280~39546187:-
KIRC	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-7.62	1.3e-13	7.55e-11	-0.3	-0.32	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
KIRC	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-7.62	1.3e-13	7.55e-11	-0.33	-0.32	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
KIRC	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	7.62	1.3e-13	7.55e-11	0.4	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
KIRC	cis	rs11018904	0.906	rs7925507	ENSG00000280385.1	AP000648.5	-7.62	1.3e-13	7.56e-11	-0.36	-0.32	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90193614~90198120:+
KIRC	cis	rs10971721	0.584	rs10971940	ENSG00000260947.1	RP11-384P7.7	7.62	1.3e-13	7.56e-11	0.58	0.32	Body mass index;	chr9:34127213	chr9:33697459~33700986:+
KIRC	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	7.62	1.3e-13	7.57e-11	0.43	0.32	Height;	chr6:109357908	chr6:109382795~109383666:+
KIRC	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-7.62	1.31e-13	7.57e-11	-0.35	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
KIRC	cis	rs79040073	0.576	rs17477923	ENSG00000259531.2	RP11-295H24.3	7.62	1.31e-13	7.59e-11	0.39	0.32	Lung cancer in ever smokers;	chr15:49418988	chr15:49365124~49366685:-
KIRC	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-7.62	1.31e-13	7.6e-11	-0.42	-0.32	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
KIRC	cis	rs17772222	0.582	rs1288122	ENSG00000222990.1	RNU4-22P	-7.62	1.31e-13	7.6e-11	-0.34	-0.32	Coronary artery calcification;	chr14:88472736	chr14:88513498~88513663:+
KIRC	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.62	1.31e-13	7.61e-11	-0.33	-0.32	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
KIRC	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	7.62	1.31e-13	7.62e-11	0.44	0.32	Height;	chr6:109347085	chr6:109382795~109383666:+
KIRC	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	7.62	1.31e-13	7.62e-11	0.44	0.32	Height;	chr6:109347277	chr6:109382795~109383666:+
KIRC	cis	rs2486288	0.656	rs11632419	ENSG00000259433.2	CTD-2651B20.4	7.62	1.31e-13	7.62e-11	0.23	0.32	Glomerular filtration rate;	chr15:45265258	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs2271438	ENSG00000259433.2	CTD-2651B20.4	7.62	1.31e-13	7.62e-11	0.23	0.32	Glomerular filtration rate;	chr15:45265270	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11854365	ENSG00000259433.2	CTD-2651B20.4	7.62	1.31e-13	7.62e-11	0.23	0.32	Glomerular filtration rate;	chr15:45265885	chr15:45330209~45332634:-
KIRC	cis	rs7672749	0.73	rs7696460	ENSG00000249973.2	CHCHD2P7	7.62	1.32e-13	7.64e-11	0.67	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87855784	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs72877143	ENSG00000249973.2	CHCHD2P7	7.62	1.32e-13	7.64e-11	0.67	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87856263	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs66747117	ENSG00000249973.2	CHCHD2P7	7.62	1.32e-13	7.64e-11	0.67	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87857347	chr4:87785920~87786371:-
KIRC	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	7.62	1.32e-13	7.65e-11	0.44	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
KIRC	cis	rs72634501	0.574	rs111623477	ENSG00000237624.1	OXCT2P1	7.62	1.32e-13	7.66e-11	0.59	0.32	HDL cholesterol;	chr1:39345533	chr1:39514956~39516490:+
KIRC	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-7.62	1.32e-13	7.66e-11	-0.41	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-7.62	1.32e-13	7.67e-11	-0.36	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
KIRC	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	7.62	1.32e-13	7.67e-11	0.49	0.32	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
KIRC	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.33e-13	7.68e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.33e-13	7.68e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-7.62	1.33e-13	7.68e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
KIRC	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	7.62	1.33e-13	7.68e-11	0.31	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
KIRC	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	7.62	1.33e-13	7.68e-11	0.44	0.32	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	7.62	1.33e-13	7.68e-11	0.44	0.32	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
KIRC	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-7.62	1.33e-13	7.69e-11	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
KIRC	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-7.62	1.33e-13	7.69e-11	-0.38	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
KIRC	cis	rs3820928	0.874	rs10439363	ENSG00000212391.1	SNORA48	-7.62	1.33e-13	7.69e-11	-0.38	-0.32	Pulmonary function;	chr2:226950349	chr2:226968989~226969122:-
KIRC	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-7.62	1.33e-13	7.69e-11	-0.26	-0.32	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
KIRC	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-7.62	1.33e-13	7.71e-11	-0.69	-0.32	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
KIRC	cis	rs79040073	0.637	rs73398264	ENSG00000259531.2	RP11-295H24.3	7.62	1.33e-13	7.71e-11	0.39	0.32	Lung cancer in ever smokers;	chr15:49414220	chr15:49365124~49366685:-
KIRC	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	7.62	1.33e-13	7.72e-11	0.29	0.32	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
KIRC	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	7.62	1.34e-13	7.73e-11	0.47	0.32	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
KIRC	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-7.62	1.34e-13	7.74e-11	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
KIRC	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	7.62	1.34e-13	7.75e-11	0.39	0.32	Height;	chr4:55518776	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	7.62	1.34e-13	7.75e-11	0.39	0.32	Height;	chr4:55518922	chr4:55387949~55388271:+
KIRC	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.62	1.34e-13	7.75e-11	-0.33	-0.32	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	7.62	1.34e-13	7.76e-11	0.45	0.32	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
KIRC	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-7.62	1.34e-13	7.76e-11	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-7.62	1.34e-13	7.76e-11	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-7.62	1.35e-13	7.78e-11	-0.36	-0.32	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
KIRC	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-7.62	1.35e-13	7.79e-11	-0.34	-0.32	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
KIRC	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	7.62	1.35e-13	7.79e-11	0.41	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
KIRC	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	7.61	1.35e-13	7.81e-11	0.33	0.32	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
KIRC	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-7.61	1.35e-13	7.81e-11	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	7.61	1.35e-13	7.81e-11	0.45	0.32	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
KIRC	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-7.61	1.35e-13	7.82e-11	-0.34	-0.32	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
KIRC	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-7.61	1.36e-13	7.85e-11	-0.37	-0.32	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
KIRC	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-7.61	1.36e-13	7.86e-11	-0.35	-0.32	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
KIRC	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	7.61	1.36e-13	7.86e-11	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
KIRC	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	7.61	1.36e-13	7.87e-11	0.33	0.32	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
KIRC	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	7.61	1.36e-13	7.88e-11	0.5	0.32	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	7.61	1.36e-13	7.88e-11	0.5	0.32	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	7.61	1.36e-13	7.88e-11	0.5	0.32	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	7.61	1.36e-13	7.88e-11	0.5	0.32	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	7.61	1.36e-13	7.88e-11	0.5	0.32	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
KIRC	cis	rs7672749	0.73	rs7667813	ENSG00000249973.2	CHCHD2P7	7.61	1.36e-13	7.88e-11	0.68	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87862025	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs57195379	ENSG00000249973.2	CHCHD2P7	7.61	1.36e-13	7.88e-11	0.68	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87862860	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.643	rs72877193	ENSG00000249973.2	CHCHD2P7	7.61	1.36e-13	7.88e-11	0.68	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87863625	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.73	rs17013352	ENSG00000249973.2	CHCHD2P7	7.61	1.36e-13	7.88e-11	0.68	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87864677	chr4:87785920~87786371:-
KIRC	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-7.61	1.36e-13	7.89e-11	-0.3	-0.32	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
KIRC	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	7.61	1.37e-13	7.9e-11	0.65	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
KIRC	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	7.61	1.37e-13	7.91e-11	0.45	0.32	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
KIRC	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	7.61	1.37e-13	7.92e-11	0.41	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
KIRC	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-7.61	1.37e-13	7.92e-11	-0.4	-0.32	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
KIRC	cis	rs4356975	0.563	rs7657423	ENSG00000248763.2	RP13-644M16.5	7.61	1.37e-13	7.93e-11	0.41	0.32	Obesity-related traits;	chr4:69090196	chr4:69066395~69069888:+
KIRC	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-7.61	1.37e-13	7.94e-11	-0.26	-0.32	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
KIRC	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-7.61	1.37e-13	7.94e-11	-0.41	-0.32	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
KIRC	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.37e-13	7.94e-11	-0.33	-0.32	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
KIRC	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	7.61	1.38e-13	7.94e-11	0.37	0.32	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
KIRC	cis	rs4713118	0.539	rs200967	ENSG00000216901.1	AL022393.7	7.61	1.38e-13	7.94e-11	0.42	0.32	Parkinson's disease;	chr6:27894349	chr6:28176188~28176674:+
KIRC	cis	rs10971721	0.543	rs72731230	ENSG00000260947.1	RP11-384P7.7	7.61	1.38e-13	7.95e-11	0.58	0.32	Body mass index;	chr9:34133733	chr9:33697459~33700986:+
KIRC	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	7.61	1.38e-13	7.99e-11	0.36	0.32	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
KIRC	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	7.61	1.39e-13	8e-11	0.44	0.32	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
KIRC	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	7.61	1.39e-13	8.01e-11	0.32	0.32	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
KIRC	cis	rs2012796	0.785	rs61986597	ENSG00000270343.1	UNGP3	7.61	1.39e-13	8.03e-11	0.4	0.32	Night sleep phenotypes;	chr14:81386763	chr14:81259565~81260239:-
KIRC	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	7.61	1.39e-13	8.03e-11	0.41	0.32	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
KIRC	cis	rs7017914	0.905	rs1353058	ENSG00000254031.4	RP11-326E22.1	7.61	1.39e-13	8.04e-11	0.35	0.32	Bone mineral density;	chr8:71009783	chr8:71155457~71204223:+
KIRC	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	7.61	1.39e-13	8.04e-11	0.2	0.32	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	7.61	1.39e-13	8.04e-11	0.22	0.32	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
KIRC	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	7.61	1.39e-13	8.04e-11	0.36	0.32	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
KIRC	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-7.61	1.4e-13	8.06e-11	-0.45	-0.32	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
KIRC	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	7.61	1.4e-13	8.06e-11	0.66	0.32	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	7.61	1.4e-13	8.06e-11	0.66	0.32	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	7.61	1.4e-13	8.06e-11	0.66	0.32	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	7.61	1.4e-13	8.06e-11	0.66	0.32	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
KIRC	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-7.61	1.4e-13	8.08e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-7.61	1.4e-13	8.08e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
KIRC	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	7.61	1.4e-13	8.09e-11	0.33	0.32	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
KIRC	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-7.61	1.4e-13	8.09e-11	-0.36	-0.32	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-7.61	1.4e-13	8.09e-11	-0.36	-0.32	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-7.61	1.4e-13	8.09e-11	-0.36	-0.32	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
KIRC	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	7.61	1.4e-13	8.09e-11	0.47	0.32	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	7.61	1.4e-13	8.09e-11	0.47	0.32	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
KIRC	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	7.61	1.4e-13	8.1e-11	0.41	0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
KIRC	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	7.61	1.41e-13	8.12e-11	0.43	0.32	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
KIRC	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	7.61	1.41e-13	8.13e-11	0.33	0.32	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
KIRC	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	7.61	1.41e-13	8.15e-11	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
KIRC	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-7.61	1.42e-13	8.16e-11	-0.43	-0.32	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
KIRC	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	7.61	1.42e-13	8.17e-11	0.41	0.32	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
KIRC	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-7.61	1.42e-13	8.17e-11	-0.32	-0.32	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000251284.2	RP13-644M16.1	-7.61	1.42e-13	8.18e-11	-0.39	-0.32	Obesity-related traits;	chr4:69079224	chr4:69125274~69126451:+
KIRC	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.61	1.42e-13	8.18e-11	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
KIRC	cis	rs2281636	0.66	rs11190184	ENSG00000233690.1	EBAG9P1	7.61	1.42e-13	8.18e-11	0.36	0.32	Obesity-related traits;	chr10:99608442	chr10:99697407~99697949:-
KIRC	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	7.61	1.42e-13	8.18e-11	0.4	0.32	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	7.61	1.42e-13	8.18e-11	0.4	0.32	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	7.61	1.42e-13	8.18e-11	0.4	0.32	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
KIRC	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-7.61	1.42e-13	8.19e-11	-0.35	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-7.61	1.42e-13	8.19e-11	-0.36	-0.32	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
KIRC	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-7.61	1.42e-13	8.2e-11	-0.37	-0.32	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
KIRC	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-7.61	1.42e-13	8.2e-11	-0.34	-0.32	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
KIRC	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	7.61	1.42e-13	8.21e-11	0.45	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
KIRC	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28147378	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28147406	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28148143	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28149979	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28151096	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28152885	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-7.61	1.42e-13	8.21e-11	-0.44	-0.32	Depression;	chr6:28153120	chr6:28115628~28116551:+
KIRC	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	7.61	1.42e-13	8.21e-11	0.46	0.32	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
KIRC	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-7.61	1.43e-13	8.21e-11	-0.4	-0.32	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
KIRC	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	7.61	1.43e-13	8.22e-11	0.61	0.32	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
KIRC	cis	rs3820928	0.845	rs7570869	ENSG00000212391.1	SNORA48	-7.61	1.43e-13	8.23e-11	-0.37	-0.32	Pulmonary function;	chr2:227014102	chr2:226968989~226969122:-
KIRC	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	7.61	1.43e-13	8.23e-11	0.21	0.32	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
KIRC	cis	rs6600671	1	rs2319969	ENSG00000227082.1	CH17-437K3.1	-7.61	1.43e-13	8.24e-11	-0.36	-0.32	Hip geometry;	chr1:121465481	chr1:121396754~121463129:+
KIRC	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	7.61	1.44e-13	8.27e-11	0.73	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
KIRC	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-7.61	1.44e-13	8.29e-11	-0.28	-0.32	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
KIRC	cis	rs7592578	0.766	rs35818159	ENSG00000272979.1	RP11-647K16.1	-7.61	1.44e-13	8.3e-11	-0.49	-0.32	Diastolic blood pressure;	chr2:190544890	chr2:190454092~190454521:-
KIRC	cis	rs79040073	0.532	rs73398284	ENSG00000259531.2	RP11-295H24.3	7.61	1.44e-13	8.31e-11	0.41	0.32	Lung cancer in ever smokers;	chr15:49422203	chr15:49365124~49366685:-
KIRC	cis	rs4789693	0.544	rs4789770	ENSG00000265458.1	RP13-20L14.6	7.61	1.44e-13	8.31e-11	0.44	0.32	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82454273~82458521:-
KIRC	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	7.6	1.44e-13	8.32e-11	0.44	0.32	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
KIRC	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	7.6	1.45e-13	8.36e-11	0.37	0.32	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
KIRC	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-7.6	1.45e-13	8.36e-11	-0.37	-0.32	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-7.6	1.46e-13	8.38e-11	-0.32	-0.32	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
KIRC	cis	rs13423976	0.631	rs2373405	ENSG00000231367.4	AC016995.3	7.6	1.46e-13	8.39e-11	0.42	0.32	Gut microbiome composition (summer);	chr2:38513072	chr2:38406719~38515740:-
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000198277.6	RP11-468N14.09	7.6	1.46e-13	8.4e-11	0.41	0.32	Obesity-related traits;	chr4:69101657	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000198277.6	RP11-468N14.09	7.6	1.46e-13	8.4e-11	0.41	0.32	Obesity-related traits;	chr4:69102209	chr4:68914928~68924741:-
KIRC	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	7.6	1.46e-13	8.4e-11	0.44	0.32	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	7.6	1.46e-13	8.4e-11	0.44	0.32	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	7.6	1.46e-13	8.4e-11	0.44	0.32	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	7.6	1.46e-13	8.4e-11	0.44	0.32	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	7.6	1.46e-13	8.4e-11	0.44	0.32	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
KIRC	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-7.6	1.47e-13	8.43e-11	-0.3	-0.32	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
KIRC	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	7.6	1.47e-13	8.44e-11	0.42	0.32	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
KIRC	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-7.6	1.47e-13	8.44e-11	-0.27	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
KIRC	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.6	1.47e-13	8.46e-11	-0.34	-0.32	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	7.6	1.47e-13	8.47e-11	0.4	0.32	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
KIRC	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	7.6	1.47e-13	8.47e-11	0.45	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
KIRC	cis	rs7017914	0.905	rs2639898	ENSG00000254031.4	RP11-326E22.1	7.6	1.47e-13	8.48e-11	0.35	0.32	Bone mineral density;	chr8:71008075	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.84	rs2732099	ENSG00000254031.4	RP11-326E22.1	7.6	1.47e-13	8.48e-11	0.35	0.32	Bone mineral density;	chr8:71008815	chr8:71155457~71204223:+
KIRC	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	7.6	1.48e-13	8.48e-11	0.59	0.32	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
KIRC	cis	rs4356975	0.509	rs4309908	ENSG00000248763.2	RP13-644M16.5	-7.6	1.48e-13	8.49e-11	-0.42	-0.32	Obesity-related traits;	chr4:69086022	chr4:69066395~69069888:+
KIRC	cis	rs3820928	0.839	rs58580037	ENSG00000212391.1	SNORA48	-7.6	1.48e-13	8.51e-11	-0.37	-0.32	Pulmonary function;	chr2:227011558	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs10188770	ENSG00000212391.1	SNORA48	-7.6	1.48e-13	8.51e-11	-0.37	-0.32	Pulmonary function;	chr2:227012321	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-7.6	1.48e-13	8.51e-11	-0.33	-0.32	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
KIRC	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	7.6	1.48e-13	8.52e-11	0.49	0.32	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
KIRC	cis	rs2018683	1	rs4719963	ENSG00000228421.2	AC005013.5	-7.6	1.48e-13	8.53e-11	-0.33	-0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28957667~28959345:+
KIRC	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-7.6	1.48e-13	8.53e-11	-0.38	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
KIRC	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	7.6	1.49e-13	8.54e-11	0.39	0.32	Height;	chr4:55524246	chr4:55387949~55388271:+
KIRC	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-7.6	1.49e-13	8.55e-11	-0.35	-0.32	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
KIRC	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-7.6	1.49e-13	8.56e-11	-0.36	-0.32	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
KIRC	cis	rs17772222	0.682	rs1152377	ENSG00000222990.1	RNU4-22P	-7.6	1.49e-13	8.57e-11	-0.34	-0.32	Coronary artery calcification;	chr14:88496243	chr14:88513498~88513663:+
KIRC	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	7.6	1.49e-13	8.57e-11	0.4	0.32	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
KIRC	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.57e-11	0.45	0.32	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.57e-11	0.45	0.32	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.57e-11	0.45	0.32	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.57e-11	0.45	0.32	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.57e-11	0.45	0.32	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	7.6	1.49e-13	8.58e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	7.6	1.49e-13	8.58e-11	0.44	0.32	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
KIRC	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	7.6	1.5e-13	8.6e-11	0.38	0.32	Height;	chr4:55487368	chr4:55387949~55388271:+
KIRC	cis	rs897984	0.762	rs7204459	ENSG00000260911.2	RP11-196G11.2	-7.6	1.5e-13	8.61e-11	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30972891	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs4889604	ENSG00000260911.2	RP11-196G11.2	-7.6	1.5e-13	8.62e-11	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30974673	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs12931046	ENSG00000260911.2	RP11-196G11.2	-7.6	1.5e-13	8.62e-11	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30975823	chr16:31043150~31049868:+
KIRC	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-7.6	1.5e-13	8.63e-11	-0.4	-0.32	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
KIRC	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	7.6	1.5e-13	8.64e-11	0.25	0.32	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
KIRC	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-7.6	1.5e-13	8.64e-11	-0.39	-0.32	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
KIRC	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-7.6	1.51e-13	8.65e-11	-0.29	-0.32	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
KIRC	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	7.6	1.51e-13	8.66e-11	0.41	0.32	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	7.6	1.51e-13	8.66e-11	0.41	0.32	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
KIRC	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-7.6	1.51e-13	8.68e-11	-0.37	-0.32	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
KIRC	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-7.6	1.51e-13	8.69e-11	-0.3	-0.32	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
KIRC	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	7.6	1.52e-13	8.7e-11	0.38	0.32	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
KIRC	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-7.6	1.52e-13	8.73e-11	-0.37	-0.32	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-7.6	1.52e-13	8.73e-11	-0.37	-0.32	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-7.6	1.52e-13	8.73e-11	-0.37	-0.32	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
KIRC	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-7.6	1.52e-13	8.73e-11	-0.5	-0.32	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
KIRC	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	7.6	1.52e-13	8.74e-11	0.39	0.32	Height;	chr4:55520278	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	7.6	1.52e-13	8.74e-11	0.39	0.32	Height;	chr4:55523835	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	7.6	1.52e-13	8.74e-11	0.39	0.32	Height;	chr4:55525589	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	7.6	1.52e-13	8.74e-11	0.39	0.32	Height;	chr4:55525781	chr4:55387949~55388271:+
KIRC	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	7.6	1.53e-13	8.77e-11	0.47	0.32	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
KIRC	cis	rs10129255	0.576	rs2157616	ENSG00000223648.3	IGHV3-64	7.6	1.53e-13	8.77e-11	0.28	0.32	Kawasaki disease;	chr14:106767802	chr14:106643132~106658258:-
KIRC	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-7.6	1.53e-13	8.78e-11	-0.36	-0.32	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
KIRC	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	7.6	1.53e-13	8.8e-11	0.44	0.32	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
KIRC	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-7.6	1.54e-13	8.86e-11	-0.38	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
KIRC	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-7.6	1.54e-13	8.86e-11	-0.35	-0.32	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
KIRC	cis	rs3820928	0.874	rs4675133	ENSG00000212391.1	SNORA48	7.6	1.55e-13	8.86e-11	0.39	0.32	Pulmonary function;	chr2:226978294	chr2:226968989~226969122:-
KIRC	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-7.6	1.55e-13	8.88e-11	-0.36	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-7.6	1.55e-13	8.88e-11	-0.36	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
KIRC	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-7.59	1.55e-13	8.89e-11	-0.37	-0.32	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
KIRC	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	7.59	1.55e-13	8.91e-11	0.45	0.32	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
KIRC	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	7.59	1.56e-13	8.94e-11	0.39	0.32	Height;	chr4:55515292	chr4:55387949~55388271:+
KIRC	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	7.59	1.56e-13	8.94e-11	0.41	0.32	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
KIRC	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	7.59	1.56e-13	8.95e-11	0.37	0.32	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
KIRC	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	7.59	1.56e-13	8.95e-11	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
KIRC	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-7.59	1.56e-13	8.96e-11	-0.36	-0.32	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
KIRC	cis	rs3820928	0.904	rs2396432	ENSG00000212391.1	SNORA48	-7.59	1.56e-13	8.96e-11	-0.38	-0.32	Pulmonary function;	chr2:226901175	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.904	rs2894623	ENSG00000212391.1	SNORA48	-7.59	1.56e-13	8.96e-11	-0.38	-0.32	Pulmonary function;	chr2:226901396	chr2:226968989~226969122:-
KIRC	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-7.59	1.56e-13	8.97e-11	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
KIRC	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
KIRC	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	7.59	1.56e-13	8.97e-11	0.45	0.32	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
KIRC	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-7.59	1.57e-13	8.97e-11	-0.4	-0.32	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
KIRC	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-7.59	1.57e-13	8.97e-11	-0.42	-0.32	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
KIRC	cis	rs7017914	0.905	rs2732104	ENSG00000254031.4	RP11-326E22.1	7.59	1.57e-13	8.98e-11	0.35	0.32	Bone mineral density;	chr8:71011284	chr8:71155457~71204223:+
KIRC	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-7.59	1.57e-13	8.99e-11	-0.3	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
KIRC	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	7.59	1.57e-13	8.99e-11	0.44	0.32	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
KIRC	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	7.59	1.57e-13	9e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
KIRC	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-7.59	1.57e-13	9e-11	-0.37	-0.32	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
KIRC	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-7.59	1.57e-13	9.02e-11	-0.43	-0.32	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
KIRC	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	7.59	1.57e-13	9.02e-11	0.39	0.32	Height;	chr4:55531150	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	7.59	1.57e-13	9.02e-11	0.39	0.32	Height;	chr4:55531218	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	7.59	1.57e-13	9.02e-11	0.39	0.32	Height;	chr4:55531811	chr4:55387949~55388271:+
KIRC	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	7.59	1.57e-13	9.02e-11	0.24	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
KIRC	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	7.59	1.57e-13	9.02e-11	0.24	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
KIRC	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-7.59	1.58e-13	9.02e-11	-0.4	-0.32	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
KIRC	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	7.59	1.58e-13	9.03e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	7.59	1.58e-13	9.03e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	7.59	1.58e-13	9.03e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	7.59	1.58e-13	9.03e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
KIRC	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	7.59	1.58e-13	9.03e-11	0.65	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
KIRC	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	7.59	1.58e-13	9.05e-11	0.33	0.32	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
KIRC	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	7.59	1.59e-13	9.08e-11	0.49	0.32	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
KIRC	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	7.59	1.59e-13	9.08e-11	0.49	0.32	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
KIRC	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-7.59	1.59e-13	9.08e-11	-0.42	-0.32	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
KIRC	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	7.59	1.59e-13	9.09e-11	0.44	0.32	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	7.59	1.6e-13	9.14e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
KIRC	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	7.59	1.6e-13	9.15e-11	0.39	0.32	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
KIRC	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	7.59	1.6e-13	9.16e-11	0.5	0.32	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
KIRC	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	7.59	1.6e-13	9.17e-11	0.45	0.32	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
KIRC	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	7.59	1.61e-13	9.19e-11	0.34	0.32	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
KIRC	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-7.59	1.61e-13	9.19e-11	-0.39	-0.32	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
KIRC	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.59	1.61e-13	9.2e-11	-0.35	-0.32	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
KIRC	cis	rs3820928	0.967	rs16822905	ENSG00000212391.1	SNORA48	-7.59	1.61e-13	9.2e-11	-0.38	-0.32	Pulmonary function;	chr2:226906011	chr2:226968989~226969122:-
KIRC	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	7.59	1.61e-13	9.23e-11	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
KIRC	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	7.59	1.61e-13	9.23e-11	0.42	0.32	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
KIRC	cis	rs897984	0.76	rs11076	ENSG00000260911.2	RP11-196G11.2	-7.59	1.61e-13	9.24e-11	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30984207	chr16:31043150~31049868:+
KIRC	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-7.59	1.61e-13	9.24e-11	-0.37	-0.32	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
KIRC	cis	rs10971721	0.643	rs41315997	ENSG00000281128.1	PTENP1-AS	7.59	1.61e-13	9.24e-11	0.72	0.32	Body mass index;	chr9:33798840	chr9:33677268~33688011:+
KIRC	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-7.59	1.62e-13	9.24e-11	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-7.59	1.62e-13	9.24e-11	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
KIRC	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	7.59	1.62e-13	9.24e-11	0.45	0.32	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
KIRC	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	7.59	1.62e-13	9.25e-11	0.39	0.32	Height;	chr4:55526514	chr4:55387949~55388271:+
KIRC	cis	rs2486288	0.656	rs9921025	ENSG00000259433.2	CTD-2651B20.4	7.59	1.62e-13	9.26e-11	0.23	0.32	Glomerular filtration rate;	chr15:45254404	chr15:45330209~45332634:-
KIRC	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	7.59	1.62e-13	9.26e-11	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	7.59	1.62e-13	9.27e-11	0.39	0.32	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-7.59	1.62e-13	9.27e-11	-0.31	-0.32	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
KIRC	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-7.59	1.62e-13	9.28e-11	-0.36	-0.32	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-7.59	1.62e-13	9.28e-11	-0.36	-0.32	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
KIRC	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	7.59	1.62e-13	9.28e-11	0.4	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
KIRC	cis	rs13434995	0.513	rs4865006	ENSG00000249700.7	SRD5A3-AS1	7.59	1.63e-13	9.3e-11	0.32	0.32	Adiponectin levels;	chr4:55526112	chr4:55363971~55395847:-
KIRC	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-7.59	1.63e-13	9.31e-11	-0.46	-0.32	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
KIRC	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	7.59	1.63e-13	9.31e-11	0.31	0.32	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
KIRC	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	7.59	1.63e-13	9.33e-11	0.45	0.32	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
KIRC	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	7.59	1.63e-13	9.33e-11	0.38	0.32	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
KIRC	cis	rs17772222	0.655	rs1152376	ENSG00000222990.1	RNU4-22P	-7.59	1.63e-13	9.33e-11	-0.34	-0.32	Coronary artery calcification;	chr14:88495121	chr14:88513498~88513663:+
KIRC	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	7.59	1.63e-13	9.34e-11	0.39	0.32	Height;	chr4:55570311	chr4:55387949~55388271:+
KIRC	cis	rs925255	0.81	rs2048240	ENSG00000270210.1	RP11-373D23.3	7.59	1.63e-13	9.34e-11	0.32	0.32	Inflammatory bowel disease;Crohn's disease;	chr2:28417460	chr2:28425945~28426719:+
KIRC	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-7.59	1.64e-13	9.36e-11	-0.41	-0.32	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
KIRC	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	7.59	1.64e-13	9.37e-11	0.45	0.32	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	7.59	1.64e-13	9.4e-11	0.44	0.32	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
KIRC	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-7.59	1.65e-13	9.42e-11	-0.36	-0.32	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
KIRC	cis	rs6600671	0.692	rs11249430	ENSG00000227082.1	CH17-437K3.1	-7.59	1.65e-13	9.42e-11	-0.38	-0.32	Hip geometry;	chr1:121547115	chr1:121396754~121463129:+
KIRC	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	7.59	1.65e-13	9.43e-11	0.45	0.32	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
KIRC	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-7.59	1.65e-13	9.45e-11	-0.25	-0.32	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-7.59	1.65e-13	9.45e-11	-0.25	-0.32	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-7.59	1.65e-13	9.45e-11	-0.25	-0.32	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-7.59	1.65e-13	9.45e-11	-0.25	-0.32	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-7.59	1.65e-13	9.45e-11	-0.25	-0.32	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
KIRC	cis	rs11018904	0.906	rs36177012	ENSG00000280385.1	AP000648.5	-7.59	1.66e-13	9.47e-11	-0.36	-0.32	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90193614~90198120:+
KIRC	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	7.59	1.66e-13	9.47e-11	0.35	0.32	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
KIRC	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	7.58	1.66e-13	9.47e-11	0.4	0.32	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
KIRC	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	7.58	1.66e-13	9.48e-11	0.35	0.32	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
KIRC	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-7.58	1.66e-13	9.49e-11	-0.22	-0.32	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
KIRC	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-7.58	1.66e-13	9.49e-11	-0.3	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
KIRC	cis	rs3820928	0.845	rs13419076	ENSG00000212391.1	SNORA48	-7.58	1.66e-13	9.5e-11	-0.37	-0.32	Pulmonary function;	chr2:227008312	chr2:226968989~226969122:-
KIRC	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-7.58	1.67e-13	9.52e-11	-0.44	-0.32	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
KIRC	cis	rs2486288	0.656	rs11637838	ENSG00000235390.4	CTD-2651B20.5	7.58	1.67e-13	9.53e-11	0.3	0.32	Glomerular filtration rate;	chr15:45258459	chr15:45321077~45321692:-
KIRC	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	7.58	1.67e-13	9.55e-11	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-7.58	1.67e-13	9.55e-11	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
KIRC	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-7.58	1.67e-13	9.56e-11	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
KIRC	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	7.58	1.68e-13	9.58e-11	0.46	0.32	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
KIRC	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-7.58	1.68e-13	9.58e-11	-0.36	-0.32	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
KIRC	cis	rs4356975	0.522	rs7679184	ENSG00000250696.4	RP11-704M14.1	7.58	1.68e-13	9.59e-11	0.34	0.32	Obesity-related traits;	chr4:69100212	chr4:69182100~69216766:+
KIRC	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	7.58	1.68e-13	9.6e-11	0.46	0.32	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
KIRC	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	7.58	1.68e-13	9.6e-11	0.23	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
KIRC	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-7.58	1.68e-13	9.6e-11	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
KIRC	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	7.58	1.68e-13	9.61e-11	0.28	0.32	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
KIRC	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-7.58	1.69e-13	9.62e-11	-0.43	-0.32	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
KIRC	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-7.58	1.69e-13	9.64e-11	-0.32	-0.32	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
KIRC	cis	rs1062177	0.502	rs10463321	ENSG00000253921.1	CTB-113P19.3	-7.58	1.69e-13	9.65e-11	-0.46	-0.32	Preschool internalizing problems;	chr5:151944344	chr5:151753992~151767247:+
KIRC	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	7.58	1.7e-13	9.68e-11	0.44	0.32	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	7.58	1.7e-13	9.68e-11	0.44	0.32	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	7.58	1.7e-13	9.68e-11	0.44	0.32	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
KIRC	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.7e-13	9.69e-11	-0.32	-0.32	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
KIRC	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	7.58	1.7e-13	9.71e-11	0.57	0.32	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
KIRC	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-7.58	1.7e-13	9.71e-11	-0.47	-0.32	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
KIRC	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	7.58	1.7e-13	9.72e-11	0.39	0.32	Height;	chr4:55425312	chr4:55387949~55388271:+
KIRC	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-7.58	1.7e-13	9.72e-11	-0.37	-0.32	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
KIRC	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-7.58	1.7e-13	9.72e-11	-0.36	-0.32	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	7.58	1.7e-13	9.72e-11	0.4	0.32	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	7.58	1.7e-13	9.72e-11	0.4	0.32	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	7.58	1.71e-13	9.74e-11	0.4	0.32	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
KIRC	cis	rs10971721	0.584	rs12375716	ENSG00000260947.1	RP11-384P7.7	7.58	1.71e-13	9.76e-11	0.57	0.32	Body mass index;	chr9:34100034	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs12379730	ENSG00000260947.1	RP11-384P7.7	7.58	1.71e-13	9.76e-11	0.57	0.32	Body mass index;	chr9:34100072	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs1378	ENSG00000260947.1	RP11-384P7.7	7.58	1.71e-13	9.76e-11	0.57	0.32	Body mass index;	chr9:34107506	chr9:33697459~33700986:+
KIRC	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-7.58	1.71e-13	9.78e-11	-0.37	-0.32	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
KIRC	cis	rs6600671	0.693	rs1853731	ENSG00000227082.1	CH17-437K3.1	-7.58	1.71e-13	9.78e-11	-0.38	-0.32	Hip geometry;	chr1:121510262	chr1:121396754~121463129:+
KIRC	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-7.58	1.71e-13	9.78e-11	-0.37	-0.32	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-7.58	1.71e-13	9.78e-11	-0.37	-0.32	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-7.58	1.71e-13	9.78e-11	-0.37	-0.32	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-7.58	1.71e-13	9.78e-11	-0.37	-0.32	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
KIRC	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	7.58	1.72e-13	9.78e-11	0.39	0.32	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
KIRC	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-7.58	1.72e-13	9.78e-11	-0.39	-0.32	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
KIRC	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	7.58	1.72e-13	9.79e-11	0.35	0.32	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
KIRC	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-7.58	1.72e-13	9.8e-11	-0.37	-0.32	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
KIRC	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.58	1.72e-13	9.8e-11	0.24	0.32	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
KIRC	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	7.58	1.73e-13	9.83e-11	0.43	0.32	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
KIRC	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-7.58	1.73e-13	9.86e-11	-0.41	-0.32	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
KIRC	cis	rs58873874	0.737	rs78565801	ENSG00000251405.2	CTB-109A12.1	7.58	1.73e-13	9.86e-11	0.6	0.32	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157362615~157460078:-
KIRC	cis	rs58873874	0.737	rs79951742	ENSG00000251405.2	CTB-109A12.1	7.58	1.73e-13	9.86e-11	0.6	0.32	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157362615~157460078:-
KIRC	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	7.58	1.73e-13	9.87e-11	0.25	0.32	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
KIRC	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	7.58	1.73e-13	9.87e-11	0.25	0.32	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
KIRC	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.73e-13	9.88e-11	-0.32	-0.32	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-7.58	1.74e-13	9.89e-11	-0.34	-0.32	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
KIRC	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	7.58	1.74e-13	9.89e-11	0.38	0.32	Height;	chr4:55479996	chr4:55387949~55388271:+
KIRC	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-7.58	1.74e-13	9.9e-11	-0.3	-0.32	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
KIRC	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	7.58	1.74e-13	9.93e-11	0.32	0.32	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
KIRC	cis	rs10971721	0.584	rs72731216	ENSG00000260947.1	RP11-384P7.7	7.58	1.74e-13	9.93e-11	0.57	0.32	Body mass index;	chr9:34115066	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971933	ENSG00000260947.1	RP11-384P7.7	7.58	1.74e-13	9.93e-11	0.57	0.32	Body mass index;	chr9:34117073	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971935	ENSG00000260947.1	RP11-384P7.7	7.58	1.74e-13	9.93e-11	0.57	0.32	Body mass index;	chr9:34118147	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs10971936	ENSG00000260947.1	RP11-384P7.7	7.58	1.74e-13	9.93e-11	0.57	0.32	Body mass index;	chr9:34118988	chr9:33697459~33700986:+
KIRC	cis	rs755249	0.727	rs12028034	ENSG00000182109.6	RP11-69E11.4	-7.58	1.74e-13	9.93e-11	-0.25	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39522280~39546187:-
KIRC	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	7.58	1.75e-13	9.95e-11	0.44	0.32	Height;	chr6:109352730	chr6:109382795~109383666:+
KIRC	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-7.58	1.75e-13	9.97e-11	-0.39	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
KIRC	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	7.58	1.76e-13	9.99e-11	0.44	0.32	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
KIRC	cis	rs6479901	0.793	rs4450077	ENSG00000232075.1	MRPL35P2	-7.58	1.76e-13	1e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-7.58	1.76e-13	1e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
KIRC	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	7.58	1.76e-13	1e-10	0.37	0.32	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
KIRC	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	7.58	1.76e-13	1e-10	0.4	0.32	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	7.58	1.76e-13	1e-10	0.4	0.32	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	7.58	1.76e-13	1e-10	0.4	0.32	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
KIRC	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	7.58	1.76e-13	1e-10	0.29	0.32	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
KIRC	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	7.58	1.77e-13	1.01e-10	0.45	0.32	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
KIRC	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	7.58	1.77e-13	1.01e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
KIRC	cis	rs4072705	0.967	rs10818985	ENSG00000224020.1	MIR181A2HG	-7.58	1.77e-13	1.01e-10	-0.32	-0.32	Menarche (age at onset);	chr9:124688292	chr9:124658467~124698631:+
KIRC	cis	rs10276381	0.786	rs10255700	ENSG00000234336.5	JAZF1-AS1	-7.58	1.77e-13	1.01e-10	-0.58	-0.32	Crohn's disease;	chr7:28180609	chr7:28180322~28243917:+
KIRC	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	7.58	1.77e-13	1.01e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
KIRC	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-7.58	1.77e-13	1.01e-10	-0.37	-0.32	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-7.58	1.77e-13	1.01e-10	-0.37	-0.32	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
KIRC	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-7.58	1.77e-13	1.01e-10	-0.43	-0.32	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
KIRC	cis	rs10971721	0.584	rs72731212	ENSG00000260947.1	RP11-384P7.7	7.58	1.77e-13	1.01e-10	0.57	0.32	Body mass index;	chr9:34109710	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs12376939	ENSG00000260947.1	RP11-384P7.7	7.58	1.77e-13	1.01e-10	0.57	0.32	Body mass index;	chr9:34110139	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs72731214	ENSG00000260947.1	RP11-384P7.7	7.58	1.77e-13	1.01e-10	0.57	0.32	Body mass index;	chr9:34113019	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs117997985	ENSG00000260947.1	RP11-384P7.7	7.58	1.77e-13	1.01e-10	0.57	0.32	Body mass index;	chr9:34113176	chr9:33697459~33700986:+
KIRC	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	7.58	1.78e-13	1.01e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
KIRC	cis	rs7592578	0.771	rs62181034	ENSG00000272979.1	RP11-647K16.1	-7.58	1.78e-13	1.01e-10	-0.46	-0.32	Diastolic blood pressure;	chr2:190490237	chr2:190454092~190454521:-
KIRC	cis	rs10971721	0.554	rs55917897	ENSG00000281128.1	PTENP1-AS	7.58	1.78e-13	1.01e-10	0.72	0.32	Body mass index;	chr9:33795952	chr9:33677268~33688011:+
KIRC	cis	rs10971721	0.643	rs12378415	ENSG00000281128.1	PTENP1-AS	7.58	1.78e-13	1.01e-10	0.72	0.32	Body mass index;	chr9:33797335	chr9:33677268~33688011:+
KIRC	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	7.57	1.78e-13	1.01e-10	0.44	0.32	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	7.57	1.78e-13	1.01e-10	0.44	0.32	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
KIRC	cis	rs9388451	0.874	rs9398787	ENSG00000237742.5	RP11-624M8.1	-7.57	1.78e-13	1.01e-10	-0.37	-0.32	Brugada syndrome;	chr6:125769462	chr6:125578558~125749190:-
KIRC	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	7.57	1.78e-13	1.01e-10	0.25	0.32	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	7.57	1.78e-13	1.01e-10	0.25	0.32	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
KIRC	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	7.57	1.79e-13	1.01e-10	0.54	0.32	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
KIRC	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-7.57	1.79e-13	1.02e-10	-0.4	-0.32	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-7.57	1.79e-13	1.02e-10	-0.4	-0.32	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
KIRC	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-7.57	1.79e-13	1.02e-10	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
KIRC	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-7.57	1.79e-13	1.02e-10	-0.37	-0.32	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
KIRC	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.57	1.79e-13	1.02e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
KIRC	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	7.57	1.79e-13	1.02e-10	0.33	0.32	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
KIRC	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-7.57	1.8e-13	1.02e-10	-0.46	-0.32	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
KIRC	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-7.57	1.8e-13	1.02e-10	-0.28	-0.32	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
KIRC	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	7.57	1.8e-13	1.02e-10	0.4	0.32	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
KIRC	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-7.57	1.81e-13	1.03e-10	-0.39	-0.32	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
KIRC	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	7.57	1.81e-13	1.03e-10	0.45	0.32	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs62309729	ENSG00000249700.7	SRD5A3-AS1	-7.57	1.81e-13	1.03e-10	-0.33	-0.32	Adiponectin levels;	chr4:55536679	chr4:55363971~55395847:-
KIRC	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	7.57	1.81e-13	1.03e-10	0.41	0.32	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
KIRC	cis	rs11018904	0.906	rs61903722	ENSG00000280385.1	AP000648.5	-7.57	1.82e-13	1.03e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90193614~90198120:+
KIRC	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	7.57	1.82e-13	1.03e-10	0.35	0.32	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
KIRC	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	7.57	1.82e-13	1.03e-10	0.5	0.32	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
KIRC	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	7.57	1.83e-13	1.04e-10	0.25	0.32	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
KIRC	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-7.57	1.84e-13	1.04e-10	-0.35	-0.32	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
KIRC	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-7.57	1.84e-13	1.04e-10	-0.3	-0.32	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
KIRC	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	7.57	1.84e-13	1.04e-10	0.25	0.32	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
KIRC	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	7.57	1.84e-13	1.04e-10	0.41	0.32	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
KIRC	cis	rs7176527	0.848	rs17600128	ENSG00000188388.10	GOLGA6L3	7.57	1.84e-13	1.04e-10	0.44	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:85240472~85247170:+
KIRC	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	7.57	1.84e-13	1.04e-10	0.25	0.32	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
KIRC	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-7.57	1.85e-13	1.05e-10	-0.43	-0.32	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
KIRC	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	7.57	1.85e-13	1.05e-10	0.57	0.32	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	7.57	1.85e-13	1.05e-10	0.57	0.32	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	7.57	1.85e-13	1.05e-10	0.57	0.32	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
KIRC	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	7.57	1.85e-13	1.05e-10	0.41	0.32	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
KIRC	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-7.57	1.85e-13	1.05e-10	-0.36	-0.32	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	7.57	1.85e-13	1.05e-10	0.46	0.32	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs6554282	ENSG00000273257.1	RP11-177J6.1	7.57	1.85e-13	1.05e-10	0.43	0.32	Adiponectin levels;	chr4:55519812	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs6554283	ENSG00000273257.1	RP11-177J6.1	7.57	1.85e-13	1.05e-10	0.43	0.32	Adiponectin levels;	chr4:55521053	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs1546004	ENSG00000273257.1	RP11-177J6.1	7.57	1.85e-13	1.05e-10	0.43	0.32	Adiponectin levels;	chr4:55521612	chr4:55387949~55388271:+
KIRC	cis	rs12893668	0.703	rs729438	ENSG00000269910.1	RP11-73M18.10	-7.57	1.86e-13	1.05e-10	-0.22	-0.32	Reticulocyte count;	chr14:103626452	chr14:103694516~103695050:-
KIRC	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	7.57	1.86e-13	1.05e-10	0.44	0.32	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
KIRC	cis	rs6600671	1	rs4844616	ENSG00000270231.3	NBPF8P	7.57	1.86e-13	1.06e-10	0.25	0.32	Hip geometry;	chr1:121429348	chr1:120436353~120467739:+
KIRC	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	7.57	1.86e-13	1.06e-10	0.41	0.32	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
KIRC	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-7.57	1.86e-13	1.06e-10	-0.4	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
KIRC	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-7.57	1.87e-13	1.06e-10	-0.25	-0.32	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-7.57	1.87e-13	1.06e-10	-0.25	-0.32	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
KIRC	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	7.57	1.87e-13	1.06e-10	0.39	0.32	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-7.57	1.87e-13	1.06e-10	-0.33	-0.32	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
KIRC	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	7.57	1.87e-13	1.06e-10	0.41	0.32	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
KIRC	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	7.57	1.87e-13	1.06e-10	0.44	0.32	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	7.57	1.87e-13	1.06e-10	0.44	0.32	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
KIRC	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	7.57	1.88e-13	1.06e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
KIRC	cis	rs2847281	0.587	rs2542157	ENSG00000267654.1	RP11-973H7.4	-7.57	1.88e-13	1.06e-10	-0.37	-0.32	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12787248	chr18:12739490~12749421:-
KIRC	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-7.57	1.88e-13	1.06e-10	-0.44	-0.32	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
KIRC	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-7.57	1.88e-13	1.07e-10	-0.4	-0.32	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
KIRC	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	7.57	1.88e-13	1.07e-10	0.42	0.32	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
KIRC	cis	rs6061231	0.544	rs2427314	ENSG00000275437.1	RP5-908M14.10	7.57	1.88e-13	1.07e-10	0.26	0.32	Colorectal cancer;	chr20:62398610	chr20:62402236~62405935:-
KIRC	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	7.57	1.88e-13	1.07e-10	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
KIRC	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	7.57	1.89e-13	1.07e-10	0.41	0.32	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
KIRC	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-7.57	1.89e-13	1.07e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
KIRC	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
KIRC	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	7.57	1.89e-13	1.07e-10	0.43	0.32	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
KIRC	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.57	1.89e-13	1.07e-10	0.39	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
KIRC	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-7.57	1.89e-13	1.07e-10	-0.39	-0.32	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
KIRC	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	7.57	1.89e-13	1.07e-10	0.25	0.32	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
KIRC	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	7.57	1.9e-13	1.07e-10	0.47	0.32	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
KIRC	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	7.57	1.9e-13	1.08e-10	0.4	0.32	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	7.57	1.9e-13	1.08e-10	0.4	0.32	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
KIRC	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	7.57	1.9e-13	1.08e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
KIRC	cis	rs890448	0.726	rs2850369	ENSG00000254531.1	FLJ20021	-7.57	1.9e-13	1.08e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311828	chr4:101347780~101348883:+
KIRC	cis	rs890448	0.726	rs2044043	ENSG00000254531.1	FLJ20021	-7.57	1.9e-13	1.08e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101314983	chr4:101347780~101348883:+
KIRC	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-7.56	1.9e-13	1.08e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.759	rs13708	ENSG00000260911.2	RP11-196G11.2	-7.56	1.9e-13	1.08e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30989488	chr16:31043150~31049868:+
KIRC	cis	rs4713118	0.513	rs200971	ENSG00000216901.1	AL022393.7	7.56	1.91e-13	1.08e-10	0.41	0.32	Parkinson's disease;	chr6:27891126	chr6:28176188~28176674:+
KIRC	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-7.56	1.91e-13	1.08e-10	-0.3	-0.32	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
KIRC	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-7.56	1.91e-13	1.08e-10	-0.4	-0.32	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
KIRC	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	7.56	1.92e-13	1.08e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
KIRC	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	7.56	1.92e-13	1.08e-10	0.43	0.32	Depression;	chr6:28399886	chr6:28943877~28944537:+
KIRC	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	7.56	1.92e-13	1.08e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	7.56	1.92e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	7.56	1.92e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
KIRC	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-7.56	1.92e-13	1.09e-10	-0.41	-0.32	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
KIRC	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-7.56	1.92e-13	1.09e-10	-0.42	-0.32	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-7.56	1.92e-13	1.09e-10	-0.42	-0.32	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
KIRC	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	7.56	1.93e-13	1.09e-10	0.41	0.32	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
KIRC	cis	rs10971721	0.584	rs55672700	ENSG00000260947.1	RP11-384P7.7	7.56	1.93e-13	1.09e-10	0.57	0.32	Body mass index;	chr9:34102723	chr9:33697459~33700986:+
KIRC	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-7.56	1.93e-13	1.09e-10	-0.36	-0.32	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
KIRC	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-7.56	1.93e-13	1.09e-10	-0.33	-0.32	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
KIRC	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	7.56	1.93e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	7.56	1.93e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	7.56	1.93e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	7.56	1.93e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	7.56	1.93e-13	1.09e-10	0.41	0.32	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
KIRC	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	7.56	1.93e-13	1.09e-10	0.24	0.32	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
KIRC	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	7.56	1.93e-13	1.09e-10	0.39	0.32	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	7.56	1.93e-13	1.09e-10	0.39	0.32	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
KIRC	cis	rs7017914	0.87	rs2639953	ENSG00000254031.4	RP11-326E22.1	7.56	1.93e-13	1.09e-10	0.35	0.32	Bone mineral density;	chr8:71013425	chr8:71155457~71204223:+
KIRC	cis	rs4072705	0.967	rs6478677	ENSG00000224020.1	MIR181A2HG	-7.56	1.94e-13	1.09e-10	-0.33	-0.32	Menarche (age at onset);	chr9:124659900	chr9:124658467~124698631:+
KIRC	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-7.56	1.94e-13	1.1e-10	-0.39	-0.32	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-7.56	1.94e-13	1.1e-10	-0.39	-0.32	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-7.56	1.94e-13	1.1e-10	-0.39	-0.32	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-7.56	1.94e-13	1.1e-10	-0.39	-0.32	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-7.56	1.94e-13	1.1e-10	-0.39	-0.32	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
KIRC	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	7.56	1.95e-13	1.1e-10	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
KIRC	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	7.56	1.95e-13	1.1e-10	0.44	0.32	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
KIRC	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-7.56	1.95e-13	1.1e-10	-0.39	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
KIRC	cis	rs34375054	0.573	rs12823172	ENSG00000279233.1	RP11-158L12.4	7.56	1.95e-13	1.1e-10	0.28	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125161737	chr12:125138245~125141711:+
KIRC	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	7.56	1.95e-13	1.1e-10	0.53	0.32	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
KIRC	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	7.56	1.95e-13	1.1e-10	0.28	0.32	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
KIRC	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	7.56	1.96e-13	1.11e-10	0.51	0.32	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	7.56	1.96e-13	1.11e-10	0.51	0.32	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	7.56	1.96e-13	1.11e-10	0.51	0.32	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	7.56	1.96e-13	1.11e-10	0.51	0.32	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
KIRC	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-7.56	1.96e-13	1.11e-10	-0.29	-0.32	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
KIRC	cis	rs6600671	1	rs6600671	ENSG00000227082.1	CH17-437K3.1	7.56	1.97e-13	1.11e-10	0.36	0.32	Hip geometry;	chr1:121458637	chr1:121396754~121463129:+
KIRC	cis	rs11079159	0.837	rs4794559	ENSG00000263096.1	RP11-515O17.2	7.56	1.97e-13	1.11e-10	0.51	0.32	QRS duration;	chr17:55286939	chr17:55271504~55273653:-
KIRC	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-7.56	1.97e-13	1.11e-10	-0.4	-0.32	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
KIRC	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-7.56	1.97e-13	1.11e-10	-0.4	-0.32	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
KIRC	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	7.56	1.97e-13	1.11e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	7.56	1.97e-13	1.11e-10	0.37	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
KIRC	cis	rs2486288	0.656	rs11632419	ENSG00000235390.4	CTD-2651B20.5	7.56	1.97e-13	1.11e-10	0.3	0.32	Glomerular filtration rate;	chr15:45265258	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs2271438	ENSG00000235390.4	CTD-2651B20.5	7.56	1.97e-13	1.11e-10	0.3	0.32	Glomerular filtration rate;	chr15:45265270	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11854365	ENSG00000235390.4	CTD-2651B20.5	7.56	1.97e-13	1.11e-10	0.3	0.32	Glomerular filtration rate;	chr15:45265885	chr15:45321077~45321692:-
KIRC	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-7.56	1.97e-13	1.11e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
KIRC	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	7.56	1.98e-13	1.12e-10	0.43	0.32	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
KIRC	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	7.56	1.98e-13	1.12e-10	0.45	0.32	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
KIRC	cis	rs3820928	0.904	rs1835159	ENSG00000212391.1	SNORA48	-7.56	1.98e-13	1.12e-10	-0.38	-0.32	Pulmonary function;	chr2:226899341	chr2:226968989~226969122:-
KIRC	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	7.56	1.98e-13	1.12e-10	0.41	0.32	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
KIRC	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-7.56	1.98e-13	1.12e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
KIRC	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-7.56	1.98e-13	1.12e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
KIRC	cis	rs11018904	0.861	rs61903723	ENSG00000280385.1	AP000648.5	-7.56	1.98e-13	1.12e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90193614~90198120:+
KIRC	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	7.56	1.99e-13	1.12e-10	0.48	0.32	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
KIRC	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	7.56	2e-13	1.13e-10	0.28	0.32	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
KIRC	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	7.56	2e-13	1.13e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
KIRC	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-7.56	2e-13	1.13e-10	-0.25	-0.32	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-7.56	2e-13	1.13e-10	-0.26	-0.32	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
KIRC	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-7.56	2.01e-13	1.13e-10	-0.47	-0.32	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
KIRC	cis	rs13423976	0.6	rs2373404	ENSG00000231367.4	AC016995.3	7.56	2.01e-13	1.14e-10	0.42	0.32	Gut microbiome composition (summer);	chr2:38512959	chr2:38406719~38515740:-
KIRC	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-7.56	2.02e-13	1.14e-10	-0.27	-0.32	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
KIRC	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	7.56	2.02e-13	1.14e-10	0.42	0.32	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
KIRC	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55506498	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55507248	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55507729	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55508587	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55509367	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55510352	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	7.56	2.02e-13	1.14e-10	0.39	0.32	Height;	chr4:55511198	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs17722979	ENSG00000273257.1	RP11-177J6.1	-7.56	2.02e-13	1.14e-10	-0.42	-0.32	Adiponectin levels;	chr4:55480244	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	7.56	2.02e-13	1.14e-10	0.32	0.32	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	7.56	2.02e-13	1.14e-10	0.32	0.32	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	7.56	2.02e-13	1.14e-10	0.32	0.32	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
KIRC	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	7.56	2.02e-13	1.14e-10	0.41	0.32	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
KIRC	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	7.56	2.03e-13	1.14e-10	0.44	0.32	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
KIRC	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	7.56	2.03e-13	1.14e-10	0.32	0.32	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
KIRC	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	7.56	2.03e-13	1.14e-10	0.44	0.32	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000198277.6	RP11-468N14.09	7.56	2.03e-13	1.15e-10	0.41	0.32	Obesity-related traits;	chr4:69104054	chr4:68914928~68924741:-
KIRC	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-7.56	2.03e-13	1.15e-10	-0.27	-0.32	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
KIRC	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-7.56	2.03e-13	1.15e-10	-0.39	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
KIRC	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	7.56	2.04e-13	1.15e-10	0.41	0.32	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
KIRC	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	7.55	2.04e-13	1.15e-10	0.36	0.32	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
KIRC	cis	rs3820928	0.874	rs13393894	ENSG00000212391.1	SNORA48	-7.55	2.04e-13	1.15e-10	-0.37	-0.32	Pulmonary function;	chr2:227015827	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs13393902	ENSG00000212391.1	SNORA48	-7.55	2.04e-13	1.15e-10	-0.37	-0.32	Pulmonary function;	chr2:227015838	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.845	rs4234065	ENSG00000212391.1	SNORA48	-7.55	2.04e-13	1.15e-10	-0.37	-0.32	Pulmonary function;	chr2:227017290	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs4234066	ENSG00000212391.1	SNORA48	-7.55	2.04e-13	1.15e-10	-0.37	-0.32	Pulmonary function;	chr2:227017464	chr2:226968989~226969122:-
KIRC	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	7.55	2.04e-13	1.15e-10	0.28	0.32	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
KIRC	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	7.55	2.05e-13	1.15e-10	0.4	0.32	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
KIRC	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-7.55	2.05e-13	1.15e-10	-0.34	-0.32	Height;	chr3:52971094	chr3:53064283~53065091:-
KIRC	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	7.55	2.05e-13	1.15e-10	0.39	0.32	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
KIRC	cis	rs4819052	0.851	rs4819046	ENSG00000223768.1	LINC00205	-7.55	2.05e-13	1.16e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45293285~45297354:+
KIRC	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-7.55	2.06e-13	1.16e-10	-0.39	-0.32	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	7.55	2.06e-13	1.16e-10	0.33	0.32	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	7.55	2.06e-13	1.16e-10	0.33	0.32	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
KIRC	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	7.55	2.06e-13	1.16e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
KIRC	cis	rs13434995	0.513	rs7681414	ENSG00000273257.1	RP11-177J6.1	-7.55	2.06e-13	1.16e-10	-0.43	-0.32	Adiponectin levels;	chr4:55508890	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62305271	ENSG00000273257.1	RP11-177J6.1	-7.55	2.06e-13	1.16e-10	-0.43	-0.32	Adiponectin levels;	chr4:55509715	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs10462033	ENSG00000273257.1	RP11-177J6.1	-7.55	2.06e-13	1.16e-10	-0.43	-0.32	Adiponectin levels;	chr4:55511552	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs1915905	ENSG00000273257.1	RP11-177J6.1	-7.55	2.06e-13	1.16e-10	-0.43	-0.32	Adiponectin levels;	chr4:55512381	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs1522109	ENSG00000273257.1	RP11-177J6.1	-7.55	2.06e-13	1.16e-10	-0.43	-0.32	Adiponectin levels;	chr4:55514403	chr4:55387949~55388271:+
KIRC	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-7.55	2.06e-13	1.16e-10	-0.34	-0.32	Height;	chr3:53027969	chr3:53064283~53065091:-
KIRC	cis	rs2288884	0.767	rs17835716	ENSG00000275055.1	CTC-471J1.11	-7.55	2.06e-13	1.16e-10	-0.4	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.767	rs3752119	ENSG00000275055.1	CTC-471J1.11	-7.55	2.06e-13	1.16e-10	-0.4	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.767	rs3450	ENSG00000275055.1	CTC-471J1.11	-7.55	2.06e-13	1.16e-10	-0.4	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52049007~52049754:+
KIRC	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-7.55	2.07e-13	1.16e-10	-0.43	-0.32	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
KIRC	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	7.55	2.07e-13	1.17e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
KIRC	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-7.55	2.07e-13	1.17e-10	-0.35	-0.32	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-7.55	2.07e-13	1.17e-10	-0.35	-0.32	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-7.55	2.07e-13	1.17e-10	-0.35	-0.32	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-7.55	2.07e-13	1.17e-10	-0.35	-0.32	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
KIRC	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-7.55	2.07e-13	1.17e-10	-0.34	-0.32	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
KIRC	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	7.55	2.08e-13	1.17e-10	0.41	0.32	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
KIRC	cis	rs7017914	0.837	rs2639952	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71013495	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732108	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71013864	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732109	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71013988	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs1493203	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71014272	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732110	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71014576	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639951	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71014990	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732112	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71015606	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.811	rs1389204	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71016063	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732113	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71016314	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732114	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71016477	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2732116	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71017092	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2956610	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71017298	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098868	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71017457	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098870	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71017700	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110240	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71017869	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.875	rs3098871	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71018180	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098873	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71020351	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110241	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71020729	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110242	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71020732	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110243	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71020834	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs3098874	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71022103	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110247	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71022652	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110248	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71022700	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110249	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71023310	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098876	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71024009	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs3098877	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71024211	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.875	rs3110251	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71024739	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110252	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71024985	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110253	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71025318	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110254	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71025627	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs3110256	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71025901	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110257	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71025916	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098879	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71026225	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.935	rs3110258	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71026297	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.87	rs3098880	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71026686	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3098881	ENSG00000254031.4	RP11-326E22.1	7.55	2.08e-13	1.17e-10	0.35	0.32	Bone mineral density;	chr8:71027455	chr8:71155457~71204223:+
KIRC	cis	rs3820928	0.904	rs4439949	ENSG00000212391.1	SNORA48	-7.55	2.08e-13	1.17e-10	-0.38	-0.32	Pulmonary function;	chr2:226900238	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.904	rs2396431	ENSG00000212391.1	SNORA48	-7.55	2.08e-13	1.17e-10	-0.38	-0.32	Pulmonary function;	chr2:226900772	chr2:226968989~226969122:-
KIRC	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-7.55	2.08e-13	1.17e-10	-0.34	-0.32	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
KIRC	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	7.55	2.08e-13	1.17e-10	0.44	0.32	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	7.55	2.08e-13	1.17e-10	0.44	0.32	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
KIRC	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	7.55	2.08e-13	1.17e-10	0.36	0.32	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	7.55	2.08e-13	1.17e-10	0.36	0.32	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
KIRC	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	7.55	2.08e-13	1.17e-10	0.36	0.32	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
KIRC	cis	rs2361718	0.5	rs4889970	ENSG00000275479.1	RP11-334C17.6	-7.55	2.09e-13	1.17e-10	-0.34	-0.32	Yeast infection;	chr17:80122287	chr17:80149627~80149798:+
KIRC	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-7.55	2.09e-13	1.17e-10	-0.31	-0.32	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
KIRC	cis	rs7592578	0.766	rs62181052	ENSG00000272979.1	RP11-647K16.1	-7.55	2.09e-13	1.17e-10	-0.48	-0.32	Diastolic blood pressure;	chr2:190523132	chr2:190454092~190454521:-
KIRC	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	7.55	2.09e-13	1.18e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
KIRC	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	7.55	2.09e-13	1.18e-10	0.28	0.32	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
KIRC	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	7.55	2.09e-13	1.18e-10	0.5	0.32	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
KIRC	cis	rs890448	0.726	rs2850326	ENSG00000254531.1	FLJ20021	-7.55	2.1e-13	1.18e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101343418	chr4:101347780~101348883:+
KIRC	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	7.55	2.1e-13	1.18e-10	0.34	0.32	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
KIRC	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	7.55	2.1e-13	1.18e-10	0.71	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
KIRC	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	7.55	2.1e-13	1.18e-10	0.71	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
KIRC	cis	rs2486288	0.656	rs9921025	ENSG00000235390.4	CTD-2651B20.5	7.55	2.11e-13	1.18e-10	0.3	0.32	Glomerular filtration rate;	chr15:45254404	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11629858	ENSG00000259433.2	CTD-2651B20.4	7.55	2.11e-13	1.18e-10	0.23	0.32	Glomerular filtration rate;	chr15:45254916	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11629859	ENSG00000259433.2	CTD-2651B20.4	7.55	2.11e-13	1.18e-10	0.23	0.32	Glomerular filtration rate;	chr15:45254923	chr15:45330209~45332634:-
KIRC	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-7.55	2.11e-13	1.19e-10	-0.41	-0.32	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
KIRC	cis	rs2361718	0.501	rs12944619	ENSG00000275479.1	RP11-334C17.6	7.55	2.11e-13	1.19e-10	0.35	0.32	Yeast infection;	chr17:80170310	chr17:80149627~80149798:+
KIRC	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	7.55	2.11e-13	1.19e-10	0.46	0.32	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
KIRC	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	7.55	2.11e-13	1.19e-10	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
KIRC	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	7.55	2.11e-13	1.19e-10	0.34	0.32	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
KIRC	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-7.55	2.11e-13	1.19e-10	-0.36	-0.32	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
KIRC	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	7.55	2.12e-13	1.19e-10	0.38	0.32	Height;	chr4:55476736	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	7.55	2.12e-13	1.19e-10	0.38	0.32	Height;	chr4:55477426	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	7.55	2.12e-13	1.19e-10	0.38	0.32	Height;	chr4:55477545	chr4:55387949~55388271:+
KIRC	cis	rs1528149	0.78	rs28422957	ENSG00000224683.1	RPL36AP29	7.55	2.12e-13	1.19e-10	0.39	0.32	Sitting height ratio;	chr7:16059895	chr7:16208945~16209265:+
KIRC	cis	rs13434995	0.513	rs4865006	ENSG00000273257.1	RP11-177J6.1	7.55	2.12e-13	1.19e-10	0.43	0.32	Adiponectin levels;	chr4:55526112	chr4:55387949~55388271:+
KIRC	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	7.55	2.12e-13	1.19e-10	0.25	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
KIRC	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-7.55	2.12e-13	1.19e-10	-0.28	-0.32	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
KIRC	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	7.55	2.13e-13	1.2e-10	0.39	0.32	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
KIRC	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-7.55	2.13e-13	1.2e-10	-0.39	-0.32	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
KIRC	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-7.55	2.13e-13	1.2e-10	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-7.55	2.13e-13	1.2e-10	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-7.55	2.13e-13	1.2e-10	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-7.55	2.13e-13	1.2e-10	-0.46	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000198277.6	RP11-468N14.09	7.55	2.13e-13	1.2e-10	0.4	0.32	Obesity-related traits;	chr4:69107521	chr4:68914928~68924741:-
KIRC	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	7.55	2.13e-13	1.2e-10	0.37	0.32	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
KIRC	cis	rs13434995	0.513	rs550144	ENSG00000273257.1	RP11-177J6.1	7.55	2.13e-13	1.2e-10	0.43	0.32	Adiponectin levels;	chr4:55415317	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62303681	ENSG00000249700.7	SRD5A3-AS1	-7.55	2.14e-13	1.2e-10	-0.33	-0.32	Adiponectin levels;	chr4:55403812	chr4:55363971~55395847:-
KIRC	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	7.55	2.14e-13	1.2e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
KIRC	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-7.55	2.14e-13	1.2e-10	-0.41	-0.32	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
KIRC	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-7.55	2.14e-13	1.2e-10	-0.42	-0.32	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-7.55	2.14e-13	1.2e-10	-0.42	-0.32	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
KIRC	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	7.55	2.14e-13	1.2e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
KIRC	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-7.55	2.14e-13	1.2e-10	-0.33	-0.32	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
KIRC	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	7.55	2.15e-13	1.21e-10	0.28	0.32	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
KIRC	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	7.55	2.15e-13	1.21e-10	0.28	0.32	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
KIRC	cis	rs9322193	0.886	rs4039600	ENSG00000268592.3	RAET1E-AS1	7.55	2.15e-13	1.21e-10	0.45	0.32	Lung cancer;	chr6:149576319	chr6:149863494~149919507:+
KIRC	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-7.55	2.15e-13	1.21e-10	-0.37	-0.32	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
KIRC	cis	rs7176527	0.796	rs72630464	ENSG00000188388.10	GOLGA6L3	7.55	2.15e-13	1.21e-10	0.44	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84754895	chr15:85240472~85247170:+
KIRC	cis	rs7927771	0.8	rs11039200	ENSG00000280615.1	Y_RNA	-7.55	2.15e-13	1.21e-10	-0.36	-0.32	Subjective well-being;	chr11:47358095	chr11:47614898~47614994:-
KIRC	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	7.55	2.16e-13	1.21e-10	0.56	0.32	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
KIRC	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	7.55	2.16e-13	1.21e-10	0.37	0.32	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
KIRC	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-7.55	2.16e-13	1.21e-10	-0.37	-0.32	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
KIRC	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	7.55	2.16e-13	1.21e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	7.55	2.16e-13	1.21e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
KIRC	cis	rs2288884	0.708	rs59104696	ENSG00000275055.1	CTC-471J1.11	-7.55	2.16e-13	1.21e-10	-0.4	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52049007~52049754:+
KIRC	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	7.55	2.16e-13	1.21e-10	0.39	0.32	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
KIRC	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	7.55	2.16e-13	1.21e-10	0.44	0.32	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
KIRC	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	7.55	2.16e-13	1.21e-10	0.37	0.32	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
KIRC	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	7.55	2.17e-13	1.22e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
KIRC	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	7.55	2.17e-13	1.22e-10	0.61	0.32	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	7.55	2.17e-13	1.22e-10	0.61	0.32	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
KIRC	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-7.55	2.17e-13	1.22e-10	-0.37	-0.32	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-7.55	2.17e-13	1.22e-10	-0.37	-0.32	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-7.55	2.17e-13	1.22e-10	-0.37	-0.32	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
KIRC	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	7.55	2.17e-13	1.22e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
KIRC	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-7.55	2.17e-13	1.22e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
KIRC	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	7.55	2.17e-13	1.22e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
KIRC	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	7.55	2.17e-13	1.22e-10	0.5	0.32	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
KIRC	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-7.55	2.17e-13	1.22e-10	-0.34	-0.32	Height;	chr3:53070344	chr3:53064283~53065091:-
KIRC	cis	rs10214930	0.697	rs6462029	ENSG00000235574.1	AC073150.6	-7.55	2.17e-13	1.22e-10	-0.38	-0.32	Hypospadias;	chr7:27541876	chr7:27491682~27492765:-
KIRC	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	7.55	2.18e-13	1.22e-10	0.41	0.32	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
KIRC	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	7.55	2.18e-13	1.22e-10	0.25	0.32	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
KIRC	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	7.54	2.19e-13	1.23e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
KIRC	cis	rs2486288	0.656	rs2413772	ENSG00000235390.4	CTD-2651B20.5	7.54	2.19e-13	1.23e-10	0.3	0.32	Glomerular filtration rate;	chr15:45257664	chr15:45321077~45321692:-
KIRC	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	7.54	2.19e-13	1.23e-10	0.42	0.32	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
KIRC	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-7.54	2.19e-13	1.23e-10	-0.43	-0.32	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
KIRC	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-7.54	2.2e-13	1.23e-10	-0.56	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
KIRC	cis	rs13434995	0.513	rs6554282	ENSG00000249700.7	SRD5A3-AS1	7.54	2.2e-13	1.23e-10	0.32	0.32	Adiponectin levels;	chr4:55519812	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs6554283	ENSG00000249700.7	SRD5A3-AS1	7.54	2.2e-13	1.23e-10	0.32	0.32	Adiponectin levels;	chr4:55521053	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs1546004	ENSG00000249700.7	SRD5A3-AS1	7.54	2.2e-13	1.23e-10	0.32	0.32	Adiponectin levels;	chr4:55521612	chr4:55363971~55395847:-
KIRC	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-7.54	2.2e-13	1.23e-10	-0.25	-0.32	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
KIRC	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-7.54	2.2e-13	1.23e-10	-0.38	-0.32	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
KIRC	cis	rs890448	0.694	rs2583392	ENSG00000254531.1	FLJ20021	-7.54	2.2e-13	1.23e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101338208	chr4:101347780~101348883:+
KIRC	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	7.54	2.21e-13	1.24e-10	0.4	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-7.54	2.21e-13	1.24e-10	-0.4	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
KIRC	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	7.54	2.21e-13	1.24e-10	0.32	0.32	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	7.54	2.21e-13	1.24e-10	0.32	0.32	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-7.54	2.21e-13	1.24e-10	-0.33	-0.32	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
KIRC	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-7.54	2.21e-13	1.24e-10	-0.24	-0.32	Breast cancer;	chr11:743813	chr11:777578~784297:+
KIRC	cis	rs7017914	0.837	rs2732105	ENSG00000254031.4	RP11-326E22.1	7.54	2.22e-13	1.24e-10	0.35	0.32	Bone mineral density;	chr8:71011410	chr8:71155457~71204223:+
KIRC	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-7.54	2.22e-13	1.24e-10	-0.3	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
KIRC	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-7.54	2.22e-13	1.24e-10	-0.51	-0.32	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
KIRC	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-7.54	2.22e-13	1.24e-10	-0.31	-0.32	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
KIRC	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	7.54	2.22e-13	1.24e-10	0.28	0.32	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
KIRC	cis	rs950027	0.787	rs1547487	ENSG00000235390.4	CTD-2651B20.5	-7.54	2.22e-13	1.25e-10	-0.31	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45321077~45321692:-
KIRC	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	7.54	2.23e-13	1.25e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
KIRC	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	7.54	2.23e-13	1.25e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
KIRC	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	7.54	2.23e-13	1.25e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
KIRC	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	7.54	2.23e-13	1.25e-10	0.25	0.32	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
KIRC	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	7.54	2.23e-13	1.25e-10	0.45	0.32	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
KIRC	cis	rs7017914	0.905	rs3110255	ENSG00000254031.4	RP11-326E22.1	7.54	2.23e-13	1.25e-10	0.35	0.32	Bone mineral density;	chr8:71025815	chr8:71155457~71204223:+
KIRC	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-7.54	2.23e-13	1.25e-10	-0.3	-0.32	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
KIRC	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	7.54	2.24e-13	1.25e-10	0.41	0.32	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
KIRC	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-7.54	2.24e-13	1.25e-10	-0.4	-0.32	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
KIRC	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	7.54	2.24e-13	1.25e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
KIRC	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	7.54	2.24e-13	1.26e-10	0.41	0.32	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
KIRC	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	7.54	2.24e-13	1.26e-10	0.41	0.32	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
KIRC	cis	rs1476679	0.962	rs34995835	ENSG00000078319.8	PMS2P1	7.54	2.24e-13	1.26e-10	0.41	0.32	Alzheimer's disease (late onset);	chr7:100392741	chr7:100320992~100341908:-
KIRC	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	7.54	2.24e-13	1.26e-10	0.42	0.32	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
KIRC	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	7.54	2.25e-13	1.26e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	7.54	2.25e-13	1.26e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	7.54	2.25e-13	1.26e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
KIRC	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	7.54	2.25e-13	1.26e-10	0.47	0.32	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
KIRC	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	7.54	2.25e-13	1.26e-10	0.47	0.32	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
KIRC	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	7.54	2.26e-13	1.26e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
KIRC	cis	rs4356975	0.522	rs7679184	ENSG00000248763.2	RP13-644M16.5	-7.54	2.26e-13	1.27e-10	-0.41	-0.32	Obesity-related traits;	chr4:69100212	chr4:69066395~69069888:+
KIRC	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-7.54	2.26e-13	1.27e-10	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
KIRC	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	7.54	2.27e-13	1.27e-10	0.25	0.32	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
KIRC	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	7.54	2.28e-13	1.27e-10	0.41	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
KIRC	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	7.54	2.28e-13	1.28e-10	0.42	0.32	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
KIRC	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.54	2.28e-13	1.28e-10	-0.39	-0.32	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
KIRC	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-7.54	2.28e-13	1.28e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
KIRC	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	7.54	2.29e-13	1.28e-10	0.41	0.32	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	7.54	2.29e-13	1.28e-10	0.41	0.32	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
KIRC	cis	rs10971721	0.584	rs56145814	ENSG00000260947.1	RP11-384P7.7	7.54	2.29e-13	1.28e-10	0.57	0.32	Body mass index;	chr9:34088953	chr9:33697459~33700986:+
KIRC	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	7.54	2.29e-13	1.28e-10	0.41	0.32	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
KIRC	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	7.54	2.29e-13	1.28e-10	0.35	0.32	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
KIRC	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-7.54	2.3e-13	1.29e-10	-0.34	-0.32	Height;	chr3:53029908	chr3:53064283~53065091:-
KIRC	cis	rs6908034	0.556	rs77486465	ENSG00000228412.5	RP4-625H18.2	7.54	2.3e-13	1.29e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19802164~19804752:-
KIRC	cis	rs7672749	0.73	rs6820909	ENSG00000249973.2	CHCHD2P7	7.54	2.3e-13	1.29e-10	0.67	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87882542	chr4:87785920~87786371:-
KIRC	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	7.54	2.31e-13	1.29e-10	0.28	0.32	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
KIRC	cis	rs9388451	0.874	rs13209968	ENSG00000237742.5	RP11-624M8.1	-7.54	2.31e-13	1.29e-10	-0.38	-0.32	Brugada syndrome;	chr6:125768139	chr6:125578558~125749190:-
KIRC	cis	rs17801127	0.818	rs34131478	ENSG00000231969.1	AC144449.1	7.54	2.31e-13	1.29e-10	0.6	0.32	Liver enzyme levels (alanine transaminase);	chr2:149802126	chr2:149587196~149848233:+
KIRC	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-7.54	2.32e-13	1.29e-10	-0.37	-0.32	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
KIRC	cis	rs75920871	0.588	rs6589580	ENSG00000254851.1	RP11-109L13.1	7.54	2.32e-13	1.3e-10	0.45	0.32	Subjective well-being;	chr11:116949157	chr11:117135528~117138582:+
KIRC	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-7.54	2.32e-13	1.3e-10	-0.37	-0.32	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
KIRC	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-7.54	2.32e-13	1.3e-10	-0.36	-0.32	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
KIRC	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	7.54	2.32e-13	1.3e-10	0.35	0.32	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
KIRC	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-7.54	2.32e-13	1.3e-10	-0.41	-0.32	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
KIRC	cis	rs13434995	0.513	rs1021307	ENSG00000249700.7	SRD5A3-AS1	7.54	2.33e-13	1.3e-10	0.32	0.32	Adiponectin levels;	chr4:55529547	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs1021306	ENSG00000249700.7	SRD5A3-AS1	7.54	2.33e-13	1.3e-10	0.32	0.32	Adiponectin levels;	chr4:55529777	chr4:55363971~55395847:-
KIRC	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.54	2.33e-13	1.3e-10	-0.31	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
KIRC	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-7.54	2.34e-13	1.31e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
KIRC	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-7.54	2.34e-13	1.31e-10	-0.41	-0.32	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
KIRC	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	7.54	2.34e-13	1.31e-10	0.28	0.32	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
KIRC	cis	rs6600671	0.934	rs7528274	ENSG00000227082.1	CH17-437K3.1	-7.53	2.34e-13	1.31e-10	-0.36	-0.32	Hip geometry;	chr1:121545103	chr1:121396754~121463129:+
KIRC	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-7.53	2.34e-13	1.31e-10	-0.41	-0.32	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
KIRC	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-7.53	2.35e-13	1.31e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
KIRC	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-7.53	2.35e-13	1.31e-10	-0.34	-0.32	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
KIRC	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-7.53	2.35e-13	1.31e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
KIRC	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	7.53	2.35e-13	1.31e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
KIRC	cis	rs17801127	0.901	rs16827293	ENSG00000231969.1	AC144449.1	-7.53	2.35e-13	1.31e-10	-0.55	-0.32	Liver enzyme levels (alanine transaminase);	chr2:149652818	chr2:149587196~149848233:+
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000251284.2	RP13-644M16.1	-7.53	2.35e-13	1.31e-10	-0.39	-0.32	Obesity-related traits;	chr4:69073715	chr4:69125274~69126451:+
KIRC	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	7.53	2.35e-13	1.31e-10	0.4	0.32	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
KIRC	cis	rs2486288	0.656	rs2413773	ENSG00000259433.2	CTD-2651B20.4	7.53	2.36e-13	1.32e-10	0.23	0.32	Glomerular filtration rate;	chr15:45257244	chr15:45330209~45332634:-
KIRC	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	7.53	2.36e-13	1.32e-10	0.21	0.32	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	7.53	2.36e-13	1.32e-10	0.44	0.32	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
KIRC	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	7.53	2.36e-13	1.32e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
KIRC	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	7.53	2.36e-13	1.32e-10	0.49	0.32	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
KIRC	cis	rs34375054	0.687	rs35540170	ENSG00000279233.1	RP11-158L12.4	7.53	2.36e-13	1.32e-10	0.26	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125184576	chr12:125138245~125141711:+
KIRC	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	7.53	2.37e-13	1.32e-10	0.41	0.32	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	7.53	2.37e-13	1.32e-10	0.41	0.32	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
KIRC	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	7.53	2.37e-13	1.32e-10	0.36	0.32	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
KIRC	cis	rs12936587	0.536	rs8075153	ENSG00000223979.2	SMCR2	7.53	2.37e-13	1.32e-10	0.34	0.32	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17719352	chr17:17674026~17677688:-
KIRC	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	7.53	2.37e-13	1.32e-10	0.41	0.32	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
KIRC	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	7.53	2.37e-13	1.32e-10	0.43	0.32	Height;	chr6:109359747	chr6:109382795~109383666:+
KIRC	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-7.53	2.37e-13	1.32e-10	-0.3	-0.32	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
KIRC	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	7.53	2.37e-13	1.32e-10	0.36	0.32	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
KIRC	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	7.53	2.37e-13	1.33e-10	0.45	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
KIRC	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-7.53	2.38e-13	1.33e-10	-0.36	-0.32	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
KIRC	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-7.53	2.38e-13	1.33e-10	-0.35	-0.32	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
KIRC	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-7.53	2.38e-13	1.33e-10	-0.33	-0.32	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
KIRC	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-7.53	2.38e-13	1.33e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
KIRC	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	7.53	2.38e-13	1.33e-10	0.4	0.32	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
KIRC	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-7.53	2.39e-13	1.33e-10	-0.41	-0.32	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
KIRC	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	7.53	2.39e-13	1.33e-10	0.45	0.32	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
KIRC	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-7.53	2.39e-13	1.34e-10	-0.38	-0.32	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
KIRC	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	7.53	2.4e-13	1.34e-10	0.31	0.32	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
KIRC	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	7.53	2.4e-13	1.34e-10	0.24	0.32	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
KIRC	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-7.53	2.4e-13	1.34e-10	-0.32	-0.32	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-7.53	2.4e-13	1.34e-10	-0.32	-0.32	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-7.53	2.4e-13	1.34e-10	-0.32	-0.32	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
KIRC	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	7.53	2.41e-13	1.34e-10	0.42	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
KIRC	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	7.53	2.41e-13	1.35e-10	0.43	0.32	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	7.53	2.41e-13	1.35e-10	0.43	0.32	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	7.53	2.41e-13	1.35e-10	0.43	0.32	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	7.53	2.41e-13	1.35e-10	0.43	0.32	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
KIRC	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	7.53	2.42e-13	1.35e-10	0.45	0.32	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
KIRC	cis	rs7017914	0.905	rs3110244	ENSG00000254031.4	RP11-326E22.1	-7.53	2.42e-13	1.35e-10	-0.35	-0.32	Bone mineral density;	chr8:71020962	chr8:71155457~71204223:+
KIRC	cis	rs71403859	0.685	rs12927044	ENSG00000260886.1	TAT-AS1	7.53	2.42e-13	1.35e-10	0.74	0.32	Post bronchodilator FEV1;	chr16:71896202	chr16:71565789~71578187:+
KIRC	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-7.53	2.42e-13	1.35e-10	-0.4	-0.32	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
KIRC	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	7.53	2.43e-13	1.35e-10	0.44	0.32	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.589	rs861029	ENSG00000249700.7	SRD5A3-AS1	-7.53	2.43e-13	1.36e-10	-0.33	-0.32	Adiponectin levels;	chr4:55379470	chr4:55363971~55395847:-
KIRC	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	7.53	2.43e-13	1.36e-10	0.42	0.32	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
KIRC	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	7.53	2.44e-13	1.36e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
KIRC	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	7.53	2.44e-13	1.36e-10	0.5	0.32	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
KIRC	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	7.53	2.44e-13	1.36e-10	0.35	0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
KIRC	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	7.53	2.45e-13	1.36e-10	0.44	0.32	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
KIRC	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	7.53	2.45e-13	1.37e-10	0.45	0.32	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
KIRC	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	7.53	2.46e-13	1.37e-10	0.45	0.32	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	7.53	2.46e-13	1.37e-10	0.45	0.32	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
KIRC	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	7.53	2.46e-13	1.37e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
KIRC	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	7.53	2.46e-13	1.37e-10	0.39	0.32	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
KIRC	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	7.53	2.47e-13	1.38e-10	0.5	0.32	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
KIRC	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-7.53	2.47e-13	1.38e-10	-0.41	-0.32	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
KIRC	cis	rs890448	0.726	rs2583399	ENSG00000254531.1	FLJ20021	-7.53	2.47e-13	1.38e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315757	chr4:101347780~101348883:+
KIRC	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-7.53	2.48e-13	1.38e-10	-0.3	-0.32	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
KIRC	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	7.53	2.49e-13	1.38e-10	0.44	0.32	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
KIRC	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-7.53	2.49e-13	1.39e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
KIRC	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-7.53	2.49e-13	1.39e-10	-0.37	-0.32	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
KIRC	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	7.53	2.49e-13	1.39e-10	0.28	0.32	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
KIRC	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	7.53	2.49e-13	1.39e-10	0.36	0.32	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
KIRC	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-7.53	2.5e-13	1.39e-10	-0.44	-0.32	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
KIRC	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	7.53	2.5e-13	1.39e-10	0.77	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
KIRC	cis	rs11512640	0.655	rs77468344	ENSG00000254671.2	STT3A-AS1	7.53	2.5e-13	1.4e-10	0.67	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125586910	chr11:125570284~125592568:-
KIRC	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	7.53	2.51e-13	1.4e-10	0.38	0.32	Height;	chr4:55459921	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62303728	ENSG00000249700.7	SRD5A3-AS1	-7.53	2.51e-13	1.4e-10	-0.32	-0.32	Adiponectin levels;	chr4:55495762	chr4:55363971~55395847:-
KIRC	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-7.53	2.51e-13	1.4e-10	-0.38	-0.32	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
KIRC	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-7.52	2.51e-13	1.4e-10	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
KIRC	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	7.52	2.51e-13	1.4e-10	0.33	0.32	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
KIRC	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	7.52	2.51e-13	1.4e-10	0.46	0.32	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	7.52	2.51e-13	1.4e-10	0.46	0.32	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	7.52	2.51e-13	1.4e-10	0.46	0.32	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	7.52	2.51e-13	1.4e-10	0.46	0.32	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
KIRC	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-7.52	2.52e-13	1.4e-10	-0.25	-0.32	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
KIRC	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.52e-13	1.4e-10	-0.32	-0.32	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
KIRC	cis	rs897984	0.806	rs10782001	ENSG00000260911.2	RP11-196G11.2	-7.52	2.52e-13	1.4e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30931304	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.806	rs12928852	ENSG00000260911.2	RP11-196G11.2	-7.52	2.52e-13	1.4e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30932667	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.887	rs4870139	ENSG00000268592.3	RAET1E-AS1	7.52	2.52e-13	1.4e-10	0.46	0.32	Lung cancer;	chr6:149575182	chr6:149863494~149919507:+
KIRC	cis	rs58873874	0.737	rs76634949	ENSG00000251405.2	CTB-109A12.1	7.52	2.53e-13	1.41e-10	0.59	0.32	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157362615~157460078:-
KIRC	cis	rs58873874	0.737	rs79339674	ENSG00000251405.2	CTB-109A12.1	7.52	2.53e-13	1.41e-10	0.59	0.32	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157362615~157460078:-
KIRC	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-7.52	2.53e-13	1.41e-10	-0.34	-0.32	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
KIRC	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	7.52	2.54e-13	1.41e-10	0.48	0.32	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
KIRC	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-7.52	2.54e-13	1.41e-10	-0.36	-0.32	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-7.52	2.54e-13	1.41e-10	-0.36	-0.32	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-7.52	2.54e-13	1.41e-10	-0.36	-0.32	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-7.52	2.54e-13	1.41e-10	-0.36	-0.32	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
KIRC	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.52	2.54e-13	1.41e-10	-0.29	-0.32	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
KIRC	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-7.52	2.54e-13	1.41e-10	-0.29	-0.32	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
KIRC	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	7.52	2.55e-13	1.42e-10	0.25	0.32	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	7.52	2.55e-13	1.42e-10	0.25	0.32	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
KIRC	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-7.52	2.55e-13	1.42e-10	-0.39	-0.32	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-7.52	2.55e-13	1.42e-10	-0.39	-0.32	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
KIRC	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-7.52	2.55e-13	1.42e-10	-0.34	-0.32	Height;	chr3:53052712	chr3:53064283~53065091:-
KIRC	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	7.52	2.55e-13	1.42e-10	0.25	0.32	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
KIRC	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-7.52	2.55e-13	1.42e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
KIRC	cis	rs13113518	0.545	rs6810483	ENSG00000273257.1	RP11-177J6.1	7.52	2.55e-13	1.42e-10	0.38	0.32	Height;	chr4:55424406	chr4:55387949~55388271:+
KIRC	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-7.52	2.56e-13	1.42e-10	-0.51	-0.32	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
KIRC	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-7.52	2.56e-13	1.42e-10	-0.7	-0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
KIRC	cis	rs10971721	0.631	rs10971945	ENSG00000260947.1	RP11-384P7.7	7.52	2.57e-13	1.43e-10	0.57	0.32	Body mass index;	chr9:34129397	chr9:33697459~33700986:+
KIRC	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-7.52	2.57e-13	1.43e-10	-0.33	-0.32	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
KIRC	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-7.52	2.57e-13	1.43e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
KIRC	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	7.52	2.57e-13	1.43e-10	0.33	0.32	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
KIRC	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-7.52	2.57e-13	1.43e-10	-0.27	-0.32	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
KIRC	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-7.52	2.58e-13	1.43e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
KIRC	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	7.52	2.58e-13	1.43e-10	0.41	0.32	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
KIRC	cis	rs2486288	0.656	rs11629858	ENSG00000235390.4	CTD-2651B20.5	7.52	2.58e-13	1.43e-10	0.3	0.32	Glomerular filtration rate;	chr15:45254916	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11629859	ENSG00000235390.4	CTD-2651B20.5	7.52	2.58e-13	1.43e-10	0.3	0.32	Glomerular filtration rate;	chr15:45254923	chr15:45321077~45321692:-
KIRC	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	7.52	2.58e-13	1.44e-10	0.4	0.32	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
KIRC	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	7.52	2.58e-13	1.44e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
KIRC	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	7.52	2.59e-13	1.44e-10	0.45	0.32	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
KIRC	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	7.52	2.59e-13	1.44e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
KIRC	cis	rs950027	0.787	rs2433616	ENSG00000235390.4	CTD-2651B20.5	-7.52	2.59e-13	1.44e-10	-0.3	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45321077~45321692:-
KIRC	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	7.52	2.59e-13	1.44e-10	0.44	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
KIRC	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-7.52	2.6e-13	1.44e-10	-0.37	-0.32	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
KIRC	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	7.52	2.6e-13	1.44e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	7.52	2.6e-13	1.44e-10	0.41	0.32	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	7.52	2.6e-13	1.44e-10	0.41	0.32	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
KIRC	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-7.52	2.6e-13	1.45e-10	-0.43	-0.32	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
KIRC	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	7.52	2.6e-13	1.45e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
KIRC	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-7.52	2.6e-13	1.45e-10	-0.31	-0.32	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
KIRC	cis	rs3745672	1	rs10419620	ENSG00000219665.7	CTD-2006C1.2	-7.52	2.61e-13	1.45e-10	-0.62	-0.32	Multiple sclerosis;	chr19:12038132	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs10414248	ENSG00000219665.7	CTD-2006C1.2	-7.52	2.61e-13	1.45e-10	-0.62	-0.32	Multiple sclerosis;	chr19:12040811	chr19:11987617~12046275:+
KIRC	cis	rs6061231	0.631	rs2427317	ENSG00000275437.1	RP5-908M14.10	7.52	2.61e-13	1.45e-10	0.24	0.32	Colorectal cancer;	chr20:62400669	chr20:62402236~62405935:-
KIRC	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.52	2.61e-13	1.45e-10	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
KIRC	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.52	2.61e-13	1.45e-10	0.41	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
KIRC	cis	rs2486288	0.656	rs2413773	ENSG00000235390.4	CTD-2651B20.5	7.52	2.62e-13	1.45e-10	0.3	0.32	Glomerular filtration rate;	chr15:45257244	chr15:45321077~45321692:-
KIRC	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	7.52	2.62e-13	1.45e-10	0.41	0.32	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
KIRC	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-7.52	2.62e-13	1.45e-10	-0.39	-0.32	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
KIRC	cis	rs7592578	0.771	rs75579212	ENSG00000272979.1	RP11-647K16.1	-7.52	2.62e-13	1.45e-10	-0.46	-0.32	Diastolic blood pressure;	chr2:190511849	chr2:190454092~190454521:-
KIRC	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	7.52	2.62e-13	1.45e-10	0.42	0.32	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
KIRC	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.62e-13	1.46e-10	-0.33	-0.32	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
KIRC	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	7.52	2.62e-13	1.46e-10	0.42	0.32	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
KIRC	cis	rs13434995	0.513	rs62305270	ENSG00000273257.1	RP11-177J6.1	-7.52	2.62e-13	1.46e-10	-0.42	-0.32	Adiponectin levels;	chr4:55507842	chr4:55387949~55388271:+
KIRC	cis	rs10971721	1	rs10971721	ENSG00000260947.1	RP11-384P7.7	7.52	2.62e-13	1.46e-10	0.62	0.32	Body mass index;	chr9:33827696	chr9:33697459~33700986:+
KIRC	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	7.52	2.63e-13	1.46e-10	0.44	0.32	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	7.52	2.63e-13	1.46e-10	0.44	0.32	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	7.52	2.64e-13	1.46e-10	0.45	0.32	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	7.52	2.64e-13	1.46e-10	0.45	0.32	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	7.52	2.64e-13	1.46e-10	0.45	0.32	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
KIRC	cis	rs748404	0.578	rs2244746	ENSG00000205771.5	CATSPER2P1	-7.52	2.64e-13	1.46e-10	-0.39	-0.32	Lung cancer;	chr15:43402885	chr15:43726918~43747094:-
KIRC	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	7.52	2.64e-13	1.46e-10	0.49	0.32	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
KIRC	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-7.52	2.64e-13	1.46e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
KIRC	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-7.52	2.64e-13	1.47e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
KIRC	cis	rs79040073	0.765	rs7169304	ENSG00000259531.2	RP11-295H24.3	7.52	2.64e-13	1.47e-10	0.38	0.32	Lung cancer in ever smokers;	chr15:49186829	chr15:49365124~49366685:-
KIRC	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-7.52	2.64e-13	1.47e-10	-0.31	-0.32	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
KIRC	cis	rs7017914	0.967	rs2732090	ENSG00000254031.4	RP11-326E22.1	-7.52	2.65e-13	1.47e-10	-0.35	-0.32	Bone mineral density;	chr8:71006022	chr8:71155457~71204223:+
KIRC	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55435912	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55436576	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55436985	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55439472	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55439652	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55440643	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55441110	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55441567	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55441907	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55450812	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55452853	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55454154	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55455650	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55456620	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55457027	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55457086	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55461320	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55462689	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55463606	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55466010	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55467308	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55470266	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55470874	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55474259	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	7.52	2.65e-13	1.47e-10	0.38	0.32	Height;	chr4:55475130	chr4:55387949~55388271:+
KIRC	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	7.52	2.65e-13	1.47e-10	0.25	0.32	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	7.52	2.65e-13	1.47e-10	0.25	0.32	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
KIRC	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	7.52	2.65e-13	1.47e-10	0.47	0.32	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
KIRC	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-7.52	2.66e-13	1.47e-10	-0.38	-0.32	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
KIRC	cis	rs897984	0.762	rs12930545	ENSG00000260911.2	RP11-196G11.2	-7.52	2.66e-13	1.47e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30927490	chr16:31043150~31049868:+
KIRC	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-7.52	2.66e-13	1.47e-10	-0.39	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
KIRC	cis	rs3820928	0.874	rs4234064	ENSG00000212391.1	SNORA48	-7.52	2.66e-13	1.48e-10	-0.37	-0.32	Pulmonary function;	chr2:226992781	chr2:226968989~226969122:-
KIRC	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	7.52	2.67e-13	1.48e-10	0.35	0.32	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	7.52	2.67e-13	1.48e-10	0.35	0.32	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
KIRC	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-7.52	2.67e-13	1.48e-10	-0.43	-0.32	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-7.52	2.67e-13	1.48e-10	-0.43	-0.32	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
KIRC	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	7.52	2.68e-13	1.48e-10	0.25	0.32	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
KIRC	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	7.52	2.68e-13	1.49e-10	0.77	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
KIRC	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	7.51	2.69e-13	1.49e-10	0.35	0.32	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	7.51	2.69e-13	1.49e-10	0.45	0.32	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
KIRC	cis	rs2337406	1	rs11850600	ENSG00000274576.2	IGHV2-70	-7.51	2.69e-13	1.49e-10	-0.41	-0.32	Alzheimer's disease (late onset);	chr14:106670765	chr14:106770577~106771020:-
KIRC	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	7.51	2.69e-13	1.49e-10	0.45	0.32	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
KIRC	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-7.51	2.7e-13	1.49e-10	-0.25	-0.32	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
KIRC	cis	rs710913	0.717	rs2068473	ENSG00000237624.1	OXCT2P1	-7.51	2.7e-13	1.5e-10	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39514956~39516490:+
KIRC	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.38	0.32	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.38	0.32	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.38	0.32	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.38	0.32	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.38	0.32	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
KIRC	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.51	2.7e-13	1.5e-10	-0.34	-0.32	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
KIRC	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	7.51	2.7e-13	1.5e-10	0.35	0.32	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
KIRC	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-7.51	2.7e-13	1.5e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
KIRC	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	7.51	2.7e-13	1.5e-10	0.39	0.32	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
KIRC	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-7.51	2.71e-13	1.5e-10	-0.44	-0.32	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
KIRC	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-7.51	2.72e-13	1.51e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
KIRC	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	7.51	2.72e-13	1.51e-10	0.43	0.32	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	7.51	2.72e-13	1.51e-10	0.4	0.32	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	7.51	2.72e-13	1.51e-10	0.4	0.32	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	7.51	2.72e-13	1.51e-10	0.4	0.32	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	7.51	2.72e-13	1.51e-10	0.4	0.32	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69071281	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69071328	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69071698	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072135	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072143	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072154	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072229	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072402	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072745	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072777	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69073025	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69073381	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000251284.2	RP13-644M16.1	-7.51	2.72e-13	1.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69073429	chr4:69125274~69126451:+
KIRC	cis	rs950776	0.616	rs3743077	ENSG00000261762.1	RP11-650L12.2	7.51	2.73e-13	1.51e-10	0.42	0.32	Sudden cardiac arrest;	chr15:78602554	chr15:78589123~78591276:-
KIRC	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-7.51	2.73e-13	1.51e-10	-0.39	-0.32	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
KIRC	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55429416	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55430596	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55430730	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55430740	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55431595	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	7.51	2.73e-13	1.51e-10	0.38	0.32	Height;	chr4:55434518	chr4:55387949~55388271:+
KIRC	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-7.51	2.74e-13	1.51e-10	-0.41	-0.32	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
KIRC	cis	rs897984	0.77	rs3813020	ENSG00000260911.2	RP11-196G11.2	-7.51	2.74e-13	1.52e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30922754	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	7.51	2.74e-13	1.52e-10	0.45	0.32	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
KIRC	cis	rs1268083	0.546	rs9398785	ENSG00000237742.5	RP11-624M8.1	-7.51	2.74e-13	1.52e-10	-0.38	-0.32	Migraine;	chr6:125736602	chr6:125578558~125749190:-
KIRC	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-7.51	2.75e-13	1.52e-10	-0.42	-0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
KIRC	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	7.51	2.75e-13	1.52e-10	0.38	0.32	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
KIRC	cis	rs4972806	0.775	rs2857534	ENSG00000226363.3	HAGLROS	-7.51	2.76e-13	1.53e-10	-0.41	-0.32	IgG glycosylation;	chr2:176170948	chr2:176177717~176179008:+
KIRC	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	7.51	2.76e-13	1.53e-10	0.34	0.32	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
KIRC	cis	rs890448	0.726	rs2850367	ENSG00000254531.1	FLJ20021	-7.51	2.76e-13	1.53e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101310306	chr4:101347780~101348883:+
KIRC	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-7.51	2.77e-13	1.53e-10	-0.36	-0.32	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
KIRC	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	7.51	2.77e-13	1.53e-10	0.43	0.32	Height;	chr6:109366911	chr6:109382795~109383666:+
KIRC	cis	rs6600671	1	rs1832558	ENSG00000270231.3	NBPF8P	7.51	2.78e-13	1.54e-10	0.24	0.32	Hip geometry;	chr1:121435521	chr1:120436353~120467739:+
KIRC	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	7.51	2.79e-13	1.54e-10	0.39	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
KIRC	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	7.51	2.79e-13	1.55e-10	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
KIRC	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	7.51	2.8e-13	1.55e-10	0.44	0.32	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	7.51	2.8e-13	1.55e-10	0.44	0.32	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
KIRC	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-7.51	2.8e-13	1.55e-10	-0.33	-0.32	Height;	chr3:52967831	chr3:53064283~53065091:-
KIRC	cis	rs13434995	0.513	rs7681414	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.81e-13	1.55e-10	-0.32	-0.32	Adiponectin levels;	chr4:55508890	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62305271	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.81e-13	1.55e-10	-0.32	-0.32	Adiponectin levels;	chr4:55509715	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs10462033	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.81e-13	1.55e-10	-0.32	-0.32	Adiponectin levels;	chr4:55511552	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs1915905	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.81e-13	1.55e-10	-0.32	-0.32	Adiponectin levels;	chr4:55512381	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs1522109	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.81e-13	1.55e-10	-0.32	-0.32	Adiponectin levels;	chr4:55514403	chr4:55363971~55395847:-
KIRC	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	7.51	2.81e-13	1.55e-10	0.35	0.32	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
KIRC	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	7.51	2.81e-13	1.55e-10	0.32	0.32	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
KIRC	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-7.51	2.81e-13	1.55e-10	-0.29	-0.32	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-7.51	2.81e-13	1.55e-10	-0.29	-0.32	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
KIRC	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-7.51	2.81e-13	1.56e-10	-0.31	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
KIRC	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	7.51	2.82e-13	1.56e-10	0.36	0.32	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
KIRC	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-7.51	2.82e-13	1.56e-10	-0.29	-0.32	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-7.51	2.82e-13	1.56e-10	-0.29	-0.32	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
KIRC	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-7.51	2.82e-13	1.56e-10	-0.38	-0.32	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
KIRC	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-7.51	2.82e-13	1.56e-10	-0.35	-0.32	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
KIRC	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	7.51	2.82e-13	1.56e-10	0.28	0.32	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
KIRC	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-7.51	2.82e-13	1.56e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
KIRC	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	7.51	2.83e-13	1.56e-10	0.43	0.32	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
KIRC	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-7.51	2.83e-13	1.57e-10	-0.34	-0.32	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
KIRC	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-7.51	2.84e-13	1.57e-10	-0.36	-0.32	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
KIRC	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-7.51	2.84e-13	1.57e-10	-0.33	-0.32	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
KIRC	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-7.51	2.84e-13	1.57e-10	-0.37	-0.32	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
KIRC	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	7.51	2.84e-13	1.57e-10	0.31	0.32	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
KIRC	cis	rs13434995	0.513	rs62303730	ENSG00000249700.7	SRD5A3-AS1	-7.51	2.84e-13	1.57e-10	-0.32	-0.32	Adiponectin levels;	chr4:55498948	chr4:55363971~55395847:-
KIRC	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	7.51	2.85e-13	1.57e-10	0.44	0.32	Depression;	chr6:28167882	chr6:28115628~28116551:+
KIRC	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-7.51	2.85e-13	1.57e-10	-0.39	-0.32	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
KIRC	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	7.51	2.85e-13	1.57e-10	0.34	0.32	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
KIRC	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	7.51	2.85e-13	1.58e-10	0.44	0.32	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
KIRC	cis	rs4660214	0.671	rs72661956	ENSG00000237624.1	OXCT2P1	7.51	2.86e-13	1.58e-10	0.58	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39514956~39516490:+
KIRC	cis	rs4660214	0.671	rs16826068	ENSG00000237624.1	OXCT2P1	7.51	2.86e-13	1.58e-10	0.58	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39514956~39516490:+
KIRC	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	7.51	2.86e-13	1.58e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
KIRC	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	7.51	2.86e-13	1.58e-10	0.33	0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
KIRC	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-7.51	2.86e-13	1.58e-10	-0.29	-0.32	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
KIRC	cis	rs17772222	0.682	rs28482235	ENSG00000222990.1	RNU4-22P	7.51	2.86e-13	1.58e-10	0.34	0.32	Coronary artery calcification;	chr14:88472857	chr14:88513498~88513663:+
KIRC	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	7.51	2.86e-13	1.58e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
KIRC	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	7.51	2.86e-13	1.58e-10	0.43	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
KIRC	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-7.51	2.86e-13	1.58e-10	-0.33	-0.32	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
KIRC	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	7.51	2.87e-13	1.58e-10	0.44	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
KIRC	cis	rs13113518	0.507	rs4549456	ENSG00000273257.1	RP11-177J6.1	7.51	2.87e-13	1.59e-10	0.38	0.32	Height;	chr4:55398586	chr4:55387949~55388271:+
KIRC	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-7.51	2.87e-13	1.59e-10	-0.3	-0.32	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
KIRC	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-7.5	2.88e-13	1.59e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-7.5	2.88e-13	1.59e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-7.5	2.88e-13	1.59e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-7.5	2.88e-13	1.59e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
KIRC	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-7.5	2.88e-13	1.59e-10	-0.25	-0.32	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-7.5	2.88e-13	1.59e-10	-0.25	-0.32	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
KIRC	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	7.5	2.88e-13	1.59e-10	0.43	0.32	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	7.5	2.88e-13	1.59e-10	0.43	0.32	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	7.5	2.88e-13	1.59e-10	0.43	0.32	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
KIRC	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	7.5	2.89e-13	1.59e-10	0.41	0.32	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	7.5	2.89e-13	1.59e-10	0.41	0.32	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
KIRC	cis	rs11647589	0.678	rs6497489	ENSG00000262995.1	CTD-2194A8.2	-7.5	2.89e-13	1.59e-10	-0.34	-0.32	Blood metabolite levels;	chr16:20460042	chr16:20440266~20447000:-
KIRC	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	7.5	2.89e-13	1.59e-10	0.38	0.32	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
KIRC	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	7.5	2.89e-13	1.59e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
KIRC	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-7.5	2.89e-13	1.59e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
KIRC	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-7.5	2.89e-13	1.6e-10	-0.39	-0.32	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
KIRC	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.5	2.9e-13	1.6e-10	0.37	0.32	Migraine;	chr4:56881468	chr4:56960927~56961373:-
KIRC	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-7.5	2.9e-13	1.6e-10	-0.39	-0.32	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
KIRC	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	7.5	2.9e-13	1.6e-10	0.46	0.32	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	7.5	2.9e-13	1.6e-10	0.46	0.32	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	7.5	2.9e-13	1.6e-10	0.46	0.32	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	7.5	2.9e-13	1.6e-10	0.46	0.32	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
KIRC	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-7.5	2.9e-13	1.6e-10	-0.4	-0.32	Height;	chr4:55593918	chr4:55387949~55388271:+
KIRC	cis	rs3820928	0.874	rs2228557	ENSG00000212391.1	SNORA48	-7.5	2.9e-13	1.6e-10	-0.37	-0.32	Pulmonary function;	chr2:227007466	chr2:226968989~226969122:-
KIRC	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-7.5	2.91e-13	1.61e-10	-0.34	-0.32	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
KIRC	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	7.5	2.92e-13	1.61e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
KIRC	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-7.5	2.92e-13	1.61e-10	-0.42	-0.32	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
KIRC	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	7.5	2.92e-13	1.61e-10	0.45	0.32	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
KIRC	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-7.5	2.93e-13	1.62e-10	-0.38	-0.32	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
KIRC	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	7.5	2.93e-13	1.62e-10	0.41	0.32	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
KIRC	cis	rs7017914	0.869	rs2639954	ENSG00000254031.4	RP11-326E22.1	7.5	2.94e-13	1.62e-10	0.34	0.32	Bone mineral density;	chr8:71013340	chr8:71155457~71204223:+
KIRC	cis	rs13434995	0.513	rs60097207	ENSG00000249700.7	SRD5A3-AS1	-7.5	2.94e-13	1.62e-10	-0.33	-0.32	Adiponectin levels;	chr4:55406696	chr4:55363971~55395847:-
KIRC	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	7.5	2.94e-13	1.62e-10	0.23	0.32	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
KIRC	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	7.5	2.94e-13	1.62e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	7.5	2.94e-13	1.62e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
KIRC	cis	rs11512640	1	rs11220138	ENSG00000254671.2	STT3A-AS1	7.5	2.95e-13	1.63e-10	0.67	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125585927	chr11:125570284~125592568:-
KIRC	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	7.5	2.95e-13	1.63e-10	0.45	0.32	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
KIRC	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-7.5	2.95e-13	1.63e-10	-0.36	-0.32	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
KIRC	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-7.5	2.95e-13	1.63e-10	-0.36	-0.32	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
KIRC	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	7.5	2.95e-13	1.63e-10	0.37	0.32	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
KIRC	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	7.5	2.95e-13	1.63e-10	0.45	0.32	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
KIRC	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-7.5	2.96e-13	1.63e-10	-0.37	-0.32	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
KIRC	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	7.5	2.96e-13	1.63e-10	0.38	0.32	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	7.5	2.96e-13	1.63e-10	0.38	0.32	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
KIRC	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	7.5	2.96e-13	1.63e-10	0.39	0.32	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000251284.2	RP13-644M16.1	-7.5	2.96e-13	1.63e-10	-0.38	-0.32	Obesity-related traits;	chr4:69075473	chr4:69125274~69126451:+
KIRC	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	7.5	2.97e-13	1.63e-10	0.34	0.32	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
KIRC	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	7.5	2.97e-13	1.63e-10	0.44	0.32	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	7.5	2.97e-13	1.63e-10	0.44	0.32	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
KIRC	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	7.5	2.97e-13	1.64e-10	0.54	0.32	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	7.5	2.97e-13	1.64e-10	0.54	0.32	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
KIRC	cis	rs7017914	0.905	rs1389206	ENSG00000254031.4	RP11-326E22.1	7.5	2.97e-13	1.64e-10	0.34	0.32	Bone mineral density;	chr8:71012627	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs2639955	ENSG00000254031.4	RP11-326E22.1	7.5	2.97e-13	1.64e-10	0.34	0.32	Bone mineral density;	chr8:71013107	chr8:71155457~71204223:+
KIRC	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	7.5	2.98e-13	1.64e-10	0.45	0.32	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
KIRC	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	7.5	2.98e-13	1.64e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-7.5	2.98e-13	1.64e-10	-0.49	-0.32	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
KIRC	cis	rs6061231	0.63	rs62196294	ENSG00000275437.1	RP5-908M14.10	7.5	2.99e-13	1.64e-10	0.24	0.32	Colorectal cancer;	chr20:62398376	chr20:62402236~62405935:-
KIRC	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-7.5	3e-13	1.65e-10	-0.25	-0.32	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
KIRC	cis	rs4072705	0.967	rs4144630	ENSG00000224020.1	MIR181A2HG	-7.5	3.01e-13	1.66e-10	-0.32	-0.32	Menarche (age at onset);	chr9:124676921	chr9:124658467~124698631:+
KIRC	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-7.5	3.01e-13	1.66e-10	-0.36	-0.32	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
KIRC	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-7.5	3.01e-13	1.66e-10	-0.39	-0.32	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
KIRC	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-7.5	3.02e-13	1.66e-10	-0.51	-0.32	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
KIRC	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-7.5	3.02e-13	1.66e-10	-0.44	-0.32	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
KIRC	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-7.5	3.02e-13	1.66e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
KIRC	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	7.5	3.02e-13	1.66e-10	0.21	0.32	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
KIRC	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	7.5	3.02e-13	1.66e-10	0.41	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
KIRC	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	7.5	3.02e-13	1.66e-10	0.37	0.32	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
KIRC	cis	rs3820928	0.904	rs10933161	ENSG00000212391.1	SNORA48	-7.5	3.03e-13	1.66e-10	-0.38	-0.32	Pulmonary function;	chr2:226900156	chr2:226968989~226969122:-
KIRC	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-7.5	3.03e-13	1.67e-10	-0.39	-0.32	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
KIRC	cis	rs11647589	0.834	rs1910802	ENSG00000262995.1	CTD-2194A8.2	-7.5	3.03e-13	1.67e-10	-0.34	-0.32	Blood metabolite levels;	chr16:20464245	chr16:20440266~20447000:-
KIRC	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	7.5	3.04e-13	1.67e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
KIRC	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	7.5	3.05e-13	1.68e-10	0.6	0.32	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
KIRC	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	7.5	3.05e-13	1.68e-10	0.39	0.32	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.683	rs7923868	ENSG00000151963.4	RP11-775A3.1	-7.5	3.06e-13	1.68e-10	-0.37	-0.32	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:37883594~37884109:+
KIRC	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	7.5	3.06e-13	1.68e-10	0.45	0.32	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
KIRC	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-7.5	3.06e-13	1.68e-10	-0.37	-0.32	Migraine;	chr4:56881195	chr4:56960927~56961373:-
KIRC	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-7.5	3.06e-13	1.68e-10	-0.35	-0.32	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
KIRC	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	7.5	3.06e-13	1.68e-10	0.34	0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
KIRC	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-7.5	3.07e-13	1.69e-10	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-7.5	3.07e-13	1.69e-10	-0.46	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
KIRC	cis	rs7945705	0.715	rs10840123	ENSG00000254860.4	TMEM9B-AS1	-7.5	3.07e-13	1.69e-10	-0.35	-0.32	Hemoglobin concentration;	chr11:8797468	chr11:8964675~8977527:+
KIRC	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-7.5	3.07e-13	1.69e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
KIRC	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	7.5	3.08e-13	1.69e-10	0.29	0.32	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
KIRC	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	7.49	3.08e-13	1.69e-10	0.47	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
KIRC	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.49	3.08e-13	1.69e-10	-0.29	-0.32	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
KIRC	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	7.49	3.08e-13	1.69e-10	0.43	0.32	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
KIRC	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	7.49	3.09e-13	1.7e-10	0.37	0.32	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
KIRC	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-7.49	3.09e-13	1.7e-10	-0.36	-0.32	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
KIRC	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	7.49	3.1e-13	1.7e-10	0.4	0.32	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
KIRC	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-7.49	3.1e-13	1.7e-10	-0.24	-0.32	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
KIRC	cis	rs7672749	0.643	rs7690494	ENSG00000249973.2	CHCHD2P7	7.49	3.1e-13	1.7e-10	0.66	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87879387	chr4:87785920~87786371:-
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000251284.2	RP13-644M16.1	-7.49	3.1e-13	1.7e-10	-0.38	-0.32	Obesity-related traits;	chr4:69071215	chr4:69125274~69126451:+
KIRC	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	7.49	3.11e-13	1.71e-10	0.6	0.32	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
KIRC	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	7.49	3.11e-13	1.71e-10	0.6	0.32	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
KIRC	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-7.49	3.11e-13	1.71e-10	-0.4	-0.32	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
KIRC	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-7.49	3.11e-13	1.71e-10	-0.36	-0.32	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
KIRC	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-7.49	3.11e-13	1.71e-10	-0.36	-0.32	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
KIRC	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-7.49	3.12e-13	1.71e-10	-0.54	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
KIRC	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	7.49	3.12e-13	1.71e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
KIRC	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	7.49	3.12e-13	1.71e-10	0.51	0.32	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	7.49	3.12e-13	1.71e-10	0.51	0.32	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	7.49	3.12e-13	1.71e-10	0.51	0.32	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
KIRC	cis	rs7017914	0.934	rs3110239	ENSG00000254031.4	RP11-326E22.1	7.49	3.13e-13	1.72e-10	0.35	0.32	Bone mineral density;	chr8:71004510	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs3098867	ENSG00000254031.4	RP11-326E22.1	7.49	3.13e-13	1.72e-10	0.35	0.32	Bone mineral density;	chr8:71004636	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.934	rs2639904	ENSG00000254031.4	RP11-326E22.1	7.49	3.13e-13	1.72e-10	0.35	0.32	Bone mineral density;	chr8:71004895	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.967	rs2639901	ENSG00000254031.4	RP11-326E22.1	7.49	3.13e-13	1.72e-10	0.35	0.32	Bone mineral density;	chr8:71005516	chr8:71155457~71204223:+
KIRC	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-7.49	3.13e-13	1.72e-10	-0.38	-0.32	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
KIRC	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-7.49	3.13e-13	1.72e-10	-0.52	-0.32	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	7.49	3.13e-13	1.72e-10	0.45	0.32	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
KIRC	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-7.49	3.13e-13	1.72e-10	-0.41	-0.32	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
KIRC	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	7.49	3.13e-13	1.72e-10	0.41	0.32	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
KIRC	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-7.49	3.13e-13	1.72e-10	-0.25	-0.32	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
KIRC	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-7.49	3.13e-13	1.72e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
KIRC	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	7.49	3.14e-13	1.72e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	7.49	3.14e-13	1.72e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
KIRC	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	7.49	3.14e-13	1.72e-10	0.26	0.32	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
KIRC	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-7.49	3.14e-13	1.72e-10	-0.39	-0.32	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
KIRC	cis	rs11512640	0.826	rs76118307	ENSG00000254671.2	STT3A-AS1	7.49	3.14e-13	1.72e-10	0.74	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125573106	chr11:125570284~125592568:-
KIRC	cis	rs11512640	0.826	rs74986931	ENSG00000254671.2	STT3A-AS1	7.49	3.14e-13	1.72e-10	0.74	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125573240	chr11:125570284~125592568:-
KIRC	cis	rs11512640	0.826	rs78682798	ENSG00000254671.2	STT3A-AS1	7.49	3.14e-13	1.72e-10	0.74	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125575621	chr11:125570284~125592568:-
KIRC	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-7.49	3.15e-13	1.73e-10	-0.29	-0.32	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
KIRC	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-7.49	3.15e-13	1.73e-10	-0.38	-0.32	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
KIRC	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-7.49	3.15e-13	1.73e-10	-0.38	-0.32	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
KIRC	cis	rs9926296	0.568	rs417323	ENSG00000260259.1	RP11-368I7.4	7.49	3.15e-13	1.73e-10	0.29	0.32	Vitiligo;	chr16:89679869	chr16:89682620~89686569:-
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000275400.1	RP4-756H11.5	-7.49	3.15e-13	1.73e-10	-0.33	-0.32	Calcium levels;	chr7:65751755	chr7:66553805~66554199:-
KIRC	cis	rs897984	0.806	rs12924903	ENSG00000260911.2	RP11-196G11.2	7.49	3.15e-13	1.73e-10	0.21	0.32	Dementia with Lewy bodies;	chr16:30917649	chr16:31043150~31049868:+
KIRC	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-7.49	3.16e-13	1.73e-10	-0.39	-0.32	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
KIRC	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	7.49	3.16e-13	1.73e-10	0.38	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
KIRC	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	7.49	3.16e-13	1.74e-10	0.32	0.32	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
KIRC	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	7.49	3.17e-13	1.74e-10	0.49	0.32	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
KIRC	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-7.49	3.17e-13	1.74e-10	-0.41	-0.32	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
KIRC	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-7.49	3.17e-13	1.74e-10	-0.38	-0.32	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
KIRC	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-7.49	3.17e-13	1.74e-10	-0.3	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
KIRC	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	7.49	3.17e-13	1.74e-10	0.43	0.32	Height;	chr4:57019797	chr4:56960927~56961373:-
KIRC	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-7.49	3.17e-13	1.74e-10	-0.29	-0.32	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
KIRC	cis	rs950027	0.549	rs11070452	ENSG00000235390.4	CTD-2651B20.5	7.49	3.18e-13	1.74e-10	0.31	0.32	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45321077~45321692:-
KIRC	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	7.49	3.18e-13	1.74e-10	0.59	0.32	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	7.49	3.18e-13	1.74e-10	0.59	0.32	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	7.49	3.18e-13	1.74e-10	0.59	0.32	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
KIRC	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	7.49	3.18e-13	1.74e-10	0.38	0.32	Height;	chr4:55442184	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	7.49	3.18e-13	1.74e-10	0.38	0.32	Height;	chr4:55442875	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	7.49	3.18e-13	1.74e-10	0.38	0.32	Height;	chr4:55444253	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	7.49	3.18e-13	1.74e-10	0.38	0.32	Height;	chr4:55446869	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	7.49	3.18e-13	1.74e-10	0.38	0.32	Height;	chr4:55447523	chr4:55387949~55388271:+
KIRC	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-7.49	3.18e-13	1.74e-10	-0.41	-0.32	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
KIRC	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	7.49	3.19e-13	1.75e-10	0.38	0.32	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
KIRC	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	7.49	3.2e-13	1.75e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
KIRC	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	7.49	3.2e-13	1.75e-10	0.57	0.32	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
KIRC	cis	rs7017914	0.967	rs2639903	ENSG00000254031.4	RP11-326E22.1	7.49	3.2e-13	1.76e-10	0.35	0.32	Bone mineral density;	chr8:71005209	chr8:71155457~71204223:+
KIRC	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	7.49	3.21e-13	1.76e-10	0.44	0.32	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
KIRC	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-7.49	3.21e-13	1.76e-10	-0.36	-0.32	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
KIRC	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-7.49	3.22e-13	1.76e-10	-0.35	-0.32	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
KIRC	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	7.49	3.22e-13	1.76e-10	0.36	0.32	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
KIRC	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-7.49	3.22e-13	1.76e-10	-0.39	-0.32	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-7.49	3.22e-13	1.76e-10	-0.39	-0.32	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-7.49	3.22e-13	1.76e-10	-0.39	-0.32	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
KIRC	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-7.49	3.22e-13	1.76e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
KIRC	cis	rs2486288	0.656	rs11629807	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45254839	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.587	rs12899942	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45255082	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs12899058	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45255126	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs12904150	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45255407	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs9920290	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45255837	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11854325	ENSG00000235390.4	CTD-2651B20.5	7.49	3.22e-13	1.77e-10	0.3	0.32	Glomerular filtration rate;	chr15:45256761	chr15:45321077~45321692:-
KIRC	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.49	3.23e-13	1.77e-10	-0.29	-0.32	Gout;	chr7:66671562	chr7:66902857~66906297:+
KIRC	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	7.49	3.24e-13	1.78e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
KIRC	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-7.49	3.24e-13	1.78e-10	-0.29	-0.32	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
KIRC	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	7.49	3.25e-13	1.78e-10	0.3	0.32	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
KIRC	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-7.49	3.25e-13	1.78e-10	-0.29	-0.32	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-7.49	3.25e-13	1.78e-10	-0.29	-0.32	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
KIRC	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	7.49	3.25e-13	1.78e-10	0.42	0.32	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	7.49	3.25e-13	1.78e-10	0.3	0.32	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
KIRC	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	7.49	3.25e-13	1.78e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
KIRC	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-7.49	3.25e-13	1.78e-10	-0.48	-0.32	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
KIRC	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	7.49	3.26e-13	1.78e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
KIRC	cis	rs13434995	0.513	rs62303726	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55490415	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs55729020	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55491681	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs3805156	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55497925	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62303731	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55499667	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62303732	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55499868	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs56196624	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55500340	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62305264	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55502968	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62305265	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55503474	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62305268	ENSG00000273257.1	RP11-177J6.1	-7.49	3.27e-13	1.79e-10	-0.42	-0.32	Adiponectin levels;	chr4:55506991	chr4:55387949~55388271:+
KIRC	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	7.49	3.27e-13	1.79e-10	0.38	0.32	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
KIRC	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-7.49	3.27e-13	1.79e-10	-0.38	-0.32	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
KIRC	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	7.49	3.28e-13	1.8e-10	0.35	0.32	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
KIRC	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	7.49	3.29e-13	1.8e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
KIRC	cis	rs2486288	0.656	rs11637920	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258707	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11632777	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258847	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11632778	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258858	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11632752	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258942	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs12911186	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45259225	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs12915314	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45259293	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs8039138	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45259394	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs8039540	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45259644	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs8040185	ENSG00000235390.4	CTD-2651B20.5	7.49	3.29e-13	1.8e-10	0.3	0.32	Glomerular filtration rate;	chr15:45259883	chr15:45321077~45321692:-
KIRC	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	7.49	3.29e-13	1.8e-10	0.33	0.32	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
KIRC	cis	rs3820928	1	rs3820928	ENSG00000212391.1	SNORA48	-7.49	3.29e-13	1.8e-10	-0.37	-0.32	Pulmonary function;	chr2:226908750	chr2:226968989~226969122:-
KIRC	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-7.48	3.3e-13	1.8e-10	-0.34	-0.32	Height;	chr3:53047596	chr3:53064283~53065091:-
KIRC	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	7.48	3.3e-13	1.81e-10	0.27	0.32	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
KIRC	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-7.48	3.3e-13	1.81e-10	-0.36	-0.32	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
KIRC	cis	rs710913	0.717	rs1180349	ENSG00000237624.1	OXCT2P1	-7.48	3.31e-13	1.81e-10	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39514956~39516490:+
KIRC	cis	rs2847281	0.614	rs888269	ENSG00000267654.1	RP11-973H7.4	-7.48	3.31e-13	1.81e-10	-0.37	-0.32	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12774861	chr18:12739490~12749421:-
KIRC	cis	rs2847281	0.561	rs888271	ENSG00000267654.1	RP11-973H7.4	-7.48	3.31e-13	1.81e-10	-0.37	-0.32	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12774982	chr18:12739490~12749421:-
KIRC	cis	rs2847281	0.614	rs2847262	ENSG00000267654.1	RP11-973H7.4	-7.48	3.31e-13	1.81e-10	-0.37	-0.32	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12775296	chr18:12739490~12749421:-
KIRC	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-7.48	3.31e-13	1.81e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
KIRC	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	7.48	3.32e-13	1.81e-10	0.43	0.32	Height;	chr6:109361318	chr6:109382795~109383666:+
KIRC	cis	rs13434995	0.513	rs7665846	ENSG00000273257.1	RP11-177J6.1	7.48	3.32e-13	1.81e-10	0.42	0.32	Adiponectin levels;	chr4:55573078	chr4:55387949~55388271:+
KIRC	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	7.48	3.32e-13	1.81e-10	0.39	0.32	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
KIRC	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-7.48	3.32e-13	1.81e-10	-0.36	-0.32	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
KIRC	cis	rs1823913	0.538	rs13432697	ENSG00000280083.1	RP11-317J9.1	-7.48	3.32e-13	1.82e-10	-0.31	-0.32	Obesity-related traits;	chr2:191345944	chr2:191154118~191156070:-
KIRC	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	7.48	3.32e-13	1.82e-10	0.46	0.32	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
KIRC	cis	rs13434995	0.513	rs62305270	ENSG00000249700.7	SRD5A3-AS1	-7.48	3.33e-13	1.82e-10	-0.32	-0.32	Adiponectin levels;	chr4:55507842	chr4:55363971~55395847:-
KIRC	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-7.48	3.33e-13	1.82e-10	-0.38	-0.32	Height;	chr4:55487920	chr4:55387949~55388271:+
KIRC	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-7.48	3.33e-13	1.82e-10	-0.36	-0.32	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
KIRC	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-7.48	3.33e-13	1.82e-10	-0.35	-0.32	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
KIRC	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-7.48	3.34e-13	1.82e-10	-0.27	-0.32	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
KIRC	cis	rs1431005	1	rs72723291	ENSG00000250620.1	RP11-91J3.3	7.48	3.34e-13	1.82e-10	0.42	0.32	Response to statin therapy;	chr4:187425714	chr4:187413564~187415697:+
KIRC	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	7.48	3.34e-13	1.83e-10	0.44	0.32	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	7.48	3.34e-13	1.83e-10	0.44	0.32	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
KIRC	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	7.48	3.34e-13	1.83e-10	0.35	0.32	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
KIRC	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-7.48	3.35e-13	1.83e-10	-0.42	-0.32	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
KIRC	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	7.48	3.35e-13	1.83e-10	0.48	0.32	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	7.48	3.35e-13	1.83e-10	0.48	0.32	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-7.48	3.35e-13	1.83e-10	-0.48	-0.32	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-7.48	3.35e-13	1.83e-10	-0.48	-0.32	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-7.48	3.35e-13	1.83e-10	-0.48	-0.32	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-7.48	3.35e-13	1.83e-10	-0.48	-0.32	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
KIRC	cis	rs950027	0.549	rs2899375	ENSG00000235390.4	CTD-2651B20.5	7.48	3.35e-13	1.83e-10	0.3	0.32	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45321077~45321692:-
KIRC	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	7.48	3.35e-13	1.83e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
KIRC	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	7.48	3.35e-13	1.83e-10	0.41	0.32	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
KIRC	cis	rs6600671	0.967	rs4844613	ENSG00000270231.3	NBPF8P	7.48	3.36e-13	1.83e-10	0.24	0.32	Hip geometry;	chr1:121431913	chr1:120436353~120467739:+
KIRC	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	7.48	3.36e-13	1.83e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
KIRC	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-7.48	3.36e-13	1.84e-10	-0.38	-0.32	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
KIRC	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-7.48	3.37e-13	1.84e-10	-0.39	-0.32	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
KIRC	cis	rs1431005	1	rs72723294	ENSG00000250620.1	RP11-91J3.3	7.48	3.37e-13	1.84e-10	0.42	0.32	Response to statin therapy;	chr4:187426641	chr4:187413564~187415697:+
KIRC	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	7.48	3.38e-13	1.84e-10	0.3	0.32	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
KIRC	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-7.48	3.38e-13	1.85e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
KIRC	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	7.48	3.39e-13	1.85e-10	0.4	0.32	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
KIRC	cis	rs2486288	0.656	rs8039354	ENSG00000259433.2	CTD-2651B20.4	-7.48	3.39e-13	1.85e-10	-0.23	-0.32	Glomerular filtration rate;	chr15:45259558	chr15:45330209~45332634:-
KIRC	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	7.48	3.39e-13	1.85e-10	0.43	0.32	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
KIRC	cis	rs13113518	1	rs2279458	ENSG00000273257.1	RP11-177J6.1	7.48	3.39e-13	1.85e-10	0.38	0.32	Height;	chr4:55562653	chr4:55387949~55388271:+
KIRC	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	7.48	3.4e-13	1.86e-10	0.25	0.32	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
KIRC	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-7.48	3.4e-13	1.86e-10	-0.41	-0.32	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
KIRC	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-7.48	3.41e-13	1.86e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
KIRC	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-7.48	3.41e-13	1.86e-10	-0.38	-0.32	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-7.48	3.41e-13	1.86e-10	-0.38	-0.32	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-7.48	3.41e-13	1.86e-10	-0.38	-0.32	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
KIRC	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	7.48	3.42e-13	1.87e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	7.48	3.42e-13	1.87e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
KIRC	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-7.48	3.42e-13	1.87e-10	-0.39	-0.32	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
KIRC	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-7.48	3.42e-13	1.87e-10	-0.39	-0.32	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
KIRC	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-7.48	3.43e-13	1.87e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
KIRC	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-7.48	3.43e-13	1.87e-10	-0.36	-0.32	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
KIRC	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	7.48	3.44e-13	1.88e-10	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
KIRC	cis	rs2486288	0.656	rs2413772	ENSG00000259433.2	CTD-2651B20.4	7.48	3.44e-13	1.88e-10	0.23	0.32	Glomerular filtration rate;	chr15:45257664	chr15:45330209~45332634:-
KIRC	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	7.48	3.44e-13	1.88e-10	0.34	0.32	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
KIRC	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-7.48	3.45e-13	1.88e-10	-0.25	-0.32	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
KIRC	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-7.48	3.45e-13	1.88e-10	-0.25	-0.32	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
KIRC	cis	rs3820928	0.874	rs4675137	ENSG00000212391.1	SNORA48	-7.48	3.45e-13	1.88e-10	-0.37	-0.32	Pulmonary function;	chr2:227019194	chr2:226968989~226969122:-
KIRC	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	7.48	3.45e-13	1.88e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
KIRC	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	7.48	3.46e-13	1.89e-10	0.45	0.32	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
KIRC	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	7.48	3.46e-13	1.89e-10	0.39	0.32	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
KIRC	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	7.48	3.46e-13	1.89e-10	0.35	0.32	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
KIRC	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	7.48	3.47e-13	1.89e-10	0.22	0.32	Breast cancer;	chr11:750849	chr11:781645~782105:+
KIRC	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.48	3.47e-13	1.89e-10	-0.35	-0.32	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
KIRC	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-7.48	3.48e-13	1.9e-10	-0.44	-0.32	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
KIRC	cis	rs897984	0.806	rs11640534	ENSG00000260911.2	RP11-196G11.2	-7.48	3.48e-13	1.9e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30938194	chr16:31043150~31049868:+
KIRC	cis	rs12449964	0.515	rs9899364	ENSG00000223979.2	SMCR2	7.48	3.48e-13	1.9e-10	0.37	0.32	Coronary artery disease or ischemic stroke;	chr17:17663798	chr17:17674026~17677688:-
KIRC	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	7.48	3.49e-13	1.9e-10	0.34	0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
KIRC	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-7.48	3.5e-13	1.91e-10	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	7.48	3.5e-13	1.91e-10	0.38	0.32	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
KIRC	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-7.48	3.5e-13	1.91e-10	-0.34	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
KIRC	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	7.48	3.51e-13	1.91e-10	0.43	0.32	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
KIRC	cis	rs2486288	0.656	rs2413774	ENSG00000235390.4	CTD-2651B20.5	7.48	3.51e-13	1.91e-10	0.3	0.32	Glomerular filtration rate;	chr15:45257225	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11632724	ENSG00000235390.4	CTD-2651B20.5	7.48	3.51e-13	1.91e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258593	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs11632651	ENSG00000235390.4	CTD-2651B20.5	7.48	3.51e-13	1.91e-10	0.3	0.32	Glomerular filtration rate;	chr15:45258640	chr15:45321077~45321692:-
KIRC	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	7.48	3.51e-13	1.91e-10	0.4	0.32	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
KIRC	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-7.48	3.53e-13	1.92e-10	-0.38	-0.32	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-7.48	3.53e-13	1.92e-10	-0.38	-0.32	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-7.48	3.53e-13	1.92e-10	-0.38	-0.32	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
KIRC	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	7.48	3.53e-13	1.92e-10	0.44	0.32	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
KIRC	cis	rs1431005	0.927	rs72725278	ENSG00000250620.1	RP11-91J3.3	7.47	3.53e-13	1.92e-10	0.42	0.32	Response to statin therapy;	chr4:187465625	chr4:187413564~187415697:+
KIRC	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	7.47	3.54e-13	1.93e-10	0.38	0.32	Height;	chr4:55589624	chr4:55387949~55388271:+
KIRC	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	7.47	3.55e-13	1.93e-10	0.36	0.32	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000251284.2	RP13-644M16.1	-7.47	3.55e-13	1.93e-10	-0.38	-0.32	Obesity-related traits;	chr4:69070955	chr4:69125274~69126451:+
KIRC	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	7.47	3.55e-13	1.93e-10	0.41	0.32	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
KIRC	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-7.47	3.55e-13	1.93e-10	-0.41	-0.32	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
KIRC	cis	rs890448	0.726	rs2583394	ENSG00000254531.1	FLJ20021	7.47	3.56e-13	1.94e-10	0.31	0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101330625	chr4:101347780~101348883:+
KIRC	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-7.47	3.57e-13	1.94e-10	-0.42	-0.32	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
KIRC	cis	rs17801127	0.818	rs16827337	ENSG00000231969.1	AC144449.1	7.47	3.58e-13	1.95e-10	0.54	0.32	Liver enzyme levels (alanine transaminase);	chr2:149690094	chr2:149587196~149848233:+
KIRC	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	7.47	3.58e-13	1.95e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	7.47	3.58e-13	1.95e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	7.47	3.58e-13	1.95e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
KIRC	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	7.47	3.59e-13	1.95e-10	0.32	0.32	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000251284.2	RP13-644M16.1	-7.47	3.59e-13	1.95e-10	-0.38	-0.32	Obesity-related traits;	chr4:69072070	chr4:69125274~69126451:+
KIRC	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-7.47	3.59e-13	1.96e-10	-0.32	-0.32	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
KIRC	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	7.47	3.6e-13	1.96e-10	0.4	0.32	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
KIRC	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-7.47	3.61e-13	1.96e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-7.47	3.61e-13	1.96e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
KIRC	cis	rs13434995	0.513	rs17779627	ENSG00000273257.1	RP11-177J6.1	-7.47	3.61e-13	1.96e-10	-0.42	-0.32	Adiponectin levels;	chr4:55483775	chr4:55387949~55388271:+
KIRC	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-7.47	3.61e-13	1.96e-10	-0.36	-0.32	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
KIRC	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-7.47	3.61e-13	1.97e-10	-0.36	-0.32	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
KIRC	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-7.47	3.62e-13	1.97e-10	-0.38	-0.32	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
KIRC	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	7.47	3.64e-13	1.98e-10	0.25	0.32	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
KIRC	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-7.47	3.65e-13	1.98e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-7.47	3.65e-13	1.98e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000251284.2	RP13-644M16.1	-7.47	3.65e-13	1.99e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069420	chr4:69125274~69126451:+
KIRC	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	7.47	3.66e-13	1.99e-10	0.4	0.32	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
KIRC	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	7.47	3.66e-13	1.99e-10	0.61	0.32	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
KIRC	cis	rs2012796	0.704	rs57670850	ENSG00000270343.1	UNGP3	7.47	3.66e-13	1.99e-10	0.4	0.32	Night sleep phenotypes;	chr14:81375233	chr14:81259565~81260239:-
KIRC	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-7.47	3.67e-13	1.99e-10	-0.3	-0.32	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-7.47	3.67e-13	1.99e-10	-0.3	-0.32	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-7.47	3.67e-13	1.99e-10	-0.3	-0.32	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-7.47	3.67e-13	1.99e-10	-0.3	-0.32	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-7.47	3.67e-13	1.99e-10	-0.3	-0.32	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-7.47	3.67e-13	1.99e-10	-0.4	-0.32	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
KIRC	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.47	3.67e-13	2e-10	-0.31	-0.32	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
KIRC	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	7.47	3.68e-13	2e-10	0.36	0.32	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
KIRC	cis	rs7017914	0.84	rs1481804	ENSG00000254031.4	RP11-326E22.1	7.47	3.68e-13	2e-10	0.35	0.32	Bone mineral density;	chr8:71057195	chr8:71155457~71204223:+
KIRC	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-7.47	3.69e-13	2e-10	-0.43	-0.32	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
KIRC	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	7.47	3.69e-13	2e-10	0.38	0.32	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	7.47	3.69e-13	2e-10	0.38	0.32	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	7.47	3.69e-13	2e-10	0.38	0.32	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	7.47	3.69e-13	2e-10	0.38	0.32	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
KIRC	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-7.47	3.69e-13	2.01e-10	-0.38	-0.32	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-7.47	3.69e-13	2.01e-10	-0.38	-0.32	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
KIRC	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-7.47	3.7e-13	2.01e-10	-0.44	-0.32	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
KIRC	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	7.47	3.7e-13	2.01e-10	0.41	0.32	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
KIRC	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	7.47	3.71e-13	2.01e-10	0.22	0.32	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
KIRC	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	7.47	3.71e-13	2.01e-10	0.46	0.32	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
KIRC	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-7.47	3.71e-13	2.01e-10	-0.41	-0.32	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
KIRC	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	7.47	3.71e-13	2.02e-10	0.35	0.32	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	7.47	3.71e-13	2.02e-10	0.35	0.32	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	7.47	3.71e-13	2.02e-10	0.35	0.32	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
KIRC	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	7.47	3.72e-13	2.02e-10	0.21	0.32	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
KIRC	cis	rs13434995	0.588	rs114571142	ENSG00000273257.1	RP11-177J6.1	-7.47	3.72e-13	2.02e-10	-0.42	-0.32	Adiponectin levels;	chr4:55412991	chr4:55387949~55388271:+
KIRC	cis	rs2833693	0.524	rs8129993	ENSG00000261610.1	AP000265.1	7.47	3.72e-13	2.02e-10	0.37	0.32	Temperament;	chr21:32268841	chr21:32259804~32261585:-
KIRC	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	7.47	3.72e-13	2.02e-10	0.45	0.32	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
KIRC	cis	rs4072705	0.967	rs4836986	ENSG00000224020.1	MIR181A2HG	-7.47	3.73e-13	2.02e-10	-0.32	-0.32	Menarche (age at onset);	chr9:124645780	chr9:124658467~124698631:+
KIRC	cis	rs2486288	0.656	rs10519018	ENSG00000259433.2	CTD-2651B20.4	7.47	3.73e-13	2.02e-10	0.23	0.32	Glomerular filtration rate;	chr15:45257067	chr15:45330209~45332634:-
KIRC	cis	rs11085466	0.51	rs8108399	ENSG00000268278.1	RP11-420K14.1	7.47	3.73e-13	2.02e-10	0.38	0.32	Colorectal or endometrial cancer;	chr19:21618479	chr19:21637974~21656300:+
KIRC	cis	rs10214930	0.602	rs2098315	ENSG00000235574.1	AC073150.6	-7.47	3.73e-13	2.03e-10	-0.37	-0.32	Hypospadias;	chr7:27541026	chr7:27491682~27492765:-
KIRC	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-7.47	3.73e-13	2.03e-10	-0.38	-0.32	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
KIRC	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.47	3.74e-13	2.03e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
KIRC	cis	rs2486288	0.656	rs1060896	ENSG00000235390.4	CTD-2651B20.5	7.47	3.74e-13	2.03e-10	0.3	0.32	Glomerular filtration rate;	chr15:45262069	chr15:45321077~45321692:-
KIRC	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-7.47	3.74e-13	2.03e-10	-0.38	-0.32	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
KIRC	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	7.47	3.76e-13	2.04e-10	0.36	0.32	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
KIRC	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	7.47	3.76e-13	2.04e-10	0.36	0.32	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000251284.2	RP13-644M16.1	-7.47	3.76e-13	2.04e-10	-0.38	-0.32	Obesity-related traits;	chr4:69074144	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000251284.2	RP13-644M16.1	-7.47	3.76e-13	2.04e-10	-0.38	-0.32	Obesity-related traits;	chr4:69074157	chr4:69125274~69126451:+
KIRC	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-7.47	3.76e-13	2.04e-10	-0.36	-0.32	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
KIRC	cis	rs3820928	0.874	rs4234063	ENSG00000212391.1	SNORA48	7.47	3.76e-13	2.04e-10	0.37	0.32	Pulmonary function;	chr2:226963619	chr2:226968989~226969122:-
KIRC	cis	rs7916697	0.626	rs3858144	ENSG00000233590.1	RP11-153K11.3	-7.47	3.77e-13	2.04e-10	-0.34	-0.32	Optic disc area;	chr10:68251597	chr10:68233251~68242379:-
KIRC	cis	rs17772222	0.637	rs879932	ENSG00000222990.1	RNU4-22P	7.47	3.77e-13	2.04e-10	0.33	0.32	Coronary artery calcification;	chr14:88479247	chr14:88513498~88513663:+
KIRC	cis	rs1560104	0.597	rs735819	ENSG00000274834.1	CTD-3037G24.5	-7.47	3.77e-13	2.04e-10	-0.34	-0.32	Obesity-related traits;	chr16:12618370	chr16:12614451~12614852:+
KIRC	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-7.47	3.77e-13	2.05e-10	-0.41	-0.32	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
KIRC	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-7.47	3.78e-13	2.05e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
KIRC	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	7.47	3.78e-13	2.05e-10	0.53	0.32	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	7.47	3.78e-13	2.05e-10	0.53	0.32	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
KIRC	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	7.46	3.79e-13	2.05e-10	0.44	0.32	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
KIRC	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	7.46	3.79e-13	2.05e-10	0.42	0.32	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
KIRC	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	7.46	3.79e-13	2.05e-10	0.41	0.32	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
KIRC	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	7.46	3.79e-13	2.06e-10	0.37	0.32	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
KIRC	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-7.46	3.8e-13	2.06e-10	-0.38	-0.32	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000251284.2	RP13-644M16.1	-7.46	3.8e-13	2.06e-10	-0.38	-0.32	Obesity-related traits;	chr4:69074077	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000251284.2	RP13-644M16.1	-7.46	3.8e-13	2.06e-10	-0.38	-0.32	Obesity-related traits;	chr4:69075085	chr4:69125274~69126451:+
KIRC	cis	rs755249	0.958	rs17264866	ENSG00000182109.6	RP11-69E11.4	7.46	3.8e-13	2.06e-10	0.27	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39522280~39546187:-
KIRC	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	7.46	3.81e-13	2.06e-10	0.37	0.32	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
KIRC	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	7.46	3.81e-13	2.06e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
KIRC	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	7.46	3.82e-13	2.07e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
KIRC	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-7.46	3.82e-13	2.07e-10	-0.29	-0.32	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
KIRC	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-7.46	3.83e-13	2.07e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	7.46	3.84e-13	2.08e-10	0.45	0.32	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
KIRC	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	7.46	3.84e-13	2.08e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
KIRC	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-7.46	3.84e-13	2.08e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
KIRC	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	7.46	3.84e-13	2.08e-10	0.61	0.32	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
KIRC	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	7.46	3.85e-13	2.08e-10	0.42	0.32	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
KIRC	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	7.46	3.85e-13	2.08e-10	0.38	0.32	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
KIRC	cis	rs10916248	0.511	rs1060386	ENSG00000232628.4	RP11-365O16.3	7.46	3.85e-13	2.08e-10	0.52	0.32	QT interval (drug interaction);	chr1:224192776	chr1:224208747~224213279:-
KIRC	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-7.46	3.85e-13	2.09e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
KIRC	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-7.46	3.87e-13	2.09e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-7.46	3.87e-13	2.09e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
KIRC	cis	rs2486288	0.656	rs11629807	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45254839	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.587	rs12899942	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45255082	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs12899058	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45255126	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs12904150	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45255407	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs9920290	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45255837	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11854325	ENSG00000259433.2	CTD-2651B20.4	7.46	3.87e-13	2.09e-10	0.23	0.32	Glomerular filtration rate;	chr15:45256761	chr15:45330209~45332634:-
KIRC	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	7.46	3.87e-13	2.09e-10	0.46	0.32	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
KIRC	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	7.46	3.87e-13	2.09e-10	0.46	0.32	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	7.46	3.87e-13	2.09e-10	0.46	0.32	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	7.46	3.87e-13	2.09e-10	0.46	0.32	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
KIRC	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-7.46	3.87e-13	2.09e-10	-0.46	-0.32	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
KIRC	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-7.46	3.87e-13	2.1e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
KIRC	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-7.46	3.87e-13	2.1e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
KIRC	cis	rs897984	0.806	rs11150600	ENSG00000260911.2	RP11-196G11.2	-7.46	3.87e-13	2.1e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30929010	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs4889599	ENSG00000260911.2	RP11-196G11.2	-7.46	3.87e-13	2.1e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30957268	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.721	rs2305884	ENSG00000260911.2	RP11-196G11.2	-7.46	3.87e-13	2.1e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30959420	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs11150601	ENSG00000260911.2	RP11-196G11.2	-7.46	3.87e-13	2.1e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30966478	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-7.46	3.87e-13	2.1e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
KIRC	cis	rs7672749	0.73	rs17013324	ENSG00000249973.2	CHCHD2P7	7.46	3.88e-13	2.1e-10	0.66	0.32	TB-LM or TBLH-BMD (pleiotropy);	chr4:87850762	chr4:87785920~87786371:-
KIRC	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-7.46	3.88e-13	2.1e-10	-0.36	-0.32	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
KIRC	cis	rs13434995	0.513	rs17722870	ENSG00000273257.1	RP11-177J6.1	-7.46	3.88e-13	2.1e-10	-0.42	-0.32	Adiponectin levels;	chr4:55478519	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs55885973	ENSG00000273257.1	RP11-177J6.1	-7.46	3.88e-13	2.1e-10	-0.42	-0.32	Adiponectin levels;	chr4:55480054	chr4:55387949~55388271:+
KIRC	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	7.46	3.89e-13	2.1e-10	0.38	0.32	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
KIRC	cis	rs17214007	0.518	rs35694612	ENSG00000263335.1	AF001548.5	-7.46	3.89e-13	2.1e-10	-0.46	-0.32	Cognitive function;	chr16:15674392	chr16:15726674~15732993:+
KIRC	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	7.46	3.89e-13	2.1e-10	0.41	0.32	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	7.46	3.89e-13	2.1e-10	0.41	0.32	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
KIRC	cis	rs1560104	0.597	rs11075126	ENSG00000274834.1	CTD-3037G24.5	7.46	3.89e-13	2.11e-10	0.34	0.32	Obesity-related traits;	chr16:12613117	chr16:12614451~12614852:+
KIRC	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-7.46	3.9e-13	2.11e-10	-0.36	-0.32	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
KIRC	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-7.46	3.9e-13	2.11e-10	-0.39	-0.32	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
KIRC	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	7.46	3.91e-13	2.12e-10	0.34	0.32	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
KIRC	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-7.46	3.91e-13	2.12e-10	-0.38	-0.32	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
KIRC	cis	rs897984	0.721	rs4889525	ENSG00000260911.2	RP11-196G11.2	-7.46	3.92e-13	2.12e-10	-0.2	-0.32	Dementia with Lewy bodies;	chr16:30978537	chr16:31043150~31049868:+
KIRC	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-7.46	3.92e-13	2.12e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
KIRC	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	7.46	3.92e-13	2.12e-10	0.41	0.32	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	7.46	3.92e-13	2.12e-10	0.41	0.32	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	7.46	3.92e-13	2.12e-10	0.41	0.32	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
KIRC	cis	rs13434995	0.513	rs880358	ENSG00000273257.1	RP11-177J6.1	-7.46	3.92e-13	2.12e-10	-0.43	-0.32	Adiponectin levels;	chr4:55410311	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs17776975	ENSG00000273257.1	RP11-177J6.1	-7.46	3.92e-13	2.12e-10	-0.43	-0.32	Adiponectin levels;	chr4:55410728	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	7.46	3.92e-13	2.12e-10	0.41	0.32	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
KIRC	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	7.46	3.93e-13	2.12e-10	0.48	0.32	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
KIRC	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-7.46	3.93e-13	2.12e-10	-0.39	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
KIRC	cis	rs13434995	0.513	rs7660668	ENSG00000249700.7	SRD5A3-AS1	7.46	3.93e-13	2.13e-10	0.32	0.32	Adiponectin levels;	chr4:55535530	chr4:55363971~55395847:-
KIRC	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-7.46	3.93e-13	2.13e-10	-0.32	-0.32	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-7.46	3.93e-13	2.13e-10	-0.32	-0.32	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
KIRC	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-7.46	3.93e-13	2.13e-10	-0.32	-0.32	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
KIRC	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	7.46	3.94e-13	2.13e-10	0.51	0.32	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
KIRC	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-7.46	3.94e-13	2.13e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-7.46	3.94e-13	2.13e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-7.46	3.94e-13	2.13e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
KIRC	cis	rs1431005	0.964	rs978629	ENSG00000250620.1	RP11-91J3.3	7.46	3.94e-13	2.13e-10	0.42	0.32	Response to statin therapy;	chr4:187426241	chr4:187413564~187415697:+
KIRC	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	7.46	3.95e-13	2.13e-10	0.38	0.32	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
KIRC	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.46	3.95e-13	2.13e-10	-0.43	-0.32	Depression;	chr6:28096845	chr6:28115628~28116551:+
KIRC	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-7.46	3.95e-13	2.13e-10	-0.38	-0.32	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-7.46	3.95e-13	2.13e-10	-0.38	-0.32	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
KIRC	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-7.46	3.95e-13	2.13e-10	-0.38	-0.32	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
KIRC	cis	rs12500482	0.5	rs6834219	ENSG00000206113.6	RP11-503N18.1	7.46	3.95e-13	2.14e-10	0.4	0.32	Cognitive function;	chr4:2422373	chr4:2418974~2450360:+
KIRC	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	7.46	3.96e-13	2.14e-10	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
KIRC	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-7.46	3.96e-13	2.14e-10	-0.39	-0.32	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
KIRC	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	7.46	3.97e-13	2.14e-10	0.23	0.32	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	7.46	3.97e-13	2.14e-10	0.23	0.32	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
KIRC	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-7.46	3.97e-13	2.14e-10	-0.36	-0.32	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
KIRC	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-7.46	3.98e-13	2.15e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
KIRC	cis	rs2486288	0.656	rs1060896	ENSG00000259433.2	CTD-2651B20.4	7.46	3.99e-13	2.16e-10	0.23	0.32	Glomerular filtration rate;	chr15:45262069	chr15:45330209~45332634:-
KIRC	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-7.46	4e-13	2.16e-10	-0.28	-0.32	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
KIRC	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	7.46	4e-13	2.16e-10	0.38	0.32	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
KIRC	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-7.46	4e-13	2.16e-10	-0.33	-0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
KIRC	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	7.46	4e-13	2.16e-10	0.3	0.32	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
KIRC	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	7.46	4e-13	2.16e-10	0.34	0.32	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
KIRC	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	7.46	4e-13	2.16e-10	0.35	0.32	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
KIRC	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-7.46	4.01e-13	2.16e-10	-0.38	-0.32	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
KIRC	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	7.46	4.02e-13	2.17e-10	0.41	0.32	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
KIRC	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	7.46	4.03e-13	2.17e-10	0.39	0.32	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	7.46	4.03e-13	2.17e-10	0.39	0.32	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
KIRC	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	7.46	4.03e-13	2.18e-10	0.42	0.32	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
KIRC	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	7.45	4.05e-13	2.18e-10	0.29	0.32	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
KIRC	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-7.45	4.05e-13	2.19e-10	-0.45	-0.32	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
KIRC	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-7.45	4.07e-13	2.19e-10	-0.24	-0.32	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
KIRC	cis	rs2847281	0.614	rs2847261	ENSG00000267654.1	RP11-973H7.4	-7.45	4.07e-13	2.2e-10	-0.37	-0.32	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12775297	chr18:12739490~12749421:-
KIRC	cis	rs13434995	0.513	rs1979605	ENSG00000249700.7	SRD5A3-AS1	7.45	4.08e-13	2.2e-10	0.32	0.32	Adiponectin levels;	chr4:55552706	chr4:55363971~55395847:-
KIRC	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-7.45	4.08e-13	2.2e-10	-0.31	-0.32	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
KIRC	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	7.45	4.08e-13	2.2e-10	0.43	0.32	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000251284.2	RP13-644M16.1	-7.45	4.1e-13	2.21e-10	-0.38	-0.32	Obesity-related traits;	chr4:69068460	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000251284.2	RP13-644M16.1	-7.45	4.1e-13	2.21e-10	-0.38	-0.32	Obesity-related traits;	chr4:69068643	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000251284.2	RP13-644M16.1	-7.45	4.1e-13	2.21e-10	-0.38	-0.32	Obesity-related traits;	chr4:69068755	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000251284.2	RP13-644M16.1	-7.45	4.1e-13	2.21e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069090	chr4:69125274~69126451:+
KIRC	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	7.45	4.1e-13	2.21e-10	0.28	0.32	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
KIRC	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-7.45	4.1e-13	2.21e-10	-0.36	-0.32	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
KIRC	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	7.45	4.11e-13	2.22e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
KIRC	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-7.45	4.12e-13	2.22e-10	-0.34	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
KIRC	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-7.45	4.12e-13	2.22e-10	-0.39	-0.32	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
KIRC	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	7.45	4.12e-13	2.22e-10	0.35	0.32	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000251284.2	RP13-644M16.1	-7.45	4.13e-13	2.22e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069614	chr4:69125274~69126451:+
KIRC	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	7.45	4.13e-13	2.22e-10	0.3	0.32	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
KIRC	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-7.45	4.13e-13	2.23e-10	-0.43	-0.32	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
KIRC	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-7.45	4.14e-13	2.23e-10	-0.44	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
KIRC	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-7.45	4.14e-13	2.23e-10	-0.38	-0.32	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
KIRC	cis	rs3820928	0.874	rs1917123	ENSG00000212391.1	SNORA48	-7.45	4.14e-13	2.23e-10	-0.37	-0.32	Pulmonary function;	chr2:227025067	chr2:226968989~226969122:-
KIRC	cis	rs2486288	0.656	rs10519018	ENSG00000235390.4	CTD-2651B20.5	7.45	4.14e-13	2.23e-10	0.3	0.32	Glomerular filtration rate;	chr15:45257067	chr15:45321077~45321692:-
KIRC	cis	rs11647589	0.648	rs7192310	ENSG00000262995.1	CTD-2194A8.2	-7.45	4.15e-13	2.23e-10	-0.34	-0.32	Blood metabolite levels;	chr16:20465373	chr16:20440266~20447000:-
KIRC	cis	rs4819052	0.807	rs4819047	ENSG00000223768.1	LINC00205	-7.45	4.15e-13	2.23e-10	-0.33	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	7.45	4.15e-13	2.24e-10	0.35	0.32	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
KIRC	cis	rs13434995	0.513	rs6554285	ENSG00000249700.7	SRD5A3-AS1	7.45	4.16e-13	2.24e-10	0.32	0.32	Adiponectin levels;	chr4:55533953	chr4:55363971~55395847:-
KIRC	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	7.45	4.17e-13	2.25e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
KIRC	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-7.45	4.17e-13	2.25e-10	-0.34	-0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
KIRC	cis	rs17801127	0.688	rs13000594	ENSG00000231969.1	AC144449.1	7.45	4.18e-13	2.25e-10	0.58	0.32	Liver enzyme levels (alanine transaminase);	chr2:149810533	chr2:149587196~149848233:+
KIRC	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-7.45	4.19e-13	2.25e-10	-0.31	-0.32	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
KIRC	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	7.45	4.2e-13	2.26e-10	0.44	0.32	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
KIRC	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	7.45	4.2e-13	2.26e-10	0.38	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
KIRC	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-7.45	4.22e-13	2.27e-10	-0.4	-0.32	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
KIRC	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	7.45	4.23e-13	2.27e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	7.45	4.23e-13	2.27e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	7.45	4.23e-13	2.27e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
KIRC	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	7.45	4.23e-13	2.28e-10	0.37	0.32	Height;	chr4:55537960	chr4:55387949~55388271:+
KIRC	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-7.45	4.23e-13	2.28e-10	-0.27	-0.32	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
KIRC	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	7.45	4.25e-13	2.29e-10	0.61	0.32	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
KIRC	cis	rs9897596	1	rs9897596	ENSG00000223979.2	SMCR2	7.45	4.25e-13	2.29e-10	0.32	0.32	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr17:17690139	chr17:17674026~17677688:-
KIRC	cis	rs6908034	0.66	rs111509549	ENSG00000228412.5	RP4-625H18.2	7.45	4.26e-13	2.29e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.6	rs79733895	ENSG00000228412.5	RP4-625H18.2	7.45	4.26e-13	2.29e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.66	rs111231540	ENSG00000228412.5	RP4-625H18.2	7.45	4.26e-13	2.29e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs112824001	ENSG00000228412.5	RP4-625H18.2	7.45	4.26e-13	2.29e-10	0.72	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19802164~19804752:-
KIRC	cis	rs3745672	1	rs76403598	ENSG00000219665.7	CTD-2006C1.2	-7.45	4.26e-13	2.29e-10	-0.55	-0.32	Multiple sclerosis;	chr19:12055367	chr19:11987617~12046275:+
KIRC	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-7.45	4.26e-13	2.29e-10	-0.4	-0.32	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
KIRC	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-7.45	4.26e-13	2.29e-10	-0.4	-0.32	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
KIRC	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	7.45	4.26e-13	2.29e-10	0.41	0.32	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
KIRC	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	7.45	4.27e-13	2.3e-10	0.39	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
KIRC	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	7.45	4.27e-13	2.3e-10	0.28	0.32	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
KIRC	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	7.45	4.27e-13	2.3e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
KIRC	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-7.45	4.28e-13	2.3e-10	-0.38	-0.32	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
KIRC	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-7.45	4.28e-13	2.3e-10	-0.35	-0.32	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
KIRC	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-7.45	4.3e-13	2.31e-10	-0.35	-0.32	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
KIRC	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-7.45	4.3e-13	2.31e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-7.45	4.3e-13	2.31e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-7.45	4.3e-13	2.31e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-7.45	4.3e-13	2.31e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
KIRC	cis	rs1560104	0.597	rs881667	ENSG00000274834.1	CTD-3037G24.5	7.45	4.31e-13	2.32e-10	0.35	0.32	Obesity-related traits;	chr16:12618569	chr16:12614451~12614852:+
KIRC	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	7.45	4.31e-13	2.32e-10	0.42	0.32	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
KIRC	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	7.45	4.31e-13	2.32e-10	0.42	0.32	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
KIRC	cis	rs13113518	1	rs4864993	ENSG00000273257.1	RP11-177J6.1	7.45	4.32e-13	2.32e-10	0.38	0.32	Height;	chr4:55450662	chr4:55387949~55388271:+
KIRC	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	7.45	4.32e-13	2.32e-10	0.29	0.32	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
KIRC	cis	rs13434995	0.513	rs62303728	ENSG00000273257.1	RP11-177J6.1	-7.45	4.32e-13	2.32e-10	-0.42	-0.32	Adiponectin levels;	chr4:55495762	chr4:55387949~55388271:+
KIRC	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-7.45	4.33e-13	2.33e-10	-0.35	-0.32	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-7.45	4.33e-13	2.33e-10	-0.35	-0.32	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-7.45	4.33e-13	2.33e-10	-0.35	-0.32	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
KIRC	cis	rs897984	0.806	rs4889571	ENSG00000260911.2	RP11-196G11.2	-7.44	4.33e-13	2.33e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30937726	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.762	rs7206511	ENSG00000260911.2	RP11-196G11.2	-7.44	4.33e-13	2.33e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30939031	chr16:31043150~31049868:+
KIRC	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-7.44	4.33e-13	2.33e-10	-0.31	-0.32	QT interval;	chr12:29297620	chr12:29280418~29317848:-
KIRC	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	7.44	4.35e-13	2.34e-10	0.3	0.32	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	7.44	4.35e-13	2.34e-10	0.3	0.32	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	7.44	4.35e-13	2.34e-10	0.3	0.32	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
KIRC	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	7.44	4.35e-13	2.34e-10	0.42	0.32	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
KIRC	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	7.44	4.36e-13	2.34e-10	0.36	0.32	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
KIRC	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	7.44	4.36e-13	2.34e-10	0.36	0.32	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
KIRC	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-7.44	4.38e-13	2.35e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
KIRC	cis	rs13434995	0.513	rs60097207	ENSG00000273257.1	RP11-177J6.1	-7.44	4.38e-13	2.35e-10	-0.43	-0.32	Adiponectin levels;	chr4:55406696	chr4:55387949~55388271:+
KIRC	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.38e-13	2.35e-10	-0.3	-0.32	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
KIRC	cis	rs9388451	0.513	rs1268069	ENSG00000237742.5	RP11-624M8.1	-7.44	4.38e-13	2.35e-10	-0.38	-0.32	Brugada syndrome;	chr6:125718848	chr6:125578558~125749190:-
KIRC	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	7.44	4.38e-13	2.35e-10	0.44	0.32	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
KIRC	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	7.44	4.38e-13	2.35e-10	0.44	0.32	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
KIRC	cis	rs3745672	1	rs113033627	ENSG00000219665.7	CTD-2006C1.2	-7.44	4.39e-13	2.36e-10	-0.55	-0.32	Multiple sclerosis;	chr19:12055554	chr19:11987617~12046275:+
KIRC	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	7.44	4.39e-13	2.36e-10	0.38	0.32	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
KIRC	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	7.44	4.39e-13	2.36e-10	0.4	0.32	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
KIRC	cis	rs13434995	0.513	rs62310862	ENSG00000273257.1	RP11-177J6.1	-7.44	4.39e-13	2.36e-10	-0.42	-0.32	Adiponectin levels;	chr4:55572594	chr4:55387949~55388271:+
KIRC	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-7.44	4.39e-13	2.36e-10	-0.39	-0.32	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
KIRC	cis	rs13434995	0.513	rs62303718	ENSG00000273257.1	RP11-177J6.1	-7.44	4.41e-13	2.37e-10	-0.42	-0.32	Adiponectin levels;	chr4:55476770	chr4:55387949~55388271:+
KIRC	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	7.44	4.41e-13	2.37e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
KIRC	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-7.44	4.41e-13	2.37e-10	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
KIRC	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-7.44	4.41e-13	2.37e-10	-0.4	-0.32	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
KIRC	cis	rs9388451	0.839	rs9401845	ENSG00000237742.5	RP11-624M8.1	-7.44	4.43e-13	2.38e-10	-0.38	-0.32	Brugada syndrome;	chr6:125782972	chr6:125578558~125749190:-
KIRC	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	7.44	4.43e-13	2.38e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-7.44	4.43e-13	2.38e-10	-0.31	-0.32	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
KIRC	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	7.44	4.43e-13	2.38e-10	0.46	0.32	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	7.44	4.43e-13	2.38e-10	0.44	0.32	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
KIRC	cis	rs7176527	0.848	rs72630461	ENSG00000188388.10	GOLGA6L3	7.44	4.43e-13	2.38e-10	0.44	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:85240472~85247170:+
KIRC	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-7.44	4.46e-13	2.39e-10	-0.33	-0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
KIRC	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-7.44	4.46e-13	2.39e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
KIRC	cis	rs13434995	0.513	rs62303722	ENSG00000249700.7	SRD5A3-AS1	-7.44	4.46e-13	2.39e-10	-0.32	-0.32	Adiponectin levels;	chr4:55482076	chr4:55363971~55395847:-
KIRC	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-7.44	4.46e-13	2.4e-10	-0.39	-0.32	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
KIRC	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	7.44	4.47e-13	2.4e-10	0.4	0.32	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
KIRC	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-7.44	4.47e-13	2.4e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
KIRC	cis	rs17772222	0.682	rs3783889	ENSG00000222990.1	RNU4-22P	7.44	4.49e-13	2.41e-10	0.33	0.32	Coronary artery calcification;	chr14:88475637	chr14:88513498~88513663:+
KIRC	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	7.44	4.49e-13	2.41e-10	0.39	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
KIRC	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-7.44	4.49e-13	2.41e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-7.44	4.49e-13	2.41e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
KIRC	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	7.44	4.49e-13	2.41e-10	0.71	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
KIRC	cis	rs10971721	0.643	rs7040130	ENSG00000281128.1	PTENP1-AS	7.44	4.49e-13	2.41e-10	0.63	0.32	Body mass index;	chr9:33785075	chr9:33677268~33688011:+
KIRC	cis	rs2486288	0.656	rs2413774	ENSG00000259433.2	CTD-2651B20.4	7.44	4.51e-13	2.42e-10	0.23	0.32	Glomerular filtration rate;	chr15:45257225	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11632724	ENSG00000259433.2	CTD-2651B20.4	7.44	4.51e-13	2.42e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258593	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11632651	ENSG00000259433.2	CTD-2651B20.4	7.44	4.51e-13	2.42e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258640	chr15:45330209~45332634:-
KIRC	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	7.44	4.52e-13	2.42e-10	0.39	0.32	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	7.44	4.52e-13	2.42e-10	0.39	0.32	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	7.44	4.52e-13	2.42e-10	0.39	0.32	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
KIRC	cis	rs2281636	0.66	rs7072263	ENSG00000233690.1	EBAG9P1	7.44	4.53e-13	2.43e-10	0.36	0.32	Obesity-related traits;	chr10:99607888	chr10:99697407~99697949:-
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000251284.2	RP13-644M16.1	-7.44	4.53e-13	2.43e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069219	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000251284.2	RP13-644M16.1	-7.44	4.53e-13	2.43e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069397	chr4:69125274~69126451:+
KIRC	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-7.44	4.53e-13	2.43e-10	-0.27	-0.32	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
KIRC	cis	rs1431005	0.963	rs72725286	ENSG00000250620.1	RP11-91J3.3	7.44	4.54e-13	2.43e-10	0.42	0.32	Response to statin therapy;	chr4:187475655	chr4:187413564~187415697:+
KIRC	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-7.44	4.55e-13	2.44e-10	-0.39	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
KIRC	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-7.44	4.55e-13	2.44e-10	-0.27	-0.32	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
KIRC	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	7.44	4.55e-13	2.44e-10	0.48	0.32	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	7.44	4.57e-13	2.45e-10	0.46	0.32	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
KIRC	cis	rs2486288	0.656	rs11637920	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258707	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11632777	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258847	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11632778	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258858	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs11632752	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45258942	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs12911186	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45259225	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs12915314	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45259293	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs8039138	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45259394	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs8039540	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45259644	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs8040185	ENSG00000259433.2	CTD-2651B20.4	7.44	4.58e-13	2.46e-10	0.23	0.32	Glomerular filtration rate;	chr15:45259883	chr15:45330209~45332634:-
KIRC	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-7.44	4.59e-13	2.46e-10	-0.54	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
KIRC	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	7.44	4.59e-13	2.46e-10	0.61	0.32	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
KIRC	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	7.44	4.59e-13	2.46e-10	0.58	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
KIRC	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	7.44	4.6e-13	2.46e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
KIRC	cis	rs13423976	0.631	rs7582463	ENSG00000231367.4	AC016995.3	-7.44	4.61e-13	2.47e-10	-0.4	-0.32	Gut microbiome composition (summer);	chr2:38511226	chr2:38406719~38515740:-
KIRC	cis	rs17801127	0.818	rs35993252	ENSG00000231969.1	AC144449.1	7.44	4.61e-13	2.47e-10	0.61	0.32	Liver enzyme levels (alanine transaminase);	chr2:149763303	chr2:149587196~149848233:+
KIRC	cis	rs11089937	0.597	rs4145535	ENSG00000211638.2	IGLV8-61	-7.44	4.62e-13	2.47e-10	-0.32	-0.32	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22098700~22099212:+
KIRC	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-7.44	4.62e-13	2.47e-10	-0.36	-0.32	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
KIRC	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-7.44	4.62e-13	2.48e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs4821784	ENSG00000211638.2	IGLV8-61	-7.44	4.62e-13	2.48e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22098700~22099212:+
KIRC	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-7.44	4.63e-13	2.48e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
KIRC	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	7.44	4.63e-13	2.48e-10	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
KIRC	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-7.44	4.63e-13	2.48e-10	-0.35	-0.32	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
KIRC	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-7.44	4.63e-13	2.48e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
KIRC	cis	rs2486288	0.656	rs11639420	ENSG00000235390.4	CTD-2651B20.5	7.43	4.64e-13	2.48e-10	0.3	0.32	Glomerular filtration rate;	chr15:45267070	chr15:45321077~45321692:-
KIRC	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-7.43	4.64e-13	2.48e-10	-0.59	-0.32	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
KIRC	cis	rs1431005	0.964	rs112852905	ENSG00000250620.1	RP11-91J3.3	7.43	4.64e-13	2.48e-10	0.42	0.32	Response to statin therapy;	chr4:187427031	chr4:187413564~187415697:+
KIRC	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	7.43	4.65e-13	2.49e-10	0.45	0.32	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs7698022	ENSG00000249700.7	SRD5A3-AS1	7.43	4.66e-13	2.49e-10	0.32	0.32	Adiponectin levels;	chr4:55541180	chr4:55363971~55395847:-
KIRC	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	7.43	4.66e-13	2.49e-10	0.57	0.32	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
KIRC	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	7.43	4.69e-13	2.51e-10	0.28	0.32	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
KIRC	cis	rs9388451	0.805	rs1028481	ENSG00000237742.5	RP11-624M8.1	-7.43	4.69e-13	2.51e-10	-0.38	-0.32	Brugada syndrome;	chr6:125785427	chr6:125578558~125749190:-
KIRC	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	7.43	4.69e-13	2.51e-10	0.4	0.32	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000251284.2	RP13-644M16.1	-7.43	4.69e-13	2.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69075937	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000251284.2	RP13-644M16.1	-7.43	4.69e-13	2.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69075944	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000251284.2	RP13-644M16.1	-7.43	4.69e-13	2.51e-10	-0.38	-0.32	Obesity-related traits;	chr4:69076309	chr4:69125274~69126451:+
KIRC	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	7.43	4.7e-13	2.51e-10	0.44	0.32	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
KIRC	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	7.43	4.7e-13	2.52e-10	0.37	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
KIRC	cis	rs13434995	0.513	rs1021307	ENSG00000273257.1	RP11-177J6.1	7.43	4.7e-13	2.52e-10	0.42	0.32	Adiponectin levels;	chr4:55529547	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs1021306	ENSG00000273257.1	RP11-177J6.1	7.43	4.7e-13	2.52e-10	0.42	0.32	Adiponectin levels;	chr4:55529777	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	7.43	4.71e-13	2.52e-10	0.44	0.32	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
KIRC	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	7.43	4.72e-13	2.53e-10	0.51	0.32	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
KIRC	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	7.43	4.73e-13	2.53e-10	0.48	0.32	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
KIRC	cis	rs375066	0.762	rs171238	ENSG00000267058.1	RP11-15A1.3	-7.43	4.73e-13	2.53e-10	-0.37	-0.32	Breast cancer;	chr19:43875402	chr19:43891804~43901805:-
KIRC	cis	rs440932	0.757	rs330943	ENSG00000254340.1	RP11-10A14.3	7.43	4.74e-13	2.53e-10	0.42	0.32	High light scatter reticulocyte percentage of red cells;	chr8:9163516	chr8:9141424~9145435:+
KIRC	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	7.43	4.75e-13	2.54e-10	0.24	0.32	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
KIRC	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-7.43	4.75e-13	2.54e-10	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
KIRC	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-7.43	4.76e-13	2.54e-10	-0.34	-0.32	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
KIRC	cis	rs17772222	0.682	rs2297129	ENSG00000222990.1	RNU4-22P	7.43	4.77e-13	2.55e-10	0.33	0.32	Coronary artery calcification;	chr14:88469581	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.682	rs61542857	ENSG00000222990.1	RNU4-22P	7.43	4.77e-13	2.55e-10	0.33	0.32	Coronary artery calcification;	chr14:88470358	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.637	rs7161660	ENSG00000222990.1	RNU4-22P	7.43	4.77e-13	2.55e-10	0.33	0.32	Coronary artery calcification;	chr14:88471832	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.682	rs7141363	ENSG00000222990.1	RNU4-22P	7.43	4.77e-13	2.55e-10	0.33	0.32	Coronary artery calcification;	chr14:88471879	chr14:88513498~88513663:+
KIRC	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-7.43	4.77e-13	2.55e-10	-0.41	-0.32	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
KIRC	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-7.43	4.77e-13	2.55e-10	-0.39	-0.32	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
KIRC	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-7.43	4.77e-13	2.55e-10	-0.39	-0.32	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
KIRC	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	7.43	4.77e-13	2.55e-10	0.37	0.32	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
KIRC	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	7.43	4.78e-13	2.55e-10	0.44	0.32	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	7.43	4.79e-13	2.56e-10	0.44	0.32	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
KIRC	cis	rs2012796	0.743	rs8020575	ENSG00000270343.1	UNGP3	7.43	4.79e-13	2.56e-10	0.39	0.32	Night sleep phenotypes;	chr14:81393177	chr14:81259565~81260239:-
KIRC	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-7.43	4.8e-13	2.56e-10	-0.31	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
KIRC	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
KIRC	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	7.43	4.8e-13	2.56e-10	0.38	0.32	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
KIRC	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-7.43	4.8e-13	2.56e-10	-0.35	-0.32	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
KIRC	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	7.43	4.81e-13	2.57e-10	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
KIRC	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-7.43	4.81e-13	2.57e-10	-0.39	-0.32	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
KIRC	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-7.43	4.82e-13	2.57e-10	-0.38	-0.32	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
KIRC	cis	rs13434995	0.513	rs62303730	ENSG00000273257.1	RP11-177J6.1	-7.43	4.83e-13	2.58e-10	-0.42	-0.32	Adiponectin levels;	chr4:55498948	chr4:55387949~55388271:+
KIRC	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	7.43	4.83e-13	2.58e-10	0.46	0.32	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
KIRC	cis	rs2012796	0.785	rs61986593	ENSG00000270343.1	UNGP3	7.43	4.83e-13	2.58e-10	0.39	0.32	Night sleep phenotypes;	chr14:81374315	chr14:81259565~81260239:-
KIRC	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	7.43	4.83e-13	2.58e-10	0.4	0.32	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
KIRC	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	7.43	4.84e-13	2.59e-10	0.37	0.32	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
KIRC	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-7.43	4.85e-13	2.59e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-7.43	4.85e-13	2.59e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
KIRC	cis	rs3820928	0.904	rs60906902	ENSG00000212391.1	SNORA48	-7.43	4.85e-13	2.59e-10	-0.37	-0.32	Pulmonary function;	chr2:226895318	chr2:226968989~226969122:-
KIRC	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	7.43	4.85e-13	2.59e-10	0.47	0.32	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000251284.2	RP13-644M16.1	-7.43	4.87e-13	2.6e-10	-0.39	-0.32	Obesity-related traits;	chr4:69063770	chr4:69125274~69126451:+
KIRC	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-7.43	4.88e-13	2.6e-10	-0.38	-0.32	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
KIRC	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	7.43	4.88e-13	2.6e-10	0.4	0.32	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	7.43	4.88e-13	2.6e-10	0.4	0.32	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
KIRC	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-7.43	4.88e-13	2.61e-10	-0.35	-0.32	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
KIRC	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	7.43	4.89e-13	2.61e-10	0.28	0.32	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
KIRC	cis	rs58873874	0.737	rs11134767	ENSG00000251405.2	CTB-109A12.1	7.43	4.89e-13	2.61e-10	0.59	0.32	Bipolar disorder (body mass index interaction);	chr5:157481645	chr5:157362615~157460078:-
KIRC	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-7.43	4.92e-13	2.63e-10	-0.29	-0.32	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
KIRC	cis	rs897984	0.806	rs9319588	ENSG00000260911.2	RP11-196G11.2	-7.43	4.93e-13	2.63e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30919662	chr16:31043150~31049868:+
KIRC	cis	rs897984	0.77	rs12930657	ENSG00000260911.2	RP11-196G11.2	-7.43	4.93e-13	2.63e-10	-0.21	-0.32	Dementia with Lewy bodies;	chr16:30920647	chr16:31043150~31049868:+
KIRC	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	7.43	4.93e-13	2.63e-10	0.36	0.32	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
KIRC	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	7.43	4.93e-13	2.63e-10	0.39	0.32	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	7.43	4.93e-13	2.63e-10	0.39	0.32	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
KIRC	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	7.43	4.93e-13	2.63e-10	0.27	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
KIRC	cis	rs3820928	1	rs2163041	ENSG00000212391.1	SNORA48	-7.43	4.93e-13	2.63e-10	-0.37	-0.32	Pulmonary function;	chr2:226907764	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs2396433	ENSG00000212391.1	SNORA48	-7.43	4.93e-13	2.63e-10	-0.37	-0.32	Pulmonary function;	chr2:226907786	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs10204368	ENSG00000212391.1	SNORA48	-7.43	4.93e-13	2.63e-10	-0.37	-0.32	Pulmonary function;	chr2:226909528	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs10210763	ENSG00000212391.1	SNORA48	-7.43	4.93e-13	2.63e-10	-0.37	-0.32	Pulmonary function;	chr2:226911313	chr2:226968989~226969122:-
KIRC	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-7.43	4.93e-13	2.63e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
KIRC	cis	rs7176527	0.848	rs72630462	ENSG00000188388.10	GOLGA6L3	7.43	4.94e-13	2.63e-10	0.43	0.32	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:85240472~85247170:+
KIRC	cis	rs1560104	0.597	rs17227296	ENSG00000274834.1	CTD-3037G24.5	7.43	4.94e-13	2.63e-10	0.34	0.32	Obesity-related traits;	chr16:12618342	chr16:12614451~12614852:+
KIRC	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	7.43	4.94e-13	2.64e-10	0.33	0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
KIRC	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	7.43	4.94e-13	2.64e-10	0.42	0.32	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
KIRC	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	7.43	4.94e-13	2.64e-10	0.42	0.32	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
KIRC	cis	rs3820928	0.934	rs1366756	ENSG00000212391.1	SNORA48	-7.43	4.94e-13	2.64e-10	-0.37	-0.32	Pulmonary function;	chr2:226907322	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs7561378	ENSG00000212391.1	SNORA48	-7.43	4.94e-13	2.64e-10	-0.37	-0.32	Pulmonary function;	chr2:226907532	chr2:226968989~226969122:-
KIRC	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	7.43	4.95e-13	2.64e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	7.43	4.96e-13	2.64e-10	0.45	0.32	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	7.42	4.97e-13	2.65e-10	0.39	0.32	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
KIRC	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-7.42	4.97e-13	2.65e-10	-0.41	-0.32	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
KIRC	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-7.42	4.97e-13	2.65e-10	-0.41	-0.32	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
KIRC	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	7.42	4.97e-13	2.65e-10	0.52	0.32	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	7.42	4.97e-13	2.65e-10	0.44	0.32	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
KIRC	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-7.42	4.97e-13	2.65e-10	-0.28	-0.32	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-7.42	4.97e-13	2.65e-10	-0.28	-0.32	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
KIRC	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	7.42	4.98e-13	2.65e-10	0.35	0.32	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	7.42	4.98e-13	2.65e-10	0.35	0.32	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
KIRC	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-7.42	4.99e-13	2.66e-10	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
KIRC	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-7.42	5e-13	2.67e-10	-0.26	-0.32	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
KIRC	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-7.42	5e-13	2.67e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
KIRC	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-7.42	5e-13	2.67e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
KIRC	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	7.42	5.02e-13	2.67e-10	0.25	0.32	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
KIRC	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-7.42	5.02e-13	2.68e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-7.42	5.02e-13	2.68e-10	-0.6	-0.32	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
KIRC	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	7.42	5.02e-13	2.68e-10	0.23	0.32	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
KIRC	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	7.42	5.02e-13	2.68e-10	0.38	0.32	Height;	chr4:55534788	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	7.42	5.02e-13	2.68e-10	0.38	0.32	Height;	chr4:55535489	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	7.42	5.02e-13	2.68e-10	0.38	0.32	Height;	chr4:55536421	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	7.42	5.02e-13	2.68e-10	0.38	0.32	Height;	chr4:55537080	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	7.42	5.02e-13	2.68e-10	0.52	0.32	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
KIRC	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	7.42	5.03e-13	2.68e-10	0.34	0.32	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
KIRC	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	7.42	5.04e-13	2.68e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	7.42	5.04e-13	2.69e-10	0.39	0.32	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
KIRC	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-7.42	5.04e-13	2.69e-10	-0.35	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
KIRC	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	7.42	5.05e-13	2.69e-10	0.25	0.32	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
KIRC	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	7.42	5.05e-13	2.69e-10	0.45	0.32	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
KIRC	cis	rs17711722	0.522	rs6957759	ENSG00000275400.1	RP4-756H11.5	-7.42	5.06e-13	2.69e-10	-0.32	-0.32	Calcium levels;	chr7:65806798	chr7:66553805~66554199:-
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000251284.2	RP13-644M16.1	-7.42	5.06e-13	2.7e-10	-0.38	-0.32	Obesity-related traits;	chr4:69069866	chr4:69125274~69126451:+
KIRC	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	7.42	5.06e-13	2.7e-10	0.66	0.32	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
KIRC	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	7.42	5.07e-13	2.7e-10	0.28	0.32	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
KIRC	cis	rs11512640	1	rs11220120	ENSG00000254671.2	STT3A-AS1	7.42	5.08e-13	2.7e-10	0.66	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr11:125570284~125592568:-
KIRC	cis	rs6496044	1	rs6496044	ENSG00000202081.1	RNU6-1280P	7.42	5.08e-13	2.7e-10	0.34	0.32	Interstitial lung disease;	chr15:85524075	chr15:85651522~85651628:-
KIRC	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-7.42	5.08e-13	2.7e-10	-0.37	-0.32	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
KIRC	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-7.42	5.08e-13	2.71e-10	-0.36	-0.32	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
KIRC	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-7.42	5.09e-13	2.71e-10	-0.41	-0.32	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
KIRC	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	7.42	5.09e-13	2.71e-10	0.38	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
KIRC	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	7.42	5.09e-13	2.71e-10	0.44	0.32	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
KIRC	cis	rs4273100	0.526	rs2074280	ENSG00000262319.1	CTC-457L16.2	-7.42	5.1e-13	2.71e-10	-0.39	-0.32	Schizophrenia;	chr17:19014602	chr17:19141017~19143689:-
KIRC	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-7.42	5.1e-13	2.71e-10	-0.44	-0.32	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
KIRC	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.42	5.1e-13	2.72e-10	-0.34	-0.32	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
KIRC	cis	rs13434995	0.513	rs17779627	ENSG00000249700.7	SRD5A3-AS1	-7.42	5.1e-13	2.72e-10	-0.32	-0.32	Adiponectin levels;	chr4:55483775	chr4:55363971~55395847:-
KIRC	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-7.42	5.11e-13	2.72e-10	-0.35	-0.32	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-7.42	5.11e-13	2.72e-10	-0.35	-0.32	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
KIRC	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-7.42	5.11e-13	2.72e-10	-0.41	-0.32	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
KIRC	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	7.42	5.12e-13	2.72e-10	0.39	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
KIRC	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-7.42	5.12e-13	2.72e-10	-0.4	-0.32	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
KIRC	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	7.42	5.14e-13	2.73e-10	0.29	0.32	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
KIRC	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.42	5.14e-13	2.74e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
KIRC	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	7.42	5.15e-13	2.74e-10	0.71	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	7.42	5.15e-13	2.74e-10	0.71	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
KIRC	cis	rs13434995	0.513	rs2412658	ENSG00000273257.1	RP11-177J6.1	7.42	5.15e-13	2.74e-10	0.42	0.32	Adiponectin levels;	chr4:55577050	chr4:55387949~55388271:+
KIRC	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-7.42	5.16e-13	2.75e-10	-0.35	-0.32	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
KIRC	cis	rs3820928	0.904	rs2195487	ENSG00000212391.1	SNORA48	-7.42	5.17e-13	2.75e-10	-0.38	-0.32	Pulmonary function;	chr2:226895004	chr2:226968989~226969122:-
KIRC	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	7.42	5.17e-13	2.75e-10	0.33	0.32	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
KIRC	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	7.42	5.17e-13	2.75e-10	0.3	0.32	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
KIRC	cis	rs13434995	0.513	rs62303722	ENSG00000273257.1	RP11-177J6.1	-7.42	5.17e-13	2.75e-10	-0.42	-0.32	Adiponectin levels;	chr4:55482076	chr4:55387949~55388271:+
KIRC	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-7.42	5.17e-13	2.75e-10	-0.18	-0.32	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
KIRC	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-7.42	5.17e-13	2.75e-10	-0.18	-0.32	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
KIRC	cis	rs17711722	0.522	rs62469933	ENSG00000275400.1	RP4-756H11.5	-7.42	5.17e-13	2.75e-10	-0.32	-0.32	Calcium levels;	chr7:65800652	chr7:66553805~66554199:-
KIRC	cis	rs13434995	0.513	rs6554291	ENSG00000273257.1	RP11-177J6.1	-7.42	5.18e-13	2.76e-10	-0.42	-0.32	Adiponectin levels;	chr4:55571204	chr4:55387949~55388271:+
KIRC	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	7.42	5.19e-13	2.76e-10	0.35	0.32	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
KIRC	cis	rs10754283	0.782	rs7534384	ENSG00000231613.1	RP5-943J3.1	7.42	5.19e-13	2.76e-10	0.32	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89626018	chr1:89788914~89790492:+
KIRC	cis	rs3820928	0.874	rs10182307	ENSG00000212391.1	SNORA48	-7.42	5.2e-13	2.77e-10	-0.37	-0.32	Pulmonary function;	chr2:227010644	chr2:226968989~226969122:-
KIRC	cis	rs647097	0.655	rs471016	ENSG00000272788.1	RP11-674N23.4	-7.42	5.2e-13	2.77e-10	-0.4	-0.32	Chronic obstructive pulmonary disease;	chr18:8803229	chr18:8801656~8802305:+
KIRC	cis	rs1560104	0.597	rs735820	ENSG00000274834.1	CTD-3037G24.5	7.42	5.2e-13	2.77e-10	0.34	0.32	Obesity-related traits;	chr16:12618269	chr16:12614451~12614852:+
KIRC	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-7.42	5.2e-13	2.77e-10	-0.38	-0.32	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
KIRC	cis	rs17772222	0.682	rs2274736	ENSG00000222990.1	RNU4-22P	7.42	5.21e-13	2.77e-10	0.33	0.32	Coronary artery calcification;	chr14:88472308	chr14:88513498~88513663:+
KIRC	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-7.42	5.22e-13	2.77e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-7.42	5.22e-13	2.77e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-7.42	5.22e-13	2.77e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-7.42	5.22e-13	2.77e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-7.42	5.22e-13	2.77e-10	-0.39	-0.32	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
KIRC	cis	rs7017914	0.967	rs2732091	ENSG00000254031.4	RP11-326E22.1	-7.42	5.22e-13	2.77e-10	-0.34	-0.32	Bone mineral density;	chr8:71006188	chr8:71155457~71204223:+
KIRC	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	7.42	5.22e-13	2.77e-10	0.42	0.32	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
KIRC	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-7.42	5.22e-13	2.77e-10	-0.27	-0.32	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
KIRC	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	7.42	5.22e-13	2.78e-10	0.52	0.32	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
KIRC	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-7.42	5.23e-13	2.78e-10	-0.35	-0.32	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-7.42	5.23e-13	2.78e-10	-0.35	-0.32	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
KIRC	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-7.42	5.23e-13	2.78e-10	-0.57	-0.32	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
KIRC	cis	rs80285556	1	rs80285556	ENSG00000161643.11	SIGLEC16	7.42	5.23e-13	2.78e-10	0.71	0.32	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036913	chr19:49969673~49975814:+
KIRC	cis	rs10214930	0.697	rs1052741	ENSG00000235574.1	AC073150.6	-7.42	5.23e-13	2.78e-10	-0.37	-0.32	Hypospadias;	chr7:27525542	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1052724	ENSG00000235574.1	AC073150.6	-7.42	5.23e-13	2.78e-10	-0.37	-0.32	Hypospadias;	chr7:27525587	chr7:27491682~27492765:-
KIRC	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-7.42	5.23e-13	2.78e-10	-0.45	-0.32	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
KIRC	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-7.42	5.24e-13	2.78e-10	-0.27	-0.32	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
KIRC	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	7.42	5.25e-13	2.79e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
KIRC	cis	rs890448	0.662	rs2850372	ENSG00000254531.1	FLJ20021	-7.42	5.25e-13	2.79e-10	-0.32	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101326034	chr4:101347780~101348883:+
KIRC	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	7.42	5.25e-13	2.79e-10	0.35	0.32	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	7.42	5.25e-13	2.79e-10	0.35	0.32	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	7.42	5.25e-13	2.79e-10	0.35	0.32	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	7.42	5.25e-13	2.79e-10	0.35	0.32	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
KIRC	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	7.42	5.25e-13	2.79e-10	0.4	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
KIRC	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	7.42	5.26e-13	2.8e-10	0.3	0.32	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
KIRC	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	7.42	5.26e-13	2.8e-10	0.66	0.32	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
KIRC	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	7.42	5.27e-13	2.8e-10	0.41	0.32	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
KIRC	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-7.42	5.28e-13	2.8e-10	-0.39	-0.32	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
KIRC	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-7.42	5.28e-13	2.8e-10	-0.37	-0.32	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
KIRC	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-7.42	5.28e-13	2.8e-10	-0.37	-0.32	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
KIRC	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-7.42	5.28e-13	2.81e-10	-0.42	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
KIRC	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-7.42	5.29e-13	2.81e-10	-0.29	-0.32	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
KIRC	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	7.42	5.3e-13	2.81e-10	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
KIRC	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.42	5.3e-13	2.81e-10	-0.35	-0.32	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
KIRC	cis	rs79040073	0.594	rs75929244	ENSG00000259531.2	RP11-295H24.3	7.42	5.31e-13	2.82e-10	0.4	0.32	Lung cancer in ever smokers;	chr15:49419763	chr15:49365124~49366685:-
KIRC	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	7.41	5.31e-13	2.82e-10	0.35	0.32	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
KIRC	cis	rs4819052	0.851	rs2838833	ENSG00000223768.1	LINC00205	-7.41	5.32e-13	2.82e-10	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45293285~45297354:+
KIRC	cis	rs4819052	0.885	rs9980676	ENSG00000223768.1	LINC00205	-7.41	5.32e-13	2.82e-10	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45293285~45297354:+
KIRC	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-7.41	5.32e-13	2.82e-10	-0.35	-0.32	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
KIRC	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-7.41	5.33e-13	2.83e-10	-0.18	-0.32	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
KIRC	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-7.41	5.33e-13	2.83e-10	-0.38	-0.32	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
KIRC	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	7.41	5.34e-13	2.83e-10	0.37	0.32	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
KIRC	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-7.41	5.34e-13	2.84e-10	-0.35	-0.32	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
KIRC	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	7.41	5.36e-13	2.84e-10	0.44	0.32	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
KIRC	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	7.41	5.37e-13	2.85e-10	0.39	0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
KIRC	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	7.41	5.37e-13	2.85e-10	0.6	0.32	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
KIRC	cis	rs4660214	0.627	rs16837533	ENSG00000237624.1	OXCT2P1	7.41	5.38e-13	2.85e-10	0.57	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39514956~39516490:+
KIRC	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	7.41	5.38e-13	2.85e-10	0.46	0.32	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
KIRC	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-7.41	5.38e-13	2.86e-10	-0.56	-0.32	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
KIRC	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	7.41	5.39e-13	2.86e-10	0.4	0.32	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
KIRC	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-7.41	5.39e-13	2.86e-10	-0.35	-0.32	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
KIRC	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	7.41	5.39e-13	2.86e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
KIRC	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-7.41	5.39e-13	2.86e-10	-0.29	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
KIRC	cis	rs4819052	0.851	rs2838836	ENSG00000223768.1	LINC00205	-7.41	5.39e-13	2.86e-10	-0.32	-0.32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45293285~45297354:+
KIRC	cis	rs13434995	0.513	rs62303726	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55490415	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs55729020	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55491681	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs3805156	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55497925	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62303731	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55499667	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62303732	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55499868	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs56196624	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55500340	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62305264	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55502968	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62305265	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55503474	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62305268	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.4e-13	2.86e-10	-0.32	-0.32	Adiponectin levels;	chr4:55506991	chr4:55363971~55395847:-
KIRC	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	7.41	5.43e-13	2.88e-10	0.4	0.32	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
KIRC	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	7.41	5.44e-13	2.88e-10	0.43	0.32	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	7.41	5.44e-13	2.88e-10	0.43	0.32	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
KIRC	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	7.41	5.44e-13	2.88e-10	0.43	0.32	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
KIRC	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	7.41	5.44e-13	2.88e-10	0.37	0.32	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
KIRC	cis	rs6061231	0.675	rs755726	ENSG00000275437.1	RP5-908M14.10	7.41	5.44e-13	2.88e-10	0.24	0.32	Colorectal cancer;	chr20:62387568	chr20:62402236~62405935:-
KIRC	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	7.41	5.45e-13	2.89e-10	0.33	0.32	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
KIRC	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-7.41	5.46e-13	2.89e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-7.41	5.46e-13	2.89e-10	-0.44	-0.32	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
KIRC	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-7.41	5.46e-13	2.89e-10	-0.29	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
KIRC	cis	rs6479901	0.841	rs10761721	ENSG00000232075.1	MRPL35P2	-7.41	5.46e-13	2.89e-10	-0.41	-0.32	Intelligence (multi-trait analysis);	chr10:63178644	chr10:63634317~63634827:-
KIRC	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-7.41	5.5e-13	2.91e-10	-0.4	-0.32	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
KIRC	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	7.41	5.52e-13	2.92e-10	0.41	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
KIRC	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	7.41	5.52e-13	2.92e-10	0.37	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
KIRC	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	7.41	5.54e-13	2.93e-10	0.61	0.32	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
KIRC	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	7.41	5.54e-13	2.93e-10	0.44	0.32	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.589	rs499110	ENSG00000249700.7	SRD5A3-AS1	-7.41	5.54e-13	2.93e-10	-0.32	-0.32	Adiponectin levels;	chr4:55381628	chr4:55363971~55395847:-
KIRC	cis	rs6908034	0.607	rs79406203	ENSG00000228412.5	RP4-625H18.2	7.41	5.54e-13	2.93e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs74559916	ENSG00000228412.5	RP4-625H18.2	7.41	5.54e-13	2.93e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.505	rs76391302	ENSG00000228412.5	RP4-625H18.2	7.41	5.54e-13	2.93e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.505	rs77880623	ENSG00000228412.5	RP4-625H18.2	7.41	5.54e-13	2.93e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs12526109	ENSG00000228412.5	RP4-625H18.2	7.41	5.54e-13	2.93e-10	0.73	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19802164~19804752:-
KIRC	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.41	5.55e-13	2.93e-10	-0.36	-0.32	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
KIRC	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-7.41	5.55e-13	2.94e-10	-0.3	-0.32	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
KIRC	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	7.41	5.55e-13	2.94e-10	0.4	0.32	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
KIRC	cis	rs13434995	0.513	rs62303681	ENSG00000273257.1	RP11-177J6.1	-7.41	5.58e-13	2.95e-10	-0.43	-0.32	Adiponectin levels;	chr4:55403812	chr4:55387949~55388271:+
KIRC	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	7.41	5.58e-13	2.95e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	7.41	5.58e-13	2.95e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	7.41	5.58e-13	2.95e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	7.41	5.58e-13	2.95e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
KIRC	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-7.41	5.59e-13	2.96e-10	-0.44	-0.32	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
KIRC	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-7.41	5.6e-13	2.96e-10	-0.33	-0.32	Height;	chr3:53015087	chr3:53064283~53065091:-
KIRC	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	7.41	5.6e-13	2.96e-10	0.71	0.32	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
KIRC	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	7.41	5.6e-13	2.96e-10	0.4	0.32	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
KIRC	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-7.41	5.61e-13	2.96e-10	-0.3	-0.32	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
KIRC	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-7.41	5.61e-13	2.96e-10	-0.44	-0.32	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
KIRC	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-7.41	5.61e-13	2.96e-10	-0.36	-0.32	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
KIRC	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.41	5.62e-13	2.97e-10	-0.3	-0.32	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
KIRC	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-7.41	5.63e-13	2.97e-10	-0.27	-0.32	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
KIRC	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	7.41	5.63e-13	2.97e-10	0.34	0.32	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
KIRC	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-7.41	5.64e-13	2.98e-10	-0.31	-0.32	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
KIRC	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-7.41	5.66e-13	2.99e-10	-0.4	-0.32	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
KIRC	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-7.41	5.67e-13	2.99e-10	-0.32	-0.32	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
KIRC	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	7.41	5.67e-13	3e-10	0.45	0.32	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
KIRC	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-7.41	5.68e-13	3e-10	-0.3	-0.32	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-7.41	5.68e-13	3e-10	-0.3	-0.32	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
KIRC	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-7.41	5.68e-13	3e-10	-0.49	-0.32	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
KIRC	cis	rs12936587	0.535	rs8065154	ENSG00000223979.2	SMCR2	-7.4	5.69e-13	3e-10	-0.33	-0.32	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17711633	chr17:17674026~17677688:-
KIRC	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	7.4	5.69e-13	3.01e-10	0.46	0.32	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
KIRC	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	7.4	5.69e-13	3.01e-10	0.43	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
KIRC	cis	rs17772222	0.565	rs845759	ENSG00000222990.1	RNU4-22P	-7.4	5.7e-13	3.01e-10	-0.34	-0.32	Coronary artery calcification;	chr14:88415538	chr14:88513498~88513663:+
KIRC	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	7.4	5.7e-13	3.01e-10	0.33	0.32	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
KIRC	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	7.4	5.72e-13	3.02e-10	0.41	0.32	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
KIRC	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-7.4	5.72e-13	3.02e-10	-0.35	-0.32	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
KIRC	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	7.4	5.73e-13	3.02e-10	0.59	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
KIRC	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.4	5.73e-13	3.02e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
KIRC	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	7.4	5.74e-13	3.03e-10	0.57	0.32	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
KIRC	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	7.4	5.74e-13	3.03e-10	0.41	0.32	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
KIRC	cis	rs13434995	0.513	rs880358	ENSG00000249700.7	SRD5A3-AS1	-7.4	5.76e-13	3.04e-10	-0.32	-0.32	Adiponectin levels;	chr4:55410311	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs17776975	ENSG00000249700.7	SRD5A3-AS1	-7.4	5.76e-13	3.04e-10	-0.32	-0.32	Adiponectin levels;	chr4:55410728	chr4:55363971~55395847:-
KIRC	cis	rs3820928	0.874	rs6706802	ENSG00000212391.1	SNORA48	-7.4	5.77e-13	3.04e-10	-0.38	-0.32	Pulmonary function;	chr2:226986060	chr2:226968989~226969122:-
KIRC	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-7.4	5.78e-13	3.05e-10	-0.29	-0.32	Height;	chr11:118808920	chr11:118791254~118793137:+
KIRC	cis	rs17772222	0.701	rs1627444	ENSG00000222990.1	RNU4-22P	-7.4	5.78e-13	3.05e-10	-0.34	-0.32	Coronary artery calcification;	chr14:88413784	chr14:88513498~88513663:+
KIRC	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	7.4	5.79e-13	3.05e-10	0.56	0.32	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	7.4	5.79e-13	3.05e-10	0.56	0.32	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
KIRC	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	7.4	5.81e-13	3.06e-10	0.38	0.32	Height;	chr4:55548261	chr4:55387949~55388271:+
KIRC	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-7.4	5.81e-13	3.06e-10	-0.39	-0.32	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
KIRC	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.4	5.81e-13	3.07e-10	-0.35	-0.32	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
KIRC	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	7.4	5.82e-13	3.07e-10	0.38	0.32	Height;	chr4:55546002	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	7.4	5.82e-13	3.07e-10	0.38	0.32	Height;	chr4:55546378	chr4:55387949~55388271:+
KIRC	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-7.4	5.82e-13	3.07e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-7.4	5.82e-13	3.07e-10	-0.34	-0.32	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
KIRC	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	7.4	5.82e-13	3.07e-10	0.29	0.32	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
KIRC	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-7.4	5.82e-13	3.07e-10	-0.37	-0.32	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
KIRC	cis	rs3820928	0.874	rs12614648	ENSG00000212391.1	SNORA48	-7.4	5.82e-13	3.07e-10	-0.37	-0.32	Pulmonary function;	chr2:226920819	chr2:226968989~226969122:-
KIRC	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-7.4	5.84e-13	3.08e-10	-0.38	-0.32	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
KIRC	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	7.4	5.84e-13	3.08e-10	0.22	0.32	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
KIRC	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-7.4	5.84e-13	3.08e-10	-0.29	-0.32	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
KIRC	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.4	5.85e-13	3.08e-10	-0.3	-0.32	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
KIRC	cis	rs3760982	0.967	rs3760984	ENSG00000267058.1	RP11-15A1.3	-7.4	5.85e-13	3.09e-10	-0.36	-0.32	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43891804~43901805:-
KIRC	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-7.4	5.86e-13	3.09e-10	-0.42	-0.32	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-7.4	5.86e-13	3.09e-10	-0.42	-0.32	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-7.4	5.86e-13	3.09e-10	-0.42	-0.32	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
KIRC	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	7.4	5.86e-13	3.09e-10	0.38	0.32	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
KIRC	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-7.4	5.86e-13	3.09e-10	-0.36	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
KIRC	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-7.4	5.88e-13	3.1e-10	-0.28	-0.32	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-7.4	5.88e-13	3.1e-10	-0.28	-0.32	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-7.4	5.88e-13	3.1e-10	-0.28	-0.32	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
KIRC	cis	rs7592578	1	rs7592578	ENSG00000272979.1	RP11-647K16.1	7.4	5.89e-13	3.11e-10	0.46	0.32	Diastolic blood pressure;	chr2:190574865	chr2:190454092~190454521:-
KIRC	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	7.4	5.91e-13	3.11e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	7.4	5.91e-13	3.11e-10	0.48	0.32	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
KIRC	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	7.4	5.92e-13	3.12e-10	0.42	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
KIRC	cis	rs10971721	0.643	rs10971699	ENSG00000281128.1	PTENP1-AS	7.4	5.92e-13	3.12e-10	0.7	0.32	Body mass index;	chr9:33777186	chr9:33677268~33688011:+
KIRC	cis	rs987710	1	rs987710	ENSG00000211639.2	IGLV4-60	-7.4	5.93e-13	3.12e-10	-0.31	-0.32	Iron status biomarkers;Iron deficiency;	chr22:22158022	chr22:22162199~22162681:+
KIRC	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	7.4	5.93e-13	3.12e-10	0.39	0.32	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
KIRC	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	7.4	5.93e-13	3.12e-10	0.61	0.32	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
KIRC	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.4	5.93e-13	3.12e-10	-0.3	-0.32	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
KIRC	cis	rs1005277	0.638	rs1005278	ENSG00000151963.4	RP11-775A3.1	7.4	5.93e-13	3.13e-10	0.37	0.32	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:37883594~37884109:+
KIRC	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	7.4	5.94e-13	3.13e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
KIRC	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	7.4	5.94e-13	3.13e-10	0.35	0.32	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
KIRC	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-7.4	5.96e-13	3.14e-10	-0.39	-0.32	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
KIRC	cis	rs890448	0.726	rs1031035	ENSG00000254531.1	FLJ20021	-7.4	5.96e-13	3.14e-10	-0.31	-0.32	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101301927	chr4:101347780~101348883:+
KIRC	cis	rs17213965	0.925	rs62030569	ENSG00000207425.1	Y_RNA	-7.4	5.98e-13	3.15e-10	-0.5	-0.32	Waist-hip ratio;	chr16:15786892	chr16:14915457~14915556:-
KIRC	cis	rs2361718	0.5	rs8068856	ENSG00000275479.1	RP11-334C17.6	7.4	5.98e-13	3.15e-10	0.33	0.32	Yeast infection;	chr17:80126932	chr17:80149627~80149798:+
KIRC	cis	rs11647589	0.834	rs9806821	ENSG00000262995.1	CTD-2194A8.2	-7.4	5.99e-13	3.15e-10	-0.33	-0.32	Blood metabolite levels;	chr16:20473857	chr16:20440266~20447000:-
KIRC	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	7.4	6.01e-13	3.16e-10	0.35	0.32	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
KIRC	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	7.4	6.02e-13	3.17e-10	0.43	0.32	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
KIRC	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	7.4	6.02e-13	3.17e-10	0.43	0.32	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
KIRC	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	7.4	6.02e-13	3.17e-10	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	7.4	6.02e-13	3.17e-10	0.4	0.32	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000251284.2	RP13-644M16.1	-7.4	6.04e-13	3.18e-10	-0.38	-0.32	Obesity-related traits;	chr4:69075351	chr4:69125274~69126451:+
KIRC	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	7.4	6.04e-13	3.18e-10	0.44	0.32	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	7.4	6.04e-13	3.18e-10	0.44	0.32	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	7.4	6.05e-13	3.18e-10	0.45	0.32	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs6851971	ENSG00000249700.7	SRD5A3-AS1	7.4	6.06e-13	3.19e-10	0.31	0.32	Adiponectin levels;	chr4:55561897	chr4:55363971~55395847:-
KIRC	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-7.4	6.06e-13	3.19e-10	-0.32	-0.32	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
KIRC	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	7.4	6.07e-13	3.19e-10	0.6	0.32	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	7.4	6.07e-13	3.19e-10	0.6	0.32	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	7.4	6.07e-13	3.19e-10	0.6	0.32	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
KIRC	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-7.4	6.08e-13	3.2e-10	-0.45	-0.32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
KIRC	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-7.39	6.09e-13	3.2e-10	-0.24	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
KIRC	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	7.39	6.13e-13	3.22e-10	0.36	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
KIRC	cis	rs12500482	0.5	rs2013276	ENSG00000206113.6	RP11-503N18.1	7.39	6.13e-13	3.22e-10	0.39	0.32	Cognitive function;	chr4:2426172	chr4:2418974~2450360:+
KIRC	cis	rs755249	0.959	rs72663520	ENSG00000237624.1	OXCT2P1	7.39	6.14e-13	3.23e-10	0.47	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39514956~39516490:+
KIRC	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	7.39	6.16e-13	3.24e-10	0.47	0.32	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
KIRC	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	7.39	6.17e-13	3.24e-10	0.35	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
KIRC	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	7.39	6.18e-13	3.25e-10	0.38	0.32	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
KIRC	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-7.39	6.19e-13	3.25e-10	-0.3	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
KIRC	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	7.39	6.19e-13	3.25e-10	0.49	0.32	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
KIRC	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-7.39	6.2e-13	3.25e-10	-0.58	-0.32	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
KIRC	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	7.39	6.21e-13	3.26e-10	0.48	0.32	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
KIRC	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	7.39	6.23e-13	3.27e-10	0.35	0.32	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	7.39	6.23e-13	3.27e-10	0.35	0.32	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
KIRC	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	7.39	6.24e-13	3.28e-10	0.41	0.32	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
KIRC	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-7.39	6.25e-13	3.28e-10	-0.29	-0.32	Gout;	chr7:66645053	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.39	6.25e-13	3.28e-10	0.28	0.32	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.697	rs3847001	ENSG00000235574.1	AC073150.6	-7.39	6.26e-13	3.29e-10	-0.37	-0.32	Hypospadias;	chr7:27524686	chr7:27491682~27492765:-
KIRC	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	7.39	6.27e-13	3.29e-10	0.43	0.32	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
KIRC	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-7.39	6.27e-13	3.29e-10	-0.4	-0.32	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
KIRC	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-7.39	6.27e-13	3.29e-10	-0.76	-0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
KIRC	cis	rs17772222	0.682	rs28711639	ENSG00000222990.1	RNU4-22P	7.39	6.27e-13	3.29e-10	0.33	0.32	Coronary artery calcification;	chr14:88482277	chr14:88513498~88513663:+
KIRC	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	7.39	6.28e-13	3.3e-10	0.29	0.32	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
KIRC	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-7.39	6.28e-13	3.3e-10	-0.34	-0.32	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
KIRC	cis	rs3760982	1	rs3760982	ENSG00000267058.1	RP11-15A1.3	-7.39	6.28e-13	3.3e-10	-0.36	-0.32	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43891804~43901805:-
KIRC	cis	rs12936587	0.564	rs7208561	ENSG00000223979.2	SMCR2	-7.39	6.28e-13	3.3e-10	-0.33	-0.32	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17712214	chr17:17674026~17677688:-
KIRC	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-7.39	6.28e-13	3.3e-10	-0.38	-0.32	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
KIRC	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	7.39	6.29e-13	3.3e-10	0.53	0.32	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
KIRC	cis	rs9388451	0.839	rs4897157	ENSG00000237742.5	RP11-624M8.1	-7.39	6.29e-13	3.3e-10	-0.37	-0.32	Brugada syndrome;	chr6:125781835	chr6:125578558~125749190:-
KIRC	cis	rs13423976	0.663	rs7559097	ENSG00000231367.4	AC016995.3	-7.39	6.29e-13	3.3e-10	-0.4	-0.32	Gut microbiome composition (summer);	chr2:38517625	chr2:38406719~38515740:-
KIRC	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-7.39	6.29e-13	3.3e-10	-0.35	-0.32	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-7.39	6.29e-13	3.3e-10	-0.35	-0.32	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
KIRC	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-7.39	6.3e-13	3.31e-10	-0.33	-0.32	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
KIRC	cis	rs34375054	0.624	rs4073534	ENSG00000279233.1	RP11-158L12.4	7.39	6.3e-13	3.31e-10	0.25	0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125187254	chr12:125138245~125141711:+
KIRC	cis	rs375066	0.762	rs239939	ENSG00000267058.1	RP11-15A1.3	-7.39	6.31e-13	3.31e-10	-0.37	-0.32	Breast cancer;	chr19:43883815	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs239938	ENSG00000267058.1	RP11-15A1.3	-7.39	6.31e-13	3.31e-10	-0.37	-0.32	Breast cancer;	chr19:43886153	chr19:43891804~43901805:-
KIRC	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-7.39	6.31e-13	3.31e-10	-0.38	-0.32	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
KIRC	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-7.39	6.34e-13	3.33e-10	-0.29	-0.32	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
KIRC	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-7.39	6.34e-13	3.33e-10	-0.29	-0.32	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
KIRC	cis	rs17772222	0.682	rs28371093	ENSG00000222990.1	RNU4-22P	7.39	6.35e-13	3.33e-10	0.33	0.32	Coronary artery calcification;	chr14:88486112	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.655	rs10150594	ENSG00000222990.1	RNU4-22P	7.39	6.35e-13	3.33e-10	0.33	0.32	Coronary artery calcification;	chr14:88489613	chr14:88513498~88513663:+
KIRC	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-7.39	6.35e-13	3.33e-10	-0.35	-0.32	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-7.39	6.35e-13	3.33e-10	-0.35	-0.32	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-7.39	6.35e-13	3.33e-10	-0.35	-0.32	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
KIRC	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	7.39	6.37e-13	3.34e-10	0.44	0.32	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
KIRC	cis	rs6061231	0.631	rs927133	ENSG00000275437.1	RP5-908M14.10	7.39	6.37e-13	3.34e-10	0.24	0.32	Colorectal cancer;	chr20:62397053	chr20:62402236~62405935:-
KIRC	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-7.39	6.38e-13	3.35e-10	-0.23	-0.32	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
KIRC	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	7.39	6.4e-13	3.36e-10	0.34	0.32	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
KIRC	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	7.39	6.41e-13	3.36e-10	0.61	0.32	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
KIRC	cis	rs11647589	0.689	rs8045136	ENSG00000262995.1	CTD-2194A8.2	7.39	6.41e-13	3.36e-10	0.34	0.32	Blood metabolite levels;	chr16:20442599	chr16:20440266~20447000:-
KIRC	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	7.39	6.42e-13	3.37e-10	0.44	0.32	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	7.39	6.42e-13	3.37e-10	0.44	0.32	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
KIRC	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	7.39	6.42e-13	3.37e-10	0.51	0.32	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
KIRC	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	7.39	6.43e-13	3.37e-10	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
KIRC	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-7.39	6.43e-13	3.37e-10	-0.47	-0.32	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
KIRC	cis	rs13434995	0.635	rs1818461	ENSG00000249700.7	SRD5A3-AS1	-7.39	6.43e-13	3.37e-10	-0.32	-0.32	Adiponectin levels;	chr4:55379156	chr4:55363971~55395847:-
KIRC	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-7.39	6.44e-13	3.38e-10	-0.37	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
KIRC	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	7.39	6.47e-13	3.39e-10	0.3	0.32	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
KIRC	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	7.39	6.48e-13	3.39e-10	0.41	0.32	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
KIRC	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-7.39	6.48e-13	3.39e-10	-0.39	-0.32	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
KIRC	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	7.39	6.49e-13	3.4e-10	0.39	0.32	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
KIRC	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-7.39	6.49e-13	3.4e-10	-0.46	-0.32	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
KIRC	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	7.39	6.49e-13	3.4e-10	0.5	0.32	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
KIRC	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-7.39	6.49e-13	3.4e-10	-0.4	-0.32	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-7.39	6.49e-13	3.4e-10	-0.4	-0.32	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
KIRC	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	7.39	6.5e-13	3.4e-10	0.36	0.32	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
KIRC	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	7.39	6.5e-13	3.4e-10	0.25	0.32	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
KIRC	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	7.39	6.5e-13	3.4e-10	0.25	0.32	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
KIRC	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	7.39	6.5e-13	3.4e-10	0.45	0.32	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
KIRC	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	7.38	6.52e-13	3.41e-10	0.36	0.32	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
KIRC	cis	rs6061231	0.631	rs2427318	ENSG00000273619.1	RP5-908M14.9	-7.38	6.52e-13	3.41e-10	-0.24	-0.32	Colorectal cancer;	chr20:62400671	chr20:62386303~62386970:-
KIRC	cis	rs710913	0.717	rs1180352	ENSG00000237624.1	OXCT2P1	-7.38	6.52e-13	3.41e-10	-0.39	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39514956~39516490:+
KIRC	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-7.38	6.52e-13	3.41e-10	-0.29	-0.32	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
KIRC	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	7.38	6.53e-13	3.42e-10	0.44	0.32	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
KIRC	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-7.38	6.53e-13	3.42e-10	-0.24	-0.32	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
KIRC	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	7.38	6.53e-13	3.42e-10	0.43	0.32	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
KIRC	cis	rs17801127	0.748	rs34247742	ENSG00000231969.1	AC144449.1	7.38	6.53e-13	3.42e-10	0.58	0.32	Liver enzyme levels (alanine transaminase);	chr2:149771152	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.748	rs72992402	ENSG00000231969.1	AC144449.1	7.38	6.53e-13	3.42e-10	0.58	0.32	Liver enzyme levels (alanine transaminase);	chr2:149771773	chr2:149587196~149848233:+
KIRC	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	7.38	6.54e-13	3.42e-10	0.4	0.32	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
KIRC	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	7.38	6.54e-13	3.42e-10	0.38	0.32	Height;	chr4:55540912	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	7.38	6.54e-13	3.42e-10	0.38	0.32	Height;	chr4:55540972	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	7.38	6.54e-13	3.42e-10	0.43	0.32	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
KIRC	cis	rs10754283	0.557	rs1215508	ENSG00000231613.1	RP5-943J3.1	7.38	6.54e-13	3.43e-10	0.32	0.32	Amyotrophic lateral sclerosis (sporadic);	chr1:89623138	chr1:89788914~89790492:+
KIRC	cis	rs3820928	0.9	rs6754155	ENSG00000212391.1	SNORA48	-7.38	6.55e-13	3.43e-10	-0.37	-0.32	Pulmonary function;	chr2:226920245	chr2:226968989~226969122:-
KIRC	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	7.38	6.55e-13	3.43e-10	0.4	0.31	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
KIRC	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	7.38	6.55e-13	3.43e-10	0.4	0.31	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
KIRC	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	7.38	6.55e-13	3.43e-10	0.4	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
KIRC	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-7.38	6.56e-13	3.43e-10	-0.31	-0.31	QT interval;	chr12:29298788	chr12:29280418~29317848:-
KIRC	cis	rs58873874	0.522	rs111370613	ENSG00000251405.2	CTB-109A12.1	7.38	6.59e-13	3.45e-10	0.54	0.31	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157362615~157460078:-
KIRC	cis	rs58873874	0.522	rs77458926	ENSG00000251405.2	CTB-109A12.1	7.38	6.59e-13	3.45e-10	0.54	0.31	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157362615~157460078:-
KIRC	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	7.38	6.59e-13	3.45e-10	0.6	0.31	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	7.38	6.59e-13	3.45e-10	0.6	0.31	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	7.38	6.59e-13	3.45e-10	0.6	0.31	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	7.38	6.59e-13	3.45e-10	0.6	0.31	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
KIRC	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	7.38	6.6e-13	3.45e-10	0.45	0.31	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
KIRC	cis	rs10214930	0.697	rs2080246	ENSG00000235574.1	AC073150.6	-7.38	6.6e-13	3.45e-10	-0.37	-0.31	Hypospadias;	chr7:27530085	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1014373	ENSG00000235574.1	AC073150.6	-7.38	6.6e-13	3.45e-10	-0.37	-0.31	Hypospadias;	chr7:27531474	chr7:27491682~27492765:-
KIRC	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-7.38	6.61e-13	3.46e-10	-0.29	-0.31	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
KIRC	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-7.38	6.64e-13	3.47e-10	-0.24	-0.31	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
KIRC	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	7.38	6.64e-13	3.47e-10	0.39	0.31	Height;	chr4:55611014	chr4:55387949~55388271:+
KIRC	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-7.38	6.64e-13	3.47e-10	-0.35	-0.31	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
KIRC	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	7.38	6.65e-13	3.47e-10	0.57	0.31	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
KIRC	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	7.38	6.65e-13	3.48e-10	0.46	0.31	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
KIRC	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	7.38	6.66e-13	3.48e-10	0.4	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
KIRC	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	7.38	6.66e-13	3.48e-10	0.4	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
KIRC	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-7.38	6.67e-13	3.49e-10	-0.39	-0.31	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
KIRC	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-7.38	6.69e-13	3.5e-10	-0.39	-0.31	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
KIRC	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	7.38	6.69e-13	3.5e-10	0.25	0.31	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
KIRC	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	7.38	6.7e-13	3.5e-10	0.39	0.31	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
KIRC	cis	rs58873874	0.737	rs11744671	ENSG00000251405.2	CTB-109A12.1	7.38	6.72e-13	3.51e-10	0.58	0.31	Bipolar disorder (body mass index interaction);	chr5:157494223	chr5:157362615~157460078:-
KIRC	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-7.38	6.72e-13	3.51e-10	-0.36	-0.31	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
KIRC	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-7.38	6.72e-13	3.51e-10	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
KIRC	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-7.38	6.72e-13	3.51e-10	-0.38	-0.31	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
KIRC	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-7.38	6.74e-13	3.52e-10	-0.29	-0.31	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
KIRC	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	7.38	6.74e-13	3.52e-10	0.43	0.31	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
KIRC	cis	rs897984	0.647	rs8060857	ENSG00000260911.2	RP11-196G11.2	-7.38	6.76e-13	3.53e-10	-0.2	-0.31	Dementia with Lewy bodies;	chr16:30991399	chr16:31043150~31049868:+
KIRC	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	7.38	6.76e-13	3.53e-10	0.45	0.31	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
KIRC	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-7.38	6.77e-13	3.54e-10	-0.32	-0.31	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
KIRC	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-7.38	6.77e-13	3.54e-10	-0.32	-0.31	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
KIRC	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-7.38	6.77e-13	3.54e-10	-0.36	-0.31	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
KIRC	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.38	6.77e-13	3.54e-10	-0.34	-0.31	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
KIRC	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-7.38	6.77e-13	3.54e-10	-0.41	-0.31	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
KIRC	cis	rs2361718	0.521	rs2361724	ENSG00000275479.1	RP11-334C17.6	7.38	6.82e-13	3.56e-10	0.33	0.31	Yeast infection;	chr17:80125315	chr17:80149627~80149798:+
KIRC	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	7.38	6.83e-13	3.57e-10	0.3	0.31	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
KIRC	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-7.38	6.84e-13	3.57e-10	-0.39	-0.31	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
KIRC	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	7.38	6.85e-13	3.58e-10	0.25	0.31	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
KIRC	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	7.38	6.86e-13	3.58e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
KIRC	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	7.38	6.86e-13	3.58e-10	0.48	0.31	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
KIRC	cis	rs13113518	1	rs4864994	ENSG00000273257.1	RP11-177J6.1	7.38	6.86e-13	3.58e-10	0.37	0.31	Height;	chr4:55451955	chr4:55387949~55388271:+
KIRC	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-7.38	6.86e-13	3.58e-10	-0.38	-0.31	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
KIRC	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-7.38	6.87e-13	3.59e-10	-0.39	-0.31	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
KIRC	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	7.38	6.87e-13	3.59e-10	0.22	0.31	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
KIRC	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	7.38	6.89e-13	3.6e-10	0.49	0.31	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
KIRC	cis	rs710913	0.691	rs1180351	ENSG00000237624.1	OXCT2P1	-7.38	6.91e-13	3.61e-10	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39514956~39516490:+
KIRC	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	7.38	6.92e-13	3.61e-10	0.37	0.31	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
KIRC	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	7.38	6.92e-13	3.61e-10	0.41	0.31	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
KIRC	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	7.38	6.93e-13	3.62e-10	0.37	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
KIRC	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	7.38	6.95e-13	3.62e-10	0.48	0.31	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
KIRC	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-7.37	6.97e-13	3.63e-10	-0.34	-0.31	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-7.37	6.97e-13	3.63e-10	-0.34	-0.31	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
KIRC	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	7.37	6.98e-13	3.64e-10	0.33	0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
KIRC	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	7.37	6.99e-13	3.64e-10	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
KIRC	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	7.37	6.99e-13	3.64e-10	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
KIRC	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-7.37	7.01e-13	3.65e-10	-0.35	-0.31	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
KIRC	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	7.37	7.03e-13	3.66e-10	0.4	0.31	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
KIRC	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	7.37	7.03e-13	3.67e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
KIRC	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	7.37	7.05e-13	3.67e-10	0.4	0.31	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
KIRC	cis	rs13434995	0.513	rs13133077	ENSG00000273257.1	RP11-177J6.1	7.37	7.08e-13	3.69e-10	0.42	0.31	Adiponectin levels;	chr4:55577642	chr4:55387949~55388271:+
KIRC	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-7.37	7.08e-13	3.69e-10	-0.42	-0.31	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
KIRC	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-7.37	7.08e-13	3.69e-10	-0.29	-0.31	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
KIRC	cis	rs13434995	0.513	rs12509047	ENSG00000249700.7	SRD5A3-AS1	7.37	7.09e-13	3.7e-10	0.32	0.31	Adiponectin levels;	chr4:55545245	chr4:55363971~55395847:-
KIRC	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	7.37	7.1e-13	3.7e-10	0.38	0.31	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
KIRC	cis	rs7945705	0.782	rs3763918	ENSG00000254860.4	TMEM9B-AS1	-7.37	7.11e-13	3.7e-10	-0.33	-0.31	Hemoglobin concentration;	chr11:8798136	chr11:8964675~8977527:+
KIRC	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	7.37	7.11e-13	3.71e-10	0.35	0.31	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
KIRC	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	7.37	7.12e-13	3.71e-10	0.38	0.31	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	7.37	7.12e-13	3.71e-10	0.38	0.31	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	7.37	7.12e-13	3.71e-10	0.38	0.31	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
KIRC	cis	rs7592578	0.882	rs2192010	ENSG00000272979.1	RP11-647K16.1	-7.37	7.15e-13	3.73e-10	-0.45	-0.31	Diastolic blood pressure;	chr2:190597407	chr2:190454092~190454521:-
KIRC	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	7.37	7.16e-13	3.73e-10	0.26	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
KIRC	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-7.37	7.16e-13	3.73e-10	-0.29	-0.31	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
KIRC	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-7.37	7.17e-13	3.73e-10	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
KIRC	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	7.37	7.17e-13	3.74e-10	0.39	0.31	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
KIRC	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	7.37	7.18e-13	3.74e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
KIRC	cis	rs2486288	0.656	rs8039354	ENSG00000235390.4	CTD-2651B20.5	-7.37	7.18e-13	3.74e-10	-0.3	-0.31	Glomerular filtration rate;	chr15:45259558	chr15:45321077~45321692:-
KIRC	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.37	7.19e-13	3.75e-10	0.42	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
KIRC	cis	rs2018683	0.621	rs10261556	ENSG00000228421.2	AC005013.5	7.37	7.2e-13	3.75e-10	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28957667~28959345:+
KIRC	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	7.37	7.21e-13	3.75e-10	0.39	0.31	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	7.37	7.21e-13	3.75e-10	0.39	0.31	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	7.37	7.21e-13	3.75e-10	0.39	0.31	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	7.37	7.21e-13	3.75e-10	0.39	0.31	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
KIRC	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	7.37	7.21e-13	3.75e-10	0.44	0.31	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
KIRC	cis	rs3820928	0.967	rs4675118	ENSG00000212391.1	SNORA48	-7.37	7.21e-13	3.76e-10	-0.37	-0.31	Pulmonary function;	chr2:226908441	chr2:226968989~226969122:-
KIRC	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	7.37	7.23e-13	3.76e-10	0.4	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
KIRC	cis	rs11512640	0.655	rs80057612	ENSG00000254671.2	STT3A-AS1	7.37	7.24e-13	3.77e-10	0.66	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125542949	chr11:125570284~125592568:-
KIRC	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-7.37	7.24e-13	3.77e-10	-0.34	-0.31	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
KIRC	cis	rs2486288	0.656	rs9921035	ENSG00000235390.4	CTD-2651B20.5	7.37	7.26e-13	3.78e-10	0.29	0.31	Glomerular filtration rate;	chr15:45254462	chr15:45321077~45321692:-
KIRC	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	7.37	7.26e-13	3.78e-10	0.39	0.31	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
KIRC	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-7.37	7.27e-13	3.78e-10	-0.34	-0.31	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
KIRC	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	7.37	7.28e-13	3.79e-10	0.33	0.31	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
KIRC	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	7.37	7.29e-13	3.79e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
KIRC	cis	rs11647589	0.689	rs12599141	ENSG00000262995.1	CTD-2194A8.2	-7.37	7.29e-13	3.8e-10	-0.34	-0.31	Blood metabolite levels;	chr16:20440775	chr16:20440266~20447000:-
KIRC	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	7.37	7.3e-13	3.8e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
KIRC	cis	rs755249	0.517	rs66880209	ENSG00000237624.1	OXCT2P1	7.37	7.31e-13	3.8e-10	0.57	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39514956~39516490:+
KIRC	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	7.37	7.32e-13	3.81e-10	0.35	0.31	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
KIRC	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	7.37	7.32e-13	3.81e-10	0.42	0.31	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
KIRC	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-7.37	7.33e-13	3.81e-10	-0.33	-0.31	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-7.37	7.33e-13	3.81e-10	-0.33	-0.31	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
KIRC	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.37	7.33e-13	3.81e-10	0.42	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
KIRC	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	7.37	7.33e-13	3.81e-10	0.43	0.31	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	7.37	7.34e-13	3.82e-10	0.44	0.31	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	7.37	7.35e-13	3.83e-10	0.44	0.31	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
KIRC	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	7.37	7.35e-13	3.83e-10	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
KIRC	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	7.37	7.36e-13	3.83e-10	0.31	0.31	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
KIRC	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	7.37	7.36e-13	3.83e-10	0.38	0.31	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
KIRC	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-7.37	7.37e-13	3.83e-10	-0.3	-0.31	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
KIRC	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	7.37	7.37e-13	3.83e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
KIRC	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	7.37	7.43e-13	3.86e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	7.37	7.43e-13	3.86e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	7.37	7.43e-13	3.86e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	7.37	7.43e-13	3.86e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	7.37	7.43e-13	3.86e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	7.37	7.43e-13	3.86e-10	0.44	0.31	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
KIRC	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-7.37	7.44e-13	3.87e-10	-0.35	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
KIRC	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-7.37	7.45e-13	3.87e-10	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
KIRC	cis	rs375066	0.762	rs239943	ENSG00000267058.1	RP11-15A1.3	-7.37	7.45e-13	3.87e-10	-0.36	-0.31	Breast cancer;	chr19:43870564	chr19:43891804~43901805:-
KIRC	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	7.36	7.46e-13	3.88e-10	0.24	0.31	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
KIRC	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-7.36	7.46e-13	3.88e-10	-0.31	-0.31	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
KIRC	cis	rs6600671	1	rs10794671	ENSG00000270231.3	NBPF8P	7.36	7.46e-13	3.88e-10	0.24	0.31	Hip geometry;	chr1:121426382	chr1:120436353~120467739:+
KIRC	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	7.36	7.47e-13	3.88e-10	0.6	0.31	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
KIRC	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-7.36	7.47e-13	3.88e-10	-0.38	-0.31	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
KIRC	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	7.36	7.49e-13	3.89e-10	0.38	0.31	Height;	chr4:55559957	chr4:55387949~55388271:+
KIRC	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	7.36	7.51e-13	3.9e-10	0.38	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
KIRC	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66679692	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66692349	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66693433	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66694214	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66701371	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66702658	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66706390	chr7:66902857~66906297:+
KIRC	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-7.36	7.51e-13	3.9e-10	-0.28	-0.31	Gout;	chr7:66710076	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	7.36	7.51e-13	3.9e-10	0.28	0.31	Gout;	chr7:66682070	chr7:66902857~66906297:+
KIRC	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	7.36	7.51e-13	3.9e-10	0.28	0.31	Gout;	chr7:66682162	chr7:66902857~66906297:+
KIRC	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-7.36	7.54e-13	3.92e-10	-0.24	-0.31	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
KIRC	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	7.36	7.54e-13	3.92e-10	0.45	0.31	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	7.36	7.56e-13	3.93e-10	0.41	0.31	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
KIRC	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-7.36	7.57e-13	3.93e-10	-0.41	-0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
KIRC	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-7.36	7.57e-13	3.93e-10	-0.38	-0.31	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
KIRC	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	7.36	7.57e-13	3.93e-10	0.2	0.31	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
KIRC	cis	rs1823913	0.503	rs6706578	ENSG00000280083.1	RP11-317J9.1	-7.36	7.58e-13	3.93e-10	-0.31	-0.31	Obesity-related traits;	chr2:191346992	chr2:191154118~191156070:-
KIRC	cis	rs58873874	0.737	rs77273565	ENSG00000251405.2	CTB-109A12.1	7.36	7.59e-13	3.94e-10	0.59	0.31	Bipolar disorder (body mass index interaction);	chr5:157489547	chr5:157362615~157460078:-
KIRC	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-7.36	7.59e-13	3.94e-10	-0.26	-0.31	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
KIRC	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	7.36	7.6e-13	3.95e-10	0.28	0.31	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
KIRC	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	7.36	7.61e-13	3.95e-10	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
KIRC	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	7.36	7.62e-13	3.96e-10	0.52	0.31	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	7.36	7.62e-13	3.96e-10	0.52	0.31	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
KIRC	cis	rs17801127	0.688	rs34250677	ENSG00000231969.1	AC144449.1	7.36	7.63e-13	3.96e-10	0.59	0.31	Liver enzyme levels (alanine transaminase);	chr2:149790443	chr2:149587196~149848233:+
KIRC	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	7.36	7.65e-13	3.97e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
KIRC	cis	rs3745672	1	rs3745672	ENSG00000219665.7	CTD-2006C1.2	-7.36	7.67e-13	3.98e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12035555	chr19:11987617~12046275:+
KIRC	cis	rs3820928	1	rs10197757	ENSG00000212391.1	SNORA48	-7.36	7.7e-13	3.99e-10	-0.37	-0.31	Pulmonary function;	chr2:226898528	chr2:226968989~226969122:-
KIRC	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	7.36	7.7e-13	3.99e-10	0.37	0.31	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
KIRC	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	7.36	7.7e-13	3.99e-10	0.41	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
KIRC	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-7.36	7.7e-13	4e-10	-0.39	-0.31	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
KIRC	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-7.36	7.71e-13	4e-10	-0.4	-0.31	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
KIRC	cis	rs9915657	0.933	rs17246133	ENSG00000234899.8	SOX9-AS1	-7.36	7.71e-13	4e-10	-0.39	-0.31	Thyroid hormone levels;	chr17:72144344	chr17:72034107~72237203:-
KIRC	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	7.36	7.71e-13	4e-10	0.41	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
KIRC	cis	rs2562456	0.55	rs4809143	ENSG00000268555.1	RP11-678G14.3	7.36	7.72e-13	4e-10	0.48	0.31	Pain;	chr19:21589926	chr19:21570822~21587322:-
KIRC	cis	rs2562456	0.583	rs4809144	ENSG00000268555.1	RP11-678G14.3	7.36	7.72e-13	4e-10	0.48	0.31	Pain;	chr19:21589928	chr19:21570822~21587322:-
KIRC	cis	rs2562456	0.652	rs62110214	ENSG00000268555.1	RP11-678G14.3	7.36	7.72e-13	4e-10	0.48	0.31	Pain;	chr19:21592406	chr19:21570822~21587322:-
KIRC	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	7.36	7.72e-13	4.01e-10	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
KIRC	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	7.36	7.72e-13	4.01e-10	0.44	0.31	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	7.36	7.73e-13	4.01e-10	0.44	0.31	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	7.36	7.73e-13	4.01e-10	0.44	0.31	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
KIRC	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-7.36	7.73e-13	4.01e-10	-0.3	-0.31	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
KIRC	cis	rs6600671	1	rs1856572	ENSG00000270231.3	NBPF8P	7.36	7.76e-13	4.02e-10	0.24	0.31	Hip geometry;	chr1:121427719	chr1:120436353~120467739:+
KIRC	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	7.36	7.76e-13	4.02e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
KIRC	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	7.36	7.79e-13	4.04e-10	0.28	0.31	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
KIRC	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	7.36	7.79e-13	4.04e-10	0.23	0.31	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
KIRC	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	7.36	7.81e-13	4.05e-10	0.39	0.31	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
KIRC	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-7.36	7.81e-13	4.05e-10	-0.49	-0.31	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
KIRC	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-7.36	7.81e-13	4.05e-10	-0.34	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
KIRC	cis	rs1964356	0.524	rs7839585	ENSG00000253893.2	FAM85B	7.36	7.82e-13	4.05e-10	0.41	0.31	Mean corpuscular volume;	chr8:8996725	chr8:8167819~8226614:-
KIRC	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	7.36	7.82e-13	4.05e-10	0.38	0.31	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
KIRC	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	7.36	7.82e-13	4.05e-10	0.41	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
KIRC	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-7.36	7.84e-13	4.06e-10	-0.42	-0.31	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000251284.2	RP13-644M16.1	-7.36	7.84e-13	4.06e-10	-0.38	-0.31	Obesity-related traits;	chr4:69078113	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000251284.2	RP13-644M16.1	-7.36	7.84e-13	4.06e-10	-0.38	-0.31	Obesity-related traits;	chr4:69078247	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000251284.2	RP13-644M16.1	-7.36	7.84e-13	4.06e-10	-0.38	-0.31	Obesity-related traits;	chr4:69078533	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000251284.2	RP13-644M16.1	-7.36	7.84e-13	4.06e-10	-0.38	-0.31	Obesity-related traits;	chr4:69078868	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000251284.2	RP13-644M16.1	-7.36	7.84e-13	4.06e-10	-0.38	-0.31	Obesity-related traits;	chr4:69078897	chr4:69125274~69126451:+
KIRC	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	7.36	7.86e-13	4.07e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	7.36	7.86e-13	4.07e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
KIRC	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	7.36	7.87e-13	4.08e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	7.36	7.87e-13	4.08e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	7.36	7.87e-13	4.08e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	7.36	7.87e-13	4.08e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
KIRC	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-7.36	7.89e-13	4.09e-10	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
KIRC	cis	rs17772222	0.545	rs1758846	ENSG00000222990.1	RNU4-22P	-7.36	7.89e-13	4.09e-10	-0.34	-0.31	Coronary artery calcification;	chr14:88449288	chr14:88513498~88513663:+
KIRC	cis	rs3820928	1	rs10193404	ENSG00000212391.1	SNORA48	-7.36	7.91e-13	4.1e-10	-0.37	-0.31	Pulmonary function;	chr2:226913041	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs4675116	ENSG00000212391.1	SNORA48	-7.36	7.91e-13	4.1e-10	-0.37	-0.31	Pulmonary function;	chr2:226904891	chr2:226968989~226969122:-
KIRC	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	7.36	7.92e-13	4.1e-10	0.47	0.31	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
KIRC	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-7.36	7.93e-13	4.1e-10	-0.28	-0.31	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
KIRC	cis	rs4819052	0.851	rs2838837	ENSG00000223768.1	LINC00205	-7.36	7.93e-13	4.11e-10	-0.32	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45293285~45297354:+
KIRC	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	7.36	7.93e-13	4.11e-10	0.44	0.31	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
KIRC	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-7.36	7.93e-13	4.11e-10	-0.23	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
KIRC	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-7.35	7.99e-13	4.13e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-7.35	7.99e-13	4.13e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-7.35	7.99e-13	4.13e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
KIRC	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	7.35	7.99e-13	4.13e-10	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
KIRC	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	7.35	7.99e-13	4.13e-10	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
KIRC	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.35	8e-13	4.14e-10	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
KIRC	cis	rs375066	0.736	rs62114649	ENSG00000267058.1	RP11-15A1.3	7.35	8e-13	4.14e-10	0.37	0.31	Breast cancer;	chr19:43912415	chr19:43891804~43901805:-
KIRC	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	7.35	8.01e-13	4.14e-10	0.39	0.31	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
KIRC	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-7.35	8.02e-13	4.15e-10	-0.39	-0.31	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
KIRC	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-7.35	8.02e-13	4.15e-10	-0.3	-0.31	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
KIRC	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-7.35	8.03e-13	4.15e-10	-0.33	-0.31	Height;	chr3:52991821	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	7.35	8.04e-13	4.16e-10	0.5	0.31	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
KIRC	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-7.35	8.05e-13	4.16e-10	-0.39	-0.31	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
KIRC	cis	rs10214930	0.647	rs2098316	ENSG00000235574.1	AC073150.6	-7.35	8.08e-13	4.18e-10	-0.37	-0.31	Hypospadias;	chr7:27529018	chr7:27491682~27492765:-
KIRC	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-7.35	8.08e-13	4.18e-10	-0.36	-0.31	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
KIRC	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	7.35	8.09e-13	4.18e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
KIRC	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-7.35	8.18e-13	4.23e-10	-0.34	-0.31	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
KIRC	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-7.35	8.18e-13	4.23e-10	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
KIRC	cis	rs17772222	0.582	rs11625009	ENSG00000258983.2	RP11-507K2.2	-7.35	8.19e-13	4.23e-10	-0.32	-0.31	Coronary artery calcification;	chr14:88521018	chr14:88499334~88515502:+
KIRC	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-7.35	8.19e-13	4.23e-10	-0.3	-0.31	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
KIRC	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-7.35	8.21e-13	4.24e-10	-0.39	-0.31	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
KIRC	cis	rs3820928	0.904	rs6735069	ENSG00000212391.1	SNORA48	-7.35	8.25e-13	4.26e-10	-0.37	-0.31	Pulmonary function;	chr2:227028944	chr2:226968989~226969122:-
KIRC	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-7.35	8.25e-13	4.26e-10	-0.33	-0.31	Height;	chr3:53064759	chr3:53064283~53065091:-
KIRC	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-7.35	8.26e-13	4.27e-10	-0.32	-0.31	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
KIRC	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-7.35	8.29e-13	4.28e-10	-0.31	-0.31	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
KIRC	cis	rs11512640	1	rs11220129	ENSG00000254671.2	STT3A-AS1	7.35	8.29e-13	4.28e-10	0.66	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125564929	chr11:125570284~125592568:-
KIRC	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	7.35	8.3e-13	4.28e-10	0.44	0.31	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
KIRC	cis	rs8048589	1	rs16958964	ENSG00000175604.2	RP11-276H1.3	-7.35	8.3e-13	4.29e-10	-0.37	-0.31	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092729	chr16:12086746~12090302:-
KIRC	cis	rs3820928	0.874	rs2272198	ENSG00000212391.1	SNORA48	7.35	8.3e-13	4.29e-10	0.36	0.31	Pulmonary function;	chr2:227028301	chr2:226968989~226969122:-
KIRC	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	7.35	8.3e-13	4.29e-10	0.48	0.31	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	7.35	8.3e-13	4.29e-10	0.48	0.31	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	7.35	8.3e-13	4.29e-10	0.48	0.31	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
KIRC	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	7.35	8.31e-13	4.29e-10	0.54	0.31	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
KIRC	cis	rs3820928	0.967	rs2396435	ENSG00000212391.1	SNORA48	-7.35	8.33e-13	4.3e-10	-0.37	-0.31	Pulmonary function;	chr2:226913681	chr2:226968989~226969122:-
KIRC	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.35	8.33e-13	4.3e-10	-0.35	-0.31	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
KIRC	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	7.35	8.33e-13	4.3e-10	0.44	0.31	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	7.35	8.33e-13	4.3e-10	0.44	0.31	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
KIRC	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	7.35	8.34e-13	4.31e-10	0.47	0.31	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
KIRC	cis	rs13434995	0.513	rs13134079	ENSG00000249700.7	SRD5A3-AS1	7.35	8.35e-13	4.31e-10	0.32	0.31	Adiponectin levels;	chr4:55542021	chr4:55363971~55395847:-
KIRC	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-7.35	8.37e-13	4.32e-10	-0.36	-0.31	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
KIRC	cis	rs3820928	0.874	rs10177995	ENSG00000212391.1	SNORA48	-7.35	8.4e-13	4.33e-10	-0.37	-0.31	Pulmonary function;	chr2:226916884	chr2:226968989~226969122:-
KIRC	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-7.35	8.41e-13	4.34e-10	-0.5	-0.31	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
KIRC	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	7.35	8.41e-13	4.34e-10	0.39	0.31	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
KIRC	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	7.35	8.41e-13	4.34e-10	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
KIRC	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	7.35	8.41e-13	4.34e-10	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
KIRC	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-7.35	8.43e-13	4.35e-10	-0.4	-0.31	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
KIRC	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-7.35	8.44e-13	4.35e-10	-0.33	-0.31	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
KIRC	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-7.35	8.46e-13	4.36e-10	-0.34	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
KIRC	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-7.35	8.46e-13	4.37e-10	-0.23	-0.31	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
KIRC	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-7.35	8.47e-13	4.37e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
KIRC	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	7.35	8.47e-13	4.37e-10	0.44	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
KIRC	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-7.35	8.47e-13	4.37e-10	-0.37	-0.31	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
KIRC	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	7.35	8.47e-13	4.37e-10	0.38	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
KIRC	cis	rs2018683	0.745	rs917217	ENSG00000228421.2	AC005013.5	-7.35	8.48e-13	4.37e-10	-0.32	-0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28957667~28959345:+
KIRC	cis	rs7017914	0.902	rs6472562	ENSG00000254031.4	RP11-326E22.1	7.35	8.48e-13	4.38e-10	0.34	0.31	Bone mineral density;	chr8:71057643	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.902	rs6472563	ENSG00000254031.4	RP11-326E22.1	7.35	8.48e-13	4.38e-10	0.34	0.31	Bone mineral density;	chr8:71057672	chr8:71155457~71204223:+
KIRC	cis	rs17772222	0.582	rs11625009	ENSG00000258789.1	RP11-507K2.3	7.35	8.5e-13	4.38e-10	0.28	0.31	Coronary artery calcification;	chr14:88521018	chr14:88551597~88552493:+
KIRC	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	7.35	8.52e-13	4.39e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
KIRC	cis	rs4698412	0.874	rs3213710	ENSG00000214846.4	RP11-115L11.1	-7.34	8.54e-13	4.4e-10	-0.39	-0.31	Parkinson's disease;	chr4:15715698	chr4:15730962~15731627:-
KIRC	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	7.34	8.56e-13	4.41e-10	0.35	0.31	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
KIRC	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	7.34	8.56e-13	4.41e-10	0.44	0.31	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
KIRC	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	7.34	8.56e-13	4.41e-10	0.39	0.31	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
KIRC	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-7.34	8.56e-13	4.41e-10	-0.28	-0.31	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
KIRC	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-7.34	8.57e-13	4.42e-10	-0.34	-0.31	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-7.34	8.57e-13	4.42e-10	-0.34	-0.31	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
KIRC	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-7.34	8.57e-13	4.42e-10	-0.34	-0.31	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
KIRC	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-7.34	8.57e-13	4.42e-10	-0.46	-0.31	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
KIRC	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	7.34	8.62e-13	4.44e-10	0.56	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
KIRC	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	7.34	8.62e-13	4.44e-10	0.35	0.31	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
KIRC	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-7.34	8.62e-13	4.44e-10	-0.31	-0.31	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	7.34	8.63e-13	4.45e-10	0.34	0.31	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
KIRC	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	7.34	8.64e-13	4.45e-10	0.33	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
KIRC	cis	rs13434995	0.513	rs7665286	ENSG00000273257.1	RP11-177J6.1	7.34	8.65e-13	4.45e-10	0.42	0.31	Adiponectin levels;	chr4:55578765	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs7683997	ENSG00000273257.1	RP11-177J6.1	7.34	8.65e-13	4.45e-10	0.42	0.31	Adiponectin levels;	chr4:55581272	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs4336288	ENSG00000273257.1	RP11-177J6.1	7.34	8.65e-13	4.45e-10	0.42	0.31	Adiponectin levels;	chr4:55584088	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs9993599	ENSG00000273257.1	RP11-177J6.1	7.34	8.65e-13	4.45e-10	0.42	0.31	Adiponectin levels;	chr4:55586798	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	7.34	8.65e-13	4.46e-10	0.44	0.31	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	7.34	8.65e-13	4.46e-10	0.44	0.31	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	7.34	8.66e-13	4.46e-10	0.39	0.31	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	7.34	8.66e-13	4.46e-10	0.39	0.31	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
KIRC	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	7.34	8.66e-13	4.46e-10	0.24	0.31	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	7.34	8.66e-13	4.46e-10	0.24	0.31	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
KIRC	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-7.34	8.66e-13	4.46e-10	-0.45	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-7.34	8.66e-13	4.46e-10	-0.45	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
KIRC	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-7.34	8.67e-13	4.47e-10	-0.4	-0.31	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
KIRC	cis	rs3820928	0.874	rs3752896	ENSG00000212391.1	SNORA48	-7.34	8.68e-13	4.47e-10	-0.36	-0.31	Pulmonary function;	chr2:227022209	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs10183633	ENSG00000212391.1	SNORA48	-7.34	8.68e-13	4.47e-10	-0.36	-0.31	Pulmonary function;	chr2:227023112	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	7.34	8.69e-13	4.47e-10	0.39	0.31	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
KIRC	cis	rs3820928	0.967	rs4675113	ENSG00000212391.1	SNORA48	-7.34	8.69e-13	4.47e-10	-0.37	-0.31	Pulmonary function;	chr2:226901623	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs6752707	ENSG00000212391.1	SNORA48	-7.34	8.69e-13	4.47e-10	-0.37	-0.31	Pulmonary function;	chr2:226902106	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.933	rs1429267	ENSG00000212391.1	SNORA48	-7.34	8.69e-13	4.47e-10	-0.37	-0.31	Pulmonary function;	chr2:226902877	chr2:226968989~226969122:-
KIRC	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-7.34	8.69e-13	4.47e-10	-0.27	-0.31	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
KIRC	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	7.34	8.72e-13	4.49e-10	0.52	0.31	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
KIRC	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	7.34	8.72e-13	4.49e-10	0.36	0.31	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
KIRC	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-7.34	8.75e-13	4.5e-10	-0.27	-0.31	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
KIRC	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-7.34	8.75e-13	4.5e-10	-0.27	-0.31	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
KIRC	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	7.34	8.75e-13	4.51e-10	0.51	0.31	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
KIRC	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	7.34	8.76e-13	4.51e-10	0.47	0.31	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
KIRC	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	7.34	8.76e-13	4.51e-10	0.23	0.31	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
KIRC	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	7.34	8.78e-13	4.52e-10	0.44	0.31	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
KIRC	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-7.34	8.78e-13	4.52e-10	-0.29	-0.31	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
KIRC	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-7.34	8.78e-13	4.52e-10	-0.29	-0.31	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
KIRC	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	7.34	8.79e-13	4.52e-10	0.3	0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
KIRC	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-7.34	8.82e-13	4.54e-10	-0.22	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
KIRC	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-7.34	8.84e-13	4.55e-10	-0.34	-0.31	Height;	chr3:53034139	chr3:53064283~53065091:-
KIRC	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-7.34	8.85e-13	4.55e-10	-0.43	-0.31	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
KIRC	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.34	8.87e-13	4.56e-10	0.4	0.31	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
KIRC	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	7.34	8.88e-13	4.57e-10	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
KIRC	cis	rs7672749	0.73	rs17013278	ENSG00000249973.2	CHCHD2P7	7.34	8.89e-13	4.57e-10	0.65	0.31	TB-LM or TBLH-BMD (pleiotropy);	chr4:87839550	chr4:87785920~87786371:-
KIRC	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	7.34	8.9e-13	4.58e-10	0.41	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
KIRC	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-7.34	8.92e-13	4.59e-10	-0.37	-0.31	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
KIRC	cis	rs7176527	0.706	rs35641144	ENSG00000188388.10	GOLGA6L3	7.34	8.92e-13	4.59e-10	0.43	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:85240472~85247170:+
KIRC	cis	rs904251	0.802	rs2646933	ENSG00000227920.2	RP1-153P14.5	-7.34	8.94e-13	4.6e-10	-0.37	-0.31	Cognitive performance;	chr6:37434294	chr6:37545145~37550860:+
KIRC	cis	rs3745672	1	rs112765800	ENSG00000219665.7	CTD-2006C1.2	-7.34	8.94e-13	4.6e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12014530	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs112074246	ENSG00000219665.7	CTD-2006C1.2	-7.34	8.94e-13	4.6e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12017206	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs3848588	ENSG00000219665.7	CTD-2006C1.2	-7.34	8.94e-13	4.6e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12031470	chr19:11987617~12046275:+
KIRC	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-7.34	8.95e-13	4.6e-10	-0.35	-0.31	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
KIRC	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	7.34	8.97e-13	4.61e-10	0.33	0.31	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
KIRC	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	7.34	8.97e-13	4.61e-10	0.35	0.31	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
KIRC	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-7.34	8.98e-13	4.61e-10	-0.3	-0.31	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
KIRC	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	7.34	9e-13	4.62e-10	0.29	0.31	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
KIRC	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	7.34	9e-13	4.63e-10	0.49	0.31	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
KIRC	cis	rs79040073	0.516	rs10519226	ENSG00000259531.2	RP11-295H24.3	7.34	9e-13	4.63e-10	0.39	0.31	Lung cancer in ever smokers;	chr15:49446036	chr15:49365124~49366685:-
KIRC	cis	rs79040073	0.516	rs17400427	ENSG00000259531.2	RP11-295H24.3	7.34	9e-13	4.63e-10	0.39	0.31	Lung cancer in ever smokers;	chr15:49448874	chr15:49365124~49366685:-
KIRC	cis	rs7176527	0.8	rs56747535	ENSG00000188388.10	GOLGA6L3	7.34	9.01e-13	4.63e-10	0.42	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85240472~85247170:+
KIRC	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-7.34	9.01e-13	4.63e-10	-0.35	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-7.34	9.01e-13	4.63e-10	-0.35	-0.31	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
KIRC	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-7.34	9.02e-13	4.64e-10	-0.45	-0.31	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
KIRC	cis	rs13423976	0.631	rs4670876	ENSG00000231367.4	AC016995.3	7.34	9.03e-13	4.64e-10	0.4	0.31	Gut microbiome composition (summer);	chr2:38508948	chr2:38406719~38515740:-
KIRC	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	7.34	9.03e-13	4.64e-10	0.3	0.31	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-7.34	9.03e-13	4.64e-10	-0.3	-0.31	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
KIRC	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	7.34	9.04e-13	4.64e-10	0.38	0.31	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
KIRC	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-7.34	9.04e-13	4.64e-10	-0.4	-0.31	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-7.34	9.04e-13	4.64e-10	-0.4	-0.31	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
KIRC	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-7.34	9.04e-13	4.64e-10	-0.4	-0.31	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
KIRC	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.34	9.05e-13	4.65e-10	0.42	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
KIRC	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-7.34	9.09e-13	4.67e-10	-0.48	-0.31	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
KIRC	cis	rs17772222	0.701	rs845757	ENSG00000222990.1	RNU4-22P	-7.34	9.09e-13	4.67e-10	-0.34	-0.31	Coronary artery calcification;	chr14:88455372	chr14:88513498~88513663:+
KIRC	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	7.34	9.1e-13	4.67e-10	0.31	0.31	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
KIRC	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	7.34	9.12e-13	4.68e-10	0.45	0.31	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
KIRC	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	7.34	9.12e-13	4.68e-10	0.3	0.31	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
KIRC	cis	rs3002142	0.731	rs3008620	ENSG00000272750.1	RP11-378J18.8	-7.33	9.13e-13	4.69e-10	-0.46	-0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222629584	chr1:222658867~222661512:-
KIRC	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-7.33	9.13e-13	4.69e-10	-0.26	-0.31	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
KIRC	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-7.33	9.13e-13	4.69e-10	-0.26	-0.31	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
KIRC	cis	rs375066	0.762	rs12610287	ENSG00000267058.1	RP11-15A1.3	7.33	9.15e-13	4.69e-10	0.36	0.31	Breast cancer;	chr19:43896511	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs1073654	ENSG00000267058.1	RP11-15A1.3	7.33	9.15e-13	4.69e-10	0.36	0.31	Breast cancer;	chr19:43907268	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs1073653	ENSG00000267058.1	RP11-15A1.3	7.33	9.15e-13	4.69e-10	0.36	0.31	Breast cancer;	chr19:43907391	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs62114648	ENSG00000267058.1	RP11-15A1.3	7.33	9.15e-13	4.69e-10	0.36	0.31	Breast cancer;	chr19:43910664	chr19:43891804~43901805:-
KIRC	cis	rs17270561	0.541	rs2009610	ENSG00000272462.2	U91328.19	-7.33	9.16e-13	4.7e-10	-0.31	-0.31	Iron status biomarkers;	chr6:25966840	chr6:25992662~26001775:+
KIRC	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	7.33	9.19e-13	4.72e-10	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
KIRC	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	7.33	9.19e-13	4.72e-10	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
KIRC	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-7.33	9.2e-13	4.72e-10	-0.37	-0.31	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
KIRC	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-7.33	9.21e-13	4.73e-10	-0.42	-0.31	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
KIRC	cis	rs9388451	0.839	rs11154331	ENSG00000237742.5	RP11-624M8.1	-7.33	9.22e-13	4.73e-10	-0.37	-0.31	Brugada syndrome;	chr6:125790283	chr6:125578558~125749190:-
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000251284.2	RP13-644M16.1	-7.33	9.22e-13	4.73e-10	-0.38	-0.31	Obesity-related traits;	chr4:69077628	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000251284.2	RP13-644M16.1	-7.33	9.22e-13	4.73e-10	-0.38	-0.31	Obesity-related traits;	chr4:69077631	chr4:69125274~69126451:+
KIRC	cis	rs17772222	0.675	rs845769	ENSG00000222990.1	RNU4-22P	-7.33	9.23e-13	4.73e-10	-0.34	-0.31	Coronary artery calcification;	chr14:88461455	chr14:88513498~88513663:+
KIRC	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	7.33	9.27e-13	4.76e-10	0.27	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
KIRC	cis	rs3760982	0.935	rs10422990	ENSG00000267058.1	RP11-15A1.3	-7.33	9.28e-13	4.76e-10	-0.37	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43791121	chr19:43891804~43901805:-
KIRC	cis	rs4072705	1	rs10760370	ENSG00000224020.1	MIR181A2HG	-7.33	9.28e-13	4.76e-10	-0.31	-0.31	Menarche (age at onset);	chr9:124655724	chr9:124658467~124698631:+
KIRC	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-7.33	9.32e-13	4.78e-10	-0.33	-0.31	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
KIRC	cis	rs4660214	0.671	rs16826012	ENSG00000237624.1	OXCT2P1	-7.33	9.35e-13	4.79e-10	-0.55	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39514956~39516490:+
KIRC	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-7.33	9.36e-13	4.8e-10	-0.34	-0.31	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
KIRC	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-7.33	9.37e-13	4.8e-10	-0.4	-0.31	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
KIRC	cis	rs10214930	0.647	rs2391438	ENSG00000235574.1	AC073150.6	-7.33	9.39e-13	4.81e-10	-0.36	-0.31	Hypospadias;	chr7:27530554	chr7:27491682~27492765:-
KIRC	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	7.33	9.39e-13	4.81e-10	0.3	0.31	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
KIRC	cis	rs710913	0.745	rs1180334	ENSG00000237624.1	OXCT2P1	-7.33	9.39e-13	4.82e-10	-0.39	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39514956~39516490:+
KIRC	cis	rs13434995	0.513	rs17722870	ENSG00000249700.7	SRD5A3-AS1	-7.33	9.4e-13	4.82e-10	-0.31	-0.31	Adiponectin levels;	chr4:55478519	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs55885973	ENSG00000249700.7	SRD5A3-AS1	-7.33	9.4e-13	4.82e-10	-0.31	-0.31	Adiponectin levels;	chr4:55480054	chr4:55363971~55395847:-
KIRC	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-7.33	9.4e-13	4.82e-10	-0.44	-0.31	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
KIRC	cis	rs13434995	0.513	rs550144	ENSG00000249700.7	SRD5A3-AS1	7.33	9.42e-13	4.83e-10	0.32	0.31	Adiponectin levels;	chr4:55415317	chr4:55363971~55395847:-
KIRC	cis	rs12449964	0.524	rs897457	ENSG00000223979.2	SMCR2	7.33	9.46e-13	4.85e-10	0.33	0.31	Coronary artery disease or ischemic stroke;	chr17:17669673	chr17:17674026~17677688:-
KIRC	cis	rs3745672	1	rs112315514	ENSG00000219665.7	CTD-2006C1.2	-7.33	9.51e-13	4.87e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12002519	chr19:11987617~12046275:+
KIRC	cis	rs3745672	0.661	rs10404882	ENSG00000219665.7	CTD-2006C1.2	-7.33	9.51e-13	4.87e-10	-0.6	-0.31	Multiple sclerosis;	chr19:12012019	chr19:11987617~12046275:+
KIRC	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	7.33	9.52e-13	4.88e-10	0.3	0.31	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
KIRC	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	7.33	9.53e-13	4.88e-10	0.44	0.31	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
KIRC	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	7.33	9.56e-13	4.9e-10	0.63	0.31	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
KIRC	cis	rs34779708	0.832	rs12764283	ENSG00000230534.5	RP11-297A16.2	7.33	9.56e-13	4.9e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35241532	chr10:35098006~35127020:-
KIRC	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	7.33	9.58e-13	4.91e-10	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
KIRC	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	7.33	9.59e-13	4.91e-10	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
KIRC	cis	rs4819052	1	rs733739	ENSG00000223768.1	LINC00205	-7.33	9.59e-13	4.91e-10	-0.33	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45293285~45297354:+
KIRC	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-7.33	9.61e-13	4.92e-10	-0.37	-0.31	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
KIRC	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-7.33	9.61e-13	4.92e-10	-0.38	-0.31	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-7.33	9.61e-13	4.92e-10	-0.38	-0.31	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-7.33	9.61e-13	4.92e-10	-0.38	-0.31	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
KIRC	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	7.33	9.62e-13	4.92e-10	0.22	0.31	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
KIRC	cis	rs7250849	0.79	rs7259861	ENSG00000273837.1	LLNLR-470E3.1	-7.33	9.62e-13	4.93e-10	-0.55	-0.31	Blood protein levels;	chr19:51657490	chr19:51639478~51639931:-
KIRC	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	7.33	9.64e-13	4.93e-10	0.57	0.31	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	7.33	9.65e-13	4.94e-10	0.52	0.31	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
KIRC	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-7.33	9.66e-13	4.95e-10	-0.43	-0.31	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
KIRC	cis	rs2337406	0.925	rs873534	ENSG00000274576.2	IGHV2-70	-7.33	9.67e-13	4.95e-10	-0.4	-0.31	Alzheimer's disease (late onset);	chr14:106667423	chr14:106770577~106771020:-
KIRC	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	7.33	9.67e-13	4.95e-10	0.28	0.31	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
KIRC	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	7.33	9.67e-13	4.95e-10	0.28	0.31	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
KIRC	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-7.33	9.67e-13	4.95e-10	-0.42	-0.31	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
KIRC	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-7.33	9.68e-13	4.95e-10	-0.31	-0.31	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
KIRC	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	7.33	9.69e-13	4.96e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	7.33	9.69e-13	4.96e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	7.33	9.69e-13	4.96e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	7.33	9.69e-13	4.96e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
KIRC	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-7.33	9.7e-13	4.96e-10	-0.38	-0.31	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
KIRC	cis	rs11647589	0.834	rs4603548	ENSG00000262995.1	CTD-2194A8.2	-7.33	9.7e-13	4.97e-10	-0.33	-0.31	Blood metabolite levels;	chr16:20472639	chr16:20440266~20447000:-
KIRC	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	7.33	9.73e-13	4.98e-10	0.76	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
KIRC	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-7.33	9.74e-13	4.99e-10	-0.36	-0.31	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
KIRC	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	7.32	9.77e-13	5e-10	0.35	0.31	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	7.32	9.77e-13	5e-10	0.35	0.31	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
KIRC	cis	rs1560104	0.536	rs12446050	ENSG00000274834.1	CTD-3037G24.5	-7.32	9.77e-13	5e-10	-0.34	-0.31	Obesity-related traits;	chr16:12621408	chr16:12614451~12614852:+
KIRC	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-7.32	9.79e-13	5.01e-10	-0.4	-0.31	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
KIRC	cis	rs1431005	0.963	rs6553064	ENSG00000250620.1	RP11-91J3.3	7.32	9.79e-13	5.01e-10	0.41	0.31	Response to statin therapy;	chr4:187423507	chr4:187413564~187415697:+
KIRC	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	7.32	9.79e-13	5.01e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
KIRC	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-7.32	9.8e-13	5.01e-10	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
KIRC	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	7.32	9.81e-13	5.02e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
KIRC	cis	rs17801127	0.901	rs7608496	ENSG00000231969.1	AC144449.1	7.32	9.81e-13	5.02e-10	0.55	0.31	Liver enzyme levels (alanine transaminase);	chr2:149784299	chr2:149587196~149848233:+
KIRC	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	7.32	9.82e-13	5.03e-10	0.36	0.31	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
KIRC	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-7.32	9.82e-13	5.03e-10	-0.39	-0.31	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	7.32	9.83e-13	5.03e-10	0.33	0.31	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
KIRC	cis	rs1431005	1	rs72499925	ENSG00000250620.1	RP11-91J3.3	7.32	9.83e-13	5.03e-10	0.41	0.31	Response to statin therapy;	chr4:187432596	chr4:187413564~187415697:+
KIRC	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-7.32	9.86e-13	5.04e-10	-0.31	-0.31	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
KIRC	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-7.32	9.86e-13	5.04e-10	-0.34	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
KIRC	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	7.32	9.86e-13	5.04e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
KIRC	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	7.32	9.86e-13	5.04e-10	0.37	0.31	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
KIRC	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	7.32	9.86e-13	5.04e-10	0.49	0.31	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
KIRC	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	7.32	9.89e-13	5.06e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
KIRC	cis	rs647097	0.655	rs470450	ENSG00000272788.1	RP11-674N23.4	-7.32	9.9e-13	5.06e-10	-0.39	-0.31	Chronic obstructive pulmonary disease;	chr18:8802957	chr18:8801656~8802305:+
KIRC	cis	rs3820928	0.904	rs4414671	ENSG00000212391.1	SNORA48	-7.32	9.91e-13	5.07e-10	-0.36	-0.31	Pulmonary function;	chr2:226951484	chr2:226968989~226969122:-
KIRC	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-7.32	9.92e-13	5.07e-10	-0.36	-0.31	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
KIRC	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-7.32	9.92e-13	5.07e-10	-0.28	-0.31	Gout;	chr7:66715944	chr7:66902857~66906297:+
KIRC	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	7.32	9.93e-13	5.07e-10	0.35	0.31	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
KIRC	cis	rs2562456	0.617	rs34203148	ENSG00000268555.1	RP11-678G14.3	7.32	9.93e-13	5.07e-10	0.47	0.31	Pain;	chr19:21590743	chr19:21570822~21587322:-
KIRC	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	7.32	9.94e-13	5.08e-10	0.41	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
KIRC	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-7.32	9.94e-13	5.08e-10	-0.3	-0.31	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
KIRC	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	7.32	9.94e-13	5.08e-10	0.58	0.31	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
KIRC	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-7.32	9.95e-13	5.09e-10	-0.35	-0.31	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
KIRC	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-7.32	9.95e-13	5.09e-10	-0.35	-0.31	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
KIRC	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-7.32	9.95e-13	5.09e-10	-0.32	-0.31	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000251284.2	RP13-644M16.1	-7.32	9.96e-13	5.09e-10	-0.37	-0.31	Obesity-related traits;	chr4:69079387	chr4:69125274~69126451:+
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000251284.2	RP13-644M16.1	-7.32	9.96e-13	5.09e-10	-0.37	-0.31	Obesity-related traits;	chr4:69079446	chr4:69125274~69126451:+
KIRC	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	7.32	9.97e-13	5.1e-10	0.48	0.31	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
KIRC	cis	rs755249	0.761	rs61781390	ENSG00000237624.1	OXCT2P1	7.32	9.98e-13	5.1e-10	0.5	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.876	rs61781391	ENSG00000237624.1	OXCT2P1	7.32	9.98e-13	5.1e-10	0.5	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39514956~39516490:+
KIRC	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-7.32	9.98e-13	5.1e-10	-0.56	-0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
KIRC	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-7.32	1e-12	5.11e-10	-0.25	-0.31	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
KIRC	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	7.32	1e-12	5.12e-10	0.38	0.31	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
KIRC	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-7.32	1e-12	5.12e-10	-0.3	-0.31	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
KIRC	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-7.32	1.01e-12	5.14e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
KIRC	cis	rs13434995	0.513	rs1048004	ENSG00000273257.1	RP11-177J6.1	-7.32	1.01e-12	5.15e-10	-0.41	-0.31	Adiponectin levels;	chr4:55434042	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs1801260	ENSG00000273257.1	RP11-177J6.1	-7.32	1.01e-12	5.15e-10	-0.41	-0.31	Adiponectin levels;	chr4:55435202	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs17721215	ENSG00000273257.1	RP11-177J6.1	-7.32	1.01e-12	5.15e-10	-0.41	-0.31	Adiponectin levels;	chr4:55437620	chr4:55387949~55388271:+
KIRC	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	7.32	1.01e-12	5.15e-10	0.23	0.31	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	7.32	1.01e-12	5.15e-10	0.23	0.31	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	7.32	1.01e-12	5.15e-10	0.23	0.31	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
KIRC	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-7.32	1.01e-12	5.16e-10	-0.28	-0.31	Gout;	chr7:66654674	chr7:66902857~66906297:+
KIRC	cis	rs4072705	1	rs7032937	ENSG00000224020.1	MIR181A2HG	-7.32	1.01e-12	5.16e-10	-0.31	-0.31	Menarche (age at onset);	chr9:124575894	chr9:124658467~124698631:+
KIRC	cis	rs12025262	0.546	rs10754539	ENSG00000215795.2	RP11-488L18.3	7.32	1.01e-12	5.17e-10	0.32	0.31	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247183813~247185482:-
KIRC	cis	rs7176527	0.848	rs72630463	ENSG00000188388.10	GOLGA6L3	7.32	1.01e-12	5.18e-10	0.43	0.31	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84750699	chr15:85240472~85247170:+
KIRC	cis	rs13434995	0.513	rs6554285	ENSG00000273257.1	RP11-177J6.1	7.32	1.02e-12	5.18e-10	0.41	0.31	Adiponectin levels;	chr4:55533953	chr4:55387949~55388271:+
KIRC	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	7.32	1.02e-12	5.18e-10	0.36	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
KIRC	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-7.32	1.02e-12	5.18e-10	-0.39	-0.31	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
KIRC	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	7.32	1.02e-12	5.19e-10	0.24	0.31	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
KIRC	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-7.32	1.02e-12	5.19e-10	-0.28	-0.31	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
KIRC	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	7.32	1.02e-12	5.2e-10	0.39	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
KIRC	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	7.32	1.02e-12	5.2e-10	0.39	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
KIRC	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	7.32	1.02e-12	5.21e-10	0.47	0.31	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
KIRC	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	7.32	1.02e-12	5.21e-10	0.26	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
KIRC	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-7.32	1.02e-12	5.21e-10	-0.38	-0.31	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
KIRC	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	7.32	1.03e-12	5.23e-10	0.4	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
KIRC	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	7.32	1.03e-12	5.23e-10	0.5	0.31	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
KIRC	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.23e-10	0.3	0.31	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
KIRC	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-7.32	1.03e-12	5.24e-10	-0.36	-0.31	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
KIRC	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	7.32	1.03e-12	5.24e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
KIRC	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	7.32	1.03e-12	5.25e-10	0.34	0.31	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
KIRC	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	7.32	1.03e-12	5.26e-10	0.33	0.31	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-7.32	1.03e-12	5.27e-10	-0.3	-0.31	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
KIRC	cis	rs1823874	0.653	rs12902823	ENSG00000182397.13	DNM1P46	-7.32	1.04e-12	5.28e-10	-0.33	-0.31	IgG glycosylation;	chr15:99812013	chr15:99790156~99806927:-
KIRC	cis	rs13113518	0.934	rs10866425	ENSG00000273257.1	RP11-177J6.1	7.32	1.04e-12	5.28e-10	0.38	0.31	Height;	chr4:55582068	chr4:55387949~55388271:+
KIRC	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-7.32	1.04e-12	5.29e-10	-0.29	-0.31	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
KIRC	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-7.32	1.04e-12	5.29e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-7.32	1.04e-12	5.29e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
KIRC	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	7.32	1.04e-12	5.3e-10	0.58	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
KIRC	cis	rs890448	0.726	rs2583395	ENSG00000254531.1	FLJ20021	-7.32	1.04e-12	5.31e-10	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101320584	chr4:101347780~101348883:+
KIRC	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	7.32	1.04e-12	5.31e-10	0.37	0.31	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
KIRC	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	7.32	1.04e-12	5.31e-10	0.38	0.31	Height;	chr4:55533481	chr4:55387949~55388271:+
KIRC	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-7.32	1.04e-12	5.31e-10	-0.35	-0.31	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
KIRC	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	7.32	1.04e-12	5.31e-10	0.29	0.31	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
KIRC	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-7.32	1.04e-12	5.32e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-7.32	1.04e-12	5.32e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
KIRC	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-7.32	1.04e-12	5.32e-10	-0.36	-0.31	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
KIRC	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	7.32	1.04e-12	5.32e-10	0.51	0.31	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
KIRC	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-7.32	1.04e-12	5.32e-10	-0.39	-0.31	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
KIRC	cis	rs3820928	0.874	rs4423583	ENSG00000212391.1	SNORA48	7.32	1.04e-12	5.32e-10	0.37	0.31	Pulmonary function;	chr2:227010241	chr2:226968989~226969122:-
KIRC	cis	rs6600671	0.691	rs6600662	ENSG00000227082.1	CH17-437K3.1	-7.31	1.05e-12	5.33e-10	-0.37	-0.31	Hip geometry;	chr1:121488992	chr1:121396754~121463129:+
KIRC	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	7.31	1.05e-12	5.33e-10	0.4	0.31	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
KIRC	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-7.31	1.05e-12	5.34e-10	-0.43	-0.31	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
KIRC	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-7.31	1.05e-12	5.34e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
KIRC	cis	rs34375054	0.573	rs12579211	ENSG00000279233.1	RP11-158L12.4	7.31	1.05e-12	5.34e-10	0.27	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125163206	chr12:125138245~125141711:+
KIRC	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	7.31	1.05e-12	5.35e-10	0.61	0.31	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
KIRC	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-7.31	1.05e-12	5.37e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
KIRC	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-7.31	1.05e-12	5.37e-10	-0.3	-0.31	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
KIRC	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-7.31	1.06e-12	5.38e-10	-0.37	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
KIRC	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	7.31	1.06e-12	5.39e-10	0.3	0.31	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	7.31	1.06e-12	5.39e-10	0.3	0.31	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	7.31	1.06e-12	5.39e-10	0.3	0.31	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
KIRC	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	7.31	1.06e-12	5.39e-10	0.3	0.31	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
KIRC	cis	rs12449964	0.524	rs4925093	ENSG00000223979.2	SMCR2	-7.31	1.06e-12	5.4e-10	-0.33	-0.31	Coronary artery disease or ischemic stroke;	chr17:17665632	chr17:17674026~17677688:-
KIRC	cis	rs890448	0.726	rs2850371	ENSG00000254531.1	FLJ20021	-7.31	1.06e-12	5.41e-10	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101319590	chr4:101347780~101348883:+
KIRC	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-7.31	1.07e-12	5.43e-10	-0.29	-0.31	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
KIRC	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	7.31	1.07e-12	5.43e-10	0.48	0.31	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
KIRC	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-7.31	1.07e-12	5.43e-10	-0.32	-0.31	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
KIRC	cis	rs17772222	0.682	rs7142053	ENSG00000222990.1	RNU4-22P	7.31	1.07e-12	5.44e-10	0.33	0.31	Coronary artery calcification;	chr14:88511594	chr14:88513498~88513663:+
KIRC	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-7.31	1.07e-12	5.44e-10	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-7.31	1.07e-12	5.44e-10	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
KIRC	cis	rs11647589	0.553	rs7195201	ENSG00000262995.1	CTD-2194A8.2	-7.31	1.07e-12	5.44e-10	-0.33	-0.31	Blood metabolite levels;	chr16:20467280	chr16:20440266~20447000:-
KIRC	cis	rs11512640	1	rs12363935	ENSG00000254671.2	STT3A-AS1	7.31	1.07e-12	5.44e-10	0.65	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr11:125570284~125592568:-
KIRC	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	7.31	1.07e-12	5.44e-10	0.31	0.31	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	7.31	1.07e-12	5.44e-10	0.31	0.31	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
KIRC	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	7.31	1.07e-12	5.45e-10	0.34	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
KIRC	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	7.31	1.07e-12	5.46e-10	0.34	0.31	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
KIRC	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-7.31	1.07e-12	5.46e-10	-0.32	-0.31	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
KIRC	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	7.31	1.07e-12	5.47e-10	0.33	0.31	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
KIRC	cis	rs2012796	0.785	rs61986599	ENSG00000270343.1	UNGP3	7.31	1.08e-12	5.48e-10	0.39	0.31	Night sleep phenotypes;	chr14:81394573	chr14:81259565~81260239:-
KIRC	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	7.31	1.08e-12	5.49e-10	0.32	0.31	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
KIRC	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.31	1.08e-12	5.49e-10	0.23	0.31	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
KIRC	cis	rs3820928	0.874	rs1114562	ENSG00000212391.1	SNORA48	-7.31	1.08e-12	5.51e-10	-0.36	-0.31	Pulmonary function;	chr2:226923876	chr2:226968989~226969122:-
KIRC	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	7.31	1.09e-12	5.53e-10	0.41	0.31	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
KIRC	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	7.31	1.09e-12	5.56e-10	0.61	0.31	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
KIRC	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	7.31	1.09e-12	5.56e-10	0.39	0.31	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
KIRC	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	7.31	1.09e-12	5.56e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000251284.2	RP13-644M16.1	-7.31	1.09e-12	5.56e-10	-0.37	-0.31	Obesity-related traits;	chr4:69079589	chr4:69125274~69126451:+
KIRC	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	7.31	1.1e-12	5.57e-10	0.3	0.31	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
KIRC	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.31	1.1e-12	5.58e-10	-0.45	-0.31	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
KIRC	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	7.31	1.1e-12	5.59e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	7.31	1.1e-12	5.59e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
KIRC	cis	rs6908034	0.66	rs74457659	ENSG00000228412.5	RP4-625H18.2	7.31	1.1e-12	5.59e-10	0.74	0.31	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19760494	chr6:19802164~19804752:-
KIRC	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-7.31	1.1e-12	5.59e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
KIRC	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-7.31	1.1e-12	5.6e-10	-0.35	-0.31	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
KIRC	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	7.31	1.1e-12	5.6e-10	0.2	0.31	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
KIRC	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-7.31	1.1e-12	5.61e-10	-0.21	-0.31	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
KIRC	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-7.31	1.1e-12	5.61e-10	-0.37	-0.31	Height;	chr4:55547636	chr4:55387949~55388271:+
KIRC	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	7.31	1.1e-12	5.61e-10	0.32	0.31	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
KIRC	cis	rs17711722	0.523	rs313812	ENSG00000275400.1	RP4-756H11.5	7.31	1.1e-12	5.61e-10	0.32	0.31	Calcium levels;	chr7:66040056	chr7:66553805~66554199:-
KIRC	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-7.31	1.11e-12	5.62e-10	-0.36	-0.31	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
KIRC	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-7.31	1.11e-12	5.62e-10	-0.36	-0.31	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
KIRC	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	7.31	1.11e-12	5.62e-10	0.43	0.31	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
KIRC	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-7.31	1.11e-12	5.62e-10	-0.3	-0.31	QT interval;	chr12:29300845	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-7.31	1.11e-12	5.62e-10	-0.3	-0.31	QT interval;	chr12:29302457	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-7.31	1.11e-12	5.62e-10	-0.3	-0.31	QT interval;	chr12:29302458	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-7.31	1.11e-12	5.62e-10	-0.3	-0.31	QT interval;	chr12:29309811	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-7.31	1.11e-12	5.62e-10	-0.3	-0.31	QT interval;	chr12:29310155	chr12:29280418~29317848:-
KIRC	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	7.31	1.11e-12	5.63e-10	0.26	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
KIRC	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	7.31	1.11e-12	5.64e-10	0.4	0.31	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
KIRC	cis	rs755249	0.761	rs61781390	ENSG00000182109.6	RP11-69E11.4	7.31	1.11e-12	5.65e-10	0.29	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.876	rs61781391	ENSG00000182109.6	RP11-69E11.4	7.31	1.11e-12	5.65e-10	0.29	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39522280~39546187:-
KIRC	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	7.31	1.11e-12	5.66e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
KIRC	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-7.31	1.12e-12	5.67e-10	-0.28	-0.31	Gout;	chr7:66693028	chr7:66902857~66906297:+
KIRC	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	7.3	1.12e-12	5.68e-10	0.38	0.31	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
KIRC	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	7.3	1.12e-12	5.69e-10	0.4	0.31	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
KIRC	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	7.3	1.12e-12	5.69e-10	0.42	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
KIRC	cis	rs1431005	0.893	rs68010462	ENSG00000250620.1	RP11-91J3.3	7.3	1.12e-12	5.69e-10	0.41	0.31	Response to statin therapy;	chr4:187418181	chr4:187413564~187415697:+
KIRC	cis	rs58873874	0.737	rs11466807	ENSG00000251405.2	CTB-109A12.1	7.3	1.12e-12	5.7e-10	0.58	0.31	Bipolar disorder (body mass index interaction);	chr5:157487920	chr5:157362615~157460078:-
KIRC	cis	rs7017914	0.905	rs3110246	ENSG00000254031.4	RP11-326E22.1	7.3	1.12e-12	5.7e-10	0.34	0.31	Bone mineral density;	chr8:71022378	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.905	rs3110250	ENSG00000254031.4	RP11-326E22.1	7.3	1.12e-12	5.7e-10	0.34	0.31	Bone mineral density;	chr8:71024149	chr8:71155457~71204223:+
KIRC	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	7.3	1.12e-12	5.71e-10	0.31	0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
KIRC	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-7.3	1.12e-12	5.71e-10	-0.3	-0.31	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
KIRC	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	7.3	1.13e-12	5.72e-10	0.25	0.31	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
KIRC	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-7.3	1.13e-12	5.73e-10	-0.24	-0.31	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
KIRC	cis	rs3820928	1	rs4675120	ENSG00000212391.1	SNORA48	-7.3	1.13e-12	5.73e-10	-0.37	-0.31	Pulmonary function;	chr2:226910172	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs7579961	ENSG00000212391.1	SNORA48	-7.3	1.13e-12	5.73e-10	-0.37	-0.31	Pulmonary function;	chr2:226912260	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs7592387	ENSG00000212391.1	SNORA48	-7.3	1.13e-12	5.73e-10	-0.37	-0.31	Pulmonary function;	chr2:226912379	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs11686072	ENSG00000212391.1	SNORA48	-7.3	1.13e-12	5.73e-10	-0.37	-0.31	Pulmonary function;	chr2:226912777	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs10167422	ENSG00000212391.1	SNORA48	-7.3	1.13e-12	5.73e-10	-0.37	-0.31	Pulmonary function;	chr2:226912838	chr2:226968989~226969122:-
KIRC	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	7.3	1.13e-12	5.75e-10	0.4	0.31	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
KIRC	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-7.3	1.13e-12	5.75e-10	-0.28	-0.31	Gout;	chr7:66661502	chr7:66902857~66906297:+
KIRC	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-7.3	1.13e-12	5.76e-10	-0.29	-0.31	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
KIRC	cis	rs58873874	0.737	rs112160357	ENSG00000251405.2	CTB-109A12.1	7.3	1.13e-12	5.76e-10	0.56	0.31	Bipolar disorder (body mass index interaction);	chr5:157501696	chr5:157362615~157460078:-
KIRC	cis	rs13434995	0.513	rs2101476	ENSG00000273257.1	RP11-177J6.1	-7.3	1.14e-12	5.76e-10	-0.42	-0.31	Adiponectin levels;	chr4:55578961	chr4:55387949~55388271:+
KIRC	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-7.3	1.14e-12	5.77e-10	-0.27	-0.31	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
KIRC	cis	rs7592578	0.882	rs61117285	ENSG00000272979.1	RP11-647K16.1	-7.3	1.14e-12	5.77e-10	-0.45	-0.31	Diastolic blood pressure;	chr2:190604260	chr2:190454092~190454521:-
KIRC	cis	rs7592578	0.882	rs58568707	ENSG00000272979.1	RP11-647K16.1	-7.3	1.14e-12	5.77e-10	-0.45	-0.31	Diastolic blood pressure;	chr2:190604261	chr2:190454092~190454521:-
KIRC	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	7.3	1.14e-12	5.77e-10	0.3	0.31	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
KIRC	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	7.3	1.14e-12	5.77e-10	0.32	0.31	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	7.3	1.14e-12	5.77e-10	0.32	0.31	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
KIRC	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	7.3	1.14e-12	5.78e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
KIRC	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-7.3	1.14e-12	5.78e-10	-0.35	-0.31	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
KIRC	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-7.3	1.14e-12	5.78e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-7.3	1.14e-12	5.78e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
KIRC	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	7.3	1.14e-12	5.79e-10	0.38	0.31	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
KIRC	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	7.3	1.14e-12	5.79e-10	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
KIRC	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	7.3	1.14e-12	5.79e-10	0.33	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
KIRC	cis	rs17772222	0.682	rs8017689	ENSG00000222990.1	RNU4-22P	7.3	1.14e-12	5.8e-10	0.33	0.31	Coronary artery calcification;	chr14:88483442	chr14:88513498~88513663:+
KIRC	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	7.3	1.14e-12	5.8e-10	0.38	0.31	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
KIRC	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-7.3	1.14e-12	5.8e-10	-0.36	-0.31	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
KIRC	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	7.3	1.14e-12	5.8e-10	0.47	0.31	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
KIRC	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	7.3	1.15e-12	5.81e-10	0.39	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
KIRC	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	7.3	1.15e-12	5.81e-10	0.44	0.31	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
KIRC	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-7.3	1.15e-12	5.81e-10	-0.3	-0.31	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
KIRC	cis	rs2698530	0.535	rs2254856	ENSG00000225889.6	AC074289.1	-7.3	1.15e-12	5.82e-10	-0.3	-0.31	Iron status biomarkers;	chr2:64260559	chr2:64143239~64252859:+
KIRC	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.82e-10	0.37	0.31	Height;	chr4:55551447	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.82e-10	0.37	0.31	Height;	chr4:55551845	chr4:55387949~55388271:+
KIRC	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-7.3	1.15e-12	5.83e-10	-0.25	-0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
KIRC	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-7.3	1.15e-12	5.83e-10	-0.3	-0.31	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
KIRC	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	7.3	1.15e-12	5.83e-10	0.46	0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
KIRC	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-7.3	1.15e-12	5.83e-10	-0.4	-0.31	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
KIRC	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-7.3	1.15e-12	5.83e-10	-0.29	-0.31	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
KIRC	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-7.3	1.15e-12	5.84e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
KIRC	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	7.3	1.15e-12	5.84e-10	0.34	0.31	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
KIRC	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.85e-10	0.37	0.31	Height;	chr4:55553396	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.85e-10	0.37	0.31	Height;	chr4:55554025	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.85e-10	0.37	0.31	Height;	chr4:55554380	chr4:55387949~55388271:+
KIRC	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	7.3	1.15e-12	5.85e-10	0.37	0.31	Height;	chr4:55554456	chr4:55387949~55388271:+
KIRC	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-7.3	1.16e-12	5.87e-10	-0.39	-0.31	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
KIRC	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	7.3	1.16e-12	5.88e-10	0.57	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
KIRC	cis	rs13434995	0.513	rs6802	ENSG00000249700.7	SRD5A3-AS1	-7.3	1.16e-12	5.88e-10	-0.31	-0.31	Adiponectin levels;	chr4:55425934	chr4:55363971~55395847:-
KIRC	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-7.3	1.16e-12	5.89e-10	-0.3	-0.31	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
KIRC	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-7.3	1.16e-12	5.89e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
KIRC	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-7.3	1.16e-12	5.89e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
KIRC	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	7.3	1.17e-12	5.91e-10	0.37	0.31	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
KIRC	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	7.3	1.17e-12	5.91e-10	0.39	0.31	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
KIRC	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-7.3	1.17e-12	5.91e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
KIRC	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-7.3	1.17e-12	5.91e-10	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-7.3	1.17e-12	5.91e-10	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
KIRC	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-7.3	1.17e-12	5.92e-10	-0.41	-0.31	Depression;	chr6:28201380	chr6:28115628~28116551:+
KIRC	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-7.3	1.17e-12	5.93e-10	-0.24	-0.31	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
KIRC	cis	rs890448	0.726	rs1348161	ENSG00000254531.1	FLJ20021	7.3	1.17e-12	5.93e-10	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101331539	chr4:101347780~101348883:+
KIRC	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	7.3	1.18e-12	5.95e-10	0.3	0.31	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	7.3	1.18e-12	5.95e-10	0.3	0.31	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
KIRC	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-7.3	1.18e-12	5.95e-10	-0.38	-0.31	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
KIRC	cis	rs11647589	0.834	rs2271061	ENSG00000262995.1	CTD-2194A8.2	-7.3	1.18e-12	5.96e-10	-0.33	-0.31	Blood metabolite levels;	chr16:20471429	chr16:20440266~20447000:-
KIRC	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-7.3	1.18e-12	5.98e-10	-0.33	-0.31	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
KIRC	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	7.3	1.18e-12	5.99e-10	0.28	0.31	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
KIRC	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	7.3	1.18e-12	5.99e-10	0.43	0.31	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
KIRC	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	7.3	1.18e-12	5.99e-10	0.41	0.31	Height;	chr6:109350642	chr6:109382795~109383666:+
KIRC	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-7.3	1.18e-12	6e-10	-0.31	-0.31	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
KIRC	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	7.3	1.19e-12	6e-10	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
KIRC	cis	rs58873874	0.737	rs11134766	ENSG00000251405.2	CTB-109A12.1	7.3	1.19e-12	6e-10	0.58	0.31	Bipolar disorder (body mass index interaction);	chr5:157481309	chr5:157362615~157460078:-
KIRC	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	7.3	1.19e-12	6.01e-10	0.52	0.31	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
KIRC	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-7.3	1.19e-12	6.01e-10	-0.29	-0.31	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-7.3	1.19e-12	6.01e-10	-0.29	-0.31	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
KIRC	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	7.3	1.19e-12	6.02e-10	0.58	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	7.3	1.19e-12	6.02e-10	0.58	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	7.3	1.19e-12	6.02e-10	0.58	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
KIRC	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	7.3	1.19e-12	6.02e-10	0.58	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
KIRC	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	7.3	1.19e-12	6.02e-10	0.44	0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
KIRC	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-7.3	1.19e-12	6.02e-10	-0.43	-0.31	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
KIRC	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	7.3	1.19e-12	6.03e-10	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
KIRC	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	7.29	1.2e-12	6.05e-10	0.4	0.31	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-7.29	1.2e-12	6.06e-10	-0.3	-0.31	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-7.29	1.2e-12	6.06e-10	-0.3	-0.31	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-7.29	1.2e-12	6.06e-10	-0.3	-0.31	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
KIRC	cis	rs6600671	1	rs7532615	ENSG00000270231.3	NBPF8P	-7.29	1.2e-12	6.06e-10	-0.24	-0.31	Hip geometry;	chr1:121430980	chr1:120436353~120467739:+
KIRC	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	7.29	1.2e-12	6.06e-10	0.39	0.31	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
KIRC	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	7.29	1.2e-12	6.07e-10	0.61	0.31	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
KIRC	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	7.29	1.2e-12	6.07e-10	0.33	0.31	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
KIRC	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-7.29	1.2e-12	6.08e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
KIRC	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	7.29	1.2e-12	6.09e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	7.29	1.2e-12	6.09e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	7.29	1.2e-12	6.09e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	7.29	1.21e-12	6.09e-10	0.32	0.31	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	7.29	1.21e-12	6.09e-10	0.32	0.31	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	7.29	1.21e-12	6.09e-10	0.32	0.31	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
KIRC	cis	rs4984778	0.717	rs2738892	ENSG00000277010.1	RP11-616M22.12	-7.29	1.21e-12	6.11e-10	-0.4	-0.31	Blood protein levels;	chr16:1218758	chr16:1223639~1224143:+
KIRC	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	7.29	1.21e-12	6.13e-10	0.29	0.31	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
KIRC	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-7.29	1.22e-12	6.14e-10	-0.43	-0.31	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
KIRC	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-7.29	1.22e-12	6.16e-10	-0.4	-0.31	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
KIRC	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	7.29	1.22e-12	6.17e-10	0.38	0.31	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
KIRC	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	7.29	1.22e-12	6.17e-10	0.27	0.31	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	7.29	1.22e-12	6.17e-10	0.27	0.31	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
KIRC	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-7.29	1.22e-12	6.17e-10	-0.4	-0.31	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
KIRC	cis	rs58873874	0.737	rs11739062	ENSG00000251405.2	CTB-109A12.1	7.29	1.22e-12	6.17e-10	0.57	0.31	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157362615~157460078:-
KIRC	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-7.29	1.22e-12	6.18e-10	-0.3	-0.31	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
KIRC	cis	rs375066	0.762	rs17713001	ENSG00000267058.1	RP11-15A1.3	7.29	1.22e-12	6.18e-10	0.36	0.31	Breast cancer;	chr19:43917073	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs2284245	ENSG00000267058.1	RP11-15A1.3	7.29	1.22e-12	6.18e-10	0.36	0.31	Breast cancer;	chr19:43918437	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.762	rs17656688	ENSG00000267058.1	RP11-15A1.3	7.29	1.22e-12	6.18e-10	0.36	0.31	Breast cancer;	chr19:43920925	chr19:43891804~43901805:-
KIRC	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-7.29	1.22e-12	6.19e-10	-0.3	-0.31	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-7.29	1.23e-12	6.19e-10	-0.37	-0.31	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
KIRC	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	7.29	1.23e-12	6.2e-10	0.24	0.31	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
KIRC	cis	rs2337406	0.85	rs11849578	ENSG00000274576.2	IGHV2-70	-7.29	1.23e-12	6.22e-10	-0.4	-0.31	Alzheimer's disease (late onset);	chr14:106670302	chr14:106770577~106771020:-
KIRC	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-7.29	1.23e-12	6.22e-10	-0.27	-0.31	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
KIRC	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-7.29	1.23e-12	6.23e-10	-0.37	-0.31	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
KIRC	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	7.29	1.24e-12	6.24e-10	0.37	0.31	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
KIRC	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-7.29	1.24e-12	6.24e-10	-0.32	-0.31	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
KIRC	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-7.29	1.24e-12	6.26e-10	-0.2	-0.31	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
KIRC	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-7.29	1.24e-12	6.26e-10	-0.41	-0.31	Depression;	chr6:28184805	chr6:28115628~28116551:+
KIRC	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	7.29	1.24e-12	6.27e-10	0.29	0.31	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
KIRC	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	7.29	1.24e-12	6.27e-10	0.37	0.31	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
KIRC	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-7.29	1.24e-12	6.27e-10	-0.39	-0.31	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
KIRC	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-7.29	1.24e-12	6.27e-10	-0.39	-0.31	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
KIRC	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	7.29	1.24e-12	6.27e-10	0.43	0.31	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs1979604	ENSG00000249700.7	SRD5A3-AS1	7.29	1.24e-12	6.28e-10	0.31	0.31	Adiponectin levels;	chr4:55552588	chr4:55363971~55395847:-
KIRC	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-7.29	1.25e-12	6.29e-10	-0.39	-0.31	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
KIRC	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-7.29	1.25e-12	6.29e-10	-0.39	-0.31	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
KIRC	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	7.29	1.25e-12	6.3e-10	0.56	0.31	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
KIRC	cis	rs12936587	0.535	rs6502615	ENSG00000223979.2	SMCR2	7.29	1.25e-12	6.3e-10	0.32	0.31	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17708709	chr17:17674026~17677688:-
KIRC	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	7.29	1.25e-12	6.31e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
KIRC	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.29	1.25e-12	6.32e-10	0.27	0.31	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
KIRC	cis	rs890448	0.726	rs2850329	ENSG00000254531.1	FLJ20021	7.29	1.26e-12	6.34e-10	0.31	0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101354107	chr4:101347780~101348883:+
KIRC	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-7.29	1.26e-12	6.35e-10	-0.33	-0.31	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
KIRC	cis	rs3820928	0.967	rs4675114	ENSG00000212391.1	SNORA48	-7.29	1.26e-12	6.35e-10	-0.36	-0.31	Pulmonary function;	chr2:226903646	chr2:226968989~226969122:-
KIRC	cis	rs10214930	0.697	rs978447	ENSG00000235574.1	AC073150.6	-7.29	1.26e-12	6.35e-10	-0.37	-0.31	Hypospadias;	chr7:27543164	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1880370	ENSG00000235574.1	AC073150.6	-7.29	1.26e-12	6.35e-10	-0.37	-0.31	Hypospadias;	chr7:27543693	chr7:27491682~27492765:-
KIRC	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-7.29	1.26e-12	6.35e-10	-0.33	-0.31	Height;	chr3:53007328	chr3:53064283~53065091:-
KIRC	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-7.29	1.27e-12	6.38e-10	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
KIRC	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	7.29	1.27e-12	6.39e-10	0.45	0.31	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
KIRC	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	7.29	1.27e-12	6.39e-10	0.25	0.31	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
KIRC	cis	rs7924176	0.521	rs1904062	ENSG00000213731.2	RAB5CP1	-7.29	1.27e-12	6.39e-10	-0.31	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74423435~74424014:-
KIRC	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	7.29	1.27e-12	6.39e-10	0.25	0.31	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
KIRC	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	7.29	1.27e-12	6.4e-10	0.44	0.31	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	7.29	1.27e-12	6.4e-10	0.44	0.31	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
KIRC	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	7.29	1.27e-12	6.41e-10	0.34	0.31	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
KIRC	cis	rs10028773	0.632	rs34481394	ENSG00000249244.1	RP11-548H18.2	7.29	1.27e-12	6.42e-10	0.39	0.31	Educational attainment;	chr4:119327219	chr4:119391831~119395335:-
KIRC	cis	rs10028773	0.666	rs35231872	ENSG00000249244.1	RP11-548H18.2	7.29	1.27e-12	6.42e-10	0.39	0.31	Educational attainment;	chr4:119327221	chr4:119391831~119395335:-
KIRC	cis	rs10028773	0.7	rs35653026	ENSG00000249244.1	RP11-548H18.2	7.29	1.27e-12	6.42e-10	0.39	0.31	Educational attainment;	chr4:119327223	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	7.29	1.27e-12	6.42e-10	0.39	0.31	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
KIRC	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-7.29	1.27e-12	6.42e-10	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
KIRC	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	7.28	1.28e-12	6.44e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	7.28	1.28e-12	6.44e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
KIRC	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	7.28	1.28e-12	6.45e-10	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
KIRC	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	7.28	1.28e-12	6.46e-10	0.63	0.31	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	7.28	1.28e-12	6.46e-10	0.63	0.31	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	7.28	1.28e-12	6.46e-10	0.63	0.31	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
KIRC	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.28	1.28e-12	6.47e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
KIRC	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-7.28	1.29e-12	6.48e-10	-0.35	-0.31	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
KIRC	cis	rs3820928	0.845	rs13384342	ENSG00000212391.1	SNORA48	-7.28	1.29e-12	6.48e-10	-0.36	-0.31	Pulmonary function;	chr2:226940294	chr2:226968989~226969122:-
KIRC	cis	rs7924176	0.521	rs11000986	ENSG00000213731.2	RAB5CP1	-7.28	1.29e-12	6.48e-10	-0.3	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74423435~74424014:-
KIRC	cis	rs7924176	0.521	rs10824147	ENSG00000213731.2	RAB5CP1	-7.28	1.29e-12	6.48e-10	-0.3	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74423435~74424014:-
KIRC	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-7.28	1.29e-12	6.48e-10	-0.3	-0.31	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
KIRC	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	7.28	1.29e-12	6.5e-10	0.48	0.31	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
KIRC	cis	rs1552244	1	rs17032295	ENSG00000180385.7	EMC3-AS1	7.28	1.29e-12	6.5e-10	0.3	0.31	Alzheimer's disease;	chr3:10044996	chr3:9986893~10006990:+
KIRC	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	7.28	1.29e-12	6.51e-10	0.43	0.31	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
KIRC	cis	rs13434995	0.513	rs62303718	ENSG00000249700.7	SRD5A3-AS1	-7.28	1.29e-12	6.51e-10	-0.31	-0.31	Adiponectin levels;	chr4:55476770	chr4:55363971~55395847:-
KIRC	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	7.28	1.29e-12	6.52e-10	0.39	0.31	Height;	chr11:118856460	chr11:118688039~118690600:-
KIRC	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	7.28	1.29e-12	6.52e-10	0.39	0.31	Height;	chr11:118856623	chr11:118688039~118690600:-
KIRC	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	7.28	1.3e-12	6.52e-10	0.39	0.31	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	7.28	1.3e-12	6.52e-10	0.39	0.31	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	7.28	1.3e-12	6.52e-10	0.39	0.31	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	7.28	1.3e-12	6.52e-10	0.39	0.31	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	7.28	1.3e-12	6.52e-10	0.39	0.31	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
KIRC	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-7.28	1.3e-12	6.53e-10	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
KIRC	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-7.28	1.3e-12	6.53e-10	-0.37	-0.31	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
KIRC	cis	rs3745672	0.744	rs10403392	ENSG00000219665.7	CTD-2006C1.2	-7.28	1.3e-12	6.55e-10	-0.58	-0.31	Multiple sclerosis;	chr19:12042774	chr19:11987617~12046275:+
KIRC	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-7.28	1.3e-12	6.56e-10	-0.31	-0.31	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
KIRC	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-7.28	1.3e-12	6.56e-10	-0.56	-0.31	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
KIRC	cis	rs10214930	0.697	rs1404276	ENSG00000235574.1	AC073150.6	-7.28	1.3e-12	6.56e-10	-0.37	-0.31	Hypospadias;	chr7:27551228	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs12700817	ENSG00000235574.1	AC073150.6	-7.28	1.3e-12	6.56e-10	-0.37	-0.31	Hypospadias;	chr7:27551474	chr7:27491682~27492765:-
KIRC	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	7.28	1.3e-12	6.56e-10	0.33	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
KIRC	cis	rs9388451	0.903	rs7758115	ENSG00000237742.5	RP11-624M8.1	-7.28	1.3e-12	6.57e-10	-0.38	-0.31	Brugada syndrome;	chr6:125740356	chr6:125578558~125749190:-
KIRC	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-7.28	1.31e-12	6.58e-10	-0.24	-0.31	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
KIRC	cis	rs13434995	0.513	rs972446	ENSG00000273257.1	RP11-177J6.1	7.28	1.31e-12	6.58e-10	0.41	0.31	Adiponectin levels;	chr4:55569581	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs11732481	ENSG00000273257.1	RP11-177J6.1	7.28	1.31e-12	6.58e-10	0.41	0.31	Adiponectin levels;	chr4:55570212	chr4:55387949~55388271:+
KIRC	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	7.28	1.31e-12	6.59e-10	0.45	0.31	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	7.28	1.31e-12	6.59e-10	0.45	0.31	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
KIRC	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-7.28	1.31e-12	6.6e-10	-0.37	-0.31	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
KIRC	cis	rs2288884	1	rs11673286	ENSG00000275055.1	CTC-471J1.11	-7.28	1.31e-12	6.6e-10	-0.42	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52049007~52049754:+
KIRC	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-7.28	1.31e-12	6.61e-10	-0.33	-0.31	Height;	chr3:53009621	chr3:53064283~53065091:-
KIRC	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	7.28	1.31e-12	6.61e-10	0.39	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
KIRC	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-7.28	1.31e-12	6.62e-10	-0.29	-0.31	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
KIRC	cis	rs12500482	0.5	rs6857794	ENSG00000206113.6	RP11-503N18.1	7.28	1.32e-12	6.62e-10	0.39	0.31	Cognitive function;	chr4:2424480	chr4:2418974~2450360:+
KIRC	cis	rs13434995	0.513	rs73236153	ENSG00000273257.1	RP11-177J6.1	-7.28	1.32e-12	6.62e-10	-0.42	-0.31	Adiponectin levels;	chr4:55585600	chr4:55387949~55388271:+
KIRC	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.28	1.32e-12	6.64e-10	-0.41	-0.31	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.28	1.32e-12	6.64e-10	-0.41	-0.31	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
KIRC	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	7.28	1.32e-12	6.65e-10	0.35	0.31	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
KIRC	cis	rs12449964	0.524	rs7224756	ENSG00000223979.2	SMCR2	7.28	1.32e-12	6.65e-10	0.33	0.31	Coronary artery disease or ischemic stroke;	chr17:17669028	chr17:17674026~17677688:-
KIRC	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	7.28	1.32e-12	6.65e-10	0.37	0.31	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
KIRC	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	7.28	1.32e-12	6.66e-10	0.4	0.31	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
KIRC	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-7.28	1.32e-12	6.66e-10	-0.27	-0.31	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
KIRC	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-7.28	1.33e-12	6.67e-10	-0.3	-0.31	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
KIRC	cis	rs7182948	0.874	rs3210227	ENSG00000259531.2	RP11-295H24.3	7.28	1.33e-12	6.68e-10	0.39	0.31	Lung adenocarcinoma;	chr15:49625144	chr15:49365124~49366685:-
KIRC	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	7.28	1.33e-12	6.69e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
KIRC	cis	rs4819052	1	rs4818769	ENSG00000223768.1	LINC00205	-7.28	1.33e-12	6.7e-10	-0.33	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45293285~45297354:+
KIRC	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	7.28	1.33e-12	6.7e-10	0.41	0.31	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
KIRC	cis	rs13434995	0.513	rs41324951	ENSG00000249700.7	SRD5A3-AS1	7.28	1.33e-12	6.7e-10	0.32	0.31	Adiponectin levels;	chr4:55422576	chr4:55363971~55395847:-
KIRC	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	7.28	1.33e-12	6.7e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
KIRC	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	7.28	1.33e-12	6.7e-10	0.44	0.31	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
KIRC	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	7.28	1.33e-12	6.7e-10	0.21	0.31	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
KIRC	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	7.28	1.33e-12	6.7e-10	0.43	0.31	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	7.28	1.33e-12	6.7e-10	0.3	0.31	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
KIRC	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	7.28	1.34e-12	6.72e-10	0.29	0.31	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
KIRC	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-7.28	1.34e-12	6.72e-10	-0.41	-0.31	Depression;	chr6:28198669	chr6:28115628~28116551:+
KIRC	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	7.28	1.34e-12	6.72e-10	0.26	0.31	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	7.28	1.34e-12	6.72e-10	0.26	0.31	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
KIRC	cis	rs13434995	0.513	rs62303711	ENSG00000273257.1	RP11-177J6.1	-7.28	1.34e-12	6.73e-10	-0.41	-0.31	Adiponectin levels;	chr4:55458325	chr4:55387949~55388271:+
KIRC	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.28	1.34e-12	6.73e-10	-0.42	-0.31	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
KIRC	cis	rs13434995	0.513	rs6802	ENSG00000273257.1	RP11-177J6.1	-7.28	1.34e-12	6.73e-10	-0.41	-0.31	Adiponectin levels;	chr4:55425934	chr4:55387949~55388271:+
KIRC	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-7.28	1.34e-12	6.73e-10	-0.37	-0.31	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
KIRC	cis	rs7731783	1	rs7731783	ENSG00000249109.1	RP11-1026M7.2	-7.28	1.34e-12	6.74e-10	-0.38	-0.31	Methadone dose in opioid dependence;	chr5:177633311	chr5:177782197~177794396:+
KIRC	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	7.28	1.34e-12	6.74e-10	0.41	0.31	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
KIRC	cis	rs3093024	0.839	rs968334	ENSG00000265828.1	MIR3939	7.28	1.34e-12	6.74e-10	0.35	0.31	Rheumatoid arthritis;	chr6:167112608	chr6:166997807~166997912:-
KIRC	cis	rs7017914	0.902	rs34856835	ENSG00000254031.4	RP11-326E22.1	7.28	1.34e-12	6.74e-10	0.34	0.31	Bone mineral density;	chr8:71058376	chr8:71155457~71204223:+
KIRC	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	7.28	1.34e-12	6.74e-10	0.29	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
KIRC	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-7.28	1.34e-12	6.75e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-7.28	1.34e-12	6.75e-10	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
KIRC	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	7.28	1.35e-12	6.78e-10	0.39	0.31	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
KIRC	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	7.28	1.35e-12	6.78e-10	0.37	0.31	Height;	chr4:55538228	chr4:55387949~55388271:+
KIRC	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-7.28	1.35e-12	6.8e-10	-0.3	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
KIRC	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	7.28	1.35e-12	6.8e-10	0.31	0.31	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
KIRC	cis	rs75422866	0.51	rs73104197	ENSG00000280054.1	RP1-197B17.7	7.28	1.36e-12	6.81e-10	0.63	0.31	Pneumonia;	chr12:47717273	chr12:47728151~47730598:-
KIRC	cis	rs7017914	0.905	rs2732115	ENSG00000254031.4	RP11-326E22.1	7.28	1.36e-12	6.83e-10	0.33	0.31	Bone mineral density;	chr8:71016619	chr8:71155457~71204223:+
KIRC	cis	rs890448	0.726	rs2850328	ENSG00000254531.1	FLJ20021	-7.28	1.36e-12	6.84e-10	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101347783	chr4:101347780~101348883:+
KIRC	cis	rs7017914	0.905	rs2732106	ENSG00000254031.4	RP11-326E22.1	7.28	1.36e-12	6.84e-10	0.34	0.31	Bone mineral density;	chr8:71011604	chr8:71155457~71204223:+
KIRC	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-7.28	1.36e-12	6.84e-10	-0.39	-0.31	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
KIRC	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
KIRC	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	7.28	1.36e-12	6.84e-10	0.5	0.31	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
KIRC	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-7.28	1.36e-12	6.84e-10	-0.3	-0.31	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
KIRC	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	7.28	1.36e-12	6.84e-10	0.41	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
KIRC	cis	rs2012796	0.661	rs59969857	ENSG00000270343.1	UNGP3	7.28	1.37e-12	6.85e-10	0.38	0.31	Night sleep phenotypes;	chr14:81375235	chr14:81259565~81260239:-
KIRC	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	7.28	1.37e-12	6.85e-10	0.28	0.31	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
KIRC	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	7.27	1.37e-12	6.86e-10	0.27	0.31	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
KIRC	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	7.27	1.37e-12	6.87e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	7.27	1.37e-12	6.87e-10	0.38	0.31	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
KIRC	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	7.27	1.37e-12	6.89e-10	0.42	0.31	Myopia;	chr6:28302807	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	7.27	1.37e-12	6.9e-10	0.44	0.31	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
KIRC	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-7.27	1.37e-12	6.9e-10	-0.37	-0.31	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
KIRC	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-7.27	1.38e-12	6.9e-10	-0.29	-0.31	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
KIRC	cis	rs17772222	0.839	rs2274735	ENSG00000222990.1	RNU4-22P	7.27	1.38e-12	6.92e-10	0.33	0.31	Coronary artery calcification;	chr14:88505414	chr14:88513498~88513663:+
KIRC	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-7.27	1.38e-12	6.92e-10	-0.48	-0.31	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
KIRC	cis	rs12449964	0.524	rs4925094	ENSG00000223979.2	SMCR2	7.27	1.38e-12	6.92e-10	0.33	0.31	Coronary artery disease or ischemic stroke;	chr17:17665698	chr17:17674026~17677688:-
KIRC	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-7.27	1.38e-12	6.92e-10	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
KIRC	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-7.27	1.38e-12	6.93e-10	-0.38	-0.31	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-7.27	1.38e-12	6.93e-10	-0.38	-0.31	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
KIRC	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	7.27	1.38e-12	6.94e-10	0.61	0.31	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
KIRC	cis	rs1122900	1	rs56039629	ENSG00000250155.1	CTD-2353F22.1	7.27	1.38e-12	6.94e-10	0.35	0.31	Aggressive periodontitis;	chr5:36683801	chr5:36666214~36725195:-
KIRC	cis	rs13434995	0.513	rs73236142	ENSG00000273257.1	RP11-177J6.1	-7.27	1.38e-12	6.95e-10	-0.41	-0.31	Adiponectin levels;	chr4:55446143	chr4:55387949~55388271:+
KIRC	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	7.27	1.39e-12	6.99e-10	0.29	0.31	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
KIRC	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-7.27	1.41e-12	7.05e-10	-0.51	-0.31	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
KIRC	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	7.27	1.41e-12	7.05e-10	0.27	0.31	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
KIRC	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	7.27	1.41e-12	7.07e-10	0.46	0.31	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
KIRC	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-7.27	1.41e-12	7.07e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
KIRC	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-7.27	1.41e-12	7.07e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-7.27	1.41e-12	7.07e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
KIRC	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-7.27	1.41e-12	7.07e-10	-0.5	-0.31	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
KIRC	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	7.27	1.41e-12	7.08e-10	0.36	0.31	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
KIRC	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	7.27	1.41e-12	7.08e-10	0.36	0.31	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
KIRC	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	7.27	1.41e-12	7.08e-10	0.39	0.31	Height;	chr11:118857611	chr11:118688039~118690600:-
KIRC	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-7.27	1.42e-12	7.09e-10	-0.44	-0.31	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
KIRC	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	7.27	1.42e-12	7.09e-10	0.3	0.31	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
KIRC	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-7.27	1.42e-12	7.1e-10	-0.45	-0.31	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
KIRC	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	7.27	1.42e-12	7.1e-10	0.38	0.31	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
KIRC	cis	rs1560104	1	rs4780465	ENSG00000274834.1	CTD-3037G24.5	-7.27	1.42e-12	7.1e-10	-0.35	-0.31	Obesity-related traits;	chr16:12613666	chr16:12614451~12614852:+
KIRC	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-7.27	1.42e-12	7.11e-10	-0.3	-0.31	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-7.27	1.42e-12	7.11e-10	-0.3	-0.31	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
KIRC	cis	rs6061231	0.631	rs2427318	ENSG00000275437.1	RP5-908M14.10	7.27	1.42e-12	7.11e-10	0.23	0.31	Colorectal cancer;	chr20:62400671	chr20:62402236~62405935:-
KIRC	cis	rs9371601	0.859	rs177330	ENSG00000226193.1	RP3-398G3.5	-7.27	1.42e-12	7.11e-10	-0.33	-0.31	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152401093	chr6:152402398~152404966:+
KIRC	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-7.27	1.42e-12	7.12e-10	-0.3	-0.31	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
KIRC	cis	rs13434995	0.513	rs67963898	ENSG00000273257.1	RP11-177J6.1	-7.27	1.42e-12	7.12e-10	-0.41	-0.31	Adiponectin levels;	chr4:55475520	chr4:55387949~55388271:+
KIRC	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-7.27	1.42e-12	7.13e-10	-0.39	-0.31	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
KIRC	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	7.27	1.43e-12	7.14e-10	0.4	0.31	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-7.27	1.43e-12	7.14e-10	-0.29	-0.31	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-7.27	1.43e-12	7.14e-10	-0.29	-0.31	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
KIRC	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-7.27	1.43e-12	7.15e-10	-0.28	-0.31	Gout;	chr7:66721259	chr7:66902857~66906297:+
KIRC	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-7.27	1.43e-12	7.16e-10	-0.3	-0.31	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
KIRC	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-7.27	1.43e-12	7.16e-10	-0.33	-0.31	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
KIRC	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	7.27	1.43e-12	7.17e-10	0.3	0.31	QT interval;	chr12:29292489	chr12:29280418~29317848:-
KIRC	cis	rs9322193	0.961	rs4870144	ENSG00000268592.3	RAET1E-AS1	7.27	1.43e-12	7.18e-10	0.43	0.31	Lung cancer;	chr6:149575540	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-7.27	1.44e-12	7.2e-10	-0.38	-0.31	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
KIRC	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-7.27	1.44e-12	7.22e-10	-0.44	-0.31	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
KIRC	cis	rs1560104	0.709	rs6498334	ENSG00000274834.1	CTD-3037G24.5	-7.27	1.44e-12	7.22e-10	-0.35	-0.31	Obesity-related traits;	chr16:12602789	chr16:12614451~12614852:+
KIRC	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	7.27	1.44e-12	7.23e-10	0.41	0.31	Height;	chr6:109471826	chr6:109382795~109383666:+
KIRC	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-7.27	1.45e-12	7.23e-10	-0.33	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
KIRC	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	7.27	1.45e-12	7.23e-10	0.26	0.31	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
KIRC	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	7.27	1.45e-12	7.25e-10	0.38	0.31	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
KIRC	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-7.27	1.45e-12	7.26e-10	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-7.27	1.45e-12	7.26e-10	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
KIRC	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	7.27	1.45e-12	7.27e-10	0.39	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
KIRC	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	7.27	1.45e-12	7.27e-10	0.22	0.31	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
KIRC	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	7.27	1.45e-12	7.27e-10	0.34	0.31	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
KIRC	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-7.27	1.45e-12	7.27e-10	-0.4	-0.31	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
KIRC	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	7.27	1.45e-12	7.27e-10	0.44	0.31	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
KIRC	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	7.27	1.46e-12	7.28e-10	0.23	0.31	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
KIRC	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-7.27	1.46e-12	7.28e-10	-0.35	-0.31	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
KIRC	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	7.27	1.46e-12	7.28e-10	0.43	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	7.27	1.46e-12	7.28e-10	0.43	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
KIRC	cis	rs11841001	0.556	rs1470273	ENSG00000261105.4	LMO7-AS1	-7.27	1.46e-12	7.29e-10	-0.5	-0.31	Corneal astigmatism;	chr13:75768241	chr13:75604700~75635994:-
KIRC	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-7.26	1.46e-12	7.3e-10	-0.3	-0.31	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
KIRC	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-7.26	1.46e-12	7.3e-10	-0.35	-0.31	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
KIRC	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-7.26	1.46e-12	7.32e-10	-0.35	-0.31	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
KIRC	cis	rs12500482	0.5	rs733033	ENSG00000206113.6	RP11-503N18.1	7.26	1.46e-12	7.32e-10	0.38	0.31	Cognitive function;	chr4:2426258	chr4:2418974~2450360:+
KIRC	cis	rs13434995	0.513	rs1979604	ENSG00000273257.1	RP11-177J6.1	7.26	1.46e-12	7.32e-10	0.41	0.31	Adiponectin levels;	chr4:55552588	chr4:55387949~55388271:+
KIRC	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-7.26	1.47e-12	7.34e-10	-0.4	-0.31	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
KIRC	cis	rs2486288	0.656	rs11632920	ENSG00000235390.4	CTD-2651B20.5	7.26	1.47e-12	7.34e-10	0.29	0.31	Glomerular filtration rate;	chr15:45259066	chr15:45321077~45321692:-
KIRC	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	7.26	1.48e-12	7.39e-10	0.6	0.31	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
KIRC	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	7.26	1.48e-12	7.4e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
KIRC	cis	rs7927771	0.756	rs2856661	ENSG00000280615.1	Y_RNA	7.26	1.48e-12	7.4e-10	0.35	0.31	Subjective well-being;	chr11:47353447	chr11:47614898~47614994:-
KIRC	cis	rs79040073	0.516	rs4338740	ENSG00000259531.2	RP11-295H24.3	7.26	1.48e-12	7.4e-10	0.38	0.31	Lung cancer in ever smokers;	chr15:49443100	chr15:49365124~49366685:-
KIRC	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	7.26	1.48e-12	7.4e-10	0.51	0.31	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	7.26	1.48e-12	7.4e-10	0.51	0.31	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
KIRC	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-7.26	1.48e-12	7.4e-10	-0.29	-0.31	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-7.26	1.48e-12	7.4e-10	-0.29	-0.31	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-7.26	1.48e-12	7.4e-10	-0.29	-0.31	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-7.26	1.48e-12	7.4e-10	-0.29	-0.31	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
KIRC	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	7.26	1.48e-12	7.4e-10	0.29	0.31	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
KIRC	cis	rs13434995	0.513	rs2130040	ENSG00000273257.1	RP11-177J6.1	7.26	1.48e-12	7.4e-10	0.41	0.31	Adiponectin levels;	chr4:55564036	chr4:55387949~55388271:+
KIRC	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	7.26	1.48e-12	7.41e-10	0.56	0.31	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
KIRC	cis	rs17772222	0.63	rs2778936	ENSG00000222990.1	RNU4-22P	-7.26	1.48e-12	7.41e-10	-0.34	-0.31	Coronary artery calcification;	chr14:88505959	chr14:88513498~88513663:+
KIRC	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	7.26	1.49e-12	7.43e-10	0.5	0.31	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	7.26	1.49e-12	7.43e-10	0.5	0.31	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
KIRC	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	7.26	1.49e-12	7.45e-10	0.38	0.31	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
KIRC	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	7.26	1.49e-12	7.46e-10	0.32	0.31	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
KIRC	cis	rs13434995	0.537	rs4865012	ENSG00000273257.1	RP11-177J6.1	7.26	1.49e-12	7.46e-10	0.41	0.31	Adiponectin levels;	chr4:55554619	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs6846764	ENSG00000273257.1	RP11-177J6.1	7.26	1.49e-12	7.46e-10	0.41	0.31	Adiponectin levels;	chr4:55557322	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs6853506	ENSG00000273257.1	RP11-177J6.1	7.26	1.49e-12	7.46e-10	0.41	0.31	Adiponectin levels;	chr4:55558207	chr4:55387949~55388271:+
KIRC	cis	rs10916248	0.559	rs116083281	ENSG00000232628.4	RP11-365O16.3	7.26	1.5e-12	7.47e-10	0.54	0.31	QT interval (drug interaction);	chr1:224199365	chr1:224208747~224213279:-
KIRC	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	7.26	1.5e-12	7.5e-10	0.34	0.31	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
KIRC	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	7.26	1.5e-12	7.51e-10	0.44	0.31	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
KIRC	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-7.26	1.5e-12	7.51e-10	-0.37	-0.31	Height;	chr4:55537550	chr4:55387949~55388271:+
KIRC	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-7.26	1.51e-12	7.51e-10	-0.42	-0.31	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
KIRC	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-7.26	1.51e-12	7.51e-10	-0.49	-0.31	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
KIRC	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-7.26	1.51e-12	7.51e-10	-0.28	-0.31	Gout;	chr7:66642037	chr7:66902857~66906297:+
KIRC	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	7.26	1.51e-12	7.52e-10	0.56	0.31	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	7.26	1.51e-12	7.52e-10	0.56	0.31	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
KIRC	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	7.26	1.51e-12	7.52e-10	0.56	0.31	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
KIRC	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	7.26	1.51e-12	7.53e-10	0.26	0.31	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
KIRC	cis	rs13434995	0.537	rs4865012	ENSG00000249700.7	SRD5A3-AS1	7.26	1.51e-12	7.53e-10	0.31	0.31	Adiponectin levels;	chr4:55554619	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs6846764	ENSG00000249700.7	SRD5A3-AS1	7.26	1.51e-12	7.53e-10	0.31	0.31	Adiponectin levels;	chr4:55557322	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs6853506	ENSG00000249700.7	SRD5A3-AS1	7.26	1.51e-12	7.53e-10	0.31	0.31	Adiponectin levels;	chr4:55558207	chr4:55363971~55395847:-
KIRC	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	7.26	1.51e-12	7.55e-10	0.37	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
KIRC	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-7.26	1.51e-12	7.55e-10	-0.35	-0.31	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-7.26	1.51e-12	7.55e-10	-0.35	-0.31	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
KIRC	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-7.26	1.52e-12	7.57e-10	-0.37	-0.31	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
KIRC	cis	rs2012796	0.743	rs61986598	ENSG00000270343.1	UNGP3	7.26	1.52e-12	7.57e-10	0.39	0.31	Night sleep phenotypes;	chr14:81390521	chr14:81259565~81260239:-
KIRC	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	7.26	1.52e-12	7.58e-10	0.38	0.31	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
KIRC	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	7.26	1.52e-12	7.58e-10	0.28	0.31	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
KIRC	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	7.26	1.52e-12	7.58e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
KIRC	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	7.26	1.52e-12	7.58e-10	0.51	0.31	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
KIRC	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-7.26	1.52e-12	7.58e-10	-0.41	-0.31	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
KIRC	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-7.26	1.52e-12	7.59e-10	-0.29	-0.31	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
KIRC	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-7.26	1.52e-12	7.59e-10	-0.42	-0.31	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
KIRC	cis	rs75422866	0.51	rs73105845	ENSG00000280054.1	RP1-197B17.7	7.26	1.52e-12	7.6e-10	0.64	0.31	Pneumonia;	chr12:47741824	chr12:47728151~47730598:-
KIRC	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-7.26	1.52e-12	7.6e-10	-0.34	-0.31	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
KIRC	cis	rs3820928	1	rs1835158	ENSG00000212391.1	SNORA48	-7.26	1.52e-12	7.6e-10	-0.36	-0.31	Pulmonary function;	chr2:226899277	chr2:226968989~226969122:-
KIRC	cis	rs13434995	0.562	rs10529258	ENSG00000249700.7	SRD5A3-AS1	-7.26	1.52e-12	7.6e-10	-0.32	-0.31	Adiponectin levels;	chr4:55546702	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.512	rs115635692	ENSG00000249700.7	SRD5A3-AS1	-7.26	1.52e-12	7.6e-10	-0.32	-0.31	Adiponectin levels;	chr4:55546706	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.626	rs116135676	ENSG00000249700.7	SRD5A3-AS1	-7.26	1.52e-12	7.6e-10	-0.32	-0.31	Adiponectin levels;	chr4:55546707	chr4:55363971~55395847:-
KIRC	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	7.26	1.53e-12	7.61e-10	0.65	0.31	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	7.26	1.53e-12	7.61e-10	0.65	0.31	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
KIRC	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	7.26	1.53e-12	7.61e-10	0.47	0.31	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
KIRC	cis	rs75422866	0.558	rs73104190	ENSG00000280054.1	RP1-197B17.7	7.26	1.53e-12	7.62e-10	0.63	0.31	Pneumonia;	chr12:47716040	chr12:47728151~47730598:-
KIRC	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-7.26	1.53e-12	7.64e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-7.26	1.53e-12	7.64e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-7.26	1.53e-12	7.64e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
KIRC	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-7.26	1.53e-12	7.65e-10	-0.29	-0.31	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-7.26	1.53e-12	7.65e-10	-0.29	-0.31	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-7.26	1.53e-12	7.65e-10	-0.29	-0.31	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-7.26	1.53e-12	7.65e-10	-0.29	-0.31	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
KIRC	cis	rs1552244	0.938	rs56274701	ENSG00000180385.7	EMC3-AS1	7.26	1.54e-12	7.66e-10	0.31	0.31	Alzheimer's disease;	chr3:10126106	chr3:9986893~10006990:+
KIRC	cis	rs13434995	0.513	rs7660668	ENSG00000273257.1	RP11-177J6.1	7.26	1.54e-12	7.66e-10	0.41	0.31	Adiponectin levels;	chr4:55535530	chr4:55387949~55388271:+
KIRC	cis	rs3760982	1	rs3760983	ENSG00000267058.1	RP11-15A1.3	7.26	1.54e-12	7.66e-10	0.36	0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782508	chr19:43891804~43901805:-
KIRC	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-7.26	1.54e-12	7.67e-10	-0.27	-0.31	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
KIRC	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-7.26	1.54e-12	7.67e-10	-0.27	-0.31	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
KIRC	cis	rs17801127	0.579	rs61198982	ENSG00000231969.1	AC144449.1	7.26	1.54e-12	7.67e-10	0.57	0.31	Liver enzyme levels (alanine transaminase);	chr2:149756549	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.688	rs35224448	ENSG00000231969.1	AC144449.1	7.26	1.54e-12	7.67e-10	0.57	0.31	Liver enzyme levels (alanine transaminase);	chr2:149762838	chr2:149587196~149848233:+
KIRC	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	7.26	1.54e-12	7.67e-10	0.38	0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
KIRC	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	7.26	1.54e-12	7.68e-10	0.41	0.31	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
KIRC	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-7.26	1.54e-12	7.69e-10	-0.38	-0.31	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
KIRC	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	7.26	1.55e-12	7.7e-10	0.3	0.31	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
KIRC	cis	rs6061231	0.63	rs62196294	ENSG00000273619.1	RP5-908M14.9	-7.26	1.55e-12	7.71e-10	-0.24	-0.31	Colorectal cancer;	chr20:62398376	chr20:62386303~62386970:-
KIRC	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-7.26	1.55e-12	7.71e-10	-0.31	-0.31	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
KIRC	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-7.26	1.56e-12	7.75e-10	-0.4	-0.31	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
KIRC	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-7.26	1.56e-12	7.75e-10	-0.22	-0.31	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
KIRC	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-7.26	1.56e-12	7.76e-10	-0.29	-0.31	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-7.26	1.56e-12	7.76e-10	-0.29	-0.31	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-7.26	1.56e-12	7.76e-10	-0.29	-0.31	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-7.26	1.56e-12	7.76e-10	-0.29	-0.31	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
KIRC	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	7.26	1.56e-12	7.77e-10	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
KIRC	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-7.26	1.56e-12	7.77e-10	-0.29	-0.31	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
KIRC	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	7.25	1.56e-12	7.77e-10	0.41	0.31	Height;	chr6:109332929	chr6:109382795~109383666:+
KIRC	cis	rs6061231	0.654	rs2427322	ENSG00000273619.1	RP5-908M14.9	-7.25	1.56e-12	7.78e-10	-0.24	-0.31	Colorectal cancer;	chr20:62404314	chr20:62386303~62386970:-
KIRC	cis	rs13434995	0.562	rs73236140	ENSG00000249700.7	SRD5A3-AS1	-7.25	1.56e-12	7.79e-10	-0.31	-0.31	Adiponectin levels;	chr4:55440049	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs62303691	ENSG00000249700.7	SRD5A3-AS1	-7.25	1.56e-12	7.79e-10	-0.31	-0.31	Adiponectin levels;	chr4:55442085	chr4:55363971~55395847:-
KIRC	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	7.25	1.56e-12	7.79e-10	0.41	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
KIRC	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-7.25	1.57e-12	7.79e-10	-0.49	-0.31	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
KIRC	cis	rs4789693	0.679	rs7217570	ENSG00000265458.1	RP13-20L14.6	-7.25	1.57e-12	7.81e-10	-0.42	-0.31	Glucocorticoid-induced osteonecrosis;	chr17:82421456	chr17:82454273~82458521:-
KIRC	cis	rs13434995	0.513	rs11240	ENSG00000273257.1	RP11-177J6.1	-7.25	1.58e-12	7.87e-10	-0.41	-0.31	Adiponectin levels;	chr4:55453183	chr4:55387949~55388271:+
KIRC	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-7.25	1.59e-12	7.89e-10	-0.3	-0.31	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
KIRC	cis	rs1431005	0.927	rs12651176	ENSG00000250620.1	RP11-91J3.3	7.25	1.59e-12	7.9e-10	0.4	0.31	Response to statin therapy;	chr4:187439724	chr4:187413564~187415697:+
KIRC	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	7.25	1.59e-12	7.9e-10	0.41	0.31	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	7.25	1.59e-12	7.9e-10	0.41	0.31	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
KIRC	cis	rs13434995	0.589	rs496055	ENSG00000249700.7	SRD5A3-AS1	-7.25	1.59e-12	7.91e-10	-0.32	-0.31	Adiponectin levels;	chr4:55383670	chr4:55363971~55395847:-
KIRC	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-7.25	1.59e-12	7.92e-10	-0.37	-0.31	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
KIRC	cis	rs2018683	1	rs740252	ENSG00000228421.2	AC005013.5	7.25	1.59e-12	7.92e-10	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28957667~28959345:+
KIRC	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	7.25	1.6e-12	7.94e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
KIRC	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-7.25	1.6e-12	7.96e-10	-0.42	-0.31	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
KIRC	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-7.25	1.6e-12	7.98e-10	-0.37	-0.31	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-7.25	1.6e-12	7.98e-10	-0.37	-0.31	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
KIRC	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-7.25	1.6e-12	7.98e-10	-0.34	-0.31	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
KIRC	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	7.25	1.6e-12	7.98e-10	0.37	0.31	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
KIRC	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	7.25	1.61e-12	7.98e-10	0.41	0.31	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
KIRC	cis	rs2018683	1	rs4719962	ENSG00000228421.2	AC005013.5	7.25	1.61e-12	8.03e-10	0.32	0.31	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28957667~28959345:+
KIRC	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	7.25	1.61e-12	8.03e-10	0.41	0.31	Depression;	chr6:28205232	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-7.25	1.61e-12	8.03e-10	-0.41	-0.31	Depression;	chr6:28197321	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-7.25	1.61e-12	8.03e-10	-0.41	-0.31	Depression;	chr6:28197412	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-7.25	1.61e-12	8.03e-10	-0.41	-0.31	Depression;	chr6:28205175	chr6:28115628~28116551:+
KIRC	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-7.25	1.62e-12	8.04e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
KIRC	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	7.25	1.62e-12	8.05e-10	0.38	0.31	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
KIRC	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-7.25	1.62e-12	8.07e-10	-0.36	-0.31	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
KIRC	cis	rs13113518	1	rs7660980	ENSG00000273257.1	RP11-177J6.1	-7.25	1.63e-12	8.08e-10	-0.37	-0.31	Height;	chr4:55542948	chr4:55387949~55388271:+
KIRC	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	8.09e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
KIRC	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	7.25	1.63e-12	8.09e-10	0.27	0.31	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
KIRC	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-7.25	1.63e-12	8.1e-10	-0.69	-0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
KIRC	cis	rs3760982	1	rs60184524	ENSG00000267058.1	RP11-15A1.3	-7.25	1.63e-12	8.12e-10	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790063	chr19:43891804~43901805:-
KIRC	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	7.25	1.64e-12	8.13e-10	0.44	0.31	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
KIRC	cis	rs11079159	0.848	rs17817923	ENSG00000263096.1	RP11-515O17.2	7.25	1.64e-12	8.13e-10	0.41	0.31	QRS duration;	chr17:55310516	chr17:55271504~55273653:-
KIRC	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	7.25	1.64e-12	8.15e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
KIRC	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-7.25	1.65e-12	8.18e-10	-0.34	-0.31	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
KIRC	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	7.25	1.65e-12	8.19e-10	0.32	0.31	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
KIRC	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	7.25	1.65e-12	8.19e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
KIRC	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-7.25	1.65e-12	8.2e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
KIRC	cis	rs3093024	0.904	rs3093019	ENSG00000265828.1	MIR3939	7.25	1.65e-12	8.21e-10	0.36	0.31	Rheumatoid arthritis;	chr6:167126167	chr6:166997807~166997912:-
KIRC	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	7.25	1.65e-12	8.21e-10	0.34	0.31	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	7.25	1.65e-12	8.21e-10	0.34	0.31	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
KIRC	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	7.25	1.65e-12	8.21e-10	0.32	0.31	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
KIRC	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-7.25	1.65e-12	8.21e-10	-0.33	-0.31	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
KIRC	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	7.25	1.65e-12	8.22e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	7.25	1.65e-12	8.22e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
KIRC	cis	rs526231	0.756	rs556560	ENSG00000175749.11	EIF3KP1	-7.25	1.65e-12	8.22e-10	-0.37	-0.31	Primary biliary cholangitis;	chr5:103288223	chr5:103032376~103033031:+
KIRC	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	7.25	1.66e-12	8.23e-10	0.44	0.31	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
KIRC	cis	rs3820928	1	rs4675119	ENSG00000212391.1	SNORA48	-7.25	1.66e-12	8.23e-10	-0.36	-0.31	Pulmonary function;	chr2:226909919	chr2:226968989~226969122:-
KIRC	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	7.25	1.66e-12	8.23e-10	0.41	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
KIRC	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-7.25	1.66e-12	8.24e-10	-0.28	-0.31	Gout;	chr7:66732812	chr7:66902857~66906297:+
KIRC	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	7.25	1.66e-12	8.25e-10	0.35	0.31	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
KIRC	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	7.25	1.67e-12	8.28e-10	0.56	0.31	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
KIRC	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-7.25	1.67e-12	8.28e-10	-0.25	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
KIRC	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.24	1.67e-12	8.29e-10	-0.34	-0.31	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
KIRC	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	7.24	1.67e-12	8.29e-10	0.41	0.31	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
KIRC	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-7.24	1.67e-12	8.31e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
KIRC	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-7.24	1.67e-12	8.31e-10	-0.41	-0.31	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
KIRC	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-7.24	1.68e-12	8.32e-10	-0.32	-0.31	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
KIRC	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	7.24	1.68e-12	8.33e-10	0.27	0.31	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
KIRC	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	7.24	1.68e-12	8.33e-10	0.43	0.31	Depression;	chr6:28407125	chr6:28943877~28944537:+
KIRC	cis	rs12220777	0.818	rs7918223	ENSG00000230091.5	TMEM254-AS1	7.24	1.68e-12	8.36e-10	0.47	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090023	chr10:80046860~80078912:-
KIRC	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	7.24	1.69e-12	8.36e-10	0.56	0.31	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	7.24	1.69e-12	8.36e-10	0.56	0.31	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
KIRC	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	7.24	1.69e-12	8.36e-10	0.56	0.31	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
KIRC	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	7.24	1.69e-12	8.37e-10	0.71	0.31	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
KIRC	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-7.24	1.69e-12	8.37e-10	-0.46	-0.31	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
KIRC	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	7.24	1.69e-12	8.37e-10	0.45	0.31	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	7.24	1.69e-12	8.37e-10	0.45	0.31	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
KIRC	cis	rs890448	0.726	rs2583391	ENSG00000254531.1	FLJ20021	-7.24	1.69e-12	8.38e-10	-0.31	-0.31	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101346296	chr4:101347780~101348883:+
KIRC	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-7.24	1.69e-12	8.38e-10	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
KIRC	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-7.24	1.7e-12	8.42e-10	-0.33	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
KIRC	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-7.24	1.7e-12	8.42e-10	-0.35	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	7.24	1.7e-12	8.42e-10	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
KIRC	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	7.24	1.7e-12	8.43e-10	0.44	0.31	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
KIRC	cis	rs7924176	0.521	rs12359775	ENSG00000213731.2	RAB5CP1	-7.24	1.7e-12	8.43e-10	-0.3	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74423435~74424014:-
KIRC	cis	rs2012796	0.665	rs72703728	ENSG00000270343.1	UNGP3	7.24	1.7e-12	8.44e-10	0.38	0.31	Night sleep phenotypes;	chr14:81368179	chr14:81259565~81260239:-
KIRC	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-7.24	1.7e-12	8.44e-10	-0.5	-0.31	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
KIRC	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-7.24	1.7e-12	8.45e-10	-0.32	-0.31	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	7.24	1.71e-12	8.46e-10	0.44	0.31	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
KIRC	cis	rs9388451	0.839	rs1811852	ENSG00000237742.5	RP11-624M8.1	-7.24	1.71e-12	8.46e-10	-0.38	-0.31	Brugada syndrome;	chr6:125750429	chr6:125578558~125749190:-
KIRC	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-7.24	1.71e-12	8.47e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
KIRC	cis	rs3002142	1	rs3002142	ENSG00000272750.1	RP11-378J18.8	-7.24	1.71e-12	8.48e-10	-0.42	-0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222614720	chr1:222658867~222661512:-
KIRC	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	7.24	1.71e-12	8.48e-10	0.75	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
KIRC	cis	rs2281558	0.55	rs68007865	ENSG00000125804.12	FAM182A	-7.24	1.71e-12	8.48e-10	-0.6	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25249342	chr20:26054655~26086917:+
KIRC	cis	rs13434995	0.513	rs7676245	ENSG00000273257.1	RP11-177J6.1	-7.24	1.71e-12	8.5e-10	-0.41	-0.31	Adiponectin levels;	chr4:55455150	chr4:55387949~55388271:+
KIRC	cis	rs3820928	0.967	rs720501	ENSG00000212391.1	SNORA48	-7.24	1.72e-12	8.51e-10	-0.37	-0.31	Pulmonary function;	chr2:226913729	chr2:226968989~226969122:-
KIRC	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	7.24	1.72e-12	8.51e-10	0.33	0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
KIRC	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-7.24	1.72e-12	8.52e-10	-0.42	-0.31	Height;	chr6:109444615	chr6:109382795~109383666:+
KIRC	cis	rs1528149	0.576	rs1881242	ENSG00000224683.1	RPL36AP29	-7.24	1.72e-12	8.52e-10	-0.38	-0.31	Sitting height ratio;	chr7:16073822	chr7:16208945~16209265:+
KIRC	cis	rs10214930	0.671	rs6963585	ENSG00000235574.1	AC073150.6	-7.24	1.72e-12	8.53e-10	-0.37	-0.31	Hypospadias;	chr7:27544204	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1851913	ENSG00000235574.1	AC073150.6	-7.24	1.72e-12	8.53e-10	-0.37	-0.31	Hypospadias;	chr7:27545457	chr7:27491682~27492765:-
KIRC	cis	rs17711722	0.565	rs4275112	ENSG00000275400.1	RP4-756H11.5	7.24	1.72e-12	8.53e-10	0.32	0.31	Calcium levels;	chr7:65733651	chr7:66553805~66554199:-
KIRC	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-7.24	1.72e-12	8.53e-10	-0.41	-0.31	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
KIRC	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-7.24	1.73e-12	8.56e-10	-0.25	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
KIRC	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-7.24	1.73e-12	8.57e-10	-0.37	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
KIRC	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-7.24	1.73e-12	8.58e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-7.24	1.73e-12	8.58e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
KIRC	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	7.24	1.73e-12	8.58e-10	0.35	0.31	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
KIRC	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	8.61e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	8.61e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	8.61e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	8.61e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
KIRC	cis	rs3820928	0.934	rs60141402	ENSG00000212391.1	SNORA48	-7.24	1.74e-12	8.61e-10	-0.36	-0.31	Pulmonary function;	chr2:226896729	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.934	rs16822890	ENSG00000212391.1	SNORA48	-7.24	1.74e-12	8.61e-10	-0.36	-0.31	Pulmonary function;	chr2:226896761	chr2:226968989~226969122:-
KIRC	cis	rs3820928	1	rs9288617	ENSG00000212391.1	SNORA48	-7.24	1.74e-12	8.61e-10	-0.36	-0.31	Pulmonary function;	chr2:226898099	chr2:226968989~226969122:-
KIRC	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	7.24	1.74e-12	8.62e-10	0.39	0.31	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
KIRC	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	7.24	1.74e-12	8.62e-10	0.39	0.31	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
KIRC	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	7.24	1.74e-12	8.62e-10	0.26	0.31	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
KIRC	cis	rs10214930	0.671	rs9639553	ENSG00000235574.1	AC073150.6	7.24	1.74e-12	8.62e-10	0.36	0.31	Hypospadias;	chr7:27538548	chr7:27491682~27492765:-
KIRC	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-7.24	1.74e-12	8.64e-10	-0.37	-0.31	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
KIRC	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	7.24	1.75e-12	8.64e-10	0.27	0.31	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
KIRC	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-7.24	1.75e-12	8.65e-10	-0.36	-0.31	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
KIRC	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-7.24	1.75e-12	8.67e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
KIRC	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	7.24	1.75e-12	8.68e-10	0.23	0.31	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	7.24	1.75e-12	8.68e-10	0.23	0.31	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
KIRC	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-7.24	1.75e-12	8.68e-10	-0.56	-0.31	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-7.24	1.75e-12	8.68e-10	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-7.24	1.75e-12	8.68e-10	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
KIRC	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	7.24	1.75e-12	8.69e-10	0.32	0.31	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
KIRC	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-7.24	1.76e-12	8.69e-10	-0.38	-0.31	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
KIRC	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-7.24	1.76e-12	8.69e-10	-0.38	-0.31	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
KIRC	cis	rs10214930	0.697	rs6462026	ENSG00000235574.1	AC073150.6	-7.24	1.76e-12	8.69e-10	-0.37	-0.31	Hypospadias;	chr7:27522749	chr7:27491682~27492765:-
KIRC	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-7.24	1.76e-12	8.69e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-7.24	1.76e-12	8.69e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
KIRC	cis	rs11148252	0.669	rs61958050	ENSG00000278238.1	RP11-245D16.4	-7.24	1.76e-12	8.69e-10	-0.36	-0.31	Lewy body disease;	chr13:52420292	chr13:52454775~52455331:-
KIRC	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	7.24	1.76e-12	8.7e-10	0.38	0.31	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
KIRC	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	7.24	1.76e-12	8.7e-10	0.51	0.31	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
KIRC	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	7.24	1.76e-12	8.7e-10	0.51	0.31	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
KIRC	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	7.24	1.76e-12	8.71e-10	0.45	0.31	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
KIRC	cis	rs13434995	0.588	rs114571142	ENSG00000249700.7	SRD5A3-AS1	-7.24	1.76e-12	8.71e-10	-0.31	-0.31	Adiponectin levels;	chr4:55412991	chr4:55363971~55395847:-
KIRC	cis	rs4072705	0.967	rs10818984	ENSG00000224020.1	MIR181A2HG	-7.24	1.76e-12	8.72e-10	-0.32	-0.31	Menarche (age at onset);	chr9:124651272	chr9:124658467~124698631:+
KIRC	cis	rs4789693	0.679	rs7213057	ENSG00000265458.1	RP13-20L14.6	7.24	1.76e-12	8.72e-10	0.42	0.31	Glucocorticoid-induced osteonecrosis;	chr17:82421063	chr17:82454273~82458521:-
KIRC	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-7.24	1.77e-12	8.73e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
KIRC	cis	rs11647589	0.815	rs7194852	ENSG00000262995.1	CTD-2194A8.2	-7.24	1.77e-12	8.74e-10	-0.33	-0.31	Blood metabolite levels;	chr16:20461954	chr16:20440266~20447000:-
KIRC	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-7.24	1.77e-12	8.74e-10	-0.45	-0.31	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
KIRC	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-7.24	1.77e-12	8.74e-10	-0.32	-0.31	Height;	chr3:52992698	chr3:53064283~53065091:-
KIRC	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-7.24	1.77e-12	8.76e-10	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
KIRC	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-7.24	1.78e-12	8.78e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
KIRC	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	7.24	1.78e-12	8.79e-10	0.37	0.31	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	7.24	1.78e-12	8.79e-10	0.37	0.31	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	7.24	1.78e-12	8.79e-10	0.37	0.31	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
KIRC	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	7.24	1.78e-12	8.81e-10	0.42	0.31	Height;	chr6:109403287	chr6:109382795~109383666:+
KIRC	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	7.24	1.78e-12	8.81e-10	0.47	0.31	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
KIRC	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	7.24	1.78e-12	8.81e-10	0.47	0.31	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
KIRC	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	7.23	1.79e-12	8.83e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
KIRC	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-7.23	1.79e-12	8.85e-10	-0.28	-0.31	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
KIRC	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-7.23	1.79e-12	8.86e-10	-0.34	-0.31	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
KIRC	cis	rs58873874	1	rs75720504	ENSG00000251405.2	CTB-109A12.1	7.23	1.79e-12	8.86e-10	0.57	0.31	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157362615~157460078:-
KIRC	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	7.23	1.8e-12	8.88e-10	0.23	0.31	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
KIRC	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	7.23	1.8e-12	8.88e-10	0.32	0.31	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
KIRC	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-7.23	1.8e-12	8.88e-10	-0.48	-0.31	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
KIRC	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-7.23	1.8e-12	8.89e-10	-0.34	-0.31	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
KIRC	cis	rs10276381	1	rs10276381	ENSG00000234336.5	JAZF1-AS1	7.23	1.8e-12	8.89e-10	0.55	0.31	Crohn's disease;	chr7:28150502	chr7:28180322~28243917:+
KIRC	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-7.23	1.8e-12	8.91e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
KIRC	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-7.23	1.8e-12	8.91e-10	-0.29	-0.31	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
KIRC	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-7.23	1.81e-12	8.92e-10	-0.29	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	7.23	1.81e-12	8.95e-10	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
KIRC	cis	rs13236243	0.747	rs7811989	ENSG00000226598.1	AC017060.1	7.23	1.81e-12	8.95e-10	0.4	0.31	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17331739	chr7:17463445~17558909:-
KIRC	cis	rs3820928	0.874	rs4675128	ENSG00000212391.1	SNORA48	-7.23	1.81e-12	8.95e-10	-0.36	-0.31	Pulmonary function;	chr2:226950041	chr2:226968989~226969122:-
KIRC	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-7.23	1.82e-12	8.96e-10	-0.31	-0.31	QT interval;	chr12:29331030	chr12:29280418~29317848:-
KIRC	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-7.23	1.82e-12	8.98e-10	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
KIRC	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-7.23	1.82e-12	8.98e-10	-0.48	-0.31	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	7.23	1.82e-12	8.99e-10	0.49	0.31	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
KIRC	cis	rs7592578	0.679	rs59929070	ENSG00000272979.1	RP11-647K16.1	-7.23	1.82e-12	9e-10	-0.44	-0.31	Diastolic blood pressure;	chr2:190463126	chr2:190454092~190454521:-
KIRC	cis	rs58873874	0.737	rs111759027	ENSG00000251405.2	CTB-109A12.1	7.23	1.82e-12	9e-10	0.57	0.31	Bipolar disorder (body mass index interaction);	chr5:157489628	chr5:157362615~157460078:-
KIRC	cis	rs11089937	0.626	rs9622968	ENSG00000211638.2	IGLV8-61	-7.23	1.82e-12	9.01e-10	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22144916	chr22:22098700~22099212:+
KIRC	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-7.23	1.82e-12	9.01e-10	-0.36	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
KIRC	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-7.23	1.83e-12	9.02e-10	-0.29	-0.31	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-7.23	1.83e-12	9.02e-10	-0.29	-0.31	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-7.23	1.83e-12	9.02e-10	-0.29	-0.31	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-7.23	1.83e-12	9.02e-10	-0.29	-0.31	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	7.23	1.83e-12	9.02e-10	0.37	0.31	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
KIRC	cis	rs58873874	0.737	rs11746837	ENSG00000251405.2	CTB-109A12.1	7.23	1.83e-12	9.03e-10	0.57	0.31	Bipolar disorder (body mass index interaction);	chr5:157491138	chr5:157362615~157460078:-
KIRC	cis	rs755249	0.546	rs7533743	ENSG00000182109.6	RP11-69E11.4	-7.23	1.83e-12	9.05e-10	-0.23	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.565	rs7555699	ENSG00000182109.6	RP11-69E11.4	-7.23	1.83e-12	9.05e-10	-0.23	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39522280~39546187:-
KIRC	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-7.23	1.83e-12	9.05e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
KIRC	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-7.23	1.84e-12	9.06e-10	-0.23	-0.31	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
KIRC	cis	rs11148252	0.904	rs9568734	ENSG00000278238.1	RP11-245D16.4	-7.23	1.84e-12	9.06e-10	-0.34	-0.31	Lewy body disease;	chr13:52430087	chr13:52454775~52455331:-
KIRC	cis	rs1528149	0.504	rs7795348	ENSG00000224683.1	RPL36AP29	7.23	1.84e-12	9.07e-10	0.37	0.31	Sitting height ratio;	chr7:16110647	chr7:16208945~16209265:+
KIRC	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-7.23	1.84e-12	9.08e-10	-0.37	-0.31	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
KIRC	cis	rs13434995	0.562	rs73236140	ENSG00000273257.1	RP11-177J6.1	-7.23	1.84e-12	9.09e-10	-0.41	-0.31	Adiponectin levels;	chr4:55440049	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.513	rs62303691	ENSG00000273257.1	RP11-177J6.1	-7.23	1.84e-12	9.09e-10	-0.41	-0.31	Adiponectin levels;	chr4:55442085	chr4:55387949~55388271:+
KIRC	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	7.23	1.84e-12	9.09e-10	0.26	0.31	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
KIRC	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-7.23	1.84e-12	9.1e-10	-0.46	-0.31	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
KIRC	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	7.23	1.85e-12	9.11e-10	0.75	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
KIRC	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs17050699	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9995483	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	7.23	1.85e-12	9.11e-10	0.3	0.31	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
KIRC	cis	rs13434995	0.589	rs62306207	ENSG00000249700.7	SRD5A3-AS1	-7.23	1.85e-12	9.12e-10	-0.32	-0.31	Adiponectin levels;	chr4:55384548	chr4:55363971~55395847:-
KIRC	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-7.23	1.85e-12	9.12e-10	-0.37	-0.31	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
KIRC	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	7.23	1.85e-12	9.13e-10	0.26	0.31	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
KIRC	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	7.23	1.85e-12	9.13e-10	0.26	0.31	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
KIRC	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	7.23	1.85e-12	9.13e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
KIRC	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-7.23	1.85e-12	9.14e-10	-0.29	-0.31	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
KIRC	cis	rs11647589	0.641	rs9922446	ENSG00000262995.1	CTD-2194A8.2	-7.23	1.86e-12	9.15e-10	-0.33	-0.31	Blood metabolite levels;	chr16:20470093	chr16:20440266~20447000:-
KIRC	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	7.23	1.86e-12	9.17e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
KIRC	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-7.23	1.86e-12	9.18e-10	-0.29	-0.31	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
KIRC	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	7.23	1.87e-12	9.2e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
KIRC	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-7.23	1.87e-12	9.21e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
KIRC	cis	rs6061231	0.631	rs2427310	ENSG00000273619.1	RP5-908M14.9	-7.23	1.87e-12	9.21e-10	-0.24	-0.31	Colorectal cancer;	chr20:62394873	chr20:62386303~62386970:-
KIRC	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	7.23	1.87e-12	9.23e-10	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
KIRC	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	7.23	1.87e-12	9.23e-10	0.42	0.31	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
KIRC	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	7.23	1.87e-12	9.24e-10	0.35	0.31	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
KIRC	cis	rs13434995	0.513	rs2130040	ENSG00000249700.7	SRD5A3-AS1	7.23	1.88e-12	9.25e-10	0.31	0.31	Adiponectin levels;	chr4:55564036	chr4:55363971~55395847:-
KIRC	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	7.23	1.88e-12	9.26e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
KIRC	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-7.23	1.88e-12	9.26e-10	-0.27	-0.31	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
KIRC	cis	rs3820928	0.874	rs6707265	ENSG00000212391.1	SNORA48	-7.23	1.88e-12	9.26e-10	-0.37	-0.31	Pulmonary function;	chr2:226984539	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-7.23	1.88e-12	9.26e-10	-0.31	-0.31	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
KIRC	cis	rs3093024	0.874	rs3093018	ENSG00000265828.1	MIR3939	7.23	1.88e-12	9.27e-10	0.36	0.31	Rheumatoid arthritis;	chr6:167126317	chr6:166997807~166997912:-
KIRC	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-7.23	1.89e-12	9.3e-10	-0.31	-0.31	QT interval;	chr12:29344573	chr12:29280418~29317848:-
KIRC	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	7.23	1.89e-12	9.3e-10	0.4	0.31	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
KIRC	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	7.23	1.89e-12	9.31e-10	0.28	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
KIRC	cis	rs11096990	0.613	rs12643415	ENSG00000249685.1	RP11-360F5.3	-7.23	1.89e-12	9.31e-10	-0.29	-0.31	Cognitive function;	chr4:39270375	chr4:39133913~39135608:+
KIRC	cis	rs13434995	0.513	rs7698022	ENSG00000273257.1	RP11-177J6.1	7.23	1.89e-12	9.32e-10	0.41	0.31	Adiponectin levels;	chr4:55541180	chr4:55387949~55388271:+
KIRC	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-7.23	1.89e-12	9.32e-10	-0.39	-0.31	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
KIRC	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-7.23	1.9e-12	9.34e-10	-0.36	-0.31	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
KIRC	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-7.23	1.9e-12	9.35e-10	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
KIRC	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	7.23	1.9e-12	9.36e-10	0.32	0.31	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
KIRC	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-7.23	1.9e-12	9.38e-10	-0.24	-0.31	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
KIRC	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	7.22	1.91e-12	9.4e-10	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
KIRC	cis	rs375066	0.71	rs11881193	ENSG00000267058.1	RP11-15A1.3	7.22	1.91e-12	9.41e-10	0.36	0.31	Breast cancer;	chr19:43917364	chr19:43891804~43901805:-
KIRC	cis	rs755249	0.917	rs61781392	ENSG00000182109.6	RP11-69E11.4	7.22	1.91e-12	9.42e-10	0.29	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.917	rs61232586	ENSG00000182109.6	RP11-69E11.4	7.22	1.91e-12	9.42e-10	0.29	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.917	rs61781393	ENSG00000182109.6	RP11-69E11.4	7.22	1.91e-12	9.42e-10	0.29	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39522280~39546187:-
KIRC	cis	rs1552244	0.938	rs67667957	ENSG00000180385.7	EMC3-AS1	7.22	1.91e-12	9.42e-10	0.31	0.31	Alzheimer's disease;	chr3:10125580	chr3:9986893~10006990:+
KIRC	cis	rs13434995	0.513	rs13134079	ENSG00000273257.1	RP11-177J6.1	7.22	1.91e-12	9.43e-10	0.41	0.31	Adiponectin levels;	chr4:55542021	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	7.22	1.92e-12	9.43e-10	0.43	0.31	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
KIRC	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	7.22	1.92e-12	9.44e-10	0.39	0.31	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
KIRC	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-7.22	1.92e-12	9.44e-10	-0.37	-0.31	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-7.22	1.92e-12	9.44e-10	-0.37	-0.31	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
KIRC	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-7.22	1.92e-12	9.44e-10	-0.39	-0.31	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
KIRC	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	7.22	1.92e-12	9.44e-10	0.23	0.31	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
KIRC	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-7.22	1.92e-12	9.45e-10	-0.34	-0.31	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
KIRC	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-7.22	1.92e-12	9.46e-10	-0.41	-0.31	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
KIRC	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-7.22	1.92e-12	9.46e-10	-0.37	-0.31	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
KIRC	cis	rs7592578	0.882	rs7569128	ENSG00000272979.1	RP11-647K16.1	7.22	1.93e-12	9.48e-10	0.45	0.31	Diastolic blood pressure;	chr2:190581965	chr2:190454092~190454521:-
KIRC	cis	rs904251	0.772	rs2776906	ENSG00000227920.2	RP1-153P14.5	-7.22	1.93e-12	9.49e-10	-0.37	-0.31	Cognitive performance;	chr6:37463981	chr6:37545145~37550860:+
KIRC	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	7.22	1.93e-12	9.51e-10	0.27	0.31	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
KIRC	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-7.22	1.93e-12	9.51e-10	-0.31	-0.31	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
KIRC	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	7.22	1.94e-12	9.52e-10	0.25	0.31	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
KIRC	cis	rs17772222	0.675	rs1099698	ENSG00000222990.1	RNU4-22P	-7.22	1.94e-12	9.53e-10	-0.33	-0.31	Coronary artery calcification;	chr14:88414904	chr14:88513498~88513663:+
KIRC	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	7.22	1.95e-12	9.57e-10	0.6	0.31	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	7.22	1.95e-12	9.57e-10	0.6	0.31	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	7.22	1.95e-12	9.57e-10	0.6	0.31	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.584	rs72731224	ENSG00000260947.1	RP11-384P7.7	7.22	1.95e-12	9.57e-10	0.53	0.31	Body mass index;	chr9:34122888	chr9:33697459~33700986:+
KIRC	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	7.22	1.95e-12	9.59e-10	0.34	0.31	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
KIRC	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-7.22	1.96e-12	9.62e-10	-0.42	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
KIRC	cis	rs2562456	0.525	rs62108369	ENSG00000268555.1	RP11-678G14.3	7.22	1.96e-12	9.62e-10	0.47	0.31	Pain;	chr19:21618648	chr19:21570822~21587322:-
KIRC	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	7.22	1.97e-12	9.66e-10	0.6	0.31	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
KIRC	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-7.22	1.97e-12	9.67e-10	-0.45	-0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
KIRC	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-7.22	1.97e-12	9.68e-10	-0.35	-0.31	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
KIRC	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	7.22	1.97e-12	9.68e-10	0.37	0.31	Height;	chr4:55541259	chr4:55387949~55388271:+
KIRC	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	7.22	1.97e-12	9.7e-10	0.49	0.31	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
KIRC	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-7.22	1.97e-12	9.7e-10	-0.37	-0.31	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
KIRC	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-7.22	1.98e-12	9.7e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-7.22	1.98e-12	9.7e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
KIRC	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-7.22	1.98e-12	9.71e-10	-0.38	-0.31	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
KIRC	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-7.22	1.98e-12	9.71e-10	-0.25	-0.31	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
KIRC	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-7.22	1.98e-12	9.72e-10	-0.27	-0.31	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
KIRC	cis	rs3820928	0.874	rs2276593	ENSG00000212391.1	SNORA48	7.22	1.98e-12	9.73e-10	0.36	0.31	Pulmonary function;	chr2:227033718	chr2:226968989~226969122:-
KIRC	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-7.22	1.98e-12	9.74e-10	-0.29	-0.31	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
KIRC	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	7.22	1.99e-12	9.75e-10	0.54	0.31	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
KIRC	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	7.22	1.99e-12	9.75e-10	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
KIRC	cis	rs7592578	0.679	rs62181018	ENSG00000272979.1	RP11-647K16.1	-7.22	1.99e-12	9.75e-10	-0.44	-0.31	Diastolic blood pressure;	chr2:190458569	chr2:190454092~190454521:-
KIRC	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	7.22	1.99e-12	9.78e-10	0.43	0.31	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
KIRC	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	7.22	1.99e-12	9.78e-10	0.75	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
KIRC	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-7.22	2e-12	9.8e-10	-0.35	-0.31	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-7.22	2e-12	9.8e-10	-0.35	-0.31	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
KIRC	cis	rs2797160	0.714	rs1777220	ENSG00000237742.5	RP11-624M8.1	7.22	2e-12	9.82e-10	0.36	0.31	Endometrial cancer;	chr6:125701456	chr6:125578558~125749190:-
KIRC	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	7.22	2e-12	9.83e-10	0.34	0.31	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	7.22	2e-12	9.83e-10	0.34	0.31	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	7.22	2e-12	9.83e-10	0.34	0.31	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	7.22	2e-12	9.83e-10	0.34	0.31	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
KIRC	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-7.22	2e-12	9.83e-10	-0.35	-0.31	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
KIRC	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-7.22	2e-12	9.84e-10	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
KIRC	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-7.22	2.01e-12	9.84e-10	-0.35	-0.31	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
KIRC	cis	rs9322193	0.886	rs4039600	ENSG00000223701.3	RAET1E-AS1	7.22	2.01e-12	9.85e-10	0.39	0.31	Lung cancer;	chr6:149576319	chr6:149884431~149919508:+
KIRC	cis	rs17213965	0.925	rs3898632	ENSG00000207425.1	Y_RNA	-7.22	2.01e-12	9.86e-10	-0.49	-0.31	Waist-hip ratio;	chr16:15789384	chr16:14915457~14915556:-
KIRC	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	7.22	2.01e-12	9.86e-10	0.37	0.31	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
KIRC	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	7.22	2.01e-12	9.87e-10	0.54	0.31	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
KIRC	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	7.22	2.01e-12	9.87e-10	0.29	0.31	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
KIRC	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	7.22	2.02e-12	9.91e-10	0.27	0.31	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
KIRC	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-7.22	2.02e-12	9.91e-10	-0.34	-0.31	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
KIRC	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	7.22	2.02e-12	9.91e-10	0.35	0.31	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
KIRC	cis	rs13434995	0.513	rs62309729	ENSG00000273257.1	RP11-177J6.1	-7.22	2.02e-12	9.92e-10	-0.41	-0.31	Adiponectin levels;	chr4:55536679	chr4:55387949~55388271:+
KIRC	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-7.22	2.03e-12	9.94e-10	-0.18	-0.31	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
KIRC	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	7.22	2.03e-12	9.96e-10	0.33	0.31	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
KIRC	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	7.22	2.03e-12	9.96e-10	0.33	0.31	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
KIRC	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	7.22	2.03e-12	9.97e-10	0.4	0.31	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
KIRC	cis	rs6061231	0.631	rs927133	ENSG00000273619.1	RP5-908M14.9	-7.22	2.04e-12	9.98e-10	-0.24	-0.31	Colorectal cancer;	chr20:62397053	chr20:62386303~62386970:-
KIRC	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-7.21	2.04e-12	1e-09	-0.3	-0.31	QT interval;	chr12:29319943	chr12:29280418~29317848:-
KIRC	cis	rs17772222	0.606	rs449338	ENSG00000222990.1	RNU4-22P	-7.21	2.04e-12	1e-09	-0.33	-0.31	Coronary artery calcification;	chr14:88411690	chr14:88513498~88513663:+
KIRC	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	7.21	2.05e-12	1e-09	0.47	0.31	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	7.21	2.05e-12	1e-09	0.47	0.31	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
KIRC	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-7.21	2.05e-12	1.01e-09	-0.41	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
KIRC	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	7.21	2.05e-12	1.01e-09	0.3	0.31	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
KIRC	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	7.21	2.06e-12	1.01e-09	0.4	0.31	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
KIRC	cis	rs1552244	0.882	rs113268531	ENSG00000180385.7	EMC3-AS1	7.21	2.06e-12	1.01e-09	0.31	0.31	Alzheimer's disease;	chr3:10125385	chr3:9986893~10006990:+
KIRC	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-7.21	2.06e-12	1.01e-09	-0.32	-0.31	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
KIRC	cis	rs3820928	0.874	rs10176882	ENSG00000212391.1	SNORA48	-7.21	2.06e-12	1.01e-09	-0.36	-0.31	Pulmonary function;	chr2:227031716	chr2:226968989~226969122:-
KIRC	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	7.21	2.06e-12	1.01e-09	0.36	0.31	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
KIRC	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-7.21	2.06e-12	1.01e-09	-0.34	-0.31	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
KIRC	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-7.21	2.07e-12	1.01e-09	-0.22	-0.31	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
KIRC	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	7.21	2.07e-12	1.01e-09	0.3	0.31	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
KIRC	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-7.21	2.07e-12	1.01e-09	-0.38	-0.31	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
KIRC	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-7.21	2.08e-12	1.02e-09	-0.22	-0.31	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-7.21	2.08e-12	1.02e-09	-0.22	-0.31	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
KIRC	cis	rs17772222	0.655	rs7160717	ENSG00000222990.1	RNU4-22P	7.21	2.08e-12	1.02e-09	0.33	0.31	Coronary artery calcification;	chr14:88498232	chr14:88513498~88513663:+
KIRC	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	7.21	2.08e-12	1.02e-09	0.21	0.31	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
KIRC	cis	rs1552244	0.81	rs7612908	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10047464	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.935	rs7649243	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10047786	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs7615646	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10048089	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.81	rs6809572	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10058461	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs35198334	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10062869	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.935	rs7652190	ENSG00000180385.7	EMC3-AS1	7.21	2.08e-12	1.02e-09	0.31	0.31	Alzheimer's disease;	chr3:10063466	chr3:9986893~10006990:+
KIRC	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	7.21	2.08e-12	1.02e-09	0.39	0.31	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
KIRC	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	7.21	2.08e-12	1.02e-09	0.42	0.31	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
KIRC	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-7.21	2.08e-12	1.02e-09	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
KIRC	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	7.21	2.08e-12	1.02e-09	0.3	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	7.21	2.08e-12	1.02e-09	0.3	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
KIRC	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-7.21	2.09e-12	1.02e-09	-0.26	-0.31	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
KIRC	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.21	2.09e-12	1.02e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
KIRC	cis	rs13434995	0.589	rs62305201	ENSG00000249700.7	SRD5A3-AS1	-7.21	2.1e-12	1.03e-09	-0.32	-0.31	Adiponectin levels;	chr4:55386778	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.589	rs62305202	ENSG00000249700.7	SRD5A3-AS1	-7.21	2.1e-12	1.03e-09	-0.32	-0.31	Adiponectin levels;	chr4:55386861	chr4:55363971~55395847:-
KIRC	cis	rs17711722	0.523	rs365896	ENSG00000275400.1	RP4-756H11.5	7.21	2.1e-12	1.03e-09	0.31	0.31	Calcium levels;	chr7:66045710	chr7:66553805~66554199:-
KIRC	cis	rs62025270	0.632	rs62022924	ENSG00000202081.1	RNU6-1280P	-7.21	2.11e-12	1.03e-09	-0.39	-0.31	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.576	rs62022925	ENSG00000202081.1	RNU6-1280P	-7.21	2.11e-12	1.03e-09	-0.39	-0.31	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85651522~85651628:-
KIRC	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	7.21	2.11e-12	1.03e-09	0.51	0.31	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
KIRC	cis	rs4819052	0.704	rs2297283	ENSG00000223768.1	LINC00205	-7.21	2.11e-12	1.03e-09	-0.3	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45293285~45297354:+
KIRC	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	7.21	2.11e-12	1.03e-09	0.42	0.31	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
KIRC	cis	rs4072705	1	rs2067791	ENSG00000224020.1	MIR181A2HG	-7.21	2.11e-12	1.03e-09	-0.32	-0.31	Menarche (age at onset);	chr9:124676015	chr9:124658467~124698631:+
KIRC	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	7.21	2.11e-12	1.03e-09	0.43	0.31	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
KIRC	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-7.21	2.11e-12	1.03e-09	-0.34	-0.31	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
KIRC	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	7.21	2.11e-12	1.03e-09	0.63	0.31	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	7.21	2.11e-12	1.03e-09	0.63	0.31	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	7.21	2.11e-12	1.03e-09	0.63	0.31	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
KIRC	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	7.21	2.11e-12	1.03e-09	0.44	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
KIRC	cis	rs13434995	0.536	rs62303712	ENSG00000273257.1	RP11-177J6.1	-7.21	2.12e-12	1.03e-09	-0.41	-0.31	Adiponectin levels;	chr4:55460484	chr4:55387949~55388271:+
KIRC	cis	rs9388451	0.839	rs3966775	ENSG00000237742.5	RP11-624M8.1	-7.21	2.12e-12	1.04e-09	-0.38	-0.31	Brugada syndrome;	chr6:125746509	chr6:125578558~125749190:-
KIRC	cis	rs6908034	0.607	rs112599867	ENSG00000228412.5	RP4-625H18.2	7.21	2.12e-12	1.04e-09	0.68	0.31	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs73376651	ENSG00000228412.5	RP4-625H18.2	7.21	2.12e-12	1.04e-09	0.68	0.31	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs73376655	ENSG00000228412.5	RP4-625H18.2	7.21	2.12e-12	1.04e-09	0.68	0.31	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19802164~19804752:-
KIRC	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-7.21	2.13e-12	1.04e-09	-0.3	-0.31	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
KIRC	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-7.21	2.13e-12	1.04e-09	-0.3	-0.31	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
KIRC	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-7.21	2.13e-12	1.04e-09	-0.3	-0.31	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
KIRC	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	7.21	2.13e-12	1.04e-09	0.29	0.31	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
KIRC	cis	rs11647589	0.784	rs1910803	ENSG00000262995.1	CTD-2194A8.2	-7.21	2.13e-12	1.04e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20464412	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.636	rs7186805	ENSG00000262995.1	CTD-2194A8.2	-7.21	2.13e-12	1.04e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20465841	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.636	rs7186307	ENSG00000262995.1	CTD-2194A8.2	-7.21	2.13e-12	1.04e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20465843	chr16:20440266~20447000:-
KIRC	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-7.21	2.13e-12	1.04e-09	-0.35	-0.31	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-7.21	2.13e-12	1.04e-09	-0.35	-0.31	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-7.21	2.13e-12	1.04e-09	-0.35	-0.31	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-7.21	2.13e-12	1.04e-09	-0.35	-0.31	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
KIRC	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	7.21	2.13e-12	1.04e-09	0.23	0.31	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
KIRC	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	7.21	2.14e-12	1.05e-09	0.45	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
KIRC	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	7.21	2.14e-12	1.05e-09	0.32	0.31	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
KIRC	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	7.21	2.14e-12	1.05e-09	0.43	0.31	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
KIRC	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	7.21	2.15e-12	1.05e-09	0.32	0.31	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
KIRC	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	7.21	2.15e-12	1.05e-09	0.45	0.31	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	7.21	2.15e-12	1.05e-09	0.45	0.31	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
KIRC	cis	rs7182621	0.509	rs12917012	ENSG00000182397.13	DNM1P46	7.21	2.15e-12	1.05e-09	0.32	0.31	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99790156~99806927:-
KIRC	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-7.21	2.15e-12	1.05e-09	-0.38	-0.31	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
KIRC	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	7.21	2.16e-12	1.05e-09	0.24	0.31	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
KIRC	cis	rs13434995	0.536	rs62303712	ENSG00000249700.7	SRD5A3-AS1	-7.21	2.16e-12	1.06e-09	-0.31	-0.31	Adiponectin levels;	chr4:55460484	chr4:55363971~55395847:-
KIRC	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	7.21	2.16e-12	1.06e-09	0.36	0.31	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
KIRC	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-7.21	2.16e-12	1.06e-09	-0.41	-0.31	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
KIRC	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-7.21	2.17e-12	1.06e-09	-0.34	-0.31	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-7.21	2.17e-12	1.06e-09	-0.34	-0.31	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-7.21	2.17e-12	1.06e-09	-0.34	-0.31	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
KIRC	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	7.21	2.17e-12	1.06e-09	0.37	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
KIRC	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	7.21	2.17e-12	1.06e-09	0.28	0.31	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
KIRC	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-7.21	2.17e-12	1.06e-09	-0.4	-0.31	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
KIRC	cis	rs1560104	0.675	rs8063669	ENSG00000274834.1	CTD-3037G24.5	-7.21	2.17e-12	1.06e-09	-0.35	-0.31	Obesity-related traits;	chr16:12603379	chr16:12614451~12614852:+
KIRC	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	7.21	2.17e-12	1.06e-09	0.41	0.31	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
KIRC	cis	rs13434995	0.513	rs2101476	ENSG00000249700.7	SRD5A3-AS1	-7.21	2.18e-12	1.06e-09	-0.32	-0.31	Adiponectin levels;	chr4:55578961	chr4:55363971~55395847:-
KIRC	cis	rs17772222	0.63	rs816069	ENSG00000222990.1	RNU4-22P	-7.2	2.18e-12	1.06e-09	-0.33	-0.31	Coronary artery calcification;	chr14:88500992	chr14:88513498~88513663:+
KIRC	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-7.2	2.18e-12	1.06e-09	-0.39	-0.31	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
KIRC	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	7.2	2.19e-12	1.07e-09	0.29	0.31	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
KIRC	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	7.2	2.19e-12	1.07e-09	0.41	0.31	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
KIRC	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	7.2	2.19e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
KIRC	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	7.2	2.19e-12	1.07e-09	0.34	0.31	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
KIRC	cis	rs8048589	1	rs9925009	ENSG00000175604.2	RP11-276H1.3	-7.2	2.19e-12	1.07e-09	-0.36	-0.31	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092495	chr16:12086746~12090302:-
KIRC	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	7.2	2.19e-12	1.07e-09	0.39	0.31	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
KIRC	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	7.2	2.2e-12	1.07e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
KIRC	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-7.2	2.2e-12	1.07e-09	-0.3	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
KIRC	cis	rs3745672	1	rs113790048	ENSG00000219665.7	CTD-2006C1.2	-7.2	2.2e-12	1.07e-09	-0.59	-0.31	Multiple sclerosis;	chr19:12013180	chr19:11987617~12046275:+
KIRC	cis	rs3745672	0.661	rs111970048	ENSG00000219665.7	CTD-2006C1.2	-7.2	2.2e-12	1.07e-09	-0.59	-0.31	Multiple sclerosis;	chr19:12013192	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs10420683	ENSG00000219665.7	CTD-2006C1.2	-7.2	2.2e-12	1.07e-09	-0.59	-0.31	Multiple sclerosis;	chr19:12022954	chr19:11987617~12046275:+
KIRC	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	7.2	2.2e-12	1.07e-09	0.38	0.31	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
KIRC	cis	rs7017914	0.905	rs2639956	ENSG00000254031.4	RP11-326E22.1	7.2	2.21e-12	1.08e-09	0.33	0.31	Bone mineral density;	chr8:71011856	chr8:71155457~71204223:+
KIRC	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	7.2	2.21e-12	1.08e-09	0.32	0.31	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
KIRC	cis	rs6061231	0.631	rs2427317	ENSG00000273619.1	RP5-908M14.9	-7.2	2.21e-12	1.08e-09	-0.23	-0.31	Colorectal cancer;	chr20:62400669	chr20:62386303~62386970:-
KIRC	cis	rs10129255	0.576	rs2157616	ENSG00000211970.3	IGHV4-61	-7.2	2.22e-12	1.08e-09	-0.24	-0.31	Kawasaki disease;	chr14:106767802	chr14:106639119~106639657:-
KIRC	cis	rs10214930	0.624	rs6949496	ENSG00000235574.1	AC073150.6	-7.2	2.22e-12	1.08e-09	-0.37	-0.31	Hypospadias;	chr7:27520075	chr7:27491682~27492765:-
KIRC	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-7.2	2.22e-12	1.08e-09	-0.36	-0.31	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
KIRC	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	7.2	2.22e-12	1.08e-09	0.29	0.31	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
KIRC	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	7.2	2.23e-12	1.09e-09	0.41	0.31	Depression;	chr6:28199145	chr6:28115628~28116551:+
KIRC	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-7.2	2.23e-12	1.09e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-7.2	2.23e-12	1.09e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-7.2	2.23e-12	1.09e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-7.2	2.23e-12	1.09e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-7.2	2.23e-12	1.09e-09	-0.22	-0.31	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
KIRC	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	7.2	2.23e-12	1.09e-09	0.38	0.31	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
KIRC	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-7.2	2.24e-12	1.09e-09	-0.4	-0.31	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
KIRC	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	7.2	2.24e-12	1.09e-09	0.47	0.31	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
KIRC	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-7.2	2.24e-12	1.09e-09	-0.32	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
KIRC	cis	rs10214930	0.697	rs10951171	ENSG00000235574.1	AC073150.6	-7.2	2.24e-12	1.09e-09	-0.36	-0.31	Hypospadias;	chr7:27571988	chr7:27491682~27492765:-
KIRC	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-7.2	2.24e-12	1.09e-09	-0.34	-0.31	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
KIRC	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	7.2	2.25e-12	1.09e-09	0.38	0.31	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
KIRC	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	7.2	2.25e-12	1.1e-09	0.39	0.31	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
KIRC	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-7.2	2.25e-12	1.1e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-7.2	2.25e-12	1.1e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-7.2	2.25e-12	1.1e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-7.2	2.25e-12	1.1e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-7.2	2.25e-12	1.1e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
KIRC	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	7.2	2.26e-12	1.1e-09	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
KIRC	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	7.2	2.26e-12	1.1e-09	0.25	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
KIRC	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-7.2	2.26e-12	1.1e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
KIRC	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-7.2	2.27e-12	1.1e-09	-0.39	-0.31	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
KIRC	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-7.2	2.27e-12	1.1e-09	-0.39	-0.31	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	7.2	2.27e-12	1.1e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
KIRC	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.27e-12	1.1e-09	-0.32	-0.31	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
KIRC	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	7.2	2.28e-12	1.11e-09	0.34	0.31	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
KIRC	cis	rs3760982	1	rs12460161	ENSG00000267058.1	RP11-15A1.3	-7.2	2.28e-12	1.11e-09	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789834	chr19:43891804~43901805:-
KIRC	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	7.2	2.28e-12	1.11e-09	0.23	0.31	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
KIRC	cis	rs10214930	0.697	rs4719898	ENSG00000235574.1	AC073150.6	-7.2	2.28e-12	1.11e-09	-0.37	-0.31	Hypospadias;	chr7:27524042	chr7:27491682~27492765:-
KIRC	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	7.2	2.28e-12	1.11e-09	0.37	0.31	Height;	chr4:55545574	chr4:55387949~55388271:+
KIRC	cis	rs6496044	0.963	rs6496050	ENSG00000202081.1	RNU6-1280P	7.2	2.28e-12	1.11e-09	0.33	0.31	Interstitial lung disease;	chr15:85526019	chr15:85651522~85651628:-
KIRC	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-7.2	2.28e-12	1.11e-09	-0.37	-0.31	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
KIRC	cis	rs11089937	0.667	rs5757081	ENSG00000211638.2	IGLV8-61	-7.2	2.28e-12	1.11e-09	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22146272	chr22:22098700~22099212:+
KIRC	cis	rs755249	0.917	rs61779331	ENSG00000237624.1	OXCT2P1	7.2	2.29e-12	1.11e-09	0.45	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39514956~39516490:+
KIRC	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-7.2	2.29e-12	1.11e-09	-0.24	-0.31	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
KIRC	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-7.2	2.29e-12	1.11e-09	-0.33	-0.31	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
KIRC	cis	rs13434995	0.513	rs62303711	ENSG00000249700.7	SRD5A3-AS1	-7.2	2.3e-12	1.12e-09	-0.31	-0.31	Adiponectin levels;	chr4:55458325	chr4:55363971~55395847:-
KIRC	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	7.2	2.3e-12	1.12e-09	0.43	0.31	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
KIRC	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	7.2	2.3e-12	1.12e-09	0.37	0.31	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
KIRC	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	7.2	2.3e-12	1.12e-09	0.29	0.31	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
KIRC	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	7.2	2.31e-12	1.12e-09	0.32	0.31	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
KIRC	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-7.2	2.31e-12	1.12e-09	-0.32	-0.31	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
KIRC	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	7.2	2.31e-12	1.12e-09	0.44	0.31	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
KIRC	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	7.2	2.31e-12	1.12e-09	0.38	0.31	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
KIRC	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	7.2	2.31e-12	1.12e-09	0.38	0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
KIRC	cis	rs17772222	0.682	rs4904452	ENSG00000222990.1	RNU4-22P	-7.2	2.32e-12	1.12e-09	-0.33	-0.31	Coronary artery calcification;	chr14:88517329	chr14:88513498~88513663:+
KIRC	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-7.2	2.32e-12	1.13e-09	-0.18	-0.31	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
KIRC	cis	rs3760982	1	rs4802200	ENSG00000267058.1	RP11-15A1.3	-7.2	2.32e-12	1.13e-09	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785366	chr19:43891804~43901805:-
KIRC	cis	rs10971721	0.822	rs56160720	ENSG00000260947.1	RP11-384P7.7	7.19	2.33e-12	1.13e-09	0.6	0.31	Body mass index;	chr9:33899827	chr9:33697459~33700986:+
KIRC	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-7.19	2.33e-12	1.13e-09	-0.38	-0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
KIRC	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-7.19	2.33e-12	1.13e-09	-0.48	-0.31	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-7.19	2.33e-12	1.13e-09	-0.48	-0.31	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-7.19	2.33e-12	1.13e-09	-0.48	-0.31	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
KIRC	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-7.19	2.33e-12	1.13e-09	-0.29	-0.31	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
KIRC	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	7.19	2.33e-12	1.13e-09	0.48	0.31	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
KIRC	cis	rs13434995	0.513	rs41324951	ENSG00000273257.1	RP11-177J6.1	7.19	2.34e-12	1.13e-09	0.41	0.31	Adiponectin levels;	chr4:55422576	chr4:55387949~55388271:+
KIRC	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-7.19	2.34e-12	1.13e-09	-0.33	-0.31	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
KIRC	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	7.19	2.34e-12	1.13e-09	0.26	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
KIRC	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-7.19	2.34e-12	1.13e-09	-0.29	-0.31	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-7.19	2.34e-12	1.13e-09	-0.29	-0.31	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-7.19	2.34e-12	1.13e-09	-0.29	-0.31	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	7.19	2.34e-12	1.14e-09	0.3	0.31	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	7.19	2.34e-12	1.14e-09	0.3	0.31	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
KIRC	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	7.19	2.34e-12	1.14e-09	0.49	0.31	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	7.19	2.34e-12	1.14e-09	0.49	0.31	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
KIRC	cis	rs17711722	0.565	rs4717276	ENSG00000275400.1	RP4-756H11.5	-7.19	2.34e-12	1.14e-09	-0.31	-0.31	Calcium levels;	chr7:65829754	chr7:66553805~66554199:-
KIRC	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	7.19	2.35e-12	1.14e-09	0.34	0.31	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
KIRC	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-7.19	2.35e-12	1.14e-09	-0.4	-0.31	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
KIRC	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-7.19	2.35e-12	1.14e-09	-0.24	-0.31	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
KIRC	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	7.19	2.36e-12	1.14e-09	0.38	0.31	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	7.19	2.36e-12	1.14e-09	0.38	0.31	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
KIRC	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-7.19	2.37e-12	1.15e-09	-0.26	-0.31	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
KIRC	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	7.19	2.37e-12	1.15e-09	0.3	0.31	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
KIRC	cis	rs13434995	0.513	rs62310862	ENSG00000249700.7	SRD5A3-AS1	-7.19	2.37e-12	1.15e-09	-0.31	-0.31	Adiponectin levels;	chr4:55572594	chr4:55363971~55395847:-
KIRC	cis	rs9388451	0.869	rs7764016	ENSG00000237742.5	RP11-624M8.1	-7.19	2.37e-12	1.15e-09	-0.37	-0.31	Brugada syndrome;	chr6:125749643	chr6:125578558~125749190:-
KIRC	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-7.19	2.37e-12	1.15e-09	-0.29	-0.31	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
KIRC	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	7.19	2.37e-12	1.15e-09	0.43	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
KIRC	cis	rs3760982	0.813	rs10426528	ENSG00000267058.1	RP11-15A1.3	-7.19	2.38e-12	1.15e-09	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43795146	chr19:43891804~43901805:-
KIRC	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	7.19	2.38e-12	1.15e-09	0.29	0.31	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	7.19	2.38e-12	1.15e-09	0.29	0.31	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
KIRC	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	7.19	2.38e-12	1.15e-09	0.41	0.31	Height;	chr6:109422189	chr6:109382795~109383666:+
KIRC	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-7.19	2.38e-12	1.16e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
KIRC	cis	rs9388451	0.839	rs980014	ENSG00000237742.5	RP11-624M8.1	-7.19	2.38e-12	1.16e-09	-0.38	-0.31	Brugada syndrome;	chr6:125746855	chr6:125578558~125749190:-
KIRC	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	7.19	2.39e-12	1.16e-09	0.27	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
KIRC	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-7.19	2.39e-12	1.16e-09	-0.24	-0.31	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
KIRC	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-7.19	2.4e-12	1.16e-09	-0.44	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
KIRC	cis	rs13434995	0.513	rs1048004	ENSG00000249700.7	SRD5A3-AS1	-7.19	2.4e-12	1.16e-09	-0.31	-0.31	Adiponectin levels;	chr4:55434042	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs1801260	ENSG00000249700.7	SRD5A3-AS1	-7.19	2.4e-12	1.16e-09	-0.31	-0.31	Adiponectin levels;	chr4:55435202	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs17721215	ENSG00000249700.7	SRD5A3-AS1	-7.19	2.4e-12	1.16e-09	-0.31	-0.31	Adiponectin levels;	chr4:55437620	chr4:55363971~55395847:-
KIRC	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-7.19	2.4e-12	1.16e-09	-0.37	-0.31	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
KIRC	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-7.19	2.4e-12	1.16e-09	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-7.19	2.4e-12	1.16e-09	-0.57	-0.31	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
KIRC	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-7.19	2.41e-12	1.17e-09	-0.26	-0.31	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
KIRC	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-7.19	2.41e-12	1.17e-09	-0.26	-0.31	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
KIRC	cis	rs1552244	0.938	rs34750074	ENSG00000180385.7	EMC3-AS1	7.19	2.42e-12	1.17e-09	0.31	0.31	Alzheimer's disease;	chr3:10050056	chr3:9986893~10006990:+
KIRC	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-7.19	2.42e-12	1.17e-09	-0.41	-0.31	Depression;	chr6:28193021	chr6:28115628~28116551:+
KIRC	cis	rs9388451	0.839	rs3757217	ENSG00000237742.5	RP11-624M8.1	-7.19	2.42e-12	1.17e-09	-0.37	-0.31	Brugada syndrome;	chr6:125748490	chr6:125578558~125749190:-
KIRC	cis	rs11148252	0.904	rs7990581	ENSG00000278238.1	RP11-245D16.4	-7.19	2.42e-12	1.17e-09	-0.34	-0.31	Lewy body disease;	chr13:52445298	chr13:52454775~52455331:-
KIRC	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-7.19	2.42e-12	1.17e-09	-0.42	-0.31	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
KIRC	cis	rs1560104	0.5	rs11075127	ENSG00000274834.1	CTD-3037G24.5	7.19	2.42e-12	1.17e-09	0.34	0.31	Obesity-related traits;	chr16:12620700	chr16:12614451~12614852:+
KIRC	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-7.19	2.43e-12	1.18e-09	-0.38	-0.31	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
KIRC	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-7.19	2.43e-12	1.18e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-7.19	2.43e-12	1.18e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
KIRC	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-7.19	2.43e-12	1.18e-09	-0.35	-0.31	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-7.19	2.43e-12	1.18e-09	-0.35	-0.31	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-7.19	2.43e-12	1.18e-09	-0.35	-0.31	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
KIRC	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	7.19	2.43e-12	1.18e-09	0.29	0.31	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	7.19	2.43e-12	1.18e-09	0.29	0.31	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
KIRC	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	7.19	2.44e-12	1.18e-09	0.43	0.31	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
KIRC	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-7.19	2.44e-12	1.18e-09	-0.42	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
KIRC	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	7.19	2.44e-12	1.18e-09	0.57	0.31	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
KIRC	cis	rs10214930	0.697	rs10951169	ENSG00000235574.1	AC073150.6	7.19	2.44e-12	1.18e-09	0.36	0.31	Hypospadias;	chr7:27516295	chr7:27491682~27492765:-
KIRC	cis	rs11512640	1	rs11512640	ENSG00000254671.2	STT3A-AS1	-7.19	2.45e-12	1.18e-09	-0.65	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125556427	chr11:125570284~125592568:-
KIRC	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	7.19	2.45e-12	1.18e-09	0.54	0.31	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
KIRC	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	7.19	2.45e-12	1.19e-09	0.37	0.31	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
KIRC	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-7.19	2.45e-12	1.19e-09	-0.39	-0.31	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
KIRC	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	7.19	2.46e-12	1.19e-09	0.38	0.31	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
KIRC	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-7.19	2.46e-12	1.19e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
KIRC	cis	rs12500482	0.5	rs6842928	ENSG00000206113.6	RP11-503N18.1	7.19	2.47e-12	1.19e-09	0.38	0.31	Cognitive function;	chr4:2427340	chr4:2418974~2450360:+
KIRC	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	7.19	2.47e-12	1.19e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
KIRC	cis	rs11647589	0.834	rs1394677	ENSG00000262995.1	CTD-2194A8.2	-7.19	2.47e-12	1.19e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20478195	chr16:20440266~20447000:-
KIRC	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	7.19	2.47e-12	1.19e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	7.19	2.47e-12	1.19e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
KIRC	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-7.19	2.47e-12	1.2e-09	-0.58	-0.31	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
KIRC	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	7.19	2.48e-12	1.2e-09	0.28	0.31	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
KIRC	cis	rs12999373	0.501	rs2867134	ENSG00000223751.1	AC116609.2	-7.19	2.48e-12	1.2e-09	-0.39	-0.31	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:742488~747767:+
KIRC	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	7.19	2.49e-12	1.2e-09	0.59	0.31	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
KIRC	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-7.19	2.49e-12	1.2e-09	-0.35	-0.31	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-7.19	2.49e-12	1.2e-09	-0.35	-0.31	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
KIRC	cis	rs2288884	1	rs17779301	ENSG00000275055.1	CTC-471J1.11	7.18	2.49e-12	1.2e-09	0.42	0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52049007~52049754:+
KIRC	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	7.18	2.49e-12	1.2e-09	0.4	0.31	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
KIRC	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	7.18	2.49e-12	1.2e-09	0.47	0.31	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
KIRC	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-7.18	2.5e-12	1.21e-09	-0.24	-0.31	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
KIRC	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-7.18	2.5e-12	1.21e-09	-0.35	-0.31	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
KIRC	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	7.18	2.5e-12	1.21e-09	0.4	0.31	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
KIRC	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	7.18	2.5e-12	1.21e-09	0.27	0.31	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
KIRC	cis	rs62025270	0.632	rs17636096	ENSG00000202081.1	RNU6-1280P	-7.18	2.52e-12	1.21e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85651522~85651628:-
KIRC	cis	rs7250849	0.565	rs73052859	ENSG00000273837.1	LLNLR-470E3.1	-7.18	2.52e-12	1.21e-09	-0.47	-0.31	Blood protein levels;	chr19:51661210	chr19:51639478~51639931:-
KIRC	cis	rs7250849	0.565	rs73052861	ENSG00000273837.1	LLNLR-470E3.1	-7.18	2.52e-12	1.21e-09	-0.47	-0.31	Blood protein levels;	chr19:51661217	chr19:51639478~51639931:-
KIRC	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-7.18	2.52e-12	1.22e-09	-0.34	-0.31	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
KIRC	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	7.18	2.52e-12	1.22e-09	0.27	0.31	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
KIRC	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	7.18	2.52e-12	1.22e-09	0.44	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
KIRC	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	7.18	2.52e-12	1.22e-09	0.52	0.31	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
KIRC	cis	rs11148252	0.904	rs9568732	ENSG00000278238.1	RP11-245D16.4	7.18	2.52e-12	1.22e-09	0.34	0.31	Lewy body disease;	chr13:52419277	chr13:52454775~52455331:-
KIRC	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-7.18	2.53e-12	1.22e-09	-0.35	-0.31	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
KIRC	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	7.18	2.53e-12	1.22e-09	0.3	0.31	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
KIRC	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	7.18	2.54e-12	1.22e-09	0.39	0.31	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	7.18	2.54e-12	1.22e-09	0.39	0.31	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
KIRC	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	7.18	2.54e-12	1.22e-09	0.39	0.31	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
KIRC	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.18	2.54e-12	1.22e-09	0.41	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
KIRC	cis	rs1560104	0.536	rs11075131	ENSG00000274834.1	CTD-3037G24.5	7.18	2.54e-12	1.22e-09	0.34	0.31	Obesity-related traits;	chr16:12623130	chr16:12614451~12614852:+
KIRC	cis	rs1431005	0.964	rs79181778	ENSG00000250620.1	RP11-91J3.3	7.18	2.55e-12	1.23e-09	0.4	0.31	Response to statin therapy;	chr4:187425756	chr4:187413564~187415697:+
KIRC	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.18	2.55e-12	1.23e-09	-0.35	-0.31	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	7.18	2.55e-12	1.23e-09	0.38	0.31	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
KIRC	cis	rs1552244	0.882	rs3846168	ENSG00000180385.7	EMC3-AS1	7.18	2.56e-12	1.23e-09	0.29	0.31	Alzheimer's disease;	chr3:9955241	chr3:9986893~10006990:+
KIRC	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	7.18	2.56e-12	1.24e-09	0.43	0.31	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
KIRC	cis	rs11085466	0.51	rs8108399	ENSG00000268555.1	RP11-678G14.3	7.18	2.57e-12	1.24e-09	0.39	0.31	Colorectal or endometrial cancer;	chr19:21618479	chr19:21570822~21587322:-
KIRC	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	7.18	2.57e-12	1.24e-09	0.32	0.31	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
KIRC	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	7.18	2.57e-12	1.24e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
KIRC	cis	rs62025270	0.632	rs16943251	ENSG00000202081.1	RNU6-1280P	-7.18	2.57e-12	1.24e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85651522~85651628:-
KIRC	cis	rs2288884	1	rs2288884	ENSG00000275055.1	CTC-471J1.11	-7.18	2.58e-12	1.24e-09	-0.42	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52049007~52049754:+
KIRC	cis	rs755249	0.833	rs61779313	ENSG00000237624.1	OXCT2P1	7.18	2.58e-12	1.24e-09	0.44	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39514956~39516490:+
KIRC	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	7.18	2.58e-12	1.24e-09	0.37	0.31	Height;	chr4:55476159	chr4:55387949~55388271:+
KIRC	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	7.18	2.58e-12	1.24e-09	0.36	0.31	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
KIRC	cis	rs9438901	0.592	rs1293259	ENSG00000224183.1	SDHDP6	7.18	2.58e-12	1.24e-09	0.61	0.31	Red cell distribution width;	chr1:25369344	chr1:25294164~25294643:-
KIRC	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	7.18	2.58e-12	1.24e-09	0.53	0.31	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
KIRC	cis	rs3760982	0.813	rs8111664	ENSG00000267058.1	RP11-15A1.3	7.18	2.59e-12	1.25e-09	0.36	0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790940	chr19:43891804~43901805:-
KIRC	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	7.18	2.59e-12	1.25e-09	0.28	0.31	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	7.18	2.59e-12	1.25e-09	0.28	0.31	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	7.18	2.59e-12	1.25e-09	0.28	0.31	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
KIRC	cis	rs11647589	0.906	rs6416611	ENSG00000262995.1	CTD-2194A8.2	-7.18	2.59e-12	1.25e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20459768	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.815	rs11646536	ENSG00000262995.1	CTD-2194A8.2	-7.18	2.59e-12	1.25e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20462274	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.723	rs9937581	ENSG00000262995.1	CTD-2194A8.2	-7.18	2.59e-12	1.25e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20462581	chr16:20440266~20447000:-
KIRC	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	7.18	2.59e-12	1.25e-09	0.36	0.31	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
KIRC	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-7.18	2.6e-12	1.25e-09	-0.24	-0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
KIRC	cis	rs2288884	0.943	rs11084131	ENSG00000275055.1	CTC-471J1.11	-7.18	2.6e-12	1.25e-09	-0.43	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.943	rs11084132	ENSG00000275055.1	CTC-471J1.11	-7.18	2.6e-12	1.25e-09	-0.43	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52049007~52049754:+
KIRC	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	7.18	2.6e-12	1.25e-09	0.36	0.31	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
KIRC	cis	rs4072705	1	rs10760373	ENSG00000224020.1	MIR181A2HG	-7.18	2.6e-12	1.25e-09	-0.3	-0.31	Menarche (age at onset);	chr9:124723166	chr9:124658467~124698631:+
KIRC	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	7.18	2.6e-12	1.25e-09	0.28	0.31	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
KIRC	cis	rs4820539	1	rs916584	ENSG00000221069.1	AC000029.1	-7.18	2.61e-12	1.26e-09	-0.37	-0.31	Bone mineral density;	chr22:23127246	chr22:23136620~23136710:+
KIRC	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	7.18	2.61e-12	1.26e-09	0.34	0.31	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
KIRC	cis	rs904251	0.772	rs1812186	ENSG00000227920.2	RP1-153P14.5	-7.18	2.61e-12	1.26e-09	-0.37	-0.31	Cognitive performance;	chr6:37498140	chr6:37545145~37550860:+
KIRC	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	7.18	2.62e-12	1.26e-09	0.28	0.31	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
KIRC	cis	rs13434995	0.513	rs73236153	ENSG00000249700.7	SRD5A3-AS1	-7.18	2.62e-12	1.26e-09	-0.31	-0.31	Adiponectin levels;	chr4:55585600	chr4:55363971~55395847:-
KIRC	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	7.18	2.63e-12	1.26e-09	0.37	0.31	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
KIRC	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-7.18	2.63e-12	1.26e-09	-0.26	-0.31	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
KIRC	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-7.18	2.63e-12	1.27e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
KIRC	cis	rs375092	0.543	rs449271	ENSG00000230658.1	KLHL7-AS1	7.18	2.63e-12	1.27e-09	0.52	0.31	Personality dimensions;	chr7:23376798	chr7:23101228~23105703:-
KIRC	cis	rs3760982	1	rs10405457	ENSG00000267058.1	RP11-15A1.3	-7.18	2.64e-12	1.27e-09	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43792430	chr19:43891804~43901805:-
KIRC	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	7.18	2.64e-12	1.27e-09	0.44	0.31	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
KIRC	cis	rs10971721	0.643	rs10971701	ENSG00000281128.1	PTENP1-AS	7.18	2.64e-12	1.27e-09	0.68	0.31	Body mass index;	chr9:33781900	chr9:33677268~33688011:+
KIRC	cis	rs10971721	0.643	rs10971702	ENSG00000281128.1	PTENP1-AS	7.18	2.64e-12	1.27e-09	0.68	0.31	Body mass index;	chr9:33784104	chr9:33677268~33688011:+
KIRC	cis	rs10971721	0.643	rs12375483	ENSG00000281128.1	PTENP1-AS	7.18	2.64e-12	1.27e-09	0.68	0.31	Body mass index;	chr9:33784910	chr9:33677268~33688011:+
KIRC	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	7.18	2.64e-12	1.27e-09	0.28	0.31	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000251284.2	RP13-644M16.1	-7.18	2.64e-12	1.27e-09	-0.37	-0.31	Obesity-related traits;	chr4:69079704	chr4:69125274~69126451:+
KIRC	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	7.18	2.65e-12	1.27e-09	0.33	0.31	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
KIRC	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	7.18	2.65e-12	1.27e-09	0.44	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
KIRC	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-7.18	2.65e-12	1.28e-09	-0.35	-0.31	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-7.18	2.65e-12	1.28e-09	-0.35	-0.31	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
KIRC	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-7.17	2.66e-12	1.28e-09	-0.48	-0.31	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
KIRC	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-7.17	2.66e-12	1.28e-09	-0.24	-0.31	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
KIRC	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-7.17	2.66e-12	1.28e-09	-0.3	-0.31	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
KIRC	cis	rs11647589	0.834	rs9933872	ENSG00000262995.1	CTD-2194A8.2	-7.17	2.67e-12	1.28e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20473849	chr16:20440266~20447000:-
KIRC	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	7.17	2.68e-12	1.29e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
KIRC	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-7.17	2.68e-12	1.29e-09	-0.37	-0.31	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
KIRC	cis	rs3760982	1	rs11665924	ENSG00000267058.1	RP11-15A1.3	-7.17	2.68e-12	1.29e-09	-0.35	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782830	chr19:43891804~43901805:-
KIRC	cis	rs3760982	0.845	rs62116962	ENSG00000267058.1	RP11-15A1.3	7.17	2.68e-12	1.29e-09	0.35	0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43783082	chr19:43891804~43901805:-
KIRC	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	7.17	2.68e-12	1.29e-09	0.46	0.31	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
KIRC	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.17	2.68e-12	1.29e-09	0.41	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
KIRC	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-7.17	2.69e-12	1.29e-09	-0.34	-0.31	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
KIRC	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	7.17	2.69e-12	1.29e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	7.17	2.69e-12	1.29e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
KIRC	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-7.17	2.7e-12	1.3e-09	-0.48	-0.31	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
KIRC	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	7.17	2.7e-12	1.3e-09	0.36	0.31	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
KIRC	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-7.17	2.7e-12	1.3e-09	-0.47	-0.31	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
KIRC	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-7.17	2.7e-12	1.3e-09	-0.34	-0.31	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
KIRC	cis	rs11148252	0.904	rs9526927	ENSG00000278238.1	RP11-245D16.4	-7.17	2.71e-12	1.3e-09	-0.34	-0.31	Lewy body disease;	chr13:52477492	chr13:52454775~52455331:-
KIRC	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	7.17	2.71e-12	1.3e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
KIRC	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-7.17	2.71e-12	1.3e-09	-0.27	-0.31	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
KIRC	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	7.17	2.71e-12	1.3e-09	0.37	0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
KIRC	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-7.17	2.71e-12	1.3e-09	-0.38	-0.31	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
KIRC	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	7.17	2.72e-12	1.31e-09	0.5	0.31	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
KIRC	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	7.17	2.72e-12	1.31e-09	0.42	0.31	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
KIRC	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	7.17	2.73e-12	1.31e-09	0.37	0.31	Height;	chr11:118852670	chr11:118688039~118690600:-
KIRC	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	7.17	2.73e-12	1.31e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	7.17	2.73e-12	1.31e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
KIRC	cis	rs2361718	0.501	rs11869566	ENSG00000279259.1	RP11-334C17.3	7.17	2.73e-12	1.31e-09	0.32	0.31	Yeast infection;	chr17:80169449	chr17:80147250~80148596:+
KIRC	cis	rs4072705	0.935	rs2184219	ENSG00000224020.1	MIR181A2HG	-7.17	2.73e-12	1.31e-09	-0.31	-0.31	Menarche (age at onset);	chr9:124770625	chr9:124658467~124698631:+
KIRC	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	7.17	2.74e-12	1.32e-09	0.48	0.31	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
KIRC	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	7.17	2.75e-12	1.32e-09	0.38	0.31	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
KIRC	cis	rs1552244	0.935	rs41520445	ENSG00000180385.7	EMC3-AS1	-7.17	2.75e-12	1.32e-09	-0.3	-0.31	Alzheimer's disease;	chr3:10111457	chr3:9986893~10006990:+
KIRC	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-7.17	2.76e-12	1.32e-09	-0.35	-0.31	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
KIRC	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-7.17	2.76e-12	1.32e-09	-0.17	-0.31	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-7.17	2.76e-12	1.32e-09	-0.17	-0.31	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
KIRC	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	7.17	2.76e-12	1.32e-09	0.4	0.31	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
KIRC	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	7.17	2.76e-12	1.32e-09	0.4	0.31	Height;	chr6:109415411	chr6:109382795~109383666:+
KIRC	cis	rs61776719	0.747	rs28428561	ENSG00000212541.1	RNU6-510P	7.17	2.76e-12	1.33e-09	0.28	0.31	Coronary artery disease;	chr1:37968634	chr1:37991462~37991569:+
KIRC	cis	rs11647589	0.798	rs9923280	ENSG00000262995.1	CTD-2194A8.2	-7.17	2.76e-12	1.33e-09	-0.33	-0.31	Blood metabolite levels;	chr16:20465155	chr16:20440266~20447000:-
KIRC	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-7.17	2.77e-12	1.33e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
KIRC	cis	rs62025270	0.632	rs8029034	ENSG00000202081.1	RNU6-1280P	-7.17	2.77e-12	1.33e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85651522~85651628:-
KIRC	cis	rs919433	0.75	rs788012	ENSG00000231621.1	AC013264.2	-7.17	2.77e-12	1.33e-09	-0.33	-0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197365132	chr2:197197991~197199273:+
KIRC	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-7.17	2.77e-12	1.33e-09	-0.34	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
KIRC	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	7.17	2.77e-12	1.33e-09	0.23	0.31	Monocyte count;	chr11:307036	chr11:310139~311141:-
KIRC	cis	rs13434995	0.513	rs12509047	ENSG00000273257.1	RP11-177J6.1	7.17	2.77e-12	1.33e-09	0.41	0.31	Adiponectin levels;	chr4:55545245	chr4:55387949~55388271:+
KIRC	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-7.17	2.78e-12	1.33e-09	-0.27	-0.31	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
KIRC	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-7.17	2.78e-12	1.33e-09	-0.3	-0.31	QT interval;	chr12:29349303	chr12:29280418~29317848:-
KIRC	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-7.17	2.78e-12	1.33e-09	-0.29	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
KIRC	cis	rs4072705	0.967	rs2148787	ENSG00000224020.1	MIR181A2HG	-7.17	2.78e-12	1.33e-09	-0.3	-0.31	Menarche (age at onset);	chr9:124705925	chr9:124658467~124698631:+
KIRC	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-7.17	2.78e-12	1.33e-09	-0.22	-0.31	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
KIRC	cis	rs7592578	0.679	rs62181020	ENSG00000272979.1	RP11-647K16.1	-7.17	2.78e-12	1.33e-09	-0.43	-0.31	Diastolic blood pressure;	chr2:190460875	chr2:190454092~190454521:-
KIRC	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	7.17	2.79e-12	1.34e-09	0.37	0.31	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
KIRC	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-7.17	2.8e-12	1.34e-09	-0.28	-0.31	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-7.17	2.8e-12	1.34e-09	-0.29	-0.31	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
KIRC	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	7.17	2.8e-12	1.34e-09	0.39	0.31	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	7.17	2.8e-12	1.34e-09	0.32	0.31	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
KIRC	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	7.17	2.8e-12	1.34e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
KIRC	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-7.17	2.81e-12	1.35e-09	-0.31	-0.31	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
KIRC	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	7.17	2.81e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
KIRC	cis	rs11657217	0.677	rs8067469	ENSG00000267719.1	HP09025	-7.17	2.82e-12	1.35e-09	-0.33	-0.31	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724552	chr17:79707266~79712317:+
KIRC	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-7.17	2.82e-12	1.35e-09	-0.41	-0.31	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
KIRC	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-7.17	2.82e-12	1.35e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
KIRC	cis	rs12449964	0.524	rs7225934	ENSG00000223979.2	SMCR2	7.17	2.82e-12	1.35e-09	0.33	0.31	Coronary artery disease or ischemic stroke;	chr17:17669230	chr17:17674026~17677688:-
KIRC	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	7.17	2.82e-12	1.35e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
KIRC	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	7.17	2.83e-12	1.35e-09	0.38	0.31	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	7.17	2.83e-12	1.35e-09	0.38	0.31	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
KIRC	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-7.17	2.83e-12	1.35e-09	-0.39	-0.31	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
KIRC	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	7.17	2.83e-12	1.35e-09	0.29	0.31	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.932	rs56879009	ENSG00000198277.6	RP11-468N14.09	7.17	2.83e-12	1.36e-09	0.33	0.31	Obesity-related traits;	chr4:69079589	chr4:68914928~68924741:-
KIRC	cis	rs755249	0.917	rs61781392	ENSG00000237624.1	OXCT2P1	7.17	2.84e-12	1.36e-09	0.49	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.917	rs61232586	ENSG00000237624.1	OXCT2P1	7.17	2.84e-12	1.36e-09	0.49	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.917	rs61781393	ENSG00000237624.1	OXCT2P1	7.17	2.84e-12	1.36e-09	0.49	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39514956~39516490:+
KIRC	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-7.17	2.84e-12	1.36e-09	-0.24	-0.31	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
KIRC	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	7.17	2.84e-12	1.36e-09	0.34	0.31	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
KIRC	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-7.17	2.84e-12	1.36e-09	-0.41	-0.31	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
KIRC	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	7.16	2.84e-12	1.36e-09	0.42	0.31	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	7.16	2.84e-12	1.36e-09	0.42	0.31	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	7.16	2.84e-12	1.36e-09	0.42	0.31	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	7.16	2.84e-12	1.36e-09	0.42	0.31	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	7.16	2.84e-12	1.36e-09	0.42	0.31	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
KIRC	cis	rs11657217	0.502	rs4442854	ENSG00000267719.1	HP09025	-7.16	2.84e-12	1.36e-09	-0.33	-0.31	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724454	chr17:79707266~79712317:+
KIRC	cis	rs13434995	0.513	rs73236142	ENSG00000249700.7	SRD5A3-AS1	-7.16	2.85e-12	1.36e-09	-0.31	-0.31	Adiponectin levels;	chr4:55446143	chr4:55363971~55395847:-
KIRC	cis	rs7672749	0.73	rs17013280	ENSG00000249973.2	CHCHD2P7	-7.16	2.85e-12	1.36e-09	-0.6	-0.31	TB-LM or TBLH-BMD (pleiotropy);	chr4:87841144	chr4:87785920~87786371:-
KIRC	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	7.16	2.85e-12	1.36e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
KIRC	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-7.16	2.85e-12	1.37e-09	-0.23	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
KIRC	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-7.16	2.86e-12	1.37e-09	-0.24	-0.31	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
KIRC	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-7.16	2.87e-12	1.37e-09	-0.17	-0.31	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-7.16	2.87e-12	1.37e-09	-0.17	-0.31	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
KIRC	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	7.16	2.87e-12	1.37e-09	0.35	0.31	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
KIRC	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-7.16	2.87e-12	1.37e-09	-0.29	-0.31	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
KIRC	cis	rs9901225	1	rs9901225	ENSG00000267185.1	PTP4A2P1	7.16	2.87e-12	1.37e-09	0.38	0.31	Colorectal or endometrial cancer;	chr17:42603793	chr17:42533532~42534009:+
KIRC	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-7.16	2.87e-12	1.37e-09	-0.32	-0.31	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
KIRC	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	7.16	2.87e-12	1.37e-09	0.3	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
KIRC	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-7.16	2.87e-12	1.38e-09	-0.31	-0.31	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
KIRC	cis	rs6479901	0.841	rs10995453	ENSG00000232075.1	MRPL35P2	-7.16	2.88e-12	1.38e-09	-0.4	-0.31	Intelligence (multi-trait analysis);	chr10:63174571	chr10:63634317~63634827:-
KIRC	cis	rs7672749	0.73	rs7672924	ENSG00000249973.2	CHCHD2P7	7.16	2.88e-12	1.38e-09	0.65	0.31	TB-LM or TBLH-BMD (pleiotropy);	chr4:87847095	chr4:87785920~87786371:-
KIRC	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-7.16	2.88e-12	1.38e-09	-0.38	-0.31	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
KIRC	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	7.16	2.89e-12	1.38e-09	0.35	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
KIRC	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	7.16	2.89e-12	1.38e-09	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
KIRC	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-7.16	2.9e-12	1.38e-09	-0.23	-0.31	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
KIRC	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	7.16	2.9e-12	1.39e-09	0.61	0.31	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
KIRC	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	7.16	2.9e-12	1.39e-09	0.44	0.31	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
KIRC	cis	rs13434995	0.513	rs11240	ENSG00000249700.7	SRD5A3-AS1	-7.16	2.9e-12	1.39e-09	-0.31	-0.31	Adiponectin levels;	chr4:55453183	chr4:55363971~55395847:-
KIRC	cis	rs4936099	0.766	rs10894192	ENSG00000175773.11	RP11-121M22.1	7.16	2.9e-12	1.39e-09	0.32	0.31	Optic cup area;Vertical cup-disc ratio;	chr11:130396222	chr11:130314993~130403657:+
KIRC	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	7.16	2.91e-12	1.39e-09	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	7.16	2.91e-12	1.39e-09	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
KIRC	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	7.16	2.91e-12	1.39e-09	0.27	0.31	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
KIRC	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-7.16	2.91e-12	1.39e-09	-0.25	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
KIRC	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-7.16	2.91e-12	1.39e-09	-0.29	-0.31	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
KIRC	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	7.16	2.92e-12	1.39e-09	0.39	0.31	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	7.16	2.92e-12	1.39e-09	0.43	0.31	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
KIRC	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	7.16	2.92e-12	1.39e-09	0.6	0.31	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	7.16	2.92e-12	1.39e-09	0.6	0.31	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	7.16	2.92e-12	1.39e-09	0.6	0.31	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	7.16	2.92e-12	1.39e-09	0.6	0.31	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	7.16	2.92e-12	1.39e-09	0.6	0.31	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
KIRC	cis	rs897984	0.806	rs10782002	ENSG00000260911.2	RP11-196G11.2	-7.16	2.92e-12	1.4e-09	-0.2	-0.31	Dementia with Lewy bodies;	chr16:30935185	chr16:31043150~31049868:+
KIRC	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-7.16	2.92e-12	1.4e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-7.16	2.92e-12	1.4e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
KIRC	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-7.16	2.92e-12	1.4e-09	-0.25	-0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
KIRC	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	7.16	2.92e-12	1.4e-09	0.61	0.31	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
KIRC	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-7.16	2.93e-12	1.4e-09	-0.32	-0.31	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
KIRC	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	7.16	2.93e-12	1.4e-09	0.35	0.31	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
KIRC	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	7.16	2.93e-12	1.4e-09	0.32	0.31	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
KIRC	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	7.16	2.94e-12	1.4e-09	0.5	0.31	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
KIRC	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-7.16	2.95e-12	1.41e-09	-0.3	-0.31	QT interval;	chr12:29343291	chr12:29280418~29317848:-
KIRC	cis	rs62025270	0.632	rs62022918	ENSG00000202081.1	RNU6-1280P	-7.16	2.95e-12	1.41e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.632	rs111906684	ENSG00000202081.1	RNU6-1280P	-7.16	2.95e-12	1.41e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85651522~85651628:-
KIRC	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	7.16	2.96e-12	1.41e-09	0.37	0.31	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
KIRC	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	7.16	2.96e-12	1.42e-09	0.38	0.31	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
KIRC	cis	rs13434995	0.513	rs972446	ENSG00000249700.7	SRD5A3-AS1	7.16	2.97e-12	1.42e-09	0.31	0.31	Adiponectin levels;	chr4:55569581	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs11732481	ENSG00000249700.7	SRD5A3-AS1	7.16	2.97e-12	1.42e-09	0.31	0.31	Adiponectin levels;	chr4:55570212	chr4:55363971~55395847:-
KIRC	cis	rs62025270	0.632	rs1807309	ENSG00000202081.1	RNU6-1280P	-7.16	2.97e-12	1.42e-09	-0.39	-0.31	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85651522~85651628:-
KIRC	cis	rs710913	0.604	rs1180343	ENSG00000237624.1	OXCT2P1	-7.16	2.97e-12	1.42e-09	-0.4	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39514956~39516490:+
KIRC	cis	rs7160336	0.728	rs4899488	ENSG00000259065.1	RP5-1021I20.1	7.16	2.98e-12	1.42e-09	0.39	0.31	Blood protein levels;	chr14:74008147	chr14:73787360~73803270:+
KIRC	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-7.16	2.99e-12	1.43e-09	-0.43	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
KIRC	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-7.16	2.99e-12	1.43e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
KIRC	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	7.16	3e-12	1.43e-09	0.34	0.31	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
KIRC	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-7.16	3e-12	1.43e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.697	rs4722719	ENSG00000235574.1	AC073150.6	-7.16	3.01e-12	1.44e-09	-0.36	-0.31	Hypospadias;	chr7:27575303	chr7:27491682~27492765:-
KIRC	cis	rs17801127	0.901	rs6709817	ENSG00000231969.1	AC144449.1	7.16	3.01e-12	1.44e-09	0.53	0.31	Liver enzyme levels (alanine transaminase);	chr2:149701004	chr2:149587196~149848233:+
KIRC	cis	rs4820539	1	rs916583	ENSG00000221069.1	AC000029.1	-7.16	3.01e-12	1.44e-09	-0.37	-0.31	Bone mineral density;	chr22:23127080	chr22:23136620~23136710:+
KIRC	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-7.16	3.02e-12	1.44e-09	-0.3	-0.31	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
KIRC	cis	rs1560104	0.709	rs7194367	ENSG00000274834.1	CTD-3037G24.5	-7.16	3.02e-12	1.44e-09	-0.34	-0.31	Obesity-related traits;	chr16:12604376	chr16:12614451~12614852:+
KIRC	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-7.16	3.02e-12	1.44e-09	-0.34	-0.31	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	7.16	3.03e-12	1.44e-09	0.29	0.31	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	7.16	3.03e-12	1.44e-09	0.29	0.31	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	7.16	3.03e-12	1.44e-09	0.29	0.31	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
KIRC	cis	rs10214930	0.697	rs2091171	ENSG00000235574.1	AC073150.6	-7.15	3.04e-12	1.45e-09	-0.37	-0.31	Hypospadias;	chr7:27519599	chr7:27491682~27492765:-
KIRC	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	7.15	3.04e-12	1.45e-09	0.28	0.31	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
KIRC	cis	rs10971721	0.643	rs72711741	ENSG00000281128.1	PTENP1-AS	7.15	3.05e-12	1.45e-09	0.68	0.31	Body mass index;	chr9:33785113	chr9:33677268~33688011:+
KIRC	cis	rs62025270	0.632	rs10520594	ENSG00000202081.1	RNU6-1280P	7.15	3.05e-12	1.45e-09	0.39	0.31	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85651522~85651628:-
KIRC	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-7.15	3.05e-12	1.46e-09	-0.34	-0.31	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
KIRC	cis	rs1552244	1	rs68067759	ENSG00000180385.7	EMC3-AS1	7.15	3.06e-12	1.46e-09	0.31	0.31	Alzheimer's disease;	chr3:10108851	chr3:9986893~10006990:+
KIRC	cis	rs13113518	0.51	rs6858749	ENSG00000249700.7	SRD5A3-AS1	7.15	3.06e-12	1.46e-09	0.27	0.31	Height;	chr4:55424270	chr4:55363971~55395847:-
KIRC	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	7.15	3.06e-12	1.46e-09	0.37	0.31	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
KIRC	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	7.15	3.07e-12	1.46e-09	0.36	0.31	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
KIRC	cis	rs62025270	0.593	rs7166540	ENSG00000202081.1	RNU6-1280P	-7.15	3.07e-12	1.46e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85651522~85651628:-
KIRC	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	7.15	3.07e-12	1.46e-09	0.29	0.31	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
KIRC	cis	rs4888671	0.901	rs17773587	ENSG00000261707.1	RP11-264M12.2	-7.15	3.08e-12	1.47e-09	-0.46	-0.31	Obesity-related traits;	chr16:77738517	chr16:77741468~77743000:-
KIRC	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	7.15	3.08e-12	1.47e-09	0.5	0.31	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	7.15	3.08e-12	1.47e-09	0.5	0.31	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
KIRC	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	7.15	3.08e-12	1.47e-09	0.25	0.31	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
KIRC	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	7.15	3.08e-12	1.47e-09	0.3	0.31	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
KIRC	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-7.15	3.09e-12	1.47e-09	-0.25	-0.31	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
KIRC	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	7.15	3.1e-12	1.48e-09	0.27	0.31	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
KIRC	cis	rs66887589	0.934	rs2715016	ENSG00000245958.5	RP11-33B1.1	7.15	3.1e-12	1.48e-09	0.23	0.31	Diastolic blood pressure;	chr4:119531201	chr4:119454791~119552025:+
KIRC	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	7.15	3.1e-12	1.48e-09	0.27	0.31	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
KIRC	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	7.15	3.1e-12	1.48e-09	0.23	0.31	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
KIRC	cis	rs62025270	0.632	rs62022919	ENSG00000202081.1	RNU6-1280P	-7.15	3.1e-12	1.48e-09	-0.38	-0.31	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85651522~85651628:-
KIRC	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-7.15	3.11e-12	1.48e-09	-0.29	-0.31	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
KIRC	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-7.15	3.11e-12	1.48e-09	-0.34	-0.31	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
KIRC	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	7.15	3.12e-12	1.48e-09	0.23	0.31	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
KIRC	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-7.15	3.12e-12	1.48e-09	-0.41	-0.31	Depression;	chr6:28206812	chr6:28115628~28116551:+
KIRC	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	7.15	3.12e-12	1.48e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
KIRC	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	7.15	3.12e-12	1.49e-09	0.33	0.31	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
KIRC	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-7.15	3.13e-12	1.49e-09	-0.22	-0.31	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-7.15	3.13e-12	1.49e-09	-0.22	-0.31	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
KIRC	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	7.15	3.13e-12	1.49e-09	0.32	0.31	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	7.15	3.13e-12	1.49e-09	0.32	0.31	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
KIRC	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.15	3.13e-12	1.49e-09	-0.35	-0.31	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
KIRC	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	7.15	3.14e-12	1.49e-09	0.37	0.31	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
KIRC	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.15	3.14e-12	1.5e-09	-0.27	-0.31	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
KIRC	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-7.15	3.15e-12	1.5e-09	-0.23	-0.31	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
KIRC	cis	rs10214930	0.697	rs2080245	ENSG00000235574.1	AC073150.6	-7.15	3.15e-12	1.5e-09	-0.36	-0.31	Hypospadias;	chr7:27529911	chr7:27491682~27492765:-
KIRC	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	7.15	3.15e-12	1.5e-09	0.37	0.31	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
KIRC	cis	rs10214930	0.624	rs4719902	ENSG00000235574.1	AC073150.6	-7.15	3.15e-12	1.5e-09	-0.37	-0.31	Hypospadias;	chr7:27548723	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6462031	ENSG00000235574.1	AC073150.6	-7.15	3.15e-12	1.5e-09	-0.37	-0.31	Hypospadias;	chr7:27549871	chr7:27491682~27492765:-
KIRC	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	7.15	3.15e-12	1.5e-09	0.32	0.31	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
KIRC	cis	rs17801127	0.748	rs12990272	ENSG00000231969.1	AC144449.1	7.15	3.16e-12	1.5e-09	0.52	0.31	Liver enzyme levels (alanine transaminase);	chr2:149670563	chr2:149587196~149848233:+
KIRC	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-7.15	3.17e-12	1.51e-09	-0.39	-0.31	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-7.15	3.17e-12	1.51e-09	-0.39	-0.31	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
KIRC	cis	rs10214930	0.651	rs42085	ENSG00000235574.1	AC073150.6	7.15	3.18e-12	1.51e-09	0.36	0.31	Hypospadias;	chr7:27658320	chr7:27491682~27492765:-
KIRC	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	7.15	3.18e-12	1.51e-09	0.32	0.31	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	7.15	3.18e-12	1.51e-09	0.32	0.31	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
KIRC	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	7.15	3.18e-12	1.51e-09	0.47	0.31	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
KIRC	cis	rs1552244	1	rs55822690	ENSG00000180385.7	EMC3-AS1	7.15	3.19e-12	1.51e-09	0.31	0.31	Alzheimer's disease;	chr3:10086319	chr3:9986893~10006990:+
KIRC	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.51e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.51e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.51e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
KIRC	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-7.15	3.19e-12	1.51e-09	-0.41	-0.31	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
KIRC	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	7.15	3.19e-12	1.52e-09	0.24	0.31	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
KIRC	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	7.15	3.19e-12	1.52e-09	0.36	0.31	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
KIRC	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	7.15	3.19e-12	1.52e-09	0.36	0.31	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
KIRC	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	7.15	3.19e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	7.15	3.2e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	7.15	3.2e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	7.15	3.2e-12	1.52e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
KIRC	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	7.15	3.2e-12	1.52e-09	0.5	0.31	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
KIRC	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	7.15	3.2e-12	1.52e-09	0.37	0.31	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
KIRC	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-7.15	3.2e-12	1.52e-09	-0.29	-0.31	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-7.15	3.2e-12	1.52e-09	-0.29	-0.31	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
KIRC	cis	rs10214930	0.697	rs12155430	ENSG00000235574.1	AC073150.6	-7.15	3.21e-12	1.53e-09	-0.36	-0.31	Hypospadias;	chr7:27631677	chr7:27491682~27492765:-
KIRC	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
KIRC	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-7.15	3.22e-12	1.53e-09	-0.41	-0.31	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
KIRC	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	7.15	3.22e-12	1.53e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
KIRC	cis	rs1560104	0.709	rs2217271	ENSG00000274834.1	CTD-3037G24.5	-7.15	3.22e-12	1.53e-09	-0.35	-0.31	Obesity-related traits;	chr16:12610623	chr16:12614451~12614852:+
KIRC	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	7.15	3.23e-12	1.53e-09	0.28	0.31	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
KIRC	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	7.15	3.24e-12	1.54e-09	0.35	0.31	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
KIRC	cis	rs6061231	0.583	rs2427313	ENSG00000275437.1	RP5-908M14.10	7.14	3.24e-12	1.54e-09	0.25	0.31	Colorectal cancer;	chr20:62395619	chr20:62402236~62405935:-
KIRC	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-7.14	3.25e-12	1.54e-09	-0.35	-0.31	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
KIRC	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.14	3.25e-12	1.54e-09	-0.35	-0.31	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
KIRC	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	7.14	3.25e-12	1.54e-09	0.33	0.31	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.932	rs4694611	ENSG00000198277.6	RP11-468N14.09	7.14	3.27e-12	1.55e-09	0.32	0.31	Obesity-related traits;	chr4:69079387	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694612	ENSG00000198277.6	RP11-468N14.09	7.14	3.27e-12	1.55e-09	0.32	0.31	Obesity-related traits;	chr4:69079446	chr4:68914928~68924741:-
KIRC	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	7.14	3.27e-12	1.55e-09	0.43	0.31	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
KIRC	cis	rs1552244	1	rs113153120	ENSG00000180385.7	EMC3-AS1	7.14	3.27e-12	1.55e-09	0.31	0.31	Alzheimer's disease;	chr3:10114714	chr3:9986893~10006990:+
KIRC	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.14	3.28e-12	1.56e-09	-0.39	-0.31	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
KIRC	cis	rs440932	0.798	rs330942	ENSG00000254340.1	RP11-10A14.3	7.14	3.28e-12	1.56e-09	0.39	0.31	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:9141424~9145435:+
KIRC	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-7.14	3.28e-12	1.56e-09	-0.34	-0.31	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
KIRC	cis	rs10214930	0.671	rs6957674	ENSG00000235574.1	AC073150.6	-7.14	3.28e-12	1.56e-09	-0.36	-0.31	Hypospadias;	chr7:27518691	chr7:27491682~27492765:-
KIRC	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	7.14	3.29e-12	1.56e-09	0.42	0.31	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
KIRC	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	7.14	3.29e-12	1.56e-09	0.31	0.31	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
KIRC	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	7.14	3.29e-12	1.56e-09	0.75	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
KIRC	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	7.14	3.29e-12	1.56e-09	0.28	0.31	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	7.14	3.29e-12	1.56e-09	0.28	0.31	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	7.14	3.29e-12	1.56e-09	0.28	0.31	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
KIRC	cis	rs62025270	0.632	rs62022915	ENSG00000202081.1	RNU6-1280P	-7.14	3.29e-12	1.56e-09	-0.39	-0.31	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85651522~85651628:-
KIRC	cis	rs11089937	0.626	rs11089933	ENSG00000211638.2	IGLV8-61	-7.14	3.3e-12	1.56e-09	-0.33	-0.31	Periodontitis (PAL4Q3);	chr22:22145708	chr22:22098700~22099212:+
KIRC	cis	rs17801127	0.818	rs34462373	ENSG00000231969.1	AC144449.1	7.14	3.3e-12	1.57e-09	0.53	0.31	Liver enzyme levels (alanine transaminase);	chr2:149674998	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs16825494	ENSG00000231969.1	AC144449.1	7.14	3.3e-12	1.57e-09	0.53	0.31	Liver enzyme levels (alanine transaminase);	chr2:149675536	chr2:149587196~149848233:+
KIRC	cis	rs1552244	1	rs6764068	ENSG00000180385.7	EMC3-AS1	7.14	3.31e-12	1.57e-09	0.31	0.31	Alzheimer's disease;	chr3:10112158	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs113522867	ENSG00000180385.7	EMC3-AS1	7.14	3.31e-12	1.57e-09	0.31	0.31	Alzheimer's disease;	chr3:10112819	chr3:9986893~10006990:+
KIRC	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-7.14	3.31e-12	1.57e-09	-0.41	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
KIRC	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.14	3.31e-12	1.57e-09	-0.28	-0.31	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
KIRC	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	7.14	3.31e-12	1.57e-09	0.37	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
KIRC	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-7.14	3.32e-12	1.57e-09	-0.28	-0.31	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-7.14	3.32e-12	1.57e-09	-0.28	-0.31	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
KIRC	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	7.14	3.32e-12	1.57e-09	0.27	0.31	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
KIRC	cis	rs13434995	0.513	rs7676245	ENSG00000249700.7	SRD5A3-AS1	-7.14	3.32e-12	1.57e-09	-0.3	-0.31	Adiponectin levels;	chr4:55455150	chr4:55363971~55395847:-
KIRC	cis	rs3096299	0.589	rs3114898	ENSG00000274627.1	RP11-104N10.2	7.14	3.33e-12	1.58e-09	0.21	0.31	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89516797~89522217:+
KIRC	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	7.14	3.33e-12	1.58e-09	0.43	0.31	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
KIRC	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-7.14	3.33e-12	1.58e-09	-0.34	-0.31	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-7.14	3.33e-12	1.58e-09	-0.34	-0.31	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
KIRC	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-7.14	3.33e-12	1.58e-09	-0.29	-0.31	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
KIRC	cis	rs4072705	0.967	rs10760369	ENSG00000224020.1	MIR181A2HG	-7.14	3.34e-12	1.58e-09	-0.31	-0.31	Menarche (age at onset);	chr9:124635121	chr9:124658467~124698631:+
KIRC	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	7.14	3.34e-12	1.58e-09	0.42	0.31	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
KIRC	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	7.14	3.35e-12	1.59e-09	0.29	0.31	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
KIRC	cis	rs7829975	0.56	rs6994131	ENSG00000253893.2	FAM85B	7.14	3.35e-12	1.59e-09	0.38	0.31	Mood instability;	chr8:8693448	chr8:8167819~8226614:-
KIRC	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.14	3.35e-12	1.59e-09	0.27	0.31	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
KIRC	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	7.14	3.35e-12	1.59e-09	0.36	0.31	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
KIRC	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	7.14	3.36e-12	1.59e-09	0.28	0.31	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
KIRC	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-7.14	3.36e-12	1.59e-09	-0.41	-0.31	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
KIRC	cis	rs1560104	0.709	rs8063664	ENSG00000274834.1	CTD-3037G24.5	-7.14	3.37e-12	1.6e-09	-0.34	-0.31	Obesity-related traits;	chr16:12603354	chr16:12614451~12614852:+
KIRC	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-7.14	3.38e-12	1.6e-09	-0.49	-0.31	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
KIRC	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	7.14	3.4e-12	1.61e-09	0.44	0.31	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
KIRC	cis	rs783540	0.872	rs2678445	ENSG00000278603.1	RP13-608F4.5	-7.14	3.4e-12	1.61e-09	-0.4	-0.31	Schizophrenia;	chr15:82577391	chr15:82472203~82472426:+
KIRC	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-7.14	3.41e-12	1.61e-09	-0.35	-0.31	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
KIRC	cis	rs1552244	1	rs2272123	ENSG00000180385.7	EMC3-AS1	7.14	3.41e-12	1.61e-09	0.31	0.31	Alzheimer's disease;	chr3:10098431	chr3:9986893~10006990:+
KIRC	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-7.14	3.42e-12	1.62e-09	-0.35	-0.31	Depression;	chr6:28086929	chr6:28073316~28074233:+
KIRC	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	7.14	3.42e-12	1.62e-09	0.42	0.31	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
KIRC	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	7.14	3.42e-12	1.62e-09	0.34	0.31	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
KIRC	cis	rs2288884	0.943	rs75722407	ENSG00000275055.1	CTC-471J1.11	-7.14	3.42e-12	1.62e-09	-0.42	-0.31	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52049007~52049754:+
KIRC	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-7.14	3.43e-12	1.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-7.14	3.43e-12	1.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
KIRC	cis	rs10214930	0.697	rs6462024	ENSG00000235574.1	AC073150.6	-7.14	3.44e-12	1.63e-09	-0.36	-0.31	Hypospadias;	chr7:27522721	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6462025	ENSG00000235574.1	AC073150.6	-7.14	3.44e-12	1.63e-09	-0.36	-0.31	Hypospadias;	chr7:27522722	chr7:27491682~27492765:-
KIRC	cis	rs6456156	0.766	rs150112	ENSG00000265828.1	MIR3939	7.14	3.45e-12	1.63e-09	0.35	0.31	Primary biliary cholangitis;	chr6:167096390	chr6:166997807~166997912:-
KIRC	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	7.13	3.46e-12	1.64e-09	0.62	0.31	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
KIRC	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-7.13	3.47e-12	1.64e-09	-0.36	-0.31	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
KIRC	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-7.13	3.48e-12	1.64e-09	-0.34	-0.31	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
KIRC	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	7.13	3.48e-12	1.65e-09	0.29	0.31	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
KIRC	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	7.13	3.49e-12	1.65e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	7.13	3.49e-12	1.65e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	7.13	3.49e-12	1.65e-09	0.4	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
KIRC	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-7.13	3.49e-12	1.65e-09	-0.22	-0.31	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
KIRC	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	7.13	3.49e-12	1.65e-09	0.28	0.31	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
KIRC	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-7.13	3.5e-12	1.65e-09	-0.22	-0.31	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
KIRC	cis	rs7924176	0.521	rs7477710	ENSG00000213731.2	RAB5CP1	-7.13	3.5e-12	1.65e-09	-0.3	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74423435~74424014:-
KIRC	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	7.13	3.5e-12	1.65e-09	0.28	0.31	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
KIRC	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-7.13	3.51e-12	1.66e-09	-0.22	-0.31	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-7.13	3.51e-12	1.66e-09	-0.22	-0.31	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
KIRC	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-7.13	3.51e-12	1.66e-09	-0.17	-0.31	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
KIRC	cis	rs12887734	0.524	rs4906363	ENSG00000269910.1	RP11-73M18.10	7.13	3.52e-12	1.66e-09	0.22	0.31	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694516~103695050:-
KIRC	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	7.13	3.52e-12	1.66e-09	0.74	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
KIRC	cis	rs4820539	1	rs916585	ENSG00000221069.1	AC000029.1	-7.13	3.52e-12	1.66e-09	-0.37	-0.31	Bone mineral density;	chr22:23127251	chr22:23136620~23136710:+
KIRC	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-7.13	3.52e-12	1.66e-09	-0.48	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
KIRC	cis	rs10214930	0.697	rs6974932	ENSG00000235574.1	AC073150.6	7.13	3.53e-12	1.66e-09	0.36	0.31	Hypospadias;	chr7:27657211	chr7:27491682~27492765:-
KIRC	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-7.13	3.53e-12	1.67e-09	-0.36	-0.31	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
KIRC	cis	rs10214930	0.697	rs12537499	ENSG00000235574.1	AC073150.6	7.13	3.53e-12	1.67e-09	0.36	0.31	Hypospadias;	chr7:27551976	chr7:27491682~27492765:-
KIRC	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	7.13	3.53e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	7.13	3.53e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	7.13	3.53e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
KIRC	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	7.13	3.53e-12	1.67e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
KIRC	cis	rs1552244	0.882	rs55808392	ENSG00000180385.7	EMC3-AS1	7.13	3.54e-12	1.67e-09	0.3	0.31	Alzheimer's disease;	chr3:10012997	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13075842	ENSG00000180385.7	EMC3-AS1	7.13	3.54e-12	1.67e-09	0.3	0.31	Alzheimer's disease;	chr3:10014129	chr3:9986893~10006990:+
KIRC	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-7.13	3.54e-12	1.67e-09	-0.24	-0.31	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
KIRC	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	7.13	3.54e-12	1.67e-09	0.29	0.31	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
KIRC	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	7.13	3.54e-12	1.67e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	7.13	3.54e-12	1.67e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	7.13	3.54e-12	1.67e-09	0.39	0.31	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
KIRC	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	7.13	3.55e-12	1.68e-09	0.33	0.31	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
KIRC	cis	rs11647589	0.834	rs1827711	ENSG00000262995.1	CTD-2194A8.2	-7.13	3.55e-12	1.68e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20471046	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.834	rs1700801	ENSG00000262995.1	CTD-2194A8.2	-7.13	3.55e-12	1.68e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20474158	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.834	rs1354577	ENSG00000262995.1	CTD-2194A8.2	-7.13	3.55e-12	1.68e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20474341	chr16:20440266~20447000:-
KIRC	cis	rs3760982	0.967	rs12463346	ENSG00000267058.1	RP11-15A1.3	-7.13	3.55e-12	1.68e-09	-0.36	-0.31	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788092	chr19:43891804~43901805:-
KIRC	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	7.13	3.55e-12	1.68e-09	0.44	0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
KIRC	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	7.13	3.57e-12	1.68e-09	0.33	0.31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
KIRC	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	7.13	3.57e-12	1.68e-09	0.33	0.31	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
KIRC	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	7.13	3.57e-12	1.68e-09	0.23	0.31	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	7.13	3.57e-12	1.68e-09	0.23	0.31	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
KIRC	cis	rs4072705	1	rs4838203	ENSG00000224020.1	MIR181A2HG	-7.13	3.57e-12	1.68e-09	-0.31	-0.31	Menarche (age at onset);	chr9:124736095	chr9:124658467~124698631:+
KIRC	cis	rs10214930	0.697	rs5009225	ENSG00000235574.1	AC073150.6	-7.13	3.57e-12	1.69e-09	-0.35	-0.31	Hypospadias;	chr7:27577166	chr7:27491682~27492765:-
KIRC	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-7.13	3.57e-12	1.69e-09	-0.34	-0.31	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
KIRC	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	7.13	3.57e-12	1.69e-09	0.46	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
KIRC	cis	rs4356975	0.83	rs4481286	ENSG00000250696.4	RP11-704M14.1	7.13	3.58e-12	1.69e-09	0.32	0.31	Obesity-related traits;	chr4:69056631	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs4583828	ENSG00000250696.4	RP11-704M14.1	7.13	3.58e-12	1.69e-09	0.32	0.31	Obesity-related traits;	chr4:69056669	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs4235113	ENSG00000250696.4	RP11-704M14.1	7.13	3.58e-12	1.69e-09	0.32	0.31	Obesity-related traits;	chr4:69056739	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs4235114	ENSG00000250696.4	RP11-704M14.1	7.13	3.58e-12	1.69e-09	0.32	0.31	Obesity-related traits;	chr4:69056953	chr4:69182100~69216766:+
KIRC	cis	rs4820539	1	rs6003518	ENSG00000221069.1	AC000029.1	-7.13	3.58e-12	1.69e-09	-0.37	-0.31	Bone mineral density;	chr22:23129346	chr22:23136620~23136710:+
KIRC	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-7.13	3.58e-12	1.69e-09	-0.36	-0.31	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
KIRC	cis	rs919433	0.679	rs13000656	ENSG00000231621.1	AC013264.2	7.13	3.59e-12	1.69e-09	0.34	0.31	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657402	chr2:197197991~197199273:+
KIRC	cis	rs1552244	1	rs112509186	ENSG00000180385.7	EMC3-AS1	7.13	3.59e-12	1.69e-09	0.31	0.31	Alzheimer's disease;	chr3:10114849	chr3:9986893~10006990:+
KIRC	cis	rs2486288	0.656	rs11632920	ENSG00000259433.2	CTD-2651B20.4	7.13	3.59e-12	1.69e-09	0.22	0.31	Glomerular filtration rate;	chr15:45259066	chr15:45330209~45332634:-
KIRC	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-7.13	3.6e-12	1.7e-09	-0.37	-0.31	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
KIRC	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-7.13	3.6e-12	1.7e-09	-0.26	-0.31	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
KIRC	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	7.13	3.61e-12	1.7e-09	0.34	0.31	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	7.13	3.61e-12	1.7e-09	0.34	0.31	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	7.13	3.61e-12	1.7e-09	0.34	0.31	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
KIRC	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	7.13	3.61e-12	1.7e-09	0.35	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
KIRC	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	7.13	3.62e-12	1.71e-09	0.49	0.31	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
KIRC	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	7.13	3.63e-12	1.71e-09	0.32	0.31	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
KIRC	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-7.13	3.63e-12	1.71e-09	-0.48	-0.31	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
KIRC	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-7.13	3.64e-12	1.71e-09	-0.36	-0.31	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
KIRC	cis	rs11647589	0.552	rs1632600	ENSG00000262995.1	CTD-2194A8.2	-7.13	3.64e-12	1.72e-09	-0.32	-0.31	Blood metabolite levels;	chr16:20476182	chr16:20440266~20447000:-
KIRC	cis	rs4820539	1	rs5759595	ENSG00000221069.1	AC000029.1	-7.13	3.64e-12	1.72e-09	-0.37	-0.31	Bone mineral density;	chr22:23129437	chr22:23136620~23136710:+
KIRC	cis	rs4820539	0.966	rs5751587	ENSG00000221069.1	AC000029.1	-7.13	3.65e-12	1.72e-09	-0.37	-0.31	Bone mineral density;	chr22:23127903	chr22:23136620~23136710:+
KIRC	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-7.13	3.65e-12	1.72e-09	-0.28	-0.31	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
KIRC	cis	rs9915657	0.87	rs12600458	ENSG00000234899.8	SOX9-AS1	-7.13	3.65e-12	1.72e-09	-0.39	-0.31	Thyroid hormone levels;	chr17:72134404	chr17:72034107~72237203:-
KIRC	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	7.13	3.65e-12	1.72e-09	0.42	0.31	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
KIRC	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	7.13	3.65e-12	1.72e-09	0.73	0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
KIRC	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.13	3.66e-12	1.72e-09	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
KIRC	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	7.13	3.66e-12	1.72e-09	0.47	0.31	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
KIRC	cis	rs7924176	0.521	rs10824142	ENSG00000213731.2	RAB5CP1	-7.13	3.66e-12	1.72e-09	-0.29	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74423435~74424014:-
KIRC	cis	rs7924176	0.521	rs11000965	ENSG00000213731.2	RAB5CP1	-7.13	3.66e-12	1.72e-09	-0.29	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74423435~74424014:-
KIRC	cis	rs7924176	0.521	rs12357370	ENSG00000213731.2	RAB5CP1	-7.13	3.66e-12	1.72e-09	-0.29	-0.31	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74423435~74424014:-
KIRC	cis	rs11647589	0.689	rs12599141	ENSG00000260762.1	ACSM5P1	7.13	3.67e-12	1.73e-09	0.31	0.31	Blood metabolite levels;	chr16:20440775	chr16:20586550~20607107:-
KIRC	cis	rs12936587	0.581	rs7209595	ENSG00000223979.2	SMCR2	7.13	3.68e-12	1.73e-09	0.33	0.31	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17729605	chr17:17674026~17677688:-
KIRC	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-7.13	3.68e-12	1.73e-09	-0.32	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
KIRC	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
KIRC	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-7.13	3.69e-12	1.74e-09	-0.34	-0.3	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
KIRC	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-7.12	3.7e-12	1.74e-09	-0.46	-0.3	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
KIRC	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-7.12	3.7e-12	1.74e-09	-0.49	-0.3	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
KIRC	cis	rs899997	0.862	rs11072787	ENSG00000261143.1	ADAMTS7P3	-7.12	3.7e-12	1.74e-09	-0.37	-0.3	Coronary artery disease or large artery stroke;	chr15:78680635	chr15:77976042~77993057:+
KIRC	cis	rs10214930	0.697	rs2391443	ENSG00000235574.1	AC073150.6	-7.12	3.7e-12	1.74e-09	-0.36	-0.3	Hypospadias;	chr7:27586310	chr7:27491682~27492765:-
KIRC	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-7.12	3.7e-12	1.74e-09	-0.34	-0.3	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
KIRC	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-7.12	3.71e-12	1.74e-09	-0.23	-0.3	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
KIRC	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-7.12	3.71e-12	1.74e-09	-0.24	-0.3	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
KIRC	cis	rs2797160	0.651	rs6569437	ENSG00000237742.5	RP11-624M8.1	7.12	3.72e-12	1.75e-09	0.37	0.3	Endometrial cancer;	chr6:125713394	chr6:125578558~125749190:-
KIRC	cis	rs13434995	0.513	rs67963898	ENSG00000249700.7	SRD5A3-AS1	-7.12	3.72e-12	1.75e-09	-0.3	-0.3	Adiponectin levels;	chr4:55475520	chr4:55363971~55395847:-
KIRC	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-7.12	3.73e-12	1.75e-09	-0.34	-0.3	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
KIRC	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-7.12	3.73e-12	1.76e-09	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
KIRC	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-7.12	3.73e-12	1.76e-09	-0.34	-0.3	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
KIRC	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	7.12	3.73e-12	1.76e-09	0.42	0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
KIRC	cis	rs10214930	0.697	rs1404278	ENSG00000235574.1	AC073150.6	-7.12	3.74e-12	1.76e-09	-0.35	-0.3	Hypospadias;	chr7:27595107	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.723	rs6960834	ENSG00000235574.1	AC073150.6	-7.12	3.74e-12	1.76e-09	-0.35	-0.3	Hypospadias;	chr7:27596367	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6980382	ENSG00000235574.1	AC073150.6	-7.12	3.74e-12	1.76e-09	-0.35	-0.3	Hypospadias;	chr7:27598043	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6947731	ENSG00000235574.1	AC073150.6	-7.12	3.74e-12	1.76e-09	-0.35	-0.3	Hypospadias;	chr7:27599076	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.625	rs6462037	ENSG00000235574.1	AC073150.6	-7.12	3.74e-12	1.76e-09	-0.35	-0.3	Hypospadias;	chr7:27601481	chr7:27491682~27492765:-
KIRC	cis	rs3744061	0.52	rs4322697	ENSG00000277382.1	RP11-318A15.8	7.12	3.74e-12	1.76e-09	0.34	0.3	Retinal arteriolar caliber;	chr17:76652560	chr17:76709760~76710045:+
KIRC	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	7.12	3.75e-12	1.76e-09	0.4	0.3	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
KIRC	cis	rs10214930	0.671	rs1005128	ENSG00000235574.1	AC073150.6	-7.12	3.75e-12	1.76e-09	-0.36	-0.3	Hypospadias;	chr7:27569057	chr7:27491682~27492765:-
KIRC	cis	rs7937127	0.696	rs72902770	ENSG00000254907.1	RP11-484D2.2	7.12	3.75e-12	1.76e-09	0.41	0.3	Fibrinogen levels;	chr11:43513632	chr11:43328748~43359296:-
KIRC	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	7.12	3.76e-12	1.77e-09	0.25	0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
KIRC	cis	rs7250849	0.565	rs73052857	ENSG00000273837.1	LLNLR-470E3.1	-7.12	3.76e-12	1.77e-09	-0.47	-0.3	Blood protein levels;	chr19:51661182	chr19:51639478~51639931:-
KIRC	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.67	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	7.12	3.76e-12	1.77e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	7.12	3.76e-12	1.77e-09	0.31	0.3	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
KIRC	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-7.12	3.76e-12	1.77e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-7.12	3.76e-12	1.77e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
KIRC	cis	rs526231	0.718	rs402962	ENSG00000175749.11	EIF3KP1	7.12	3.77e-12	1.77e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103288307	chr5:103032376~103033031:+
KIRC	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	7.12	3.77e-12	1.77e-09	0.45	0.3	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
KIRC	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-7.12	3.77e-12	1.77e-09	-0.28	-0.3	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-7.12	3.77e-12	1.77e-09	-0.28	-0.3	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-7.12	3.77e-12	1.77e-09	-0.28	-0.3	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
KIRC	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-7.12	3.78e-12	1.78e-09	-0.24	-0.3	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
KIRC	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-7.12	3.79e-12	1.78e-09	-0.26	-0.3	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
KIRC	cis	rs3820928	0.904	rs2217359	ENSG00000212391.1	SNORA48	-7.12	3.79e-12	1.78e-09	-0.36	-0.3	Pulmonary function;	chr2:226895176	chr2:226968989~226969122:-
KIRC	cis	rs3760982	0.626	rs12463370	ENSG00000267058.1	RP11-15A1.3	-7.12	3.8e-12	1.78e-09	-0.35	-0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788014	chr19:43891804~43901805:-
KIRC	cis	rs17772222	0.701	rs376698	ENSG00000222990.1	RNU4-22P	-7.12	3.8e-12	1.79e-09	-0.33	-0.3	Coronary artery calcification;	chr14:88391886	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.701	rs453112	ENSG00000222990.1	RNU4-22P	-7.12	3.8e-12	1.79e-09	-0.33	-0.3	Coronary artery calcification;	chr14:88392657	chr14:88513498~88513663:+
KIRC	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	7.12	3.81e-12	1.79e-09	0.28	0.3	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
KIRC	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-7.12	3.81e-12	1.79e-09	-0.5	-0.3	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
KIRC	cis	rs11671005	0.656	rs73066228	ENSG00000269600.1	AC016629.3	-7.12	3.82e-12	1.79e-09	-0.53	-0.3	Mean platelet volume;	chr19:58501829	chr19:58593896~58599355:-
KIRC	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	7.12	3.82e-12	1.79e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
KIRC	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	7.12	3.82e-12	1.79e-09	0.34	0.3	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
KIRC	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	7.12	3.82e-12	1.8e-09	0.47	0.3	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	7.12	3.82e-12	1.8e-09	0.47	0.3	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	7.12	3.82e-12	1.8e-09	0.47	0.3	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
KIRC	cis	rs4356975	0.83	rs60212682	ENSG00000250696.4	RP11-704M14.1	7.12	3.84e-12	1.8e-09	0.32	0.3	Obesity-related traits;	chr4:69052849	chr4:69182100~69216766:+
KIRC	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-7.12	3.84e-12	1.81e-09	-0.18	-0.3	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
KIRC	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	7.12	3.86e-12	1.81e-09	0.28	0.3	Height;	chr2:46635447	chr2:46668870~46670778:+
KIRC	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-7.12	3.86e-12	1.81e-09	-0.34	-0.3	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-7.12	3.86e-12	1.81e-09	-0.34	-0.3	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
KIRC	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-7.12	3.86e-12	1.81e-09	-0.34	-0.3	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
KIRC	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-7.12	3.87e-12	1.82e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-7.12	3.88e-12	1.82e-09	-0.29	-0.3	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
KIRC	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	7.12	3.89e-12	1.82e-09	0.38	0.3	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
KIRC	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	7.12	3.89e-12	1.82e-09	0.36	0.3	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
KIRC	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-7.12	3.89e-12	1.83e-09	-0.29	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
KIRC	cis	rs3760982	1	rs11669175	ENSG00000267058.1	RP11-15A1.3	-7.12	3.9e-12	1.83e-09	-0.35	-0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785672	chr19:43891804~43901805:-
KIRC	cis	rs3760982	1	rs4803658	ENSG00000267058.1	RP11-15A1.3	-7.12	3.9e-12	1.83e-09	-0.35	-0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785861	chr19:43891804~43901805:-
KIRC	cis	rs6479901	0.841	rs10761720	ENSG00000232075.1	MRPL35P2	-7.12	3.9e-12	1.83e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63634317~63634827:-
KIRC	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	7.12	3.9e-12	1.83e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
KIRC	cis	rs7176527	0.747	rs28363946	ENSG00000188388.10	GOLGA6L3	7.12	3.9e-12	1.83e-09	0.42	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:85240472~85247170:+
KIRC	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-7.12	3.9e-12	1.83e-09	-0.2	-0.3	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
KIRC	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-7.12	3.91e-12	1.84e-09	-0.27	-0.3	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-7.12	3.91e-12	1.84e-09	-0.27	-0.3	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
KIRC	cis	rs62025270	0.522	rs16943120	ENSG00000202081.1	RNU6-1280P	-7.12	3.91e-12	1.84e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85651522~85651628:-
KIRC	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	7.12	3.92e-12	1.84e-09	0.35	0.3	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
KIRC	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-7.12	3.92e-12	1.84e-09	-0.38	-0.3	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
KIRC	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-7.12	3.92e-12	1.84e-09	-0.35	-0.3	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
KIRC	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-7.12	3.93e-12	1.84e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
KIRC	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	7.12	3.93e-12	1.84e-09	0.31	0.3	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
KIRC	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	7.11	3.95e-12	1.85e-09	0.38	0.3	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
KIRC	cis	rs6061231	0.793	rs6061512	ENSG00000275437.1	RP5-908M14.10	7.11	3.96e-12	1.85e-09	0.27	0.3	Colorectal cancer;	chr20:62401873	chr20:62402236~62405935:-
KIRC	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.11	3.96e-12	1.85e-09	-0.35	-0.3	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
KIRC	cis	rs1552244	1	rs112847840	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10059968	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs722509	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10060693	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs7619340	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10066494	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs6793396	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10069243	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs6772315	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10071960	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.935	rs7621551	ENSG00000180385.7	EMC3-AS1	7.11	3.96e-12	1.86e-09	0.31	0.3	Alzheimer's disease;	chr3:10072521	chr3:9986893~10006990:+
KIRC	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-7.11	3.99e-12	1.87e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
KIRC	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-7.11	3.99e-12	1.87e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
KIRC	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-7.11	3.99e-12	1.87e-09	-0.3	-0.3	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
KIRC	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	7.11	4e-12	1.87e-09	0.44	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
KIRC	cis	rs17801127	0.818	rs12233116	ENSG00000231969.1	AC144449.1	7.11	4e-12	1.88e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149690652	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs12992502	ENSG00000231969.1	AC144449.1	7.11	4e-12	1.88e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149691124	chr2:149587196~149848233:+
KIRC	cis	rs9915657	0.933	rs8075603	ENSG00000234899.8	SOX9-AS1	-7.11	4e-12	1.88e-09	-0.38	-0.3	Thyroid hormone levels;	chr17:72140692	chr17:72034107~72237203:-
KIRC	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	7.11	4.01e-12	1.88e-09	0.3	0.3	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
KIRC	cis	rs13434995	0.513	rs2171617	ENSG00000273257.1	RP11-177J6.1	7.11	4.02e-12	1.88e-09	0.41	0.3	Adiponectin levels;	chr4:55591023	chr4:55387949~55388271:+
KIRC	cis	rs4819052	0.851	rs2255774	ENSG00000215447.6	BX322557.10	-7.11	4.02e-12	1.88e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45288052~45291738:+
KIRC	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	7.11	4.03e-12	1.89e-09	0.6	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
KIRC	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-7.11	4.04e-12	1.89e-09	-0.22	-0.3	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
KIRC	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	7.11	4.04e-12	1.89e-09	0.43	0.3	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
KIRC	cis	rs11647589	0.911	rs9923452	ENSG00000262995.1	CTD-2194A8.2	-7.11	4.04e-12	1.89e-09	-0.33	-0.3	Blood metabolite levels;	chr16:20457882	chr16:20440266~20447000:-
KIRC	cis	rs11647589	0.911	rs71373192	ENSG00000262995.1	CTD-2194A8.2	-7.11	4.04e-12	1.89e-09	-0.33	-0.3	Blood metabolite levels;	chr16:20458840	chr16:20440266~20447000:-
KIRC	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	7.11	4.05e-12	1.9e-09	0.75	0.3	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
KIRC	cis	rs34375054	0.573	rs35698828	ENSG00000279233.1	RP11-158L12.4	7.11	4.06e-12	1.9e-09	0.26	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125174057	chr12:125138245~125141711:+
KIRC	cis	rs2797160	0.651	rs1268093	ENSG00000237742.5	RP11-624M8.1	7.11	4.06e-12	1.9e-09	0.36	0.3	Endometrial cancer;	chr6:125708089	chr6:125578558~125749190:-
KIRC	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-7.11	4.06e-12	1.9e-09	-0.38	-0.3	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
KIRC	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	7.11	4.06e-12	1.9e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
KIRC	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	7.11	4.06e-12	1.9e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
KIRC	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	7.11	4.07e-12	1.9e-09	0.45	0.3	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
KIRC	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-7.11	4.08e-12	1.91e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
KIRC	cis	rs13113518	0.51	rs6828454	ENSG00000249700.7	SRD5A3-AS1	7.11	4.08e-12	1.91e-09	0.27	0.3	Height;	chr4:55424329	chr4:55363971~55395847:-
KIRC	cis	rs10214930	0.697	rs10807841	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27580132	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs7789788	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27582992	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1608664	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27584309	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs4140899	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27585408	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs1524532	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27586067	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs7783447	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27587236	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.65	rs4348389	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27589331	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs12667235	ENSG00000235574.1	AC073150.6	-7.11	4.08e-12	1.91e-09	-0.35	-0.3	Hypospadias;	chr7:27592012	chr7:27491682~27492765:-
KIRC	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-7.11	4.09e-12	1.91e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
KIRC	cis	rs3820928	0.874	rs7421491	ENSG00000212391.1	SNORA48	-7.11	4.09e-12	1.91e-09	-0.36	-0.3	Pulmonary function;	chr2:226974562	chr2:226968989~226969122:-
KIRC	cis	rs1560104	0.709	rs9806858	ENSG00000274834.1	CTD-3037G24.5	-7.11	4.09e-12	1.91e-09	-0.35	-0.3	Obesity-related traits;	chr16:12610564	chr16:12614451~12614852:+
KIRC	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	7.11	4.09e-12	1.91e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
KIRC	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	7.11	4.1e-12	1.92e-09	0.27	0.3	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
KIRC	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	7.11	4.1e-12	1.92e-09	0.27	0.3	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
KIRC	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	7.11	4.1e-12	1.92e-09	0.27	0.3	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
KIRC	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-7.11	4.1e-12	1.92e-09	-0.24	-0.3	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
KIRC	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	7.11	4.1e-12	1.92e-09	0.35	0.3	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
KIRC	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	7.11	4.11e-12	1.92e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
KIRC	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-7.11	4.11e-12	1.92e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
KIRC	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	7.11	4.11e-12	1.92e-09	0.31	0.3	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	7.11	4.11e-12	1.92e-09	0.31	0.3	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.651	rs1950280	ENSG00000222990.1	RNU4-22P	-7.11	4.13e-12	1.93e-09	-0.33	-0.3	Coronary artery calcification;	chr14:88366259	chr14:88513498~88513663:+
KIRC	cis	rs13113518	0.51	rs10049561	ENSG00000249700.7	SRD5A3-AS1	7.11	4.13e-12	1.93e-09	0.27	0.3	Height;	chr4:55426623	chr4:55363971~55395847:-
KIRC	cis	rs10214930	0.697	rs6958747	ENSG00000235574.1	AC073150.6	7.11	4.14e-12	1.93e-09	0.35	0.3	Hypospadias;	chr7:27652244	chr7:27491682~27492765:-
KIRC	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-7.11	4.14e-12	1.93e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
KIRC	cis	rs2337406	0.85	rs1858678	ENSG00000274576.2	IGHV2-70	-7.11	4.14e-12	1.93e-09	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106706790	chr14:106770577~106771020:-
KIRC	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	7.11	4.15e-12	1.94e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
KIRC	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-7.11	4.15e-12	1.94e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-7.11	4.15e-12	1.94e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-7.11	4.15e-12	1.94e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-7.11	4.15e-12	1.94e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
KIRC	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-7.11	4.15e-12	1.94e-09	-0.31	-0.3	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
KIRC	cis	rs357618	1	rs441652	ENSG00000260581.1	CTB-113P19.4	7.11	4.16e-12	1.94e-09	0.36	0.3	Basophil percentage of white cells;	chr5:151467944	chr5:151652275~151655449:+
KIRC	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-7.11	4.17e-12	1.95e-09	-0.34	-0.3	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
KIRC	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-7.11	4.18e-12	1.95e-09	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
KIRC	cis	rs2337406	1	rs78857163	ENSG00000274576.2	IGHV2-70	-7.11	4.18e-12	1.95e-09	-0.36	-0.3	Alzheimer's disease (late onset);	chr14:106707435	chr14:106770577~106771020:-
KIRC	cis	rs3820928	0.874	rs4675131	ENSG00000212391.1	SNORA48	-7.11	4.19e-12	1.95e-09	-0.36	-0.3	Pulmonary function;	chr2:226972026	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs2396452	ENSG00000212391.1	SNORA48	-7.11	4.19e-12	1.95e-09	-0.36	-0.3	Pulmonary function;	chr2:226973324	chr2:226968989~226969122:-
KIRC	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	7.11	4.19e-12	1.96e-09	0.42	0.3	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
KIRC	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	7.11	4.19e-12	1.96e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
KIRC	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-7.11	4.2e-12	1.96e-09	-0.38	-0.3	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
KIRC	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	7.11	4.2e-12	1.96e-09	0.35	0.3	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
KIRC	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-7.11	4.2e-12	1.96e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
KIRC	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	7.11	4.2e-12	1.96e-09	0.27	0.3	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
KIRC	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	7.11	4.2e-12	1.96e-09	0.47	0.3	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
KIRC	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	7.11	4.21e-12	1.97e-09	0.27	0.3	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
KIRC	cis	rs13113518	0.51	rs3749473	ENSG00000249700.7	SRD5A3-AS1	7.11	4.21e-12	1.97e-09	0.27	0.3	Height;	chr4:55428461	chr4:55363971~55395847:-
KIRC	cis	rs7592578	0.771	rs12052514	ENSG00000272979.1	RP11-647K16.1	-7.1	4.22e-12	1.97e-09	-0.44	-0.3	Diastolic blood pressure;	chr2:190513444	chr2:190454092~190454521:-
KIRC	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	7.1	4.22e-12	1.97e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
KIRC	cis	rs12500482	0.5	rs2269493	ENSG00000206113.6	RP11-503N18.1	7.1	4.22e-12	1.97e-09	0.37	0.3	Cognitive function;	chr4:2426736	chr4:2418974~2450360:+
KIRC	cis	rs11647589	1	rs7201498	ENSG00000260762.1	ACSM5P1	7.1	4.23e-12	1.97e-09	0.31	0.3	Blood metabolite levels;	chr16:20438127	chr16:20586550~20607107:-
KIRC	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	7.1	4.23e-12	1.97e-09	0.26	0.3	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
KIRC	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-7.1	4.23e-12	1.98e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
KIRC	cis	rs17801127	0.818	rs16825497	ENSG00000231969.1	AC144449.1	7.1	4.24e-12	1.98e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149675672	chr2:149587196~149848233:+
KIRC	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-7.1	4.24e-12	1.98e-09	-0.37	-0.3	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
KIRC	cis	rs7924176	0.521	rs7899920	ENSG00000213731.2	RAB5CP1	7.1	4.25e-12	1.98e-09	0.3	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74423435~74424014:-
KIRC	cis	rs957448	0.848	rs113630732	ENSG00000253704.1	RP11-267M23.4	7.1	4.25e-12	1.98e-09	0.4	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94483802	chr8:94553722~94569745:+
KIRC	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-7.1	4.26e-12	1.99e-09	-0.35	-0.3	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
KIRC	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	7.1	4.26e-12	1.99e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
KIRC	cis	rs7592578	0.603	rs12476782	ENSG00000272979.1	RP11-647K16.1	-7.1	4.27e-12	1.99e-09	-0.41	-0.3	Diastolic blood pressure;	chr2:190608154	chr2:190454092~190454521:-
KIRC	cis	rs4356975	0.692	rs7691361	ENSG00000198277.6	RP11-468N14.09	7.1	4.27e-12	1.99e-09	0.32	0.3	Obesity-related traits;	chr4:69077628	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.72	rs7691362	ENSG00000198277.6	RP11-468N14.09	7.1	4.27e-12	1.99e-09	0.32	0.3	Obesity-related traits;	chr4:69077631	chr4:68914928~68924741:-
KIRC	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-7.1	4.27e-12	1.99e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
KIRC	cis	rs904251	0.772	rs1224127	ENSG00000227920.2	RP1-153P14.5	-7.1	4.29e-12	2e-09	-0.36	-0.3	Cognitive performance;	chr6:37449780	chr6:37545145~37550860:+
KIRC	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-7.1	4.29e-12	2e-09	-0.39	-0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
KIRC	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-7.1	4.29e-12	2e-09	-0.38	-0.3	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
KIRC	cis	rs1552244	1	rs67006488	ENSG00000180385.7	EMC3-AS1	7.1	4.29e-12	2e-09	0.31	0.3	Alzheimer's disease;	chr3:10111309	chr3:9986893~10006990:+
KIRC	cis	rs4356975	0.899	rs72501227	ENSG00000198277.6	RP11-468N14.09	7.1	4.3e-12	2e-09	0.32	0.3	Obesity-related traits;	chr4:69069866	chr4:68914928~68924741:-
KIRC	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-7.1	4.3e-12	2e-09	-0.59	-0.3	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
KIRC	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	7.1	4.3e-12	2e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
KIRC	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	7.1	4.3e-12	2.01e-09	0.33	0.3	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.63	rs4904454	ENSG00000222990.1	RNU4-22P	-7.1	4.31e-12	2.01e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88537777	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.63	rs2033418	ENSG00000222990.1	RNU4-22P	-7.1	4.31e-12	2.01e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88539331	chr14:88513498~88513663:+
KIRC	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	7.1	4.31e-12	2.01e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
KIRC	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	7.1	4.32e-12	2.01e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	7.1	4.32e-12	2.01e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
KIRC	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-7.1	4.32e-12	2.01e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
KIRC	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-7.1	4.32e-12	2.01e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
KIRC	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-7.1	4.32e-12	2.01e-09	-0.21	-0.3	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
KIRC	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	7.1	4.32e-12	2.01e-09	0.43	0.3	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
KIRC	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-7.1	4.32e-12	2.02e-09	-0.41	-0.3	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
KIRC	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	7.1	4.33e-12	2.02e-09	0.58	0.3	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
KIRC	cis	rs13434995	0.513	rs17722979	ENSG00000249700.7	SRD5A3-AS1	-7.1	4.33e-12	2.02e-09	-0.3	-0.3	Adiponectin levels;	chr4:55480244	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs13133077	ENSG00000249700.7	SRD5A3-AS1	7.1	4.34e-12	2.02e-09	0.31	0.3	Adiponectin levels;	chr4:55577642	chr4:55363971~55395847:-
KIRC	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	7.1	4.34e-12	2.02e-09	0.22	0.3	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
KIRC	cis	rs17801127	0.748	rs6747199	ENSG00000231969.1	AC144449.1	7.1	4.35e-12	2.03e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149676139	chr2:149587196~149848233:+
KIRC	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	7.1	4.35e-12	2.03e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	7.1	4.35e-12	2.03e-09	0.32	0.3	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
KIRC	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	7.1	4.35e-12	2.03e-09	0.27	0.3	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
KIRC	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	7.1	4.35e-12	2.03e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
KIRC	cis	rs11647589	0.834	rs2271060	ENSG00000262995.1	CTD-2194A8.2	-7.1	4.35e-12	2.03e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20471301	chr16:20440266~20447000:-
KIRC	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	7.1	4.36e-12	2.03e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
KIRC	cis	rs7592578	0.64	rs56127319	ENSG00000272979.1	RP11-647K16.1	-7.1	4.37e-12	2.03e-09	-0.43	-0.3	Diastolic blood pressure;	chr2:190431703	chr2:190454092~190454521:-
KIRC	cis	rs7924176	0.502	rs10824134	ENSG00000213731.2	RAB5CP1	-7.1	4.37e-12	2.03e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74423435~74424014:-
KIRC	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	7.1	4.38e-12	2.04e-09	0.29	0.3	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	7.1	4.38e-12	2.04e-09	0.29	0.3	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	7.1	4.38e-12	2.04e-09	0.29	0.3	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	7.1	4.38e-12	2.04e-09	0.29	0.3	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
KIRC	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-7.1	4.38e-12	2.04e-09	-0.22	-0.3	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
KIRC	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	7.1	4.38e-12	2.04e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
KIRC	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-7.1	4.4e-12	2.05e-09	-0.47	-0.3	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
KIRC	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-7.1	4.4e-12	2.05e-09	-0.47	-0.3	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
KIRC	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	7.1	4.4e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	7.1	4.4e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	7.1	4.4e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
KIRC	cis	rs6908034	0.607	rs78774173	ENSG00000228412.5	RP4-625H18.2	7.1	4.4e-12	2.05e-09	0.72	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19802164~19804752:-
KIRC	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-7.1	4.41e-12	2.05e-09	-0.36	-0.3	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
KIRC	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-7.1	4.41e-12	2.05e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
KIRC	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-7.1	4.41e-12	2.05e-09	-0.4	-0.3	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
KIRC	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs68153882	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9971426	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs3732967	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9973753	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs3732966	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9974056	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13062917	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9975348	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.816	rs13076197	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9978089	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs34779351	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9980117	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13077641	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9981251	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13074282	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9983015	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs67895180	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9984395	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs3755782	ENSG00000180385.7	EMC3-AS1	7.1	4.41e-12	2.05e-09	0.3	0.3	Alzheimer's disease;	chr3:9987621	chr3:9986893~10006990:+
KIRC	cis	rs62025270	0.632	rs62022920	ENSG00000202081.1	RNU6-1280P	-7.1	4.41e-12	2.05e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85651522~85651628:-
KIRC	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-7.1	4.42e-12	2.05e-09	-0.35	-0.3	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
KIRC	cis	rs17772222	0.63	rs10873392	ENSG00000222990.1	RNU4-22P	-7.1	4.42e-12	2.06e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88545124	chr14:88513498~88513663:+
KIRC	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-7.1	4.42e-12	2.06e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-7.1	4.42e-12	2.06e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-7.1	4.42e-12	2.06e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-7.1	4.42e-12	2.06e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-7.1	4.42e-12	2.06e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
KIRC	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	7.1	4.44e-12	2.06e-09	0.26	0.3	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
KIRC	cis	rs6496044	0.963	rs7165300	ENSG00000202081.1	RNU6-1280P	7.1	4.44e-12	2.06e-09	0.33	0.3	Interstitial lung disease;	chr15:85526838	chr15:85651522~85651628:-
KIRC	cis	rs4356975	0.932	rs7692377	ENSG00000198277.6	RP11-468N14.09	7.1	4.44e-12	2.07e-09	0.32	0.3	Obesity-related traits;	chr4:69078113	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs61612343	ENSG00000198277.6	RP11-468N14.09	7.1	4.44e-12	2.07e-09	0.32	0.3	Obesity-related traits;	chr4:69078247	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs7679418	ENSG00000198277.6	RP11-468N14.09	7.1	4.44e-12	2.07e-09	0.32	0.3	Obesity-related traits;	chr4:69078533	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs7680156	ENSG00000198277.6	RP11-468N14.09	7.1	4.44e-12	2.07e-09	0.32	0.3	Obesity-related traits;	chr4:69078868	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs7698430	ENSG00000198277.6	RP11-468N14.09	7.1	4.44e-12	2.07e-09	0.32	0.3	Obesity-related traits;	chr4:69078897	chr4:68914928~68924741:-
KIRC	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-7.1	4.44e-12	2.07e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
KIRC	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	7.1	4.45e-12	2.07e-09	0.24	0.3	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
KIRC	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	7.1	4.45e-12	2.07e-09	0.35	0.3	Depression;	chr6:28110254	chr6:28073316~28074233:+
KIRC	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	7.1	4.45e-12	2.07e-09	0.29	0.3	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
KIRC	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-7.1	4.45e-12	2.07e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.606	rs4719900	ENSG00000235574.1	AC073150.6	-7.1	4.46e-12	2.07e-09	-0.36	-0.3	Hypospadias;	chr7:27528502	chr7:27491682~27492765:-
KIRC	cis	rs2288884	1	rs76368799	ENSG00000275055.1	CTC-471J1.11	-7.1	4.46e-12	2.08e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52049007~52049754:+
KIRC	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	7.1	4.47e-12	2.08e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	7.1	4.47e-12	2.08e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
KIRC	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	7.1	4.48e-12	2.08e-09	0.58	0.3	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
KIRC	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	7.1	4.48e-12	2.08e-09	0.33	0.3	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	7.1	4.48e-12	2.08e-09	0.33	0.3	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
KIRC	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-7.1	4.48e-12	2.08e-09	-0.17	-0.3	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
KIRC	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	7.1	4.48e-12	2.08e-09	0.28	0.3	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
KIRC	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	7.1	4.48e-12	2.08e-09	0.49	0.3	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
KIRC	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-7.1	4.49e-12	2.09e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
KIRC	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	7.1	4.5e-12	2.09e-09	0.22	0.3	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	7.1	4.5e-12	2.09e-09	0.22	0.3	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	7.1	4.5e-12	2.09e-09	0.22	0.3	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	7.1	4.5e-12	2.09e-09	0.22	0.3	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
KIRC	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	7.09	4.5e-12	2.09e-09	0.29	0.3	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.83	rs7666894	ENSG00000196472.4	RP13-644M16.4	7.09	4.51e-12	2.09e-09	0.34	0.3	Obesity-related traits;	chr4:69078780	chr4:69181660~69182372:+
KIRC	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	7.09	4.51e-12	2.1e-09	0.39	0.3	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
KIRC	cis	rs904251	0.965	rs1317563	ENSG00000227920.2	RP1-153P14.5	-7.09	4.51e-12	2.1e-09	-0.33	-0.3	Cognitive performance;	chr6:37484078	chr6:37545145~37550860:+
KIRC	cis	rs1552244	1	rs35741213	ENSG00000180385.7	EMC3-AS1	7.09	4.52e-12	2.1e-09	0.3	0.3	Alzheimer's disease;	chr3:10045977	chr3:9986893~10006990:+
KIRC	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-7.09	4.54e-12	2.11e-09	-0.36	-0.3	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
KIRC	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	7.09	4.54e-12	2.11e-09	0.69	0.3	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
KIRC	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-7.09	4.54e-12	2.11e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
KIRC	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	7.09	4.54e-12	2.11e-09	0.24	0.3	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
KIRC	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-7.09	4.54e-12	2.11e-09	-0.24	-0.3	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
KIRC	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-7.09	4.54e-12	2.11e-09	-0.24	-0.3	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
KIRC	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	7.09	4.54e-12	2.11e-09	0.38	0.3	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
KIRC	cis	rs6456156	0.819	rs9457273	ENSG00000265828.1	MIR3939	7.09	4.55e-12	2.11e-09	0.35	0.3	Primary biliary cholangitis;	chr6:167107261	chr6:166997807~166997912:-
KIRC	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	7.09	4.55e-12	2.11e-09	0.35	0.3	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
KIRC	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-7.09	4.55e-12	2.11e-09	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
KIRC	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-7.09	4.56e-12	2.12e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
KIRC	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-7.09	4.56e-12	2.12e-09	-0.34	-0.3	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
KIRC	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	7.09	4.56e-12	2.12e-09	0.47	0.3	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
KIRC	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-7.09	4.57e-12	2.12e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
KIRC	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	7.09	4.57e-12	2.12e-09	0.3	0.3	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
KIRC	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	7.09	4.58e-12	2.12e-09	0.33	0.3	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
KIRC	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-7.09	4.58e-12	2.13e-09	-0.4	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
KIRC	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	7.09	4.58e-12	2.13e-09	0.32	0.3	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
KIRC	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	7.09	4.58e-12	2.13e-09	0.35	0.3	Depression;	chr6:28108492	chr6:28073316~28074233:+
KIRC	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	7.09	4.58e-12	2.13e-09	0.32	0.3	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
KIRC	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-7.09	4.58e-12	2.13e-09	-0.24	-0.3	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
KIRC	cis	rs13434995	0.513	rs7665286	ENSG00000249700.7	SRD5A3-AS1	7.09	4.59e-12	2.13e-09	0.31	0.3	Adiponectin levels;	chr4:55578765	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs7683997	ENSG00000249700.7	SRD5A3-AS1	7.09	4.59e-12	2.13e-09	0.31	0.3	Adiponectin levels;	chr4:55581272	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs4336288	ENSG00000249700.7	SRD5A3-AS1	7.09	4.59e-12	2.13e-09	0.31	0.3	Adiponectin levels;	chr4:55584088	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.513	rs9993599	ENSG00000249700.7	SRD5A3-AS1	7.09	4.59e-12	2.13e-09	0.31	0.3	Adiponectin levels;	chr4:55586798	chr4:55363971~55395847:-
KIRC	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-7.09	4.59e-12	2.13e-09	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-7.09	4.59e-12	2.13e-09	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
KIRC	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	7.09	4.59e-12	2.13e-09	0.49	0.3	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	7.09	4.59e-12	2.13e-09	0.49	0.3	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
KIRC	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	7.09	4.59e-12	2.13e-09	0.49	0.3	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
KIRC	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	7.09	4.6e-12	2.13e-09	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
KIRC	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	7.09	4.6e-12	2.13e-09	0.43	0.3	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	7.09	4.6e-12	2.13e-09	0.43	0.3	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	7.09	4.6e-12	2.13e-09	0.43	0.3	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
KIRC	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	7.09	4.61e-12	2.14e-09	0.58	0.3	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
KIRC	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	7.09	4.61e-12	2.14e-09	0.38	0.3	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
KIRC	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-7.09	4.61e-12	2.14e-09	-0.35	-0.3	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
KIRC	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	7.09	4.62e-12	2.14e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
KIRC	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-7.09	4.63e-12	2.15e-09	-0.26	-0.3	Height;	chr2:46629946	chr2:46668870~46670778:+
KIRC	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-7.09	4.63e-12	2.15e-09	-0.26	-0.3	Height;	chr2:46630262	chr2:46668870~46670778:+
KIRC	cis	rs11148252	0.904	rs9536079	ENSG00000278238.1	RP11-245D16.4	-7.09	4.63e-12	2.15e-09	-0.34	-0.3	Lewy body disease;	chr13:52456430	chr13:52454775~52455331:-
KIRC	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	7.09	4.63e-12	2.15e-09	0.39	0.3	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
KIRC	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-7.09	4.64e-12	2.15e-09	-0.46	-0.3	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
KIRC	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	7.09	4.64e-12	2.15e-09	0.35	0.3	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
KIRC	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-7.09	4.65e-12	2.16e-09	-0.35	-0.3	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.09	4.65e-12	2.16e-09	-0.35	-0.3	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
KIRC	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	7.09	4.65e-12	2.16e-09	0.3	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
KIRC	cis	rs600231	0.665	rs1626021	ENSG00000173727.10	CMB9-22P13.1	7.09	4.66e-12	2.16e-09	0.35	0.3	Bone mineral density;	chr11:65458716	chr11:65455258~65466720:+
KIRC	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-7.09	4.66e-12	2.16e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
KIRC	cis	rs62025270	0.632	rs7177107	ENSG00000202081.1	RNU6-1280P	-7.09	4.66e-12	2.16e-09	-0.39	-0.3	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85651522~85651628:-
KIRC	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	7.09	4.67e-12	2.17e-09	0.4	0.3	Height;	chr6:109423330	chr6:109382795~109383666:+
KIRC	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	7.09	4.67e-12	2.17e-09	0.33	0.3	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	7.09	4.67e-12	2.17e-09	0.33	0.3	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	7.09	4.67e-12	2.17e-09	0.33	0.3	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
KIRC	cis	rs8048589	0.898	rs8063329	ENSG00000175604.2	RP11-276H1.3	-7.09	4.68e-12	2.17e-09	-0.35	-0.3	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092190	chr16:12086746~12090302:-
KIRC	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-7.09	4.68e-12	2.17e-09	-0.22	-0.3	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
KIRC	cis	rs7924176	0.521	rs11000960	ENSG00000213731.2	RAB5CP1	-7.09	4.69e-12	2.18e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74423435~74424014:-
KIRC	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-7.09	4.7e-12	2.18e-09	-0.23	-0.3	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
KIRC	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-7.09	4.71e-12	2.18e-09	-0.38	-0.3	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
KIRC	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	7.09	4.72e-12	2.19e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	7.09	4.72e-12	2.19e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
KIRC	cis	rs1560104	0.709	rs2903042	ENSG00000274834.1	CTD-3037G24.5	-7.09	4.73e-12	2.19e-09	-0.34	-0.3	Obesity-related traits;	chr16:12604249	chr16:12614451~12614852:+
KIRC	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	7.09	4.73e-12	2.19e-09	0.41	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
KIRC	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-7.09	4.74e-12	2.2e-09	-0.25	-0.3	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
KIRC	cis	rs1552244	0.882	rs68080705	ENSG00000180385.7	EMC3-AS1	7.09	4.74e-12	2.2e-09	0.3	0.3	Alzheimer's disease;	chr3:9984059	chr3:9986893~10006990:+
KIRC	cis	rs17772222	0.63	rs12437422	ENSG00000222990.1	RNU4-22P	-7.09	4.74e-12	2.2e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88529621	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.605	rs4899955	ENSG00000222990.1	RNU4-22P	-7.09	4.74e-12	2.2e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88530381	chr14:88513498~88513663:+
KIRC	cis	rs11647589	0.689	rs8045136	ENSG00000260762.1	ACSM5P1	-7.09	4.74e-12	2.2e-09	-0.31	-0.3	Blood metabolite levels;	chr16:20442599	chr16:20586550~20607107:-
KIRC	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	7.09	4.75e-12	2.2e-09	0.28	0.3	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
KIRC	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-7.09	4.75e-12	2.2e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-7.09	4.75e-12	2.2e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-7.09	4.75e-12	2.2e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-7.09	4.75e-12	2.2e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
KIRC	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	7.09	4.76e-12	2.2e-09	0.31	0.3	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	7.09	4.76e-12	2.2e-09	0.38	0.3	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
KIRC	cis	rs7182948	0.958	rs10048065	ENSG00000259531.2	RP11-295H24.3	-7.09	4.76e-12	2.21e-09	-0.37	-0.3	Lung adenocarcinoma;	chr15:49458210	chr15:49365124~49366685:-
KIRC	cis	rs7182948	0.918	rs7178101	ENSG00000259531.2	RP11-295H24.3	-7.09	4.76e-12	2.21e-09	-0.37	-0.3	Lung adenocarcinoma;	chr15:49460497	chr15:49365124~49366685:-
KIRC	cis	rs7182948	0.918	rs2413958	ENSG00000259531.2	RP11-295H24.3	-7.09	4.76e-12	2.21e-09	-0.37	-0.3	Lung adenocarcinoma;	chr15:49468349	chr15:49365124~49366685:-
KIRC	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	7.09	4.76e-12	2.21e-09	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
KIRC	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	7.09	4.76e-12	2.21e-09	0.39	0.3	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
KIRC	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	7.09	4.77e-12	2.21e-09	0.32	0.3	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	7.09	4.77e-12	2.21e-09	0.32	0.3	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
KIRC	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	7.09	4.77e-12	2.21e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-7.09	4.77e-12	2.21e-09	-0.29	-0.3	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
KIRC	cis	rs1552244	0.748	rs113890152	ENSG00000180385.7	EMC3-AS1	7.09	4.78e-12	2.21e-09	0.3	0.3	Alzheimer's disease;	chr3:10044302	chr3:9986893~10006990:+
KIRC	cis	rs10214930	0.813	rs7786973	ENSG00000235574.1	AC073150.6	-7.09	4.79e-12	2.22e-09	-0.39	-0.3	Hypospadias;	chr7:27542629	chr7:27491682~27492765:-
KIRC	cis	rs11647589	0.642	rs7193826	ENSG00000262995.1	CTD-2194A8.2	-7.09	4.8e-12	2.22e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20467260	chr16:20440266~20447000:-
KIRC	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-7.09	4.8e-12	2.22e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
KIRC	cis	rs11148252	0.904	rs3892337	ENSG00000278238.1	RP11-245D16.4	-7.08	4.81e-12	2.23e-09	-0.34	-0.3	Lewy body disease;	chr13:52455350	chr13:52454775~52455331:-
KIRC	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	7.08	4.81e-12	2.23e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	7.08	4.81e-12	2.23e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
KIRC	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-7.08	4.82e-12	2.23e-09	-0.27	-0.3	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-7.08	4.82e-12	2.23e-09	-0.27	-0.3	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
KIRC	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-7.08	4.83e-12	2.23e-09	-0.35	-0.3	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
KIRC	cis	rs6061231	0.837	rs6061235	ENSG00000275437.1	RP5-908M14.10	7.08	4.83e-12	2.23e-09	0.27	0.3	Colorectal cancer;	chr20:62403468	chr20:62402236~62405935:-
KIRC	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	7.08	4.83e-12	2.24e-09	0.37	0.3	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
KIRC	cis	rs34375054	0.573	rs34579346	ENSG00000279233.1	RP11-158L12.4	7.08	4.84e-12	2.24e-09	0.25	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125173628	chr12:125138245~125141711:+
KIRC	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	7.08	4.84e-12	2.24e-09	0.29	0.3	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
KIRC	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-7.08	4.84e-12	2.24e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
KIRC	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-7.08	4.85e-12	2.24e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
KIRC	cis	rs1431005	1	rs56063429	ENSG00000250620.1	RP11-91J3.3	7.08	4.85e-12	2.24e-09	0.39	0.3	Response to statin therapy;	chr4:187450476	chr4:187413564~187415697:+
KIRC	cis	rs13434995	0.513	rs7665846	ENSG00000249700.7	SRD5A3-AS1	7.08	4.85e-12	2.24e-09	0.3	0.3	Adiponectin levels;	chr4:55573078	chr4:55363971~55395847:-
KIRC	cis	rs2288884	1	rs58817690	ENSG00000275055.1	CTC-471J1.11	-7.08	4.85e-12	2.24e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52049007~52049754:+
KIRC	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	7.08	4.86e-12	2.25e-09	0.33	0.3	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
KIRC	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	7.08	4.87e-12	2.25e-09	0.37	0.3	Height;	chr4:55558258	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	7.08	4.87e-12	2.25e-09	0.37	0.3	Height;	chr4:55558259	chr4:55387949~55388271:+
KIRC	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	7.08	4.87e-12	2.25e-09	0.37	0.3	Height;	chr4:55558261	chr4:55387949~55388271:+
KIRC	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	7.08	4.88e-12	2.25e-09	0.33	0.3	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
KIRC	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	7.08	4.88e-12	2.26e-09	0.36	0.3	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
KIRC	cis	rs17801127	0.818	rs34272267	ENSG00000231969.1	AC144449.1	7.08	4.89e-12	2.26e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149679511	chr2:149587196~149848233:+
KIRC	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	7.08	4.89e-12	2.26e-09	0.27	0.3	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
KIRC	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-7.08	4.9e-12	2.26e-09	-0.17	-0.3	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
KIRC	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-7.08	4.9e-12	2.26e-09	-0.17	-0.3	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
KIRC	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-7.08	4.9e-12	2.27e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
KIRC	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-7.08	4.91e-12	2.27e-09	-0.35	-0.3	Depression;	chr6:28110525	chr6:28073316~28074233:+
KIRC	cis	rs6061231	0.834	rs2427307	ENSG00000275437.1	RP5-908M14.10	7.08	4.91e-12	2.27e-09	0.24	0.3	Colorectal cancer;	chr20:62391630	chr20:62402236~62405935:-
KIRC	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-7.08	4.92e-12	2.28e-09	-0.56	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
KIRC	cis	rs6908034	0.66	rs6918235	ENSG00000228412.5	RP4-625H18.2	7.08	4.92e-12	2.28e-09	0.69	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19802164~19804752:-
KIRC	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	7.08	4.93e-12	2.28e-09	0.31	0.3	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
KIRC	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-7.08	4.93e-12	2.28e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
KIRC	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-7.08	4.93e-12	2.28e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
KIRC	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-7.08	4.94e-12	2.28e-09	-0.45	-0.3	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
KIRC	cis	rs3744061	0.776	rs9916811	ENSG00000277382.1	RP11-318A15.8	-7.08	4.94e-12	2.28e-09	-0.34	-0.3	Retinal arteriolar caliber;	chr17:76753191	chr17:76709760~76710045:+
KIRC	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	7.08	4.95e-12	2.29e-09	0.38	0.3	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
KIRC	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	7.08	4.96e-12	2.29e-09	0.32	0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
KIRC	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	7.08	4.96e-12	2.29e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
KIRC	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	7.08	4.97e-12	2.29e-09	0.4	0.3	Depression;	chr6:28200948	chr6:28115628~28116551:+
KIRC	cis	rs1552244	1	rs61052895	ENSG00000180385.7	EMC3-AS1	7.08	4.97e-12	2.3e-09	0.31	0.3	Alzheimer's disease;	chr3:10105832	chr3:9986893~10006990:+
KIRC	cis	rs4356975	0.896	rs58496756	ENSG00000198277.6	RP11-468N14.09	7.08	4.99e-12	2.31e-09	0.32	0.3	Obesity-related traits;	chr4:69072070	chr4:68914928~68924741:-
KIRC	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-7.08	5e-12	2.31e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
KIRC	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-7.08	5.01e-12	2.31e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
KIRC	cis	rs11079159	0.917	rs12452367	ENSG00000263096.1	RP11-515O17.2	7.08	5.01e-12	2.31e-09	0.44	0.3	QRS duration;	chr17:55297249	chr17:55271504~55273653:-
KIRC	cis	rs1552244	0.81	rs35711405	ENSG00000180385.7	EMC3-AS1	7.08	5.01e-12	2.32e-09	0.3	0.3	Alzheimer's disease;	chr3:10075255	chr3:9986893~10006990:+
KIRC	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-7.08	5.02e-12	2.32e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
KIRC	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-7.08	5.02e-12	2.32e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
KIRC	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.08	5.02e-12	2.32e-09	0.36	0.3	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
KIRC	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-7.08	5.02e-12	2.32e-09	-0.4	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
KIRC	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-7.08	5.03e-12	2.32e-09	-0.22	-0.3	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
KIRC	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	7.08	5.03e-12	2.32e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
KIRC	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	7.08	5.03e-12	2.32e-09	0.41	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
KIRC	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-7.08	5.04e-12	2.32e-09	-0.38	-0.3	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
KIRC	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	2.33e-09	0.27	0.3	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
KIRC	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	7.08	5.05e-12	2.33e-09	0.24	0.3	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
KIRC	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	7.08	5.06e-12	2.33e-09	0.44	0.3	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	7.08	5.06e-12	2.33e-09	0.44	0.3	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	7.08	5.06e-12	2.33e-09	0.44	0.3	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	7.08	5.06e-12	2.33e-09	0.44	0.3	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	7.08	5.06e-12	2.33e-09	0.44	0.3	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
KIRC	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	7.08	5.06e-12	2.33e-09	0.31	0.3	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
KIRC	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-7.08	5.06e-12	2.33e-09	-0.33	-0.3	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
KIRC	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	7.08	5.06e-12	2.33e-09	0.22	0.3	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
KIRC	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-7.08	5.06e-12	2.33e-09	-0.59	-0.3	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
KIRC	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-7.08	5.07e-12	2.34e-09	-0.39	-0.3	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
KIRC	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	7.08	5.08e-12	2.34e-09	0.27	0.3	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	7.08	5.08e-12	2.34e-09	0.27	0.3	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
KIRC	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-7.08	5.08e-12	2.34e-09	-0.27	-0.3	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
KIRC	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	7.08	5.1e-12	2.35e-09	0.36	0.3	Depression;	chr6:28104824	chr6:28073316~28074233:+
KIRC	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	7.08	5.11e-12	2.36e-09	0.36	0.3	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
KIRC	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-7.08	5.11e-12	2.36e-09	-0.38	-0.3	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
KIRC	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	7.08	5.12e-12	2.36e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
KIRC	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	7.08	5.12e-12	2.36e-09	0.25	0.3	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
KIRC	cis	rs2486288	0.656	rs8037583	ENSG00000235390.4	CTD-2651B20.5	7.08	5.12e-12	2.36e-09	0.29	0.3	Glomerular filtration rate;	chr15:45254180	chr15:45321077~45321692:-
KIRC	cis	rs17711722	0.565	rs73372653	ENSG00000275400.1	RP4-756H11.5	-7.08	5.13e-12	2.36e-09	-0.32	-0.3	Calcium levels;	chr7:65977808	chr7:66553805~66554199:-
KIRC	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-7.07	5.13e-12	2.37e-09	-0.17	-0.3	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
KIRC	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-7.07	5.15e-12	2.37e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-7.07	5.15e-12	2.37e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
KIRC	cis	rs9601248	0.627	rs2876741	ENSG00000227354.5	RBM26-AS1	-7.07	5.15e-12	2.37e-09	-0.36	-0.3	Major depressive disorder;	chr13:79612577	chr13:79406309~79424328:+
KIRC	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	7.07	5.15e-12	2.37e-09	0.5	0.3	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
KIRC	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	7.07	5.15e-12	2.37e-09	0.31	0.3	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
KIRC	cis	rs11647589	0.642	rs1532842	ENSG00000262995.1	CTD-2194A8.2	-7.07	5.15e-12	2.37e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20468067	chr16:20440266~20447000:-
KIRC	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	7.07	5.16e-12	2.38e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
KIRC	cis	rs11148252	0.904	rs7321964	ENSG00000278238.1	RP11-245D16.4	-7.07	5.16e-12	2.38e-09	-0.34	-0.3	Lewy body disease;	chr13:52466687	chr13:52454775~52455331:-
KIRC	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	7.07	5.17e-12	2.38e-09	0.33	0.3	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
KIRC	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	7.07	5.18e-12	2.39e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	7.07	5.18e-12	2.39e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
KIRC	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-7.07	5.18e-12	2.39e-09	-0.37	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
KIRC	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	7.07	5.19e-12	2.39e-09	0.34	0.3	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
KIRC	cis	rs3820928	0.874	rs6717168	ENSG00000212391.1	SNORA48	-7.07	5.19e-12	2.39e-09	-0.35	-0.3	Pulmonary function;	chr2:227036626	chr2:226968989~226969122:-
KIRC	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-7.07	5.19e-12	2.39e-09	-0.22	-0.3	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
KIRC	cis	rs6061231	0.793	rs2427320	ENSG00000275437.1	RP5-908M14.10	7.07	5.19e-12	2.39e-09	0.26	0.3	Colorectal cancer;	chr20:62401667	chr20:62402236~62405935:-
KIRC	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-7.07	5.21e-12	2.4e-09	-0.32	-0.3	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
KIRC	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	7.07	5.21e-12	2.4e-09	0.41	0.3	Depression;	chr6:28187640	chr6:28115628~28116551:+
KIRC	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-7.07	5.22e-12	2.4e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-7.07	5.22e-12	2.4e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-7.07	5.22e-12	2.4e-09	-0.28	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
KIRC	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	7.07	5.23e-12	2.41e-09	0.38	0.3	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
KIRC	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-7.07	5.24e-12	2.41e-09	-0.23	-0.3	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
KIRC	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	7.07	5.25e-12	2.42e-09	0.3	0.3	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
KIRC	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-7.07	5.25e-12	2.42e-09	-0.17	-0.3	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
KIRC	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-7.07	5.25e-12	2.42e-09	-0.2	-0.3	Breast cancer;	chr11:743813	chr11:781645~782105:+
KIRC	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	7.07	5.26e-12	2.42e-09	0.4	0.3	Height;	chr6:109423487	chr6:109382795~109383666:+
KIRC	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-7.07	5.27e-12	2.42e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
KIRC	cis	rs62025270	0.632	rs62023935	ENSG00000202081.1	RNU6-1280P	-7.07	5.27e-12	2.42e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85651522~85651628:-
KIRC	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	7.07	5.27e-12	2.43e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	7.07	5.27e-12	2.43e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	7.07	5.27e-12	2.43e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	7.07	5.27e-12	2.43e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	7.07	5.27e-12	2.43e-09	0.37	0.3	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
KIRC	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-7.07	5.27e-12	2.43e-09	-0.22	-0.3	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-7.07	5.28e-12	2.43e-09	-0.22	-0.3	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
KIRC	cis	rs4888671	0.614	rs75165142	ENSG00000261707.1	RP11-264M12.2	7.07	5.29e-12	2.43e-09	0.46	0.3	Obesity-related traits;	chr16:77741022	chr16:77741468~77743000:-
KIRC	cis	rs897984	0.806	rs8052245	ENSG00000260911.2	RP11-196G11.2	-7.07	5.29e-12	2.44e-09	-0.2	-0.3	Dementia with Lewy bodies;	chr16:30905109	chr16:31043150~31049868:+
KIRC	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-7.07	5.29e-12	2.44e-09	-0.34	-0.3	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
KIRC	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	7.07	5.29e-12	2.44e-09	0.46	0.3	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
KIRC	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	7.07	5.3e-12	2.44e-09	0.26	0.3	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
KIRC	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.31e-12	2.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
KIRC	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-7.07	5.31e-12	2.44e-09	-0.24	-0.3	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
KIRC	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-7.07	5.31e-12	2.44e-09	-0.45	-0.3	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
KIRC	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	7.07	5.31e-12	2.44e-09	0.41	0.3	Depression;	chr6:28303421	chr6:28943877~28944537:+
KIRC	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-7.07	5.32e-12	2.45e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-7.07	5.32e-12	2.45e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-7.07	5.32e-12	2.45e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
KIRC	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-7.07	5.32e-12	2.45e-09	-0.34	-0.3	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
KIRC	cis	rs7592578	0.581	rs59109438	ENSG00000272979.1	RP11-647K16.1	-7.07	5.32e-12	2.45e-09	-0.42	-0.3	Diastolic blood pressure;	chr2:190422957	chr2:190454092~190454521:-
KIRC	cis	rs7592578	0.639	rs61709084	ENSG00000272979.1	RP11-647K16.1	-7.07	5.32e-12	2.45e-09	-0.42	-0.3	Diastolic blood pressure;	chr2:190422959	chr2:190454092~190454521:-
KIRC	cis	rs4356975	0.932	rs7654272	ENSG00000198277.6	RP11-468N14.09	7.07	5.32e-12	2.45e-09	0.32	0.3	Obesity-related traits;	chr4:69074144	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs6600867	ENSG00000198277.6	RP11-468N14.09	7.07	5.32e-12	2.45e-09	0.32	0.3	Obesity-related traits;	chr4:69074157	chr4:68914928~68924741:-
KIRC	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-7.07	5.33e-12	2.45e-09	-0.35	-0.3	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
KIRC	cis	rs11647589	0.641	rs1394676	ENSG00000262995.1	CTD-2194A8.2	-7.07	5.33e-12	2.45e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20477880	chr16:20440266~20447000:-
KIRC	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-7.07	5.33e-12	2.45e-09	-0.37	-0.3	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
KIRC	cis	rs1476679	1	rs1476679	ENSG00000078319.8	PMS2P1	7.07	5.34e-12	2.46e-09	0.38	0.3	Alzheimer's disease (late onset);	chr7:100406823	chr7:100320992~100341908:-
KIRC	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	7.07	5.34e-12	2.46e-09	0.38	0.3	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
KIRC	cis	rs600231	0.665	rs2105608	ENSG00000173727.10	CMB9-22P13.1	7.07	5.34e-12	2.46e-09	0.35	0.3	Bone mineral density;	chr11:65461147	chr11:65455258~65466720:+
KIRC	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	7.07	5.35e-12	2.46e-09	0.23	0.3	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
KIRC	cis	rs4072705	0.967	rs10739651	ENSG00000224020.1	MIR181A2HG	-7.07	5.35e-12	2.46e-09	-0.31	-0.3	Menarche (age at onset);	chr9:124561794	chr9:124658467~124698631:+
KIRC	cis	rs2288884	1	rs80278704	ENSG00000275055.1	CTC-471J1.11	-7.07	5.35e-12	2.46e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs11669540	ENSG00000275055.1	CTC-471J1.11	-7.07	5.35e-12	2.46e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs78543982	ENSG00000275055.1	CTC-471J1.11	-7.07	5.35e-12	2.46e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.943	rs3752120	ENSG00000275055.1	CTC-471J1.11	-7.07	5.35e-12	2.46e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52049007~52049754:+
KIRC	cis	rs10214930	0.697	rs6974052	ENSG00000235574.1	AC073150.6	-7.07	5.35e-12	2.46e-09	-0.36	-0.3	Hypospadias;	chr7:27515978	chr7:27491682~27492765:-
KIRC	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	7.07	5.36e-12	2.46e-09	0.37	0.3	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
KIRC	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	7.07	5.36e-12	2.46e-09	0.33	0.3	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	7.07	5.36e-12	2.46e-09	0.33	0.3	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
KIRC	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-7.07	5.37e-12	2.47e-09	-0.31	-0.3	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
KIRC	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.37e-12	2.47e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
KIRC	cis	rs17801127	0.901	rs13026469	ENSG00000231969.1	AC144449.1	7.07	5.37e-12	2.47e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149698874	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.901	rs13011748	ENSG00000231969.1	AC144449.1	7.07	5.37e-12	2.47e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149699081	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs16827311	ENSG00000231969.1	AC144449.1	7.07	5.38e-12	2.47e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149666306	chr2:149587196~149848233:+
KIRC	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	7.07	5.38e-12	2.47e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
KIRC	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-7.07	5.38e-12	2.47e-09	-0.35	-0.3	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
KIRC	cis	rs3750965	0.806	rs7107680	ENSG00000260895.1	RP11-554A11.7	7.07	5.39e-12	2.48e-09	0.38	0.3	Hair color;	chr11:69092426	chr11:69103493~69109094:+
KIRC	cis	rs4356975	0.83	rs7435274	ENSG00000250696.4	RP11-704M14.1	7.07	5.39e-12	2.48e-09	0.32	0.3	Obesity-related traits;	chr4:69050281	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs7438808	ENSG00000250696.4	RP11-704M14.1	7.07	5.39e-12	2.48e-09	0.32	0.3	Obesity-related traits;	chr4:69050666	chr4:69182100~69216766:+
KIRC	cis	rs6908034	0.66	rs74795718	ENSG00000228412.5	RP4-625H18.2	7.07	5.39e-12	2.48e-09	0.69	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19802164~19804752:-
KIRC	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	7.07	5.4e-12	2.48e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
KIRC	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-7.07	5.42e-12	2.49e-09	-0.62	-0.3	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
KIRC	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-7.07	5.42e-12	2.49e-09	-0.39	-0.3	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
KIRC	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-7.07	5.42e-12	2.49e-09	-0.43	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
KIRC	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	7.07	5.44e-12	2.5e-09	0.37	0.3	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
KIRC	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	7.07	5.45e-12	2.5e-09	0.34	0.3	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
KIRC	cis	rs13434995	0.513	rs2412658	ENSG00000249700.7	SRD5A3-AS1	7.07	5.46e-12	2.51e-09	0.3	0.3	Adiponectin levels;	chr4:55577050	chr4:55363971~55395847:-
KIRC	cis	rs755249	1	rs755249	ENSG00000237624.1	OXCT2P1	7.07	5.47e-12	2.51e-09	0.44	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39514956~39516490:+
KIRC	cis	rs1552244	0.882	rs6443279	ENSG00000180385.7	EMC3-AS1	7.07	5.47e-12	2.51e-09	0.3	0.3	Alzheimer's disease;	chr3:10011915	chr3:9986893~10006990:+
KIRC	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-7.07	5.47e-12	2.51e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
KIRC	cis	rs7937127	0.696	rs56388058	ENSG00000254907.1	RP11-484D2.2	7.07	5.48e-12	2.51e-09	0.4	0.3	Fibrinogen levels;	chr11:43512927	chr11:43328748~43359296:-
KIRC	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	7.06	5.48e-12	2.52e-09	0.44	0.3	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
KIRC	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	7.06	5.49e-12	2.52e-09	0.36	0.3	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
KIRC	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	7.06	5.49e-12	2.52e-09	0.43	0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
KIRC	cis	rs2797160	0.651	rs6939969	ENSG00000237742.5	RP11-624M8.1	7.06	5.49e-12	2.52e-09	0.36	0.3	Endometrial cancer;	chr6:125713417	chr6:125578558~125749190:-
KIRC	cis	rs8048589	1	rs8048589	ENSG00000175604.2	RP11-276H1.3	-7.06	5.5e-12	2.52e-09	-0.35	-0.3	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091953	chr16:12086746~12090302:-
KIRC	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-7.06	5.5e-12	2.52e-09	-0.29	-0.3	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-7.06	5.5e-12	2.52e-09	-0.29	-0.3	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
KIRC	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-7.06	5.5e-12	2.52e-09	-0.36	-0.3	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
KIRC	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-7.06	5.5e-12	2.53e-09	-0.24	-0.3	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
KIRC	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	7.06	5.5e-12	2.53e-09	0.33	0.3	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
KIRC	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	7.06	5.51e-12	2.53e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	7.06	5.51e-12	2.53e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
KIRC	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-7.06	5.51e-12	2.53e-09	-0.24	-0.3	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
KIRC	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-7.06	5.51e-12	2.53e-09	-0.24	-0.3	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
KIRC	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-7.06	5.51e-12	2.53e-09	-0.24	-0.3	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
KIRC	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-7.06	5.51e-12	2.53e-09	-0.24	-0.3	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
KIRC	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	7.06	5.52e-12	2.53e-09	0.39	0.3	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
KIRC	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-7.06	5.52e-12	2.53e-09	-0.35	-0.3	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
KIRC	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	7.06	5.53e-12	2.54e-09	0.28	0.3	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
KIRC	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-7.06	5.55e-12	2.55e-09	-0.34	-0.3	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
KIRC	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-7.06	5.55e-12	2.55e-09	-0.25	-0.3	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
KIRC	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-7.06	5.56e-12	2.55e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
KIRC	cis	rs7017914	0.652	rs950903	ENSG00000254031.4	RP11-326E22.1	7.06	5.56e-12	2.55e-09	0.35	0.3	Bone mineral density;	chr8:70988539	chr8:71155457~71204223:+
KIRC	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-7.06	5.56e-12	2.55e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
KIRC	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-7.06	5.56e-12	2.55e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
KIRC	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-7.06	5.57e-12	2.55e-09	-0.26	-0.3	Height;	chr6:25872956	chr6:25992662~26001775:+
KIRC	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	7.06	5.57e-12	2.56e-09	0.25	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
KIRC	cis	rs10214930	0.697	rs12700822	ENSG00000235574.1	AC073150.6	-7.06	5.57e-12	2.56e-09	-0.35	-0.3	Hypospadias;	chr7:27605807	chr7:27491682~27492765:-
KIRC	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-7.06	5.58e-12	2.56e-09	-0.24	-0.3	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
KIRC	cis	rs3750965	0.919	rs12280942	ENSG00000260895.1	RP11-554A11.7	-7.06	5.59e-12	2.56e-09	-0.37	-0.3	Hair color;	chr11:69092215	chr11:69103493~69109094:+
KIRC	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	7.06	5.6e-12	2.57e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
KIRC	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-7.06	5.6e-12	2.57e-09	-0.22	-0.3	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
KIRC	cis	rs4072705	1	rs2416949	ENSG00000224020.1	MIR181A2HG	-7.06	5.6e-12	2.57e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124712832	chr9:124658467~124698631:+
KIRC	cis	rs62025270	0.632	rs55981798	ENSG00000202081.1	RNU6-1280P	-7.06	5.6e-12	2.57e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.576	rs17633959	ENSG00000202081.1	RNU6-1280P	-7.06	5.6e-12	2.57e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85651522~85651628:-
KIRC	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	7.06	5.61e-12	2.57e-09	0.39	0.3	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
KIRC	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	7.06	5.61e-12	2.57e-09	0.31	0.3	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
KIRC	cis	rs11671005	0.504	rs2305119	ENSG00000269600.1	AC016629.3	-7.06	5.62e-12	2.57e-09	-0.43	-0.3	Mean platelet volume;	chr19:58556256	chr19:58593896~58599355:-
KIRC	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-7.06	5.62e-12	2.58e-09	-0.24	-0.3	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
KIRC	cis	rs10214930	0.671	rs6959495	ENSG00000235574.1	AC073150.6	-7.06	5.62e-12	2.58e-09	-0.35	-0.3	Hypospadias;	chr7:27652673	chr7:27491682~27492765:-
KIRC	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	7.06	5.64e-12	2.58e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
KIRC	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-7.06	5.65e-12	2.59e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
KIRC	cis	rs13434995	0.891	rs62309728	ENSG00000249700.7	SRD5A3-AS1	-7.06	5.65e-12	2.59e-09	-0.34	-0.3	Adiponectin levels;	chr4:55530648	chr4:55363971~55395847:-
KIRC	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	7.06	5.66e-12	2.59e-09	0.26	0.3	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	7.06	5.66e-12	2.59e-09	0.26	0.3	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
KIRC	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	7.06	5.67e-12	2.6e-09	0.29	0.3	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
KIRC	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	7.06	5.68e-12	2.6e-09	0.29	0.3	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
KIRC	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	7.06	5.69e-12	2.61e-09	0.39	0.3	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
KIRC	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-7.06	5.69e-12	2.61e-09	-0.26	-0.3	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
KIRC	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	7.06	5.7e-12	2.61e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
KIRC	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-7.06	5.7e-12	2.61e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
KIRC	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	7.06	5.7e-12	2.61e-09	0.37	0.3	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
KIRC	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-7.06	5.7e-12	2.61e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
KIRC	cis	rs10214930	0.697	rs13308974	ENSG00000235574.1	AC073150.6	-7.06	5.71e-12	2.61e-09	-0.35	-0.3	Hypospadias;	chr7:27612719	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs12534603	ENSG00000235574.1	AC073150.6	-7.06	5.71e-12	2.61e-09	-0.35	-0.3	Hypospadias;	chr7:27613034	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.647	rs7790498	ENSG00000235574.1	AC073150.6	-7.06	5.71e-12	2.61e-09	-0.35	-0.3	Hypospadias;	chr7:27613588	chr7:27491682~27492765:-
KIRC	cis	rs17801127	0.892	rs13005911	ENSG00000231969.1	AC144449.1	-7.06	5.72e-12	2.62e-09	-0.51	-0.3	Liver enzyme levels (alanine transaminase);	chr2:149698695	chr2:149587196~149848233:+
KIRC	cis	rs62025270	0.632	rs6496109	ENSG00000202081.1	RNU6-1280P	-7.06	5.72e-12	2.62e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85651522~85651628:-
KIRC	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	7.06	5.72e-12	2.62e-09	0.29	0.3	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
KIRC	cis	rs11647589	0.834	rs1505100	ENSG00000262995.1	CTD-2194A8.2	7.06	5.72e-12	2.62e-09	0.32	0.3	Blood metabolite levels;	chr16:20470350	chr16:20440266~20447000:-
KIRC	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	7.06	5.73e-12	2.62e-09	0.37	0.3	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
KIRC	cis	rs9388451	0.872	rs2008027	ENSG00000237742.5	RP11-624M8.1	-7.06	5.74e-12	2.63e-09	-0.37	-0.3	Brugada syndrome;	chr6:125731213	chr6:125578558~125749190:-
KIRC	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-7.06	5.75e-12	2.63e-09	-0.34	-0.3	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
KIRC	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	7.06	5.76e-12	2.64e-09	0.46	0.3	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
KIRC	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	7.06	5.76e-12	2.64e-09	0.38	0.3	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
KIRC	cis	rs9371601	0.859	rs214980	ENSG00000226193.1	RP3-398G3.5	-7.06	5.77e-12	2.64e-09	-0.33	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152411483	chr6:152402398~152404966:+
KIRC	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.06	5.77e-12	2.64e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
KIRC	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-7.06	5.78e-12	2.65e-09	-0.29	-0.3	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.675	rs845758	ENSG00000222990.1	RNU4-22P	-7.06	5.81e-12	2.66e-09	-0.33	-0.3	Coronary artery calcification;	chr14:88433746	chr14:88513498~88513663:+
KIRC	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-7.06	5.81e-12	2.66e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
KIRC	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-7.06	5.81e-12	2.66e-09	-0.32	-0.3	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
KIRC	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	7.06	5.83e-12	2.67e-09	0.42	0.3	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
KIRC	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-7.06	5.83e-12	2.67e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
KIRC	cis	rs755249	0.874	rs61779310	ENSG00000237624.1	OXCT2P1	7.06	5.84e-12	2.67e-09	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39514956~39516490:+
KIRC	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	7.06	5.84e-12	2.67e-09	0.26	0.3	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
KIRC	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-7.06	5.85e-12	2.67e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
KIRC	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	7.05	5.85e-12	2.68e-09	0.23	0.3	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	7.05	5.85e-12	2.68e-09	0.23	0.3	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
KIRC	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	7.05	5.85e-12	2.68e-09	0.23	0.3	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
KIRC	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-7.05	5.86e-12	2.68e-09	-0.33	-0.3	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
KIRC	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-7.05	5.86e-12	2.68e-09	-0.31	-0.3	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
KIRC	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-7.05	5.88e-12	2.69e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
KIRC	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	7.05	5.88e-12	2.69e-09	0.34	0.3	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
KIRC	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-7.05	5.89e-12	2.7e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-7.05	5.89e-12	2.7e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
KIRC	cis	rs1552244	1	rs6442150	ENSG00000180385.7	EMC3-AS1	7.05	5.9e-12	2.7e-09	0.3	0.3	Alzheimer's disease;	chr3:10080891	chr3:9986893~10006990:+
KIRC	cis	rs9901225	1	rs9901225	ENSG00000108785.7	HSD17B1P1	-7.05	5.91e-12	2.7e-09	-0.27	-0.3	Colorectal or endometrial cancer;	chr17:42603793	chr17:42546764~42548706:+
KIRC	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-7.05	5.91e-12	2.7e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
KIRC	cis	rs1552244	0.935	rs35148833	ENSG00000180385.7	EMC3-AS1	7.05	5.93e-12	2.71e-09	0.3	0.3	Alzheimer's disease;	chr3:10075253	chr3:9986893~10006990:+
KIRC	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	7.05	5.94e-12	2.72e-09	0.31	0.3	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
KIRC	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-7.05	5.96e-12	2.72e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
KIRC	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-7.05	5.96e-12	2.72e-09	-0.36	-0.3	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
KIRC	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28111382	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28111650	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28112175	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28113616	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28113851	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28114487	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28114933	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28115743	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Depression;	chr6:28116411	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	7.05	5.96e-12	2.72e-09	0.35	0.3	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
KIRC	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	7.05	5.96e-12	2.72e-09	0.68	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
KIRC	cis	rs2288884	1	rs76768215	ENSG00000275055.1	CTC-471J1.11	-7.05	5.96e-12	2.72e-09	-0.42	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52049007~52049754:+
KIRC	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-7.05	5.97e-12	2.73e-09	-0.36	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
KIRC	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-7.05	5.97e-12	2.73e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
KIRC	cis	rs1552244	0.882	rs6443276	ENSG00000180385.7	EMC3-AS1	7.05	5.98e-12	2.73e-09	0.29	0.3	Alzheimer's disease;	chr3:9967221	chr3:9986893~10006990:+
KIRC	cis	rs35264875	0.846	rs2924534	ENSG00000259799.1	RP11-554A11.9	-7.05	5.98e-12	2.73e-09	-0.38	-0.3	Blond vs. brown hair color;	chr11:69103048	chr11:69155910~69159752:+
KIRC	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	7.05	5.98e-12	2.73e-09	0.44	0.3	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
KIRC	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	7.05	5.98e-12	2.73e-09	0.37	0.3	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
KIRC	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	7.05	5.98e-12	2.73e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
KIRC	cis	rs2288884	1	rs2043298	ENSG00000275055.1	CTC-471J1.11	7.05	5.99e-12	2.74e-09	0.42	0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52049007~52049754:+
KIRC	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-7.05	6e-12	2.74e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
KIRC	cis	rs526231	0.756	rs448086	ENSG00000175749.11	EIF3KP1	7.05	6e-12	2.74e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103287880	chr5:103032376~103033031:+
KIRC	cis	rs1552244	1	rs66838678	ENSG00000180385.7	EMC3-AS1	7.05	6.02e-12	2.75e-09	0.3	0.3	Alzheimer's disease;	chr3:10108666	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.935	rs7618815	ENSG00000180385.7	EMC3-AS1	7.05	6.02e-12	2.75e-09	0.3	0.3	Alzheimer's disease;	chr3:10109361	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs7652935	ENSG00000180385.7	EMC3-AS1	7.05	6.02e-12	2.75e-09	0.3	0.3	Alzheimer's disease;	chr3:10109454	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs67134728	ENSG00000180385.7	EMC3-AS1	7.05	6.02e-12	2.75e-09	0.3	0.3	Alzheimer's disease;	chr3:10109747	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs68045038	ENSG00000180385.7	EMC3-AS1	7.05	6.02e-12	2.75e-09	0.3	0.3	Alzheimer's disease;	chr3:10110144	chr3:9986893~10006990:+
KIRC	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	7.05	6.02e-12	2.75e-09	0.49	0.3	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
KIRC	cis	rs9388451	0.903	rs9388446	ENSG00000237742.5	RP11-624M8.1	-7.05	6.02e-12	2.75e-09	-0.37	-0.3	Brugada syndrome;	chr6:125743774	chr6:125578558~125749190:-
KIRC	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	7.05	6.03e-12	2.75e-09	0.46	0.3	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
KIRC	cis	rs8048589	1	rs8059989	ENSG00000175604.2	RP11-276H1.3	-7.05	6.04e-12	2.76e-09	-0.35	-0.3	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091889	chr16:12086746~12090302:-
KIRC	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-7.05	6.04e-12	2.76e-09	-0.4	-0.3	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
KIRC	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-7.05	6.04e-12	2.76e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
KIRC	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-7.05	6.05e-12	2.76e-09	-0.38	-0.3	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
KIRC	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-7.05	6.05e-12	2.76e-09	-0.38	-0.3	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
KIRC	cis	rs6908034	0.556	rs79028848	ENSG00000228412.5	RP4-625H18.2	7.05	6.05e-12	2.76e-09	0.69	0.3	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19802164~19804752:-
KIRC	cis	rs13434995	0.513	rs6554291	ENSG00000249700.7	SRD5A3-AS1	-7.05	6.08e-12	2.78e-09	-0.3	-0.3	Adiponectin levels;	chr4:55571204	chr4:55363971~55395847:-
KIRC	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	7.05	6.09e-12	2.78e-09	0.4	0.3	Height;	chr6:109355573	chr6:109382795~109383666:+
KIRC	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	7.05	6.09e-12	2.78e-09	0.35	0.3	Depression;	chr6:28099759	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	7.05	6.09e-12	2.78e-09	0.35	0.3	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	7.05	6.09e-12	2.78e-09	0.35	0.3	Depression;	chr6:28100648	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	7.05	6.09e-12	2.78e-09	0.35	0.3	Depression;	chr6:28107222	chr6:28073316~28074233:+
KIRC	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-7.05	6.09e-12	2.78e-09	-0.24	-0.3	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
KIRC	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-7.05	6.1e-12	2.78e-09	-0.27	-0.3	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
KIRC	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.05	6.12e-12	2.79e-09	-0.35	-0.3	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.05	6.12e-12	2.79e-09	-0.35	-0.3	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.05	6.12e-12	2.79e-09	-0.35	-0.3	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-7.05	6.12e-12	2.79e-09	-0.35	-0.3	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	7.05	6.12e-12	2.79e-09	0.34	0.3	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
KIRC	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	7.05	6.14e-12	2.8e-09	0.37	0.3	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
KIRC	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-7.05	6.16e-12	2.81e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
KIRC	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	7.05	6.17e-12	2.81e-09	0.27	0.3	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
KIRC	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-7.05	6.18e-12	2.82e-09	-0.24	-0.3	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
KIRC	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-7.05	6.19e-12	2.82e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
KIRC	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	7.05	6.19e-12	2.82e-09	0.22	0.3	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
KIRC	cis	rs7924176	0.521	rs11000999	ENSG00000213731.2	RAB5CP1	-7.05	6.2e-12	2.82e-09	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74423435~74424014:-
KIRC	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	7.05	6.2e-12	2.83e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	7.05	6.2e-12	2.83e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
KIRC	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	7.05	6.21e-12	2.83e-09	0.26	0.3	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
KIRC	cis	rs755249	0.588	rs6665948	ENSG00000182109.6	RP11-69E11.4	-7.05	6.21e-12	2.83e-09	-0.23	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39522280~39546187:-
KIRC	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	7.05	6.22e-12	2.83e-09	0.35	0.3	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
KIRC	cis	rs904251	0.772	rs2252920	ENSG00000227920.2	RP1-153P14.5	-7.05	6.22e-12	2.84e-09	-0.36	-0.3	Cognitive performance;	chr6:37450551	chr6:37545145~37550860:+
KIRC	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-7.05	6.22e-12	2.84e-09	-0.37	-0.3	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
KIRC	cis	rs2018683	0.834	rs733485	ENSG00000228421.2	AC005013.5	7.05	6.23e-12	2.84e-09	0.31	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28957667~28959345:+
KIRC	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	7.05	6.23e-12	2.84e-09	0.29	0.3	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
KIRC	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-7.05	6.24e-12	2.84e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
KIRC	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-7.05	6.24e-12	2.84e-09	-0.23	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
KIRC	cis	rs9915657	0.87	rs11077595	ENSG00000234899.8	SOX9-AS1	-7.05	6.24e-12	2.84e-09	-0.38	-0.3	Thyroid hormone levels;	chr17:72133889	chr17:72034107~72237203:-
KIRC	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.05	6.24e-12	2.84e-09	0.45	0.3	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
KIRC	cis	rs11085466	0.519	rs12150872	ENSG00000268278.1	RP11-420K14.1	7.04	6.25e-12	2.85e-09	0.36	0.3	Colorectal or endometrial cancer;	chr19:21610708	chr19:21637974~21656300:+
KIRC	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-7.04	6.25e-12	2.85e-09	-0.29	-0.3	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
KIRC	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-7.04	6.25e-12	2.85e-09	-0.26	-0.3	Height;	chr2:46627569	chr2:46668870~46670778:+
KIRC	cis	rs10214930	0.697	rs12665991	ENSG00000235574.1	AC073150.6	-7.04	6.26e-12	2.85e-09	-0.35	-0.3	Hypospadias;	chr7:27620152	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs9639559	ENSG00000235574.1	AC073150.6	-7.04	6.26e-12	2.85e-09	-0.39	-0.3	Hypospadias;	chr7:27565876	chr7:27491682~27492765:-
KIRC	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-7.04	6.26e-12	2.85e-09	-0.25	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
KIRC	cis	rs4660214	0.671	rs72637904	ENSG00000237624.1	OXCT2P1	7.04	6.26e-12	2.85e-09	0.54	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39514956~39516490:+
KIRC	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-7.04	6.26e-12	2.85e-09	-0.29	-0.3	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-7.04	6.26e-12	2.85e-09	-0.29	-0.3	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
KIRC	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-7.04	6.27e-12	2.85e-09	-0.31	-0.3	Height;	chr3:52972039	chr3:53064283~53065091:-
KIRC	cis	rs11846409	0.521	rs10143547	ENSG00000274576.2	IGHV2-70	-7.04	6.27e-12	2.85e-09	-0.34	-0.3	Rheumatic heart disease;	chr14:106644638	chr14:106770577~106771020:-
KIRC	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	7.04	6.27e-12	2.86e-09	0.43	0.3	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
KIRC	cis	rs17801127	0.901	rs12233106	ENSG00000231969.1	AC144449.1	7.04	6.28e-12	2.86e-09	0.54	0.3	Liver enzyme levels (alanine transaminase);	chr2:149687521	chr2:149587196~149848233:+
KIRC	cis	rs1552244	1	rs6786638	ENSG00000180385.7	EMC3-AS1	7.04	6.28e-12	2.86e-09	0.3	0.3	Alzheimer's disease;	chr3:10076391	chr3:9986893~10006990:+
KIRC	cis	rs4072705	1	rs10818987	ENSG00000224020.1	MIR181A2HG	-7.04	6.3e-12	2.87e-09	-0.31	-0.3	Menarche (age at onset);	chr9:124758450	chr9:124658467~124698631:+
KIRC	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-7.04	6.3e-12	2.87e-09	-0.23	-0.3	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
KIRC	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	7.04	6.31e-12	2.87e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	7.04	6.31e-12	2.87e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	7.04	6.31e-12	2.87e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	7.04	6.31e-12	2.87e-09	0.76	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
KIRC	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	7.04	6.32e-12	2.87e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
KIRC	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	7.04	6.32e-12	2.87e-09	0.3	0.3	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
KIRC	cis	rs526231	0.756	rs35804	ENSG00000175749.11	EIF3KP1	7.04	6.32e-12	2.88e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103289634	chr5:103032376~103033031:+
KIRC	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	7.04	6.33e-12	2.88e-09	0.4	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
KIRC	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-7.04	6.34e-12	2.89e-09	-0.2	-0.3	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
KIRC	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-7.04	6.35e-12	2.89e-09	-0.29	-0.3	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
KIRC	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-7.04	6.36e-12	2.89e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
KIRC	cis	rs10214930	0.697	rs986706	ENSG00000235574.1	AC073150.6	-7.04	6.36e-12	2.89e-09	-0.35	-0.3	Hypospadias;	chr7:27573133	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs7806605	ENSG00000235574.1	AC073150.6	-7.04	6.36e-12	2.89e-09	-0.35	-0.3	Hypospadias;	chr7:27573966	chr7:27491682~27492765:-
KIRC	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	7.04	6.36e-12	2.89e-09	0.38	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
KIRC	cis	rs4072705	1	rs4836985	ENSG00000224020.1	MIR181A2HG	-7.04	6.37e-12	2.9e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124645615	chr9:124658467~124698631:+
KIRC	cis	rs4356975	0.932	rs4400061	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69071281	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4446390	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69071328	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs7434389	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69071698	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.599	rs7660019	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072135	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.574	rs7660021	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072143	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.549	rs7687692	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072154	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.899	rs7687725	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072229	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4516791	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072402	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694604	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072745	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694605	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69072777	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694607	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69073025	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.899	rs4410590	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69073381	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4611997	ENSG00000198277.6	RP11-468N14.09	7.04	6.37e-12	2.9e-09	0.32	0.3	Obesity-related traits;	chr4:69073429	chr4:68914928~68924741:-
KIRC	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	7.04	6.37e-12	2.9e-09	0.36	0.3	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-7.04	6.37e-12	2.9e-09	-0.37	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
KIRC	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-7.04	6.37e-12	2.9e-09	-0.29	-0.3	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
KIRC	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	7.04	6.38e-12	2.9e-09	0.45	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
KIRC	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	7.04	6.38e-12	2.9e-09	0.45	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
KIRC	cis	rs4356975	0.932	rs7658748	ENSG00000198277.6	RP11-468N14.09	7.04	6.4e-12	2.91e-09	0.32	0.3	Obesity-related traits;	chr4:69069219	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.899	rs7687336	ENSG00000198277.6	RP11-468N14.09	7.04	6.4e-12	2.91e-09	0.32	0.3	Obesity-related traits;	chr4:69069397	chr4:68914928~68924741:-
KIRC	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-7.04	6.4e-12	2.91e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
KIRC	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-7.04	6.4e-12	2.91e-09	-0.38	-0.3	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
KIRC	cis	rs4072705	1	rs3739760	ENSG00000224020.1	MIR181A2HG	-7.04	6.41e-12	2.91e-09	-0.31	-0.3	Menarche (age at onset);	chr9:124690925	chr9:124658467~124698631:+
KIRC	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	7.04	6.42e-12	2.92e-09	0.33	0.3	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
KIRC	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	7.04	6.43e-12	2.92e-09	0.46	0.3	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
KIRC	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-7.04	6.45e-12	2.93e-09	-0.22	-0.3	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
KIRC	cis	rs1560104	0.597	rs4780468	ENSG00000274834.1	CTD-3037G24.5	7.04	6.46e-12	2.93e-09	0.33	0.3	Obesity-related traits;	chr16:12620390	chr16:12614451~12614852:+
KIRC	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-7.04	6.46e-12	2.93e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
KIRC	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-7.04	6.46e-12	2.93e-09	-0.53	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
KIRC	cis	rs7937127	0.696	rs1001459	ENSG00000254907.1	RP11-484D2.2	7.04	6.46e-12	2.94e-09	0.39	0.3	Fibrinogen levels;	chr11:43516986	chr11:43328748~43359296:-
KIRC	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	7.04	6.48e-12	2.94e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
KIRC	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-7.04	6.49e-12	2.95e-09	-0.24	-0.3	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
KIRC	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-7.04	6.49e-12	2.95e-09	-0.24	-0.3	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
KIRC	cis	rs9926296	0.744	rs352939	ENSG00000260259.1	RP11-368I7.4	7.04	6.49e-12	2.95e-09	0.27	0.3	Vitiligo;	chr16:89643970	chr16:89682620~89686569:-
KIRC	cis	rs2273788	0.583	rs13296201	ENSG00000204173.9	LRRC37A5P	7.04	6.5e-12	2.95e-09	0.49	0.3	Monocyte count;	chr9:111579691	chr9:111602831~111631289:-
KIRC	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-7.04	6.5e-12	2.95e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
KIRC	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-7.04	6.51e-12	2.95e-09	-0.39	-0.3	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
KIRC	cis	rs7224610	0.931	rs7223342	ENSG00000263096.1	RP11-515O17.2	7.04	6.51e-12	2.96e-09	0.41	0.3	Urate levels;	chr17:55292233	chr17:55271504~55273653:-
KIRC	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-7.04	6.53e-12	2.96e-09	-0.22	-0.3	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-7.04	6.53e-12	2.96e-09	-0.22	-0.3	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
KIRC	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-7.04	6.53e-12	2.96e-09	-0.37	-0.3	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
KIRC	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-7.04	6.55e-12	2.97e-09	-0.27	-0.3	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
KIRC	cis	rs11657217	0.677	rs8071194	ENSG00000267719.1	HP09025	-7.04	6.55e-12	2.97e-09	-0.32	-0.3	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724688	chr17:79707266~79712317:+
KIRC	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-7.04	6.55e-12	2.97e-09	-0.36	-0.3	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
KIRC	cis	rs2281636	0.66	rs61871318	ENSG00000233690.1	EBAG9P1	7.04	6.55e-12	2.97e-09	0.33	0.3	Obesity-related traits;	chr10:99606784	chr10:99697407~99697949:-
KIRC	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	7.04	6.56e-12	2.98e-09	0.49	0.3	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
KIRC	cis	rs1552244	1	rs6768102	ENSG00000180385.7	EMC3-AS1	7.04	6.56e-12	2.98e-09	0.3	0.3	Alzheimer's disease;	chr3:10107696	chr3:9986893~10006990:+
KIRC	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	7.04	6.56e-12	2.98e-09	0.35	0.3	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
KIRC	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	7.04	6.58e-12	2.98e-09	0.24	0.3	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
KIRC	cis	rs12449964	0.515	rs7225141	ENSG00000223979.2	SMCR2	7.04	6.58e-12	2.98e-09	0.34	0.3	Coronary artery disease or ischemic stroke;	chr17:17667513	chr17:17674026~17677688:-
KIRC	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-7.04	6.58e-12	2.99e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
KIRC	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-7.04	6.58e-12	2.99e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-7.04	6.58e-12	2.99e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-7.04	6.58e-12	2.99e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
KIRC	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	7.04	6.58e-12	2.99e-09	0.32	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
KIRC	cis	rs10214930	0.697	rs10447552	ENSG00000235574.1	AC073150.6	7.04	6.6e-12	2.99e-09	0.36	0.3	Hypospadias;	chr7:27643679	chr7:27491682~27492765:-
KIRC	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-7.04	6.6e-12	3e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-7.04	6.6e-12	3e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
KIRC	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	7.04	6.61e-12	3e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
KIRC	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-7.04	6.61e-12	3e-09	-0.5	-0.3	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
KIRC	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	7.04	6.61e-12	3e-09	0.33	0.3	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
KIRC	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-7.04	6.62e-12	3e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
KIRC	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-7.04	6.64e-12	3.01e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
KIRC	cis	rs600231	0.665	rs2846861	ENSG00000173727.10	CMB9-22P13.1	7.04	6.64e-12	3.01e-09	0.35	0.3	Bone mineral density;	chr11:65454834	chr11:65455258~65466720:+
KIRC	cis	rs7672749	0.642	rs66814999	ENSG00000249973.2	CHCHD2P7	7.04	6.64e-12	3.01e-09	0.65	0.3	TB-LM or TBLH-BMD (pleiotropy);	chr4:87849949	chr4:87785920~87786371:-
KIRC	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	7.04	6.65e-12	3.01e-09	0.41	0.3	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
KIRC	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	7.04	6.65e-12	3.01e-09	0.41	0.3	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
KIRC	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-7.04	6.65e-12	3.02e-09	-0.34	-0.3	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
KIRC	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-7.04	6.65e-12	3.02e-09	-0.41	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
KIRC	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-7.04	6.66e-12	3.02e-09	-0.32	-0.3	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
KIRC	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	7.04	6.66e-12	3.02e-09	0.22	0.3	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
KIRC	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-7.03	6.68e-12	3.03e-09	-0.37	-0.3	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
KIRC	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-7.03	6.68e-12	3.03e-09	-0.37	-0.3	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
KIRC	cis	rs4356975	0.932	rs4694159	ENSG00000198277.6	RP11-468N14.09	7.03	6.68e-12	3.03e-09	0.32	0.3	Obesity-related traits;	chr4:69068460	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694597	ENSG00000198277.6	RP11-468N14.09	7.03	6.68e-12	3.03e-09	0.32	0.3	Obesity-related traits;	chr4:69068643	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.899	rs4694160	ENSG00000198277.6	RP11-468N14.09	7.03	6.68e-12	3.03e-09	0.32	0.3	Obesity-related traits;	chr4:69068755	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.899	rs7439419	ENSG00000198277.6	RP11-468N14.09	7.03	6.68e-12	3.03e-09	0.32	0.3	Obesity-related traits;	chr4:69069090	chr4:68914928~68924741:-
KIRC	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	7.03	6.69e-12	3.03e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	7.03	6.69e-12	3.03e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
KIRC	cis	rs4538475	0.53	rs6449168	ENSG00000214846.4	RP11-115L11.1	7.03	6.71e-12	3.04e-09	0.42	0.3	Parkinson's disease;	chr4:15726090	chr4:15730962~15731627:-
KIRC	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-7.03	6.71e-12	3.04e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
KIRC	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	7.03	6.72e-12	3.04e-09	0.36	0.3	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
KIRC	cis	rs9915657	0.87	rs759499	ENSG00000234899.8	SOX9-AS1	-7.03	6.72e-12	3.04e-09	-0.38	-0.3	Thyroid hormone levels;	chr17:72137036	chr17:72034107~72237203:-
KIRC	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-7.03	6.72e-12	3.05e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
KIRC	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-7.03	6.72e-12	3.05e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
KIRC	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	7.03	6.72e-12	3.05e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	7.03	6.72e-12	3.05e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
KIRC	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	7.03	6.72e-12	3.05e-09	0.23	0.3	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
KIRC	cis	rs10214930	0.697	rs12670771	ENSG00000235574.1	AC073150.6	-7.03	6.72e-12	3.05e-09	-0.35	-0.3	Hypospadias;	chr7:27616971	chr7:27491682~27492765:-
KIRC	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	7.03	6.73e-12	3.05e-09	0.54	0.3	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
KIRC	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-7.03	6.73e-12	3.05e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
KIRC	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-7.03	6.75e-12	3.06e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
KIRC	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	7.03	6.75e-12	3.06e-09	0.43	0.3	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
KIRC	cis	rs17801127	0.748	rs79717439	ENSG00000231969.1	AC144449.1	7.03	6.75e-12	3.06e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149668550	chr2:149587196~149848233:+
KIRC	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-7.03	6.77e-12	3.06e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
KIRC	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-7.03	6.78e-12	3.07e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
KIRC	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-7.03	6.78e-12	3.07e-09	-0.35	-0.3	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
KIRC	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	7.03	6.78e-12	3.07e-09	0.37	0.3	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
KIRC	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	7.03	6.79e-12	3.07e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
KIRC	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-7.03	6.79e-12	3.07e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.647	rs11767188	ENSG00000235574.1	AC073150.6	-7.03	6.79e-12	3.07e-09	-0.36	-0.3	Hypospadias;	chr7:27532326	chr7:27491682~27492765:-
KIRC	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-7.03	6.79e-12	3.08e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
KIRC	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-7.03	6.81e-12	3.08e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-7.03	6.81e-12	3.08e-09	-0.28	-0.3	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
KIRC	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	7.03	6.83e-12	3.09e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	7.03	6.83e-12	3.09e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	7.03	6.84e-12	3.09e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
KIRC	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-7.03	6.84e-12	3.09e-09	-0.33	-0.3	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
KIRC	cis	rs1552244	1	rs6764168	ENSG00000180385.7	EMC3-AS1	7.03	6.85e-12	3.1e-09	0.3	0.3	Alzheimer's disease;	chr3:10082121	chr3:9986893~10006990:+
KIRC	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	7.03	6.85e-12	3.1e-09	0.31	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-7.03	6.85e-12	3.1e-09	-0.31	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
KIRC	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-7.03	6.85e-12	3.1e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
KIRC	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	7.03	6.85e-12	3.1e-09	0.37	0.3	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
KIRC	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-7.03	6.86e-12	3.1e-09	-0.22	-0.3	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
KIRC	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-7.03	6.86e-12	3.1e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
KIRC	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	7.03	6.87e-12	3.11e-09	0.3	0.3	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	7.03	6.88e-12	3.11e-09	0.32	0.3	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	7.03	6.88e-12	3.11e-09	0.32	0.3	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
KIRC	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	7.03	6.88e-12	3.11e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	7.03	6.88e-12	3.11e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
KIRC	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-7.03	6.89e-12	3.11e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
KIRC	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-7.03	6.89e-12	3.11e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
KIRC	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-7.03	6.89e-12	3.11e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
KIRC	cis	rs10214930	0.697	rs9639552	ENSG00000235574.1	AC073150.6	-7.03	6.89e-12	3.12e-09	-0.35	-0.3	Hypospadias;	chr7:27535904	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs2110528	ENSG00000235574.1	AC073150.6	-7.03	6.9e-12	3.12e-09	-0.35	-0.3	Hypospadias;	chr7:27603400	chr7:27491682~27492765:-
KIRC	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-7.03	6.91e-12	3.12e-09	-0.5	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
KIRC	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-7.03	6.91e-12	3.12e-09	-0.4	-0.3	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-7.03	6.91e-12	3.12e-09	-0.4	-0.3	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-7.03	6.91e-12	3.12e-09	-0.4	-0.3	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
KIRC	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-7.03	6.91e-12	3.12e-09	-0.4	-0.3	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
KIRC	cis	rs4072705	0.614	rs35929043	ENSG00000224020.1	MIR181A2HG	-7.03	6.92e-12	3.13e-09	-0.32	-0.3	Menarche (age at onset);	chr9:124472077	chr9:124658467~124698631:+
KIRC	cis	rs13434995	0.513	rs58476959	ENSG00000273257.1	RP11-177J6.1	-7.03	6.92e-12	3.13e-09	-0.39	-0.3	Adiponectin levels;	chr4:55496234	chr4:55387949~55388271:+
KIRC	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	7.03	6.92e-12	3.13e-09	0.29	0.3	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
KIRC	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-7.03	6.92e-12	3.13e-09	-0.32	-0.3	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
KIRC	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-7.03	6.92e-12	3.13e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
KIRC	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-7.03	6.94e-12	3.13e-09	-0.23	-0.3	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
KIRC	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-7.03	6.98e-12	3.16e-09	-0.37	-0.3	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
KIRC	cis	rs10214930	0.723	rs6948814	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27593782	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs12668430	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27593899	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs28416309	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27594123	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs28429439	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27594180	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs2110526	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27596061	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6462036	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27601444	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs7811436	ENSG00000235574.1	AC073150.6	-7.03	6.99e-12	3.16e-09	-0.35	-0.3	Hypospadias;	chr7:27601667	chr7:27491682~27492765:-
KIRC	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	7.03	7e-12	3.16e-09	0.71	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
KIRC	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-7.03	7.01e-12	3.17e-09	-0.34	-0.3	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-7.03	7.01e-12	3.17e-09	-0.34	-0.3	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
KIRC	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	7.03	7.02e-12	3.17e-09	0.35	0.3	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
KIRC	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	7.03	7.03e-12	3.17e-09	0.44	0.3	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
KIRC	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	7.03	7.04e-12	3.18e-09	0.38	0.3	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
KIRC	cis	rs17772222	0.727	rs3179969	ENSG00000222990.1	RNU4-22P	7.03	7.04e-12	3.18e-09	0.32	0.3	Coronary artery calcification;	chr14:88396185	chr14:88513498~88513663:+
KIRC	cis	rs11647589	0.815	rs7194852	ENSG00000260762.1	ACSM5P1	7.03	7.05e-12	3.18e-09	0.31	0.3	Blood metabolite levels;	chr16:20461954	chr16:20586550~20607107:-
KIRC	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	7.03	7.06e-12	3.19e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	7.03	7.06e-12	3.19e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
KIRC	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-7.03	7.06e-12	3.19e-09	-0.24	-0.3	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
KIRC	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	7.03	7.07e-12	3.19e-09	0.37	0.3	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	7.03	7.07e-12	3.19e-09	0.37	0.3	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
KIRC	cis	rs3760982	0.813	rs8104447	ENSG00000267058.1	RP11-15A1.3	7.03	7.07e-12	3.19e-09	0.35	0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789126	chr19:43891804~43901805:-
KIRC	cis	rs13434995	0.842	rs62305269	ENSG00000249700.7	SRD5A3-AS1	-7.03	7.07e-12	3.19e-09	-0.34	-0.3	Adiponectin levels;	chr4:55507237	chr4:55363971~55395847:-
KIRC	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	7.03	7.08e-12	3.2e-09	0.39	0.3	Height;	chr6:109420812	chr6:109382795~109383666:+
KIRC	cis	rs2288884	0.943	rs12611112	ENSG00000275055.1	CTC-471J1.11	-7.03	7.08e-12	3.2e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs17835749	ENSG00000275055.1	CTC-471J1.11	-7.03	7.08e-12	3.2e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52049007~52049754:+
KIRC	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	7.03	7.08e-12	3.2e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
KIRC	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	7.03	7.08e-12	3.2e-09	0.32	0.3	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
KIRC	cis	rs13434995	0.842	rs55869433	ENSG00000249700.7	SRD5A3-AS1	-7.03	7.09e-12	3.2e-09	-0.34	-0.3	Adiponectin levels;	chr4:55544770	chr4:55363971~55395847:-
KIRC	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	7.03	7.1e-12	3.2e-09	0.41	0.3	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
KIRC	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	7.03	7.1e-12	3.21e-09	0.32	0.3	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
KIRC	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	7.03	7.1e-12	3.21e-09	0.21	0.3	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
KIRC	cis	rs375092	0.543	rs6461708	ENSG00000230658.1	KLHL7-AS1	-7.02	7.12e-12	3.21e-09	-0.51	-0.3	Personality dimensions;	chr7:23375698	chr7:23101228~23105703:-
KIRC	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-7.02	7.15e-12	3.22e-09	-0.36	-0.3	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-7.02	7.15e-12	3.23e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
KIRC	cis	rs9915657	0.933	rs4793272	ENSG00000234899.8	SOX9-AS1	-7.02	7.16e-12	3.23e-09	-0.38	-0.3	Thyroid hormone levels;	chr17:72143116	chr17:72034107~72237203:-
KIRC	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-7.02	7.16e-12	3.23e-09	-0.3	-0.3	QT interval;	chr12:29287150	chr12:29280418~29317848:-
KIRC	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-7.02	7.17e-12	3.23e-09	-0.28	-0.3	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-7.02	7.17e-12	3.23e-09	-0.28	-0.3	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
KIRC	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-7.02	7.17e-12	3.24e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.697	rs1524533	ENSG00000235574.1	AC073150.6	-7.02	7.17e-12	3.24e-09	-0.35	-0.3	Hypospadias;	chr7:27586177	chr7:27491682~27492765:-
KIRC	cis	rs4356975	0.899	rs4412058	ENSG00000198277.6	RP11-468N14.09	7.02	7.18e-12	3.24e-09	0.32	0.3	Obesity-related traits;	chr4:69073715	chr4:68914928~68924741:-
KIRC	cis	rs2486288	0.656	rs8037583	ENSG00000259433.2	CTD-2651B20.4	7.02	7.18e-12	3.24e-09	0.22	0.3	Glomerular filtration rate;	chr15:45254180	chr15:45330209~45332634:-
KIRC	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	7.02	7.18e-12	3.24e-09	0.39	0.3	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
KIRC	cis	rs1077773	0.7	rs7804230	ENSG00000236318.1	AC019117.1	7.02	7.19e-12	3.24e-09	0.38	0.3	Ulcerative colitis;Inflammatory bowel disease;	chr7:17405884	chr7:17374867~17466664:+
KIRC	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-7.02	7.19e-12	3.24e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
KIRC	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-7.02	7.2e-12	3.25e-09	-0.41	-0.3	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
KIRC	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	7.02	7.2e-12	3.25e-09	0.39	0.3	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
KIRC	cis	rs11647589	0.834	rs1827711	ENSG00000260762.1	ACSM5P1	7.02	7.21e-12	3.25e-09	0.3	0.3	Blood metabolite levels;	chr16:20471046	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.834	rs1700801	ENSG00000260762.1	ACSM5P1	7.02	7.21e-12	3.25e-09	0.3	0.3	Blood metabolite levels;	chr16:20474158	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.834	rs1354577	ENSG00000260762.1	ACSM5P1	7.02	7.21e-12	3.25e-09	0.3	0.3	Blood metabolite levels;	chr16:20474341	chr16:20586550~20607107:-
KIRC	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-7.02	7.21e-12	3.25e-09	-0.38	-0.3	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
KIRC	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-7.02	7.22e-12	3.25e-09	-0.42	-0.3	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
KIRC	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	7.02	7.22e-12	3.25e-09	0.23	0.3	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
KIRC	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-7.02	7.23e-12	3.26e-09	-0.22	-0.3	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
KIRC	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	7.02	7.23e-12	3.26e-09	0.35	0.3	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
KIRC	cis	rs7937127	0.557	rs113179541	ENSG00000254907.1	RP11-484D2.2	7.02	7.23e-12	3.26e-09	0.4	0.3	Fibrinogen levels;	chr11:43510640	chr11:43328748~43359296:-
KIRC	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	7.02	7.24e-12	3.26e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
KIRC	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	7.02	7.24e-12	3.26e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
KIRC	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	7.02	7.25e-12	3.27e-09	0.38	0.3	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
KIRC	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-7.02	7.25e-12	3.27e-09	-0.37	-0.3	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
KIRC	cis	rs1552244	1	rs58275763	ENSG00000180385.7	EMC3-AS1	7.02	7.26e-12	3.27e-09	0.3	0.3	Alzheimer's disease;	chr3:10101590	chr3:9986893~10006990:+
KIRC	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	7.02	7.28e-12	3.28e-09	0.38	0.3	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
KIRC	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	7.02	7.29e-12	3.29e-09	0.31	0.3	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
KIRC	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	7.02	7.29e-12	3.29e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
KIRC	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-7.02	7.31e-12	3.29e-09	-0.46	-0.3	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-7.02	7.31e-12	3.29e-09	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
KIRC	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-7.02	7.31e-12	3.29e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-7.02	7.31e-12	3.29e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-7.02	7.31e-12	3.29e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-7.02	7.31e-12	3.29e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-7.02	7.31e-12	3.29e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
KIRC	cis	rs4356975	0.83	rs6600865	ENSG00000250696.4	RP11-704M14.1	7.02	7.33e-12	3.3e-09	0.31	0.3	Obesity-related traits;	chr4:69057904	chr4:69182100~69216766:+
KIRC	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-7.02	7.33e-12	3.3e-09	-0.37	-0.3	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
KIRC	cis	rs17772222	0.63	rs7146241	ENSG00000222990.1	RNU4-22P	-7.02	7.35e-12	3.31e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88551622	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.63	rs930181	ENSG00000222990.1	RNU4-22P	-7.02	7.35e-12	3.31e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88552364	chr14:88513498~88513663:+
KIRC	cis	rs4356975	0.83	rs6600868	ENSG00000196472.4	RP13-644M16.4	7.02	7.35e-12	3.31e-09	0.34	0.3	Obesity-related traits;	chr4:69075923	chr4:69181660~69182372:+
KIRC	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-7.02	7.35e-12	3.31e-09	-0.35	-0.3	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
KIRC	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	7.02	7.36e-12	3.31e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	7.02	7.36e-12	3.31e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
KIRC	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	7.02	7.36e-12	3.31e-09	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
KIRC	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-7.02	7.36e-12	3.32e-09	-0.17	-0.3	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
KIRC	cis	rs10276381	1	rs10260837	ENSG00000234336.5	JAZF1-AS1	-7.02	7.37e-12	3.32e-09	-0.56	-0.3	Crohn's disease;	chr7:28141510	chr7:28180322~28243917:+
KIRC	cis	rs10276381	1	rs10280937	ENSG00000234336.5	JAZF1-AS1	-7.02	7.37e-12	3.32e-09	-0.56	-0.3	Crohn's disease;	chr7:28142687	chr7:28180322~28243917:+
KIRC	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	7.02	7.39e-12	3.33e-09	0.57	0.3	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
KIRC	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-7.02	7.39e-12	3.33e-09	-0.48	-0.3	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
KIRC	cis	rs17747401	0.507	rs12360399	ENSG00000213731.2	RAB5CP1	-7.02	7.4e-12	3.33e-09	-0.28	-0.3	Hypospadias;	chr10:74687338	chr10:74423435~74424014:-
KIRC	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-7.02	7.41e-12	3.34e-09	-0.34	-0.3	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
KIRC	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	7.02	7.42e-12	3.34e-09	0.34	0.3	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
KIRC	cis	rs890448	0.796	rs2471683	ENSG00000254531.1	FLJ20021	7.02	7.43e-12	3.34e-09	0.3	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436777	chr4:101347780~101348883:+
KIRC	cis	rs2797160	0.904	rs1739370	ENSG00000237742.5	RP11-624M8.1	7.02	7.43e-12	3.35e-09	0.36	0.3	Endometrial cancer;	chr6:125690085	chr6:125578558~125749190:-
KIRC	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	7.02	7.45e-12	3.35e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
KIRC	cis	rs1552244	0.882	rs35056669	ENSG00000180385.7	EMC3-AS1	7.02	7.45e-12	3.36e-09	0.29	0.3	Alzheimer's disease;	chr3:9972487	chr3:9986893~10006990:+
KIRC	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	7.02	7.46e-12	3.36e-09	0.27	0.3	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	7.02	7.46e-12	3.36e-09	0.27	0.3	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	7.02	7.46e-12	3.36e-09	0.27	0.3	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	7.02	7.46e-12	3.36e-09	0.27	0.3	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
KIRC	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-7.02	7.48e-12	3.37e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
KIRC	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-7.02	7.48e-12	3.37e-09	-0.35	-0.3	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
KIRC	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	7.02	7.5e-12	3.37e-09	0.29	0.3	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
KIRC	cis	rs4820539	0.902	rs9612237	ENSG00000221069.1	AC000029.1	-7.02	7.51e-12	3.38e-09	-0.37	-0.3	Bone mineral density;	chr22:23130767	chr22:23136620~23136710:+
KIRC	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-7.02	7.52e-12	3.38e-09	-0.72	-0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
KIRC	cis	rs7937127	0.696	rs72902746	ENSG00000254907.1	RP11-484D2.2	7.02	7.53e-12	3.39e-09	0.4	0.3	Fibrinogen levels;	chr11:43509423	chr11:43328748~43359296:-
KIRC	cis	rs1552244	1	rs7615764	ENSG00000180385.7	EMC3-AS1	7.02	7.54e-12	3.39e-09	0.3	0.3	Alzheimer's disease;	chr3:10040908	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs35220123	ENSG00000180385.7	EMC3-AS1	7.02	7.54e-12	3.39e-09	0.3	0.3	Alzheimer's disease;	chr3:10041485	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.935	rs4441636	ENSG00000180385.7	EMC3-AS1	7.02	7.54e-12	3.39e-09	0.3	0.3	Alzheimer's disease;	chr3:10042192	chr3:9986893~10006990:+
KIRC	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	7.02	7.55e-12	3.4e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	7.02	7.55e-12	3.4e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	7.02	7.55e-12	3.4e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	7.02	7.55e-12	3.4e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	7.02	7.56e-12	3.4e-09	0.35	0.3	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
KIRC	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-7.02	7.56e-12	3.4e-09	-0.34	-0.3	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
KIRC	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-7.02	7.57e-12	3.4e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
KIRC	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	7.02	7.57e-12	3.4e-09	0.4	0.3	Height;	chr6:109340338	chr6:109382795~109383666:+
KIRC	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	7.01	7.59e-12	3.42e-09	0.31	0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
KIRC	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	7.01	7.6e-12	3.42e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
KIRC	cis	rs10214930	0.697	rs12539707	ENSG00000235574.1	AC073150.6	-7.01	7.61e-12	3.42e-09	-0.35	-0.3	Hypospadias;	chr7:27586546	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6462034	ENSG00000235574.1	AC073150.6	-7.01	7.61e-12	3.42e-09	-0.35	-0.3	Hypospadias;	chr7:27588965	chr7:27491682~27492765:-
KIRC	cis	rs4888671	1	rs4888667	ENSG00000261707.1	RP11-264M12.2	7.01	7.62e-12	3.43e-09	0.46	0.3	Obesity-related traits;	chr16:77745583	chr16:77741468~77743000:-
KIRC	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	7.01	7.62e-12	3.43e-09	0.29	0.3	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	7.01	7.62e-12	3.43e-09	0.29	0.3	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
KIRC	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-7.01	7.63e-12	3.43e-09	-0.31	-0.3	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-7.01	7.63e-12	3.43e-09	-0.31	-0.3	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	7.01	7.63e-12	3.43e-09	0.31	0.3	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
KIRC	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-7.01	7.63e-12	3.43e-09	-0.38	-0.3	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
KIRC	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-7.01	7.63e-12	3.43e-09	-0.37	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
KIRC	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-7.01	7.63e-12	3.43e-09	-0.35	-0.3	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
KIRC	cis	rs710913	0.717	rs11206377	ENSG00000237624.1	OXCT2P1	7.01	7.64e-12	3.43e-09	0.36	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39514956~39516490:+
KIRC	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-7.01	7.65e-12	3.44e-09	-0.35	-0.3	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-7.01	7.65e-12	3.44e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-7.01	7.65e-12	3.44e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
KIRC	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-7.01	7.68e-12	3.45e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
KIRC	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-7.01	7.68e-12	3.45e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
KIRC	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-7.01	7.68e-12	3.45e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
KIRC	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	7.01	7.69e-12	3.46e-09	0.59	0.3	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
KIRC	cis	rs10214930	0.781	rs974883	ENSG00000235574.1	AC073150.6	-7.01	7.7e-12	3.46e-09	-0.39	-0.3	Hypospadias;	chr7:27549115	chr7:27491682~27492765:-
KIRC	cis	rs4356975	0.932	rs7436912	ENSG00000198277.6	RP11-468N14.09	7.01	7.7e-12	3.46e-09	0.32	0.3	Obesity-related traits;	chr4:69074077	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs72852416	ENSG00000198277.6	RP11-468N14.09	7.01	7.7e-12	3.46e-09	0.32	0.3	Obesity-related traits;	chr4:69075085	chr4:68914928~68924741:-
KIRC	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	7.01	7.71e-12	3.46e-09	0.44	0.3	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
KIRC	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	7.01	7.72e-12	3.47e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
KIRC	cis	rs7924176	0.521	rs7098200	ENSG00000213731.2	RAB5CP1	7.01	7.72e-12	3.47e-09	0.3	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74423435~74424014:-
KIRC	cis	rs1552244	1	rs56394721	ENSG00000180385.7	EMC3-AS1	7.01	7.73e-12	3.47e-09	0.3	0.3	Alzheimer's disease;	chr3:10109111	chr3:9986893~10006990:+
KIRC	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	7.01	7.73e-12	3.47e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
KIRC	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-7.01	7.73e-12	3.47e-09	-0.46	-0.3	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
KIRC	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	7.01	7.75e-12	3.48e-09	0.35	0.3	Depression;	chr6:28070115	chr6:28073316~28074233:+
KIRC	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	7.01	7.75e-12	3.48e-09	0.4	0.3	Height;	chr6:109415123	chr6:109382795~109383666:+
KIRC	cis	rs11647589	0.834	rs6497491	ENSG00000262995.1	CTD-2194A8.2	-7.01	7.77e-12	3.49e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20468691	chr16:20440266~20447000:-
KIRC	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	7.01	7.77e-12	3.49e-09	0.33	0.3	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	7.01	7.77e-12	3.49e-09	0.33	0.3	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
KIRC	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-7.01	7.79e-12	3.5e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
KIRC	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-7.01	7.79e-12	3.5e-09	-0.3	-0.3	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
KIRC	cis	rs17270561	0.541	rs17586946	ENSG00000272462.2	U91328.19	-7.01	7.79e-12	3.5e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25938825	chr6:25992662~26001775:+
KIRC	cis	rs9532669	0.963	rs9566607	ENSG00000176268.5	CYCSP34	-7.01	7.8e-12	3.5e-09	-0.32	-0.3	Cervical cancer;	chr13:40921788	chr13:40863599~40863902:-
KIRC	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-7.01	7.8e-12	3.5e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
KIRC	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	7.01	7.81e-12	3.5e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
KIRC	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	7.01	7.81e-12	3.5e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
KIRC	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	7.01	7.81e-12	3.51e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	7.01	7.81e-12	3.51e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
KIRC	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	7.01	7.82e-12	3.51e-09	0.38	0.3	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
KIRC	cis	rs17772222	0.682	rs1864744	ENSG00000222990.1	RNU4-22P	-7.01	7.83e-12	3.51e-09	-0.31	-0.3	Coronary artery calcification;	chr14:88484662	chr14:88513498~88513663:+
KIRC	cis	rs10129255	0.576	rs2157616	ENSG00000280411.1	IGHV1-69-2	-7.01	7.85e-12	3.52e-09	-0.22	-0.3	Kawasaki disease;	chr14:106767802	chr14:106762092~106762588:-
KIRC	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-7.01	7.85e-12	3.52e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-7.01	7.85e-12	3.52e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
KIRC	cis	rs4356975	0.932	rs72852450	ENSG00000198277.6	RP11-468N14.09	7.01	7.86e-12	3.53e-09	0.32	0.3	Obesity-related traits;	chr4:69079704	chr4:68914928~68924741:-
KIRC	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	7.01	7.86e-12	3.53e-09	0.39	0.3	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
KIRC	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	7.01	7.87e-12	3.53e-09	0.39	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
KIRC	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-7.01	7.88e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
KIRC	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-7.01	7.88e-12	3.54e-09	-0.41	-0.3	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
KIRC	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-7.01	7.88e-12	3.54e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
KIRC	cis	rs7267979	0.668	rs2387977	ENSG00000125804.12	FAM182A	7.01	7.89e-12	3.54e-09	0.38	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:26054655~26086917:+
KIRC	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
KIRC	cis	rs17747401	0.507	rs11001107	ENSG00000213731.2	RAB5CP1	-7.01	7.89e-12	3.54e-09	-0.28	-0.3	Hypospadias;	chr10:74673397	chr10:74423435~74424014:-
KIRC	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-7.01	7.89e-12	3.54e-09	-0.38	-0.3	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
KIRC	cis	rs4072705	1	rs10760374	ENSG00000224020.1	MIR181A2HG	-7.01	7.9e-12	3.54e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124733229	chr9:124658467~124698631:+
KIRC	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	7.01	7.91e-12	3.55e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
KIRC	cis	rs1560104	0.675	rs9927256	ENSG00000274834.1	CTD-3037G24.5	-7.01	7.92e-12	3.55e-09	-0.34	-0.3	Obesity-related traits;	chr16:12611158	chr16:12614451~12614852:+
KIRC	cis	rs10214930	0.723	rs56139857	ENSG00000235574.1	AC073150.6	-7.01	7.92e-12	3.55e-09	-0.35	-0.3	Hypospadias;	chr7:27639352	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs11973492	ENSG00000235574.1	AC073150.6	-7.01	7.92e-12	3.55e-09	-0.35	-0.3	Hypospadias;	chr7:27640770	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs6945993	ENSG00000235574.1	AC073150.6	-7.01	7.92e-12	3.55e-09	-0.35	-0.3	Hypospadias;	chr7:27641391	chr7:27491682~27492765:-
KIRC	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	7.01	7.92e-12	3.56e-09	0.3	0.3	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
KIRC	cis	rs10214930	0.56	rs1015750	ENSG00000235574.1	AC073150.6	-7.01	7.93e-12	3.56e-09	-0.35	-0.3	Hypospadias;	chr7:27553600	chr7:27491682~27492765:-
KIRC	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	7.01	7.94e-12	3.56e-09	0.24	0.3	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
KIRC	cis	rs4356975	0.899	rs7659138	ENSG00000198277.6	RP11-468N14.09	7.01	7.96e-12	3.57e-09	0.32	0.3	Obesity-related traits;	chr4:69069420	chr4:68914928~68924741:-
KIRC	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	7.01	7.96e-12	3.57e-09	0.31	0.3	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
KIRC	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-7.01	7.99e-12	3.58e-09	-0.2	-0.3	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
KIRC	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-7.01	8e-12	3.59e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
KIRC	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	7.01	8e-12	3.59e-09	0.27	0.3	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
KIRC	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	7.01	8e-12	3.59e-09	0.36	0.3	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
KIRC	cis	rs2032366	0.583	rs1452594	ENSG00000267279.1	RP11-879F14.2	-7.01	8.02e-12	3.59e-09	-0.38	-0.3	Obesity-related traits;	chr18:61590689	chr18:61585746~61606916:-
KIRC	cis	rs11647589	0.834	rs2271060	ENSG00000260762.1	ACSM5P1	7.01	8.02e-12	3.6e-09	0.3	0.3	Blood metabolite levels;	chr16:20471301	chr16:20586550~20607107:-
KIRC	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-7.01	8.02e-12	3.6e-09	-0.37	-0.3	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
KIRC	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	7.01	8.03e-12	3.6e-09	0.32	0.3	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
KIRC	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	7.01	8.04e-12	3.6e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
KIRC	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-7.01	8.04e-12	3.6e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
KIRC	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	7.01	8.04e-12	3.6e-09	0.28	0.3	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
KIRC	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	7.01	8.05e-12	3.61e-09	0.3	0.3	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
KIRC	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	7.01	8.05e-12	3.61e-09	0.49	0.3	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
KIRC	cis	rs13113518	0.51	rs11732723	ENSG00000249700.7	SRD5A3-AS1	-7.01	8.07e-12	3.61e-09	-0.27	-0.3	Height;	chr4:55424391	chr4:55363971~55395847:-
KIRC	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-7.01	8.07e-12	3.62e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
KIRC	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	7.01	8.09e-12	3.62e-09	0.32	0.3	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
KIRC	cis	rs4888671	0.901	rs80192970	ENSG00000261707.1	RP11-264M12.2	7.01	8.09e-12	3.63e-09	0.46	0.3	Obesity-related traits;	chr16:77738961	chr16:77741468~77743000:-
KIRC	cis	rs4888671	0.708	rs116932258	ENSG00000261707.1	RP11-264M12.2	7.01	8.09e-12	3.63e-09	0.46	0.3	Obesity-related traits;	chr16:77739427	chr16:77741468~77743000:-
KIRC	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-7.01	8.09e-12	3.63e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
KIRC	cis	rs62025270	0.632	rs56153788	ENSG00000202081.1	RNU6-1280P	-7	8.11e-12	3.63e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85651522~85651628:-
KIRC	cis	rs6480314	0.636	rs34888891	ENSG00000233590.1	RP11-153K11.3	-7	8.11e-12	3.63e-09	-0.42	-0.3	Optic nerve measurement (disc area);	chr10:68242351	chr10:68233251~68242379:-
KIRC	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	7	8.12e-12	3.64e-09	0.32	0.3	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
KIRC	cis	rs1552244	1	rs61077902	ENSG00000180385.7	EMC3-AS1	7	8.12e-12	3.64e-09	0.3	0.3	Alzheimer's disease;	chr3:10084469	chr3:9986893~10006990:+
KIRC	cis	rs10214930	0.697	rs13242248	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27643252	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs12672811	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27645264	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs2391449	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27645527	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs2391452	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27646533	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.624	rs13244903	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27649292	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs12530626	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27650189	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs12535844	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27650205	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.671	rs6948460	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27650619	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.647	rs6966587	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27650744	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.625	rs2391453	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27650968	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs6963421	ENSG00000235574.1	AC073150.6	-7	8.12e-12	3.64e-09	-0.35	-0.3	Hypospadias;	chr7:27652809	chr7:27491682~27492765:-
KIRC	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	7	8.13e-12	3.64e-09	0.34	0.3	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
KIRC	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-7	8.13e-12	3.64e-09	-0.35	-0.3	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
KIRC	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-7	8.14e-12	3.64e-09	-0.39	-0.3	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
KIRC	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-7	8.14e-12	3.65e-09	-0.32	-0.3	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
KIRC	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	7	8.15e-12	3.65e-09	0.48	0.3	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
KIRC	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	7	8.15e-12	3.65e-09	0.35	0.3	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
KIRC	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-7	8.15e-12	3.65e-09	-0.4	-0.3	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
KIRC	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	7	8.16e-12	3.65e-09	0.42	0.3	Depression;	chr6:28386473	chr6:28943877~28944537:+
KIRC	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	7	8.17e-12	3.66e-09	0.22	0.3	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
KIRC	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-7	8.17e-12	3.66e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-7	8.17e-12	3.66e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-7	8.17e-12	3.66e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-7	8.17e-12	3.66e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
KIRC	cis	rs11647589	0.642	rs7193826	ENSG00000260762.1	ACSM5P1	7	8.17e-12	3.66e-09	0.3	0.3	Blood metabolite levels;	chr16:20467260	chr16:20586550~20607107:-
KIRC	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	7	8.18e-12	3.66e-09	0.37	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
KIRC	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-7	8.2e-12	3.67e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
KIRC	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	7	8.2e-12	3.67e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
KIRC	cis	rs2698530	0.77	rs1426710	ENSG00000225889.6	AC074289.1	-7	8.2e-12	3.67e-09	-0.33	-0.3	Iron status biomarkers;	chr2:64274541	chr2:64143239~64252859:+
KIRC	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	7	8.2e-12	3.67e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
KIRC	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	7	8.22e-12	3.68e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
KIRC	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	7	8.22e-12	3.68e-09	0.2	0.3	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
KIRC	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	7	8.22e-12	3.68e-09	0.37	0.3	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
KIRC	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	7	8.22e-12	3.68e-09	0.39	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
KIRC	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-7	8.23e-12	3.68e-09	-0.25	-0.3	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
KIRC	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-7	8.23e-12	3.68e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
KIRC	cis	rs13434995	0.842	rs73236149	ENSG00000249700.7	SRD5A3-AS1	-7	8.24e-12	3.69e-09	-0.34	-0.3	Adiponectin levels;	chr4:55507307	chr4:55363971~55395847:-
KIRC	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-7	8.24e-12	3.69e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
KIRC	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	7	8.25e-12	3.69e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
KIRC	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	7	8.25e-12	3.69e-09	0.28	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
KIRC	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-7	8.25e-12	3.69e-09	-0.21	-0.3	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
KIRC	cis	rs1560104	0.597	rs17227492	ENSG00000274834.1	CTD-3037G24.5	7	8.26e-12	3.69e-09	0.33	0.3	Obesity-related traits;	chr16:12620186	chr16:12614451~12614852:+
KIRC	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7	8.26e-12	3.69e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
KIRC	cis	rs2012796	0.743	rs12435764	ENSG00000270343.1	UNGP3	7	8.27e-12	3.7e-09	0.37	0.3	Night sleep phenotypes;	chr14:81370522	chr14:81259565~81260239:-
KIRC	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-7	8.27e-12	3.7e-09	-0.59	-0.3	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
KIRC	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-7	8.29e-12	3.71e-09	-0.32	-0.3	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
KIRC	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-7	8.3e-12	3.71e-09	-0.3	-0.3	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
KIRC	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	7	8.3e-12	3.71e-09	0.31	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	7	8.3e-12	3.71e-09	0.31	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
KIRC	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-7	8.31e-12	3.72e-09	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
KIRC	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-7	8.32e-12	3.72e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
KIRC	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-7	8.32e-12	3.72e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
KIRC	cis	rs10214930	0.697	rs12700819	ENSG00000235574.1	AC073150.6	-7	8.32e-12	3.72e-09	-0.35	-0.3	Hypospadias;	chr7:27560271	chr7:27491682~27492765:-
KIRC	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-7	8.33e-12	3.73e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
KIRC	cis	rs2288884	0.943	rs1433089	ENSG00000275055.1	CTC-471J1.11	-7	8.34e-12	3.73e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52049007~52049754:+
KIRC	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	7	8.37e-12	3.74e-09	0.29	0.3	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
KIRC	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7	8.37e-12	3.74e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7	8.37e-12	3.74e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
KIRC	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-7	8.38e-12	3.74e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
KIRC	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-7	8.38e-12	3.74e-09	-0.17	-0.3	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
KIRC	cis	rs3820928	0.874	rs12467261	ENSG00000212391.1	SNORA48	-7	8.39e-12	3.75e-09	-0.34	-0.3	Pulmonary function;	chr2:227024122	chr2:226968989~226969122:-
KIRC	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	7	8.39e-12	3.75e-09	0.34	0.3	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
KIRC	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	7	8.4e-12	3.75e-09	0.27	0.3	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	7	8.4e-12	3.75e-09	0.27	0.3	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	7	8.4e-12	3.75e-09	0.27	0.3	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	7	8.4e-12	3.75e-09	0.27	0.3	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	7	8.4e-12	3.75e-09	0.27	0.3	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
KIRC	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	7	8.4e-12	3.75e-09	0.29	0.3	QT interval;	chr12:29310426	chr12:29280418~29317848:-
KIRC	cis	rs10214930	0.706	rs4722726	ENSG00000235574.1	AC073150.6	-7	8.4e-12	3.75e-09	-0.38	-0.3	Hypospadias;	chr7:27654589	chr7:27491682~27492765:-
KIRC	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-7	8.4e-12	3.75e-09	-0.31	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
KIRC	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-7	8.41e-12	3.76e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
KIRC	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-7	8.41e-12	3.76e-09	-0.31	-0.3	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
KIRC	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-7	8.42e-12	3.76e-09	-0.25	-0.3	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
KIRC	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	7	8.45e-12	3.78e-09	0.3	0.3	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
KIRC	cis	rs9516	0.966	rs2887135	ENSG00000254974.1	RP11-702H23.2	7	8.47e-12	3.78e-09	0.36	0.3	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74485580~74486051:-
KIRC	cis	rs58873874	0.579	rs56666304	ENSG00000251405.2	CTB-109A12.1	7	8.49e-12	3.79e-09	0.5	0.3	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157362615~157460078:-
KIRC	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	7	8.5e-12	3.79e-09	0.3	0.3	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
KIRC	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	7	8.5e-12	3.79e-09	0.3	0.3	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
KIRC	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7	8.51e-12	3.8e-09	-0.29	-0.3	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
KIRC	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	7	8.52e-12	3.8e-09	0.36	0.3	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
KIRC	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-7	8.53e-12	3.8e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
KIRC	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-7	8.53e-12	3.81e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
KIRC	cis	rs7829975	0.545	rs13261926	ENSG00000253893.2	FAM85B	7	8.54e-12	3.81e-09	0.38	0.3	Mood instability;	chr8:8694100	chr8:8167819~8226614:-
KIRC	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-7	8.54e-12	3.81e-09	-0.28	-0.3	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-7	8.54e-12	3.81e-09	-0.28	-0.3	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
KIRC	cis	rs526231	0.857	rs2569013	ENSG00000175749.11	EIF3KP1	7	8.55e-12	3.82e-09	0.37	0.3	Primary biliary cholangitis;	chr5:103305870	chr5:103032376~103033031:+
KIRC	cis	rs375066	0.762	rs10424336	ENSG00000267058.1	RP11-15A1.3	-7	8.56e-12	3.82e-09	-0.35	-0.3	Breast cancer;	chr19:43887948	chr19:43891804~43901805:-
KIRC	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-7	8.56e-12	3.82e-09	-0.35	-0.3	Depression;	chr6:28109824	chr6:28073316~28074233:+
KIRC	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-7	8.58e-12	3.83e-09	-0.23	-0.3	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
KIRC	cis	rs4356975	0.932	rs4400060	ENSG00000198277.6	RP11-468N14.09	7	8.6e-12	3.84e-09	0.32	0.3	Obesity-related traits;	chr4:69071215	chr4:68914928~68924741:-
KIRC	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-7	8.6e-12	3.84e-09	-0.45	-0.3	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
KIRC	cis	rs10214930	0.671	rs1009252	ENSG00000235574.1	AC073150.6	-7	8.61e-12	3.84e-09	-0.35	-0.3	Hypospadias;	chr7:27582054	chr7:27491682~27492765:-
KIRC	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.99	8.66e-12	3.86e-09	-0.25	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
KIRC	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.99	8.67e-12	3.86e-09	0.41	0.3	Depression;	chr6:28379133	chr6:28943877~28944537:+
KIRC	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.99	8.67e-12	3.86e-09	0.41	0.3	Depression;	chr6:28379168	chr6:28943877~28944537:+
KIRC	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-6.99	8.67e-12	3.86e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
KIRC	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	6.99	8.67e-12	3.87e-09	0.26	0.3	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
KIRC	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-6.99	8.67e-12	3.87e-09	-0.36	-0.3	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
KIRC	cis	rs2797160	0.904	rs1612274	ENSG00000237742.5	RP11-624M8.1	6.99	8.7e-12	3.88e-09	0.36	0.3	Endometrial cancer;	chr6:125693761	chr6:125578558~125749190:-
KIRC	cis	rs11671005	0.656	rs73066226	ENSG00000269600.1	AC016629.3	-6.99	8.71e-12	3.88e-09	-0.52	-0.3	Mean platelet volume;	chr19:58496846	chr19:58593896~58599355:-
KIRC	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	6.99	8.73e-12	3.89e-09	0.41	0.3	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
KIRC	cis	rs2562456	0.652	rs4809145	ENSG00000268555.1	RP11-678G14.3	6.99	8.74e-12	3.89e-09	0.46	0.3	Pain;	chr19:21597907	chr19:21570822~21587322:-
KIRC	cis	rs2288884	1	rs79817140	ENSG00000275055.1	CTC-471J1.11	-6.99	8.75e-12	3.9e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs11669385	ENSG00000275055.1	CTC-471J1.11	-6.99	8.75e-12	3.9e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs72483951	ENSG00000275055.1	CTC-471J1.11	-6.99	8.75e-12	3.9e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52049007~52049754:+
KIRC	cis	rs2288884	1	rs56808319	ENSG00000275055.1	CTC-471J1.11	-6.99	8.75e-12	3.9e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52049007~52049754:+
KIRC	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-6.99	8.76e-12	3.9e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
KIRC	cis	rs1198872	0.892	rs1198859	ENSG00000272275.1	RP11-791G15.2	-6.99	8.77e-12	3.9e-09	-0.4	-0.3	Cardiac Troponin-T levels;	chr2:10759143	chr2:10767875~10770058:-
KIRC	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	6.99	8.77e-12	3.91e-09	0.39	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
KIRC	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	6.99	8.77e-12	3.91e-09	0.32	0.3	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
KIRC	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-6.99	8.78e-12	3.91e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
KIRC	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	6.99	8.81e-12	3.92e-09	0.29	0.3	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
KIRC	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	6.99	8.82e-12	3.93e-09	0.4	0.3	Depression;	chr6:28301886	chr6:28943877~28944537:+
KIRC	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	6.99	8.84e-12	3.94e-09	0.31	0.3	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
KIRC	cis	rs10214930	0.697	rs12670415	ENSG00000235574.1	AC073150.6	-6.99	8.85e-12	3.94e-09	-0.35	-0.3	Hypospadias;	chr7:27562604	chr7:27491682~27492765:-
KIRC	cis	rs4072705	1	rs10760371	ENSG00000224020.1	MIR181A2HG	-6.99	8.86e-12	3.94e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124690698	chr9:124658467~124698631:+
KIRC	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-6.99	8.86e-12	3.95e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-6.99	8.86e-12	3.95e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-6.99	8.86e-12	3.95e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-6.99	8.86e-12	3.95e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
KIRC	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-6.99	8.86e-12	3.95e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
KIRC	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-6.99	8.87e-12	3.95e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
KIRC	cis	rs17801127	0.748	rs67065535	ENSG00000231969.1	AC144449.1	6.99	8.87e-12	3.95e-09	0.55	0.3	Liver enzyme levels (alanine transaminase);	chr2:149819760	chr2:149587196~149848233:+
KIRC	cis	rs58873874	0.737	rs11746314	ENSG00000251405.2	CTB-109A12.1	6.99	8.88e-12	3.95e-09	0.61	0.3	Bipolar disorder (body mass index interaction);	chr5:157325949	chr5:157362615~157460078:-
KIRC	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-6.99	8.88e-12	3.95e-09	-0.33	-0.3	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
KIRC	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	6.99	8.88e-12	3.95e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
KIRC	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.99	8.9e-12	3.96e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
KIRC	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.99	8.9e-12	3.96e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
KIRC	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	6.99	8.92e-12	3.97e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	6.99	8.92e-12	3.97e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
KIRC	cis	rs1552244	0.882	rs36006511	ENSG00000180385.7	EMC3-AS1	6.99	8.92e-12	3.97e-09	0.29	0.3	Alzheimer's disease;	chr3:10012507	chr3:9986893~10006990:+
KIRC	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-6.99	8.93e-12	3.97e-09	-0.35	-0.3	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
KIRC	cis	rs7017914	0.652	rs11992027	ENSG00000254031.4	RP11-326E22.1	6.99	8.94e-12	3.98e-09	0.35	0.3	Bone mineral density;	chr8:70776635	chr8:71155457~71204223:+
KIRC	cis	rs62025270	0.632	rs7181796	ENSG00000202081.1	RNU6-1280P	-6.99	8.95e-12	3.98e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85651522~85651628:-
KIRC	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	6.99	8.95e-12	3.98e-09	0.33	0.3	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
KIRC	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	6.99	8.95e-12	3.98e-09	0.22	0.3	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
KIRC	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-6.99	8.96e-12	3.99e-09	-0.31	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
KIRC	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	6.99	8.97e-12	3.99e-09	0.29	0.3	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
KIRC	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-6.99	8.97e-12	3.99e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
KIRC	cis	rs7176527	0.848	rs3748374	ENSG00000188388.10	GOLGA6L3	6.99	8.99e-12	4e-09	0.39	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85240472~85247170:+
KIRC	cis	rs7592578	0.639	rs13417431	ENSG00000272979.1	RP11-647K16.1	-6.99	8.99e-12	4e-09	-0.42	-0.3	Diastolic blood pressure;	chr2:190428329	chr2:190454092~190454521:-
KIRC	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	6.99	9.01e-12	4.01e-09	0.3	0.3	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	6.99	9.01e-12	4.01e-09	0.3	0.3	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-6.99	9.03e-12	4.02e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
KIRC	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-6.99	9.03e-12	4.02e-09	-0.47	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
KIRC	cis	rs2281558	0.517	rs68154819	ENSG00000125804.12	FAM182A	-6.99	9.05e-12	4.02e-09	-0.59	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25244167	chr20:26054655~26086917:+
KIRC	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	6.99	9.07e-12	4.03e-09	0.3	0.3	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	6.99	9.07e-12	4.03e-09	0.3	0.3	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	6.99	9.07e-12	4.03e-09	0.3	0.3	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
KIRC	cis	rs13236243	0.673	rs4721596	ENSG00000226598.1	AC017060.1	6.99	9.08e-12	4.03e-09	0.38	0.3	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17380483	chr7:17463445~17558909:-
KIRC	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	6.99	9.1e-12	4.04e-09	0.26	0.3	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	6.99	9.1e-12	4.04e-09	0.26	0.3	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
KIRC	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-6.99	9.13e-12	4.06e-09	-0.26	-0.3	Height;	chr2:46627225	chr2:46668870~46670778:+
KIRC	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-6.99	9.13e-12	4.06e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
KIRC	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-6.99	9.14e-12	4.06e-09	-0.22	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
KIRC	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	6.99	9.15e-12	4.06e-09	0.35	0.3	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
KIRC	cis	rs3820928	0.874	rs4675132	ENSG00000212391.1	SNORA48	-6.99	9.15e-12	4.06e-09	-0.35	-0.3	Pulmonary function;	chr2:226977076	chr2:226968989~226969122:-
KIRC	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-6.99	9.15e-12	4.07e-09	-0.22	-0.3	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
KIRC	cis	rs4072705	0.967	rs10217141	ENSG00000224020.1	MIR181A2HG	-6.99	9.15e-12	4.07e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124641656	chr9:124658467~124698631:+
KIRC	cis	rs62025270	0.632	rs7163838	ENSG00000202081.1	RNU6-1280P	-6.99	9.17e-12	4.07e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85651522~85651628:-
KIRC	cis	rs7017914	0.605	rs55865599	ENSG00000254031.4	RP11-326E22.1	6.99	9.17e-12	4.07e-09	0.35	0.3	Bone mineral density;	chr8:70792351	chr8:71155457~71204223:+
KIRC	cis	rs899997	0.862	rs8032552	ENSG00000261143.1	ADAMTS7P3	-6.99	9.17e-12	4.07e-09	-0.37	-0.3	Coronary artery disease or large artery stroke;	chr15:78678794	chr15:77976042~77993057:+
KIRC	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	6.99	9.18e-12	4.08e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
KIRC	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	6.99	9.18e-12	4.08e-09	0.27	0.3	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
KIRC	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	6.99	9.2e-12	4.09e-09	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
KIRC	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.99	9.21e-12	4.09e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
KIRC	cis	rs11647589	1	rs7201498	ENSG00000262995.1	CTD-2194A8.2	-6.99	9.23e-12	4.1e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20438127	chr16:20440266~20447000:-
KIRC	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-6.98	9.24e-12	4.1e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
KIRC	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	6.98	9.24e-12	4.1e-09	0.44	0.3	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
KIRC	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	6.98	9.24e-12	4.1e-09	0.44	0.3	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
KIRC	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	6.98	9.24e-12	4.1e-09	0.44	0.3	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
KIRC	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	6.98	9.24e-12	4.1e-09	0.44	0.3	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
KIRC	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	6.98	9.24e-12	4.1e-09	0.44	0.3	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
KIRC	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-6.98	9.24e-12	4.1e-09	-0.22	-0.3	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
KIRC	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-6.98	9.26e-12	4.11e-09	-0.23	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
KIRC	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	6.98	9.28e-12	4.12e-09	0.4	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
KIRC	cis	rs3820928	0.874	rs13430941	ENSG00000212391.1	SNORA48	-6.98	9.28e-12	4.12e-09	-0.35	-0.3	Pulmonary function;	chr2:227039731	chr2:226968989~226969122:-
KIRC	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	6.98	9.29e-12	4.12e-09	0.31	0.3	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-6.98	9.29e-12	4.12e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
KIRC	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-6.98	9.3e-12	4.13e-09	-0.28	-0.3	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
KIRC	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-6.98	9.31e-12	4.13e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-6.98	9.31e-12	4.13e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
KIRC	cis	rs2288884	1	rs12609219	ENSG00000275055.1	CTC-471J1.11	-6.98	9.32e-12	4.13e-09	-0.41	-0.3	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52049007~52049754:+
KIRC	cis	rs4660214	0.671	rs17491275	ENSG00000237624.1	OXCT2P1	6.98	9.33e-12	4.14e-09	0.54	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39514956~39516490:+
KIRC	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-6.98	9.34e-12	4.14e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-6.98	9.34e-12	4.14e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-6.98	9.34e-12	4.14e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
KIRC	cis	rs1552244	0.688	rs7645137	ENSG00000180385.7	EMC3-AS1	6.98	9.34e-12	4.14e-09	0.29	0.3	Alzheimer's disease;	chr3:9978865	chr3:9986893~10006990:+
KIRC	cis	rs950776	0.752	rs62010327	ENSG00000261762.1	RP11-650L12.2	6.98	9.34e-12	4.14e-09	0.4	0.3	Sudden cardiac arrest;	chr15:78600442	chr15:78589123~78591276:-
KIRC	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	6.98	9.35e-12	4.15e-09	0.3	0.3	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	6.98	9.36e-12	4.15e-09	0.37	0.3	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
KIRC	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-6.98	9.36e-12	4.15e-09	-0.17	-0.3	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-6.98	9.36e-12	4.15e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
KIRC	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	6.98	9.37e-12	4.15e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
KIRC	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-6.98	9.37e-12	4.15e-09	-0.25	-0.3	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
KIRC	cis	rs17801127	0.748	rs1526282	ENSG00000231969.1	AC144449.1	6.98	9.37e-12	4.16e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149658765	chr2:149587196~149848233:+
KIRC	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-6.98	9.37e-12	4.16e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
KIRC	cis	rs2361718	0.5	rs4889818	ENSG00000275479.1	RP11-334C17.6	6.98	9.37e-12	4.16e-09	0.33	0.3	Yeast infection;	chr17:80111429	chr17:80149627~80149798:+
KIRC	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	6.98	9.38e-12	4.16e-09	0.35	0.3	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
KIRC	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-6.98	9.39e-12	4.16e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
KIRC	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	6.98	9.4e-12	4.17e-09	0.33	0.3	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
KIRC	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-6.98	9.4e-12	4.17e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
KIRC	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-6.98	9.43e-12	4.18e-09	-0.23	-0.3	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
KIRC	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-6.98	9.43e-12	4.18e-09	-0.4	-0.3	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
KIRC	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	6.98	9.43e-12	4.18e-09	0.3	0.3	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
KIRC	cis	rs7924176	0.521	rs10762599	ENSG00000213731.2	RAB5CP1	-6.98	9.44e-12	4.18e-09	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74423435~74424014:-
KIRC	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-6.98	9.44e-12	4.18e-09	-0.37	-0.3	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
KIRC	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	6.98	9.45e-12	4.19e-09	0.33	0.3	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
KIRC	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	6.98	9.46e-12	4.19e-09	0.41	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
KIRC	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	6.98	9.46e-12	4.19e-09	0.41	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
KIRC	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-6.98	9.47e-12	4.2e-09	-0.43	-0.3	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
KIRC	cis	rs10214930	0.697	rs759269	ENSG00000235574.1	AC073150.6	-6.98	9.48e-12	4.2e-09	-0.35	-0.3	Hypospadias;	chr7:27552728	chr7:27491682~27492765:-
KIRC	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-6.98	9.48e-12	4.2e-09	-0.37	-0.3	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
KIRC	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.98	9.49e-12	4.2e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
KIRC	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	6.98	9.49e-12	4.2e-09	0.59	0.3	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
KIRC	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	6.98	9.5e-12	4.21e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	6.98	9.5e-12	4.21e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	6.98	9.5e-12	4.21e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
KIRC	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	6.98	9.5e-12	4.21e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
KIRC	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	6.98	9.5e-12	4.21e-09	0.31	0.3	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
KIRC	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	6.98	9.51e-12	4.21e-09	0.36	0.3	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
KIRC	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-6.98	9.52e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
KIRC	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	6.98	9.52e-12	4.22e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
KIRC	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-6.98	9.53e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-6.98	9.53e-12	4.22e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
KIRC	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.98	9.53e-12	4.22e-09	0.31	0.3	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
KIRC	cis	rs13434995	0.842	rs62309730	ENSG00000249700.7	SRD5A3-AS1	-6.98	9.54e-12	4.22e-09	-0.34	-0.3	Adiponectin levels;	chr4:55541530	chr4:55363971~55395847:-
KIRC	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	6.98	9.55e-12	4.23e-09	0.38	0.3	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
KIRC	cis	rs3750965	0.959	rs3376	ENSG00000260895.1	RP11-554A11.7	6.98	9.55e-12	4.23e-09	0.37	0.3	Hair color;	chr11:69089212	chr11:69103493~69109094:+
KIRC	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	6.98	9.55e-12	4.23e-09	0.27	0.3	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	6.98	9.55e-12	4.23e-09	0.27	0.3	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	6.98	9.55e-12	4.23e-09	0.27	0.3	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	6.98	9.55e-12	4.23e-09	0.27	0.3	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-6.98	9.55e-12	4.23e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-6.98	9.55e-12	4.23e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-6.98	9.55e-12	4.23e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-6.98	9.55e-12	4.23e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
KIRC	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-6.98	9.55e-12	4.23e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
KIRC	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-6.98	9.55e-12	4.23e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
KIRC	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	6.98	9.56e-12	4.23e-09	0.29	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
KIRC	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	6.98	9.57e-12	4.24e-09	0.24	0.3	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
KIRC	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-6.98	9.59e-12	4.25e-09	-0.35	-0.3	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
KIRC	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.98	9.59e-12	4.25e-09	-0.32	-0.3	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.98	9.59e-12	4.25e-09	-0.32	-0.3	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
KIRC	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-6.98	9.6e-12	4.25e-09	-0.22	-0.3	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
KIRC	cis	rs7924176	0.521	rs11516630	ENSG00000213731.2	RAB5CP1	-6.98	9.62e-12	4.26e-09	-0.3	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74423435~74424014:-
KIRC	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	6.98	9.62e-12	4.26e-09	0.3	0.3	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
KIRC	cis	rs1552244	1	rs67569278	ENSG00000180385.7	EMC3-AS1	6.98	9.62e-12	4.26e-09	0.3	0.3	Alzheimer's disease;	chr3:10108209	chr3:9986893~10006990:+
KIRC	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-6.98	9.62e-12	4.26e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
KIRC	cis	rs1552244	1	rs17032396	ENSG00000180385.7	EMC3-AS1	-6.98	9.64e-12	4.27e-09	-0.28	-0.3	Alzheimer's disease;	chr3:10111875	chr3:9986893~10006990:+
KIRC	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	6.98	9.65e-12	4.27e-09	0.34	0.3	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
KIRC	cis	rs17361889	0.517	rs62440455	ENSG00000224683.1	RPL36AP29	6.98	9.66e-12	4.28e-09	0.43	0.3	Pediatric bone mineral content (hip);	chr7:16285646	chr7:16208945~16209265:+
KIRC	cis	rs3820928	0.874	rs4675134	ENSG00000212391.1	SNORA48	-6.98	9.68e-12	4.28e-09	-0.35	-0.3	Pulmonary function;	chr2:226978773	chr2:226968989~226969122:-
KIRC	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-6.98	9.7e-12	4.29e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-6.98	9.7e-12	4.29e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-6.98	9.7e-12	4.29e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
KIRC	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-6.98	9.72e-12	4.3e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
KIRC	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-6.98	9.73e-12	4.3e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
KIRC	cis	rs1153858	1	rs2467864	ENSG00000235390.4	CTD-2651B20.5	6.98	9.73e-12	4.3e-09	0.29	0.3	Homoarginine levels;	chr15:45348900	chr15:45321077~45321692:-
KIRC	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	6.98	9.73e-12	4.3e-09	0.27	0.3	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
KIRC	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-6.98	9.73e-12	4.31e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000251284.2	RP13-644M16.1	-6.98	9.74e-12	4.31e-09	-0.36	-0.3	Obesity-related traits;	chr4:69062256	chr4:69125274~69126451:+
KIRC	cis	rs17213965	1	rs17213965	ENSG00000207425.1	Y_RNA	-6.98	9.77e-12	4.32e-09	-0.48	-0.3	Waist-hip ratio;	chr16:15788110	chr16:14915457~14915556:-
KIRC	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-6.98	9.77e-12	4.32e-09	-0.35	-0.3	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
KIRC	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	6.98	9.77e-12	4.32e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
KIRC	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	6.98	9.77e-12	4.32e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
KIRC	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	6.98	9.77e-12	4.32e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
KIRC	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	6.98	9.77e-12	4.32e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
KIRC	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-6.98	9.81e-12	4.34e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
KIRC	cis	rs600231	0.665	rs1784859	ENSG00000173727.10	CMB9-22P13.1	-6.98	9.83e-12	4.35e-09	-0.34	-0.3	Bone mineral density;	chr11:65453278	chr11:65455258~65466720:+
KIRC	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	6.97	9.84e-12	4.35e-09	0.39	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
KIRC	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-6.97	9.86e-12	4.36e-09	-0.3	-0.3	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
KIRC	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	6.97	9.86e-12	4.36e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-6.97	9.89e-12	4.37e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
KIRC	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-6.97	9.92e-12	4.38e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
KIRC	cis	rs710913	0.717	rs2243761	ENSG00000237624.1	OXCT2P1	-6.97	9.93e-12	4.39e-09	-0.36	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39514956~39516490:+
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000251284.2	RP13-644M16.1	-6.97	9.94e-12	4.39e-09	-0.35	-0.3	Obesity-related traits;	chr4:69079291	chr4:69125274~69126451:+
KIRC	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-6.97	9.95e-12	4.4e-09	-0.26	-0.3	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
KIRC	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-6.97	9.96e-12	4.4e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
KIRC	cis	rs6456156	0.846	rs7774396	ENSG00000265828.1	MIR3939	-6.97	9.99e-12	4.41e-09	-0.35	-0.3	Primary biliary cholangitis;	chr6:167106298	chr6:166997807~166997912:-
KIRC	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-6.97	1e-11	4.42e-09	-0.32	-0.3	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
KIRC	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	6.97	1e-11	4.42e-09	0.25	0.3	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
KIRC	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	6.97	1e-11	4.43e-09	0.4	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
KIRC	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	6.97	1e-11	4.43e-09	0.4	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
KIRC	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	6.97	1e-11	4.43e-09	0.4	0.3	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
KIRC	cis	rs4356975	0.932	rs7674600	ENSG00000198277.6	RP11-468N14.09	6.97	1e-11	4.43e-09	0.32	0.3	Obesity-related traits;	chr4:69069614	chr4:68914928~68924741:-
KIRC	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-6.97	1e-11	4.43e-09	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
KIRC	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	6.97	1e-11	4.43e-09	0.4	0.3	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
KIRC	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	6.97	1e-11	4.43e-09	0.59	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
KIRC	cis	rs17772222	0.63	rs1344747	ENSG00000222990.1	RNU4-22P	-6.97	1e-11	4.44e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88548091	chr14:88513498~88513663:+
KIRC	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	6.97	1e-11	4.44e-09	0.31	0.3	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
KIRC	cis	rs9847710	0.869	rs2564917	ENSG00000280417.1	RP11-5O17.1	-6.97	1.01e-11	4.44e-09	-0.35	-0.3	Ulcerative colitis;	chr3:53003679	chr3:53046166~53048122:+
KIRC	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	6.97	1.01e-11	4.45e-09	0.38	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
KIRC	cis	rs7017914	0.652	rs62508770	ENSG00000254031.4	RP11-326E22.1	6.97	1.01e-11	4.46e-09	0.35	0.3	Bone mineral density;	chr8:70780269	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs55862702	ENSG00000254031.4	RP11-326E22.1	6.97	1.01e-11	4.46e-09	0.35	0.3	Bone mineral density;	chr8:70781502	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs6998989	ENSG00000254031.4	RP11-326E22.1	6.97	1.01e-11	4.46e-09	0.35	0.3	Bone mineral density;	chr8:70782296	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs6981149	ENSG00000254031.4	RP11-326E22.1	6.97	1.01e-11	4.46e-09	0.35	0.3	Bone mineral density;	chr8:70782447	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1596565	ENSG00000254031.4	RP11-326E22.1	6.97	1.01e-11	4.46e-09	0.35	0.3	Bone mineral density;	chr8:70786597	chr8:71155457~71204223:+
KIRC	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-6.97	1.01e-11	4.47e-09	-0.25	-0.3	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
KIRC	cis	rs6700559	0.643	rs1540683	ENSG00000260088.1	RP11-92G12.3	6.97	1.02e-11	4.49e-09	0.38	0.3	Coronary artery disease;	chr1:200693050	chr1:200669507~200694250:+
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	6.97	1.02e-11	4.49e-09	0.36	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
KIRC	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	6.97	1.02e-11	4.49e-09	0.26	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	6.97	1.02e-11	4.49e-09	0.26	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
KIRC	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-6.97	1.02e-11	4.49e-09	-0.39	-0.3	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
KIRC	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	6.97	1.02e-11	4.49e-09	0.73	0.3	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
KIRC	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	6.97	1.02e-11	4.5e-09	0.44	0.3	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
KIRC	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-6.97	1.02e-11	4.51e-09	-0.52	-0.3	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
KIRC	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-6.97	1.02e-11	4.51e-09	-0.35	-0.3	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
KIRC	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-6.97	1.02e-11	4.51e-09	-0.37	-0.3	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
KIRC	cis	rs600231	0.651	rs2846862	ENSG00000173727.10	CMB9-22P13.1	6.97	1.02e-11	4.51e-09	0.34	0.3	Bone mineral density;	chr11:65452319	chr11:65455258~65466720:+
KIRC	cis	rs643506	0.817	rs1940392	ENSG00000230911.1	PPIHP1	-6.97	1.02e-11	4.51e-09	-0.35	-0.3	Breast cancer;	chr11:111906122	chr11:112029858~112030367:-
KIRC	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	6.97	1.02e-11	4.51e-09	0.4	0.3	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
KIRC	cis	rs4072705	1	rs721862	ENSG00000224020.1	MIR181A2HG	-6.97	1.02e-11	4.52e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124773713	chr9:124658467~124698631:+
KIRC	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-6.97	1.02e-11	4.52e-09	-0.26	-0.3	Height;	chr2:46631182	chr2:46668870~46670778:+
KIRC	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	6.97	1.03e-11	4.52e-09	0.46	0.3	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
KIRC	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	6.97	1.03e-11	4.53e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
KIRC	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	6.97	1.03e-11	4.53e-09	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
KIRC	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-6.97	1.03e-11	4.53e-09	-0.24	-0.3	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
KIRC	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-6.97	1.03e-11	4.53e-09	-0.24	-0.3	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
KIRC	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.97	1.03e-11	4.54e-09	-0.32	-0.3	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
KIRC	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	6.97	1.03e-11	4.54e-09	0.72	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
KIRC	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-6.97	1.03e-11	4.55e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-6.97	1.03e-11	4.55e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
KIRC	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-6.97	1.03e-11	4.55e-09	-0.37	-0.3	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
KIRC	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	6.97	1.03e-11	4.55e-09	0.47	0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
KIRC	cis	rs4356975	0.806	rs12648808	ENSG00000198277.6	RP11-468N14.09	6.97	1.03e-11	4.55e-09	0.32	0.3	Obesity-related traits;	chr4:69075351	chr4:68914928~68924741:-
KIRC	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-6.97	1.03e-11	4.56e-09	-0.38	-0.3	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
KIRC	cis	rs375092	0.543	rs7808331	ENSG00000230658.1	KLHL7-AS1	6.97	1.03e-11	4.56e-09	0.52	0.3	Personality dimensions;	chr7:23374070	chr7:23101228~23105703:-
KIRC	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-6.97	1.04e-11	4.56e-09	-0.51	-0.3	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
KIRC	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-6.97	1.04e-11	4.56e-09	-0.37	-0.3	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
KIRC	cis	rs1552244	0.572	rs6442154	ENSG00000180385.7	EMC3-AS1	6.97	1.04e-11	4.57e-09	0.32	0.3	Alzheimer's disease;	chr3:10127101	chr3:9986893~10006990:+
KIRC	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-6.97	1.04e-11	4.57e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
KIRC	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-6.97	1.04e-11	4.57e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
KIRC	cis	rs2797160	1	rs2747725	ENSG00000237742.5	RP11-624M8.1	6.97	1.04e-11	4.57e-09	0.36	0.3	Endometrial cancer;	chr6:125691251	chr6:125578558~125749190:-
KIRC	cis	rs3750965	0.959	rs2253658	ENSG00000260895.1	RP11-554A11.7	6.97	1.04e-11	4.58e-09	0.37	0.3	Hair color;	chr11:69089336	chr11:69103493~69109094:+
KIRC	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-6.97	1.04e-11	4.58e-09	-0.33	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
KIRC	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	6.97	1.04e-11	4.58e-09	0.28	0.3	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
KIRC	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.97	1.04e-11	4.58e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
KIRC	cis	rs1560104	0.718	rs36003824	ENSG00000274834.1	CTD-3037G24.5	-6.97	1.04e-11	4.58e-09	-0.34	-0.3	Obesity-related traits;	chr16:12611781	chr16:12614451~12614852:+
KIRC	cis	rs11647589	0.642	rs1532842	ENSG00000260762.1	ACSM5P1	6.97	1.04e-11	4.58e-09	0.3	0.3	Blood metabolite levels;	chr16:20468067	chr16:20586550~20607107:-
KIRC	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.97	1.04e-11	4.59e-09	0.28	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
KIRC	cis	rs2698530	0.535	rs2114432	ENSG00000225889.6	AC074289.1	-6.97	1.04e-11	4.59e-09	-0.29	-0.3	Iron status biomarkers;	chr2:64258678	chr2:64143239~64252859:+
KIRC	cis	rs643506	0.874	rs645411	ENSG00000230911.1	PPIHP1	-6.97	1.04e-11	4.59e-09	-0.36	-0.3	Breast cancer;	chr11:111823766	chr11:112029858~112030367:-
KIRC	cis	rs4538475	0.556	rs4263397	ENSG00000214846.4	RP11-115L11.1	-6.97	1.04e-11	4.59e-09	-0.4	-0.3	Parkinson's disease;	chr4:15737767	chr4:15730962~15731627:-
KIRC	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-6.97	1.04e-11	4.6e-09	-0.29	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
KIRC	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-6.97	1.04e-11	4.6e-09	-0.4	-0.3	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
KIRC	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-6.97	1.05e-11	4.6e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
KIRC	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	6.97	1.05e-11	4.6e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
KIRC	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-6.97	1.05e-11	4.61e-09	-0.22	-0.3	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
KIRC	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	6.97	1.05e-11	4.61e-09	0.31	0.3	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
KIRC	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	6.97	1.05e-11	4.62e-09	0.4	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
KIRC	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-6.97	1.05e-11	4.62e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-6.97	1.05e-11	4.62e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
KIRC	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	6.97	1.05e-11	4.62e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
KIRC	cis	rs1552244	0.882	rs13064570	ENSG00000180385.7	EMC3-AS1	6.97	1.05e-11	4.62e-09	0.29	0.3	Alzheimer's disease;	chr3:9955861	chr3:9986893~10006990:+
KIRC	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-6.97	1.05e-11	4.62e-09	-0.31	-0.3	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
KIRC	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	6.96	1.05e-11	4.62e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
KIRC	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-6.96	1.05e-11	4.63e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
KIRC	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	6.96	1.05e-11	4.63e-09	0.72	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
KIRC	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-6.96	1.05e-11	4.64e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
KIRC	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-6.96	1.05e-11	4.64e-09	-0.22	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
KIRC	cis	rs899997	0.773	rs7178423	ENSG00000261143.1	ADAMTS7P3	6.96	1.05e-11	4.64e-09	0.4	0.3	Coronary artery disease or large artery stroke;	chr15:78672619	chr15:77976042~77993057:+
KIRC	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-6.96	1.06e-11	4.65e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
KIRC	cis	rs17801127	0.748	rs6708998	ENSG00000231969.1	AC144449.1	6.96	1.06e-11	4.65e-09	0.52	0.3	Liver enzyme levels (alanine transaminase);	chr2:149656004	chr2:149587196~149848233:+
KIRC	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-6.96	1.06e-11	4.65e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
KIRC	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-6.96	1.06e-11	4.66e-09	-0.22	-0.3	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
KIRC	cis	rs10214930	0.813	rs6462027	ENSG00000235574.1	AC073150.6	-6.96	1.06e-11	4.66e-09	-0.38	-0.3	Hypospadias;	chr7:27523619	chr7:27491682~27492765:-
KIRC	cis	rs459482	0.504	rs469073	ENSG00000228318.3	AP001610.5	6.96	1.06e-11	4.66e-09	0.3	0.3	IgG glycosylation;	chr21:41444274	chr21:41441056~41445708:-
KIRC	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	6.96	1.06e-11	4.67e-09	0.43	0.3	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
KIRC	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-6.96	1.06e-11	4.68e-09	-0.24	-0.3	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
KIRC	cis	rs10971721	0.731	rs72727392	ENSG00000260947.1	RP11-384P7.7	6.96	1.06e-11	4.68e-09	0.57	0.3	Body mass index;	chr9:33988921	chr9:33697459~33700986:+
KIRC	cis	rs17801127	0.818	rs12233215	ENSG00000231969.1	AC144449.1	6.96	1.06e-11	4.68e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149690793	chr2:149587196~149848233:+
KIRC	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-6.96	1.06e-11	4.68e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
KIRC	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	6.96	1.07e-11	4.69e-09	0.36	0.3	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	6.96	1.07e-11	4.69e-09	0.36	0.3	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	6.96	1.07e-11	4.69e-09	0.36	0.3	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	6.96	1.07e-11	4.69e-09	0.36	0.3	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	6.96	1.07e-11	4.69e-09	0.36	0.3	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
KIRC	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	6.96	1.07e-11	4.69e-09	0.3	0.3	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
KIRC	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	6.96	1.07e-11	4.69e-09	0.37	0.3	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
KIRC	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-6.96	1.07e-11	4.69e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
KIRC	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-6.96	1.07e-11	4.69e-09	-0.38	-0.3	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
KIRC	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-6.96	1.07e-11	4.69e-09	-0.3	-0.3	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-6.96	1.07e-11	4.69e-09	-0.3	-0.3	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
KIRC	cis	rs890448	0.792	rs1372242	ENSG00000254531.1	FLJ20021	6.96	1.07e-11	4.69e-09	0.29	0.3	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369371	chr4:101347780~101348883:+
KIRC	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-6.96	1.07e-11	4.7e-09	-0.31	-0.3	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
KIRC	cis	rs7224610	0.932	rs10852974	ENSG00000263096.1	RP11-515O17.2	6.96	1.07e-11	4.7e-09	0.4	0.3	Urate levels;	chr17:55295205	chr17:55271504~55273653:-
KIRC	cis	rs3750965	0.959	rs4930265	ENSG00000260895.1	RP11-554A11.7	6.96	1.07e-11	4.7e-09	0.37	0.3	Hair color;	chr11:69088486	chr11:69103493~69109094:+
KIRC	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-6.96	1.07e-11	4.7e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-6.96	1.07e-11	4.7e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-6.96	1.07e-11	4.7e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
KIRC	cis	rs17747401	0.507	rs11001105	ENSG00000213731.2	RAB5CP1	-6.96	1.07e-11	4.71e-09	-0.28	-0.3	Hypospadias;	chr10:74672050	chr10:74423435~74424014:-
KIRC	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	6.96	1.07e-11	4.71e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
KIRC	cis	rs7567389	0.889	rs1504136	ENSG00000236682.1	AC068282.3	6.96	1.07e-11	4.71e-09	0.39	0.3	Self-rated health;	chr2:127219542	chr2:127389130~127400580:+
KIRC	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-6.96	1.07e-11	4.72e-09	-0.37	-0.3	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	6.96	1.08e-11	4.74e-09	0.37	0.3	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
KIRC	cis	rs4356975	0.83	rs10012215	ENSG00000250696.4	RP11-704M14.1	6.96	1.08e-11	4.75e-09	0.31	0.3	Obesity-related traits;	chr4:69048448	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs10012240	ENSG00000250696.4	RP11-704M14.1	6.96	1.08e-11	4.75e-09	0.31	0.3	Obesity-related traits;	chr4:69048519	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs10012607	ENSG00000250696.4	RP11-704M14.1	6.96	1.08e-11	4.75e-09	0.31	0.3	Obesity-related traits;	chr4:69048866	chr4:69182100~69216766:+
KIRC	cis	rs11647589	0.784	rs1910803	ENSG00000260762.1	ACSM5P1	6.96	1.08e-11	4.75e-09	0.3	0.3	Blood metabolite levels;	chr16:20464412	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.636	rs7186805	ENSG00000260762.1	ACSM5P1	6.96	1.08e-11	4.75e-09	0.3	0.3	Blood metabolite levels;	chr16:20465841	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.636	rs7186307	ENSG00000260762.1	ACSM5P1	6.96	1.08e-11	4.75e-09	0.3	0.3	Blood metabolite levels;	chr16:20465843	chr16:20586550~20607107:-
KIRC	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	6.96	1.08e-11	4.75e-09	0.47	0.3	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
KIRC	cis	rs11647589	0.834	rs6497491	ENSG00000260762.1	ACSM5P1	6.96	1.08e-11	4.76e-09	0.3	0.3	Blood metabolite levels;	chr16:20468691	chr16:20586550~20607107:-
KIRC	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	6.96	1.08e-11	4.76e-09	0.25	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
KIRC	cis	rs17270561	0.666	rs9356988	ENSG00000272462.2	U91328.19	-6.96	1.09e-11	4.77e-09	-0.26	-0.3	Iron status biomarkers;	chr6:25777253	chr6:25992662~26001775:+
KIRC	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-6.96	1.09e-11	4.77e-09	-0.35	-0.3	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
KIRC	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	6.96	1.09e-11	4.77e-09	0.58	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
KIRC	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	6.96	1.09e-11	4.78e-09	0.26	0.3	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
KIRC	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-6.96	1.09e-11	4.78e-09	-0.39	-0.3	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
KIRC	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-6.96	1.09e-11	4.79e-09	-0.4	-0.3	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
KIRC	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	6.96	1.09e-11	4.79e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
KIRC	cis	rs3750965	0.959	rs3168115	ENSG00000260895.1	RP11-554A11.7	-6.96	1.09e-11	4.8e-09	-0.37	-0.3	Hair color;	chr11:69090622	chr11:69103493~69109094:+
KIRC	cis	rs10214930	0.697	rs2041714	ENSG00000235574.1	AC073150.6	-6.96	1.09e-11	4.81e-09	-0.35	-0.3	Hypospadias;	chr7:27559228	chr7:27491682~27492765:-
KIRC	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	6.96	1.09e-11	4.81e-09	0.34	0.3	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
KIRC	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	6.96	1.1e-11	4.82e-09	0.32	0.3	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
KIRC	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-6.96	1.1e-11	4.83e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
KIRC	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	6.96	1.1e-11	4.83e-09	0.54	0.3	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
KIRC	cis	rs4820539	0.966	rs5759594	ENSG00000221069.1	AC000029.1	-6.96	1.1e-11	4.83e-09	-0.37	-0.3	Bone mineral density;	chr22:23128473	chr22:23136620~23136710:+
KIRC	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-6.96	1.1e-11	4.83e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
KIRC	cis	rs10214930	0.671	rs10951172	ENSG00000235574.1	AC073150.6	-6.96	1.1e-11	4.84e-09	-0.35	-0.3	Hypospadias;	chr7:27574492	chr7:27491682~27492765:-
KIRC	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-6.96	1.1e-11	4.84e-09	-0.31	-0.3	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
KIRC	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	6.96	1.1e-11	4.84e-09	0.52	0.3	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
KIRC	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-6.96	1.1e-11	4.84e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
KIRC	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-6.96	1.1e-11	4.85e-09	-0.22	-0.3	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
KIRC	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	6.96	1.1e-11	4.85e-09	0.27	0.3	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
KIRC	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-6.96	1.11e-11	4.86e-09	-0.22	-0.3	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
KIRC	cis	rs10214930	0.697	rs1030003	ENSG00000235574.1	AC073150.6	-6.96	1.11e-11	4.86e-09	-0.35	-0.3	Hypospadias;	chr7:27600240	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs3925338	ENSG00000235574.1	AC073150.6	-6.96	1.11e-11	4.87e-09	-0.35	-0.3	Hypospadias;	chr7:27553820	chr7:27491682~27492765:-
KIRC	cis	rs3750965	0.959	rs11228490	ENSG00000260895.1	RP11-554A11.7	-6.96	1.11e-11	4.87e-09	-0.37	-0.3	Hair color;	chr11:69093404	chr11:69103493~69109094:+
KIRC	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	6.96	1.11e-11	4.88e-09	0.28	0.3	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
KIRC	cis	rs17801127	0.818	rs35185541	ENSG00000231969.1	AC144449.1	6.96	1.11e-11	4.89e-09	0.54	0.3	Liver enzyme levels (alanine transaminase);	chr2:149682320	chr2:149587196~149848233:+
KIRC	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-6.96	1.12e-11	4.89e-09	-0.38	-0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
KIRC	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-6.96	1.12e-11	4.89e-09	-0.36	-0.3	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
KIRC	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-6.96	1.12e-11	4.9e-09	-0.4	-0.3	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	6.96	1.12e-11	4.9e-09	0.35	0.3	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
KIRC	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-6.96	1.12e-11	4.9e-09	-0.37	-0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
KIRC	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
KIRC	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	6.96	1.12e-11	4.91e-09	0.74	0.3	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
KIRC	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	6.95	1.12e-11	4.91e-09	0.36	0.3	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
KIRC	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-6.95	1.12e-11	4.92e-09	-0.28	-0.3	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-6.95	1.12e-11	4.92e-09	-0.28	-0.3	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
KIRC	cis	rs35306767	0.807	rs11253513	ENSG00000229869.1	RP11-363N22.2	-6.95	1.12e-11	4.92e-09	-0.35	-0.3	Eosinophil percentage of granulocytes;	chr10:922510	chr10:933026~942743:+
KIRC	cis	rs35306767	0.953	rs12259338	ENSG00000229869.1	RP11-363N22.2	-6.95	1.12e-11	4.92e-09	-0.35	-0.3	Eosinophil percentage of granulocytes;	chr10:923437	chr10:933026~942743:+
KIRC	cis	rs2018683	0.711	rs2158788	ENSG00000228421.2	AC005013.5	6.95	1.12e-11	4.92e-09	0.31	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28957667~28959345:+
KIRC	cis	rs7688540	0.8	rs28531997	ENSG00000211553.1	AC253576.2	-6.95	1.13e-11	4.93e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:136461~136568:+
KIRC	cis	rs4356975	0.83	rs72851348	ENSG00000250696.4	RP11-704M14.1	6.95	1.13e-11	4.93e-09	0.31	0.3	Obesity-related traits;	chr4:69054305	chr4:69182100~69216766:+
KIRC	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-6.95	1.13e-11	4.94e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
KIRC	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-6.95	1.13e-11	4.94e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
KIRC	cis	rs9371601	0.859	rs169975	ENSG00000226193.1	RP3-398G3.5	-6.95	1.13e-11	4.96e-09	-0.32	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152410486	chr6:152402398~152404966:+
KIRC	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-6.95	1.13e-11	4.96e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
KIRC	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-6.95	1.13e-11	4.97e-09	-0.4	-0.3	Depression;	chr6:28206179	chr6:28115628~28116551:+
KIRC	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	6.95	1.13e-11	4.97e-09	0.37	0.3	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
KIRC	cis	rs17801127	0.901	rs34550472	ENSG00000231969.1	AC144449.1	6.95	1.14e-11	4.99e-09	0.56	0.3	Liver enzyme levels (alanine transaminase);	chr2:149685555	chr2:149587196~149848233:+
KIRC	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-6.95	1.14e-11	4.99e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
KIRC	cis	rs6456156	0.526	rs3093025	ENSG00000265828.1	MIR3939	6.95	1.14e-11	4.99e-09	0.33	0.3	Primary biliary cholangitis;	chr6:167119243	chr6:166997807~166997912:-
KIRC	cis	rs600231	0.665	rs1784858	ENSG00000173727.10	CMB9-22P13.1	6.95	1.14e-11	5e-09	0.34	0.3	Bone mineral density;	chr11:65455481	chr11:65455258~65466720:+
KIRC	cis	rs17801127	0.818	rs16827316	ENSG00000231969.1	AC144449.1	6.95	1.14e-11	5e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149674565	chr2:149587196~149848233:+
KIRC	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	6.95	1.14e-11	5.01e-09	0.27	0.3	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
KIRC	cis	rs4356975	0.83	rs7438033	ENSG00000250696.4	RP11-704M14.1	-6.95	1.14e-11	5.01e-09	-0.3	-0.3	Obesity-related traits;	chr4:69059343	chr4:69182100~69216766:+
KIRC	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-6.95	1.14e-11	5.01e-09	-0.47	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
KIRC	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	6.95	1.15e-11	5.02e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	6.95	1.15e-11	5.02e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
KIRC	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.95	1.15e-11	5.02e-09	0.34	0.3	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
KIRC	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.95	1.15e-11	5.02e-09	0.34	0.3	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
KIRC	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	6.95	1.15e-11	5.03e-09	0.37	0.3	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
KIRC	cis	rs17772222	1	rs60310240	ENSG00000222990.1	RNU4-22P	6.95	1.15e-11	5.03e-09	0.35	0.3	Coronary artery calcification;	chr14:88356365	chr14:88513498~88513663:+
KIRC	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-6.95	1.15e-11	5.03e-09	-0.48	-0.3	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
KIRC	cis	rs643506	0.874	rs618421	ENSG00000230911.1	PPIHP1	-6.95	1.15e-11	5.04e-09	-0.35	-0.3	Breast cancer;	chr11:111778085	chr11:112029858~112030367:-
KIRC	cis	rs643506	0.874	rs618031	ENSG00000230911.1	PPIHP1	-6.95	1.15e-11	5.04e-09	-0.35	-0.3	Breast cancer;	chr11:111778139	chr11:112029858~112030367:-
KIRC	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	6.95	1.15e-11	5.05e-09	0.25	0.3	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
KIRC	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	6.95	1.15e-11	5.05e-09	0.35	0.3	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
KIRC	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-6.95	1.15e-11	5.05e-09	-0.39	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
KIRC	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	6.95	1.15e-11	5.05e-09	0.32	0.3	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	6.95	1.15e-11	5.05e-09	0.32	0.3	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	6.95	1.15e-11	5.05e-09	0.32	0.3	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	6.95	1.15e-11	5.05e-09	0.32	0.3	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
KIRC	cis	rs3820928	0.874	rs10166736	ENSG00000212391.1	SNORA48	-6.95	1.15e-11	5.05e-09	-0.34	-0.3	Pulmonary function;	chr2:227035703	chr2:226968989~226969122:-
KIRC	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-6.95	1.15e-11	5.05e-09	-0.36	-0.3	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
KIRC	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	6.95	1.16e-11	5.06e-09	0.28	0.3	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
KIRC	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-6.95	1.16e-11	5.06e-09	-0.31	-0.3	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
KIRC	cis	rs10214930	0.624	rs6959126	ENSG00000235574.1	AC073150.6	-6.95	1.16e-11	5.07e-09	-0.35	-0.3	Hypospadias;	chr7:27564631	chr7:27491682~27492765:-
KIRC	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-6.95	1.16e-11	5.07e-09	-0.23	-0.3	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
KIRC	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-6.95	1.16e-11	5.08e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
KIRC	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-6.95	1.16e-11	5.09e-09	-0.3	-0.3	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
KIRC	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-6.95	1.16e-11	5.09e-09	-0.28	-0.3	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-6.95	1.16e-11	5.09e-09	-0.28	-0.3	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
KIRC	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	6.95	1.16e-11	5.1e-09	0.73	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
KIRC	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	6.95	1.16e-11	5.1e-09	0.34	0.3	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
KIRC	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	6.95	1.17e-11	5.1e-09	0.35	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
KIRC	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	6.95	1.17e-11	5.1e-09	0.28	0.3	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
KIRC	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	6.95	1.17e-11	5.1e-09	0.28	0.3	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
KIRC	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	6.95	1.17e-11	5.1e-09	0.28	0.3	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
KIRC	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	6.95	1.17e-11	5.1e-09	0.26	0.3	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
KIRC	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.17e-11	5.11e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
KIRC	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	6.95	1.17e-11	5.11e-09	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
KIRC	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	6.95	1.17e-11	5.11e-09	0.29	0.3	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
KIRC	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	6.95	1.17e-11	5.11e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	6.95	1.17e-11	5.11e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	6.95	1.17e-11	5.11e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	6.95	1.17e-11	5.11e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	6.95	1.17e-11	5.11e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
KIRC	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-6.95	1.17e-11	5.11e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
KIRC	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-6.95	1.17e-11	5.11e-09	-0.34	-0.3	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
KIRC	cis	rs2797160	0.837	rs1739364	ENSG00000237742.5	RP11-624M8.1	-6.95	1.17e-11	5.11e-09	-0.35	-0.3	Endometrial cancer;	chr6:125701237	chr6:125578558~125749190:-
KIRC	cis	rs9915657	0.966	rs8071717	ENSG00000234899.8	SOX9-AS1	-6.95	1.17e-11	5.12e-09	-0.37	-0.3	Thyroid hormone levels;	chr17:72132564	chr17:72034107~72237203:-
KIRC	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-6.95	1.17e-11	5.12e-09	-0.24	-0.3	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
KIRC	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-6.95	1.17e-11	5.12e-09	-0.28	-0.3	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
KIRC	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	6.95	1.17e-11	5.12e-09	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
KIRC	cis	rs1560104	0.665	rs4381587	ENSG00000274834.1	CTD-3037G24.5	-6.95	1.17e-11	5.13e-09	-0.34	-0.3	Obesity-related traits;	chr16:12609047	chr16:12614451~12614852:+
KIRC	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	6.95	1.18e-11	5.14e-09	0.33	0.3	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
KIRC	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	6.95	1.18e-11	5.15e-09	0.26	0.3	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
KIRC	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-6.95	1.18e-11	5.15e-09	-0.32	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
KIRC	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-6.95	1.18e-11	5.15e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
KIRC	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-6.95	1.18e-11	5.16e-09	-0.28	-0.3	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-6.95	1.18e-11	5.16e-09	-0.28	-0.3	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-6.95	1.18e-11	5.16e-09	-0.28	-0.3	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-6.95	1.18e-11	5.16e-09	-0.28	-0.3	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
KIRC	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	6.95	1.18e-11	5.16e-09	0.31	0.3	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
KIRC	cis	rs7927771	0.793	rs3740686	ENSG00000280615.1	Y_RNA	6.95	1.18e-11	5.17e-09	0.33	0.3	Subjective well-being;	chr11:47354812	chr11:47614898~47614994:-
KIRC	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-6.95	1.19e-11	5.18e-09	-0.45	-0.3	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
KIRC	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-6.95	1.19e-11	5.18e-09	-0.45	-0.3	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
KIRC	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	6.95	1.19e-11	5.2e-09	0.32	0.3	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
KIRC	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	5.2e-09	0.3	0.3	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
KIRC	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	6.95	1.19e-11	5.2e-09	0.33	0.3	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
KIRC	cis	rs9371601	0.859	rs214943	ENSG00000226193.1	RP3-398G3.5	-6.95	1.19e-11	5.2e-09	-0.32	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152390260	chr6:152402398~152404966:+
KIRC	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	5.2e-09	0.3	0.3	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	5.2e-09	0.3	0.3	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
KIRC	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	6.95	1.19e-11	5.21e-09	0.38	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
KIRC	cis	rs4356975	0.867	rs6600869	ENSG00000198277.6	RP11-468N14.09	6.95	1.19e-11	5.22e-09	0.32	0.3	Obesity-related traits;	chr4:69075937	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.836	rs6600870	ENSG00000198277.6	RP11-468N14.09	6.95	1.19e-11	5.22e-09	0.32	0.3	Obesity-related traits;	chr4:69075944	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs7442394	ENSG00000198277.6	RP11-468N14.09	6.95	1.19e-11	5.22e-09	0.32	0.3	Obesity-related traits;	chr4:69076309	chr4:68914928~68924741:-
KIRC	cis	rs919433	0.756	rs7575389	ENSG00000231621.1	AC013264.2	6.94	1.2e-11	5.22e-09	0.31	0.3	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197333765	chr2:197197991~197199273:+
KIRC	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	6.94	1.2e-11	5.22e-09	0.23	0.3	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
KIRC	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-6.94	1.2e-11	5.24e-09	-0.39	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
KIRC	cis	rs4356975	0.798	rs4694588	ENSG00000250696.4	RP11-704M14.1	-6.94	1.2e-11	5.24e-09	-0.31	-0.3	Obesity-related traits;	chr4:69044664	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs6422321	ENSG00000250696.4	RP11-704M14.1	-6.94	1.2e-11	5.24e-09	-0.31	-0.3	Obesity-related traits;	chr4:69044911	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.768	rs4518318	ENSG00000250696.4	RP11-704M14.1	-6.94	1.2e-11	5.24e-09	-0.31	-0.3	Obesity-related traits;	chr4:69045479	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs4351079	ENSG00000250696.4	RP11-704M14.1	-6.94	1.2e-11	5.24e-09	-0.31	-0.3	Obesity-related traits;	chr4:69045631	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.798	rs4607293	ENSG00000250696.4	RP11-704M14.1	-6.94	1.2e-11	5.24e-09	-0.31	-0.3	Obesity-related traits;	chr4:69045714	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.795	rs4694599	ENSG00000196472.4	RP13-644M16.4	6.94	1.2e-11	5.24e-09	0.33	0.3	Obesity-related traits;	chr4:69070858	chr4:69181660~69182372:+
KIRC	cis	rs4356975	1	rs4356975	ENSG00000251284.2	RP13-644M16.1	-6.94	1.2e-11	5.24e-09	-0.36	-0.3	Obesity-related traits;	chr4:69106745	chr4:69125274~69126451:+
KIRC	cis	rs10214930	0.697	rs1980329	ENSG00000235574.1	AC073150.6	-6.94	1.2e-11	5.25e-09	-0.35	-0.3	Hypospadias;	chr7:27590681	chr7:27491682~27492765:-
KIRC	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	6.94	1.2e-11	5.25e-09	0.4	0.3	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
KIRC	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	6.94	1.2e-11	5.25e-09	0.33	0.3	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
KIRC	cis	rs4072705	1	rs13283284	ENSG00000224020.1	MIR181A2HG	-6.94	1.2e-11	5.26e-09	-0.29	-0.3	Menarche (age at onset);	chr9:124753898	chr9:124658467~124698631:+
KIRC	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-6.94	1.21e-11	5.26e-09	-0.2	-0.3	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
KIRC	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	6.94	1.21e-11	5.27e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	6.94	1.21e-11	5.27e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	6.94	1.21e-11	5.27e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
KIRC	cis	rs2018683	0.834	rs2012754	ENSG00000228421.2	AC005013.5	6.94	1.21e-11	5.27e-09	0.31	0.3	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28957667~28959345:+
KIRC	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-6.94	1.21e-11	5.28e-09	-0.17	-0.3	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
KIRC	cis	rs17801127	0.818	rs16827347	ENSG00000231969.1	AC144449.1	6.94	1.21e-11	5.28e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149694371	chr2:149587196~149848233:+
KIRC	cis	rs17801127	1	rs16827351	ENSG00000231969.1	AC144449.1	6.94	1.21e-11	5.28e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149698116	chr2:149587196~149848233:+
KIRC	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-6.94	1.21e-11	5.29e-09	-0.39	-0.3	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
KIRC	cis	rs7688540	0.76	rs7687833	ENSG00000211553.1	AC253576.2	-6.94	1.21e-11	5.3e-09	-0.35	-0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:136461~136568:+
KIRC	cis	rs10214930	0.813	rs1404282	ENSG00000235574.1	AC073150.6	-6.94	1.22e-11	5.31e-09	-0.38	-0.3	Hypospadias;	chr7:27545832	chr7:27491682~27492765:-
KIRC	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-6.94	1.22e-11	5.31e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
KIRC	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-6.94	1.22e-11	5.31e-09	-0.33	-0.3	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
KIRC	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	6.94	1.22e-11	5.31e-09	0.34	0.3	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
KIRC	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-6.94	1.22e-11	5.31e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
KIRC	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	6.94	1.22e-11	5.31e-09	0.28	0.3	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
KIRC	cis	rs600231	0.665	rs1616810	ENSG00000173727.10	CMB9-22P13.1	6.94	1.22e-11	5.31e-09	0.34	0.3	Bone mineral density;	chr11:65452634	chr11:65455258~65466720:+
KIRC	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	6.94	1.22e-11	5.32e-09	0.29	0.3	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
KIRC	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-6.94	1.22e-11	5.32e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
KIRC	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	6.94	1.22e-11	5.32e-09	0.72	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	6.94	1.22e-11	5.32e-09	0.72	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
KIRC	cis	rs4356975	0.83	rs7693166	ENSG00000250696.4	RP11-704M14.1	-6.94	1.22e-11	5.34e-09	-0.31	-0.3	Obesity-related traits;	chr4:69044866	chr4:69182100~69216766:+
KIRC	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	6.94	1.22e-11	5.34e-09	0.35	0.3	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
KIRC	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-6.94	1.23e-11	5.34e-09	-0.47	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
KIRC	cis	rs11647589	0.552	rs1632600	ENSG00000260762.1	ACSM5P1	6.94	1.23e-11	5.34e-09	0.3	0.3	Blood metabolite levels;	chr16:20476182	chr16:20586550~20607107:-
KIRC	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-6.94	1.23e-11	5.35e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
KIRC	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-6.94	1.23e-11	5.36e-09	-0.39	-0.3	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
KIRC	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	6.94	1.23e-11	5.37e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
KIRC	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	6.94	1.23e-11	5.37e-09	0.31	0.3	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
KIRC	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-6.94	1.23e-11	5.37e-09	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
KIRC	cis	rs62025270	0.593	rs62022926	ENSG00000202081.1	RNU6-1280P	-6.94	1.23e-11	5.37e-09	-0.38	-0.3	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85651522~85651628:-
KIRC	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	6.94	1.23e-11	5.37e-09	0.27	0.3	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
KIRC	cis	rs11647589	0.906	rs6416611	ENSG00000260762.1	ACSM5P1	6.94	1.24e-11	5.38e-09	0.3	0.3	Blood metabolite levels;	chr16:20459768	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.815	rs11646536	ENSG00000260762.1	ACSM5P1	6.94	1.24e-11	5.38e-09	0.3	0.3	Blood metabolite levels;	chr16:20462274	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.723	rs9937581	ENSG00000260762.1	ACSM5P1	6.94	1.24e-11	5.38e-09	0.3	0.3	Blood metabolite levels;	chr16:20462581	chr16:20586550~20607107:-
KIRC	cis	rs10214930	0.813	rs6954905	ENSG00000235574.1	AC073150.6	-6.94	1.24e-11	5.39e-09	-0.38	-0.3	Hypospadias;	chr7:27625206	chr7:27491682~27492765:-
KIRC	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	6.94	1.24e-11	5.39e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	6.94	1.24e-11	5.39e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
KIRC	cis	rs4356975	0.509	rs5014975	ENSG00000196472.4	RP13-644M16.4	6.94	1.24e-11	5.4e-09	0.35	0.3	Obesity-related traits;	chr4:69130244	chr4:69181660~69182372:+
KIRC	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	6.94	1.24e-11	5.4e-09	0.36	0.3	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
KIRC	cis	rs17772222	0.651	rs12586714	ENSG00000222990.1	RNU4-22P	6.94	1.24e-11	5.41e-09	0.32	0.3	Coronary artery calcification;	chr14:88360497	chr14:88513498~88513663:+
KIRC	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-6.94	1.24e-11	5.41e-09	-0.31	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-6.94	1.24e-11	5.42e-09	-0.31	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
KIRC	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-6.94	1.25e-11	5.42e-09	-0.32	-0.3	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
KIRC	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-6.94	1.25e-11	5.42e-09	-0.49	-0.3	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
KIRC	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	6.94	1.25e-11	5.42e-09	0.38	0.3	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
KIRC	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-6.94	1.25e-11	5.42e-09	-0.37	-0.3	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-6.94	1.25e-11	5.42e-09	-0.37	-0.3	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
KIRC	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-6.94	1.25e-11	5.42e-09	-0.37	-0.3	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
KIRC	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	6.94	1.25e-11	5.42e-09	0.45	0.3	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
KIRC	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-6.94	1.25e-11	5.44e-09	-0.33	-0.3	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
KIRC	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-6.94	1.25e-11	5.44e-09	-0.26	-0.3	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
KIRC	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	6.94	1.25e-11	5.45e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
KIRC	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-6.94	1.25e-11	5.45e-09	-0.31	-0.3	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
KIRC	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	6.94	1.25e-11	5.46e-09	0.35	0.3	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
KIRC	cis	rs7567389	0.812	rs6710496	ENSG00000236682.1	AC068282.3	6.94	1.26e-11	5.47e-09	0.38	0.3	Self-rated health;	chr2:127218798	chr2:127389130~127400580:+
KIRC	cis	rs9847710	0.869	rs2581793	ENSG00000280417.1	RP11-5O17.1	-6.94	1.26e-11	5.48e-09	-0.35	-0.3	Ulcerative colitis;	chr3:53001639	chr3:53046166~53048122:+
KIRC	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	6.94	1.26e-11	5.48e-09	0.3	0.3	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
KIRC	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	6.94	1.26e-11	5.48e-09	0.36	0.3	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
KIRC	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-6.94	1.26e-11	5.49e-09	-0.28	-0.3	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
KIRC	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-6.94	1.26e-11	5.49e-09	-0.23	-0.3	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
KIRC	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-6.94	1.26e-11	5.49e-09	-0.23	-0.3	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
KIRC	cis	rs916888	0.779	rs199526	ENSG00000261575.2	RP11-259G18.1	-6.94	1.26e-11	5.49e-09	-0.38	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46267037~46268694:+
KIRC	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	6.94	1.26e-11	5.5e-09	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	6.94	1.26e-11	5.5e-09	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
KIRC	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	6.94	1.26e-11	5.5e-09	0.25	0.3	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
KIRC	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	6.94	1.26e-11	5.5e-09	0.25	0.3	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
KIRC	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	6.94	1.26e-11	5.5e-09	0.25	0.3	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
KIRC	cis	rs3820928	0.904	rs10188570	ENSG00000212391.1	SNORA48	-6.94	1.26e-11	5.5e-09	-0.37	-0.3	Pulmonary function;	chr2:226927824	chr2:226968989~226969122:-
KIRC	cis	rs11647589	0.724	rs7499667	ENSG00000262995.1	CTD-2194A8.2	-6.94	1.27e-11	5.5e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20437198	chr16:20440266~20447000:-
KIRC	cis	rs10214930	0.813	rs2391444	ENSG00000235574.1	AC073150.6	-6.94	1.27e-11	5.51e-09	-0.38	-0.3	Hypospadias;	chr7:27602801	chr7:27491682~27492765:-
KIRC	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	6.94	1.27e-11	5.51e-09	0.4	0.3	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
KIRC	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-6.94	1.27e-11	5.52e-09	-0.26	-0.3	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
KIRC	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.94	1.27e-11	5.52e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
KIRC	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	6.94	1.27e-11	5.52e-09	0.27	0.3	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
KIRC	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	6.94	1.27e-11	5.52e-09	0.27	0.3	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
KIRC	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-6.94	1.27e-11	5.53e-09	-0.36	-0.3	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
KIRC	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-6.94	1.27e-11	5.54e-09	-0.41	-0.3	Depression;	chr6:28422360	chr6:28943877~28944537:+
KIRC	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-6.93	1.28e-11	5.55e-09	-0.45	-0.3	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
KIRC	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-6.93	1.28e-11	5.56e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-6.93	1.28e-11	5.56e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
KIRC	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-6.93	1.28e-11	5.56e-09	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
KIRC	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-6.93	1.28e-11	5.56e-09	-0.56	-0.3	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
KIRC	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-6.93	1.28e-11	5.57e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
KIRC	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-6.93	1.28e-11	5.57e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
KIRC	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	6.93	1.28e-11	5.58e-09	0.25	0.3	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
KIRC	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	6.93	1.28e-11	5.58e-09	0.57	0.3	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	6.93	1.28e-11	5.58e-09	0.57	0.3	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
KIRC	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	6.93	1.29e-11	5.59e-09	0.64	0.3	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
KIRC	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	6.93	1.29e-11	5.62e-09	0.35	0.3	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
KIRC	cis	rs9915657	0.773	rs9896360	ENSG00000234899.8	SOX9-AS1	-6.93	1.29e-11	5.62e-09	-0.37	-0.3	Thyroid hormone levels;	chr17:72103328	chr17:72034107~72237203:-
KIRC	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-6.93	1.3e-11	5.63e-09	-0.34	-0.3	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
KIRC	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-6.93	1.3e-11	5.63e-09	-0.34	-0.3	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
KIRC	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	6.93	1.3e-11	5.63e-09	0.37	0.3	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
KIRC	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-6.93	1.3e-11	5.64e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
KIRC	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-6.93	1.3e-11	5.64e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
KIRC	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-6.93	1.3e-11	5.65e-09	-0.4	-0.3	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
KIRC	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	6.93	1.3e-11	5.65e-09	0.32	0.3	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
KIRC	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-6.93	1.3e-11	5.65e-09	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
KIRC	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	6.93	1.3e-11	5.65e-09	0.25	0.3	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
KIRC	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-6.93	1.3e-11	5.66e-09	-0.24	-0.3	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
KIRC	cis	rs1198872	0.892	rs1198864	ENSG00000272275.1	RP11-791G15.2	-6.93	1.3e-11	5.66e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr2:10760869	chr2:10767875~10770058:-
KIRC	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	6.93	1.31e-11	5.67e-09	0.32	0.3	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
KIRC	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	6.93	1.31e-11	5.67e-09	0.31	0.3	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
KIRC	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	6.93	1.31e-11	5.67e-09	0.73	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
KIRC	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	6.93	1.31e-11	5.68e-09	0.4	0.3	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
KIRC	cis	rs1153858	1	rs7169818	ENSG00000235390.4	CTD-2651B20.5	-6.93	1.31e-11	5.68e-09	-0.28	-0.3	Homoarginine levels;	chr15:45347993	chr15:45321077~45321692:-
KIRC	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-6.93	1.31e-11	5.68e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
KIRC	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	6.93	1.31e-11	5.68e-09	0.38	0.3	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
KIRC	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-6.93	1.31e-11	5.68e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
KIRC	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	6.93	1.31e-11	5.7e-09	0.38	0.3	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	6.93	1.31e-11	5.7e-09	0.38	0.3	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	6.93	1.31e-11	5.7e-09	0.38	0.3	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
KIRC	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-6.93	1.31e-11	5.7e-09	-0.39	-0.3	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
KIRC	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	6.93	1.32e-11	5.71e-09	0.38	0.3	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
KIRC	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-6.93	1.32e-11	5.71e-09	-0.39	-0.3	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
KIRC	cis	rs3820928	0.874	rs9288618	ENSG00000212391.1	SNORA48	-6.93	1.32e-11	5.72e-09	-0.35	-0.3	Pulmonary function;	chr2:227007901	chr2:226968989~226969122:-
KIRC	cis	rs7592578	0.679	rs4287794	ENSG00000272979.1	RP11-647K16.1	-6.93	1.32e-11	5.73e-09	-0.42	-0.3	Diastolic blood pressure;	chr2:190462421	chr2:190454092~190454521:-
KIRC	cis	rs1552244	0.872	rs115331527	ENSG00000180385.7	EMC3-AS1	6.93	1.32e-11	5.74e-09	0.3	0.3	Alzheimer's disease;	chr3:10112820	chr3:9986893~10006990:+
KIRC	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	6.93	1.32e-11	5.74e-09	0.29	0.3	QT interval;	chr12:29304617	chr12:29280418~29317848:-
KIRC	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	6.93	1.32e-11	5.74e-09	0.29	0.3	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
KIRC	cis	rs3760982	1	rs10421887	ENSG00000267058.1	RP11-15A1.3	6.93	1.32e-11	5.74e-09	0.35	0.3	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43891804~43901805:-
KIRC	cis	rs7592578	0.599	rs62180992	ENSG00000272979.1	RP11-647K16.1	-6.93	1.32e-11	5.74e-09	-0.43	-0.3	Diastolic blood pressure;	chr2:190421006	chr2:190454092~190454521:-
KIRC	cis	rs17801127	0.818	rs13023298	ENSG00000231969.1	AC144449.1	6.93	1.32e-11	5.75e-09	0.54	0.3	Liver enzyme levels (alanine transaminase);	chr2:149680521	chr2:149587196~149848233:+
KIRC	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	6.93	1.32e-11	5.75e-09	0.25	0.3	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
KIRC	cis	rs1153858	1	rs1049508	ENSG00000235390.4	CTD-2651B20.5	-6.93	1.32e-11	5.75e-09	-0.28	-0.3	Homoarginine levels;	chr15:45361394	chr15:45321077~45321692:-
KIRC	cis	rs1153858	1	rs1145085	ENSG00000235390.4	CTD-2651B20.5	-6.93	1.32e-11	5.75e-09	-0.28	-0.3	Homoarginine levels;	chr15:45365606	chr15:45321077~45321692:-
KIRC	cis	rs1153858	1	rs1288775	ENSG00000235390.4	CTD-2651B20.5	-6.93	1.32e-11	5.75e-09	-0.28	-0.3	Homoarginine levels;	chr15:45369480	chr15:45321077~45321692:-
KIRC	cis	rs4356975	0.83	rs4422474	ENSG00000250696.4	RP11-704M14.1	6.93	1.33e-11	5.75e-09	0.31	0.3	Obesity-related traits;	chr4:69051322	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs4377650	ENSG00000250696.4	RP11-704M14.1	6.93	1.33e-11	5.75e-09	0.31	0.3	Obesity-related traits;	chr4:69051355	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs72851338	ENSG00000250696.4	RP11-704M14.1	6.93	1.33e-11	5.75e-09	0.31	0.3	Obesity-related traits;	chr4:69052555	chr4:69182100~69216766:+
KIRC	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-6.93	1.33e-11	5.76e-09	-0.34	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
KIRC	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-6.93	1.33e-11	5.77e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
KIRC	cis	rs4072705	0.967	rs4838195	ENSG00000224020.1	MIR181A2HG	-6.93	1.33e-11	5.77e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124588938	chr9:124658467~124698631:+
KIRC	cis	rs10754283	0.557	rs1215511	ENSG00000231613.1	RP5-943J3.1	6.93	1.33e-11	5.78e-09	0.3	0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89621984	chr1:89788914~89790492:+
KIRC	cis	rs4072705	1	rs4838206	ENSG00000224020.1	MIR181A2HG	-6.93	1.34e-11	5.79e-09	-0.29	-0.3	Menarche (age at onset);	chr9:124749645	chr9:124658467~124698631:+
KIRC	cis	rs2749592	0.611	rs2505199	ENSG00000151963.4	RP11-775A3.1	-6.93	1.34e-11	5.8e-09	-0.37	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:37883594~37884109:+
KIRC	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.93	1.34e-11	5.82e-09	-0.32	-0.3	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
KIRC	cis	rs4888671	1	rs17716830	ENSG00000261707.1	RP11-264M12.2	6.93	1.34e-11	5.82e-09	0.45	0.3	Obesity-related traits;	chr16:77738102	chr16:77741468~77743000:-
KIRC	cis	rs17772222	0.56	rs3742681	ENSG00000222990.1	RNU4-22P	-6.93	1.34e-11	5.83e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88554903	chr14:88513498~88513663:+
KIRC	cis	rs4072705	0.967	rs4838210	ENSG00000224020.1	MIR181A2HG	6.93	1.35e-11	5.83e-09	0.29	0.3	Menarche (age at onset);	chr9:124783904	chr9:124658467~124698631:+
KIRC	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	6.93	1.35e-11	5.83e-09	0.68	0.3	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
KIRC	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.93	1.35e-11	5.84e-09	-0.47	-0.3	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
KIRC	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.93	1.35e-11	5.84e-09	-0.47	-0.3	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
KIRC	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-6.93	1.35e-11	5.85e-09	-0.29	-0.3	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
KIRC	cis	rs17801127	0.901	rs6727151	ENSG00000231969.1	AC144449.1	6.93	1.35e-11	5.85e-09	0.53	0.3	Liver enzyme levels (alanine transaminase);	chr2:149697470	chr2:149587196~149848233:+
KIRC	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	5.85e-09	0.55	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
KIRC	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	6.93	1.35e-11	5.86e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
KIRC	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-6.93	1.35e-11	5.86e-09	-0.4	-0.3	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
KIRC	cis	rs4356975	0.83	rs57386454	ENSG00000250696.4	RP11-704M14.1	6.93	1.35e-11	5.86e-09	0.31	0.3	Obesity-related traits;	chr4:69052968	chr4:69182100~69216766:+
KIRC	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-6.93	1.35e-11	5.86e-09	-0.39	-0.3	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
KIRC	cis	rs11647589	0.834	rs9933872	ENSG00000260762.1	ACSM5P1	6.93	1.35e-11	5.87e-09	0.3	0.3	Blood metabolite levels;	chr16:20473849	chr16:20586550~20607107:-
KIRC	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	6.93	1.35e-11	5.87e-09	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
KIRC	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	6.93	1.36e-11	5.87e-09	0.42	0.3	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
KIRC	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-6.93	1.36e-11	5.87e-09	-0.32	-0.3	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
KIRC	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-6.93	1.36e-11	5.87e-09	-0.29	-0.3	QT interval;	chr12:29314736	chr12:29280418~29317848:-
KIRC	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	6.93	1.36e-11	5.87e-09	0.37	0.3	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
KIRC	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	6.93	1.36e-11	5.87e-09	0.34	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
KIRC	cis	rs801193	0.591	rs9986881	ENSG00000275400.1	RP4-756H11.5	-6.93	1.36e-11	5.87e-09	-0.3	-0.3	Aortic root size;	chr7:66708053	chr7:66553805~66554199:-
KIRC	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	6.93	1.36e-11	5.88e-09	0.27	0.3	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	6.93	1.36e-11	5.88e-09	0.27	0.3	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
KIRC	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-6.93	1.36e-11	5.88e-09	-0.3	-0.3	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
KIRC	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	6.93	1.36e-11	5.88e-09	0.35	0.3	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
KIRC	cis	rs643506	0.874	rs4245045	ENSG00000230911.1	PPIHP1	-6.93	1.36e-11	5.88e-09	-0.35	-0.3	Breast cancer;	chr11:111789200	chr11:112029858~112030367:-
KIRC	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	6.92	1.36e-11	5.9e-09	0.73	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
KIRC	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	6.92	1.36e-11	5.9e-09	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
KIRC	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-6.92	1.36e-11	5.9e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
KIRC	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-6.92	1.36e-11	5.9e-09	-0.3	-0.3	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
KIRC	cis	rs13434995	0.787	rs62303724	ENSG00000249700.7	SRD5A3-AS1	-6.92	1.36e-11	5.9e-09	-0.34	-0.3	Adiponectin levels;	chr4:55485114	chr4:55363971~55395847:-
KIRC	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	6.92	1.36e-11	5.9e-09	0.26	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
KIRC	cis	rs17772222	1	rs17772064	ENSG00000222990.1	RNU4-22P	6.92	1.37e-11	5.92e-09	0.34	0.3	Coronary artery calcification;	chr14:88356527	chr14:88513498~88513663:+
KIRC	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-6.92	1.37e-11	5.93e-09	-0.38	-0.3	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
KIRC	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	6.92	1.37e-11	5.93e-09	0.41	0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
KIRC	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-6.92	1.37e-11	5.93e-09	-0.4	-0.3	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
KIRC	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-6.92	1.37e-11	5.94e-09	-0.3	-0.3	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
KIRC	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-6.92	1.38e-11	5.96e-09	-0.36	-0.3	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
KIRC	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	6.92	1.38e-11	5.96e-09	0.62	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
KIRC	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	6.92	1.38e-11	5.97e-09	0.31	0.3	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
KIRC	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-6.92	1.38e-11	5.97e-09	-0.46	-0.3	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
KIRC	cis	rs17801127	0.818	rs16827349	ENSG00000231969.1	AC144449.1	6.92	1.38e-11	5.97e-09	0.51	0.3	Liver enzyme levels (alanine transaminase);	chr2:149695891	chr2:149587196~149848233:+
KIRC	cis	rs2337406	0.778	rs56965016	ENSG00000274576.2	IGHV2-70	-6.92	1.38e-11	5.97e-09	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106656649	chr14:106770577~106771020:-
KIRC	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-6.92	1.38e-11	5.97e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
KIRC	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-6.92	1.38e-11	5.97e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
KIRC	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-6.92	1.38e-11	5.97e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
KIRC	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	6.92	1.38e-11	5.98e-09	0.38	0.3	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
KIRC	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	6.92	1.39e-11	6e-09	0.43	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
KIRC	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	6.92	1.39e-11	6e-09	0.3	0.3	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	6.92	1.39e-11	6e-09	0.3	0.3	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	6.92	1.39e-11	6e-09	0.3	0.3	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
KIRC	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-6.92	1.39e-11	6.01e-09	-0.4	-0.3	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
KIRC	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	6.92	1.39e-11	6.01e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
KIRC	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	6.92	1.39e-11	6.01e-09	0.34	0.3	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
KIRC	cis	rs1552244	1	rs67852463	ENSG00000180385.7	EMC3-AS1	6.92	1.4e-11	6.04e-09	0.31	0.3	Alzheimer's disease;	chr3:10115521	chr3:9986893~10006990:+
KIRC	cis	rs357618	0.897	rs165362	ENSG00000260581.1	CTB-113P19.4	6.92	1.4e-11	6.05e-09	0.35	0.3	Basophil percentage of white cells;	chr5:151483526	chr5:151652275~151655449:+
KIRC	cis	rs3820928	0.845	rs10165767	ENSG00000212391.1	SNORA48	-6.92	1.4e-11	6.05e-09	-0.35	-0.3	Pulmonary function;	chr2:226917147	chr2:226968989~226969122:-
KIRC	cis	rs7916697	0.947	rs7916410	ENSG00000233590.1	RP11-153K11.3	6.92	1.4e-11	6.06e-09	0.33	0.3	Optic disc area;	chr10:68235910	chr10:68233251~68242379:-
KIRC	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	6.92	1.4e-11	6.07e-09	0.3	0.3	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	6.92	1.4e-11	6.07e-09	0.3	0.3	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	6.92	1.4e-11	6.07e-09	0.3	0.3	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
KIRC	cis	rs17772222	0.651	rs865285	ENSG00000222990.1	RNU4-22P	-6.92	1.4e-11	6.07e-09	-0.32	-0.3	Coronary artery calcification;	chr14:88391138	chr14:88513498~88513663:+
KIRC	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-6.92	1.41e-11	6.07e-09	-0.4	-0.3	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
KIRC	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-6.92	1.41e-11	6.07e-09	-0.37	-0.3	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
KIRC	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	6.92	1.41e-11	6.07e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
KIRC	cis	rs10740039	0.583	rs10740042	ENSG00000254271.1	RP11-131N11.4	6.92	1.41e-11	6.08e-09	0.37	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60736828	chr10:60734342~60741828:+
KIRC	cis	rs17747401	0.507	rs61862570	ENSG00000213731.2	RAB5CP1	-6.92	1.41e-11	6.08e-09	-0.28	-0.3	Hypospadias;	chr10:74687113	chr10:74423435~74424014:-
KIRC	cis	rs17801127	1	rs13014503	ENSG00000231969.1	AC144449.1	6.92	1.41e-11	6.08e-09	0.54	0.3	Liver enzyme levels (alanine transaminase);	chr2:149684562	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.901	rs71413658	ENSG00000231969.1	AC144449.1	6.92	1.41e-11	6.08e-09	0.54	0.3	Liver enzyme levels (alanine transaminase);	chr2:149685661	chr2:149587196~149848233:+
KIRC	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-6.92	1.41e-11	6.09e-09	-0.31	-0.3	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
KIRC	cis	rs1552244	1	rs7648104	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10031627	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs113771705	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10034299	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs111392584	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10034307	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs17032276	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10035291	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs17032277	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10035339	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs17032278	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10036271	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs66797209	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10036842	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs76041173	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10037011	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs7631678	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10037132	chr3:9986893~10006990:+
KIRC	cis	rs1552244	1	rs7637888	ENSG00000180385.7	EMC3-AS1	6.92	1.41e-11	6.09e-09	0.29	0.3	Alzheimer's disease;	chr3:10039038	chr3:9986893~10006990:+
KIRC	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-6.92	1.41e-11	6.11e-09	-0.36	-0.3	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
KIRC	cis	rs4072705	0.967	rs10818979	ENSG00000224020.1	MIR181A2HG	-6.92	1.41e-11	6.11e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124574634	chr9:124658467~124698631:+
KIRC	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-6.92	1.42e-11	6.13e-09	-0.25	-0.3	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
KIRC	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	6.92	1.42e-11	6.13e-09	0.34	0.3	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
KIRC	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	6.92	1.42e-11	6.13e-09	0.43	0.3	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
KIRC	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-6.92	1.42e-11	6.13e-09	-0.37	-0.3	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
KIRC	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	6.92	1.42e-11	6.14e-09	0.34	0.3	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
KIRC	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-6.92	1.43e-11	6.16e-09	-0.38	-0.3	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
KIRC	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.16e-09	0.43	0.3	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.16e-09	0.43	0.3	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.16e-09	0.43	0.3	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.16e-09	0.43	0.3	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.16e-09	0.43	0.3	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
KIRC	cis	rs6456156	0.792	rs9366089	ENSG00000265828.1	MIR3939	-6.92	1.43e-11	6.16e-09	-0.34	-0.3	Primary biliary cholangitis;	chr6:167099408	chr6:166997807~166997912:-
KIRC	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	6.92	1.43e-11	6.16e-09	0.28	0.3	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
KIRC	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-6.92	1.43e-11	6.16e-09	-0.36	-0.3	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
KIRC	cis	rs1153858	1	rs1145081	ENSG00000235390.4	CTD-2651B20.5	-6.92	1.43e-11	6.17e-09	-0.28	-0.3	Homoarginine levels;	chr15:45387469	chr15:45321077~45321692:-
KIRC	cis	rs1153858	0.943	rs1145079	ENSG00000235390.4	CTD-2651B20.5	-6.92	1.43e-11	6.17e-09	-0.28	-0.3	Homoarginine levels;	chr15:45389563	chr15:45321077~45321692:-
KIRC	cis	rs9915657	0.743	rs9894720	ENSG00000234899.8	SOX9-AS1	-6.92	1.43e-11	6.17e-09	-0.37	-0.3	Thyroid hormone levels;	chr17:72101466	chr17:72034107~72237203:-
KIRC	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	6.92	1.43e-11	6.17e-09	0.42	0.3	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
KIRC	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28071237	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28074687	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28076559	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28076704	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28078391	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28079011	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28080757	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	6.92	1.43e-11	6.18e-09	0.34	0.3	Depression;	chr6:28080760	chr6:28073316~28074233:+
KIRC	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-6.92	1.43e-11	6.18e-09	-0.35	-0.3	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
KIRC	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	6.92	1.44e-11	6.2e-09	0.41	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
KIRC	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-6.92	1.44e-11	6.21e-09	-0.23	-0.3	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
KIRC	cis	rs4601821	0.635	rs11214579	ENSG00000270179.1	RP11-159N11.4	6.92	1.44e-11	6.21e-09	0.3	0.3	Alcoholic chronic pancreatitis;	chr11:113337464	chr11:113368478~113369117:+
KIRC	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	6.92	1.44e-11	6.21e-09	0.36	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
KIRC	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	6.92	1.44e-11	6.21e-09	0.36	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
KIRC	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-6.92	1.44e-11	6.23e-09	-0.31	-0.3	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
KIRC	cis	rs6456156	0.792	rs4710178	ENSG00000265828.1	MIR3939	-6.92	1.45e-11	6.23e-09	-0.34	-0.3	Primary biliary cholangitis;	chr6:167100044	chr6:166997807~166997912:-
KIRC	cis	rs7246657	0.722	rs2287229	ENSG00000267422.1	CTD-2554C21.1	6.92	1.45e-11	6.24e-09	0.43	0.3	Coronary artery calcification;	chr19:37697751	chr19:37779686~37792865:+
KIRC	cis	rs2797160	0.651	rs1268066	ENSG00000237742.5	RP11-624M8.1	6.92	1.45e-11	6.25e-09	0.36	0.3	Endometrial cancer;	chr6:125713895	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.651	rs1343121	ENSG00000237742.5	RP11-624M8.1	6.92	1.45e-11	6.25e-09	0.36	0.3	Endometrial cancer;	chr6:125715038	chr6:125578558~125749190:-
KIRC	cis	rs2337406	0.925	rs10131226	ENSG00000274576.2	IGHV2-70	-6.91	1.45e-11	6.25e-09	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106665764	chr14:106770577~106771020:-
KIRC	cis	rs4072705	0.967	rs4240486	ENSG00000224020.1	MIR181A2HG	-6.91	1.45e-11	6.26e-09	-0.3	-0.3	Menarche (age at onset);	chr9:124578831	chr9:124658467~124698631:+
KIRC	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-6.91	1.45e-11	6.26e-09	-0.22	-0.3	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
KIRC	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-6.91	1.45e-11	6.26e-09	-0.37	-0.3	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
KIRC	cis	rs17772222	0.74	rs7160647	ENSG00000258789.1	RP11-507K2.3	-6.91	1.46e-11	6.28e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88507340	chr14:88551597~88552493:+
KIRC	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-6.91	1.46e-11	6.29e-09	-0.28	-0.3	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
KIRC	cis	rs7924176	0.521	rs11001022	ENSG00000213731.2	RAB5CP1	-6.91	1.46e-11	6.29e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74423435~74424014:-
KIRC	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.91	1.46e-11	6.29e-09	0.25	0.3	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
KIRC	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-6.91	1.46e-11	6.3e-09	-0.3	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
KIRC	cis	rs35306767	0.953	rs12354639	ENSG00000229869.1	RP11-363N22.2	-6.91	1.46e-11	6.31e-09	-0.35	-0.3	Eosinophil percentage of granulocytes;	chr10:917741	chr10:933026~942743:+
KIRC	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-6.91	1.47e-11	6.32e-09	-0.37	-0.3	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
KIRC	cis	rs9371601	0.667	rs214979	ENSG00000226193.1	RP3-398G3.5	-6.91	1.47e-11	6.33e-09	-0.32	-0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152410425	chr6:152402398~152404966:+
KIRC	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	6.91	1.47e-11	6.33e-09	0.43	0.3	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
KIRC	cis	rs7246657	0.722	rs3095726	ENSG00000267422.1	CTD-2554C21.1	6.91	1.48e-11	6.35e-09	0.47	0.3	Coronary artery calcification;	chr19:37738923	chr19:37779686~37792865:+
KIRC	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-6.91	1.48e-11	6.35e-09	-0.28	-0.3	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
KIRC	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	6.91	1.48e-11	6.35e-09	0.27	0.3	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
KIRC	cis	rs17361889	0.517	rs62440456	ENSG00000224683.1	RPL36AP29	6.91	1.48e-11	6.36e-09	0.42	0.3	Pediatric bone mineral content (hip);	chr7:16285655	chr7:16208945~16209265:+
KIRC	cis	rs3820928	0.845	rs2177596	ENSG00000212391.1	SNORA48	-6.91	1.48e-11	6.36e-09	-0.34	-0.3	Pulmonary function;	chr2:227025567	chr2:226968989~226969122:-
KIRC	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-6.91	1.48e-11	6.36e-09	-0.23	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
KIRC	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-6.91	1.48e-11	6.37e-09	-0.33	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
KIRC	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	6.91	1.48e-11	6.39e-09	0.26	0.3	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
KIRC	cis	rs4356975	0.527	rs60423649	ENSG00000196472.4	RP13-644M16.4	6.91	1.49e-11	6.39e-09	0.34	0.3	Obesity-related traits;	chr4:69127952	chr4:69181660~69182372:+
KIRC	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	6.91	1.49e-11	6.4e-09	0.3	0.3	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
KIRC	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	6.91	1.49e-11	6.4e-09	0.26	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
KIRC	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	6.91	1.49e-11	6.42e-09	0.33	0.3	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	6.91	1.49e-11	6.42e-09	0.33	0.3	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	6.91	1.49e-11	6.42e-09	0.33	0.3	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	6.91	1.49e-11	6.42e-09	0.33	0.3	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
KIRC	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-6.91	1.49e-11	6.42e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
KIRC	cis	rs35306767	0.953	rs11253509	ENSG00000229869.1	RP11-363N22.2	-6.91	1.49e-11	6.42e-09	-0.35	-0.3	Eosinophil percentage of granulocytes;	chr10:918366	chr10:933026~942743:+
KIRC	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	6.91	1.49e-11	6.42e-09	0.34	0.3	Depression;	chr6:28159666	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	6.91	1.49e-11	6.42e-09	0.34	0.3	Depression;	chr6:28162598	chr6:28073316~28074233:+
KIRC	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	6.91	1.49e-11	6.42e-09	0.36	0.3	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
KIRC	cis	rs11148252	0.967	rs11620062	ENSG00000278238.1	RP11-245D16.4	-6.91	1.49e-11	6.43e-09	-0.32	-0.3	Lewy body disease;	chr13:52419891	chr13:52454775~52455331:-
KIRC	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	6.91	1.49e-11	6.43e-09	0.29	0.3	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	6.91	1.49e-11	6.43e-09	0.29	0.3	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	6.91	1.49e-11	6.43e-09	0.29	0.3	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
KIRC	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-6.91	1.49e-11	6.43e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
KIRC	cis	rs2337406	0.778	rs56658355	ENSG00000274576.2	IGHV2-70	-6.91	1.5e-11	6.43e-09	-0.37	-0.3	Alzheimer's disease (late onset);	chr14:106662151	chr14:106770577~106771020:-
KIRC	cis	rs11671005	0.656	rs55652736	ENSG00000269600.1	AC016629.3	-6.91	1.5e-11	6.43e-09	-0.52	-0.3	Mean platelet volume;	chr19:58496199	chr19:58593896~58599355:-
KIRC	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	6.91	1.5e-11	6.43e-09	0.34	0.3	Depression;	chr6:28173770	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	6.91	1.5e-11	6.43e-09	0.34	0.3	Depression;	chr6:28174809	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	6.91	1.5e-11	6.43e-09	0.34	0.3	Depression;	chr6:28175233	chr6:28073316~28074233:+
KIRC	cis	rs9601248	0.627	rs9545151	ENSG00000227354.5	RBM26-AS1	-6.91	1.5e-11	6.43e-09	-0.36	-0.3	Major depressive disorder;	chr13:79608400	chr13:79406309~79424328:+
KIRC	cis	rs13434995	0.842	rs62303716	ENSG00000249700.7	SRD5A3-AS1	-6.91	1.5e-11	6.44e-09	-0.34	-0.3	Adiponectin levels;	chr4:55468085	chr4:55363971~55395847:-
KIRC	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.91	1.5e-11	6.44e-09	0.25	0.3	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
KIRC	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	6.91	1.5e-11	6.44e-09	0.31	0.3	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
KIRC	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-6.91	1.5e-11	6.44e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
KIRC	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	6.91	1.5e-11	6.46e-09	0.34	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
KIRC	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.91	1.5e-11	6.46e-09	0.34	0.3	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
KIRC	cis	rs1153858	1	rs1153858	ENSG00000235390.4	CTD-2651B20.5	6.91	1.5e-11	6.46e-09	0.28	0.3	Homoarginine levels;	chr15:45360505	chr15:45321077~45321692:-
KIRC	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-6.91	1.5e-11	6.47e-09	-0.37	-0.3	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
KIRC	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	6.91	1.51e-11	6.47e-09	0.69	0.3	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
KIRC	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	6.91	1.51e-11	6.49e-09	0.34	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
KIRC	cis	rs4761702	0.524	rs12581099	ENSG00000257252.4	RP11-486A14.2	-6.91	1.51e-11	6.49e-09	-0.44	-0.3	Immature fraction of reticulocytes;	chr12:93333720	chr12:93317135~93377736:-
KIRC	cis	rs710913	0.604	rs1180343	ENSG00000182109.6	RP11-69E11.4	-6.91	1.51e-11	6.49e-09	-0.23	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527760	chr1:39522280~39546187:-
KIRC	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	6.91	1.51e-11	6.49e-09	0.41	0.3	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
KIRC	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-6.91	1.51e-11	6.5e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
KIRC	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	6.91	1.52e-11	6.51e-09	0.56	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
KIRC	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-6.91	1.52e-11	6.51e-09	-0.36	-0.3	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
KIRC	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-6.91	1.52e-11	6.52e-09	-0.23	-0.3	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
KIRC	cis	rs3750965	0.92	rs10896420	ENSG00000260895.1	RP11-554A11.7	6.91	1.52e-11	6.53e-09	0.37	0.3	Hair color;	chr11:69095579	chr11:69103493~69109094:+
KIRC	cis	rs3750965	0.92	rs10896421	ENSG00000260895.1	RP11-554A11.7	6.91	1.52e-11	6.53e-09	0.37	0.3	Hair color;	chr11:69095580	chr11:69103493~69109094:+
KIRC	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	6.91	1.52e-11	6.53e-09	0.26	0.3	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
KIRC	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	6.91	1.52e-11	6.53e-09	0.26	0.3	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
KIRC	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	6.91	1.52e-11	6.53e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
KIRC	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-6.91	1.52e-11	6.54e-09	-0.33	-0.3	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
KIRC	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-6.91	1.52e-11	6.54e-09	-0.4	-0.3	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-6.91	1.52e-11	6.54e-09	-0.4	-0.3	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
KIRC	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.91	1.52e-11	6.54e-09	-0.47	-0.3	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
KIRC	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.91	1.52e-11	6.54e-09	-0.47	-0.3	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
KIRC	cis	rs12999373	0.501	rs11127496	ENSG00000223751.1	AC116609.2	6.91	1.52e-11	6.55e-09	0.38	0.3	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:742488~747767:+
KIRC	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-6.91	1.53e-11	6.55e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
KIRC	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-6.91	1.53e-11	6.55e-09	-0.38	-0.3	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
KIRC	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-6.91	1.53e-11	6.55e-09	-0.38	-0.3	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
KIRC	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-6.91	1.53e-11	6.57e-09	-0.26	-0.3	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
KIRC	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-6.91	1.53e-11	6.59e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
KIRC	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-6.91	1.53e-11	6.59e-09	-0.45	-0.3	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
KIRC	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	6.91	1.54e-11	6.6e-09	0.5	0.3	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
KIRC	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-6.91	1.54e-11	6.61e-09	-0.21	-0.3	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
KIRC	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	6.91	1.54e-11	6.62e-09	0.34	0.3	Depression;	chr6:28161802	chr6:28073316~28074233:+
KIRC	cis	rs9915657	0.803	rs12449851	ENSG00000234899.8	SOX9-AS1	6.91	1.54e-11	6.62e-09	0.36	0.3	Thyroid hormone levels;	chr17:72102861	chr17:72034107~72237203:-
KIRC	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	6.91	1.54e-11	6.62e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
KIRC	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	6.91	1.54e-11	6.62e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
KIRC	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	6.91	1.54e-11	6.63e-09	0.33	0.3	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
KIRC	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-6.91	1.54e-11	6.63e-09	-0.42	-0.3	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
KIRC	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-6.9	1.55e-11	6.66e-09	-0.4	-0.3	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-6.9	1.55e-11	6.66e-09	-0.4	-0.3	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
KIRC	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.55e-11	6.66e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
KIRC	cis	rs1153858	1	rs1145091	ENSG00000235390.4	CTD-2651B20.5	-6.9	1.55e-11	6.66e-09	-0.29	-0.3	Homoarginine levels;	chr15:45357798	chr15:45321077~45321692:-
KIRC	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	6.9	1.55e-11	6.67e-09	0.28	0.3	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
KIRC	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	6.9	1.55e-11	6.67e-09	0.28	0.3	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
KIRC	cis	rs4356975	0.83	rs6422322	ENSG00000250696.4	RP11-704M14.1	6.9	1.56e-11	6.68e-09	0.31	0.3	Obesity-related traits;	chr4:69055571	chr4:69182100~69216766:+
KIRC	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-6.9	1.56e-11	6.69e-09	-0.37	-0.3	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
KIRC	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	6.9	1.56e-11	6.69e-09	0.25	0.3	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
KIRC	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-6.9	1.56e-11	6.7e-09	-0.29	-0.3	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
KIRC	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-6.9	1.56e-11	6.71e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
KIRC	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	6.9	1.56e-11	6.71e-09	0.28	0.3	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
KIRC	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	6.9	1.56e-11	6.71e-09	0.38	0.3	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
KIRC	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-6.9	1.57e-11	6.72e-09	-0.33	-0.3	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
KIRC	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-6.9	1.57e-11	6.73e-09	-0.29	-0.3	QT interval;	chr12:29303562	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-6.9	1.57e-11	6.73e-09	-0.29	-0.3	QT interval;	chr12:29306799	chr12:29280418~29317848:-
KIRC	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-6.9	1.57e-11	6.73e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
KIRC	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-6.9	1.57e-11	6.73e-09	-0.38	-0.3	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
KIRC	cis	rs10214930	0.813	rs6462033	ENSG00000235574.1	AC073150.6	-6.9	1.57e-11	6.74e-09	-0.37	-0.3	Hypospadias;	chr7:27579066	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.723	rs1524529	ENSG00000235574.1	AC073150.6	-6.9	1.57e-11	6.74e-09	-0.37	-0.3	Hypospadias;	chr7:27580796	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs1608663	ENSG00000235574.1	AC073150.6	-6.9	1.57e-11	6.74e-09	-0.37	-0.3	Hypospadias;	chr7:27584157	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.767	rs1980330	ENSG00000235574.1	AC073150.6	-6.9	1.57e-11	6.74e-09	-0.37	-0.3	Hypospadias;	chr7:27590704	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs1015265	ENSG00000235574.1	AC073150.6	-6.9	1.57e-11	6.74e-09	-0.37	-0.3	Hypospadias;	chr7:27599990	chr7:27491682~27492765:-
KIRC	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	6.9	1.57e-11	6.74e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
KIRC	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	6.9	1.57e-11	6.75e-09	0.29	0.3	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	6.9	1.57e-11	6.75e-09	0.29	0.3	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
KIRC	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	6.9	1.57e-11	6.75e-09	0.29	0.3	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
KIRC	cis	rs17801127	0.748	rs13007543	ENSG00000231969.1	AC144449.1	6.9	1.57e-11	6.75e-09	0.51	0.3	Liver enzyme levels (alanine transaminase);	chr2:149682573	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.901	rs1017151	ENSG00000231969.1	AC144449.1	6.9	1.57e-11	6.75e-09	0.51	0.3	Liver enzyme levels (alanine transaminase);	chr2:149684159	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.901	rs6708629	ENSG00000231969.1	AC144449.1	6.9	1.57e-11	6.75e-09	0.51	0.3	Liver enzyme levels (alanine transaminase);	chr2:149685243	chr2:149587196~149848233:+
KIRC	cis	rs4356975	0.563	rs4293848	ENSG00000196472.4	RP13-644M16.4	6.9	1.57e-11	6.75e-09	0.34	0.3	Obesity-related traits;	chr4:69099784	chr4:69181660~69182372:+
KIRC	cis	rs4072705	1	rs4838207	ENSG00000224020.1	MIR181A2HG	-6.9	1.57e-11	6.75e-09	-0.31	-0.3	Menarche (age at onset);	chr9:124756855	chr9:124658467~124698631:+
KIRC	cis	rs75422866	0.764	rs67408202	ENSG00000280054.1	RP1-197B17.7	6.9	1.58e-11	6.76e-09	0.61	0.3	Pneumonia;	chr12:47713564	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.867	rs57848393	ENSG00000280054.1	RP1-197B17.7	6.9	1.58e-11	6.76e-09	0.61	0.3	Pneumonia;	chr12:47714734	chr12:47728151~47730598:-
KIRC	cis	rs75422866	0.764	rs67201012	ENSG00000280054.1	RP1-197B17.7	6.9	1.58e-11	6.76e-09	0.61	0.3	Pneumonia;	chr12:47715881	chr12:47728151~47730598:-
KIRC	cis	rs1153858	1	rs2453541	ENSG00000235390.4	CTD-2651B20.5	-6.9	1.58e-11	6.76e-09	-0.28	-0.3	Homoarginine levels;	chr15:45353180	chr15:45321077~45321692:-
KIRC	cis	rs1153858	1	rs2461702	ENSG00000235390.4	CTD-2651B20.5	-6.9	1.58e-11	6.78e-09	-0.29	-0.3	Homoarginine levels;	chr15:45355229	chr15:45321077~45321692:-
KIRC	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-6.9	1.58e-11	6.78e-09	-0.29	-0.3	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
KIRC	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-6.9	1.58e-11	6.78e-09	-0.29	-0.3	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
KIRC	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.9	1.58e-11	6.78e-09	-0.38	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
KIRC	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	6.9	1.58e-11	6.78e-09	0.24	0.3	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
KIRC	cis	rs4072705	1	rs10986391	ENSG00000224020.1	MIR181A2HG	-6.9	1.58e-11	6.78e-09	-0.29	-0.3	Menarche (age at onset);	chr9:124665956	chr9:124658467~124698631:+
KIRC	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	6.9	1.58e-11	6.79e-09	0.28	0.3	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
KIRC	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-6.9	1.58e-11	6.79e-09	-0.29	-0.3	QT interval;	chr12:29319476	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-6.9	1.58e-11	6.79e-09	-0.29	-0.3	QT interval;	chr12:29320175	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-6.9	1.58e-11	6.79e-09	-0.29	-0.3	QT interval;	chr12:29321177	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-6.9	1.58e-11	6.79e-09	-0.29	-0.3	QT interval;	chr12:29321323	chr12:29280418~29317848:-
KIRC	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-6.9	1.58e-11	6.79e-09	-0.29	-0.3	QT interval;	chr12:29322770	chr12:29280418~29317848:-
KIRC	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-6.9	1.58e-11	6.79e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-6.9	1.58e-11	6.79e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
KIRC	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	6.9	1.59e-11	6.79e-09	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
KIRC	cis	rs7712401	1	rs7712401	ENSG00000249996.1	RP11-359P5.1	6.9	1.59e-11	6.8e-09	0.35	0.3	Mean platelet volume;	chr5:123038764	chr5:123036271~123054667:+
KIRC	cis	rs10214930	0.781	rs759271	ENSG00000235574.1	AC073150.6	-6.9	1.59e-11	6.8e-09	-0.38	-0.3	Hypospadias;	chr7:27607494	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs2391445	ENSG00000235574.1	AC073150.6	-6.9	1.59e-11	6.8e-09	-0.38	-0.3	Hypospadias;	chr7:27609252	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs2391446	ENSG00000235574.1	AC073150.6	-6.9	1.59e-11	6.8e-09	-0.38	-0.3	Hypospadias;	chr7:27609301	chr7:27491682~27492765:-
KIRC	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	6.9	1.59e-11	6.81e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	6.9	1.59e-11	6.81e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	6.9	1.59e-11	6.81e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
KIRC	cis	rs6456156	0.792	rs4710179	ENSG00000265828.1	MIR3939	-6.9	1.6e-11	6.84e-09	-0.34	-0.3	Primary biliary cholangitis;	chr6:167100204	chr6:166997807~166997912:-
KIRC	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-6.9	1.6e-11	6.84e-09	-0.17	-0.3	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
KIRC	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-6.9	1.6e-11	6.86e-09	-0.29	-0.3	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
KIRC	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	6.9	1.6e-11	6.86e-09	0.4	0.3	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
KIRC	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	6.9	1.6e-11	6.87e-09	0.3	0.3	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
KIRC	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	6.9	1.61e-11	6.88e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
KIRC	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-6.9	1.61e-11	6.88e-09	-0.33	-0.3	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
KIRC	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.61e-11	6.89e-09	-0.28	-0.3	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
KIRC	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	6.9	1.61e-11	6.89e-09	0.24	0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
KIRC	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	6.9	1.61e-11	6.9e-09	0.37	0.3	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
KIRC	cis	rs643506	0.845	rs7114594	ENSG00000230911.1	PPIHP1	-6.9	1.61e-11	6.9e-09	-0.35	-0.3	Breast cancer;	chr11:111897389	chr11:112029858~112030367:-
KIRC	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-6.9	1.61e-11	6.9e-09	-0.22	-0.3	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
KIRC	cis	rs13113518	0.51	rs6828454	ENSG00000273257.1	RP11-177J6.1	6.9	1.61e-11	6.9e-09	0.35	0.3	Height;	chr4:55424329	chr4:55387949~55388271:+
KIRC	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	6.9	1.61e-11	6.9e-09	0.36	0.3	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
KIRC	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	6.9	1.61e-11	6.91e-09	0.34	0.3	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
KIRC	cis	rs4072705	0.967	rs10120039	ENSG00000224020.1	MIR181A2HG	-6.9	1.61e-11	6.91e-09	-0.32	-0.3	Menarche (age at onset);	chr9:124644682	chr9:124658467~124698631:+
KIRC	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-6.9	1.62e-11	6.92e-09	-0.28	-0.3	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
KIRC	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	6.9	1.62e-11	6.92e-09	0.36	0.3	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
KIRC	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	6.9	1.62e-11	6.93e-09	0.52	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
KIRC	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-6.9	1.62e-11	6.94e-09	-0.41	-0.3	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
KIRC	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	6.9	1.62e-11	6.95e-09	0.75	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
KIRC	cis	rs13113518	0.51	rs10049561	ENSG00000273257.1	RP11-177J6.1	6.9	1.63e-11	6.95e-09	0.35	0.3	Height;	chr4:55426623	chr4:55387949~55388271:+
KIRC	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-6.9	1.63e-11	6.96e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
KIRC	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-6.9	1.63e-11	6.96e-09	-0.28	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
KIRC	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	6.9	1.63e-11	6.96e-09	0.34	0.3	Depression;	chr6:28176973	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	6.9	1.63e-11	6.96e-09	0.34	0.3	Depression;	chr6:28180209	chr6:28073316~28074233:+
KIRC	cis	rs1077773	0.7	rs10259316	ENSG00000236318.1	AC019117.1	6.9	1.63e-11	6.97e-09	0.38	0.3	Ulcerative colitis;Inflammatory bowel disease;	chr7:17406082	chr7:17374867~17466664:+
KIRC	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	6.9	1.63e-11	6.97e-09	0.34	0.3	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
KIRC	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	6.9	1.63e-11	6.97e-09	0.3	0.3	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
KIRC	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-6.9	1.63e-11	6.99e-09	-0.22	-0.3	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
KIRC	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-6.9	1.64e-11	7e-09	-0.36	-0.3	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
KIRC	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	6.9	1.64e-11	7.01e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
KIRC	cis	rs13113518	0.51	rs3749473	ENSG00000273257.1	RP11-177J6.1	6.9	1.64e-11	7.02e-09	0.35	0.3	Height;	chr4:55428461	chr4:55387949~55388271:+
KIRC	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.9	1.65e-11	7.04e-09	-0.47	-0.3	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
KIRC	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	6.9	1.65e-11	7.04e-09	0.35	0.3	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
KIRC	cis	rs9915657	0.87	rs12941066	ENSG00000234899.8	SOX9-AS1	-6.89	1.65e-11	7.06e-09	-0.38	-0.3	Thyroid hormone levels;	chr17:72145085	chr17:72034107~72237203:-
KIRC	cis	rs7924176	0.521	rs10509347	ENSG00000213731.2	RAB5CP1	-6.89	1.65e-11	7.06e-09	-0.29	-0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74423435~74424014:-
KIRC	cis	rs919433	0.617	rs4850436	ENSG00000231621.1	AC013264.2	6.89	1.65e-11	7.06e-09	0.32	0.3	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197676674	chr2:197197991~197199273:+
KIRC	cis	rs6456156	0.792	rs7775443	ENSG00000265828.1	MIR3939	6.89	1.65e-11	7.07e-09	0.34	0.3	Primary biliary cholangitis;	chr6:167099764	chr6:166997807~166997912:-
KIRC	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	6.89	1.65e-11	7.07e-09	0.31	0.3	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
KIRC	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	6.89	1.65e-11	7.07e-09	0.42	0.3	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
KIRC	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.66e-11	7.08e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.66e-11	7.08e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
KIRC	cis	rs7182621	0.793	rs12904168	ENSG00000182397.13	DNM1P46	6.89	1.66e-11	7.08e-09	0.34	0.3	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99790156~99806927:-
KIRC	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.89	1.66e-11	7.08e-09	0.42	0.3	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
KIRC	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	6.89	1.66e-11	7.09e-09	0.3	0.3	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
KIRC	cis	rs643506	0.845	rs607327	ENSG00000230911.1	PPIHP1	-6.89	1.66e-11	7.09e-09	-0.35	-0.3	Breast cancer;	chr11:111824985	chr11:112029858~112030367:-
KIRC	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-6.89	1.66e-11	7.09e-09	-0.34	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
KIRC	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	6.89	1.66e-11	7.1e-09	0.33	0.3	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
KIRC	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	6.89	1.66e-11	7.1e-09	0.33	0.3	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
KIRC	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-6.89	1.66e-11	7.11e-09	-0.27	-0.3	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
KIRC	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-6.89	1.67e-11	7.12e-09	-0.25	-0.3	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
KIRC	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	6.89	1.67e-11	7.13e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
KIRC	cis	rs375066	0.592	rs349045	ENSG00000267058.1	RP11-15A1.3	6.89	1.67e-11	7.13e-09	0.33	0.3	Breast cancer;	chr19:43795740	chr19:43891804~43901805:-
KIRC	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-6.89	1.67e-11	7.13e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
KIRC	cis	rs10214930	0.752	rs2391448	ENSG00000235574.1	AC073150.6	-6.89	1.67e-11	7.14e-09	-0.37	-0.3	Hypospadias;	chr7:27638566	chr7:27491682~27492765:-
KIRC	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-6.89	1.67e-11	7.14e-09	-0.23	-0.3	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
KIRC	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	6.89	1.67e-11	7.14e-09	0.34	0.3	Depression;	chr6:28131566	chr6:28073316~28074233:+
KIRC	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-6.89	1.68e-11	7.16e-09	-0.29	-0.3	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
KIRC	cis	rs7592578	0.679	rs62181019	ENSG00000272979.1	RP11-647K16.1	-6.89	1.68e-11	7.16e-09	-0.42	-0.3	Diastolic blood pressure;	chr2:190460688	chr2:190454092~190454521:-
KIRC	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	6.89	1.68e-11	7.16e-09	0.33	0.3	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
KIRC	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	6.89	1.68e-11	7.16e-09	0.23	0.3	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
KIRC	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-6.89	1.68e-11	7.17e-09	-0.27	-0.3	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
KIRC	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-6.89	1.7e-11	7.26e-09	-0.22	-0.3	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
KIRC	cis	rs643506	0.79	rs688095	ENSG00000230911.1	PPIHP1	-6.89	1.7e-11	7.27e-09	-0.35	-0.3	Breast cancer;	chr11:111808047	chr11:112029858~112030367:-
KIRC	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-6.89	1.71e-11	7.28e-09	-0.33	-0.3	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
KIRC	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	6.89	1.71e-11	7.29e-09	0.25	0.3	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
KIRC	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-6.89	1.72e-11	7.33e-09	-0.47	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
KIRC	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-6.89	1.72e-11	7.34e-09	-0.43	-0.3	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
KIRC	cis	rs3820928	0.874	rs1949807	ENSG00000212391.1	SNORA48	-6.89	1.72e-11	7.34e-09	-0.34	-0.3	Pulmonary function;	chr2:227027145	chr2:226968989~226969122:-
KIRC	cis	rs643506	0.845	rs762550	ENSG00000230911.1	PPIHP1	-6.89	1.72e-11	7.35e-09	-0.35	-0.3	Breast cancer;	chr11:111912376	chr11:112029858~112030367:-
KIRC	cis	rs12893668	0.581	rs34843146	ENSG00000269910.1	RP11-73M18.10	6.89	1.72e-11	7.35e-09	0.22	0.3	Reticulocyte count;	chr14:103613527	chr14:103694516~103695050:-
KIRC	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-6.89	1.72e-11	7.35e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-6.89	1.72e-11	7.35e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
KIRC	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-6.89	1.73e-11	7.36e-09	-0.33	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
KIRC	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-6.89	1.73e-11	7.38e-09	-0.35	-0.3	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
KIRC	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-6.89	1.73e-11	7.38e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
KIRC	cis	rs17772222	0.74	rs7160647	ENSG00000222990.1	RNU4-22P	6.89	1.73e-11	7.38e-09	0.33	0.3	Coronary artery calcification;	chr14:88507340	chr14:88513498~88513663:+
KIRC	cis	rs3745672	1	rs11880710	ENSG00000219665.7	CTD-2006C1.2	6.89	1.73e-11	7.39e-09	0.45	0.3	Multiple sclerosis;	chr19:12046080	chr19:11987617~12046275:+
KIRC	cis	rs13236243	0.632	rs713150	ENSG00000236318.1	AC019117.1	6.89	1.73e-11	7.39e-09	0.42	0.3	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17300533	chr7:17374867~17466664:+
KIRC	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.73e-11	7.39e-09	-0.26	-0.3	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
KIRC	cis	rs35306767	0.903	rs12761424	ENSG00000229869.1	RP11-363N22.2	-6.89	1.74e-11	7.4e-09	-0.35	-0.3	Eosinophil percentage of granulocytes;	chr10:921355	chr10:933026~942743:+
KIRC	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-6.89	1.74e-11	7.41e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
KIRC	cis	rs6456156	0.792	rs4710181	ENSG00000265828.1	MIR3939	-6.89	1.74e-11	7.42e-09	-0.34	-0.3	Primary biliary cholangitis;	chr6:167100510	chr6:166997807~166997912:-
KIRC	cis	rs6456156	0.755	rs4710182	ENSG00000265828.1	MIR3939	-6.89	1.74e-11	7.42e-09	-0.34	-0.3	Primary biliary cholangitis;	chr6:167100573	chr6:166997807~166997912:-
KIRC	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-6.89	1.75e-11	7.44e-09	-0.29	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
KIRC	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.75e-11	7.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.75e-11	7.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.75e-11	7.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.75e-11	7.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.75e-11	7.44e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
KIRC	cis	rs2797160	0.651	rs1268067	ENSG00000237742.5	RP11-624M8.1	6.89	1.75e-11	7.44e-09	0.36	0.3	Endometrial cancer;	chr6:125715475	chr6:125578558~125749190:-
KIRC	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	6.89	1.75e-11	7.45e-09	0.39	0.3	Height;	chr6:109416903	chr6:109382795~109383666:+
KIRC	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	6.89	1.75e-11	7.46e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
KIRC	cis	rs62025270	0.632	rs78572940	ENSG00000202081.1	RNU6-1280P	-6.89	1.75e-11	7.46e-09	-0.37	-0.3	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85651522~85651628:-
KIRC	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	6.89	1.75e-11	7.47e-09	0.4	0.3	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
KIRC	cis	rs7924176	0.521	rs10824137	ENSG00000213731.2	RAB5CP1	6.89	1.76e-11	7.48e-09	0.28	0.3	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74423435~74424014:-
KIRC	cis	rs10276381	1	rs7796417	ENSG00000234336.5	JAZF1-AS1	-6.88	1.76e-11	7.49e-09	-0.54	-0.3	Crohn's disease;	chr7:28146500	chr7:28180322~28243917:+
KIRC	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	6.88	1.76e-11	7.49e-09	0.28	0.3	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.932	rs4694610	ENSG00000198277.6	RP11-468N14.09	6.88	1.76e-11	7.49e-09	0.31	0.3	Obesity-related traits;	chr4:69079224	chr4:68914928~68924741:-
KIRC	cis	rs4356975	0.932	rs4694602	ENSG00000198277.6	RP11-468N14.09	6.88	1.76e-11	7.5e-09	0.32	0.3	Obesity-related traits;	chr4:69070955	chr4:68914928~68924741:-
KIRC	cis	rs10214930	0.697	rs1554641	ENSG00000235574.1	AC073150.6	-6.88	1.76e-11	7.51e-09	-0.35	-0.3	Hypospadias;	chr7:27555068	chr7:27491682~27492765:-
KIRC	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-6.88	1.77e-11	7.53e-09	-0.24	-0.3	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
KIRC	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	6.88	1.77e-11	7.54e-09	0.47	0.3	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
KIRC	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-6.88	1.77e-11	7.56e-09	-0.32	-0.3	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
KIRC	cis	rs13434995	0.842	rs62303685	ENSG00000249700.7	SRD5A3-AS1	-6.88	1.78e-11	7.56e-09	-0.34	-0.3	Adiponectin levels;	chr4:55418915	chr4:55363971~55395847:-
KIRC	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	6.88	1.78e-11	7.57e-09	0.26	0.3	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
KIRC	cis	rs7017914	0.616	rs11987260	ENSG00000254031.4	RP11-326E22.1	6.88	1.78e-11	7.58e-09	0.34	0.3	Bone mineral density;	chr8:70861647	chr8:71155457~71204223:+
KIRC	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	6.88	1.78e-11	7.58e-09	0.26	0.3	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
KIRC	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	6.88	1.78e-11	7.58e-09	0.37	0.3	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
KIRC	cis	rs10214930	0.781	rs6943883	ENSG00000235574.1	AC073150.6	-6.88	1.79e-11	7.6e-09	-0.37	-0.3	Hypospadias;	chr7:27653274	chr7:27491682~27492765:-
KIRC	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-6.88	1.79e-11	7.61e-09	-0.29	-0.3	QT interval;	chr12:29306357	chr12:29280418~29317848:-
KIRC	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.88	1.79e-11	7.61e-09	0.35	0.3	Height;	chr11:118854014	chr11:118688039~118690600:-
KIRC	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	6.88	1.79e-11	7.62e-09	0.34	0.3	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
KIRC	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-6.88	1.79e-11	7.62e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-6.88	1.79e-11	7.62e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
KIRC	cis	rs2361718	0.501	rs8065486	ENSG00000279259.1	RP11-334C17.3	-6.88	1.79e-11	7.63e-09	-0.3	-0.3	Yeast infection;	chr17:80164397	chr17:80147250~80148596:+
KIRC	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	6.88	1.79e-11	7.64e-09	0.32	0.3	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
KIRC	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-6.88	1.79e-11	7.64e-09	-0.32	-0.3	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
KIRC	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-6.88	1.8e-11	7.64e-09	-0.25	-0.3	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
KIRC	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	6.88	1.8e-11	7.64e-09	0.34	0.3	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
KIRC	cis	rs12887734	0.546	rs66676135	ENSG00000269910.1	RP11-73M18.10	6.88	1.8e-11	7.65e-09	0.21	0.3	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694516~103695050:-
KIRC	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-6.88	1.8e-11	7.67e-09	-0.28	-0.3	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Depression;	chr6:28123153	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Depression;	chr6:28124529	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Depression;	chr6:28126588	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Depression;	chr6:28126953	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	6.88	1.8e-11	7.67e-09	0.34	0.3	Depression;	chr6:28127577	chr6:28073316~28074233:+
KIRC	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-6.88	1.8e-11	7.67e-09	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
KIRC	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	6.88	1.8e-11	7.68e-09	0.42	0.3	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
KIRC	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-6.88	1.81e-11	7.68e-09	-0.4	-0.3	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
KIRC	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	6.88	1.81e-11	7.68e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
KIRC	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	6.88	1.81e-11	7.68e-09	0.28	0.3	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
KIRC	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	6.88	1.81e-11	7.68e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	6.88	1.81e-11	7.68e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
KIRC	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-6.88	1.81e-11	7.69e-09	-0.27	-0.3	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
KIRC	cis	rs4356975	0.527	rs57102579	ENSG00000196472.4	RP13-644M16.4	6.88	1.81e-11	7.69e-09	0.34	0.3	Obesity-related traits;	chr4:69125476	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.527	rs4385139	ENSG00000196472.4	RP13-644M16.4	6.88	1.81e-11	7.69e-09	0.34	0.3	Obesity-related traits;	chr4:69125911	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.527	rs4694645	ENSG00000196472.4	RP13-644M16.4	6.88	1.81e-11	7.69e-09	0.34	0.3	Obesity-related traits;	chr4:69127200	chr4:69181660~69182372:+
KIRC	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	6.88	1.81e-11	7.7e-09	0.34	0.3	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
KIRC	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	6.88	1.81e-11	7.7e-09	0.26	0.3	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
KIRC	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.88	1.81e-11	7.71e-09	0.34	0.3	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
KIRC	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	6.88	1.82e-11	7.73e-09	0.26	0.3	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
KIRC	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	6.88	1.82e-11	7.73e-09	0.4	0.3	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
KIRC	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	6.88	1.82e-11	7.74e-09	0.26	0.3	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
KIRC	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.88	1.82e-11	7.74e-09	-0.27	-0.3	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
KIRC	cis	rs7182948	0.846	rs1354920	ENSG00000259531.2	RP11-295H24.3	-6.88	1.82e-11	7.75e-09	-0.35	-0.3	Lung adenocarcinoma;	chr15:49533326	chr15:49365124~49366685:-
KIRC	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-6.88	1.83e-11	7.76e-09	-0.28	-0.3	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
KIRC	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-6.88	1.83e-11	7.76e-09	-0.34	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
KIRC	cis	rs11148252	1	rs4886018	ENSG00000278238.1	RP11-245D16.4	-6.88	1.83e-11	7.77e-09	-0.32	-0.3	Lewy body disease;	chr13:52416582	chr13:52454775~52455331:-
KIRC	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-6.88	1.83e-11	7.79e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
KIRC	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	6.88	1.84e-11	7.8e-09	0.63	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
KIRC	cis	rs643506	0.874	rs625477	ENSG00000230911.1	PPIHP1	-6.88	1.84e-11	7.81e-09	-0.35	-0.3	Breast cancer;	chr11:111790962	chr11:112029858~112030367:-
KIRC	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-6.88	1.84e-11	7.82e-09	-0.34	-0.3	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
KIRC	cis	rs7017914	0.667	rs34972504	ENSG00000254031.4	RP11-326E22.1	6.88	1.84e-11	7.82e-09	0.34	0.3	Bone mineral density;	chr8:70689486	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs12681588	ENSG00000254031.4	RP11-326E22.1	6.88	1.84e-11	7.82e-09	0.34	0.3	Bone mineral density;	chr8:70689652	chr8:71155457~71204223:+
KIRC	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-6.88	1.84e-11	7.83e-09	-0.4	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
KIRC	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	6.88	1.84e-11	7.83e-09	0.31	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
KIRC	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.88	1.84e-11	7.83e-09	-0.31	-0.3	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
KIRC	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.88	1.85e-11	7.84e-09	0.25	0.3	Height;	chr2:46624894	chr2:46668870~46670778:+
KIRC	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	6.88	1.85e-11	7.84e-09	0.29	0.3	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
KIRC	cis	rs643506	0.817	rs658373	ENSG00000230911.1	PPIHP1	-6.88	1.85e-11	7.84e-09	-0.35	-0.3	Breast cancer;	chr11:111812267	chr11:112029858~112030367:-
KIRC	cis	rs4888671	1	rs79704582	ENSG00000261707.1	RP11-264M12.2	6.88	1.85e-11	7.85e-09	0.45	0.3	Obesity-related traits;	chr16:77747262	chr16:77741468~77743000:-
KIRC	cis	rs4888671	0.803	rs78291339	ENSG00000261707.1	RP11-264M12.2	6.88	1.85e-11	7.85e-09	0.45	0.3	Obesity-related traits;	chr16:77747318	chr16:77741468~77743000:-
KIRC	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.88	1.85e-11	7.85e-09	-0.38	-0.3	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
KIRC	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-6.88	1.85e-11	7.85e-09	-0.36	-0.3	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-6.88	1.85e-11	7.86e-09	-0.35	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
KIRC	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-6.88	1.85e-11	7.87e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
KIRC	cis	rs2337406	1	rs7145172	ENSG00000274576.2	IGHV2-70	-6.88	1.86e-11	7.88e-09	-0.35	-0.3	Alzheimer's disease (late onset);	chr14:106704924	chr14:106770577~106771020:-
KIRC	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	6.88	1.86e-11	7.88e-09	0.36	0.3	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
KIRC	cis	rs4888671	1	rs59630213	ENSG00000261707.1	RP11-264M12.2	6.88	1.86e-11	7.9e-09	0.45	0.3	Obesity-related traits;	chr16:77743133	chr16:77741468~77743000:-
KIRC	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-6.88	1.86e-11	7.9e-09	-0.32	-0.3	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
KIRC	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	6.88	1.86e-11	7.9e-09	0.25	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
KIRC	cis	rs2486288	0.656	rs7171312	ENSG00000235390.4	CTD-2651B20.5	6.88	1.86e-11	7.91e-09	0.27	0.3	Glomerular filtration rate;	chr15:45278027	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs6493143	ENSG00000235390.4	CTD-2651B20.5	6.88	1.86e-11	7.91e-09	0.27	0.3	Glomerular filtration rate;	chr15:45278583	chr15:45321077~45321692:-
KIRC	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	6.88	1.87e-11	7.93e-09	0.33	0.3	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
KIRC	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	6.88	1.87e-11	7.93e-09	0.26	0.3	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
KIRC	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	6.88	1.87e-11	7.93e-09	0.33	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
KIRC	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-6.88	1.87e-11	7.93e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
KIRC	cis	rs12216125	0.537	rs12207059	ENSG00000272462.2	U91328.19	-6.88	1.87e-11	7.93e-09	-0.29	-0.3	Iron status biomarkers;	chr6:25922157	chr6:25992662~26001775:+
KIRC	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-6.88	1.87e-11	7.94e-09	-0.23	-0.3	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
KIRC	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	6.88	1.87e-11	7.94e-09	0.3	0.3	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
KIRC	cis	rs3820928	1	rs4675115	ENSG00000212391.1	SNORA48	-6.88	1.87e-11	7.94e-09	-0.35	-0.3	Pulmonary function;	chr2:226904407	chr2:226968989~226969122:-
KIRC	cis	rs12893668	0.638	rs11851616	ENSG00000269910.1	RP11-73M18.10	6.87	1.87e-11	7.95e-09	0.21	0.3	Reticulocyte count;	chr14:103599263	chr14:103694516~103695050:-
KIRC	cis	rs12893668	0.667	rs11844466	ENSG00000269910.1	RP11-73M18.10	6.87	1.87e-11	7.95e-09	0.21	0.3	Reticulocyte count;	chr14:103600085	chr14:103694516~103695050:-
KIRC	cis	rs6452524	0.648	rs27364	ENSG00000248112.1	RP11-78C3.1	6.87	1.88e-11	7.96e-09	0.33	0.3	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82919376~82921119:-
KIRC	cis	rs17801127	0.901	rs13030023	ENSG00000231969.1	AC144449.1	6.87	1.88e-11	7.96e-09	0.51	0.3	Liver enzyme levels (alanine transaminase);	chr2:149653337	chr2:149587196~149848233:+
KIRC	cis	rs712039	0.617	rs36081240	ENSG00000276054.1	RP11-378E13.3	6.87	1.88e-11	7.96e-09	0.39	0.3	Tuberculosis;	chr17:37424955	chr17:37386886~37387926:+
KIRC	cis	rs712039	0.652	rs853224	ENSG00000276054.1	RP11-378E13.3	6.87	1.88e-11	7.96e-09	0.39	0.3	Tuberculosis;	chr17:37431229	chr17:37386886~37387926:+
KIRC	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-6.87	1.88e-11	7.97e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-6.87	1.88e-11	7.97e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
KIRC	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	6.87	1.88e-11	7.97e-09	0.33	0.3	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
KIRC	cis	rs11079159	0.958	rs11656277	ENSG00000263096.1	RP11-515O17.2	6.87	1.88e-11	7.97e-09	0.44	0.3	QRS duration;	chr17:55293686	chr17:55271504~55273653:-
KIRC	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	6.87	1.88e-11	7.97e-09	0.41	0.3	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
KIRC	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.87	1.88e-11	7.99e-09	0.31	0.3	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
KIRC	cis	rs4820539	1	rs4822357	ENSG00000221069.1	AC000029.1	-6.87	1.89e-11	8e-09	-0.36	-0.3	Bone mineral density;	chr22:23131044	chr22:23136620~23136710:+
KIRC	cis	rs4888671	1	rs79409507	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747583	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs78839411	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747617	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs79885511	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747642	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs74783281	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747704	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs76243942	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747740	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs75936301	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747845	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs78780050	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77747891	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs78515849	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77748101	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs78599153	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77748157	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs80279339	ENSG00000261707.1	RP11-264M12.2	6.87	1.89e-11	8e-09	0.45	0.3	Obesity-related traits;	chr16:77748165	chr16:77741468~77743000:-
KIRC	cis	rs4356975	0.563	rs12506962	ENSG00000196472.4	RP13-644M16.4	6.87	1.89e-11	8.01e-09	0.34	0.3	Obesity-related traits;	chr4:69100306	chr4:69181660~69182372:+
KIRC	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-6.87	1.89e-11	8.02e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-6.87	1.89e-11	8.02e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-6.87	1.89e-11	8.02e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-6.87	1.89e-11	8.02e-09	-0.24	-0.3	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
KIRC	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-6.87	1.89e-11	8.02e-09	-0.28	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
KIRC	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.87	1.89e-11	8.03e-09	0.25	0.3	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
KIRC	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	6.87	1.9e-11	8.03e-09	0.36	0.3	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	6.87	1.9e-11	8.03e-09	0.36	0.3	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
KIRC	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-6.87	1.9e-11	8.04e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-6.87	1.9e-11	8.04e-09	-0.37	-0.3	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
KIRC	cis	rs13434995	0.842	rs62303715	ENSG00000249700.7	SRD5A3-AS1	-6.87	1.9e-11	8.05e-09	-0.34	-0.3	Adiponectin levels;	chr4:55466893	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.842	rs6828474	ENSG00000249700.7	SRD5A3-AS1	-6.87	1.9e-11	8.05e-09	-0.34	-0.3	Adiponectin levels;	chr4:55475740	chr4:55363971~55395847:-
KIRC	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-6.87	1.9e-11	8.05e-09	-0.47	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
KIRC	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	6.87	1.9e-11	8.06e-09	0.26	0.3	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
KIRC	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-6.87	1.9e-11	8.06e-09	-0.31	-0.3	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
KIRC	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	6.87	1.9e-11	8.07e-09	0.45	0.3	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
KIRC	cis	rs2749592	0.588	rs2505192	ENSG00000151963.4	RP11-775A3.1	-6.87	1.91e-11	8.08e-09	-0.37	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:37883594~37884109:+
KIRC	cis	rs9371601	0.859	rs214944	ENSG00000226193.1	RP3-398G3.5	6.87	1.91e-11	8.09e-09	0.32	0.3	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152391617	chr6:152402398~152404966:+
KIRC	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	6.87	1.91e-11	8.09e-09	0.38	0.3	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
KIRC	cis	rs17270561	0.666	rs4712971	ENSG00000272462.2	U91328.19	-6.87	1.91e-11	8.1e-09	-0.26	-0.3	Iron status biomarkers;	chr6:25771672	chr6:25992662~26001775:+
KIRC	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.12e-09	0.43	0.3	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.12e-09	0.43	0.3	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.12e-09	0.43	0.3	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.12e-09	0.43	0.3	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.12e-09	0.43	0.3	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
KIRC	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	6.87	1.92e-11	8.12e-09	0.34	0.3	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
KIRC	cis	rs4356975	0.509	rs10006452	ENSG00000250696.4	RP11-704M14.1	6.87	1.92e-11	8.12e-09	0.31	0.3	Obesity-related traits;	chr4:69112090	chr4:69182100~69216766:+
KIRC	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	6.87	1.92e-11	8.14e-09	0.42	0.3	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
KIRC	cis	rs4820539	1	rs4822362	ENSG00000221069.1	AC000029.1	-6.87	1.92e-11	8.15e-09	-0.36	-0.3	Bone mineral density;	chr22:23140557	chr22:23136620~23136710:+
KIRC	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	6.87	1.92e-11	8.15e-09	0.43	0.3	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
KIRC	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-6.87	1.92e-11	8.15e-09	-0.32	-0.3	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
KIRC	cis	rs7017914	0.652	rs958605	ENSG00000254031.4	RP11-326E22.1	6.87	1.92e-11	8.15e-09	0.34	0.3	Bone mineral density;	chr8:70988356	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2732122	ENSG00000254031.4	RP11-326E22.1	6.87	1.92e-11	8.15e-09	0.34	0.3	Bone mineral density;	chr8:70988908	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639926	ENSG00000254031.4	RP11-326E22.1	6.87	1.92e-11	8.15e-09	0.34	0.3	Bone mineral density;	chr8:70988976	chr8:71155457~71204223:+
KIRC	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	6.87	1.93e-11	8.17e-09	0.39	0.3	Height;	chr6:109417941	chr6:109382795~109383666:+
KIRC	cis	rs11647589	0.689	rs59318790	ENSG00000262995.1	CTD-2194A8.2	-6.87	1.93e-11	8.17e-09	-0.32	-0.3	Blood metabolite levels;	chr16:20438062	chr16:20440266~20447000:-
KIRC	cis	rs11148252	1	rs11148252	ENSG00000278238.1	RP11-245D16.4	-6.87	1.93e-11	8.18e-09	-0.32	-0.3	Lewy body disease;	chr13:52434913	chr13:52454775~52455331:-
KIRC	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-6.87	1.94e-11	8.2e-09	-0.24	-0.3	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
KIRC	cis	rs7246657	0.722	rs2075284	ENSG00000267422.1	CTD-2554C21.1	6.87	1.94e-11	8.2e-09	0.43	0.3	Coronary artery calcification;	chr19:37698715	chr19:37779686~37792865:+
KIRC	cis	rs9649213	0.593	rs6967576	ENSG00000272950.1	RP11-307C18.1	-6.87	1.94e-11	8.21e-09	-0.38	-0.3	Prostate cancer (SNP x SNP interaction);	chr7:98387061	chr7:98322853~98323430:+
KIRC	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	6.87	1.94e-11	8.21e-09	0.45	0.3	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
KIRC	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	6.87	1.94e-11	8.23e-09	0.55	0.3	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
KIRC	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	6.87	1.95e-11	8.24e-09	0.26	0.3	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
KIRC	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-6.87	1.95e-11	8.26e-09	-0.5	-0.29	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
KIRC	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-6.87	1.95e-11	8.26e-09	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
KIRC	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-6.87	1.96e-11	8.28e-09	-0.42	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
KIRC	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-6.87	1.96e-11	8.28e-09	-0.41	-0.29	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
KIRC	cis	rs62355901	0.505	rs62355912	ENSG00000271828.1	CTD-2310F14.1	6.87	1.96e-11	8.29e-09	0.71	0.29	Breast cancer;	chr5:56788004	chr5:56927874~56929573:+
KIRC	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-6.87	1.96e-11	8.29e-09	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
KIRC	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-6.87	1.96e-11	8.29e-09	-0.32	-0.29	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
KIRC	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-6.87	1.96e-11	8.29e-09	-0.32	-0.29	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
KIRC	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	6.87	1.96e-11	8.29e-09	0.4	0.29	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
KIRC	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-6.87	1.96e-11	8.3e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
KIRC	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28154567	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28156691	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28158424	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28159056	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28159925	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28159932	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28162053	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28163375	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28163759	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28164580	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28164825	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28164948	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28165025	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28165528	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28168434	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28169019	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28169249	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28169676	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28169755	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28169791	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	6.87	1.96e-11	8.3e-09	0.34	0.29	Depression;	chr6:28170075	chr6:28073316~28074233:+
KIRC	cis	rs7246657	0.722	rs2909093	ENSG00000267422.1	CTD-2554C21.1	6.87	1.96e-11	8.31e-09	0.43	0.29	Coronary artery calcification;	chr19:37708561	chr19:37779686~37792865:+
KIRC	cis	rs919433	0.75	rs788010	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366225	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs2565165	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368851	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs788007	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368952	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs2565158	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371379	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs2565155	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371701	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs3097383	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372163	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.662	rs2043018	ENSG00000231621.1	AC013264.2	-6.87	1.97e-11	8.31e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372234	chr2:197197991~197199273:+
KIRC	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	6.87	1.97e-11	8.32e-09	0.34	0.29	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
KIRC	cis	rs904251	0.772	rs756202	ENSG00000227920.2	RP1-153P14.5	-6.87	1.97e-11	8.33e-09	-0.35	-0.29	Cognitive performance;	chr6:37492574	chr6:37545145~37550860:+
KIRC	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	6.87	1.97e-11	8.34e-09	0.68	0.29	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
KIRC	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-6.87	1.97e-11	8.34e-09	-0.38	-0.29	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
KIRC	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	6.87	1.97e-11	8.34e-09	0.33	0.29	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
KIRC	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-6.87	1.97e-11	8.35e-09	-0.29	-0.29	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
KIRC	cis	rs7246657	0.722	rs2909098	ENSG00000267422.1	CTD-2554C21.1	6.87	1.97e-11	8.35e-09	0.43	0.29	Coronary artery calcification;	chr19:37713347	chr19:37779686~37792865:+
KIRC	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	6.87	1.97e-11	8.35e-09	0.46	0.29	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
KIRC	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.87	1.98e-11	8.35e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
KIRC	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	6.87	1.98e-11	8.36e-09	0.36	0.29	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
KIRC	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	6.87	1.98e-11	8.36e-09	0.36	0.29	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
KIRC	cis	rs13434995	0.842	rs62303709	ENSG00000249700.7	SRD5A3-AS1	-6.87	1.98e-11	8.37e-09	-0.34	-0.29	Adiponectin levels;	chr4:55449015	chr4:55363971~55395847:-
KIRC	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	6.87	1.99e-11	8.39e-09	0.42	0.29	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
KIRC	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.87	1.99e-11	8.39e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
KIRC	cis	rs7246657	0.722	rs2972430	ENSG00000267422.1	CTD-2554C21.1	6.87	1.99e-11	8.41e-09	0.43	0.29	Coronary artery calcification;	chr19:37691210	chr19:37779686~37792865:+
KIRC	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	6.87	1.99e-11	8.43e-09	0.47	0.29	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
KIRC	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-6.87	2e-11	8.43e-09	-0.17	-0.29	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
KIRC	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	6.87	2e-11	8.44e-09	0.39	0.29	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
KIRC	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	6.87	2e-11	8.44e-09	0.31	0.29	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
KIRC	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	6.86	2e-11	8.45e-09	0.34	0.29	Depression;	chr6:28139049	chr6:28073316~28074233:+
KIRC	cis	rs4820539	0.966	rs2301554	ENSG00000221069.1	AC000029.1	-6.86	2e-11	8.45e-09	-0.36	-0.29	Bone mineral density;	chr22:23142067	chr22:23136620~23136710:+
KIRC	cis	rs11079159	0.585	rs8079998	ENSG00000263096.1	RP11-515O17.2	6.86	2e-11	8.45e-09	0.37	0.29	QRS duration;	chr17:55308138	chr17:55271504~55273653:-
KIRC	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-6.86	2e-11	8.46e-09	-0.35	-0.29	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
KIRC	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-6.86	2e-11	8.46e-09	-0.35	-0.29	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
KIRC	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	6.86	2.01e-11	8.47e-09	0.36	0.29	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
KIRC	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-6.86	2.01e-11	8.5e-09	-0.31	-0.29	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
KIRC	cis	rs1198872	0.812	rs1198860	ENSG00000272275.1	RP11-791G15.2	-6.86	2.01e-11	8.5e-09	-0.4	-0.29	Cardiac Troponin-T levels;	chr2:10759727	chr2:10767875~10770058:-
KIRC	cis	rs1431005	1	rs55849435	ENSG00000250620.1	RP11-91J3.3	6.86	2.01e-11	8.51e-09	0.38	0.29	Response to statin therapy;	chr4:187455185	chr4:187413564~187415697:+
KIRC	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	6.86	2.02e-11	8.52e-09	0.33	0.29	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
KIRC	cis	rs375066	0.62	rs349049	ENSG00000267058.1	RP11-15A1.3	6.86	2.02e-11	8.52e-09	0.34	0.29	Breast cancer;	chr19:43797248	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.592	rs349050	ENSG00000267058.1	RP11-15A1.3	6.86	2.02e-11	8.52e-09	0.34	0.29	Breast cancer;	chr19:43797273	chr19:43891804~43901805:-
KIRC	cis	rs17772222	0.74	rs10138002	ENSG00000222990.1	RNU4-22P	-6.86	2.02e-11	8.54e-09	-0.33	-0.29	Coronary artery calcification;	chr14:88510071	chr14:88513498~88513663:+
KIRC	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	6.86	2.02e-11	8.55e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
KIRC	cis	rs13113518	0.51	rs6858749	ENSG00000273257.1	RP11-177J6.1	6.86	2.03e-11	8.57e-09	0.34	0.29	Height;	chr4:55424270	chr4:55387949~55388271:+
KIRC	cis	rs10214930	0.706	rs10081338	ENSG00000235574.1	AC073150.6	6.86	2.03e-11	8.58e-09	0.37	0.29	Hypospadias;	chr7:27658969	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.767	rs56282178	ENSG00000235574.1	AC073150.6	6.86	2.03e-11	8.58e-09	0.37	0.29	Hypospadias;	chr7:27658973	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.767	rs10081339	ENSG00000235574.1	AC073150.6	6.86	2.03e-11	8.58e-09	0.37	0.29	Hypospadias;	chr7:27658975	chr7:27491682~27492765:-
KIRC	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-6.86	2.03e-11	8.59e-09	-0.28	-0.29	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
KIRC	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	6.86	2.04e-11	8.59e-09	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
KIRC	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-6.86	2.04e-11	8.6e-09	-0.29	-0.29	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
KIRC	cis	rs7927771	0.832	rs1542321	ENSG00000280615.1	Y_RNA	6.86	2.04e-11	8.6e-09	0.32	0.29	Subjective well-being;	chr11:47358064	chr11:47614898~47614994:-
KIRC	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.86	2.04e-11	8.6e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
KIRC	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	6.86	2.04e-11	8.6e-09	0.46	0.29	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
KIRC	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	6.86	2.04e-11	8.61e-09	0.28	0.29	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
KIRC	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-6.86	2.04e-11	8.61e-09	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
KIRC	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	6.86	2.04e-11	8.62e-09	0.39	0.29	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
KIRC	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-6.86	2.04e-11	8.62e-09	-0.29	-0.29	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
KIRC	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	6.86	2.05e-11	8.63e-09	0.32	0.29	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
KIRC	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-6.86	2.05e-11	8.64e-09	-0.35	-0.29	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
KIRC	cis	rs7182621	0.509	rs12917012	ENSG00000259363.4	CTD-2054N24.2	-6.86	2.05e-11	8.66e-09	-0.33	-0.29	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99807023~99877148:+
KIRC	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	6.86	2.05e-11	8.66e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
KIRC	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-6.86	2.06e-11	8.68e-09	-0.34	-0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
KIRC	cis	rs2562456	0.617	rs60206762	ENSG00000268555.1	RP11-678G14.3	6.86	2.06e-11	8.69e-09	0.46	0.29	Pain;	chr19:21600094	chr19:21570822~21587322:-
KIRC	cis	rs4888671	1	rs79116314	ENSG00000261707.1	RP11-264M12.2	6.86	2.06e-11	8.7e-09	0.45	0.29	Obesity-related traits;	chr16:77748535	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs77528108	ENSG00000261707.1	RP11-264M12.2	6.86	2.06e-11	8.7e-09	0.45	0.29	Obesity-related traits;	chr16:77748538	chr16:77741468~77743000:-
KIRC	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.86	2.06e-11	8.7e-09	0.31	0.29	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.86	2.06e-11	8.7e-09	0.31	0.29	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
KIRC	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	6.86	2.06e-11	8.7e-09	0.42	0.29	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
KIRC	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-6.86	2.07e-11	8.71e-09	-0.36	-0.29	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
KIRC	cis	rs643506	0.874	rs673679	ENSG00000230911.1	PPIHP1	-6.86	2.07e-11	8.72e-09	-0.35	-0.29	Breast cancer;	chr11:111816076	chr11:112029858~112030367:-
KIRC	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-6.86	2.07e-11	8.72e-09	-0.24	-0.29	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
KIRC	cis	rs853679	0.723	rs1736904	ENSG00000219392.1	RP1-265C24.5	-6.86	2.07e-11	8.73e-09	-0.39	-0.29	Depression;	chr6:28251492	chr6:28115628~28116551:+
KIRC	cis	rs4820539	1	rs4822361	ENSG00000221069.1	AC000029.1	6.86	2.08e-11	8.75e-09	0.36	0.29	Bone mineral density;	chr22:23140531	chr22:23136620~23136710:+
KIRC	cis	rs1005277	0.522	rs289649	ENSG00000235197.1	ZNF33AP1	-6.86	2.08e-11	8.76e-09	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:37894637~37896666:+
KIRC	cis	rs62025270	0.632	rs17571078	ENSG00000202081.1	RNU6-1280P	-6.86	2.08e-11	8.77e-09	-0.37	-0.29	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85651522~85651628:-
KIRC	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	6.86	2.08e-11	8.77e-09	0.28	0.29	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
KIRC	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	6.86	2.08e-11	8.77e-09	0.4	0.29	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
KIRC	cis	rs7017914	0.524	rs35544920	ENSG00000254031.4	RP11-326E22.1	6.86	2.08e-11	8.78e-09	0.34	0.29	Bone mineral density;	chr8:70687552	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs34719517	ENSG00000254031.4	RP11-326E22.1	6.86	2.08e-11	8.78e-09	0.34	0.29	Bone mineral density;	chr8:70687866	chr8:71155457~71204223:+
KIRC	cis	rs2361718	0.501	rs11869566	ENSG00000275479.1	RP11-334C17.6	6.86	2.09e-11	8.79e-09	0.31	0.29	Yeast infection;	chr17:80169449	chr17:80149627~80149798:+
KIRC	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	6.86	2.09e-11	8.79e-09	0.34	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
KIRC	cis	rs4356975	0.83	rs3922514	ENSG00000250696.4	RP11-704M14.1	6.86	2.09e-11	8.79e-09	0.3	0.29	Obesity-related traits;	chr4:69060905	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.83	rs28775401	ENSG00000250696.4	RP11-704M14.1	6.86	2.09e-11	8.79e-09	0.3	0.29	Obesity-related traits;	chr4:69060999	chr4:69182100~69216766:+
KIRC	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	8.8e-09	-0.51	-0.29	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
KIRC	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-6.86	2.09e-11	8.8e-09	-0.42	-0.29	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
KIRC	cis	rs2288884	0.747	rs11668885	ENSG00000275055.1	CTC-471J1.11	-6.86	2.09e-11	8.82e-09	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52087848	chr19:52049007~52049754:+
KIRC	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	6.86	2.1e-11	8.85e-09	0.33	0.29	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
KIRC	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	6.86	2.1e-11	8.86e-09	0.22	0.29	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
KIRC	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-6.86	2.1e-11	8.86e-09	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
KIRC	cis	rs3002142	1	rs3008607	ENSG00000272750.1	RP11-378J18.8	-6.86	2.1e-11	8.86e-09	-0.42	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222612350	chr1:222658867~222661512:-
KIRC	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	6.86	2.11e-11	8.87e-09	0.42	0.29	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
KIRC	cis	rs2564921	0.704	rs62253649	ENSG00000280417.1	RP11-5O17.1	6.86	2.11e-11	8.87e-09	0.37	0.29	Height;	chr3:52967831	chr3:53046166~53048122:+
KIRC	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	6.86	2.11e-11	8.87e-09	0.37	0.29	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
KIRC	cis	rs58873874	0.579	rs74804793	ENSG00000251405.2	CTB-109A12.1	6.86	2.11e-11	8.87e-09	0.5	0.29	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157362615~157460078:-
KIRC	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-6.86	2.11e-11	8.88e-09	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
KIRC	cis	rs11671005	0.656	rs11671092	ENSG00000269600.1	AC016629.3	-6.86	2.11e-11	8.88e-09	-0.52	-0.29	Mean platelet volume;	chr19:58497742	chr19:58593896~58599355:-
KIRC	cis	rs6061231	0.546	rs482220	ENSG00000273619.1	RP5-908M14.9	6.86	2.11e-11	8.88e-09	0.25	0.29	Colorectal cancer;	chr20:62352426	chr20:62386303~62386970:-
KIRC	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	6.86	2.11e-11	8.88e-09	0.34	0.29	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	6.86	2.11e-11	8.88e-09	0.34	0.29	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
KIRC	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	6.86	2.11e-11	8.9e-09	0.28	0.29	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
KIRC	cis	rs10214930	0.651	rs4722728	ENSG00000235574.1	AC073150.6	6.86	2.12e-11	8.9e-09	0.34	0.29	Hypospadias;	chr7:27654669	chr7:27491682~27492765:-
KIRC	cis	rs62025270	0.632	rs62022942	ENSG00000202081.1	RNU6-1280P	-6.86	2.12e-11	8.92e-09	-0.37	-0.29	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85651522~85651628:-
KIRC	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-6.86	2.12e-11	8.92e-09	-0.42	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
KIRC	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-6.86	2.12e-11	8.92e-09	-0.32	-0.29	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
KIRC	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	6.86	2.12e-11	8.92e-09	0.34	0.29	Depression;	chr6:28140307	chr6:28073316~28074233:+
KIRC	cis	rs7267979	0.899	rs2179459	ENSG00000125804.12	FAM182A	-6.86	2.12e-11	8.93e-09	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:26054655~26086917:+
KIRC	cis	rs4888671	1	rs76412521	ENSG00000261707.1	RP11-264M12.2	6.86	2.12e-11	8.94e-09	0.45	0.29	Obesity-related traits;	chr16:77747019	chr16:77741468~77743000:-
KIRC	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	6.86	2.13e-11	8.95e-09	0.36	0.29	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
KIRC	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	6.86	2.13e-11	8.96e-09	0.28	0.29	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
KIRC	cis	rs4356975	0.83	rs4413468	ENSG00000250696.4	RP11-704M14.1	6.85	2.14e-11	9e-09	0.3	0.29	Obesity-related traits;	chr4:69061845	chr4:69182100~69216766:+
KIRC	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-6.85	2.14e-11	9.01e-09	-0.38	-0.29	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
KIRC	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	6.85	2.14e-11	9.01e-09	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
KIRC	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	6.85	2.14e-11	9.01e-09	0.42	0.29	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
KIRC	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	6.85	2.14e-11	9.02e-09	0.42	0.29	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
KIRC	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-6.85	2.15e-11	9.02e-09	-0.28	-0.29	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
KIRC	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-6.85	2.15e-11	9.02e-09	-0.55	-0.29	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
KIRC	cis	rs6456156	0.819	rs7765739	ENSG00000265828.1	MIR3939	-6.85	2.15e-11	9.03e-09	-0.34	-0.29	Primary biliary cholangitis;	chr6:167104984	chr6:166997807~166997912:-
KIRC	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.85	2.15e-11	9.03e-09	-0.31	-0.29	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.85	2.15e-11	9.03e-09	-0.31	-0.29	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.85	2.15e-11	9.03e-09	-0.31	-0.29	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
KIRC	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	6.85	2.15e-11	9.04e-09	0.34	0.29	Migraine;	chr4:56861145	chr4:56960927~56961373:-
KIRC	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	6.85	2.15e-11	9.04e-09	0.38	0.29	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
KIRC	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	6.85	2.15e-11	9.04e-09	0.25	0.29	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
KIRC	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	6.85	2.15e-11	9.04e-09	0.39	0.29	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
KIRC	cis	rs2236295	0.605	rs10995311	ENSG00000238280.1	RP11-436D10.3	-6.85	2.15e-11	9.05e-09	-0.36	-0.29	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62805174	chr10:62793562~62805887:-
KIRC	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-6.85	2.15e-11	9.05e-09	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
KIRC	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	6.85	2.15e-11	9.05e-09	0.38	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
KIRC	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	6.85	2.15e-11	9.05e-09	0.38	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
KIRC	cis	rs10214930	0.752	rs12531518	ENSG00000235574.1	AC073150.6	-6.85	2.16e-11	9.06e-09	-0.37	-0.29	Hypospadias;	chr7:27621520	chr7:27491682~27492765:-
KIRC	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-6.85	2.16e-11	9.06e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
KIRC	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-6.85	2.16e-11	9.06e-09	-0.33	-0.29	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
KIRC	cis	rs1153858	1	rs1719247	ENSG00000235390.4	CTD-2651B20.5	-6.85	2.16e-11	9.07e-09	-0.28	-0.29	Homoarginine levels;	chr15:45328787	chr15:45321077~45321692:-
KIRC	cis	rs7250849	0.688	rs78019331	ENSG00000273837.1	LLNLR-470E3.1	-6.85	2.16e-11	9.08e-09	-0.45	-0.29	Blood protein levels;	chr19:51658484	chr19:51639478~51639931:-
KIRC	cis	rs250518	0.735	rs26575	ENSG00000272081.1	CTD-2376I4.2	-6.85	2.16e-11	9.09e-09	-0.37	-0.29	Mean corpuscular hemoglobin concentration;	chr5:72998631	chr5:72955206~72955699:-
KIRC	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	6.85	2.17e-11	9.09e-09	0.3	0.29	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	6.85	2.17e-11	9.09e-09	0.3	0.29	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
KIRC	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	6.85	2.17e-11	9.09e-09	0.34	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
KIRC	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	6.85	2.17e-11	9.1e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
KIRC	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	6.85	2.17e-11	9.12e-09	0.28	0.29	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
KIRC	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	6.85	2.17e-11	9.12e-09	0.34	0.29	Depression;	chr6:28133900	chr6:28073316~28074233:+
KIRC	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-6.85	2.18e-11	9.14e-09	-0.32	-0.29	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
KIRC	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.18e-11	9.14e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.18e-11	9.14e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.18e-11	9.14e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
KIRC	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-6.85	2.18e-11	9.15e-09	-0.33	-0.29	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
KIRC	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-6.85	2.18e-11	9.16e-09	-0.25	-0.29	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
KIRC	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-6.85	2.18e-11	9.16e-09	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
KIRC	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	6.85	2.18e-11	9.17e-09	0.36	0.29	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
KIRC	cis	rs3820928	0.839	rs13413292	ENSG00000212391.1	SNORA48	-6.85	2.19e-11	9.17e-09	-0.34	-0.29	Pulmonary function;	chr2:227029031	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs13413235	ENSG00000212391.1	SNORA48	-6.85	2.19e-11	9.17e-09	-0.34	-0.29	Pulmonary function;	chr2:227029147	chr2:226968989~226969122:-
KIRC	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	6.85	2.19e-11	9.18e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
KIRC	cis	rs3820928	0.874	rs2229813	ENSG00000212391.1	SNORA48	-6.85	2.19e-11	9.18e-09	-0.34	-0.29	Pulmonary function;	chr2:227028004	chr2:226968989~226969122:-
KIRC	cis	rs13434995	0.842	rs3792603	ENSG00000249700.7	SRD5A3-AS1	-6.85	2.19e-11	9.19e-09	-0.34	-0.29	Adiponectin levels;	chr4:55435891	chr4:55363971~55395847:-
KIRC	cis	rs13434995	0.755	rs62303690	ENSG00000249700.7	SRD5A3-AS1	-6.85	2.19e-11	9.19e-09	-0.34	-0.29	Adiponectin levels;	chr4:55439838	chr4:55363971~55395847:-
KIRC	cis	rs6061231	0.834	rs2427311	ENSG00000275437.1	RP5-908M14.10	6.85	2.19e-11	9.2e-09	0.23	0.29	Colorectal cancer;	chr20:62395067	chr20:62402236~62405935:-
KIRC	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	6.85	2.19e-11	9.2e-09	0.32	0.29	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
KIRC	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	6.85	2.19e-11	9.21e-09	0.34	0.29	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
KIRC	cis	rs17772222	1	rs17772222	ENSG00000222990.1	RNU4-22P	-6.85	2.2e-11	9.21e-09	-0.36	-0.29	Coronary artery calcification;	chr14:88360138	chr14:88513498~88513663:+
KIRC	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	6.85	2.2e-11	9.22e-09	0.62	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
KIRC	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-6.85	2.2e-11	9.23e-09	-0.37	-0.29	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
KIRC	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	6.85	2.21e-11	9.25e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	6.85	2.21e-11	9.25e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
KIRC	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	6.85	2.21e-11	9.25e-09	0.25	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
KIRC	cis	rs35306767	0.953	rs10904581	ENSG00000229869.1	RP11-363N22.2	-6.85	2.21e-11	9.26e-09	-0.35	-0.29	Eosinophil percentage of granulocytes;	chr10:918745	chr10:933026~942743:+
KIRC	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	6.85	2.21e-11	9.27e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	6.85	2.21e-11	9.27e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	6.85	2.21e-11	9.27e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	6.85	2.21e-11	9.27e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
KIRC	cis	rs2288884	0.806	rs59667666	ENSG00000275055.1	CTC-471J1.11	-6.85	2.21e-11	9.27e-09	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082941	chr19:52049007~52049754:+
KIRC	cis	rs17801127	0.901	rs16827309	ENSG00000231969.1	AC144449.1	6.85	2.21e-11	9.28e-09	0.54	0.29	Liver enzyme levels (alanine transaminase);	chr2:149666098	chr2:149587196~149848233:+
KIRC	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-6.85	2.21e-11	9.28e-09	-0.33	-0.29	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
KIRC	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	6.85	2.21e-11	9.28e-09	0.42	0.29	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	6.85	2.21e-11	9.28e-09	0.42	0.29	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
KIRC	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	6.85	2.21e-11	9.29e-09	0.22	0.29	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
KIRC	cis	rs11148252	0.967	rs4286007	ENSG00000278238.1	RP11-245D16.4	-6.85	2.22e-11	9.29e-09	-0.32	-0.29	Lewy body disease;	chr13:52448383	chr13:52454775~52455331:-
KIRC	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	6.85	2.22e-11	9.29e-09	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
KIRC	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	6.85	2.22e-11	9.32e-09	0.34	0.29	Depression;	chr6:28137418	chr6:28073316~28074233:+
KIRC	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-6.85	2.22e-11	9.32e-09	-0.37	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
KIRC	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-6.85	2.22e-11	9.32e-09	-0.39	-0.29	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
KIRC	cis	rs10214930	0.813	rs759270	ENSG00000235574.1	AC073150.6	-6.85	2.22e-11	9.33e-09	-0.37	-0.29	Hypospadias;	chr7:27606842	chr7:27491682~27492765:-
KIRC	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	6.85	2.23e-11	9.34e-09	0.25	0.29	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	6.85	2.23e-11	9.34e-09	0.25	0.29	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	6.85	2.23e-11	9.34e-09	0.25	0.29	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
KIRC	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	6.85	2.23e-11	9.34e-09	0.31	0.29	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
KIRC	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.23e-11	9.34e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.23e-11	9.34e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.85	2.23e-11	9.34e-09	-0.27	-0.29	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
KIRC	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-6.85	2.23e-11	9.34e-09	-0.34	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
KIRC	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-6.85	2.23e-11	9.34e-09	-0.34	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
KIRC	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-6.85	2.23e-11	9.34e-09	-0.25	-0.29	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
KIRC	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	6.85	2.23e-11	9.34e-09	0.3	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
KIRC	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	6.85	2.23e-11	9.35e-09	0.4	0.29	Depression;	chr6:28323463	chr6:28943877~28944537:+
KIRC	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-6.85	2.24e-11	9.37e-09	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
KIRC	cis	rs3820928	0.874	rs10199655	ENSG00000212391.1	SNORA48	-6.85	2.24e-11	9.37e-09	-0.34	-0.29	Pulmonary function;	chr2:227027712	chr2:226968989~226969122:-
KIRC	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	6.85	2.24e-11	9.37e-09	0.23	0.29	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
KIRC	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	6.85	2.24e-11	9.38e-09	0.32	0.29	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
KIRC	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-6.85	2.24e-11	9.39e-09	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
KIRC	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-6.85	2.24e-11	9.39e-09	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
KIRC	cis	rs8048589	0.948	rs11648228	ENSG00000175604.2	RP11-276H1.3	-6.85	2.24e-11	9.4e-09	-0.35	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087845	chr16:12086746~12090302:-
KIRC	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	6.85	2.24e-11	9.4e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	6.85	2.24e-11	9.4e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	6.85	2.24e-11	9.4e-09	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
KIRC	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.85	2.24e-11	9.4e-09	-0.37	-0.29	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
KIRC	cis	rs919433	0.68	rs7582536	ENSG00000231621.1	AC013264.2	6.85	2.25e-11	9.41e-09	0.32	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197571379	chr2:197197991~197199273:+
KIRC	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-6.85	2.25e-11	9.42e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
KIRC	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	6.85	2.25e-11	9.43e-09	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
KIRC	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	6.85	2.25e-11	9.43e-09	0.43	0.29	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
KIRC	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	6.85	2.25e-11	9.43e-09	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
KIRC	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	6.85	2.25e-11	9.44e-09	0.25	0.29	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	6.85	2.25e-11	9.44e-09	0.25	0.29	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	6.85	2.25e-11	9.44e-09	0.25	0.29	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	6.85	2.25e-11	9.44e-09	0.25	0.29	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
KIRC	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-6.85	2.25e-11	9.44e-09	-0.25	-0.29	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
KIRC	cis	rs7688540	0.8	rs1578898	ENSG00000211553.1	AC253576.2	-6.85	2.25e-11	9.44e-09	-0.34	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:136461~136568:+
KIRC	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	6.85	2.25e-11	9.44e-09	0.33	0.29	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
KIRC	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-6.85	2.26e-11	9.45e-09	-0.37	-0.29	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
KIRC	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	6.85	2.26e-11	9.45e-09	0.32	0.29	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	6.85	2.26e-11	9.45e-09	0.32	0.29	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	6.85	2.26e-11	9.45e-09	0.32	0.29	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
KIRC	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	6.85	2.26e-11	9.45e-09	0.34	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
KIRC	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	6.85	2.26e-11	9.45e-09	0.34	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
KIRC	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	6.85	2.26e-11	9.46e-09	0.36	0.29	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
KIRC	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	6.85	2.26e-11	9.46e-09	0.4	0.29	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
KIRC	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	6.85	2.26e-11	9.46e-09	0.45	0.29	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	6.85	2.26e-11	9.46e-09	0.45	0.29	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
KIRC	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	6.85	2.27e-11	9.49e-09	0.33	0.29	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
KIRC	cis	rs1198872	0.892	rs1198863	ENSG00000272275.1	RP11-791G15.2	-6.84	2.27e-11	9.51e-09	-0.39	-0.29	Cardiac Troponin-T levels;	chr2:10760349	chr2:10767875~10770058:-
KIRC	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-6.84	2.27e-11	9.52e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
KIRC	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-6.84	2.27e-11	9.52e-09	-0.26	-0.29	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
KIRC	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	6.84	2.28e-11	9.53e-09	0.39	0.29	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
KIRC	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	6.84	2.29e-11	9.59e-09	0.29	0.29	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
KIRC	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	6.84	2.29e-11	9.6e-09	0.33	0.29	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
KIRC	cis	rs4356975	0.899	rs7677996	ENSG00000198277.6	RP11-468N14.09	6.84	2.3e-11	9.62e-09	0.31	0.29	Obesity-related traits;	chr4:69075473	chr4:68914928~68924741:-
KIRC	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-6.84	2.31e-11	9.65e-09	-0.28	-0.29	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
KIRC	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.84	2.31e-11	9.65e-09	-0.31	-0.29	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
KIRC	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	6.84	2.31e-11	9.66e-09	0.3	0.29	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
KIRC	cis	rs4888671	1	rs79112827	ENSG00000261707.1	RP11-264M12.2	6.84	2.31e-11	9.66e-09	0.45	0.29	Obesity-related traits;	chr16:77748661	chr16:77741468~77743000:-
KIRC	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	6.84	2.31e-11	9.67e-09	0.42	0.29	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
KIRC	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-6.84	2.31e-11	9.67e-09	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
KIRC	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	6.84	2.31e-11	9.68e-09	0.22	0.29	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
KIRC	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-6.84	2.32e-11	9.68e-09	-0.22	-0.29	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
KIRC	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-6.84	2.32e-11	9.68e-09	-0.22	-0.29	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
KIRC	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	6.84	2.32e-11	9.69e-09	0.5	0.29	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
KIRC	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.84	2.32e-11	9.7e-09	-0.31	-0.29	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
KIRC	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-6.84	2.32e-11	9.7e-09	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
KIRC	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-6.84	2.32e-11	9.7e-09	-0.39	-0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
KIRC	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	6.84	2.32e-11	9.7e-09	0.29	0.29	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
KIRC	cis	rs10214930	0.957	rs10230973	ENSG00000235574.1	AC073150.6	6.84	2.32e-11	9.7e-09	0.4	0.29	Hypospadias;	chr7:27743305	chr7:27491682~27492765:-
KIRC	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	6.84	2.32e-11	9.71e-09	0.3	0.29	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
KIRC	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-6.84	2.32e-11	9.71e-09	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
KIRC	cis	rs6456156	1	rs9457274	ENSG00000265828.1	MIR3939	-6.84	2.32e-11	9.72e-09	-0.33	-0.29	Primary biliary cholangitis;	chr6:167107377	chr6:166997807~166997912:-
KIRC	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	6.84	2.33e-11	9.72e-09	0.33	0.29	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
KIRC	cis	rs1153858	0.832	rs1145078	ENSG00000235390.4	CTD-2651B20.5	-6.84	2.33e-11	9.74e-09	-0.28	-0.29	Homoarginine levels;	chr15:45390079	chr15:45321077~45321692:-
KIRC	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.84	2.33e-11	9.74e-09	0.25	0.29	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	6.84	2.33e-11	9.74e-09	0.25	0.29	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
KIRC	cis	rs4601821	0.635	rs7114433	ENSG00000270179.1	RP11-159N11.4	-6.84	2.33e-11	9.75e-09	-0.3	-0.29	Alcoholic chronic pancreatitis;	chr11:113337376	chr11:113368478~113369117:+
KIRC	cis	rs62025270	0.576	rs55639123	ENSG00000202081.1	RNU6-1280P	-6.84	2.34e-11	9.77e-09	-0.38	-0.29	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85651522~85651628:-
KIRC	cis	rs1198872	0.892	rs1198862	ENSG00000272275.1	RP11-791G15.2	-6.84	2.34e-11	9.77e-09	-0.39	-0.29	Cardiac Troponin-T levels;	chr2:10760201	chr2:10767875~10770058:-
KIRC	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-6.84	2.34e-11	9.77e-09	-0.35	-0.29	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
KIRC	cis	rs7124681	0.584	rs12226590	ENSG00000280615.1	Y_RNA	6.84	2.34e-11	9.78e-09	0.31	0.29	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47550256	chr11:47614898~47614994:-
KIRC	cis	rs7927771	0.757	rs1057233	ENSG00000280615.1	Y_RNA	6.84	2.34e-11	9.8e-09	0.33	0.29	Subjective well-being;	chr11:47354897	chr11:47614898~47614994:-
KIRC	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	6.84	2.35e-11	9.81e-09	0.33	0.29	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
KIRC	cis	rs6600671	0.719	rs9728991	ENSG00000227082.1	CH17-437K3.1	-6.84	2.35e-11	9.82e-09	-0.34	-0.29	Hip geometry;	chr1:121522281	chr1:121396754~121463129:+
KIRC	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	6.84	2.35e-11	9.83e-09	0.26	0.29	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
KIRC	cis	rs11647589	0.834	rs2271061	ENSG00000260762.1	ACSM5P1	6.84	2.36e-11	9.84e-09	0.3	0.29	Blood metabolite levels;	chr16:20471429	chr16:20586550~20607107:-
KIRC	cis	rs919433	0.783	rs788011	ENSG00000231621.1	AC013264.2	-6.84	2.36e-11	9.86e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366047	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs55725278	ENSG00000231621.1	AC013264.2	-6.84	2.36e-11	9.86e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373499	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.783	rs787980	ENSG00000231621.1	AC013264.2	-6.84	2.36e-11	9.86e-09	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197374501	chr2:197197991~197199273:+
KIRC	cis	rs7176527	0.848	rs1374463	ENSG00000188388.10	GOLGA6L3	6.84	2.36e-11	9.86e-09	0.41	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84668027	chr15:85240472~85247170:+
KIRC	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	6.84	2.36e-11	9.87e-09	0.3	0.29	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
KIRC	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	6.84	2.36e-11	9.87e-09	0.42	0.29	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
KIRC	cis	rs1153858	0.945	rs2467854	ENSG00000235390.4	CTD-2651B20.5	-6.84	2.36e-11	9.87e-09	-0.28	-0.29	Homoarginine levels;	chr15:45409399	chr15:45321077~45321692:-
KIRC	cis	rs1153858	1	rs2461701	ENSG00000235390.4	CTD-2651B20.5	-6.84	2.36e-11	9.87e-09	-0.28	-0.29	Homoarginine levels;	chr15:45411193	chr15:45321077~45321692:-
KIRC	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	6.84	2.36e-11	9.88e-09	0.4	0.29	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
KIRC	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-6.84	2.37e-11	9.88e-09	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
KIRC	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-6.84	2.37e-11	9.89e-09	-0.25	-0.29	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
KIRC	cis	rs17772222	0.582	rs11625009	ENSG00000222990.1	RNU4-22P	-6.84	2.37e-11	9.9e-09	-0.32	-0.29	Coronary artery calcification;	chr14:88521018	chr14:88513498~88513663:+
KIRC	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	6.84	2.37e-11	9.9e-09	0.49	0.29	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
KIRC	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-6.84	2.37e-11	9.9e-09	-0.39	-0.29	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
KIRC	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	6.84	2.37e-11	9.9e-09	0.36	0.29	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
KIRC	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-6.84	2.37e-11	9.91e-09	-0.3	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
KIRC	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-6.84	2.37e-11	9.91e-09	-0.3	-0.29	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
KIRC	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	6.84	2.37e-11	9.92e-09	0.41	0.29	Depression;	chr6:28402301	chr6:28943877~28944537:+
KIRC	cis	rs643506	0.874	rs582465	ENSG00000230911.1	PPIHP1	-6.84	2.38e-11	9.93e-09	-0.35	-0.29	Breast cancer;	chr11:111797861	chr11:112029858~112030367:-
KIRC	cis	rs643506	0.874	rs613292	ENSG00000230911.1	PPIHP1	-6.84	2.38e-11	9.93e-09	-0.35	-0.29	Breast cancer;	chr11:111798081	chr11:112029858~112030367:-
KIRC	cis	rs890448	0.519	rs10027194	ENSG00000254531.1	FLJ20021	6.84	2.38e-11	9.93e-09	0.29	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371280	chr4:101347780~101348883:+
KIRC	cis	rs890448	0.76	rs12642424	ENSG00000254531.1	FLJ20021	6.84	2.38e-11	9.93e-09	0.29	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382629	chr4:101347780~101348883:+
KIRC	cis	rs4888671	1	rs77464790	ENSG00000261707.1	RP11-264M12.2	6.84	2.38e-11	9.93e-09	0.45	0.29	Obesity-related traits;	chr16:77743712	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs79270274	ENSG00000261707.1	RP11-264M12.2	6.84	2.38e-11	9.93e-09	0.45	0.29	Obesity-related traits;	chr16:77743727	chr16:77741468~77743000:-
KIRC	cis	rs6452524	0.618	rs1871203	ENSG00000248112.1	RP11-78C3.1	6.84	2.39e-11	9.96e-09	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82919376~82921119:-
KIRC	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	6.84	2.39e-11	9.96e-09	0.28	0.29	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
KIRC	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	6.84	2.39e-11	9.97e-09	0.3	0.29	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
KIRC	cis	rs919433	0.617	rs700646	ENSG00000231621.1	AC013264.2	-6.84	2.39e-11	9.99e-09	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197743787	chr2:197197991~197199273:+
KIRC	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	6.84	2.4e-11	9.99e-09	0.32	0.29	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
KIRC	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-6.84	2.4e-11	1e-08	-0.39	-0.29	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
KIRC	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	6.84	2.4e-11	1e-08	0.34	0.29	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
KIRC	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.4e-11	1e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
KIRC	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	6.84	2.4e-11	1e-08	0.31	0.29	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
KIRC	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-6.84	2.41e-11	1e-08	-0.55	-0.29	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
KIRC	cis	rs2847281	0.587	rs2542152	ENSG00000267654.1	RP11-973H7.4	6.84	2.41e-11	1e-08	0.34	0.29	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12782762	chr18:12739490~12749421:-
KIRC	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	6.84	2.41e-11	1e-08	0.43	0.29	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
KIRC	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	6.84	2.41e-11	1e-08	0.43	0.29	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
KIRC	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	6.84	2.41e-11	1e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
KIRC	cis	rs17801127	0.748	rs57536657	ENSG00000231969.1	AC144449.1	6.84	2.41e-11	1e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149665638	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.748	rs78209888	ENSG00000231969.1	AC144449.1	6.84	2.41e-11	1e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149668565	chr2:149587196~149848233:+
KIRC	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	6.84	2.41e-11	1e-08	0.4	0.29	Depression;	chr6:28327262	chr6:28943877~28944537:+
KIRC	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	6.84	2.41e-11	1.01e-08	0.29	0.29	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
KIRC	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	6.84	2.41e-11	1.01e-08	0.21	0.29	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
KIRC	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	6.84	2.41e-11	1.01e-08	0.43	0.29	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
KIRC	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-6.84	2.42e-11	1.01e-08	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
KIRC	cis	rs79040073	0.911	rs11638981	ENSG00000259531.2	RP11-295H24.3	6.84	2.42e-11	1.01e-08	0.36	0.29	Lung cancer in ever smokers;	chr15:49029332	chr15:49365124~49366685:-
KIRC	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	6.83	2.42e-11	1.01e-08	0.31	0.29	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
KIRC	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-6.83	2.42e-11	1.01e-08	-0.25	-0.29	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
KIRC	cis	rs10214930	0.781	rs961723	ENSG00000235574.1	AC073150.6	-6.83	2.42e-11	1.01e-08	-0.37	-0.29	Hypospadias;	chr7:27618354	chr7:27491682~27492765:-
KIRC	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	6.83	2.43e-11	1.01e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
KIRC	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-6.83	2.43e-11	1.01e-08	-0.28	-0.29	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
KIRC	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-6.83	2.43e-11	1.01e-08	-0.38	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
KIRC	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.83	2.44e-11	1.02e-08	0.39	0.29	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
KIRC	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.83	2.44e-11	1.02e-08	0.41	0.29	Depression;	chr6:28391932	chr6:28943877~28944537:+
KIRC	cis	rs2281636	0.625	rs7075305	ENSG00000233690.1	EBAG9P1	-6.83	2.44e-11	1.02e-08	-0.33	-0.29	Obesity-related traits;	chr10:99604767	chr10:99697407~99697949:-
KIRC	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-6.83	2.44e-11	1.02e-08	-0.27	-0.29	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
KIRC	cis	rs17801127	1	rs848226	ENSG00000231969.1	AC144449.1	-6.83	2.45e-11	1.02e-08	-0.47	-0.29	Liver enzyme levels (alanine transaminase);	chr2:149700260	chr2:149587196~149848233:+
KIRC	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-6.83	2.45e-11	1.02e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
KIRC	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	6.83	2.45e-11	1.02e-08	0.32	0.29	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
KIRC	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-6.83	2.45e-11	1.02e-08	-0.31	-0.29	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
KIRC	cis	rs919433	0.617	rs700645	ENSG00000231621.1	AC013264.2	-6.83	2.46e-11	1.02e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197740790	chr2:197197991~197199273:+
KIRC	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	6.83	2.46e-11	1.02e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
KIRC	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	6.83	2.46e-11	1.03e-08	0.28	0.29	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
KIRC	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	6.83	2.46e-11	1.03e-08	0.31	0.29	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
KIRC	cis	rs4820539	0.966	rs5996470	ENSG00000221069.1	AC000029.1	-6.83	2.47e-11	1.03e-08	-0.36	-0.29	Bone mineral density;	chr22:23141068	chr22:23136620~23136710:+
KIRC	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-6.83	2.47e-11	1.03e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-6.83	2.47e-11	1.03e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-6.83	2.47e-11	1.03e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
KIRC	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-6.83	2.47e-11	1.03e-08	-0.45	-0.29	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
KIRC	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-6.83	2.48e-11	1.03e-08	-0.24	-0.29	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
KIRC	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	6.83	2.48e-11	1.03e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
KIRC	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.83	2.48e-11	1.03e-08	-0.47	-0.29	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
KIRC	cis	rs58873874	0.737	rs12654973	ENSG00000251405.2	CTB-109A12.1	6.83	2.48e-11	1.03e-08	0.5	0.29	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157362615~157460078:-
KIRC	cis	rs1153858	1	rs1613559	ENSG00000235390.4	CTD-2651B20.5	-6.83	2.48e-11	1.03e-08	-0.28	-0.29	Homoarginine levels;	chr15:45329918	chr15:45321077~45321692:-
KIRC	cis	rs1153858	1	rs1618874	ENSG00000235390.4	CTD-2651B20.5	-6.83	2.48e-11	1.03e-08	-0.28	-0.29	Homoarginine levels;	chr15:45330588	chr15:45321077~45321692:-
KIRC	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	6.83	2.48e-11	1.03e-08	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
KIRC	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.83	2.48e-11	1.03e-08	-0.31	-0.29	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
KIRC	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-6.83	2.49e-11	1.04e-08	-0.44	-0.29	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
KIRC	cis	rs9601248	0.756	rs2146592	ENSG00000227354.5	RBM26-AS1	-6.83	2.49e-11	1.04e-08	-0.33	-0.29	Major depressive disorder;	chr13:79606146	chr13:79406309~79424328:+
KIRC	cis	rs12049351	0.774	rs6657735	ENSG00000229367.1	HMGN2P19	6.83	2.49e-11	1.04e-08	0.41	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229491085	chr1:229570532~229570796:+
KIRC	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	6.83	2.5e-11	1.04e-08	0.34	0.29	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
KIRC	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	6.83	2.5e-11	1.04e-08	0.25	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
KIRC	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	6.83	2.51e-11	1.04e-08	0.28	0.29	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
KIRC	cis	rs7017914	0.652	rs13262205	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70659690	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs2279128	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70669324	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.583	rs1477943	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70670528	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639931	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70974202	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639932	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70974216	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2956615	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70974519	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.583	rs2732129	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70982734	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639912	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70983134	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.629	rs2732126	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70986257	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.629	rs2732125	ENSG00000254031.4	RP11-326E22.1	6.83	2.51e-11	1.04e-08	0.34	0.29	Bone mineral density;	chr8:70986266	chr8:71155457~71204223:+
KIRC	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	6.83	2.51e-11	1.04e-08	0.29	0.29	QT interval;	chr12:29379056	chr12:29280418~29317848:-
KIRC	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-6.83	2.51e-11	1.05e-08	-0.44	-0.29	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
KIRC	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	6.83	2.51e-11	1.05e-08	0.34	0.29	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
KIRC	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	6.83	2.52e-11	1.05e-08	0.25	0.29	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
KIRC	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	6.83	2.52e-11	1.05e-08	0.25	0.29	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
KIRC	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	6.83	2.52e-11	1.05e-08	0.32	0.29	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
KIRC	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	6.83	2.53e-11	1.05e-08	0.26	0.29	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
KIRC	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-6.83	2.53e-11	1.05e-08	-0.22	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
KIRC	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	6.83	2.53e-11	1.05e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
KIRC	cis	rs3820928	0.874	rs6740108	ENSG00000212391.1	SNORA48	6.83	2.53e-11	1.05e-08	0.33	0.29	Pulmonary function;	chr2:227024843	chr2:226968989~226969122:-
KIRC	cis	rs11079159	1	rs11079159	ENSG00000263096.1	RP11-515O17.2	6.83	2.53e-11	1.05e-08	0.43	0.29	QRS duration;	chr17:55296189	chr17:55271504~55273653:-
KIRC	cis	rs7246657	0.722	rs968073	ENSG00000267422.1	CTD-2554C21.1	6.83	2.53e-11	1.05e-08	0.43	0.29	Coronary artery calcification;	chr19:37701120	chr19:37779686~37792865:+
KIRC	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	6.83	2.53e-11	1.05e-08	0.26	0.29	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
KIRC	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	6.83	2.54e-11	1.05e-08	0.45	0.29	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
KIRC	cis	rs10214930	1	rs10250333	ENSG00000235574.1	AC073150.6	6.83	2.54e-11	1.06e-08	0.4	0.29	Hypospadias;	chr7:27723003	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.958	rs28521509	ENSG00000235574.1	AC073150.6	6.83	2.54e-11	1.06e-08	0.4	0.29	Hypospadias;	chr7:27723008	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.958	rs10268051	ENSG00000235574.1	AC073150.6	6.83	2.54e-11	1.06e-08	0.4	0.29	Hypospadias;	chr7:27723971	chr7:27491682~27492765:-
KIRC	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-6.83	2.54e-11	1.06e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
KIRC	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-6.83	2.55e-11	1.06e-08	-0.43	-0.29	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
KIRC	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.55e-11	1.06e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.55e-11	1.06e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
KIRC	cis	rs17772222	0.63	rs8017811	ENSG00000222990.1	RNU4-22P	-6.83	2.55e-11	1.06e-08	-0.31	-0.29	Coronary artery calcification;	chr14:88534559	chr14:88513498~88513663:+
KIRC	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	6.83	2.55e-11	1.06e-08	0.29	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
KIRC	cis	rs11647589	0.678	rs7499668	ENSG00000262995.1	CTD-2194A8.2	-6.83	2.56e-11	1.06e-08	-0.32	-0.29	Blood metabolite levels;	chr16:20437205	chr16:20440266~20447000:-
KIRC	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-6.83	2.56e-11	1.06e-08	-0.36	-0.29	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-6.83	2.56e-11	1.06e-08	-0.36	-0.29	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
KIRC	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	6.83	2.56e-11	1.06e-08	0.28	0.29	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	6.83	2.56e-11	1.06e-08	0.28	0.29	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
KIRC	cis	rs17801127	0.818	rs35536703	ENSG00000231969.1	AC144449.1	6.83	2.56e-11	1.06e-08	0.56	0.29	Liver enzyme levels (alanine transaminase);	chr2:149840947	chr2:149587196~149848233:+
KIRC	cis	rs9915657	0.966	rs8071725	ENSG00000234899.8	SOX9-AS1	-6.83	2.57e-11	1.07e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72132585	chr17:72034107~72237203:-
KIRC	cis	rs12893668	0.637	rs12892038	ENSG00000269910.1	RP11-73M18.10	6.83	2.57e-11	1.07e-08	0.21	0.29	Reticulocyte count;	chr14:103602292	chr14:103694516~103695050:-
KIRC	cis	rs12893668	0.637	rs4525427	ENSG00000269910.1	RP11-73M18.10	6.83	2.57e-11	1.07e-08	0.21	0.29	Reticulocyte count;	chr14:103606456	chr14:103694516~103695050:-
KIRC	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	6.83	2.57e-11	1.07e-08	0.27	0.29	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
KIRC	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	6.83	2.57e-11	1.07e-08	0.27	0.29	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
KIRC	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-6.83	2.57e-11	1.07e-08	-0.3	-0.29	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
KIRC	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.57e-11	1.07e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
KIRC	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-6.83	2.57e-11	1.07e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-6.83	2.57e-11	1.07e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-6.83	2.57e-11	1.07e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-6.83	2.57e-11	1.07e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
KIRC	cis	rs6597981	0.604	rs7945912	ENSG00000255284.1	AP006621.5	6.83	2.58e-11	1.07e-08	0.22	0.29	Breast cancer;	chr11:750849	chr11:777578~784297:+
KIRC	cis	rs7572733	0.534	rs1589162	ENSG00000231621.1	AC013264.2	-6.83	2.58e-11	1.07e-08	-0.32	-0.29	Dermatomyositis;	chr2:197917968	chr2:197197991~197199273:+
KIRC	cis	rs11647589	0.834	rs1505100	ENSG00000260762.1	ACSM5P1	-6.82	2.58e-11	1.07e-08	-0.3	-0.29	Blood metabolite levels;	chr16:20470350	chr16:20586550~20607107:-
KIRC	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.82	2.58e-11	1.07e-08	-0.25	-0.29	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
KIRC	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-6.82	2.58e-11	1.07e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-6.82	2.58e-11	1.07e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
KIRC	cis	rs62025270	0.688	rs76902341	ENSG00000202081.1	RNU6-1280P	-6.82	2.59e-11	1.07e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85651522~85651628:-
KIRC	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	6.82	2.59e-11	1.07e-08	0.22	0.29	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	6.82	2.59e-11	1.07e-08	0.22	0.29	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	6.82	2.59e-11	1.07e-08	0.22	0.29	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	6.82	2.59e-11	1.07e-08	0.22	0.29	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
KIRC	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-6.82	2.59e-11	1.07e-08	-0.17	-0.29	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
KIRC	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	6.82	2.59e-11	1.07e-08	0.32	0.29	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
KIRC	cis	rs934734	0.532	rs7569257	ENSG00000281920.1	RP11-418H16.1	-6.82	2.59e-11	1.08e-08	-0.36	-0.29	Rheumatoid arthritis;	chr2:65429842	chr2:65623272~65628424:+
KIRC	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-6.82	2.6e-11	1.08e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
KIRC	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-6.82	2.6e-11	1.08e-08	-0.36	-0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
KIRC	cis	rs459482	0.501	rs148214	ENSG00000228318.3	AP001610.5	6.82	2.6e-11	1.08e-08	0.29	0.29	IgG glycosylation;	chr21:41442291	chr21:41441056~41445708:-
KIRC	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-6.82	2.61e-11	1.08e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
KIRC	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	6.82	2.61e-11	1.08e-08	0.29	0.29	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	6.82	2.61e-11	1.08e-08	0.29	0.29	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	6.82	2.61e-11	1.08e-08	0.29	0.29	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
KIRC	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	6.82	2.61e-11	1.08e-08	0.51	0.29	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
KIRC	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	6.82	2.61e-11	1.08e-08	0.34	0.29	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
KIRC	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-6.82	2.61e-11	1.08e-08	-0.32	-0.29	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
KIRC	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	6.82	2.62e-11	1.08e-08	0.34	0.29	Depression;	chr6:28139876	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	6.82	2.62e-11	1.08e-08	0.34	0.29	Depression;	chr6:28139998	chr6:28073316~28074233:+
KIRC	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-6.82	2.62e-11	1.08e-08	-0.28	-0.29	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
KIRC	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-6.82	2.62e-11	1.09e-08	-0.28	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
KIRC	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	6.82	2.62e-11	1.09e-08	0.28	0.29	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	6.82	2.62e-11	1.09e-08	0.28	0.29	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
KIRC	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	6.82	2.63e-11	1.09e-08	0.31	0.29	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
KIRC	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	6.82	2.63e-11	1.09e-08	0.4	0.29	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
KIRC	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-6.82	2.63e-11	1.09e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
KIRC	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-6.82	2.64e-11	1.09e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
KIRC	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-6.82	2.64e-11	1.09e-08	-0.31	-0.29	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-6.82	2.64e-11	1.09e-08	-0.31	-0.29	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
KIRC	cis	rs7017914	0.652	rs62532068	ENSG00000254031.4	RP11-326E22.1	6.82	2.64e-11	1.09e-08	0.34	0.29	Bone mineral density;	chr8:70750952	chr8:71155457~71204223:+
KIRC	cis	rs11168351	0.889	rs12817104	ENSG00000240399.1	RP1-228P16.1	6.82	2.65e-11	1.1e-08	0.25	0.29	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48054813~48055591:-
KIRC	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	6.82	2.65e-11	1.1e-08	0.34	0.29	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
KIRC	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	6.82	2.65e-11	1.1e-08	0.24	0.29	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
KIRC	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	6.82	2.66e-11	1.1e-08	0.39	0.29	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
KIRC	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	6.82	2.66e-11	1.1e-08	0.42	0.29	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
KIRC	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-6.82	2.66e-11	1.1e-08	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-6.82	2.66e-11	1.1e-08	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-6.82	2.66e-11	1.1e-08	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
KIRC	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-6.82	2.66e-11	1.1e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
KIRC	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-6.82	2.66e-11	1.1e-08	-0.24	-0.29	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
KIRC	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-6.82	2.67e-11	1.1e-08	-0.39	-0.29	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
KIRC	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	6.82	2.67e-11	1.1e-08	0.35	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-6.82	2.67e-11	1.11e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
KIRC	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	6.82	2.67e-11	1.11e-08	0.4	0.29	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
KIRC	cis	rs6061231	0.518	rs639836	ENSG00000275437.1	RP5-908M14.10	-6.82	2.68e-11	1.11e-08	-0.24	-0.29	Colorectal cancer;	chr20:62351167	chr20:62402236~62405935:-
KIRC	cis	rs6061231	0.597	rs624313	ENSG00000275437.1	RP5-908M14.10	-6.82	2.68e-11	1.11e-08	-0.24	-0.29	Colorectal cancer;	chr20:62352356	chr20:62402236~62405935:-
KIRC	cis	rs6061231	0.571	rs482010	ENSG00000275437.1	RP5-908M14.10	-6.82	2.68e-11	1.11e-08	-0.24	-0.29	Colorectal cancer;	chr20:62352495	chr20:62402236~62405935:-
KIRC	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	6.82	2.68e-11	1.11e-08	0.29	0.29	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
KIRC	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-6.82	2.68e-11	1.11e-08	-0.37	-0.29	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-6.82	2.68e-11	1.11e-08	-0.37	-0.29	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-6.82	2.68e-11	1.11e-08	-0.37	-0.29	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
KIRC	cis	rs600231	0.571	rs10896000	ENSG00000173727.10	CMB9-22P13.1	6.82	2.69e-11	1.11e-08	0.34	0.29	Bone mineral density;	chr11:65450547	chr11:65455258~65466720:+
KIRC	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-6.82	2.69e-11	1.11e-08	-0.3	-0.29	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
KIRC	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	6.82	2.69e-11	1.12e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
KIRC	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6.82	2.69e-11	1.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
KIRC	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-6.82	2.7e-11	1.12e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
KIRC	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.12e-08	0.22	0.29	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
KIRC	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	6.82	2.71e-11	1.12e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
KIRC	cis	rs79040073	0.911	rs17393193	ENSG00000259531.2	RP11-295H24.3	6.82	2.71e-11	1.12e-08	0.36	0.29	Lung cancer in ever smokers;	chr15:49039882	chr15:49365124~49366685:-
KIRC	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-6.82	2.71e-11	1.12e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
KIRC	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-6.82	2.71e-11	1.12e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-6.82	2.71e-11	1.12e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-6.82	2.71e-11	1.12e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-6.82	2.71e-11	1.12e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
KIRC	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-6.82	2.71e-11	1.12e-08	-0.28	-0.29	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	6.82	2.71e-11	1.12e-08	0.3	0.29	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
KIRC	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28147378	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28147406	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28148143	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28149979	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28151096	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28152885	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	6.82	2.72e-11	1.12e-08	0.34	0.29	Depression;	chr6:28153120	chr6:28073316~28074233:+
KIRC	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-6.82	2.72e-11	1.12e-08	-0.21	-0.29	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
KIRC	cis	rs6700559	0.643	rs4915451	ENSG00000260088.1	RP11-92G12.3	6.82	2.73e-11	1.13e-08	0.38	0.29	Coronary artery disease;	chr1:200690726	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.643	rs6427844	ENSG00000260088.1	RP11-92G12.3	6.82	2.73e-11	1.13e-08	0.38	0.29	Coronary artery disease;	chr1:200692216	chr1:200669507~200694250:+
KIRC	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	6.82	2.73e-11	1.13e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
KIRC	cis	rs6700559	0.643	rs1540682	ENSG00000260088.1	RP11-92G12.3	6.82	2.73e-11	1.13e-08	0.38	0.29	Coronary artery disease;	chr1:200693231	chr1:200669507~200694250:+
KIRC	cis	rs6700559	0.643	rs4556395	ENSG00000260088.1	RP11-92G12.3	6.82	2.73e-11	1.13e-08	0.38	0.29	Coronary artery disease;	chr1:200693813	chr1:200669507~200694250:+
KIRC	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-6.82	2.73e-11	1.13e-08	-0.17	-0.29	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
KIRC	cis	rs4356975	0.563	rs12505466	ENSG00000196472.4	RP13-644M16.4	6.82	2.74e-11	1.13e-08	0.34	0.29	Obesity-related traits;	chr4:69119944	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600896	ENSG00000196472.4	RP13-644M16.4	6.82	2.74e-11	1.13e-08	0.34	0.29	Obesity-related traits;	chr4:69121000	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600897	ENSG00000196472.4	RP13-644M16.4	6.82	2.74e-11	1.13e-08	0.34	0.29	Obesity-related traits;	chr4:69121531	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4274916	ENSG00000196472.4	RP13-644M16.4	6.82	2.74e-11	1.13e-08	0.34	0.29	Obesity-related traits;	chr4:69122660	chr4:69181660~69182372:+
KIRC	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-6.82	2.74e-11	1.13e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
KIRC	cis	rs2288884	0.806	rs12460587	ENSG00000275055.1	CTC-471J1.11	-6.82	2.74e-11	1.13e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52083666	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.806	rs11084141	ENSG00000275055.1	CTC-471J1.11	-6.82	2.74e-11	1.13e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084654	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.806	rs11084142	ENSG00000275055.1	CTC-471J1.11	-6.82	2.74e-11	1.13e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084664	chr19:52049007~52049754:+
KIRC	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28089816	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28090857	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28091242	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28091439	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28091659	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28093966	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	6.82	2.74e-11	1.13e-08	0.34	0.29	Depression;	chr6:28094014	chr6:28073316~28074233:+
KIRC	cis	rs10214930	0.781	rs12700823	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27619602	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs6966091	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27620394	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs7808275	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27621885	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs12540063	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27621926	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.705	rs12700824	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27622135	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs7782422	ENSG00000235574.1	AC073150.6	-6.82	2.75e-11	1.13e-08	-0.37	-0.29	Hypospadias;	chr7:27623884	chr7:27491682~27492765:-
KIRC	cis	rs7017914	0.652	rs7842091	ENSG00000254031.4	RP11-326E22.1	6.82	2.75e-11	1.14e-08	0.34	0.29	Bone mineral density;	chr8:70702546	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1477945	ENSG00000254031.4	RP11-326E22.1	6.82	2.75e-11	1.14e-08	0.34	0.29	Bone mineral density;	chr8:70703318	chr8:71155457~71204223:+
KIRC	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	6.82	2.75e-11	1.14e-08	0.3	0.29	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	6.82	2.75e-11	1.14e-08	0.3	0.29	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	6.82	2.75e-11	1.14e-08	0.3	0.29	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	6.82	2.75e-11	1.14e-08	0.3	0.29	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	6.82	2.75e-11	1.14e-08	0.3	0.29	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
KIRC	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-6.81	2.75e-11	1.14e-08	-0.41	-0.29	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
KIRC	cis	rs17772222	0.74	rs11845147	ENSG00000222990.1	RNU4-22P	6.81	2.75e-11	1.14e-08	0.33	0.29	Coronary artery calcification;	chr14:88502804	chr14:88513498~88513663:+
KIRC	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-6.81	2.76e-11	1.14e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-6.81	2.76e-11	1.14e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-6.81	2.76e-11	1.14e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
KIRC	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	6.81	2.76e-11	1.14e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
KIRC	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	6.81	2.76e-11	1.14e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	6.81	2.76e-11	1.14e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	6.81	2.76e-11	1.14e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	6.81	2.76e-11	1.14e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	6.81	2.76e-11	1.14e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
KIRC	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	6.81	2.76e-11	1.14e-08	0.42	0.29	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
KIRC	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-6.81	2.77e-11	1.14e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-6.81	2.77e-11	1.14e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
KIRC	cis	rs10214930	0.697	rs4722724	ENSG00000235574.1	AC073150.6	6.81	2.77e-11	1.14e-08	0.34	0.29	Hypospadias;	chr7:27615314	chr7:27491682~27492765:-
KIRC	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-6.81	2.77e-11	1.14e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
KIRC	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	6.81	2.77e-11	1.14e-08	0.36	0.29	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
KIRC	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	6.81	2.77e-11	1.15e-08	0.34	0.29	Depression;	chr6:28140454	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	6.81	2.77e-11	1.15e-08	0.34	0.29	Depression;	chr6:28141189	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	6.81	2.77e-11	1.15e-08	0.34	0.29	Depression;	chr6:28141484	chr6:28073316~28074233:+
KIRC	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	6.81	2.78e-11	1.15e-08	0.36	0.29	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
KIRC	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	6.81	2.78e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	6.81	2.78e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
KIRC	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.81	2.78e-11	1.15e-08	-0.31	-0.29	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
KIRC	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	6.81	2.79e-11	1.15e-08	0.31	0.29	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
KIRC	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	6.81	2.79e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	6.81	2.79e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	6.81	2.79e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	6.81	2.79e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
KIRC	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-6.81	2.79e-11	1.15e-08	-0.32	-0.29	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
KIRC	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-6.81	2.79e-11	1.15e-08	-0.22	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
KIRC	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-6.81	2.79e-11	1.15e-08	-0.57	-0.29	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
KIRC	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	6.81	2.79e-11	1.15e-08	0.25	0.29	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	6.81	2.79e-11	1.15e-08	0.25	0.29	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
KIRC	cis	rs12887734	0.524	rs12888002	ENSG00000269910.1	RP11-73M18.10	6.81	2.79e-11	1.15e-08	0.21	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694516~103695050:-
KIRC	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-6.81	2.79e-11	1.15e-08	-0.41	-0.29	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
KIRC	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	6.81	2.8e-11	1.15e-08	0.28	0.29	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
KIRC	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	6.81	2.8e-11	1.16e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
KIRC	cis	rs2288884	0.806	rs76094721	ENSG00000275055.1	CTC-471J1.11	-6.81	2.8e-11	1.16e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52089630	chr19:52049007~52049754:+
KIRC	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	6.81	2.8e-11	1.16e-08	0.24	0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
KIRC	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-6.81	2.8e-11	1.16e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
KIRC	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-6.81	2.8e-11	1.16e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
KIRC	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	6.81	2.81e-11	1.16e-08	0.28	0.29	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
KIRC	cis	rs10214930	0.697	rs6958467	ENSG00000235574.1	AC073150.6	-6.81	2.81e-11	1.16e-08	-0.34	-0.29	Hypospadias;	chr7:27564193	chr7:27491682~27492765:-
KIRC	cis	rs17361889	0.517	rs12699776	ENSG00000224683.1	RPL36AP29	6.81	2.81e-11	1.16e-08	0.42	0.29	Pediatric bone mineral content (hip);	chr7:16286676	chr7:16208945~16209265:+
KIRC	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-6.81	2.81e-11	1.16e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-6.81	2.81e-11	1.16e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
KIRC	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	6.81	2.81e-11	1.16e-08	0.43	0.29	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
KIRC	cis	rs13434995	0.842	rs62309759	ENSG00000249700.7	SRD5A3-AS1	-6.81	2.82e-11	1.16e-08	-0.34	-0.29	Adiponectin levels;	chr4:55557826	chr4:55363971~55395847:-
KIRC	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	6.81	2.82e-11	1.16e-08	0.27	0.29	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
KIRC	cis	rs919433	0.653	rs700651	ENSG00000231621.1	AC013264.2	-6.81	2.82e-11	1.17e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197766990	chr2:197197991~197199273:+
KIRC	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	6.81	2.83e-11	1.17e-08	0.28	0.29	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
KIRC	cis	rs3820928	0.874	rs1917127	ENSG00000212391.1	SNORA48	-6.81	2.83e-11	1.17e-08	-0.33	-0.29	Pulmonary function;	chr2:227030409	chr2:226968989~226969122:-
KIRC	cis	rs6480314	0.542	rs17231630	ENSG00000233590.1	RP11-153K11.3	-6.81	2.83e-11	1.17e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68268960	chr10:68233251~68242379:-
KIRC	cis	rs919433	0.617	rs34632716	ENSG00000231621.1	AC013264.2	6.81	2.83e-11	1.17e-08	0.32	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197677895	chr2:197197991~197199273:+
KIRC	cis	rs7246657	0.639	rs3112434	ENSG00000267422.1	CTD-2554C21.1	6.81	2.83e-11	1.17e-08	0.43	0.29	Coronary artery calcification;	chr19:37707247	chr19:37779686~37792865:+
KIRC	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-6.81	2.83e-11	1.17e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
KIRC	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-6.81	2.83e-11	1.17e-08	-0.28	-0.29	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
KIRC	cis	rs7647973	0.58	rs11716334	ENSG00000225399.4	RP11-3B7.1	6.81	2.83e-11	1.17e-08	0.31	0.29	Menarche (age at onset);	chr3:49192663	chr3:49260085~49261316:+
KIRC	cis	rs3002142	0.908	rs3002143	ENSG00000272750.1	RP11-378J18.8	-6.81	2.84e-11	1.17e-08	-0.41	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222615512	chr1:222658867~222661512:-
KIRC	cis	rs6456156	0.875	rs55802221	ENSG00000265828.1	MIR3939	6.81	2.84e-11	1.17e-08	0.34	0.29	Primary biliary cholangitis;	chr6:167103832	chr6:166997807~166997912:-
KIRC	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-6.81	2.84e-11	1.17e-08	-0.28	-0.29	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
KIRC	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	6.81	2.84e-11	1.17e-08	0.34	0.29	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
KIRC	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	6.81	2.84e-11	1.17e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	6.81	2.84e-11	1.17e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
KIRC	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-6.81	2.84e-11	1.17e-08	-0.39	-0.29	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
KIRC	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-6.81	2.84e-11	1.17e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
KIRC	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	6.81	2.85e-11	1.17e-08	0.29	0.29	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
KIRC	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	6.81	2.85e-11	1.17e-08	0.29	0.29	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-6.81	2.85e-11	1.17e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-6.81	2.85e-11	1.17e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
KIRC	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	6.81	2.86e-11	1.18e-08	0.32	0.29	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
KIRC	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	6.81	2.86e-11	1.18e-08	0.42	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
KIRC	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	6.81	2.87e-11	1.18e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
KIRC	cis	rs1198872	0.892	rs1198866	ENSG00000272275.1	RP11-791G15.2	-6.81	2.87e-11	1.18e-08	-0.39	-0.29	Cardiac Troponin-T levels;	chr2:10761664	chr2:10767875~10770058:-
KIRC	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	6.81	2.87e-11	1.18e-08	0.3	0.29	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	6.81	2.87e-11	1.18e-08	0.3	0.29	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
KIRC	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	6.81	2.87e-11	1.18e-08	0.31	0.29	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
KIRC	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-6.81	2.87e-11	1.18e-08	-0.25	-0.29	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
KIRC	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	6.81	2.87e-11	1.18e-08	0.28	0.29	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
KIRC	cis	rs13434995	0.513	rs2171617	ENSG00000249700.7	SRD5A3-AS1	6.81	2.87e-11	1.18e-08	0.3	0.29	Adiponectin levels;	chr4:55591023	chr4:55363971~55395847:-
KIRC	cis	rs10214930	0.697	rs1111647	ENSG00000235574.1	AC073150.6	-6.81	2.87e-11	1.18e-08	-0.34	-0.29	Hypospadias;	chr7:27521114	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs961724	ENSG00000235574.1	AC073150.6	-6.81	2.87e-11	1.18e-08	-0.37	-0.29	Hypospadias;	chr7:27618416	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs961725	ENSG00000235574.1	AC073150.6	-6.81	2.87e-11	1.18e-08	-0.37	-0.29	Hypospadias;	chr7:27618451	chr7:27491682~27492765:-
KIRC	cis	rs10276381	1	rs10281214	ENSG00000234336.5	JAZF1-AS1	-6.81	2.87e-11	1.18e-08	-0.53	-0.29	Crohn's disease;	chr7:28145925	chr7:28180322~28243917:+
KIRC	cis	rs10276381	0.786	rs73089302	ENSG00000234336.5	JAZF1-AS1	-6.81	2.87e-11	1.18e-08	-0.53	-0.29	Crohn's disease;	chr7:28147515	chr7:28180322~28243917:+
KIRC	cis	rs10276381	1	rs10263857	ENSG00000234336.5	JAZF1-AS1	-6.81	2.87e-11	1.18e-08	-0.53	-0.29	Crohn's disease;	chr7:28147665	chr7:28180322~28243917:+
KIRC	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-6.81	2.87e-11	1.18e-08	-0.44	-0.29	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
KIRC	cis	rs6908034	0.607	rs112659166	ENSG00000228412.5	RP4-625H18.2	6.81	2.87e-11	1.18e-08	0.63	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19802164~19804752:-
KIRC	cis	rs2980439	0.517	rs793753	ENSG00000253893.2	FAM85B	6.81	2.87e-11	1.18e-08	0.38	0.29	Neuroticism;	chr8:8247837	chr8:8167819~8226614:-
KIRC	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-6.81	2.87e-11	1.18e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-6.81	2.87e-11	1.18e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
KIRC	cis	rs2564921	0.704	rs35671032	ENSG00000280417.1	RP11-5O17.1	6.81	2.87e-11	1.18e-08	0.36	0.29	Height;	chr3:52972039	chr3:53046166~53048122:+
KIRC	cis	rs4578769	0.569	rs4800438	ENSG00000266850.1	RP11-370A5.1	6.81	2.88e-11	1.19e-08	0.39	0.29	Eosinophil percentage of white cells;	chr18:22920482	chr18:22723491~22907721:-
KIRC	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-6.81	2.88e-11	1.19e-08	-0.31	-0.29	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
KIRC	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	6.81	2.88e-11	1.19e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	6.81	2.88e-11	1.19e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	6.81	2.88e-11	1.19e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	6.81	2.88e-11	1.19e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
KIRC	cis	rs6456156	0.792	rs10946213	ENSG00000265828.1	MIR3939	6.81	2.89e-11	1.19e-08	0.34	0.29	Primary biliary cholangitis;	chr6:167102607	chr6:166997807~166997912:-
KIRC	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-6.81	2.89e-11	1.19e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-6.81	2.89e-11	1.19e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
KIRC	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	6.81	2.9e-11	1.19e-08	0.35	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
KIRC	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	6.81	2.9e-11	1.19e-08	0.26	0.29	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
KIRC	cis	rs4072705	0.967	rs10739650	ENSG00000224020.1	MIR181A2HG	-6.81	2.9e-11	1.19e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124561497	chr9:124658467~124698631:+
KIRC	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-6.81	2.9e-11	1.19e-08	-0.29	-0.29	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-6.81	2.9e-11	1.19e-08	-0.29	-0.29	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
KIRC	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	6.81	2.9e-11	1.19e-08	0.32	0.29	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
KIRC	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	6.81	2.91e-11	1.2e-08	0.27	0.29	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
KIRC	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.91e-11	1.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.91e-11	1.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.91e-11	1.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
KIRC	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	6.81	2.91e-11	1.2e-08	0.33	0.29	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
KIRC	cis	rs755249	1	rs17513135	ENSG00000237624.1	OXCT2P1	6.81	2.91e-11	1.2e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39514956~39516490:+
KIRC	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	6.81	2.91e-11	1.2e-08	0.38	0.29	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
KIRC	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-6.81	2.91e-11	1.2e-08	-0.31	-0.29	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
KIRC	cis	rs3820928	1	rs10193316	ENSG00000212391.1	SNORA48	-6.81	2.92e-11	1.2e-08	-0.34	-0.29	Pulmonary function;	chr2:226912934	chr2:226968989~226969122:-
KIRC	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	6.81	2.92e-11	1.2e-08	0.29	0.29	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
KIRC	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-6.81	2.92e-11	1.2e-08	-0.44	-0.29	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
KIRC	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	6.81	2.92e-11	1.2e-08	0.29	0.29	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	6.81	2.92e-11	1.2e-08	0.29	0.29	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
KIRC	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	6.81	2.93e-11	1.2e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
KIRC	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-6.8	2.93e-11	1.21e-08	-0.35	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
KIRC	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-6.8	2.93e-11	1.21e-08	-0.37	-0.29	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-6.8	2.93e-11	1.21e-08	-0.37	-0.29	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
KIRC	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-6.8	2.93e-11	1.21e-08	-0.37	-0.29	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
KIRC	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	6.8	2.93e-11	1.21e-08	0.3	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
KIRC	cis	rs2018683	0.523	rs886834	ENSG00000228421.2	AC005013.5	6.8	2.93e-11	1.21e-08	0.34	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28957667~28959345:+
KIRC	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	6.8	2.93e-11	1.21e-08	0.45	0.29	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
KIRC	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.8	2.94e-11	1.21e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
KIRC	cis	rs7924176	0.521	rs11000959	ENSG00000213731.2	RAB5CP1	-6.8	2.94e-11	1.21e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74423435~74424014:-
KIRC	cis	rs7017914	0.652	rs11991584	ENSG00000254031.4	RP11-326E22.1	6.8	2.94e-11	1.21e-08	0.34	0.29	Bone mineral density;	chr8:70859112	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs11991605	ENSG00000254031.4	RP11-326E22.1	6.8	2.94e-11	1.21e-08	0.34	0.29	Bone mineral density;	chr8:70859117	chr8:71155457~71204223:+
KIRC	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-6.8	2.95e-11	1.21e-08	-0.25	-0.29	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
KIRC	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	6.8	2.95e-11	1.21e-08	0.4	0.29	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
KIRC	cis	rs2797160	0.904	rs2326292	ENSG00000237742.5	RP11-624M8.1	-6.8	2.95e-11	1.21e-08	-0.35	-0.29	Endometrial cancer;	chr6:125678528	chr6:125578558~125749190:-
KIRC	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-6.8	2.95e-11	1.21e-08	-0.36	-0.29	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-6.8	2.95e-11	1.21e-08	-0.36	-0.29	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-6.8	2.95e-11	1.21e-08	-0.36	-0.29	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-6.8	2.95e-11	1.21e-08	-0.36	-0.29	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
KIRC	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	6.8	2.95e-11	1.21e-08	0.28	0.29	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
KIRC	cis	rs919433	0.617	rs13018267	ENSG00000231621.1	AC013264.2	6.8	2.95e-11	1.21e-08	0.32	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197680868	chr2:197197991~197199273:+
KIRC	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	6.8	2.95e-11	1.21e-08	0.36	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
KIRC	cis	rs7182621	0.767	rs11247132	ENSG00000182397.13	DNM1P46	6.8	2.96e-11	1.22e-08	0.33	0.29	Colonoscopy-negative controls vs population controls;	chr15:99875536	chr15:99790156~99806927:-
KIRC	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-6.8	2.96e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
KIRC	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-6.8	2.96e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
KIRC	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-6.8	2.96e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
KIRC	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-6.8	2.96e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
KIRC	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-6.8	2.96e-11	1.22e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
KIRC	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-6.8	2.96e-11	1.22e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
KIRC	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	6.8	2.97e-11	1.22e-08	0.34	0.29	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
KIRC	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-6.8	2.97e-11	1.22e-08	-0.2	-0.29	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
KIRC	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	6.8	2.97e-11	1.22e-08	0.26	0.29	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
KIRC	cis	rs9915657	1	rs9915657	ENSG00000234899.8	SOX9-AS1	-6.8	2.98e-11	1.22e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72131395	chr17:72034107~72237203:-
KIRC	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-6.8	2.98e-11	1.22e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-6.8	2.98e-11	1.22e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-6.8	2.98e-11	1.22e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-6.8	2.98e-11	1.22e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
KIRC	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-6.8	2.98e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
KIRC	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-6.8	2.98e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
KIRC	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-6.8	2.98e-11	1.22e-08	-0.39	-0.29	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
KIRC	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	6.8	2.98e-11	1.22e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
KIRC	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-6.8	2.98e-11	1.22e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
KIRC	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	6.8	2.98e-11	1.23e-08	0.51	0.29	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
KIRC	cis	rs1005277	0.522	rs1208684	ENSG00000235197.1	ZNF33AP1	-6.8	2.99e-11	1.23e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:37894637~37896666:+
KIRC	cis	rs7647973	0.58	rs12629759	ENSG00000225399.4	RP11-3B7.1	6.8	2.99e-11	1.23e-08	0.31	0.29	Menarche (age at onset);	chr3:49199961	chr3:49260085~49261316:+
KIRC	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	6.8	2.99e-11	1.23e-08	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
KIRC	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	6.8	2.99e-11	1.23e-08	0.23	0.29	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
KIRC	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-6.8	2.99e-11	1.23e-08	-0.39	-0.29	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
KIRC	cis	rs919433	0.617	rs700643	ENSG00000231621.1	AC013264.2	-6.8	2.99e-11	1.23e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736646	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.617	rs4850809	ENSG00000231621.1	AC013264.2	6.8	3e-11	1.23e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197718679	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.617	rs2037590	ENSG00000231621.1	AC013264.2	6.8	3e-11	1.23e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197720051	chr2:197197991~197199273:+
KIRC	cis	rs62025270	0.631	rs55968154	ENSG00000202081.1	RNU6-1280P	-6.8	3e-11	1.23e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.688	rs55851385	ENSG00000202081.1	RNU6-1280P	-6.8	3e-11	1.23e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85651522~85651628:-
KIRC	cis	rs755249	0.588	rs6665948	ENSG00000237624.1	OXCT2P1	-6.8	3e-11	1.23e-08	-0.38	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39514956~39516490:+
KIRC	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	6.8	3e-11	1.23e-08	0.34	0.29	Depression;	chr6:28145952	chr6:28073316~28074233:+
KIRC	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	6.8	3.01e-11	1.23e-08	0.32	0.29	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
KIRC	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.01e-11	1.23e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
KIRC	cis	rs11671005	0.656	rs55928441	ENSG00000269600.1	AC016629.3	-6.8	3.01e-11	1.24e-08	-0.51	-0.29	Mean platelet volume;	chr19:58498307	chr19:58593896~58599355:-
KIRC	cis	rs4601821	0.635	rs12282356	ENSG00000270179.1	RP11-159N11.4	-6.8	3.01e-11	1.24e-08	-0.29	-0.29	Alcoholic chronic pancreatitis;	chr11:113337660	chr11:113368478~113369117:+
KIRC	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-6.8	3.02e-11	1.24e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
KIRC	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	6.8	3.02e-11	1.24e-08	0.35	0.29	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
KIRC	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-6.8	3.02e-11	1.24e-08	-0.28	-0.29	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-6.8	3.02e-11	1.24e-08	-0.28	-0.29	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
KIRC	cis	rs58873874	0.579	rs10040318	ENSG00000251405.2	CTB-109A12.1	6.8	3.02e-11	1.24e-08	0.46	0.29	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157362615~157460078:-
KIRC	cis	rs12049351	0.613	rs3738185	ENSG00000229367.1	HMGN2P19	6.8	3.03e-11	1.24e-08	0.41	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229499520	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs12033713	ENSG00000229367.1	HMGN2P19	6.8	3.03e-11	1.24e-08	0.41	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229502693	chr1:229570532~229570796:+
KIRC	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-6.8	3.03e-11	1.24e-08	-0.32	-0.29	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
KIRC	cis	rs3002142	0.908	rs3008606	ENSG00000272750.1	RP11-378J18.8	-6.8	3.03e-11	1.24e-08	-0.43	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222611351	chr1:222658867~222661512:-
KIRC	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-6.8	3.03e-11	1.24e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
KIRC	cis	rs1431005	0.963	rs58289169	ENSG00000250620.1	RP11-91J3.3	6.8	3.04e-11	1.25e-08	0.38	0.29	Response to statin therapy;	chr4:187476388	chr4:187413564~187415697:+
KIRC	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-6.8	3.04e-11	1.25e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
KIRC	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	6.8	3.04e-11	1.25e-08	0.31	0.29	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
KIRC	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.05e-11	1.25e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.05e-11	1.25e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.05e-11	1.25e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	6.8	3.05e-11	1.25e-08	0.28	0.29	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
KIRC	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-6.8	3.05e-11	1.25e-08	-0.28	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
KIRC	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-6.8	3.05e-11	1.25e-08	-0.31	-0.29	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
KIRC	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-6.8	3.05e-11	1.25e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
KIRC	cis	rs890448	0.694	rs13108283	ENSG00000254531.1	FLJ20021	6.8	3.05e-11	1.25e-08	0.29	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371711	chr4:101347780~101348883:+
KIRC	cis	rs10214930	0.697	rs12667610	ENSG00000235574.1	AC073150.6	-6.8	3.06e-11	1.26e-08	-0.34	-0.29	Hypospadias;	chr7:27627866	chr7:27491682~27492765:-
KIRC	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	6.8	3.07e-11	1.26e-08	0.32	0.29	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
KIRC	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-6.8	3.07e-11	1.26e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
KIRC	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-6.8	3.07e-11	1.26e-08	-0.23	-0.29	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
KIRC	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-6.8	3.07e-11	1.26e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
KIRC	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-6.8	3.08e-11	1.26e-08	-0.28	-0.29	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
KIRC	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	6.8	3.08e-11	1.26e-08	0.32	0.29	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
KIRC	cis	rs10276381	0.786	rs10281102	ENSG00000234336.5	JAZF1-AS1	-6.8	3.09e-11	1.26e-08	-0.53	-0.29	Crohn's disease;	chr7:28203854	chr7:28180322~28243917:+
KIRC	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-6.8	3.1e-11	1.27e-08	-0.23	-0.29	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
KIRC	cis	rs3820928	1	rs978909	ENSG00000212391.1	SNORA48	-6.8	3.11e-11	1.27e-08	-0.34	-0.29	Pulmonary function;	chr2:226906673	chr2:226968989~226969122:-
KIRC	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-6.8	3.11e-11	1.27e-08	-0.39	-0.29	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
KIRC	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-6.8	3.11e-11	1.27e-08	-0.32	-0.29	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-6.8	3.11e-11	1.27e-08	-0.32	-0.29	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
KIRC	cis	rs2288884	0.806	rs78369132	ENSG00000275055.1	CTC-471J1.11	-6.8	3.11e-11	1.27e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090465	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.806	rs10164297	ENSG00000275055.1	CTC-471J1.11	-6.8	3.11e-11	1.27e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52090996	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.69	rs10164294	ENSG00000275055.1	CTC-471J1.11	-6.8	3.11e-11	1.27e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52091128	chr19:52049007~52049754:+
KIRC	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	6.8	3.11e-11	1.27e-08	0.36	0.29	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
KIRC	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	6.8	3.11e-11	1.27e-08	0.36	0.29	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
KIRC	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	6.8	3.11e-11	1.27e-08	0.36	0.29	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
KIRC	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	6.8	3.11e-11	1.28e-08	0.41	0.29	Depression;	chr6:28399846	chr6:28943877~28944537:+
KIRC	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-6.8	3.12e-11	1.28e-08	-0.35	-0.29	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
KIRC	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-6.8	3.12e-11	1.28e-08	-0.66	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
KIRC	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-6.8	3.12e-11	1.28e-08	-0.45	-0.29	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
KIRC	cis	rs7017914	0.652	rs12674966	ENSG00000254031.4	RP11-326E22.1	6.8	3.12e-11	1.28e-08	0.34	0.29	Bone mineral density;	chr8:70772175	chr8:71155457~71204223:+
KIRC	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-6.79	3.12e-11	1.28e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
KIRC	cis	rs7916697	0.891	rs7897809	ENSG00000233590.1	RP11-153K11.3	-6.79	3.13e-11	1.28e-08	-0.32	-0.29	Optic disc area;	chr10:68240536	chr10:68233251~68242379:-
KIRC	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-6.79	3.13e-11	1.28e-08	-0.3	-0.29	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
KIRC	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-6.79	3.13e-11	1.28e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
KIRC	cis	rs11512640	1	rs118093992	ENSG00000254671.2	STT3A-AS1	6.79	3.13e-11	1.28e-08	0.64	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125515784	chr11:125570284~125592568:-
KIRC	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.79	3.13e-11	1.28e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	6.79	3.14e-11	1.29e-08	0.3	0.29	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
KIRC	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.79	3.14e-11	1.29e-08	0.28	0.29	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
KIRC	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-6.79	3.14e-11	1.29e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
KIRC	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-6.79	3.14e-11	1.29e-08	-0.27	-0.29	Height;	chr2:46617930	chr2:46668870~46670778:+
KIRC	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-6.79	3.15e-11	1.29e-08	-0.22	-0.29	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
KIRC	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
KIRC	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-6.79	3.15e-11	1.29e-08	-0.37	-0.29	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
KIRC	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
KIRC	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	6.79	3.15e-11	1.29e-08	0.29	0.29	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
KIRC	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-6.79	3.16e-11	1.29e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
KIRC	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.79	3.16e-11	1.29e-08	0.34	0.29	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
KIRC	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.79	3.16e-11	1.29e-08	0.34	0.29	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
KIRC	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-6.79	3.17e-11	1.29e-08	-0.43	-0.29	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
KIRC	cis	rs6480314	0.542	rs7476012	ENSG00000233590.1	RP11-153K11.3	-6.79	3.17e-11	1.3e-08	-0.43	-0.29	Optic nerve measurement (disc area);	chr10:68259950	chr10:68233251~68242379:-
KIRC	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28082231	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28082261	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28082984	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28083994	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28084025	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	6.79	3.18e-11	1.3e-08	0.34	0.29	Depression;	chr6:28085319	chr6:28073316~28074233:+
KIRC	cis	rs7017914	0.652	rs7831507	ENSG00000254031.4	RP11-326E22.1	6.79	3.18e-11	1.3e-08	0.34	0.29	Bone mineral density;	chr8:70682991	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13256093	ENSG00000254031.4	RP11-326E22.1	6.79	3.18e-11	1.3e-08	0.34	0.29	Bone mineral density;	chr8:70684142	chr8:71155457~71204223:+
KIRC	cis	rs7647973	0.58	rs2334958	ENSG00000225399.4	RP11-3B7.1	6.79	3.18e-11	1.3e-08	0.31	0.29	Menarche (age at onset);	chr3:49214931	chr3:49260085~49261316:+
KIRC	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	6.79	3.18e-11	1.3e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
KIRC	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	6.79	3.18e-11	1.3e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
KIRC	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	6.79	3.19e-11	1.3e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
KIRC	cis	rs11671005	0.656	rs11672609	ENSG00000269600.1	AC016629.3	-6.79	3.19e-11	1.3e-08	-0.51	-0.29	Mean platelet volume;	chr19:58495557	chr19:58593896~58599355:-
KIRC	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	6.79	3.19e-11	1.3e-08	0.32	0.29	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
KIRC	cis	rs11647589	0.684	rs12051080	ENSG00000260762.1	ACSM5P1	6.79	3.19e-11	1.3e-08	0.29	0.29	Blood metabolite levels;	chr16:20428968	chr16:20586550~20607107:-
KIRC	cis	rs11647589	1	rs11647589	ENSG00000262995.1	CTD-2194A8.2	-6.79	3.2e-11	1.31e-08	-0.31	-0.29	Blood metabolite levels;	chr16:20438294	chr16:20440266~20447000:-
KIRC	cis	rs13113518	0.51	rs11732723	ENSG00000273257.1	RP11-177J6.1	-6.79	3.2e-11	1.31e-08	-0.34	-0.29	Height;	chr4:55424391	chr4:55387949~55388271:+
KIRC	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-6.79	3.2e-11	1.31e-08	-0.45	-0.29	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
KIRC	cis	rs1153858	1	rs2467858	ENSG00000235390.4	CTD-2651B20.5	-6.79	3.21e-11	1.31e-08	-0.28	-0.29	Homoarginine levels;	chr15:45419294	chr15:45321077~45321692:-
KIRC	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.79	3.21e-11	1.31e-08	-0.27	-0.29	Height;	chr11:118703185	chr11:118791254~118793137:+
KIRC	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.79	3.21e-11	1.31e-08	-0.27	-0.29	Height;	chr11:118703207	chr11:118791254~118793137:+
KIRC	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.79	3.21e-11	1.31e-08	-0.27	-0.29	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
KIRC	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	6.79	3.21e-11	1.31e-08	0.31	0.29	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
KIRC	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	6.79	3.21e-11	1.31e-08	0.32	0.29	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	6.79	3.21e-11	1.31e-08	0.32	0.29	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	6.79	3.21e-11	1.31e-08	0.32	0.29	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
KIRC	cis	rs12500482	0.5	rs73205480	ENSG00000206113.6	RP11-503N18.1	6.79	3.21e-11	1.31e-08	0.37	0.29	Cognitive function;	chr4:2429338	chr4:2418974~2450360:+
KIRC	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-6.79	3.21e-11	1.31e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
KIRC	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	6.79	3.22e-11	1.31e-08	0.29	0.29	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
KIRC	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	6.79	3.22e-11	1.31e-08	0.29	0.29	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
KIRC	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	6.79	3.22e-11	1.31e-08	0.29	0.29	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	6.79	3.22e-11	1.31e-08	0.34	0.29	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
KIRC	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	6.79	3.23e-11	1.32e-08	0.31	0.29	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
KIRC	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.79	3.23e-11	1.32e-08	0.31	0.29	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
KIRC	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-6.79	3.23e-11	1.32e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
KIRC	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	6.79	3.24e-11	1.32e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	6.79	3.24e-11	1.32e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
KIRC	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	6.79	3.24e-11	1.32e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
KIRC	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-6.79	3.24e-11	1.32e-08	-0.44	-0.29	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
KIRC	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-6.79	3.24e-11	1.32e-08	-0.26	-0.29	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
KIRC	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Depression;	chr6:28136698	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Depression;	chr6:28136856	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Depression;	chr6:28138363	chr6:28073316~28074233:+
KIRC	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Depression;	chr6:28138981	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	6.79	3.25e-11	1.33e-08	0.33	0.29	Depression;	chr6:28139012	chr6:28073316~28074233:+
KIRC	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.79	3.25e-11	1.33e-08	0.44	0.29	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
KIRC	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.79	3.25e-11	1.33e-08	0.44	0.29	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
KIRC	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-6.79	3.25e-11	1.33e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
KIRC	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-6.79	3.25e-11	1.33e-08	-0.34	-0.29	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
KIRC	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-6.79	3.26e-11	1.33e-08	-0.42	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
KIRC	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-6.79	3.26e-11	1.33e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
KIRC	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-6.79	3.27e-11	1.34e-08	-0.28	-0.29	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
KIRC	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
KIRC	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	6.79	3.27e-11	1.34e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
KIRC	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	6.79	3.28e-11	1.34e-08	0.23	0.29	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
KIRC	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-6.79	3.28e-11	1.34e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
KIRC	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	6.79	3.28e-11	1.34e-08	0.29	0.29	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
KIRC	cis	rs919433	0.68	rs4685	ENSG00000231621.1	AC013264.2	6.79	3.29e-11	1.34e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197393071	chr2:197197991~197199273:+
KIRC	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	6.79	3.3e-11	1.34e-08	0.4	0.29	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
KIRC	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-6.79	3.3e-11	1.34e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-6.79	3.3e-11	1.34e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
KIRC	cis	rs6452524	0.618	rs10462394	ENSG00000248112.1	RP11-78C3.1	6.79	3.3e-11	1.35e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82919376~82921119:-
KIRC	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-6.79	3.3e-11	1.35e-08	-0.31	-0.29	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
KIRC	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-6.79	3.3e-11	1.35e-08	-0.24	-0.29	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
KIRC	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	6.79	3.3e-11	1.35e-08	0.56	0.29	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
KIRC	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	6.79	3.31e-11	1.35e-08	0.41	0.29	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
KIRC	cis	rs12188164	0.543	rs2434695	ENSG00000188242.4	PP7080	-6.79	3.31e-11	1.35e-08	-0.39	-0.29	Cystic fibrosis severity;	chr5:464062	chr5:466124~473098:-
KIRC	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	6.79	3.32e-11	1.35e-08	0.32	0.29	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
KIRC	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	6.79	3.32e-11	1.35e-08	0.32	0.29	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
KIRC	cis	rs4578769	0.569	rs11659166	ENSG00000266850.1	RP11-370A5.1	6.79	3.32e-11	1.35e-08	0.39	0.29	Eosinophil percentage of white cells;	chr18:22926143	chr18:22723491~22907721:-
KIRC	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
KIRC	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-6.78	3.33e-11	1.36e-08	-0.37	-0.29	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
KIRC	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	6.78	3.33e-11	1.36e-08	0.56	0.29	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
KIRC	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	6.78	3.33e-11	1.36e-08	0.34	0.29	Depression;	chr6:28092227	chr6:28073316~28074233:+
KIRC	cis	rs1153858	1	rs1346266	ENSG00000235390.4	CTD-2651B20.5	-6.78	3.33e-11	1.36e-08	-0.28	-0.29	Homoarginine levels;	chr15:45402318	chr15:45321077~45321692:-
KIRC	cis	rs7045881	0.808	rs73436047	ENSG00000254396.1	RP11-56F10.3	6.78	3.33e-11	1.36e-08	0.4	0.29	Schizophrenia;	chr9:27001191	chr9:27102630~27104728:+
KIRC	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6.78	3.34e-11	1.36e-08	0.32	0.29	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6.78	3.34e-11	1.36e-08	0.32	0.29	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
KIRC	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-6.78	3.34e-11	1.36e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
KIRC	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	6.78	3.34e-11	1.36e-08	0.5	0.29	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
KIRC	cis	rs7916697	0.947	rs4745950	ENSG00000233590.1	RP11-153K11.3	6.78	3.34e-11	1.36e-08	0.32	0.29	Optic disc area;	chr10:68236698	chr10:68233251~68242379:-
KIRC	cis	rs6908034	0.607	rs62404179	ENSG00000228412.5	RP4-625H18.2	6.78	3.34e-11	1.36e-08	0.64	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19802164~19804752:-
KIRC	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-6.78	3.35e-11	1.36e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-6.78	3.35e-11	1.36e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-6.78	3.35e-11	1.36e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-6.78	3.35e-11	1.36e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-6.78	3.35e-11	1.36e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
KIRC	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.35e-11	1.36e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
KIRC	cis	rs7916697	0.947	rs1900004	ENSG00000233590.1	RP11-153K11.3	-6.78	3.35e-11	1.36e-08	-0.31	-0.29	Optic disc area;	chr10:68241124	chr10:68233251~68242379:-
KIRC	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	6.78	3.35e-11	1.36e-08	0.31	0.29	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
KIRC	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-6.78	3.35e-11	1.37e-08	-0.25	-0.29	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
KIRC	cis	rs4072705	0.614	rs1570581	ENSG00000224020.1	MIR181A2HG	-6.78	3.36e-11	1.37e-08	-0.31	-0.29	Menarche (age at onset);	chr9:124471780	chr9:124658467~124698631:+
KIRC	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	6.78	3.36e-11	1.37e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
KIRC	cis	rs13434995	0.842	rs56139168	ENSG00000249700.7	SRD5A3-AS1	-6.78	3.37e-11	1.37e-08	-0.34	-0.29	Adiponectin levels;	chr4:55407120	chr4:55363971~55395847:-
KIRC	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	6.78	3.37e-11	1.37e-08	0.26	0.29	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
KIRC	cis	rs2337406	0.85	rs75196489	ENSG00000274576.2	IGHV2-70	-6.78	3.37e-11	1.37e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106699438	chr14:106770577~106771020:-
KIRC	cis	rs6452524	0.618	rs3899556	ENSG00000248112.1	RP11-78C3.1	6.78	3.37e-11	1.37e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82919376~82921119:-
KIRC	cis	rs1005277	0.54	rs7903942	ENSG00000235197.1	ZNF33AP1	6.78	3.38e-11	1.37e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:37894637~37896666:+
KIRC	cis	rs7017914	0.652	rs754846	ENSG00000254031.4	RP11-326E22.1	6.78	3.38e-11	1.38e-08	0.34	0.29	Bone mineral density;	chr8:70832304	chr8:71155457~71204223:+
KIRC	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	6.78	3.39e-11	1.38e-08	0.28	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
KIRC	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.39e-11	1.38e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.39e-11	1.38e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.39e-11	1.38e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
KIRC	cis	rs9601248	0.756	rs928640	ENSG00000227354.5	RBM26-AS1	-6.78	3.39e-11	1.38e-08	-0.33	-0.29	Major depressive disorder;	chr13:79603348	chr13:79406309~79424328:+
KIRC	cis	rs62025270	0.688	rs11073516	ENSG00000202081.1	RNU6-1280P	-6.78	3.4e-11	1.38e-08	-0.37	-0.29	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85651522~85651628:-
KIRC	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	6.78	3.4e-11	1.38e-08	0.28	0.29	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.563	rs6851533	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69113032	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7666195	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69113765	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7685151	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69114055	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.583	rs11936822	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69114229	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs34814736	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69114760	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs11933459	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69116045	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600895	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69117694	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4508963	ENSG00000196472.4	RP13-644M16.4	6.78	3.4e-11	1.38e-08	0.34	0.29	Obesity-related traits;	chr4:69118770	chr4:69181660~69182372:+
KIRC	cis	rs11089937	0.616	rs5757247	ENSG00000211639.2	IGLV4-60	6.78	3.4e-11	1.38e-08	0.29	0.29	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22162199~22162681:+
KIRC	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-6.78	3.4e-11	1.38e-08	-0.31	-0.29	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
KIRC	cis	rs2337406	0.704	rs1858679	ENSG00000274576.2	IGHV2-70	-6.78	3.41e-11	1.39e-08	-0.34	-0.29	Alzheimer's disease (late onset);	chr14:106706726	chr14:106770577~106771020:-
KIRC	cis	rs4356975	0.563	rs12512526	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69100700	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs34386959	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69100837	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs55834557	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69100876	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs56388229	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69100940	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs34318523	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69101135	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.583	rs34630750	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69101208	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs12508257	ENSG00000196472.4	RP13-644M16.4	6.78	3.41e-11	1.39e-08	0.33	0.29	Obesity-related traits;	chr4:69101921	chr4:69181660~69182372:+
KIRC	cis	rs904251	0.772	rs10692	ENSG00000227920.2	RP1-153P14.5	-6.78	3.42e-11	1.39e-08	-0.35	-0.29	Cognitive performance;	chr6:37483138	chr6:37545145~37550860:+
KIRC	cis	rs3096299	0.583	rs1078577	ENSG00000274627.1	RP11-104N10.2	6.78	3.42e-11	1.39e-08	0.22	0.29	Multiple myeloma (IgH translocation);	chr16:89320680	chr16:89516797~89522217:+
KIRC	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-6.78	3.43e-11	1.39e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
KIRC	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
KIRC	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-6.78	3.43e-11	1.39e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.563	rs4327554	ENSG00000196472.4	RP13-644M16.4	-6.78	3.44e-11	1.4e-08	-0.33	-0.29	Obesity-related traits;	chr4:69120690	chr4:69181660~69182372:+
KIRC	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	6.78	3.44e-11	1.4e-08	0.26	0.29	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
KIRC	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-6.78	3.44e-11	1.4e-08	-0.36	-0.29	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
KIRC	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-6.78	3.44e-11	1.4e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
KIRC	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.44e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.44e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
KIRC	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	6.78	3.45e-11	1.4e-08	0.36	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
KIRC	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	6.78	3.45e-11	1.4e-08	0.36	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
KIRC	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	6.78	3.45e-11	1.4e-08	0.21	0.29	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
KIRC	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	6.78	3.45e-11	1.4e-08	0.21	0.29	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
KIRC	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-6.78	3.45e-11	1.4e-08	-0.32	-0.29	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
KIRC	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	6.78	3.45e-11	1.4e-08	0.31	0.29	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
KIRC	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-6.78	3.46e-11	1.4e-08	-0.28	-0.29	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
KIRC	cis	rs6480314	0.542	rs17231637	ENSG00000233590.1	RP11-153K11.3	6.78	3.46e-11	1.4e-08	0.42	0.29	Optic nerve measurement (disc area);	chr10:68270137	chr10:68233251~68242379:-
KIRC	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.46e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.46e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.46e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.46e-11	1.4e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
KIRC	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-6.78	3.46e-11	1.4e-08	-0.33	-0.29	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
KIRC	cis	rs4356975	0.509	rs4309908	ENSG00000250696.4	RP11-704M14.1	6.78	3.46e-11	1.41e-08	0.31	0.29	Obesity-related traits;	chr4:69086022	chr4:69182100~69216766:+
KIRC	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.46e-11	1.41e-08	-0.37	-0.29	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
KIRC	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.78	3.47e-11	1.41e-08	-0.44	-0.29	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
KIRC	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.78	3.47e-11	1.41e-08	-0.25	-0.29	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
KIRC	cis	rs4356975	0.509	rs6600884	ENSG00000250696.4	RP11-704M14.1	6.78	3.47e-11	1.41e-08	0.31	0.29	Obesity-related traits;	chr4:69102348	chr4:69182100~69216766:+
KIRC	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	6.78	3.47e-11	1.41e-08	0.28	0.29	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
KIRC	cis	rs4820539	1	rs5751589	ENSG00000221069.1	AC000029.1	6.78	3.48e-11	1.41e-08	0.36	0.29	Bone mineral density;	chr22:23133575	chr22:23136620~23136710:+
KIRC	cis	rs6480314	0.706	rs2394465	ENSG00000233590.1	RP11-153K11.3	6.78	3.48e-11	1.41e-08	0.35	0.29	Optic nerve measurement (disc area);	chr10:68224349	chr10:68233251~68242379:-
KIRC	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.49e-11	1.42e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
KIRC	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	6.78	3.49e-11	1.42e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
KIRC	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.49e-11	1.42e-08	-0.37	-0.29	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
KIRC	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	6.78	3.49e-11	1.42e-08	0.21	0.29	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	6.78	3.49e-11	1.42e-08	0.21	0.29	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
KIRC	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-6.78	3.5e-11	1.42e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
KIRC	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	6.78	3.5e-11	1.42e-08	0.43	0.29	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
KIRC	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-6.78	3.5e-11	1.42e-08	-0.31	-0.29	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
KIRC	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-6.78	3.5e-11	1.42e-08	-0.4	-0.29	Depression;	chr6:28229408	chr6:28115628~28116551:+
KIRC	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	6.78	3.5e-11	1.42e-08	0.41	0.29	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
KIRC	cis	rs17772222	0.63	rs12436642	ENSG00000222990.1	RNU4-22P	-6.78	3.51e-11	1.43e-08	-0.31	-0.29	Coronary artery calcification;	chr14:88559032	chr14:88513498~88513663:+
KIRC	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	6.78	3.51e-11	1.43e-08	0.34	0.29	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
KIRC	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-6.78	3.52e-11	1.43e-08	-0.24	-0.29	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
KIRC	cis	rs755249	0.567	rs16826069	ENSG00000182109.6	RP11-69E11.4	6.78	3.52e-11	1.43e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39522280~39546187:-
KIRC	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.53e-11	1.43e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.53e-11	1.43e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.53e-11	1.43e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.78	3.53e-11	1.43e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
KIRC	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	6.78	3.53e-11	1.43e-08	0.29	0.29	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
KIRC	cis	rs8048589	1	rs13336687	ENSG00000175604.2	RP11-276H1.3	-6.78	3.53e-11	1.43e-08	-0.34	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093208	chr16:12086746~12090302:-
KIRC	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-6.78	3.53e-11	1.43e-08	-0.34	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
KIRC	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-6.78	3.53e-11	1.43e-08	-0.36	-0.29	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
KIRC	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-6.78	3.53e-11	1.43e-08	-0.31	-0.29	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	6.78	3.53e-11	1.43e-08	0.3	0.29	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
KIRC	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.77	3.54e-11	1.44e-08	-0.25	-0.29	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
KIRC	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.77	3.54e-11	1.44e-08	-0.25	-0.29	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
KIRC	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	6.77	3.55e-11	1.44e-08	0.34	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
KIRC	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-6.77	3.55e-11	1.44e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
KIRC	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	6.77	3.55e-11	1.44e-08	0.27	0.29	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
KIRC	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	6.77	3.55e-11	1.44e-08	0.27	0.29	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
KIRC	cis	rs11657217	0.638	rs4313839	ENSG00000267719.1	HP09025	6.77	3.56e-11	1.45e-08	0.31	0.29	Diastolic blood pressure response to hydrochlorothiazide in hypertension;	chr17:79724849	chr17:79707266~79712317:+
KIRC	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	6.77	3.57e-11	1.45e-08	0.29	0.29	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
KIRC	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	6.77	3.57e-11	1.45e-08	0.4	0.29	Depression;	chr6:28317705	chr6:28943877~28944537:+
KIRC	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-6.77	3.57e-11	1.45e-08	-0.21	-0.29	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
KIRC	cis	rs62025270	0.632	rs74025655	ENSG00000202081.1	RNU6-1280P	-6.77	3.57e-11	1.45e-08	-0.35	-0.29	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85651522~85651628:-
KIRC	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	6.77	3.58e-11	1.45e-08	0.32	0.29	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	6.77	3.58e-11	1.45e-08	0.32	0.29	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	6.77	3.58e-11	1.45e-08	0.32	0.29	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	6.77	3.58e-11	1.45e-08	0.32	0.29	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
KIRC	cis	rs111580313	0.534	rs4843169	ENSG00000270020.1	RP11-463O9.9	6.77	3.58e-11	1.45e-08	0.44	0.29	Systemic juvenile idiopathic arthritis;	chr16:86576206	chr16:86520383~86523897:-
KIRC	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6.77	3.58e-11	1.45e-08	-0.37	-0.29	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
KIRC	cis	rs35934224	0.542	rs8139091	ENSG00000232926.1	AC000078.5	6.77	3.59e-11	1.45e-08	0.23	0.29	Glaucoma (primary open-angle);	chr22:19857760	chr22:19887289~19887970:+
KIRC	cis	rs1552244	0.572	rs17032440	ENSG00000180385.7	EMC3-AS1	-6.77	3.59e-11	1.45e-08	-0.32	-0.29	Alzheimer's disease;	chr3:10128135	chr3:9986893~10006990:+
KIRC	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	6.77	3.59e-11	1.45e-08	0.45	0.29	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
KIRC	cis	rs6452524	0.618	rs7723639	ENSG00000248112.1	RP11-78C3.1	6.77	3.59e-11	1.45e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82919376~82921119:-
KIRC	cis	rs6452524	0.618	rs2306336	ENSG00000248112.1	RP11-78C3.1	6.77	3.59e-11	1.45e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82919376~82921119:-
KIRC	cis	rs6452524	0.589	rs6882386	ENSG00000248112.1	RP11-78C3.1	6.77	3.59e-11	1.45e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82919376~82921119:-
KIRC	cis	rs6452524	0.618	rs6860752	ENSG00000248112.1	RP11-78C3.1	6.77	3.59e-11	1.45e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82919376~82921119:-
KIRC	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	6.77	3.59e-11	1.45e-08	0.33	0.29	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
KIRC	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-6.77	3.59e-11	1.45e-08	-0.33	-0.29	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
KIRC	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-6.77	3.59e-11	1.45e-08	-0.33	-0.29	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
KIRC	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-6.77	3.59e-11	1.45e-08	-0.33	-0.29	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
KIRC	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-6.77	3.59e-11	1.45e-08	-0.33	-0.29	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
KIRC	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-6.77	3.59e-11	1.46e-08	-0.31	-0.29	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
KIRC	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-6.77	3.59e-11	1.46e-08	-0.31	-0.29	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
KIRC	cis	rs7017914	0.652	rs35380538	ENSG00000254031.4	RP11-326E22.1	6.77	3.59e-11	1.46e-08	0.34	0.29	Bone mineral density;	chr8:70845432	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs10957532	ENSG00000254031.4	RP11-326E22.1	6.77	3.59e-11	1.46e-08	0.34	0.29	Bone mineral density;	chr8:70845775	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs62510667	ENSG00000254031.4	RP11-326E22.1	6.77	3.59e-11	1.46e-08	0.34	0.29	Bone mineral density;	chr8:70850458	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.69	rs13274981	ENSG00000254031.4	RP11-326E22.1	6.77	3.59e-11	1.46e-08	0.34	0.29	Bone mineral density;	chr8:70853045	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6985251	ENSG00000254031.4	RP11-326E22.1	6.77	3.59e-11	1.46e-08	0.34	0.29	Bone mineral density;	chr8:70853620	chr8:71155457~71204223:+
KIRC	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	6.77	3.6e-11	1.46e-08	0.44	0.29	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
KIRC	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-6.77	3.6e-11	1.46e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-6.77	3.6e-11	1.46e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
KIRC	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	6.77	3.6e-11	1.46e-08	0.26	0.29	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
KIRC	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-6.77	3.61e-11	1.46e-08	-0.31	-0.29	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
KIRC	cis	rs4072705	0.967	rs4076333	ENSG00000224020.1	MIR181A2HG	-6.77	3.62e-11	1.46e-08	-0.3	-0.29	Menarche (age at onset);	chr9:124623330	chr9:124658467~124698631:+
KIRC	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-6.77	3.62e-11	1.47e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-6.77	3.62e-11	1.47e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-6.77	3.62e-11	1.47e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
KIRC	cis	rs9915657	0.84	rs10512582	ENSG00000234899.8	SOX9-AS1	-6.77	3.62e-11	1.47e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72143252	chr17:72034107~72237203:-
KIRC	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	6.77	3.62e-11	1.47e-08	0.28	0.29	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
KIRC	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-6.77	3.63e-11	1.47e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
KIRC	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	6.77	3.63e-11	1.47e-08	0.23	0.29	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
KIRC	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-6.77	3.63e-11	1.47e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-6.77	3.63e-11	1.47e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
KIRC	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-6.77	3.63e-11	1.47e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
KIRC	cis	rs2018683	0.711	rs1874977	ENSG00000228421.2	AC005013.5	6.77	3.64e-11	1.47e-08	0.3	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928466	chr7:28957667~28959345:+
KIRC	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	6.77	3.64e-11	1.47e-08	0.29	0.29	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
KIRC	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	6.77	3.65e-11	1.48e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
KIRC	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-6.77	3.65e-11	1.48e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
KIRC	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.77	3.65e-11	1.48e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
KIRC	cis	rs1865760	0.519	rs2275904	ENSG00000272462.2	U91328.19	-6.77	3.65e-11	1.48e-08	-0.26	-0.29	Height;	chr6:25767857	chr6:25992662~26001775:+
KIRC	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6.77	3.66e-11	1.48e-08	-0.32	-0.29	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6.77	3.66e-11	1.48e-08	-0.32	-0.29	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
KIRC	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	6.77	3.66e-11	1.48e-08	0.29	0.29	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
KIRC	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	6.77	3.66e-11	1.48e-08	0.28	0.29	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	6.77	3.66e-11	1.48e-08	0.28	0.29	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
KIRC	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	6.77	3.66e-11	1.48e-08	0.36	0.29	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
KIRC	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	6.77	3.66e-11	1.48e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
KIRC	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-6.77	3.66e-11	1.48e-08	-0.34	-0.29	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
KIRC	cis	rs7924176	0.54	rs61866073	ENSG00000213731.2	RAB5CP1	-6.77	3.66e-11	1.48e-08	-0.29	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74423435~74424014:-
KIRC	cis	rs643506	0.874	rs648544	ENSG00000230911.1	PPIHP1	-6.77	3.67e-11	1.48e-08	-0.34	-0.29	Breast cancer;	chr11:111795404	chr11:112029858~112030367:-
KIRC	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-6.77	3.67e-11	1.48e-08	-0.34	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
KIRC	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-6.77	3.67e-11	1.49e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
KIRC	cis	rs6452524	0.618	rs255561	ENSG00000248112.1	RP11-78C3.1	6.77	3.68e-11	1.49e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82919376~82921119:-
KIRC	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	6.77	3.68e-11	1.49e-08	0.39	0.29	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
KIRC	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-6.77	3.68e-11	1.49e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
KIRC	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-6.77	3.69e-11	1.49e-08	-0.36	-0.29	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
KIRC	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-6.77	3.7e-11	1.5e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
KIRC	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-6.77	3.71e-11	1.5e-08	-0.28	-0.29	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
KIRC	cis	rs4578769	0.589	rs9964726	ENSG00000266850.1	RP11-370A5.1	6.77	3.71e-11	1.5e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22925516	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs9958831	ENSG00000266850.1	RP11-370A5.1	6.77	3.71e-11	1.5e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22926050	chr18:22723491~22907721:-
KIRC	cis	rs17772222	0.696	rs28666030	ENSG00000222990.1	RNU4-22P	6.77	3.72e-11	1.5e-08	0.33	0.29	Coronary artery calcification;	chr14:88511463	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs28493481	ENSG00000222990.1	RNU4-22P	6.77	3.72e-11	1.5e-08	0.33	0.29	Coronary artery calcification;	chr14:88511491	chr14:88513498~88513663:+
KIRC	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	6.77	3.72e-11	1.5e-08	0.31	0.29	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
KIRC	cis	rs9900062	0.844	rs9908143	ENSG00000270714.1	MINOS1P2	-6.77	3.72e-11	1.51e-08	-0.43	-0.29	QT interval;	chr17:64758468	chr17:64747264~64747492:-
KIRC	cis	rs9915657	0.773	rs9912974	ENSG00000234899.8	SOX9-AS1	-6.77	3.73e-11	1.51e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72099822	chr17:72034107~72237203:-
KIRC	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	6.77	3.73e-11	1.51e-08	0.36	0.29	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
KIRC	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	6.77	3.74e-11	1.51e-08	0.31	0.29	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
KIRC	cis	rs3820928	0.839	rs12470666	ENSG00000212391.1	SNORA48	-6.77	3.75e-11	1.51e-08	-0.36	-0.29	Pulmonary function;	chr2:227011809	chr2:226968989~226969122:-
KIRC	cis	rs4072705	0.967	rs4590537	ENSG00000224020.1	MIR181A2HG	-6.77	3.75e-11	1.52e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124573475	chr9:124658467~124698631:+
KIRC	cis	rs17801127	0.818	rs73003921	ENSG00000231969.1	AC144449.1	6.77	3.75e-11	1.52e-08	0.55	0.29	Liver enzyme levels (alanine transaminase);	chr2:149844297	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs9679510	ENSG00000231969.1	AC144449.1	6.77	3.75e-11	1.52e-08	0.55	0.29	Liver enzyme levels (alanine transaminase);	chr2:149844964	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs35875583	ENSG00000231969.1	AC144449.1	6.77	3.75e-11	1.52e-08	0.55	0.29	Liver enzyme levels (alanine transaminase);	chr2:149845854	chr2:149587196~149848233:+
KIRC	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.77	3.76e-11	1.52e-08	-0.38	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
KIRC	cis	rs7674212	0.531	rs4698876	ENSG00000230069.3	LRRC37A15P	-6.77	3.76e-11	1.52e-08	-0.31	-0.29	Type 2 diabetes;	chr4:103012410	chr4:102727274~102730721:-
KIRC	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	6.77	3.76e-11	1.52e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
KIRC	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-6.77	3.77e-11	1.52e-08	-0.41	-0.29	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
KIRC	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-6.76	3.78e-11	1.53e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
KIRC	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-6.76	3.78e-11	1.53e-08	-0.26	-0.29	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
KIRC	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-6.76	3.78e-11	1.53e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
KIRC	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	6.76	3.78e-11	1.53e-08	0.49	0.29	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
KIRC	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-6.76	3.79e-11	1.53e-08	-0.31	-0.29	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.83	rs4481286	ENSG00000196472.4	RP13-644M16.4	6.76	3.8e-11	1.53e-08	0.33	0.29	Obesity-related traits;	chr4:69056631	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs4583828	ENSG00000196472.4	RP13-644M16.4	6.76	3.8e-11	1.53e-08	0.33	0.29	Obesity-related traits;	chr4:69056669	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs4235113	ENSG00000196472.4	RP13-644M16.4	6.76	3.8e-11	1.53e-08	0.33	0.29	Obesity-related traits;	chr4:69056739	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs4235114	ENSG00000196472.4	RP13-644M16.4	6.76	3.8e-11	1.53e-08	0.33	0.29	Obesity-related traits;	chr4:69056953	chr4:69181660~69182372:+
KIRC	cis	rs9601248	0.756	rs7997134	ENSG00000227354.5	RBM26-AS1	-6.76	3.8e-11	1.53e-08	-0.33	-0.29	Major depressive disorder;	chr13:79619594	chr13:79406309~79424328:+
KIRC	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-6.76	3.81e-11	1.54e-08	-0.31	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
KIRC	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-6.76	3.83e-11	1.54e-08	-0.39	-0.29	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
KIRC	cis	rs919433	0.647	rs1979239	ENSG00000231621.1	AC013264.2	-6.76	3.83e-11	1.54e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197633592	chr2:197197991~197199273:+
KIRC	cis	rs4578769	0.55	rs8092358	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22911835	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs1379805	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22914589	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs1031652	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22916035	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs9967326	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22916787	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs9946660	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22917007	chr18:22723491~22907721:-
KIRC	cis	rs12962334	0.568	rs2034932	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Breast cancer;	chr18:22918727	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.55	rs721578	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22922719	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.569	rs7229422	ENSG00000266850.1	RP11-370A5.1	6.76	3.84e-11	1.55e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22923157	chr18:22723491~22907721:-
KIRC	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	6.76	3.84e-11	1.55e-08	0.3	0.29	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
KIRC	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-6.76	3.85e-11	1.55e-08	-0.36	-0.29	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
KIRC	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-6.76	3.85e-11	1.55e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
KIRC	cis	rs3820928	0.935	rs113195824	ENSG00000212391.1	SNORA48	-6.76	3.85e-11	1.55e-08	-0.34	-0.29	Pulmonary function;	chr2:226904423	chr2:226968989~226969122:-
KIRC	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-6.76	3.85e-11	1.55e-08	-0.36	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
KIRC	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-6.76	3.85e-11	1.55e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
KIRC	cis	rs7017914	0.652	rs12681420	ENSG00000254031.4	RP11-326E22.1	6.76	3.86e-11	1.56e-08	0.34	0.29	Bone mineral density;	chr8:70680963	chr8:71155457~71204223:+
KIRC	cis	rs4356975	0.541	rs6600892	ENSG00000250919.1	RP11-813N20.3	-6.76	3.88e-11	1.56e-08	-0.37	-0.29	Obesity-related traits;	chr4:69107521	chr4:69027831~69044578:+
KIRC	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	6.76	3.88e-11	1.56e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
KIRC	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	6.76	3.88e-11	1.56e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
KIRC	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	6.76	3.88e-11	1.56e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
KIRC	cis	rs4356975	0.563	rs4554144	ENSG00000196472.4	RP13-644M16.4	6.76	3.88e-11	1.56e-08	0.33	0.29	Obesity-related traits;	chr4:69094837	chr4:69181660~69182372:+
KIRC	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	6.76	3.88e-11	1.57e-08	0.42	0.29	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
KIRC	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-6.76	3.89e-11	1.57e-08	-0.19	-0.29	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
KIRC	cis	rs2281636	0.754	rs4919364	ENSG00000233690.1	EBAG9P1	6.76	3.89e-11	1.57e-08	0.28	0.29	Obesity-related traits;	chr10:99604947	chr10:99697407~99697949:-
KIRC	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
KIRC	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	6.76	3.89e-11	1.57e-08	0.43	0.29	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
KIRC	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-6.76	3.91e-11	1.57e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-6.76	3.91e-11	1.57e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
KIRC	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-6.76	3.91e-11	1.57e-08	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
KIRC	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-6.76	3.91e-11	1.57e-08	-0.23	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
KIRC	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	6.76	3.91e-11	1.58e-08	0.32	0.29	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
KIRC	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-6.76	3.91e-11	1.58e-08	-0.21	-0.29	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
KIRC	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-6.76	3.92e-11	1.58e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
KIRC	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-6.76	3.92e-11	1.58e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
KIRC	cis	rs12922317	0.556	rs11648938	ENSG00000260488.1	RP11-166B2.7	6.76	3.92e-11	1.58e-08	0.28	0.29	Schizophrenia;	chr16:12000292	chr16:11976851~11977850:-
KIRC	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	6.76	3.92e-11	1.58e-08	0.34	0.29	Depression;	chr6:28096077	chr6:28073316~28074233:+
KIRC	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	6.76	3.93e-11	1.58e-08	0.43	0.29	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
KIRC	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6.76	3.93e-11	1.58e-08	-0.31	-0.29	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
KIRC	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	6.76	3.94e-11	1.58e-08	0.35	0.29	Height;	chr11:118859432	chr11:118688039~118690600:-
KIRC	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-6.76	3.94e-11	1.58e-08	-0.54	-0.29	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
KIRC	cis	rs11168351	0.927	rs11168342	ENSG00000240399.1	RP1-228P16.1	6.76	3.94e-11	1.59e-08	0.25	0.29	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48054813~48055591:-
KIRC	cis	rs72772090	0.539	rs11742261	ENSG00000248734.2	CTD-2260A17.1	-6.76	3.95e-11	1.59e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96831905	chr5:96784777~96785999:+
KIRC	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	6.76	3.95e-11	1.59e-08	0.28	0.29	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
KIRC	cis	rs6480314	0.542	rs1007848	ENSG00000233590.1	RP11-153K11.3	-6.76	3.96e-11	1.59e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68258549	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs61854807	ENSG00000233590.1	RP11-153K11.3	-6.76	3.96e-11	1.59e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68258948	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.616	rs12571093	ENSG00000233590.1	RP11-153K11.3	-6.76	3.96e-11	1.59e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68259614	chr10:68233251~68242379:-
KIRC	cis	rs293748	0.882	rs34525350	ENSG00000250155.1	CTD-2353F22.1	-6.76	3.96e-11	1.59e-08	-0.42	-0.29	Obesity-related traits;	chr5:37089535	chr5:36666214~36725195:-
KIRC	cis	rs4888671	1	rs78623713	ENSG00000261707.1	RP11-264M12.2	6.76	3.97e-11	1.6e-08	0.44	0.29	Obesity-related traits;	chr16:77748842	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs59045389	ENSG00000261707.1	RP11-264M12.2	6.76	3.97e-11	1.6e-08	0.44	0.29	Obesity-related traits;	chr16:77748966	chr16:77741468~77743000:-
KIRC	cis	rs3745672	1	rs60697554	ENSG00000219665.7	CTD-2006C1.2	-6.76	3.98e-11	1.6e-08	-0.55	-0.29	Multiple sclerosis;	chr19:11946944	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs58336952	ENSG00000219665.7	CTD-2006C1.2	-6.76	3.98e-11	1.6e-08	-0.55	-0.29	Multiple sclerosis;	chr19:11947101	chr19:11987617~12046275:+
KIRC	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-6.76	3.99e-11	1.6e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
KIRC	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	6.76	3.99e-11	1.6e-08	0.29	0.29	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
KIRC	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-6.76	3.99e-11	1.6e-08	-0.31	-0.29	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
KIRC	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	6.76	3.99e-11	1.61e-08	0.68	0.29	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
KIRC	cis	rs6480314	0.542	rs61854811	ENSG00000233590.1	RP11-153K11.3	-6.76	3.99e-11	1.61e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68264474	chr10:68233251~68242379:-
KIRC	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	6.76	4e-11	1.61e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
KIRC	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	6.76	4e-11	1.61e-08	0.4	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
KIRC	cis	rs7647973	0.58	rs11130184	ENSG00000225399.4	RP11-3B7.1	6.76	4e-11	1.61e-08	0.31	0.29	Menarche (age at onset);	chr3:49192497	chr3:49260085~49261316:+
KIRC	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	6.76	4e-11	1.61e-08	0.55	0.29	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	6.76	4e-11	1.61e-08	0.55	0.29	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	6.76	4e-11	1.61e-08	0.55	0.29	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	6.76	4e-11	1.61e-08	0.55	0.29	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	6.76	4e-11	1.61e-08	0.55	0.29	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
KIRC	cis	rs11085466	0.519	rs12150872	ENSG00000268555.1	RP11-678G14.3	6.76	4.01e-11	1.61e-08	0.37	0.29	Colorectal or endometrial cancer;	chr19:21610708	chr19:21570822~21587322:-
KIRC	cis	rs919433	0.679	rs10497806	ENSG00000231621.1	AC013264.2	-6.76	4.01e-11	1.61e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197644227	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.679	rs10166328	ENSG00000231621.1	AC013264.2	-6.76	4.01e-11	1.61e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197647193	chr2:197197991~197199273:+
KIRC	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	6.76	4.01e-11	1.61e-08	0.29	0.29	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
KIRC	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-6.76	4.02e-11	1.61e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
KIRC	cis	rs890448	0.796	rs2471673	ENSG00000254531.1	FLJ20021	6.76	4.02e-11	1.62e-08	0.29	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101432430	chr4:101347780~101348883:+
KIRC	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	6.75	4.02e-11	1.62e-08	0.29	0.29	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
KIRC	cis	rs3750965	1	rs7937006	ENSG00000260895.1	RP11-554A11.7	6.75	4.03e-11	1.62e-08	0.36	0.29	Hair color;	chr11:69076464	chr11:69103493~69109094:+
KIRC	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	6.75	4.03e-11	1.62e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	6.75	4.03e-11	1.62e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
KIRC	cis	rs9807989	0.801	rs4851566	ENSG00000234389.1	AC007278.3	6.75	4.03e-11	1.62e-08	0.28	0.29	Asthma;	chr2:102356339	chr2:102438713~102440475:+
KIRC	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-6.75	4.04e-11	1.62e-08	-0.25	-0.29	Height;	chr2:46636733	chr2:46668870~46670778:+
KIRC	cis	rs7923609	0.54	rs10733789	ENSG00000232075.1	MRPL35P2	6.75	4.04e-11	1.62e-08	0.32	0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63188924	chr10:63634317~63634827:-
KIRC	cis	rs17711722	0.503	rs453835	ENSG00000275400.1	RP4-756H11.5	6.75	4.05e-11	1.63e-08	0.3	0.29	Calcium levels;	chr7:66046172	chr7:66553805~66554199:-
KIRC	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	6.75	4.05e-11	1.63e-08	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
KIRC	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	6.75	4.05e-11	1.63e-08	0.32	0.29	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
KIRC	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	6.75	4.05e-11	1.63e-08	0.3	0.29	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
KIRC	cis	rs7017914	0.69	rs13261146	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70814684	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13263047	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70815061	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs62508827	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70815820	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs62508828	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70815974	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs56108781	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70816519	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs34751830	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70818239	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35318824	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70820387	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13281838	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70822207	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1822651	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70824426	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6982838	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70830504	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1457198	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70834934	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35921782	ENSG00000254031.4	RP11-326E22.1	6.75	4.06e-11	1.63e-08	0.34	0.29	Bone mineral density;	chr8:70836689	chr8:71155457~71204223:+
KIRC	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	6.75	4.06e-11	1.63e-08	0.4	0.29	Depression;	chr6:28226851	chr6:28176188~28176674:+
KIRC	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-6.75	4.06e-11	1.63e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-6.75	4.06e-11	1.63e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-6.75	4.06e-11	1.63e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
KIRC	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-6.75	4.06e-11	1.63e-08	-0.43	-0.29	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
KIRC	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-6.75	4.06e-11	1.63e-08	-0.43	-0.29	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
KIRC	cis	rs3760982	0.52	rs425578	ENSG00000267058.1	RP11-15A1.3	6.75	4.07e-11	1.63e-08	0.33	0.29	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43798104	chr19:43891804~43901805:-
KIRC	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	6.75	4.07e-11	1.63e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	6.75	4.07e-11	1.63e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	6.75	4.07e-11	1.63e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	6.75	4.07e-11	1.63e-08	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
KIRC	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	6.75	4.07e-11	1.64e-08	0.33	0.29	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
KIRC	cis	rs6480314	0.542	rs4592311	ENSG00000233590.1	RP11-153K11.3	-6.75	4.07e-11	1.64e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68268492	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs79081413	ENSG00000233590.1	RP11-153K11.3	-6.75	4.07e-11	1.64e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68268746	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs61854816	ENSG00000233590.1	RP11-153K11.3	-6.75	4.07e-11	1.64e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68269051	chr10:68233251~68242379:-
KIRC	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-6.75	4.07e-11	1.64e-08	-0.25	-0.29	Height;	chr2:46635327	chr2:46668870~46670778:+
KIRC	cis	rs755249	0.958	rs17264866	ENSG00000237624.1	OXCT2P1	6.75	4.08e-11	1.64e-08	0.42	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39514956~39516490:+
KIRC	cis	rs3820928	0.874	rs1054413	ENSG00000212391.1	SNORA48	6.75	4.08e-11	1.64e-08	0.34	0.29	Pulmonary function;	chr2:227003003	chr2:226968989~226969122:-
KIRC	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-6.75	4.08e-11	1.64e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
KIRC	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	6.75	4.08e-11	1.64e-08	0.29	0.29	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
KIRC	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-6.75	4.08e-11	1.64e-08	-0.34	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
KIRC	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	6.75	4.09e-11	1.64e-08	0.33	0.29	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
KIRC	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	6.75	4.09e-11	1.64e-08	0.33	0.29	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
KIRC	cis	rs11976180	0.569	rs12703565	ENSG00000228960.5	OR2A9P	-6.75	4.09e-11	1.64e-08	-0.51	-0.29	Obesity-related traits;	chr7:144057308	chr7:144294480~144300934:+
KIRC	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	6.75	4.09e-11	1.64e-08	0.28	0.29	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
KIRC	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-6.75	4.09e-11	1.64e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
KIRC	cis	rs4888671	1	rs17716789	ENSG00000261707.1	RP11-264M12.2	6.75	4.09e-11	1.64e-08	0.45	0.29	Obesity-related traits;	chr16:77735782	chr16:77741468~77743000:-
KIRC	cis	rs6456156	0.792	rs10946212	ENSG00000265828.1	MIR3939	-6.75	4.1e-11	1.64e-08	-0.33	-0.29	Primary biliary cholangitis;	chr6:167102459	chr6:166997807~166997912:-
KIRC	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-6.75	4.1e-11	1.65e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-6.75	4.1e-11	1.65e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
KIRC	cis	rs12049351	0.774	rs12033236	ENSG00000229367.1	HMGN2P19	6.75	4.1e-11	1.65e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229504724	chr1:229570532~229570796:+
KIRC	cis	rs3820928	0.935	rs10203363	ENSG00000212391.1	SNORA48	-6.75	4.1e-11	1.65e-08	-0.33	-0.29	Pulmonary function;	chr2:227032260	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.775	rs10179756	ENSG00000212391.1	SNORA48	-6.75	4.1e-11	1.65e-08	-0.33	-0.29	Pulmonary function;	chr2:227032360	chr2:226968989~226969122:-
KIRC	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	6.75	4.1e-11	1.65e-08	0.33	0.29	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
KIRC	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-6.75	4.11e-11	1.65e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
KIRC	cis	rs7267979	0.932	rs1985737	ENSG00000125804.12	FAM182A	-6.75	4.11e-11	1.65e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:26054655~26086917:+
KIRC	cis	rs4888671	1	rs4888668	ENSG00000261707.1	RP11-264M12.2	6.75	4.11e-11	1.65e-08	0.44	0.29	Obesity-related traits;	chr16:77745584	chr16:77741468~77743000:-
KIRC	cis	rs4888671	0.901	rs78916165	ENSG00000261707.1	RP11-264M12.2	6.75	4.11e-11	1.65e-08	0.44	0.29	Obesity-related traits;	chr16:77746056	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs59945106	ENSG00000261707.1	RP11-264M12.2	6.75	4.11e-11	1.65e-08	0.44	0.29	Obesity-related traits;	chr16:77746257	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs61402842	ENSG00000261707.1	RP11-264M12.2	6.75	4.11e-11	1.65e-08	0.44	0.29	Obesity-related traits;	chr16:77746501	chr16:77741468~77743000:-
KIRC	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	6.75	4.12e-11	1.65e-08	0.38	0.29	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
KIRC	cis	rs11148252	0.967	rs11618716	ENSG00000278238.1	RP11-245D16.4	6.75	4.12e-11	1.65e-08	0.32	0.29	Lewy body disease;	chr13:52472701	chr13:52454775~52455331:-
KIRC	cis	rs4356975	0.563	rs7438135	ENSG00000196472.4	RP13-644M16.4	6.75	4.13e-11	1.66e-08	0.33	0.29	Obesity-related traits;	chr4:69095621	chr4:69181660~69182372:+
KIRC	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-6.75	4.13e-11	1.66e-08	-0.38	-0.29	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
KIRC	cis	rs919433	0.726	rs11904247	ENSG00000231621.1	AC013264.2	-6.75	4.13e-11	1.66e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373700	chr2:197197991~197199273:+
KIRC	cis	rs4820539	0.966	rs5751590	ENSG00000221069.1	AC000029.1	-6.75	4.13e-11	1.66e-08	-0.36	-0.29	Bone mineral density;	chr22:23144643	chr22:23136620~23136710:+
KIRC	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	6.75	4.13e-11	1.66e-08	0.4	0.29	Depression;	chr6:28229408	chr6:28176188~28176674:+
KIRC	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	6.75	4.14e-11	1.66e-08	0.35	0.29	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
KIRC	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	6.75	4.14e-11	1.66e-08	0.34	0.29	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
KIRC	cis	rs4578769	0.531	rs12964304	ENSG00000266850.1	RP11-370A5.1	6.75	4.14e-11	1.66e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22928641	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.531	rs12968784	ENSG00000266850.1	RP11-370A5.1	6.75	4.14e-11	1.66e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22928645	chr18:22723491~22907721:-
KIRC	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-6.75	4.15e-11	1.66e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
KIRC	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-6.75	4.15e-11	1.66e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
KIRC	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	6.75	4.15e-11	1.66e-08	0.38	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
KIRC	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-6.75	4.16e-11	1.67e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-6.75	4.16e-11	1.67e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-6.75	4.16e-11	1.67e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-6.75	4.16e-11	1.67e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-6.75	4.16e-11	1.67e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
KIRC	cis	rs9371601	0.859	rs1203233	ENSG00000226193.1	RP3-398G3.5	6.75	4.16e-11	1.67e-08	0.31	0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393471	chr6:152402398~152404966:+
KIRC	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-6.75	4.16e-11	1.67e-08	-0.38	-0.29	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
KIRC	cis	rs4072705	0.904	rs721863	ENSG00000224020.1	MIR181A2HG	-6.75	4.16e-11	1.67e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124773988	chr9:124658467~124698631:+
KIRC	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	6.75	4.16e-11	1.67e-08	0.3	0.29	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	6.75	4.16e-11	1.67e-08	0.3	0.29	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	6.75	4.16e-11	1.67e-08	0.3	0.29	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	6.75	4.16e-11	1.67e-08	0.3	0.29	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
KIRC	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-6.75	4.16e-11	1.67e-08	-0.26	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
KIRC	cis	rs3820928	0.874	rs3769646	ENSG00000212391.1	SNORA48	-6.75	4.16e-11	1.67e-08	-0.33	-0.29	Pulmonary function;	chr2:227031614	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs2229812	ENSG00000212391.1	SNORA48	-6.75	4.17e-11	1.67e-08	-0.33	-0.29	Pulmonary function;	chr2:227032170	chr2:226968989~226969122:-
KIRC	cis	rs755249	0.567	rs16826093	ENSG00000237624.1	OXCT2P1	6.75	4.17e-11	1.67e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs17264671	ENSG00000237624.1	OXCT2P1	6.75	4.17e-11	1.67e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs4660690	ENSG00000237624.1	OXCT2P1	6.75	4.17e-11	1.67e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39514956~39516490:+
KIRC	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-6.75	4.17e-11	1.67e-08	-0.26	-0.29	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
KIRC	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-6.75	4.17e-11	1.67e-08	-0.26	-0.29	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
KIRC	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-6.75	4.17e-11	1.67e-08	-0.26	-0.29	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
KIRC	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-6.75	4.17e-11	1.67e-08	-0.26	-0.29	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
KIRC	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-6.75	4.17e-11	1.67e-08	-0.26	-0.29	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
KIRC	cis	rs643506	0.845	rs2850245	ENSG00000230911.1	PPIHP1	-6.75	4.17e-11	1.67e-08	-0.34	-0.29	Breast cancer;	chr11:111890014	chr11:112029858~112030367:-
KIRC	cis	rs6908034	0.607	rs80355837	ENSG00000228412.5	RP4-625H18.2	6.75	4.18e-11	1.67e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19802164~19804752:-
KIRC	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-6.75	4.18e-11	1.67e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-6.75	4.18e-11	1.67e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
KIRC	cis	rs7212590	0.655	rs34687426	ENSG00000263422.1	AC005702.1	6.75	4.18e-11	1.68e-08	0.53	0.29	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59920496	chr17:60042361~60042442:-
KIRC	cis	rs4356975	0.563	rs6600878	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69092618	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.583	rs6819757	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69092946	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs57216626	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69093105	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs59415892	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69093191	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs62296942	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69093401	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7437039	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69093758	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7439792	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69093881	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs62296944	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69094492	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600879	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69094669	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600880	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69094762	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4538548	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69094951	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600883	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69094953	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4455491	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69095215	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs11940220	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69095222	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs11940316	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69095409	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7668258	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69096360	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs12647681	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69097442	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs12647682	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69097450	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs58544196	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69097740	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7439326	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69098462	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7438244	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69098491	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7441750	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69098803	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7441774	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69098836	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs7434332	ENSG00000196472.4	RP13-644M16.4	6.75	4.18e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69099141	chr4:69181660~69182372:+
KIRC	cis	rs919433	0.679	rs7564924	ENSG00000231621.1	AC013264.2	-6.75	4.18e-11	1.68e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197649153	chr2:197197991~197199273:+
KIRC	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	6.75	4.19e-11	1.68e-08	0.39	0.29	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
KIRC	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	6.75	4.19e-11	1.68e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
KIRC	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	6.75	4.19e-11	1.68e-08	0.29	0.29	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
KIRC	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	6.75	4.19e-11	1.68e-08	0.38	0.29	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
KIRC	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-6.75	4.19e-11	1.68e-08	-0.3	-0.29	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
KIRC	cis	rs6456156	0.792	rs2039321	ENSG00000265828.1	MIR3939	-6.75	4.2e-11	1.68e-08	-0.33	-0.29	Primary biliary cholangitis;	chr6:167102811	chr6:166997807~166997912:-
KIRC	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	6.75	4.2e-11	1.68e-08	0.21	0.29	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
KIRC	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-6.75	4.2e-11	1.68e-08	-0.31	-0.29	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
KIRC	cis	rs4356975	0.563	rs7676472	ENSG00000196472.4	RP13-644M16.4	6.75	4.21e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69090226	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7663584	ENSG00000196472.4	RP13-644M16.4	6.75	4.21e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69090392	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600876	ENSG00000196472.4	RP13-644M16.4	6.75	4.21e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69091212	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.583	rs6600877	ENSG00000196472.4	RP13-644M16.4	6.75	4.21e-11	1.68e-08	0.33	0.29	Obesity-related traits;	chr4:69091505	chr4:69181660~69182372:+
KIRC	cis	rs6480314	0.542	rs10998045	ENSG00000233590.1	RP11-153K11.3	-6.75	4.21e-11	1.69e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68269626	chr10:68233251~68242379:-
KIRC	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	6.75	4.22e-11	1.69e-08	0.42	0.29	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
KIRC	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.75	4.22e-11	1.69e-08	-0.25	-0.29	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
KIRC	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-6.75	4.23e-11	1.69e-08	-0.44	-0.29	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
KIRC	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-6.75	4.23e-11	1.69e-08	-0.31	-0.29	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
KIRC	cis	rs7017914	0.617	rs34917985	ENSG00000254031.4	RP11-326E22.1	6.75	4.23e-11	1.69e-08	0.33	0.29	Bone mineral density;	chr8:70662426	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6993326	ENSG00000254031.4	RP11-326E22.1	6.75	4.23e-11	1.69e-08	0.33	0.29	Bone mineral density;	chr8:70663365	chr8:71155457~71204223:+
KIRC	cis	rs4356975	0.509	rs6422323	ENSG00000250696.4	RP11-704M14.1	6.75	4.23e-11	1.69e-08	0.31	0.29	Obesity-related traits;	chr4:69087362	chr4:69182100~69216766:+
KIRC	cis	rs4888671	1	rs76315659	ENSG00000261707.1	RP11-264M12.2	6.75	4.23e-11	1.69e-08	0.45	0.29	Obesity-related traits;	chr16:77747753	chr16:77741468~77743000:-
KIRC	cis	rs2337406	1	rs61268362	ENSG00000274576.2	IGHV2-70	-6.75	4.23e-11	1.69e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106697010	chr14:106770577~106771020:-
KIRC	cis	rs2337406	0.85	rs8014460	ENSG00000274576.2	IGHV2-70	-6.75	4.23e-11	1.69e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106697140	chr14:106770577~106771020:-
KIRC	cis	rs1153858	1	rs1153849	ENSG00000235390.4	CTD-2651B20.5	-6.75	4.24e-11	1.7e-08	-0.28	-0.29	Homoarginine levels;	chr15:45403497	chr15:45321077~45321692:-
KIRC	cis	rs375066	0.592	rs10401203	ENSG00000267058.1	RP11-15A1.3	6.75	4.24e-11	1.7e-08	0.33	0.29	Breast cancer;	chr19:43795514	chr19:43891804~43901805:-
KIRC	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	6.75	4.24e-11	1.7e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	6.75	4.24e-11	1.7e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
KIRC	cis	rs17801127	0.748	rs71413665	ENSG00000231969.1	AC144449.1	6.75	4.24e-11	1.7e-08	0.58	0.29	Liver enzyme levels (alanine transaminase);	chr2:149827099	chr2:149587196~149848233:+
KIRC	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.75	4.25e-11	1.7e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
KIRC	cis	rs7017914	0.628	rs2380691	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70872942	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6998354	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70873934	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.644	rs12156377	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70875457	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1908032	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70876735	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs7003788	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70876889	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs13272343	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70882272	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6984618	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70883334	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.69	rs12675094	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70884968	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs12675116	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70885056	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13252230	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70886081	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6996049	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70887771	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.629	rs35762981	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70889405	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13271286	ENSG00000254031.4	RP11-326E22.1	6.75	4.25e-11	1.7e-08	0.33	0.29	Bone mineral density;	chr8:70894364	chr8:71155457~71204223:+
KIRC	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-6.75	4.25e-11	1.7e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
KIRC	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	6.75	4.26e-11	1.7e-08	0.38	0.29	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
KIRC	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	6.75	4.26e-11	1.7e-08	0.21	0.29	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
KIRC	cis	rs2337406	0.706	rs74090742	ENSG00000274576.2	IGHV2-70	-6.75	4.26e-11	1.7e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106696601	chr14:106770577~106771020:-
KIRC	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-6.75	4.28e-11	1.71e-08	-0.31	-0.29	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-6.75	4.28e-11	1.71e-08	-0.31	-0.29	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
KIRC	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	6.75	4.28e-11	1.71e-08	0.34	0.29	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
KIRC	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-6.74	4.3e-11	1.72e-08	-0.44	-0.29	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
KIRC	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	6.74	4.3e-11	1.72e-08	0.28	0.29	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	6.74	4.3e-11	1.72e-08	0.28	0.29	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
KIRC	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.74	4.3e-11	1.72e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.74	4.3e-11	1.72e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
KIRC	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-6.74	4.31e-11	1.72e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
KIRC	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-6.74	4.32e-11	1.73e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
KIRC	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	6.74	4.32e-11	1.73e-08	0.3	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
KIRC	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
KIRC	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-6.74	4.32e-11	1.73e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
KIRC	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	6.74	4.32e-11	1.73e-08	0.6	0.29	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
KIRC	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	6.74	4.33e-11	1.73e-08	0.39	0.29	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
KIRC	cis	rs11647589	0.641	rs9922446	ENSG00000260762.1	ACSM5P1	6.74	4.34e-11	1.73e-08	0.29	0.29	Blood metabolite levels;	chr16:20470093	chr16:20586550~20607107:-
KIRC	cis	rs6456156	0.792	rs10946214	ENSG00000265828.1	MIR3939	-6.74	4.34e-11	1.73e-08	-0.33	-0.29	Primary biliary cholangitis;	chr6:167102634	chr6:166997807~166997912:-
KIRC	cis	rs7017914	0.653	rs13273718	ENSG00000254031.4	RP11-326E22.1	6.74	4.35e-11	1.74e-08	0.34	0.29	Bone mineral density;	chr8:70757485	chr8:71155457~71204223:+
KIRC	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6.74	4.35e-11	1.74e-08	0.32	0.29	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
KIRC	cis	rs375066	0.592	rs349046	ENSG00000267058.1	RP11-15A1.3	6.74	4.36e-11	1.74e-08	0.33	0.29	Breast cancer;	chr19:43796474	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.592	rs349047	ENSG00000267058.1	RP11-15A1.3	6.74	4.36e-11	1.74e-08	0.33	0.29	Breast cancer;	chr19:43796732	chr19:43891804~43901805:-
KIRC	cis	rs375066	0.592	rs349048	ENSG00000267058.1	RP11-15A1.3	6.74	4.36e-11	1.74e-08	0.33	0.29	Breast cancer;	chr19:43796785	chr19:43891804~43901805:-
KIRC	cis	rs12449964	0.524	rs7224619	ENSG00000223979.2	SMCR2	6.74	4.36e-11	1.74e-08	0.31	0.29	Coronary artery disease or ischemic stroke;	chr17:17669070	chr17:17674026~17677688:-
KIRC	cis	rs10971721	0.822	rs307673	ENSG00000260947.1	RP11-384P7.7	6.74	4.37e-11	1.75e-08	0.54	0.29	Body mass index;	chr9:33968821	chr9:33697459~33700986:+
KIRC	cis	rs919433	0.617	rs700638	ENSG00000231621.1	AC013264.2	-6.74	4.38e-11	1.75e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197724226	chr2:197197991~197199273:+
KIRC	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	6.74	4.38e-11	1.75e-08	0.26	0.29	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
KIRC	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-6.74	4.38e-11	1.75e-08	-0.31	-0.29	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
KIRC	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-6.74	4.39e-11	1.75e-08	-0.38	-0.29	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
KIRC	cis	rs934734	0.532	rs2028150	ENSG00000281920.1	RP11-418H16.1	-6.74	4.39e-11	1.75e-08	-0.35	-0.29	Rheumatoid arthritis;	chr2:65427878	chr2:65623272~65628424:+
KIRC	cis	rs934734	0.532	rs2028151	ENSG00000281920.1	RP11-418H16.1	-6.74	4.39e-11	1.75e-08	-0.35	-0.29	Rheumatoid arthritis;	chr2:65428479	chr2:65623272~65628424:+
KIRC	cis	rs17711722	0.528	rs73138179	ENSG00000275400.1	RP4-756H11.5	-6.74	4.39e-11	1.75e-08	-0.3	-0.29	Calcium levels;	chr7:65829495	chr7:66553805~66554199:-
KIRC	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-6.74	4.4e-11	1.76e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
KIRC	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-6.74	4.4e-11	1.76e-08	-0.3	-0.29	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
KIRC	cis	rs1200821	0.671	rs2226276	ENSG00000151963.4	RP11-775A3.1	6.74	4.41e-11	1.76e-08	0.33	0.29	Hemostatic factors and hematological phenotypes;	chr10:37384124	chr10:37883594~37884109:+
KIRC	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	6.74	4.42e-11	1.76e-08	0.32	0.29	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
KIRC	cis	rs11079159	0.637	rs7218159	ENSG00000263096.1	RP11-515O17.2	-6.74	4.42e-11	1.76e-08	-0.47	-0.29	QRS duration;	chr17:55277434	chr17:55271504~55273653:-
KIRC	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.74	4.42e-11	1.76e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
KIRC	cis	rs9915657	0.87	rs35271702	ENSG00000234899.8	SOX9-AS1	-6.74	4.42e-11	1.77e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72144375	chr17:72034107~72237203:-
KIRC	cis	rs12936587	0.564	rs7224739	ENSG00000223979.2	SMCR2	6.74	4.42e-11	1.77e-08	0.32	0.29	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17729164	chr17:17674026~17677688:-
KIRC	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-6.74	4.43e-11	1.77e-08	-0.43	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
KIRC	cis	rs8177876	0.686	rs2602402	ENSG00000261838.4	RP11-303E16.6	6.74	4.43e-11	1.77e-08	0.45	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81069854~81076598:+
KIRC	cis	rs7927771	0.56	rs4752858	ENSG00000280615.1	Y_RNA	-6.74	4.43e-11	1.77e-08	-0.3	-0.29	Subjective well-being;	chr11:47664277	chr11:47614898~47614994:-
KIRC	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-6.74	4.43e-11	1.77e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
KIRC	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	6.74	4.44e-11	1.77e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
KIRC	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	6.74	4.44e-11	1.77e-08	0.45	0.29	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	6.74	4.44e-11	1.77e-08	0.45	0.29	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
KIRC	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-6.74	4.44e-11	1.77e-08	-0.21	-0.29	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
KIRC	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-6.74	4.44e-11	1.77e-08	-0.25	-0.29	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
KIRC	cis	rs6908034	0.607	rs73376680	ENSG00000228412.5	RP4-625H18.2	6.74	4.45e-11	1.78e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs73376681	ENSG00000228412.5	RP4-625H18.2	6.74	4.45e-11	1.78e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19802164~19804752:-
KIRC	cis	rs62025270	0.688	rs62022940	ENSG00000202081.1	RNU6-1280P	-6.74	4.46e-11	1.78e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85651522~85651628:-
KIRC	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-6.74	4.46e-11	1.78e-08	-0.37	-0.29	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
KIRC	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-6.74	4.46e-11	1.78e-08	-0.36	-0.29	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
KIRC	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-6.74	4.47e-11	1.78e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
KIRC	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	6.74	4.47e-11	1.78e-08	0.27	0.29	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
KIRC	cis	rs7923609	0.54	rs10995455	ENSG00000232075.1	MRPL35P2	-6.74	4.47e-11	1.78e-08	-0.33	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63176601	chr10:63634317~63634827:-
KIRC	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	6.74	4.48e-11	1.79e-08	0.31	0.29	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
KIRC	cis	rs58873874	1	rs11740562	ENSG00000251405.2	CTB-109A12.1	-6.74	4.48e-11	1.79e-08	-0.53	-0.29	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157362615~157460078:-
KIRC	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	6.74	4.48e-11	1.79e-08	0.25	0.29	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
KIRC	cis	rs7017914	0.652	rs4629903	ENSG00000254031.4	RP11-326E22.1	6.74	4.48e-11	1.79e-08	0.33	0.29	Bone mineral density;	chr8:70892897	chr8:71155457~71204223:+
KIRC	cis	rs17772222	1	rs3814855	ENSG00000222990.1	RNU4-22P	6.74	4.48e-11	1.79e-08	0.35	0.29	Coronary artery calcification;	chr14:88467016	chr14:88513498~88513663:+
KIRC	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-6.74	4.49e-11	1.79e-08	-0.24	-0.29	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
KIRC	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	6.74	4.49e-11	1.79e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
KIRC	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	6.74	4.49e-11	1.79e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
KIRC	cis	rs4888671	1	rs78900394	ENSG00000261707.1	RP11-264M12.2	6.74	4.49e-11	1.79e-08	0.45	0.29	Obesity-related traits;	chr16:77750212	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs79282796	ENSG00000261707.1	RP11-264M12.2	6.74	4.49e-11	1.79e-08	0.45	0.29	Obesity-related traits;	chr16:77750385	chr16:77741468~77743000:-
KIRC	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	6.74	4.49e-11	1.79e-08	0.29	0.29	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
KIRC	cis	rs755249	0.565	rs2695324	ENSG00000182109.6	RP11-69E11.4	6.74	4.49e-11	1.79e-08	0.22	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39522280~39546187:-
KIRC	cis	rs2288884	0.806	rs17779439	ENSG00000275055.1	CTC-471J1.11	-6.74	4.49e-11	1.79e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:52049007~52049754:+
KIRC	cis	rs2288884	0.806	rs60193983	ENSG00000275055.1	CTC-471J1.11	-6.74	4.49e-11	1.79e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082659	chr19:52049007~52049754:+
KIRC	cis	rs12893668	0.663	rs12889731	ENSG00000269910.1	RP11-73M18.10	6.74	4.49e-11	1.79e-08	0.21	0.29	Reticulocyte count;	chr14:103621145	chr14:103694516~103695050:-
KIRC	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	6.74	4.5e-11	1.79e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
KIRC	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-6.74	4.5e-11	1.79e-08	-0.2	-0.29	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
KIRC	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-6.74	4.5e-11	1.79e-08	-0.2	-0.29	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
KIRC	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-6.74	4.5e-11	1.79e-08	-0.2	-0.29	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
KIRC	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-6.74	4.5e-11	1.8e-08	-0.3	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
KIRC	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.74	4.5e-11	1.8e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
KIRC	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	6.74	4.51e-11	1.8e-08	0.28	0.29	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
KIRC	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	6.74	4.51e-11	1.8e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
KIRC	cis	rs4356975	0.518	rs4694628	ENSG00000250919.1	RP11-813N20.3	-6.74	4.52e-11	1.8e-08	-0.37	-0.29	Obesity-related traits;	chr4:69104054	chr4:69027831~69044578:+
KIRC	cis	rs7124681	0.565	rs2203712	ENSG00000280615.1	Y_RNA	6.74	4.52e-11	1.8e-08	0.31	0.29	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47513412	chr11:47614898~47614994:-
KIRC	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	6.74	4.52e-11	1.8e-08	0.34	0.29	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	6.74	4.52e-11	1.8e-08	0.34	0.29	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
KIRC	cis	rs11079159	0.959	rs17817857	ENSG00000263096.1	RP11-515O17.2	6.74	4.52e-11	1.8e-08	0.42	0.29	QRS duration;	chr17:55299581	chr17:55271504~55273653:-
KIRC	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	6.74	4.53e-11	1.8e-08	0.33	0.29	Depression;	chr6:28096855	chr6:28073316~28074233:+
KIRC	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-6.74	4.53e-11	1.81e-08	-0.31	-0.29	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
KIRC	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	6.74	4.53e-11	1.81e-08	0.38	0.29	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
KIRC	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-6.74	4.53e-11	1.81e-08	-0.3	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
KIRC	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	6.74	4.53e-11	1.81e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
KIRC	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	6.74	4.53e-11	1.81e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
KIRC	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	6.74	4.54e-11	1.81e-08	0.33	0.29	Depression;	chr6:28143758	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	6.74	4.54e-11	1.81e-08	0.33	0.29	Depression;	chr6:28144784	chr6:28073316~28074233:+
KIRC	cis	rs4356975	1	rs4356975	ENSG00000198277.6	RP11-468N14.09	6.74	4.55e-11	1.81e-08	0.31	0.29	Obesity-related traits;	chr4:69106745	chr4:68914928~68924741:-
KIRC	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	6.74	4.55e-11	1.81e-08	0.26	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
KIRC	cis	rs7924176	0.521	rs12415957	ENSG00000213731.2	RAB5CP1	6.74	4.55e-11	1.81e-08	0.28	0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74423435~74424014:-
KIRC	cis	rs6480314	0.542	rs7079054	ENSG00000233590.1	RP11-153K11.3	-6.74	4.55e-11	1.81e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68266404	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs12570281	ENSG00000233590.1	RP11-153K11.3	-6.74	4.55e-11	1.81e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68267237	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs61854813	ENSG00000233590.1	RP11-153K11.3	-6.74	4.55e-11	1.81e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68267464	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.803	rs61854814	ENSG00000233590.1	RP11-153K11.3	-6.74	4.55e-11	1.81e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68267639	chr10:68233251~68242379:-
KIRC	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	6.74	4.56e-11	1.82e-08	0.32	0.29	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
KIRC	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-6.73	4.57e-11	1.82e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
KIRC	cis	rs4888671	0.901	rs78017841	ENSG00000261707.1	RP11-264M12.2	6.73	4.58e-11	1.82e-08	0.45	0.29	Obesity-related traits;	chr16:77750268	chr16:77741468~77743000:-
KIRC	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-6.73	4.58e-11	1.82e-08	-0.32	-0.29	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
KIRC	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	6.73	4.58e-11	1.82e-08	0.33	0.29	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
KIRC	cis	rs4356975	0.509	rs4587017	ENSG00000250696.4	RP11-704M14.1	6.73	4.58e-11	1.82e-08	0.31	0.29	Obesity-related traits;	chr4:69081680	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.509	rs4458521	ENSG00000250696.4	RP11-704M14.1	6.73	4.58e-11	1.82e-08	0.31	0.29	Obesity-related traits;	chr4:69086240	chr4:69182100~69216766:+
KIRC	cis	rs4356975	0.509	rs4694169	ENSG00000250696.4	RP11-704M14.1	6.73	4.58e-11	1.82e-08	0.31	0.29	Obesity-related traits;	chr4:69088433	chr4:69182100~69216766:+
KIRC	cis	rs710913	0.618	rs6587	ENSG00000237624.1	OXCT2P1	6.73	4.58e-11	1.82e-08	0.37	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39514956~39516490:+
KIRC	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
KIRC	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	6.73	4.58e-11	1.82e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
KIRC	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-6.73	4.59e-11	1.83e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
KIRC	cis	rs7017914	0.652	rs11994581	ENSG00000254031.4	RP11-326E22.1	6.73	4.59e-11	1.83e-08	0.33	0.29	Bone mineral density;	chr8:70862172	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs34301443	ENSG00000254031.4	RP11-326E22.1	6.73	4.59e-11	1.83e-08	0.33	0.29	Bone mineral density;	chr8:70863161	chr8:71155457~71204223:+
KIRC	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-6.73	4.59e-11	1.83e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
KIRC	cis	rs17772222	0.74	rs10138309	ENSG00000222990.1	RNU4-22P	6.73	4.59e-11	1.83e-08	0.32	0.29	Coronary artery calcification;	chr14:88510352	chr14:88513498~88513663:+
KIRC	cis	rs2018683	0.711	rs917213	ENSG00000228421.2	AC005013.5	6.73	4.6e-11	1.83e-08	0.3	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28957667~28959345:+
KIRC	cis	rs2018683	0.711	rs917214	ENSG00000228421.2	AC005013.5	6.73	4.6e-11	1.83e-08	0.3	0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28957667~28959345:+
KIRC	cis	rs526231	0.786	rs171695	ENSG00000175749.11	EIF3KP1	6.73	4.6e-11	1.83e-08	0.35	0.29	Primary biliary cholangitis;	chr5:103296339	chr5:103032376~103033031:+
KIRC	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-6.73	4.6e-11	1.83e-08	-0.33	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
KIRC	cis	rs10214930	0.813	rs6946305	ENSG00000235574.1	AC073150.6	-6.73	4.61e-11	1.84e-08	-0.36	-0.29	Hypospadias;	chr7:27641576	chr7:27491682~27492765:-
KIRC	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-6.73	4.62e-11	1.84e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
KIRC	cis	rs7017914	0.69	rs35767277	ENSG00000254031.4	RP11-326E22.1	6.73	4.62e-11	1.84e-08	0.34	0.29	Bone mineral density;	chr8:70806262	chr8:71155457~71204223:+
KIRC	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	6.73	4.62e-11	1.84e-08	0.23	0.29	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
KIRC	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-6.73	4.63e-11	1.84e-08	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
KIRC	cis	rs6480314	0.542	rs61854824	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68270438	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs12572954	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68270766	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs12572967	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68270873	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs12572960	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68270966	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.803	rs2241969	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68271253	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.803	rs61854825	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68271535	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.803	rs61854826	ENSG00000233590.1	RP11-153K11.3	-6.73	4.63e-11	1.84e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68271801	chr10:68233251~68242379:-
KIRC	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	6.73	4.64e-11	1.85e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
KIRC	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.73	4.64e-11	1.85e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
KIRC	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	6.73	4.65e-11	1.85e-08	0.3	0.29	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
KIRC	cis	rs8048589	0.948	rs35053871	ENSG00000175604.2	RP11-276H1.3	-6.73	4.65e-11	1.85e-08	-0.34	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088580	chr16:12086746~12090302:-
KIRC	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-6.73	4.66e-11	1.85e-08	-0.4	-0.29	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
KIRC	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-6.73	4.66e-11	1.85e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-6.73	4.66e-11	1.85e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-6.73	4.66e-11	1.85e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-6.73	4.66e-11	1.85e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
KIRC	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.73	4.67e-11	1.86e-08	-0.31	-0.29	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
KIRC	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	6.73	4.67e-11	1.86e-08	0.3	0.29	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
KIRC	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-6.73	4.68e-11	1.86e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
KIRC	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	6.73	4.68e-11	1.86e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
KIRC	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	6.73	4.68e-11	1.86e-08	0.39	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
KIRC	cis	rs10214930	0.813	rs6462039	ENSG00000235574.1	AC073150.6	6.73	4.68e-11	1.86e-08	0.36	0.29	Hypospadias;	chr7:27626763	chr7:27491682~27492765:-
KIRC	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	6.73	4.69e-11	1.87e-08	0.34	0.29	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
KIRC	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-6.73	4.69e-11	1.87e-08	-0.24	-0.29	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
KIRC	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-6.73	4.69e-11	1.87e-08	-0.31	-0.29	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
KIRC	cis	rs12887734	0.566	rs3742366	ENSG00000269910.1	RP11-73M18.10	6.73	4.7e-11	1.87e-08	0.21	0.29	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694516~103695050:-
KIRC	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-6.73	4.7e-11	1.87e-08	-0.41	-0.29	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
KIRC	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-6.73	4.7e-11	1.87e-08	-0.29	-0.29	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
KIRC	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	6.73	4.7e-11	1.87e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	6.73	4.7e-11	1.87e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	6.73	4.7e-11	1.87e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	6.73	4.7e-11	1.87e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
KIRC	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	6.73	4.7e-11	1.87e-08	0.41	0.29	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
KIRC	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-6.73	4.7e-11	1.87e-08	-0.35	-0.29	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
KIRC	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	6.73	4.71e-11	1.87e-08	0.35	0.29	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
KIRC	cis	rs7927771	0.689	rs10734557	ENSG00000280615.1	Y_RNA	6.73	4.71e-11	1.87e-08	0.32	0.29	Subjective well-being;	chr11:47358510	chr11:47614898~47614994:-
KIRC	cis	rs755249	0.588	rs2275767	ENSG00000237624.1	OXCT2P1	-6.73	4.72e-11	1.87e-08	-0.36	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39514956~39516490:+
KIRC	cis	rs7017914	0.629	rs2956611	ENSG00000254031.4	RP11-326E22.1	6.73	4.72e-11	1.88e-08	0.33	0.29	Bone mineral density;	chr8:70985633	chr8:71155457~71204223:+
KIRC	cis	rs4888671	1	rs17769643	ENSG00000261707.1	RP11-264M12.2	6.73	4.73e-11	1.88e-08	0.44	0.29	Obesity-related traits;	chr16:77751078	chr16:77741468~77743000:-
KIRC	cis	rs4072705	0.967	rs12339980	ENSG00000224020.1	MIR181A2HG	-6.73	4.74e-11	1.88e-08	-0.28	-0.29	Menarche (age at onset);	chr9:124556424	chr9:124658467~124698631:+
KIRC	cis	rs6456156	1	rs6911766	ENSG00000265828.1	MIR3939	6.73	4.74e-11	1.88e-08	0.34	0.29	Primary biliary cholangitis;	chr6:167109682	chr6:166997807~166997912:-
KIRC	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	6.73	4.74e-11	1.88e-08	0.27	0.29	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
KIRC	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-6.73	4.74e-11	1.88e-08	-0.28	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
KIRC	cis	rs4578769	0.531	rs12969559	ENSG00000266850.1	RP11-370A5.1	6.73	4.74e-11	1.88e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22913702	chr18:22723491~22907721:-
KIRC	cis	rs4888671	0.803	rs117140693	ENSG00000261707.1	RP11-264M12.2	6.73	4.75e-11	1.88e-08	0.44	0.29	Obesity-related traits;	chr16:77746887	chr16:77741468~77743000:-
KIRC	cis	rs919433	0.679	rs55656916	ENSG00000231621.1	AC013264.2	-6.73	4.75e-11	1.89e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197654904	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.679	rs13394214	ENSG00000231621.1	AC013264.2	-6.73	4.75e-11	1.89e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197662647	chr2:197197991~197199273:+
KIRC	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	6.73	4.75e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	6.73	4.75e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	6.73	4.75e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	6.73	4.75e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	6.73	4.75e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
KIRC	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	6.73	4.76e-11	1.89e-08	0.35	0.29	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
KIRC	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	6.73	4.76e-11	1.89e-08	0.39	0.29	Height;	chr6:109350188	chr6:109382795~109383666:+
KIRC	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-6.73	4.77e-11	1.89e-08	-0.35	-0.29	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-6.73	4.77e-11	1.89e-08	-0.35	-0.29	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
KIRC	cis	rs7927771	0.524	rs10838732	ENSG00000280615.1	Y_RNA	6.73	4.77e-11	1.89e-08	0.31	0.29	Subjective well-being;	chr11:47586388	chr11:47614898~47614994:-
KIRC	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	6.73	4.77e-11	1.89e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
KIRC	cis	rs13236243	0.559	rs7810862	ENSG00000236318.1	AC019117.1	6.73	4.77e-11	1.9e-08	0.41	0.29	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17283975	chr7:17374867~17466664:+
KIRC	cis	rs1005277	0.54	rs2145487	ENSG00000235197.1	ZNF33AP1	-6.73	4.78e-11	1.9e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:37894637~37896666:+
KIRC	cis	rs643506	0.715	rs11214031	ENSG00000230911.1	PPIHP1	-6.73	4.78e-11	1.9e-08	-0.34	-0.29	Breast cancer;	chr11:111895315	chr11:112029858~112030367:-
KIRC	cis	rs643506	0.774	rs11214033	ENSG00000230911.1	PPIHP1	6.73	4.78e-11	1.9e-08	0.34	0.29	Breast cancer;	chr11:111898978	chr11:112029858~112030367:-
KIRC	cis	rs6480314	0.542	rs2120902	ENSG00000233590.1	RP11-153K11.3	-6.73	4.79e-11	1.9e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68260465	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.773	rs4142047	ENSG00000233590.1	RP11-153K11.3	-6.73	4.79e-11	1.9e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68261498	chr10:68233251~68242379:-
KIRC	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-6.73	4.79e-11	1.9e-08	-0.31	-0.29	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
KIRC	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	6.73	4.79e-11	1.9e-08	0.32	0.29	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
KIRC	cis	rs1153858	1	rs1145074	ENSG00000235390.4	CTD-2651B20.5	-6.73	4.79e-11	1.9e-08	-0.28	-0.29	Homoarginine levels;	chr15:45411626	chr15:45321077~45321692:-
KIRC	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-6.73	4.8e-11	1.9e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
KIRC	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	6.73	4.81e-11	1.91e-08	0.27	0.29	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
KIRC	cis	rs950776	0.752	rs62010328	ENSG00000261762.1	RP11-650L12.2	6.73	4.81e-11	1.91e-08	0.39	0.29	Sudden cardiac arrest;	chr15:78602629	chr15:78589123~78591276:-
KIRC	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	6.73	4.81e-11	1.91e-08	0.35	0.29	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
KIRC	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-6.73	4.82e-11	1.91e-08	-0.26	-0.29	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
KIRC	cis	rs7674212	0.531	rs7665026	ENSG00000230069.3	LRRC37A15P	-6.73	4.82e-11	1.91e-08	-0.31	-0.29	Type 2 diabetes;	chr4:103015491	chr4:102727274~102730721:-
KIRC	cis	rs7017914	0.628	rs12156041	ENSG00000254031.4	RP11-326E22.1	6.73	4.83e-11	1.91e-08	0.33	0.29	Bone mineral density;	chr8:70914690	chr8:71155457~71204223:+
KIRC	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-6.73	4.83e-11	1.91e-08	-0.3	-0.29	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
KIRC	cis	rs588177	0.919	rs2244625	ENSG00000236935.1	AP003774.1	6.73	4.83e-11	1.92e-08	0.25	0.29	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64258672	chr11:64325050~64329504:-
KIRC	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-6.73	4.83e-11	1.92e-08	-0.17	-0.29	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
KIRC	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	6.73	4.83e-11	1.92e-08	0.41	0.29	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
KIRC	cis	rs3096299	0.583	rs889574	ENSG00000274627.1	RP11-104N10.2	6.73	4.84e-11	1.92e-08	0.22	0.29	Multiple myeloma (IgH translocation);	chr16:89320400	chr16:89516797~89522217:+
KIRC	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	6.73	4.84e-11	1.92e-08	0.32	0.29	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
KIRC	cis	rs755249	0.532	rs2296173	ENSG00000237624.1	OXCT2P1	6.73	4.84e-11	1.92e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs3118014	ENSG00000237624.1	OXCT2P1	6.73	4.84e-11	1.92e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39514956~39516490:+
KIRC	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-6.73	4.84e-11	1.92e-08	-0.37	-0.29	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-6.73	4.84e-11	1.92e-08	-0.37	-0.29	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
KIRC	cis	rs7017914	0.628	rs7833211	ENSG00000254031.4	RP11-326E22.1	6.73	4.84e-11	1.92e-08	0.33	0.29	Bone mineral density;	chr8:70691903	chr8:71155457~71204223:+
KIRC	cis	rs4819052	0.765	rs2838868	ENSG00000215447.6	BX322557.10	6.73	4.84e-11	1.92e-08	0.25	0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45288052~45291738:+
KIRC	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	6.73	4.85e-11	1.92e-08	0.54	0.29	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
KIRC	cis	rs7927771	0.524	rs6485763	ENSG00000280615.1	Y_RNA	6.73	4.85e-11	1.92e-08	0.31	0.29	Subjective well-being;	chr11:47605750	chr11:47614898~47614994:-
KIRC	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-6.72	4.86e-11	1.93e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
KIRC	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	6.72	4.86e-11	1.93e-08	0.45	0.29	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
KIRC	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.72	4.87e-11	1.93e-08	0.31	0.29	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
KIRC	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	6.72	4.87e-11	1.93e-08	0.56	0.29	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
KIRC	cis	rs2486288	0.656	rs12911861	ENSG00000235390.4	CTD-2651B20.5	6.72	4.88e-11	1.93e-08	0.26	0.29	Glomerular filtration rate;	chr15:45274520	chr15:45321077~45321692:-
KIRC	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.72	4.88e-11	1.93e-08	0.32	0.29	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.72	4.88e-11	1.93e-08	0.32	0.29	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.72	4.88e-11	1.93e-08	0.32	0.29	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
KIRC	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	6.72	4.88e-11	1.93e-08	0.21	0.29	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
KIRC	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	6.72	4.88e-11	1.93e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	6.72	4.88e-11	1.93e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	6.72	4.88e-11	1.93e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	6.72	4.88e-11	1.93e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	6.72	4.88e-11	1.93e-08	0.26	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
KIRC	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	6.72	4.89e-11	1.94e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
KIRC	cis	rs10214930	0.813	rs6415252	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27629241	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs7779990	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27632280	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs12700825	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27632952	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs11764753	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27633340	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs7806415	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27633918	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs2391451	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27646203	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs12700829	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27647483	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs2160125	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27648667	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.813	rs12700830	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27649240	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs2391454	ENSG00000235574.1	AC073150.6	-6.72	4.89e-11	1.94e-08	-0.36	-0.29	Hypospadias;	chr7:27651005	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.767	rs6957378	ENSG00000235574.1	AC073150.6	6.72	4.89e-11	1.94e-08	0.36	0.29	Hypospadias;	chr7:27657330	chr7:27491682~27492765:-
KIRC	cis	rs3750965	1	rs3750965	ENSG00000260895.1	RP11-554A11.7	6.72	4.89e-11	1.94e-08	0.36	0.29	Hair color;	chr11:69072692	chr11:69103493~69109094:+
KIRC	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-6.72	4.89e-11	1.94e-08	-0.16	-0.29	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
KIRC	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	6.72	4.89e-11	1.94e-08	0.25	0.29	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
KIRC	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	6.72	4.89e-11	1.94e-08	0.29	0.29	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
KIRC	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	6.72	4.89e-11	1.94e-08	0.27	0.29	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
KIRC	cis	rs7017914	0.605	rs13269410	ENSG00000254031.4	RP11-326E22.1	6.72	4.9e-11	1.94e-08	0.34	0.29	Bone mineral density;	chr8:70725773	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.583	rs11986334	ENSG00000254031.4	RP11-326E22.1	6.72	4.9e-11	1.94e-08	0.34	0.29	Bone mineral density;	chr8:70732239	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2290702	ENSG00000254031.4	RP11-326E22.1	6.72	4.9e-11	1.94e-08	0.34	0.29	Bone mineral density;	chr8:70734745	chr8:71155457~71204223:+
KIRC	cis	rs7927771	0.524	rs10742814	ENSG00000280615.1	Y_RNA	6.72	4.9e-11	1.94e-08	0.31	0.29	Subjective well-being;	chr11:47532785	chr11:47614898~47614994:-
KIRC	cis	rs4072705	0.585	rs7852843	ENSG00000224020.1	MIR181A2HG	6.72	4.9e-11	1.94e-08	0.3	0.29	Menarche (age at onset);	chr9:124471544	chr9:124658467~124698631:+
KIRC	cis	rs4356975	0.563	rs7662029	ENSG00000196472.4	RP13-644M16.4	6.72	4.91e-11	1.94e-08	0.33	0.29	Obesity-related traits;	chr4:69096194	chr4:69181660~69182372:+
KIRC	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-6.72	4.91e-11	1.95e-08	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
KIRC	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	6.72	4.92e-11	1.95e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	6.72	4.92e-11	1.95e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
KIRC	cis	rs899997	0.773	rs8032156	ENSG00000261143.1	ADAMTS7P3	6.72	4.92e-11	1.95e-08	0.38	0.29	Coronary artery disease or large artery stroke;	chr15:78672156	chr15:77976042~77993057:+
KIRC	cis	rs899997	0.773	rs11072783	ENSG00000261143.1	ADAMTS7P3	6.72	4.92e-11	1.95e-08	0.38	0.29	Coronary artery disease or large artery stroke;	chr15:78673624	chr15:77976042~77993057:+
KIRC	cis	rs899997	0.773	rs11072784	ENSG00000261143.1	ADAMTS7P3	6.72	4.92e-11	1.95e-08	0.38	0.29	Coronary artery disease or large artery stroke;	chr15:78673716	chr15:77976042~77993057:+
KIRC	cis	rs755249	0.567	rs61779275	ENSG00000237624.1	OXCT2P1	6.72	4.92e-11	1.95e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39514956~39516490:+
KIRC	cis	rs4245535	1	rs62427094	ENSG00000225174.1	OSTM1-AS1	6.72	4.93e-11	1.95e-08	0.6	0.29	Major depressive disorder;	chr6:108133026	chr6:108123515~108159392:+
KIRC	cis	rs4950322	0.57	rs4950315	ENSG00000278811.3	LINC00624	-6.72	4.93e-11	1.95e-08	-0.3	-0.29	Protein quantitative trait loci;	chr1:147264433	chr1:147258885~147517875:-
KIRC	cis	rs934734	0.571	rs7572922	ENSG00000281920.1	RP11-418H16.1	-6.72	4.93e-11	1.95e-08	-0.36	-0.29	Rheumatoid arthritis;	chr2:65425022	chr2:65623272~65628424:+
KIRC	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-6.72	4.93e-11	1.95e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
KIRC	cis	rs2288884	0.943	rs11671792	ENSG00000275055.1	CTC-471J1.11	-6.72	4.93e-11	1.95e-08	-0.4	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52049007~52049754:+
KIRC	cis	rs643506	0.874	rs687152	ENSG00000230911.1	PPIHP1	-6.72	4.93e-11	1.95e-08	-0.34	-0.29	Breast cancer;	chr11:111850950	chr11:112029858~112030367:-
KIRC	cis	rs643506	0.874	rs4936786	ENSG00000230911.1	PPIHP1	-6.72	4.93e-11	1.95e-08	-0.34	-0.29	Breast cancer;	chr11:111856504	chr11:112029858~112030367:-
KIRC	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-6.72	4.94e-11	1.96e-08	-0.31	-0.29	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
KIRC	cis	rs4888671	1	rs113450334	ENSG00000261707.1	RP11-264M12.2	6.72	4.94e-11	1.96e-08	0.43	0.29	Obesity-related traits;	chr16:77746712	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs113269636	ENSG00000261707.1	RP11-264M12.2	6.72	4.94e-11	1.96e-08	0.43	0.29	Obesity-related traits;	chr16:77746713	chr16:77741468~77743000:-
KIRC	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-6.72	4.94e-11	1.96e-08	-0.32	-0.29	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
KIRC	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	6.72	4.94e-11	1.96e-08	0.36	0.29	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
KIRC	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-6.72	4.94e-11	1.96e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
KIRC	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	6.72	4.95e-11	1.96e-08	0.39	0.29	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
KIRC	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	6.72	4.95e-11	1.96e-08	0.31	0.29	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
KIRC	cis	rs62025270	0.632	rs62022943	ENSG00000202081.1	RNU6-1280P	-6.72	4.95e-11	1.96e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85651522~85651628:-
KIRC	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	6.72	4.95e-11	1.96e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
KIRC	cis	rs7045881	0.778	rs62542667	ENSG00000254396.1	RP11-56F10.3	6.72	4.96e-11	1.96e-08	0.39	0.29	Schizophrenia;	chr9:26999013	chr9:27102630~27104728:+
KIRC	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.72	4.96e-11	1.96e-08	-0.35	-0.29	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
KIRC	cis	rs2018683	0.523	rs4513881	ENSG00000228421.2	AC005013.5	-6.72	4.96e-11	1.96e-08	-0.34	-0.29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28957667~28959345:+
KIRC	cis	rs17772222	0.74	rs10138139	ENSG00000222990.1	RNU4-22P	6.72	4.96e-11	1.96e-08	0.32	0.29	Coronary artery calcification;	chr14:88510027	chr14:88513498~88513663:+
KIRC	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-6.72	4.96e-11	1.96e-08	-0.31	-0.29	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
KIRC	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-6.72	4.98e-11	1.97e-08	-0.34	-0.29	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
KIRC	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-6.72	4.98e-11	1.97e-08	-0.31	-0.29	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
KIRC	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	6.72	4.99e-11	1.97e-08	0.28	0.29	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
KIRC	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-6.72	4.99e-11	1.97e-08	-0.33	-0.29	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
KIRC	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-6.72	4.99e-11	1.97e-08	-0.45	-0.29	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
KIRC	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	6.72	4.99e-11	1.97e-08	0.28	0.29	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
KIRC	cis	rs6061231	0.837	rs6121558	ENSG00000275437.1	RP5-908M14.10	6.72	4.99e-11	1.98e-08	0.25	0.29	Colorectal cancer;	chr20:62386309	chr20:62402236~62405935:-
KIRC	cis	rs4245535	1	rs4946906	ENSG00000225174.1	OSTM1-AS1	6.72	5e-11	1.98e-08	0.6	0.29	Major depressive disorder;	chr6:108135980	chr6:108123515~108159392:+
KIRC	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-6.72	5e-11	1.98e-08	-0.23	-0.29	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
KIRC	cis	rs12049351	0.719	rs10916492	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229498649	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.719	rs10916493	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229498650	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs10916495	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229499774	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs6670553	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229500120	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs754025	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229501550	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs2381108	ENSG00000229367.1	HMGN2P19	6.72	5e-11	1.98e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229502134	chr1:229570532~229570796:+
KIRC	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-6.72	5.01e-11	1.98e-08	-0.45	-0.29	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
KIRC	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	6.72	5.01e-11	1.98e-08	0.34	0.29	Depression;	chr6:28159843	chr6:28073316~28074233:+
KIRC	cis	rs1198872	0.812	rs1198867	ENSG00000272275.1	RP11-791G15.2	-6.72	5.01e-11	1.98e-08	-0.38	-0.29	Cardiac Troponin-T levels;	chr2:10762281	chr2:10767875~10770058:-
KIRC	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-6.72	5.01e-11	1.98e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
KIRC	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-6.72	5.02e-11	1.98e-08	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
KIRC	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-6.72	5.02e-11	1.98e-08	-0.31	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
KIRC	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-6.72	5.02e-11	1.99e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
KIRC	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	6.72	5.02e-11	1.99e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	6.72	5.02e-11	1.99e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	6.72	5.02e-11	1.99e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	6.72	5.02e-11	1.99e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
KIRC	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-6.72	5.03e-11	1.99e-08	-0.26	-0.29	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
KIRC	cis	rs1198872	0.892	rs1198869	ENSG00000272275.1	RP11-791G15.2	-6.72	5.03e-11	1.99e-08	-0.38	-0.29	Cardiac Troponin-T levels;	chr2:10762319	chr2:10767875~10770058:-
KIRC	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.72	5.03e-11	1.99e-08	-0.24	-0.29	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
KIRC	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
KIRC	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	6.72	5.03e-11	1.99e-08	0.49	0.29	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
KIRC	cis	rs6452524	0.618	rs6867727	ENSG00000248112.1	RP11-78C3.1	6.72	5.03e-11	1.99e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82919376~82921119:-
KIRC	cis	rs4356975	0.563	rs6600893	ENSG00000196472.4	RP13-644M16.4	6.72	5.04e-11	1.99e-08	0.33	0.29	Obesity-related traits;	chr4:69113183	chr4:69181660~69182372:+
KIRC	cis	rs6728642	0.831	rs10496325	ENSG00000230606.9	AC159540.1	-6.72	5.04e-11	1.99e-08	-0.31	-0.29	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97017592	chr2:97416165~97433527:-
KIRC	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	6.72	5.04e-11	1.99e-08	0.35	0.29	Height;	chr11:118855233	chr11:118688039~118690600:-
KIRC	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	6.72	5.04e-11	1.99e-08	0.35	0.29	Height;	chr11:118855938	chr11:118688039~118690600:-
KIRC	cis	rs2797160	0.651	rs6569436	ENSG00000237742.5	RP11-624M8.1	6.72	5.05e-11	2e-08	0.34	0.29	Endometrial cancer;	chr6:125710958	chr6:125578558~125749190:-
KIRC	cis	rs17772222	1	rs7145588	ENSG00000222990.1	RNU4-22P	6.72	5.05e-11	2e-08	0.34	0.29	Coronary artery calcification;	chr14:88360452	chr14:88513498~88513663:+
KIRC	cis	rs17772222	1	rs61977049	ENSG00000222990.1	RNU4-22P	6.72	5.05e-11	2e-08	0.34	0.29	Coronary artery calcification;	chr14:88360656	chr14:88513498~88513663:+
KIRC	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	6.72	5.06e-11	2e-08	0.32	0.29	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
KIRC	cis	rs13434995	0.513	rs58476959	ENSG00000249700.7	SRD5A3-AS1	-6.72	5.06e-11	2e-08	-0.29	-0.29	Adiponectin levels;	chr4:55496234	chr4:55363971~55395847:-
KIRC	cis	rs4356975	0.83	rs6600865	ENSG00000196472.4	RP13-644M16.4	6.72	5.06e-11	2e-08	0.32	0.29	Obesity-related traits;	chr4:69057904	chr4:69181660~69182372:+
KIRC	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-6.72	5.06e-11	2e-08	-0.4	-0.29	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
KIRC	cis	rs10214930	0.957	rs7786569	ENSG00000235574.1	AC073150.6	6.72	5.06e-11	2e-08	0.41	0.29	Hypospadias;	chr7:27682832	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.957	rs42113	ENSG00000235574.1	AC073150.6	6.72	5.06e-11	2e-08	0.41	0.29	Hypospadias;	chr7:27682977	chr7:27491682~27492765:-
KIRC	cis	rs7246657	0.722	rs2972437	ENSG00000267422.1	CTD-2554C21.1	-6.72	5.06e-11	2e-08	-0.42	-0.29	Coronary artery calcification;	chr19:37719610	chr19:37779686~37792865:+
KIRC	cis	rs2337406	0.85	rs4774179	ENSG00000274576.2	IGHV2-70	-6.72	5.06e-11	2e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106700837	chr14:106770577~106771020:-
KIRC	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	6.72	5.07e-11	2e-08	0.36	0.29	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
KIRC	cis	rs7017914	0.628	rs7822474	ENSG00000254031.4	RP11-326E22.1	6.72	5.07e-11	2e-08	0.33	0.29	Bone mineral density;	chr8:70793498	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35323776	ENSG00000254031.4	RP11-326E22.1	6.72	5.07e-11	2e-08	0.33	0.29	Bone mineral density;	chr8:70797931	chr8:71155457~71204223:+
KIRC	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-6.72	5.08e-11	2.01e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
KIRC	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	6.72	5.08e-11	2.01e-08	0.42	0.29	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
KIRC	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	6.72	5.08e-11	2.01e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
KIRC	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	6.72	5.09e-11	2.01e-08	0.42	0.29	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
KIRC	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-6.72	5.09e-11	2.01e-08	-0.34	-0.29	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
KIRC	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-6.72	5.09e-11	2.01e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
KIRC	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	6.72	5.09e-11	2.01e-08	0.38	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
KIRC	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.72	5.1e-11	2.01e-08	-0.31	-0.29	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
KIRC	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.72	5.1e-11	2.01e-08	-0.31	-0.29	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
KIRC	cis	rs10214930	0.697	rs10951175	ENSG00000235574.1	AC073150.6	-6.72	5.1e-11	2.02e-08	-0.33	-0.29	Hypospadias;	chr7:27631439	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.723	rs12700826	ENSG00000235574.1	AC073150.6	-6.72	5.1e-11	2.02e-08	-0.33	-0.29	Hypospadias;	chr7:27633107	chr7:27491682~27492765:-
KIRC	cis	rs17213965	0.852	rs4781691	ENSG00000207425.1	Y_RNA	-6.72	5.1e-11	2.02e-08	-0.48	-0.29	Waist-hip ratio;	chr16:15783798	chr16:14915457~14915556:-
KIRC	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-6.72	5.1e-11	2.02e-08	-0.41	-0.29	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
KIRC	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-6.72	5.1e-11	2.02e-08	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
KIRC	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-6.72	5.1e-11	2.02e-08	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
KIRC	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	6.72	5.11e-11	2.02e-08	0.32	0.29	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
KIRC	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-6.72	5.11e-11	2.02e-08	-0.3	-0.29	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
KIRC	cis	rs17801127	0.748	rs2192896	ENSG00000231969.1	AC144449.1	6.72	5.11e-11	2.02e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149659554	chr2:149587196~149848233:+
KIRC	cis	rs138087875	1	rs138087875	ENSG00000264247.1	LINC00909	-6.72	5.11e-11	2.02e-08	-0.45	-0.29	Brain volume in infants (grey matter);	chr18:74593493	chr18:74591774~74598508:-
KIRC	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	6.72	5.11e-11	2.02e-08	0.44	0.29	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
KIRC	cis	rs10754283	0.535	rs1215507	ENSG00000231613.1	RP5-943J3.1	6.72	5.12e-11	2.02e-08	0.3	0.29	Amyotrophic lateral sclerosis (sporadic);	chr1:89623336	chr1:89788914~89790492:+
KIRC	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-6.72	5.12e-11	2.02e-08	-0.22	-0.29	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
KIRC	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-6.72	5.13e-11	2.02e-08	-0.33	-0.29	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
KIRC	cis	rs7937127	0.744	rs2862958	ENSG00000254907.1	RP11-484D2.2	6.72	5.13e-11	2.02e-08	0.39	0.29	Fibrinogen levels;	chr11:43497572	chr11:43328748~43359296:-
KIRC	cis	rs17801127	0.901	rs16827376	ENSG00000231969.1	AC144449.1	6.72	5.14e-11	2.03e-08	0.52	0.29	Liver enzyme levels (alanine transaminase);	chr2:149708333	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs12995026	ENSG00000231969.1	AC144449.1	6.72	5.14e-11	2.03e-08	0.52	0.29	Liver enzyme levels (alanine transaminase);	chr2:149708526	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs16827383	ENSG00000231969.1	AC144449.1	6.72	5.14e-11	2.03e-08	0.52	0.29	Liver enzyme levels (alanine transaminase);	chr2:149709562	chr2:149587196~149848233:+
KIRC	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	6.72	5.14e-11	2.03e-08	0.33	0.29	Depression;	chr6:28135913	chr6:28073316~28074233:+
KIRC	cis	rs198426	0.506	rs198465	ENSG00000124915.9	DKFZP434K028	6.72	5.14e-11	2.03e-08	0.34	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61753846	chr11:61746493~61757655:-
KIRC	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-6.72	5.14e-11	2.03e-08	-0.36	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
KIRC	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	6.72	5.14e-11	2.03e-08	0.3	0.29	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
KIRC	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-6.72	5.15e-11	2.03e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
KIRC	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-6.72	5.15e-11	2.03e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
KIRC	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-6.72	5.15e-11	2.03e-08	-0.25	-0.29	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
KIRC	cis	rs4356975	0.932	rs12648830	ENSG00000198277.6	RP11-468N14.09	-6.72	5.15e-11	2.03e-08	-0.31	-0.29	Obesity-related traits;	chr4:69075436	chr4:68914928~68924741:-
KIRC	cis	rs2797160	0.935	rs926855	ENSG00000237742.5	RP11-624M8.1	6.72	5.16e-11	2.04e-08	0.35	0.29	Endometrial cancer;	chr6:125700636	chr6:125578558~125749190:-
KIRC	cis	rs6480314	0.831	rs7071208	ENSG00000233590.1	RP11-153K11.3	6.72	5.16e-11	2.04e-08	0.4	0.29	Optic nerve measurement (disc area);	chr10:68213350	chr10:68233251~68242379:-
KIRC	cis	rs4356975	0.563	rs4535394	ENSG00000196472.4	RP13-644M16.4	-6.72	5.16e-11	2.04e-08	-0.33	-0.29	Obesity-related traits;	chr4:69122735	chr4:69181660~69182372:+
KIRC	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-6.72	5.16e-11	2.04e-08	-0.4	-0.29	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
KIRC	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	6.72	5.16e-11	2.04e-08	0.28	0.29	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
KIRC	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-6.72	5.17e-11	2.04e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
KIRC	cis	rs6452524	0.56	rs6895174	ENSG00000248112.1	RP11-78C3.1	6.72	5.17e-11	2.04e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82919376~82921119:-
KIRC	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	6.72	5.17e-11	2.04e-08	0.35	0.29	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
KIRC	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	6.71	5.17e-11	2.04e-08	0.31	0.29	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
KIRC	cis	rs7927771	0.524	rs10742817	ENSG00000280615.1	Y_RNA	-6.71	5.18e-11	2.04e-08	-0.3	-0.29	Subjective well-being;	chr11:47667791	chr11:47614898~47614994:-
KIRC	cis	rs17772222	0.74	rs1999177	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88508298	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs1999176	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88508371	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs1864746	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88508455	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs1864747	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88508523	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs7151164	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88509329	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs12433026	ENSG00000222990.1	RNU4-22P	6.71	5.18e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88509495	chr14:88513498~88513663:+
KIRC	cis	rs7674212	0.531	rs4699048	ENSG00000230069.3	LRRC37A15P	-6.71	5.18e-11	2.05e-08	-0.31	-0.29	Type 2 diabetes;	chr4:103005570	chr4:102727274~102730721:-
KIRC	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-6.71	5.19e-11	2.05e-08	-0.39	-0.29	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
KIRC	cis	rs17772222	0.74	rs61975276	ENSG00000222990.1	RNU4-22P	6.71	5.19e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88511193	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs61975277	ENSG00000222990.1	RNU4-22P	6.71	5.19e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88511202	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs61975278	ENSG00000222990.1	RNU4-22P	6.71	5.19e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88511223	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs61984675	ENSG00000222990.1	RNU4-22P	6.71	5.19e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88511236	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs73317739	ENSG00000222990.1	RNU4-22P	6.71	5.19e-11	2.05e-08	0.32	0.29	Coronary artery calcification;	chr14:88511400	chr14:88513498~88513663:+
KIRC	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-6.71	5.19e-11	2.05e-08	-0.54	-0.29	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
KIRC	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-6.71	5.19e-11	2.05e-08	-0.27	-0.29	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
KIRC	cis	rs11089937	0.523	rs4821832	ENSG00000211639.2	IGLV4-60	6.71	5.19e-11	2.05e-08	0.27	0.29	Periodontitis (PAL4Q3);	chr22:22188499	chr22:22162199~22162681:+
KIRC	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	6.71	5.19e-11	2.05e-08	0.27	0.29	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
KIRC	cis	rs6504622	0.728	rs7222781	ENSG00000262879.4	RP11-156P1.3	-6.71	5.19e-11	2.05e-08	-0.24	-0.29	Orofacial clefts;	chr17:47100059	chr17:46984045~47100323:-
KIRC	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	6.71	5.2e-11	2.05e-08	0.21	0.29	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
KIRC	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	6.71	5.2e-11	2.05e-08	0.42	0.29	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
KIRC	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	6.71	5.2e-11	2.05e-08	0.39	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
KIRC	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	6.71	5.2e-11	2.05e-08	0.24	0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
KIRC	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	6.71	5.21e-11	2.06e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
KIRC	cis	rs7017914	0.652	rs10957533	ENSG00000254031.4	RP11-326E22.1	-6.71	5.21e-11	2.06e-08	-0.33	-0.29	Bone mineral density;	chr8:70912872	chr8:71155457~71204223:+
KIRC	cis	rs3002142	0.908	rs3002139	ENSG00000272750.1	RP11-378J18.8	-6.71	5.22e-11	2.06e-08	-0.41	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222611722	chr1:222658867~222661512:-
KIRC	cis	rs62025270	0.632	rs13379832	ENSG00000202081.1	RNU6-1280P	-6.71	5.22e-11	2.06e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85651522~85651628:-
KIRC	cis	rs17772222	1	rs1955599	ENSG00000222990.1	RNU4-22P	6.71	5.23e-11	2.06e-08	0.34	0.29	Coronary artery calcification;	chr14:88358788	chr14:88513498~88513663:+
KIRC	cis	rs17772222	1	rs1955600	ENSG00000222990.1	RNU4-22P	6.71	5.23e-11	2.06e-08	0.34	0.29	Coronary artery calcification;	chr14:88359040	chr14:88513498~88513663:+
KIRC	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-6.71	5.23e-11	2.06e-08	-0.24	-0.29	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
KIRC	cis	rs919433	0.617	rs4850807	ENSG00000231621.1	AC013264.2	6.71	5.24e-11	2.06e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197711251	chr2:197197991~197199273:+
KIRC	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	6.71	5.24e-11	2.07e-08	0.42	0.29	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
KIRC	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-6.71	5.25e-11	2.07e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
KIRC	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-6.71	5.26e-11	2.07e-08	-0.38	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
KIRC	cis	rs10214930	0.767	rs42087	ENSG00000235574.1	AC073150.6	6.71	5.26e-11	2.07e-08	0.36	0.29	Hypospadias;	chr7:27660863	chr7:27491682~27492765:-
KIRC	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	6.71	5.26e-11	2.07e-08	0.28	0.29	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.527	rs62296943	ENSG00000196472.4	RP13-644M16.4	6.71	5.27e-11	2.08e-08	0.33	0.29	Obesity-related traits;	chr4:69093465	chr4:69181660~69182372:+
KIRC	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-6.71	5.27e-11	2.08e-08	-0.51	-0.29	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
KIRC	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-6.71	5.28e-11	2.08e-08	-0.29	-0.29	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
KIRC	cis	rs919433	0.713	rs2045245	ENSG00000231621.1	AC013264.2	-6.71	5.29e-11	2.08e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197620617	chr2:197197991~197199273:+
KIRC	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	6.71	5.29e-11	2.08e-08	0.26	0.29	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
KIRC	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.3e-11	2.09e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
KIRC	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	6.71	5.3e-11	2.09e-08	0.3	0.29	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
KIRC	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	6.71	5.3e-11	2.09e-08	0.39	0.29	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
KIRC	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.3e-11	2.09e-08	-0.31	-0.29	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.3e-11	2.09e-08	-0.31	-0.29	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
KIRC	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	6.71	5.31e-11	2.09e-08	0.28	0.29	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
KIRC	cis	rs4356975	0.518	rs78408800	ENSG00000250919.1	RP11-813N20.3	-6.71	5.31e-11	2.09e-08	-0.36	-0.29	Obesity-related traits;	chr4:69101657	chr4:69027831~69044578:+
KIRC	cis	rs4356975	0.518	rs4314347	ENSG00000250919.1	RP11-813N20.3	-6.71	5.31e-11	2.09e-08	-0.36	-0.29	Obesity-related traits;	chr4:69102209	chr4:69027831~69044578:+
KIRC	cis	rs72772090	0.539	rs11748795	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.31e-11	2.09e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96832353	chr5:96784777~96785999:+
KIRC	cis	rs4072705	0.557	rs1886124	ENSG00000224020.1	MIR181A2HG	-6.71	5.32e-11	2.09e-08	-0.31	-0.29	Menarche (age at onset);	chr9:124470928	chr9:124658467~124698631:+
KIRC	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	6.71	5.32e-11	2.09e-08	0.45	0.29	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	6.71	5.32e-11	2.09e-08	0.45	0.29	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
KIRC	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.32e-11	2.09e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
KIRC	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-6.71	5.33e-11	2.1e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
KIRC	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-6.71	5.33e-11	2.1e-08	-0.21	-0.29	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
KIRC	cis	rs755249	0.567	rs67408364	ENSG00000182109.6	RP11-69E11.4	6.71	5.34e-11	2.1e-08	0.25	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39522280~39546187:-
KIRC	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-6.71	5.34e-11	2.1e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
KIRC	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	6.71	5.34e-11	2.1e-08	0.21	0.29	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
KIRC	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-6.71	5.34e-11	2.1e-08	-0.32	-0.29	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
KIRC	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	6.71	5.34e-11	2.1e-08	0.3	0.29	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
KIRC	cis	rs3820928	0.648	rs1997484	ENSG00000212391.1	SNORA48	-6.71	5.35e-11	2.1e-08	-0.33	-0.29	Pulmonary function;	chr2:227034246	chr2:226968989~226969122:-
KIRC	cis	rs934734	0.532	rs7569113	ENSG00000281920.1	RP11-418H16.1	6.71	5.35e-11	2.11e-08	0.35	0.29	Rheumatoid arthritis;	chr2:65429907	chr2:65623272~65628424:+
KIRC	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-6.71	5.35e-11	2.11e-08	-0.32	-0.29	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
KIRC	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	6.71	5.35e-11	2.11e-08	0.68	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
KIRC	cis	rs13434995	0.562	rs10529258	ENSG00000273257.1	RP11-177J6.1	-6.71	5.35e-11	2.11e-08	-0.39	-0.29	Adiponectin levels;	chr4:55546702	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.512	rs115635692	ENSG00000273257.1	RP11-177J6.1	-6.71	5.35e-11	2.11e-08	-0.39	-0.29	Adiponectin levels;	chr4:55546706	chr4:55387949~55388271:+
KIRC	cis	rs13434995	0.626	rs116135676	ENSG00000273257.1	RP11-177J6.1	-6.71	5.35e-11	2.11e-08	-0.39	-0.29	Adiponectin levels;	chr4:55546707	chr4:55387949~55388271:+
KIRC	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
KIRC	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.36e-11	2.11e-08	-0.31	-0.29	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
KIRC	cis	rs2486288	0.656	rs8039153	ENSG00000235390.4	CTD-2651B20.5	6.71	5.36e-11	2.11e-08	0.27	0.29	Glomerular filtration rate;	chr15:45287615	chr15:45321077~45321692:-
KIRC	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-6.71	5.37e-11	2.11e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
KIRC	cis	rs9847710	0.838	rs2581795	ENSG00000280417.1	RP11-5O17.1	6.71	5.38e-11	2.12e-08	0.33	0.29	Ulcerative colitis;	chr3:53004770	chr3:53046166~53048122:+
KIRC	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.71	5.38e-11	2.12e-08	0.27	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
KIRC	cis	rs72772090	0.539	rs11135480	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.39e-11	2.12e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774878	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs13601	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.39e-11	2.12e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774892	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs56120748	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.39e-11	2.12e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96774918	chr5:96784777~96785999:+
KIRC	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	6.71	5.39e-11	2.12e-08	0.52	0.29	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
KIRC	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.39e-11	2.12e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
KIRC	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	6.71	5.41e-11	2.13e-08	0.17	0.29	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
KIRC	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-6.71	5.41e-11	2.13e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
KIRC	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-6.71	5.41e-11	2.13e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
KIRC	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	6.71	5.42e-11	2.13e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
KIRC	cis	rs7246657	0.606	rs2972439	ENSG00000267422.1	CTD-2554C21.1	6.71	5.42e-11	2.13e-08	0.42	0.29	Coronary artery calcification;	chr19:37721680	chr19:37779686~37792865:+
KIRC	cis	rs7246657	0.722	rs2909100	ENSG00000267422.1	CTD-2554C21.1	6.71	5.42e-11	2.13e-08	0.42	0.29	Coronary artery calcification;	chr19:37721779	chr19:37779686~37792865:+
KIRC	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.71	5.43e-11	2.13e-08	-0.31	-0.29	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
KIRC	cis	rs6908034	0.607	rs34109983	ENSG00000228412.5	RP4-625H18.2	6.71	5.43e-11	2.14e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19802164~19804752:-
KIRC	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-6.71	5.43e-11	2.14e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
KIRC	cis	rs6480314	0.542	rs61854810	ENSG00000233590.1	RP11-153K11.3	-6.71	5.44e-11	2.14e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68264139	chr10:68233251~68242379:-
KIRC	cis	rs17801127	0.688	rs73003910	ENSG00000231969.1	AC144449.1	6.71	5.44e-11	2.14e-08	0.54	0.29	Liver enzyme levels (alanine transaminase);	chr2:149822905	chr2:149587196~149848233:+
KIRC	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-6.71	5.45e-11	2.14e-08	-0.31	-0.29	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
KIRC	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	6.71	5.45e-11	2.14e-08	0.37	0.29	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
KIRC	cis	rs9601248	0.627	rs9545151	ENSG00000227676.3	LINC01068	-6.71	5.45e-11	2.14e-08	-0.38	-0.29	Major depressive disorder;	chr13:79608400	chr13:79566727~79571436:+
KIRC	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	6.71	5.45e-11	2.14e-08	0.28	0.29	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
KIRC	cis	rs2749592	0.611	rs176888	ENSG00000151963.4	RP11-775A3.1	-6.71	5.46e-11	2.14e-08	-0.36	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:37883594~37884109:+
KIRC	cis	rs8048589	1	rs12596549	ENSG00000175604.2	RP11-276H1.3	-6.71	5.46e-11	2.15e-08	-0.34	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12089643	chr16:12086746~12090302:-
KIRC	cis	rs7829975	0.523	rs9644774	ENSG00000253893.2	FAM85B	6.71	5.46e-11	2.15e-08	0.37	0.29	Mood instability;	chr8:8702322	chr8:8167819~8226614:-
KIRC	cis	rs7017914	0.652	rs62530770	ENSG00000254031.4	RP11-326E22.1	6.71	5.47e-11	2.15e-08	0.33	0.29	Bone mineral density;	chr8:70688761	chr8:71155457~71204223:+
KIRC	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	6.71	5.47e-11	2.15e-08	0.28	0.29	QT interval;	chr12:29284120	chr12:29280418~29317848:-
KIRC	cis	rs919433	0.617	rs12619333	ENSG00000231621.1	AC013264.2	6.71	5.47e-11	2.15e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197702914	chr2:197197991~197199273:+
KIRC	cis	rs2337406	0.714	rs7152055	ENSG00000274576.2	IGHV2-70	-6.71	5.48e-11	2.15e-08	-0.35	-0.29	Alzheimer's disease (late onset);	chr14:106818996	chr14:106770577~106771020:-
KIRC	cis	rs8048589	1	rs12599090	ENSG00000175604.2	RP11-276H1.3	-6.71	5.48e-11	2.15e-08	-0.35	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093484	chr16:12086746~12090302:-
KIRC	cis	rs7017914	0.652	rs1845217	ENSG00000254031.4	RP11-326E22.1	6.71	5.48e-11	2.15e-08	0.33	0.29	Bone mineral density;	chr8:70985016	chr8:71155457~71204223:+
KIRC	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	6.71	5.49e-11	2.16e-08	0.49	0.29	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	6.71	5.49e-11	2.16e-08	0.49	0.29	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
KIRC	cis	rs4888671	1	rs79917044	ENSG00000261707.1	RP11-264M12.2	6.71	5.49e-11	2.16e-08	0.44	0.29	Obesity-related traits;	chr16:77750514	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs74805725	ENSG00000261707.1	RP11-264M12.2	6.71	5.49e-11	2.16e-08	0.44	0.29	Obesity-related traits;	chr16:77750587	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs76986350	ENSG00000261707.1	RP11-264M12.2	6.71	5.49e-11	2.16e-08	0.44	0.29	Obesity-related traits;	chr16:77750841	chr16:77741468~77743000:-
KIRC	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-6.71	5.49e-11	2.16e-08	-0.29	-0.29	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
KIRC	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-6.7	5.52e-11	2.17e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-6.7	5.52e-11	2.17e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-6.7	5.52e-11	2.17e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
KIRC	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-6.7	5.52e-11	2.17e-08	-0.31	-0.29	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
KIRC	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-6.7	5.53e-11	2.17e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
KIRC	cis	rs2281636	0.754	rs7092699	ENSG00000233690.1	EBAG9P1	6.7	5.53e-11	2.17e-08	0.28	0.29	Obesity-related traits;	chr10:99605545	chr10:99697407~99697949:-
KIRC	cis	rs2797160	0.651	rs1268092	ENSG00000237742.5	RP11-624M8.1	-6.7	5.53e-11	2.17e-08	-0.34	-0.29	Endometrial cancer;	chr6:125707897	chr6:125578558~125749190:-
KIRC	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-6.7	5.54e-11	2.18e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
KIRC	cis	rs755249	0.567	rs41270821	ENSG00000237624.1	OXCT2P1	6.7	5.55e-11	2.18e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs2296175	ENSG00000237624.1	OXCT2P1	6.7	5.55e-11	2.18e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39514956~39516490:+
KIRC	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-6.7	5.55e-11	2.18e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
KIRC	cis	rs3820928	0.874	rs12105952	ENSG00000212391.1	SNORA48	-6.7	5.55e-11	2.18e-08	-0.33	-0.29	Pulmonary function;	chr2:226999805	chr2:226968989~226969122:-
KIRC	cis	rs9915657	0.87	rs918081	ENSG00000234899.8	SOX9-AS1	-6.7	5.56e-11	2.18e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72131667	chr17:72034107~72237203:-
KIRC	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	6.7	5.56e-11	2.18e-08	0.31	0.29	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
KIRC	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	6.7	5.57e-11	2.18e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
KIRC	cis	rs7017914	0.652	rs62508777	ENSG00000254031.4	RP11-326E22.1	6.7	5.57e-11	2.19e-08	0.33	0.29	Bone mineral density;	chr8:70782769	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs6986479	ENSG00000254031.4	RP11-326E22.1	6.7	5.57e-11	2.19e-08	0.33	0.29	Bone mineral density;	chr8:70785323	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35115647	ENSG00000254031.4	RP11-326E22.1	6.7	5.57e-11	2.19e-08	0.33	0.29	Bone mineral density;	chr8:70785777	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1444339	ENSG00000254031.4	RP11-326E22.1	6.7	5.57e-11	2.19e-08	0.33	0.29	Bone mineral density;	chr8:70788407	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.616	rs55855305	ENSG00000254031.4	RP11-326E22.1	6.7	5.57e-11	2.19e-08	0.33	0.29	Bone mineral density;	chr8:70790642	chr8:71155457~71204223:+
KIRC	cis	rs11647589	0.834	rs4603548	ENSG00000260762.1	ACSM5P1	6.7	5.57e-11	2.19e-08	0.29	0.29	Blood metabolite levels;	chr16:20472639	chr16:20586550~20607107:-
KIRC	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	6.7	5.57e-11	2.19e-08	0.19	0.29	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
KIRC	cis	rs17772222	0.958	rs2297128	ENSG00000222990.1	RNU4-22P	6.7	5.58e-11	2.19e-08	0.35	0.29	Coronary artery calcification;	chr14:88469910	chr14:88513498~88513663:+
KIRC	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	6.7	5.58e-11	2.19e-08	0.26	0.29	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
KIRC	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	6.7	5.59e-11	2.19e-08	0.35	0.29	Height;	chr11:118860890	chr11:118688039~118690600:-
KIRC	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	6.7	5.59e-11	2.19e-08	0.35	0.29	Height;	chr11:118861053	chr11:118688039~118690600:-
KIRC	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-6.7	5.6e-11	2.2e-08	-0.21	-0.29	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
KIRC	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-6.7	5.6e-11	2.2e-08	-0.37	-0.29	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
KIRC	cis	rs643506	0.874	rs634983	ENSG00000230911.1	PPIHP1	-6.7	5.6e-11	2.2e-08	-0.34	-0.29	Breast cancer;	chr11:111876703	chr11:112029858~112030367:-
KIRC	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-6.7	5.61e-11	2.2e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
KIRC	cis	rs919433	0.617	rs10460394	ENSG00000231621.1	AC013264.2	6.7	5.61e-11	2.2e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197684017	chr2:197197991~197199273:+
KIRC	cis	rs1198872	0.892	rs1198865	ENSG00000272275.1	RP11-791G15.2	-6.7	5.61e-11	2.2e-08	-0.38	-0.29	Cardiac Troponin-T levels;	chr2:10760936	chr2:10767875~10770058:-
KIRC	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.7	5.62e-11	2.2e-08	0.32	0.29	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.7	5.62e-11	2.2e-08	0.32	0.29	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.7	5.62e-11	2.2e-08	0.32	0.29	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	6.7	5.62e-11	2.2e-08	0.32	0.29	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
KIRC	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.62e-11	2.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.62e-11	2.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.62e-11	2.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.62e-11	2.2e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
KIRC	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-6.7	5.64e-11	2.21e-08	-0.33	-0.29	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
KIRC	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-6.7	5.64e-11	2.21e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
KIRC	cis	rs12188164	0.686	rs72711367	ENSG00000225138.6	CTD-2228K2.7	6.7	5.64e-11	2.21e-08	0.33	0.29	Cystic fibrosis severity;	chr5:418379	chr5:473236~480884:+
KIRC	cis	rs4934494	0.911	rs7098233	ENSG00000232936.4	RP11-80H5.2	-6.7	5.64e-11	2.21e-08	-0.38	-0.29	Red blood cell count;	chr10:89663111	chr10:89645282~89650667:+
KIRC	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-6.7	5.64e-11	2.21e-08	-0.36	-0.29	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-6.7	5.64e-11	2.21e-08	-0.36	-0.29	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
KIRC	cis	rs7264396	0.79	rs4519606	ENSG00000088340.14	FER1L4	-6.7	5.65e-11	2.21e-08	-0.22	-0.29	Total cholesterol levels;	chr20:35736726	chr20:35558737~35607562:-
KIRC	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-6.7	5.65e-11	2.21e-08	-0.26	-0.29	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
KIRC	cis	rs17772222	0.917	rs77382318	ENSG00000222990.1	RNU4-22P	6.7	5.65e-11	2.21e-08	0.34	0.29	Coronary artery calcification;	chr14:88355785	chr14:88513498~88513663:+
KIRC	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-6.7	5.65e-11	2.21e-08	-0.44	-0.29	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
KIRC	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	6.7	5.66e-11	2.22e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
KIRC	cis	rs4664293	0.715	rs13002625	ENSG00000226266.5	AC009961.3	6.7	5.67e-11	2.22e-08	0.32	0.29	Monocyte percentage of white cells;	chr2:159648114	chr2:159670708~159712435:-
KIRC	cis	rs2337406	1	rs7145100	ENSG00000274576.2	IGHV2-70	-6.7	5.67e-11	2.22e-08	-0.34	-0.29	Alzheimer's disease (late onset);	chr14:106704673	chr14:106770577~106771020:-
KIRC	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-6.7	5.67e-11	2.22e-08	-0.31	-0.29	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-6.7	5.69e-11	2.23e-08	-0.28	-0.29	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
KIRC	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-6.7	5.7e-11	2.23e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
KIRC	cis	rs3745672	1	rs10405348	ENSG00000219665.7	CTD-2006C1.2	-6.7	5.71e-11	2.23e-08	-0.54	-0.29	Multiple sclerosis;	chr19:11952038	chr19:11987617~12046275:+
KIRC	cis	rs3745672	1	rs7256759	ENSG00000219665.7	CTD-2006C1.2	-6.7	5.71e-11	2.23e-08	-0.54	-0.29	Multiple sclerosis;	chr19:11954195	chr19:11987617~12046275:+
KIRC	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	6.7	5.71e-11	2.23e-08	0.38	0.29	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
KIRC	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-6.7	5.71e-11	2.23e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-6.7	5.71e-11	2.23e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
KIRC	cis	rs6061231	0.724	rs1570027	ENSG00000275437.1	RP5-908M14.10	6.7	5.71e-11	2.24e-08	0.26	0.29	Colorectal cancer;	chr20:62393540	chr20:62402236~62405935:-
KIRC	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-6.7	5.71e-11	2.24e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
KIRC	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	6.7	5.72e-11	2.24e-08	0.29	0.29	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	6.7	5.72e-11	2.24e-08	0.29	0.29	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	6.7	5.72e-11	2.24e-08	0.29	0.29	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
KIRC	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	6.7	5.72e-11	2.24e-08	0.55	0.29	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
KIRC	cis	rs2797160	0.904	rs1418637	ENSG00000237742.5	RP11-624M8.1	-6.7	5.73e-11	2.24e-08	-0.34	-0.29	Endometrial cancer;	chr6:125671407	chr6:125578558~125749190:-
KIRC	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	6.7	5.74e-11	2.25e-08	0.33	0.29	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
KIRC	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	6.7	5.74e-11	2.25e-08	0.33	0.29	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
KIRC	cis	rs6728642	0.908	rs10203833	ENSG00000230606.9	AC159540.1	6.7	5.75e-11	2.25e-08	0.32	0.29	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97356336	chr2:97416165~97433527:-
KIRC	cis	rs17801127	0.818	rs16827301	ENSG00000231969.1	AC144449.1	6.7	5.75e-11	2.25e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149654608	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs17496121	ENSG00000231969.1	AC144449.1	6.7	5.75e-11	2.25e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149654906	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.748	rs71413657	ENSG00000231969.1	AC144449.1	6.7	5.75e-11	2.25e-08	0.53	0.29	Liver enzyme levels (alanine transaminase);	chr2:149656807	chr2:149587196~149848233:+
KIRC	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-6.7	5.76e-11	2.25e-08	-0.23	-0.29	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
KIRC	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-6.7	5.76e-11	2.25e-08	-0.47	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
KIRC	cis	rs7017914	0.652	rs7814774	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70934881	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs62506898	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70935267	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs17689989	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70936769	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs17768191	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70939642	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.629	rs17690181	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70942231	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13273873	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70942984	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs13280740	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70946286	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639910	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70949649	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs3098859	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70952797	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.545	rs3110268	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70953933	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.617	rs2732144	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70954384	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.617	rs2639949	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70954781	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.617	rs2639950	ENSG00000254031.4	RP11-326E22.1	6.7	5.76e-11	2.25e-08	0.33	0.29	Bone mineral density;	chr8:70954823	chr8:71155457~71204223:+
KIRC	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-6.7	5.76e-11	2.25e-08	-0.44	-0.29	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
KIRC	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-6.7	5.76e-11	2.25e-08	-0.44	-0.29	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
KIRC	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6.7	5.76e-11	2.25e-08	0.32	0.29	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
KIRC	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-6.7	5.77e-11	2.25e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
KIRC	cis	rs17772222	0.74	rs10143744	ENSG00000222990.1	RNU4-22P	6.7	5.77e-11	2.26e-08	0.32	0.29	Coronary artery calcification;	chr14:88508073	chr14:88513498~88513663:+
KIRC	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	6.7	5.78e-11	2.26e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
KIRC	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-6.7	5.79e-11	2.26e-08	-0.38	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
KIRC	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.79e-11	2.26e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
KIRC	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	6.7	5.79e-11	2.26e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
KIRC	cis	rs12681420	0.754	rs34471605	ENSG00000254031.4	RP11-326E22.1	6.7	5.8e-11	2.27e-08	0.33	0.29	Erythrocyte cadmium concentration in never smokers;	chr8:70849983	chr8:71155457~71204223:+
KIRC	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-6.7	5.81e-11	2.27e-08	-0.25	-0.29	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
KIRC	cis	rs2486288	0.656	rs11637364	ENSG00000235390.4	CTD-2651B20.5	6.7	5.81e-11	2.27e-08	0.27	0.29	Glomerular filtration rate;	chr15:45287040	chr15:45321077~45321692:-
KIRC	cis	rs1552244	0.572	rs41464050	ENSG00000180385.7	EMC3-AS1	6.7	5.81e-11	2.27e-08	0.31	0.29	Alzheimer's disease;	chr3:10116709	chr3:9986893~10006990:+
KIRC	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-6.7	5.81e-11	2.27e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
KIRC	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-6.7	5.81e-11	2.27e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
KIRC	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	6.7	5.81e-11	2.27e-08	0.35	0.29	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
KIRC	cis	rs12049351	0.774	rs6662732	ENSG00000229367.1	HMGN2P19	-6.7	5.81e-11	2.27e-08	-0.39	-0.29	Circulating myeloperoxidase levels (plasma);	chr1:229493498	chr1:229570532~229570796:+
KIRC	cis	rs4888671	1	rs57935196	ENSG00000261707.1	RP11-264M12.2	6.7	5.83e-11	2.28e-08	0.44	0.29	Obesity-related traits;	chr16:77751417	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs57678958	ENSG00000261707.1	RP11-264M12.2	6.7	5.83e-11	2.28e-08	0.44	0.29	Obesity-related traits;	chr16:77751418	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs78841515	ENSG00000261707.1	RP11-264M12.2	6.7	5.83e-11	2.28e-08	0.44	0.29	Obesity-related traits;	chr16:77751558	chr16:77741468~77743000:-
KIRC	cis	rs4820539	0.902	rs4822359	ENSG00000221069.1	AC000029.1	-6.7	5.83e-11	2.28e-08	-0.35	-0.29	Bone mineral density;	chr22:23132785	chr22:23136620~23136710:+
KIRC	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-6.7	5.83e-11	2.28e-08	-0.22	-0.29	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
KIRC	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-6.7	5.83e-11	2.28e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
KIRC	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	6.7	5.83e-11	2.28e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	6.7	5.83e-11	2.28e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	6.7	5.83e-11	2.28e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
KIRC	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	6.7	5.84e-11	2.28e-08	0.19	0.29	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
KIRC	cis	rs2980439	0.517	rs712253	ENSG00000253893.2	FAM85B	6.7	5.85e-11	2.28e-08	0.38	0.29	Neuroticism;	chr8:8246260	chr8:8167819~8226614:-
KIRC	cis	rs4538475	0.556	rs4613561	ENSG00000214846.4	RP11-115L11.1	6.7	5.85e-11	2.29e-08	0.4	0.29	Parkinson's disease;	chr4:15736267	chr4:15730962~15731627:-
KIRC	cis	rs17772222	0.958	rs74074098	ENSG00000222990.1	RNU4-22P	6.7	5.85e-11	2.29e-08	0.35	0.29	Coronary artery calcification;	chr14:88484213	chr14:88513498~88513663:+
KIRC	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	6.7	5.85e-11	2.29e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
KIRC	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-6.7	5.86e-11	2.29e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
KIRC	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	6.7	5.86e-11	2.29e-08	0.25	0.29	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
KIRC	cis	rs7267979	0.932	rs6115200	ENSG00000125804.12	FAM182A	-6.7	5.86e-11	2.29e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.932	rs6138588	ENSG00000125804.12	FAM182A	-6.7	5.86e-11	2.29e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:26054655~26086917:+
KIRC	cis	rs4888671	1	rs58484838	ENSG00000261707.1	RP11-264M12.2	6.7	5.86e-11	2.29e-08	0.44	0.29	Obesity-related traits;	chr16:77749240	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs60923631	ENSG00000261707.1	RP11-264M12.2	6.7	5.86e-11	2.29e-08	0.44	0.29	Obesity-related traits;	chr16:77749472	chr16:77741468~77743000:-
KIRC	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-6.69	5.87e-11	2.29e-08	-0.31	-0.29	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
KIRC	cis	rs1552244	1	rs7628448	ENSG00000180385.7	EMC3-AS1	6.69	5.88e-11	2.3e-08	0.3	0.29	Alzheimer's disease;	chr3:10105144	chr3:9986893~10006990:+
KIRC	cis	rs35264875	0.796	rs72930637	ENSG00000259799.1	RP11-554A11.9	6.69	5.88e-11	2.3e-08	0.37	0.29	Blond vs. brown hair color;	chr11:69102499	chr11:69155910~69159752:+
KIRC	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	6.69	5.88e-11	2.3e-08	0.29	0.29	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
KIRC	cis	rs3093024	0.935	rs10946216	ENSG00000265828.1	MIR3939	6.69	5.88e-11	2.3e-08	0.33	0.29	Rheumatoid arthritis;	chr6:167125409	chr6:166997807~166997912:-
KIRC	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-6.69	5.89e-11	2.3e-08	-0.38	-0.29	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
KIRC	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-6.69	5.89e-11	2.3e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
KIRC	cis	rs1153858	1	rs2668747	ENSG00000235390.4	CTD-2651B20.5	-6.69	5.89e-11	2.3e-08	-0.28	-0.29	Homoarginine levels;	chr15:45325018	chr15:45321077~45321692:-
KIRC	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	6.69	5.89e-11	2.3e-08	0.31	0.29	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
KIRC	cis	rs8048589	0.948	rs11648468	ENSG00000175604.2	RP11-276H1.3	6.69	5.9e-11	2.3e-08	0.34	0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087653	chr16:12086746~12090302:-
KIRC	cis	rs3820928	0.709	rs2894627	ENSG00000212391.1	SNORA48	-6.69	5.94e-11	2.32e-08	-0.35	-0.29	Pulmonary function;	chr2:227045455	chr2:226968989~226969122:-
KIRC	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	6.69	5.94e-11	2.32e-08	0.28	0.29	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
KIRC	cis	rs4820539	0.641	rs5759602	ENSG00000221069.1	AC000029.1	6.69	5.94e-11	2.32e-08	0.36	0.29	Bone mineral density;	chr22:23147175	chr22:23136620~23136710:+
KIRC	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-6.69	5.95e-11	2.32e-08	-0.22	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
KIRC	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	6.69	5.95e-11	2.32e-08	0.27	0.29	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
KIRC	cis	rs7397814	0.558	rs4764447	ENSG00000260423.1	RP13-735L24.1	6.69	5.95e-11	2.32e-08	0.28	0.29	IgG glycosylation;	chr12:9426513	chr12:9367464~9397617:+
KIRC	cis	rs10214930	0.813	rs2391447	ENSG00000235574.1	AC073150.6	-6.69	5.95e-11	2.32e-08	-0.36	-0.29	Hypospadias;	chr7:27634945	chr7:27491682~27492765:-
KIRC	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-6.69	5.95e-11	2.32e-08	-0.38	-0.29	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-6.69	5.95e-11	2.32e-08	-0.38	-0.29	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-6.69	5.95e-11	2.32e-08	-0.38	-0.29	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-6.69	5.95e-11	2.32e-08	-0.38	-0.29	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
KIRC	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-6.69	5.96e-11	2.32e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-6.69	5.96e-11	2.32e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-6.69	5.96e-11	2.32e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-6.69	5.96e-11	2.32e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
KIRC	cis	rs12049351	0.774	rs6668018	ENSG00000229367.1	HMGN2P19	6.69	5.96e-11	2.32e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229493306	chr1:229570532~229570796:+
KIRC	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-6.69	5.97e-11	2.33e-08	-0.36	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
KIRC	cis	rs62025270	0.649	rs12148610	ENSG00000202081.1	RNU6-1280P	-6.69	5.97e-11	2.33e-08	-0.37	-0.29	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85651522~85651628:-
KIRC	cis	rs919433	0.783	rs787979	ENSG00000231621.1	AC013264.2	-6.69	5.97e-11	2.33e-08	-0.3	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197378144	chr2:197197991~197199273:+
KIRC	cis	rs7017914	0.616	rs12681114	ENSG00000254031.4	RP11-326E22.1	6.69	5.98e-11	2.33e-08	0.34	0.29	Bone mineral density;	chr8:70750263	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.616	rs12679132	ENSG00000254031.4	RP11-326E22.1	6.69	5.98e-11	2.33e-08	0.34	0.29	Bone mineral density;	chr8:70750270	chr8:71155457~71204223:+
KIRC	cis	rs1005277	0.522	rs7090858	ENSG00000235197.1	ZNF33AP1	6.69	5.98e-11	2.33e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:37894637~37896666:+
KIRC	cis	rs2439831	0.867	rs2255042	ENSG00000249839.1	AC011330.5	6.69	5.98e-11	2.33e-08	0.51	0.29	Lung cancer in ever smokers;	chr15:43542120	chr15:43663654~43684339:-
KIRC	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	6.69	5.98e-11	2.33e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	6.69	5.98e-11	2.33e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
KIRC	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-6.69	5.99e-11	2.34e-08	-0.27	-0.29	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
KIRC	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	6.69	6e-11	2.34e-08	0.42	0.29	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
KIRC	cis	rs2412819	0.52	rs17727763	ENSG00000249839.1	AC011330.5	-6.69	6e-11	2.34e-08	-0.49	-0.29	Lung cancer;	chr15:43623873	chr15:43663654~43684339:-
KIRC	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.69	6e-11	2.34e-08	-0.34	-0.29	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
KIRC	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-6.69	6e-11	2.34e-08	-0.31	-0.29	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
KIRC	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	6.69	6e-11	2.34e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
KIRC	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	6.69	6.01e-11	2.34e-08	0.3	0.29	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
KIRC	cis	rs2564921	0.73	rs62255898	ENSG00000280417.1	RP11-5O17.1	6.69	6.02e-11	2.35e-08	0.37	0.29	Height;	chr3:53029908	chr3:53046166~53048122:+
KIRC	cis	rs2564921	0.73	rs62255895	ENSG00000280417.1	RP11-5O17.1	6.69	6.03e-11	2.35e-08	0.37	0.29	Height;	chr3:53027969	chr3:53046166~53048122:+
KIRC	cis	rs6480314	0.542	rs4403687	ENSG00000233590.1	RP11-153K11.3	-6.69	6.03e-11	2.35e-08	-0.41	-0.29	Optic nerve measurement (disc area);	chr10:68268295	chr10:68233251~68242379:-
KIRC	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	6.69	6.04e-11	2.36e-08	0.31	0.29	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
KIRC	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	6.69	6.05e-11	2.36e-08	0.29	0.29	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
KIRC	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	6.69	6.05e-11	2.36e-08	0.35	0.29	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
KIRC	cis	rs919433	0.68	rs7568250	ENSG00000231621.1	AC013264.2	-6.69	6.05e-11	2.36e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197544887	chr2:197197991~197199273:+
KIRC	cis	rs755249	0.567	rs41270803	ENSG00000237624.1	OXCT2P1	6.69	6.05e-11	2.36e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs61783376	ENSG00000237624.1	OXCT2P1	6.69	6.05e-11	2.36e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39514956~39516490:+
KIRC	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-6.69	6.07e-11	2.37e-08	-0.32	-0.29	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
KIRC	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-6.69	6.07e-11	2.37e-08	-0.23	-0.29	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
KIRC	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	6.69	6.07e-11	2.37e-08	0.38	0.29	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
KIRC	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	6.69	6.08e-11	2.37e-08	0.32	0.29	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	6.69	6.08e-11	2.37e-08	0.32	0.29	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
KIRC	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	6.69	6.08e-11	2.37e-08	0.3	0.29	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
KIRC	cis	rs755249	0.567	rs61779306	ENSG00000237624.1	OXCT2P1	6.69	6.09e-11	2.37e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39514956~39516490:+
KIRC	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	6.69	6.1e-11	2.38e-08	0.42	0.29	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
KIRC	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	6.69	6.1e-11	2.38e-08	0.42	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
KIRC	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	6.69	6.1e-11	2.38e-08	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	6.69	6.1e-11	2.38e-08	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.69	6.1e-11	2.38e-08	0.7	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
KIRC	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-6.69	6.11e-11	2.38e-08	-0.27	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
KIRC	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-6.69	6.11e-11	2.38e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
KIRC	cis	rs17772222	1	rs79579293	ENSG00000222990.1	RNU4-22P	6.69	6.11e-11	2.38e-08	0.34	0.29	Coronary artery calcification;	chr14:88355724	chr14:88513498~88513663:+
KIRC	cis	rs755249	0.567	rs113214136	ENSG00000237624.1	OXCT2P1	6.69	6.11e-11	2.38e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs3768302	ENSG00000237624.1	OXCT2P1	6.69	6.11e-11	2.38e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.532	rs17343193	ENSG00000237624.1	OXCT2P1	6.69	6.11e-11	2.38e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs61779300	ENSG00000237624.1	OXCT2P1	6.69	6.11e-11	2.38e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39514956~39516490:+
KIRC	cis	rs1560104	1	rs1560104	ENSG00000274834.1	CTD-3037G24.5	-6.69	6.12e-11	2.38e-08	-0.32	-0.29	Obesity-related traits;	chr16:12614351	chr16:12614451~12614852:+
KIRC	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-6.69	6.12e-11	2.39e-08	-0.38	-0.29	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-6.69	6.12e-11	2.39e-08	-0.38	-0.29	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-6.69	6.12e-11	2.39e-08	-0.38	-0.29	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-6.69	6.12e-11	2.39e-08	-0.38	-0.29	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
KIRC	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-6.69	6.13e-11	2.39e-08	-0.4	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
KIRC	cis	rs4925386	1	rs4925382	ENSG00000275437.1	RP5-908M14.10	-6.69	6.14e-11	2.39e-08	-0.24	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62402236~62405935:-
KIRC	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-6.69	6.14e-11	2.39e-08	-0.3	-0.29	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
KIRC	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	6.69	6.14e-11	2.39e-08	0.34	0.29	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
KIRC	cis	rs1005277	0.522	rs11011343	ENSG00000235197.1	ZNF33AP1	-6.69	6.16e-11	2.4e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:37894637~37896666:+
KIRC	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-6.69	6.16e-11	2.4e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
KIRC	cis	rs6061231	0.546	rs482220	ENSG00000275437.1	RP5-908M14.10	-6.69	6.16e-11	2.4e-08	-0.24	-0.29	Colorectal cancer;	chr20:62352426	chr20:62402236~62405935:-
KIRC	cis	rs11647589	0.834	rs1910802	ENSG00000260762.1	ACSM5P1	6.69	6.16e-11	2.4e-08	0.29	0.29	Blood metabolite levels;	chr16:20464245	chr16:20586550~20607107:-
KIRC	cis	rs11079159	1	rs876719	ENSG00000263096.1	RP11-515O17.2	6.69	6.18e-11	2.4e-08	0.43	0.29	QRS duration;	chr17:55289205	chr17:55271504~55273653:-
KIRC	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-6.69	6.18e-11	2.41e-08	-0.25	-0.29	Height;	chr2:46640019	chr2:46668870~46670778:+
KIRC	cis	rs17772222	0.74	rs3783885	ENSG00000222990.1	RNU4-22P	6.69	6.19e-11	2.41e-08	0.32	0.29	Coronary artery calcification;	chr14:88510714	chr14:88513498~88513663:+
KIRC	cis	rs1552244	0.572	rs6797536	ENSG00000180385.7	EMC3-AS1	-6.69	6.19e-11	2.41e-08	-0.31	-0.29	Alzheimer's disease;	chr3:10127118	chr3:9986893~10006990:+
KIRC	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	6.69	6.2e-11	2.41e-08	0.28	0.29	Asthma;	chr2:102351547	chr2:102438713~102440475:+
KIRC	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	6.69	6.2e-11	2.41e-08	0.4	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
KIRC	cis	rs3002142	0.908	rs3008608	ENSG00000272750.1	RP11-378J18.8	-6.69	6.2e-11	2.41e-08	-0.41	-0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222612656	chr1:222658867~222661512:-
KIRC	cis	rs919433	0.617	rs10931793	ENSG00000231621.1	AC013264.2	6.69	6.2e-11	2.41e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197712861	chr2:197197991~197199273:+
KIRC	cis	rs6565653	1	rs6565653	ENSG00000262580.4	RP11-334C17.5	6.69	6.21e-11	2.42e-08	0.17	0.29	Ischemic stroke;	chr17:80227984	chr17:80200673~80205949:-
KIRC	cis	rs755249	0.567	rs61779308	ENSG00000237624.1	OXCT2P1	6.69	6.21e-11	2.42e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39514956~39516490:+
KIRC	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	6.69	6.21e-11	2.42e-08	0.37	0.29	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
KIRC	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-6.69	6.21e-11	2.42e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
KIRC	cis	rs12049351	0.774	rs16849844	ENSG00000229367.1	HMGN2P19	-6.69	6.22e-11	2.42e-08	-0.39	-0.29	Circulating myeloperoxidase levels (plasma);	chr1:229484649	chr1:229570532~229570796:+
KIRC	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	6.69	6.22e-11	2.42e-08	0.27	0.29	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
KIRC	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	6.69	6.23e-11	2.42e-08	0.25	0.29	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
KIRC	cis	rs11647589	0.553	rs7195201	ENSG00000260762.1	ACSM5P1	6.69	6.23e-11	2.42e-08	0.29	0.29	Blood metabolite levels;	chr16:20467280	chr16:20586550~20607107:-
KIRC	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-6.69	6.23e-11	2.42e-08	-0.44	-0.29	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
KIRC	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-6.69	6.23e-11	2.42e-08	-0.44	-0.29	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
KIRC	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-6.69	6.23e-11	2.42e-08	-0.44	-0.29	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
KIRC	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-6.69	6.24e-11	2.43e-08	-0.35	-0.29	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
KIRC	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-6.68	6.24e-11	2.43e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-6.68	6.24e-11	2.43e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-6.68	6.24e-11	2.43e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
KIRC	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.68	6.24e-11	2.43e-08	-0.31	-0.29	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
KIRC	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	6.68	6.25e-11	2.43e-08	0.33	0.29	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
KIRC	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-6.68	6.25e-11	2.43e-08	-0.28	-0.29	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-6.68	6.25e-11	2.43e-08	-0.28	-0.29	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
KIRC	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	6.68	6.26e-11	2.43e-08	0.27	0.29	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
KIRC	cis	rs9915657	0.87	rs4140902	ENSG00000234899.8	SOX9-AS1	-6.68	6.26e-11	2.44e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72137609	chr17:72034107~72237203:-
KIRC	cis	rs6061231	0.798	rs2427308	ENSG00000275437.1	RP5-908M14.10	6.68	6.27e-11	2.44e-08	0.26	0.29	Colorectal cancer;	chr20:62394395	chr20:62402236~62405935:-
KIRC	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-6.68	6.28e-11	2.44e-08	-0.46	-0.29	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
KIRC	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-6.68	6.28e-11	2.44e-08	-0.4	-0.29	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
KIRC	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	6.68	6.29e-11	2.45e-08	0.25	0.29	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
KIRC	cis	rs4767841	0.562	rs10849683	ENSG00000248636.5	RP11-768F21.1	-6.68	6.3e-11	2.45e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119624203	chr12:119387987~119668079:-
KIRC	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-6.68	6.3e-11	2.45e-08	-0.39	-0.29	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
KIRC	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	6.68	6.3e-11	2.45e-08	0.28	0.29	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
KIRC	cis	rs10214930	0.651	rs42111	ENSG00000235574.1	AC073150.6	6.68	6.31e-11	2.45e-08	0.33	0.29	Hypospadias;	chr7:27682962	chr7:27491682~27492765:-
KIRC	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-6.68	6.32e-11	2.46e-08	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
KIRC	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	6.68	6.32e-11	2.46e-08	0.35	0.29	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
KIRC	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
KIRC	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	6.68	6.32e-11	2.46e-08	0.44	0.29	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
KIRC	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-6.68	6.33e-11	2.46e-08	-0.31	-0.29	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
KIRC	cis	rs4888671	1	rs4888671	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749683	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs4888672	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749769	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs4888673	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749806	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs4888674	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749852	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs4888675	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749860	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs4888676	ENSG00000261707.1	RP11-264M12.2	6.68	6.34e-11	2.46e-08	0.44	0.29	Obesity-related traits;	chr16:77749999	chr16:77741468~77743000:-
KIRC	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-6.68	6.34e-11	2.46e-08	-0.38	-0.29	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
KIRC	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-6.68	6.34e-11	2.46e-08	-0.3	-0.29	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
KIRC	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-6.68	6.34e-11	2.46e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
KIRC	cis	rs2361718	0.5	rs12451697	ENSG00000279259.1	RP11-334C17.3	6.68	6.34e-11	2.47e-08	0.29	0.29	Yeast infection;	chr17:80126891	chr17:80147250~80148596:+
KIRC	cis	rs6480314	0.542	rs61854809	ENSG00000233590.1	RP11-153K11.3	-6.68	6.34e-11	2.47e-08	-0.42	-0.29	Optic nerve measurement (disc area);	chr10:68262847	chr10:68233251~68242379:-
KIRC	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	6.68	6.35e-11	2.47e-08	0.21	0.29	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
KIRC	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	6.68	6.35e-11	2.47e-08	0.29	0.29	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
KIRC	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-6.68	6.35e-11	2.47e-08	-0.31	-0.29	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
KIRC	cis	rs4578769	0.569	rs12957183	ENSG00000266850.1	RP11-370A5.1	6.68	6.36e-11	2.47e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22927124	chr18:22723491~22907721:-
KIRC	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	6.68	6.37e-11	2.47e-08	0.3	0.29	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
KIRC	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	6.68	6.37e-11	2.47e-08	0.31	0.29	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
KIRC	cis	rs3750965	1	rs12285715	ENSG00000260895.1	RP11-554A11.7	6.68	6.37e-11	2.47e-08	0.38	0.29	Hair color;	chr11:69054180	chr11:69103493~69109094:+
KIRC	cis	rs2273788	0.837	rs1053968	ENSG00000204173.9	LRRC37A5P	6.68	6.37e-11	2.48e-08	0.43	0.29	Monocyte count;	chr9:111590312	chr9:111602831~111631289:-
KIRC	cis	rs7100025	0.67	rs10827778	ENSG00000151963.4	RP11-775A3.1	6.68	6.37e-11	2.48e-08	0.35	0.29	Pediatric autoimmune diseases;	chr10:37388741	chr10:37883594~37884109:+
KIRC	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-6.68	6.38e-11	2.48e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
KIRC	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-6.68	6.38e-11	2.48e-08	-0.31	-0.29	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
KIRC	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-6.68	6.39e-11	2.48e-08	-0.16	-0.29	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
KIRC	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-6.68	6.39e-11	2.48e-08	-0.16	-0.29	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
KIRC	cis	rs4888671	1	rs78036474	ENSG00000261707.1	RP11-264M12.2	6.68	6.39e-11	2.48e-08	0.44	0.29	Obesity-related traits;	chr16:77751824	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs59181394	ENSG00000261707.1	RP11-264M12.2	6.68	6.39e-11	2.48e-08	0.44	0.29	Obesity-related traits;	chr16:77752058	chr16:77741468~77743000:-
KIRC	cis	rs4888671	1	rs58729171	ENSG00000261707.1	RP11-264M12.2	6.68	6.39e-11	2.48e-08	0.44	0.29	Obesity-related traits;	chr16:77752121	chr16:77741468~77743000:-
KIRC	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-6.68	6.39e-11	2.48e-08	-0.28	-0.29	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
KIRC	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.68	6.39e-11	2.48e-08	0.3	0.29	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
KIRC	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-6.68	6.4e-11	2.48e-08	-0.39	-0.29	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
KIRC	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	6.68	6.4e-11	2.49e-08	0.27	0.29	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
KIRC	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-6.68	6.41e-11	2.49e-08	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
KIRC	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	6.68	6.41e-11	2.49e-08	0.3	0.29	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
KIRC	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	6.68	6.41e-11	2.49e-08	0.29	0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
KIRC	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-6.68	6.41e-11	2.49e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
KIRC	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-6.68	6.42e-11	2.49e-08	-0.32	-0.29	Height;	chr2:231516587	chr2:231508426~231514339:-
KIRC	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	6.68	6.43e-11	2.5e-08	0.21	0.29	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
KIRC	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	6.68	6.44e-11	2.5e-08	0.35	0.29	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
KIRC	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	6.68	6.44e-11	2.5e-08	0.35	0.29	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
KIRC	cis	rs11846409	0.86	rs73378154	ENSG00000274576.2	IGHV2-70	-6.68	6.44e-11	2.5e-08	-0.32	-0.29	Rheumatic heart disease;	chr14:106637687	chr14:106770577~106771020:-
KIRC	cis	rs10276381	0.786	rs10272155	ENSG00000234336.5	JAZF1-AS1	-6.68	6.45e-11	2.5e-08	-0.52	-0.29	Crohn's disease;	chr7:28207370	chr7:28180322~28243917:+
KIRC	cis	rs7267979	0.899	rs6115213	ENSG00000125804.12	FAM182A	-6.68	6.45e-11	2.5e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:26054655~26086917:+
KIRC	cis	rs7924176	0.521	rs61863363	ENSG00000213731.2	RAB5CP1	-6.68	6.45e-11	2.5e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74423435~74424014:-
KIRC	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-6.68	6.45e-11	2.5e-08	-0.28	-0.29	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
KIRC	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-6.68	6.47e-11	2.51e-08	-0.43	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
KIRC	cis	rs6496932	0.563	rs2344083	ENSG00000202081.1	RNU6-1280P	-6.68	6.47e-11	2.51e-08	-0.3	-0.29	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85651522~85651628:-
KIRC	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	6.68	6.48e-11	2.51e-08	0.31	0.29	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
KIRC	cis	rs643506	0.874	rs663511	ENSG00000230911.1	PPIHP1	-6.68	6.48e-11	2.51e-08	-0.34	-0.29	Breast cancer;	chr11:111839311	chr11:112029858~112030367:-
KIRC	cis	rs4767841	0.552	rs11064855	ENSG00000248636.5	RP11-768F21.1	-6.68	6.48e-11	2.51e-08	-0.3	-0.29	Urgency urinary incontinence;	chr12:119626986	chr12:119387987~119668079:-
KIRC	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-6.68	6.49e-11	2.52e-08	-0.29	-0.29	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
KIRC	cis	rs919433	0.68	rs1563340	ENSG00000231621.1	AC013264.2	-6.68	6.49e-11	2.52e-08	-0.32	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197549989	chr2:197197991~197199273:+
KIRC	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	6.68	6.49e-11	2.52e-08	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
KIRC	cis	rs7017914	0.628	rs1389198	ENSG00000254031.4	RP11-326E22.1	6.68	6.5e-11	2.52e-08	0.33	0.29	Bone mineral density;	chr8:70921872	chr8:71155457~71204223:+
KIRC	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-6.68	6.5e-11	2.52e-08	-0.31	-0.29	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
KIRC	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	6.68	6.52e-11	2.53e-08	0.35	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
KIRC	cis	rs7017914	0.652	rs62533063	ENSG00000254031.4	RP11-326E22.1	6.68	6.53e-11	2.53e-08	0.33	0.29	Bone mineral density;	chr8:70673824	chr8:71155457~71204223:+
KIRC	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-6.68	6.53e-11	2.53e-08	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
KIRC	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102350776	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.765	rs6751967	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102350953	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.765	rs6751977	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102350970	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.765	rs6704565	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102350971	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.801	rs6734742	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102351397	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.801	rs6752482	ENSG00000234389.1	AC007278.3	6.68	6.53e-11	2.53e-08	0.28	0.29	Asthma;	chr2:102351398	chr2:102438713~102440475:+
KIRC	cis	rs6908034	0.607	rs73376657	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs74573060	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs113592672	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs113894708	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.546	rs73376662	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19802164~19804752:-
KIRC	cis	rs6908034	0.607	rs12529148	ENSG00000228412.5	RP4-625H18.2	6.68	6.54e-11	2.53e-08	0.62	0.29	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19802164~19804752:-
KIRC	cis	rs7267979	1	rs2500424	ENSG00000125804.12	FAM182A	6.68	6.54e-11	2.54e-08	0.36	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:26054655~26086917:+
KIRC	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6.68	6.54e-11	2.54e-08	-0.31	-0.29	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
KIRC	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-6.68	6.54e-11	2.54e-08	-0.28	-0.29	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
KIRC	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	6.68	6.54e-11	2.54e-08	0.45	0.29	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
KIRC	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	6.68	6.54e-11	2.54e-08	0.29	0.29	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
KIRC	cis	rs4761702	0.661	rs12423139	ENSG00000257252.4	RP11-486A14.2	-6.68	6.55e-11	2.54e-08	-0.38	-0.29	Immature fraction of reticulocytes;	chr12:93336482	chr12:93317135~93377736:-
KIRC	cis	rs9388451	0.868	rs1268083	ENSG00000237742.5	RP11-624M8.1	6.68	6.55e-11	2.54e-08	0.35	0.29	Brugada syndrome;	chr6:125727894	chr6:125578558~125749190:-
KIRC	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-6.68	6.55e-11	2.54e-08	-0.37	-0.29	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
KIRC	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	6.68	6.55e-11	2.54e-08	0.35	0.29	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-6.68	6.55e-11	2.54e-08	-0.35	-0.29	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
KIRC	cis	rs2797160	0.651	rs9491503	ENSG00000237742.5	RP11-624M8.1	6.68	6.56e-11	2.54e-08	0.34	0.29	Endometrial cancer;	chr6:125710536	chr6:125578558~125749190:-
KIRC	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-6.68	6.56e-11	2.54e-08	-0.28	-0.29	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-6.68	6.56e-11	2.54e-08	-0.28	-0.29	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-6.68	6.56e-11	2.54e-08	-0.28	-0.29	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
KIRC	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-6.68	6.57e-11	2.54e-08	-0.23	-0.29	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
KIRC	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	6.68	6.57e-11	2.55e-08	0.43	0.29	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
KIRC	cis	rs7916697	0.947	rs9783176	ENSG00000233590.1	RP11-153K11.3	-6.68	6.58e-11	2.55e-08	-0.31	-0.29	Optic disc area;	chr10:68242636	chr10:68233251~68242379:-
KIRC	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	6.68	6.58e-11	2.55e-08	0.32	0.29	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
KIRC	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-6.68	6.58e-11	2.55e-08	-0.31	-0.29	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
KIRC	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	6.68	6.58e-11	2.55e-08	0.3	0.29	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	6.68	6.58e-11	2.55e-08	0.3	0.29	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	6.68	6.58e-11	2.55e-08	0.3	0.29	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
KIRC	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-6.68	6.58e-11	2.55e-08	-0.28	-0.29	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
KIRC	cis	rs755249	0.529	rs4660732	ENSG00000237624.1	OXCT2P1	6.68	6.59e-11	2.55e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	6.68	6.59e-11	2.55e-08	0.25	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
KIRC	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.68	6.6e-11	2.56e-08	0.33	0.29	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
KIRC	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.68	6.6e-11	2.56e-08	0.33	0.29	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
KIRC	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	6.68	6.61e-11	2.56e-08	0.67	0.29	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
KIRC	cis	rs17270561	0.666	rs4712976	ENSG00000272462.2	U91328.19	-6.68	6.61e-11	2.56e-08	-0.25	-0.29	Iron status biomarkers;	chr6:25841975	chr6:25992662~26001775:+
KIRC	cis	rs4925386	0.959	rs6121989	ENSG00000275437.1	RP5-908M14.10	-6.68	6.62e-11	2.56e-08	-0.23	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62402236~62405935:-
KIRC	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-6.68	6.62e-11	2.57e-08	-0.27	-0.29	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
KIRC	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	6.68	6.64e-11	2.57e-08	0.44	0.29	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
KIRC	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-6.67	6.66e-11	2.58e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
KIRC	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-6.67	6.66e-11	2.58e-08	-0.39	-0.29	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
KIRC	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	6.67	6.68e-11	2.58e-08	0.28	0.29	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
KIRC	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-6.67	6.68e-11	2.59e-08	-0.28	-0.29	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
KIRC	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.67	6.68e-11	2.59e-08	0.31	0.29	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
KIRC	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	6.67	6.68e-11	2.59e-08	0.5	0.29	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
KIRC	cis	rs62025270	0.632	rs80036674	ENSG00000202081.1	RNU6-1280P	-6.67	6.7e-11	2.59e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85651522~85651628:-
KIRC	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-6.67	6.7e-11	2.6e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
KIRC	cis	rs6452524	0.618	rs10051445	ENSG00000248112.1	RP11-78C3.1	6.67	6.71e-11	2.6e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82919376~82921119:-
KIRC	cis	rs12049351	0.774	rs12125125	ENSG00000229367.1	HMGN2P19	6.67	6.71e-11	2.6e-08	0.4	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229491919	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs12125978	ENSG00000229367.1	HMGN2P19	6.67	6.71e-11	2.6e-08	0.4	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229491975	chr1:229570532~229570796:+
KIRC	cis	rs10214930	0.697	rs7780431	ENSG00000235574.1	AC073150.6	-6.67	6.71e-11	2.6e-08	-0.34	-0.29	Hypospadias;	chr7:27553749	chr7:27491682~27492765:-
KIRC	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	6.67	6.72e-11	2.6e-08	0.35	0.29	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
KIRC	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.67	6.72e-11	2.6e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.67	6.72e-11	2.6e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
KIRC	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-6.67	6.72e-11	2.6e-08	-0.29	-0.29	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
KIRC	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	6.67	6.73e-11	2.6e-08	0.41	0.29	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
KIRC	cis	rs12893668	0.667	rs71417869	ENSG00000269910.1	RP11-73M18.10	6.67	6.73e-11	2.61e-08	0.2	0.29	Reticulocyte count;	chr14:103611097	chr14:103694516~103695050:-
KIRC	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-6.67	6.73e-11	2.61e-08	-0.3	-0.29	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
KIRC	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-6.67	6.74e-11	2.61e-08	-0.31	-0.29	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
KIRC	cis	rs7927771	0.524	rs11039329	ENSG00000280615.1	Y_RNA	6.67	6.74e-11	2.61e-08	0.3	0.29	Subjective well-being;	chr11:47663356	chr11:47614898~47614994:-
KIRC	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-6.67	6.74e-11	2.61e-08	-0.3	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
KIRC	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-6.67	6.75e-11	2.61e-08	-0.28	-0.29	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
KIRC	cis	rs1790761	0.559	rs10896190	ENSG00000255318.1	RP11-655M14.13	6.67	6.75e-11	2.61e-08	0.31	0.29	Mean corpuscular volume;	chr11:67638652	chr11:67618279~67627304:-
KIRC	cis	rs7267979	0.932	rs6132848	ENSG00000125804.12	FAM182A	-6.67	6.75e-11	2.61e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.932	rs6115215	ENSG00000125804.12	FAM182A	-6.67	6.75e-11	2.61e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:26054655~26086917:+
KIRC	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	6.67	6.76e-11	2.61e-08	0.37	0.29	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
KIRC	cis	rs712039	0.652	rs1829453	ENSG00000276054.1	RP11-378E13.3	6.67	6.76e-11	2.61e-08	0.37	0.29	Tuberculosis;	chr17:37449741	chr17:37386886~37387926:+
KIRC	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-6.67	6.76e-11	2.61e-08	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
KIRC	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	6.67	6.76e-11	2.62e-08	0.31	0.29	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	6.67	6.76e-11	2.62e-08	0.31	0.29	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
KIRC	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-6.67	6.76e-11	2.62e-08	-0.36	-0.29	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
KIRC	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	6.67	6.78e-11	2.62e-08	0.3	0.29	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
KIRC	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-6.67	6.79e-11	2.63e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
KIRC	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-6.67	6.8e-11	2.63e-08	-0.27	-0.29	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
KIRC	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-6.67	6.8e-11	2.63e-08	-0.27	-0.29	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
KIRC	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-6.67	6.8e-11	2.63e-08	-0.41	-0.29	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
KIRC	cis	rs375066	0.62	rs10401170	ENSG00000267058.1	RP11-15A1.3	6.67	6.81e-11	2.63e-08	0.33	0.29	Breast cancer;	chr19:43795471	chr19:43891804~43901805:-
KIRC	cis	rs8048589	1	rs11648816	ENSG00000175604.2	RP11-276H1.3	-6.67	6.82e-11	2.64e-08	-0.33	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090250	chr16:12086746~12090302:-
KIRC	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-6.67	6.82e-11	2.64e-08	-0.24	-0.29	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
KIRC	cis	rs9807989	0.773	rs72823661	ENSG00000234389.1	AC007278.3	6.67	6.83e-11	2.64e-08	0.28	0.29	Asthma;	chr2:102352256	chr2:102438713~102440475:+
KIRC	cis	rs13423976	1	rs13423976	ENSG00000231367.4	AC016995.3	-6.67	6.85e-11	2.65e-08	-0.38	-0.29	Gut microbiome composition (summer);	chr2:38518482	chr2:38406719~38515740:-
KIRC	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	6.67	6.87e-11	2.66e-08	0.27	0.29	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
KIRC	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-6.67	6.87e-11	2.66e-08	-0.3	-0.29	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
KIRC	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	6.67	6.89e-11	2.66e-08	0.33	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
KIRC	cis	rs919433	0.68	rs2564383	ENSG00000231621.1	AC013264.2	-6.67	6.89e-11	2.66e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197446138	chr2:197197991~197199273:+
KIRC	cis	rs7182621	0.622	rs12904160	ENSG00000182397.13	DNM1P46	6.67	6.89e-11	2.66e-08	0.32	0.29	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99790156~99806927:-
KIRC	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-6.67	6.89e-11	2.66e-08	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
KIRC	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	6.67	6.9e-11	2.67e-08	0.31	0.29	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
KIRC	cis	rs6061231	0.834	rs2427311	ENSG00000273619.1	RP5-908M14.9	-6.67	6.91e-11	2.67e-08	-0.23	-0.29	Colorectal cancer;	chr20:62395067	chr20:62386303~62386970:-
KIRC	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	6.67	6.91e-11	2.67e-08	0.27	0.29	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
KIRC	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-6.67	6.92e-11	2.67e-08	-0.41	-0.29	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
KIRC	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-6.67	6.92e-11	2.67e-08	-0.41	-0.29	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
KIRC	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-6.67	6.92e-11	2.67e-08	-0.41	-0.29	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
KIRC	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	6.67	6.92e-11	2.67e-08	0.31	0.29	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
KIRC	cis	rs7209700	0.963	rs1000232	ENSG00000228782.6	CTD-2026D20.3	-6.67	6.92e-11	2.68e-08	-0.33	-0.29	IgG glycosylation;	chr17:47279195	chr17:47450568~47492492:-
KIRC	cis	rs10214930	0.697	rs6974387	ENSG00000235574.1	AC073150.6	-6.67	6.92e-11	2.68e-08	-0.33	-0.29	Hypospadias;	chr7:27626788	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.697	rs7806812	ENSG00000235574.1	AC073150.6	-6.67	6.92e-11	2.68e-08	-0.33	-0.29	Hypospadias;	chr7:27626960	chr7:27491682~27492765:-
KIRC	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-6.67	6.93e-11	2.68e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
KIRC	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-6.67	6.93e-11	2.68e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-6.67	6.93e-11	2.68e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-6.67	6.93e-11	2.68e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
KIRC	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-6.67	6.94e-11	2.68e-08	-0.28	-0.29	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
KIRC	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-6.67	6.95e-11	2.68e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
KIRC	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	6.67	6.98e-11	2.69e-08	0.32	0.29	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
KIRC	cis	rs7246657	0.722	rs2909102	ENSG00000267422.1	CTD-2554C21.1	6.67	6.98e-11	2.7e-08	0.42	0.29	Coronary artery calcification;	chr19:37676463	chr19:37779686~37792865:+
KIRC	cis	rs919433	0.713	rs10172961	ENSG00000231621.1	AC013264.2	-6.67	6.98e-11	2.7e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197582135	chr2:197197991~197199273:+
KIRC	cis	rs6480314	0.831	rs6480316	ENSG00000233590.1	RP11-153K11.3	6.67	6.98e-11	2.7e-08	0.4	0.29	Optic nerve measurement (disc area);	chr10:68212943	chr10:68233251~68242379:-
KIRC	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-6.67	6.98e-11	2.7e-08	-0.38	-0.29	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
KIRC	cis	rs2282300	0.91	rs528292	ENSG00000242353.1	RP4-710M3.1	6.67	6.99e-11	2.7e-08	0.35	0.29	Morning vs. evening chronotype;	chr11:30368163	chr11:30368148~30368646:+
KIRC	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	6.67	6.99e-11	2.7e-08	0.35	0.29	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
KIRC	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	6.67	6.99e-11	2.7e-08	0.38	0.29	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
KIRC	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-6.67	7e-11	2.7e-08	-0.23	-0.29	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
KIRC	cis	rs3745672	1	rs28655955	ENSG00000219665.7	CTD-2006C1.2	-6.67	7e-11	2.7e-08	-0.58	-0.29	Multiple sclerosis;	chr19:11953956	chr19:11987617~12046275:+
KIRC	cis	rs11647589	0.641	rs1394676	ENSG00000260762.1	ACSM5P1	6.67	7e-11	2.7e-08	0.29	0.29	Blood metabolite levels;	chr16:20477880	chr16:20586550~20607107:-
KIRC	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	6.67	7.01e-11	2.71e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
KIRC	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	6.67	7.02e-11	2.71e-08	0.3	0.29	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
KIRC	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	6.67	7.02e-11	2.71e-08	0.26	0.29	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
KIRC	cis	rs6452524	0.618	rs6452506	ENSG00000248112.1	RP11-78C3.1	6.67	7.03e-11	2.72e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82919376~82921119:-
KIRC	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-6.67	7.04e-11	2.72e-08	-0.4	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
KIRC	cis	rs12681963	0.688	rs73242322	ENSG00000248159.1	HSPA8P11	6.67	7.04e-11	2.72e-08	0.48	0.29	Migraine;	chr8:30177573	chr8:30237382~30240997:+
KIRC	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-6.67	7.05e-11	2.72e-08	-0.41	-0.29	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
KIRC	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-6.67	7.06e-11	2.73e-08	-0.27	-0.29	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
KIRC	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.67	7.07e-11	2.73e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
KIRC	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	6.66	7.08e-11	2.73e-08	0.32	0.29	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
KIRC	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	6.66	7.08e-11	2.73e-08	0.24	0.29	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	6.66	7.08e-11	2.73e-08	0.24	0.29	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
KIRC	cis	rs13236243	0.673	rs11764350	ENSG00000226598.1	AC017060.1	-6.66	7.08e-11	2.73e-08	-0.35	-0.29	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17382489	chr7:17463445~17558909:-
KIRC	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-6.66	7.09e-11	2.73e-08	-0.19	-0.29	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
KIRC	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.66	7.09e-11	2.73e-08	0.25	0.29	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.66	7.09e-11	2.73e-08	0.25	0.29	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.66	7.09e-11	2.73e-08	0.25	0.29	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
KIRC	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	6.66	7.1e-11	2.74e-08	0.31	0.29	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
KIRC	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-6.66	7.1e-11	2.74e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
KIRC	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	6.66	7.1e-11	2.74e-08	0.38	0.29	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
KIRC	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	6.66	7.1e-11	2.74e-08	0.32	0.29	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	6.66	7.1e-11	2.74e-08	0.32	0.29	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
KIRC	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	6.66	7.1e-11	2.74e-08	0.28	0.29	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
KIRC	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	6.66	7.1e-11	2.74e-08	0.28	0.29	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
KIRC	cis	rs9915657	0.933	rs4793272	ENSG00000226101.1	AC007461.2	-6.66	7.11e-11	2.74e-08	-0.29	-0.29	Thyroid hormone levels;	chr17:72143116	chr17:72072333~72093481:+
KIRC	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-6.66	7.11e-11	2.74e-08	-0.44	-0.29	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
KIRC	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-6.66	7.12e-11	2.74e-08	-0.19	-0.29	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
KIRC	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.66	7.12e-11	2.75e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.66	7.12e-11	2.75e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	6.66	7.12e-11	2.75e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	6.66	7.12e-11	2.75e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
KIRC	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	6.66	7.12e-11	2.75e-08	0.42	0.29	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
KIRC	cis	rs7100025	0.72	rs1938420	ENSG00000151963.4	RP11-775A3.1	6.66	7.12e-11	2.75e-08	0.34	0.29	Pediatric autoimmune diseases;	chr10:37372416	chr10:37883594~37884109:+
KIRC	cis	rs7100025	0.67	rs7097666	ENSG00000151963.4	RP11-775A3.1	6.66	7.12e-11	2.75e-08	0.34	0.29	Pediatric autoimmune diseases;	chr10:37372878	chr10:37883594~37884109:+
KIRC	cis	rs7017914	0.652	rs34643336	ENSG00000254031.4	RP11-326E22.1	6.66	7.12e-11	2.75e-08	0.33	0.29	Bone mineral density;	chr8:70715718	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.629	rs35621553	ENSG00000254031.4	RP11-326E22.1	6.66	7.12e-11	2.75e-08	0.33	0.29	Bone mineral density;	chr8:70715840	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs78322467	ENSG00000254031.4	RP11-326E22.1	6.66	7.12e-11	2.75e-08	0.33	0.29	Bone mineral density;	chr8:70716439	chr8:71155457~71204223:+
KIRC	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	6.66	7.13e-11	2.75e-08	0.33	0.29	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
KIRC	cis	rs7017914	0.652	rs12156043	ENSG00000254031.4	RP11-326E22.1	6.66	7.14e-11	2.75e-08	0.33	0.29	Bone mineral density;	chr8:70701808	chr8:71155457~71204223:+
KIRC	cis	rs17772222	1	rs56987357	ENSG00000222990.1	RNU4-22P	6.66	7.14e-11	2.75e-08	0.34	0.29	Coronary artery calcification;	chr14:88358019	chr14:88513498~88513663:+
KIRC	cis	rs4356975	0.563	rs7439152	ENSG00000196472.4	RP13-644M16.4	6.66	7.14e-11	2.75e-08	0.33	0.29	Obesity-related traits;	chr4:69103288	chr4:69181660~69182372:+
KIRC	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-6.66	7.15e-11	2.75e-08	-0.39	-0.29	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
KIRC	cis	rs1005277	0.54	rs4934907	ENSG00000235197.1	ZNF33AP1	-6.66	7.15e-11	2.75e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:37894637~37896666:+
KIRC	cis	rs1005277	0.54	rs11011351	ENSG00000235197.1	ZNF33AP1	-6.66	7.15e-11	2.75e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:37894637~37896666:+
KIRC	cis	rs7924176	0.668	rs7895133	ENSG00000213731.2	RAB5CP1	-6.66	7.15e-11	2.76e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74423435~74424014:-
KIRC	cis	rs1005277	0.522	rs1208767	ENSG00000235197.1	ZNF33AP1	-6.66	7.16e-11	2.76e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:37894637~37896666:+
KIRC	cis	rs3093024	0.967	rs1571878	ENSG00000265828.1	MIR3939	6.66	7.16e-11	2.76e-08	0.33	0.29	Rheumatoid arthritis;	chr6:167127354	chr6:166997807~166997912:-
KIRC	cis	rs1790761	0.52	rs4930461	ENSG00000255318.1	RP11-655M14.13	6.66	7.16e-11	2.76e-08	0.33	0.29	Mean corpuscular volume;	chr11:67627424	chr11:67618279~67627304:-
KIRC	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-6.66	7.16e-11	2.76e-08	-0.59	-0.29	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
KIRC	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-6.66	7.17e-11	2.76e-08	-0.44	-0.29	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
KIRC	cis	rs4578769	0.513	rs2034933	ENSG00000266850.1	RP11-370A5.1	6.66	7.18e-11	2.77e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22918788	chr18:22723491~22907721:-
KIRC	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-6.66	7.19e-11	2.77e-08	-0.3	-0.29	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
KIRC	cis	rs7017914	0.667	rs3098862	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70965706	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639914	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70967418	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs2732139	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70967802	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639913	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70967929	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2639928	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70971414	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs2933847	ENSG00000254031.4	RP11-326E22.1	6.66	7.19e-11	2.77e-08	0.33	0.29	Bone mineral density;	chr8:70972946	chr8:71155457~71204223:+
KIRC	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	6.66	7.21e-11	2.77e-08	0.33	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
KIRC	cis	rs62025270	0.688	rs55738258	ENSG00000202081.1	RNU6-1280P	-6.66	7.21e-11	2.78e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.688	rs55957626	ENSG00000202081.1	RNU6-1280P	-6.66	7.21e-11	2.78e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.688	rs62025297	ENSG00000202081.1	RNU6-1280P	-6.66	7.21e-11	2.78e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.688	rs62025298	ENSG00000202081.1	RNU6-1280P	-6.66	7.21e-11	2.78e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85651522~85651628:-
KIRC	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-6.66	7.22e-11	2.78e-08	-0.38	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
KIRC	cis	rs3820928	0.874	rs10166456	ENSG00000212391.1	SNORA48	-6.66	7.22e-11	2.78e-08	-0.33	-0.29	Pulmonary function;	chr2:227035397	chr2:226968989~226969122:-
KIRC	cis	rs7267979	0.899	rs2104734	ENSG00000125804.12	FAM182A	-6.66	7.22e-11	2.78e-08	-0.36	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:26054655~26086917:+
KIRC	cis	rs1153858	1	rs11858495	ENSG00000235390.4	CTD-2651B20.5	6.66	7.23e-11	2.78e-08	0.28	0.29	Homoarginine levels;	chr15:45345464	chr15:45321077~45321692:-
KIRC	cis	rs890448	0.796	rs2471682	ENSG00000254531.1	FLJ20021	6.66	7.23e-11	2.79e-08	0.29	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428822	chr4:101347780~101348883:+
KIRC	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-6.66	7.25e-11	2.79e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
KIRC	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	6.66	7.25e-11	2.79e-08	0.28	0.29	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	6.66	7.25e-11	2.79e-08	0.28	0.29	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
KIRC	cis	rs2564921	0.704	rs57916015	ENSG00000280417.1	RP11-5O17.1	6.66	7.26e-11	2.79e-08	0.36	0.29	Height;	chr3:52971094	chr3:53046166~53048122:+
KIRC	cis	rs1552244	0.572	rs12107622	ENSG00000180385.7	EMC3-AS1	6.66	7.26e-11	2.8e-08	0.32	0.29	Alzheimer's disease;	chr3:10130214	chr3:9986893~10006990:+
KIRC	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	6.66	7.26e-11	2.8e-08	0.35	0.29	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
KIRC	cis	rs1560104	0.709	rs7200211	ENSG00000274834.1	CTD-3037G24.5	-6.66	7.26e-11	2.8e-08	-0.32	-0.29	Obesity-related traits;	chr16:12605083	chr16:12614451~12614852:+
KIRC	cis	rs2749592	0.588	rs2504144	ENSG00000151963.4	RP11-775A3.1	-6.66	7.27e-11	2.8e-08	-0.36	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:37883594~37884109:+
KIRC	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-6.66	7.27e-11	2.8e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
KIRC	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	6.66	7.27e-11	2.8e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
KIRC	cis	rs4538475	0.556	rs4266290	ENSG00000214846.4	RP11-115L11.1	6.66	7.28e-11	2.8e-08	0.4	0.29	Parkinson's disease;	chr4:15735495	chr4:15730962~15731627:-
KIRC	cis	rs4538475	0.556	rs4403048	ENSG00000214846.4	RP11-115L11.1	6.66	7.28e-11	2.8e-08	0.4	0.29	Parkinson's disease;	chr4:15735497	chr4:15730962~15731627:-
KIRC	cis	rs4356975	0.83	rs7435274	ENSG00000196472.4	RP13-644M16.4	6.66	7.28e-11	2.8e-08	0.33	0.29	Obesity-related traits;	chr4:69050281	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs7438808	ENSG00000196472.4	RP13-644M16.4	6.66	7.28e-11	2.8e-08	0.33	0.29	Obesity-related traits;	chr4:69050666	chr4:69181660~69182372:+
KIRC	cis	rs62025270	0.747	rs12324721	ENSG00000202081.1	RNU6-1280P	-6.66	7.29e-11	2.8e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85651522~85651628:-
KIRC	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-6.66	7.29e-11	2.81e-08	-0.3	-0.29	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
KIRC	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-6.66	7.32e-11	2.81e-08	-0.28	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
KIRC	cis	rs2797160	0.967	rs926854	ENSG00000237742.5	RP11-624M8.1	6.66	7.32e-11	2.82e-08	0.34	0.29	Endometrial cancer;	chr6:125700634	chr6:125578558~125749190:-
KIRC	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-6.66	7.33e-11	2.82e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
KIRC	cis	rs950776	0.714	rs17408276	ENSG00000261762.1	RP11-650L12.2	6.66	7.33e-11	2.82e-08	0.38	0.29	Sudden cardiac arrest;	chr15:78589276	chr15:78589123~78591276:-
KIRC	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.33e-11	2.82e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
KIRC	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.33e-11	2.82e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
KIRC	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.33e-11	2.82e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
KIRC	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	6.66	7.34e-11	2.82e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
KIRC	cis	rs3096299	0.542	rs1078578	ENSG00000274627.1	RP11-104N10.2	6.66	7.34e-11	2.82e-08	0.22	0.29	Multiple myeloma (IgH translocation);	chr16:89320526	chr16:89516797~89522217:+
KIRC	cis	rs890448	0.796	rs10009249	ENSG00000254531.1	FLJ20021	6.66	7.34e-11	2.82e-08	0.28	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369460	chr4:101347780~101348883:+
KIRC	cis	rs1005277	0.505	rs200910	ENSG00000235197.1	ZNF33AP1	-6.66	7.35e-11	2.83e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:37894637~37896666:+
KIRC	cis	rs4820539	1	rs4822358	ENSG00000221069.1	AC000029.1	-6.66	7.36e-11	2.83e-08	-0.35	-0.29	Bone mineral density;	chr22:23132608	chr22:23136620~23136710:+
KIRC	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-6.66	7.36e-11	2.83e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
KIRC	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	6.66	7.36e-11	2.83e-08	0.23	0.29	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
KIRC	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-6.66	7.38e-11	2.84e-08	-0.23	-0.29	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
KIRC	cis	rs7017914	0.652	rs2639911	ENSG00000254031.4	RP11-326E22.1	6.66	7.39e-11	2.84e-08	0.33	0.29	Bone mineral density;	chr8:70948477	chr8:71155457~71204223:+
KIRC	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-6.66	7.39e-11	2.84e-08	-0.31	-0.29	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
KIRC	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.66	7.41e-11	2.85e-08	0.3	0.29	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
KIRC	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.66	7.41e-11	2.85e-08	0.3	0.29	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
KIRC	cis	rs62025270	0.688	rs7182210	ENSG00000202081.1	RNU6-1280P	-6.66	7.45e-11	2.86e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85651522~85651628:-
KIRC	cis	rs4072705	0.9	rs4836992	ENSG00000224020.1	MIR181A2HG	-6.66	7.45e-11	2.86e-08	-0.3	-0.29	Menarche (age at onset);	chr9:124796011	chr9:124658467~124698631:+
KIRC	cis	rs62025270	0.688	rs7179917	ENSG00000202081.1	RNU6-1280P	-6.66	7.46e-11	2.87e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85651522~85651628:-
KIRC	cis	rs919433	0.68	rs787983	ENSG00000231621.1	AC013264.2	-6.66	7.47e-11	2.87e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197481073	chr2:197197991~197199273:+
KIRC	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-6.66	7.47e-11	2.87e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
KIRC	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-6.66	7.47e-11	2.87e-08	-0.31	-0.29	Gout;	chr7:66671562	chr7:66848496~66858136:+
KIRC	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-6.66	7.49e-11	2.88e-08	-0.31	-0.29	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
KIRC	cis	rs8048589	0.948	rs71385189	ENSG00000175604.2	RP11-276H1.3	-6.66	7.49e-11	2.88e-08	-0.34	-0.29	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088322	chr16:12086746~12090302:-
KIRC	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	6.66	7.5e-11	2.88e-08	0.32	0.29	Depression;	chr6:28198669	chr6:28073316~28074233:+
KIRC	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	6.66	7.51e-11	2.88e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
KIRC	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.66	7.51e-11	2.89e-08	0.4	0.29	Depression;	chr6:28364057	chr6:28943877~28944537:+
KIRC	cis	rs4578769	0.569	rs12326874	ENSG00000266850.1	RP11-370A5.1	6.66	7.51e-11	2.89e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22926670	chr18:22723491~22907721:-
KIRC	cis	rs17772222	0.74	rs11159857	ENSG00000222990.1	RNU4-22P	6.66	7.52e-11	2.89e-08	0.32	0.29	Coronary artery calcification;	chr14:88510796	chr14:88513498~88513663:+
KIRC	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	6.66	7.52e-11	2.89e-08	0.39	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
KIRC	cis	rs3744061	0.53	rs8182300	ENSG00000277382.1	RP11-318A15.8	6.66	7.52e-11	2.89e-08	0.33	0.29	Retinal arteriolar caliber;	chr17:76654526	chr17:76709760~76710045:+
KIRC	cis	rs712039	0.652	rs853222	ENSG00000276054.1	RP11-378E13.3	6.65	7.54e-11	2.9e-08	0.38	0.29	Tuberculosis;	chr17:37429923	chr17:37386886~37387926:+
KIRC	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-6.65	7.54e-11	2.9e-08	-0.7	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
KIRC	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-6.65	7.55e-11	2.9e-08	-0.23	-0.29	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
KIRC	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	6.65	7.55e-11	2.9e-08	0.28	0.29	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
KIRC	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-6.65	7.56e-11	2.9e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
KIRC	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	6.65	7.57e-11	2.91e-08	0.39	0.29	Depression;	chr6:28192182	chr6:28176188~28176674:+
KIRC	cis	rs9371601	0.859	rs214942	ENSG00000226193.1	RP3-398G3.5	-6.65	7.58e-11	2.91e-08	-0.31	-0.29	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152389867	chr6:152402398~152404966:+
KIRC	cis	rs7017914	0.652	rs1156955	ENSG00000254031.4	RP11-326E22.1	6.65	7.58e-11	2.91e-08	0.33	0.29	Bone mineral density;	chr8:70842724	chr8:71155457~71204223:+
KIRC	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-6.65	7.58e-11	2.91e-08	-0.23	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
KIRC	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-6.65	7.58e-11	2.91e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
KIRC	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-6.65	7.58e-11	2.91e-08	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
KIRC	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	6.65	7.58e-11	2.91e-08	0.29	0.29	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
KIRC	cis	rs1005277	0.505	rs13503	ENSG00000235197.1	ZNF33AP1	6.65	7.59e-11	2.91e-08	0.31	0.29	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:37894637~37896666:+
KIRC	cis	rs755249	0.567	rs72661961	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.532	rs61779277	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.532	rs61779278	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs2296172	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs61779279	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs76111861	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs72661965	ENSG00000237624.1	OXCT2P1	6.65	7.59e-11	2.91e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39514956~39516490:+
KIRC	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	6.65	7.6e-11	2.92e-08	0.44	0.29	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
KIRC	cis	rs1005277	0.505	rs1208689	ENSG00000235197.1	ZNF33AP1	-6.65	7.61e-11	2.92e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:37894637~37896666:+
KIRC	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	6.65	7.62e-11	2.92e-08	0.54	0.29	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
KIRC	cis	rs3820928	0.874	rs13423046	ENSG00000212391.1	SNORA48	-6.65	7.62e-11	2.92e-08	-0.33	-0.29	Pulmonary function;	chr2:227037089	chr2:226968989~226969122:-
KIRC	cis	rs3820928	0.874	rs10202239	ENSG00000212391.1	SNORA48	-6.65	7.62e-11	2.92e-08	-0.33	-0.29	Pulmonary function;	chr2:227037103	chr2:226968989~226969122:-
KIRC	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	6.65	7.62e-11	2.92e-08	0.31	0.29	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
KIRC	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	6.65	7.63e-11	2.93e-08	0.3	0.29	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
KIRC	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-6.65	7.63e-11	2.93e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-6.65	7.63e-11	2.93e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-6.65	7.63e-11	2.93e-08	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
KIRC	cis	rs4578769	0.569	rs12960915	ENSG00000266850.1	RP11-370A5.1	6.65	7.63e-11	2.93e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22924013	chr18:22723491~22907721:-
KIRC	cis	rs2436845	0.627	rs2679750	ENSG00000253669.3	KB-1732A1.1	-6.65	7.63e-11	2.93e-08	-0.33	-0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102805517~102809971:+
KIRC	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	6.65	7.64e-11	2.93e-08	0.4	0.29	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
KIRC	cis	rs7045881	0.558	rs62542707	ENSG00000254396.1	RP11-56F10.3	6.65	7.64e-11	2.93e-08	0.39	0.29	Schizophrenia;	chr9:27066936	chr9:27102630~27104728:+
KIRC	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	6.65	7.65e-11	2.94e-08	0.38	0.29	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
KIRC	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	6.65	7.66e-11	2.94e-08	0.25	0.29	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-6.65	7.66e-11	2.94e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
KIRC	cis	rs4356975	0.842	rs6600899	ENSG00000198277.6	RP11-468N14.09	6.65	7.66e-11	2.94e-08	0.31	0.29	Obesity-related traits;	chr4:69132295	chr4:68914928~68924741:-
KIRC	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-6.65	7.67e-11	2.94e-08	-0.31	-0.29	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
KIRC	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	6.65	7.67e-11	2.94e-08	0.28	0.29	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-6.65	7.68e-11	2.95e-08	-0.31	-0.29	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
KIRC	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	6.65	7.68e-11	2.95e-08	0.2	0.29	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
KIRC	cis	rs2797160	0.602	rs4897150	ENSG00000237742.5	RP11-624M8.1	-6.65	7.69e-11	2.95e-08	-0.34	-0.29	Endometrial cancer;	chr6:125664394	chr6:125578558~125749190:-
KIRC	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-6.65	7.7e-11	2.95e-08	-0.35	-0.29	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
KIRC	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-6.65	7.7e-11	2.95e-08	-0.35	-0.29	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
KIRC	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-6.65	7.7e-11	2.95e-08	-0.35	-0.29	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
KIRC	cis	rs4356975	0.563	rs7658752	ENSG00000196472.4	RP13-644M16.4	6.65	7.7e-11	2.95e-08	0.33	0.29	Obesity-related traits;	chr4:69112350	chr4:69181660~69182372:+
KIRC	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	6.65	7.7e-11	2.95e-08	0.26	0.29	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
KIRC	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-6.65	7.71e-11	2.96e-08	-0.24	-0.29	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
KIRC	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-6.65	7.71e-11	2.96e-08	-0.24	-0.29	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
KIRC	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	6.65	7.71e-11	2.96e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	6.65	7.71e-11	2.96e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
KIRC	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-6.65	7.71e-11	2.96e-08	-0.4	-0.29	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
KIRC	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-6.65	7.72e-11	2.96e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
KIRC	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	6.65	7.73e-11	2.96e-08	0.31	0.29	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
KIRC	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-6.65	7.74e-11	2.97e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
KIRC	cis	rs10214930	0.671	rs6462038	ENSG00000235574.1	AC073150.6	-6.65	7.75e-11	2.97e-08	-0.33	-0.29	Hypospadias;	chr7:27620831	chr7:27491682~27492765:-
KIRC	cis	rs10214930	0.752	rs1115347	ENSG00000235574.1	AC073150.6	-6.65	7.75e-11	2.97e-08	-0.33	-0.29	Hypospadias;	chr7:27622979	chr7:27491682~27492765:-
KIRC	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	6.65	7.76e-11	2.97e-08	0.39	0.29	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
KIRC	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	6.65	7.76e-11	2.97e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
KIRC	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	6.65	7.76e-11	2.97e-08	0.28	0.29	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
KIRC	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-6.65	7.77e-11	2.98e-08	-0.24	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
KIRC	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	6.65	7.77e-11	2.98e-08	0.24	0.29	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	6.65	7.77e-11	2.98e-08	0.24	0.29	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	6.65	7.77e-11	2.98e-08	0.24	0.29	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	6.65	7.77e-11	2.98e-08	0.24	0.29	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
KIRC	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-6.65	7.78e-11	2.98e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
KIRC	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-6.65	7.78e-11	2.98e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
KIRC	cis	rs62025270	0.632	rs17637411	ENSG00000202081.1	RNU6-1280P	-6.65	7.78e-11	2.98e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.58	rs62022938	ENSG00000202081.1	RNU6-1280P	-6.65	7.78e-11	2.98e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85651522~85651628:-
KIRC	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	6.65	7.78e-11	2.98e-08	0.42	0.29	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
KIRC	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	6.65	7.78e-11	2.98e-08	0.27	0.29	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
KIRC	cis	rs11647589	0.911	rs9923452	ENSG00000260762.1	ACSM5P1	6.65	7.79e-11	2.98e-08	0.29	0.29	Blood metabolite levels;	chr16:20457882	chr16:20586550~20607107:-
KIRC	cis	rs11647589	0.911	rs71373192	ENSG00000260762.1	ACSM5P1	6.65	7.79e-11	2.98e-08	0.29	0.29	Blood metabolite levels;	chr16:20458840	chr16:20586550~20607107:-
KIRC	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	6.65	7.79e-11	2.98e-08	0.41	0.29	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
KIRC	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	6.65	7.79e-11	2.99e-08	0.27	0.29	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
KIRC	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	6.65	7.79e-11	2.99e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
KIRC	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.65	7.79e-11	2.99e-08	0.3	0.29	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
KIRC	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-6.65	7.81e-11	2.99e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
KIRC	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.65	7.81e-11	2.99e-08	0.37	0.29	Height;	chr6:109370985	chr6:109382795~109383666:+
KIRC	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-6.65	7.82e-11	3e-08	-0.45	-0.29	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
KIRC	cis	rs4767841	0.552	rs10849682	ENSG00000248636.5	RP11-768F21.1	-6.65	7.82e-11	3e-08	-0.29	-0.29	Urgency urinary incontinence;	chr12:119622325	chr12:119387987~119668079:-
KIRC	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-6.65	7.86e-11	3.01e-08	-0.28	-0.29	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
KIRC	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-6.65	7.86e-11	3.01e-08	-0.28	-0.29	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
KIRC	cis	rs712039	0.652	rs853200	ENSG00000276054.1	RP11-378E13.3	6.65	7.87e-11	3.01e-08	0.38	0.29	Tuberculosis;	chr17:37444013	chr17:37386886~37387926:+
KIRC	cis	rs2486288	0.586	rs12909625	ENSG00000235390.4	CTD-2651B20.5	6.65	7.87e-11	3.02e-08	0.26	0.29	Glomerular filtration rate;	chr15:45279855	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.586	rs12909883	ENSG00000235390.4	CTD-2651B20.5	6.65	7.87e-11	3.02e-08	0.26	0.29	Glomerular filtration rate;	chr15:45279856	chr15:45321077~45321692:-
KIRC	cis	rs7017914	0.628	rs55740254	ENSG00000254031.4	RP11-326E22.1	6.65	7.88e-11	3.02e-08	0.33	0.29	Bone mineral density;	chr8:70928325	chr8:71155457~71204223:+
KIRC	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
KIRC	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	6.65	7.88e-11	3.02e-08	0.53	0.29	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
KIRC	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-6.65	7.9e-11	3.02e-08	-0.38	-0.29	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
KIRC	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	6.65	7.91e-11	3.03e-08	0.26	0.29	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
KIRC	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	6.65	7.91e-11	3.03e-08	0.28	0.29	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
KIRC	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	6.65	7.92e-11	3.03e-08	0.24	0.29	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	6.65	7.92e-11	3.03e-08	0.24	0.29	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	6.65	7.92e-11	3.03e-08	0.24	0.29	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	6.65	7.92e-11	3.03e-08	0.24	0.29	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
KIRC	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-6.65	7.92e-11	3.03e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
KIRC	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-6.65	7.92e-11	3.03e-08	-0.3	-0.29	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
KIRC	cis	rs11089937	0.616	rs66651705	ENSG00000211639.2	IGLV4-60	6.65	7.92e-11	3.03e-08	0.28	0.29	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22162199~22162681:+
KIRC	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	6.65	7.93e-11	3.04e-08	0.27	0.29	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
KIRC	cis	rs2564921	0.679	rs2115779	ENSG00000280417.1	RP11-5O17.1	6.65	7.93e-11	3.04e-08	0.36	0.29	Height;	chr3:52992698	chr3:53046166~53048122:+
KIRC	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-6.65	7.94e-11	3.04e-08	-0.38	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
KIRC	cis	rs9915657	0.933	rs17246133	ENSG00000226101.1	AC007461.2	-6.65	7.96e-11	3.04e-08	-0.29	-0.29	Thyroid hormone levels;	chr17:72144344	chr17:72072333~72093481:+
KIRC	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-6.65	7.97e-11	3.05e-08	-0.23	-0.29	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
KIRC	cis	rs4578769	0.55	rs4800442	ENSG00000266850.1	RP11-370A5.1	6.65	7.97e-11	3.05e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22958337	chr18:22723491~22907721:-
KIRC	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-6.65	7.98e-11	3.05e-08	-0.27	-0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
KIRC	cis	rs3750965	0.959	rs4930264	ENSG00000260895.1	RP11-554A11.7	6.65	7.98e-11	3.05e-08	0.36	0.29	Hair color;	chr11:69084713	chr11:69103493~69109094:+
KIRC	cis	rs1560104	0.584	rs12921820	ENSG00000274834.1	CTD-3037G24.5	-6.65	7.99e-11	3.06e-08	-0.32	-0.29	Obesity-related traits;	chr16:12606775	chr16:12614451~12614852:+
KIRC	cis	rs1560104	0.709	rs3919630	ENSG00000274834.1	CTD-3037G24.5	-6.65	7.99e-11	3.06e-08	-0.32	-0.29	Obesity-related traits;	chr16:12607086	chr16:12614451~12614852:+
KIRC	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	6.65	7.99e-11	3.06e-08	0.38	0.29	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
KIRC	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-6.65	7.99e-11	3.06e-08	-0.45	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
KIRC	cis	rs890448	0.796	rs10433980	ENSG00000254531.1	FLJ20021	6.65	8e-11	3.06e-08	0.28	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362429	chr4:101347780~101348883:+
KIRC	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	6.65	8.02e-11	3.07e-08	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
KIRC	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	6.64	8.02e-11	3.07e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	6.64	8.02e-11	3.07e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
KIRC	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	6.64	8.02e-11	3.07e-08	0.21	0.29	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
KIRC	cis	rs6860806	0.507	rs270615	ENSG00000233006.5	AC034220.3	6.64	8.03e-11	3.07e-08	0.23	0.29	Breast cancer;	chr5:132305880	chr5:132311285~132369916:-
KIRC	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	6.64	8.03e-11	3.07e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
KIRC	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-6.64	8.03e-11	3.07e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
KIRC	cis	rs11647589	0.678	rs6497489	ENSG00000260762.1	ACSM5P1	6.64	8.04e-11	3.08e-08	0.29	0.29	Blood metabolite levels;	chr16:20460042	chr16:20586550~20607107:-
KIRC	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-6.64	8.05e-11	3.08e-08	-0.27	-0.29	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
KIRC	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.64	8.05e-11	3.08e-08	0.26	0.29	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
KIRC	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	6.64	8.05e-11	3.08e-08	0.37	0.29	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
KIRC	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	6.64	8.06e-11	3.08e-08	0.24	0.29	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
KIRC	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.64	8.06e-11	3.08e-08	0.3	0.29	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
KIRC	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-6.64	8.07e-11	3.08e-08	-0.46	-0.29	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
KIRC	cis	rs4925386	1	rs6089351	ENSG00000275437.1	RP5-908M14.10	-6.64	8.07e-11	3.09e-08	-0.23	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62402236~62405935:-
KIRC	cis	rs4925386	1	rs6121990	ENSG00000275437.1	RP5-908M14.10	-6.64	8.07e-11	3.09e-08	-0.23	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62402236~62405935:-
KIRC	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	6.64	8.08e-11	3.09e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
KIRC	cis	rs919433	0.617	rs700642	ENSG00000231621.1	AC013264.2	6.64	8.08e-11	3.09e-08	0.31	0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736006	chr2:197197991~197199273:+
KIRC	cis	rs62025270	0.688	rs7164373	ENSG00000202081.1	RNU6-1280P	-6.64	8.08e-11	3.09e-08	-0.35	-0.29	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85651522~85651628:-
KIRC	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	6.64	8.08e-11	3.09e-08	0.35	0.29	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
KIRC	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	6.64	8.1e-11	3.1e-08	0.33	0.29	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
KIRC	cis	rs9915657	0.87	rs4140903	ENSG00000234899.8	SOX9-AS1	-6.64	8.1e-11	3.1e-08	-0.37	-0.29	Thyroid hormone levels;	chr17:72137630	chr17:72034107~72237203:-
KIRC	cis	rs13236243	0.502	rs2237299	ENSG00000236318.1	AC019117.1	6.64	8.11e-11	3.1e-08	0.35	0.29	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17308274	chr7:17374867~17466664:+
KIRC	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	6.64	8.12e-11	3.1e-08	0.3	0.29	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
KIRC	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	6.64	8.14e-11	3.11e-08	0.25	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
KIRC	cis	rs4761702	0.629	rs7966997	ENSG00000257252.4	RP11-486A14.2	-6.64	8.14e-11	3.11e-08	-0.37	-0.29	Immature fraction of reticulocytes;	chr12:93337570	chr12:93317135~93377736:-
KIRC	cis	rs2337406	1	rs79452530	ENSG00000274576.2	IGHV2-70	-6.64	8.15e-11	3.11e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106699992	chr14:106770577~106771020:-
KIRC	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-6.64	8.15e-11	3.12e-08	-0.27	-0.29	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
KIRC	cis	rs4578769	0.569	rs12958551	ENSG00000266850.1	RP11-370A5.1	6.64	8.17e-11	3.12e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22897885	chr18:22723491~22907721:-
KIRC	cis	rs17801127	0.901	rs35635376	ENSG00000231969.1	AC144449.1	6.64	8.19e-11	3.13e-08	0.51	0.29	Liver enzyme levels (alanine transaminase);	chr2:149707555	chr2:149587196~149848233:+
KIRC	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.64	8.2e-11	3.13e-08	0.41	0.29	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
KIRC	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.64	8.2e-11	3.13e-08	0.41	0.29	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
KIRC	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.64	8.2e-11	3.13e-08	0.41	0.29	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
KIRC	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-6.64	8.21e-11	3.14e-08	-0.51	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
KIRC	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-6.64	8.21e-11	3.14e-08	-0.23	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
KIRC	cis	rs919433	0.68	rs6434934	ENSG00000231621.1	AC013264.2	-6.64	8.22e-11	3.14e-08	-0.3	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197572662	chr2:197197991~197199273:+
KIRC	cis	rs588177	1	rs588177	ENSG00000236935.1	AP003774.1	6.64	8.22e-11	3.14e-08	0.25	0.29	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64256584	chr11:64325050~64329504:-
KIRC	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	6.64	8.23e-11	3.14e-08	0.24	0.29	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
KIRC	cis	rs6452524	0.618	rs2075685	ENSG00000248112.1	RP11-78C3.1	6.64	8.23e-11	3.14e-08	0.32	0.29	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82919376~82921119:-
KIRC	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.64	8.24e-11	3.15e-08	0.31	0.29	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
KIRC	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	6.64	8.25e-11	3.15e-08	0.46	0.29	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
KIRC	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-6.64	8.25e-11	3.15e-08	-0.28	-0.29	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
KIRC	cis	rs12468226	0.882	rs116437099	ENSG00000273456.1	RP11-686O6.2	6.64	8.25e-11	3.15e-08	0.42	0.29	Urate levels;	chr2:202299250	chr2:202374932~202375604:-
KIRC	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-6.64	8.25e-11	3.15e-08	-0.27	-0.29	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
KIRC	cis	rs755249	0.567	rs61779285	ENSG00000237624.1	OXCT2P1	6.64	8.26e-11	3.15e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs3768301	ENSG00000237624.1	OXCT2P1	6.64	8.26e-11	3.15e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39514956~39516490:+
KIRC	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-6.64	8.26e-11	3.15e-08	-0.49	-0.29	Depression;	chr6:28139579	chr6:28115628~28116551:+
KIRC	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-6.64	8.26e-11	3.15e-08	-0.26	-0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
KIRC	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-6.64	8.27e-11	3.16e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
KIRC	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-6.64	8.27e-11	3.16e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
KIRC	cis	rs11089937	0.616	rs5750675	ENSG00000211639.2	IGLV4-60	6.64	8.27e-11	3.16e-08	0.28	0.29	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22162199~22162681:+
KIRC	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-6.64	8.28e-11	3.16e-08	-0.35	-0.29	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
KIRC	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-6.64	8.29e-11	3.17e-08	-0.37	-0.29	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
KIRC	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	6.64	8.3e-11	3.17e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
KIRC	cis	rs1200821	0.738	rs1926128	ENSG00000151963.4	RP11-775A3.1	6.64	8.31e-11	3.17e-08	0.32	0.29	Hemostatic factors and hematological phenotypes;	chr10:37365692	chr10:37883594~37884109:+
KIRC	cis	rs1200821	0.704	rs9888115	ENSG00000151963.4	RP11-775A3.1	6.64	8.31e-11	3.17e-08	0.32	0.29	Hemostatic factors and hematological phenotypes;	chr10:37369423	chr10:37883594~37884109:+
KIRC	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	6.64	8.31e-11	3.17e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	6.64	8.31e-11	3.17e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	6.64	8.31e-11	3.17e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
KIRC	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-6.64	8.33e-11	3.18e-08	-0.33	-0.29	Depression;	chr6:28142370	chr6:28073316~28074233:+
KIRC	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-6.64	8.33e-11	3.18e-08	-0.31	-0.29	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
KIRC	cis	rs2436845	0.627	rs1019976	ENSG00000253669.3	KB-1732A1.1	6.64	8.33e-11	3.18e-08	0.33	0.29	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852043	chr8:102805517~102809971:+
KIRC	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-6.64	8.33e-11	3.18e-08	-0.27	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
KIRC	cis	rs10214930	0.671	rs6415251	ENSG00000235574.1	AC073150.6	-6.64	8.33e-11	3.18e-08	-0.33	-0.29	Hypospadias;	chr7:27629079	chr7:27491682~27492765:-
KIRC	cis	rs6480314	0.831	rs10740287	ENSG00000233590.1	RP11-153K11.3	6.64	8.37e-11	3.19e-08	0.4	0.29	Optic nerve measurement (disc area);	chr10:68214133	chr10:68233251~68242379:-
KIRC	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	6.64	8.37e-11	3.19e-08	0.22	0.29	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
KIRC	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	6.64	8.37e-11	3.19e-08	0.32	0.29	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
KIRC	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	6.64	8.41e-11	3.21e-08	0.34	0.29	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
KIRC	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	6.64	8.41e-11	3.21e-08	0.16	0.29	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
KIRC	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	6.64	8.41e-11	3.21e-08	0.32	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	6.64	8.42e-11	3.21e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	6.64	8.42e-11	3.21e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
KIRC	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-6.64	8.43e-11	3.22e-08	-0.23	-0.29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
KIRC	cis	rs4356975	0.83	rs60212682	ENSG00000196472.4	RP13-644M16.4	6.64	8.43e-11	3.22e-08	0.33	0.29	Obesity-related traits;	chr4:69052849	chr4:69181660~69182372:+
KIRC	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	6.64	8.43e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
KIRC	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.64	8.43e-11	3.22e-08	-0.32	-0.29	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
KIRC	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.64	8.43e-11	3.22e-08	0.32	0.29	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
KIRC	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
KIRC	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	6.64	8.44e-11	3.22e-08	0.29	0.29	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
KIRC	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.64	8.44e-11	3.22e-08	0.26	0.29	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
KIRC	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.64	8.44e-11	3.22e-08	0.31	0.29	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.64	8.44e-11	3.22e-08	0.31	0.29	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.64	8.44e-11	3.22e-08	0.31	0.29	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.64	8.44e-11	3.22e-08	0.31	0.29	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
KIRC	cis	rs2797160	0.935	rs12717178	ENSG00000237742.5	RP11-624M8.1	6.64	8.45e-11	3.22e-08	0.34	0.29	Endometrial cancer;	chr6:125695353	chr6:125578558~125749190:-
KIRC	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	6.64	8.45e-11	3.22e-08	0.28	0.29	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
KIRC	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	6.64	8.45e-11	3.22e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
KIRC	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-6.64	8.46e-11	3.22e-08	-0.38	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
KIRC	cis	rs3820928	0.839	rs13398103	ENSG00000212391.1	SNORA48	-6.64	8.46e-11	3.22e-08	-0.36	-0.29	Pulmonary function;	chr2:226994977	chr2:226968989~226969122:-
KIRC	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	6.64	8.46e-11	3.23e-08	0.25	0.29	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
KIRC	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-6.64	8.47e-11	3.23e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
KIRC	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.64	8.48e-11	3.23e-08	0.31	0.29	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.64	8.48e-11	3.23e-08	0.31	0.29	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
KIRC	cis	rs330048	0.51	rs11784654	ENSG00000254340.1	RP11-10A14.3	-6.64	8.5e-11	3.24e-08	-0.37	-0.29	Systemic lupus erythematosus;	chr8:9112101	chr8:9141424~9145435:+
KIRC	cis	rs4578769	0.569	rs9948922	ENSG00000266850.1	RP11-370A5.1	6.64	8.51e-11	3.24e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22930198	chr18:22723491~22907721:-
KIRC	cis	rs1005277	0.54	rs289638	ENSG00000235197.1	ZNF33AP1	-6.64	8.51e-11	3.24e-08	-0.3	-0.29	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:37894637~37896666:+
KIRC	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-6.64	8.52e-11	3.25e-08	-0.23	-0.29	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
KIRC	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	6.64	8.52e-11	3.25e-08	0.33	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	6.64	8.52e-11	3.25e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
KIRC	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-6.64	8.53e-11	3.25e-08	-0.24	-0.29	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
KIRC	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-6.63	8.54e-11	3.25e-08	-0.25	-0.29	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
KIRC	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-6.63	8.54e-11	3.26e-08	-0.49	-0.29	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
KIRC	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-6.63	8.55e-11	3.26e-08	-0.3	-0.29	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
KIRC	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-6.63	8.56e-11	3.26e-08	-0.32	-0.29	Depression;	chr6:28199145	chr6:28073316~28074233:+
KIRC	cis	rs12049351	0.774	rs6678721	ENSG00000229367.1	HMGN2P19	6.63	8.58e-11	3.27e-08	0.39	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229487384	chr1:229570532~229570796:+
KIRC	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-6.63	8.58e-11	3.27e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
KIRC	cis	rs3796352	1	rs6445557	ENSG00000280417.1	RP11-5O17.1	6.63	8.58e-11	3.27e-08	0.46	0.29	Immune reponse to smallpox (secreted IL-2);	chr3:53049953	chr3:53046166~53048122:+
KIRC	cis	rs12497850	0.864	rs4955410	ENSG00000225399.4	RP11-3B7.1	6.63	8.59e-11	3.27e-08	0.32	0.29	Parkinson's disease;	chr3:49143785	chr3:49260085~49261316:+
KIRC	cis	rs7017914	0.652	rs7841286	ENSG00000254031.4	RP11-326E22.1	6.63	8.6e-11	3.28e-08	0.33	0.29	Bone mineral density;	chr8:70890908	chr8:71155457~71204223:+
KIRC	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	6.63	8.61e-11	3.28e-08	0.43	0.29	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
KIRC	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	6.63	8.61e-11	3.28e-08	0.44	0.29	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
KIRC	cis	rs9601248	0.756	rs9601251	ENSG00000227354.5	RBM26-AS1	-6.63	8.61e-11	3.28e-08	-0.32	-0.29	Major depressive disorder;	chr13:79615582	chr13:79406309~79424328:+
KIRC	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-6.63	8.62e-11	3.28e-08	-0.34	-0.29	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
KIRC	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-6.63	8.62e-11	3.28e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
KIRC	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-6.63	8.63e-11	3.29e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
KIRC	cis	rs9915657	0.773	rs9894696	ENSG00000234899.8	SOX9-AS1	-6.63	8.63e-11	3.29e-08	-0.35	-0.29	Thyroid hormone levels;	chr17:72103346	chr17:72034107~72237203:-
KIRC	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-6.63	8.63e-11	3.29e-08	-0.34	-0.29	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
KIRC	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-6.63	8.64e-11	3.29e-08	-0.43	-0.29	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
KIRC	cis	rs8077577	0.789	rs62072546	ENSG00000273018.4	CTD-2303H24.2	-6.63	8.64e-11	3.29e-08	-0.46	-0.29	Obesity-related traits;	chr17:18350525	chr17:18511221~18551705:-
KIRC	cis	rs13236243	0.502	rs3802083	ENSG00000236318.1	AC019117.1	6.63	8.65e-11	3.29e-08	0.35	0.29	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17309283	chr7:17374867~17466664:+
KIRC	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-6.63	8.65e-11	3.29e-08	-0.27	-0.29	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
KIRC	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-6.63	8.67e-11	3.3e-08	-0.22	-0.29	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
KIRC	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-6.63	8.67e-11	3.3e-08	-0.22	-0.29	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
KIRC	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-6.63	8.67e-11	3.3e-08	-0.22	-0.29	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
KIRC	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-6.63	8.67e-11	3.3e-08	-0.22	-0.29	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
KIRC	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-6.63	8.67e-11	3.3e-08	-0.22	-0.29	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
KIRC	cis	rs9601248	0.756	rs9601252	ENSG00000227354.5	RBM26-AS1	-6.63	8.67e-11	3.3e-08	-0.32	-0.29	Major depressive disorder;	chr13:79615607	chr13:79406309~79424328:+
KIRC	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	6.63	8.68e-11	3.3e-08	0.35	0.29	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
KIRC	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	6.63	8.7e-11	3.31e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
KIRC	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.63	8.7e-11	3.31e-08	0.24	0.29	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
KIRC	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-6.63	8.71e-11	3.31e-08	-0.16	-0.29	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
KIRC	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-6.63	8.71e-11	3.31e-08	-0.47	-0.29	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
KIRC	cis	rs867529	0.722	rs67110763	ENSG00000234028.3	AC062029.1	6.63	8.71e-11	3.32e-08	0.33	0.29	Height;	chr2:88651398	chr2:88627539~88631821:+
KIRC	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	6.63	8.72e-11	3.32e-08	0.27	0.29	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
KIRC	cis	rs7246657	0.722	rs2909105	ENSG00000267422.1	CTD-2554C21.1	6.63	8.73e-11	3.32e-08	0.42	0.29	Coronary artery calcification;	chr19:37677005	chr19:37779686~37792865:+
KIRC	cis	rs7927771	0.524	rs4539273	ENSG00000280615.1	Y_RNA	-6.63	8.73e-11	3.32e-08	-0.3	-0.29	Subjective well-being;	chr11:47673147	chr11:47614898~47614994:-
KIRC	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.63	8.76e-11	3.33e-08	0.29	0.29	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
KIRC	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	6.63	8.77e-11	3.33e-08	0.25	0.29	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
KIRC	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-6.63	8.78e-11	3.34e-08	-0.46	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
KIRC	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-6.63	8.78e-11	3.34e-08	-0.46	-0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
KIRC	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	6.63	8.78e-11	3.34e-08	0.28	0.29	Asthma;	chr2:102370999	chr2:102438713~102440475:+
KIRC	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-6.63	8.79e-11	3.34e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
KIRC	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-6.63	8.79e-11	3.34e-08	-0.38	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
KIRC	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-6.63	8.8e-11	3.34e-08	-0.31	-0.29	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
KIRC	cis	rs11647589	0.834	rs9806821	ENSG00000260762.1	ACSM5P1	6.63	8.8e-11	3.35e-08	0.29	0.29	Blood metabolite levels;	chr16:20473857	chr16:20586550~20607107:-
KIRC	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.63	8.81e-11	3.35e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
KIRC	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-6.63	8.81e-11	3.35e-08	-0.27	-0.29	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
KIRC	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-6.63	8.82e-11	3.35e-08	-0.38	-0.29	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
KIRC	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-6.63	8.83e-11	3.36e-08	-0.23	-0.29	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
KIRC	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	6.63	8.84e-11	3.36e-08	0.24	0.29	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
KIRC	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	6.63	8.85e-11	3.36e-08	0.44	0.29	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
KIRC	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.63	8.86e-11	3.36e-08	0.32	0.29	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.63	8.86e-11	3.36e-08	0.32	0.29	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.63	8.86e-11	3.36e-08	0.32	0.29	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
KIRC	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-6.63	8.86e-11	3.37e-08	-0.38	-0.29	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
KIRC	cis	rs6480314	0.636	rs7914274	ENSG00000233590.1	RP11-153K11.3	-6.63	8.87e-11	3.37e-08	-0.41	-0.29	Optic nerve measurement (disc area);	chr10:68240300	chr10:68233251~68242379:-
KIRC	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.63	8.87e-11	3.37e-08	-0.26	-0.29	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
KIRC	cis	rs1005277	0.54	rs1814077	ENSG00000235197.1	ZNF33AP1	-6.63	8.88e-11	3.37e-08	-0.31	-0.29	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:37894637~37896666:+
KIRC	cis	rs755249	0.567	rs61779284	ENSG00000237624.1	OXCT2P1	6.63	8.88e-11	3.37e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39514956~39516490:+
KIRC	cis	rs17772222	0.958	rs2274737	ENSG00000222990.1	RNU4-22P	6.63	8.88e-11	3.38e-08	0.34	0.29	Coronary artery calcification;	chr14:88469307	chr14:88513498~88513663:+
KIRC	cis	rs7045881	0.674	rs3429	ENSG00000254396.1	RP11-56F10.3	6.63	8.89e-11	3.38e-08	0.4	0.29	Schizophrenia;	chr9:27062723	chr9:27102630~27104728:+
KIRC	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-6.63	8.9e-11	3.38e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
KIRC	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-6.63	8.9e-11	3.38e-08	-0.27	-0.29	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
KIRC	cis	rs17772222	1	rs12587386	ENSG00000222990.1	RNU4-22P	6.63	8.91e-11	3.39e-08	0.34	0.29	Coronary artery calcification;	chr14:88361420	chr14:88513498~88513663:+
KIRC	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	6.63	8.91e-11	3.39e-08	0.37	0.29	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
KIRC	cis	rs7017914	0.652	rs34768553	ENSG00000254031.4	RP11-326E22.1	6.63	8.92e-11	3.39e-08	0.33	0.29	Bone mineral density;	chr8:70864755	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35343840	ENSG00000254031.4	RP11-326E22.1	6.63	8.92e-11	3.39e-08	0.33	0.29	Bone mineral density;	chr8:70865160	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs7015825	ENSG00000254031.4	RP11-326E22.1	6.63	8.92e-11	3.39e-08	0.33	0.29	Bone mineral density;	chr8:70866438	chr8:71155457~71204223:+
KIRC	cis	rs890448	0.796	rs2583387	ENSG00000254531.1	FLJ20021	6.63	8.94e-11	3.4e-08	0.28	0.29	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101359241	chr4:101347780~101348883:+
KIRC	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-6.63	8.95e-11	3.4e-08	-0.36	-0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
KIRC	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-6.63	8.96e-11	3.4e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
KIRC	cis	rs2337406	0.929	rs11847182	ENSG00000274576.2	IGHV2-70	-6.63	8.98e-11	3.41e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106697724	chr14:106770577~106771020:-
KIRC	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	6.63	8.98e-11	3.41e-08	0.29	0.29	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
KIRC	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	6.63	8.99e-11	3.41e-08	0.24	0.29	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	6.63	8.99e-11	3.41e-08	0.24	0.29	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	6.63	8.99e-11	3.41e-08	0.24	0.29	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
KIRC	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-6.63	9e-11	3.42e-08	-0.38	-0.29	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-6.63	9e-11	3.42e-08	-0.38	-0.29	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
KIRC	cis	rs8077577	0.747	rs11869582	ENSG00000273018.4	CTD-2303H24.2	-6.63	9e-11	3.42e-08	-0.47	-0.29	Obesity-related traits;	chr17:18233267	chr17:18511221~18551705:-
KIRC	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	6.63	9e-11	3.42e-08	0.31	0.29	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
KIRC	cis	rs2361718	0.5	rs8064429	ENSG00000279259.1	RP11-334C17.3	6.63	9e-11	3.42e-08	0.28	0.29	Yeast infection;	chr17:80122388	chr17:80147250~80148596:+
KIRC	cis	rs2486288	0.656	rs2413771	ENSG00000235390.4	CTD-2651B20.5	6.63	9.02e-11	3.42e-08	0.26	0.29	Glomerular filtration rate;	chr15:45260942	chr15:45321077~45321692:-
KIRC	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-6.63	9.02e-11	3.42e-08	-0.39	-0.29	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
KIRC	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-6.63	9.02e-11	3.42e-08	-0.22	-0.29	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
KIRC	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-6.63	9.04e-11	3.43e-08	-0.27	-0.29	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
KIRC	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-6.63	9.04e-11	3.43e-08	-0.44	-0.29	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
KIRC	cis	rs919433	0.713	rs6719729	ENSG00000231621.1	AC013264.2	-6.63	9.05e-11	3.43e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197615348	chr2:197197991~197199273:+
KIRC	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	6.63	9.05e-11	3.43e-08	0.33	0.29	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
KIRC	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	6.63	9.05e-11	3.43e-08	0.33	0.29	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
KIRC	cis	rs4925386	1	rs4925386	ENSG00000275437.1	RP5-908M14.10	6.63	9.05e-11	3.43e-08	0.23	0.29	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62402236~62405935:-
KIRC	cis	rs9388451	0.868	rs10457467	ENSG00000237742.5	RP11-624M8.1	-6.63	9.06e-11	3.44e-08	-0.36	-0.29	Brugada syndrome;	chr6:125724002	chr6:125578558~125749190:-
KIRC	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-6.63	9.06e-11	3.44e-08	-0.34	-0.29	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
KIRC	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	6.63	9.06e-11	3.44e-08	0.26	0.29	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
KIRC	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-6.63	9.07e-11	3.44e-08	-0.44	-0.29	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
KIRC	cis	rs2486288	0.656	rs62026703	ENSG00000235390.4	CTD-2651B20.5	6.63	9.07e-11	3.44e-08	0.26	0.29	Glomerular filtration rate;	chr15:45277731	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs7165039	ENSG00000235390.4	CTD-2651B20.5	6.63	9.07e-11	3.44e-08	0.26	0.29	Glomerular filtration rate;	chr15:45278215	chr15:45321077~45321692:-
KIRC	cis	rs2486288	0.656	rs7166580	ENSG00000235390.4	CTD-2651B20.5	6.63	9.07e-11	3.44e-08	0.26	0.29	Glomerular filtration rate;	chr15:45279011	chr15:45321077~45321692:-
KIRC	cis	rs17772222	0.876	rs12587528	ENSG00000222990.1	RNU4-22P	6.62	9.1e-11	3.45e-08	0.34	0.29	Coronary artery calcification;	chr14:88487652	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.916	rs77306894	ENSG00000222990.1	RNU4-22P	6.62	9.1e-11	3.45e-08	0.34	0.29	Coronary artery calcification;	chr14:88494507	chr14:88513498~88513663:+
KIRC	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-6.62	9.11e-11	3.45e-08	-0.27	-0.29	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
KIRC	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-6.62	9.12e-11	3.46e-08	-0.37	-0.29	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
KIRC	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-6.62	9.12e-11	3.46e-08	-0.34	-0.29	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
KIRC	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	6.62	9.12e-11	3.46e-08	0.32	0.29	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
KIRC	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	6.62	9.13e-11	3.46e-08	0.35	0.29	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
KIRC	cis	rs7688540	0.515	rs28415975	ENSG00000211553.1	AC253576.2	-6.62	9.13e-11	3.46e-08	-0.34	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:136461~136568:+
KIRC	cis	rs919433	0.68	rs67580728	ENSG00000231621.1	AC013264.2	-6.62	9.13e-11	3.46e-08	-0.31	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197566534	chr2:197197991~197199273:+
KIRC	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	6.62	9.13e-11	3.46e-08	0.33	0.29	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
KIRC	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	6.62	9.17e-11	3.47e-08	0.28	0.29	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
KIRC	cis	rs17082664	0.79	rs9479313	ENSG00000226193.1	RP3-398G3.5	6.62	9.17e-11	3.47e-08	0.41	0.29	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);	chr6:152423615	chr6:152402398~152404966:+
KIRC	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-6.62	9.17e-11	3.47e-08	-0.19	-0.29	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
KIRC	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-6.62	9.17e-11	3.48e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
KIRC	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-6.62	9.18e-11	3.48e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
KIRC	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-6.62	9.18e-11	3.48e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
KIRC	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-6.62	9.18e-11	3.48e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
KIRC	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	6.62	9.19e-11	3.48e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
KIRC	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	6.62	9.19e-11	3.48e-08	0.4	0.29	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
KIRC	cis	rs7647973	0.58	rs12637576	ENSG00000225399.4	RP11-3B7.1	6.62	9.2e-11	3.49e-08	0.3	0.29	Menarche (age at onset);	chr3:49199901	chr3:49260085~49261316:+
KIRC	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	6.62	9.21e-11	3.49e-08	0.3	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
KIRC	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-6.62	9.22e-11	3.49e-08	-0.36	-0.29	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
KIRC	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-6.62	9.24e-11	3.5e-08	-0.38	-0.29	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
KIRC	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-6.62	9.24e-11	3.5e-08	-0.27	-0.29	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	6.62	9.24e-11	3.5e-08	0.27	0.29	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	6.62	9.24e-11	3.5e-08	0.27	0.29	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
KIRC	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	6.62	9.24e-11	3.5e-08	0.27	0.29	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
KIRC	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.24e-11	3.5e-08	-0.3	-0.29	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
KIRC	cis	rs2797160	1	rs926853	ENSG00000237742.5	RP11-624M8.1	6.62	9.24e-11	3.5e-08	0.34	0.29	Endometrial cancer;	chr6:125700289	chr6:125578558~125749190:-
KIRC	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	6.62	9.25e-11	3.5e-08	0.28	0.29	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	6.62	9.25e-11	3.5e-08	0.28	0.29	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	6.62	9.25e-11	3.5e-08	0.28	0.29	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
KIRC	cis	rs7927771	0.524	rs7933184	ENSG00000280615.1	Y_RNA	6.62	9.26e-11	3.51e-08	0.3	0.29	Subjective well-being;	chr11:47660850	chr11:47614898~47614994:-
KIRC	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-6.62	9.27e-11	3.51e-08	-0.28	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
KIRC	cis	rs2288884	0.775	rs7508491	ENSG00000275055.1	CTC-471J1.11	-6.62	9.28e-11	3.52e-08	-0.39	-0.29	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52001631	chr19:52049007~52049754:+
KIRC	cis	rs4356975	0.563	rs11249527	ENSG00000196472.4	RP13-644M16.4	6.62	9.28e-11	3.52e-08	0.33	0.29	Obesity-related traits;	chr4:69089267	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6846298	ENSG00000196472.4	RP13-644M16.4	6.62	9.28e-11	3.52e-08	0.33	0.29	Obesity-related traits;	chr4:69089278	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs11249528	ENSG00000196472.4	RP13-644M16.4	6.62	9.28e-11	3.52e-08	0.33	0.29	Obesity-related traits;	chr4:69089337	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs55757747	ENSG00000196472.4	RP13-644M16.4	6.62	9.28e-11	3.52e-08	0.33	0.29	Obesity-related traits;	chr4:69089919	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs56217918	ENSG00000196472.4	RP13-644M16.4	6.62	9.28e-11	3.52e-08	0.33	0.29	Obesity-related traits;	chr4:69089925	chr4:69181660~69182372:+
KIRC	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	6.62	9.29e-11	3.52e-08	0.31	0.29	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
KIRC	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	6.62	9.31e-11	3.53e-08	0.39	0.29	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
KIRC	cis	rs12500482	0.5	rs6841989	ENSG00000206113.6	RP11-503N18.1	6.62	9.32e-11	3.53e-08	0.35	0.29	Cognitive function;	chr4:2427474	chr4:2418974~2450360:+
KIRC	cis	rs2797160	1	rs1777222	ENSG00000237742.5	RP11-624M8.1	6.62	9.32e-11	3.53e-08	0.34	0.29	Endometrial cancer;	chr6:125699884	chr6:125578558~125749190:-
KIRC	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-6.62	9.33e-11	3.53e-08	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
KIRC	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	6.62	9.35e-11	3.54e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	6.62	9.35e-11	3.54e-08	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
KIRC	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-6.62	9.36e-11	3.54e-08	-0.33	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
KIRC	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-6.62	9.36e-11	3.54e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
KIRC	cis	rs62025270	0.576	rs62022947	ENSG00000202081.1	RNU6-1280P	-6.62	9.37e-11	3.54e-08	-0.36	-0.29	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85651522~85651628:-
KIRC	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.62	9.38e-11	3.55e-08	-0.37	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
KIRC	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	6.62	9.38e-11	3.55e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
KIRC	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	6.62	9.38e-11	3.55e-08	0.39	0.29	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
KIRC	cis	rs7937127	0.64	rs12792780	ENSG00000254907.1	RP11-484D2.2	6.62	9.39e-11	3.55e-08	0.37	0.29	Fibrinogen levels;	chr11:43505357	chr11:43328748~43359296:-
KIRC	cis	rs17772222	0.917	rs10143767	ENSG00000222990.1	RNU4-22P	6.62	9.39e-11	3.55e-08	0.34	0.29	Coronary artery calcification;	chr14:88514867	chr14:88513498~88513663:+
KIRC	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-6.62	9.4e-11	3.56e-08	-0.33	-0.29	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	6.62	9.4e-11	3.56e-08	0.33	0.29	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
KIRC	cis	rs7017914	0.677	rs67781030	ENSG00000254031.4	RP11-326E22.1	6.62	9.41e-11	3.56e-08	0.33	0.29	Bone mineral density;	chr8:70836619	chr8:71155457~71204223:+
KIRC	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	6.62	9.41e-11	3.56e-08	0.27	0.29	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
KIRC	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	6.62	9.41e-11	3.56e-08	0.28	0.29	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
KIRC	cis	rs4072705	0.646	rs915032	ENSG00000224020.1	MIR181A2HG	-6.62	9.43e-11	3.57e-08	-0.29	-0.29	Menarche (age at onset);	chr9:124483403	chr9:124658467~124698631:+
KIRC	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-6.62	9.43e-11	3.57e-08	-0.25	-0.29	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
KIRC	cis	rs7045881	0.808	rs7039400	ENSG00000254396.1	RP11-56F10.3	6.62	9.44e-11	3.57e-08	0.38	0.29	Schizophrenia;	chr9:26946251	chr9:27102630~27104728:+
KIRC	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-6.62	9.44e-11	3.57e-08	-0.28	-0.29	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-6.62	9.44e-11	3.57e-08	-0.28	-0.29	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-6.62	9.44e-11	3.57e-08	-0.28	-0.29	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
KIRC	cis	rs755249	0.567	rs2018212	ENSG00000237624.1	OXCT2P1	6.62	9.44e-11	3.57e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs4660751	ENSG00000237624.1	OXCT2P1	6.62	9.44e-11	3.57e-08	0.43	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39514956~39516490:+
KIRC	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-6.62	9.45e-11	3.57e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-6.62	9.45e-11	3.57e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
KIRC	cis	rs17772222	1	rs12589480	ENSG00000222990.1	RNU4-22P	6.62	9.45e-11	3.57e-08	0.35	0.29	Coronary artery calcification;	chr14:88414926	chr14:88513498~88513663:+
KIRC	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-6.62	9.45e-11	3.57e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-6.62	9.45e-11	3.57e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-6.62	9.45e-11	3.57e-08	-0.39	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
KIRC	cis	rs7267979	1	rs2482943	ENSG00000125804.12	FAM182A	6.62	9.46e-11	3.58e-08	0.36	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:26054655~26086917:+
KIRC	cis	rs2564921	0.73	rs73079924	ENSG00000280417.1	RP11-5O17.1	6.62	9.46e-11	3.58e-08	0.37	0.29	Height;	chr3:53034139	chr3:53046166~53048122:+
KIRC	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	6.62	9.49e-11	3.59e-08	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
KIRC	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.5e-11	3.59e-08	-0.28	-0.29	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
KIRC	cis	rs3750965	1	rs731974	ENSG00000260895.1	RP11-554A11.7	6.62	9.5e-11	3.59e-08	0.36	0.29	Hair color;	chr11:69079688	chr11:69103493~69109094:+
KIRC	cis	rs919433	0.68	rs7590010	ENSG00000231621.1	AC013264.2	-6.62	9.5e-11	3.59e-08	-0.3	-0.29	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197535944	chr2:197197991~197199273:+
KIRC	cis	rs4578769	0.569	rs8094359	ENSG00000266850.1	RP11-370A5.1	6.62	9.51e-11	3.6e-08	0.38	0.29	Eosinophil percentage of white cells;	chr18:22907743	chr18:22723491~22907721:-
KIRC	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	6.62	9.51e-11	3.6e-08	0.28	0.29	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
KIRC	cis	rs3750965	1	rs61881024	ENSG00000260895.1	RP11-554A11.7	6.62	9.52e-11	3.6e-08	0.36	0.29	Hair color;	chr11:69070326	chr11:69103493~69109094:+
KIRC	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	6.62	9.52e-11	3.6e-08	0.27	0.29	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
KIRC	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-6.62	9.53e-11	3.6e-08	-0.34	-0.29	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
KIRC	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-6.62	9.54e-11	3.61e-08	-0.26	-0.29	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
KIRC	cis	rs4888671	1	rs57110085	ENSG00000261707.1	RP11-264M12.2	6.62	9.54e-11	3.61e-08	0.43	0.29	Obesity-related traits;	chr16:77749416	chr16:77741468~77743000:-
KIRC	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	6.62	9.54e-11	3.61e-08	0.4	0.29	Depression;	chr6:28240757	chr6:28943877~28944537:+
KIRC	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-6.62	9.55e-11	3.61e-08	-0.27	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
KIRC	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	6.62	9.55e-11	3.61e-08	0.28	0.29	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
KIRC	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	6.62	9.55e-11	3.61e-08	0.32	0.29	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
KIRC	cis	rs12571093	0.803	rs17297418	ENSG00000233590.1	RP11-153K11.3	6.62	9.56e-11	3.61e-08	0.4	0.29	Optic nerve measurement (disc area);	chr10:68271894	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs17297383	ENSG00000233590.1	RP11-153K11.3	-6.62	9.56e-11	3.61e-08	-0.4	-0.29	Optic nerve measurement (disc area);	chr10:68269106	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.542	rs10998044	ENSG00000233590.1	RP11-153K11.3	-6.62	9.56e-11	3.61e-08	-0.4	-0.29	Optic nerve measurement (disc area);	chr10:68269508	chr10:68233251~68242379:-
KIRC	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	6.62	9.56e-11	3.61e-08	0.31	0.29	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
KIRC	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	6.62	9.57e-11	3.62e-08	0.21	0.29	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
KIRC	cis	rs62025270	0.688	rs62022939	ENSG00000202081.1	RNU6-1280P	-6.62	9.58e-11	3.62e-08	-0.37	-0.29	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85651522~85651628:-
KIRC	cis	rs17772222	0.74	rs10150311	ENSG00000222990.1	RNU4-22P	6.62	9.6e-11	3.63e-08	0.31	0.29	Coronary artery calcification;	chr14:88510128	chr14:88513498~88513663:+
KIRC	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-6.62	9.61e-11	3.63e-08	-0.4	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
KIRC	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-6.62	9.62e-11	3.63e-08	-0.39	-0.29	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
KIRC	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	6.62	9.62e-11	3.63e-08	0.42	0.29	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
KIRC	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	6.62	9.62e-11	3.63e-08	0.34	0.29	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
KIRC	cis	rs934734	0.509	rs12185577	ENSG00000281920.1	RP11-418H16.1	-6.62	9.63e-11	3.64e-08	-0.36	-0.29	Rheumatoid arthritis;	chr2:65432354	chr2:65623272~65628424:+
KIRC	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	6.62	9.63e-11	3.64e-08	0.43	0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
KIRC	cis	rs11096990	0.793	rs9997050	ENSG00000249207.1	RP11-360F5.1	6.62	9.64e-11	3.64e-08	0.3	0.29	Cognitive function;	chr4:39301045	chr4:39112677~39126818:-
KIRC	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	6.61	9.67e-11	3.65e-08	0.27	0.28	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
KIRC	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	6.61	9.67e-11	3.65e-08	0.4	0.28	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
KIRC	cis	rs7045881	0.935	rs7851582	ENSG00000254396.1	RP11-56F10.3	6.61	9.67e-11	3.65e-08	0.38	0.28	Schizophrenia;	chr9:26902782	chr9:27102630~27104728:+
KIRC	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-6.61	9.67e-11	3.65e-08	-0.24	-0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
KIRC	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-6.61	9.68e-11	3.65e-08	-0.24	-0.28	Height;	chr2:46641180	chr2:46668870~46670778:+
KIRC	cis	rs7017914	0.652	rs17760532	ENSG00000254031.4	RP11-326E22.1	6.61	9.68e-11	3.65e-08	0.33	0.28	Bone mineral density;	chr8:70708052	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs56173818	ENSG00000254031.4	RP11-326E22.1	6.61	9.68e-11	3.65e-08	0.33	0.28	Bone mineral density;	chr8:70710138	chr8:71155457~71204223:+
KIRC	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	6.61	9.68e-11	3.65e-08	0.21	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
KIRC	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-6.61	9.69e-11	3.66e-08	-0.36	-0.28	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
KIRC	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-6.61	9.69e-11	3.66e-08	-0.5	-0.28	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
KIRC	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-6.61	9.69e-11	3.66e-08	-0.28	-0.28	Asthma;	chr2:102351615	chr2:102438713~102440475:+
KIRC	cis	rs1198872	0.892	rs10427170	ENSG00000272275.1	RP11-791G15.2	6.61	9.69e-11	3.66e-08	0.37	0.28	Cardiac Troponin-T levels;	chr2:10762044	chr2:10767875~10770058:-
KIRC	cis	rs7267979	0.932	rs1541061	ENSG00000125804.12	FAM182A	-6.61	9.69e-11	3.66e-08	-0.35	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.932	rs6138600	ENSG00000125804.12	FAM182A	-6.61	9.69e-11	3.66e-08	-0.35	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:26054655~26086917:+
KIRC	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	6.61	9.7e-11	3.66e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
KIRC	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	6.61	9.7e-11	3.66e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
KIRC	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	6.61	9.71e-11	3.66e-08	0.32	0.28	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
KIRC	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	6.61	9.72e-11	3.67e-08	0.21	0.28	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
KIRC	cis	rs7267979	1	rs6138572	ENSG00000125804.12	FAM182A	-6.61	9.72e-11	3.67e-08	-0.36	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs6138575	ENSG00000125804.12	FAM182A	-6.61	9.72e-11	3.67e-08	-0.36	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs11087521	ENSG00000125804.12	FAM182A	-6.61	9.72e-11	3.67e-08	-0.36	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26054655~26086917:+
KIRC	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	6.61	9.73e-11	3.67e-08	0.28	0.28	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
KIRC	cis	rs2337406	1	rs17113331	ENSG00000274576.2	IGHV2-70	-6.61	9.73e-11	3.67e-08	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106703843	chr14:106770577~106771020:-
KIRC	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	6.61	9.74e-11	3.67e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
KIRC	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-6.61	9.75e-11	3.68e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
KIRC	cis	rs919433	0.68	rs3792160	ENSG00000231621.1	AC013264.2	-6.61	9.77e-11	3.69e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538795	chr2:197197991~197199273:+
KIRC	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-6.61	9.8e-11	3.7e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
KIRC	cis	rs7924176	0.601	rs17676126	ENSG00000213731.2	RAB5CP1	-6.61	9.81e-11	3.7e-08	-0.28	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74423435~74424014:-
KIRC	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-6.61	9.81e-11	3.7e-08	-0.38	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
KIRC	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	6.61	9.81e-11	3.7e-08	0.32	0.28	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
KIRC	cis	rs4072705	1	rs4240487	ENSG00000224020.1	MIR181A2HG	-6.61	9.82e-11	3.7e-08	-0.28	-0.28	Menarche (age at onset);	chr9:124608028	chr9:124658467~124698631:+
KIRC	cis	rs2562456	0.617	rs57879343	ENSG00000268555.1	RP11-678G14.3	6.61	9.82e-11	3.71e-08	0.44	0.28	Pain;	chr19:21600056	chr19:21570822~21587322:-
KIRC	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-6.61	9.85e-11	3.71e-08	-0.43	-0.28	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
KIRC	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-6.61	9.85e-11	3.71e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
KIRC	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	6.61	9.85e-11	3.71e-08	0.16	0.28	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
KIRC	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	6.61	9.88e-11	3.72e-08	0.37	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
KIRC	cis	rs4356975	0.563	rs7442453	ENSG00000196472.4	RP13-644M16.4	6.61	9.88e-11	3.72e-08	0.33	0.28	Obesity-related traits;	chr4:69103462	chr4:69181660~69182372:+
KIRC	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	6.61	9.88e-11	3.72e-08	0.26	0.28	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
KIRC	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	6.61	9.88e-11	3.72e-08	0.26	0.28	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
KIRC	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-6.61	9.89e-11	3.73e-08	-0.39	-0.28	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
KIRC	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	6.61	9.9e-11	3.73e-08	0.37	0.28	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
KIRC	cis	rs3820928	1	rs12615988	ENSG00000212391.1	SNORA48	-6.61	9.9e-11	3.73e-08	-0.34	-0.28	Pulmonary function;	chr2:226904284	chr2:226968989~226969122:-
KIRC	cis	rs10214930	0.813	rs10486548	ENSG00000235574.1	AC073150.6	-6.61	9.91e-11	3.73e-08	-0.35	-0.28	Hypospadias;	chr7:27633076	chr7:27491682~27492765:-
KIRC	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-6.61	9.92e-11	3.74e-08	-0.5	-0.28	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
KIRC	cis	rs2337406	0.714	rs8022729	ENSG00000274576.2	IGHV2-70	6.61	9.92e-11	3.74e-08	0.32	0.28	Alzheimer's disease (late onset);	chr14:106816928	chr14:106770577~106771020:-
KIRC	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	6.61	9.93e-11	3.74e-08	0.21	0.28	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
KIRC	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-6.61	9.93e-11	3.74e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-6.61	9.93e-11	3.74e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
KIRC	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-6.61	9.93e-11	3.74e-08	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
KIRC	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-6.61	9.94e-11	3.75e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
KIRC	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	6.61	9.94e-11	3.75e-08	0.24	0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
KIRC	cis	rs7017914	0.652	rs11987148	ENSG00000254031.4	RP11-326E22.1	6.61	9.95e-11	3.75e-08	0.33	0.28	Bone mineral density;	chr8:70749075	chr8:71155457~71204223:+
KIRC	cis	rs890448	0.796	rs7698946	ENSG00000254531.1	FLJ20021	6.61	9.96e-11	3.75e-08	0.28	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436919	chr4:101347780~101348883:+
KIRC	cis	rs2797160	1	rs984040	ENSG00000237742.5	RP11-624M8.1	6.61	9.97e-11	3.75e-08	0.34	0.28	Endometrial cancer;	chr6:125700131	chr6:125578558~125749190:-
KIRC	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.61	9.97e-11	3.76e-08	0.31	0.28	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
KIRC	cis	rs9516	1	rs10898990	ENSG00000254974.1	RP11-702H23.2	-6.61	9.97e-11	3.76e-08	-0.34	-0.28	Facial morphology (factor 15, philtrum width);	chr11:74454121	chr11:74485580~74486051:-
KIRC	cis	rs9516	1	rs10898991	ENSG00000254974.1	RP11-702H23.2	-6.61	9.97e-11	3.76e-08	-0.34	-0.28	Facial morphology (factor 15, philtrum width);	chr11:74454148	chr11:74485580~74486051:-
KIRC	cis	rs7927771	0.524	rs2242081	ENSG00000280615.1	Y_RNA	6.61	9.99e-11	3.76e-08	0.3	0.28	Subjective well-being;	chr11:47478715	chr11:47614898~47614994:-
KIRC	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	6.61	9.99e-11	3.76e-08	0.49	0.28	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
KIRC	cis	rs17772222	0.74	rs11847417	ENSG00000222990.1	RNU4-22P	-6.61	9.99e-11	3.76e-08	-0.31	-0.28	Coronary artery calcification;	chr14:88510606	chr14:88513498~88513663:+
KIRC	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	6.61	1e-10	3.76e-08	0.31	0.28	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
KIRC	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	6.61	1e-10	3.76e-08	0.36	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
KIRC	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	6.61	1e-10	3.77e-08	0.44	0.28	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
KIRC	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	6.61	1e-10	3.77e-08	0.44	0.28	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
KIRC	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	6.61	1e-10	3.77e-08	0.37	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
KIRC	cis	rs17772222	0.74	rs7143642	ENSG00000222990.1	RNU4-22P	6.61	1e-10	3.77e-08	0.32	0.28	Coronary artery calcification;	chr14:88507616	chr14:88513498~88513663:+
KIRC	cis	rs7017914	0.652	rs3098858	ENSG00000254031.4	RP11-326E22.1	6.61	1e-10	3.77e-08	0.33	0.28	Bone mineral density;	chr8:70951038	chr8:71155457~71204223:+
KIRC	cis	rs12049351	0.774	rs6704265	ENSG00000229367.1	HMGN2P19	6.61	1e-10	3.78e-08	0.39	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229497309	chr1:229570532~229570796:+
KIRC	cis	rs12049351	0.774	rs4925457	ENSG00000229367.1	HMGN2P19	6.61	1e-10	3.78e-08	0.39	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229497824	chr1:229570532~229570796:+
KIRC	cis	rs10214930	1	rs4719906	ENSG00000235574.1	AC073150.6	6.61	1e-10	3.78e-08	0.38	0.28	Hypospadias;	chr7:27733233	chr7:27491682~27492765:-
KIRC	cis	rs2439831	0.867	rs2245715	ENSG00000249839.1	AC011330.5	-6.61	1e-10	3.78e-08	-0.51	-0.28	Lung cancer in ever smokers;	chr15:43525854	chr15:43663654~43684339:-
KIRC	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	6.61	1.01e-10	3.78e-08	0.39	0.28	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
KIRC	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	6.61	1.01e-10	3.79e-08	0.27	0.28	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
KIRC	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	6.61	1.01e-10	3.79e-08	0.3	0.28	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
KIRC	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-6.61	1.01e-10	3.79e-08	-0.26	-0.28	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
KIRC	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	6.61	1.01e-10	3.8e-08	0.28	0.28	Asthma;	chr2:102351751	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	6.61	1.01e-10	3.8e-08	0.28	0.28	Asthma;	chr2:102351752	chr2:102438713~102440475:+
KIRC	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-6.61	1.01e-10	3.8e-08	-0.34	-0.28	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
KIRC	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	6.61	1.01e-10	3.8e-08	0.36	0.28	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
KIRC	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	6.61	1.01e-10	3.8e-08	0.32	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
KIRC	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-6.61	1.01e-10	3.8e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
KIRC	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-6.61	1.01e-10	3.81e-08	-0.29	-0.28	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
KIRC	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	6.61	1.01e-10	3.81e-08	0.49	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	6.61	1.01e-10	3.81e-08	0.49	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	6.61	1.01e-10	3.81e-08	0.49	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	6.61	1.01e-10	3.81e-08	0.49	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	6.61	1.01e-10	3.81e-08	0.49	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
KIRC	cis	rs1005277	0.505	rs10827835	ENSG00000235197.1	ZNF33AP1	6.61	1.01e-10	3.81e-08	0.31	0.28	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:37894637~37896666:+
KIRC	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	6.61	1.01e-10	3.81e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
KIRC	cis	rs6456156	0.792	rs10946215	ENSG00000265828.1	MIR3939	6.61	1.01e-10	3.81e-08	0.33	0.28	Primary biliary cholangitis;	chr6:167102693	chr6:166997807~166997912:-
KIRC	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	6.61	1.01e-10	3.81e-08	0.33	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
KIRC	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-6.61	1.02e-10	3.82e-08	-0.36	-0.28	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
KIRC	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	6.61	1.02e-10	3.83e-08	0.27	0.28	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
KIRC	cis	rs6600671	0.934	rs12060031	ENSG00000231429.2	RP11-343N15.2	6.61	1.02e-10	3.83e-08	0.33	0.28	Hip geometry;	chr1:121501652	chr1:121412719~121429274:+
KIRC	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.61	1.02e-10	3.83e-08	-0.36	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
KIRC	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.61	1.02e-10	3.83e-08	-0.36	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
KIRC	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-6.61	1.02e-10	3.84e-08	-0.27	-0.28	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
KIRC	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	6.61	1.02e-10	3.84e-08	0.3	0.28	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
KIRC	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	6.61	1.02e-10	3.84e-08	0.32	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
KIRC	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	6.61	1.02e-10	3.84e-08	0.32	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
KIRC	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	6.61	1.02e-10	3.84e-08	0.29	0.28	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
KIRC	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-6.61	1.02e-10	3.84e-08	-0.35	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
KIRC	cis	rs2427308	0.607	rs1741635	ENSG00000275437.1	RP5-908M14.10	-6.61	1.02e-10	3.85e-08	-0.26	-0.28	Colorectal cancer;	chr20:62363141	chr20:62402236~62405935:-
KIRC	cis	rs7937127	0.744	rs72902723	ENSG00000254907.1	RP11-484D2.2	6.61	1.02e-10	3.85e-08	0.37	0.28	Fibrinogen levels;	chr11:43497105	chr11:43328748~43359296:-
KIRC	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	6.61	1.02e-10	3.85e-08	0.45	0.28	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
KIRC	cis	rs4356975	0.932	rs7662632	ENSG00000198277.6	RP11-468N14.09	6.61	1.02e-10	3.85e-08	0.3	0.28	Obesity-related traits;	chr4:69062256	chr4:68914928~68924741:-
KIRC	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	6.61	1.02e-10	3.85e-08	0.22	0.28	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
KIRC	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-6.61	1.03e-10	3.86e-08	-0.41	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
KIRC	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-6.61	1.03e-10	3.86e-08	-0.39	-0.28	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
KIRC	cis	rs7267979	1	rs2500448	ENSG00000125804.12	FAM182A	6.61	1.03e-10	3.86e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:26054655~26086917:+
KIRC	cis	rs4072705	0.616	rs915033	ENSG00000224020.1	MIR181A2HG	-6.61	1.03e-10	3.86e-08	-0.29	-0.28	Menarche (age at onset);	chr9:124483279	chr9:124658467~124698631:+
KIRC	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.61	1.03e-10	3.86e-08	0.42	0.28	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
KIRC	cis	rs6452524	0.618	rs1993948	ENSG00000248112.1	RP11-78C3.1	6.61	1.03e-10	3.86e-08	0.32	0.28	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82919376~82921119:-
KIRC	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-6.6	1.03e-10	3.87e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
KIRC	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	6.6	1.03e-10	3.87e-08	0.33	0.28	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
KIRC	cis	rs1005277	0.522	rs9417256	ENSG00000235197.1	ZNF33AP1	-6.6	1.03e-10	3.87e-08	-0.31	-0.28	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:37894637~37896666:+
KIRC	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
KIRC	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-6.6	1.03e-10	3.87e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
KIRC	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	6.6	1.03e-10	3.88e-08	0.35	0.28	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
KIRC	cis	rs8177876	0.749	rs2970076	ENSG00000261838.4	RP11-303E16.6	6.6	1.03e-10	3.88e-08	0.46	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81069854~81076598:+
KIRC	cis	rs11647589	0.687	rs12598584	ENSG00000262995.1	CTD-2194A8.2	6.6	1.03e-10	3.88e-08	0.32	0.28	Blood metabolite levels;	chr16:20476785	chr16:20440266~20447000:-
KIRC	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-6.6	1.03e-10	3.88e-08	-0.25	-0.28	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
KIRC	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-6.6	1.03e-10	3.89e-08	-0.23	-0.28	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
KIRC	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	6.6	1.03e-10	3.89e-08	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	6.6	1.03e-10	3.89e-08	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	6.6	1.03e-10	3.89e-08	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
KIRC	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-6.6	1.04e-10	3.89e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-6.6	1.04e-10	3.89e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
KIRC	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-6.6	1.04e-10	3.89e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
KIRC	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	6.6	1.04e-10	3.89e-08	0.29	0.28	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
KIRC	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-6.6	1.04e-10	3.9e-08	-0.28	-0.28	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
KIRC	cis	rs1528149	0.576	rs10277151	ENSG00000224683.1	RPL36AP29	6.6	1.04e-10	3.9e-08	0.34	0.28	Sitting height ratio;	chr7:16075788	chr7:16208945~16209265:+
KIRC	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	6.6	1.04e-10	3.9e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
KIRC	cis	rs712039	0.652	rs736424	ENSG00000276054.1	RP11-378E13.3	6.6	1.04e-10	3.91e-08	0.37	0.28	Tuberculosis;	chr17:37429263	chr17:37386886~37387926:+
KIRC	cis	rs1005277	0.54	rs1987431	ENSG00000235197.1	ZNF33AP1	-6.6	1.04e-10	3.91e-08	-0.31	-0.28	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:37894637~37896666:+
KIRC	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-6.6	1.04e-10	3.92e-08	-0.33	-0.28	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
KIRC	cis	rs4072705	0.835	rs10122154	ENSG00000224020.1	MIR181A2HG	-6.6	1.04e-10	3.92e-08	-0.3	-0.28	Menarche (age at onset);	chr9:124796759	chr9:124658467~124698631:+
KIRC	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	6.6	1.05e-10	3.93e-08	0.34	0.28	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
KIRC	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	6.6	1.05e-10	3.94e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
KIRC	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-6.6	1.05e-10	3.95e-08	-0.35	-0.28	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
KIRC	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-6.6	1.05e-10	3.95e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-6.6	1.05e-10	3.95e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-6.6	1.05e-10	3.95e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-6.6	1.05e-10	3.95e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
KIRC	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-6.6	1.05e-10	3.95e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
KIRC	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-6.6	1.05e-10	3.95e-08	-0.45	-0.28	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
KIRC	cis	rs1005277	0.505	rs7917943	ENSG00000235197.1	ZNF33AP1	6.6	1.05e-10	3.96e-08	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:37894637~37896666:+
KIRC	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	6.6	1.05e-10	3.96e-08	0.28	0.28	Asthma;	chr2:102351825	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	6.6	1.05e-10	3.96e-08	0.28	0.28	Asthma;	chr2:102351896	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	6.6	1.05e-10	3.96e-08	0.28	0.28	Asthma;	chr2:102351902	chr2:102438713~102440475:+
KIRC	cis	rs1005277	0.505	rs7099777	ENSG00000235197.1	ZNF33AP1	6.6	1.06e-10	3.96e-08	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:37894637~37896666:+
KIRC	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	6.6	1.06e-10	3.97e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	6.6	1.06e-10	3.97e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	6.6	1.06e-10	3.97e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
KIRC	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.6	1.06e-10	3.97e-08	0.3	0.28	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
KIRC	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	6.6	1.06e-10	3.97e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
KIRC	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	6.6	1.06e-10	3.98e-08	0.31	0.28	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
KIRC	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	6.6	1.06e-10	3.98e-08	0.31	0.28	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
KIRC	cis	rs1005277	0.505	rs10827836	ENSG00000235197.1	ZNF33AP1	6.6	1.06e-10	3.98e-08	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:37894637~37896666:+
KIRC	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.6	1.06e-10	3.98e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-6.6	1.06e-10	3.98e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
KIRC	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	6.6	1.06e-10	3.98e-08	0.42	0.28	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
KIRC	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-6.6	1.06e-10	3.98e-08	-0.23	-0.28	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
KIRC	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	6.6	1.06e-10	3.99e-08	0.31	0.28	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
KIRC	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.6	1.06e-10	3.99e-08	0.31	0.28	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
KIRC	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	6.6	1.07e-10	4e-08	0.41	0.28	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
KIRC	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	6.6	1.07e-10	4e-08	0.34	0.28	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
KIRC	cis	rs7017914	0.652	rs2017035	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70929571	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs10504487	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70931364	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs34366597	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70932658	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs7839977	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70933067	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs1493199	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70934269	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.616	rs17689943	ENSG00000254031.4	RP11-326E22.1	6.6	1.07e-10	4e-08	0.33	0.28	Bone mineral density;	chr8:70936145	chr8:71155457~71204223:+
KIRC	cis	rs6480314	0.573	rs12573244	ENSG00000233590.1	RP11-153K11.3	-6.6	1.07e-10	4e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68241488	chr10:68233251~68242379:-
KIRC	cis	rs17772222	0.74	rs4390529	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4e-08	0.32	0.28	Coronary artery calcification;	chr14:88510853	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.771	rs4516145	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4e-08	0.32	0.28	Coronary artery calcification;	chr14:88510953	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs4594187	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4e-08	0.32	0.28	Coronary artery calcification;	chr14:88511071	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs4514599	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4e-08	0.32	0.28	Coronary artery calcification;	chr14:88511083	chr14:88513498~88513663:+
KIRC	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	6.6	1.07e-10	4.01e-08	0.33	0.28	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
KIRC	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	6.6	1.07e-10	4.01e-08	0.33	0.28	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
KIRC	cis	rs7688540	0.8	rs9328737	ENSG00000211553.1	AC253576.2	-6.6	1.07e-10	4.01e-08	-0.33	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:136461~136568:+
KIRC	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-6.6	1.07e-10	4.02e-08	-0.33	-0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
KIRC	cis	rs9900062	1	rs2521879	ENSG00000270714.1	MINOS1P2	-6.6	1.07e-10	4.02e-08	-0.41	-0.28	QT interval;	chr17:64746560	chr17:64747264~64747492:-
KIRC	cis	rs17772222	1	rs11159856	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4.02e-08	0.35	0.28	Coronary artery calcification;	chr14:88417585	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.917	rs17124652	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4.02e-08	0.35	0.28	Coronary artery calcification;	chr14:88424384	chr14:88513498~88513663:+
KIRC	cis	rs17772222	1	rs2295135	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4.02e-08	0.35	0.28	Coronary artery calcification;	chr14:88427866	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.876	rs4375590	ENSG00000222990.1	RNU4-22P	6.6	1.07e-10	4.02e-08	0.35	0.28	Coronary artery calcification;	chr14:88451334	chr14:88513498~88513663:+
KIRC	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-6.6	1.07e-10	4.02e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-6.6	1.07e-10	4.02e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
KIRC	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-6.6	1.07e-10	4.02e-08	-0.27	-0.28	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
KIRC	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	6.6	1.07e-10	4.02e-08	0.32	0.28	Depression;	chr6:28184805	chr6:28073316~28074233:+
KIRC	cis	rs12049351	0.719	rs34804247	ENSG00000229367.1	HMGN2P19	6.6	1.08e-10	4.03e-08	0.39	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229484938	chr1:229570532~229570796:+
KIRC	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-6.6	1.08e-10	4.03e-08	-0.35	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
KIRC	cis	rs4356975	0.83	rs3922514	ENSG00000196472.4	RP13-644M16.4	6.6	1.08e-10	4.03e-08	0.32	0.28	Obesity-related traits;	chr4:69060905	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs28775401	ENSG00000196472.4	RP13-644M16.4	6.6	1.08e-10	4.03e-08	0.32	0.28	Obesity-related traits;	chr4:69060999	chr4:69181660~69182372:+
KIRC	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	6.6	1.08e-10	4.03e-08	0.4	0.28	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
KIRC	cis	rs7267979	1	rs2482931	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2482940	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2027003	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2027004	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.934	rs2500399	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2500404	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2500405	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2482941	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.903	rs2500423	ENSG00000125804.12	FAM182A	6.6	1.08e-10	4.04e-08	0.36	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:26054655~26086917:+
KIRC	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-6.6	1.08e-10	4.04e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
KIRC	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-6.6	1.08e-10	4.05e-08	-0.36	-0.28	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
KIRC	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-6.6	1.08e-10	4.05e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
KIRC	cis	rs3820928	0.874	rs7594505	ENSG00000212391.1	SNORA48	-6.6	1.08e-10	4.05e-08	-0.33	-0.28	Pulmonary function;	chr2:227013846	chr2:226968989~226969122:-
KIRC	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-6.6	1.08e-10	4.06e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
KIRC	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-6.6	1.08e-10	4.06e-08	-0.26	-0.28	Height;	chr2:46632247	chr2:46668870~46670778:+
KIRC	cis	rs919433	0.68	rs3792159	ENSG00000231621.1	AC013264.2	6.6	1.09e-10	4.06e-08	0.31	0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538973	chr2:197197991~197199273:+
KIRC	cis	rs17361889	0.517	rs62441879	ENSG00000224683.1	RPL36AP29	6.6	1.09e-10	4.07e-08	0.4	0.28	Pediatric bone mineral content (hip);	chr7:16290195	chr7:16208945~16209265:+
KIRC	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-6.6	1.09e-10	4.07e-08	-0.5	-0.28	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
KIRC	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	6.6	1.09e-10	4.07e-08	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-6.6	1.09e-10	4.07e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-6.6	1.09e-10	4.07e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-6.6	1.09e-10	4.07e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
KIRC	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	6.6	1.09e-10	4.07e-08	0.36	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
KIRC	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	6.6	1.09e-10	4.07e-08	0.38	0.28	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
KIRC	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	6.6	1.09e-10	4.07e-08	0.36	0.28	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
KIRC	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-6.6	1.09e-10	4.08e-08	-0.38	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
KIRC	cis	rs7267979	0.932	rs6115214	ENSG00000125804.12	FAM182A	6.6	1.09e-10	4.08e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:26054655~26086917:+
KIRC	cis	rs12681963	0.61	rs75739606	ENSG00000248159.1	HSPA8P11	6.6	1.09e-10	4.08e-08	0.5	0.28	Migraine;	chr8:30178768	chr8:30237382~30240997:+
KIRC	cis	rs62025270	0.688	rs17638180	ENSG00000202081.1	RNU6-1280P	-6.6	1.09e-10	4.08e-08	-0.36	-0.28	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85651522~85651628:-
KIRC	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-6.6	1.09e-10	4.08e-08	-0.33	-0.28	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
KIRC	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	4.08e-08	-0.5	-0.28	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
KIRC	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-6.6	1.09e-10	4.08e-08	-0.49	-0.28	Depression;	chr6:28124907	chr6:28115628~28116551:+
KIRC	cis	rs7017914	0.652	rs2639924	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.08e-08	0.33	0.28	Bone mineral density;	chr8:70993306	chr8:71155457~71204223:+
KIRC	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	6.6	1.09e-10	4.08e-08	0.32	0.28	Depression;	chr6:28193021	chr6:28073316~28074233:+
KIRC	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-6.6	1.09e-10	4.09e-08	-0.39	-0.28	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
KIRC	cis	rs7017914	0.652	rs6994814	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70656903	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.628	rs7830515	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70657999	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs12674694	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70658599	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs35863913	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70661024	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs10504480	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70666012	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs11987501	ENSG00000254031.4	RP11-326E22.1	6.6	1.09e-10	4.09e-08	0.33	0.28	Bone mineral density;	chr8:70666283	chr8:71155457~71204223:+
KIRC	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	6.6	1.09e-10	4.09e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
KIRC	cis	rs7212590	0.748	rs7211208	ENSG00000263422.1	AC005702.1	6.59	1.09e-10	4.09e-08	0.53	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59879748	chr17:60042361~60042442:-
KIRC	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	6.59	1.09e-10	4.1e-08	0.33	0.28	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
KIRC	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	6.59	1.1e-10	4.1e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
KIRC	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	6.59	1.1e-10	4.1e-08	0.37	0.28	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
KIRC	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-6.59	1.1e-10	4.11e-08	-0.36	-0.28	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
KIRC	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	6.59	1.1e-10	4.11e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
KIRC	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	6.59	1.1e-10	4.11e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
KIRC	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-6.59	1.1e-10	4.11e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-6.59	1.1e-10	4.11e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-6.59	1.1e-10	4.11e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
KIRC	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	6.59	1.1e-10	4.11e-08	0.33	0.28	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
KIRC	cis	rs453301	0.624	rs6987558	ENSG00000254340.1	RP11-10A14.3	6.59	1.1e-10	4.12e-08	0.35	0.28	Joint mobility (Beighton score);	chr8:9005011	chr8:9141424~9145435:+
KIRC	cis	rs3750965	1	rs7950657	ENSG00000260895.1	RP11-554A11.7	6.59	1.1e-10	4.12e-08	0.36	0.28	Hair color;	chr11:69067363	chr11:69103493~69109094:+
KIRC	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-6.59	1.1e-10	4.13e-08	-0.47	-0.28	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
KIRC	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	6.59	1.1e-10	4.13e-08	0.5	0.28	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
KIRC	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	6.59	1.11e-10	4.14e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
KIRC	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-6.59	1.11e-10	4.15e-08	-0.27	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
KIRC	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	6.59	1.11e-10	4.15e-08	0.39	0.28	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	6.59	1.11e-10	4.15e-08	0.39	0.28	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	6.59	1.11e-10	4.15e-08	0.39	0.28	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
KIRC	cis	rs3744061	0.505	rs9907915	ENSG00000277382.1	RP11-318A15.8	6.59	1.11e-10	4.15e-08	0.33	0.28	Retinal arteriolar caliber;	chr17:76655154	chr17:76709760~76710045:+
KIRC	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	6.59	1.11e-10	4.15e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
KIRC	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	6.59	1.11e-10	4.15e-08	0.44	0.28	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
KIRC	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	6.59	1.11e-10	4.15e-08	0.41	0.28	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
KIRC	cis	rs9807989	0.839	rs6749114	ENSG00000234389.1	AC007278.3	6.59	1.11e-10	4.15e-08	0.28	0.28	Asthma;	chr2:102351127	chr2:102438713~102440475:+
KIRC	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-6.59	1.11e-10	4.16e-08	-0.38	-0.28	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
KIRC	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-6.59	1.11e-10	4.16e-08	-0.28	-0.28	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
KIRC	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-6.59	1.11e-10	4.17e-08	-0.34	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
KIRC	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-6.59	1.12e-10	4.17e-08	-0.29	-0.28	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
KIRC	cis	rs6860806	0.507	rs270614	ENSG00000233006.5	AC034220.3	6.59	1.12e-10	4.17e-08	0.23	0.28	Breast cancer;	chr5:132305120	chr5:132311285~132369916:-
KIRC	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	4.17e-08	-0.49	-0.28	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
KIRC	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-6.59	1.12e-10	4.18e-08	-0.22	-0.28	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
KIRC	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-6.59	1.12e-10	4.18e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
KIRC	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-6.59	1.12e-10	4.18e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
KIRC	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	6.59	1.12e-10	4.19e-08	0.27	0.28	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
KIRC	cis	rs7017914	0.617	rs111678999	ENSG00000254031.4	RP11-326E22.1	6.59	1.12e-10	4.19e-08	0.33	0.28	Bone mineral density;	chr8:70755748	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.69	rs35074484	ENSG00000254031.4	RP11-326E22.1	6.59	1.12e-10	4.19e-08	0.33	0.28	Bone mineral density;	chr8:70762526	chr8:71155457~71204223:+
KIRC	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-6.59	1.12e-10	4.19e-08	-0.27	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
KIRC	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-6.59	1.12e-10	4.19e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
KIRC	cis	rs12188164	0.686	rs11741946	ENSG00000225138.6	CTD-2228K2.7	6.59	1.12e-10	4.19e-08	0.33	0.28	Cystic fibrosis severity;	chr5:421288	chr5:473236~480884:+
KIRC	cis	rs4356975	0.83	rs10012215	ENSG00000196472.4	RP13-644M16.4	6.59	1.13e-10	4.21e-08	0.32	0.28	Obesity-related traits;	chr4:69048448	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs10012240	ENSG00000196472.4	RP13-644M16.4	6.59	1.13e-10	4.21e-08	0.32	0.28	Obesity-related traits;	chr4:69048519	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs10012607	ENSG00000196472.4	RP13-644M16.4	6.59	1.13e-10	4.21e-08	0.32	0.28	Obesity-related traits;	chr4:69048866	chr4:69181660~69182372:+
KIRC	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	6.59	1.13e-10	4.21e-08	0.28	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
KIRC	cis	rs4072705	1	rs4836981	ENSG00000224020.1	MIR181A2HG	-6.59	1.13e-10	4.21e-08	-0.28	-0.28	Menarche (age at onset);	chr9:124577866	chr9:124658467~124698631:+
KIRC	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-6.59	1.13e-10	4.21e-08	-0.31	-0.28	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
KIRC	cis	rs17772222	1	rs12589467	ENSG00000222990.1	RNU4-22P	6.59	1.13e-10	4.22e-08	0.34	0.28	Coronary artery calcification;	chr14:88357239	chr14:88513498~88513663:+
KIRC	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-6.59	1.13e-10	4.22e-08	-0.31	-0.28	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
KIRC	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	6.59	1.13e-10	4.22e-08	0.4	0.28	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
KIRC	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	6.59	1.13e-10	4.23e-08	0.33	0.28	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
KIRC	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-6.59	1.13e-10	4.23e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
KIRC	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	6.59	1.13e-10	4.23e-08	0.38	0.28	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
KIRC	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	6.59	1.13e-10	4.24e-08	0.31	0.28	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
KIRC	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-6.59	1.14e-10	4.24e-08	-0.22	-0.28	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
KIRC	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
KIRC	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
KIRC	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
KIRC	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	6.59	1.14e-10	4.25e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
KIRC	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	6.59	1.14e-10	4.25e-08	0.32	0.28	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	6.59	1.14e-10	4.25e-08	0.32	0.28	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
KIRC	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	6.59	1.14e-10	4.25e-08	0.32	0.28	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
KIRC	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-6.59	1.14e-10	4.26e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
KIRC	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	6.59	1.14e-10	4.27e-08	0.24	0.28	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
KIRC	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-6.59	1.15e-10	4.27e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
KIRC	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	6.59	1.15e-10	4.27e-08	0.32	0.28	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
KIRC	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	6.59	1.15e-10	4.27e-08	0.32	0.28	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
KIRC	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	6.59	1.15e-10	4.27e-08	0.38	0.28	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
KIRC	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-6.59	1.15e-10	4.28e-08	-0.48	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
KIRC	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	6.59	1.15e-10	4.28e-08	0.34	0.28	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
KIRC	cis	rs600231	0.683	rs588298	ENSG00000173727.10	CMB9-22P13.1	6.59	1.15e-10	4.28e-08	0.32	0.28	Bone mineral density;	chr11:65486103	chr11:65455258~65466720:+
KIRC	cis	rs4356975	0.83	rs4413468	ENSG00000196472.4	RP13-644M16.4	6.59	1.15e-10	4.28e-08	0.32	0.28	Obesity-related traits;	chr4:69061845	chr4:69181660~69182372:+
KIRC	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	6.59	1.15e-10	4.29e-08	0.31	0.28	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
KIRC	cis	rs17711722	0.51	rs11767457	ENSG00000275400.1	RP4-756H11.5	-6.59	1.15e-10	4.29e-08	-0.29	-0.28	Calcium levels;	chr7:65825628	chr7:66553805~66554199:-
KIRC	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-6.59	1.15e-10	4.29e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
KIRC	cis	rs4356975	0.798	rs4694588	ENSG00000196472.4	RP13-644M16.4	-6.59	1.15e-10	4.3e-08	-0.32	-0.28	Obesity-related traits;	chr4:69044664	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs6422321	ENSG00000196472.4	RP13-644M16.4	-6.59	1.15e-10	4.3e-08	-0.32	-0.28	Obesity-related traits;	chr4:69044911	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.768	rs4518318	ENSG00000196472.4	RP13-644M16.4	-6.59	1.15e-10	4.3e-08	-0.32	-0.28	Obesity-related traits;	chr4:69045479	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs4351079	ENSG00000196472.4	RP13-644M16.4	-6.59	1.15e-10	4.3e-08	-0.32	-0.28	Obesity-related traits;	chr4:69045631	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.798	rs4607293	ENSG00000196472.4	RP13-644M16.4	-6.59	1.15e-10	4.3e-08	-0.32	-0.28	Obesity-related traits;	chr4:69045714	chr4:69181660~69182372:+
KIRC	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	6.59	1.15e-10	4.3e-08	0.41	0.28	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
KIRC	cis	rs1005277	0.505	rs719569	ENSG00000235197.1	ZNF33AP1	6.59	1.15e-10	4.3e-08	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:37894637~37896666:+
KIRC	cis	rs1005277	0.522	rs200943	ENSG00000235197.1	ZNF33AP1	-6.59	1.15e-10	4.3e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:37894637~37896666:+
KIRC	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-6.59	1.15e-10	4.3e-08	-0.24	-0.28	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
KIRC	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-6.59	1.15e-10	4.3e-08	-0.3	-0.28	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
KIRC	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-6.59	1.15e-10	4.31e-08	-0.27	-0.28	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
KIRC	cis	rs11846409	1	rs11846409	ENSG00000274576.2	IGHV2-70	-6.59	1.16e-10	4.31e-08	-0.32	-0.28	Rheumatic heart disease;	chr14:106645692	chr14:106770577~106771020:-
KIRC	cis	rs7916697	0.578	rs61854799	ENSG00000233590.1	RP11-153K11.3	-6.59	1.16e-10	4.31e-08	-0.37	-0.28	Optic disc area;	chr10:68246902	chr10:68233251~68242379:-
KIRC	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-6.59	1.16e-10	4.31e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
KIRC	cis	rs4820539	1	rs5759596	ENSG00000221069.1	AC000029.1	-6.59	1.16e-10	4.32e-08	-0.35	-0.28	Bone mineral density;	chr22:23133563	chr22:23136620~23136710:+
KIRC	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-6.59	1.16e-10	4.32e-08	-0.41	-0.28	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
KIRC	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-6.59	1.16e-10	4.32e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.866	rs6138609	ENSG00000125804.12	FAM182A	-6.59	1.16e-10	4.32e-08	-0.35	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:26054655~26086917:+
KIRC	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-6.59	1.16e-10	4.32e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
KIRC	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.59	1.16e-10	4.33e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
KIRC	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-6.59	1.16e-10	4.33e-08	-0.35	-0.28	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
KIRC	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-6.59	1.16e-10	4.33e-08	-0.39	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
KIRC	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-6.58	1.16e-10	4.34e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
KIRC	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-6.58	1.16e-10	4.34e-08	-0.31	-0.28	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
KIRC	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-6.58	1.16e-10	4.34e-08	-0.31	-0.28	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
KIRC	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.58	1.17e-10	4.35e-08	0.31	0.28	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
KIRC	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	6.58	1.17e-10	4.36e-08	0.22	0.28	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
KIRC	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-6.58	1.17e-10	4.36e-08	-0.21	-0.28	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
KIRC	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-6.58	1.17e-10	4.37e-08	-0.27	-0.28	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
KIRC	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-6.58	1.17e-10	4.37e-08	-0.27	-0.28	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
KIRC	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-6.58	1.17e-10	4.38e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
KIRC	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-6.58	1.18e-10	4.38e-08	-0.4	-0.28	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
KIRC	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-6.58	1.18e-10	4.38e-08	-0.32	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
KIRC	cis	rs62025270	0.688	rs10163064	ENSG00000202081.1	RNU6-1280P	-6.58	1.18e-10	4.38e-08	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85651522~85651628:-
KIRC	cis	rs853679	0.513	rs13437444	ENSG00000216901.1	AL022393.7	6.58	1.18e-10	4.38e-08	0.44	0.28	Depression;	chr6:28103220	chr6:28176188~28176674:+
KIRC	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-6.58	1.18e-10	4.38e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
KIRC	cis	rs4356975	0.583	rs4632729	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69080286	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs11249524	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69080653	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs11249526	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69080934	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.602	rs7674851	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69081113	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7679550	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69081187	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4478248	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69081498	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7680709	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69081745	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4131317	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083280	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4540108	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083614	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs4640729	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083642	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4522933	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083780	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs11937683	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69084102	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7659306	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69084560	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4454000	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69084853	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4273534	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69084927	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.522	rs4642304	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69085832	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4446391	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69086364	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7437174	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69086885	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6600874	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69087695	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs6843382	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69087884	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs4694171	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69088579	chr4:69181660~69182372:+
KIRC	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	6.58	1.18e-10	4.39e-08	0.28	0.28	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
KIRC	cis	rs4356975	0.563	rs11932131	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083829	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs35297888	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083855	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.545	rs35749478	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.39e-08	0.33	0.28	Obesity-related traits;	chr4:69083862	chr4:69181660~69182372:+
KIRC	cis	rs11089937	0.616	rs1076851	ENSG00000211639.2	IGLV4-60	6.58	1.18e-10	4.39e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22177442	chr22:22162199~22162681:+
KIRC	cis	rs11089937	0.522	rs2005239	ENSG00000211639.2	IGLV4-60	6.58	1.18e-10	4.39e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22162199~22162681:+
KIRC	cis	rs11089937	0.616	rs743520	ENSG00000211639.2	IGLV4-60	6.58	1.18e-10	4.39e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22162199~22162681:+
KIRC	cis	rs4356975	0.83	rs4422474	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.4e-08	0.32	0.28	Obesity-related traits;	chr4:69051322	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs4377650	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.4e-08	0.32	0.28	Obesity-related traits;	chr4:69051355	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.83	rs72851338	ENSG00000196472.4	RP13-644M16.4	6.58	1.18e-10	4.4e-08	0.32	0.28	Obesity-related traits;	chr4:69052555	chr4:69181660~69182372:+
KIRC	cis	rs919433	0.51	rs34631382	ENSG00000231621.1	AC013264.2	-6.58	1.18e-10	4.4e-08	-0.31	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197525285	chr2:197197991~197199273:+
KIRC	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	6.58	1.18e-10	4.4e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
KIRC	cis	rs35306767	0.953	rs11253521	ENSG00000229869.1	RP11-363N22.2	-6.58	1.19e-10	4.41e-08	-0.33	-0.28	Eosinophil percentage of granulocytes;	chr10:930476	chr10:933026~942743:+
KIRC	cis	rs2018683	0.691	rs4722881	ENSG00000228421.2	AC005013.5	-6.58	1.19e-10	4.41e-08	-0.31	-0.28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28957667~28959345:+
KIRC	cis	rs4356975	0.563	rs6422324	ENSG00000196472.4	RP13-644M16.4	6.58	1.19e-10	4.41e-08	0.33	0.28	Obesity-related traits;	chr4:69087385	chr4:69181660~69182372:+
KIRC	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-6.58	1.19e-10	4.41e-08	-0.38	-0.28	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
KIRC	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	6.58	1.19e-10	4.42e-08	0.33	0.28	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
KIRC	cis	rs890448	0.76	rs293210	ENSG00000254531.1	FLJ20021	6.58	1.19e-10	4.42e-08	0.28	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395248	chr4:101347780~101348883:+
KIRC	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-6.58	1.19e-10	4.43e-08	-0.39	-0.28	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
KIRC	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-6.58	1.19e-10	4.43e-08	-0.39	-0.28	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
KIRC	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-6.58	1.19e-10	4.43e-08	-0.39	-0.28	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
KIRC	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-6.58	1.19e-10	4.43e-08	-0.39	-0.28	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
KIRC	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-6.58	1.19e-10	4.43e-08	-0.39	-0.28	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
KIRC	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-6.58	1.19e-10	4.44e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
KIRC	cis	rs4072705	1	rs4524900	ENSG00000224020.1	MIR181A2HG	-6.58	1.19e-10	4.44e-08	-0.28	-0.28	Menarche (age at onset);	chr9:124580930	chr9:124658467~124698631:+
KIRC	cis	rs755249	0.567	rs6668369	ENSG00000237624.1	OXCT2P1	6.58	1.19e-10	4.44e-08	0.43	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39514956~39516490:+
KIRC	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-6.58	1.2e-10	4.44e-08	-0.43	-0.28	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
KIRC	cis	rs10995505	0.578	rs1533068	ENSG00000232075.1	MRPL35P2	-6.58	1.2e-10	4.45e-08	-0.37	-0.28	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63634317~63634827:-
KIRC	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-6.58	1.2e-10	4.45e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
KIRC	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-6.58	1.2e-10	4.45e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
KIRC	cis	rs4356975	0.932	rs7657426	ENSG00000198277.6	RP11-468N14.09	6.58	1.2e-10	4.46e-08	0.3	0.28	Obesity-related traits;	chr4:69079291	chr4:68914928~68924741:-
KIRC	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-6.58	1.2e-10	4.47e-08	-0.48	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
KIRC	cis	rs7212590	0.529	rs60283440	ENSG00000263422.1	AC005702.1	6.58	1.2e-10	4.47e-08	0.53	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59916887	chr17:60042361~60042442:-
KIRC	cis	rs950776	0.667	rs57728226	ENSG00000261762.1	RP11-650L12.2	6.58	1.2e-10	4.47e-08	0.38	0.28	Sudden cardiac arrest;	chr15:78637008	chr15:78589123~78591276:-
KIRC	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-6.58	1.2e-10	4.47e-08	-0.3	-0.28	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
KIRC	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	6.58	1.2e-10	4.47e-08	0.4	0.28	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
KIRC	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	6.58	1.2e-10	4.47e-08	0.4	0.28	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
KIRC	cis	rs7688540	0.76	rs4510422	ENSG00000211553.1	AC253576.2	-6.58	1.2e-10	4.47e-08	-0.34	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:136461~136568:+
KIRC	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	6.58	1.21e-10	4.48e-08	0.21	0.28	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
KIRC	cis	rs8048589	1	rs11642386	ENSG00000175604.2	RP11-276H1.3	-6.58	1.21e-10	4.49e-08	-0.33	-0.28	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090207	chr16:12086746~12090302:-
KIRC	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-6.58	1.21e-10	4.49e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
KIRC	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-6.58	1.21e-10	4.49e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
KIRC	cis	rs4925386	0.959	rs4925385	ENSG00000275437.1	RP5-908M14.10	-6.58	1.21e-10	4.49e-08	-0.23	-0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62402236~62405935:-
KIRC	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-6.58	1.21e-10	4.49e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
KIRC	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-6.58	1.21e-10	4.49e-08	-0.35	-0.28	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
KIRC	cis	rs11647589	0.651	rs7498385	ENSG00000260762.1	ACSM5P1	6.58	1.21e-10	4.49e-08	0.29	0.28	Blood metabolite levels;	chr16:20435517	chr16:20586550~20607107:-
KIRC	cis	rs4356975	0.83	rs72851348	ENSG00000196472.4	RP13-644M16.4	6.58	1.21e-10	4.49e-08	0.32	0.28	Obesity-related traits;	chr4:69054305	chr4:69181660~69182372:+
KIRC	cis	rs890448	0.796	rs1426541	ENSG00000254531.1	FLJ20021	6.58	1.21e-10	4.5e-08	0.28	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101435702	chr4:101347780~101348883:+
KIRC	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.58	1.21e-10	4.5e-08	0.31	0.28	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
KIRC	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-6.58	1.21e-10	4.51e-08	-0.39	-0.28	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
KIRC	cis	rs4072705	0.835	rs7855360	ENSG00000224020.1	MIR181A2HG	-6.58	1.21e-10	4.51e-08	-0.29	-0.28	Menarche (age at onset);	chr9:124794425	chr9:124658467~124698631:+
KIRC	cis	rs6480314	0.542	rs11814858	ENSG00000233590.1	RP11-153K11.3	-6.58	1.21e-10	4.51e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68241950	chr10:68233251~68242379:-
KIRC	cis	rs6480314	0.636	rs61854788	ENSG00000233590.1	RP11-153K11.3	-6.58	1.21e-10	4.51e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68241980	chr10:68233251~68242379:-
KIRC	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	6.58	1.21e-10	4.51e-08	0.35	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
KIRC	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	6.58	1.21e-10	4.51e-08	0.33	0.28	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
KIRC	cis	rs42648	0.869	rs12374728	ENSG00000225498.1	AC002064.5	6.58	1.21e-10	4.51e-08	0.27	0.28	Homocysteine levels;	chr7:90312570	chr7:90312496~90322592:+
KIRC	cis	rs7017914	0.593	rs2732140	ENSG00000254031.4	RP11-326E22.1	6.58	1.22e-10	4.52e-08	0.33	0.28	Bone mineral density;	chr8:70998491	chr8:71155457~71204223:+
KIRC	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	6.58	1.22e-10	4.52e-08	0.36	0.28	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
KIRC	cis	rs755249	0.565	rs12138051	ENSG00000237624.1	OXCT2P1	-6.58	1.22e-10	4.52e-08	-0.36	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39514956~39516490:+
KIRC	cis	rs2486288	0.656	rs11637364	ENSG00000259433.2	CTD-2651B20.4	6.58	1.22e-10	4.53e-08	0.2	0.28	Glomerular filtration rate;	chr15:45287040	chr15:45330209~45332634:-
KIRC	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	6.58	1.22e-10	4.53e-08	0.35	0.28	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
KIRC	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	6.58	1.22e-10	4.53e-08	0.35	0.28	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
KIRC	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	6.58	1.22e-10	4.53e-08	0.29	0.28	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
KIRC	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-6.58	1.22e-10	4.53e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
KIRC	cis	rs7017914	0.549	rs3098863	ENSG00000254031.4	RP11-326E22.1	6.58	1.22e-10	4.53e-08	0.33	0.28	Bone mineral density;	chr8:70965931	chr8:71155457~71204223:+
KIRC	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-6.58	1.22e-10	4.54e-08	-0.28	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
KIRC	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	6.58	1.22e-10	4.54e-08	0.26	0.28	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
KIRC	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-6.58	1.22e-10	4.54e-08	-0.39	-0.28	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
KIRC	cis	rs12571093	0.803	rs2241970	ENSG00000233590.1	RP11-153K11.3	6.58	1.22e-10	4.54e-08	0.41	0.28	Optic nerve measurement (disc area);	chr10:68271310	chr10:68233251~68242379:-
KIRC	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-6.58	1.22e-10	4.55e-08	-0.5	-0.28	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
KIRC	cis	rs4356975	0.83	rs7693166	ENSG00000196472.4	RP13-644M16.4	-6.58	1.22e-10	4.55e-08	-0.32	-0.28	Obesity-related traits;	chr4:69044866	chr4:69181660~69182372:+
KIRC	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-6.58	1.23e-10	4.55e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
KIRC	cis	rs11647589	0.651	rs7195862	ENSG00000260762.1	ACSM5P1	6.58	1.23e-10	4.55e-08	0.29	0.28	Blood metabolite levels;	chr16:20431561	chr16:20586550~20607107:-
KIRC	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	6.58	1.23e-10	4.55e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
KIRC	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	6.58	1.23e-10	4.55e-08	0.38	0.28	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	6.58	1.23e-10	4.55e-08	0.38	0.28	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	6.58	1.23e-10	4.55e-08	0.38	0.28	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
KIRC	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-6.58	1.23e-10	4.55e-08	-0.31	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
KIRC	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	6.58	1.23e-10	4.56e-08	0.53	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
KIRC	cis	rs919433	0.679	rs7600862	ENSG00000231621.1	AC013264.2	-6.58	1.23e-10	4.56e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197669790	chr2:197197991~197199273:+
KIRC	cis	rs7916410	0.512	rs1900003	ENSG00000233590.1	RP11-153K11.3	-6.58	1.23e-10	4.56e-08	-0.32	-0.28	Optic disc area;	chr10:68244794	chr10:68233251~68242379:-
KIRC	cis	rs7916697	0.578	rs1900002	ENSG00000233590.1	RP11-153K11.3	-6.58	1.23e-10	4.56e-08	-0.32	-0.28	Optic disc area;	chr10:68244795	chr10:68233251~68242379:-
KIRC	cis	rs17772222	0.74	rs10150986	ENSG00000222990.1	RNU4-22P	6.58	1.23e-10	4.57e-08	0.31	0.28	Coronary artery calcification;	chr14:88517326	chr14:88513498~88513663:+
KIRC	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.58	1.23e-10	4.58e-08	0.31	0.28	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.58	1.23e-10	4.58e-08	0.31	0.28	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.58	1.23e-10	4.58e-08	0.31	0.28	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.58	1.23e-10	4.58e-08	0.31	0.28	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
KIRC	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.58	1.23e-10	4.58e-08	0.31	0.28	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
KIRC	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	6.58	1.24e-10	4.58e-08	0.37	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
KIRC	cis	rs7045881	0.674	rs62542706	ENSG00000254396.1	RP11-56F10.3	6.58	1.24e-10	4.58e-08	0.39	0.28	Schizophrenia;	chr9:27054959	chr9:27102630~27104728:+
KIRC	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	6.58	1.24e-10	4.58e-08	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
KIRC	cis	rs11098499	0.866	rs10518329	ENSG00000249244.1	RP11-548H18.2	6.58	1.24e-10	4.59e-08	0.33	0.28	Corneal astigmatism;	chr4:119480680	chr4:119391831~119395335:-
KIRC	cis	rs2797160	0.967	rs2226158	ENSG00000237742.5	RP11-624M8.1	-6.57	1.24e-10	4.59e-08	-0.34	-0.28	Endometrial cancer;	chr6:125674321	chr6:125578558~125749190:-
KIRC	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-6.57	1.24e-10	4.59e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
KIRC	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-6.57	1.24e-10	4.6e-08	-0.41	-0.28	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
KIRC	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	6.57	1.24e-10	4.61e-08	0.32	0.28	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
KIRC	cis	rs1005277	0.522	rs289648	ENSG00000235197.1	ZNF33AP1	-6.57	1.24e-10	4.61e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:37894637~37896666:+
KIRC	cis	rs1005277	0.505	rs200939	ENSG00000235197.1	ZNF33AP1	-6.57	1.24e-10	4.61e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:37894637~37896666:+
KIRC	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-6.57	1.25e-10	4.62e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
KIRC	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-6.57	1.25e-10	4.62e-08	-0.35	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
KIRC	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-6.57	1.25e-10	4.62e-08	-0.4	-0.28	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
KIRC	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	6.57	1.25e-10	4.62e-08	0.33	0.28	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
KIRC	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	6.57	1.25e-10	4.62e-08	0.38	0.28	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
KIRC	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	6.57	1.25e-10	4.62e-08	0.4	0.28	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
KIRC	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-6.57	1.25e-10	4.63e-08	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
KIRC	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-6.57	1.25e-10	4.63e-08	-0.35	-0.28	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-6.57	1.25e-10	4.63e-08	-0.35	-0.28	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
KIRC	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	6.57	1.25e-10	4.64e-08	0.21	0.28	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
KIRC	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-6.57	1.25e-10	4.64e-08	-0.28	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
KIRC	cis	rs4356975	0.83	rs57386454	ENSG00000196472.4	RP13-644M16.4	6.57	1.25e-10	4.64e-08	0.32	0.28	Obesity-related traits;	chr4:69052968	chr4:69181660~69182372:+
KIRC	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.57	1.25e-10	4.65e-08	0.75	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
KIRC	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-6.57	1.26e-10	4.65e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
KIRC	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	6.57	1.26e-10	4.66e-08	0.35	0.28	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
KIRC	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-6.57	1.26e-10	4.66e-08	-0.32	-0.28	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
KIRC	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-6.57	1.26e-10	4.67e-08	-0.3	-0.28	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
KIRC	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-6.57	1.26e-10	4.67e-08	-0.35	-0.28	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-6.57	1.26e-10	4.67e-08	-0.35	-0.28	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-6.57	1.26e-10	4.67e-08	-0.35	-0.28	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
KIRC	cis	rs755249	0.564	rs6691194	ENSG00000237624.1	OXCT2P1	-6.57	1.26e-10	4.68e-08	-0.36	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39514956~39516490:+
KIRC	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-6.57	1.26e-10	4.68e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
KIRC	cis	rs7017914	0.652	rs6987515	ENSG00000254031.4	RP11-326E22.1	6.57	1.26e-10	4.68e-08	0.33	0.28	Bone mineral density;	chr8:70728067	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs56156614	ENSG00000254031.4	RP11-326E22.1	6.57	1.26e-10	4.68e-08	0.33	0.28	Bone mineral density;	chr8:70730816	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.652	rs56094661	ENSG00000254031.4	RP11-326E22.1	6.57	1.26e-10	4.68e-08	0.33	0.28	Bone mineral density;	chr8:70732493	chr8:71155457~71204223:+
KIRC	cis	rs7017914	0.592	rs6980835	ENSG00000254031.4	RP11-326E22.1	6.57	1.26e-10	4.68e-08	0.33	0.28	Bone mineral density;	chr8:70733691	chr8:71155457~71204223:+
KIRC	cis	rs4888671	1	rs17696958	ENSG00000261707.1	RP11-264M12.2	6.57	1.26e-10	4.68e-08	0.43	0.28	Obesity-related traits;	chr16:77751116	chr16:77741468~77743000:-
KIRC	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	6.57	1.27e-10	4.69e-08	0.21	0.28	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
KIRC	cis	rs4356975	0.509	rs4371688	ENSG00000250696.4	RP11-704M14.1	6.57	1.27e-10	4.7e-08	0.3	0.28	Obesity-related traits;	chr4:69124323	chr4:69182100~69216766:+
KIRC	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-6.57	1.27e-10	4.7e-08	-0.34	-0.28	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
KIRC	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-6.57	1.27e-10	4.7e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-6.57	1.27e-10	4.7e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-6.57	1.27e-10	4.7e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-6.57	1.27e-10	4.7e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
KIRC	cis	rs7924176	0.601	rs7896660	ENSG00000213731.2	RAB5CP1	-6.57	1.27e-10	4.71e-08	-0.28	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74423435~74424014:-
KIRC	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-6.57	1.27e-10	4.72e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
KIRC	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	6.57	1.28e-10	4.72e-08	0.36	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
KIRC	cis	rs1005277	0.522	rs289647	ENSG00000235197.1	ZNF33AP1	-6.57	1.28e-10	4.72e-08	-0.29	-0.28	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:37894637~37896666:+
KIRC	cis	rs4578769	0.524	rs9956919	ENSG00000266850.1	RP11-370A5.1	6.57	1.28e-10	4.73e-08	0.37	0.28	Eosinophil percentage of white cells;	chr18:22896538	chr18:22723491~22907721:-
KIRC	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	6.57	1.28e-10	4.73e-08	0.3	0.28	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
KIRC	cis	rs10214930	0.697	rs6970104	ENSG00000235574.1	AC073150.6	6.57	1.28e-10	4.74e-08	0.33	0.28	Hypospadias;	chr7:27624575	chr7:27491682~27492765:-
KIRC	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-6.57	1.28e-10	4.75e-08	-0.26	-0.28	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
KIRC	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	6.57	1.29e-10	4.76e-08	0.27	0.28	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
KIRC	cis	rs919433	0.68	rs2564389	ENSG00000231621.1	AC013264.2	-6.57	1.29e-10	4.76e-08	-0.31	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197395374	chr2:197197991~197199273:+
KIRC	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	6.57	1.29e-10	4.76e-08	0.66	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
KIRC	cis	rs919433	0.648	rs787975	ENSG00000231621.1	AC013264.2	-6.57	1.29e-10	4.76e-08	-0.31	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197383404	chr2:197197991~197199273:+
KIRC	cis	rs4578769	0.531	rs4616385	ENSG00000266850.1	RP11-370A5.1	6.57	1.29e-10	4.77e-08	0.37	0.28	Eosinophil percentage of white cells;	chr18:22895327	chr18:22723491~22907721:-
KIRC	cis	rs2361718	0.564	rs2304844	ENSG00000279259.1	RP11-334C17.3	6.57	1.29e-10	4.77e-08	0.29	0.28	Yeast infection;	chr17:80110708	chr17:80147250~80148596:+
KIRC	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-6.57	1.29e-10	4.77e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
KIRC	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-6.57	1.29e-10	4.77e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
KIRC	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	6.57	1.29e-10	4.77e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
KIRC	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-6.57	1.29e-10	4.77e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
KIRC	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-6.57	1.29e-10	4.78e-08	-0.37	-0.28	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
KIRC	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.57	1.29e-10	4.78e-08	-0.26	-0.28	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
KIRC	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-6.57	1.29e-10	4.79e-08	-0.24	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
KIRC	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-6.57	1.29e-10	4.79e-08	-0.31	-0.28	Height;	chr5:36832039	chr5:36666214~36725195:-
KIRC	cis	rs17801127	0.748	rs35762145	ENSG00000231969.1	AC144449.1	6.57	1.3e-10	4.79e-08	0.54	0.28	Liver enzyme levels (alanine transaminase);	chr2:149822604	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs35325983	ENSG00000231969.1	AC144449.1	6.57	1.3e-10	4.79e-08	0.54	0.28	Liver enzyme levels (alanine transaminase);	chr2:149823057	chr2:149587196~149848233:+
KIRC	cis	rs12188164	0.686	rs72711369	ENSG00000225138.6	CTD-2228K2.7	6.57	1.3e-10	4.8e-08	0.33	0.28	Cystic fibrosis severity;	chr5:420402	chr5:473236~480884:+
KIRC	cis	rs12188164	0.686	rs72711370	ENSG00000225138.6	CTD-2228K2.7	6.57	1.3e-10	4.8e-08	0.33	0.28	Cystic fibrosis severity;	chr5:420942	chr5:473236~480884:+
KIRC	cis	rs12188164	0.714	rs11741954	ENSG00000225138.6	CTD-2228K2.7	6.57	1.3e-10	4.8e-08	0.33	0.28	Cystic fibrosis severity;	chr5:421340	chr5:473236~480884:+
KIRC	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	6.57	1.3e-10	4.8e-08	0.32	0.28	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
KIRC	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-6.57	1.3e-10	4.8e-08	-0.44	-0.28	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
KIRC	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-6.57	1.3e-10	4.8e-08	-0.44	-0.28	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
KIRC	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-6.57	1.3e-10	4.8e-08	-0.32	-0.28	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
KIRC	cis	rs17772222	0.837	rs1864748	ENSG00000222990.1	RNU4-22P	6.57	1.3e-10	4.8e-08	0.34	0.28	Coronary artery calcification;	chr14:88488847	chr14:88513498~88513663:+
KIRC	cis	rs7212590	0.618	rs35806089	ENSG00000263422.1	AC005702.1	6.57	1.3e-10	4.8e-08	0.53	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59866545	chr17:60042361~60042442:-
KIRC	cis	rs17772222	1	rs12433464	ENSG00000222990.1	RNU4-22P	6.57	1.3e-10	4.8e-08	0.34	0.28	Coronary artery calcification;	chr14:88357671	chr14:88513498~88513663:+
KIRC	cis	rs7209700	0.889	rs16941801	ENSG00000228782.6	CTD-2026D20.3	-6.57	1.3e-10	4.81e-08	-0.32	-0.28	IgG glycosylation;	chr17:47277177	chr17:47450568~47492492:-
KIRC	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-6.57	1.3e-10	4.82e-08	-0.31	-0.28	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
KIRC	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	6.57	1.31e-10	4.82e-08	0.37	0.28	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
KIRC	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-6.57	1.31e-10	4.83e-08	-0.35	-0.28	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
KIRC	cis	rs7017914	0.69	rs3098872	ENSG00000254031.4	RP11-326E22.1	-6.57	1.31e-10	4.83e-08	-0.31	-0.28	Bone mineral density;	chr8:71019969	chr8:71155457~71204223:+
KIRC	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-6.57	1.31e-10	4.83e-08	-0.3	-0.28	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
KIRC	cis	rs67311347	1	rs4571217	ENSG00000230274.1	PGAM1P3	6.57	1.31e-10	4.83e-08	0.33	0.28	Renal cell carcinoma;	chr3:40480482	chr3:40322715~40323279:-
KIRC	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	6.57	1.31e-10	4.83e-08	0.32	0.28	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
KIRC	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	6.57	1.31e-10	4.84e-08	0.32	0.28	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
KIRC	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	6.57	1.31e-10	4.84e-08	0.33	0.28	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
KIRC	cis	rs11647589	1	rs11647589	ENSG00000260762.1	ACSM5P1	6.57	1.31e-10	4.84e-08	0.29	0.28	Blood metabolite levels;	chr16:20438294	chr16:20586550~20607107:-
KIRC	cis	rs890448	0.796	rs7434301	ENSG00000254531.1	FLJ20021	-6.57	1.31e-10	4.84e-08	-0.28	-0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101445370	chr4:101347780~101348883:+
KIRC	cis	rs228614	0.509	rs223481	ENSG00000230069.3	LRRC37A15P	-6.57	1.31e-10	4.84e-08	-0.28	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102727274~102730721:-
KIRC	cis	rs647097	0.614	rs690215	ENSG00000272788.1	RP11-674N23.4	-6.57	1.31e-10	4.84e-08	-0.35	-0.28	Chronic obstructive pulmonary disease;	chr18:8807351	chr18:8801656~8802305:+
KIRC	cis	rs71403859	0.554	rs12920245	ENSG00000260886.1	TAT-AS1	6.57	1.31e-10	4.84e-08	0.63	0.28	Post bronchodilator FEV1;	chr16:71995170	chr16:71565789~71578187:+
KIRC	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-6.57	1.31e-10	4.84e-08	-0.38	-0.28	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-6.57	1.31e-10	4.84e-08	-0.38	-0.28	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
KIRC	cis	rs2797160	0.905	rs1418641	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125678708	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.905	rs1418640	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125678720	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1418639	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125678794	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs4895798	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125679016	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs8180614	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125679453	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.935	rs60515555	ENSG00000237742.5	RP11-624M8.1	-6.57	1.31e-10	4.85e-08	-0.34	-0.28	Endometrial cancer;	chr6:125679492	chr6:125578558~125749190:-
KIRC	cis	rs4907240	0.731	rs11900310	ENSG00000237510.6	AC008268.2	6.57	1.31e-10	4.85e-08	0.34	0.28	Event-related brain oscillations;	chr2:96476093	chr2:95789654~95800166:+
KIRC	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-6.57	1.31e-10	4.85e-08	-0.27	-0.28	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
KIRC	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-6.57	1.31e-10	4.86e-08	-0.33	-0.28	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-6.57	1.31e-10	4.86e-08	-0.33	-0.28	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
KIRC	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-6.57	1.32e-10	4.86e-08	-0.33	-0.28	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
KIRC	cis	rs4356975	0.83	rs7438033	ENSG00000196472.4	RP13-644M16.4	-6.57	1.32e-10	4.86e-08	-0.31	-0.28	Obesity-related traits;	chr4:69059343	chr4:69181660~69182372:+
KIRC	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-6.57	1.32e-10	4.86e-08	-0.46	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
KIRC	cis	rs12571093	0.803	rs36103935	ENSG00000233590.1	RP11-153K11.3	-6.56	1.32e-10	4.86e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68273171	chr10:68233251~68242379:-
KIRC	cis	rs12571093	0.803	rs61854829	ENSG00000233590.1	RP11-153K11.3	-6.56	1.32e-10	4.86e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68273286	chr10:68233251~68242379:-
KIRC	cis	rs2439831	0.717	rs2470132	ENSG00000249839.1	AC011330.5	-6.56	1.32e-10	4.87e-08	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43543283	chr15:43663654~43684339:-
KIRC	cis	rs7045881	0.61	rs62542672	ENSG00000254396.1	RP11-56F10.3	6.56	1.32e-10	4.88e-08	0.38	0.28	Schizophrenia;	chr9:27022938	chr9:27102630~27104728:+
KIRC	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	6.56	1.32e-10	4.88e-08	0.34	0.28	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
KIRC	cis	rs58873874	0.579	rs3815829	ENSG00000251405.2	CTB-109A12.1	6.56	1.32e-10	4.88e-08	0.47	0.28	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157362615~157460078:-
KIRC	cis	rs9371601	0.859	rs214945	ENSG00000226193.1	RP3-398G3.5	-6.56	1.32e-10	4.88e-08	-0.31	-0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152391770	chr6:152402398~152404966:+
KIRC	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-6.56	1.32e-10	4.88e-08	-0.26	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
KIRC	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	6.56	1.32e-10	4.89e-08	0.29	0.28	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
KIRC	cis	rs58873874	0.737	rs11745566	ENSG00000251405.2	CTB-109A12.1	6.56	1.33e-10	4.9e-08	0.5	0.28	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157362615~157460078:-
KIRC	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-6.56	1.33e-10	4.9e-08	-0.34	-0.28	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
KIRC	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-6.56	1.33e-10	4.9e-08	-0.33	-0.28	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
KIRC	cis	rs12049351	0.774	rs12030128	ENSG00000229367.1	HMGN2P19	6.56	1.33e-10	4.9e-08	0.39	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229487116	chr1:229570532~229570796:+
KIRC	cis	rs17772222	0.653	rs1346996	ENSG00000222990.1	RNU4-22P	6.56	1.33e-10	4.9e-08	0.31	0.28	Coronary artery calcification;	chr14:88507174	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs7160471	ENSG00000222990.1	RNU4-22P	6.56	1.33e-10	4.9e-08	0.31	0.28	Coronary artery calcification;	chr14:88507241	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.74	rs9323830	ENSG00000222990.1	RNU4-22P	6.56	1.33e-10	4.9e-08	0.31	0.28	Coronary artery calcification;	chr14:88507260	chr14:88513498~88513663:+
KIRC	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	6.56	1.33e-10	4.9e-08	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
KIRC	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.56	1.33e-10	4.9e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
KIRC	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-6.56	1.33e-10	4.9e-08	-0.28	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
KIRC	cis	rs7045881	0.825	rs10967625	ENSG00000254396.1	RP11-56F10.3	6.56	1.33e-10	4.92e-08	0.37	0.28	Schizophrenia;	chr9:26962490	chr9:27102630~27104728:+
KIRC	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	6.56	1.33e-10	4.92e-08	0.27	0.28	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
KIRC	cis	rs11647589	0.834	rs1394677	ENSG00000260762.1	ACSM5P1	6.56	1.33e-10	4.92e-08	0.29	0.28	Blood metabolite levels;	chr16:20478195	chr16:20586550~20607107:-
KIRC	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	6.56	1.33e-10	4.92e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
KIRC	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-6.56	1.34e-10	4.93e-08	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-6.56	1.34e-10	4.93e-08	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
KIRC	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-6.56	1.34e-10	4.93e-08	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
KIRC	cis	rs919433	0.519	rs700656	ENSG00000231621.1	AC013264.2	-6.56	1.34e-10	4.94e-08	-0.31	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197788943	chr2:197197991~197199273:+
KIRC	cis	rs7916697	0.898	rs1900005	ENSG00000233590.1	RP11-153K11.3	6.56	1.34e-10	4.94e-08	0.31	0.28	Optic disc area;	chr10:68238298	chr10:68233251~68242379:-
KIRC	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-6.56	1.34e-10	4.94e-08	-0.38	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
KIRC	cis	rs10506328	0.689	rs4759348	ENSG00000248265.1	FLJ12825	6.56	1.34e-10	4.94e-08	0.41	0.28	Mean platelet volume;	chr12:54236733	chr12:54058254~54122234:+
KIRC	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	6.56	1.34e-10	4.94e-08	0.27	0.28	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
KIRC	cis	rs10214930	0.602	rs1115346	ENSG00000235574.1	AC073150.6	-6.56	1.34e-10	4.95e-08	-0.33	-0.28	Hypospadias;	chr7:27622485	chr7:27491682~27492765:-
KIRC	cis	rs755249	0.565	rs722357	ENSG00000237624.1	OXCT2P1	-6.56	1.34e-10	4.95e-08	-0.36	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39514956~39516490:+
KIRC	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-6.56	1.34e-10	4.95e-08	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
KIRC	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	6.56	1.34e-10	4.96e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
KIRC	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	6.56	1.34e-10	4.96e-08	0.3	0.28	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
KIRC	cis	rs919433	0.713	rs1455653	ENSG00000231621.1	AC013264.2	-6.56	1.34e-10	4.96e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197613596	chr2:197197991~197199273:+
KIRC	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	6.56	1.34e-10	4.96e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
KIRC	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	6.56	1.35e-10	4.96e-08	0.28	0.28	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
KIRC	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	6.56	1.35e-10	4.96e-08	0.35	0.28	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
KIRC	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-6.56	1.35e-10	4.96e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
KIRC	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	6.56	1.35e-10	4.97e-08	0.32	0.28	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
KIRC	cis	rs9915657	0.87	rs720244	ENSG00000234899.8	SOX9-AS1	-6.56	1.35e-10	4.97e-08	-0.37	-0.28	Thyroid hormone levels;	chr17:72135502	chr17:72034107~72237203:-
KIRC	cis	rs111580313	0.792	rs79430710	ENSG00000270020.1	RP11-463O9.9	6.56	1.35e-10	4.97e-08	0.67	0.28	Systemic juvenile idiopathic arthritis;	chr16:86575505	chr16:86520383~86523897:-
KIRC	cis	rs111580313	0.685	rs78285663	ENSG00000270020.1	RP11-463O9.9	6.56	1.35e-10	4.97e-08	0.67	0.28	Systemic juvenile idiopathic arthritis;	chr16:86575638	chr16:86520383~86523897:-
KIRC	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	6.56	1.35e-10	4.98e-08	0.37	0.28	Height;	chr6:109458989	chr6:109382795~109383666:+
KIRC	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	6.56	1.35e-10	4.98e-08	0.31	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
KIRC	cis	rs600231	0.598	rs2508712	ENSG00000173727.10	CMB9-22P13.1	6.56	1.35e-10	4.98e-08	0.32	0.28	Bone mineral density;	chr11:65464790	chr11:65455258~65466720:+
KIRC	cis	rs600231	0.708	rs3132767	ENSG00000173727.10	CMB9-22P13.1	6.56	1.35e-10	4.98e-08	0.32	0.28	Bone mineral density;	chr11:65467389	chr11:65455258~65466720:+
KIRC	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-6.56	1.35e-10	4.99e-08	-0.27	-0.28	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
KIRC	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	6.56	1.35e-10	4.99e-08	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
KIRC	cis	rs2436845	0.627	rs974758	ENSG00000253669.3	KB-1732A1.1	-6.56	1.35e-10	4.99e-08	-0.33	-0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102825263	chr8:102805517~102809971:+
KIRC	cis	rs2436845	0.627	rs1062048	ENSG00000253669.3	KB-1732A1.1	-6.56	1.35e-10	4.99e-08	-0.33	-0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102838824	chr8:102805517~102809971:+
KIRC	cis	rs2436845	0.627	rs2570941	ENSG00000253669.3	KB-1732A1.1	-6.56	1.35e-10	4.99e-08	-0.33	-0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845253	chr8:102805517~102809971:+
KIRC	cis	rs2436845	0.627	rs2679747	ENSG00000253669.3	KB-1732A1.1	-6.56	1.35e-10	4.99e-08	-0.33	-0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102845886	chr8:102805517~102809971:+
KIRC	cis	rs9516	1	rs2367995	ENSG00000254974.1	RP11-702H23.2	-6.56	1.36e-10	5e-08	-0.34	-0.28	Facial morphology (factor 15, philtrum width);	chr11:74452791	chr11:74485580~74486051:-
KIRC	cis	rs896854	0.608	rs6991067	ENSG00000253528.2	RP11-347C18.4	6.56	1.36e-10	5e-08	0.26	0.28	Type 2 diabetes;	chr8:94863448	chr8:94974573~94974853:-
KIRC	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-6.56	1.36e-10	5e-08	-0.31	-0.28	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
KIRC	cis	rs13434995	0.842	rs62303685	ENSG00000273257.1	RP11-177J6.1	-6.56	1.36e-10	5e-08	-0.43	-0.28	Adiponectin levels;	chr4:55418915	chr4:55387949~55388271:+
KIRC	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-6.56	1.36e-10	5e-08	-0.43	-0.28	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
KIRC	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	6.56	1.36e-10	5e-08	0.25	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
KIRC	cis	rs4356975	0.509	rs28375964	ENSG00000250696.4	RP11-704M14.1	6.56	1.36e-10	5e-08	0.3	0.28	Obesity-related traits;	chr4:69098070	chr4:69182100~69216766:+
KIRC	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	6.56	1.36e-10	5e-08	0.39	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
KIRC	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	6.56	1.36e-10	5.01e-08	0.28	0.28	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
KIRC	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-6.56	1.36e-10	5.01e-08	-0.55	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
KIRC	cis	rs7688540	0.76	rs12506250	ENSG00000211553.1	AC253576.2	-6.56	1.36e-10	5.01e-08	-0.33	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:136461~136568:+
KIRC	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	6.56	1.36e-10	5.02e-08	0.69	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
KIRC	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-6.56	1.36e-10	5.03e-08	-0.31	-0.28	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
KIRC	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-6.56	1.37e-10	5.03e-08	-0.32	-0.28	Depression;	chr6:28205232	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	6.56	1.37e-10	5.03e-08	0.32	0.28	Depression;	chr6:28197321	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	6.56	1.37e-10	5.03e-08	0.32	0.28	Depression;	chr6:28197412	chr6:28073316~28074233:+
KIRC	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	6.56	1.37e-10	5.03e-08	0.32	0.28	Depression;	chr6:28205175	chr6:28073316~28074233:+
KIRC	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-6.56	1.37e-10	5.03e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
KIRC	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-6.56	1.37e-10	5.03e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
KIRC	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-6.56	1.37e-10	5.03e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
KIRC	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-6.56	1.37e-10	5.03e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
KIRC	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	6.56	1.37e-10	5.04e-08	0.34	0.28	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
KIRC	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-6.56	1.37e-10	5.04e-08	-0.35	-0.28	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
KIRC	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-6.56	1.37e-10	5.04e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
KIRC	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	6.56	1.37e-10	5.04e-08	0.21	0.28	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
KIRC	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-6.56	1.37e-10	5.05e-08	-0.31	-0.28	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
KIRC	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-6.56	1.37e-10	5.05e-08	-0.26	-0.28	Height;	chr2:46633262	chr2:46668870~46670778:+
KIRC	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	6.56	1.37e-10	5.05e-08	0.29	0.28	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
KIRC	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-6.56	1.37e-10	5.05e-08	-0.4	-0.28	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
KIRC	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-6.56	1.37e-10	5.05e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
KIRC	cis	rs17772222	0.755	rs12435019	ENSG00000258789.1	RP11-507K2.3	-6.56	1.37e-10	5.06e-08	-0.25	-0.28	Coronary artery calcification;	chr14:88365074	chr14:88551597~88552493:+
KIRC	cis	rs11098499	0.532	rs12512646	ENSG00000249244.1	RP11-548H18.2	6.56	1.37e-10	5.06e-08	0.34	0.28	Corneal astigmatism;	chr4:119664578	chr4:119391831~119395335:-
KIRC	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-6.56	1.37e-10	5.06e-08	-0.33	-0.28	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
KIRC	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-6.56	1.38e-10	5.06e-08	-0.27	-0.28	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
KIRC	cis	rs6480314	0.636	rs61854790	ENSG00000233590.1	RP11-153K11.3	-6.56	1.38e-10	5.06e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68242491	chr10:68233251~68242379:-
KIRC	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-6.56	1.38e-10	5.06e-08	-0.26	-0.28	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
KIRC	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-6.56	1.38e-10	5.07e-08	-0.38	-0.28	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
KIRC	cis	rs17772222	0.636	rs3850390	ENSG00000258983.2	RP11-507K2.2	6.56	1.38e-10	5.08e-08	0.3	0.28	Coronary artery calcification;	chr14:88829185	chr14:88499334~88515502:+
KIRC	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102358304	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102359712	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102360736	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102361051	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102361270	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102361999	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102363164	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102364083	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102364846	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.08e-08	0.27	0.28	Asthma;	chr2:102365634	chr2:102438713~102440475:+
KIRC	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	6.56	1.38e-10	5.08e-08	0.4	0.28	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
KIRC	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-6.56	1.38e-10	5.08e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
KIRC	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	6.56	1.38e-10	5.08e-08	0.43	0.28	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
KIRC	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-6.56	1.38e-10	5.09e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
KIRC	cis	rs9371601	0.859	rs20585	ENSG00000226193.1	RP3-398G3.5	-6.56	1.38e-10	5.09e-08	-0.3	-0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152393311	chr6:152402398~152404966:+
KIRC	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-6.56	1.38e-10	5.09e-08	-0.37	-0.28	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-6.56	1.38e-10	5.09e-08	-0.37	-0.28	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-6.56	1.38e-10	5.09e-08	-0.37	-0.28	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
KIRC	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-6.56	1.38e-10	5.09e-08	-0.28	-0.28	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
KIRC	cis	rs6456156	0.792	rs4710183	ENSG00000265828.1	MIR3939	6.56	1.38e-10	5.09e-08	0.33	0.28	Primary biliary cholangitis;	chr6:167100595	chr6:166997807~166997912:-
KIRC	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	6.56	1.38e-10	5.09e-08	0.21	0.28	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
KIRC	cis	rs2797160	0.651	rs1269176	ENSG00000237742.5	RP11-624M8.1	-6.56	1.38e-10	5.09e-08	-0.34	-0.28	Endometrial cancer;	chr6:125708536	chr6:125578558~125749190:-
KIRC	cis	rs919433	0.647	rs2045242	ENSG00000231621.1	AC013264.2	-6.56	1.38e-10	5.09e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197642925	chr2:197197991~197199273:+
KIRC	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	6.56	1.38e-10	5.09e-08	0.27	0.28	Asthma;	chr2:102369762	chr2:102438713~102440475:+
KIRC	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	6.56	1.39e-10	5.1e-08	0.26	0.28	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
KIRC	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	6.56	1.39e-10	5.11e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
KIRC	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	6.56	1.39e-10	5.12e-08	0.39	0.28	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
KIRC	cis	rs919433	0.589	rs7601800	ENSG00000231621.1	AC013264.2	-6.56	1.39e-10	5.12e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197530375	chr2:197197991~197199273:+
KIRC	cis	rs12188164	0.515	rs11745246	ENSG00000225138.6	CTD-2228K2.7	6.56	1.39e-10	5.12e-08	0.31	0.28	Cystic fibrosis severity;	chr5:410828	chr5:473236~480884:+
KIRC	cis	rs7267979	0.873	rs6083853	ENSG00000125804.12	FAM182A	6.56	1.39e-10	5.12e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.934	rs2482913	ENSG00000125804.12	FAM182A	6.56	1.39e-10	5.12e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26054655~26086917:+
KIRC	cis	rs7267979	0.966	rs2387885	ENSG00000125804.12	FAM182A	6.56	1.39e-10	5.12e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26054655~26086917:+
KIRC	cis	rs7267979	1	rs2424713	ENSG00000125804.12	FAM182A	-6.56	1.39e-10	5.12e-08	-0.35	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26054655~26086917:+
KIRC	cis	rs526231	0.756	rs2561479	ENSG00000175749.11	EIF3KP1	6.56	1.39e-10	5.12e-08	0.34	0.28	Primary biliary cholangitis;	chr5:103286176	chr5:103032376~103033031:+
KIRC	cis	rs7626444	0.625	rs9872035	ENSG00000272359.1	U4	-6.56	1.39e-10	5.12e-08	-0.31	-0.28	Monocyte count;	chr3:196767831	chr3:196747192~196747324:-
KIRC	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	6.56	1.4e-10	5.13e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
KIRC	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	6.56	1.4e-10	5.14e-08	0.69	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
KIRC	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	6.56	1.4e-10	5.14e-08	0.25	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
KIRC	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.4e-10	5.15e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
KIRC	cis	rs1005277	0.577	rs4934906	ENSG00000235197.1	ZNF33AP1	-6.55	1.4e-10	5.15e-08	-0.31	-0.28	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37894637~37896666:+
KIRC	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	6.55	1.4e-10	5.16e-08	0.33	0.28	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
KIRC	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-6.55	1.4e-10	5.16e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-6.55	1.4e-10	5.16e-08	-0.25	-0.28	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
KIRC	cis	rs17772222	1	rs17124700	ENSG00000222990.1	RNU4-22P	6.55	1.4e-10	5.16e-08	0.35	0.28	Coronary artery calcification;	chr14:88439285	chr14:88513498~88513663:+
KIRC	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	6.55	1.4e-10	5.16e-08	0.2	0.28	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
KIRC	cis	rs899997	1	rs11633170	ENSG00000261143.1	ADAMTS7P3	-6.55	1.41e-10	5.16e-08	-0.36	-0.28	Coronary artery disease or large artery stroke;	chr15:78712300	chr15:77976042~77993057:+
KIRC	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	6.55	1.41e-10	5.17e-08	0.26	0.28	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
KIRC	cis	rs2797160	0.967	rs1343120	ENSG00000237742.5	RP11-624M8.1	-6.55	1.41e-10	5.17e-08	-0.34	-0.28	Endometrial cancer;	chr6:125671664	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs4897151	ENSG00000237742.5	RP11-624M8.1	-6.55	1.41e-10	5.17e-08	-0.34	-0.28	Endometrial cancer;	chr6:125672056	chr6:125578558~125749190:-
KIRC	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-6.55	1.41e-10	5.17e-08	-0.39	-0.28	Depression;	chr6:28226851	chr6:28115628~28116551:+
KIRC	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-6.55	1.41e-10	5.17e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
KIRC	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-6.55	1.41e-10	5.17e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
KIRC	cis	rs17772222	0.958	rs61579615	ENSG00000222990.1	RNU4-22P	6.55	1.41e-10	5.17e-08	0.35	0.28	Coronary artery calcification;	chr14:88400054	chr14:88513498~88513663:+
KIRC	cis	rs17772222	0.958	rs60213984	ENSG00000222990.1	RNU4-22P	6.55	1.41e-10	5.17e-08	0.35	0.28	Coronary artery calcification;	chr14:88401473	chr14:88513498~88513663:+
KIRC	cis	rs17772222	1	rs55722539	ENSG00000222990.1	RNU4-22P	6.55	1.41e-10	5.17e-08	0.35	0.28	Coronary artery calcification;	chr14:88411691	chr14:88513498~88513663:+
KIRC	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-6.55	1.41e-10	5.18e-08	-0.27	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
KIRC	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-6.55	1.41e-10	5.18e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
KIRC	cis	rs2797160	1	rs2747717	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125687289	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs2747718	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125687963	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2747719	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688068	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2797158	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688252	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2747720	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688312	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs2797159	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688411	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2747722	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688483	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2797160	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125688970	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.935	rs1739372	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125690179	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs2797162	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.18e-08	0.34	0.28	Endometrial cancer;	chr6:125690235	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs61299898	ENSG00000237742.5	RP11-624M8.1	6.55	1.41e-10	5.19e-08	0.34	0.28	Endometrial cancer;	chr6:125686505	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs1954360	ENSG00000237742.5	RP11-624M8.1	-6.55	1.41e-10	5.19e-08	-0.34	-0.28	Endometrial cancer;	chr6:125679918	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1954361	ENSG00000237742.5	RP11-624M8.1	-6.55	1.41e-10	5.19e-08	-0.34	-0.28	Endometrial cancer;	chr6:125680277	chr6:125578558~125749190:-
KIRC	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-6.55	1.41e-10	5.19e-08	-0.44	-0.28	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
KIRC	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-6.55	1.41e-10	5.19e-08	-0.32	-0.28	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
KIRC	cis	rs4888671	0.803	rs59848833	ENSG00000261707.1	RP11-264M12.2	6.55	1.41e-10	5.19e-08	0.44	0.28	Obesity-related traits;	chr16:77752198	chr16:77741468~77743000:-
KIRC	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-6.55	1.41e-10	5.2e-08	-0.4	-0.28	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
KIRC	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-6.55	1.42e-10	5.2e-08	-0.23	-0.28	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
KIRC	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-6.55	1.42e-10	5.2e-08	-0.23	-0.28	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
KIRC	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	6.55	1.42e-10	5.2e-08	0.36	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
KIRC	cis	rs17772222	0.606	rs1955598	ENSG00000222990.1	RNU4-22P	6.55	1.42e-10	5.21e-08	0.28	0.28	Coronary artery calcification;	chr14:88357311	chr14:88513498~88513663:+
KIRC	cis	rs6452524	0.618	rs6452504	ENSG00000248112.1	RP11-78C3.1	6.55	1.42e-10	5.21e-08	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82919376~82921119:-
KIRC	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	6.55	1.42e-10	5.21e-08	0.48	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	6.55	1.42e-10	5.21e-08	0.48	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	6.55	1.42e-10	5.21e-08	0.48	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
KIRC	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	6.55	1.42e-10	5.21e-08	0.48	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
KIRC	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-6.55	1.42e-10	5.21e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
KIRC	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	6.55	1.42e-10	5.21e-08	0.36	0.28	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
KIRC	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	6.55	1.42e-10	5.22e-08	0.33	0.28	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
KIRC	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-6.55	1.42e-10	5.22e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
KIRC	cis	rs2797160	1	rs1739367	ENSG00000237742.5	RP11-624M8.1	-6.55	1.42e-10	5.22e-08	-0.34	-0.28	Endometrial cancer;	chr6:125683574	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2747724	ENSG00000237742.5	RP11-624M8.1	-6.55	1.42e-10	5.22e-08	-0.34	-0.28	Endometrial cancer;	chr6:125683789	chr6:125578558~125749190:-
KIRC	cis	rs2749592	0.513	rs1208708	ENSG00000235197.1	ZNF33AP1	-6.55	1.42e-10	5.22e-08	-0.3	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37894637~37896666:+
KIRC	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-6.55	1.42e-10	5.22e-08	-0.5	-0.28	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
KIRC	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-6.55	1.42e-10	5.22e-08	-0.48	-0.28	Gout;	chr7:66732812	chr7:66654538~66669855:+
KIRC	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	6.55	1.42e-10	5.23e-08	0.29	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
KIRC	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.55	1.42e-10	5.23e-08	0.31	0.28	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
KIRC	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	6.55	1.43e-10	5.24e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	6.55	1.43e-10	5.24e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	6.55	1.43e-10	5.24e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	6.55	1.43e-10	5.24e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	6.55	1.43e-10	5.24e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
KIRC	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	6.55	1.43e-10	5.24e-08	0.32	0.28	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
KIRC	cis	rs2337406	1	rs75651733	ENSG00000274576.2	IGHV2-70	-6.55	1.43e-10	5.24e-08	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106701309	chr14:106770577~106771020:-
KIRC	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	6.55	1.43e-10	5.24e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	6.55	1.43e-10	5.24e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
KIRC	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	6.55	1.43e-10	5.25e-08	0.41	0.28	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
KIRC	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-6.55	1.43e-10	5.26e-08	-0.3	-0.28	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
KIRC	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	6.55	1.43e-10	5.26e-08	0.27	0.28	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
KIRC	cis	rs712039	0.652	rs17137970	ENSG00000276054.1	RP11-378E13.3	6.55	1.44e-10	5.26e-08	0.37	0.28	Tuberculosis;	chr17:37411739	chr17:37386886~37387926:+
KIRC	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.55	1.44e-10	5.27e-08	0.27	0.28	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
KIRC	cis	rs9371601	0.819	rs214946	ENSG00000226193.1	RP3-398G3.5	-6.55	1.44e-10	5.27e-08	-0.3	-0.28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr6:152392677	chr6:152402398~152404966:+
KIRC	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-6.55	1.44e-10	5.28e-08	-0.32	-0.28	Height;	chr2:231516587	chr2:231501990~231502201:-
KIRC	cis	rs4936099	0.931	rs7936928	ENSG00000175773.11	RP11-121M22.1	6.55	1.44e-10	5.28e-08	0.31	0.28	Optic cup area;Vertical cup-disc ratio;	chr11:130409273	chr11:130314993~130403657:+
KIRC	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-6.55	1.44e-10	5.28e-08	-0.33	-0.28	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
KIRC	cis	rs7017914	0.652	rs13273773	ENSG00000254031.4	RP11-326E22.1	6.55	1.44e-10	5.28e-08	0.32	0.28	Bone mineral density;	chr8:70867012	chr8:71155457~71204223:+
KIRC	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	6.55	1.44e-10	5.28e-08	0.27	0.28	Asthma;	chr2:102369915	chr2:102438713~102440475:+
KIRC	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	6.55	1.44e-10	5.28e-08	0.34	0.28	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
KIRC	cis	rs2797160	1	rs2747714	ENSG00000237742.5	RP11-624M8.1	6.55	1.44e-10	5.28e-08	0.34	0.28	Endometrial cancer;	chr6:125686474	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs2797154	ENSG00000237742.5	RP11-624M8.1	-6.55	1.44e-10	5.28e-08	-0.34	-0.28	Endometrial cancer;	chr6:125684051	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1739352	ENSG00000237742.5	RP11-624M8.1	-6.55	1.44e-10	5.28e-08	-0.34	-0.28	Endometrial cancer;	chr6:125684164	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs983543	ENSG00000237742.5	RP11-624M8.1	-6.55	1.44e-10	5.28e-08	-0.34	-0.28	Endometrial cancer;	chr6:125684621	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1739378	ENSG00000237742.5	RP11-624M8.1	6.55	1.44e-10	5.28e-08	0.34	0.28	Endometrial cancer;	chr6:125691116	chr6:125578558~125749190:-
KIRC	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
KIRC	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
KIRC	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
KIRC	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
KIRC	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
KIRC	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	6.55	1.44e-10	5.29e-08	0.33	0.28	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
KIRC	cis	rs7916697	0.588	rs10823165	ENSG00000233590.1	RP11-153K11.3	6.55	1.44e-10	5.29e-08	0.36	0.28	Optic disc area;	chr10:68248269	chr10:68233251~68242379:-
KIRC	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	6.55	1.44e-10	5.29e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
KIRC	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	6.55	1.45e-10	5.3e-08	0.29	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
KIRC	cis	rs2486288	0.656	rs12908581	ENSG00000259433.2	CTD-2651B20.4	6.55	1.45e-10	5.31e-08	0.2	0.28	Glomerular filtration rate;	chr15:45256437	chr15:45330209~45332634:-
KIRC	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-6.55	1.45e-10	5.31e-08	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
KIRC	cis	rs4660214	0.666	rs10888788	ENSG00000182109.6	RP11-69E11.4	-6.55	1.45e-10	5.31e-08	-0.22	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39522280~39546187:-
KIRC	cis	rs7264396	0.635	rs6058363	ENSG00000088340.14	FER1L4	-6.55	1.45e-10	5.31e-08	-0.21	-0.28	Total cholesterol levels;	chr20:35917132	chr20:35558737~35607562:-
KIRC	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-6.55	1.45e-10	5.33e-08	-0.33	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
KIRC	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	6.55	1.45e-10	5.33e-08	0.39	0.28	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
KIRC	cis	rs2439831	0.867	rs2255051	ENSG00000249839.1	AC011330.5	-6.55	1.45e-10	5.33e-08	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43553963	chr15:43663654~43684339:-
KIRC	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	6.55	1.46e-10	5.33e-08	0.27	0.28	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
KIRC	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	6.55	1.46e-10	5.34e-08	0.29	0.28	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
KIRC	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	6.55	1.46e-10	5.34e-08	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
KIRC	cis	rs62025270	0.688	rs62025272	ENSG00000202081.1	RNU6-1280P	-6.55	1.46e-10	5.34e-08	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85651522~85651628:-
KIRC	cis	rs62025270	0.688	rs56388190	ENSG00000202081.1	RNU6-1280P	-6.55	1.46e-10	5.34e-08	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85651522~85651628:-
KIRC	cis	rs2439831	0.571	rs689883	ENSG00000249839.1	AC011330.5	-6.55	1.46e-10	5.35e-08	-0.5	-0.28	Lung cancer in ever smokers;	chr15:43520398	chr15:43663654~43684339:-
KIRC	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-6.55	1.46e-10	5.36e-08	-0.28	-0.28	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-6.55	1.46e-10	5.36e-08	-0.28	-0.28	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
KIRC	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.55	1.46e-10	5.36e-08	0.3	0.28	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
KIRC	cis	rs62025270	0.688	rs17575870	ENSG00000202081.1	RNU6-1280P	-6.55	1.47e-10	5.37e-08	-0.36	-0.28	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85651522~85651628:-
KIRC	cis	rs459482	0.504	rs469390	ENSG00000228318.3	AP001610.5	-6.55	1.47e-10	5.37e-08	-0.28	-0.28	IgG glycosylation;	chr21:41446003	chr21:41441056~41445708:-
KIRC	cis	rs11647589	0.648	rs7192310	ENSG00000260762.1	ACSM5P1	6.55	1.47e-10	5.37e-08	0.29	0.28	Blood metabolite levels;	chr16:20465373	chr16:20586550~20607107:-
KIRC	cis	rs7045881	0.877	rs7035755	ENSG00000254396.1	RP11-56F10.3	-6.55	1.47e-10	5.38e-08	-0.36	-0.28	Schizophrenia;	chr9:26945978	chr9:27102630~27104728:+
KIRC	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	6.55	1.47e-10	5.38e-08	0.38	0.28	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
KIRC	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-6.55	1.47e-10	5.38e-08	-0.27	-0.28	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
KIRC	cis	rs1005277	0.505	rs7069702	ENSG00000235197.1	ZNF33AP1	6.55	1.47e-10	5.39e-08	0.3	0.28	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:37894637~37896666:+
KIRC	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	6.55	1.47e-10	5.39e-08	0.24	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	6.55	1.47e-10	5.39e-08	0.24	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	6.55	1.47e-10	5.39e-08	0.24	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
KIRC	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	6.55	1.47e-10	5.39e-08	0.24	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
KIRC	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	6.55	1.47e-10	5.4e-08	0.37	0.28	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
KIRC	cis	rs2486288	0.656	rs12911861	ENSG00000259433.2	CTD-2651B20.4	6.55	1.48e-10	5.4e-08	0.2	0.28	Glomerular filtration rate;	chr15:45274520	chr15:45330209~45332634:-
KIRC	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	6.55	1.48e-10	5.41e-08	0.39	0.28	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
KIRC	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	6.55	1.48e-10	5.41e-08	0.31	0.28	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
KIRC	cis	rs12188164	0.686	rs56279338	ENSG00000225138.6	CTD-2228K2.7	6.55	1.48e-10	5.41e-08	0.32	0.28	Cystic fibrosis severity;	chr5:416003	chr5:473236~480884:+
KIRC	cis	rs7688540	0.76	rs2883229	ENSG00000211553.1	AC253576.2	-6.55	1.48e-10	5.42e-08	-0.33	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:136461~136568:+
KIRC	cis	rs17801127	0.748	rs12990176	ENSG00000231969.1	AC144449.1	-6.55	1.48e-10	5.43e-08	-0.52	-0.28	Liver enzyme levels (alanine transaminase);	chr2:149820562	chr2:149587196~149848233:+
KIRC	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	6.55	1.48e-10	5.43e-08	0.37	0.28	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
KIRC	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-6.55	1.48e-10	5.43e-08	-0.28	-0.28	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
KIRC	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	5.44e-08	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	5.44e-08	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	5.44e-08	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
KIRC	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	5.44e-08	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
KIRC	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	6.54	1.49e-10	5.45e-08	0.32	0.28	Depression;	chr6:28201380	chr6:28073316~28074233:+
KIRC	cis	rs1552244	0.572	rs59132826	ENSG00000180385.7	EMC3-AS1	6.54	1.49e-10	5.45e-08	0.31	0.28	Alzheimer's disease;	chr3:10128041	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.572	rs58223482	ENSG00000180385.7	EMC3-AS1	6.54	1.49e-10	5.45e-08	0.31	0.28	Alzheimer's disease;	chr3:10128062	chr3:9986893~10006990:+
KIRC	cis	rs1552244	0.572	rs113406084	ENSG00000180385.7	EMC3-AS1	6.54	1.49e-10	5.45e-08	0.31	0.28	Alzheimer's disease;	chr3:10128506	chr3:9986893~10006990:+
KIRC	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-6.54	1.49e-10	5.45e-08	-0.27	-0.28	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
KIRC	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-6.54	1.49e-10	5.46e-08	-0.24	-0.28	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
KIRC	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-6.54	1.49e-10	5.46e-08	-0.24	-0.28	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
KIRC	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-6.54	1.49e-10	5.46e-08	-0.24	-0.28	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
KIRC	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-6.54	1.49e-10	5.46e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
KIRC	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-6.54	1.49e-10	5.46e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-6.54	1.49e-10	5.46e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-6.54	1.49e-10	5.46e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-6.54	1.49e-10	5.46e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
KIRC	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-6.54	1.49e-10	5.46e-08	-0.35	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
KIRC	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-6.54	1.49e-10	5.46e-08	-0.21	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
KIRC	cis	rs75422866	0.51	rs73105845	ENSG00000276691.1	RP5-1057I20.5	6.54	1.49e-10	5.47e-08	0.42	0.28	Pneumonia;	chr12:47741824	chr12:47788426~47788971:+
KIRC	cis	rs17772222	1	rs61977058	ENSG00000222990.1	RNU4-22P	6.54	1.49e-10	5.47e-08	0.35	0.28	Coronary artery calcification;	chr14:88415571	chr14:88513498~88513663:+
KIRC	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	6.54	1.5e-10	5.47e-08	0.22	0.28	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
KIRC	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-6.54	1.5e-10	5.47e-08	-0.41	-0.28	Depression;	chr6:28300675	chr6:28176188~28176674:+
KIRC	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-6.54	1.5e-10	5.47e-08	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
KIRC	cis	rs919433	0.68	rs11680291	ENSG00000231621.1	AC013264.2	-6.54	1.5e-10	5.48e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197545160	chr2:197197991~197199273:+
KIRC	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	6.54	1.5e-10	5.48e-08	0.41	0.28	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
KIRC	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-6.54	1.5e-10	5.48e-08	-0.35	-0.28	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
KIRC	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-6.54	1.5e-10	5.48e-08	-0.35	-0.28	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
KIRC	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	6.54	1.5e-10	5.49e-08	0.28	0.28	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
KIRC	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-6.54	1.5e-10	5.49e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
KIRC	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	6.54	1.5e-10	5.49e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
KIRC	cis	rs6480314	0.636	rs61854792	ENSG00000233590.1	RP11-153K11.3	-6.54	1.5e-10	5.5e-08	-0.41	-0.28	Optic nerve measurement (disc area);	chr10:68243902	chr10:68233251~68242379:-
KIRC	cis	rs4578769	0.513	rs9953640	ENSG00000266850.1	RP11-370A5.1	6.54	1.51e-10	5.51e-08	0.38	0.28	Eosinophil percentage of white cells;	chr18:22947856	chr18:22723491~22907721:-
KIRC	cis	rs12049351	0.719	rs6587338	ENSG00000229367.1	HMGN2P19	6.54	1.51e-10	5.51e-08	0.38	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229496891	chr1:229570532~229570796:+
KIRC	cis	rs755249	0.51	rs599892	ENSG00000237624.1	OXCT2P1	6.54	1.51e-10	5.51e-08	0.38	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39514956~39516490:+
KIRC	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-6.54	1.51e-10	5.51e-08	-0.34	-0.28	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
KIRC	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.54	1.51e-10	5.52e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.54	1.51e-10	5.52e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.54	1.51e-10	5.52e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
KIRC	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.54	1.51e-10	5.52e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
KIRC	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.54	1.51e-10	5.52e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
KIRC	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-6.54	1.51e-10	5.52e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-6.54	1.51e-10	5.52e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
KIRC	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	6.54	1.51e-10	5.52e-08	0.37	0.28	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
KIRC	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	6.54	1.51e-10	5.52e-08	0.28	0.28	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
KIRC	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	6.54	1.51e-10	5.53e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
KIRC	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-6.54	1.51e-10	5.53e-08	-0.22	-0.28	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
KIRC	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-6.54	1.51e-10	5.53e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-6.54	1.51e-10	5.53e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
KIRC	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-6.54	1.52e-10	5.54e-08	-0.29	-0.28	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
KIRC	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-6.54	1.52e-10	5.54e-08	-0.28	-0.28	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
KIRC	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-6.54	1.52e-10	5.54e-08	-0.28	-0.28	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
KIRC	cis	rs3820928	0.874	rs13423714	ENSG00000212391.1	SNORA48	6.54	1.52e-10	5.55e-08	0.32	0.28	Pulmonary function;	chr2:227031936	chr2:226968989~226969122:-
KIRC	cis	rs12049351	0.774	rs12039754	ENSG00000229367.1	HMGN2P19	6.54	1.52e-10	5.56e-08	0.38	0.28	Circulating myeloperoxidase levels (plasma);	chr1:229509149	chr1:229570532~229570796:+
KIRC	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	6.54	1.52e-10	5.56e-08	0.28	0.28	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
KIRC	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	6.54	1.52e-10	5.56e-08	0.36	0.28	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
KIRC	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	6.54	1.52e-10	5.56e-08	0.36	0.28	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
KIRC	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	6.54	1.52e-10	5.56e-08	0.36	0.28	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
KIRC	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	6.54	1.52e-10	5.56e-08	0.36	0.28	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
KIRC	cis	rs6728642	0.908	rs11901495	ENSG00000230606.9	AC159540.1	-6.54	1.52e-10	5.56e-08	-0.3	-0.28	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355895	chr2:97416165~97433527:-
KIRC	cis	rs950776	0.745	rs36045869	ENSG00000261762.1	RP11-650L12.2	6.54	1.52e-10	5.56e-08	0.38	0.28	Sudden cardiac arrest;	chr15:78637156	chr15:78589123~78591276:-
KIRC	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-6.54	1.52e-10	5.57e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
KIRC	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.54	1.53e-10	5.57e-08	0.24	0.28	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
KIRC	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-6.54	1.53e-10	5.58e-08	-0.26	-0.28	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
KIRC	cis	rs4072705	0.615	rs4838189	ENSG00000224020.1	MIR181A2HG	-6.54	1.53e-10	5.59e-08	-0.3	-0.28	Menarche (age at onset);	chr9:124486647	chr9:124658467~124698631:+
KIRC	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	6.54	1.53e-10	5.59e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
KIRC	cis	rs7672749	0.63	rs1463100	ENSG00000249973.2	CHCHD2P7	-6.54	1.53e-10	5.59e-08	-0.47	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87872447	chr4:87785920~87786371:-
KIRC	cis	rs7672749	0.63	rs1463101	ENSG00000249973.2	CHCHD2P7	-6.54	1.53e-10	5.59e-08	-0.47	-0.28	TB-LM or TBLH-BMD (pleiotropy);	chr4:87872502	chr4:87785920~87786371:-
KIRC	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-6.54	1.53e-10	5.6e-08	-0.54	-0.28	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
KIRC	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-6.54	1.53e-10	5.6e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-6.54	1.53e-10	5.6e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
KIRC	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-6.54	1.53e-10	5.6e-08	-0.33	-0.28	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
KIRC	cis	rs4925386	0.921	rs11204472	ENSG00000275437.1	RP5-908M14.10	-6.54	1.53e-10	5.61e-08	-0.23	-0.28	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62402236~62405935:-
KIRC	cis	rs6479901	0.588	rs10740105	ENSG00000232075.1	MRPL35P2	-6.54	1.53e-10	5.61e-08	-0.36	-0.28	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63634317~63634827:-
KIRC	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	6.54	1.54e-10	5.61e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
KIRC	cis	rs228614	0.509	rs223482	ENSG00000230069.3	LRRC37A15P	-6.54	1.54e-10	5.62e-08	-0.28	-0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102727274~102730721:-
KIRC	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-6.54	1.54e-10	5.62e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
KIRC	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-6.54	1.54e-10	5.62e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
KIRC	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	6.54	1.54e-10	5.62e-08	0.21	0.28	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
KIRC	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	6.54	1.54e-10	5.62e-08	0.24	0.28	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
KIRC	cis	rs62025270	0.806	rs62025266	ENSG00000202081.1	RNU6-1280P	-6.54	1.54e-10	5.62e-08	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85651522~85651628:-
KIRC	cis	rs17772222	0.958	rs17203789	ENSG00000222990.1	RNU4-22P	6.54	1.54e-10	5.62e-08	0.33	0.28	Coronary artery calcification;	chr14:88541362	chr14:88513498~88513663:+
KIRC	cis	rs755249	0.567	rs112672438	ENSG00000237624.1	OXCT2P1	6.54	1.54e-10	5.63e-08	0.41	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39514956~39516490:+
KIRC	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	6.54	1.54e-10	5.63e-08	0.25	0.28	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
KIRC	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	6.54	1.54e-10	5.64e-08	0.27	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
KIRC	cis	rs7017914	0.652	rs35931247	ENSG00000254031.4	RP11-326E22.1	6.54	1.54e-10	5.64e-08	0.33	0.28	Bone mineral density;	chr8:70743849	chr8:71155457~71204223:+
KIRC	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-6.54	1.55e-10	5.65e-08	-0.32	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
KIRC	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-6.54	1.55e-10	5.65e-08	-0.27	-0.28	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
KIRC	cis	rs2980439	0.517	rs17594065	ENSG00000253893.2	FAM85B	6.54	1.55e-10	5.65e-08	0.37	0.28	Neuroticism;	chr8:8247883	chr8:8167819~8226614:-
KIRC	cis	rs1005277	0.522	rs289650	ENSG00000235197.1	ZNF33AP1	-6.54	1.55e-10	5.65e-08	-0.29	-0.28	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:37894637~37896666:+
KIRC	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-6.54	1.55e-10	5.65e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
KIRC	cis	rs2486288	0.656	rs8024620	ENSG00000235390.4	CTD-2651B20.5	6.54	1.55e-10	5.65e-08	0.26	0.28	Glomerular filtration rate;	chr15:45282131	chr15:45321077~45321692:-
KIRC	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	6.54	1.55e-10	5.65e-08	0.36	0.28	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
KIRC	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	6.54	1.55e-10	5.66e-08	0.33	0.28	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
KIRC	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	6.54	1.55e-10	5.66e-08	0.33	0.28	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
KIRC	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	6.54	1.55e-10	5.66e-08	0.33	0.28	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
KIRC	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-6.54	1.55e-10	5.67e-08	-0.24	-0.28	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
KIRC	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-6.54	1.55e-10	5.67e-08	-0.24	-0.28	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
KIRC	cis	rs17801127	0.818	rs16827307	ENSG00000231969.1	AC144449.1	-6.54	1.55e-10	5.67e-08	-0.5	-0.28	Liver enzyme levels (alanine transaminase);	chr2:149663444	chr2:149587196~149848233:+
KIRC	cis	rs12962334	0.508	rs9966036	ENSG00000266850.1	RP11-370A5.1	6.54	1.55e-10	5.67e-08	0.37	0.28	Breast cancer;	chr18:22936105	chr18:22723491~22907721:-
KIRC	cis	rs1005277	0.505	rs200937	ENSG00000235197.1	ZNF33AP1	-6.54	1.56e-10	5.68e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:37894637~37896666:+
KIRC	cis	rs6479901	0.639	rs871690	ENSG00000232075.1	MRPL35P2	-6.54	1.56e-10	5.68e-08	-0.36	-0.28	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63634317~63634827:-
KIRC	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	6.54	1.56e-10	5.68e-08	0.25	0.28	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
KIRC	cis	rs7045881	0.558	rs17694631	ENSG00000254396.1	RP11-56F10.3	-6.54	1.56e-10	5.68e-08	-0.38	-0.28	Schizophrenia;	chr9:27066072	chr9:27102630~27104728:+
KIRC	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	6.54	1.56e-10	5.68e-08	0.24	0.28	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
KIRC	cis	rs11098499	0.532	rs4833624	ENSG00000249244.1	RP11-548H18.2	6.54	1.56e-10	5.68e-08	0.34	0.28	Corneal astigmatism;	chr4:119664342	chr4:119391831~119395335:-
KIRC	cis	rs2486288	0.656	rs12908818	ENSG00000235390.4	CTD-2651B20.5	6.54	1.56e-10	5.69e-08	0.26	0.28	Glomerular filtration rate;	chr15:45279470	chr15:45321077~45321692:-
KIRC	cis	rs35306767	0.953	rs34405399	ENSG00000229869.1	RP11-363N22.2	-6.54	1.56e-10	5.69e-08	-0.33	-0.28	Eosinophil percentage of granulocytes;	chr10:935075	chr10:933026~942743:+
KIRC	cis	rs35306767	0.904	rs10904584	ENSG00000229869.1	RP11-363N22.2	-6.54	1.56e-10	5.69e-08	-0.33	-0.28	Eosinophil percentage of granulocytes;	chr10:937807	chr10:933026~942743:+
KIRC	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	6.54	1.56e-10	5.69e-08	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
KIRC	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	6.54	1.56e-10	5.71e-08	0.53	0.28	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
KIRC	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	6.54	1.56e-10	5.71e-08	0.29	0.28	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
KIRC	cis	rs4767841	0.552	rs2893796	ENSG00000248636.5	RP11-768F21.1	-6.54	1.57e-10	5.71e-08	-0.29	-0.28	Urgency urinary incontinence;	chr12:119613464	chr12:119387987~119668079:-
KIRC	cis	rs2797160	1	rs1612249	ENSG00000237742.5	RP11-624M8.1	6.54	1.57e-10	5.71e-08	0.34	0.28	Endometrial cancer;	chr6:125693770	chr6:125578558~125749190:-
KIRC	cis	rs4660214	0.666	rs12025847	ENSG00000237624.1	OXCT2P1	-6.54	1.57e-10	5.71e-08	-0.37	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39514956~39516490:+
KIRC	cis	rs7212590	0.655	rs8070039	ENSG00000263422.1	AC005702.1	6.54	1.57e-10	5.71e-08	0.53	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59896224	chr17:60042361~60042442:-
KIRC	cis	rs7212590	0.655	rs56198517	ENSG00000263422.1	AC005702.1	6.54	1.57e-10	5.71e-08	0.53	0.28	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59899221	chr17:60042361~60042442:-
KIRC	cis	rs4578769	0.55	rs12954377	ENSG00000266850.1	RP11-370A5.1	6.54	1.57e-10	5.72e-08	0.38	0.28	Eosinophil percentage of white cells;	chr18:22940862	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.55	rs9957690	ENSG00000266850.1	RP11-370A5.1	6.54	1.57e-10	5.72e-08	0.38	0.28	Eosinophil percentage of white cells;	chr18:22942697	chr18:22723491~22907721:-
KIRC	cis	rs4578769	0.55	rs12956837	ENSG00000266850.1	RP11-370A5.1	6.54	1.57e-10	5.72e-08	0.38	0.28	Eosinophil percentage of white cells;	chr18:22946865	chr18:22723491~22907721:-
KIRC	cis	rs3744061	0.52	rs9908979	ENSG00000277382.1	RP11-318A15.8	6.54	1.57e-10	5.72e-08	0.32	0.28	Retinal arteriolar caliber;	chr17:76649404	chr17:76709760~76710045:+
KIRC	cis	rs12887734	0.566	rs8548	ENSG00000269910.1	RP11-73M18.10	6.54	1.57e-10	5.72e-08	0.2	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694516~103695050:-
KIRC	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-6.54	1.57e-10	5.72e-08	-0.32	-0.28	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
KIRC	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-6.54	1.57e-10	5.73e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
KIRC	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-6.54	1.57e-10	5.73e-08	-0.37	-0.28	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
KIRC	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6.54	1.57e-10	5.73e-08	-0.27	-0.28	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
KIRC	cis	rs17213965	0.789	rs4781688	ENSG00000207425.1	Y_RNA	-6.54	1.57e-10	5.74e-08	-0.47	-0.28	Waist-hip ratio;	chr16:15771332	chr16:14915457~14915556:-
KIRC	cis	rs13434995	0.842	rs62305269	ENSG00000273257.1	RP11-177J6.1	-6.54	1.57e-10	5.74e-08	-0.42	-0.28	Adiponectin levels;	chr4:55507237	chr4:55387949~55388271:+
KIRC	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	6.54	1.57e-10	5.74e-08	0.26	0.28	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
KIRC	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-6.54	1.57e-10	5.74e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
KIRC	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-6.54	1.58e-10	5.75e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
KIRC	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-6.54	1.58e-10	5.75e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
KIRC	cis	rs4356975	0.563	rs6858558	ENSG00000196472.4	RP13-644M16.4	6.54	1.58e-10	5.75e-08	0.32	0.28	Obesity-related traits;	chr4:69103825	chr4:69181660~69182372:+
KIRC	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	6.54	1.58e-10	5.75e-08	0.31	0.28	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
KIRC	cis	rs2797160	1	rs2211420	ENSG00000237742.5	RP11-624M8.1	-6.54	1.58e-10	5.75e-08	-0.33	-0.28	Endometrial cancer;	chr6:125674403	chr6:125578558~125749190:-
KIRC	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-6.54	1.58e-10	5.76e-08	-0.35	-0.28	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
KIRC	cis	rs1552244	0.572	rs2054478	ENSG00000180385.7	EMC3-AS1	6.54	1.58e-10	5.77e-08	0.32	0.28	Alzheimer's disease;	chr3:10130527	chr3:9986893~10006990:+
KIRC	cis	rs11089937	0.521	rs6001221	ENSG00000211639.2	IGLV4-60	6.54	1.58e-10	5.77e-08	0.26	0.28	Periodontitis (PAL4Q3);	chr22:22185176	chr22:22162199~22162681:+
KIRC	cis	rs12893668	0.697	rs67899457	ENSG00000269910.1	RP11-73M18.10	6.54	1.58e-10	5.77e-08	0.2	0.28	Reticulocyte count;	chr14:103593729	chr14:103694516~103695050:-
KIRC	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-6.54	1.58e-10	5.77e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
KIRC	cis	rs7572733	0.534	rs700667	ENSG00000231621.1	AC013264.2	-6.54	1.58e-10	5.77e-08	-0.31	-0.28	Dermatomyositis;	chr2:197812784	chr2:197197991~197199273:+
KIRC	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	6.53	1.58e-10	5.77e-08	0.35	0.28	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
KIRC	cis	rs4072705	0.562	rs7855918	ENSG00000224020.1	MIR181A2HG	-6.53	1.58e-10	5.78e-08	-0.3	-0.28	Menarche (age at onset);	chr9:124477660	chr9:124658467~124698631:+
KIRC	cis	rs17270561	0.609	rs1937127	ENSG00000272462.2	U91328.19	6.53	1.59e-10	5.78e-08	0.24	0.28	Iron status biomarkers;	chr6:25769644	chr6:25992662~26001775:+
KIRC	cis	rs4660214	0.666	rs3116398	ENSG00000237624.1	OXCT2P1	-6.53	1.59e-10	5.78e-08	-0.37	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39514956~39516490:+
KIRC	cis	rs7246657	0.722	rs2927739	ENSG00000267422.1	CTD-2554C21.1	6.53	1.59e-10	5.78e-08	0.41	0.28	Coronary artery calcification;	chr19:37658429	chr19:37779686~37792865:+
KIRC	cis	rs7647973	0.6	rs35174559	ENSG00000225399.4	RP11-3B7.1	6.53	1.59e-10	5.78e-08	0.3	0.28	Menarche (age at onset);	chr3:49250326	chr3:49260085~49261316:+
KIRC	cis	rs10214930	0.671	rs11762342	ENSG00000235574.1	AC073150.6	-6.53	1.59e-10	5.78e-08	-0.33	-0.28	Hypospadias;	chr7:27622314	chr7:27491682~27492765:-
KIRC	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-6.53	1.59e-10	5.78e-08	-0.23	-0.28	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
KIRC	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-6.53	1.59e-10	5.79e-08	-0.4	-0.28	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
KIRC	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	6.53	1.59e-10	5.79e-08	0.34	0.28	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
KIRC	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-6.53	1.59e-10	5.79e-08	-0.34	-0.28	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
KIRC	cis	rs4356975	0.583	rs62296935	ENSG00000196472.4	RP13-644M16.4	6.53	1.59e-10	5.79e-08	0.33	0.28	Obesity-related traits;	chr4:69082878	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs62296936	ENSG00000196472.4	RP13-644M16.4	6.53	1.59e-10	5.79e-08	0.33	0.28	Obesity-related traits;	chr4:69082903	chr4:69181660~69182372:+
KIRC	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	6.53	1.59e-10	5.79e-08	0.24	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
KIRC	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	6.53	1.59e-10	5.79e-08	0.22	0.28	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
KIRC	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-6.53	1.59e-10	5.8e-08	-0.36	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
KIRC	cis	rs3750965	1	rs1466222	ENSG00000260895.1	RP11-554A11.7	6.53	1.59e-10	5.81e-08	0.36	0.28	Hair color;	chr11:69065380	chr11:69103493~69109094:+
KIRC	cis	rs2486288	0.656	rs8039153	ENSG00000259433.2	CTD-2651B20.4	6.53	1.6e-10	5.82e-08	0.2	0.28	Glomerular filtration rate;	chr15:45287615	chr15:45330209~45332634:-
KIRC	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-6.53	1.6e-10	5.82e-08	-0.54	-0.28	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
KIRC	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	6.53	1.6e-10	5.82e-08	0.26	0.28	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
KIRC	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	6.53	1.6e-10	5.83e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
KIRC	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	6.53	1.6e-10	5.83e-08	0.38	0.28	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
KIRC	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	6.53	1.6e-10	5.83e-08	0.36	0.28	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
KIRC	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-6.53	1.6e-10	5.84e-08	-0.23	-0.28	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
KIRC	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-6.53	1.6e-10	5.84e-08	-0.36	-0.28	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
KIRC	cis	rs17801127	0.748	rs57695743	ENSG00000231969.1	AC144449.1	6.53	1.6e-10	5.84e-08	0.5	0.28	Liver enzyme levels (alanine transaminase);	chr2:149705204	chr2:149587196~149848233:+
KIRC	cis	rs2486288	0.656	rs7171312	ENSG00000259433.2	CTD-2651B20.4	6.53	1.61e-10	5.85e-08	0.2	0.28	Glomerular filtration rate;	chr15:45278027	chr15:45330209~45332634:-
KIRC	cis	rs2486288	0.656	rs6493143	ENSG00000259433.2	CTD-2651B20.4	6.53	1.61e-10	5.85e-08	0.2	0.28	Glomerular filtration rate;	chr15:45278583	chr15:45330209~45332634:-
KIRC	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-6.53	1.61e-10	5.85e-08	-0.31	-0.28	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
KIRC	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-6.53	1.61e-10	5.85e-08	-0.33	-0.28	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
KIRC	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	6.53	1.61e-10	5.86e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
KIRC	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-6.53	1.61e-10	5.86e-08	-0.23	-0.28	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
KIRC	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	6.53	1.61e-10	5.87e-08	0.27	0.28	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
KIRC	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	6.53	1.61e-10	5.87e-08	0.21	0.28	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
KIRC	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	6.53	1.61e-10	5.87e-08	0.21	0.28	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
KIRC	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	6.53	1.61e-10	5.88e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
KIRC	cis	rs71007656	1	rs71007656	ENSG00000235197.1	ZNF33AP1	-6.53	1.61e-10	5.88e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:37894637~37896666:+
KIRC	cis	rs12188164	0.515	rs17562461	ENSG00000225138.6	CTD-2228K2.7	6.53	1.62e-10	5.88e-08	0.31	0.28	Cystic fibrosis severity;	chr5:411246	chr5:473236~480884:+
KIRC	cis	rs17772222	0.674	rs112788894	ENSG00000222990.1	RNU4-22P	6.53	1.62e-10	5.88e-08	0.35	0.28	Coronary artery calcification;	chr14:88442850	chr14:88513498~88513663:+
KIRC	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-6.53	1.62e-10	5.88e-08	-0.25	-0.28	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
KIRC	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	6.53	1.62e-10	5.89e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
KIRC	cis	rs919433	0.679	rs1598469	ENSG00000231621.1	AC013264.2	-6.53	1.62e-10	5.89e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197650934	chr2:197197991~197199273:+
KIRC	cis	rs919433	0.679	rs10203581	ENSG00000231621.1	AC013264.2	-6.53	1.62e-10	5.89e-08	-0.3	-0.28	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197651176	chr2:197197991~197199273:+
KIRC	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	6.53	1.62e-10	5.89e-08	0.41	0.28	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
KIRC	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	6.53	1.62e-10	5.89e-08	0.27	0.28	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
KIRC	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.62e-10	5.89e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.62e-10	5.89e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.62e-10	5.89e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
KIRC	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.62e-10	5.89e-08	-0.34	-0.28	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
KIRC	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	6.53	1.62e-10	5.9e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
KIRC	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-6.53	1.62e-10	5.9e-08	-0.31	-0.28	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
KIRC	cis	rs17772222	0.917	rs61977053	ENSG00000222990.1	RNU4-22P	6.53	1.62e-10	5.9e-08	0.35	0.28	Coronary artery calcification;	chr14:88380876	chr14:88513498~88513663:+
KIRC	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	6.53	1.62e-10	5.9e-08	0.37	0.28	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
KIRC	cis	rs9545047	0.604	rs1324868	ENSG00000227676.3	LINC01068	-6.53	1.62e-10	5.9e-08	-0.36	-0.28	Schizophrenia;	chr13:79380040	chr13:79566727~79571436:+
KIRC	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	6.53	1.62e-10	5.91e-08	0.39	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
KIRC	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
KIRC	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
KIRC	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-6.53	1.62e-10	5.91e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
KIRC	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-6.53	1.62e-10	5.91e-08	-0.41	-0.28	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
KIRC	cis	rs1005277	0.505	rs200936	ENSG00000235197.1	ZNF33AP1	-6.53	1.63e-10	5.91e-08	-0.3	-0.28	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:37894637~37896666:+
KIRC	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-6.53	1.63e-10	5.92e-08	-0.38	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
KIRC	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-6.53	1.63e-10	5.92e-08	-0.23	-0.28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
KIRC	cis	rs4356975	0.563	rs6600885	ENSG00000196472.4	RP13-644M16.4	6.53	1.63e-10	5.93e-08	0.33	0.28	Obesity-related traits;	chr4:69103949	chr4:69181660~69182372:+
KIRC	cis	rs4356975	0.563	rs7375178	ENSG00000196472.4	RP13-644M16.4	6.53	1.63e-10	5.93e-08	0.33	0.28	Obesity-related traits;	chr4:69103961	chr4:69181660~69182372:+
KIRC	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	6.53	1.63e-10	5.93e-08	0.32	0.28	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
KIRC	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.53	1.63e-10	5.93e-08	-0.26	-0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
KIRC	cis	rs11846409	0.655	rs79296226	ENSG00000274576.2	IGHV2-70	6.53	1.63e-10	5.94e-08	0.33	0.28	Rheumatic heart disease;	chr14:106650436	chr14:106770577~106771020:-
KIRC	cis	rs453301	0.592	rs4841084	ENSG00000254340.1	RP11-10A14.3	6.53	1.63e-10	5.94e-08	0.35	0.28	Joint mobility (Beighton score);	chr8:9026395	chr8:9141424~9145435:+
KIRC	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-6.53	1.64e-10	5.96e-08	-0.38	-0.28	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
KIRC	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-6.53	1.64e-10	5.96e-08	-0.38	-0.28	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
KIRC	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	6.53	1.64e-10	5.96e-08	0.42	0.28	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
KIRC	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	6.53	1.64e-10	5.96e-08	0.24	0.28	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
KIRC	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	6.53	1.64e-10	5.96e-08	0.33	0.28	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
KIRC	cis	rs2337406	0.714	rs7145254	ENSG00000274576.2	IGHV2-70	-6.53	1.64e-10	5.96e-08	-0.32	-0.28	Alzheimer's disease (late onset);	chr14:106817783	chr14:106770577~106771020:-
KIRC	cis	rs4578769	0.55	rs12964830	ENSG00000266850.1	RP11-370A5.1	6.53	1.64e-10	5.96e-08	0.37	0.28	Eosinophil percentage of white cells;	chr18:22938970	chr18:22723491~22907721:-
KIRC	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	6.53	1.64e-10	5.97e-08	0.36	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
KIRC	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-6.53	1.64e-10	5.97e-08	-0.27	-0.28	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
KIRC	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.53	1.64e-10	5.97e-08	0.24	0.28	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
KIRC	cis	rs2797160	1	rs6934435	ENSG00000237742.5	RP11-624M8.1	6.53	1.64e-10	5.97e-08	0.34	0.28	Endometrial cancer;	chr6:125696335	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1739354	ENSG00000237742.5	RP11-624M8.1	6.53	1.64e-10	5.97e-08	0.34	0.28	Endometrial cancer;	chr6:125696662	chr6:125578558~125749190:-
KIRC	cis	rs17801127	0.901	rs76041558	ENSG00000231969.1	AC144449.1	6.53	1.64e-10	5.98e-08	0.5	0.28	Liver enzyme levels (alanine transaminase);	chr2:149706333	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.901	rs13030540	ENSG00000231969.1	AC144449.1	6.53	1.64e-10	5.98e-08	0.5	0.28	Liver enzyme levels (alanine transaminase);	chr2:149707085	chr2:149587196~149848233:+
KIRC	cis	rs17801127	0.818	rs16827371	ENSG00000231969.1	AC144449.1	6.53	1.64e-10	5.98e-08	0.5	0.28	Liver enzyme levels (alanine transaminase);	chr2:149707661	chr2:149587196~149848233:+
KIRC	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	5.98e-08	0.21	0.28	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	5.98e-08	0.21	0.28	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
KIRC	cis	rs4356975	0.932	rs60814050	ENSG00000198277.6	RP11-468N14.09	6.53	1.65e-10	5.98e-08	0.3	0.28	Obesity-related traits;	chr4:69063770	chr4:68914928~68924741:-
KIRC	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	5.99e-08	0.21	0.28	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
KIRC	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	5.99e-08	0.21	0.28	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
KIRC	cis	rs12049351	0.774	rs12140727	ENSG00000229367.1	HMGN2P19	-6.53	1.65e-10	5.99e-08	-0.38	-0.28	Circulating myeloperoxidase levels (plasma);	chr1:229491144	chr1:229570532~229570796:+
KIRC	cis	rs6480314	0.636	rs77760458	ENSG00000233590.1	RP11-153K11.3	-6.53	1.65e-10	5.99e-08	-0.4	-0.28	Optic nerve measurement (disc area);	chr10:68244248	chr10:68233251~68242379:-
KIRC	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-6.53	1.65e-10	5.99e-08	-0.3	-0.28	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
KIRC	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.53	1.65e-10	5.99e-08	-0.26	-0.28	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
KIRC	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	6.53	1.65e-10	5.99e-08	0.5	0.28	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
KIRC	cis	rs7005380	0.62	rs28669275	ENSG00000245330.4	KB-1471A8.1	6.53	1.66e-10	6.01e-08	0.36	0.28	Interstitial lung disease;	chr8:119889713	chr8:119867419~119874488:-
KIRC	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-6.53	1.66e-10	6.02e-08	-0.43	-0.28	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
KIRC	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-6.53	1.66e-10	6.02e-08	-0.22	-0.28	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
KIRC	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-6.53	1.66e-10	6.02e-08	-0.22	-0.28	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
KIRC	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-6.53	1.66e-10	6.02e-08	-0.22	-0.28	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
KIRC	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-6.53	1.66e-10	6.02e-08	-0.22	-0.28	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
KIRC	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	6.53	1.66e-10	6.03e-08	0.44	0.28	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
KIRC	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	6.53	1.66e-10	6.03e-08	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
KIRC	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-6.53	1.66e-10	6.03e-08	-0.24	-0.28	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
KIRC	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	6.53	1.66e-10	6.04e-08	0.33	0.28	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
KIRC	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-6.53	1.66e-10	6.05e-08	-0.48	-0.28	Gout;	chr7:66645053	chr7:66654538~66669855:+
KIRC	cis	rs9807989	0.801	rs72823663	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102352278	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs67088699	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102352291	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.773	rs5010059	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102352366	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs11688559	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353453	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs11688568	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353489	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs11688573	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353511	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs11689730	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353524	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs11695627	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353645	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.801	rs7558339	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353783	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs7608638	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102353829	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs4485584	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102354290	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.811	rs4485585	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102354299	chr2:102438713~102440475:+
KIRC	cis	rs9807989	1	rs9807989	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102354740	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs9808453	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102354846	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.839	rs4851565	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102355021	chr2:102438713~102440475:+
KIRC	cis	rs9807989	0.765	rs9807962	ENSG00000234389.1	AC007278.3	6.53	1.67e-10	6.05e-08	0.28	0.28	Asthma;	chr2:102355204	chr2:102438713~102440475:+
KIRC	cis	rs4578769	0.513	rs34623893	ENSG00000266850.1	RP11-370A5.1	6.53	1.67e-10	6.05e-08	0.38	0.28	Eosinophil percentage of white cells;	chr18:22967224	chr18:22723491~22907721:-
KIRC	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-6.53	1.67e-10	6.05e-08	-0.31	-0.28	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
KIRC	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-6.53	1.67e-10	6.06e-08	-0.35	-0.28	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
KIRC	cis	rs2797160	0.967	rs1739355	ENSG00000237742.5	RP11-624M8.1	6.53	1.67e-10	6.06e-08	0.34	0.28	Endometrial cancer;	chr6:125696968	chr6:125578558~125749190:-
KIRC	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-6.53	1.67e-10	6.07e-08	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
KIRC	cis	rs4356975	0.563	rs12642938	ENSG00000196472.4	RP13-644M16.4	6.53	1.67e-10	6.07e-08	0.33	0.28	Obesity-related traits;	chr4:69110499	chr4:69181660~69182372:+
KIRC	cis	rs7246657	0.722	rs2927746	ENSG00000267422.1	CTD-2554C21.1	6.53	1.67e-10	6.08e-08	0.41	0.28	Coronary artery calcification;	chr19:37665669	chr19:37779686~37792865:+
KIRC	cis	rs7246657	0.722	rs2927747	ENSG00000267422.1	CTD-2554C21.1	6.53	1.67e-10	6.08e-08	0.41	0.28	Coronary artery calcification;	chr19:37668629	chr19:37779686~37792865:+
KIRC	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	6.53	1.67e-10	6.08e-08	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
KIRC	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	6.53	1.68e-10	6.08e-08	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
KIRC	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-6.53	1.68e-10	6.09e-08	-0.27	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
KIRC	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	6.53	1.68e-10	6.09e-08	0.37	0.28	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
KIRC	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	6.53	1.68e-10	6.09e-08	0.27	0.28	Asthma;	chr2:102358590	chr2:102438713~102440475:+
KIRC	cis	rs4660214	0.666	rs7554206	ENSG00000237624.1	OXCT2P1	-6.53	1.68e-10	6.09e-08	-0.38	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39514956~39516490:+
KIRC	cis	rs7267979	1	rs2500418	ENSG00000125804.12	FAM182A	6.53	1.68e-10	6.09e-08	0.35	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:26054655~26086917:+
KIRC	cis	rs42490	0.652	rs374957	ENSG00000251136.7	RP11-37B2.1	-6.53	1.68e-10	6.09e-08	-0.22	-0.28	Leprosy;	chr8:89825402	chr8:89609409~89757727:-
KIRC	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-6.53	1.68e-10	6.09e-08	-0.4	-0.28	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
KIRC	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	6.53	1.68e-10	6.09e-08	0.29	0.28	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
KIRC	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	6.53	1.68e-10	6.09e-08	0.29	0.28	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
KIRC	cis	rs755249	0.567	rs41270807	ENSG00000237624.1	OXCT2P1	6.53	1.68e-10	6.09e-08	0.42	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.53	rs16826087	ENSG00000237624.1	OXCT2P1	6.53	1.68e-10	6.09e-08	0.42	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs3754346	ENSG00000237624.1	OXCT2P1	6.53	1.68e-10	6.09e-08	0.42	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs41270811	ENSG00000237624.1	OXCT2P1	6.53	1.68e-10	6.09e-08	0.42	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.567	rs61779274	ENSG00000237624.1	OXCT2P1	6.53	1.68e-10	6.09e-08	0.42	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39514956~39516490:+
KIRC	cis	rs890448	0.796	rs182393	ENSG00000254531.1	FLJ20021	6.53	1.68e-10	6.1e-08	0.28	0.28	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101403811	chr4:101347780~101348883:+
KIRC	cis	rs755249	0.546	rs7533743	ENSG00000237624.1	OXCT2P1	-6.53	1.68e-10	6.1e-08	-0.36	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39514956~39516490:+
KIRC	cis	rs755249	0.565	rs7555699	ENSG00000237624.1	OXCT2P1	-6.53	1.68e-10	6.1e-08	-0.36	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39514956~39516490:+
KIRC	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-6.53	1.68e-10	6.1e-08	-0.31	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
KIRC	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-6.53	1.68e-10	6.1e-08	-0.37	-0.28	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-6.53	1.68e-10	6.1e-08	-0.37	-0.28	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-6.53	1.68e-10	6.1e-08	-0.37	-0.28	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-6.53	1.68e-10	6.1e-08	-0.37	-0.28	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
KIRC	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-6.53	1.68e-10	6.1e-08	-0.37	-0.28	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
KIRC	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-6.52	1.68e-10	6.11e-08	-0.21	-0.28	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
KIRC	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.52	1.69e-10	6.12e-08	0.26	0.28	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
KIRC	cis	rs6452524	0.618	rs7722924	ENSG00000248112.1	RP11-78C3.1	6.52	1.69e-10	6.12e-08	0.31	0.28	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82919376~82921119:-
KIRC	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	6.52	1.69e-10	6.12e-08	0.37	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
KIRC	cis	rs950027	0.787	rs1153845	ENSG00000235390.4	CTD-2651B20.5	6.52	1.69e-10	6.12e-08	0.26	0.28	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45321077~45321692:-
KIRC	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	6.52	1.69e-10	6.12e-08	0.22	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
KIRC	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
KIRC	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	6.52	1.69e-10	6.12e-08	0.32	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
KIRC	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-6.52	1.69e-10	6.12e-08	-0.26	-0.28	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
KIRC	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-6.52	1.69e-10	6.12e-08	-0.26	-0.28	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
KIRC	cis	rs17772222	1	rs17772288	ENSG00000222990.1	RNU4-22P	6.52	1.69e-10	6.12e-08	0.33	0.28	Coronary artery calcification;	chr14:88361022	chr14:88513498~88513663:+
KIRC	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	6.52	1.69e-10	6.12e-08	0.26	0.28	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
KIRC	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	6.52	1.69e-10	6.12e-08	0.33	0.28	Depression;	chr6:28071808	chr6:28073316~28074233:+
KIRC	cis	rs2797160	1	rs1739348	ENSG00000237742.5	RP11-624M8.1	6.52	1.69e-10	6.13e-08	0.34	0.28	Endometrial cancer;	chr6:125693427	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1739349	ENSG00000237742.5	RP11-624M8.1	6.52	1.69e-10	6.13e-08	0.34	0.28	Endometrial cancer;	chr6:125693838	chr6:125578558~125749190:-
KIRC	cis	rs2797160	0.967	rs1578793	ENSG00000237742.5	RP11-624M8.1	6.52	1.69e-10	6.13e-08	0.34	0.28	Endometrial cancer;	chr6:125693911	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs1578794	ENSG00000237742.5	RP11-624M8.1	6.52	1.69e-10	6.13e-08	0.34	0.28	Endometrial cancer;	chr6:125694323	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1	rs6927161	ENSG00000237742.5	RP11-624M8.1	6.52	1.69e-10	6.13e-08	0.34	0.28	Endometrial cancer;	chr6:125694808	chr6:125578558~125749190:-
KIRC	cis	rs2797160	1